<SEC-DOCUMENT>0001179929-22-000172.txt : 20221027
<SEC-HEADER>0001179929-22-000172.hdr.sgml : 20221027
<ACCEPTANCE-DATETIME>20221027105008
ACCESSION NUMBER:		0001179929-22-000172
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		80
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20221027
DATE AS OF CHANGE:		20221027

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MOLINA HEALTHCARE, INC.
		CENTRAL INDEX KEY:			0001179929
		STANDARD INDUSTRIAL CLASSIFICATION:	HOSPITAL & MEDICAL SERVICE PLANS [6324]
		IRS NUMBER:				134204626
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31719
		FILM NUMBER:		221335544

	BUSINESS ADDRESS:	
		STREET 1:		200 OCEANGATE, SUITE 100
		CITY:			LONG BEACH
		STATE:			CA
		ZIP:			90802
		BUSINESS PHONE:		5624353666

	MAIL ADDRESS:	
		STREET 1:		200 OCEANGATE, SUITE 100
		CITY:			LONG BEACH
		STATE:			CA
		ZIP:			90802

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MOLINA HEALTHCARE INC
		DATE OF NAME CHANGE:	20020812
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>moh-20220930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:723f88a6-3111-46ae-86a6-19eac5cb9305,g:31c414f1-6fb4-4584-ba8e-291448fd334e,d:cc83361866f7481797f2215c8aedaf24--><html xmlns:moh="http://www.molinahealthcare.com/20220930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>moh-20220930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80L2ZyYWc6OTQxNjk1YzkzODY3NGFlNDg3Y2RhMzE4YzI2YTcwOGQvdGFibGU6YzBlMTE2NjU1OTcxNGY4ZTg3NzY2YTE1OTkxODA4MjEvdGFibGVyYW5nZTpjMGUxMTY2NTU5NzE0ZjhlODc3NjZhMTU5OTE4MDgyMV8zLTEtMS0xLTU4NTk4_8b7474c2-cb67-42d1-84be-8f62b934abe6">0001179929</ix:nonNumeric><ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80L2ZyYWc6OTQxNjk1YzkzODY3NGFlNDg3Y2RhMzE4YzI2YTcwOGQvdGFibGU6YzBlMTE2NjU1OTcxNGY4ZTg3NzY2YTE1OTkxODA4MjEvdGFibGVyYW5nZTpjMGUxMTY2NTU5NzE0ZjhlODc3NjZhMTU5OTE4MDgyMV80LTEtMS0xLTU4NTk4_511225d7-96d2-4f0d-b3c7-ab25e3801128">12/31</ix:nonNumeric><ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80L2ZyYWc6OTQxNjk1YzkzODY3NGFlNDg3Y2RhMzE4YzI2YTcwOGQvdGFibGU6YzBlMTE2NjU1OTcxNGY4ZTg3NzY2YTE1OTkxODA4MjEvdGFibGVyYW5nZTpjMGUxMTY2NTU5NzE0ZjhlODc3NjZhMTU5OTE4MDgyMV81LTEtMS0xLTU4NTk4_b8e2e3dc-3cc7-44b6-864e-96596db3b518">2022</ix:nonNumeric><ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80L2ZyYWc6OTQxNjk1YzkzODY3NGFlNDg3Y2RhMzE4YzI2YTcwOGQvdGFibGU6YzBlMTE2NjU1OTcxNGY4ZTg3NzY2YTE1OTkxODA4MjEvdGFibGVyYW5nZTpjMGUxMTY2NTU5NzE0ZjhlODc3NjZhMTU5OTE4MDgyMV82LTEtMS0xLTU4NTk4_848b2533-cdda-4a18-a1be-6bceda49dd0f">Q3</ix:nonNumeric><ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80L2ZyYWc6OTQxNjk1YzkzODY3NGFlNDg3Y2RhMzE4YzI2YTcwOGQvdGFibGU6YzBlMTE2NjU1OTcxNGY4ZTg3NzY2YTE1OTkxODA4MjEvdGFibGVyYW5nZTpjMGUxMTY2NTU5NzE0ZjhlODc3NjZhMTU5OTE4MDgyMV83LTEtMS0xLTU4NTk4_564b7fa0-91a9-476e-a1bf-7b9a99b71a03">false</ix:nonNumeric><ix:nonNumeric contextRef="id7583dd9238b48f98a56475a351d24c8_D20220101-20220930" name="moh:HealthPlanContractTerm" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfNjE0_de89890f-e645-4a35-a3a8-f77327830d82">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i832dd038bfde4b259f4caf8354280d4d_D20220801-20220831" name="moh:HealthPlanContractTerm" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfMTA5OTUxMTY0MjE5OA_6c2d1c0d-cdab-4160-9874-52b55f757a29">P4Y</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80OS9mcmFnOmE1ZDYyYTdhZjZjYzQ0ODZhZTVkYTIzNmU4NzQzYmVjL3RhYmxlOjU4OTFhYTYzY2M2OTQ3NmViNDk3OGE1ZWIxNmY3NDYxL3RhYmxlcmFuZ2U6NTg5MWFhNjNjYzY5NDc2ZWI0OTc4YTVlYjE2Zjc0NjFfMS0xLTEtMS01ODU5OA_1256dafd-a892-46bc-9ded-e2ae982b42e3">&#8212;</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80OS9mcmFnOmE1ZDYyYTdhZjZjYzQ0ODZhZTVkYTIzNmU4NzQzYmVjL3RhYmxlOjU4OTFhYTYzY2M2OTQ3NmViNDk3OGE1ZWIxNmY3NDYxL3RhYmxlcmFuZ2U6NTg5MWFhNjNjYzY5NDc2ZWI0OTc4YTVlYjE2Zjc0NjFfMS0yLTEtMS01ODU5OA_a8e16550-8b7f-4201-9c84-56f8bb722b5f">&#8212;</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80OS9mcmFnOmE1ZDYyYTdhZjZjYzQ0ODZhZTVkYTIzNmU4NzQzYmVjL3RhYmxlOjU4OTFhYTYzY2M2OTQ3NmViNDk3OGE1ZWIxNmY3NDYxL3RhYmxlcmFuZ2U6NTg5MWFhNjNjYzY5NDc2ZWI0OTc4YTVlYjE2Zjc0NjFfMi0xLTEtMS01ODU5OA_2690c693-d19d-461d-80c7-6207ea5d5527">&#8212;</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80OS9mcmFnOmE1ZDYyYTdhZjZjYzQ0ODZhZTVkYTIzNmU4NzQzYmVjL3RhYmxlOjU4OTFhYTYzY2M2OTQ3NmViNDk3OGE1ZWIxNmY3NDYxL3RhYmxlcmFuZ2U6NTg5MWFhNjNjYzY5NDc2ZWI0OTc4YTVlYjE2Zjc0NjFfMi0yLTEtMS01ODU5OA_8c867659-a3c7-4f42-b3ac-da7cbb72166a">&#8212;</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80OS9mcmFnOmE1ZDYyYTdhZjZjYzQ0ODZhZTVkYTIzNmU4NzQzYmVjL3RhYmxlOjU4OTFhYTYzY2M2OTQ3NmViNDk3OGE1ZWIxNmY3NDYxL3RhYmxlcmFuZ2U6NTg5MWFhNjNjYzY5NDc2ZWI0OTc4YTVlYjE2Zjc0NjFfMi0zLTEtMS01ODU5OA_5d8617b1-da1b-48b9-86aa-bafb021d7d47">&#8212;</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80OS9mcmFnOmE1ZDYyYTdhZjZjYzQ0ODZhZTVkYTIzNmU4NzQzYmVjL3RhYmxlOjU4OTFhYTYzY2M2OTQ3NmViNDk3OGE1ZWIxNmY3NDYxL3RhYmxlcmFuZ2U6NTg5MWFhNjNjYzY5NDc2ZWI0OTc4YTVlYjE2Zjc0NjFfMi00LTEtMS01ODU5OA_a06e97c8-3a2c-4ddd-bc5f-b45a13f47b0e">&#8212;</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="moh-20220930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c7c2651aec54121a7e2d1337e16d200_I20221021"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-10-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7f3faa154394153bb16052f2634e5ad_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b47298aedfe41eaaf18cdcaa7e274a7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia401e1c073f74cc0bc3f1d03b289141d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7930891295544d92bc8b7e75fd28dc75_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if63417ae06ef4f8b883c07503fb48ab9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8bb2347c1c74af789d99f414d0ee364_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42dd4296d82f4c08b4d55cc720bdb12d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2231609c373451c812f4a754b56a154_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94c67ce05a9d467fa8cb7a3f9e74c0c5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1de449cbf8144a291a8fc6482edab09_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida3920fde58740b88b1e9ac9cbfe5f21_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e2a1318dc6046958feb391581e30a94_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d767141fe3341cc9b7f0780cdd981aa_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica80de08aa4c4c9d909fb642df773c14_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75b496131ef6441490d3a25b5be4a503_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee37a02facff450d8937998e321e35c8_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16cbf61d2b0f4733ab8a1652cc5c9228_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea66be3daee34721bcd1e066d3260b58_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6415db3777c4bc0ba788481e7f6f6a4_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ea7b01bc00445d1911e3e5649c2eae4_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae60640358eb455d83e9b4666e0a100f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77bb9190b3c84feb87f1e61f1cc38b98_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e036f16290b4c31b64755ffadb70e68_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f386ed67c194239ae7a35c709bffd56_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ff0d3fa206d42d891fbf8e9323bc625_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a43605ec78e4bd4a614f90f345653d2_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieafa9072188340c68922f7235c0a9ea9_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5042921868d8416ab4c1cacfa352f6c8_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59e4f5842c904666b3fb7db23c51d515_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id664e6d044d749808e62c38646f27526_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12140879b9244c3988d010fac8673b76_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i512b545761cf451e8d1c4ca94328ff1a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i451df05f2b96426fa20d0b547ba7f6e3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic06c267aa75849648ac7102abce3ac17_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib77ad153c44c4a38a1c8a62dce893409_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54fa9d4a70464bfba0620acea592dfcf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf4e6756a1ee42d88901c783fdeb783f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a1055b0f36c4bbd91048d943dbf64df_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fc11daa88ad420c868e573c62e337b6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50e1491b70c745b18a2d6a77e80a0767_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbd7705702274d08b6c28ba730c1cb95_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if41dccce65fd47dcb255d39bf13108da_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf628f2aee5246458d9a78b310344afd_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7e7bb770a6f4c6b8a0473d3f6b6e0a0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ff566bb63944df8beba8ba4c7fb611e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic162d9697e6b4d94a6bef51a77ade2ed_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i805d18c7f2ad420b968387db21f34edd_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0213fdc467c492b85eaf3335f924d02_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifda22f12ec864b9e9f5599a56418760e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ba9041f2d9b466cb1a515f5d8e1062a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3da409025f3442429d56b3eea13ff924_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i979c2a87e5b84e029cc57393d0f5bb45_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cc1928bdc20474e8a08b2106e966451_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ff4a92d31b249949399aa9150b3fe6f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3eb5e283ce6f47e8a415eea081892818_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5995f351e20f4535ba42664bfb529a7e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1e3a144f80c4ceabad966148dbe65c1_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1891d2cf47cc4c98846d01e9e63fa59b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia20771157a414430a9cd2b49d2eaff24_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98de094b8bc642c2838aa6ef19a8ed9a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia30b2ea5e1494758ab3b2970581abe18_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9057c313471247b8a336f64bcb9d3f3a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b53263877dc45a79b580bcde5a07dcf_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5f8e83b346f4a789040e8611fbb11f6_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>moh:segment</xbrli:measure></xbrli:unit><xbrli:context id="i8ed85c9690854763a35bee8fec51d9ff_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="member"><xbrli:measure>moh:member</xbrli:measure></xbrli:unit><xbrli:unit id="state"><xbrli:measure>moh:state</xbrli:measure></xbrli:unit><xbrli:context id="id7583dd9238b48f98a56475a351d24c8_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7577c1358178462db84325596d1c3ae1_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64ed765381cb451194df42962e56b1f0_D20220901-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4564dde8b7249e29348178f0f8c6242_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a0dfc53f05140aba2d6a2c5d9aaf8ed_I20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="contract"><xbrli:measure>moh:contract</xbrli:measure></xbrli:unit><xbrli:context id="i832dd038bfde4b259f4caf8354280d4d_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88592161984e4e54bea14bf302d598e3_D20220713-20220713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:MyChoiceWisconsinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-13</xbrli:startDate><xbrli:endDate>2022-07-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80a687f2f90f401b9e47d7da8ba17754_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4a4422c70fb4ddfa9b1095fc58b9f0e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:GovernmentReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1cd70f1c470416e9209148ce673af71_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:GovernmentReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib597d981d44b40f195e0cdd71848ddf5_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:PharmacyRebateReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8343c8068f1a4df093d799fc8ff37927_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:PharmacyRebateReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dbb6f52c8d941e5b0f25c3d3e677cda_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:OtherReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id139c6fc382249198e7f8ea8f0212f81_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:OtherReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f40864acf524f78958e876e105a300f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">moh:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bd869502a4d4c3db24a30f94752e48f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">moh:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27e41e19da6946b9947bc20349bd2d6a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">moh:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6507e164e60348edb5cc46669f1a17c3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">moh:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9caa39ee3eca46f2935a54a04a4c6a37_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:StructuredSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbfe7220cac34928b948892e17e59eda_D20220930-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:AgeWellMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-30</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i304daf24495747efa3683f468f95e408_D20220101-20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc61f272749348f58770423142c1f016_D20220101-20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">moh:MemberListsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7af8f685cdb4a2d91d3b3aae5939f99_D20211025-20211025"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:AffinityHealthPlanIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-25</xbrli:startDate><xbrli:endDate>2021-10-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54a931e10c744083ad5d1a9a95d0e7f7_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:AffinityHealthPlanIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53d38d8c7935408fa0af30bea62c9c0f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99e503b9ded046b2afc06e32c386be06_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i950dd07f9ee54e9ba07c4dcd9f68f6bf_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0350794e08ab4b36a1ac51538215ba52_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1115ede7452a40c1914f7984dbb1b080_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6df1fa1ed0d04f3e8713afe89886bc9a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dcbde7850b84d7aacf9b339a9622cde_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15df11d145d34fffaa859bf80bdfc980_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56ac79c2434a4a848f5a258701b2729d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71f0d1fdbe7447868ed74e5f69926324_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i164adb7da96e462788cd4e44a57cc798_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibca4b67f345a40a898863f3cc798be1f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89c330693cd24ca895c0f7f61021a016_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fc1ad95c96a4d70b55ac85d939aa4b3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d2c3542c7de425cb80651f619d775c6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice50ff36424e47d78d882897177a7ed7_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic927869e96d94755b6560a3286b613c8_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5331694495d843a4bf88a8892738d1e9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c2dbf685f2c45e58cd349ed403d70e8_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50d78ee64ba8431dacba700dd2a8bdbf_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if95e6b6b2720412788aaa02f055f8e57_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie087b593b0544c8399e87f02d57c34f2_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51b54536f2594623b231d19ba7ca1a3d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd1da81e23914a71942537034bdbd756_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc33e78bc16f451cbbfd17b41149f635_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e214513a58b4f5a9acb2468d174594b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d6c05f8ebb14ba2abafe737776caa0d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if45c5ec7debc4e2298c33d69169aae1b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:PassportHealthPlanIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib564c222a94b4914a72dc2e0ec855b08_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12ad09b4f8ea44969f6dd60429d526fb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3b352b10300485c87431f796047c44f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0e7c52b9c5349f8bffbe5f1faf3f147_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i736beb8bf714488bb38d432dfc0890b4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d240d4e03e64770aff2769aaa40f08a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3aa389c40f6a42229f5941193027a3ab_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73fb739837584de6b651f049cc43ad72_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ba2d36cfa1140b1984c163783c2d57a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f77531e7d74403b8efb3fc5faf7b062_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52539c799fb64d0eb14c78750d80da4d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5856f1b277e43efad233155501d11a8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d4d9de95590481dad9718e28b15a44b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if802abab93b446539c01d453d4296995_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff4bfd6a6e384d5aa22561a59e8cbecf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea7d8648b1c445ab828552784316706f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic30b2001e92f42a0889f7aa593c567f1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55ac2e82cfc843eb861e766012517f6d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie507227240b34d9a9c9e73630984e2b4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bdb0cb65c134e058441720032db3ad6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0781e4f6fe144460945ffc19971a5b88_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10c0362a739347dfa9baf8391b5ebcf5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic41dd5a8ce43444caa047c867c1a7d68_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i025b5d81cf3b4ab089c2cfb73ed7fde2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e9b92c4cf3944d6bcffae91f86005e4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b0e199731ea42a99e977bd922403d3b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i786c434041fb4ace8a427a0d0e1e025f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf0d9b897df24113b68bdf8a453bb9a6_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:PassportHealthPlanIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1924badac4254104ab5cdb4dd26159ab_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:PassportHealthPlanIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">moh:MinimumMemberEnrollmentTargetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i076cf1c584a94c74b356f13c7adb5c28_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">moh:OperatingIncomeGuaranteeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:PassportHealthPlanIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2215166a13a24f4ea0beb4f9ec5386b9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ib052c71d45c24815afd7307c29d879aa_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i448407d80cec44e08a45d31f149e357a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f612d887153413e9b30f0319ba1b896_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c267f45c1bb4b4bba5c6d0aa9d3c25a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4568007f62514af188a722dbbfff6949_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafab2ab6349040358f61b4a6104ff30b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6633be4c8bbc48bcbc0664990b24b759_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec39088e3cdd4e6bb7e04b07ff271fbe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a9279d92caf4fc380a01f6bfb0014fc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68670e57970547ba9f2bb65e407ef0c3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A3875SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dfc15175d74475c91b12b778c7b87c2_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A3875SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3afb2257e99458fa208ad148ca26252_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A3875SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fd3944eda144945832b087213cd2c9d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A3875SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0939ce4f5154b368577c64da2123599_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A3875SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8580906fd604a64a726120c54b6cf42_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i150352dcdff64ad5be9688ff28c71149_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f569fe006e84fdea4bf95c5b662a515_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5aa0518df13a4a3ea99cdd1f8dc0e2cc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a952061d42f4cf594d018fa3c95b81c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7295c4737a694828803c5153905fdd31_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="position"><xbrli:measure>moh:position</xbrli:measure></xbrli:unit><xbrli:unit id="security"><xbrli:measure>moh:security</xbrli:measure></xbrli:unit><xbrli:context id="i2b797bdb341b4b52895da42aa2124960_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i869f5f0099fe46b693a48fd139483e93_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia584820ec62b4608b407558882249b92_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ec20456c73b4f1f8e73015480eac437_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0963d8c883c844e6b0f9b360576e525d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b425cf2189f45f795be7031fbb9489a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i787d3e77233e4de9930c7143d7f3e1a7_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc0945cdffc8424d957d806d4e965885_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01ba4967c8b8496c94ad918efed3e1d4_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4629290b4494a1da97fe2a340b52e86_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9817ab0688744030bccbbc4527c6ad07_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd9f5b7b16064fb4b96d01f818feee51_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7d644d1ac344e6fa4918cd4a83af717_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2212dcd7830b49eca79d05facc1aaac8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3877802cf9094a9eabfc486981832840_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1698bae97ab44ee92e15544064ddc75_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77d77fe305a64bacbf04f03c5378f673_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic24da3c878854020a39db2e88f0312b7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic26c41034fae49aeaa64c74ef2218d5a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50750950b870483d9018a954d9657216_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5dabbb9212b4359ba854b1a8c18e537_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A3875SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45addfb2824d4400bae53112a7856042_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5d5359290144d4f933ac919de58b333_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedddb1611ce1453d8bc04f5aa0c8509c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id30882aba8a04db99646163bc2413884_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37c0ca418ca74d69b9c15307c7e58df1_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa97e16d76c6408f8338e08b5bea4b44_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f6a30e4c3a945b1bae228351989449f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87816e2186d3470b93fba05f0ffe1f2d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2aaee23745f4ff297ec360508e852a7_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:OtherProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7ee1c4d62614df782f74c5d44f474c9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:OtherProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8eff537979cc43da94a627c160916e60_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:OtherProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabdb88db75e64d48bbc614f435a60acc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:OtherProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0164340d3f1942a3a1a5f79ab8a7363e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2109ad9aef8463798890611406b526f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i226c2214fece4fadb73439a12ab95d6f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i362d995290d84c1597a463618a6f4a5f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i763ba496c6a742eca5a9885bbbc7830e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cef013ef54740e8857e7e00eac7dd4d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48a45433b5894e268eab6a5f260ad9d0_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fe9ad49fa264be4b25af966a5e6c09c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1896656ef924935b656c0a3948916bf_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i454009dcb5f24035b7bb46ce50254cae_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i670ed9482960439bb9d74ff2ffeb3f5e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i812649e7c9904b4abd14942568ab571c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic51dd760fd294631a25b501d900f5f1d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:OtherProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4a763210a0a4713b5050f956ee2aac7_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:OtherProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ff31abf6c8c49da85cb7c5b5b247423_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:OtherProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i328833ca29384ce2b4440be9a5f1bf23_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:OtherProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3648beb8cc65477dac1c4d580ec26c84_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i858448d6578c463ea667e35c5c992219_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50521a7d515b41458530732201de3623_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d6e9de0146e4e0ab67af6591b50afd1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fa84dba36794309afacfe9bdfbc2bde_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e17562a155a4b4899cfccb2754c67e4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87b6e21917b64be8a7e28cf2b5ac0018_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i945971ba12124c429f508ca0dd49999b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="icc83361866f7481797f2215c8aedaf24_1"></div><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.75pt"><tr><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:385.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGV4dHJlZ2lvbjo4ZThkZDk5OTIxZGI0M2VjOGQ5ODcwYzg4N2RhYzM2Ml8yMDk5_b728e06b-6001-49c3-b956-529513e48b42">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:506.25pt"><tr><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:384.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.153%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGFibGU6YzljYjNlNjMxYmJiNDM2OGFhMTNmNjhjMTNiZjI1MGUvdGFibGVyYW5nZTpjOWNiM2U2MzFiYmI0MzY4YWExM2Y2OGMxM2JmMjUwZV8wLTAtMS0xLTU4NTk4_3a82e81a-cf8a-4830-9d43-1cbf6692447a">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGV4dHJlZ2lvbjo4ZThkZDk5OTIxZGI0M2VjOGQ5ODcwYzg4N2RhYzM2Ml8xMzc_d53ecb27-d83b-4de2-87ce-ff52cd3256cc">September 30, 2022</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.153%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGFibGU6NDFhNjBjMDM4ODZiNDFjY2E4M2ZlYTlmMzM3ZmRmZWEvdGFibGVyYW5nZTo0MWE2MGMwMzg4NmI0MWNjYTgzZmVhOWYzMzdmZGZlYV8wLTAtMS0xLTU4NTk4_a4d05cd5-caa9-48a5-8f2e-560f1ab0bb5f">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from ________&#160;to&#160;________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGV4dHJlZ2lvbjo4ZThkZDk5OTIxZGI0M2VjOGQ5ODcwYzg4N2RhYzM2Ml8yMDk0_96b34dbe-b7c5-4066-b2d5-3eebd0f9795e">001-31719</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:390.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><img src="moh-20220930_g1.jpg" alt="moh-20220930_g1.jpg" style="height:76px;margin-bottom:5pt;vertical-align:text-bottom;width:220px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGV4dHJlZ2lvbjo4ZThkZDk5OTIxZGI0M2VjOGQ5ODcwYzg4N2RhYzM2Ml8yMTAw_c39e7419-4ed6-4226-8718-ee972f35ed86">MOLINA HEALTHCARE, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:390.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:522.00pt"><tr><td style="width:1.0pt"></td><td style="width:133.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:120.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:4.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:256.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGFibGU6YWI2MjFmZWY0NGY2NDY3YWFhNTg3NzA2NTQ1NTk4ZWQvdGFibGVyYW5nZTphYjYyMWZlZjQ0ZjY0NjdhYWE1ODc3MDY1NDU1OThlZF8wLTAtMS0xLTU4NTk4_d82dd5d7-b964-4fd4-82b6-bb1f6c140436">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGFibGU6YWI2MjFmZWY0NGY2NDY3YWFhNTg3NzA2NTQ1NTk4ZWQvdGFibGVyYW5nZTphYjYyMWZlZjQ0ZjY0NjdhYWE1ODc3MDY1NDU1OThlZF8wLTMtMS0xLTU4NTk4_5262ce51-af46-4037-9e3c-15e9585937ba">13-4204626</ix:nonNumeric></span></td></tr><tr style="height:20pt"><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGFibGU6YWI2MjFmZWY0NGY2NDY3YWFhNTg3NzA2NTQ1NTk4ZWQvdGFibGVyYW5nZTphYjYyMWZlZjQ0ZjY0NjdhYWE1ODc3MDY1NDU1OThlZF8zLTAtMS0xLTU4NTk4L3RleHRyZWdpb246ZmViNTBjZDI2Njc3NDlmOGI2YTE0NzdlYTdjNmRhZTdfNA_45cdbb92-5f60-47e7-a6cb-98c676f987d6">200 Oceangate</ix:nonNumeric>, <ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGFibGU6YWI2MjFmZWY0NGY2NDY3YWFhNTg3NzA2NTQ1NTk4ZWQvdGFibGVyYW5nZTphYjYyMWZlZjQ0ZjY0NjdhYWE1ODc3MDY1NDU1OThlZF8zLTAtMS0xLTU4NTk4L3RleHRyZWdpb246ZmViNTBjZDI2Njc3NDlmOGI2YTE0NzdlYTdjNmRhZTdfOA_c2c1f857-af77-41ee-87b8-73c0e50e09c6">Suite 100</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGFibGU6YWI2MjFmZWY0NGY2NDY3YWFhNTg3NzA2NTQ1NTk4ZWQvdGFibGVyYW5nZTphYjYyMWZlZjQ0ZjY0NjdhYWE1ODc3MDY1NDU1OThlZF80LTAtMS0xLTU4NTk4_5c8fde8a-72a3-4e33-a857-4404d605b957">Long Beach,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGFibGU6YWI2MjFmZWY0NGY2NDY3YWFhNTg3NzA2NTQ1NTk4ZWQvdGFibGVyYW5nZTphYjYyMWZlZjQ0ZjY0NjdhYWE1ODc3MDY1NDU1OThlZF80LTEtMS0xLTU4NTk4_299157a1-01f4-4978-9525-1afd4059f4a6">California</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGFibGU6YWI2MjFmZWY0NGY2NDY3YWFhNTg3NzA2NTQ1NTk4ZWQvdGFibGVyYW5nZTphYjYyMWZlZjQ0ZjY0NjdhYWE1ODc3MDY1NDU1OThlZF80LTMtMS0xLTU4NTk4_54cd25e4-4254-4609-b9d5-c6b19acdaaed">90802</ix:nonNumeric></span></td></tr><tr style="height:11pt"><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGV4dHJlZ2lvbjo4ZThkZDk5OTIxZGI0M2VjOGQ5ODcwYzg4N2RhYzM2Ml8yMDk1_e06c7c81-0470-45b2-a32e-8a44e39ae05b">562</ix:nonNumeric>) <ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGV4dHJlZ2lvbjo4ZThkZDk5OTIxZGI0M2VjOGQ5ODcwYzg4N2RhYzM2Ml8yMTAx_39137fa9-8172-4623-b7ef-07eea0a081f5">435-3666</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:390.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:521.25pt"><tr><td style="width:1.0pt"></td><td style="width:199.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:115.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:199.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGFibGU6OGY4ZjIxMjJiNGUyNDdiZmE0MjVmYzQ2N2JlYjllMzAvdGFibGVyYW5nZTo4ZjhmMjEyMmI0ZTI0N2JmYTQyNWZjNDY3YmViOWUzMF8xLTAtMS0xLTU4NTk4_2d5e4bee-939b-4664-8238-a02453b6ad35">Common Stock, $0.001 Par Value</ix:nonNumeric> </span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGFibGU6OGY4ZjIxMjJiNGUyNDdiZmE0MjVmYzQ2N2JlYjllMzAvdGFibGVyYW5nZTo4ZjhmMjEyMmI0ZTI0N2JmYTQyNWZjNDY3YmViOWUzMF8xLTEtMS0xLTU4NTk4_d4358e37-ecc3-4cda-9ff8-91a2c806563a">MOH</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGFibGU6OGY4ZjIxMjJiNGUyNDdiZmE0MjVmYzQ2N2JlYjllMzAvdGFibGVyYW5nZTo4ZjhmMjEyMmI0ZTI0N2JmYTQyNWZjNDY3YmViOWUzMF8xLTItMS0xLTU4NTk4_090bbd98-7bb8-4204-82bf-236b76c9fd4f">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:7pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGV4dHJlZ2lvbjo4ZThkZDk5OTIxZGI0M2VjOGQ5ODcwYzg4N2RhYzM2Ml8yMTAy_a2220a02-6c8f-445b-ac5b-41d96f8f1712">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:7pt;margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGV4dHJlZ2lvbjo4ZThkZDk5OTIxZGI0M2VjOGQ5ODcwYzg4N2RhYzM2Ml8yMDk2_1fcdfe1d-ed2c-4f6c-a72c-b414ad3cc045">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:7pt;margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:7pt;margin-top:7pt;padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGV4dHJlZ2lvbjo4ZThkZDk5OTIxZGI0M2VjOGQ5ODcwYzg4N2RhYzM2Ml8yMDk3_ff0b5706-f1f8-4ede-86b8-d5a35a7d614d" continuedAt="i6eaa6a9bc6b84af4bf455b41e33af1c2">L</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i6eaa6a9bc6b84af4bf455b41e33af1c2">arge Accelerated Filer</ix:continuation> &#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accelerated Filer  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-Accelerated Filer  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Smaller reporting company  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGV4dHJlZ2lvbjo4ZThkZDk5OTIxZGI0M2VjOGQ5ODcwYzg4N2RhYzM2Ml8yMTAz_1e0ac975-74bc-492c-a40f-f00fe97b2313">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Emerging growth company  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGV4dHJlZ2lvbjo4ZThkZDk5OTIxZGI0M2VjOGQ5ODcwYzg4N2RhYzM2Ml8yMDk4_f03d2a44-f1ca-4bc1-84ac-9a8115a68354">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:7pt;margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">   &#9744;</span></div><div style="margin-bottom:7pt;margin-top:7pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;   Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGV4dHJlZ2lvbjo4ZThkZDk5OTIxZGI0M2VjOGQ5ODcwYzg4N2RhYzM2Ml8yMTA0_aa0319de-4e2d-4869-9673-17b0b21c0728">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-bottom:7pt;margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of shares of the issuer&#8217;s Common Stock, $0.001 par value, outstanding as of October&#160;21, 2022, was approximately <ix:nonFraction unitRef="shares" contextRef="i1c7c2651aec54121a7e2d1337e16d200_I20221021" decimals="-3" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGV4dHJlZ2lvbjo4ZThkZDk5OTIxZGI0M2VjOGQ5ODcwYzg4N2RhYzM2Ml8yMDky_d106cca2-ef8b-437a-a78b-e4ec0fc9bd25">58,400,000</ix:nonFraction>.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="icc83361866f7481797f2215c8aedaf24_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_7">Table of Contents</a></span></div></div><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MOLINA HEALTHCARE, INC. FORM 10-Q</span></div><div><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2022 </span></div><div><span><br/></span></div><div><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TABLE OF CONTENTS</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.024%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:73.277%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.399%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ITEM NUMBER</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PART I</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_10">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_10">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_79">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_79">20</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_121">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_121">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_124">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_124">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PART II</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_127">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_127">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_130">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_130">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_133">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_133">35</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Defaults Upon Senior Securities</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not Applicable.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mine Safety Disclosures</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not Applicable.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Information</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not Applicable.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_136">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_136">36</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_139">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_139">37</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="icc83361866f7481797f2215c8aedaf24_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div id="icc83361866f7481797f2215c8aedaf24_13"></div><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF INCOME</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in millions, except per-share amounts)<br/>(Unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Premium revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfNS0xLTEtMS01ODU5OA_e20a726f-c81f-4c62-88bc-b2b335adb874">7,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfNS0zLTEtMS01ODU5OA_5e936e45-994d-40e3-bbc2-41f12f46abf3">6,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfNS01LTEtMS01ODU5OA_84d6e95a-62d9-4d6a-a0fe-d807aa6009dd">22,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfNS03LTEtMS01ODU5OA_e4ef984e-f6e1-4941-a5cb-ff1dc3612c0e">19,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Premium tax revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="-6" name="moh:HealthCareOrganizationPremiumTaxRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfNi0xLTEtMS01ODU5OA_f751de98-4dac-49fc-b152-dc58fd836880">223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="-6" name="moh:HealthCareOrganizationPremiumTaxRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfNi0zLTEtMS01ODU5OA_a30fe714-5c2a-44ee-9315-bc15b90b3994">204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="moh:HealthCareOrganizationPremiumTaxRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfNi01LTEtMS01ODU5OA_0cd87d4f-a94c-4713-b862-06d8d2aa9d6e">646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="moh:HealthCareOrganizationPremiumTaxRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfNi03LTEtMS01ODU5OA_d492208c-9c17-48c1-a07f-b6dd04ba5fac">576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfOC0xLTEtMS01ODU5OA_c49de8ec-55f7-4f0a-8381-023969e2881f">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfOC0zLTEtMS01ODU5OA_1581361a-0198-4707-9489-49ad7612b57c">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfOC01LTEtMS01ODU5OA_1792c473-d1f9-4542-80ed-c772a913e1c3">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfOC03LTEtMS01ODU5OA_a44582b1-8059-4df0-9036-a4216c086a09">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="-6" name="us-gaap:InterestAndDividendIncomeOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfOS0xLTEtMS01ODU5OA_256ad9d2-e109-4e8f-bd74-0ed587e728c2">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="-6" name="us-gaap:InterestAndDividendIncomeOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfOS0zLTEtMS01ODU5OA_92213561-9c5b-4802-af20-ab42b52de013">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:InterestAndDividendIncomeOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfOS01LTEtMS01ODU5OA_5dd77448-90a5-432d-9627-35de40d34df6">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:InterestAndDividendIncomeOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfOS03LTEtMS01ODU5OA_9c8787fb-ddff-45c0-8c5a-e4d737a3f4a4">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTAtMS0xLTEtNTg1OTg_1aa6cb1f-6804-470e-8910-f245e2e060f7">7,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTAtMy0xLTEtNTg1OTg_f3057c5f-7888-4ebb-a23f-2072c505b799">7,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTAtNS0xLTEtNTg1OTg_05a6638c-2395-46be-8776-84424ea4d53d">23,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTAtNy0xLTEtNTg1OTg_ba436621-db24-4a37-bacb-89b95fcdd3d3">20,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical care costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTItMS0xLTEtNTg1OTg_048ff930-33c4-4359-b35b-acde860eada3">6,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTItMy0xLTEtNTg1OTg_50b8d3c6-95d0-4556-a737-ba440718339a">6,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTItNS0xLTEtNTg1OTg_f6177c37-1b88-4eb1-b9e2-5b43b2428efa">20,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTItNy0xLTEtNTg1OTg_ca3c5b8e-fc52-406d-91df-eb6945e1d158">17,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTMtMS0xLTEtNTg1OTg_890401ea-622b-44f9-a58e-777a548721b6">560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTMtMy0xLTEtNTg1OTg_5d7b9bc9-709e-4d5c-86bd-08e164ffe047">532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTMtNS0xLTEtNTg1OTg_59c792b9-d2cb-4584-a217-8f3c0bc77e8d">1,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTMtNy0xLTEtNTg1OTg_2e67e7e5-ced4-4fbb-88e4-f8d4d87d6f19">1,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Premium tax expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="-6" name="moh:PremiumTaxExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTQtMS0xLTEtNTg1OTg_390a5ffc-79d4-4ef4-89a4-812539f419bf">223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="-6" name="moh:PremiumTaxExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTQtMy0xLTEtNTg1OTg_0455b041-d3b0-405d-9e5b-aab2d041f780">204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="moh:PremiumTaxExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTQtNS0xLTEtNTg1OTg_8a19e1db-0832-44db-8e4b-c2e2b7156944">646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="moh:PremiumTaxExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTQtNy0xLTEtNTg1OTg_a2c0376c-2d3e-4f03-bd77-97c5a4db4e51">576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="-6" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTYtMS0xLTEtNTg1OTg_e5aca23b-330c-44c7-8412-434910420dd5">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="-6" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTYtMy0xLTEtNTg1OTg_0f6f7185-e207-4265-a8a5-f03b0dcef448">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTYtNS0xLTEtNTg1OTg_b8902bab-71c6-47dc-a4a3-417890616a7b">129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTYtNy0xLTEtNTg1OTg_6dceff49-0c31-42a6-995b-d0fe17e00e55">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="-6" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTctMS0xLTEtNTg1OTg_c9bcd341-3e53-4d2b-b649-219eb844d71d">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="-6" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTctMy0xLTEtNTg1OTg_9e7bb17c-b3de-418e-9685-b0e065c07b27">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTctNS0xLTEtNTg1OTg_5992b473-abf8-48f3-97c7-d7e28bebe516">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTctNy0xLTEtNTg1OTg_e75b8027-9c79-4592-b519-b36e65c671d8">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTgtMS0xLTEtNTg1OTg_3b5c804d-31bf-4683-8f82-fde4736806fe">7,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTgtMy0xLTEtNTg1OTg_4cc5e17d-c5e9-4b33-bf4c-f78a8fe71c94">6,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTgtNS0xLTEtNTg1OTg_e2779230-62bf-4e94-9bf4-4ff1aaa0c49a">22,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTgtNy0xLTEtNTg1OTg_5b3b1f8d-3dea-4996-8053-a486bb164686">19,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTktMS0xLTEtNTg1OTg_847631bf-870c-445d-a462-abfa0c4d812b">335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTktMy0xLTEtNTg1OTg_81bab26c-bc77-4096-9be9-ae71c221da51">221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTktNS0xLTEtNTg1OTg_db0c603b-bbcb-4969-a837-27dc258dfb7c">1,068</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTktNy0xLTEtNTg1OTg_9d3539c2-1414-412a-9867-80abd385ba64">829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expenses, net:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjEtMS0xLTEtNTg1OTg_473acc17-56f2-495f-9ca4-33836116e466">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjEtMy0xLTEtNTg1OTg_c22c8bd6-e715-49a7-a27d-7710f154ea9e">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjEtNS0xLTEtNTg1OTg_50d5a082-85bc-403e-a930-e48e436425de">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjEtNy0xLTEtNTg1OTg_985aa927-62ca-4854-b98d-5e9f3eadebbe">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other expenses, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjMtMS0xLTEtNTg1OTg_071149d2-5abf-487f-97b7-095307feff8d">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjMtMy0xLTEtNTg1OTg_fb5822f0-427f-411a-9233-9a0f2a12704d">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjMtNS0xLTEtNTg1OTg_8eb6876a-b139-49d5-90ba-19aa8279ffb1">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjMtNy0xLTEtNTg1OTg_4a3693f1-7dc3-4eec-8fc1-f9df025c6929">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjQtMS0xLTEtNTg1OTg_ed00f7fd-c269-4796-a890-2f6cac4c12fb">307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjQtMy0xLTEtNTg1OTg_bbc219cf-b4e9-4f12-8ac3-3777d0cbc96e">191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjQtNS0xLTEtNTg1OTg_e57b17a5-3014-4122-a028-55c966bfede4">985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjQtNy0xLTEtNTg1OTg_b51ea325-9b77-49b0-99a1-3c83cbbfddba">739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjUtMS0xLTEtNTg1OTg_cc4d9904-7181-4e68-8789-50f7437ceedc">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjUtMy0xLTEtNTg1OTg_b258dde0-589c-43c7-9f74-95aeda4e1731">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjUtNS0xLTEtNTg1OTg_a2d92721-ffbb-45ec-a194-984176628e9f">249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjUtNy0xLTEtNTg1OTg_a34ccd33-8a5b-4f29-86cc-1cc2daebb88f">183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjYtMS0xLTEtNTg1OTg_9eb228b3-bfde-4add-b92c-851a683d4707">230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjYtMy0xLTEtNTg1OTg_b163ba53-adeb-44ee-9b2c-c89001ddc797">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjYtNS0xLTEtNTg1OTg_7485841e-a987-4170-8a8e-eae9b548b9b0">736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjYtNy0xLTEtNTg1OTg_f14f23bf-f3dc-40cf-ae6a-d28f60c3e290">556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Basic </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjgtMS0xLTEtNTg1OTg_4d6d63a8-6bca-42e7-8abe-59e663a839da">4.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjgtMy0xLTEtNTg1OTg_49b97091-b418-4004-a290-e500e2bd4360">2.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjgtNS0xLTEtNTg1OTg_11b42f69-c366-485b-a1bd-e89d11ac6c8d">12.74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjgtNy0xLTEtNTg1OTg_9b455cd8-15dc-493b-ae24-d9f66ebff4a1">9.63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Diluted </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjktMS0xLTEtNTg1OTg_d75fb7af-7a97-4e49-b242-b1205014d850">3.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjktMy0xLTEtNTg1OTg_3a795c22-d2b0-4341-ab42-8877cb9d050c">2.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjktNS0xLTEtNTg1OTg_98ae9026-ab51-4f6d-95fc-26f28858ce7d">12.58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjktNy0xLTEtNTg1OTg_fc81afe0-846d-4b05-afbd-7e5d9d7fa19d">9.51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)<br/>(Unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmUyM2FiY2E3MjEzYjQxZTc5N2E4ZWQxM2I4OWYzOWJlL3RhYmxlcmFuZ2U6ZTIzYWJjYTcyMTNiNDFlNzk3YThlZDEzYjg5ZjM5YmVfNC0xLTEtMS01ODU5OA_f1a52862-ccd0-4b0a-84db-62dcba930792">230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmUyM2FiY2E3MjEzYjQxZTc5N2E4ZWQxM2I4OWYzOWJlL3RhYmxlcmFuZ2U6ZTIzYWJjYTcyMTNiNDFlNzk3YThlZDEzYjg5ZjM5YmVfNC0zLTEtMS01ODU5OA_8ef3e239-9a5d-4b5e-ba2d-75d45b34ceba">143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmUyM2FiY2E3MjEzYjQxZTc5N2E4ZWQxM2I4OWYzOWJlL3RhYmxlcmFuZ2U6ZTIzYWJjYTcyMTNiNDFlNzk3YThlZDEzYjg5ZjM5YmVfNC01LTEtMS01ODU5OA_950ee250-7d23-491d-83a4-3a42dd930af4">736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmUyM2FiY2E3MjEzYjQxZTc5N2E4ZWQxM2I4OWYzOWJlL3RhYmxlcmFuZ2U6ZTIzYWJjYTcyMTNiNDFlNzk3YThlZDEzYjg5ZjM5YmVfNC03LTEtMS01ODU5OA_81811332-1a08-48a4-b66d-0a434da3b756">556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized investment loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmUyM2FiY2E3MjEzYjQxZTc5N2E4ZWQxM2I4OWYzOWJlL3RhYmxlcmFuZ2U6ZTIzYWJjYTcyMTNiNDFlNzk3YThlZDEzYjg5ZjM5YmVfNi0xLTEtMS01ODU5OA_1f5c65a8-9197-4540-a69b-cdf9a40fbd39">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmUyM2FiY2E3MjEzYjQxZTc5N2E4ZWQxM2I4OWYzOWJlL3RhYmxlcmFuZ2U6ZTIzYWJjYTcyMTNiNDFlNzk3YThlZDEzYjg5ZjM5YmVfNi0zLTEtMS01ODU5OA_443dab9a-e4cc-4db1-9523-864868a7ef19">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmUyM2FiY2E3MjEzYjQxZTc5N2E4ZWQxM2I4OWYzOWJlL3RhYmxlcmFuZ2U6ZTIzYWJjYTcyMTNiNDFlNzk3YThlZDEzYjg5ZjM5YmVfNi01LTEtMS01ODU5OA_025ea16f-b6aa-4c17-8134-dbdaeb8f248c">237</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmUyM2FiY2E3MjEzYjQxZTc5N2E4ZWQxM2I4OWYzOWJlL3RhYmxlcmFuZ2U6ZTIzYWJjYTcyMTNiNDFlNzk3YThlZDEzYjg5ZjM5YmVfNi03LTEtMS01ODU5OA_535a3e27-f049-44bf-ad4c-95531a37e6a6">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: effect of income taxes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmUyM2FiY2E3MjEzYjQxZTc5N2E4ZWQxM2I4OWYzOWJlL3RhYmxlcmFuZ2U6ZTIzYWJjYTcyMTNiNDFlNzk3YThlZDEzYjg5ZjM5YmVfNy0xLTEtMS01ODU5OA_923126cc-64e8-42ac-9506-d31b20ac0012">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmUyM2FiY2E3MjEzYjQxZTc5N2E4ZWQxM2I4OWYzOWJlL3RhYmxlcmFuZ2U6ZTIzYWJjYTcyMTNiNDFlNzk3YThlZDEzYjg5ZjM5YmVfNy0zLTEtMS01ODU5OA_8814e306-fde3-4349-afbc-8f2b460faf76">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmUyM2FiY2E3MjEzYjQxZTc5N2E4ZWQxM2I4OWYzOWJlL3RhYmxlcmFuZ2U6ZTIzYWJjYTcyMTNiNDFlNzk3YThlZDEzYjg5ZjM5YmVfNy01LTEtMS01ODU5OA_b4234e96-ae01-40a8-bb15-5edba8eec0dd">57</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmUyM2FiY2E3MjEzYjQxZTc5N2E4ZWQxM2I4OWYzOWJlL3RhYmxlcmFuZ2U6ZTIzYWJjYTcyMTNiNDFlNzk3YThlZDEzYjg5ZjM5YmVfNy03LTEtMS01ODU5OA_c1688503-4b6f-4d30-8721-e635082e4db7">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmUyM2FiY2E3MjEzYjQxZTc5N2E4ZWQxM2I4OWYzOWJlL3RhYmxlcmFuZ2U6ZTIzYWJjYTcyMTNiNDFlNzk3YThlZDEzYjg5ZjM5YmVfOC0xLTEtMS01ODU5OA_336de38e-0a69-496f-b73b-145ed2bebc12">57</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmUyM2FiY2E3MjEzYjQxZTc5N2E4ZWQxM2I4OWYzOWJlL3RhYmxlcmFuZ2U6ZTIzYWJjYTcyMTNiNDFlNzk3YThlZDEzYjg5ZjM5YmVfOC0zLTEtMS01ODU5OA_1d52bdf5-23c5-4f50-b69b-cf6f67aa1eb0">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmUyM2FiY2E3MjEzYjQxZTc5N2E4ZWQxM2I4OWYzOWJlL3RhYmxlcmFuZ2U6ZTIzYWJjYTcyMTNiNDFlNzk3YThlZDEzYjg5ZjM5YmVfOC01LTEtMS01ODU5OA_e8e4f094-77db-4785-829f-f673f2c45792">180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmUyM2FiY2E3MjEzYjQxZTc5N2E4ZWQxM2I4OWYzOWJlL3RhYmxlcmFuZ2U6ZTIzYWJjYTcyMTNiNDFlNzk3YThlZDEzYjg5ZjM5YmVfOC03LTEtMS01ODU5OA_0ca4ceb5-4639-4775-99b3-e7b06ca5b325">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmUyM2FiY2E3MjEzYjQxZTc5N2E4ZWQxM2I4OWYzOWJlL3RhYmxlcmFuZ2U6ZTIzYWJjYTcyMTNiNDFlNzk3YThlZDEzYjg5ZjM5YmVfOS0xLTEtMS01ODU5OA_6a508b9a-c50c-414f-a4ec-bd68146d6f11">173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmUyM2FiY2E3MjEzYjQxZTc5N2E4ZWQxM2I4OWYzOWJlL3RhYmxlcmFuZ2U6ZTIzYWJjYTcyMTNiNDFlNzk3YThlZDEzYjg5ZjM5YmVfOS0zLTEtMS01ODU5OA_65d3bff6-a555-4140-b6b4-1127da09d07c">134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmUyM2FiY2E3MjEzYjQxZTc5N2E4ZWQxM2I4OWYzOWJlL3RhYmxlcmFuZ2U6ZTIzYWJjYTcyMTNiNDFlNzk3YThlZDEzYjg5ZjM5YmVfOS01LTEtMS01ODU5OA_f81c0edb-f528-48ac-92a1-33079cf90f98">556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmUyM2FiY2E3MjEzYjQxZTc5N2E4ZWQxM2I4OWYzOWJlL3RhYmxlcmFuZ2U6ZTIzYWJjYTcyMTNiNDFlNzk3YThlZDEzYjg5ZjM5YmVfOS03LTEtMS01ODU5OA_d68bb838-0b02-4ac8-908f-ec96875e73ba">536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September&#160;30, 2022 Form 10-Q | 3</span></div></div></div><div id="icc83361866f7481797f2215c8aedaf24_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_7">Table of Contents</a></span></div></div><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in millions,<br/>except per-share amounts)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfNi0xLTEtMS01ODU5OA_f31741a9-bafd-44d0-9239-3f698fce4de0">4,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfNi0zLTEtMS01ODU5OA_d06abd0b-f3cf-4c5b-8337-bb0e845c25b0">4,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfNy0xLTEtMS01ODU5OA_505fae8b-a294-4c13-9e34-73121c1d64c2">3,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfNy0zLTEtMS01ODU5OA_b178bdae-6028-42cd-b1e9-1b5d607ef7ae">3,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfOC0xLTEtMS01ODU5OA_1e47af74-ab28-478f-a27b-a1f75c2a8e5c">2,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfOC0zLTEtMS01ODU5OA_f2ac7629-2acb-4f2f-901b-0bba4e233def">2,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfOS0xLTEtMS01ODU5OA_9f7da568-12c1-4c97-ab9e-a6d98171e652">391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfOS0zLTEtMS01ODU5OA_dca1d00c-8395-4893-8439-c973be8aacb8">247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMTAtMS0xLTEtNTg1OTg_dd6d553a-b3db-490f-b67b-d67ed319aa98">10,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMTAtMy0xLTEtNTg1OTg_81f05f13-775a-45ef-b463-76c35ddd7fb9">10,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, equipment, and capitalized software, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMTEtMS0xLTEtNTg1OTg_1535baf2-a9c9-43e5-afbc-ce005ce32b43">412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMTEtMy0xLTEtNTg1OTg_3c5c41a2-c6df-4f08-8f91-c205029d3058">396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill, and intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMTItMS0xLTEtNTg1OTg_a5a4176d-6d93-4799-9ce4-7124ab933789">1,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMTItMy0xLTEtNTg1OTg_35c1f60b-edf2-432f-b8c8-c059ef25d332">1,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:RestrictedInvestmentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMTMtMS0xLTEtNTg1OTg_f7b01656-772f-4205-8650-25ee699a7241">242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:RestrictedInvestmentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMTMtMy0xLTEtNTg1OTg_9fcbf483-ad0e-48a0-80ab-c92c43f4907d">212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMTQtMS0xLTEtNTg1OTg_6da04f72-93f5-47b9-af0d-78b61b9b57df">198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMTQtMy0xLTEtNTg1OTg_a2ac9fc4-ce6d-4f01-b6a4-4d4db32ce3f8">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMTUtMS0xLTEtNTg1OTg_7539526d-7fd1-4667-bbe7-f5eb867e07db">186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMTUtMy0xLTEtNTg1OTg_0ed59c7a-aecb-480d-8c7c-8ab57a56a761">179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMTYtMS0xLTEtNTg1OTg_2ca70f5d-263d-4546-8dcc-f716835f1e29">12,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMTYtMy0xLTEtNTg1OTg_9258bfc8-a4ec-4a61-8d08-6e24fb5152ce">12,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMjAtMS0xLTEtNTg1OTg_7235d2a7-c962-496e-a4a7-039e8e720429">3,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMjAtMy0xLTEtNTg1OTg_02a7a1ae-730e-4475-94ec-56acbc83a5fc">3,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts due government agencies </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="moh:MedicalPremiumLiabilityDueToAgency" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMjEtMS0xLTEtNTg1OTg_cba5e457-c3e7-451a-9c60-36590894aa52">2,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="moh:MedicalPremiumLiabilityDueToAgency" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMjEtMy0xLTEtNTg1OTg_ed7d2687-d34d-45b8-af07-73d8ea474b55">2,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable, accrued liabilities and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMjItMS0xLTEtNTg1OTg_577e8f15-eac0-4846-88ae-47bb5e7372bf">818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMjItMy0xLTEtNTg1OTg_f5434984-0a10-47f1-a5fb-2fc4526051e3">842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMjMtMS0xLTEtNTg1OTg_0b5fd69e-311a-4ae0-9ee0-da8a6d658c8f">663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMjMtMy0xLTEtNTg1OTg_43087e72-346d-4c29-a5ed-fc1c006e3917">370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMjQtMS0xLTEtNTg1OTg_7ede241f-4702-4c86-aa5a-7abf8aeda896">7,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMjQtMy0xLTEtNTg1OTg_74e72d57-8880-44cf-b568-43809c2990fb">7,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMjUtMS0xLTEtNTg1OTg_af78336a-3431-4e2f-8106-858d37e2a186">2,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMjUtMy0xLTEtNTg1OTg_cdca0a25-5317-4089-9fce-4bb206079759">2,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMjYtMS0xLTEtNTg1OTg_fec502c3-5ca4-4108-8732-5c55bc6cb331">217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMjYtMy0xLTEtNTg1OTg_5ac903b2-dbcd-48fc-8cac-7a2436944df7">219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMjctMS0xLTEtNTg1OTg_99de8293-1eb6-4942-9c9d-4f15e1fd9af8">118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMjctMy0xLTEtNTg1OTg_5da2c7e3-e23e-497f-a7f4-7a4cf9ef8a5f">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMjgtMS0xLTEtNTg1OTg_1911f7f7-4584-4b4c-8255-935c6ba9ec6d">9,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMjgtMy0xLTEtNTg1OTg_814c4454-8e02-417a-b204-bef9f2743842">9,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzAtMC0xLTEtNTg1OTgvdGV4dHJlZ2lvbjoyZTczZGUxM2FiYzg0MjQyYTMyNTM2ZWJkZDJiZjI0NF8xOQ_5a6f2860-095c-41e0-b7b3-9d7a00213452"><ix:nonFraction unitRef="usdPerShare" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzAtMC0xLTEtNTg1OTgvdGV4dHJlZ2lvbjoyZTczZGUxM2FiYzg0MjQyYTMyNTM2ZWJkZDJiZjI0NF8xOQ_8011de86-ecf1-4e3e-a065-da217c3282eb">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzAtMC0xLTEtNTg1OTgvdGV4dHJlZ2lvbjoyZTczZGUxM2FiYzg0MjQyYTMyNTM2ZWJkZDJiZjI0NF8zMw_d598f5ac-f298-4329-850a-f32b12ac4c1f"><ix:nonFraction unitRef="shares" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzAtMC0xLTEtNTg1OTgvdGV4dHJlZ2lvbjoyZTczZGUxM2FiYzg0MjQyYTMyNTM2ZWJkZDJiZjI0NF8zMw_e0a338a8-3b77-437b-b6d1-3ee3c73c4846">150</ix:nonFraction></ix:nonFraction> million shares authorized; outstanding: <ix:nonFraction unitRef="shares" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzAtMC0xLTEtNTg1OTgvdGV4dHJlZ2lvbjoyZTczZGUxM2FiYzg0MjQyYTMyNTM2ZWJkZDJiZjI0NF82OA_22b8bd19-c24e-400e-a69c-a4a3eaa2952e"><ix:nonFraction unitRef="shares" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzAtMC0xLTEtNTg1OTgvdGV4dHJlZ2lvbjoyZTczZGUxM2FiYzg0MjQyYTMyNTM2ZWJkZDJiZjI0NF82OA_44871194-764c-4148-9acb-1551332b6e19">58</ix:nonFraction></ix:nonFraction> million shares at September&#160;30, 2022 and December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:CommonStockValueOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzAtMS0xLTEtNTg1OTg_bfef368c-6e8a-47dd-b38c-0090603877cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:CommonStockValueOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzAtMy0xLTEtNTg1OTg_5478787e-027f-4aab-a70f-bc5f443772e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzEtMC0xLTEtNTg1OTgvdGV4dHJlZ2lvbjpkMmJjZGVmMjMzZTk0MDM3ODJjYzQ4NGJhZDZhZTZkZl8yMg_35b7c1ca-120a-4885-864d-482e4ce9a23f"><ix:nonFraction unitRef="usdPerShare" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzEtMC0xLTEtNTg1OTgvdGV4dHJlZ2lvbjpkMmJjZGVmMjMzZTk0MDM3ODJjYzQ4NGJhZDZhZTZkZl8yMg_69724726-b3e1-4ec9-96da-e6cf3de92f4d">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzEtMC0xLTEtNTg1OTgvdGV4dHJlZ2lvbjpkMmJjZGVmMjMzZTk0MDM3ODJjYzQ4NGJhZDZhZTZkZl8zNg_3c7478e6-affe-4472-bd0a-410dcc46c8bb"><ix:nonFraction unitRef="shares" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzEtMC0xLTEtNTg1OTgvdGV4dHJlZ2lvbjpkMmJjZGVmMjMzZTk0MDM3ODJjYzQ4NGJhZDZhZTZkZl8zNg_e3c2f5b3-eaa9-4981-ac21-41f74c27e648">20</ix:nonFraction></ix:nonFraction> million shares authorized, <ix:nonFraction unitRef="shares" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzEtMC0xLTEtNTg1OTgvdGV4dHJlZ2lvbjpkMmJjZGVmMjMzZTk0MDM3ODJjYzQ4NGJhZDZhZTZkZl81OA_41642417-ecf5-4375-9e94-b9b15a94d98f"><ix:nonFraction unitRef="shares" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzEtMC0xLTEtNTg1OTgvdGV4dHJlZ2lvbjpkMmJjZGVmMjMzZTk0MDM3ODJjYzQ4NGJhZDZhZTZkZl81OA_6fd09784-be35-40e7-9d21-e5337c2d84a4"><ix:nonFraction unitRef="shares" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzEtMC0xLTEtNTg1OTgvdGV4dHJlZ2lvbjpkMmJjZGVmMjMzZTk0MDM3ODJjYzQ4NGJhZDZhZTZkZl81OA_cf0b6ecd-ff30-4b76-b105-83b2b80b12c2"><ix:nonFraction unitRef="shares" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzEtMC0xLTEtNTg1OTgvdGV4dHJlZ2lvbjpkMmJjZGVmMjMzZTk0MDM3ODJjYzQ4NGJhZDZhZTZkZl81OA_e361b13c-e090-4c2c-afae-4ff535a0e44e">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzEtMS0xLTEtNTg1OTg_cda59f12-8a1c-47a1-9b73-5c5b0c245bfa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzEtMy0xLTEtNTg1OTg_d2229e96-a87f-48cd-b569-b99452456752">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzItMS0xLTEtNTg1OTg_3dd37056-a9d5-4141-b0c5-03a8b91c457a">289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzItMy0xLTEtNTg1OTg_cc2029d5-ce77-42d6-a5f7-aae43ab8845a">236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzMtMS0xLTEtNTg1OTg_6237cf25-e951-4b8c-bf44-a4845f9fd8b8">185</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzMtMy0xLTEtNTg1OTg_39c394fd-be1c-4e7a-8b0a-9195067a0b5d">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzQtMS0xLTEtNTg1OTg_e8046ec1-4ed0-4617-a436-7550055d4d84">2,937</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzQtMy0xLTEtNTg1OTg_209bb2c9-707a-4643-8465-f2d44c804bdb">2,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzUtMS0xLTEtNTg1OTg_fa7c4c68-dd19-4588-b18e-0444c6aeaf60">3,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzUtMy0xLTEtNTg1OTg_16ffaa4f-4843-4ea9-a08d-df3e5bf862d7">2,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzYtMS0xLTEtNTg1OTg_71dedbfc-196c-43ed-8a62-eb6c2af981e0">12,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzYtMy0xLTEtNTg1OTg_047fdbfa-2d0b-4547-8fb7-d108b57645f0">12,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September&#160;30, 2022 Form 10-Q | 4</span></div></div></div><div id="icc83361866f7481797f2215c8aedaf24_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_7">Table of Contents</a></span></div></div><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.288%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b47298aedfe41eaaf18cdcaa7e274a7_I20211231" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfNS0xLTEtMS01ODU5OA_a96c4082-01f0-4604-817d-e088683fc09b">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b47298aedfe41eaaf18cdcaa7e274a7_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfNS0zLTEtMS01ODU5OA_0e7a13ff-6046-4780-b934-73981d5a1a5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia401e1c073f74cc0bc3f1d03b289141d_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfNS01LTEtMS01ODU5OA_c7a63389-1cbb-46f9-b021-6261cb69f7cc">236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7930891295544d92bc8b7e75fd28dc75_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfNS03LTEtMS01ODU5OA_a7f4e280-8435-407e-b2e5-ade278400a17">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if63417ae06ef4f8b883c07503fb48ab9_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfNS05LTEtMS01ODU5OA_aab3c334-0625-4e8f-9356-bf2cdfc61580">2,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfNS0xMS0xLTEtNTg1OTg_8afcf786-18dd-4d7c-8e2d-96d26d81ea00">2,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8bb2347c1c74af789d99f414d0ee364_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfNi05LTEtMS01ODU5OA_4b7f3194-f114-4a03-a57b-998874940a1e">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42dd4296d82f4c08b4d55cc720bdb12d_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfNi0xMS0xLTEtNTg1OTg_111db46c-6448-40da-b151-99a3a72c6bf6">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2231609c373451c812f4a754b56a154_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMTYtNy0xLTEtNTg1OTg_1f1eb3a7-8086-4283-a71b-a40f87087f99">76</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42dd4296d82f4c08b4d55cc720bdb12d_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMTYtMTEtMS0xLTU4NTk4_27defaa0-cfbb-4115-8d26-ecf7c8c14ff2">76</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i94c67ce05a9d467fa8cb7a3f9e74c0c5_D20220101-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMTctMS0xLTEtNTg1OTg_4447fc8a-92f7-4e26-8359-009907d9fc88">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1de449cbf8144a291a8fc6482edab09_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMTctNS0xLTEtNTg1OTg_382d249d-9716-4123-9771-04bf35d0716b">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42dd4296d82f4c08b4d55cc720bdb12d_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMTctMTEtMS0xLTU4NTk4_fc6c69ae-42cf-4ed0-a78c-1ed7ccf81c76">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ida3920fde58740b88b1e9ac9cbfe5f21_I20220331" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMTgtMS0xLTEtNTg1OTg_3ad2c75e-1793-4248-b25b-c128115c186d">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida3920fde58740b88b1e9ac9cbfe5f21_I20220331" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMTgtMy0xLTEtNTg1OTg_86384b78-5e8a-4bdd-8416-e49f63b30114">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e2a1318dc6046958feb391581e30a94_I20220331" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMTgtNS0xLTEtNTg1OTg_4c54e9f1-644a-4d55-ba8c-65aa293c9f8e">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d767141fe3341cc9b7f0780cdd981aa_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMTgtNy0xLTEtNTg1OTg_a3ab1669-167d-4e3c-afa9-87db23e8097a">81</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica80de08aa4c4c9d909fb642df773c14_I20220331" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMTgtOS0xLTEtNTg1OTg_2396f91f-4a23-4c16-a3fa-76967126309c">2,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75b496131ef6441490d3a25b5be4a503_I20220331" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMTgtMTEtMS0xLTU4NTk4_a5d4e549-b85a-4a02-8ce1-1194db3de759">2,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee37a02facff450d8937998e321e35c8_D20220401-20220630" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMTktOS0xLTEtNTg1OTg_dbb60eb7-f8d7-42c8-8bb0-d87ca2565151">248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16cbf61d2b0f4733ab8a1652cc5c9228_D20220401-20220630" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMTktMTEtMS0xLTU4NTk4_85bf187a-fe43-4aca-a1ac-78f20c1cb2b5">248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iea66be3daee34721bcd1e066d3260b58_D20220401-20220630" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMjAtMS0xLTEtNTg1OTg_5ded7bb3-4fed-4596-8bef-40af2d8234ba">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6415db3777c4bc0ba788481e7f6f6a4_D20220401-20220630" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMjAtNS0xLTEtNTg1OTg_89ee6d2c-5167-40e7-9973-1e251932c411">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee37a02facff450d8937998e321e35c8_D20220401-20220630" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMjAtOS0xLTEtNTg1OTg_8bcd7b83-fd17-4d92-bf40-3326bc77e139">198</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16cbf61d2b0f4733ab8a1652cc5c9228_D20220401-20220630" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMjAtMTEtMS0xLTU4NTk4_f950a8eb-994c-4db6-93d0-5d0fff0b9e6d">200</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ea7b01bc00445d1911e3e5649c2eae4_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMjktNy0xLTEtNTg1OTg_8eaace61-509c-4f46-8fe9-6e1480b22e36">47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16cbf61d2b0f4733ab8a1652cc5c9228_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMjktMTEtMS0xLTU4NTk4_5021b1da-a3fa-46b7-9fdc-be803629887a">47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6415db3777c4bc0ba788481e7f6f6a4_D20220401-20220630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMzAtNS0xLTEtNTg1OTg_93c6ee54-8fb5-466b-97a3-5d62b2e079fd">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16cbf61d2b0f4733ab8a1652cc5c9228_D20220401-20220630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMzAtMTEtMS0xLTU4NTk4_be145a4a-6dab-4946-80c1-546eb6a30f4e">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iae60640358eb455d83e9b4666e0a100f_I20220630" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMzEtMS0xLTEtNTg1OTg_d753ccf3-d431-4588-a253-8280a6f859e4">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae60640358eb455d83e9b4666e0a100f_I20220630" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMzEtMy0xLTEtNTg1OTg_7d454c87-99ea-441c-92fb-7067dceef4fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77bb9190b3c84feb87f1e61f1cc38b98_I20220630" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMzEtNS0xLTEtNTg1OTg_41580818-350f-408b-aa4d-55fdebc4f9c2">251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e036f16290b4c31b64755ffadb70e68_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMzEtNy0xLTEtNTg1OTg_27d6a41f-be66-43e7-a3f0-ad4f979d4fde">128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f386ed67c194239ae7a35c709bffd56_I20220630" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMzEtOS0xLTEtNTg1OTg_1dc40e3c-c638-443e-90e6-d07049fe8116">2,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ff0d3fa206d42d891fbf8e9323bc625_I20220630" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMzEtMTEtMS0xLTU4NTk4_1141955a-7c38-4732-b439-b0449a2627f8">2,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a43605ec78e4bd4a614f90f345653d2_D20220701-20220930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMzItOS0xLTEtNTg1OTg_7e1aed8c-708e-467c-a4d9-62a4326ef3b5">230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMzItMTEtMS0xLTU4NTk4_1d1ce41c-c2dd-4d86-8bd5-00c22b375560">230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieafa9072188340c68922f7235c0a9ea9_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfNDItNy0xLTEtNTg1OTg_551cde19-ba57-4ec7-bd89-ae3fe34d8887">57</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfNDItMTEtMS0xLTU4NTk4_b1fa7e58-83dc-4955-a970-10e36d0c61b3">57</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5042921868d8416ab4c1cacfa352f6c8_D20220701-20220930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfNDMtMS0xLTEtNTg1OTg_8843f7e4-fc7b-435c-b0b8-688ee5006347">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59e4f5842c904666b3fb7db23c51d515_D20220701-20220930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfNDMtNS0xLTEtNTg1OTg_e5603952-1575-42a0-93aa-7835db523a11">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfNDMtMTEtMS0xLTU4NTk4_2b4626c0-d040-4b2b-990c-f834a4d759c2">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id664e6d044d749808e62c38646f27526_I20220930" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfNDQtMS0xLTEtNTg1OTg_d7edd9db-1410-47be-9489-11ffbc1d76dc">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id664e6d044d749808e62c38646f27526_I20220930" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfNDQtMy0xLTEtNTg1OTg_00369e2a-332c-4f58-842c-a4ee30bf36c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12140879b9244c3988d010fac8673b76_I20220930" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfNDQtNS0xLTEtNTg1OTg_4a9b2c18-9552-4c16-be27-aca6ac3fa594">289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i512b545761cf451e8d1c4ca94328ff1a_I20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfNDQtNy0xLTEtNTg1OTg_d734cff0-1feb-485e-b2ce-f6af4f131581">185</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i451df05f2b96426fa20d0b547ba7f6e3_I20220930" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfNDQtOS0xLTEtNTg1OTg_2e01ef85-3b7e-4ef4-bce3-75f75c81ed4e">2,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfNDQtMTEtMS0xLTU4NTk4_d81012bd-1008-4f10-a143-143fa44a19a0">3,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:34.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.890%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic06c267aa75849648ac7102abce3ac17_I20201231" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNS0xLTEtMS01ODU5OA_403e5b6f-89dd-4cb1-85e1-a1cad181523d">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06c267aa75849648ac7102abce3ac17_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNS0zLTEtMS01ODU5OA_96586671-d867-4b19-b969-3a314fc60399">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib77ad153c44c4a38a1c8a62dce893409_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNS01LTEtMS01ODU5OA_811d95a0-fe47-4828-b93b-2c4d72e5a77f">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54fa9d4a70464bfba0620acea592dfcf_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNS03LTEtMS01ODU5OA_7f58b65d-0eb1-4cd0-aeb7-23815b1a72db">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf4e6756a1ee42d88901c783fdeb783f_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNS05LTEtMS01ODU5OA_eaa2d192-8e37-4509-b895-e462eb91b132">1,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a1055b0f36c4bbd91048d943dbf64df_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNS0xMS0xLTEtNTg1OTg_518544dc-ba72-44df-85c4-b523537d4950">2,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fc11daa88ad420c868e573c62e337b6_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNi05LTEtMS01ODU5OA_9048e193-ca5a-4265-88e8-46706824db41">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50e1491b70c745b18a2d6a77e80a0767_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNi0xMS0xLTEtNTg1OTg_5aae09ff-61a8-41ca-b889-fe26c45852f4">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idbd7705702274d08b6c28ba730c1cb95_D20210101-20210331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNy0xLTEtMS01ODU5OA_2e3c3ad7-3996-4712-b264-03a9ce9719da">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if41dccce65fd47dcb255d39bf13108da_D20210101-20210331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNy01LTEtMS01ODU5OA_656683aa-6a0b-4f45-8f16-99e21a5580b7">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1fc11daa88ad420c868e573c62e337b6_D20210101-20210331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNy05LTEtMS01ODU5OA_a9a84d89-c9a5-4b47-a027-049d3804aeec">120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50e1491b70c745b18a2d6a77e80a0767_D20210101-20210331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNy0xMS0xLTEtNTg1OTg_7714a3da-82eb-4dfe-867e-d2a104bb3c2b">122</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf628f2aee5246458d9a78b310344afd_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMTYtNy0xLTEtNTg1OTg_97a8d213-e4f1-49bb-9220-350ec832d798">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50e1491b70c745b18a2d6a77e80a0767_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMTYtMTEtMS0xLTU4NTk4_6a8a5696-8a55-4677-b5bc-06d58a520b98">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if41dccce65fd47dcb255d39bf13108da_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMTctNS0xLTEtNTg1OTg_35055e9f-8467-47f0-864b-4ba17788c886">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50e1491b70c745b18a2d6a77e80a0767_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMTctMTEtMS0xLTU4NTk4_82440320-65d0-471d-91d0-f2f22dc060a6">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic7e7bb770a6f4c6b8a0473d3f6b6e0a0_I20210331" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMTgtMS0xLTEtNTg1OTg_57a831fd-d154-4efe-b8cd-891f06593204">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7e7bb770a6f4c6b8a0473d3f6b6e0a0_I20210331" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMTgtMy0xLTEtNTg1OTg_ef94fd71-ba2c-4ae6-b830-7e4792d5bcd0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ff566bb63944df8beba8ba4c7fb611e_I20210331" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMTgtNS0xLTEtNTg1OTg_fcaeca2e-4acb-48ed-a3a5-39958e9121f2">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic162d9697e6b4d94a6bef51a77ade2ed_I20210331" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMTgtNy0xLTEtNTg1OTg_f9bf7e14-1aba-49d3-a39f-36e3b2eb4cf3">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i805d18c7f2ad420b968387db21f34edd_I20210331" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMTgtOS0xLTEtNTg1OTg_13eb15d5-f6f3-4666-8a53-18d0d94842e3">1,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0213fdc467c492b85eaf3335f924d02_I20210331" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMTgtMTEtMS0xLTU4NTk4_da069f49-1b84-40d1-8e3d-17858bca842c">2,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifda22f12ec864b9e9f5599a56418760e_D20210401-20210630" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMTktOS0xLTEtNTg1OTg_5f243700-ed0f-4eb4-862f-bc64f0cb2bc6">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ba9041f2d9b466cb1a515f5d8e1062a_D20210401-20210630" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMTktMTEtMS0xLTU4NTk4_a97ebee4-de91-4551-9fa4-a1a3a76f4795">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3da409025f3442429d56b3eea13ff924_D20210401-20210630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMzAtNS0xLTEtNTg1OTg_90190689-9d24-472a-b0a0-9d40248df52c">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ba9041f2d9b466cb1a515f5d8e1062a_D20210401-20210630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMzAtMTEtMS0xLTU4NTk4_bd99f30e-14b0-45e0-acf6-f10999bbed66">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i979c2a87e5b84e029cc57393d0f5bb45_I20210630" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMzEtMS0xLTEtNTg1OTg_bef50d36-1606-4219-baa5-b8683a389eb0">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i979c2a87e5b84e029cc57393d0f5bb45_I20210630" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMzEtMy0xLTEtNTg1OTg_ac6ccfbc-1aa1-47e2-90f0-319ea5fb0475">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc1928bdc20474e8a08b2106e966451_I20210630" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMzEtNS0xLTEtNTg1OTg_4ba45ad0-8144-4392-b326-2714dc3a05e5">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ff4a92d31b249949399aa9150b3fe6f_I20210630" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMzEtNy0xLTEtNTg1OTg_a9ed1a43-e8c3-4f55-b34b-7adca5be8230">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3eb5e283ce6f47e8a415eea081892818_I20210630" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMzEtOS0xLTEtNTg1OTg_f8ef94bf-194c-4ae4-a1a3-15eeb130f73a">2,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5995f351e20f4535ba42664bfb529a7e_I20210630" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMzEtMTEtMS0xLTU4NTk4_5add079a-d53e-40c5-9bca-ab93ccdd6218">2,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1e3a144f80c4ceabad966148dbe65c1_D20210701-20210930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMzItOS0xLTEtNTg1OTg_bdffc812-ed2a-42b6-9c57-c7411e1e582c">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMzItMTEtMS0xLTU4NTk4_ca264bb2-5a4a-4455-ac5e-7a77321cd9c4">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1891d2cf47cc4c98846d01e9e63fa59b_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNDItNy0xLTEtNTg1OTg_b312404d-09ce-44cb-a0b3-b9feb6125291">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNDItMTEtMS0xLTU4NTk4_c583bf7d-eb13-421d-8cec-7b06cb251d8f">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia20771157a414430a9cd2b49d2eaff24_D20210701-20210930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNDMtNS0xLTEtNTg1OTg_33bb3058-a828-48b5-926f-1838d4989893">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNDMtMTEtMS0xLTU4NTk4_9a50b175-1218-4a6e-b22d-259423fe0a13">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i98de094b8bc642c2838aa6ef19a8ed9a_I20210930" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNDQtMS0xLTEtNTg1OTg_a51a0728-4411-489a-9df4-f60f4dba36d6">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98de094b8bc642c2838aa6ef19a8ed9a_I20210930" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNDQtMy0xLTEtNTg1OTg_dda52ac7-e16c-464d-9923-d99b9ffd2d7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia30b2ea5e1494758ab3b2970581abe18_I20210930" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNDQtNS0xLTEtNTg1OTg_49e4db89-d552-4de3-89a6-4dfbbb53161b">205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9057c313471247b8a336f64bcb9d3f3a_I20210930" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNDQtNy0xLTEtNTg1OTg_814c678e-4b13-4ade-98c6-8a9f60e09d72">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b53263877dc45a79b580bcde5a07dcf_I20210930" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNDQtOS0xLTEtNTg1OTg_dce3649d-d8aa-44b7-9e83-ccb8acec10e0">2,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5f8e83b346f4a789040e8611fbb11f6_I20210930" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNDQtMTEtMS0xLTU4NTk4_8e01f7cf-4e12-4e0a-a7f1-02133fa278df">2,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September&#160;30, 2022 Form 10-Q | 5</span></div></div></div><div id="icc83361866f7481797f2215c8aedaf24_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_7">Table of Contents</a></span></div></div><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)<br/>(Unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfNS0xLTEtMS01ODU5OA_5f3fca68-182d-4e47-bf72-5a158b3c7acd">736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfNS0zLTEtMS01ODU5OA_8167ec8d-4288-4619-8828-0752b63ae0c5">556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfNy0xLTEtMS01ODU5OA_68bd70fd-cd19-4927-b3fe-bba235e000a9">129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfNy0zLTEtMS01ODU5OA_5551494c-f9c9-403c-b4e8-41b3f400bc83">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfOC0xLTEtMS01ODU5OA_01084530-c74b-4fd7-9130-3c081fac55a1">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfOC0zLTEtMS01ODU5OA_90aed60e-0e4f-4bb4-bf0d-e82fa1f02cef">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfOS0xLTEtMS01ODU5OA_41d7d4be-065b-456d-9365-0e7aa6088e2a">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfOS0zLTEtMS01ODU5OA_43dd9ccf-42dd-41dd-a848-9f587e121519">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMTEtMS0xLTEtNTg1OTg_f4fa59f2-4a83-4d15-bf44-9b9e77f36700">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMTEtMy0xLTEtNTg1OTg_404ef286-5f3a-4477-9aff-9b0ec2c4a1dd">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:IncreaseDecreaseInReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMTMtMS0xLTEtNTg1OTg_d798e780-f052-4faf-b98b-6cb8a938ec58">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:IncreaseDecreaseInReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMTMtMy0xLTEtNTg1OTg_a9448ed3-cc42-4770-a426-593ef8c8c335">247</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMTQtMS0xLTEtNTg1OTg_fc723257-91c9-43e3-afef-ea0d18931bc7">110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMTQtMy0xLTEtNTg1OTg_092e2e1f-a390-4e6d-9fbf-7db826b7f9bb">43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMTUtMS0xLTEtNTg1OTg_bcb94629-19ed-4e06-916d-4842e2de15ed">251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMTUtMy0xLTEtNTg1OTg_650c8d06-8a8d-45d2-8d5d-13ffb5dc83a0">522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts due government agencies </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" sign="-" name="moh:IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMTYtMS0xLTEtNTg1OTg_ed65c270-628a-432b-9528-81940c776f0a">360</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="moh:IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMTYtMy0xLTEtNTg1OTg_d4f32448-c9fe-4871-9820-6b2423fed81f">810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable, accrued liabilities and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMTctMS0xLTEtNTg1OTg_5491d1bb-4170-468a-802c-0ba7313d1b84">40</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMTctMy0xLTEtNTg1OTg_ee0fc6da-0da2-443d-87fb-98f1dfc0a9d0">129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMTgtMS0xLTEtNTg1OTg_e413b4cd-929d-4b8c-aca5-f835a19a68ff">293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMTgtMy0xLTEtNTg1OTg_7b9c24ed-e785-42f5-a33e-34d9f2f04f45">374</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMTktMS0xLTEtNTg1OTg_a0a85b2d-8512-4204-ace5-715c303fd119">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMTktMy0xLTEtNTg1OTg_b3360e27-2e42-427a-aa12-e23013c65472">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMjAtMS0xLTEtNTg1OTg_39cb71db-5c11-458a-ab65-87c00507334c">985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMjAtMy0xLTEtNTg1OTg_8225a273-8565-44ba-afd6-7894bb4d0ac8">1,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMjItMS0xLTEtNTg1OTg_af6abf22-81cb-447e-947e-f56d42e8f0e8">1,764</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMjItMy0xLTEtNTg1OTg_880ca2dc-2ebb-4079-9845-c2ea80bfec25">2,018</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMjMtMS0xLTEtNTg1OTg_c84fd284-333d-4312-b58c-3e11b4e329b3">1,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMjMtMy0xLTEtNTg1OTg_3b225a13-d89e-436d-9b4f-8d438255aa60">965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash paid in business combinations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMjQtMS0xLTEtNjYwNTM_b6cb9ff8-75c2-4b54-bb77-30574610ea01">134</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMjQtMy0xLTEtNjYwNTM_dec9cf35-becf-4d70-b3c8-da5deab89b21">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property, equipment and capitalized software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMjQtMS0xLTEtNTg1OTg_369b02ad-3fe3-4e36-ab54-b5e3bbd2b977">81</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMjQtMy0xLTEtNTg1OTg_e4a1bd88-be3b-44e8-af8f-e91239c53244">56</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMjYtMS0xLTEtNTg1OTg_1f511b1d-0a31-403a-bfb4-8f535fbae6f4">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMjYtMy0xLTEtNTg1OTg_46f6b141-a5b7-4ee9-b728-9f12d757b5ff">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMjctMS0xLTEtNTg1OTg_e66d25b0-25d6-4e1e-88ea-55831912876f">938</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMjctMy0xLTEtNTg1OTg_dfb42f3c-15ce-4e1f-b029-c4132c1587e1">1,106</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMjktMS0xLTEtNTg1OTg_42801f37-360b-4f1f-99cc-54f7fb834c10">200</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMjktMy0xLTEtNTg1OTg_922a6ce9-64f8-4bc5-91d9-46606f40d09c">128</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock withheld to settle employee tax obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="moh:CommonStockWithheldToSettleEmployeeTaxObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMzAtMS0xLTEtNTg1OTg_5a046d87-1a2e-4df1-a7b0-c43f26f805ed">53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="moh:CommonStockWithheldToSettleEmployeeTaxObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMzAtMy0xLTEtNTg1OTg_d4b3dfbe-37e4-4dc2-b8c5-2fb822e0b468">52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities settled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMzEtMS0xLTEtNTg1OTg_19be52cc-3787-40f4-8939-e31a16b20bbc">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMzEtMy0xLTEtNTg1OTg_44a1e1ea-75d7-435d-9fb4-5b31791bdeb7">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfNDAtMS0xLTEtNTg1OTg_b9d4c7d3-863a-4bd9-9cdd-f6991f344329">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfNDAtMy0xLTEtNTg1OTg_ee8807b9-47b2-4ea2-95f2-552943b9712f">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfNDEtMS0xLTEtNTg1OTg_7ee7fc71-5156-4607-9a79-85db36060c90">258</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfNDEtMy0xLTEtNTg1OTg_5b7972c9-b5bd-4866-8d8d-8696645070f3">204</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (decrease) increase in cash, cash equivalents, and restricted cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfNDItMS0xLTEtNTg1OTg_934f5e6f-3da4-40f7-87b7-f49ce55981ec">211</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfNDItMy0xLTEtNTg1OTg_0986602b-9d75-4694-a492-cc17519ceb52">212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfNDMtMS0xLTEtNTg1OTg_2f0edff4-6e8c-4657-beb2-498a2e42370e">4,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a1055b0f36c4bbd91048d943dbf64df_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfNDMtMy0xLTEtNTg1OTg_54e61240-4d82-4309-aa44-1dc0401d5dcc">4,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfNDQtMS0xLTEtNTg1OTg_143a70e1-9397-4ab9-811e-ef8961f55368">4,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5f8e83b346f4a789040e8611fbb11f6_I20210930" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfNDQtMy0xLTEtNTg1OTg_3042155d-5853-4457-a835-6a4523238fe9">4,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September&#160;30, 2022 Form 10-Q | 6</span></div></div></div><div id="icc83361866f7481797f2215c8aedaf24_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SEPTEMBER&#160;30, 2022 </span></div><div><span><br/></span></div><div id="icc83361866f7481797f2215c8aedaf24_31"></div><div><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. <ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfNTI1MA_8bd2f901-37d7-4500-96fd-b7ce391cfc93" continuedAt="ibc0d2a4e2cfc4c58abf714ef6f96702c" escape="true">Organization and Basis of Presentation </ix:nonNumeric></span></div><ix:continuation id="ibc0d2a4e2cfc4c58abf714ef6f96702c" continuedAt="i81f8a66420a34dc8905acc1c3910ebeb"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization and Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. provides managed healthcare services under the Medicaid and Medicare programs, and through the state insurance marketplaces (the &#8220;Marketplace&#8221;). We currently have <ix:nonFraction unitRef="segment" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfMjI4_6925dc79-7402-4807-b44c-808fb9018835">four</ix:nonFraction> reportable segments consisting of: 1)&#160;Medicaid; 2)&#160;Medicare; 3)&#160;Marketplace; and 4)&#160;Other. Our reportable segments are consistent with how we currently manage the business and view the markets we serve. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, we served approximately <ix:nonFraction unitRef="member" contextRef="i8ed85c9690854763a35bee8fec51d9ff_I20220930" decimals="-5" name="moh:BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfNDY5_a264da09-3ad3-4a4b-871b-9f15f38033b6">5.2</ix:nonFraction>&#160;million members eligible for government-sponsored healthcare programs, located across <ix:nonFraction unitRef="state" contextRef="i8ed85c9690854763a35bee8fec51d9ff_I20220930" decimals="INF" name="moh:NumberOfStatesWithGovernmentSponsoredHealthcarePrograms" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfNTUw_5d155a2a-1e13-4490-9240-2bddd7711819">19</ix:nonFraction> states.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our state Medicaid contracts typically have terms of&#160;<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfNjE0_de89890f-e645-4a35-a3a8-f77327830d82">three</span>&#160;to&#160;<ix:nonNumeric contextRef="i7577c1358178462db84325596d1c3ae1_D20220101-20220930" name="moh:HealthPlanContractTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfNjIw_0f5daf5a-7f8a-465b-96ab-8cfb8ae02c55">five years</ix:nonNumeric>, contain renewal options exercisable by the state Medicaid agency, and allow either the state or the health plan to terminate the contract with or without cause. Such contracts are subject to risk of loss in states that issue requests for proposal (&#8220;RFPs&#8221;) open to competitive bidding by other health plans. If one of our health plans is not a successful responsive bidder to a state RFP, its contract may not be renewed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to contract renewal, our state Medicaid contracts may be periodically amended to include or exclude certain health benefits (such as pharmacy services, behavioral health services, or long-term care services); populations such as the aged, blind or disabled (&#8220;ABD&#8221;); and regions or service areas.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New York Acquisition&#8212;Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2022, we closed on our acquisition of the Medicaid Managed Long Term Care business of AgeWell New York. See Note 4, &#8220;Business Combinations,&#8221; for further information. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nebraska Procurement&#8212;Medicaid.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In September 2022, we announced that our Nebraska health plan had been selected by the Nebraska Department of Health and Human Services (DHHS) to provide health care services to Nebraskans under the state&#8217;s Medicaid managed care program. The new <ix:nonNumeric contextRef="i64ed765381cb451194df42962e56b1f0_D20220901-20220930" name="moh:HealthPlanContractTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfMTA5OTUxMTYzNjc3NQ_d63a53a8-319f-4ace-a0c9-23f463ea794e">five-year</ix:nonNumeric> contract is expected to begin on January 1, 2024, and may be extended for an additional <ix:nonNumeric contextRef="i64ed765381cb451194df42962e56b1f0_D20220901-20220930" name="moh:HealthPlanExtensionOptionPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfMTA5OTUxMTY0MTE2NQ_2bc7e775-d872-4cf7-b2ef-f9983674bbb6">two-years</ix:nonNumeric>.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Iowa Procurement&#8212;Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we announced that our Iowa health plan had been notified by the Iowa Department of Health and Human Services (HHS) of its intent to award a Medicaid managed care contract pursuant to the Request for Proposal issued by HHS on February 17, 2022. The new <ix:nonNumeric contextRef="ic4564dde8b7249e29348178f0f8c6242_D20220801-20220831" name="moh:HealthPlanContractTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfMTA5OTUxMTYzNjIzNQ_4005a6de-5d16-4cb2-adae-bc02c38d062e">four-year</ix:nonNumeric> contract is expected to begin on July 1, 2023, and may be extended for an additional <ix:nonNumeric contextRef="ic4564dde8b7249e29348178f0f8c6242_D20220801-20220831" name="moh:HealthPlanExtensionOptionPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfMTA5OTUxMTYzNjIzNg_648e4286-3e04-40e9-92bf-f953d06c4d8c">four years</ix:nonNumeric>. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">California Procurement&#8212;Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we announced that our California health plan had been notified by the California Department of Health Care Services of its intent to award a Medi-Cal contract in each of Los Angeles, Riverside, San Bernardino, Sacramento, and San Diego Counties. The  <ix:nonFraction unitRef="contract" contextRef="i2a0dfc53f05140aba2d6a2c5d9aaf8ed_I20220831" decimals="INF" name="moh:HealthPlanNumberOfContracts" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfMTA5OTUxMTY0MjExMA_e8ae8c6c-c010-4760-87e1-51fb47cc45b5">five</ix:nonFraction> Medi-Cal contracts are expected to commence on January 1, 2024, which enables us to continue serving Medi-Cal members in our existing counties and expand footprint with the addition of the Los Angeles County contract. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mississippi Procurement&#8212;Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we announced that our Mississippi health plan had been notified by the Mississippi Division of Medicaid (DOM) of its intent to award a Medicaid Coordinated Care Contract for its Mississippi Coordinated Access Program and Mississippi Children&#8217;s Health Insurance Program pursuant to the Request for Qualifications issued by DOM on December 10, 2021. The <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfMTA5OTUxMTY0MjE5OA_6c2d1c0d-cdab-4160-9874-52b55f757a29">four</span>-year contract is expected to begin on July 1, 2023, and may be extended for an additional <ix:nonNumeric contextRef="i832dd038bfde4b259f4caf8354280d4d_D20220801-20220831" name="moh:HealthPlanExtensionOptionPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfMTA5OTUxMTY0MTY4OA_789a53a6-8f38-4991-bbd1-07c82183c7d9">two years</ix:nonNumeric>. The award enables us to continue serving Medicaid members across the state. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wisconsin Acquisition &#8212; Medicaid and Medicare. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 13, 2022, we announced a definitive agreement to acquire substantially all the assets of My Choice Wisconsin (&#8220;MCW&#8221;).  The purchase price for the transaction is approximately $<ix:nonFraction unitRef="usd" contextRef="i88592161984e4e54bea14bf302d598e3_D20220713-20220713" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfMTE3NDI_649e0023-5e81-4232-93e8-e738bf90b152">150</ix:nonFraction>&#160;million, net of expected tax benefits and required regulatory capital, which we intend to fund with cash on hand. The transaction is subject to receipt of applicable federal and state regulatory approvals, and the satisfaction of other customary closing conditions. We currently expect the transaction to close in early 2023. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Texas Procurement&#8212;Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the Texas Health and Human Services Commission posted the ABD program (known in Texas as STAR+PLUS) RFP. We submitted our proposal in June 2022 to continue serving STAR+PLUS members, with awards estimated to be announced in the first quarter of 2023, and start of operations in February 2024. Further, in October 2022, the draft RFP was posted for the TANF and CHIP programs (known as </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September&#160;30, 2022 Form 10-Q | 7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_7">Table of Contents</a></span></div></div><ix:continuation id="i81f8a66420a34dc8905acc1c3910ebeb" continuedAt="i8caf14be400f405da514d2a7108c9a62"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the STAR &amp; CHIP programs, and both existing contracts for us), with awards expected in late Q4 2023 or early Q1 2024 and the start of operations in late Q4 2024 or early Q1 2025. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nevada Procurement&#8212;Medicaid.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our new contract in Clark and Washoe Counties commenced on January 1, 2022, and offers health coverage to TANF, CHIP and Medicaid Expansion beneficiaries. This new contract is <ix:nonNumeric contextRef="i80a687f2f90f401b9e47d7da8ba17754_D20210901-20210930" name="moh:HealthPlanContractTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfNTI2OA_d4e70471-5698-4903-8f3f-963bec46dbe7">four years</ix:nonNumeric>  with a potential <ix:nonNumeric contextRef="i80a687f2f90f401b9e47d7da8ba17754_D20210901-20210930" name="moh:HealthPlanExtensionOptionPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfNTI4NA_f2f9e63d-8625-420b-bbe0-5efceee040bc">two-year</ix:nonNumeric> extension.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Texas Acquisition&#8212;Medicaid and Medicare. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, we closed on our acquisition of Cigna Corporation&#8217;s Texas Medicaid and Medicare-Medicaid Plan (&#8220;MMP&#8221;) contracts, along with certain operating assets. See Note 4, &#8220;Business Combinations,&#8221; for further information. </span></div><ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="moh:ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfNTI1NA_2be90a50-8b90-49de-bce0-9665d1537e51" continuedAt="if29d437fc2564e86b6d7a73bee067329" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation and Interim Financial Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Molina Healthcare, Inc., and its subsidiaries. In the opinion of management, these financial statements reflect all normal recurring adjustments, which are considered necessary for a fair presentation of the results as of the dates and for the interim periods presented. All significant intercompany balances and transactions have been eliminated. The consolidated results of operations for the nine months ended September 30, 2022 are not necessarily indicative of the results for the entire year ending December&#160;31, 2022.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if29d437fc2564e86b6d7a73bee067329">The unaudited consolidated interim financial statements have been prepared under the assumption that users of the interim financial data have either read or have access to our audited consolidated financial statements for the fiscal year ended December&#160;31, 2021. Accordingly, certain disclosures that would substantially duplicate the disclosures contained in our December&#160;31, 2021, audited consolidated financial statements have been omitted. These unaudited consolidated interim financial statements should be read in conjunction with our audited consolidated financial statements for the fiscal year ended December&#160;31, 2021.</ix:continuation> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfNTI1NQ_feb55c4e-8f1c-42e0-9d2e-f380bf0ef31a" continuedAt="i52c8d658c89f49cebc9c08b027c3becd" escape="true">Use of Estimates</ix:nonNumeric></span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8caf14be400f405da514d2a7108c9a62"><ix:continuation id="i52c8d658c89f49cebc9c08b027c3becd">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</ix:continuation></ix:continuation> </span></div><div><span><br/></span></div><div id="icc83361866f7481797f2215c8aedaf24_34"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. <ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfNzc2MQ_d4811468-b22e-4fb5-9108-b0e84d366839" continuedAt="i71ce558c117041c2891d5ba31b2fab18" escape="true">Significant Accounting Policies</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:continuation id="i71ce558c117041c2891d5ba31b2fab18" continuedAt="id4d6eb7ffde1417896a4d5db45297708"> </ix:continuation></span></div><ix:continuation id="id4d6eb7ffde1417896a4d5db45297708" continuedAt="i3aeadd8de9f6455da0a3c71ac36cb9e4"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfNzc0MQ_264c0bf0-b099-4111-b7d6-c34139d217d2" continuedAt="i0b2b349f439b4c0995206260b5c0c801" escape="true">Cash and Cash Equivalents</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0b2b349f439b4c0995206260b5c0c801">Cash and cash equivalents consist of cash and short-term, highly liquid investments that are both readily convertible into known amounts of cash and have a maturity of three months or less on the date of purchase.</ix:continuation> <ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfNzc0Mg_cccec8d4-095d-494b-93a4-7028eec4bc1c" continuedAt="i0163eec3a3964970828d2cdd7393c61c" escape="true"><ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfNzc2Mg_b570197c-9cb3-4928-b701-ff50542d1e0d" continuedAt="ifc614da2aaca45d7ba4f14bd38ad6786" escape="true">The following table provides a reconciliation of cash and cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in &#8220;Restricted investments&#8221; in the accompanying consolidated balance sheets.</ix:nonNumeric></ix:nonNumeric></span></div><div style="text-align:center"><ix:continuation id="i0163eec3a3964970828d2cdd7393c61c"><ix:continuation id="ifc614da2aaca45d7ba4f14bd38ad6786"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOjlhNTU2MGUxZDZiZjRlYTk5ZTIzMjA3ZTdiNjMyMWVjL3RhYmxlcmFuZ2U6OWE1NTYwZTFkNmJmNGVhOTllMjMyMDdlN2I2MzIxZWNfNC0xLTEtMS01ODU5OA_b1020bfe-1e6c-472c-8408-ddaa469a3829">4,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5f8e83b346f4a789040e8611fbb11f6_I20210930" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOjlhNTU2MGUxZDZiZjRlYTk5ZTIzMjA3ZTdiNjMyMWVjL3RhYmxlcmFuZ2U6OWE1NTYwZTFkNmJmNGVhOTllMjMyMDdlN2I2MzIxZWNfNC0zLTEtMS01ODU5OA_68442557-0262-4487-9293-a1edd28eb3df">4,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOjlhNTU2MGUxZDZiZjRlYTk5ZTIzMjA3ZTdiNjMyMWVjL3RhYmxlcmFuZ2U6OWE1NTYwZTFkNmJmNGVhOTllMjMyMDdlN2I2MzIxZWNfNS0xLTEtMS01ODU5OA_18658ee0-47a6-40e5-9483-455e4e8cd955">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5f8e83b346f4a789040e8611fbb11f6_I20210930" decimals="-6" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOjlhNTU2MGUxZDZiZjRlYTk5ZTIzMjA3ZTdiNjMyMWVjL3RhYmxlcmFuZ2U6OWE1NTYwZTFkNmJmNGVhOTllMjMyMDdlN2I2MzIxZWNfNS0zLTEtMS01ODU5OA_b5af287c-a0be-4bc0-a181-9ae1fda646f3">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOjlhNTU2MGUxZDZiZjRlYTk5ZTIzMjA3ZTdiNjMyMWVjL3RhYmxlcmFuZ2U6OWE1NTYwZTFkNmJmNGVhOTllMjMyMDdlN2I2MzIxZWNfNi0xLTEtMS01ODU5OA_1a95315e-0f14-4870-b3cf-a1ec41e41345">4,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5f8e83b346f4a789040e8611fbb11f6_I20210930" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOjlhNTU2MGUxZDZiZjRlYTk5ZTIzMjA3ZTdiNjMyMWVjL3RhYmxlcmFuZ2U6OWE1NTYwZTFkNmJmNGVhOTllMjMyMDdlN2I2MzIxZWNfNi0zLTEtMS01ODU5OA_1a322e8f-9f87-40ba-9399-93a5dd380a18">4,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></ix:continuation></ix:continuation></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September&#160;30, 2022 Form 10-Q | 8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_7">Table of Contents</a></span></div></div><ix:continuation id="i3aeadd8de9f6455da0a3c71ac36cb9e4" continuedAt="i6ee344de16ce4da481602a1ef9098750"><ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="us-gaap:ReceivablesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfNzc2Mw_3f124e26-ec8b-4bcc-b266-76ee170c719f" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables consist primarily of premium amounts due from government agencies, which are subject to potential retroactive adjustments. Because substantially all of our receivable amounts are readily determinable and substantially all of our creditors are governmental authorities, our allowance for credit losses is insignificant. Any amounts determined to be uncollectible are charged to expense when such determination is made.</span></div></ix:nonNumeric><div><ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfNzc4NA_bbaf92c5-f3e5-4b7b-b086-c257ae60a1fb" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:72.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government receivables</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4a4422c70fb4ddfa9b1095fc58b9f0e_I20220930" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOjZiOGUxN2Q3MmJiYjRjODRiMzM1ZTNkNzMzMGQzMmY4L3RhYmxlcmFuZ2U6NmI4ZTE3ZDcyYmJiNGM4NGIzMzVlM2Q3MzMwZDMyZjhfMy0xLTEtMS01ODU5OA_de78910f-6309-477a-9fc2-56f8b294d90c">1,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1cd70f1c470416e9209148ce673af71_I20211231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOjZiOGUxN2Q3MmJiYjRjODRiMzM1ZTNkNzMzMGQzMmY4L3RhYmxlcmFuZ2U6NmI4ZTE3ZDcyYmJiNGM4NGIzMzVlM2Q3MzMwZDMyZjhfMy0zLTEtMS01ODU5OA_7bfeec8b-154e-4271-9d85-e6148c1ffca2">1,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy rebate receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib597d981d44b40f195e0cdd71848ddf5_I20220930" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOjZiOGUxN2Q3MmJiYjRjODRiMzM1ZTNkNzMzMGQzMmY4L3RhYmxlcmFuZ2U6NmI4ZTE3ZDcyYmJiNGM4NGIzMzVlM2Q3MzMwZDMyZjhfNC0xLTEtMS01ODU5OA_e7580b01-7e44-4035-9251-e1467d419592">290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8343c8068f1a4df093d799fc8ff37927_I20211231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOjZiOGUxN2Q3MmJiYjRjODRiMzM1ZTNkNzMzMGQzMmY4L3RhYmxlcmFuZ2U6NmI4ZTE3ZDcyYmJiNGM4NGIzMzVlM2Q3MzMwZDMyZjhfNC0zLTEtMS01ODU5OA_3482f884-7a15-4c83-8f3c-df6be9de1f34">276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dbb6f52c8d941e5b0f25c3d3e677cda_I20220930" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOjZiOGUxN2Q3MmJiYjRjODRiMzM1ZTNkNzMzMGQzMmY4L3RhYmxlcmFuZ2U6NmI4ZTE3ZDcyYmJiNGM4NGIzMzVlM2Q3MzMwZDMyZjhfNi0xLTEtMS01ODU5OA_88383034-2479-4aa1-a17c-080618c2f4dc">385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id139c6fc382249198e7f8ea8f0212f81_I20211231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOjZiOGUxN2Q3MmJiYjRjODRiMzM1ZTNkNzMzMGQzMmY4L3RhYmxlcmFuZ2U6NmI4ZTE3ZDcyYmJiNGM4NGIzMzVlM2Q3MzMwZDMyZjhfNi0zLTEtMS01ODU5OA_5c002712-e50a-41fa-9e5a-0bbc80befbe7">335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOjZiOGUxN2Q3MmJiYjRjODRiMzM1ZTNkNzMzMGQzMmY4L3RhYmxlcmFuZ2U6NmI4ZTE3ZDcyYmJiNGM4NGIzMzVlM2Q3MzMwZDMyZjhfOC0xLTEtMS01ODU5OA_5c06d05a-6b8b-4a8a-9954-ef22435e079d">2,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOjZiOGUxN2Q3MmJiYjRjODRiMzM1ZTNkNzMzMGQzMmY4L3RhYmxlcmFuZ2U6NmI4ZTE3ZDcyYmJiNGM4NGIzMzVlM2Q3MzMwZDMyZjhfOC0zLTEtMS01ODU5OA_62a4967c-2bb8-4a31-99da-f365079a0fb1">2,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></ix:nonNumeric></div><ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfNzc1OA_ea21a237-9a77-4941-979e-9a42141c7e0c" continuedAt="i0b4c5220c9924156b76df1cd13eadf60" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Premium Revenue Recognition and Amounts Due Government Agencies</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium revenue is generated from our contracts with state and federal agencies, in connection with our participation in the Medicaid, Medicare, and Marketplace programs. Premium revenue is generally received based on per member per month (&#8220;PMPM&#8221;) rates established in advance of the periods covered. These premium revenues are recognized in the month that members are entitled to receive healthcare services, and premiums collected in advance are deferred. State Medicaid programs and the federal Medicare program periodically adjust premium rates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain components of premium revenue are subject to accounting estimates and are described in further detail below, and in our 2021 Annual Report on Form 10-K, Note 2, &#8220;Significant Accounting Policies,&#8221; under &#8220;Contractual Provisions That May Adjust or Limit Revenue or Profit,&#8221; and &#8220;Quality Incentives.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Provisions That May Adjust or Limit Revenue or Profit</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0b4c5220c9924156b76df1cd13eadf60" continuedAt="i67c7ba2ed13144bf8271ea3adc57d78b">Many of our contracts contain provisions that may adjust or limit revenue or profit, as described below. Consequently, we recognize premium revenue as it is earned under such provisions.</ix:continuation> <ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="us-gaap:ReservesReportedToOtherAgenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfNzc3Ng_3d5938f1-559b-412a-85a8-d3eb4e85e455" continuedAt="ie961741fa571442da77c8a08e6d07620" escape="true">Liabilities accrued for premiums to be returned under such provisions are reported in the aggregate as &#8220;Amounts due government agencies,&#8221; in the accompanying consolidated balance sheets. </ix:nonNumeric></span></div><ix:continuation id="ie961741fa571442da77c8a08e6d07620"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth amounts due government agencies, categorized by program:</span></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid program:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR and profit sharing</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOmU3MzQwNTc1OTUzNTQ3OGRiZWQ5M2E1YzlkNDIwMWNhL3RhYmxlcmFuZ2U6ZTczNDA1NzU5NTM1NDc4ZGJlZDkzYTVjOWQ0MjAxY2FfNC0xLTEtMS01ODU5OA_56b222a6-152a-4f5c-8497-45210a293d33">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOmU3MzQwNTc1OTUzNTQ3OGRiZWQ5M2E1YzlkNDIwMWNhL3RhYmxlcmFuZ2U6ZTczNDA1NzU5NTM1NDc4ZGJlZDkzYTVjOWQ0MjAxY2FfNC0zLTEtMS01ODU5OA_754486af-9c5f-4296-9768-1c205929f142">1,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesMedicaidOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOmU3MzQwNTc1OTUzNTQ3OGRiZWQ5M2E1YzlkNDIwMWNhL3RhYmxlcmFuZ2U6ZTczNDA1NzU5NTM1NDc4ZGJlZDkzYTVjOWQ0MjAxY2FfNS0xLTEtMS01ODU5OA_12ed3215-bd34-4870-9738-c5a9c5233b0e">617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesMedicaidOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOmU3MzQwNTc1OTUzNTQ3OGRiZWQ5M2E1YzlkNDIwMWNhL3RhYmxlcmFuZ2U6ZTczNDA1NzU5NTM1NDc4ZGJlZDkzYTVjOWQ0MjAxY2FfNS0zLTEtMS01ODU5OA_c8d12000-7c21-479d-8a00-067652495d41">263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare program:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR and profit sharing </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOmU3MzQwNTc1OTUzNTQ3OGRiZWQ5M2E1YzlkNDIwMWNhL3RhYmxlcmFuZ2U6ZTczNDA1NzU5NTM1NDc4ZGJlZDkzYTVjOWQ0MjAxY2FfNy0xLTEtMS02ODE4OA_2f03b235-b3e2-416f-8614-9d4f6aa87580">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOmU3MzQwNTc1OTUzNTQ3OGRiZWQ5M2E1YzlkNDIwMWNhL3RhYmxlcmFuZ2U6ZTczNDA1NzU5NTM1NDc4ZGJlZDkzYTVjOWQ0MjAxY2FfNy0zLTEtMS02ODE4OA_26595bbf-2e08-43fd-a81b-df15c3e9d58e">101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk adjustment and Part D risk sharing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOmU3MzQwNTc1OTUzNTQ3OGRiZWQ5M2E1YzlkNDIwMWNhL3RhYmxlcmFuZ2U6ZTczNDA1NzU5NTM1NDc4ZGJlZDkzYTVjOWQ0MjAxY2FfNy0xLTEtMS01ODU5OA_34105bd1-9a9e-4921-8c9a-e97a8f11933c">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOmU3MzQwNTc1OTUzNTQ3OGRiZWQ5M2E1YzlkNDIwMWNhL3RhYmxlcmFuZ2U6ZTczNDA1NzU5NTM1NDc4ZGJlZDkzYTVjOWQ0MjAxY2FfNy0zLTEtMS01ODU5OA_5589b0c9-8003-45b8-a6cb-98838a9727ba">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="moh:OtherMedicareProgram" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOmU3MzQwNTc1OTUzNTQ3OGRiZWQ5M2E1YzlkNDIwMWNhL3RhYmxlcmFuZ2U6ZTczNDA1NzU5NTM1NDc4ZGJlZDkzYTVjOWQ0MjAxY2FfOS0xLTEtMS01ODU5OA_4cb1aa2a-3416-460a-a412-cc653ec9eb10">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="moh:OtherMedicareProgram" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOmU3MzQwNTc1OTUzNTQ3OGRiZWQ5M2E1YzlkNDIwMWNhL3RhYmxlcmFuZ2U6ZTczNDA1NzU5NTM1NDc4ZGJlZDkzYTVjOWQ0MjAxY2FfOS0zLTEtMS01ODU5OA_5a0c1469-68e4-4dcb-b06b-a36e56d61603">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace program:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="moh:AmountsDuetoGovernmentAgenciesRiskAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOmU3MzQwNTc1OTUzNTQ3OGRiZWQ5M2E1YzlkNDIwMWNhL3RhYmxlcmFuZ2U6ZTczNDA1NzU5NTM1NDc4ZGJlZDkzYTVjOWQ0MjAxY2FfMTEtMS0xLTEtNTg1OTg_7a495592-2a75-4802-a110-962f8a4e802e">179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="moh:AmountsDuetoGovernmentAgenciesRiskAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOmU3MzQwNTc1OTUzNTQ3OGRiZWQ5M2E1YzlkNDIwMWNhL3RhYmxlcmFuZ2U6ZTczNDA1NzU5NTM1NDc4ZGJlZDkzYTVjOWQ0MjAxY2FfMTEtMy0xLTEtNTg1OTg_512b15d8-5061-4a92-869e-23b27d798263">902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOmU3MzQwNTc1OTUzNTQ3OGRiZWQ5M2E1YzlkNDIwMWNhL3RhYmxlcmFuZ2U6ZTczNDA1NzU5NTM1NDc4ZGJlZDkzYTVjOWQ0MjAxY2FfMTItMS0xLTEtNTg1OTg_ab665e50-a125-4434-b795-3121214f4b81">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOmU3MzQwNTc1OTUzNTQ3OGRiZWQ5M2E1YzlkNDIwMWNhL3RhYmxlcmFuZ2U6ZTczNDA1NzU5NTM1NDc4ZGJlZDkzYTVjOWQ0MjAxY2FfMTItMy0xLTEtNTg1OTg_55d9b41c-1c3c-4f93-8c5a-947486db51ce">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="moh:AmountsDuetoGovernmentAgenciesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOmU3MzQwNTc1OTUzNTQ3OGRiZWQ5M2E1YzlkNDIwMWNhL3RhYmxlcmFuZ2U6ZTczNDA1NzU5NTM1NDc4ZGJlZDkzYTVjOWQ0MjAxY2FfMTMtMS0xLTEtNTg1OTg_87972f14-bc3c-41b0-a404-834d51bc2880">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="moh:AmountsDuetoGovernmentAgenciesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOmU3MzQwNTc1OTUzNTQ3OGRiZWQ5M2E1YzlkNDIwMWNhL3RhYmxlcmFuZ2U6ZTczNDA1NzU5NTM1NDc4ZGJlZDkzYTVjOWQ0MjAxY2FfMTMtMy0xLTEtNTg1OTg_6cb2832a-a073-49b2-ab6b-1b166463f3e8">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total amounts due government agencies</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="moh:MedicalPremiumLiabilityDueToAgency" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOmU3MzQwNTc1OTUzNTQ3OGRiZWQ5M2E1YzlkNDIwMWNhL3RhYmxlcmFuZ2U6ZTczNDA1NzU5NTM1NDc4ZGJlZDkzYTVjOWQ0MjAxY2FfMTUtMS0xLTEtNTg1OTg_9864d582-4ae8-499c-a344-910305ca9e59">2,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="moh:MedicalPremiumLiabilityDueToAgency" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOmU3MzQwNTc1OTUzNTQ3OGRiZWQ5M2E1YzlkNDIwMWNhL3RhYmxlcmFuZ2U6ZTczNDA1NzU5NTM1NDc4ZGJlZDkzYTVjOWQ0MjAxY2FfMTUtMy0xLTEtNTg1OTg_0abb2dbe-a9aa-437a-aa9d-b4bbf7bf7171">2,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div></ix:continuation><ix:continuation id="i67c7ba2ed13144bf8271ea3adc57d78b" continuedAt="ic715e8f2319448ceb0890cbdaec17108"><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicaid Program</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Minimum MLR and Retroactive Premium Adjustments. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State Medicaid programs periodically adjust premium rates on a retroactive basis. In these cases, we adjust our premium revenue in the period in which we determine that the adjustment is probable and reasonably estimable, based on our best estimate of the ultimate premium we expect to realize for the period being adjusted. </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September&#160;30, 2022 Form 10-Q | 9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_7">Table of Contents</a></span></div></div><ix:continuation id="i6ee344de16ce4da481602a1ef9098750"><ix:continuation id="ic715e8f2319448ceb0890cbdaec17108" continuedAt="id9ef1be545364f0cb75a07516e4bed3c"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2020, various states enacted temporary risk corridors in response to the reduced demand for medical services stemming from COVID-1</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which have resulted in a reduction of our medical margin. In some cases, these risk corridors were retroactive to earlier periods in 2020, or as early as the beginning of the states&#8217; fiscal years in 2019. Since the second quarter of 2020, we have recognized risk corridors that we believe to be probable, and where the ultimate premium amount is reasonably estimable. For the three and nine months ended September 30, 2022, we recognized approximately $<ix:nonFraction unitRef="usd" contextRef="i4f40864acf524f78958e876e105a300f_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInPremiumsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfMzU0NA_88fe5816-427b-4d0a-9079-1f5244b59212">34</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i4bd869502a4d4c3db24a30f94752e48f_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInPremiumsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfMzU1MQ_55542289-0794-478d-81ae-def8941e7f9c">156</ix:nonFraction>&#160;million, respectively, related to such risk corridors, primarily in the Medicaid segment, compared to $<ix:nonFraction unitRef="usd" contextRef="i27e41e19da6946b9947bc20349bd2d6a_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInPremiumsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfMzY0OA_497b6ac3-0832-4c13-86d7-ec39672cac3d">17</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i6507e164e60348edb5cc46669f1a17c3_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInPremiumsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfMzY1NQ_401d286b-4db2-42b6-9dde-eda526b4242e">183</ix:nonFraction>&#160;million, respectively, recognized in the three and nine months ended September&#160;30, 2021. The decrease is due to the elimination of several of the COVID-19 risk corridors. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that certain states could change the structure of existing risk corridors, implement new risk corridors in the future or discontinue existing risk corridors. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Marketplace Program</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="id9ef1be545364f0cb75a07516e4bed3c" continuedAt="i39589d53c0c84cd4b354617c0d48d63d">Risk Adjustment.</ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i39589d53c0c84cd4b354617c0d48d63d"> Under this program, our health plans&#8217; composite risk scores are compared with the overall average risk score for the relevant state and market pool. Generally, our health plans will make a risk adjustment payment into the pool if their composite risk scores are below the average risk score (risk adjustment payable), and will receive a risk adjustment payment from the pool if their composite risk scores are above the average risk score (risk adjustment receivable). We estimate our ultimate premium based on insurance policy year-to-date experience, and recognize estimated premiums relating to the risk adjustment program as an adjustment to premium revenue in our consolidated statements of income.</ix:continuation> As of September&#160;30, 2022, Marketplace risk adjustment payables amounted to $<ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfNTA0MQ_cae11889-f62e-4ad2-9f59-f636c1d7a20e">179</ix:nonFraction> million and related receivables amounted to $<ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfNTA4MA_77831c30-7347-4347-8ff1-da7d24bc3cbd">94</ix:nonFraction> million, for a net payable of $<ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfNTEwNQ_75c6b22c-b76d-43f6-8388-936dba66b8cd">85</ix:nonFraction> million. As of December&#160;31, 2021, Marketplace risk adjustment payables amounted to $<ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfNTE2OA_1d1da0b7-be4c-453e-9d99-830470e72179">902</ix:nonFraction> million and related receivables amounted to $<ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfNTIwNw_4b9002f1-d1e8-49ed-a519-04dbab9aab4c">7</ix:nonFraction> million, for a net payable of $<ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfNTIzMg_2855360a-1aee-4fab-88f7-90c7d1d02cb1">895</ix:nonFraction> million. </span></div><ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfNzc3Mg_4e6b864c-9037-4590-99d1-2a4316918233" escape="true"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than <ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="moh:InvestmentsMaturityPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfNTg1OA_d04ac147-7ea4-4550-918d-6e620650868b">15</ix:nonNumeric> years, or less than <ix:nonNumeric contextRef="i9caa39ee3eca46f2935a54a04a4c6a37_D20220101-20220930" name="moh:InvestmentsAverageMaturityPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfNTg3NQ_f7df4e6c-7e46-4706-bcbf-a582ba7e315c">15</ix:nonNumeric> years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents, and U.S. Treasury securities. Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and governments of each state in which our health plan subsidiaries operate.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfNzc0Nw_877dfea6-69e1-490d-909a-d7fceb0b7ee8" escape="true"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is determined using an estimated annual effective tax rate, which generally differs from the U.S.&#160;federal statutory rate primarily because of foreign and state taxes, and nondeductible expenses such as certain compensation and other general and administrative expenses.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate may be subject to fluctuations during the year as new information is obtained. Such information may affect the assumptions used to estimate the annual effective tax rate, including projected pretax earnings, the mix of pretax earnings in the various tax jurisdictions in which we operate, valuation allowances against deferred tax assets, the recognition or the reversal of the recognition of tax benefits related to uncertain tax positions, and changes in or the interpretation of tax laws in jurisdictions where we conduct business. We recognize deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of our assets and liabilities, along with net operating loss and tax credit carryovers.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfNzc0NA_a0e6dab8-7f78-4039-92c2-992fb3891462" escape="true"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (&#8220;SEC&#8221;) did not have, nor does management expect such pronouncements to have, a significant impact on our present or future consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September&#160;30, 2022 Form 10-Q | 10</span></div></div></div><div id="icc83361866f7481797f2215c8aedaf24_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. <ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RleHRyZWdpb246N2U3ZTBlMzJkZGQ2NGUyMmJiYTM2ZjE4M2RlZGI2ZTNfMzEy_424c156d-211e-44f7-974e-05c4630e3dc2" continuedAt="i5cc65f65cfac443d898746b5b344887d" escape="true">Net Income Per Share </ix:nonNumeric></span></div><ix:continuation id="i5cc65f65cfac443d898746b5b344887d"><ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RleHRyZWdpb246N2U3ZTBlMzJkZGQ2NGUyMmJiYTM2ZjE4M2RlZGI2ZTNfMzEw_c539fabc-9005-4cf3-9cd4-0b6ad681c094" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the calculation of basic and diluted net income per share:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except net income per share)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfNS0xLTEtMS01ODU5OA_8592a340-c9b4-49d0-a240-e32504dbe30e">230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfNS0zLTEtMS01ODU5OA_9ffa7bb4-1c61-4654-bf20-b2597283a477">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfNS01LTEtMS01ODU5OA_59ab63a3-a7e6-4322-9910-5527c25b7a84">736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfNS03LTEtMS01ODU5OA_dd172ccb-b551-40fc-be28-9778c16b2b64">556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares outstanding at the beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4ff0d3fa206d42d891fbf8e9323bc625_I20220630" decimals="-5" name="moh:SharesOutstandingExcludingRestrictedStockAwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfNy0xLTEtMS01ODU5OA_77d65921-2d26-4c03-b47c-e94eb572019f">57.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5995f351e20f4535ba42664bfb529a7e_I20210630" decimals="-5" name="moh:SharesOutstandingExcludingRestrictedStockAwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfNy0zLTEtMS01ODU5OA_7c0e661f-1fae-474d-b729-61e45edddd51">57.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-5" name="moh:SharesOutstandingExcludingRestrictedStockAwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfNy01LTEtMS01ODU5OA_1e834812-b88b-41a7-a29d-319dfd0aa879">57.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a1055b0f36c4bbd91048d943dbf64df_I20201231" decimals="-5" name="moh:SharesOutstandingExcludingRestrictedStockAwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfNy03LTEtMS01ODU5OA_775d8400-c3b4-4fab-88e0-ac3c9a922232">58.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average number of shares issued:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="-5" name="moh:WeightedAverageNumberofSharesShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfOS0xLTEtMS01ODU5OA_8f3ceced-0d09-4fcf-9ba5-0e7f108df7de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="-5" name="moh:WeightedAverageNumberofSharesShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfOS0zLTEtMS01ODU5OA_95465dad-f3e9-4663-aa3f-a1dc4e058b77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-5" name="moh:WeightedAverageNumberofSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfOS01LTEtMS01ODU5OA_69a60b81-f14d-4e01-8baf-1fa55206437e">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-5" name="moh:WeightedAverageNumberofSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfOS03LTEtMS01ODU5OA_734a4ce8-38dc-46e1-b875-a44fd670466b">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTAtMS0xLTEtNTg1OTg_c24ab5b9-3abd-4826-b2b6-60bc905f4d84">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTAtMy0xLTEtNTg1OTg_58a79c8c-7464-4291-9e16-da0a0742c6a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTAtNS0xLTEtNTg1OTg_c794a44a-8460-41d9-b12c-c3a5be146b22">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTAtNy0xLTEtNTg1OTg_6b705bf1-f813-4cdd-9dba-dae524752a6f">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator for basic net income per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTEtMS0xLTEtNTg1OTg_2ea17dfb-a82b-4181-bf0d-5c1a7a93464f">57.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTEtMy0xLTEtNTg1OTg_7c2f6c3f-4994-4e43-be99-5ce1ec84119a">57.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTEtNS0xLTEtNTg1OTg_534a8403-3034-48e0-90e9-6fe4dbc7e334">57.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTEtNy0xLTEtNTg1OTg_0f25cab5-a598-42a2-b5ec-ec2328ee475c">57.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTMtMS0xLTEtNTg1OTg_f4eac754-66e6-4d18-9dcf-40f4deb6c353">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTMtMy0xLTEtNTg1OTg_590bae06-0f5c-43e8-9bbc-87826701e955">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTMtNS0xLTEtNTg1OTg_dc6c46ca-3ea2-4d33-974d-1bf9bd3fdf29">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTMtNy0xLTEtNTg1OTg_19015799-d3e5-473f-8ee6-3122053d7858">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator for diluted net income per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTUtMS0xLTEtNTg1OTg_c9f52d9f-31f2-48f4-a43f-4ca437f722ee">58.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTUtMy0xLTEtNTg1OTg_02329321-c149-4739-bcfd-87601e677d35">58.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTUtNS0xLTEtNTg1OTg_5687c933-9fa4-4703-ac9d-047584c051eb">58.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTUtNy0xLTEtNTg1OTg_3f32158a-6695-4dd3-b95d-0a1706e354a8">58.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Basic </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTctMS0xLTEtNTg1OTg_65a52cf1-2c34-4802-bafa-9721bcb44806">4.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTctMy0xLTEtNTg1OTg_4e876984-71a1-48af-b2c5-3868fda004af">2.49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTctNS0xLTEtNTg1OTg_12193d8b-6af4-48bb-83a7-5e59f16ec86f">12.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTctNy0xLTEtNTg1OTg_3fba9436-4189-4d65-b0e0-5b3ad8db9014">9.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Diluted </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTgtMS0xLTEtNTg1OTg_b751b4f8-c794-4b5d-92b2-8dccea84d474">3.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTgtMy0xLTEtNTg1OTg_55864f86-8b8d-46bc-af14-78d1bbaee2b4">2.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTgtNS0xLTEtNTg1OTg_109a0746-dd1b-45a3-9a9f-05defd69a3a0">12.58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTgtNy0xLTEtNTg1OTg_c5385999-f8cc-4562-9844-e5ded1702bde">9.51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Source data for calculations in thousands.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160; </span></div><div id="icc83361866f7481797f2215c8aedaf24_40"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. <ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80MC9mcmFnOjU0MjA4OTE0MTRmMjQyYTg5OGVjYmIxNGVlZWRmODUzL3RleHRyZWdpb246NTQyMDg5MTQxNGYyNDJhODk4ZWNiYjE0ZWVlZGY4NTNfMTI0NA_7b7b5fbd-846f-4611-af80-878966e91bd1" continuedAt="if4c2add672fe49df94ffbf969d9c69bb" escape="true">Business Combinations</ix:nonNumeric></span></div><ix:continuation id="if4c2add672fe49df94ffbf969d9c69bb" continuedAt="id2ea1600c4e140d7b77979a1f9eaa2b9"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AgeWell.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As described in Note 1, &#8220;Organization and Basis of Presentation,&#8221; we announced this acquisition closed on October 1, 2022. Because the closing date fell on a weekend, the $<ix:nonFraction unitRef="usd" contextRef="icbfe7220cac34928b948892e17e59eda_D20220930-20220930" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80MC9mcmFnOjU0MjA4OTE0MTRmMjQyYTg5OGVjYmIxNGVlZWRmODUzL3RleHRyZWdpb246NTQyMDg5MTQxNGYyNDJhODk4ZWNiYjE0ZWVlZGY4NTNfMjIxOQ_2492b22e-250d-40c7-816a-b91909fd11f6">134</ix:nonFraction>&#160;million purchase price was paid on September 30, 2022 and was recorded to prepaid expenses and other assets. Such amounts are reported in investing activities in the accompanying consolidated statements of cash flows. The initial accounting for this transaction is incomplete. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cigna. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, we closed on our acquisition of Cigna Corporation&#8217;s Texas Medicaid and Medicare-Medicaid Plan contracts, along with certain operating assets, for purchase consideration of approximately $<ix:nonFraction unitRef="usd" contextRef="i304daf24495747efa3683f468f95e408_D20220101-20220101" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80MC9mcmFnOjU0MjA4OTE0MTRmMjQyYTg5OGVjYmIxNGVlZWRmODUzL3RleHRyZWdpb246NTQyMDg5MTQxNGYyNDJhODk4ZWNiYjE0ZWVlZGY4NTNfMjI1_00b74921-4be3-46cf-aaab-e63d4ae6d7f6">60</ix:nonFraction>&#160;million. We acquired membership and a provider network with a preliminary fair value of approximately $<ix:nonFraction unitRef="usd" contextRef="idc61f272749348f58770423142c1f016_D20220101-20220101" decimals="-6" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80MC9mcmFnOjU0MjA4OTE0MTRmMjQyYTg5OGVjYmIxNGVlZWRmODUzL3RleHRyZWdpb246NTQyMDg5MTQxNGYyNDJhODk4ZWNiYjE0ZWVlZGY4NTNfMjE5OTAyMzI1ODIwMw_554c5f91-5d87-45e2-a390-5276044dc09f">36</ix:nonFraction>&#160;million. We allocated the remaining $<ix:nonFraction unitRef="usd" contextRef="i304daf24495747efa3683f468f95e408_D20220101-20220101" decimals="-6" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80MC9mcmFnOjU0MjA4OTE0MTRmMjQyYTg5OGVjYmIxNGVlZWRmODUzL3RleHRyZWdpb246NTQyMDg5MTQxNGYyNDJhODk4ZWNiYjE0ZWVlZGY4NTNfMzUz_a5d9bf49-1929-48c1-9ff0-900b79289e10">24</ix:nonFraction> million of purchase consideration to goodwill, primarily in the Medicaid segment, which relates to future economic benefits arising from expected synergies from the use of our existing infrastructure to support the added membership, and from the assembled workforce. The goodwill is deductible for income tax purposes. </span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="id2ea1600c4e140d7b77979a1f9eaa2b9" continuedAt="i9bdd17e5fdbd478cb5a7d1254c2607fc">Affinity. </ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9bdd17e5fdbd478cb5a7d1254c2607fc">On October 25, 2021, we closed on our acquisition of substantially all of the assets of Affinity Health Plan, Inc., a Medicaid health plan in New York, for initial purchase consideration of approximately $<ix:nonFraction unitRef="usd" contextRef="if7af8f685cdb4a2d91d3b3aae5939f99_D20211025-20211025" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80MC9mcmFnOjU0MjA4OTE0MTRmMjQyYTg5OGVjYmIxNGVlZWRmODUzL3RleHRyZWdpb246NTQyMDg5MTQxNGYyNDJhODk4ZWNiYjE0ZWVlZGY4NTNfODgy_e18295c7-9556-46c7-9fc9-9a9576bd890d">176</ix:nonFraction>&#160;million. In the nine months ended September 30, 2022, we recorded various measurement period adjustments, including an increase of $<ix:nonFraction unitRef="usd" contextRef="i54a931e10c744083ad5d1a9a95d0e7f7_D20220101-20220930" decimals="-6" name="moh:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80MC9mcmFnOjU0MjA4OTE0MTRmMjQyYTg5OGVjYmIxNGVlZWRmODUzL3RleHRyZWdpb246NTQyMDg5MTQxNGYyNDJhODk4ZWNiYjE0ZWVlZGY4NTNfOTc0_b3cda912-5395-4d58-adc6-50ccde39922c">8</ix:nonFraction>&#160;million to &#8220;Medical claims and benefits payable,&#8221; and an increase of $<ix:nonFraction unitRef="usd" contextRef="i54a931e10c744083ad5d1a9a95d0e7f7_D20220101-20220930" decimals="-6" name="moh:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80MC9mcmFnOjU0MjA4OTE0MTRmMjQyYTg5OGVjYmIxNGVlZWRmODUzL3RleHRyZWdpb246NTQyMDg5MTQxNGYyNDJhODk4ZWNiYjE0ZWVlZGY4NTNfMTAzOA_a1a49a14-4f73-4418-9668-1dde5a540003">1</ix:nonFraction>&#160;million to &#8220;Receivables&#8221; net of &#8220;Amounts due government agencies.&#8221; In the aggregate, we recorded a net increase of $<ix:nonFraction unitRef="usd" contextRef="i54a931e10c744083ad5d1a9a95d0e7f7_D20220101-20220930" decimals="-6" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80MC9mcmFnOjU0MjA4OTE0MTRmMjQyYTg5OGVjYmIxNGVlZWRmODUzL3RleHRyZWdpb246NTQyMDg5MTQxNGYyNDJhODk4ZWNiYjE0ZWVlZGY4NTNfMTE0OA_fd1fc824-4aac-4391-abdd-cd241a522dd6">7</ix:nonFraction>&#160;million to goodwill for these measurement period adjustments and various purchase price adjustments.</ix:continuation> </span></div><div style="margin-top:6pt"><span><br/></span></div><div id="icc83361866f7481797f2215c8aedaf24_43"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. <ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RleHRyZWdpb246MzZiM2FiNDY1OGFkNDdkZjhmNWY5ZTA4ODk2OWMwY2RfMjYzNA_15fd9d80-070b-4bfd-88ea-2f0f79d74dec" continuedAt="i3072d6aff3894dc4b433fdab393eaa53" escape="true">Fair Value Measurements </ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3072d6aff3894dc4b433fdab393eaa53" continuedAt="ia1a6344214a8480d80a2dd98822a38b6">We consider the carrying amounts of current assets and current liabilities to approximate their fair values because of the relatively short period of time between the origination of these instruments and their expected realization or payment. For our financial instruments measured at fair value on a recurring basis, we prioritize the inputs used in measuring fair value according to the three-tier fair value hierarchy. For a description of the methods and assumptions used to: a) estimate the fair value; and b) determine the classification according to the fair value </ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September&#160;30, 2022 Form 10-Q | 11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_7">Table of Contents</a></span></div></div><ix:continuation id="ia1a6344214a8480d80a2dd98822a38b6" continuedAt="i9adef6e61ece4b7aaae6ca9a67946403"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hierarchy for each financial instrument, refer to our 2021 Annual Report on Form 10-K, Note 5, &#8220;Fair Value Measurements.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net changes in fair value of Level 3 financial instruments are reported in &#8220;Other&#8221; operating expenses in our consolidated statements of income. In the nine months ended September 30, 2022 and 2021, we recognized a loss of $<ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RleHRyZWdpb246MzZiM2FiNDY1OGFkNDdkZjhmNWY5ZTA4ODk2OWMwY2RfODc3_d5bb701b-c789-4b17-8d00-fbcc5d40dbb5">4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RleHRyZWdpb246MzZiM2FiNDY1OGFkNDdkZjhmNWY5ZTA4ODk2OWMwY2RfODg0_83ee66ad-8f22-44c7-853c-b9dde12139c3">3</ix:nonFraction>&#160;million, respectively, for the increase in the fair value of the contingent consideration liabilities described below.</span></div><ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RleHRyZWdpb246MzZiM2FiNDY1OGFkNDdkZjhmNWY5ZTA4ODk2OWMwY2RfMjYyNQ_65781979-39f7-4b78-8591-498053150534" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments measured at fair value on a recurring basis at September&#160;30, 2022, were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Directly or Indirectly Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(Level 3)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d38d8c7935408fa0af30bea62c9c0f_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfNC0xLTEtMS01ODU5OA_99d12320-3805-49ca-860b-823e029c463f">2,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99e503b9ded046b2afc06e32c386be06_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfNC0zLTEtMS01ODU5OA_8fd4d5ae-b32b-4e1b-847d-0c810c97f9d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950dd07f9ee54e9ba07c4dcd9f68f6bf_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfNC01LTEtMS01ODU5OA_4380f31e-8f95-4b0e-8a94-4370fae7237c">2,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0350794e08ab4b36a1ac51538215ba52_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfNC03LTEtMS01ODU5OA_0c7b63cc-8321-447f-b1d8-6392aa0af7e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1115ede7452a40c1914f7984dbb1b080_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfNS0xLTEtMS01ODU5OA_e7bd9472-5006-49f1-86a2-26cabef42d30">743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6df1fa1ed0d04f3e8713afe89886bc9a_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfNS0zLTEtMS01ODU5OA_52a0ab3d-b39e-4832-824f-54d98acb162c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dcbde7850b84d7aacf9b339a9622cde_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfNS01LTEtMS01ODU5OA_e98ce094-cb73-43fc-853b-ab19c5535e53">743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15df11d145d34fffaa859bf80bdfc980_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfNS03LTEtMS01ODU5OA_25101d8c-3fbd-4c75-8632-f0c90af8aa91">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56ac79c2434a4a848f5a258701b2729d_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfNi0xLTEtMS01ODU5OA_31aba3fa-f674-454a-a20b-9ce97f37c0d7">303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71f0d1fdbe7447868ed74e5f69926324_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfNi0zLTEtMS01ODU5OA_b33bdd48-3a3a-4e03-86b3-90bc44354e0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i164adb7da96e462788cd4e44a57cc798_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfNi01LTEtMS01ODU5OA_84c3e371-b7b7-4b57-817c-b80abc94bda6">303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibca4b67f345a40a898863f3cc798be1f_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfNi03LTEtMS01ODU5OA_08ab62c6-49f5-4254-818a-d77b832982dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89c330693cd24ca895c0f7f61021a016_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfNy0xLTEtMS01ODU5OA_30484057-aa54-42f6-a018-2fb662ed1496">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fc1ad95c96a4d70b55ac85d939aa4b3_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfNy0zLTEtMS01ODU5OA_6ca527f2-9ce8-4dac-90b6-3f404ae017a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d2c3542c7de425cb80651f619d775c6_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfNy01LTEtMS01ODU5OA_4494fbcb-ec66-4a1c-8b0b-e0a9d6f49fae">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice50ff36424e47d78d882897177a7ed7_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfNy03LTEtMS01ODU5OA_a10a0fd6-2a1a-4473-b1fb-90d22bcf04b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic927869e96d94755b6560a3286b613c8_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfOC0xLTEtMS01ODU5OA_00bb375d-b4e2-4be7-8226-76d248e656c2">116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5331694495d843a4bf88a8892738d1e9_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfOC0zLTEtMS01ODU5OA_c852c97f-1a22-4b5b-904d-fe5ef7440c64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c2dbf685f2c45e58cd349ed403d70e8_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfOC01LTEtMS01ODU5OA_078c2079-8a4e-469c-9ffa-247d012ce15a">116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50d78ee64ba8431dacba700dd2a8bdbf_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfOC03LTEtMS01ODU5OA_eec75060-c0d4-4628-8e44-1fc37bdc2a89">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95e6b6b2720412788aaa02f055f8e57_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfMTItMS0xLTEtNTg1OTg_2b07fbb7-6bd5-4170-a523-9e40b4eff08c">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie087b593b0544c8399e87f02d57c34f2_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfMTItMy0xLTEtNTg1OTg_46282029-28ca-40e6-8dc7-c2b8ec3991b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51b54536f2594623b231d19ba7ca1a3d_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfMTItNS0xLTEtNTg1OTg_10a8a72e-b009-41f7-bb32-09f1a981ec68">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd1da81e23914a71942537034bdbd756_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfMTItNy0xLTEtNTg1OTg_2baff6b2-1ffe-4089-bc84-a4dffab4d2d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfMTMtMS0xLTEtNTg1OTg_7e7d12fe-958a-4a31-b866-27405070ab44">3,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc33e78bc16f451cbbfd17b41149f635_I20220930" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfMTMtMy0xLTEtNTg1OTg_e29e27b4-271a-4c51-9136-ffdf7e3267c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e214513a58b4f5a9acb2468d174594b_I20220930" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfMTMtNS0xLTEtNTg1OTg_c8bd82e7-b8a0-428a-ac84-a75a814d2154">3,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d6c05f8ebb14ba2abafe737776caa0d_I20220930" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfMTMtNy0xLTEtNTg1OTg_80eab825-a679-4ff1-9008-842dc3461273">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfMTUtMS0xLTEtNTg1OTg_fe8937e9-7e1a-4867-9e73-e9f07d31abf1">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc33e78bc16f451cbbfd17b41149f635_I20220930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfMTUtMy0xLTEtNTg1OTg_b0164977-efdd-43f7-8f46-aede4f5d6395">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e214513a58b4f5a9acb2468d174594b_I20220930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfMTUtNS0xLTEtNTg1OTg_489161f8-3520-41e7-a328-cf25d8eaca29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if45c5ec7debc4e2298c33d69169aae1b_I20220930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfMTUtNy0xLTEtNTg1OTg_7125b16e-b800-494d-a890-e0a7d974e2ec">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfMTYtMS0xLTEtNTg1OTg_b2ee4c8e-639c-4b2b-afed-3355b388ef11">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc33e78bc16f451cbbfd17b41149f635_I20220930" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfMTYtMy0xLTEtNTg1OTg_9b835db7-a439-4b0b-a974-4625577b5872">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e214513a58b4f5a9acb2468d174594b_I20220930" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfMTYtNS0xLTEtNTg1OTg_a55467c9-25d1-4b3a-a7d9-09029e006b0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d6c05f8ebb14ba2abafe737776caa0d_I20220930" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfMTYtNy0xLTEtNTg1OTg_02f8be23-cf15-4080-8e55-ad716c00c956">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments measured at fair value on a recurring basis at December&#160;31, 2021, were as follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Directly or Indirectly Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib564c222a94b4914a72dc2e0ec855b08_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfNC0xLTEtMS01ODU5OA_c2da30bf-cda1-43b6-b406-f087a668b643">1,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12ad09b4f8ea44969f6dd60429d526fb_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfNC0zLTEtMS01ODU5OA_d073f755-a0cb-4958-9fe9-ae3c8d01f421">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3b352b10300485c87431f796047c44f_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfNC01LTEtMS01ODU5OA_4d23e346-b17a-48b7-bb88-92c8b984a886">1,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0e7c52b9c5349f8bffbe5f1faf3f147_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfNC03LTEtMS01ODU5OA_48de6917-b7b6-43ac-9de0-dba6bd22eca7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i736beb8bf714488bb38d432dfc0890b4_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfNS0xLTEtMS01ODU5OA_45a3a6d1-7ed4-497a-8f6c-c9116bf2a52c">614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d240d4e03e64770aff2769aaa40f08a_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfNS0zLTEtMS01ODU5OA_f3622b4c-2c54-4b43-88ea-489eee610a17">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aa389c40f6a42229f5941193027a3ab_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfNS01LTEtMS01ODU5OA_f5d122a4-961a-4dec-b79a-1129cfe5682b">614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73fb739837584de6b651f049cc43ad72_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfNS03LTEtMS01ODU5OA_50518a36-da92-4777-84cd-35ef08e1a53a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ba2d36cfa1140b1984c163783c2d57a_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfNi0xLTEtMS01ODU5OA_ad3cbcef-3077-494c-b622-191b26d6191b">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f77531e7d74403b8efb3fc5faf7b062_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfNi0zLTEtMS01ODU5OA_353c90f2-7005-4332-b72e-16c2c4d81c41">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52539c799fb64d0eb14c78750d80da4d_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfNi01LTEtMS01ODU5OA_d9a68d11-d1af-4fbe-ac5f-b1a05abd3d78">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5856f1b277e43efad233155501d11a8_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfNi03LTEtMS01ODU5OA_d373c251-c021-4174-9ba3-6db6ff93cdef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d4d9de95590481dad9718e28b15a44b_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfNy0xLTEtMS01ODU5OA_68a1f8cf-5ac1-47b7-a2fb-9ac4c7b21f56">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if802abab93b446539c01d453d4296995_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfNy0zLTEtMS01ODU5OA_78a0a188-5fde-46dc-8da8-93bc72592d84">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4bfd6a6e384d5aa22561a59e8cbecf_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfNy01LTEtMS01ODU5OA_beb3e7ac-4a8c-41d9-981b-7c9fad262b72">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7d8648b1c445ab828552784316706f_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfNy03LTEtMS01ODU5OA_ba5e4221-f571-4140-a927-71df28b150f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic30b2001e92f42a0889f7aa593c567f1_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfOC0xLTEtMS01ODU5OA_59dae377-932a-4aac-8d9b-7df9cfe5f303">353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55ac2e82cfc843eb861e766012517f6d_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfOC0zLTEtMS01ODU5OA_dbdc876d-145e-4169-949c-c64fbca65326">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie507227240b34d9a9c9e73630984e2b4_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfOC01LTEtMS01ODU5OA_68b18119-1e15-4645-8ea6-3b58dd2eb192">353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bdb0cb65c134e058441720032db3ad6_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfOC03LTEtMS01ODU5OA_0ac40235-4069-46ea-99a8-bcdb18dec6ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0781e4f6fe144460945ffc19971a5b88_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfMTEtMS0xLTEtNTg1OTg_d4ca08ad-564c-45d5-9499-12972524f2bb">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10c0362a739347dfa9baf8391b5ebcf5_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfMTEtMy0xLTEtNTg1OTg_8f287eb6-fa13-4ae1-a9e1-e7055e52692f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic41dd5a8ce43444caa047c867c1a7d68_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfMTEtNS0xLTEtNTg1OTg_0e690063-9134-4afb-8b3b-a70010d62bb7">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i025b5d81cf3b4ab089c2cfb73ed7fde2_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfMTEtNy0xLTEtNTg1OTg_d1fa3948-31ae-4acb-87e7-bc3a75ec07cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfMTItMS0xLTEtNTg1OTg_78239e5d-68d7-4c3f-9684-d5d1ecf02f97">3,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e9b92c4cf3944d6bcffae91f86005e4_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfMTItMy0xLTEtNTg1OTg_dfb8b1f1-c243-46ae-8fd3-4d0d3992613a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b0e199731ea42a99e977bd922403d3b_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfMTItNS0xLTEtNTg1OTg_0d321bca-b910-4ad7-b38d-b3020e789166">3,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i786c434041fb4ace8a427a0d0e1e025f_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfMTItNy0xLTEtNTg1OTg_50d1e6b9-cc32-4d8b-9b8d-4d1719f3445c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfMTQtMS0xLTEtNTg1OTg_29d3f9ba-f2ab-4525-bb9e-ca8c0d735f6c">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e9b92c4cf3944d6bcffae91f86005e4_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfMTQtMy0xLTEtNTg1OTg_5d0f8899-08d5-4dff-bd17-42459d42bdc1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b0e199731ea42a99e977bd922403d3b_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfMTQtNS0xLTEtNTg1OTg_48929734-25b5-4ace-9e48-f1a34a14ed31">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i786c434041fb4ace8a427a0d0e1e025f_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfMTQtNy0xLTEtNTg1OTg_c5995e19-8739-4acb-bbd3-ea9242948531">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfMTUtMS0xLTEtNTg1OTg_0a42cd7c-c5d1-40e9-aacc-0519718581a3">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e9b92c4cf3944d6bcffae91f86005e4_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfMTUtMy0xLTEtNTg1OTg_02272c2c-8e18-4c9c-82ba-c82445ceed29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b0e199731ea42a99e977bd922403d3b_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfMTUtNS0xLTEtNTg1OTg_1239b804-9c2d-4fcb-8b00-f4d37b604a6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i786c434041fb4ace8a427a0d0e1e025f_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfMTUtNy0xLTEtNTg1OTg_f3766ca0-adc7-414e-9ee1-a8de0eac5350">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Level 3 financial instruments at September&#160;30, 2022 are comprised solely of contingent consideration liabilities of $<ix:nonFraction unitRef="usd" contextRef="if45c5ec7debc4e2298c33d69169aae1b_I20220930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RleHRyZWdpb246MzZiM2FiNDY1OGFkNDdkZjhmNWY5ZTA4ODk2OWMwY2RfMTMzMQ_7125b16e-b800-494d-a890-e0a7d974e2ec">8</ix:nonFraction> million, in connection with our 2020 acquisition of certain assets of Passport Health Plan, Inc., a Medicaid health plan in Kentucky. Such liabilities are recorded at fair value on a recurring basis. In the nine months ended September 30, 2022, the estimated fair value of contingent purchase consideration increased by approximately $<ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RleHRyZWdpb246MzZiM2FiNDY1OGFkNDdkZjhmNWY5ZTA4ODk2OWMwY2RfMTYyNg_d5bb701b-c789-4b17-8d00-fbcc5d40dbb5">4</ix:nonFraction>&#160;million, relating to an operating income guarantee. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the nine months ended September 30, 2022, we paid the seller $<ix:nonFraction unitRef="usd" contextRef="idf0d9b897df24113b68bdf8a453bb9a6_D20220101-20220930" decimals="-6" name="moh:PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RleHRyZWdpb246MzZiM2FiNDY1OGFkNDdkZjhmNWY5ZTA4ODk2OWMwY2RfMTcwNA_2c7ec7fa-c85e-4229-9234-08395f1fd3c2">43</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="i1924badac4254104ab5cdb4dd26159ab_D20220101-20220930" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RleHRyZWdpb246MzZiM2FiNDY1OGFkNDdkZjhmNWY5ZTA4ODk2OWMwY2RfMTcxNw_0d482c71-b0ba-408d-92f3-0bcb7e4aeae0">23</ix:nonFraction>&#160;million was for the remaining half of the consideration due for minimum member enrollment targets and $<ix:nonFraction unitRef="usd" contextRef="i076cf1c584a94c74b356f13c7adb5c28_D20220101-20220930" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RleHRyZWdpb246MzZiM2FiNDY1OGFkNDdkZjhmNWY5ZTA4ODk2OWMwY2RfMTgxNA_985eea67-b587-4c42-a6f5-ca782ad7af70">20</ix:nonFraction>&#160;million was for the first payment of the consideration due for the operating income guarantee. For the amounts paid in the nine months ended September 30, 2022, $<ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RleHRyZWdpb246MzZiM2FiNDY1OGFkNDdkZjhmNWY5ZTA4ODk2OWMwY2RfMTkzNg_19be52cc-3787-40f4-8939-e31a16b20bbc">20</ix:nonFraction> million has been presented in &#8220;Financing activities&#8221; in the accompanying consolidated statements of cash flows, with the balance reflected in &#8220;Operating activities.&#8221; The remaining balance of </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September&#160;30, 2022 Form 10-Q | 12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_7">Table of Contents</a></span></div></div><ix:continuation id="i9adef6e61ece4b7aaae6ca9a67946403"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the liabilities is reported in &#8220;Accounts payable, accrued liabilities and other&#8221; in the accompanying consolidated balance sheets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements &#8211; Disclosure Only</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and estimated fair values of our notes payable are classified as Level 2 financial instruments. Fair value for these securities is determined using a market approach based on quoted market prices for similar securities in active markets or quoted prices for identical securities in inactive markets.</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RleHRyZWdpb246MzZiM2FiNDY1OGFkNDdkZjhmNWY5ZTA4ODk2OWMwY2RfMjYyMw_a4cacb6a-bb8e-4a2e-a533-1cc33ab4a55c" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2215166a13a24f4ea0beb4f9ec5386b9_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOmQzMjI5MmRkZDIwMTRmMWZiNTcwZjE2NzZmNzE2YjE4L3RhYmxlcmFuZ2U6ZDMyMjkyZGRkMjAxNGYxZmI1NzBmMTY3NmY3MTZiMThfNC0wLTEtMS01ODU5OC90ZXh0cmVnaW9uOjExZGYzNGI4ZDM4MTRjYTQ4NTk3MDNmYWJmZGM1YjMwXzQ_684c7b56-c616-4156-b6af-c055e1225af1">4.375</ix:nonFraction>% Notes due 2028</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib052c71d45c24815afd7307c29d879aa_I20220930" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOmQzMjI5MmRkZDIwMTRmMWZiNTcwZjE2NzZmNzE2YjE4L3RhYmxlcmFuZ2U6ZDMyMjkyZGRkMjAxNGYxZmI1NzBmMTY3NmY3MTZiMThfNC0xLTEtMS01ODU5OA_d664b348-283f-4e7e-830b-0b5a4d505a63">792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i448407d80cec44e08a45d31f149e357a_I20220930" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOmQzMjI5MmRkZDIwMTRmMWZiNTcwZjE2NzZmNzE2YjE4L3RhYmxlcmFuZ2U6ZDMyMjkyZGRkMjAxNGYxZmI1NzBmMTY3NmY3MTZiMThfNC0zLTEtMS01ODU5OA_8cc9b90f-f47b-4650-923e-4bf63c18f5f8">715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f612d887153413e9b30f0319ba1b896_I20211231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOmQzMjI5MmRkZDIwMTRmMWZiNTcwZjE2NzZmNzE2YjE4L3RhYmxlcmFuZ2U6ZDMyMjkyZGRkMjAxNGYxZmI1NzBmMTY3NmY3MTZiMThfNC01LTEtMS01ODU5OA_9f10c229-d132-4955-9dd8-4eb8d6dcfd86">791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c267f45c1bb4b4bba5c6d0aa9d3c25a_I20211231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOmQzMjI5MmRkZDIwMTRmMWZiNTcwZjE2NzZmNzE2YjE4L3RhYmxlcmFuZ2U6ZDMyMjkyZGRkMjAxNGYxZmI1NzBmMTY3NmY3MTZiMThfNC03LTEtMS01ODU5OA_db2caa3e-e8a0-4142-b3f3-be9e1dce30a6">829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4568007f62514af188a722dbbfff6949_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOmQzMjI5MmRkZDIwMTRmMWZiNTcwZjE2NzZmNzE2YjE4L3RhYmxlcmFuZ2U6ZDMyMjkyZGRkMjAxNGYxZmI1NzBmMTY3NmY3MTZiMThfNS0wLTEtMS01ODU5OC90ZXh0cmVnaW9uOjU5NDlmZjVmNDJiNDRkMTI5OTEwYjVkMWE1MTJkZTQ2XzQ_9cdb5704-1c74-42e5-96c0-beb98c5331f6">3.875</ix:nonFraction>% Notes due 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafab2ab6349040358f61b4a6104ff30b_I20220930" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOmQzMjI5MmRkZDIwMTRmMWZiNTcwZjE2NzZmNzE2YjE4L3RhYmxlcmFuZ2U6ZDMyMjkyZGRkMjAxNGYxZmI1NzBmMTY3NmY3MTZiMThfNS0xLTEtMS01ODU5OA_7732deb6-41a0-46a1-ac2d-0694461569f6">642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6633be4c8bbc48bcbc0664990b24b759_I20220930" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOmQzMjI5MmRkZDIwMTRmMWZiNTcwZjE2NzZmNzE2YjE4L3RhYmxlcmFuZ2U6ZDMyMjkyZGRkMjAxNGYxZmI1NzBmMTY3NmY3MTZiMThfNS0zLTEtMS01ODU5OA_b111f87f-0ef7-4fae-8a72-8a5892e97e36">541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec39088e3cdd4e6bb7e04b07ff271fbe_I20211231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOmQzMjI5MmRkZDIwMTRmMWZiNTcwZjE2NzZmNzE2YjE4L3RhYmxlcmFuZ2U6ZDMyMjkyZGRkMjAxNGYxZmI1NzBmMTY3NmY3MTZiMThfNS01LTEtMS01ODU5OA_140c07ef-03f9-4e25-9a80-0860966777ee">642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a9279d92caf4fc380a01f6bfb0014fc_I20211231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOmQzMjI5MmRkZDIwMTRmMWZiNTcwZjE2NzZmNzE2YjE4L3RhYmxlcmFuZ2U6ZDMyMjkyZGRkMjAxNGYxZmI1NzBmMTY3NmY3MTZiMThfNS03LTEtMS01ODU5OA_b0a4a584-3caf-4633-9b7f-1dd4ee03efc3">675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i68670e57970547ba9f2bb65e407ef0c3_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOmQzMjI5MmRkZDIwMTRmMWZiNTcwZjE2NzZmNzE2YjE4L3RhYmxlcmFuZ2U6ZDMyMjkyZGRkMjAxNGYxZmI1NzBmMTY3NmY3MTZiMThfNi0wLTEtMS01ODU5OC90ZXh0cmVnaW9uOjIwMjU2NDI1YTY2OTRlNDY5MWM5NmNjOGRmNTc4NzhjXzQ_8eaa68b5-c180-4f43-88af-764c0af6a117">3.875</ix:nonFraction>% Notes due 2032</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfc15175d74475c91b12b778c7b87c2_I20220930" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOmQzMjI5MmRkZDIwMTRmMWZiNTcwZjE2NzZmNzE2YjE4L3RhYmxlcmFuZ2U6ZDMyMjkyZGRkMjAxNGYxZmI1NzBmMTY3NmY3MTZiMThfNi0xLTEtMS01ODU5OA_6248f10a-1fbc-47d5-9d55-67a60f49db87">741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3afb2257e99458fa208ad148ca26252_I20220930" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOmQzMjI5MmRkZDIwMTRmMWZiNTcwZjE2NzZmNzE2YjE4L3RhYmxlcmFuZ2U6ZDMyMjkyZGRkMjAxNGYxZmI1NzBmMTY3NmY3MTZiMThfNi0zLTEtMS01ODU5OA_4ccd2a35-b6db-4b19-8b5f-dc3bbf459df3">612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fd3944eda144945832b087213cd2c9d_I20211231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOmQzMjI5MmRkZDIwMTRmMWZiNTcwZjE2NzZmNzE2YjE4L3RhYmxlcmFuZ2U6ZDMyMjkyZGRkMjAxNGYxZmI1NzBmMTY3NmY3MTZiMThfNi01LTEtMS01ODU5OA_4cace53b-99b9-45ca-aa78-b4db904efae5">740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0939ce4f5154b368577c64da2123599_I20211231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOmQzMjI5MmRkZDIwMTRmMWZiNTcwZjE2NzZmNzE2YjE4L3RhYmxlcmFuZ2U6ZDMyMjkyZGRkMjAxNGYxZmI1NzBmMTY3NmY3MTZiMThfNi03LTEtMS01ODU5OA_bff44425-a1d8-4632-b0bd-4c10f1bf7d1a">760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8580906fd604a64a726120c54b6cf42_I20220930" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOmQzMjI5MmRkZDIwMTRmMWZiNTcwZjE2NzZmNzE2YjE4L3RhYmxlcmFuZ2U6ZDMyMjkyZGRkMjAxNGYxZmI1NzBmMTY3NmY3MTZiMThfNy0xLTEtMS01ODU5OA_e88237aa-7489-4a76-8ac7-7360fa4ad536">2,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i150352dcdff64ad5be9688ff28c71149_I20220930" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOmQzMjI5MmRkZDIwMTRmMWZiNTcwZjE2NzZmNzE2YjE4L3RhYmxlcmFuZ2U6ZDMyMjkyZGRkMjAxNGYxZmI1NzBmMTY3NmY3MTZiMThfNy0zLTEtMS01ODU5OA_1342af88-a1ca-4683-a6d9-395f86a1a2f6">1,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f569fe006e84fdea4bf95c5b662a515_I20211231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOmQzMjI5MmRkZDIwMTRmMWZiNTcwZjE2NzZmNzE2YjE4L3RhYmxlcmFuZ2U6ZDMyMjkyZGRkMjAxNGYxZmI1NzBmMTY3NmY3MTZiMThfNy01LTEtMS01ODU5OA_dc27be43-4346-49d7-8414-3ccdb4417b4b">2,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aa0518df13a4a3ea99cdd1f8dc0e2cc_I20211231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOmQzMjI5MmRkZDIwMTRmMWZiNTcwZjE2NzZmNzE2YjE4L3RhYmxlcmFuZ2U6ZDMyMjkyZGRkMjAxNGYxZmI1NzBmMTY3NmY3MTZiMThfNy03LTEtMS01ODU5OA_50862af9-a28b-44b6-9135-5525c38698c8">2,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="icc83361866f7481797f2215c8aedaf24_46"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6. <ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RleHRyZWdpb246MjFkNGU2Njc4YzdjNGIyYWIzNzc3YmY2NTQ4MjkyZGJfMTA2MA_d11116a4-5e3d-4b5a-ba79-6a7c0cf6b350" continuedAt="ie1982153f67d476fbe65e2fd05bf43e9" escape="true">Investments </ix:nonNumeric></span></div><ix:continuation id="ie1982153f67d476fbe65e2fd05bf43e9" continuedAt="ic6ffa5924ced43fcb8742513f08fa4db"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Available-for-Sale</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all of our investments classified as current assets to be available-for-sale. <ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RleHRyZWdpb246MjFkNGU2Njc4YzdjNGIyYWIzNzc3YmY2NTQ4MjkyZGJfMTA1Ng_baf198ca-3680-445a-95d8-d5984fcd7f92" continuedAt="id5e6ca30a65f41909396c398f44c8250" escape="true">The following tables summarize our current investments as of the dates indicated:</ix:nonNumeric></span></div><ix:continuation id="id5e6ca30a65f41909396c398f44c8250"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d38d8c7935408fa0af30bea62c9c0f_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfNS0xLTEtMS01ODU5OA_3467ac22-35a9-4766-96b9-477f78980b60">2,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d38d8c7935408fa0af30bea62c9c0f_I20220930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfNS0zLTEtMS01ODU5OA_01993423-5018-476e-9a03-8fa7455c2e79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d38d8c7935408fa0af30bea62c9c0f_I20220930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfNS01LTEtMS01ODU5OA_f8f8c9b2-d952-4965-b015-51d4a58120f5">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d38d8c7935408fa0af30bea62c9c0f_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfNS03LTEtMS01ODU5OA_a7b862bf-a071-497f-a29d-9cbf374ae33f">2,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a952061d42f4cf594d018fa3c95b81c_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfNi0xLTEtMS01ODU5OA_8c1b6a53-9744-4ad1-818f-3dd19859e0c6">804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a952061d42f4cf594d018fa3c95b81c_I20220930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfNi0zLTEtMS01ODU5OA_06ee12fc-afa5-4d8c-a0c3-cef15eaecccc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a952061d42f4cf594d018fa3c95b81c_I20220930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfNi01LTEtMS01ODU5OA_f8aca986-875c-4a3d-aa8f-37018e3c60c2">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a952061d42f4cf594d018fa3c95b81c_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfNi03LTEtMS01ODU5OA_11fd0007-a737-4d16-94d0-23714eecdceb">743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56ac79c2434a4a848f5a258701b2729d_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfNy0xLTEtMS01ODU5OA_e26c16e5-6a44-408f-a55d-747df9ad628c">322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56ac79c2434a4a848f5a258701b2729d_I20220930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfNy0zLTEtMS01ODU5OA_8fce03d5-0f21-4b45-a2e9-eb5c2d8d72a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56ac79c2434a4a848f5a258701b2729d_I20220930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfNy01LTEtMS01ODU5OA_12ecb634-1063-403f-adf9-92a6277a9d4f">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56ac79c2434a4a848f5a258701b2729d_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfNy03LTEtMS01ODU5OA_e8d36a5a-3f11-4385-8709-a221fc9f6e16">303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89c330693cd24ca895c0f7f61021a016_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfOC0xLTEtMS01ODU5OA_138c964f-e02b-452d-a47e-2b191dab0542">159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89c330693cd24ca895c0f7f61021a016_I20220930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfOC0zLTEtMS01ODU5OA_a995067d-d9aa-456d-9c24-a56a257d4531">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89c330693cd24ca895c0f7f61021a016_I20220930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfOC01LTEtMS01ODU5OA_12f42627-05ed-4b23-9c36-3770de62283e">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89c330693cd24ca895c0f7f61021a016_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfOC03LTEtMS01ODU5OA_f5e25bb2-2514-4e27-a26f-2218cdb53363">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic927869e96d94755b6560a3286b613c8_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfOS0xLTEtMS01ODU5OA_9488bbb7-21f1-4308-ad66-7e7e2b16f04b">117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic927869e96d94755b6560a3286b613c8_I20220930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfOS0zLTEtMS01ODU5OA_a4287a24-184e-4768-9445-a6e164b79968">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic927869e96d94755b6560a3286b613c8_I20220930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfOS01LTEtMS01ODU5OA_55bf3401-4f85-4108-ada6-1825b2541e8b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic927869e96d94755b6560a3286b613c8_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfOS03LTEtMS01ODU5OA_e13036e7-38d3-4c0a-8415-3e15a686c89d">116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95e6b6b2720412788aaa02f055f8e57_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfMTMtMS0xLTEtNTg1OTg_98eac3c2-516b-4e7b-81ad-88301c43fab3">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95e6b6b2720412788aaa02f055f8e57_I20220930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfMTMtMy0xLTEtNTg1OTg_6c2ff8a7-26fb-48a8-a81e-5484b6c38753">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95e6b6b2720412788aaa02f055f8e57_I20220930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfMTMtNS0xLTEtNTg1OTg_bd5957bb-6f66-4d6c-a13e-bf428c96dce7">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95e6b6b2720412788aaa02f055f8e57_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfMTMtNy0xLTEtNTg1OTg_340d5156-112d-403b-9464-805a1d3ea7b3">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfMTQtMS0xLTEtNTg1OTg_a0f5fa47-0824-4c13-8781-2a53ec99a633">3,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfMTQtMy0xLTEtNTg1OTg_d61ddea9-e855-4001-81e3-081ffec24fe9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfMTQtNS0xLTEtNTg1OTg_5453d289-4ac9-4d31-a510-cfceb3d17bb4">243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfMTQtNy0xLTEtNTg1OTg_a9ec234f-e678-4a88-9220-49562c7d7ce3">3,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib564c222a94b4914a72dc2e0ec855b08_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfNS0xLTEtMS01ODU5OA_1ee51029-df74-4d5a-bfb8-1cf13593dc52">1,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib564c222a94b4914a72dc2e0ec855b08_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfNS0zLTEtMS01ODU5OA_22a06d8f-e928-406d-ab26-a97502b7a487">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib564c222a94b4914a72dc2e0ec855b08_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfNS01LTEtMS01ODU5OA_308ab507-cb3f-4c51-9926-54744818691e">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib564c222a94b4914a72dc2e0ec855b08_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfNS03LTEtMS01ODU5OA_9092271d-7a66-4cc2-a6a8-cf4f38e5c5ae">1,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7295c4737a694828803c5153905fdd31_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfNi0xLTEtMS01ODU5OA_3914a63c-fe83-4856-9e64-26e93df163da">616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7295c4737a694828803c5153905fdd31_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfNi0zLTEtMS01ODU5OA_ffa45e44-b432-4fd0-93ce-31629d09a6b5">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7295c4737a694828803c5153905fdd31_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfNi01LTEtMS01ODU5OA_f289f17d-fe6c-4ffd-a020-204ea9aa7b34">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7295c4737a694828803c5153905fdd31_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfNi03LTEtMS01ODU5OA_146df252-8cd2-4484-9576-74f5bed463e0">614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ba2d36cfa1140b1984c163783c2d57a_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfNy0xLTEtMS01ODU5OA_0bc46308-0a1d-4be3-a06a-e3b460e12d66">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ba2d36cfa1140b1984c163783c2d57a_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfNy0zLTEtMS01ODU5OA_88926c3c-d8c5-4488-a118-9bf87c453ee5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ba2d36cfa1140b1984c163783c2d57a_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfNy01LTEtMS01ODU5OA_03476223-c35e-457a-be68-68ff73bb5cba">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ba2d36cfa1140b1984c163783c2d57a_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfNy03LTEtMS01ODU5OA_6907f45e-b87d-49b8-9d98-6cd7ee5c1383">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d4d9de95590481dad9718e28b15a44b_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfOC0xLTEtMS01ODU5OA_477b628c-9eb7-43c3-9ff6-288f90b153f4">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d4d9de95590481dad9718e28b15a44b_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfOC0zLTEtMS01ODU5OA_ff4bb3e4-2af2-4952-87ac-8ff4005a7e0b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d4d9de95590481dad9718e28b15a44b_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfOC01LTEtMS01ODU5OA_9a7ea047-79b4-4c7b-944d-33bfa1543d27">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d4d9de95590481dad9718e28b15a44b_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfOC03LTEtMS01ODU5OA_30ce1cdd-7162-42c6-9bda-913eba75d06b">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic30b2001e92f42a0889f7aa593c567f1_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfOS0xLTEtMS01ODU5OA_5dcb8e6f-7696-4431-ad68-da3be9113a82">353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic30b2001e92f42a0889f7aa593c567f1_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfOS0zLTEtMS01ODU5OA_3627c524-c166-4c95-ba4f-3ee5d1d26e41">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic30b2001e92f42a0889f7aa593c567f1_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfOS01LTEtMS01ODU5OA_a1c87e4e-b38a-4234-a93a-2338042897f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic30b2001e92f42a0889f7aa593c567f1_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfOS03LTEtMS01ODU5OA_9319c517-141e-46c8-a258-370a4a7880c0">353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0781e4f6fe144460945ffc19971a5b88_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfMTItMS0xLTEtNTg1OTg_d855a187-ffc7-43f9-812e-424da5fcf9a0">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0781e4f6fe144460945ffc19971a5b88_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfMTItMy0xLTEtNTg1OTg_d5189ed8-4cef-4373-a771-f05c03b2b972">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0781e4f6fe144460945ffc19971a5b88_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfMTItNS0xLTEtNTg1OTg_cc81e175-6436-46ce-8f04-31685f51375f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0781e4f6fe144460945ffc19971a5b88_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfMTItNy0xLTEtNTg1OTg_8e29ece3-95d2-494f-9a8d-bba4ca73773e">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfMTMtMS0xLTEtNTg1OTg_2a092012-c28b-406a-817c-c4a3b8d6e8d6">3,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfMTMtMy0xLTEtNTg1OTg_8bd9b53c-48f2-4871-ae6c-18fb753776c2">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfMTMtNS0xLTEtNTg1OTg_ff7e5f52-0cfb-4ec8-8bae-cf3403579309">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfMTMtNy0xLTEtNTg1OTg_8c654e99-3113-460e-b964-9069538fce15">3,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September&#160;30, 2022 Form 10-Q | 13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_7">Table of Contents</a></span></div></div><ix:continuation id="ic6ffa5924ced43fcb8742513f08fa4db" continuedAt="i05a2903f09974b8a8107e6884b074d5c"><ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RleHRyZWdpb246MjFkNGU2Njc4YzdjNGIyYWIzNzc3YmY2NTQ4MjkyZGJfMTA3NQ_9f5486a4-3db8-463e-93d0-f6553c55a9e3" escape="true"><div style="margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of our current investments as of September&#160;30, 2022 are summarized below:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOjJlNTUwMWFjZDY4MTQ5OWNiNzcwNzYxZWY3ZmE3M2QxL3RhYmxlcmFuZ2U6MmU1NTAxYWNkNjgxNDk5Y2I3NzA3NjFlZjdmYTczZDFfMy0xLTEtMS01ODU5OA_71db239c-f539-4bde-81aa-75398c1c52d7">378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOjJlNTUwMWFjZDY4MTQ5OWNiNzcwNzYxZWY3ZmE3M2QxL3RhYmxlcmFuZ2U6MmU1NTAxYWNkNjgxNDk5Y2I3NzA3NjFlZjdmYTczZDFfMy0zLTEtMS01ODU5OA_d59def08-f5fa-43d5-ad95-4f4decfa5bc9">374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOjJlNTUwMWFjZDY4MTQ5OWNiNzcwNzYxZWY3ZmE3M2QxL3RhYmxlcmFuZ2U6MmU1NTAxYWNkNjgxNDk5Y2I3NzA3NjFlZjdmYTczZDFfNC0xLTEtMS01ODU5OA_7f68e64f-c603-488a-902d-56b7e03e6503">2,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOjJlNTUwMWFjZDY4MTQ5OWNiNzcwNzYxZWY3ZmE3M2QxL3RhYmxlcmFuZ2U6MmU1NTAxYWNkNjgxNDk5Y2I3NzA3NjFlZjdmYTczZDFfNC0zLTEtMS01ODU5OA_7e0d78e4-6852-4cef-8b40-1239c65f2293">2,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOjJlNTUwMWFjZDY4MTQ5OWNiNzcwNzYxZWY3ZmE3M2QxL3RhYmxlcmFuZ2U6MmU1NTAxYWNkNjgxNDk5Y2I3NzA3NjFlZjdmYTczZDFfNS0xLTEtMS01ODU5OA_fce449e3-bffe-4f98-9492-56cfdc3ae654">390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOjJlNTUwMWFjZDY4MTQ5OWNiNzcwNzYxZWY3ZmE3M2QxL3RhYmxlcmFuZ2U6MmU1NTAxYWNkNjgxNDk5Y2I3NzA3NjFlZjdmYTczZDFfNS0zLTEtMS01ODU5OA_843444c1-9a82-422d-bd0d-86447686b9a2">364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOjJlNTUwMWFjZDY4MTQ5OWNiNzcwNzYxZWY3ZmE3M2QxL3RhYmxlcmFuZ2U6MmU1NTAxYWNkNjgxNDk5Y2I3NzA3NjFlZjdmYTczZDFfNi0xLTEtMS01ODU5OA_5912a710-75eb-4d7b-87e6-f5bc62a3ddd0">784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOjJlNTUwMWFjZDY4MTQ5OWNiNzcwNzYxZWY3ZmE3M2QxL3RhYmxlcmFuZ2U6MmU1NTAxYWNkNjgxNDk5Y2I3NzA3NjFlZjdmYTczZDFfNi0zLTEtMS01ODU5OA_d6e090d5-5f22-49bc-a3fb-88083ae317ef">715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOjJlNTUwMWFjZDY4MTQ5OWNiNzcwNzYxZWY3ZmE3M2QxL3RhYmxlcmFuZ2U6MmU1NTAxYWNkNjgxNDk5Y2I3NzA3NjFlZjdmYTczZDFfNy0xLTEtMS01ODU5OA_23874e7e-bda0-4376-8552-4cda07165d91">3,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOjJlNTUwMWFjZDY4MTQ5OWNiNzcwNzYxZWY3ZmE3M2QxL3RhYmxlcmFuZ2U6MmU1NTAxYWNkNjgxNDk5Y2I3NzA3NjFlZjdmYTczZDFfNy0zLTEtMS01ODU5OA_9558c7db-7997-4423-b5bb-cfc05797a0de">3,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross realized gains and losses from sales of available-for-sale securities are calculated under the specific identification method and are included in investment income. Gross realized investment gains were insignificant for the three and nine months ended September&#160;30, 2022, respectively. Gross realized investment gains amounted to $<ix:nonFraction unitRef="usd" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RleHRyZWdpb246MjFkNGU2Njc4YzdjNGIyYWIzNzc3YmY2NTQ4MjkyZGJfNjA0NzMxMzk1NDI3NQ_9c257fb3-5fc2-4230-8eea-2382020cb675">6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RleHRyZWdpb246MjFkNGU2Njc4YzdjNGIyYWIzNzc3YmY2NTQ4MjkyZGJfNjA0NzMxMzk1NDI4Nw_7157a156-ccd2-4fb4-91c5-06ace39f9185">7</ix:nonFraction>&#160;million for the three and nine months ended September&#160;30, 2021, respectively. Gross realized investment losses were insignificant for the three and nine months ended September&#160;30, 2022, and 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have determined that unrealized losses at September&#160;30, 2022, and December&#160;31, 2021, primarily resulted from fluctuating interest rates, rather than a deterioration of the creditworthiness of the issuers. Therefore, we determined that an allowance for credit losses was not necessary. So long as we maintain the intent and ability to hold these securities to maturity, we are unlikely to experience losses. In the event that we dispose of these securities before maturity, we expect that realized losses, if any, will be insignificant.</span></div></ix:continuation><div id="icc83361866f7481797f2215c8aedaf24_55"></div><ix:continuation id="i05a2903f09974b8a8107e6884b074d5c" continuedAt="if8ea9d5915854ea5bd90667f4dcff543"><ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RleHRyZWdpb246MmJlODU5YjczYzc4NDU0YzhhZTFmZDUxYWY1NmUwZjJfNDU5_19ee6908-7e1d-4b6c-a4ef-0232b5e74892" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table segregates those available-for-sale investments that have been in a continuous loss position for less than 12 months, and those that have been in a continuous loss position for 12 months or more as of September&#160;30, 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:24.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">In&#160;a&#160;Continuous&#160;Loss Position<br/>for&#160;Less&#160;than&#160;12&#160;Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">In&#160;a&#160;Continuous&#160;Loss Position<br/>for&#160;12&#160;Months or More</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Positions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Positions</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d38d8c7935408fa0af30bea62c9c0f_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNC0xLTEtMS01ODU5OA_58b05685-c706-45f9-8d65-25e24ecba19c">1,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d38d8c7935408fa0af30bea62c9c0f_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNC0zLTEtMS01ODU5OA_79664a77-2640-458e-89e8-02097c4cc68d">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="i53d38d8c7935408fa0af30bea62c9c0f_I20220930" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNC01LTEtMS01ODU5OA_ed8dee00-36a0-49d2-8e74-14cfb3605d08">909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d38d8c7935408fa0af30bea62c9c0f_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNC03LTEtMS01ODU5OA_66e89fb6-d8cb-4e69-bcc7-d28655b5e992">433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d38d8c7935408fa0af30bea62c9c0f_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNC05LTEtMS01ODU5OA_8e94cb37-d1db-4512-b5f6-2b2ea6e43d45">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="i53d38d8c7935408fa0af30bea62c9c0f_I20220930" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNC0xMS0xLTEtNTg1OTg_7b43aac6-5ba3-432d-b1e7-61bd95387b05">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a952061d42f4cf594d018fa3c95b81c_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNS0xLTEtMS01ODU5OA_d2b5b303-6d65-45eb-9f3a-a65c387d69a4">555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a952061d42f4cf594d018fa3c95b81c_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNS0zLTEtMS01ODU5OA_a80c0bba-5c6d-416f-9566-fdaf95c0d0f1">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="i9a952061d42f4cf594d018fa3c95b81c_I20220930" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNS01LTEtMS01ODU5OA_2156d05c-784f-4567-9516-65fb58efcdcd">282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a952061d42f4cf594d018fa3c95b81c_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNS03LTEtMS01ODU5OA_fa05c21d-e797-4302-9358-4ceb437a9e60">188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a952061d42f4cf594d018fa3c95b81c_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNS05LTEtMS01ODU5OA_6bdbfca2-944e-4d88-ad84-3e17e1aebf94">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="i9a952061d42f4cf594d018fa3c95b81c_I20220930" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNS0xMS0xLTEtNTg1OTg_d7aaa790-1d81-41e4-afcc-77c0359f2c72">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56ac79c2434a4a848f5a258701b2729d_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNi0xLTEtMS01ODU5OA_ab181ad9-da04-40a6-9e20-81fdf9aca2f5">242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56ac79c2434a4a848f5a258701b2729d_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNi0zLTEtMS01ODU5OA_10794bf2-630f-4ce3-b6aa-b6bd63c447fc">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i56ac79c2434a4a848f5a258701b2729d_I20220930" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNi01LTEtMS01ODU5OA_37a453c0-2882-4e45-9b1c-c4e245d8628e">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56ac79c2434a4a848f5a258701b2729d_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNi03LTEtMS01ODU5OA_e390e2c0-579f-4c36-bc5b-71f55312e1f4">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56ac79c2434a4a848f5a258701b2729d_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNi05LTEtMS01ODU5OA_3a2d7c85-4f68-4f37-a0b1-380633ff34b4">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i56ac79c2434a4a848f5a258701b2729d_I20220930" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNi0xMS0xLTEtNTg1OTg_91f898e1-8d01-43e2-b508-eba05a241845">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89c330693cd24ca895c0f7f61021a016_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNy0xLTEtMS02NjI2OQ_6e0237cf-f498-449e-b498-ec61c362282f">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89c330693cd24ca895c0f7f61021a016_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNy0zLTEtMS02NjI2OQ_9d390cea-1a52-4bce-994d-6d141da3a303">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i89c330693cd24ca895c0f7f61021a016_I20220930" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNy01LTEtMS02NjI2OQ_f541cebc-f18d-4802-96da-bcc3a230a80f">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89c330693cd24ca895c0f7f61021a016_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNy03LTEtMS02NjI2OQ_c87dd3cc-a743-4063-b7cb-655024ad2b2f">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89c330693cd24ca895c0f7f61021a016_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNy05LTEtMS02NjI2OQ_b11157cb-8b52-4966-bdad-12d39d64aad7">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i89c330693cd24ca895c0f7f61021a016_I20220930" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNy0xMS0xLTEtNjYyNjk_eca075d5-68fb-46e9-a6fe-a1577b3e3359">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic927869e96d94755b6560a3286b613c8_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNy0xLTEtMS01ODU5OA_f80c06a2-2ada-4bd8-92d5-69bf3a11e252">116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic927869e96d94755b6560a3286b613c8_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNy0zLTEtMS01ODU5OA_b9f2a295-5d54-477c-967f-2bf29d0a8728">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="ic927869e96d94755b6560a3286b613c8_I20220930" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNy01LTEtMS01ODU5OA_2baefe82-6185-4aff-b329-c064b6986096">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic927869e96d94755b6560a3286b613c8_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNy03LTEtMS01ODU5OA_d8dbea7f-b36f-4116-a3f1-7d81a9129a8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic927869e96d94755b6560a3286b613c8_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNy05LTEtMS01ODU5OA_bfb1b798-3720-4de2-a70d-369c4e3a4377">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="ic927869e96d94755b6560a3286b613c8_I20220930" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNy0xMS0xLTEtNTg1OTg_067cddcf-c445-4e25-9049-9110e9fea004">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95e6b6b2720412788aaa02f055f8e57_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfOS0xLTEtMS01ODU5OA_1dd3e2fe-65d5-480d-94a2-3e6d81699daf">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95e6b6b2720412788aaa02f055f8e57_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfOS0zLTEtMS01ODU5OA_d1faa46c-89f9-4cc9-89bb-9c92b4334d60">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="if95e6b6b2720412788aaa02f055f8e57_I20220930" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfOS01LTEtMS01ODU5OA_d59a7d8e-2386-45e4-a42f-539ba52726a6">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95e6b6b2720412788aaa02f055f8e57_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfOS03LTEtMS01ODU5OA_6a4c4fa7-e724-4db4-820f-2e3325fe095e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95e6b6b2720412788aaa02f055f8e57_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfOS05LTEtMS01ODU5OA_363b20fa-8a0c-4821-a40d-9209a186ee19">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="if95e6b6b2720412788aaa02f055f8e57_I20220930" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfOS0xMS0xLTEtNTg1OTg_41d18db0-ed87-4653-8495-5d445bcd2082">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfMTMtMS0xLTEtNTg1OTg_31e34b7b-6afa-4afa-88f1-e21981189327">2,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfMTMtMy0xLTEtNTg1OTg_f1790cec-aa47-4407-8e9b-3fb09ac0b885">163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfMTMtNS0xLTEtNTg1OTg_70f23f58-1976-4825-8182-f91aec9333f7">1,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfMTMtNy0xLTEtNTg1OTg_fb780820-ceba-4e78-8ab2-05e830e802fb">708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfMTMtOS0xLTEtNTg1OTg_26c2eef8-907e-488f-894e-a04b26de06e4">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfMTMtMTEtMS0xLTU4NTk4_0c356aab-30d9-4846-92fa-f9037d5dfca6">305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table segregates those available-for-sale investments that have been in a continuous loss position for less than 12 months, and those that have been in a continuous loss position for 12 months or more as of December&#160;31, 2021:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:24.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">In&#160;a&#160;Continuous&#160;Loss Position<br/>for&#160;Less&#160;than&#160;12&#160;Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">In&#160;a&#160;Continuous&#160;Loss Position<br/>for&#160;12&#160;Months or More</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Positions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Positions</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib564c222a94b4914a72dc2e0ec855b08_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfNC0xLTEtMS01ODU5OA_ddcdc773-4f22-4f45-8564-d2650bd5db00">1,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib564c222a94b4914a72dc2e0ec855b08_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfNC0zLTEtMS01ODU5OA_a235f1ff-26a1-40e6-add6-91003b89adb7">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="ib564c222a94b4914a72dc2e0ec855b08_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfNC01LTEtMS01ODU5OA_0919c70f-89d5-4b73-b70f-4e4d04ff9bd2">395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib564c222a94b4914a72dc2e0ec855b08_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfNC03LTEtMS01ODU5OA_0221e593-2d00-4f40-adb7-6f886b7c31ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib564c222a94b4914a72dc2e0ec855b08_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfNC05LTEtMS01ODU5OA_3913987f-d437-47c3-8a3a-b647a628fb0e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="ib564c222a94b4914a72dc2e0ec855b08_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfNC0xMS0xLTEtNTg1OTg_1e5caea7-2a34-44e5-aed6-a92d44ecc62e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7295c4737a694828803c5153905fdd31_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfNS0xLTEtMS01ODU5OA_ee577aa1-238b-43bd-802f-06aaabc2c6f9">408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7295c4737a694828803c5153905fdd31_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfNS0zLTEtMS01ODU5OA_537dedcb-8585-4183-82ae-de6ddae6ff42">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="i7295c4737a694828803c5153905fdd31_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfNS01LTEtMS01ODU5OA_5633925d-d29c-4e0b-923d-afaa93501461">146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7295c4737a694828803c5153905fdd31_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfNS03LTEtMS01ODU5OA_670e2570-7d69-4dfd-a017-d92ce197b904">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7295c4737a694828803c5153905fdd31_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfNS05LTEtMS01ODU5OA_74bbf454-ab19-4dd6-b865-721f57f55639">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="i7295c4737a694828803c5153905fdd31_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfNS0xMS0xLTEtNTg1OTg_4ae4b40d-b8b1-4a2a-8d22-be50dbcf7bcf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ba2d36cfa1140b1984c163783c2d57a_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfNi0xLTEtMS01ODU5OA_c1841208-0259-4083-a1fc-486f528ad2e3">166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ba2d36cfa1140b1984c163783c2d57a_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfNi0zLTEtMS01ODU5OA_b69c280a-1a42-4798-98b5-137b5231cdca">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i8ba2d36cfa1140b1984c163783c2d57a_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfNi01LTEtMS01ODU5OA_6ad94e9d-68ac-475b-806b-7c1a9aab33bf">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ba2d36cfa1140b1984c163783c2d57a_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfNi03LTEtMS01ODU5OA_9848f903-f950-4da8-a822-0813c67a17df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ba2d36cfa1140b1984c163783c2d57a_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfNi05LTEtMS01ODU5OA_ff96c851-6d7c-4eb8-a3b5-20ae0355541f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i8ba2d36cfa1140b1984c163783c2d57a_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfNi0xMS0xLTEtNTg1OTg_a2fa22d2-94b8-4ff9-a3fe-b01f72843cb8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d4d9de95590481dad9718e28b15a44b_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfOC0xLTEtMS01ODU5OA_e41e6316-c362-4b07-a861-723cc11c6474">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d4d9de95590481dad9718e28b15a44b_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfOC0zLTEtMS01ODU5OA_66c6b8fd-ebc5-4963-a617-544877b149ce">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i9d4d9de95590481dad9718e28b15a44b_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfOC01LTEtMS01ODU5OA_62cad2d3-838c-42e2-ab8c-275ba100b233">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d4d9de95590481dad9718e28b15a44b_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfOC03LTEtMS01ODU5OA_96674722-05f1-46b1-9107-8bb47d8549a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d4d9de95590481dad9718e28b15a44b_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfOC05LTEtMS01ODU5OA_3365246b-76d3-48bc-b0b3-bf3fed5229db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i9d4d9de95590481dad9718e28b15a44b_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfOC0xMS0xLTEtNTg1OTg_f5a419fd-919f-4b2f-a8ef-5a4626abee24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfMTItMS0xLTEtNTg1OTg_b501b49c-b23b-44c8-8ad6-455810831f74">1,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfMTItMy0xLTEtNTg1OTg_a576c5ca-2d63-4f99-a60f-bb127fd02fe7">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfMTItNS0xLTEtNTg1OTg_f316202e-1bb3-449c-a8b0-16922884fbea">677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfMTItNy0xLTEtNTg1OTg_3c028701-b736-4856-bd2a-391f63ec507f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfMTItOS0xLTEtNTg1OTg_5593fd23-f14a-4426-9d41-e475d4ac6398">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfMTItMTEtMS0xLTU4NTk4_07d09a72-52f9-4fa8-8f28-89e89064efd4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September&#160;30, 2022 Form 10-Q | 14</span></div></div></div><div id="icc83361866f7481797f2215c8aedaf24_58"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_7">Table of Contents</a></span></div></div><ix:continuation id="if8ea9d5915854ea5bd90667f4dcff543"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Investments Held-to-Maturity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the regulations governing our state health plan subsidiaries, we maintain statutory deposits and deposits required by government authorities primarily in cash, cash equivalents, U.S. Treasury securities, and corporate debt securities. We also maintain restricted investments as protection against the insolvency of certain capitated providers. The use of these funds is limited as required by regulations in the various states in which we operate, or as needed in the event of insolvency of capitated providers. Therefore, such investments are reported as &#8220;Restricted investments&#8221; in the accompanying consolidated balance sheets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have the ability to hold these restricted investments until maturity and, as a result, we would not expect the value of these investments to decline significantly due to a sudden change in market interest rates. Our held-to-maturity restricted investments are carried at amortized cost, which approximates fair value. Such investments amounted to $<ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81OC9mcmFnOmM4MDM0YzhlOWE5YjRkOWViM2ZkZjkzYTYyNzlkOTljL3RleHRyZWdpb246YzgwMzRjOGU5YTliNGQ5ZWIzZmRmOTNhNjI3OWQ5OWNfMTAxMA_c6f064e4-36e3-4131-aa28-ade50e701299">242</ix:nonFraction> million at September&#160;30, 2022, of which $<ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81OC9mcmFnOmM4MDM0YzhlOWE5YjRkOWViM2ZkZjkzYTYyNzlkOTljL3RleHRyZWdpb246YzgwMzRjOGU5YTliNGQ5ZWIzZmRmOTNhNjI3OWQ5OWNfMTAyOQ_ca1f7242-f5c1-4c19-aecd-72ef29e3ae7a">201</ix:nonFraction> million will mature in one year or less, $<ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81OC9mcmFnOmM4MDM0YzhlOWE5YjRkOWViM2ZkZjkzYTYyNzlkOTljL3RleHRyZWdpb246YzgwMzRjOGU5YTliNGQ5ZWIzZmRmOTNhNjI3OWQ5OWNfMTA2OQ_8bd36224-05fb-4b5c-b85b-06b227e1325f">37</ix:nonFraction>&#160;million will mature in one through five years, and $<ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81OC9mcmFnOmM4MDM0YzhlOWE5YjRkOWViM2ZkZjkzYTYyNzlkOTljL3RleHRyZWdpb246YzgwMzRjOGU5YTliNGQ5ZWIzZmRmOTNhNjI3OWQ5OWNfMTA5OTUxMTYyODkzNA_a935e30b-ca60-4be0-adbc-eec80bb688c9">4</ix:nonFraction> million will mature after five years.</span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div id="icc83361866f7481797f2215c8aedaf24_61"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7. <ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="moh:MedicalClaimsAndBenefitsPayableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RleHRyZWdpb246MDgyZDY1NTQ0MzdlNDgyZjkyYjQ3MjI1NTRjNTNiZmZfMTQ3Mg_b5961976-6f68-48f9-8213-010d11d9927b" continuedAt="ia5de5a09b0754bbca44011f4d9958478" escape="true">Medical Claims and Benefits Payable</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:continuation id="ia5de5a09b0754bbca44011f4d9958478" continuedAt="i9b6083c927df4e7ca9534ae99ab23034"> </ix:continuation></span></div><ix:continuation id="i9b6083c927df4e7ca9534ae99ab23034" continuedAt="i65736d950cf14317a675113a24acf268"><ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RleHRyZWdpb246MDgyZDY1NTQ0MzdlNDgyZjkyYjQ3MjI1NTRjNTNiZmZfMTQ1Nw_8d03f732-52d9-46e4-a2f7-406cb2f8e04f" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the details of our medical claims and benefits payable as of the dates indicated:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Claims incurred but not paid (&#8220;IBNP&#8221;)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOmNiMGUxYjFlODZhZTQ1NjA5N2FhZTFlMjcwYTllODFkL3RhYmxlcmFuZ2U6Y2IwZTFiMWU4NmFlNDU2MDk3YWFlMWUyNzBhOWU4MWRfMy0xLTEtMS01ODU5OA_374b7a14-527e-448c-880b-b9ec7fc3ed24">2,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOmNiMGUxYjFlODZhZTQ1NjA5N2FhZTFlMjcwYTllODFkL3RhYmxlcmFuZ2U6Y2IwZTFiMWU4NmFlNDU2MDk3YWFlMWUyNzBhOWU4MWRfMy0zLTEtMS01ODU5OA_d41f4c08-a4a2-4b1d-aec9-31e67592856a">2,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="moh:PharmacyClaimsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOmNiMGUxYjFlODZhZTQ1NjA5N2FhZTFlMjcwYTllODFkL3RhYmxlcmFuZ2U6Y2IwZTFiMWU4NmFlNDU2MDk3YWFlMWUyNzBhOWU4MWRfNC0xLTEtMS01ODU5OA_10f6ea92-f091-47af-8a70-e6525cdb0bfe">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="moh:PharmacyClaimsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOmNiMGUxYjFlODZhZTQ1NjA5N2FhZTFlMjcwYTllODFkL3RhYmxlcmFuZ2U6Y2IwZTFiMWU4NmFlNDU2MDk3YWFlMWUyNzBhOWU4MWRfNC0zLTEtMS01ODU5OA_c86882d7-7ad4-48a4-bb60-d67c60a859f2">219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitation payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="moh:CapitationClaimsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOmNiMGUxYjFlODZhZTQ1NjA5N2FhZTFlMjcwYTllODFkL3RhYmxlcmFuZ2U6Y2IwZTFiMWU4NmFlNDU2MDk3YWFlMWUyNzBhOWU4MWRfNS0xLTEtMS01ODU5OA_b508c3d0-59b3-4321-84ea-c7388deb2c6d">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="moh:CapitationClaimsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOmNiMGUxYjFlODZhZTQ1NjA5N2FhZTFlMjcwYTllODFkL3RhYmxlcmFuZ2U6Y2IwZTFiMWU4NmFlNDU2MDk3YWFlMWUyNzBhOWU4MWRfNS0zLTEtMS01ODU5OA_7abca0be-6a20-4c78-8a84-da75e056c198">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="moh:OtherClaimsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOmNiMGUxYjFlODZhZTQ1NjA5N2FhZTFlMjcwYTllODFkL3RhYmxlcmFuZ2U6Y2IwZTFiMWU4NmFlNDU2MDk3YWFlMWUyNzBhOWU4MWRfNi0xLTEtMS01ODU5OA_ff630f55-52ae-4c62-ac76-97d18d4eaabd">738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="moh:OtherClaimsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOmNiMGUxYjFlODZhZTQ1NjA5N2FhZTFlMjcwYTllODFkL3RhYmxlcmFuZ2U6Y2IwZTFiMWU4NmFlNDU2MDk3YWFlMWUyNzBhOWU4MWRfNi0zLTEtMS01ODU5OA_e2cbab1b-5f05-4da0-bc62-9f61e8f10089">576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOmNiMGUxYjFlODZhZTQ1NjA5N2FhZTFlMjcwYTllODFkL3RhYmxlcmFuZ2U6Y2IwZTFiMWU4NmFlNDU2MDk3YWFlMWUyNzBhOWU4MWRfNy0xLTEtMS01ODU5OA_5d3b981e-2362-4949-bfa4-bff8de81326f">3,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOmNiMGUxYjFlODZhZTQ1NjA5N2FhZTFlMjcwYTllODFkL3RhYmxlcmFuZ2U6Y2IwZTFiMWU4NmFlNDU2MDk3YWFlMWUyNzBhOWU4MWRfNy0zLTEtMS01ODU5OA_b382a397-d101-4117-98bf-eb7a17863ef9">3,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Other&#8221; medical claims and benefits payable include amounts payable to certain providers for which we act as an intermediary on behalf of various government agencies without assuming financial risk. Such receipts and payments do not impact our consolidated statements of income. Non-risk provider payables amounted to $<ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="moh:MedicalClaimsAndBenefitsPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RleHRyZWdpb246MDgyZDY1NTQ0MzdlNDgyZjkyYjQ3MjI1NTRjNTNiZmZfNDQ1_2b9947de-a52b-4cfe-b669-0b26fb6cb6a5">317</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="moh:MedicalClaimsAndBenefitsPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RleHRyZWdpb246MDgyZDY1NTQ0MzdlNDgyZjkyYjQ3MjI1NTRjNTNiZmZfNDUy_c0afc384-a804-49f9-9c06-fcb0c94c2a86">226</ix:nonFraction> million as of September&#160;30, 2022, and December&#160;31, 2021, respectively.</span></div><ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="moh:ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RleHRyZWdpb246MDgyZDY1NTQ0MzdlNDgyZjkyYjQ3MjI1NTRjNTNiZmZfMTQ0Nw_0f2ce2e8-e091-4ac5-a2c9-cd93f8a9f8b0" continuedAt="i5df7656e54324bb1b2810c13bfee8f5a" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the components of the change in our medical claims and benefits payable for the periods indicated. The amounts presented for &#8220;Components of medical care costs related to: Prior years&#8221; represent the amount by which our original estimate of medical claims and benefits payable at the beginning of the year varied from the actual liabilities, based on information (principally the payment of claims) developed since those liabilities were first reported. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicaid </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicare </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketplace</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b797bdb341b4b52895da42aa2124960_I20211231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfNC0xLTEtMS01ODU5OA_142f8563-76f4-436e-a47c-4c695b1c1930">2,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i869f5f0099fe46b693a48fd139483e93_I20211231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfNC0zLTEtMS01ODU5OA_5bcbf882-9b73-4e63-aace-d7f9fdf66b4e">404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia584820ec62b4608b407558882249b92_I20211231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfNC01LTEtMS01ODU5OA_beee24b3-c4e1-4eff-8b90-be19437d9230">379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfNC03LTEtMS01ODU5OA_98ddae3b-9071-4255-be19-d11675b349f4">3,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Components of medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ec20456c73b4f1f8e73015480eac437_D20220101-20220930" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfNi0xLTEtMS01ODU5OA_5471da70-45ff-4833-8152-062fb76cbc61">16,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0963d8c883c844e6b0f9b360576e525d_D20220101-20220930" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfNi0zLTEtMS01ODU5OA_613cf1a3-d557-48c2-9b17-d0706c67d935">2,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b425cf2189f45f795be7031fbb9489a_D20220101-20220930" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfNi01LTEtMS01ODU5OA_16e508a1-cfab-419a-b575-3c5f97574642">1,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfNi03LTEtMS01ODU5OA_6097a348-f0a6-4573-a84f-f369c789b18d">20,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ec20456c73b4f1f8e73015480eac437_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfNy0xLTEtMS01ODU5OA_296fb3cb-3676-48ab-86dc-6455dc3d5121">282</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0963d8c883c844e6b0f9b360576e525d_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfNy0zLTEtMS01ODU5OA_acc418bd-80a0-4726-b130-f712255074bd">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b425cf2189f45f795be7031fbb9489a_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfNy01LTEtMS01ODU5OA_87abf53d-46f8-4752-8bb9-951d07190a54">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfNy03LTEtMS01ODU5OA_1136879e-0222-4450-accf-2ee55c2b7980">338</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ec20456c73b4f1f8e73015480eac437_D20220101-20220930" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfOC0xLTEtMS01ODU5OA_dfba129e-aea8-442a-b10c-47eca61fb343">16,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0963d8c883c844e6b0f9b360576e525d_D20220101-20220930" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfOC0zLTEtMS01ODU5OA_8b507429-7a32-4dc3-a4cb-2f54dc018dff">2,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b425cf2189f45f795be7031fbb9489a_D20220101-20220930" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfOC01LTEtMS01ODU5OA_65229b1e-da8c-498e-b21c-d0c950db4ae6">1,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfOC03LTEtMS01ODU5OA_49508de9-6ee2-4cb4-baea-05bfee21e52a">20,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ec20456c73b4f1f8e73015480eac437_D20220101-20220930" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTAtMS0xLTEtNTg1OTg_6090c282-d1c9-4c42-a232-01acfb316310">14,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0963d8c883c844e6b0f9b360576e525d_D20220101-20220930" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTAtMy0xLTEtNTg1OTg_01a374cb-d3ef-45b6-9de5-876405b117ea">2,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b425cf2189f45f795be7031fbb9489a_D20220101-20220930" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTAtNS0xLTEtNTg1OTg_d6c2a94c-c473-48e5-9024-8be7385ae4fa">1,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTAtNy0xLTEtNTg1OTg_b11d2b85-44f5-44b8-baef-4f6724126c4c">17,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ec20456c73b4f1f8e73015480eac437_D20220101-20220930" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTEtMS0xLTEtNTg1OTg_b8929f15-bec5-4537-a72e-d5c5d624d742">1,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0963d8c883c844e6b0f9b360576e525d_D20220101-20220930" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTEtMy0xLTEtNTg1OTg_ee9ad45c-86ba-437a-acec-9a5b6fc63090">337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b425cf2189f45f795be7031fbb9489a_D20220101-20220930" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTEtNS0xLTEtNTg1OTg_3e311180-616e-470f-addc-b4663a06363c">283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTEtNy0xLTEtNTg1OTg_44e65bc4-e39b-42f2-beec-4224a0751898">2,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ec20456c73b4f1f8e73015480eac437_D20220101-20220930" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTItMS0xLTEtNTg1OTg_f64db07f-1cdd-4faf-bc4c-68571d71387b">15,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0963d8c883c844e6b0f9b360576e525d_D20220101-20220930" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTItMy0xLTEtNTg1OTg_bd113cc0-7637-4961-9339-31bb2a59467a">2,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b425cf2189f45f795be7031fbb9489a_D20220101-20220930" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTItNS0xLTEtNTg1OTg_defd00d7-ee73-4440-b96f-ba7193c62e71">1,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTItNy0xLTEtNTg1OTg_6273522c-e56b-4e70-84bb-914fe36ea7a3">20,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired balances, net of post-acquisition adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ec20456c73b4f1f8e73015480eac437_D20220101-20220930" decimals="-6" name="moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTMtMS0xLTEtNTg1OTg_4dcaf553-687f-415e-a35d-2cca0da7aa36">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0963d8c883c844e6b0f9b360576e525d_D20220101-20220930" decimals="-6" name="moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTMtMy0xLTEtNTg1OTg_51fe4998-1346-4add-954b-64359166c6ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b425cf2189f45f795be7031fbb9489a_D20220101-20220930" decimals="-6" name="moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTMtNS0xLTEtNTg1OTg_ba1e573b-ff61-4cb9-8956-b4056beb2eea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTMtNy0xLTEtNTg1OTg_a4656cdc-d740-45d0-a7c2-6e0cee21319e">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in non-risk and other provider payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ec20456c73b4f1f8e73015480eac437_D20220101-20220930" decimals="-6" name="moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTQtMS0xLTEtNTg1OTg_d4c87a69-36ac-440c-907f-35c0bb79d325">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0963d8c883c844e6b0f9b360576e525d_D20220101-20220930" decimals="-6" sign="-" name="moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTQtMy0xLTEtNTg1OTg_1a629d4e-b609-4bac-bf1c-6a594d74954d">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b425cf2189f45f795be7031fbb9489a_D20220101-20220930" decimals="-6" name="moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTQtNS0xLTEtNTg1OTg_958c23ec-eaa8-4e70-b425-db91b09d8c32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTQtNy0xLTEtNTg1OTg_775138eb-f68d-48c7-be26-f346768f67f8">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i787d3e77233e4de9930c7143d7f3e1a7_I20220930" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTUtMS0xLTEtNTg1OTg_3aa1a115-a815-4d2a-848d-2a4e36e1be1c">2,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0945cdffc8424d957d806d4e965885_I20220930" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTUtMy0xLTEtNTg1OTg_6d2d104d-482a-4a4b-aebb-043d53ef892c">447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01ba4967c8b8496c94ad918efed3e1d4_I20220930" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTUtNS0xLTEtNTg1OTg_e5a06f20-6842-4624-8ccf-43c0d4b6300e">252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTUtNy0xLTEtNTg1OTg_be6ee1fb-41cf-4e94-8db2-bd92002c16ce">3,622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September&#160;30, 2022 Form 10-Q | 15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_7">Table of Contents</a></span></div></div><ix:continuation id="i65736d950cf14317a675113a24acf268"><div style="margin-top:6pt"><ix:continuation id="i5df7656e54324bb1b2810c13bfee8f5a"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicaid </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicare</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketplace</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4629290b4494a1da97fe2a340b52e86_I20201231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfNC0xLTEtMS01ODU5OA_5538493d-7e7a-4ee7-928c-490b49b82124">2,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9817ab0688744030bccbbc4527c6ad07_I20201231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfNC0zLTEtMS01ODU5OA_79fd7fa4-12e1-4fbd-90ff-a81ca1dcd576">392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd9f5b7b16064fb4b96d01f818feee51_I20201231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfNC01LTEtMS01ODU5OA_e43139a6-dfe3-4215-b80b-be983841b8f4">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a1055b0f36c4bbd91048d943dbf64df_I20201231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfNC03LTEtMS01ODU5OA_5257ca7e-9250-46bb-8315-e7ddff704e63">2,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Components of medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7d644d1ac344e6fa4918cd4a83af717_D20210101-20210930" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfNi0xLTEtMS01ODU5OA_776e4417-fac4-4a7f-9100-0f50cae1b0c1">13,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2212dcd7830b49eca79d05facc1aaac8_D20210101-20210930" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfNi0zLTEtMS01ODU5OA_73d9829e-4ec6-4fc9-8205-dabee3864dd1">2,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3877802cf9094a9eabfc486981832840_D20210101-20210930" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfNi01LTEtMS01ODU5OA_cfc3af8c-a77e-4ff6-b065-cb182820285f">1,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfNi03LTEtMS01ODU5OA_eaa384de-37d8-471d-826e-66ff40346497">17,558</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7d644d1ac344e6fa4918cd4a83af717_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfNy0xLTEtMS01ODU5OA_3704311c-c8fc-4187-9565-53a2e6149714">158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2212dcd7830b49eca79d05facc1aaac8_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfNy0zLTEtMS01ODU5OA_8c0ed572-6ff0-4c55-b2a9-3d53089b72a4">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3877802cf9094a9eabfc486981832840_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfNy01LTEtMS01ODU5OA_61a0f1f3-60bd-4b78-904d-7098bee6d0ca">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfNy03LTEtMS01ODU5OA_7b818db2-ace5-4350-9ad7-88ee02fe496c">216</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7d644d1ac344e6fa4918cd4a83af717_D20210101-20210930" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfOC0xLTEtMS01ODU5OA_bceea7dd-4d16-4c17-99e4-e7b012298d98">13,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2212dcd7830b49eca79d05facc1aaac8_D20210101-20210930" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfOC0zLTEtMS01ODU5OA_7d52fc14-89c7-42b8-acff-a7678b4b0ddd">2,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3877802cf9094a9eabfc486981832840_D20210101-20210930" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfOC01LTEtMS01ODU5OA_c411edf8-2ec3-45b5-b708-da596c336cab">1,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfOC03LTEtMS01ODU5OA_4d1346a6-b8f4-4472-b337-426de04810a6">17,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7d644d1ac344e6fa4918cd4a83af717_D20210101-20210930" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTAtMS0xLTEtNTg1OTg_ec080023-3c0a-4eb9-95a4-68a6d33f4798">11,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2212dcd7830b49eca79d05facc1aaac8_D20210101-20210930" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTAtMy0xLTEtNTg1OTg_069495c9-c4c0-452a-bf20-41b824bc96fd">1,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3877802cf9094a9eabfc486981832840_D20210101-20210930" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTAtNS0xLTEtNTg1OTg_1f7b3255-2b04-42e6-a215-d3f684fdca65">1,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTAtNy0xLTEtNTg1OTg_62484998-096e-4ebf-b62c-a5a96a711486">14,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7d644d1ac344e6fa4918cd4a83af717_D20210101-20210930" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTEtMS0xLTEtNTg1OTg_d00dfaaf-c8a2-4530-9a09-0cf210d72bab">1,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2212dcd7830b49eca79d05facc1aaac8_D20210101-20210930" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTEtMy0xLTEtNTg1OTg_b0ea4082-5a9f-4812-9f1a-cc316971aee9">340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3877802cf9094a9eabfc486981832840_D20210101-20210930" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTEtNS0xLTEtNTg1OTg_2170a761-6321-4f1c-9f6f-a79b0ce6d48c">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTEtNy0xLTEtNTg1OTg_bebee4f4-222c-4433-8431-b98af8d2710a">2,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7d644d1ac344e6fa4918cd4a83af717_D20210101-20210930" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTItMS0xLTEtNTg1OTg_7b9e3560-de6a-45a5-bb0a-1c4006505be0">13,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2212dcd7830b49eca79d05facc1aaac8_D20210101-20210930" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTItMy0xLTEtNTg1OTg_66f245b4-8898-4f44-90e7-b9e7801ce899">2,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3877802cf9094a9eabfc486981832840_D20210101-20210930" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTItNS0xLTEtNTg1OTg_ba1260eb-4a01-4391-854b-2e201feb96c7">1,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTItNy0xLTEtNTg1OTg_94b33189-8ba7-48dd-baa8-009c22799bc5">16,888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired balances, net of post-acquisition adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7d644d1ac344e6fa4918cd4a83af717_D20210101-20210930" decimals="-6" sign="-" name="moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTMtMS0xLTEtNTg1OTg_7ca24cbc-fec4-4bdc-9fde-885d83071f90">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2212dcd7830b49eca79d05facc1aaac8_D20210101-20210930" decimals="-6" sign="-" name="moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTMtMy0xLTEtNTg1OTg_81a2435b-2ac2-4abf-985a-91cb3985ae3e">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3877802cf9094a9eabfc486981832840_D20210101-20210930" decimals="-6" name="moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTMtNS0xLTEtNTg1OTg_62074690-9257-46df-9b00-8a58bc2bdbfb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" sign="-" name="moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTMtNy0xLTEtNTg1OTg_fa64e710-bb4e-4c01-b1d1-4eef5b7867cc">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in non-risk and other provider payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7d644d1ac344e6fa4918cd4a83af717_D20210101-20210930" decimals="-6" name="moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTQtMS0xLTEtNTg1OTg_14efdb8b-1fb3-46cd-893f-ed1e10f9a593">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2212dcd7830b49eca79d05facc1aaac8_D20210101-20210930" decimals="-6" name="moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTQtMy0xLTEtNTg1OTg_126d12d0-6c9a-454c-ba7e-4551d62ff10e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3877802cf9094a9eabfc486981832840_D20210101-20210930" decimals="-6" name="moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTQtNS0xLTEtNTg1OTg_137732da-8796-4be2-b266-4b612f5d08d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTQtNy0xLTEtNTg1OTg_13646b27-6c51-4c1d-8306-66d26c6dfc2f">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1698bae97ab44ee92e15544064ddc75_I20210930" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTUtMS0xLTEtNTg1OTg_8f3e0f2a-650e-423f-bf56-c602f6228c3b">2,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77d77fe305a64bacbf04f03c5378f673_I20210930" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTUtMy0xLTEtNTg1OTg_e35ca902-7cfd-4a82-af45-2c30f9a2874f">387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic24da3c878854020a39db2e88f0312b7_I20210930" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTUtNS0xLTEtNTg1OTg_3122d3a9-4a6e-402b-bd61-dba49725dd61">361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5f8e83b346f4a789040e8611fbb11f6_I20210930" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTUtNy0xLTEtNTg1OTg_ae8eb354-c824-4806-b339-9e07351b43fd">3,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimates of medical claims and benefits payable recorded at December 31, 2021, and 2020 developed favorably by approximately $<ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RleHRyZWdpb246MDgyZDY1NTQ0MzdlNDgyZjkyYjQ3MjI1NTRjNTNiZmZfMTEwMA_1136879e-0222-4450-accf-2ee55c2b7980">338</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RleHRyZWdpb246MDgyZDY1NTQ0MzdlNDgyZjkyYjQ3MjI1NTRjNTNiZmZfMTEwNw_7b818db2-ace5-4350-9ad7-88ee02fe496c">216</ix:nonFraction> million as of September&#160;30, 2022, and 2021, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The favorable prior year development recognized in the nine months ended September 30, 2022 was primarily due to lower than expected utilization of medical services by our members and improved operating performance. Consequently, the ultimate costs recognized in 2022, as claims payments were processed, were lower than our estimates in 2021.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="icc83361866f7481797f2215c8aedaf24_64"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8. <ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="us-gaap:LongTermDebtTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RleHRyZWdpb246NWFhMTA3MTI0OTc5NGFkNzhlZTQyNDM2M2M3YzE0ZDVfMjY1MA_803be1ff-2e36-4586-b607-24888aa0c5d7" continuedAt="iceaff1b02b50444cb8828bf8671f57f5" escape="true">Debt </ix:nonNumeric></span></div><ix:continuation id="iceaff1b02b50444cb8828bf8671f57f5" continuedAt="iec0900e6802148b9ba9f306851ca96d0"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All our debt is held at the parent, which is reported in the Other segment. <ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RleHRyZWdpb246NWFhMTA3MTI0OTc5NGFkNzhlZTQyNDM2M2M3YzE0ZDVfMjY0Nw_12b1382c-751e-44f0-af7e-b342374c0a84" continuedAt="ia5f8f4c8fb6847869d3a11f8417eed4b" escape="true">The following table summarizes our outstanding debt obligations, all of which are non-current as of the dates reported below:</ix:nonNumeric></span></div><div style="margin-top:6pt"><ix:continuation id="ia5f8f4c8fb6847869d3a11f8417eed4b"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-current long-term debt:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2215166a13a24f4ea0beb4f9ec5386b9_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RhYmxlOmM2ODUyYzdjNDFmNzRhMzliMzg2N2E5MjAyMWU0ODY1L3RhYmxlcmFuZ2U6YzY4NTJjN2M0MWY3NGEzOWIzODY3YTkyMDIxZTQ4NjVfOC0wLTEtMS01ODU5OC90ZXh0cmVnaW9uOjhmOWVkZjkwM2QzZTQ2Mzk4MzQ3MGY0NWI3NmEwYTAwXzQ_684c7b56-c616-4156-b6af-c055e1225af1">4.375</ix:nonFraction>% Notes due 2028</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2215166a13a24f4ea0beb4f9ec5386b9_I20220930" decimals="-6" name="moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RhYmxlOmM2ODUyYzdjNDFmNzRhMzliMzg2N2E5MjAyMWU0ODY1L3RhYmxlcmFuZ2U6YzY4NTJjN2M0MWY3NGEzOWIzODY3YTkyMDIxZTQ4NjVfOC0xLTEtMS01ODU5OA_6852a502-0f57-4ae6-b1e3-c12bcb65fe27">800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic26c41034fae49aeaa64c74ef2218d5a_I20211231" decimals="-6" name="moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RhYmxlOmM2ODUyYzdjNDFmNzRhMzliMzg2N2E5MjAyMWU0ODY1L3RhYmxlcmFuZ2U6YzY4NTJjN2M0MWY3NGEzOWIzODY3YTkyMDIxZTQ4NjVfOC0zLTEtMS01ODU5OA_4e79444b-ff29-4e5b-87f3-e09a8d3095e6">800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4568007f62514af188a722dbbfff6949_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RhYmxlOmM2ODUyYzdjNDFmNzRhMzliMzg2N2E5MjAyMWU0ODY1L3RhYmxlcmFuZ2U6YzY4NTJjN2M0MWY3NGEzOWIzODY3YTkyMDIxZTQ4NjVfOS0wLTEtMS01ODU5OC90ZXh0cmVnaW9uOmFlMDA3MmVmOWEyMzQzMDQ5Nzk1YjM5M2ZmODViNWY4XzQ_9cdb5704-1c74-42e5-96c0-beb98c5331f6">3.875</ix:nonFraction>% Notes due 2030 </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4568007f62514af188a722dbbfff6949_I20220930" decimals="-6" name="moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RhYmxlOmM2ODUyYzdjNDFmNzRhMzliMzg2N2E5MjAyMWU0ODY1L3RhYmxlcmFuZ2U6YzY4NTJjN2M0MWY3NGEzOWIzODY3YTkyMDIxZTQ4NjVfOS0xLTEtMS01ODU5OA_93014218-7d8c-4ac9-8083-a7cb97e2fd3d">650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50750950b870483d9018a954d9657216_I20211231" decimals="-6" name="moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RhYmxlOmM2ODUyYzdjNDFmNzRhMzliMzg2N2E5MjAyMWU0ODY1L3RhYmxlcmFuZ2U6YzY4NTJjN2M0MWY3NGEzOWIzODY3YTkyMDIxZTQ4NjVfOS0zLTEtMS01ODU5OA_8ce04534-a0c5-4907-a0dd-0d420a173568">650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i68670e57970547ba9f2bb65e407ef0c3_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RhYmxlOmM2ODUyYzdjNDFmNzRhMzliMzg2N2E5MjAyMWU0ODY1L3RhYmxlcmFuZ2U6YzY4NTJjN2M0MWY3NGEzOWIzODY3YTkyMDIxZTQ4NjVfMTAtMC0xLTEtNTg1OTgvdGV4dHJlZ2lvbjpmMTgzN2I5YTkyNWM0ODI1YjU1MzU5ZmM5MjdlZDUwY180_8eaa68b5-c180-4f43-88af-764c0af6a117">3.875</ix:nonFraction>% Notes due 2032</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68670e57970547ba9f2bb65e407ef0c3_I20220930" decimals="-6" name="moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RhYmxlOmM2ODUyYzdjNDFmNzRhMzliMzg2N2E5MjAyMWU0ODY1L3RhYmxlcmFuZ2U6YzY4NTJjN2M0MWY3NGEzOWIzODY3YTkyMDIxZTQ4NjVfMTAtMS0xLTEtNTg1OTg_95b1ee86-47cf-4cc1-8016-d67a5651d906">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5dabbb9212b4359ba854b1a8c18e537_I20211231" decimals="-6" name="moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RhYmxlOmM2ODUyYzdjNDFmNzRhMzliMzg2N2E5MjAyMWU0ODY1L3RhYmxlcmFuZ2U6YzY4NTJjN2M0MWY3NGEzOWIzODY3YTkyMDIxZTQ4NjVfMTAtMy0xLTEtNTg1OTg_7fce9dad-9be6-4ef1-9ace-869d177d521e">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred debt issuance costs </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:DeferredFinanceCostsNoncurrentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RhYmxlOmM2ODUyYzdjNDFmNzRhMzliMzg2N2E5MjAyMWU0ODY1L3RhYmxlcmFuZ2U6YzY4NTJjN2M0MWY3NGEzOWIzODY3YTkyMDIxZTQ4NjVfMTEtMS0xLTEtNTg1OTg_3959c940-421a-4511-9d2f-8963f8e4ba85">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:DeferredFinanceCostsNoncurrentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RhYmxlOmM2ODUyYzdjNDFmNzRhMzliMzg2N2E5MjAyMWU0ODY1L3RhYmxlcmFuZ2U6YzY4NTJjN2M0MWY3NGEzOWIzODY3YTkyMDIxZTQ4NjVfMTEtMy0xLTEtNTg1OTg_78ea4980-c7ee-4852-b121-69883b77bef2">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RhYmxlOmM2ODUyYzdjNDFmNzRhMzliMzg2N2E5MjAyMWU0ODY1L3RhYmxlcmFuZ2U6YzY4NTJjN2M0MWY3NGEzOWIzODY3YTkyMDIxZTQ4NjVfMTItMS0xLTEtNTg1OTg_a9d60da3-13f6-470a-88e0-40385a47b788">2,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RhYmxlOmM2ODUyYzdjNDFmNzRhMzliMzg2N2E5MjAyMWU0ODY1L3RhYmxlcmFuZ2U6YzY4NTJjN2M0MWY3NGEzOWIzODY3YTkyMDIxZTQ4NjVfMTItMy0xLTEtNTg1OTg_ef44a177-d40c-44a6-8759-3a212b658ed5">2,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to a credit agreement (the &#8220;Credit Agreement&#8221;) which includes a revolving credit facility (&#8220;Credit Facility&#8221;) of $<ix:nonFraction unitRef="usd" contextRef="i45addfb2824d4400bae53112a7856042_I20220930" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RleHRyZWdpb246NWFhMTA3MTI0OTc5NGFkNzhlZTQyNDM2M2M3YzE0ZDVfMzYw_170240bf-aea5-4049-9085-94434278e0cb">1.0</ix:nonFraction> billion, among other provisions. The Credit Agreement has a term of <ix:nonNumeric contextRef="if5d5359290144d4f933ac919de58b333_D20220101-20220930" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RleHRyZWdpb246NWFhMTA3MTI0OTc5NGFkNzhlZTQyNDM2M2M3YzE0ZDVfNDIz_5f1013fe-af1a-463b-ab85-2a8086fa2dbe">five years</ix:nonNumeric>, and all amounts outstanding will be due and payable on June 8, 2025. Borrowings under the Credit Agreement bear interest based, at our election, on a base rate or other defined rate, plus in each case, the applicable margin. In addition to interest payable on the principal amount of indebtedness outstanding from time to time under the Credit Agreement, we are required to pay a quarterly commitment fee.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains customary non-financial and financial covenants. As of September&#160;30, 2022, we were in compliance with all financial and non-financial covenants under the Credit Agreement. As of September&#160;30, 2022, <ix:nonFraction unitRef="usd" contextRef="i45addfb2824d4400bae53112a7856042_I20220930" decimals="INF" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RleHRyZWdpb246NWFhMTA3MTI0OTc5NGFkNzhlZTQyNDM2M2M3YzE0ZDVfMTAyOQ_947a48d4-7c7e-41fb-8f96-447e6cbf789f">no</ix:nonFraction> amounts were outstanding under the Credit Facility.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Notes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our senior notes are described below. Each of these notes are senior unsecured obligations of Molina and rank equally in right of payment with all existing and future senior debt, and senior to all existing and future subordinated </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September&#160;30, 2022 Form 10-Q | 16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_7">Table of Contents</a></span></div></div><ix:continuation id="iec0900e6802148b9ba9f306851ca96d0" continuedAt="i6e91593709e74a10949b55484792be1c"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">debt of Molina. In addition, each of the indentures governing the senior notes contain customary non-financial covenants and change of control provisions. As of September&#160;30, 2022, we were in compliance with all non-financial covenants in the indentures governing the senior notes. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indentures governing the senior notes contain cross-default provisions that are triggered upon default by us or any of our subsidiaries on any indebtedness in excess of the amount specified in the applicable indenture. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i2215166a13a24f4ea0beb4f9ec5386b9_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RleHRyZWdpb246NWFhMTA3MTI0OTc5NGFkNzhlZTQyNDM2M2M3YzE0ZDVfMTgyMA_684c7b56-c616-4156-b6af-c055e1225af1">4.375</ix:nonFraction>% Notes due 2028.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $<ix:nonFraction unitRef="usd" contextRef="i2215166a13a24f4ea0beb4f9ec5386b9_I20220930" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RleHRyZWdpb246NWFhMTA3MTI0OTc5NGFkNzhlZTQyNDM2M2M3YzE0ZDVfMTg0Ng_2d132671-b06c-47b3-bf27-c0ea14f2b33c">800</ix:nonFraction> million aggregate principal amount of senior notes (the &#8220;<ix:nonFraction unitRef="number" contextRef="i2215166a13a24f4ea0beb4f9ec5386b9_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RleHRyZWdpb246NWFhMTA3MTI0OTc5NGFkNzhlZTQyNDM2M2M3YzE0ZDVfMTg5OA_684c7b56-c616-4156-b6af-c055e1225af1">4.375</ix:nonFraction>% Notes&#8221;) outstanding as of September&#160;30, 2022, which are due June 15, 2028, unless earlier redeemed. Interest, at a rate of <ix:nonFraction unitRef="number" contextRef="i2215166a13a24f4ea0beb4f9ec5386b9_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RleHRyZWdpb246NWFhMTA3MTI0OTc5NGFkNzhlZTQyNDM2M2M3YzE0ZDVfMjAwOA_684c7b56-c616-4156-b6af-c055e1225af1">4.375</ix:nonFraction>% per annum, is payable semiannually in arrears on June 15 and December 15.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i4568007f62514af188a722dbbfff6949_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RleHRyZWdpb246NWFhMTA3MTI0OTc5NGFkNzhlZTQyNDM2M2M3YzE0ZDVfMjA4NQ_9cdb5704-1c74-42e5-96c0-beb98c5331f6">3.875</ix:nonFraction>% Notes due 2030. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $<ix:nonFraction unitRef="usd" contextRef="i4568007f62514af188a722dbbfff6949_I20220930" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RleHRyZWdpb246NWFhMTA3MTI0OTc5NGFkNzhlZTQyNDM2M2M3YzE0ZDVfMjExMQ_d494ff5c-6123-46ed-9e5b-850257dfb2a5">650</ix:nonFraction> million aggregate principal amount of senior notes (the &#8220;<ix:nonFraction unitRef="number" contextRef="i4568007f62514af188a722dbbfff6949_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RleHRyZWdpb246NWFhMTA3MTI0OTc5NGFkNzhlZTQyNDM2M2M3YzE0ZDVfMjE2Mw_9cdb5704-1c74-42e5-96c0-beb98c5331f6">3.875</ix:nonFraction>% Notes due 2030&#8221;) outstanding as of September&#160;30, 2022, which are due November 15, 2030, unless earlier redeemed. Interest, at a rate of <ix:nonFraction unitRef="number" contextRef="i4568007f62514af188a722dbbfff6949_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RleHRyZWdpb246NWFhMTA3MTI0OTc5NGFkNzhlZTQyNDM2M2M3YzE0ZDVfMjI4Ng_9cdb5704-1c74-42e5-96c0-beb98c5331f6">3.875</ix:nonFraction>% per annum, is payable semiannually in arrears on May 15 and November 15.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="i6e91593709e74a10949b55484792be1c" continuedAt="idd244f8d4ccf469b88db9ccce3877426"><ix:nonFraction unitRef="number" contextRef="i68670e57970547ba9f2bb65e407ef0c3_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RleHRyZWdpb246NWFhMTA3MTI0OTc5NGFkNzhlZTQyNDM2M2M3YzE0ZDVfMjM2Mg_8eaa68b5-c180-4f43-88af-764c0af6a117">3.875</ix:nonFraction>% Notes due 2032.</ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idd244f8d4ccf469b88db9ccce3877426"> We had $<ix:nonFraction unitRef="usd" contextRef="i68670e57970547ba9f2bb65e407ef0c3_I20220930" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RleHRyZWdpb246NWFhMTA3MTI0OTc5NGFkNzhlZTQyNDM2M2M3YzE0ZDVfMjM4OA_0523e0fd-f61e-46dd-a1ca-e3418bca20e4">750</ix:nonFraction> million aggregate principal amount of senior notes (the &#8220;<ix:nonFraction unitRef="number" contextRef="i68670e57970547ba9f2bb65e407ef0c3_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RleHRyZWdpb246NWFhMTA3MTI0OTc5NGFkNzhlZTQyNDM2M2M3YzE0ZDVfMjQ0MA_8eaa68b5-c180-4f43-88af-764c0af6a117">3.875</ix:nonFraction>% Notes due 2032&#8221;) outstanding as of September&#160;30, 2022, which are due May 15, 2032, unless earlier redeemed. Interest, at a rate of <ix:nonFraction unitRef="number" contextRef="i68670e57970547ba9f2bb65e407ef0c3_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RleHRyZWdpb246NWFhMTA3MTI0OTc5NGFkNzhlZTQyNDM2M2M3YzE0ZDVfMjU1OA_8eaa68b5-c180-4f43-88af-764c0af6a117">3.875</ix:nonFraction>% per annum, is payable semiannually in arrears on May 15 and November 15.</ix:continuation> </span></div><div><span><br/></span></div><div id="icc83361866f7481797f2215c8aedaf24_67"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9. <ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82Ny9mcmFnOmY2NTIwZWZlMTJhNzRkZWU4NGQ5YWQ5MWMwMDczNzJkL3RleHRyZWdpb246ZjY1MjBlZmUxMmE3NGRlZTg0ZDlhZDkxYzAwNzM3MmRfNzMw_d51737a9-d538-4f27-b0c6-54bf6e91a7cb" continuedAt="icb53f591c3d7450e97bf4331188497f8" escape="true">Stockholders' Equity </ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icb53f591c3d7450e97bf4331188497f8">In September 2021, our board of directors authorized the purchase of up to $<ix:nonFraction unitRef="usd" contextRef="i98de094b8bc642c2838aa6ef19a8ed9a_I20210930" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82Ny9mcmFnOmY2NTIwZWZlMTJhNzRkZWU4NGQ5YWQ5MWMwMDczNzJkL3RleHRyZWdpb246ZjY1MjBlZmUxMmE3NGRlZTg0ZDlhZDkxYzAwNzM3MmRfODg_ca3c6266-f4c3-4e25-af66-bc8d72b9fad1">500</ix:nonFraction>&#160;million, in the aggregate, of our common stock. This new program, which superseded the stock purchase program approved by our board of directors in September 2020, is funded with cash on hand and extends through December 31, 2022. The exact timing and amount of any repurchase is determined by management based on market conditions and share price, in addition to other factors, and subject to the restrictions relating to volume, price, and timing under applicable law.  Under this program, pursuant to a Rule 10b5-1 trading plan, we purchased approximately <ix:nonFraction unitRef="shares" contextRef="iea66be3daee34721bcd1e066d3260b58_D20220401-20220630" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82Ny9mcmFnOmY2NTIwZWZlMTJhNzRkZWU4NGQ5YWQ5MWMwMDczNzJkL3RleHRyZWdpb246ZjY1MjBlZmUxMmE3NGRlZTg0ZDlhZDkxYzAwNzM3MmRfNjQy_200656c4-c416-495e-ad45-bf843fb87a1f">658,000</ix:nonFraction> shares for $<ix:nonFraction unitRef="usd" contextRef="iea66be3daee34721bcd1e066d3260b58_D20220401-20220630" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82Ny9mcmFnOmY2NTIwZWZlMTJhNzRkZWU4NGQ5YWQ5MWMwMDczNzJkL3RleHRyZWdpb246ZjY1MjBlZmUxMmE3NGRlZTg0ZDlhZDkxYzAwNzM3MmRfNjU2_1c043e63-66a2-432e-87d8-e75cbe6eb3ad">200</ix:nonFraction>&#160;million in the second quarter of 2022 (average cost of $<ix:nonFraction unitRef="usdPerShare" contextRef="iea66be3daee34721bcd1e066d3260b58_D20220401-20220630" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82Ny9mcmFnOmY2NTIwZWZlMTJhNzRkZWU4NGQ5YWQ5MWMwMDczNzJkL3RleHRyZWdpb246ZjY1MjBlZmUxMmE3NGRlZTg0ZDlhZDkxYzAwNzM3MmRfNzA2_14d21e77-e2a8-4131-b28b-36edafbb3ed0">304.13</ix:nonFraction> per share).</ix:continuation> </span></div><div style="margin-bottom:6pt"><span><br/></span></div><div id="icc83361866f7481797f2215c8aedaf24_70"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10. <ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RleHRyZWdpb246MzNjZTdlOWJkNTkwNDg2YmI0YTVjOTJmYjAxNTNhOGRfMjA2OA_e373b7d7-09a5-47e5-bfce-ac7eef012461" continuedAt="i667d943c6d1443a59f83b4449845ff6b" escape="true">Segments </ix:nonNumeric></span></div><ix:continuation id="i667d943c6d1443a59f83b4449845ff6b" continuedAt="i8bd57d2a814e4edf8c0e19780b5e9a4f"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have <ix:nonFraction unitRef="segment" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RleHRyZWdpb246MzNjZTdlOWJkNTkwNDg2YmI0YTVjOTJmYjAxNTNhOGRfMTY_6925dc79-7402-4807-b44c-808fb9018835">four</ix:nonFraction> reportable segments consisting of: 1)&#160;Medicaid; 2)&#160;Medicare; 3)&#160;Marketplace; and 4)&#160;Other. Our reportable segments are consistent with how we currently manage the business and view the markets we serve. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which we offer managed healthcare services. The Other segment, which is insignificant to our consolidated results of operations, includes certain corporate amounts not associated with or allocated to the Medicaid, Medicare, or Marketplace segments. Additionally, the Other segment includes service revenues and service costs associated with the long-term services and supports consultative services we provide in Wisconsin.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key metrics used to assess the performance of our Medicaid, Medicare, and Marketplace segments are premium revenue, medical margin and medical care ratio (&#8220;MCR&#8221;). MCR represents the amount of medical care costs as a percentage of premium revenue. Therefore, the underlying medical margin, or the amount earned by the Medicaid, Medicare, and Marketplace segments after medical costs are deducted from premium revenue, represents the most important measure of earnings reviewed by management, and is used by our chief executive officer to review results, assess performance, and allocate resources. The key metric used to assess the performance of our Other segment is service margin. The service margin is equal to service revenue minus cost of service revenue. We do not report total assets by segment because this is not a metric used to assess segment performance or allocate resources.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September&#160;30, 2022 Form 10-Q | 17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_7">Table of Contents</a></span></div></div><ix:continuation id="i8bd57d2a814e4edf8c0e19780b5e9a4f"><ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RleHRyZWdpb246MzNjZTdlOWJkNTkwNDg2YmI0YTVjOTJmYjAxNTNhOGRfMjA1OA_479385cf-2e05-4dfc-8e81-8c884b08122a" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total revenue by segment. Inter-segment revenue was insignificant for all periods presented.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:42.301%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.539%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedddb1611ce1453d8bc04f5aa0c8509c_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjZmYTNlMTJmMTY5MjQyZjg4Y2Q1MGM4NTkyZTk2ODQyL3RhYmxlcmFuZ2U6NmZhM2UxMmYxNjkyNDJmODhjZDUwYzg1OTJlOTY4NDJfNS0xLTEtMS01ODU5OA_63d29387-cbec-4bd5-9f7d-296e5172486d">6,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id30882aba8a04db99646163bc2413884_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjZmYTNlMTJmMTY5MjQyZjg4Y2Q1MGM4NTkyZTk2ODQyL3RhYmxlcmFuZ2U6NmZhM2UxMmYxNjkyNDJmODhjZDUwYzg1OTJlOTY4NDJfNS0zLTEtMS01ODU5OA_665439c3-918e-42c9-bb7a-e172be6f31f8">5,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ec20456c73b4f1f8e73015480eac437_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjZmYTNlMTJmMTY5MjQyZjg4Y2Q1MGM4NTkyZTk2ODQyL3RhYmxlcmFuZ2U6NmZhM2UxMmYxNjkyNDJmODhjZDUwYzg1OTJlOTY4NDJfNS01LTEtMS01ODU5OA_61e675cd-8211-4b84-a074-8c1196eed2ad">19,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7d644d1ac344e6fa4918cd4a83af717_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjZmYTNlMTJmMTY5MjQyZjg4Y2Q1MGM4NTkyZTk2ODQyL3RhYmxlcmFuZ2U6NmZhM2UxMmYxNjkyNDJmODhjZDUwYzg1OTJlOTY4NDJfNS03LTEtMS01ODU5OA_e81181a9-0be7-4d17-b366-d1f73bc93297">15,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37c0ca418ca74d69b9c15307c7e58df1_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjZmYTNlMTJmMTY5MjQyZjg4Y2Q1MGM4NTkyZTk2ODQyL3RhYmxlcmFuZ2U6NmZhM2UxMmYxNjkyNDJmODhjZDUwYzg1OTJlOTY4NDJfNi0xLTEtMS01ODU5OA_5e3d70b3-8118-48de-80f3-d7dc23651935">955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa97e16d76c6408f8338e08b5bea4b44_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjZmYTNlMTJmMTY5MjQyZjg4Y2Q1MGM4NTkyZTk2ODQyL3RhYmxlcmFuZ2U6NmZhM2UxMmYxNjkyNDJmODhjZDUwYzg1OTJlOTY4NDJfNi0zLTEtMS01ODU5OA_cb074b30-3ece-404f-aac0-dddba868bd72">875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0963d8c883c844e6b0f9b360576e525d_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjZmYTNlMTJmMTY5MjQyZjg4Y2Q1MGM4NTkyZTk2ODQyL3RhYmxlcmFuZ2U6NmZhM2UxMmYxNjkyNDJmODhjZDUwYzg1OTJlOTY4NDJfNi01LTEtMS01ODU5OA_7527b840-bca3-46dc-b03a-5f266c08f1fd">2,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2212dcd7830b49eca79d05facc1aaac8_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjZmYTNlMTJmMTY5MjQyZjg4Y2Q1MGM4NTkyZTk2ODQyL3RhYmxlcmFuZ2U6NmZhM2UxMmYxNjkyNDJmODhjZDUwYzg1OTJlOTY4NDJfNi03LTEtMS01ODU5OA_c22dd348-5f13-42c4-8a98-b0ac15968c81">2,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f6a30e4c3a945b1bae228351989449f_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjZmYTNlMTJmMTY5MjQyZjg4Y2Q1MGM4NTkyZTk2ODQyL3RhYmxlcmFuZ2U6NmZhM2UxMmYxNjkyNDJmODhjZDUwYzg1OTJlOTY4NDJfNy0xLTEtMS01ODU5OA_2ca4c708-17af-4ee6-9c6c-15d595894cd6">575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87816e2186d3470b93fba05f0ffe1f2d_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjZmYTNlMTJmMTY5MjQyZjg4Y2Q1MGM4NTkyZTk2ODQyL3RhYmxlcmFuZ2U6NmZhM2UxMmYxNjkyNDJmODhjZDUwYzg1OTJlOTY4NDJfNy0zLTEtMS01ODU5OA_07f95bab-2d26-47dc-a330-c69c529f967f">793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b425cf2189f45f795be7031fbb9489a_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjZmYTNlMTJmMTY5MjQyZjg4Y2Q1MGM4NTkyZTk2ODQyL3RhYmxlcmFuZ2U6NmZhM2UxMmYxNjkyNDJmODhjZDUwYzg1OTJlOTY4NDJfNy01LTEtMS01ODU5OA_9394be6a-48ee-433b-a40d-ff3ea271d9ea">1,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3877802cf9094a9eabfc486981832840_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjZmYTNlMTJmMTY5MjQyZjg4Y2Q1MGM4NTkyZTk2ODQyL3RhYmxlcmFuZ2U6NmZhM2UxMmYxNjkyNDJmODhjZDUwYzg1OTJlOTY4NDJfNy03LTEtMS01ODU5OA_2cbfa2e5-de0b-4c54-9478-406accb381ca">2,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2aaee23745f4ff297ec360508e852a7_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjZmYTNlMTJmMTY5MjQyZjg4Y2Q1MGM4NTkyZTk2ODQyL3RhYmxlcmFuZ2U6NmZhM2UxMmYxNjkyNDJmODhjZDUwYzg1OTJlOTY4NDJfOC0xLTEtMS01ODU5OA_059176cc-f555-459f-81e2-f575832d9881">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7ee1c4d62614df782f74c5d44f474c9_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjZmYTNlMTJmMTY5MjQyZjg4Y2Q1MGM4NTkyZTk2ODQyL3RhYmxlcmFuZ2U6NmZhM2UxMmYxNjkyNDJmODhjZDUwYzg1OTJlOTY4NDJfOC0zLTEtMS01ODU5OA_9101c30e-3056-4e51-be8b-87b87f30eeb8">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eff537979cc43da94a627c160916e60_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjZmYTNlMTJmMTY5MjQyZjg4Y2Q1MGM4NTkyZTk2ODQyL3RhYmxlcmFuZ2U6NmZhM2UxMmYxNjkyNDJmODhjZDUwYzg1OTJlOTY4NDJfOC01LTEtMS01ODU5OA_2ea2103e-ba32-4b27-ba7e-a2156d69fcf6">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabdb88db75e64d48bbc614f435a60acc_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjZmYTNlMTJmMTY5MjQyZjg4Y2Q1MGM4NTkyZTk2ODQyL3RhYmxlcmFuZ2U6NmZhM2UxMmYxNjkyNDJmODhjZDUwYzg1OTJlOTY4NDJfOC03LTEtMS01ODU5OA_9a16ce14-c75f-40aa-9513-30e7670e1af0">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjZmYTNlMTJmMTY5MjQyZjg4Y2Q1MGM4NTkyZTk2ODQyL3RhYmxlcmFuZ2U6NmZhM2UxMmYxNjkyNDJmODhjZDUwYzg1OTJlOTY4NDJfOS0xLTEtMS01ODU5OA_b063036f-11c4-4195-a89a-9037efbed185">7,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjZmYTNlMTJmMTY5MjQyZjg4Y2Q1MGM4NTkyZTk2ODQyL3RhYmxlcmFuZ2U6NmZhM2UxMmYxNjkyNDJmODhjZDUwYzg1OTJlOTY4NDJfOS0zLTEtMS01ODU5OA_a1f432d0-b53e-4b9d-aea0-943d04067b54">7,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjZmYTNlMTJmMTY5MjQyZjg4Y2Q1MGM4NTkyZTk2ODQyL3RhYmxlcmFuZ2U6NmZhM2UxMmYxNjkyNDJmODhjZDUwYzg1OTJlOTY4NDJfOS01LTEtMS01ODU5OA_c3c79997-90b3-4df9-9429-ca5a08cf2c89">23,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjZmYTNlMTJmMTY5MjQyZjg4Y2Q1MGM4NTkyZTk2ODQyL3RhYmxlcmFuZ2U6NmZhM2UxMmYxNjkyNDJmODhjZDUwYzg1OTJlOTY4NDJfOS03LTEtMS01ODU5OA_127608f4-883e-4250-a45e-640685dad388">20,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles margin by segment to consolidated income before income taxes. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Margin:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0164340d3f1942a3a1a5f79ab8a7363e_D20220701-20220930" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfNS0xLTEtMS01ODU5OA_6d338754-c5c5-4bc9-aef4-8e859289055d">703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2109ad9aef8463798890611406b526f_D20210701-20210930" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfNS0zLTEtMS01ODU5OA_99bda6a7-2d03-4927-b3ac-251ea0d73f7e">532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i226c2214fece4fadb73439a12ab95d6f_D20220101-20220930" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfNS01LTEtMS01ODU5OA_8d5f9b81-3cd3-4d06-b9c3-7f3514009599">2,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i362d995290d84c1597a463618a6f4a5f_D20210101-20210930" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfNS03LTEtMS01ODU5OA_5401c027-b5a4-43eb-8d11-6f0330272b05">1,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i763ba496c6a742eca5a9885bbbc7830e_D20220701-20220930" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfNi0xLTEtMS01ODU5OA_1eb640f4-3adb-4b07-af3e-a2115bb5b47b">108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cef013ef54740e8857e7e00eac7dd4d_D20210701-20210930" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfNi0zLTEtMS01ODU5OA_e655621e-fdfa-49fa-b8d7-9ea43e7451c2">151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48a45433b5894e268eab6a5f260ad9d0_D20220101-20220930" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfNi01LTEtMS01ODU5OA_a2aafce5-2a3a-4b72-a33e-932a0954f85f">360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe9ad49fa264be4b25af966a5e6c09c_D20210101-20210930" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfNi03LTEtMS01ODU5OA_ae96f5e6-3bff-490c-b348-042715555c4c">329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1896656ef924935b656c0a3948916bf_D20220701-20220930" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfNy0xLTEtMS01ODU5OA_c8542f65-661d-409a-ae16-64eff53580e2">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i454009dcb5f24035b7bb46ce50254cae_D20210701-20210930" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfNy0zLTEtMS01ODU5OA_fca7737e-e886-4260-a45a-9731fcb0c5e4">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i670ed9482960439bb9d74ff2ffeb3f5e_D20220101-20220930" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfNy01LTEtMS01ODU5OA_da9d6814-85de-4948-8274-514a55e97d5d">255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i812649e7c9904b4abd14942568ab571c_D20210101-20210930" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfNy03LTEtMS01ODU5OA_72296d67-d654-4ad4-bb38-1f4f7eeeff74">331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic51dd760fd294631a25b501d900f5f1d_D20220701-20220930" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfOC0xLTEtMS01ODU5OA_57118f08-499c-40c6-a10a-240d688a9104">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4a763210a0a4713b5050f956ee2aac7_D20210701-20210930" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfOC0zLTEtMS01ODU5OA_1e757f15-eef2-4806-a723-ecd904cfb32d">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ff31abf6c8c49da85cb7c5b5b247423_D20220101-20220930" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfOC01LTEtMS01ODU5OA_e779814c-9084-443a-8081-ca1928ae6941">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i328833ca29384ce2b4440be9a5f1bf23_D20210101-20210930" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfOC03LTEtMS01ODU5OA_6da4eb7e-6fb6-464d-b2ca-6d134cb17b4c">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total margin </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3648beb8cc65477dac1c4d580ec26c84_D20220701-20220930" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfOS0xLTEtMS01ODU5OA_bce981af-85f5-43bf-8109-51959d5ed848">890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i858448d6578c463ea667e35c5c992219_D20210701-20210930" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfOS0zLTEtMS01ODU5OA_38abb95c-824c-48bf-9656-6b7e4b494bdf">755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50521a7d515b41458530732201de3623_D20220101-20220930" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfOS01LTEtMS01ODU5OA_568ad711-fbb2-40cf-8cc6-45b4af51dd2e">2,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d6e9de0146e4e0ab67af6591b50afd1_D20210101-20210930" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfOS03LTEtMS01ODU5OA_2359b575-2174-4bb6-a974-fbb42974bd07">2,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: other operating revenues </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fa84dba36794309afacfe9bdfbc2bde_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfMTAtMS0xLTEtNTg1OTg_5f3bcedc-113b-4ee1-b73e-1b34194c5573">274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e17562a155a4b4899cfccb2754c67e4_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfMTAtMy0xLTEtNTg1OTg_b6b490a6-d834-4e60-97a6-e88ce6dd8307">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87b6e21917b64be8a7e28cf2b5ac0018_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfMTAtNS0xLTEtNTg1OTg_8775225f-7b41-4215-8eae-320e36c48f80">732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i945971ba12124c429f508ca0dd49999b_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfMTAtNy0xLTEtNTg1OTg_cc60e45f-73c5-4bb3-a868-db07e7e06a8e">620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: other operating expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fa84dba36794309afacfe9bdfbc2bde_D20220701-20220930" decimals="-6" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfMTEtMS0xLTEtNTg1OTg_7c2b976e-bf48-4aef-aa18-7a5d651c24f9">829</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e17562a155a4b4899cfccb2754c67e4_D20210701-20210930" decimals="-6" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfMTEtMy0xLTEtNTg1OTg_8a326bfa-e054-4279-988d-9c14dd89ee18">756</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87b6e21917b64be8a7e28cf2b5ac0018_D20220101-20220930" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfMTEtNS0xLTEtNTg1OTg_6a54729e-3549-4de9-a756-a99e41d15262">2,455</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i945971ba12124c429f508ca0dd49999b_D20210101-20210930" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfMTEtNy0xLTEtNTg1OTg_1f0c2074-e52b-4c98-827f-717c8a1375b0">2,149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfMTItMS0xLTEtNTg1OTg_91c6d8d2-0c16-46b5-a0e7-bf648ee92670">335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfMTItMy0xLTEtNTg1OTg_33ade7e7-2beb-4685-aa56-2a27c3a3041f">221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfMTItNS0xLTEtNTg1OTg_d04e35f5-c6b5-4dd0-8c02-8fa18492cbef">1,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfMTItNy0xLTEtNTg1OTg_4cfef02c-b221-4398-ba01-371b19a966d2">829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expenses, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfMTMtMS0xLTEtNTg1OTg_388e805e-f083-4725-a8de-17b2bf689783">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfMTMtMy0xLTEtNTg1OTg_29946e62-5ba6-419d-a9a1-5a3bed1f7396">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfMTMtNS0xLTEtNTg1OTg_758378fa-c835-4778-8802-e4708fb2c09e">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfMTMtNy0xLTEtNTg1OTg_86e60141-20c2-4eb3-b849-3d3a3f8711ec">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfMTQtMS0xLTEtNTg1OTg_987e2de9-9727-499d-b11a-598564d1f42c">307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfMTQtMy0xLTEtNTg1OTg_4946bb73-6c05-4b6f-8311-931e01a0013b">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfMTQtNS0xLTEtNTg1OTg_1f461045-93d2-44ed-993c-238bf0679c28">985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfMTQtNy0xLTEtNTg1OTg_39a2a65f-0b25-4911-8d62-a734fdd4ec37">739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Other operating revenues include premium tax revenue, investment income, and other revenue.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Other operating expenses include general and administrative expenses, premium tax expenses, depreciation and amortization, and other operating expenses.</span></div></ix:nonNumeric></ix:continuation><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div id="icc83361866f7481797f2215c8aedaf24_73"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11. <ix:nonNumeric contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83My9mcmFnOmUyNDYzYzEzMGU1ZTRlNWRiOTMwZTYyNTM3ZWQ0OWRhL3RleHRyZWdpb246ZTI0NjNjMTMwZTVlNGU1ZGI5MzBlNjI1MzdlZDQ5ZGFfMjYwMg_badbd20a-3be1-4314-ab35-e23586e80a78" continuedAt="ic8390c80fbd84eb0969e2affe4e23e81" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><ix:continuation id="ic8390c80fbd84eb0969e2affe4e23e81" continuedAt="i995e38a497f5427bbb78408316ebe561"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor and assess the estimated operating and financial impact of the COVID-19 pandemic on our business and, as it evolves, we continue to process, assemble, and assess member utilization information. We believe that our cash resources, borrowing capacity available under the Credit Agreement, and cash flow generated from operations will be sufficient to withstand the financial impact of the pandemic, and will enable us to continue to support our operations, regulatory requirements, debt repayment obligations, and capital expenditures for the foreseeable future.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The healthcare industry is subject to numerous laws and regulations of federal, state, and local governments. Compliance with these laws and regulations can be subject to government review and interpretation, as well as regulatory actions unknown and unasserted at this time. Penalties associated with violations of these laws and regulations include significant fines and penalties, exclusion from participating in publicly funded programs, the repayment of previously billed and collected revenues and reputational damage.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in legal actions in the ordinary course of business including, but not limited to, various employment claims, vendor disputes and provider claims. Some of these legal actions seek monetary damages, including claims for punitive damages, which may not be covered by insurance. We review legal matters and update our estimates of </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September&#160;30, 2022 Form 10-Q | 18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_7">Table of Contents</a></span></div></div><ix:continuation id="i995e38a497f5427bbb78408316ebe561"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reasonably possible losses and related disclosures, as necessary. We have accrued liabilities for legal matters for which we deem the loss to be both probable and reasonably estimable. These liability estimates could change as a result of further developments of the matters. The outcome of legal actions is inherently uncertain. An adverse determination in one or more of these pending matters could have an adverse effect on our consolidated financial position, results of operations, or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kentucky RFP</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On September 4, 2020, Anthem Kentucky Managed Care Plan, Inc. brought an action in Franklin County Circuit Court against the Kentucky Finance and Administration Cabinet, the Kentucky Cabinet for Health and Family Services, and all of the five winning bidder health plans, including our Kentucky health plan. On September 9, 2022, the Court of Appeal ruled, among other things, that the Circuit Court should not have invalidated the 2020 procurement and thus should not have awarded a contract to Anthem. Anthem filed a petition for rehearing with the Kentucky Court of Appeals and will likely seek review by the Kentucky Supreme Court. Pending further Court order, our Kentucky health plan will continue to operate for the foreseeable future under its current Medicaid contract.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Puerto Rico.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On August 13, 2021, Molina Healthcare of Puerto Rico, Inc. (&#8220;MHPR&#8221;) filed a complaint against the Puerto Rico Health Insurance Administration (&#8220;ASES&#8221;), asserting, among other claims, breach of contract. On September 13, 2021, ASES filed a counterclaim and a third-party complaint against MHPR and the Company. This matter remains subject to significant additional proceedings, and no prediction can be made as to the outcome.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September&#160;30, 2022 Form 10-Q | 19</span></div></div></div><div id="icc83361866f7481797f2215c8aedaf24_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_7">Table of Contents</a></span></div></div><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (&#8220;MD&amp;A&#8221;)</span></div><div id="icc83361866f7481797f2215c8aedaf24_82"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This quarterly report on Form 10-Q contains forward-looking statements regarding our business, financial condition, and results of operations within the meaning of Section&#160;27A of the Securities Act of 1933, or Securities Act, and Section&#160;21E of the Securities Exchange Act of 1934, or Securities Exchange Act. Many of the forward-looking statements are located under the heading &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Forward-looking statements can also be identified by words such as &#8220;guidance,&#8221; &#8220;future,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;growth,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;can,&#8221; &#8220;may,&#8221; and similar terms. Readers are cautioned not to place undue reliance on any forward-looking statements, as forward-looking statements are not guarantees of future performance and the Company&#8217;s actual results may differ significantly due to numerous known and unknown risks and uncertainties. Those known risks and uncertainties include, but are not limited to, the risk factors identified in the section titled &#8220;Risk Factors&#8221; in our 2021 Annual Report on Form 10-K, including without limitation the following:</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the COVID-19 pandemic and its associated or indirect effects on our business, operations, and financial results, including without limitation the duration of the Public Health Emergency Declaration (&#8220;PHE&#8221;) and associated suspension in redeterminations, and the potential impact on our workforce or contractors of federal or state vaccine mandates;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">significant budget pressures on state governments from diminished tax revenues incidental to the COVID-19 pandemic and their efforts to reduce rates or limit rate increases, to impose profit caps or risk corridors, or to recoup previously paid premium amounts on a retroactive basis; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the numerous political, judicial, and market-based uncertainties associated with the Affordable Care Act (the &#8220;ACA&#8221;);  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the market dynamics surrounding the ACA Marketplaces, including issues impacting enrollment, risk adjustment estimates and results, the potential for disproportionate enrollment of higher acuity members, and the discontinuation of premium tax credits;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome of the legal proceedings in Kentucky with regard to the Medicaid contract award to our Kentucky health plan and our acquisition of certain assets of Passport;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our efforts to retain existing or awarded government contracts, including our awarded contracts in California, Iowa, and Nebraska, and the success of any bid submissions in response to requests for proposal, including our contracts in Texas; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">subsequent adjustments to reported premium revenue based upon subsequent developments or new information, including changes to estimated amounts payable or receivable related to Marketplace risk adjustment; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to consummate, integrate, and realize benefits from acquisitions, including the completed acquisitions of Magellan Complete Care, Passport, Affinity, the Medicaid assets of Cigna in Texas, AgeWell New York and the announced acquisition of My Choice Wisconsin;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">effective management of our medical costs; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to predict with a reasonable degree of accuracy utilization rates, including utilization rates associated with COVID-19; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">cyber-attacks, ransomware attacks, or other privacy or data security incidents resulting in an inadvertent unauthorized disclosure of protected information;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to manage our operations, including maintaining and creating adequate internal systems and controls relating to authorizations, approvals, provider payments, and the overall success of our care management initiatives; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our receipt of adequate premium rates to support increasing pharmacy costs, including costs associated with specialty drugs and costs resulting from formulary changes that allow the option of higher-priced non-generic drugs; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to operate profitably in an environment where the trend in premium rate increases lags behind the trend in increasing medical costs; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the interpretation and implementation of federal or state medical cost expenditure floors, administrative cost and profit ceilings, premium stabilization programs, profit-sharing arrangements, and risk adjustment provisions and requirements; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates of amounts owed for such cost expenditure floors, administrative cost and profit ceilings, premium stabilization programs, profit-sharing arrangements, and risk adjustment provisions and requirements; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September&#160;30, 2022 Form 10-Q | 20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_7">Table of Contents</a></span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the Medicaid expansion medical cost corridor, and any other retroactive adjustment to revenue where methodologies and procedures are subject to interpretation or dependent upon information about the health status of participants other than Molina members; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the interpretation and implementation of at-risk premium rules and state contract performance requirements regarding the achievement of certain quality measures, and our ability to recognize revenue amounts associated therewith; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the success and renewal of our duals demonstration programs in California, Illinois, Michigan, Ohio, South Carolina, and Texas; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the accurate estimation of incurred but not reported or paid medical costs across our health plans;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">efforts by states to recoup previously paid and recognized premium amounts; </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.5pt">changes in our annual effective tax rate, due to federal and/or state legislation, or changes in our mix of earnings and other factors;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">complications, member confusion, eligibility redeterminations, or enrollment backlogs related to the renewal of Medicaid coverage;   </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">fraud, waste and abuse matters, government audits or reviews, comment letters, or potential investigations, and any fine, sanction, enrollment freeze, corrective action plan, monitoring program, or premium recovery that may result therefrom;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.5pt">our exit from Puerto Rico, including the payment in full of our outstanding accounts receivable, the effective run-out of claims, the return of our capital, and the outcome of the claims filed against our Puerto Rico health plan and us by the Puerto Rico Health Insurance Administration, or ASES;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">changes with respect to our provider contracts and the loss of providers; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">approval by state regulators of dividends and distributions by our health plan subsidiaries;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">changes in funding under our contracts as a result of regulatory changes, programmatic adjustments, or other reforms;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">high dollar claims related to catastrophic illness; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the resolution, favorable or unfavorable, of litigation, arbitration, or administrative proceedings;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the relatively small number of states in which we operate health plans, including the greater scale and revenues of our California, Ohio, Texas, and Washington health plans;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the failure to comply with the financial or other covenants in our credit agreement or the indentures governing our outstanding notes;  </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.5pt">the availability of adequate financing on acceptable terms to fund and capitalize our expansion and growth, repay our outstanding indebtedness at maturity, and meet our general liquidity needs;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the sufficiency of funds on hand to pay the amounts due upon maturity of our outstanding notes;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the failure of a state in which we operate to renew its federal Medicaid waiver;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">changes generally affecting the managed care industry; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">increases in government surcharges, taxes, and assessments;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the unexpected loss of the leadership of one or more of our senior executives; and</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">increasing competition and consolidation in the Medicaid industry.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the terms &#8220;Molina Healthcare, Inc.&#8221; &#8220;Molina Healthcare,&#8221; &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; and &#8220;us,&#8221; as used herein, refers collectively to Molina Healthcare, Inc. and its wholly owned subsidiaries, unless otherwise stated. The Company assumes no obligation to revise or update any forward-looking statements for any reason, except as required by law. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Readers should refer to the section entitled &#8220;Risk Factors&#8221; in our 2021 Annual Report on Form 10-K, for a discussion of certain risk factors that could materially affect our business, financial condition, cash flows, or results of operations. Given these risks and uncertainties, we can give no assurance that any results or events projected or contemplated by our forward-looking statements will in fact occur.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q and the following discussion of our financial condition and results of operations should be read in conjunction with the accompanying consolidated financial statements and the notes to those statements appearing elsewhere in this report, and the audited financial statements and Management&#8217;s Discussion and Analysis appearing in our 2021 Annual Report on Form 10-K.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September&#160;30, 2022 Form 10-Q | 21</span></div></div></div><div id="icc83361866f7481797f2215c8aedaf24_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">OVERVIEW</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc., a FORTUNE 500 company (currently ranked 125), provides managed healthcare services under the Medicaid and Medicare programs, and through the state insurance marketplaces (the &#8220;Marketplace&#8221;). We served approximately 5.2&#160;million members as of September&#160;30, 2022, located across 19 states.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THIRD QUARTER 2022 HIGHLIGHTS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reported net income of $230 million, or $3.95 per diluted share, for the third quarter of 2022, which reflected the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Membership increase of 337,000, or 7%, compared with September&#160;30, 2021, and a 57,000 sequential increase compared to June&#160;30, 2022;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Premium revenue of $7.6 billion increased 12% compared with the third quarter of 2021, reflecting the impact of acquisitions, increased organic membership in Medicaid and Medicare, partially offset by the impact of expected attrition in Marketplace membership;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Consolidated medical care ratio (&#8220;MCR&#8221;) was 88.4%, compared with 88.9% for the third quarter of 2021;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">General and administrative expense (&#8220;G&amp;A&#8221;) ratio of 7.1%, which compared with 7.5% in the third quarter of 2021, reflecting the benefits of scale produced by our increase in revenue and disciplined cost management; and </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">After-tax margin of 2.9%, which was in line with our expectations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We note the following factors impacting the 2022 third quarter financial results:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The net effect of COVID decreased net income by approximately $0.59 per diluted share and increased the MCR by 60 basis points in the third quarter of 2022. The net effect of COVID decreased net income by approximately $1.00 per diluted share and increased the MCR by 110 basis points in the third quarter of 2021; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Higher net investment income that was mainly driven by recent Federal Reserve interest rate increases. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September&#160;30, 2022 Form 10-Q | 22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED FINANCIAL SUMMARY</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except per-share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Premium revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: medical care costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">888&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">751&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,783&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,347&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">MCR </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">88.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">88.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">87.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">88.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Premium tax revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">G&amp;A ratio </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Premium tax expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,068&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">985&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">739&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">736&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Net income per share &#8211; Diluted</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted weighted average shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Key Statistics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending membership</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">After-tax margin </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;MCR represents medical care costs as a percentage of premium revenue.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;G&amp;A ratio represents general and administrative expenses as a percentage of total revenue. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;After-tax margin represents net income as a percentage of total revenue.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="icc83361866f7481797f2215c8aedaf24_91"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED RESULTS</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NET INCOME AND OPERATING INCOME</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income in the third quarter of 2022 amounted to $230 million, or $3.95 per diluted share, compared with $143 million, or $2.46 per diluted share, in the third quarter of 2021. The 61% increase in net income is consistent with the improvement in operating income, which increased to $335 million in the third quarter of 2022, compared with $221 million in the third quarter of 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income in the nine months ended September 30, 2022 amounted to $736 million, or $12.58 per diluted share, compared with $556 million, or $9.51 per diluted share, in the nine months ended September 30, 2021. The 32% increase in net income is consistent with the improvement in operating income of $1,068 million in the nine months ended September 30, 2022, compared with $829 million in the nine months ended September 30, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The improvement in operating income for both periods was mainly due to membership growth and higher premium revenues, and a decrease in MCR for the three and nine months ended September 30, 2022 compared to the prior year periods.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September&#160;30, 2022 Form 10-Q | 23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share in the third quarter and nine months ended September 30, 2022 was favorably impacted by the reduction in common shares outstanding as a result of our share repurchases in the second quarter of 2022. See further discussion in &#8220;Liquidity and Financial Condition,&#8221; below.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PREMIUM REVENUE</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium revenue increased $836 million, or 12%, in the third quarter of 2022, when compared with the third quarter of 2021, and increased $3.3 billion, or 17%, in the nine months ended September 30, 2022, when compared with the nine months ended September 30, 2021. The higher premium revenue reflects the impact of acquisitions, increased organic membership in the Medicaid and Medicare segments partially offset by a decline in the Marketplace segment. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MEDICAL CARE RATIO</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The consolidated MCR in the third quarter of 2022 decreased to 88.4%, compared with 88.9% in the third quarter of 2021, or 50 basis points. The improvement mainly relates to our Medicaid and Marketplace segments, partially offset by an increase in the Medicare segment. The results reflect a favorable year-over-year change in the net effect of COVID, which impacted all of our segments and increased the consolidated MCR by approximately 60 basis points in the third quarter of 2022, compared to approximately 110 basis points in the third quarter of 2021. The year-over-year change in the net effect of COVID mainly reflects lower COVID inpatient costs, partially offset by lower COVID-related utilization curtailment. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated MCR in the nine months ended September 30, 2022 decreased to 87.9%, compared with 88.1% MCR for the nine months ended September 30, 2021, or 20 basis points. Similar to the quarter-to-date consolidated MCR, net effect of COVID impacted each period; however, the results were varied by segment. See further explanation in &#8220;Segment Financial Performance,&#8221; below. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The prior year reserve development in the third quarter and nine months ended September 30, 2022 was favorable, and its impact on earnings was partially absorbed by the COVID-related risk corridors.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PREMIUM TAX REVENUE AND EXPENSES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The premium tax ratio (premium tax expense as a percentage of premium revenue plus premium tax revenue) was 2.8% and 2.9% for the third quarter of 2022 and 2021, respectively, and 2.7% and 2.8% for the nine months ended September 30, 2022 and 2021, respectively. The current year ratio decrease was mainly due to changes in business mix.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVESTMENT INCOME</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment income increased to $49 million in the third quarter of 2022, compared with $20 million in the third quarter of 2021, and increased to $82 million in the nine months ended September 30, 2022, compared with $39 million in the nine months ended September 30, 2021.The improvement in both periods was driven by recent increases in market interest rates and higher invested assets. Additionally, investment yields were lower in the first half of 2021 due to a temporary allocation in shorter-term invested assets due to the COVID-19 pandemic, which was rescinded in the second quarter of 2021. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OTHER REVENUE</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue increased to $19 million in the third quarter of 2022, compared with $16 million in the third quarter of 2021, and decreased to $57 million in the nine months ended September 30, 2022, compared with $58 million in the nine months ended September 30, 2021. Other revenue mainly includes service revenue associated with long-term services and supports consultative services we provide in Wisconsin. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G&amp;A EXPENSES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The G&amp;A expense ratio decreased to 7.1% in the third quarter of 2022, compared with 7.5% in the third quarter of 2021. The G&amp;A expense ratio was 7.1% in the nine months ended September 30, 2022, compared with 7.3% in the nine months ended September 30, 2021, which reflects the benefits of scale produced by our increase in revenue and disciplined cost management. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DEPRECIATION AND AMORTIZATION</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization increased to $45 million in the third quarter of 2022, compared with $32 million in the third quarter of 2021, and increased to $129 million in the nine months ended September 30, 2022, compared with $96 million in the nine months ended September 30, 2021. The increases in both periods were due primarily to amortization associated with acquisitions completed in the fourth quarter of 2021 and the first quarter of 2022.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September&#160;30, 2022 Form 10-Q | 24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OTHER OPERATING EXPENSES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses increased to $16 million in the third quarter of 2022, compared with $2 million in the third quarter of 2021, and increased to $43 million in the nine months ended September 30, 2022, compared with $30 million in the nine months ended September 30, 2021. Other operating expenses mainly includes service costs associated with long-term services and supports consultative services we provide in Wisconsin, as noted above. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INTEREST EXPENSE</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense decreased to $28 million in the third quarter of 2022, compared with $30 million in the third quarter of 2021, and to $83 million in the nine months ended September 30, 2022, compared with $90 million in the nine months ended September 30, 2021. The decrease resulted from our early redemption of $700 million aggregate principal amount of our 5.375% senior notes due 2022 in the fourth quarter of 2021, partially offset by interest related to the private offering of the 3.875% Notes due 2032 in the same period. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INCOME TAXES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense amounted to $77 million in the third quarter of 2022, or 24.9% of pretax income, compared with income tax expense of $48 million, or 24.8% of pretax income in the third quarter of 2021. Income tax expense amounted to $249 million in the nine months ended September 30, 2022, or 25.2% of pretax income, compared with income tax expense of $183 million, or 24.7% of pretax income in the nine months ended September 30, 2021. The difference in the effective tax rate is primarily due to an increase in nondeductible expenses and differences in discrete tax benefits recognized in the respective periods.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="icc83361866f7481797f2215c8aedaf24_94"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TRENDS AND UNCERTAINTIES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 PANDEMIC</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the COVID-19 pandemic continues to evolve, its ongoing impact to our business, results of operations, financial condition, and cash flows is uncertain and difficult to predict. Specific trends and uncertainties related to our Medicaid, Medicare, and Marketplace segments follow. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Federal Economic Stabilization and Other Programs</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective October 13, 2022, the Biden Administration extended the PHE for another 90 days and it will remain in effect until January 11, 2023, unless extended. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the uncertainty as to the duration and breadth of the pandemic, we are unable to reasonably estimate the ultimate impact of the economic stabilization and other programs to our business, financial condition, and operating results.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Enrollment and Premium Revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding acquisitions and our exit from Puerto Rico, we added over 750,000 new Medicaid members since March 31, 2020, when we first began to report on the impacts of the pandemic. We believe this membership increase was mainly due to the suspension of redeterminations for Medicaid eligibility. We expect Medicaid enrollment to continue to benefit from the extension of the PHE period, and the associated pause on membership redeterminations, at least through mid-January 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2020, various states enacted temporary risk corridors in response to the reduced demand for medical services stemming from COVID-19, which have resulted in a reduction of our medical margin. The current rate environment is stable and rational. We continue to believe that the risk-sharing corridors previously introduced are related to the declared PHE and will likely be eliminated as the COVID pandemic subsides. However, the risk corridors continue to contribute an added level of variability to our results of operations. In the three and nine months ended September&#160;30, 2022, we recognized approximately $34&#160;million and $156&#160;million, respectively, for the impact of these risk corridors, compared to $17 million and $183 million, respectively, recognized in the three and nine months ended September&#160;30, 2021. The decrease in 2022 is due to the elimination of most of the COVID-19 risk corridors.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that certain states could change the structure of existing risk corridors, implement new risk corridors in the future or discontinue existing risk corridors. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September&#160;30, 2022 Form 10-Q | 25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medical Care Costs</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect continued uncertainty regarding utilization trends as the pandemic continues. The speed and extent to which utilization rebounds will be greatly impacted by the economy and consumer behavior, provider capacity, and the potential resurgence of COVID-19 infection rates. We believe that some portion of the utilization curtailment experienced in the nine months ended September 30, 2022 is likely the result of service deferrals, and so these services will likely be provided to members over the remainder of the year.   </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Capital and Financial Resources</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor and assess the estimated operating and financial impact of the COVID-19 pandemic on our business and, as it evolves, we continue to process, assemble, and assess member utilization information. We believe that our cash resources, borrowing capacity available under the Credit Agreement, and cash flow generated from operations will be sufficient to withstand the financial impact of the pandemic, and will enable us to continue to support our operations, regulatory requirements, debt repayment obligations, and capital expenditures for the foreseeable future. Refer to &#8220;Liquidity and Financial Condition&#8221; below for further discussion of our capital and financial resources.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OTHER RECENT DEVELOPMENTS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New York Acquisition&#8212;Medicaid.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On October 1, 2022, we closed on our acquisition of the Medicaid Managed Long Term Care business of AgeWell New York.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nebraska Procurement&#8212;Medicaid.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In September 2022, we announced that our Nebraska health plan had been selected by the Nebraska Department of Health and Human Services (DHHS) to provide health care services to Nebraskans under the state&#8217;s Medicaid managed care program. The new five-year contract is expected to begin on January 1, 2024, and may be extended for an additional two-years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Iowa Procurement&#8212;Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we announced that our Iowa health plan had been notified by the Iowa Department of Health and Human Services (HHS) of its intent to award a Medicaid managed care contract pursuant to the Request for Proposal issued by HHS on February 17, 2022. The new four-year contract is expected to begin on July 1, 2023, and may be extended for an additional four years. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">California Procurement&#8212;Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we announced that our California health plan had been notified by the California Department of Health Care Services of its intent to award a Medi-Cal contract in each of Los Angeles, Riverside, San Bernardino, Sacramento, and San Diego Counties. The 5 Medi-Cal contracts are expected to commence on January 1, 2024, which enables us to continue serving Medi-Cal members in our existing counties and expand footprint with the addition of the Los Angeles County contract. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wisconsin Acquisition &#8212; Medicaid and Medicare. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 13, 2022, we announced a definitive agreement to acquire substantially all the assets of My Choice Wisconsin (&#8220;MCW&#8221;). The purchase price for the transaction is approximately $150 million, net of expected tax benefits and required regulatory capital, which we intend to fund with cash on hand. The transaction is subject to receipt of applicable federal and state regulatory approvals, and the satisfaction of other customary closing conditions. We currently expect the transaction to close in early 2023.   </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mississippi Procurement&#8212;Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we announced that our Mississippi health plan had been notified by the Mississippi Division of Medicaid (DOM) of its intent to award a Medicaid Coordinated Care Contract for its Mississippi Coordinated Access Program and Mississippi Children&#8217;s Health Insurance Program pursuant to the Request for Qualifications issued by DOM on December 10, 2021. The four-year contract is expected to begin on July 1, 2023, and may be extended for an additional two years. The award enables us to continue serving Medicaid members across the state. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Texas Procurement&#8212;Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the Texas Health and Human Services Commission posted the ABD program (known in Texas as STAR+PLUS) RFP. We submitted our proposal in June 2022 to continue serving STAR+PLUS members, with awards estimated to be announced in the first quarter of 2023, and start of operations in February 2024. Further, in October 2022, the draft RFP was posted for the TANF and CHIP programs (known as the STAR &amp; CHIP programs, and both existing contracts for us), with awards expected in late Q4 2023 or early Q1 2024 and the start of operations in late Q4 2024 or early Q1 2025.  </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nevada Procurement&#8212;Medicaid.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our new contract in Clark and Washoe Counties commenced on January 1, 2022, and offers health coverage to TANF, CHIP and Medicaid Expansion beneficiaries. This new contract is four years  with a potential two-year extension.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Texas Acquisition&#8212;Medicaid and Medicare. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, we closed on our acquisition of Cigna Corporation&#8217;s Texas Medicaid and Medicare-Medicaid Plan (&#8220;MMP&#8221;) contracts, along with certain operating assets. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September&#160;30, 2022 Form 10-Q | 26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketplace Enrollment. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to end 2022 with approximately 315,000 members, reflecting normal attrition over the remainder of the year and limited special enrollment period growth based on revised eligibility rules and our product design and distribution strategy. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Infosys.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> On September 29, 2022, we amended each of the master service agreements governing our relationship with our managed information technology (&#8220;IT&#8221;) services provider, Infosys Limited (collectively, the &#8220;Infosys Agreements&#8221;). Significant changes to the Infosys Agreements include (i) the extension of the expiration date of each Infosys Agreement to September 30, 2029 (extended from prior expiration dates in 2024), (ii) expansions in the scope of certain support services, and (iii) changes to the pricing model for certain services. As a result of these changes, we expect improvements in certain service level objectives, as well as a reduction in our IT spend.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmacy. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into an early renewal of our long-standing pharmacy benefit management (&#8220;PBM&#8221;) agreement with CVS Caremark (&#8220;Caremark&#8221;). Under the renewal, Caremark will continue to be the exclusive PBM provider to us and our health plan subsidiaries through December 31, 2026. The renewal includes improvements to network rates and administrative costs as well as improved terms around performance standards. Caremark&#8217;s services to Molina include, among other things, pharmacy network management, mail order, specialty pharmacy, pharmacy claims processing, and pharmaceutical rebate management.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Real Estate.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We intend to move permanently to a remote work environment, a model we have been working under successfully for over two years. As a result, we expect to complete a plan to reduce our real estate footprint by the end of the year, which we expect will yield substantial and sustainable G&amp;A expense savings.  </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of additional segment trends, uncertainties and other developments, refer to our 2021 Annual Report on Form 10-K, &#8220;Item 1. Business&#8212;Our Business,&#8221; and &#8220;&#8212;Legislative and Political Environment.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="icc83361866f7481797f2215c8aedaf24_100"></div><div style="margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">REPORTABLE SEGMENTS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, we served approximately 5.2 million members eligible for Medicaid, Medicare, and other government-sponsored healthcare programs for low-income families and individuals, including Marketplace members, most of whom receive government premium subsidies. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have four reportable segments consisting of: 1)&#160;Medicaid; 2)&#160;Medicare; 3)&#160;Marketplace; and 4)&#160;Other.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which we offer managed healthcare services. The Other segment, which is insignificant to our consolidated results of operations, includes certain corporate amounts not associated with or allocated to the Medicaid, Medicare, or Marketplace segments. Additionally, the Other segment includes service revenues and service costs associated with the long-term services and supports consultative services we provide in Wisconsin.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HOW WE ASSESS PERFORMANCE</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive our revenues primarily from health insurance premiums. Our primary customers are state Medicaid agencies and the federal government.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key metrics used to assess the performance of our Medicaid, Medicare, and Marketplace segments are premium revenue, medical margin and medical care ratio (&#8220;MCR&#8221;). MCR represents the amount of medical care costs as a percentage of premium revenue. Therefore, the underlying medical margin, or the amount earned by the Medicaid, Medicare, and Marketplace segments after medical costs are deducted from premium revenue, represents the most important measure of earnings reviewed by management, and is used by our chief executive officer to review results, assess performance, and allocate resources. The key metric used to assess the performance of our Other segment is service margin. The service margin is equal to service revenue minus cost of service revenue. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management&#8217;s discussion and analysis of the change in medical margin is discussed below under &#8220;Segment Financial Performance.&#8221; For more information, see Notes to Consolidated Financial Statements, Note 10, &#8220;Segments.&#8221;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September&#160;30, 2022 Form 10-Q | 27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SEGMENT MEMBERSHIP</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth our membership by segment as of the dates indicated:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,667,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,329,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,981,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">728,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">719,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,175,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,199,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,838,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SEGMENT FINANCIAL PERFORMANCE</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize premium revenue, medical margin, and MCR by segment for the periods indicated (dollars in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.118%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Premium<br/>Revenue</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical<br/>Margin</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">MCR</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Premium<br/>Revenue</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical<br/>Margin</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">MCR</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">703&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,146&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,636&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">888&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,800&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">751&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.118%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Premium<br/>Revenue</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical<br/>Margin</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">MCR</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Premium<br/>Revenue</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical<br/>Margin</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">MCR</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,406&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,020&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,687&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,966&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,783&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,689&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,347&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medicaid</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid premium revenue increased $979 million, or 19% in the third quarter of 2022, when compared with the third quarter of 2021. Medicaid premium revenue increased $3.4 billion, or 23% in the nine months ended September 30, 2022, when compared with the nine months ended September 30, 2021. The increases in both periods were mainly due to organic membership growth, including our entry into Nevada, the impact from the Affinity and Cigna acquisitions that closed in the fourth quarter of 2021 and in January 2022, respectively, and state directed payments in our Texas health plan. The organic membership growth was across several states, driven mainly by the extension of the PHE period and the associated suspension of membership redeterminations due to COVID-19. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above in &#8220;Trends and Uncertainties,&#8221; we recognized approximately $34&#160;million and $156&#160;million in the third quarter and nine months ended September 30, 2022, respectively, for the impact of risk corridors enacted in several states since the second quarter of 2020, in response to the lower utilization of medical services resulting from COVID-19. We recognized approximately $17 million and $183 million, respectively, for the impact of such risk corridors in the third quarter and nine months ended September 30, 2021. The decrease was due to the elimination of most of the COVID-19 risk corridors. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical margin in our Medicaid program increased $171 million, or 32%, in the third quarter of 2022 when compared with the third quarter of 2021, and increased $481 million, or 29%, in the nine months ended September 30, 2022 when compared with the nine months ended September 30, 2021. The increase in margin in both periods was driven by the increased membership growth and premium revenues discussed above and the MCR decrease discussed below.  </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicaid MCR decreased 110 basis points to 88.5% in the third quarter of 2022, from 89.6% in the third quarter of 2021, and decreased 60 basis points to 88.2% in the nine months ended September 30, 2022, from 88.8% in the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September&#160;30, 2022 Form 10-Q | 28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2021. The decrease for both periods is mainly attributable to medical cost management, lower utilization and the year-over-year change in the net effect of COVID, partially offset by the impact of state directed payments in our Texas health plan. The year-over-year change in the net effect of COVID for the third quarter of 2022 reflects lower COVID inpatient costs, partially offset by lower COVID-related utilization curtailment. The 2022 Medicaid MCR is at the lower end of our long-term target despite the net effect of COVID and other impacts. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medicare</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare premium revenue increased $72&#160;million, or 8%, in the third quarter of 2022 compared to the third quarter of 2021, and increased $359 million, or 14%, in the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021. The increase was primarily due to the impact of product expansion and organic membership growth in existing states, partially offset by lower premium revenue PMPM from the change in business mix. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The medical margin for Medicare decreased $43&#160;million in the third quarter of 2022, and increased $31 million in the nine months ended September 30, 2022, when compared to the same periods in 2021. The decrease in the third quarter is due to the increase in MCR discussed below, partially offset by the increase in premium revenues. The year-over-year increase for the nine months is mainly due to the increase in premium revenues, partially offset by the increase in the MCR discussed below.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicare MCR increased to 88.7% in the third quarter of 2022, from 82.8% in the third quarter of 2021, or 590 basis points. The Medicare MCR increased to 87.4% in the nine months ended September 30, 2022, compared to 86.8% in the nine months ended September 30, 2021, or 60 basis points. The MCR increase in both periods was primarily driven by the year-over-year change in the net effect of COVID. COVID-related utilization curtailment and corridor adjustments drove a lower MCR for the 2021 periods. Additionally, the increase in MCR was driven by higher non-COVID utilization, partially offset by higher risk scores that more closely reflect the acuity of our membership, and strong medical cost management. The 2022 year-to-date Medicare MCR is in line with our long-term target.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketplace</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketplace premium revenue decreased $215&#160;million in the third quarter of 2022 compared to the third quarter of 2021, and decreased $468 million in the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021. The decrease in both periods was mainly due to expected attrition of membership, partially offset by an increase in premium revenue PMPM. Our Marketplace membership as of September&#160;30, 2022, amounted to 353,000 members, representing a decrease of 366,000 members compared to September 30, 2021. The increase in premium revenue PMPM is consistent with the product and pricing strategy, reflecting an increase of members in the silver metal tier and a decrease of members in the bronze metal tier, partially offset by an increase in the 2021 risk adjustment payable that was finalized in June 2022. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Marketplace medical margin increased $9 million in the third quarter of 2022 when compared with the third quarter of 2021, and decreased $76 million in the nine months ended September 30, 2022 when compared with the nine months ended September 30, 2021. The improvement in the third quarter is due mainly to the decrease in MCR discussed below, partially offset by the decrease in premium revenue. The decrease in year to date results is primarily due to the net decrease in membership and premiums, and the increase in the MCR described below.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Marketplace MCR decreased to 86.3% in the third quarter of 2022, compared to 91.3% in the third quarter of 2021, or 500 basis points, and increased to 85.1% in the nine months ended September 30, 2022, compared to 84.8% in the nine months ended September 30, 2021, or 30 basis points. The decrease in MCR for the third quarter was driven mainly by the year-over-year change in the net effect of COVID, partially offset by changes in membership mix that includes higher acuity members. The increase for the nine-month period reflects changes in membership mix that includes higher acuity members and the unfavorable change in the 2021 risk adjustment payable recognized in the second quarter of 2022, partially offset by the year-over-year change in the net effect of COVID. We are also incurring less MCR seasonality relative to the prior year, due to the lower deductibles in the silver metal tier product.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Other segment includes service revenues and costs associated with long-term services and supports consultative services we provide in Wisconsin, and also includes certain corporate amounts not allocated to the Medicaid, Medicare, or Marketplace segments. Such amounts were immaterial to our consolidated results of operations for the third quarters of and nine months ended September 30, 2022 and 2021, respectively.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September&#160;30, 2022 Form 10-Q | 29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="icc83361866f7481797f2215c8aedaf24_103"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LIQUIDITY AND FINANCIAL CONDITION</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LIQUIDITY</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our cash, investments, and capital structure to meet the short- and long-term obligations of our business while maintaining liquidity and financial flexibility. We forecast, analyze, and monitor our cash flows to enable prudent investment management and financing within the confines of our financial strategy.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain liquidity at two levels: 1) the regulated health plan subsidiaries; and 2) the parent company. Our regulated subsidiaries generate significant cash flows from premium revenue, which is generally received a short time before related healthcare services are paid. Premium revenue is our primary source of liquidity. Thus, any decline in the receipt of premium revenue, and our profitability, could have a negative impact on our liquidity. In the first half of 2022, we did not experience noticeable delays to, or changes in, the timing or level of premium receipts as a result of the COVID-19 pandemic, but there can be no assurances that we will not experience such delays in the future. See further discussion below in &#8220;Future Sources and Uses of Liquidity&#8212;Future Uses&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Potential Impact of COVID-19 Pandemic</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A majority of the assets held by our regulated health plan subsidiaries is in the form of cash, cash equivalents, and investments. When available and as permitted by applicable regulations, cash in excess of the capital needs of our regulated health plan subsidiaries is generally paid in the form of dividends to our parent company to be used for general corporate purposes. In the third quarter and nine months ended September 30, 2022, the parent company received $120&#160;million and $400 million, respectively, in dividends and return of capital from the regulated health plan subsidiaries. See further discussion of dividends below in &#8220;Future Sources and Uses of Liquidity&#8212;Future Sources.&#8221; </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The parent company may also contribute capital to the regulated health plan subsidiaries to satisfy minimum statutory net worth requirements, including funding for newer health plans. In the third quarter and nine months ended September 30, 2022, the parent company contributed capital of</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $116&#160;million and $145 million, respectively,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the regulated health plan subsidiaries. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and investments at the parent company amounted to $298&#160;million and $348&#160;million as of September&#160;30, 2022, and December&#160;31, 2021, respectively. The decrease as of September&#160;30, 2022, was primarily due to our share repurchase program and the timing of corporate payments and capital contributions to regulated health plan subsidiaries, partially offset by dividends received from regulated health plan subsidiaries.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After considering expected cash flows from operating activities, we generally invest cash of regulated subsidiaries that exceeds our expected short-term obligations in longer term, investment-grade, and marketable debt securities to improve our overall investment return. These investments are made pursuant to board-approved investment policies which conform to applicable state laws and regulations. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment policies are designed to provide liquidity, preserve capital, and maximize total return on invested assets, all in a manner consistent with state requirements that prescribe the types of instruments in which our subsidiaries may invest. These investment policies require that our investments have final maturities of less than 15 years, or less than 15 years average life for structured securities. Professional portfolio managers operating under documented guidelines manage our investments and a portion of our cash equivalents. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the risks of the COVID-19 pandemic, as they relate to our investments, are minimal. The overall rating of our portfolio remains strong and is rated A+. Our investment policy has directives in conjunction with state guidelines to minimize risks and exposures in volatile markets. Additionally, our portfolio managers assist us in navigating volatility in the capital markets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our restricted investments are invested principally in cash, cash equivalents, U.S. Treasury securities, and corporate debt securities; we have the ability to hold such restricted investments until maturity. All of our unrestricted investments are classified as current assets.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September&#160;30, 2022 Form 10-Q | 30</span></div></div></div><div id="icc83361866f7481797f2215c8aedaf24_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flow Activities</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash flows are summarized as follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(537)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(938)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,106)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(258)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (decrease) increase in cash, cash equivalents, and restricted cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(211)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(423)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Activities</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We typically receive capitation payments monthly, in advance of payments for medical claims; however, government payors may adjust their payment schedules, positively or negatively impacting our reported cash flows from operating activities in any given period. For example, government payors may delay our premium payments, or they may prepay the following month&#8217;s premium payment.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operations for the nine months ended September 30, 2022 was $985 million, compared with $1,522 million in the nine months ended September 30, 2021. The $537 million decrease in cash flow was due to the net impact of timing differences in government receivables and payables and partially offset by an increase in net earnings.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Investing Activities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $938 million in the nine months ended September 30, 2022, compared with $1,106 million used in investing activities in the nine months ended September 30, 2021, an increase in cash flow of $168 million. This increase in cash flow was primarily due to the net activity of proceeds and purchases of investments partially, offset by funding of the AgeWell acquisition, in the nine months ended September 30, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financing Activities</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities was $258 million in the nine months ended September 30, 2022, compared with $204 million used in the nine months ended September 30, 2021, a decrease in cash flow of $54 million. In the nine months ended September 30, 2022, financing cash outflows included common stock purchases of $200 million and $53 million for common stock withheld to settle employee tax obligations. In the nine months ended September 30, 2021, financing cash outflows included common stock purchases of $128 million and $52 million for common stock withheld to settle employee tax obligations. Additionally, we paid $20 million in each of the nine months ended September 30, 2022 and 2021 to settle contingent consideration liabilities relating to our Kentucky Passport acquisition that closed in 2020. </span></div><div id="icc83361866f7481797f2215c8aedaf24_109"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FINANCIAL CONDITION</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our cash resources, borrowing capacity available under the Credit Agreement as discussed further below in &#8220;Future Sources and Uses of Liquidity&#8212;Future Sources,&#8221; and internally generated funds will be sufficient to support our operations, regulatory requirements, debt repayment obligations and capital expenditures for at least the next 12 months. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a consolidated basis, at September&#160;30, 2022, our working capital was $3.3 billion, compared with $3.0 billion at December&#160;31, 2021. At September&#160;30, 2022, our cash and investments amounted to $8.1 billion, compared with $7.9 billion at December&#160;31, 2021. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Capital and Dividend Restrictions </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of our regulated, wholly owned subsidiaries must maintain a minimum amount of statutory capital determined by statute or regulations. Such statutes, regulations and capital requirements also restrict the timing, payment and amount of dividends and other distributions, loans or advances that may be paid to us as the sole stockholder. To the extent our subsidiaries must comply with these regulations, they may not have the financial flexibility to transfer funds to us. Based upon current statutes and regulations, the minimum capital and surplus requirement for these subsidiaries was estimated to be approximately $2.2 billion at September&#160;30, 2022, compared with $2.1 billion at December&#160;31, 2021. The aggregate capital and surplus of our regulated, wholly owned subsidiaries was in excess of these minimum capital requirements as of both dates. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September&#160;30, 2022 Form 10-Q | 31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under applicable regulatory requirements, the amount of dividends that may be paid by our regulated, wholly owned subsidiaries without prior approval by regulatory authorities as of September&#160;30, 2022, was approximately $170&#160;million in the aggregate. These subsidiaries may pay dividends over this amount, but only after approval is granted by the regulatory authorities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our cash and investments balances as of September&#160;30, 2022, management believes that our regulated, wholly owned subsidiaries remain well capitalized and exceed their regulatory minimum requirements. We have the ability, and have committed to provide, additional capital to each of our health plans as necessary to ensure compliance with statutory capital and surplus requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Ratings</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of our senior notes is rated &#8220;BB-&#8221; by Standard &amp; Poor&#8217;s, and &#8220;Ba3&#8221; by Moody&#8217;s Investor Service, Inc. A downgrade in our ratings could adversely affect our borrowing capacity and increase our future borrowing costs. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Covenants</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains customary non-financial and financial covenants, including a net leverage ratio and an interest coverage ratio. Such ratios are computed as defined by the terms of the Credit Agreement. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the indentures governing each of our outstanding senior notes contain cross-default provisions that are triggered upon default by us or any of our subsidiaries on any indebtedness in excess of the amount specified in the applicable indenture. As of September&#160;30, 2022, we were in compliance with all financial and non-financial covenants under the Credit Agreement and the indentures governing our senior notes.</span></div><div id="icc83361866f7481797f2215c8aedaf24_112"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FUTURE SOURCES AND USES OF LIQUIDITY</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Sources</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our regulated subsidiaries generate significant cash flows from premium revenue, which is generally received a short time before related healthcare services are paid. Premium revenue is our primary source of liquidity. Thus, any decline in the receipt of premium revenue, and our profitability, could have a negative impact on our liquidity.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Potential Impact of COVID-19 Pandemic</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Excluding acquisitions and our exit from Puerto Rico, we added over 750,000 new Medicaid members since March 31, 2020, when we first began to report on the impacts of the pandemic. We believe this membership increase was mainly due to the suspension of redeterminations for Medicaid eligibility. We expect Medicaid enrollment to continue to benefit from the extension of the PHE period, and the associated pause on membership redeterminations, at least through mid-January 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends from Subsidiaries.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> When available and as permitted by applicable regulations, cash in excess of the capital needs of our regulated health plans is generally paid in the form of dividends to our unregulated parent company to be used for general corporate purposes. As a result of the COVID-19 pandemic, state regulators could further restrict the ability of our regulated health plan subsidiaries to pay dividends to the parent company, which would reduce the liquidity of the parent company.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Agreement Borrowing Capacity. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, we had available borrowing capacity of $1&#160;billion under the revolving credit facility of our Credit Agreement. In addition, the Credit Agreement provides for a $15&#160;million swingline sub-facility and a $100&#160;million letter of credit sub-facility, as well as incremental term loans available to finance certain acquisitions up to $500&#160;million, plus an unlimited amount of such term loans as long as our consolidated net leverage ratio is not greater than a defined maximum. See further discussion in the Notes to Consolidated Financial Statements, Note 8, &#8220;Debt.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Uses</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock Purchases. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, our board of directors authorized the purchase of up to $500 million, in the aggregate, of our common stock. This new program, which superseded the stock purchase program approved by our board of directors in September 2020, is funded with cash on hand and extends through December 31, 2022. The exact timing and amount of any repurchase is determined by management based on market conditions and share price, in addition to other factors, and subject to the restrictions relating to volume, price, and timing under applicable law.  As of October&#160;26, 2022, $300 million remained available to purchase our common stock under this program through December 31, 2022.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September&#160;30, 2022 Form 10-Q | 32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 13, 2022, we announced a definitive agreement to acquire substantially all the assets of My Choice Wisconsin (&#8220;MCW&#8221;). The purchase price for the transaction is approximately $150 million, net of expected tax benefits and required regulatory capital, which we intend to fund with cash on hand. The transaction is subject to receipt of applicable federal and state regulatory approvals, and the satisfaction of other customary closing conditions. We currently expect the transaction to close in early 2023. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Potential Impact of COVID-19 Pandemic</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As described above in &#8220;Trends and Uncertainties,&#8221; we have been subject to Medicaid risk corridors as a result of the pandemic. Beginning in 2020, various states enacted temporary risk corridors in response to the reduced demand for medical services stemming from COVID-1</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which have resulted in a reduction of our medical margin. In some cases, these risk corridors were retroactive to earlier periods in 2020, or as early as the beginning of the states&#8217; fiscal years in 2019. Since the second quarter of 2020, we have recognized risk corridors that we believe to be probable, and where the ultimate premium amount is reasonably estimable. For the three and nine months ended September 30, 2022, we recognized approximately $34&#160;million and $156&#160;million, respectively, related to such risk corridors, primarily in the Medicaid segment.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that certain states could change the structure of existing risk corridors, implement new risk corridors in the future or discontinue existing risk corridors. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Capital Requirements.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have the ability, and have committed to provide, additional capital to each of our health plans as necessary to ensure compliance with statutory capital and surplus requirements. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="icc83361866f7481797f2215c8aedaf24_115"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONTRACTUAL OBLIGATIONS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of future obligations under our various contractual obligations and commitments as of December&#160;31, 2021, was disclosed in our 2021 Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no significant changes to our contractual obligations and commitments outside the ordinary course of business during the nine months ended September 30, 2022. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="icc83361866f7481797f2215c8aedaf24_118"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING ESTIMATES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we prepare our consolidated financial statements, we use estimates based on assumptions that may affect reported amounts and disclosures; actual results could differ from these estimates. Our critical accounting estimates relate to:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Medical claims and benefits payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Refer to Notes to Consolidated Financial Statements, Note 7, &#8220;Medical Claims and Benefits Payable,&#8221; for a table that presents the components of the change in medical claims and benefits payable, and for additional information regarding the factors used to determine our changes in estimates for all periods presented in the accompanying consolidated financial statements. Other than the discussion as noted above, in the nine months ended September 30, 2022 there were no significant changes to our disclosure reported in &#8220;Critical Accounting Estimates&#8221; in our 2021 Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Contractual provisions that may adjust or limit revenue or profit</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For a discussion of this topic, including amounts recorded in our consolidated financial statements, refer to Notes to Consolidated Financial Statements, Note 2, &#8220;Significant Accounting Policies.&#8221; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Quality incentives</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In the nine months ended September 30, 2022, there were no significant changes to our disclosure reported in &#8220;Critical Accounting Estimates&#8221; in our 2021 Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Business combinations, goodwill, and intangible assets, net.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the nine months ended September 30, 2022, there were no significant changes to our disclosure reported in &#8220;Critical Accounting Estimates&#8221; in our 2021 Annual Report on Form 10-K. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September&#160;30, 2022 Form 10-Q | 33</span></div></div></div><div id="icc83361866f7481797f2215c8aedaf24_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our earnings and financial position are exposed to financial market risk relating to changes in interest rates, and the resulting impact on investment income and interest expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our investments and restricted investments are subject to interest rate risk and will decrease in value if market interest rates increase. Assuming a hypothetical and immediate 1% increase in market interest rates at September&#160;30, 2022, the fair value of our fixed income investments would decrease by approximately $85 million. Declines in interest rates over time will reduce our investment income. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further information on fair value measurements and our investment portfolio, please refer to Notes to Consolidated Financial Statements, Note 5, &#8220;Fair Value Measurements,&#8221; and Note 6, &#8220;Investments.&#8221; </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Credit Agreement bear interest based, at our election, on a base rate or other defined rate, plus in each case, the applicable margin. For further information, see Notes to Consolidated Financial Statements, Note 8, &#8220;Debt.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="icc83361866f7481797f2215c8aedaf24_124"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of Disclosure Controls and Procedures.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our management, with the participation of our chief executive officer and our chief financial officer, has concluded, based upon its evaluation as of the end of the period covered by this report, that the Company&#8217;s &#8220;disclosure controls and procedures&#8221; (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act), are effective to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Internal Control Over Financial Reporting.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> There were no changes in our internal control over financial reporting during the nine months ended September 30, 2022, that materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="icc83361866f7481797f2215c8aedaf24_127"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LEGAL PROCEEDINGS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information regarding legal proceedings, see Notes to Consolidated Financial Statements, Note 11, &#8220;Commitments and Contingencies.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="icc83361866f7481797f2215c8aedaf24_130"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RISK FACTORS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain risks may have a material adverse effect on our business, financial condition, cash flows, results of operations, or stock price, and you should carefully consider them before making an investment decision with respect to our securities. In addition to the other information set forth in this report, you should carefully consider the risk factors discussed under the caption &#8220;Risk Factors,&#8221; in our 2021 Annual Report on Form 10-K. The risk factors described in our 2021 Annual Report on Form 10-K are not the only risks that we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, cash flows, results of operations, or stock price.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September&#160;30, 2022 Form 10-Q | 34</span></div></div></div><div id="icc83361866f7481797f2215c8aedaf24_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of common stock made by us, or on our behalf, during the third quarter of 2022, including shares withheld by us to satisfy our employees&#8217; income tax obligations, are set forth below:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:44.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total&#160;Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">of Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Purchased&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average&#160;Price&#160;Paid per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of&#160;Shares<br/>Purchased as Part of<br/>Publicly&#160;<br/>Announced&#160;<br/>Plans or <br/>Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Approximate&#160;Dollar&#160;Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">of Shares that May Yet Be Purchased Under the Plans or Programs </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 1 - July 31</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">282.90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 1 - August 31</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 1 - September 30</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">282.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">During the third quarter of 2022, we withheld approximately 2,000 shares of common stock, to settle employee income tax obligations, for releases of awards granted under the Molina Healthcare, Inc. 2019 Equity Incentive Plan.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">For further information on our stock repurchase programs, refer to the accompanying Notes to Financial Statements, Note 9, &#8220;Stockholders' Equity.&#8221;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September&#160;30, 2022 Form 10-Q | 35</span></div></div></div><div id="icc83361866f7481797f2215c8aedaf24_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INDEX TO EXHIBITS</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.607%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Method of Filing</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101_changexreques.htm">Change Request #7 to the Master Services Agreement dated February 4, 2019, by and between Molina Healthcare, Inc. and Infosys Limited</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="moh3q22_ex311.htm">Section 302 Certification of Chief Executive Officer</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith. </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="moh3q22_ex312.htm">Section 302 Certification of Chief Financial Officer</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith. </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="moh3q22_ex321.htm">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith. </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="moh3q22_ex322.htm">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith. </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the inline XBRL document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith. </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith. </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith. </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith. </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith. </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith. </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data file (formatted as Inline XBRL and embedded within Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.607%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pursuant to Item 601(b)(10) of Regulation S-K, portions of this exhibit have been excluded because the information is not material and is the type that the registrant treats as confidential. The location of the redacted confidential information is indicated in the exhibit as &#8220;[redacted]&#8221;. </span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September&#160;30, 2022 Form 10-Q | 36</span></div></div></div><div id="icc83361866f7481797f2215c8aedaf24_139"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icc83361866f7481797f2215c8aedaf24_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.068%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MOLINA HEALTHCARE, INC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dated: </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 27, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ JOSEPH M. ZUBRETSKY</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Joseph M. Zubretsky</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dated: </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 27, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ MARK L. KEIM</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Mark L. Keim</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chief Financial Officer and Treasurer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Principal Financial Officer)</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September&#160;30, 2022 Form 10-Q | 37</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit101_changexreques.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>exhibit101_changexreques</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- exhibit101_changexreques001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit101_changexreques001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">Pursuant to Item 601(b)(10) of Regulation S-K, portions of this exhibit have been excluded because the  information is not material and is the type that the registrant treats as confidential. The location of the  redacted confidential information is indicated in the exhibit as &#8220;[redacted]&#8221;.   MSA Change Request   Molina &#8211; Infosys    1277001.1    Reference is made to the Master Services Agreement dated 4-February-2019 and entered into between  Molina Healthcare, Inc. (&#8220;Molina&#8221;) and Infosys Limited (&#8220;Service Provider&#8221;) (the &#8220;Infra Agreement&#8221;).    Unless otherwise defined herein, capitalized terms used in this MSA Change Request and Renewal Notice  shall have the meanings ascribed to them in that Agreement.    PART A &#8211; CHANGE REQUEST    Change Request:   CR #: 7    Effective Date of Executed Change Request:  October 1, 2022     Change Request Title:    Modification and extension of Infra  Agreement through September 2029  Change Description:    Modification and extension of Infra Agreement  through September 2029  Change Request Type:    MSA Change    NB: An &#8220;MSA Change&#8221; means a change to any of the terms of the Agreement, including any of the  Schedule or Appendices thereto, or any documents incorporated therein, but does not include any  change to (i) any of the Policies (for which, see paragraph 4 of Schedule 9) or (ii) a Project Change  (for which, see Appendix 9-B (Project Change Request)).       Request Overview (Complete with as much detail as possible)                            Document  Purpose:  &#9642; The written means by which authorized persons of Molina and Service  Provider initiate an MSA Change.    </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit101_changexreques002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit101_changexreques002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> MSA Change Request   Molina &#8211; Infosys  MSA Change Request Page 2 of 12 Change Request Number: 7  1277001.1  Summary of  Requested  Change                      This Change Request amends (a) the Charges applicable to the Infra Agreement and (b) the manner  in which the Service Provider is responsible for performing the Services.     All terms and conditions of the Agreement not expressly modified herein, shall remain in full force  and effect.  All capitalized terms shall have the meaning ascribed to them in the Agreement unless  otherwise defined herein.  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit101_changexreques003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit101_changexreques003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> MSA Change Request   Molina &#8211; Infosys  MSA Change Request Page 3 of 12 Change Request Number: 7  1277001.1  Expected  Impacts   What are the  expected  Impacts as a  result of this  Change  Request?  (i.e. Scope,  Schedule,  Cost, Other)  Infra Agreement    The Infra Agreement is hereby extended by this Renewal Notice such that the Expiry Date is  September 30, 2029.    Effective October 1, 2022, the Schedule 1 (Definitions and Interpretation) to the Infra  Agreement is hereby amended to include the following definitions:.    &#8220;Digital Cloud Service&#8221; means Build, Operate, Maintain, secure all digital cloud services  including SaaS,, IaaS, Paas and DB services on Azure cloud or on-premise data center.   &#8220;Digital Operations Service&#8221; means IT Infrastructure support, IT service management,  security monitoring, incident handling, tools support, access management, ServiceNow  administration and Batch job configurations and operations.   &#8220;Digital Workplace Service&#8221; means End User access and device management (IMACD),  End User device security, white glove services, End User tools and software management.   &#8220;Network Services &#8211; Site Services&#8221; means build, operate, maintain network devices related  to remote sites/data center.   &#8220;Contact Center Services&#8221; means call routing/script, IVR changes, recording, playback  issues, agent access issues, dialer, call queue issues, API integration issues, vendor co- ordination for product issues.     Effective October 1, 2022, the following schedules to the Infra Agreement are amended in  their entirety and replaced with the attached schedules:    Appendix 2C (End User Services), dated as of October 1, 2022, as appended hereto as  Exhibit 1 hereto,     Schedule 3 (Pricing and Invoicing), dated as of October 1, 2022, as appended hereto as  Exhibit 2 hereto.     Appendix 3-A (Pricing Matrix), dated as of October 1, 2022, as appended hereto as Exhibit 3  hereto.     Schedule 10 (Approved Service Delivery Locations), dated as of October 1, 2022, as  appended hereto as Exhibit 4 hereto.     Schedule 6A (SLA Matrix), dated as of October 1, 2022, as appended hereto as Exhibit 5  hereto.      1. Support Scope changes:    The Parties agree to amend Appendix2A, Appendix 2B to include the new services or change  existing services for Infrastructure Support set forth in below section   </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit101_changexreques004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit101_changexreques004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> MSA Change Request   Molina &#8211; Infosys  MSA Change Request Page 4 of 12 Change Request Number: 7  1277001.1  &#8226; The Parties agree to amend the agreement for Services as they are to be provided beginning  as of October 1, 2022.    &#8226; All changes to the Services implemented in the previous Change Requests (1-6) continue to  apply and all amounts payable pursuant to previous Change Requests are hereby removed  effective as of October 1, 2022, and commencing as of that date will be subsumed into or  accounted for in the Charges and Unit Rates as set out in Appendix 3-A referenced above.    a)  Additional scope of Onshore support for Virginia (VA) for Infrastructure services    Service Provider shall provide onshore based Infrastructure Services to Molina for the  state of Virginia (VA)    Tracks Considerations  &#8226; Server Support &amp; DR  &#8226; Database Support  &#8226; Security operations  center  &#8226; Administration of servers/databases, DR activity for both  dedicated and demarcated by Molina as processing VA  Business unit&#8217;s member information shall be done from US  locations.  &#8226; Action taken to close the incidents in the security Incident  Response tool for the events having VG member information  will be done by the US locations team      Scope Assumptions  &#8226; The in-scope Infrastructure components like Servers (appliances, devices, compute  platform), Databases (instances, jobs, refresh) services should be distinguishable  using standard naming conventions and the list of such components to be provided by  Molina.  &#8226; Onsite shifts will be limited to provide 8x5 on-seat support. For P1/P2 incidents during  non-business hours, on-call support will be provided,   &#8226; For SOC related tickets, incident analysis will be done from Approved Service  Delivery Locations but remediation that involves member information for Virginia  will be from onshore US Locations.    b) EIM - IT Operations L1 work    Scope of services    &#8226; Monitoring of the Critical EIM pipeline related Jobs and other batch processes.  &#8226; Building the periodic job status reports and sharing updates with NOC  &#8226; Perform basic monitoring on Hadoop/Databricks platform for any system side,  capacity, performance, contention issues.  &#8226; In case of Job failures, delays or slow throughput, engage the current operations  team, Hadoop admin and other teams via email/bridge calls to prioritize and take  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit101_changexreques005.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit101_changexreques005.jpg" title="slide5" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> MSA Change Request   Molina &#8211; Infosys  MSA Change Request Page 5 of 12 Change Request Number: 7  1277001.1  timely action  &#8226; Manage communication with NOC and other targeted business stakeholders  &#8226; Align with MIN and High Impact Process and driving problem management based  on the repetitive failures   &#8226;Build monitoring dashboards for new job workflows in Datalake Env  &#8226;Setup and operationalize monitoring and escalation process for critical jobs in  Datalake Env    Scope Assumptions  &#8226; Design, Cross platform migration, project activities are not considered in scope  &#8226; New jobs configuration, Bug Fix, code modifications to existing jobs and L2 batch  operations are not considered in scope  &#8226; L2/L3 work for [redacted] including platform maintenance.    c) [redacted]    d) Support for Middleware                Tomcat Support     Scope of services    &#8226; Production Support with 16x5 on-seat coverage and on-call support as needed.  &#8226; Handle Application deployments.  &#8226; Troubleshoot platform issues by analyzing thread dumps and heap dumps.  &#8226; Fine tune Tomcat servers to optimize performance.  &#8226; Create SOPs / Knowledge Articles.  &#8226; Create scripts for regular disk cleanup.  &#8226; Security Vulnerability Management.  &#8226; Incident / Change Management.  &#8226; Problem Management and RCA          Scope Assumptions  &#8226; Design, Cross platform migration, project activities are not considered in scope      e)  Azure Engineering support       Scope of services    Foundation build for each PaaS service includes following activities:  &#8226; [redacted]  &#8226; [redacted]  &#8226; [redacted]  &#8226; [redacted]   </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit101_changexreques006.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit101_changexreques006.jpg" title="slide6" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> MSA Change Request   Molina &#8211; Infosys  MSA Change Request Page 6 of 12 Change Request Number: 7  1277001.1  &#8226; [redacted]     Foundation Automation:   &#8226; [redacted]  &#8226; [redacted]  &#8226; [redacted]  &#8226; [redacted]    Policies and controls:  &#8226; [redacted]  &#8226; [redacted]  &#8226; [redacted]  &#8226; [redacted]  &#8226; [redacted]  &#8226; [redacted]  &#8226; [redacted]  &#8226; [redacted]    Scope Assumptions   [redacted]    f) iServe (Service Now) development     Scope of services    &#8226; [redacted]  &#8226; [redacted]  &#8226; [redacted]    Scope Assumptions  &#8226; [redacted]       </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit101_changexreques007.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit101_changexreques007.jpg" title="slide7" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> MSA Change Request   Molina &#8211; Infosys  MSA Change Request Page 7 of 12 Change Request Number: 7  1277001.1    IN WITNESS WHEREOF, the Parties have caused this Change Request to be executed by their duly  authorized representatives as of the day and year signed below.         MOLINA HEALTHCARE, INC.             INFOSYS LIMITED      Signature: ___________________________      Signature: ____________________________      Name:     ___________________________  Name:      _____________________________      Title:       ____________________________  Title:        _____________________________       Date:        ____________________________  Date:         ____________________________       </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit101_changexreques008.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit101_changexreques008.jpg" title="slide8" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> MSA Change Request   Molina &#8211; Infosys  MSA Change Request Page 8 of 12 Change Request Number: 7  1277001.1  Exhibit 1  Amended and Restated Appendix 2C (End User Services)    Please see the attached file.       </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit101_changexreques009.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit101_changexreques009.jpg" title="slide9" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> MSA Change Request   Molina &#8211; Infosys  MSA Change Request Page 9 of 12 Change Request Number: 7  1277001.1  Exhibit 2  Amended and Restated Schedule 3 (Pricing and Invoicing)    Please see the attached file.       </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit101_changexreques010.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit101_changexreques010.jpg" title="slide10" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> MSA Change Request   Molina &#8211; Infosys  MSA Change Request Page 10 of 12 Change Request Number: 7  1277001.1  Exhibit 3  Amended and Restated Appendix 3-A (Pricing Matrix)    Please see the attached file.       </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit101_changexreques011.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit101_changexreques011.jpg" title="slide11" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> MSA Change Request   Molina &#8211; Infosys  MSA Change Request Page 11 of 12 Change Request Number: 7  1277001.1  Exhibit 4  Amended and Restated Schedule 10 (Approved Service Delivery Locations)    Please see the attached file.       </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit101_changexreques012.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit101_changexreques012.jpg" title="slide12" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> MSA Change Request   Molina &#8211; Infosys  MSA Change Request Page 12 of 12 Change Request Number: 7  1277001.1  Exhibit 5  Amended and Restated Schedule 6A (SLA Matrix)    Please see the attached file.        </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>moh3q22_ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i41e90eb412374c65b3d31e57e9b2a586_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1 </font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a)&#47;15d-14(a)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNDER THE SECURITIES EXCHANGE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ACT OF 1934, AS AMENDED</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Joseph M. Zubretsky, certify that&#58;</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed the report on Form 10-Q for the period ended September&#160;30, 2022, of Molina Healthcare, Inc.&#59;</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, the report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by the report&#59;</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in the report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in the report&#59;</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended), and internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Securities Exchange Act of 1934, as amended), for the registrant and have&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period for which this report is being prepared&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in the report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by the report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in the report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and to the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:43.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.622%"></td><td style="width:0.1%"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; October 27, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Joseph M. Zubretsky</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Joseph M. Zubretsky</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer, President and Director</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>moh3q22_ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i3c5707ee8082469592cc6a52acf5e611_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2 </font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a)&#47;15d-14(a)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNDER THE SECURITIES EXCHANGE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ACT OF 1934, AS AMENDED</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Mark L. Keim, certify that&#58;</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed the report on Form 10-Q for the period ended September&#160;30, 2022, of Molina Healthcare, Inc.&#59;</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, the report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by the report&#59;</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in the report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in the report&#59;</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended), and internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Securities Exchange Act of 1934, as amended), for the registrant and have&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period for which this report is being prepared&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in the report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by the report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in the report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and to the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:43.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.850%"></td><td style="width:0.1%"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; October 27, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Mark L. Keim</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mark L. Keim</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer and Treasurer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>moh3q22_ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ia555cd7367174e1e98e6235f181e002a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1 </font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATE PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the report of Molina Healthcare, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended September&#160;30, 2022 (the &#8220;Report&#8221;), I, Joseph M. Zubretsky, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:43.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.622%"></td><td style="width:0.1%"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; October 27, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Joseph M. Zubretsky</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Joseph M. Zubretsky</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer, President and Director</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>moh3q22_ex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i3115d3a343094e22b2b128a7efb21bc3_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.2 </font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATE PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the report of Molina Healthcare, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended September&#160;30, 2022 (the &#8220;Report&#8221;), I, Mark L. Keim, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:43.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.622%"></td><td style="width:0.1%"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; October 27, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Mark L. Keim</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mark L. Keim</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer and Treasurer</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>moh-20220930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:723f88a6-3111-46ae-86a6-19eac5cb9305,g:31c414f1-6fb4-4584-ba8e-291448fd334e-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:moh="http://www.molinahealthcare.com/20220930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.molinahealthcare.com/20220930">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="moh-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="moh-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="moh-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="moh-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.molinahealthcare.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFINCOME" roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME">
        <link:definition>1001002 - Statement - CONSOLIDATED STATEMENTS OF INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME">
        <link:definition>1002003 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1003004 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1004005 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentation" roleURI="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation">
        <link:definition>2101101 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPolicies" roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShare" roleURI="http://www.molinahealthcare.com/role/NetIncomePerShare">
        <link:definition>2110103 - Disclosure - Net Income Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinations" roleURI="http://www.molinahealthcare.com/role/BusinessCombinations">
        <link:definition>2113104 - Disclosure - Business Combinations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.molinahealthcare.com/role/FairValueMeasurements">
        <link:definition>2115105 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.molinahealthcare.com/role/Investments">
        <link:definition>2120106 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsandBenefitsPayable" roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable">
        <link:definition>2126107 - Disclosure - Medical Claims and Benefits Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.molinahealthcare.com/role/Debt">
        <link:definition>2131108 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.molinahealthcare.com/role/StockholdersEquity">
        <link:definition>2135109 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Segments" roleURI="http://www.molinahealthcare.com/role/Segments">
        <link:definition>2137110 - Disclosure - Segments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.molinahealthcare.com/role/CommitmentsandContingencies">
        <link:definition>2142111 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesPolicies" roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesTables" roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareTables" roleURI="http://www.molinahealthcare.com/role/NetIncomePerShareTables">
        <link:definition>2311302 - Disclosure - Net Income Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsTables">
        <link:definition>2316303 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.molinahealthcare.com/role/InvestmentsTables">
        <link:definition>2321304 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsandBenefitsPayableTables" roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables">
        <link:definition>2327305 - Disclosure - Medical Claims and Benefits Payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.molinahealthcare.com/role/DebtTables">
        <link:definition>2332306 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsTables" roleURI="http://www.molinahealthcare.com/role/SegmentsTables">
        <link:definition>2338307 - Disclosure - Segments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationDetails" roleURI="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails">
        <link:definition>2402401 - Disclosure - Organization and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>2406402 - Disclosure - Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesReceivablesDetails" roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails">
        <link:definition>2407403 - Disclosure - Significant Accounting Policies - Receivables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails">
        <link:definition>2408404 - Disclosure - Significant Accounting Policies - Amounts Due To Government Agencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2409405 - Disclosure - Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareDetails" roleURI="http://www.molinahealthcare.com/role/NetIncomePerShareDetails">
        <link:definition>2412406 - Disclosure - Net Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsDetails" roleURI="http://www.molinahealthcare.com/role/BusinessCombinationsDetails">
        <link:definition>2414407 - Disclosure - Business Combinations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails" roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails">
        <link:definition>2417408 - Disclosure - Fair Value Measurements - Financial Instruments on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2418409 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsLongTermDebtDetails" roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails">
        <link:definition>2419410 - Disclosure - Fair Value Measurements - Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsSummaryofInvestmentsDetails" roleURI="http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails">
        <link:definition>2422411 - Disclosure - Investments - Summary of Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails" roleURI="http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails">
        <link:definition>2423412 - Disclosure - Investments - Contractual Maturities of Available-for-Sale Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsNarrativeDetails" roleURI="http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails">
        <link:definition>2424413 - Disclosure - Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsAvailableforSaleInvestmentsDetails" roleURI="http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails">
        <link:definition>2425414 - Disclosure - Investments - Available-for-Sale Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails" roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails">
        <link:definition>2428415 - Disclosure - Medical Claims and Benefits Payable - Medical Claims and Benefits Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsandBenefitsPayableNarrativeDetails" roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableNarrativeDetails">
        <link:definition>2429416 - Disclosure - Medical Claims and Benefits Payable - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails" roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails">
        <link:definition>2430417 - Disclosure - Medical Claims and Benefits Payable - Components of Change in Medical Claims and Benefits Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleofLongTermDebtDetails" roleURI="http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails">
        <link:definition>2433418 - Disclosure - Debt - Schedule of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://www.molinahealthcare.com/role/DebtNarrativeDetails">
        <link:definition>2434419 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://www.molinahealthcare.com/role/StockholdersEquityDetails">
        <link:definition>2436420 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsNarrativeDetails" roleURI="http://www.molinahealthcare.com/role/SegmentsNarrativeDetails">
        <link:definition>2439421 - Disclosure - Segments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsScheduleofOperatingSegmentInformationDetails" roleURI="http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails">
        <link:definition>2440422 - Disclosure - Segments - Schedule of Operating Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" roleURI="http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails">
        <link:definition>2441423 - Disclosure - Segments - Reconciliation of Gross Margin to Consolidated Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="moh_A4375SeniorNotesMember" abstract="true" name="A4375SeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms" abstract="false" name="NumberOfStatesWithGovernmentSponsoredHealthcarePrograms" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="moh_HealthPlanExtensionOptionPeriod" abstract="false" name="HealthPlanExtensionOptionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="moh_AffinityHealthPlanIncMember" abstract="true" name="AffinityHealthPlanIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_GovernmentReceivablesMember" abstract="true" name="GovernmentReceivablesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_OtherClaimsPayable" abstract="false" name="OtherClaimsPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_PaymentsForMedicalCareCostsAbstract" abstract="true" name="PaymentsForMedicalCareCostsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moh_PremiumTaxExpenses" abstract="false" name="PremiumTaxExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_MedicalClaimsAndBenefitsPayable" abstract="false" name="MedicalClaimsAndBenefitsPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_EarningsPerShareBasicAndDilutedEPSAbstract" abstract="true" name="EarningsPerShareBasicAndDilutedEPSAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moh_MedicaidMember" abstract="true" name="MedicaidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" abstract="false" name="LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_HealthCareOrganizationPremiumTaxRevenue" abstract="false" name="HealthCareOrganizationPremiumTaxRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_CapitationClaimsPayable" abstract="false" name="CapitationClaimsPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" abstract="false" name="ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="moh_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_MemberListsMember" abstract="true" name="MemberListsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_OtherSecuritiesMember" abstract="true" name="OtherSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_HealthPlanContractTerm" abstract="false" name="HealthPlanContractTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="moh_StructuredSecuritiesMember" abstract="true" name="StructuredSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" abstract="false" name="AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" abstract="false" name="BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="moh_MedicalClaimsAndBenefitsPayableTextBlock" abstract="false" name="MedicalClaimsAndBenefitsPayableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems" abstract="true" name="ScheduleOfPremiumRevenueByHealthPlanTypeLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moh_InvestmentsMaturityPeriod" abstract="false" name="InvestmentsMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" abstract="false" name="AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_AgeWellMember" abstract="true" name="AgeWellMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" abstract="false" name="AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_MinimumMemberEnrollmentTargetsMember" abstract="true" name="MinimumMemberEnrollmentTargetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable" abstract="true" name="ScheduleOfPremiumRevenueByHealthPlanTypeTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" abstract="false" name="MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_PharmacyRebateReceivablesMember" abstract="true" name="PharmacyRebateReceivablesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract" abstract="true" name="AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold" abstract="false" name="MedicalPremiumsLiabilityMedicalCareCostsThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities" abstract="false" name="PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_MarketplaceMember" abstract="true" name="MarketplaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_MyChoiceWisconsinMember" abstract="true" name="MyChoiceWisconsinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" abstract="false" name="AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_OtherProgramMember" abstract="true" name="OtherProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_ThreePointEightSevenFivePercentSeniorNotesMember" abstract="true" name="ThreePointEightSevenFivePercentSeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" abstract="false" name="AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_CommonStockWithheldToSettleEmployeeTaxObligations" abstract="false" name="CommonStockWithheldToSettleEmployeeTaxObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_A3875SeniorNotesMember" abstract="true" name="A3875SeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_InvestmentsAverageMaturityPeriod" abstract="false" name="InvestmentsAverageMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="moh_AmountsDueToGovernmentAgenciesMedicaidOther" abstract="false" name="AmountsDueToGovernmentAgenciesMedicaidOther" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" abstract="false" name="AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" abstract="false" name="LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_AmountsDuetoGovernmentAgenciesOther" abstract="false" name="AmountsDuetoGovernmentAgenciesOther" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_HealthPlansMember" abstract="true" name="HealthPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember" abstract="true" name="CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_OtherReceivablesMember" abstract="true" name="OtherReceivablesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_COVID19Member" abstract="true" name="COVID19Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_MedicalPremiumLiabilityDueToAgency" abstract="false" name="MedicalPremiumLiabilityDueToAgency" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_HealthPlanNumberOfContracts" abstract="false" name="HealthPlanNumberOfContracts" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock" abstract="false" name="ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" abstract="false" name="IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_OperatingIncomeGuaranteeMember" abstract="true" name="OperatingIncomeGuaranteeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_ComponentsOfMedicalCareCostsAbstract" abstract="true" name="ComponentsOfMedicalCareCostsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract" abstract="true" name="AmountsDueToGovernmentAgenciesMedicareProgramAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moh_MunicipalSecuritiesMember" abstract="true" name="MunicipalSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_SharesOutstandingExcludingRestrictedStockAwards" abstract="false" name="SharesOutstandingExcludingRestrictedStockAwards" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="moh_PharmacyClaimsPayable" abstract="false" name="PharmacyClaimsPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract" abstract="true" name="AmountsDueToGovernmentAgenciesMedicaidProgramAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moh_OtherMedicareProgram" abstract="false" name="OtherMedicareProgram" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_PassportHealthPlanIncMember" abstract="true" name="PassportHealthPlanIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" abstract="false" name="LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_AmountsDuetoGovernmentAgenciesRiskAdjustment" abstract="false" name="AmountsDuetoGovernmentAgenciesRiskAdjustment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_WeightedAverageNumberofSharesShareBasedCompensation" abstract="false" name="WeightedAverageNumberofSharesShareBasedCompensation" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>moh-20220930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:723f88a6-3111-46ae-86a6-19eac5cb9305,g:31c414f1-6fb4-4584-ba8e-291448fd334e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="moh-20220930.xsd#CONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_22d062ed-7211-48fb-b8b1-f7f9e90a9dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d7050edb-c130-4979-a505-a986c8654292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_22d062ed-7211-48fb-b8b1-f7f9e90a9dfc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d7050edb-c130-4979-a505-a986c8654292" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d705ea74-ceba-4df2-add5-42eea178fe5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_22d062ed-7211-48fb-b8b1-f7f9e90a9dfc" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d705ea74-ceba-4df2-add5-42eea178fe5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_ae335d16-d33e-4be3-ab1d-67b14dea8b20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_39da96f5-6578-4dd0-815e-0168815caeee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ae335d16-d33e-4be3-ab1d-67b14dea8b20" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_39da96f5-6578-4dd0-815e-0168815caeee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_08bde761-ef56-44a1-997e-269cab06c543" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ae335d16-d33e-4be3-ab1d-67b14dea8b20" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_08bde761-ef56-44a1-997e-269cab06c543" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PremiumTaxExpenses_475f4e6a-58e6-480d-b2a2-018efbbc9bdc" xlink:href="moh-20220930.xsd#moh_PremiumTaxExpenses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ae335d16-d33e-4be3-ab1d-67b14dea8b20" xlink:to="loc_moh_PremiumTaxExpenses_475f4e6a-58e6-480d-b2a2-018efbbc9bdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_91139eaf-5ad6-4af0-a9ce-7758238fb0dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ae335d16-d33e-4be3-ab1d-67b14dea8b20" xlink:to="loc_us-gaap_DepreciationAndAmortization_91139eaf-5ad6-4af0-a9ce-7758238fb0dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_b470af75-4516-4aa3-a99a-6a7a98db6e70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ae335d16-d33e-4be3-ab1d-67b14dea8b20" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_b470af75-4516-4aa3-a99a-6a7a98db6e70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ca65f00e-1ea4-4206-bc57-3a68fed00f72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c91058d0-03b6-4894-9024-02d694966ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ca65f00e-1ea4-4206-bc57-3a68fed00f72" xlink:to="loc_us-gaap_OperatingIncomeLoss_c91058d0-03b6-4894-9024-02d694966ba1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5af91c45-f60a-41da-86c7-14e62db1effc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ca65f00e-1ea4-4206-bc57-3a68fed00f72" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_5af91c45-f60a-41da-86c7-14e62db1effc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_42886d76-295f-4127-b8c6-a8f7fd2c447d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_de205268-4683-4e17-9516-96f1ff82a244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_42886d76-295f-4127-b8c6-a8f7fd2c447d" xlink:to="loc_us-gaap_Revenues_de205268-4683-4e17-9516-96f1ff82a244" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_651ad11a-5a14-48e2-95e3-5dd6c21519b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_42886d76-295f-4127-b8c6-a8f7fd2c447d" xlink:to="loc_us-gaap_CostsAndExpenses_651ad11a-5a14-48e2-95e3-5dd6c21519b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_ca07bb79-81ef-4aef-b846-0b55d4ef3b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_95e8ba2c-aa91-4d02-8fc1-6cd7e3c19c16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_ca07bb79-81ef-4aef-b846-0b55d4ef3b8c" xlink:to="loc_us-gaap_InterestExpense_95e8ba2c-aa91-4d02-8fc1-6cd7e3c19c16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_0113fd07-71cc-4f28-bd46-8d5eb39d22cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDividendIncomeOperating_18ee25eb-bc6a-49d2-95e8-49896d55dc29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDividendIncomeOperating"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_0113fd07-71cc-4f28-bd46-8d5eb39d22cf" xlink:to="loc_us-gaap_InterestAndDividendIncomeOperating_18ee25eb-bc6a-49d2-95e8-49896d55dc29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareOrganizationPremiumTaxRevenue_284533e3-6c4b-4eb6-aa6a-4865c635319c" xlink:href="moh-20220930.xsd#moh_HealthCareOrganizationPremiumTaxRevenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_0113fd07-71cc-4f28-bd46-8d5eb39d22cf" xlink:to="loc_moh_HealthCareOrganizationPremiumTaxRevenue_284533e3-6c4b-4eb6-aa6a-4865c635319c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_2adf9a12-2679-4342-933f-31599a25e579" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_0113fd07-71cc-4f28-bd46-8d5eb39d22cf" xlink:to="loc_us-gaap_NetInvestmentIncome_2adf9a12-2679-4342-933f-31599a25e579" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_e5599817-69a5-4c0d-bbd9-57e8bddb4c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_0113fd07-71cc-4f28-bd46-8d5eb39d22cf" xlink:to="loc_us-gaap_PremiumsEarnedNet_e5599817-69a5-4c0d-bbd9-57e8bddb4c0e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="moh-20220930.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ba4e0062-fb3e-4646-b177-93a13bc1ea10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_200d642f-1145-46c5-984e-bd6f43b52223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ba4e0062-fb3e-4646-b177-93a13bc1ea10" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_200d642f-1145-46c5-984e-bd6f43b52223" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_52391e36-57b1-4f6a-9712-faa5060dc1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ba4e0062-fb3e-4646-b177-93a13bc1ea10" xlink:to="loc_us-gaap_NetIncomeLoss_52391e36-57b1-4f6a-9712-faa5060dc1e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_296a79ce-f686-425d-8a75-d9003cdccdbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_2f85b74e-a86a-4887-a523-49deed7e224a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_296a79ce-f686-425d-8a75-d9003cdccdbe" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_2f85b74e-a86a-4887-a523-49deed7e224a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_287139a4-0228-480c-8bfb-b5f5faf23b33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_296a79ce-f686-425d-8a75-d9003cdccdbe" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_287139a4-0228-480c-8bfb-b5f5faf23b33" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="moh-20220930.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_68a71d03-0550-4afd-a236-c15f0ebb5357" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_84bc24eb-5206-4789-b2ab-0aa814c71d86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_68a71d03-0550-4afd-a236-c15f0ebb5357" xlink:to="loc_us-gaap_LiabilitiesCurrent_84bc24eb-5206-4789-b2ab-0aa814c71d86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_852ef5c7-bc69-41de-866b-ebc4e8b68a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_68a71d03-0550-4afd-a236-c15f0ebb5357" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_852ef5c7-bc69-41de-866b-ebc4e8b68a6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_aedb1880-ee25-41bf-bee6-8c7c9b1637bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_68a71d03-0550-4afd-a236-c15f0ebb5357" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_aedb1880-ee25-41bf-bee6-8c7c9b1637bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_83b4331d-0f10-4b61-a709-8374d60871fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_68a71d03-0550-4afd-a236-c15f0ebb5357" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_83b4331d-0f10-4b61-a709-8374d60871fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4a7ef23f-18ef-4ddc-bf5e-0609e168750e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2c6ec333-b85e-4573-9551-a6e4e819ef8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4a7ef23f-18ef-4ddc-bf5e-0609e168750e" xlink:to="loc_us-gaap_Liabilities_2c6ec333-b85e-4573-9551-a6e4e819ef8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_da2ed67f-1ff7-4863-96f7-8e269a0db156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4a7ef23f-18ef-4ddc-bf5e-0609e168750e" xlink:to="loc_us-gaap_StockholdersEquity_da2ed67f-1ff7-4863-96f7-8e269a0db156" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_eb076e95-e513-4488-a103-ec58a706a633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_ba041497-e37b-4a53-8663-adc60fdfb2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_eb076e95-e513-4488-a103-ec58a706a633" xlink:to="loc_us-gaap_CommonStockValueOutstanding_ba041497-e37b-4a53-8663-adc60fdfb2f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_11b92501-f63b-4459-ba72-5b99921d0234" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_eb076e95-e513-4488-a103-ec58a706a633" xlink:to="loc_us-gaap_PreferredStockValue_11b92501-f63b-4459-ba72-5b99921d0234" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_4d0d8096-e055-4f5e-8804-d4e37041f7fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_eb076e95-e513-4488-a103-ec58a706a633" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_4d0d8096-e055-4f5e-8804-d4e37041f7fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_29bce3fb-0518-4928-9eab-da224cc9ca29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_eb076e95-e513-4488-a103-ec58a706a633" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_29bce3fb-0518-4928-9eab-da224cc9ca29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_00d7fa31-54b5-46e7-84fe-48150ec3ff3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_eb076e95-e513-4488-a103-ec58a706a633" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_00d7fa31-54b5-46e7-84fe-48150ec3ff3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_debd9fdf-b7eb-4ab9-b949-66510b99c108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_af9f0100-6528-47d6-8cd4-5a2d60697e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_debd9fdf-b7eb-4ab9-b949-66510b99c108" xlink:to="loc_us-gaap_AssetsCurrent_af9f0100-6528-47d6-8cd4-5a2d60697e6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_5a872869-9dc0-478d-a1ae-33d74733c6b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_debd9fdf-b7eb-4ab9-b949-66510b99c108" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_5a872869-9dc0-478d-a1ae-33d74733c6b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_bffad40c-d9f1-46f5-9f7e-9163cc4e5939" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_debd9fdf-b7eb-4ab9-b949-66510b99c108" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_bffad40c-d9f1-46f5-9f7e-9163cc4e5939" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestmentsNoncurrent_4d3e14d1-f851-4a34-87ef-63560e09ed38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedInvestmentsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_debd9fdf-b7eb-4ab9-b949-66510b99c108" xlink:to="loc_us-gaap_RestrictedInvestmentsNoncurrent_4d3e14d1-f851-4a34-87ef-63560e09ed38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_0d8a4d30-0702-4b75-8592-51b6cba02d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_debd9fdf-b7eb-4ab9-b949-66510b99c108" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_0d8a4d30-0702-4b75-8592-51b6cba02d6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2f3b4eb7-564e-4f2c-b813-5c857fa60a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_debd9fdf-b7eb-4ab9-b949-66510b99c108" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_2f3b4eb7-564e-4f2c-b813-5c857fa60a0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_440274dd-9e59-490c-9e45-16e15b35eeb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_cf1a0dc3-0a7a-4d57-acb6-3b7da157631b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_440274dd-9e59-490c-9e45-16e15b35eeb7" xlink:to="loc_us-gaap_ReceivablesNetCurrent_cf1a0dc3-0a7a-4d57-acb6-3b7da157631b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_23203b4a-5500-4bfe-8c51-1a91e3d6d162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_440274dd-9e59-490c-9e45-16e15b35eeb7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_23203b4a-5500-4bfe-8c51-1a91e3d6d162" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_56c33f07-d9fc-4f40-9816-ab0c6546589e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_440274dd-9e59-490c-9e45-16e15b35eeb7" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_56c33f07-d9fc-4f40-9816-ab0c6546589e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_48902f78-1fb9-4a63-ad19-aabf97a402ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_440274dd-9e59-490c-9e45-16e15b35eeb7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_48902f78-1fb9-4a63-ad19-aabf97a402ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5526700e-9f8a-444a-b8de-851045822dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalPremiumLiabilityDueToAgency_8198c0d4-8c9c-4313-a90f-e2e32afbe1d5" xlink:href="moh-20220930.xsd#moh_MedicalPremiumLiabilityDueToAgency"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5526700e-9f8a-444a-b8de-851045822dd2" xlink:to="loc_moh_MedicalPremiumLiabilityDueToAgency_8198c0d4-8c9c-4313-a90f-e2e32afbe1d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_86371ce7-a1b7-4c54-bb10-308bbb663fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5526700e-9f8a-444a-b8de-851045822dd2" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_86371ce7-a1b7-4c54-bb10-308bbb663fb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1eac6cd7-1b8b-4136-8263-4e34269810c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5526700e-9f8a-444a-b8de-851045822dd2" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1eac6cd7-1b8b-4136-8263-4e34269810c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c4213fe0-24f5-45e6-94ad-866ed8409795" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5526700e-9f8a-444a-b8de-851045822dd2" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c4213fe0-24f5-45e6-94ad-866ed8409795" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="moh-20220930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1ae95774-b5fb-43a0-a638-e7ba2bcdf6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0df00725-2d57-48ec-a3c4-36ee72ee9d53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1ae95774-b5fb-43a0-a638-e7ba2bcdf6c0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0df00725-2d57-48ec-a3c4-36ee72ee9d53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_361ded4d-8bb5-4fea-b34e-c22d47294c14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1ae95774-b5fb-43a0-a638-e7ba2bcdf6c0" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_361ded4d-8bb5-4fea-b34e-c22d47294c14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_b90d7d9e-9619-434a-95a7-45c0fa4e0e69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1ae95774-b5fb-43a0-a638-e7ba2bcdf6c0" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_b90d7d9e-9619-434a-95a7-45c0fa4e0e69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_e9561ec3-386e-4cd8-a612-80f42cb67230" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1ae95774-b5fb-43a0-a638-e7ba2bcdf6c0" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_e9561ec3-386e-4cd8-a612-80f42cb67230" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_f87bd368-25c7-47b5-9aa6-0ed92801e7be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1ae95774-b5fb-43a0-a638-e7ba2bcdf6c0" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_f87bd368-25c7-47b5-9aa6-0ed92801e7be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f24fd353-d293-477a-9f4f-1c9bd0b82e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a5fac93e-90b9-4ae9-abdd-d0100ab783b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f24fd353-d293-477a-9f4f-1c9bd0b82e8f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a5fac93e-90b9-4ae9-abdd-d0100ab783b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e1a1e707-e9a5-4bec-a15b-da4fd53a2079" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f24fd353-d293-477a-9f4f-1c9bd0b82e8f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e1a1e707-e9a5-4bec-a15b-da4fd53a2079" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0d477eee-6aaf-4fdd-aea5-ca8904bab82b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f24fd353-d293-477a-9f4f-1c9bd0b82e8f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0d477eee-6aaf-4fdd-aea5-ca8904bab82b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f3ab0d1c-9e9a-4057-a3e2-e4512f54ff10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_9e54780b-8a09-4be3-a09d-dd97b38899e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f3ab0d1c-9e9a-4057-a3e2-e4512f54ff10" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_9e54780b-8a09-4be3-a09d-dd97b38899e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_3a23fac9-4cca-4258-871b-d87edd784d95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f3ab0d1c-9e9a-4057-a3e2-e4512f54ff10" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_3a23fac9-4cca-4258-871b-d87edd784d95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_a6fb714d-8114-451e-a93e-a174f6f8249c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f3ab0d1c-9e9a-4057-a3e2-e4512f54ff10" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_a6fb714d-8114-451e-a93e-a174f6f8249c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CommonStockWithheldToSettleEmployeeTaxObligations_373df961-9f5c-4c63-8d3b-f11f4465b561" xlink:href="moh-20220930.xsd#moh_CommonStockWithheldToSettleEmployeeTaxObligations"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f3ab0d1c-9e9a-4057-a3e2-e4512f54ff10" xlink:to="loc_moh_CommonStockWithheldToSettleEmployeeTaxObligations_373df961-9f5c-4c63-8d3b-f11f4465b561" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab3ccd8f-bb42-4d67-98c8-d3735f315f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_95b64076-d0f2-40ae-88ff-69d5e4adc873" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab3ccd8f-bb42-4d67-98c8-d3735f315f5d" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_95b64076-d0f2-40ae-88ff-69d5e4adc873" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4a89f237-effc-43cf-8435-839ec39009d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab3ccd8f-bb42-4d67-98c8-d3735f315f5d" xlink:to="loc_us-gaap_ShareBasedCompensation_4a89f237-effc-43cf-8435-839ec39009d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dbccb819-63ae-490e-8499-d30e8146cc05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab3ccd8f-bb42-4d67-98c8-d3735f315f5d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dbccb819-63ae-490e-8499-d30e8146cc05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency_7e094dc8-8bd4-45fb-abf4-904864f25bcf" xlink:href="moh-20220930.xsd#moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab3ccd8f-bb42-4d67-98c8-d3735f315f5d" xlink:to="loc_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency_7e094dc8-8bd4-45fb-abf4-904864f25bcf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities_14c7f253-f818-4430-a46c-cdc82e774324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab3ccd8f-bb42-4d67-98c8-d3735f315f5d" xlink:to="loc_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities_14c7f253-f818-4430-a46c-cdc82e774324" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_22f73c1f-52e3-46ed-b28a-1f61a62f3e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab3ccd8f-bb42-4d67-98c8-d3735f315f5d" xlink:to="loc_us-gaap_NetIncomeLoss_22f73c1f-52e3-46ed-b28a-1f61a62f3e6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_f71b3f9e-7948-4e1c-851b-70f38bc11144" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab3ccd8f-bb42-4d67-98c8-d3735f315f5d" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_f71b3f9e-7948-4e1c-851b-70f38bc11144" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_69d0be8b-d362-4f01-ba49-bc2c634759de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab3ccd8f-bb42-4d67-98c8-d3735f315f5d" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_69d0be8b-d362-4f01-ba49-bc2c634759de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_d8209ee4-31da-4bf5-9b38-7f63d3d69b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab3ccd8f-bb42-4d67-98c8-d3735f315f5d" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_d8209ee4-31da-4bf5-9b38-7f63d3d69b0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_be7b2f91-cf37-455a-aa06-0c99bb2bcd1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab3ccd8f-bb42-4d67-98c8-d3735f315f5d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_be7b2f91-cf37-455a-aa06-0c99bb2bcd1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_56ed6c8e-21bd-4b56-b35a-e02d78e835e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab3ccd8f-bb42-4d67-98c8-d3735f315f5d" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_56ed6c8e-21bd-4b56-b35a-e02d78e835e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_3b5a9dc8-72f9-431e-b19d-dc9780cf894d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab3ccd8f-bb42-4d67-98c8-d3735f315f5d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_3b5a9dc8-72f9-431e-b19d-dc9780cf894d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_000740c3-8dab-4f6e-b6dc-759f9d8012c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0e80e94a-e98e-4071-bf57-9b3be36e50b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_000740c3-8dab-4f6e-b6dc-759f9d8012c1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0e80e94a-e98e-4071-bf57-9b3be36e50b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_c22252ff-cd21-45f4-aa63-048ab1780ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_000740c3-8dab-4f6e-b6dc-759f9d8012c1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_c22252ff-cd21-45f4-aa63-048ab1780ac4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalPremiumLiabilityDueToAgency_a751cd97-1b33-4a91-9c93-dd0f9a29faf8" xlink:href="moh-20220930.xsd#moh_MedicalPremiumLiabilityDueToAgency"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing_60cdd813-83f1-43e6-95ae-d2550747b8e5" xlink:href="moh-20220930.xsd#moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_a751cd97-1b33-4a91-9c93-dd0f9a29faf8" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing_60cdd813-83f1-43e6-95ae-d2550747b8e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherMedicareProgram_44d9ff9c-4a64-462b-9851-593c767458d1" xlink:href="moh-20220930.xsd#moh_OtherMedicareProgram"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_a751cd97-1b33-4a91-9c93-dd0f9a29faf8" xlink:to="loc_moh_OtherMedicareProgram_44d9ff9c-4a64-462b-9851-593c767458d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold_115ff608-52c1-412a-8827-9cbe2ae26252" xlink:href="moh-20220930.xsd#moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_a751cd97-1b33-4a91-9c93-dd0f9a29faf8" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold_115ff608-52c1-412a-8827-9cbe2ae26252" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold_73464551-c08b-43c0-a01d-85db7a25afd8" xlink:href="moh-20220930.xsd#moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_a751cd97-1b33-4a91-9c93-dd0f9a29faf8" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold_73464551-c08b-43c0-a01d-85db7a25afd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicaidOther_ad8f077b-578c-4bd1-82a0-3607d5944c60" xlink:href="moh-20220930.xsd#moh_AmountsDueToGovernmentAgenciesMedicaidOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_a751cd97-1b33-4a91-9c93-dd0f9a29faf8" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMedicaidOther_ad8f077b-578c-4bd1-82a0-3607d5944c60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDuetoGovernmentAgenciesOther_e48b0827-63cb-46e8-9727-fe23a068cba4" xlink:href="moh-20220930.xsd#moh_AmountsDuetoGovernmentAgenciesOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_a751cd97-1b33-4a91-9c93-dd0f9a29faf8" xlink:to="loc_moh_AmountsDuetoGovernmentAgenciesOther_e48b0827-63cb-46e8-9727-fe23a068cba4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment_8b50b792-98d5-4476-b30d-8c97b4e768cf" xlink:href="moh-20220930.xsd#moh_AmountsDuetoGovernmentAgenciesRiskAdjustment"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_a751cd97-1b33-4a91-9c93-dd0f9a29faf8" xlink:to="loc_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment_8b50b792-98d5-4476-b30d-8c97b4e768cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold_a54d85b8-775a-4505-b53b-65cec4b9f21c" xlink:href="moh-20220930.xsd#moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_a751cd97-1b33-4a91-9c93-dd0f9a29faf8" xlink:to="loc_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold_a54d85b8-775a-4505-b53b-65cec4b9f21c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/NetIncomePerShareDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#NetIncomePerShareDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/NetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a64911bc-f7fd-43e5-a455-d6eb31048ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_aa71fccf-9a43-4092-8bf9-70271cedf7a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a64911bc-f7fd-43e5-a455-d6eb31048ab2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_aa71fccf-9a43-4092-8bf9-70271cedf7a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_f0173d8e-89fe-4f1f-ae85-cd0d2a8d03d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a64911bc-f7fd-43e5-a455-d6eb31048ab2" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_f0173d8e-89fe-4f1f-ae85-cd0d2a8d03d1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_448d59d8-5c7a-4805-9b72-c56e742e2eae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_154eacc2-a3c7-4493-9461-b2374e49ccf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_448d59d8-5c7a-4805-9b72-c56e742e2eae" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_154eacc2-a3c7-4493-9461-b2374e49ccf7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_ef9aa8cb-7ef9-44a0-8d4c-d6635005a705" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9b3e7905-7ff5-46c0-a27d-e3ee3bced4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_ef9aa8cb-7ef9-44a0-8d4c-d6635005a705" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9b3e7905-7ff5-46c0-a27d-e3ee3bced4e3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#InvestmentsSummaryofInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_6beb97ca-cb6a-488d-a442-d53c16d1a7ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3f661b94-c51b-43e7-a9d7-8d1bf09fabd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_6beb97ca-cb6a-488d-a442-d53c16d1a7ec" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3f661b94-c51b-43e7-a9d7-8d1bf09fabd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_05ccc2ef-0c37-4cb1-838d-d03eee6644c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_6beb97ca-cb6a-488d-a442-d53c16d1a7ec" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_05ccc2ef-0c37-4cb1-838d-d03eee6644c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_09a3334c-9436-49ec-a465-b1ebfbbef6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_6beb97ca-cb6a-488d-a442-d53c16d1a7ec" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_09a3334c-9436-49ec-a465-b1ebfbbef6a6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_07e079dd-3750-4bb7-a3b2-12befadcfe2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_ac525c7c-5234-48b4-b5cb-7d4857c5aee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_07e079dd-3750-4bb7-a3b2-12befadcfe2b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_ac525c7c-5234-48b4-b5cb-7d4857c5aee5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_c85bf7b4-2c96-4c5f-b729-f2ff17ffa96c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_07e079dd-3750-4bb7-a3b2-12befadcfe2b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_c85bf7b4-2c96-4c5f-b729-f2ff17ffa96c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_6181339d-3f12-4ab3-940e-8a1249616c13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_07e079dd-3750-4bb7-a3b2-12befadcfe2b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_6181339d-3f12-4ab3-940e-8a1249616c13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_425f3c52-9ff7-436d-a0cc-6db6ed1599ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_07e079dd-3750-4bb7-a3b2-12befadcfe2b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_425f3c52-9ff7-436d-a0cc-6db6ed1599ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_7d8d80e4-bf9d-441b-a902-89c0cc15ec23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_cb528f24-9a1b-4976-92d1-dd9a0633d30e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_7d8d80e4-bf9d-441b-a902-89c0cc15ec23" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_cb528f24-9a1b-4976-92d1-dd9a0633d30e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_726ee91f-ba3e-492c-8032-cd985ae68264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_7d8d80e4-bf9d-441b-a902-89c0cc15ec23" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_726ee91f-ba3e-492c-8032-cd985ae68264" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_f8591632-4811-4df1-9c2b-fc99d5c9c1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_7d8d80e4-bf9d-441b-a902-89c0cc15ec23" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_f8591632-4811-4df1-9c2b-fc99d5c9c1ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_9f51e850-e5c4-41b9-9572-dd17a2ca7e28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_7d8d80e4-bf9d-441b-a902-89c0cc15ec23" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_9f51e850-e5c4-41b9-9572-dd17a2ca7e28" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_759a39d7-e164-49a0-a41b-bdc207fb0eb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CapitationClaimsPayable_fe10f57c-fce2-42e6-8e20-3dfb7b26f819" xlink:href="moh-20220930.xsd#moh_CapitationClaimsPayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_759a39d7-e164-49a0-a41b-bdc207fb0eb6" xlink:to="loc_moh_CapitationClaimsPayable_fe10f57c-fce2-42e6-8e20-3dfb7b26f819" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount_9151e966-4e93-40d3-9b9f-ed57916bd11a" xlink:href="moh-20220930.xsd#moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_759a39d7-e164-49a0-a41b-bdc207fb0eb6" xlink:to="loc_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount_9151e966-4e93-40d3-9b9f-ed57916bd11a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PharmacyClaimsPayable_24944257-1ddb-434e-a4ef-b74e13504556" xlink:href="moh-20220930.xsd#moh_PharmacyClaimsPayable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_759a39d7-e164-49a0-a41b-bdc207fb0eb6" xlink:to="loc_moh_PharmacyClaimsPayable_24944257-1ddb-434e-a4ef-b74e13504556" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherClaimsPayable_4778f6ab-99af-48d8-9f30-6e75cbdfb07a" xlink:href="moh-20220930.xsd#moh_OtherClaimsPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_759a39d7-e164-49a0-a41b-bdc207fb0eb6" xlink:to="loc_moh_OtherClaimsPayable_4778f6ab-99af-48d8-9f30-6e75cbdfb07a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_15c60053-0899-45b2-b4cc-076d21805671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_67d23bc1-d7bb-4b62-9971-6a05a9df6774" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_15c60053-0899-45b2-b4cc-076d21805671" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_67d23bc1-d7bb-4b62-9971-6a05a9df6774" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_6244468a-dc36-44e3-8da5-e6b4fa18a3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_15c60053-0899-45b2-b4cc-076d21805671" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_6244468a-dc36-44e3-8da5-e6b4fa18a3ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_c8a78eee-e6c5-4edf-84cc-a05c8f5619b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_e232cbd0-e178-4dce-854c-9eefbdafbb12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_c8a78eee-e6c5-4edf-84cc-a05c8f5619b4" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_e232cbd0-e178-4dce-854c-9eefbdafbb12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_032f45d7-5e61-4ecb-8a59-eb0c48803878" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_c8a78eee-e6c5-4edf-84cc-a05c8f5619b4" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_032f45d7-5e61-4ecb-8a59-eb0c48803878" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#DebtScheduleofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_19fbcd54-bee8-4f79-8db5-89000641b627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_be2dc1f2-fb68-4ea6-aeb8-389bc67792f5" xlink:href="moh-20220930.xsd#moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_19fbcd54-bee8-4f79-8db5-89000641b627" xlink:to="loc_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_be2dc1f2-fb68-4ea6-aeb8-389bc67792f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_59d0f2ce-db78-4863-8290-1ffef7385fee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_19fbcd54-bee8-4f79-8db5-89000641b627" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_59d0f2ce-db78-4863-8290-1ffef7385fee" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>moh-20220930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:723f88a6-3111-46ae-86a6-19eac5cb9305,g:31c414f1-6fb4-4584-ba8e-291448fd334e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="moh-20220930.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="icf86f189c637489f8082cab15d888f52_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ee74f456-da0e-4870-b84f-1cc3526ce51a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e5cc174-ff2d-4c10-96f7-82e5d46a7ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ee74f456-da0e-4870-b84f-1cc3526ce51a" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e5cc174-ff2d-4c10-96f7-82e5d46a7ea4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_ec309b2f-2358-4744-945b-af919c89fddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e5cc174-ff2d-4c10-96f7-82e5d46a7ea4" xlink:to="loc_us-gaap_SharesOutstanding_ec309b2f-2358-4744-945b-af919c89fddd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_98a96814-0710-49a5-a83b-a6d1c77de6db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e5cc174-ff2d-4c10-96f7-82e5d46a7ea4" xlink:to="loc_us-gaap_StockholdersEquity_98a96814-0710-49a5-a83b-a6d1c77de6db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a7f459d3-f010-4496-adf6-9f0bb2ed51c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e5cc174-ff2d-4c10-96f7-82e5d46a7ea4" xlink:to="loc_us-gaap_NetIncomeLoss_a7f459d3-f010-4496-adf6-9f0bb2ed51c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_b108525b-70cc-4123-b147-b630cb85e76b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e5cc174-ff2d-4c10-96f7-82e5d46a7ea4" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_b108525b-70cc-4123-b147-b630cb85e76b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_5c0edc1c-a923-45fb-a2f1-93b64f87b8f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e5cc174-ff2d-4c10-96f7-82e5d46a7ea4" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_5c0edc1c-a923-45fb-a2f1-93b64f87b8f3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c5ac30b2-a14d-4729-9cfc-f9d9f909ff39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e5cc174-ff2d-4c10-96f7-82e5d46a7ea4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c5ac30b2-a14d-4729-9cfc-f9d9f909ff39" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_c2368d3a-81be-4179-876f-a14a8faba5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e5cc174-ff2d-4c10-96f7-82e5d46a7ea4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_c2368d3a-81be-4179-876f-a14a8faba5b7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6ad4dde4-4296-4a5d-a9d9-1df221d43a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e5cc174-ff2d-4c10-96f7-82e5d46a7ea4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6ad4dde4-4296-4a5d-a9d9-1df221d43a6c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_0f4b4d35-2581-4676-9c1d-660acfc8645d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f51ca55d-fc98-4911-8695-075db20e7490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_fed178d7-21a5-4c62-9b34-9bd901aef383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_ee74f456-da0e-4870-b84f-1cc3526ce51a" xlink:to="loc_us-gaap_StatementTable_fed178d7-21a5-4c62-9b34-9bd901aef383" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_21ec01ec-3e4c-4c20-ab63-5165f81eadad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_fed178d7-21a5-4c62-9b34-9bd901aef383" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_21ec01ec-3e4c-4c20-ab63-5165f81eadad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_21ec01ec-3e4c-4c20-ab63-5165f81eadad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_21ec01ec-3e4c-4c20-ab63-5165f81eadad" xlink:to="loc_us-gaap_EquityComponentDomain_21ec01ec-3e4c-4c20-ab63-5165f81eadad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7472d53b-b6ae-42c9-b0d0-292f75b55190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_21ec01ec-3e4c-4c20-ab63-5165f81eadad" xlink:to="loc_us-gaap_EquityComponentDomain_7472d53b-b6ae-42c9-b0d0-292f75b55190" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_039ade5d-e46c-4d22-83da-44af61700217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7472d53b-b6ae-42c9-b0d0-292f75b55190" xlink:to="loc_us-gaap_CommonStockMember_039ade5d-e46c-4d22-83da-44af61700217" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_760744e1-baa6-4816-835d-0cfff36dae2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7472d53b-b6ae-42c9-b0d0-292f75b55190" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_760744e1-baa6-4816-835d-0cfff36dae2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_19ec3bc8-4526-4c94-bbd5-91aff73c48b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7472d53b-b6ae-42c9-b0d0-292f75b55190" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_19ec3bc8-4526-4c94-bbd5-91aff73c48b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_693a09e4-4c2b-469b-8bd1-0c039bbd88fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7472d53b-b6ae-42c9-b0d0-292f75b55190" xlink:to="loc_us-gaap_RetainedEarningsMember_693a09e4-4c2b-469b-8bd1-0c039bbd88fd" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#OrganizationandBasisofPresentationDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" xlink:type="extended" id="i6d6e1e7766524172bc66487baa7b47cd_OrganizationandBasisofPresentationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_2cd31e24-2f3e-40f7-b400-ce2ca3a352a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_b1bbb22a-cd68-4f87-ad32-5530c08cde14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2cd31e24-2f3e-40f7-b400-ce2ca3a352a6" xlink:to="loc_us-gaap_NumberOfReportableSegments_b1bbb22a-cd68-4f87-ad32-5530c08cde14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms_c7e439a8-a5a7-4028-8ffd-1a4af56794db" xlink:href="moh-20220930.xsd#moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2cd31e24-2f3e-40f7-b400-ce2ca3a352a6" xlink:to="loc_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms_c7e439a8-a5a7-4028-8ffd-1a4af56794db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms_3932b51a-e9fb-46d3-8161-081f3aebd92d" xlink:href="moh-20220930.xsd#moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2cd31e24-2f3e-40f7-b400-ce2ca3a352a6" xlink:to="loc_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms_3932b51a-e9fb-46d3-8161-081f3aebd92d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlanContractTerm_d0c25b5b-76aa-45f4-802c-ed603889891c" xlink:href="moh-20220930.xsd#moh_HealthPlanContractTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2cd31e24-2f3e-40f7-b400-ce2ca3a352a6" xlink:to="loc_moh_HealthPlanContractTerm_d0c25b5b-76aa-45f4-802c-ed603889891c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlanExtensionOptionPeriod_b92f813c-4213-4143-b6d3-69469ab3d61a" xlink:href="moh-20220930.xsd#moh_HealthPlanExtensionOptionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2cd31e24-2f3e-40f7-b400-ce2ca3a352a6" xlink:to="loc_moh_HealthPlanExtensionOptionPeriod_b92f813c-4213-4143-b6d3-69469ab3d61a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlanNumberOfContracts_1a7bd2e8-8732-4e0f-be98-45d26a85c82f" xlink:href="moh-20220930.xsd#moh_HealthPlanNumberOfContracts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2cd31e24-2f3e-40f7-b400-ce2ca3a352a6" xlink:to="loc_moh_HealthPlanNumberOfContracts_1a7bd2e8-8732-4e0f-be98-45d26a85c82f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_e52f976c-66e6-44b2-9f36-4f60ecab4070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2cd31e24-2f3e-40f7-b400-ce2ca3a352a6" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_e52f976c-66e6-44b2-9f36-4f60ecab4070" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a8ced87c-d52c-48c0-9ab7-e84db808bdc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2cd31e24-2f3e-40f7-b400-ce2ca3a352a6" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a8ced87c-d52c-48c0-9ab7-e84db808bdc9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a54cc275-39c7-4a7c-9124-ebf188712730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a8ced87c-d52c-48c0-9ab7-e84db808bdc9" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a54cc275-39c7-4a7c-9124-ebf188712730" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a54cc275-39c7-4a7c-9124-ebf188712730_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a54cc275-39c7-4a7c-9124-ebf188712730" xlink:to="loc_us-gaap_SegmentDomain_a54cc275-39c7-4a7c-9124-ebf188712730_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_dad4ad6c-23e0-4bbe-8e23-d866eb1ddaaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a54cc275-39c7-4a7c-9124-ebf188712730" xlink:to="loc_us-gaap_SegmentDomain_dad4ad6c-23e0-4bbe-8e23-d866eb1ddaaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlansMember_f70953af-7d20-4933-9e1f-c6e158e39319" xlink:href="moh-20220930.xsd#moh_HealthPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_dad4ad6c-23e0-4bbe-8e23-d866eb1ddaaf" xlink:to="loc_moh_HealthPlansMember_f70953af-7d20-4933-9e1f-c6e158e39319" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_016447cc-1e68-4030-b542-04213e75bca6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a8ced87c-d52c-48c0-9ab7-e84db808bdc9" xlink:to="loc_srt_RangeAxis_016447cc-1e68-4030-b542-04213e75bca6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_016447cc-1e68-4030-b542-04213e75bca6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_016447cc-1e68-4030-b542-04213e75bca6" xlink:to="loc_srt_RangeMember_016447cc-1e68-4030-b542-04213e75bca6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_408832ba-473a-4269-a83a-024878112357" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_016447cc-1e68-4030-b542-04213e75bca6" xlink:to="loc_srt_RangeMember_408832ba-473a-4269-a83a-024878112357" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_89b238f3-e463-4eef-a99f-d9803e8aec34" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_408832ba-473a-4269-a83a-024878112357" xlink:to="loc_srt_MinimumMember_89b238f3-e463-4eef-a99f-d9803e8aec34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_adbdadcf-8aa4-4962-bcaa-1471eb10ff4c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_408832ba-473a-4269-a83a-024878112357" xlink:to="loc_srt_MaximumMember_adbdadcf-8aa4-4962-bcaa-1471eb10ff4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_293a3b39-d615-47c0-9210-8d161ea0e206" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a8ced87c-d52c-48c0-9ab7-e84db808bdc9" xlink:to="loc_srt_StatementGeographicalAxis_293a3b39-d615-47c0-9210-8d161ea0e206" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_293a3b39-d615-47c0-9210-8d161ea0e206_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_293a3b39-d615-47c0-9210-8d161ea0e206" xlink:to="loc_srt_SegmentGeographicalDomain_293a3b39-d615-47c0-9210-8d161ea0e206_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e0ee4704-325e-4d09-a482-dde8850689e6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_293a3b39-d615-47c0-9210-8d161ea0e206" xlink:to="loc_srt_SegmentGeographicalDomain_e0ee4704-325e-4d09-a482-dde8850689e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NE_b51b60dd-0dc9-48cb-9c70-14d21500f80e" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e0ee4704-325e-4d09-a482-dde8850689e6" xlink:to="loc_stpr_NE_b51b60dd-0dc9-48cb-9c70-14d21500f80e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IA_c2c589fe-0862-40f5-bfa4-4471f6bec26d" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_IA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e0ee4704-325e-4d09-a482-dde8850689e6" xlink:to="loc_stpr_IA_c2c589fe-0862-40f5-bfa4-4471f6bec26d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_375b5d43-cc7c-4f66-a682-21299248e2c0" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e0ee4704-325e-4d09-a482-dde8850689e6" xlink:to="loc_stpr_CA_375b5d43-cc7c-4f66-a682-21299248e2c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MS_fdd97d47-fbdb-41de-a8af-71fd06a79679" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e0ee4704-325e-4d09-a482-dde8850689e6" xlink:to="loc_stpr_MS_fdd97d47-fbdb-41de-a8af-71fd06a79679" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_dd1455df-44b1-41f2-9c02-1a58ddf0f1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a8ced87c-d52c-48c0-9ab7-e84db808bdc9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_dd1455df-44b1-41f2-9c02-1a58ddf0f1e1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dd1455df-44b1-41f2-9c02-1a58ddf0f1e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dd1455df-44b1-41f2-9c02-1a58ddf0f1e1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dd1455df-44b1-41f2-9c02-1a58ddf0f1e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4c2c410a-5f4c-4141-8d06-c358b286e0d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dd1455df-44b1-41f2-9c02-1a58ddf0f1e1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4c2c410a-5f4c-4141-8d06-c358b286e0d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MyChoiceWisconsinMember_60aa1477-320c-4f65-ac6a-13e38fbe0ad9" xlink:href="moh-20220930.xsd#moh_MyChoiceWisconsinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4c2c410a-5f4c-4141-8d06-c358b286e0d9" xlink:to="loc_moh_MyChoiceWisconsinMember_60aa1477-320c-4f65-ac6a-13e38fbe0ad9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#SignificantAccountingPoliciesReceivablesDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails" xlink:type="extended" id="i1416d81bbd7a43b08c3d71fe66fe588d_SignificantAccountingPoliciesReceivablesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_3503db19-56e8-4c9e-88b0-31864fddcfd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_37d50f5d-3bc5-46b0-ad91-b713eba1227a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_3503db19-56e8-4c9e-88b0-31864fddcfd8" xlink:to="loc_us-gaap_ReceivablesNetCurrent_37d50f5d-3bc5-46b0-ad91-b713eba1227a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_5b3cc6d3-63b5-4b0c-9d45-79ee83804122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_3503db19-56e8-4c9e-88b0-31864fddcfd8" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_5b3cc6d3-63b5-4b0c-9d45-79ee83804122" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_b2101f57-ce66-4a6f-a49f-31e2c569e442" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_5b3cc6d3-63b5-4b0c-9d45-79ee83804122" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_b2101f57-ce66-4a6f-a49f-31e2c569e442" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_b2101f57-ce66-4a6f-a49f-31e2c569e442_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_b2101f57-ce66-4a6f-a49f-31e2c569e442" xlink:to="loc_us-gaap_ReceivableTypeDomain_b2101f57-ce66-4a6f-a49f-31e2c569e442_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_a29feea0-ad8c-4c9b-8d2a-c4cf7ea6ca0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_b2101f57-ce66-4a6f-a49f-31e2c569e442" xlink:to="loc_us-gaap_ReceivableTypeDomain_a29feea0-ad8c-4c9b-8d2a-c4cf7ea6ca0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_GovernmentReceivablesMember_9d089689-9c67-423b-bfdf-52dba7a0dc90" xlink:href="moh-20220930.xsd#moh_GovernmentReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_a29feea0-ad8c-4c9b-8d2a-c4cf7ea6ca0b" xlink:to="loc_moh_GovernmentReceivablesMember_9d089689-9c67-423b-bfdf-52dba7a0dc90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PharmacyRebateReceivablesMember_90a5d368-d1ce-49dc-8edd-d0a26efea121" xlink:href="moh-20220930.xsd#moh_PharmacyRebateReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_a29feea0-ad8c-4c9b-8d2a-c4cf7ea6ca0b" xlink:to="loc_moh_PharmacyRebateReceivablesMember_90a5d368-d1ce-49dc-8edd-d0a26efea121" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherReceivablesMember_4c47bbf4-4aeb-4b14-8a43-bb90a840e669" xlink:href="moh-20220930.xsd#moh_OtherReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_a29feea0-ad8c-4c9b-8d2a-c4cf7ea6ca0b" xlink:to="loc_moh_OtherReceivablesMember_4c47bbf4-4aeb-4b14-8a43-bb90a840e669" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#SignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="idfe2a0f5ea1044c2a73a76d20cb0d505_SignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_f45c8015-bc90-4790-85bf-0489ce72eab3" xlink:href="moh-20220930.xsd#moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPremiumsReceivable_9be99810-5a45-4d0a-a3f4-2240312e79a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPremiumsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_f45c8015-bc90-4790-85bf-0489ce72eab3" xlink:to="loc_us-gaap_IncreaseDecreaseInPremiumsReceivable_9be99810-5a45-4d0a-a3f4-2240312e79a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable_c79104e3-14bc-4d67-b16f-ada6f027cc4f" xlink:href="moh-20220930.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_f45c8015-bc90-4790-85bf-0489ce72eab3" xlink:to="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable_c79104e3-14bc-4d67-b16f-ada6f027cc4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable_b8732573-ccd1-4102-860d-243116e3e9f5" xlink:href="moh-20220930.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_f45c8015-bc90-4790-85bf-0489ce72eab3" xlink:to="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable_b8732573-ccd1-4102-860d-243116e3e9f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable_e7f0b046-3677-4a4e-998f-35878ffb597b" xlink:href="moh-20220930.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_f45c8015-bc90-4790-85bf-0489ce72eab3" xlink:to="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable_e7f0b046-3677-4a4e-998f-35878ffb597b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_InvestmentsMaturityPeriod_cf600b6a-7f46-4b1f-82f5-fb3f52c62be6" xlink:href="moh-20220930.xsd#moh_InvestmentsMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_f45c8015-bc90-4790-85bf-0489ce72eab3" xlink:to="loc_moh_InvestmentsMaturityPeriod_cf600b6a-7f46-4b1f-82f5-fb3f52c62be6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_InvestmentsAverageMaturityPeriod_e5f60b78-4fc3-4130-8eb5-a05907e2886a" xlink:href="moh-20220930.xsd#moh_InvestmentsAverageMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_f45c8015-bc90-4790-85bf-0489ce72eab3" xlink:to="loc_moh_InvestmentsAverageMaturityPeriod_e5f60b78-4fc3-4130-8eb5-a05907e2886a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_9de62926-a9f8-4777-82d6-d7c74f581bbd" xlink:href="moh-20220930.xsd#moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_f45c8015-bc90-4790-85bf-0489ce72eab3" xlink:to="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_9de62926-a9f8-4777-82d6-d7c74f581bbd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis_8056b7e3-0c57-49f8-a929-2e08c62ca30b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_9de62926-a9f8-4777-82d6-d7c74f581bbd" xlink:to="loc_us-gaap_UnusualOrInfrequentItemAxis_8056b7e3-0c57-49f8-a929-2e08c62ca30b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_8056b7e3-0c57-49f8-a929-2e08c62ca30b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_8056b7e3-0c57-49f8-a929-2e08c62ca30b" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_8056b7e3-0c57-49f8-a929-2e08c62ca30b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_fdc93129-a077-498e-b0ad-c8be2245198b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_8056b7e3-0c57-49f8-a929-2e08c62ca30b" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_fdc93129-a077-498e-b0ad-c8be2245198b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_COVID19Member_3a6e6e90-8b58-4385-a9fd-6941ce8da9cf" xlink:href="moh-20220930.xsd#moh_COVID19Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain_fdc93129-a077-498e-b0ad-c8be2245198b" xlink:to="loc_moh_COVID19Member_3a6e6e90-8b58-4385-a9fd-6941ce8da9cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7c27f3b8-d403-46b7-960d-212ddcd191e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_9de62926-a9f8-4777-82d6-d7c74f581bbd" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7c27f3b8-d403-46b7-960d-212ddcd191e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7c27f3b8-d403-46b7-960d-212ddcd191e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7c27f3b8-d403-46b7-960d-212ddcd191e4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7c27f3b8-d403-46b7-960d-212ddcd191e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4212689a-1d0d-46bf-b21e-8268d0b73ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7c27f3b8-d403-46b7-960d-212ddcd191e4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4212689a-1d0d-46bf-b21e-8268d0b73ce8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_StructuredSecuritiesMember_8a779668-1fbf-4da8-974d-7b183c013c71" xlink:href="moh-20220930.xsd#moh_StructuredSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4212689a-1d0d-46bf-b21e-8268d0b73ce8" xlink:to="loc_moh_StructuredSecuritiesMember_8a779668-1fbf-4da8-974d-7b183c013c71" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/BusinessCombinationsDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#BusinessCombinationsDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/BusinessCombinationsDetails" xlink:type="extended" id="i4608ae3d54b54c0a8ab74a675819ca37_BusinessCombinationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_837bf588-5869-4cea-9ef8-1860a1cafea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_af9776bc-adea-480e-8965-ae3b3b950272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_837bf588-5869-4cea-9ef8-1860a1cafea0" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_af9776bc-adea-480e-8965-ae3b3b950272" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_fc0442d0-1c78-485c-800b-e8ae08a11a88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_837bf588-5869-4cea-9ef8-1860a1cafea0" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_fc0442d0-1c78-485c-800b-e8ae08a11a88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_eef0b802-44c6-4442-9e6a-fcdba6d35ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_837bf588-5869-4cea-9ef8-1860a1cafea0" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_eef0b802-44c6-4442-9e6a-fcdba6d35ad1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable_429e5f71-510b-4d3c-864f-a8785ac1739d" xlink:href="moh-20220930.xsd#moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_837bf588-5869-4cea-9ef8-1860a1cafea0" xlink:to="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable_429e5f71-510b-4d3c-864f-a8785ac1739d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables_7ea4c23a-1e73-4a94-b829-9959ad8d59e4" xlink:href="moh-20220930.xsd#moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_837bf588-5869-4cea-9ef8-1860a1cafea0" xlink:to="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables_7ea4c23a-1e73-4a94-b829-9959ad8d59e4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_ce9b9b05-7119-4b89-be4c-b893c27719bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_837bf588-5869-4cea-9ef8-1860a1cafea0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_ce9b9b05-7119-4b89-be4c-b893c27719bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_aeede69c-8657-451e-a1d2-673aaaa0c674" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_ce9b9b05-7119-4b89-be4c-b893c27719bc" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_aeede69c-8657-451e-a1d2-673aaaa0c674" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aeede69c-8657-451e-a1d2-673aaaa0c674_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_aeede69c-8657-451e-a1d2-673aaaa0c674" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aeede69c-8657-451e-a1d2-673aaaa0c674_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5faa97ac-a13d-43a0-af58-d3fb97e42ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_aeede69c-8657-451e-a1d2-673aaaa0c674" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5faa97ac-a13d-43a0-af58-d3fb97e42ab4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AgeWellMember_09d18354-8124-42ad-933c-86cb548c6017" xlink:href="moh-20220930.xsd#moh_AgeWellMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5faa97ac-a13d-43a0-af58-d3fb97e42ab4" xlink:to="loc_moh_AgeWellMember_09d18354-8124-42ad-933c-86cb548c6017" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember_c43cc9de-e035-44a3-9f1c-6774eb1f25e1" xlink:href="moh-20220930.xsd#moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5faa97ac-a13d-43a0-af58-d3fb97e42ab4" xlink:to="loc_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember_c43cc9de-e035-44a3-9f1c-6774eb1f25e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffinityHealthPlanIncMember_8a341408-617d-4580-8c87-421bb392d715" xlink:href="moh-20220930.xsd#moh_AffinityHealthPlanIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5faa97ac-a13d-43a0-af58-d3fb97e42ab4" xlink:to="loc_moh_AffinityHealthPlanIncMember_8a341408-617d-4580-8c87-421bb392d715" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e2f31cd8-878e-4e90-be24-1048ed994541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_ce9b9b05-7119-4b89-be4c-b893c27719bc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e2f31cd8-878e-4e90-be24-1048ed994541" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e2f31cd8-878e-4e90-be24-1048ed994541_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e2f31cd8-878e-4e90-be24-1048ed994541" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e2f31cd8-878e-4e90-be24-1048ed994541_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_69a38255-9f63-4de7-9ced-012461279e72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e2f31cd8-878e-4e90-be24-1048ed994541" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_69a38255-9f63-4de7-9ced-012461279e72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MemberListsMember_21c6dca2-5292-44d7-9cdf-6c4ce46daa4d" xlink:href="moh-20220930.xsd#moh_MemberListsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_69a38255-9f63-4de7-9ced-012461279e72" xlink:to="loc_moh_MemberListsMember_21c6dca2-5292-44d7-9cdf-6c4ce46daa4d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails" xlink:type="extended" id="i60c764a3e5e44078b37c5de181bcd09d_FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42897a98-3274-4048-a521-dd58260ccff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_6ebac758-75aa-4d73-b6c6-50d6ad760147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42897a98-3274-4048-a521-dd58260ccff8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_6ebac758-75aa-4d73-b6c6-50d6ad760147" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_1558e525-47cf-4222-93c1-dedeb4239d31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42897a98-3274-4048-a521-dd58260ccff8" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_1558e525-47cf-4222-93c1-dedeb4239d31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9e8e3fb3-3e87-4cbd-b754-e46207c355d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42897a98-3274-4048-a521-dd58260ccff8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9e8e3fb3-3e87-4cbd-b754-e46207c355d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_f9e074e2-a1c4-4840-9e74-a092f146cfc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42897a98-3274-4048-a521-dd58260ccff8" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_f9e074e2-a1c4-4840-9e74-a092f146cfc8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ef2e6986-e895-4eb2-b90b-01ce404e4295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42897a98-3274-4048-a521-dd58260ccff8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ef2e6986-e895-4eb2-b90b-01ce404e4295" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dbb08f00-cfcc-4fe2-a2dc-615bad3eec29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ef2e6986-e895-4eb2-b90b-01ce404e4295" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dbb08f00-cfcc-4fe2-a2dc-615bad3eec29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dbb08f00-cfcc-4fe2-a2dc-615bad3eec29_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dbb08f00-cfcc-4fe2-a2dc-615bad3eec29" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dbb08f00-cfcc-4fe2-a2dc-615bad3eec29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78668811-6c28-4468-b496-be78dec08611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dbb08f00-cfcc-4fe2-a2dc-615bad3eec29" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78668811-6c28-4468-b496-be78dec08611" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_46bb060c-2047-4659-a7c3-a0ad2bfd3681" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78668811-6c28-4468-b496-be78dec08611" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_46bb060c-2047-4659-a7c3-a0ad2bfd3681" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1bd1b0f7-860e-4a3c-a54c-f931b0ba2a08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78668811-6c28-4468-b496-be78dec08611" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1bd1b0f7-860e-4a3c-a54c-f931b0ba2a08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ff9755de-bf8b-4a68-afc2-fa7854f0ed08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78668811-6c28-4468-b496-be78dec08611" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ff9755de-bf8b-4a68-afc2-fa7854f0ed08" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_60f5ec5b-ec99-43b8-a13b-cd671904b0eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ef2e6986-e895-4eb2-b90b-01ce404e4295" xlink:to="loc_us-gaap_FinancialInstrumentAxis_60f5ec5b-ec99-43b8-a13b-cd671904b0eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_60f5ec5b-ec99-43b8-a13b-cd671904b0eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_60f5ec5b-ec99-43b8-a13b-cd671904b0eb" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_60f5ec5b-ec99-43b8-a13b-cd671904b0eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a75507f1-20a0-4d4c-b2f1-1ad028835f73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_60f5ec5b-ec99-43b8-a13b-cd671904b0eb" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a75507f1-20a0-4d4c-b2f1-1ad028835f73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9884eb38-6c70-4c2d-989a-96c7e833a191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a75507f1-20a0-4d4c-b2f1-1ad028835f73" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9884eb38-6c70-4c2d-989a-96c7e833a191" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_c771bd6e-7d6b-47e4-b0c0-2b4f0811dc93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a75507f1-20a0-4d4c-b2f1-1ad028835f73" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_c771bd6e-7d6b-47e4-b0c0-2b4f0811dc93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_4a72fb13-f33b-462d-aafa-4adc6d581279" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a75507f1-20a0-4d4c-b2f1-1ad028835f73" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_4a72fb13-f33b-462d-aafa-4adc6d581279" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MunicipalSecuritiesMember_a4e870f6-3665-4385-9b69-da748c5f127c" xlink:href="moh-20220930.xsd#moh_MunicipalSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a75507f1-20a0-4d4c-b2f1-1ad028835f73" xlink:to="loc_moh_MunicipalSecuritiesMember_a4e870f6-3665-4385-9b69-da748c5f127c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_ec1edae8-06df-4afd-9357-4dfb212f9bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a75507f1-20a0-4d4c-b2f1-1ad028835f73" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_ec1edae8-06df-4afd-9357-4dfb212f9bb8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherSecuritiesMember_fa02f0c8-1232-49d0-9103-d2d44cf1df70" xlink:href="moh-20220930.xsd#moh_OtherSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a75507f1-20a0-4d4c-b2f1-1ad028835f73" xlink:to="loc_moh_OtherSecuritiesMember_fa02f0c8-1232-49d0-9103-d2d44cf1df70" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="i0d73686878014c74923e98cc5a830f20_FairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b2240dd9-4e6e-4b7a-8f3f-5d23d9394471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_9170ac6a-d575-4208-b43a-a3df96d6df0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b2240dd9-4e6e-4b7a-8f3f-5d23d9394471" xlink:to="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_9170ac6a-d575-4208-b43a-a3df96d6df0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6ffa84a1-3c8a-4e0f-9126-727d6e397796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b2240dd9-4e6e-4b7a-8f3f-5d23d9394471" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6ffa84a1-3c8a-4e0f-9126-727d6e397796" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities_9a289766-0c8c-4c2b-a8e9-b742bc048860" xlink:href="moh-20220930.xsd#moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b2240dd9-4e6e-4b7a-8f3f-5d23d9394471" xlink:to="loc_moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities_9a289766-0c8c-4c2b-a8e9-b742bc048860" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_6d4076bc-699d-4e49-84d5-25067721f1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b2240dd9-4e6e-4b7a-8f3f-5d23d9394471" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_6d4076bc-699d-4e49-84d5-25067721f1b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_5f632fdc-4432-47d8-b195-d924402cc9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b2240dd9-4e6e-4b7a-8f3f-5d23d9394471" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_5f632fdc-4432-47d8-b195-d924402cc9f3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a57805c7-ed23-45f8-9695-a50a3c46d9b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b2240dd9-4e6e-4b7a-8f3f-5d23d9394471" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a57805c7-ed23-45f8-9695-a50a3c46d9b5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_eef31dc5-c5db-4dbd-abcb-b5b82c6470ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a57805c7-ed23-45f8-9695-a50a3c46d9b5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_eef31dc5-c5db-4dbd-abcb-b5b82c6470ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eef31dc5-c5db-4dbd-abcb-b5b82c6470ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_eef31dc5-c5db-4dbd-abcb-b5b82c6470ed" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eef31dc5-c5db-4dbd-abcb-b5b82c6470ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4eee63d7-966d-42ab-b0a9-14caa9c62681" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_eef31dc5-c5db-4dbd-abcb-b5b82c6470ed" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4eee63d7-966d-42ab-b0a9-14caa9c62681" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PassportHealthPlanIncMember_4ed2a67f-ca23-471c-8223-adee953c2c6b" xlink:href="moh-20220930.xsd#moh_PassportHealthPlanIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4eee63d7-966d-42ab-b0a9-14caa9c62681" xlink:to="loc_moh_PassportHealthPlanIncMember_4ed2a67f-ca23-471c-8223-adee953c2c6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1b660b5f-b648-42fb-ad86-cd89ce31c488" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a57805c7-ed23-45f8-9695-a50a3c46d9b5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1b660b5f-b648-42fb-ad86-cd89ce31c488" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1b660b5f-b648-42fb-ad86-cd89ce31c488_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1b660b5f-b648-42fb-ad86-cd89ce31c488" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1b660b5f-b648-42fb-ad86-cd89ce31c488_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_25de6241-62dd-4721-9d5e-53d670377cde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1b660b5f-b648-42fb-ad86-cd89ce31c488" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_25de6241-62dd-4721-9d5e-53d670377cde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ea1d999f-dbe9-4a3b-93f1-9b0ce9b6b0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_25de6241-62dd-4721-9d5e-53d670377cde" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ea1d999f-dbe9-4a3b-93f1-9b0ce9b6b0e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_3318e2a1-fc39-45b8-a38c-bbd22942704f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a57805c7-ed23-45f8-9695-a50a3c46d9b5" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_3318e2a1-fc39-45b8-a38c-bbd22942704f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_3318e2a1-fc39-45b8-a38c-bbd22942704f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_3318e2a1-fc39-45b8-a38c-bbd22942704f" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_3318e2a1-fc39-45b8-a38c-bbd22942704f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_26272709-75e7-4ff5-9817-cc20e01760de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_3318e2a1-fc39-45b8-a38c-bbd22942704f" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_26272709-75e7-4ff5-9817-cc20e01760de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MinimumMemberEnrollmentTargetsMember_dd542508-a3ba-4c07-a1b9-e9a2e9a48db6" xlink:href="moh-20220930.xsd#moh_MinimumMemberEnrollmentTargetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_26272709-75e7-4ff5-9817-cc20e01760de" xlink:to="loc_moh_MinimumMemberEnrollmentTargetsMember_dd542508-a3ba-4c07-a1b9-e9a2e9a48db6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OperatingIncomeGuaranteeMember_d7e0209d-0624-4f40-93bb-ec547ed6aa5d" xlink:href="moh-20220930.xsd#moh_OperatingIncomeGuaranteeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_26272709-75e7-4ff5-9817-cc20e01760de" xlink:to="loc_moh_OperatingIncomeGuaranteeMember_d7e0209d-0624-4f40-93bb-ec547ed6aa5d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#FairValueMeasurementsLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" xlink:type="extended" id="ifcfba7d1c4994782b286570c15ab3936_FairValueMeasurementsLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5db5e3fc-edfa-4dc1-ab4b-d41bb29300f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b454598a-c314-4b57-a530-d7afd424b3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5db5e3fc-edfa-4dc1-ab4b-d41bb29300f3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b454598a-c314-4b57-a530-d7afd424b3d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_42723e84-7948-4d86-81fe-9b35502d19fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5db5e3fc-edfa-4dc1-ab4b-d41bb29300f3" xlink:to="loc_us-gaap_DebtInstrumentFairValue_42723e84-7948-4d86-81fe-9b35502d19fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_906dd3cf-44ae-4e55-afbe-daade1902679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5db5e3fc-edfa-4dc1-ab4b-d41bb29300f3" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_906dd3cf-44ae-4e55-afbe-daade1902679" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_eb176fd5-b332-4778-8bfe-e4d2d2a33f11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_906dd3cf-44ae-4e55-afbe-daade1902679" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_eb176fd5-b332-4778-8bfe-e4d2d2a33f11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_eb176fd5-b332-4778-8bfe-e4d2d2a33f11_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_eb176fd5-b332-4778-8bfe-e4d2d2a33f11" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_eb176fd5-b332-4778-8bfe-e4d2d2a33f11_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9dcc3aa5-41bc-43d0-a892-35c568a10c63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_eb176fd5-b332-4778-8bfe-e4d2d2a33f11" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9dcc3aa5-41bc-43d0-a892-35c568a10c63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_475ff62d-b7b5-44cf-8892-d36bc7d0756f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9dcc3aa5-41bc-43d0-a892-35c568a10c63" xlink:to="loc_us-gaap_SeniorNotesMember_475ff62d-b7b5-44cf-8892-d36bc7d0756f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3f1cbe91-501e-4ad5-9432-2fd78fcb7ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_906dd3cf-44ae-4e55-afbe-daade1902679" xlink:to="loc_us-gaap_DebtInstrumentAxis_3f1cbe91-501e-4ad5-9432-2fd78fcb7ba6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3f1cbe91-501e-4ad5-9432-2fd78fcb7ba6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_3f1cbe91-501e-4ad5-9432-2fd78fcb7ba6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3f1cbe91-501e-4ad5-9432-2fd78fcb7ba6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9343f87b-d7a7-4425-8190-254c5a433ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_3f1cbe91-501e-4ad5-9432-2fd78fcb7ba6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9343f87b-d7a7-4425-8190-254c5a433ef7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4375SeniorNotesMember_ea21fe32-9510-408d-8047-447c318f560f" xlink:href="moh-20220930.xsd#moh_A4375SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9343f87b-d7a7-4425-8190-254c5a433ef7" xlink:to="loc_moh_A4375SeniorNotesMember_ea21fe32-9510-408d-8047-447c318f560f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_f416ff39-221f-49fe-833e-c77bbbbf4b2f" xlink:href="moh-20220930.xsd#moh_ThreePointEightSevenFivePercentSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9343f87b-d7a7-4425-8190-254c5a433ef7" xlink:to="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_f416ff39-221f-49fe-833e-c77bbbbf4b2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A3875SeniorNotesMember_71f83635-93ca-4cbc-824f-d5cceb178d86" xlink:href="moh-20220930.xsd#moh_A3875SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9343f87b-d7a7-4425-8190-254c5a433ef7" xlink:to="loc_moh_A3875SeniorNotesMember_71f83635-93ca-4cbc-824f-d5cceb178d86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_67f88632-719c-48d1-84d4-bb26d5486170" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_906dd3cf-44ae-4e55-afbe-daade1902679" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_67f88632-719c-48d1-84d4-bb26d5486170" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_67f88632-719c-48d1-84d4-bb26d5486170_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_67f88632-719c-48d1-84d4-bb26d5486170" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_67f88632-719c-48d1-84d4-bb26d5486170_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1bc55c6d-b095-4883-9c8a-f520ed2d6e64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_67f88632-719c-48d1-84d4-bb26d5486170" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1bc55c6d-b095-4883-9c8a-f520ed2d6e64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_739e4c63-1366-4db9-b4f7-de2f29c02e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1bc55c6d-b095-4883-9c8a-f520ed2d6e64" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_739e4c63-1366-4db9-b4f7-de2f29c02e1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_e22a7ab2-9552-4371-8e6c-88589e029f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1bc55c6d-b095-4883-9c8a-f520ed2d6e64" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_e22a7ab2-9552-4371-8e6c-88589e029f5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_ac7a3dd3-3a5b-45ac-9052-3aa50a3c65fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1bc55c6d-b095-4883-9c8a-f520ed2d6e64" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_ac7a3dd3-3a5b-45ac-9052-3aa50a3c65fa" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#InvestmentsSummaryofInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails" xlink:type="extended" id="i001c97d70dae44878a5f92f631eeea7d_InvestmentsSummaryofInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7dca7ab0-5718-43f1-b559-8d9c26012205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_73784cef-db27-426d-a6e1-d5203b8d61dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7dca7ab0-5718-43f1-b559-8d9c26012205" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_73784cef-db27-426d-a6e1-d5203b8d61dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4cc89dd0-c1f2-4259-943c-a0277e8c0aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7dca7ab0-5718-43f1-b559-8d9c26012205" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4cc89dd0-c1f2-4259-943c-a0277e8c0aaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_50a366a0-5b66-4027-b9bb-110b71436f23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7dca7ab0-5718-43f1-b559-8d9c26012205" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_50a366a0-5b66-4027-b9bb-110b71436f23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_e6e5b256-3442-4909-9e50-fa7e2bb8bb23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7dca7ab0-5718-43f1-b559-8d9c26012205" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_e6e5b256-3442-4909-9e50-fa7e2bb8bb23" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5de4e187-5587-4769-bb99-500440e6f3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7dca7ab0-5718-43f1-b559-8d9c26012205" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5de4e187-5587-4769-bb99-500440e6f3a7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_195e71a7-ef28-4e40-a26f-e6cda865d216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5de4e187-5587-4769-bb99-500440e6f3a7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_195e71a7-ef28-4e40-a26f-e6cda865d216" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_195e71a7-ef28-4e40-a26f-e6cda865d216_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_195e71a7-ef28-4e40-a26f-e6cda865d216" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_195e71a7-ef28-4e40-a26f-e6cda865d216_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8b1b1b50-d362-4959-9c2d-b864f0e19fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_195e71a7-ef28-4e40-a26f-e6cda865d216" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8b1b1b50-d362-4959-9c2d-b864f0e19fdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_7c3fbb69-e30d-442b-ad3f-18918eb27ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8b1b1b50-d362-4959-9c2d-b864f0e19fdf" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_7c3fbb69-e30d-442b-ad3f-18918eb27ccb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember_2a7c5717-4303-47de-804b-3790ccadd367" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8b1b1b50-d362-4959-9c2d-b864f0e19fdf" xlink:to="loc_us-gaap_MortgageBackedSecuritiesMember_2a7c5717-4303-47de-804b-3790ccadd367" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_a41ad8af-2dbe-4e7b-8996-dac9b2e40c85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8b1b1b50-d362-4959-9c2d-b864f0e19fdf" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_a41ad8af-2dbe-4e7b-8996-dac9b2e40c85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MunicipalSecuritiesMember_2cf40214-e7c0-4460-bb92-5db9b8c4faad" xlink:href="moh-20220930.xsd#moh_MunicipalSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8b1b1b50-d362-4959-9c2d-b864f0e19fdf" xlink:to="loc_moh_MunicipalSecuritiesMember_2cf40214-e7c0-4460-bb92-5db9b8c4faad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_d93e5c3a-20c2-4444-a7ac-c6cb5e9ec377" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8b1b1b50-d362-4959-9c2d-b864f0e19fdf" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_d93e5c3a-20c2-4444-a7ac-c6cb5e9ec377" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherSecuritiesMember_3f210c76-5bc1-4aa3-a83a-27f60d8a05ed" xlink:href="moh-20220930.xsd#moh_OtherSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8b1b1b50-d362-4959-9c2d-b864f0e19fdf" xlink:to="loc_moh_OtherSecuritiesMember_3f210c76-5bc1-4aa3-a83a-27f60d8a05ed" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#InvestmentsAvailableforSaleInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails" xlink:type="extended" id="ib3a7b27c7e7a438a85ce12d787bec515_InvestmentsAvailableforSaleInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_61a1b19e-8b97-4bb0-8ffa-f1480b1330ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_e1385939-7a87-4dc8-90ab-c1e18bddb7de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_61a1b19e-8b97-4bb0-8ffa-f1480b1330ba" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_e1385939-7a87-4dc8-90ab-c1e18bddb7de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_cebe42b7-161b-4a67-a5dc-109c72574517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_61a1b19e-8b97-4bb0-8ffa-f1480b1330ba" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_cebe42b7-161b-4a67-a5dc-109c72574517" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_2a84c9cc-cffa-4423-be3b-588c474380e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_61a1b19e-8b97-4bb0-8ffa-f1480b1330ba" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_2a84c9cc-cffa-4423-be3b-588c474380e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_f7634d85-25b7-4df2-a579-1ac28815fdd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_61a1b19e-8b97-4bb0-8ffa-f1480b1330ba" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_f7634d85-25b7-4df2-a579-1ac28815fdd8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_7181147e-a99e-4e65-9f4a-439c71cbe5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_61a1b19e-8b97-4bb0-8ffa-f1480b1330ba" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_7181147e-a99e-4e65-9f4a-439c71cbe5d6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_9bf2fbce-e0fc-4ccf-b463-647383d25885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_61a1b19e-8b97-4bb0-8ffa-f1480b1330ba" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_9bf2fbce-e0fc-4ccf-b463-647383d25885" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_75b74c17-189c-49db-ac6c-13d9a5154fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_61a1b19e-8b97-4bb0-8ffa-f1480b1330ba" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_75b74c17-189c-49db-ac6c-13d9a5154fd1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0cce8d3f-f718-4998-ba06-ee98e601ab73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_75b74c17-189c-49db-ac6c-13d9a5154fd1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0cce8d3f-f718-4998-ba06-ee98e601ab73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0cce8d3f-f718-4998-ba06-ee98e601ab73_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0cce8d3f-f718-4998-ba06-ee98e601ab73" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0cce8d3f-f718-4998-ba06-ee98e601ab73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a50ffe9f-3045-4bde-9bce-5a502cbbc149" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0cce8d3f-f718-4998-ba06-ee98e601ab73" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a50ffe9f-3045-4bde-9bce-5a502cbbc149" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_3bb7d1b6-d031-400b-b278-090ca74f0667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a50ffe9f-3045-4bde-9bce-5a502cbbc149" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_3bb7d1b6-d031-400b-b278-090ca74f0667" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember_fc84c6b7-a366-48e2-8a96-bd2c9e022afa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a50ffe9f-3045-4bde-9bce-5a502cbbc149" xlink:to="loc_us-gaap_MortgageBackedSecuritiesMember_fc84c6b7-a366-48e2-8a96-bd2c9e022afa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_271ac39e-447c-4cdf-a3f1-5990cc63722b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a50ffe9f-3045-4bde-9bce-5a502cbbc149" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_271ac39e-447c-4cdf-a3f1-5990cc63722b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MunicipalSecuritiesMember_ca8d95c3-f9a1-4087-92a2-6842c233e431" xlink:href="moh-20220930.xsd#moh_MunicipalSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a50ffe9f-3045-4bde-9bce-5a502cbbc149" xlink:to="loc_moh_MunicipalSecuritiesMember_ca8d95c3-f9a1-4087-92a2-6842c233e431" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_5ab55505-9112-4247-b42b-4a1ca5b6cb61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a50ffe9f-3045-4bde-9bce-5a502cbbc149" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_5ab55505-9112-4247-b42b-4a1ca5b6cb61" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherSecuritiesMember_7c0472fa-5c20-47fe-a7fd-cbdf8e9237ed" xlink:href="moh-20220930.xsd#moh_OtherSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a50ffe9f-3045-4bde-9bce-5a502cbbc149" xlink:to="loc_moh_OtherSecuritiesMember_7c0472fa-5c20-47fe-a7fd-cbdf8e9237ed" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails" xlink:type="extended" id="ie461448996ed4f79ac49d2190ad6077c_MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_d4549ddf-cd5e-4a20-a893-8011f46e0f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ee8b4a3f-a08b-4fec-9408-f259be457500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_d4549ddf-cd5e-4a20-a893-8011f46e0f9b" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ee8b4a3f-a08b-4fec-9408-f259be457500" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_eac4e058-8f4d-44ab-93a9-1db612ef1f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ee8b4a3f-a08b-4fec-9408-f259be457500" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_eac4e058-8f4d-44ab-93a9-1db612ef1f8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ComponentsOfMedicalCareCostsAbstract_4b3418af-7c95-4c06-b4cf-1f3060fb71cf" xlink:href="moh-20220930.xsd#moh_ComponentsOfMedicalCareCostsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ee8b4a3f-a08b-4fec-9408-f259be457500" xlink:to="loc_moh_ComponentsOfMedicalCareCostsAbstract_4b3418af-7c95-4c06-b4cf-1f3060fb71cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_8fbeeda8-2b73-4494-bcc0-499322cd8465" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ComponentsOfMedicalCareCostsAbstract_4b3418af-7c95-4c06-b4cf-1f3060fb71cf" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_8fbeeda8-2b73-4494-bcc0-499322cd8465" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_ec5cac32-4823-4b94-8bf0-9b0e1b7ec05e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ComponentsOfMedicalCareCostsAbstract_4b3418af-7c95-4c06-b4cf-1f3060fb71cf" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_ec5cac32-4823-4b94-8bf0-9b0e1b7ec05e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_58893ba3-a530-4328-aeef-6df45b80e4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ComponentsOfMedicalCareCostsAbstract_4b3418af-7c95-4c06-b4cf-1f3060fb71cf" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_58893ba3-a530-4328-aeef-6df45b80e4e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PaymentsForMedicalCareCostsAbstract_42d0bae6-c094-4f48-8007-fe14c7ffe93d" xlink:href="moh-20220930.xsd#moh_PaymentsForMedicalCareCostsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ee8b4a3f-a08b-4fec-9408-f259be457500" xlink:to="loc_moh_PaymentsForMedicalCareCostsAbstract_42d0bae6-c094-4f48-8007-fe14c7ffe93d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_4b367e0a-635e-4e7f-8847-669c2f8af742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_PaymentsForMedicalCareCostsAbstract_42d0bae6-c094-4f48-8007-fe14c7ffe93d" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_4b367e0a-635e-4e7f-8847-669c2f8af742" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_0513ae87-7e75-45b4-802a-fc5e2219c6d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_PaymentsForMedicalCareCostsAbstract_42d0bae6-c094-4f48-8007-fe14c7ffe93d" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_0513ae87-7e75-45b4-802a-fc5e2219c6d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_2dfe3a1e-34ba-4fa5-afe0-21a24a66368f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_PaymentsForMedicalCareCostsAbstract_42d0bae6-c094-4f48-8007-fe14c7ffe93d" xlink:to="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_2dfe3a1e-34ba-4fa5-afe0-21a24a66368f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments_3e96fcef-d084-4247-a45d-dc5b88490344" xlink:href="moh-20220930.xsd#moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ee8b4a3f-a08b-4fec-9408-f259be457500" xlink:to="loc_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments_3e96fcef-d084-4247-a45d-dc5b88490344" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider_dc28ef38-260c-4192-8fbe-20b2111e9034" xlink:href="moh-20220930.xsd#moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ee8b4a3f-a08b-4fec-9408-f259be457500" xlink:to="loc_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider_dc28ef38-260c-4192-8fbe-20b2111e9034" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_80d269e1-70f7-4542-a488-c10eb909aae8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_deff403c-9677-41f9-9f30-ff2316587350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_d4549ddf-cd5e-4a20-a893-8011f46e0f9b" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_deff403c-9677-41f9-9f30-ff2316587350" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_badff41d-2605-46fd-a55c-1e83d8969dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_deff403c-9677-41f9-9f30-ff2316587350" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_badff41d-2605-46fd-a55c-1e83d8969dc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_badff41d-2605-46fd-a55c-1e83d8969dc0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_badff41d-2605-46fd-a55c-1e83d8969dc0" xlink:to="loc_us-gaap_SegmentDomain_badff41d-2605-46fd-a55c-1e83d8969dc0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8c421fb6-62e9-4070-8406-7a9e9c4e9996" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_badff41d-2605-46fd-a55c-1e83d8969dc0" xlink:to="loc_us-gaap_SegmentDomain_8c421fb6-62e9-4070-8406-7a9e9c4e9996" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicaidMember_8ac03e7b-babe-48c5-97d9-77ce9d62417a" xlink:href="moh-20220930.xsd#moh_MedicaidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8c421fb6-62e9-4070-8406-7a9e9c4e9996" xlink:to="loc_moh_MedicaidMember_8ac03e7b-babe-48c5-97d9-77ce9d62417a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicareMember_7121eee6-479d-4707-a865-5d243ce8fd17" xlink:href="moh-20220930.xsd#moh_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8c421fb6-62e9-4070-8406-7a9e9c4e9996" xlink:to="loc_moh_MedicareMember_7121eee6-479d-4707-a865-5d243ce8fd17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MarketplaceMember_b6146dcf-2ee0-4fd4-ba3b-5a295fa3bdb0" xlink:href="moh-20220930.xsd#moh_MarketplaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8c421fb6-62e9-4070-8406-7a9e9c4e9996" xlink:to="loc_moh_MarketplaceMember_b6146dcf-2ee0-4fd4-ba3b-5a295fa3bdb0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#DebtScheduleofLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails" xlink:type="extended" id="ib0f713810ba94971983b0cd5d2c6f791_DebtScheduleofLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e4017093-cc35-4767-a9e0-f81801e6ba1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3aebac39-d0c6-409e-b10b-85c1dbea317c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e4017093-cc35-4767-a9e0-f81801e6ba1a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3aebac39-d0c6-409e-b10b-85c1dbea317c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_274a9a20-bbe2-4317-8da1-86cf8bdc0588" xlink:href="moh-20220930.xsd#moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e4017093-cc35-4767-a9e0-f81801e6ba1a" xlink:to="loc_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_274a9a20-bbe2-4317-8da1-86cf8bdc0588" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_9247c742-d47d-4c95-88c1-99a6215e931a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e4017093-cc35-4767-a9e0-f81801e6ba1a" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_9247c742-d47d-4c95-88c1-99a6215e931a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_57feaa79-0066-4d5b-ae36-0506b663f152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e4017093-cc35-4767-a9e0-f81801e6ba1a" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_57feaa79-0066-4d5b-ae36-0506b663f152" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c3b1f978-1718-4cd5-941e-72d5cc07efc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e4017093-cc35-4767-a9e0-f81801e6ba1a" xlink:to="loc_us-gaap_DebtInstrumentTable_c3b1f978-1718-4cd5-941e-72d5cc07efc9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a1413a45-a173-4ba4-b27a-fe76fe5c68f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c3b1f978-1718-4cd5-941e-72d5cc07efc9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a1413a45-a173-4ba4-b27a-fe76fe5c68f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a1413a45-a173-4ba4-b27a-fe76fe5c68f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a1413a45-a173-4ba4-b27a-fe76fe5c68f1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a1413a45-a173-4ba4-b27a-fe76fe5c68f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_27137f4c-9b4f-45ec-b135-835b5824cede" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a1413a45-a173-4ba4-b27a-fe76fe5c68f1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_27137f4c-9b4f-45ec-b135-835b5824cede" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_084bd4c2-4bda-42a6-b24c-15546d1397bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_27137f4c-9b4f-45ec-b135-835b5824cede" xlink:to="loc_us-gaap_SeniorNotesMember_084bd4c2-4bda-42a6-b24c-15546d1397bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3ad27dee-55f5-4e84-b574-989c2a253ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c3b1f978-1718-4cd5-941e-72d5cc07efc9" xlink:to="loc_us-gaap_DebtInstrumentAxis_3ad27dee-55f5-4e84-b574-989c2a253ec6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3ad27dee-55f5-4e84-b574-989c2a253ec6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_3ad27dee-55f5-4e84-b574-989c2a253ec6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3ad27dee-55f5-4e84-b574-989c2a253ec6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_cb32bb31-ba5c-4f7a-b37c-c9919d470ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_3ad27dee-55f5-4e84-b574-989c2a253ec6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_cb32bb31-ba5c-4f7a-b37c-c9919d470ee1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4375SeniorNotesMember_0d086cc2-fb10-4dab-a366-df45444ac82c" xlink:href="moh-20220930.xsd#moh_A4375SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cb32bb31-ba5c-4f7a-b37c-c9919d470ee1" xlink:to="loc_moh_A4375SeniorNotesMember_0d086cc2-fb10-4dab-a366-df45444ac82c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_b1ba39fc-fc50-4746-9c60-dc4a5b139372" xlink:href="moh-20220930.xsd#moh_ThreePointEightSevenFivePercentSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cb32bb31-ba5c-4f7a-b37c-c9919d470ee1" xlink:to="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_b1ba39fc-fc50-4746-9c60-dc4a5b139372" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A3875SeniorNotesMember_e0d69df7-f865-4157-8a04-b9c555cccfce" xlink:href="moh-20220930.xsd#moh_A3875SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cb32bb31-ba5c-4f7a-b37c-c9919d470ee1" xlink:to="loc_moh_A3875SeniorNotesMember_e0d69df7-f865-4157-8a04-b9c555cccfce" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/DebtNarrativeDetails" xlink:type="extended" id="i3bde736be1894c0cbfbf8fceef22dc31_DebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7f4d3bef-db79-4d60-a9fd-29da4c62ef6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d1272bce-d8c5-4fbb-a28b-9ba3e295ea21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7f4d3bef-db79-4d60-a9fd-29da4c62ef6f" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d1272bce-d8c5-4fbb-a28b-9ba3e295ea21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_009ce139-9aa9-47e7-989f-12605ca976ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7f4d3bef-db79-4d60-a9fd-29da4c62ef6f" xlink:to="loc_us-gaap_DebtInstrumentTerm_009ce139-9aa9-47e7-989f-12605ca976ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_1e246951-d7ef-4e12-b61d-863585f25dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7f4d3bef-db79-4d60-a9fd-29da4c62ef6f" xlink:to="loc_us-gaap_LineOfCredit_1e246951-d7ef-4e12-b61d-863585f25dfb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f1f3fa32-da0e-4b4d-b492-bdebf7498ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7f4d3bef-db79-4d60-a9fd-29da4c62ef6f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f1f3fa32-da0e-4b4d-b492-bdebf7498ec2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_560127ab-3237-4b8d-a043-6eab93f0ff56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7f4d3bef-db79-4d60-a9fd-29da4c62ef6f" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_560127ab-3237-4b8d-a043-6eab93f0ff56" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b4f57bc5-ccad-48e5-b833-0e4c41ca31af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7f4d3bef-db79-4d60-a9fd-29da4c62ef6f" xlink:to="loc_us-gaap_DebtInstrumentTable_b4f57bc5-ccad-48e5-b833-0e4c41ca31af" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_10a38b2c-ced6-4737-b2f7-7cd404901c30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b4f57bc5-ccad-48e5-b833-0e4c41ca31af" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_10a38b2c-ced6-4737-b2f7-7cd404901c30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_10a38b2c-ced6-4737-b2f7-7cd404901c30_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_10a38b2c-ced6-4737-b2f7-7cd404901c30" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_10a38b2c-ced6-4737-b2f7-7cd404901c30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8b19e371-71ae-4773-a246-e57aa3c11c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_10a38b2c-ced6-4737-b2f7-7cd404901c30" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8b19e371-71ae-4773-a246-e57aa3c11c8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_35763898-3552-4ce8-8a9a-f91fa69512b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8b19e371-71ae-4773-a246-e57aa3c11c8d" xlink:to="loc_us-gaap_LineOfCreditMember_35763898-3552-4ce8-8a9a-f91fa69512b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_2db4d320-b558-4c69-9405-dd4099ec4d18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8b19e371-71ae-4773-a246-e57aa3c11c8d" xlink:to="loc_us-gaap_SeniorNotesMember_2db4d320-b558-4c69-9405-dd4099ec4d18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_51c5c2ea-7baf-488f-a861-403ba9bb68b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b4f57bc5-ccad-48e5-b833-0e4c41ca31af" xlink:to="loc_us-gaap_CreditFacilityAxis_51c5c2ea-7baf-488f-a861-403ba9bb68b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_51c5c2ea-7baf-488f-a861-403ba9bb68b0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_51c5c2ea-7baf-488f-a861-403ba9bb68b0" xlink:to="loc_us-gaap_CreditFacilityDomain_51c5c2ea-7baf-488f-a861-403ba9bb68b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_91220e66-4d18-43a0-9917-109ee2baa5b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_51c5c2ea-7baf-488f-a861-403ba9bb68b0" xlink:to="loc_us-gaap_CreditFacilityDomain_91220e66-4d18-43a0-9917-109ee2baa5b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_5d56cd01-fc61-4842-8c9f-a1abad9c6fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_91220e66-4d18-43a0-9917-109ee2baa5b3" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_5d56cd01-fc61-4842-8c9f-a1abad9c6fe8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3a550b21-2b86-487f-9ac0-5782df5d9c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b4f57bc5-ccad-48e5-b833-0e4c41ca31af" xlink:to="loc_us-gaap_DebtInstrumentAxis_3a550b21-2b86-487f-9ac0-5782df5d9c9b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3a550b21-2b86-487f-9ac0-5782df5d9c9b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_3a550b21-2b86-487f-9ac0-5782df5d9c9b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3a550b21-2b86-487f-9ac0-5782df5d9c9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9ab54b49-2bbf-411d-9fb5-c93cffdd58fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_3a550b21-2b86-487f-9ac0-5782df5d9c9b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9ab54b49-2bbf-411d-9fb5-c93cffdd58fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4375SeniorNotesMember_99bf2fb4-9bb2-4178-89a3-25209c9b091e" xlink:href="moh-20220930.xsd#moh_A4375SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9ab54b49-2bbf-411d-9fb5-c93cffdd58fa" xlink:to="loc_moh_A4375SeniorNotesMember_99bf2fb4-9bb2-4178-89a3-25209c9b091e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_b092dd57-f78e-4a3f-a754-4ae059e92718" xlink:href="moh-20220930.xsd#moh_ThreePointEightSevenFivePercentSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9ab54b49-2bbf-411d-9fb5-c93cffdd58fa" xlink:to="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_b092dd57-f78e-4a3f-a754-4ae059e92718" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A3875SeniorNotesMember_b77f080f-42ab-457b-9079-64d98ba1d0b7" xlink:href="moh-20220930.xsd#moh_A3875SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9ab54b49-2bbf-411d-9fb5-c93cffdd58fa" xlink:to="loc_moh_A3875SeniorNotesMember_b77f080f-42ab-457b-9079-64d98ba1d0b7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/StockholdersEquityDetails" xlink:type="extended" id="icc53a77229884880a7b1a9bdd28ffadf_StockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_37ccf195-4c3c-41c4-b4b6-bee31341dbec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_2bf96eed-4e10-4ee9-a75e-3396cbf143fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_37ccf195-4c3c-41c4-b4b6-bee31341dbec" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_2bf96eed-4e10-4ee9-a75e-3396cbf143fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_2e9bc036-a635-4190-8cc1-f79da2b005a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_37ccf195-4c3c-41c4-b4b6-bee31341dbec" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_2e9bc036-a635-4190-8cc1-f79da2b005a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_444de233-8ae2-4271-9b4b-c9149db2702c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_37ccf195-4c3c-41c4-b4b6-bee31341dbec" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_444de233-8ae2-4271-9b4b-c9149db2702c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_8971845b-e4f6-4c74-8a40-db03672d6908" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_37ccf195-4c3c-41c4-b4b6-bee31341dbec" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_8971845b-e4f6-4c74-8a40-db03672d6908" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_7f227ecd-86af-4a5e-ad39-8b6a628d15cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_37ccf195-4c3c-41c4-b4b6-bee31341dbec" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_7f227ecd-86af-4a5e-ad39-8b6a628d15cf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f255974f-603c-4774-ad26-ea074b931ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7f227ecd-86af-4a5e-ad39-8b6a628d15cf" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f255974f-603c-4774-ad26-ea074b931ebb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f255974f-603c-4774-ad26-ea074b931ebb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f255974f-603c-4774-ad26-ea074b931ebb" xlink:to="loc_us-gaap_EquityComponentDomain_f255974f-603c-4774-ad26-ea074b931ebb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_76c537cb-3a8b-4d5f-96e9-724fec970bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f255974f-603c-4774-ad26-ea074b931ebb" xlink:to="loc_us-gaap_EquityComponentDomain_76c537cb-3a8b-4d5f-96e9-724fec970bd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5a020975-e8df-4bab-8aeb-413ddb3e327e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_76c537cb-3a8b-4d5f-96e9-724fec970bd1" xlink:to="loc_us-gaap_CommonStockMember_5a020975-e8df-4bab-8aeb-413ddb3e327e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#SegmentsScheduleofOperatingSegmentInformationDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails" xlink:type="extended" id="ieba47b6f91574ce8a61f6509a80edfdf_SegmentsScheduleofOperatingSegmentInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_96cb06a3-7acb-48ae-8319-875e5845c634" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_7a01813d-f733-4f50-8017-664ca1077509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_96cb06a3-7acb-48ae-8319-875e5845c634" xlink:to="loc_us-gaap_Revenues_7a01813d-f733-4f50-8017-664ca1077509" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e9685202-0890-425b-94fe-9d30ae1a0fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_96cb06a3-7acb-48ae-8319-875e5845c634" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e9685202-0890-425b-94fe-9d30ae1a0fa5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c7952726-87e3-4e84-9b1f-c59cf91bd016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e9685202-0890-425b-94fe-9d30ae1a0fa5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c7952726-87e3-4e84-9b1f-c59cf91bd016" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c7952726-87e3-4e84-9b1f-c59cf91bd016_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c7952726-87e3-4e84-9b1f-c59cf91bd016" xlink:to="loc_us-gaap_SegmentDomain_c7952726-87e3-4e84-9b1f-c59cf91bd016_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_72e65d59-0772-4633-8b01-02cd53148f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c7952726-87e3-4e84-9b1f-c59cf91bd016" xlink:to="loc_us-gaap_SegmentDomain_72e65d59-0772-4633-8b01-02cd53148f5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicaidMember_287a5636-fa6c-4a5b-8c75-e551595c8216" xlink:href="moh-20220930.xsd#moh_MedicaidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_72e65d59-0772-4633-8b01-02cd53148f5d" xlink:to="loc_moh_MedicaidMember_287a5636-fa6c-4a5b-8c75-e551595c8216" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicareMember_7eef5adc-be10-4a9e-875b-f26904b9a8f8" xlink:href="moh-20220930.xsd#moh_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_72e65d59-0772-4633-8b01-02cd53148f5d" xlink:to="loc_moh_MedicareMember_7eef5adc-be10-4a9e-875b-f26904b9a8f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MarketplaceMember_89a1981d-b7e0-4a3c-991b-bee3541ac913" xlink:href="moh-20220930.xsd#moh_MarketplaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_72e65d59-0772-4633-8b01-02cd53148f5d" xlink:to="loc_moh_MarketplaceMember_89a1981d-b7e0-4a3c-991b-bee3541ac913" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherProgramMember_2574360b-38c7-4afe-91d5-dfe26c3f903b" xlink:href="moh-20220930.xsd#moh_OtherProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_72e65d59-0772-4633-8b01-02cd53148f5d" xlink:to="loc_moh_OtherProgramMember_2574360b-38c7-4afe-91d5-dfe26c3f903b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" xlink:type="extended" id="i8295f35efb644fff9df3a42d8d86fbc4_SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_7e0fa74a-d157-45e7-9129-59aec91b86e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_bada00fa-0744-4607-bbec-77d57f0f1c29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7e0fa74a-d157-45e7-9129-59aec91b86e3" xlink:to="loc_us-gaap_GrossProfit_bada00fa-0744-4607-bbec-77d57f0f1c29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_8010e3eb-1c6c-40a5-8947-316ab85cac9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7e0fa74a-d157-45e7-9129-59aec91b86e3" xlink:to="loc_us-gaap_Revenues_8010e3eb-1c6c-40a5-8947-316ab85cac9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_aec94557-033c-4964-bd1c-2d1d4b3dbf79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7e0fa74a-d157-45e7-9129-59aec91b86e3" xlink:to="loc_us-gaap_CostsAndExpenses_aec94557-033c-4964-bd1c-2d1d4b3dbf79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_19c6d56d-ad98-4219-92fd-240077a19149" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7e0fa74a-d157-45e7-9129-59aec91b86e3" xlink:to="loc_us-gaap_OperatingIncomeLoss_19c6d56d-ad98-4219-92fd-240077a19149" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_7ad325e6-5cce-4054-8bef-83d8c349700e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7e0fa74a-d157-45e7-9129-59aec91b86e3" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_7ad325e6-5cce-4054-8bef-83d8c349700e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ff6a3465-0cf5-4fa3-af98-9e0da226b081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7e0fa74a-d157-45e7-9129-59aec91b86e3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ff6a3465-0cf5-4fa3-af98-9e0da226b081" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1a69f4ea-373c-45c6-9557-79adeeca6d18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7e0fa74a-d157-45e7-9129-59aec91b86e3" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1a69f4ea-373c-45c6-9557-79adeeca6d18" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_8b6417d4-161a-4f31-baa6-32fdd78008e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1a69f4ea-373c-45c6-9557-79adeeca6d18" xlink:to="loc_srt_ConsolidationItemsAxis_8b6417d4-161a-4f31-baa6-32fdd78008e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_8b6417d4-161a-4f31-baa6-32fdd78008e5_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_8b6417d4-161a-4f31-baa6-32fdd78008e5" xlink:to="loc_srt_ConsolidationItemsDomain_8b6417d4-161a-4f31-baa6-32fdd78008e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_f14cc286-0606-44bc-9b19-c0f2a78d29cd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_8b6417d4-161a-4f31-baa6-32fdd78008e5" xlink:to="loc_srt_ConsolidationItemsDomain_f14cc286-0606-44bc-9b19-c0f2a78d29cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_3f244c57-e5ec-4852-9f7f-50366d0d5df9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_f14cc286-0606-44bc-9b19-c0f2a78d29cd" xlink:to="loc_us-gaap_OperatingSegmentsMember_3f244c57-e5ec-4852-9f7f-50366d0d5df9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_6767457d-ae32-4c66-9850-15a26a7a2116" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_f14cc286-0606-44bc-9b19-c0f2a78d29cd" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_6767457d-ae32-4c66-9850-15a26a7a2116" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c40f80d4-00a9-4e61-9bfe-a2c98f14609d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1a69f4ea-373c-45c6-9557-79adeeca6d18" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c40f80d4-00a9-4e61-9bfe-a2c98f14609d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c40f80d4-00a9-4e61-9bfe-a2c98f14609d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c40f80d4-00a9-4e61-9bfe-a2c98f14609d" xlink:to="loc_us-gaap_SegmentDomain_c40f80d4-00a9-4e61-9bfe-a2c98f14609d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c0ed9049-3847-49f7-a977-7968c546e1f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c40f80d4-00a9-4e61-9bfe-a2c98f14609d" xlink:to="loc_us-gaap_SegmentDomain_c0ed9049-3847-49f7-a977-7968c546e1f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicaidMember_192d68d6-29ef-48b6-9743-86fe7c14237e" xlink:href="moh-20220930.xsd#moh_MedicaidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c0ed9049-3847-49f7-a977-7968c546e1f9" xlink:to="loc_moh_MedicaidMember_192d68d6-29ef-48b6-9743-86fe7c14237e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicareMember_9f7d5e2a-aaaf-42ef-b86e-2f98088f7d43" xlink:href="moh-20220930.xsd#moh_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c0ed9049-3847-49f7-a977-7968c546e1f9" xlink:to="loc_moh_MedicareMember_9f7d5e2a-aaaf-42ef-b86e-2f98088f7d43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MarketplaceMember_5f47dbd8-483f-454a-8e33-5d8b9776e9ba" xlink:href="moh-20220930.xsd#moh_MarketplaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c0ed9049-3847-49f7-a977-7968c546e1f9" xlink:to="loc_moh_MarketplaceMember_5f47dbd8-483f-454a-8e33-5d8b9776e9ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherProgramMember_70ff5a1c-99da-42c8-8780-cc046f1bc60d" xlink:href="moh-20220930.xsd#moh_OtherProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c0ed9049-3847-49f7-a977-7968c546e1f9" xlink:to="loc_moh_OtherProgramMember_70ff5a1c-99da-42c8-8780-cc046f1bc60d" xlink:type="arc" order="3"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>moh-20220930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:723f88a6-3111-46ae-86a6-19eac5cb9305,g:31c414f1-6fb4-4584-ba8e-291448fd334e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_2080a1cf-2703-485a-a86e-e99a6eec867e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_7ce084cd-bc27-460b-975d-b4f4f0720509_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_63d7a3ee-8cf2-42d9-a29b-66d2b2004201_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_d4e44d15-6206-40eb-990c-75e5e4ac2cdf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_9e82addb-6a7b-4ef7-87da-2521a97cd0ad_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_afc7f68a-3907-4bde-ac0f-788ddfc7658d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_OtherClaimsPayable_de5690c8-fcbe-4ea1-8cec-baca8f8c06c4_terseLabel_en-US" xlink:label="lab_moh_OtherClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_moh_OtherClaimsPayable_label_en-US" xlink:label="lab_moh_OtherClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Claims Payable</link:label>
    <link:label id="lab_moh_OtherClaimsPayable_documentation_en-US" xlink:label="lab_moh_OtherClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Claims Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherClaimsPayable" xlink:href="moh-20220930.xsd#moh_OtherClaimsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_OtherClaimsPayable" xlink:to="lab_moh_OtherClaimsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_6599ce48-5c2a-411c-be63-230cf7dc09a9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_fc0f7a95-a379-4b45-8650-bf3dbf17e691_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MinimumMemberEnrollmentTargetsMember_b68b384d-1b6b-4cf5-b818-0ede88a9b850_terseLabel_en-US" xlink:label="lab_moh_MinimumMemberEnrollmentTargetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Member Enrollment Targets</link:label>
    <link:label id="lab_moh_MinimumMemberEnrollmentTargetsMember_label_en-US" xlink:label="lab_moh_MinimumMemberEnrollmentTargetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Member Enrollment Targets [Member]</link:label>
    <link:label id="lab_moh_MinimumMemberEnrollmentTargetsMember_documentation_en-US" xlink:label="lab_moh_MinimumMemberEnrollmentTargetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Member Enrollment Targets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MinimumMemberEnrollmentTargetsMember" xlink:href="moh-20220930.xsd#moh_MinimumMemberEnrollmentTargetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MinimumMemberEnrollmentTargetsMember" xlink:to="lab_moh_MinimumMemberEnrollmentTargetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_1e22c566-4e7c-4e1d-984b-1d51e88b0849_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Liability for Unpaid Claims and Claims Adjustment Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_d517c84f-ecdb-4982-be45-5462f1077b35_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ab8821d5-0ef5-41b7-affc-a7ff0037547f_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_849a10da-fc7a-466b-8561-5b7a19827232_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_b1233da0-f319-4f72-92cc-425d86b3d7b0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable_b4378165-1285-40e1-96b2-b033cfd29a49_terseLabel_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk adjustment receivable</link:label>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable_label_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable</link:label>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable_documentation_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" xlink:href="moh-20220930.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" xlink:to="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MedicalPremiumLiabilityDueToAgency_32fee0bb-fd96-4231-9967-792580605fd6_terseLabel_en-US" xlink:label="lab_moh_MedicalPremiumLiabilityDueToAgency" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts due government agencies</link:label>
    <link:label id="lab_moh_MedicalPremiumLiabilityDueToAgency_95c0ff78-b599-4bc9-976e-e59929fe00b4_totalLabel_en-US" xlink:label="lab_moh_MedicalPremiumLiabilityDueToAgency" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total amounts due government agencies</link:label>
    <link:label id="lab_moh_MedicalPremiumLiabilityDueToAgency_label_en-US" xlink:label="lab_moh_MedicalPremiumLiabilityDueToAgency" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Premium Liability Due To Agency</link:label>
    <link:label id="lab_moh_MedicalPremiumLiabilityDueToAgency_documentation_en-US" xlink:label="lab_moh_MedicalPremiumLiabilityDueToAgency" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Premium Liability Due to Agency</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalPremiumLiabilityDueToAgency" xlink:href="moh-20220930.xsd#moh_MedicalPremiumLiabilityDueToAgency"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency" xlink:to="lab_moh_MedicalPremiumLiabilityDueToAgency" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_f30fa549-f0f5-4fb8-aae0-6107b44e3057_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical claims and benefits payable</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_5cae8148-4cc1-4013-9b6e-8a169f7ed7c2_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_8912de21-8b10-40fb-ae81-13feb23d2fbe_periodStartLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical claims and benefits payable, beginning balance</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_2d96e49f-28d3-4c49-bb75-34b5ab628c74_periodEndLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical claims and benefits payable, ending balance</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_ace48137-4065-447f-8d33-57e3f9cd2404_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_d3fb3adb-0a7a-4c9a-a8b3-fcc84fefef00_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5006cb6b-6933-42b5-bcc9-082ad748f38a_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_95a42d7e-fd62-437a-a059-d1702b45a75a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_8d45e389-3ee5-4b44-9a3a-1cc158ee7b90_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_9b581bd8-b040-47fe-90b9-293783c8cca2_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, interest rate, stated percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_4750f552-a7fe-48a5-abbc-031c2fe07a62_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of contractual interest rate on notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_d21d415f-4016-4fe4-a7c1-e8d3e259f742_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_74dc231b-026e-4525-b6ce-a81186b2dda3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense [Table]</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_cc3bead3-bf7e-45f8-9684-d99eff575b48_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_160faab0-32fa-4984-aba5-4e82c4b2dbbe_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment, and capitalized software, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_a9abbcf0-a24a-4bd9-aa1d-2ede37910dfc_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_8a7188cb-a48f-4759-be46-ead1ffc28d75_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6d99e8a4-4af5-47bb-9f49-b0fa2cbc5847_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_3e5745b8-b5ac-4aaf-bc71-36563c76c997_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentIncome_467f6a38-d61f-45c6-aff9-764eb30758e2_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income</link:label>
    <link:label id="lab_us-gaap_NetInvestmentIncome_label_en-US" xlink:label="lab_us-gaap_NetInvestmentIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentIncome" xlink:to="lab_us-gaap_NetInvestmentIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_fbf6200c-ea00-437d-8567-2b29232269b8_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_328cf32f-3cf9-4c2e-8ede-2be69369c5c2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Claims</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_66b7e624-91b3-4d3c-a97c-c1fd93302d0b_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_A3875SeniorNotesMember_394cfdf0-bcd4-4c6e-a62c-c691b0ef236c_terseLabel_en-US" xlink:label="lab_moh_A3875SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.875% Notes due 2032</link:label>
    <link:label id="lab_moh_A3875SeniorNotesMember_label_en-US" xlink:label="lab_moh_A3875SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.875% Senior Notes [Member]</link:label>
    <link:label id="lab_moh_A3875SeniorNotesMember_documentation_en-US" xlink:label="lab_moh_A3875SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.875% Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A3875SeniorNotesMember" xlink:href="moh-20220930.xsd#moh_A3875SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_A3875SeniorNotesMember" xlink:to="lab_moh_A3875SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_StructuredSecuritiesMember_96c4c475-983c-4914-a506-98238a5dacfa_terseLabel_en-US" xlink:label="lab_moh_StructuredSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Structured Securities</link:label>
    <link:label id="lab_moh_StructuredSecuritiesMember_label_en-US" xlink:label="lab_moh_StructuredSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Structured Securities [Member]</link:label>
    <link:label id="lab_moh_StructuredSecuritiesMember_documentation_en-US" xlink:label="lab_moh_StructuredSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Structured Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_StructuredSecuritiesMember" xlink:href="moh-20220930.xsd#moh_StructuredSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_StructuredSecuritiesMember" xlink:to="lab_moh_StructuredSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_ca42b8c4-5352-4529-8420-b860cb357388_terseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_HealthPlanExtensionOptionPeriod_29634fe5-fd22-4576-b022-2daac01fe561_terseLabel_en-US" xlink:label="lab_moh_HealthPlanExtensionOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extension option</link:label>
    <link:label id="lab_moh_HealthPlanExtensionOptionPeriod_label_en-US" xlink:label="lab_moh_HealthPlanExtensionOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Plan, Extension Option, Period</link:label>
    <link:label id="lab_moh_HealthPlanExtensionOptionPeriod_documentation_en-US" xlink:label="lab_moh_HealthPlanExtensionOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Plan, Extension Option, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlanExtensionOptionPeriod" xlink:href="moh-20220930.xsd#moh_HealthPlanExtensionOptionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_HealthPlanExtensionOptionPeriod" xlink:to="lab_moh_HealthPlanExtensionOptionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_OperatingIncomeGuaranteeMember_f43bbee4-69d3-4b79-aec3-402921d059bf_terseLabel_en-US" xlink:label="lab_moh_OperatingIncomeGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income Guarantee</link:label>
    <link:label id="lab_moh_OperatingIncomeGuaranteeMember_label_en-US" xlink:label="lab_moh_OperatingIncomeGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income Guarantee [Member]</link:label>
    <link:label id="lab_moh_OperatingIncomeGuaranteeMember_documentation_en-US" xlink:label="lab_moh_OperatingIncomeGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income Guarantee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OperatingIncomeGuaranteeMember" xlink:href="moh-20220930.xsd#moh_OperatingIncomeGuaranteeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_OperatingIncomeGuaranteeMember" xlink:to="lab_moh_OperatingIncomeGuaranteeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_4bb2d313-3394-42d1-ba87-6a7420c465fb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_85c62f83-a801-4bde-8ac3-df22650d14f1_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount outstanding under letter of credit</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_c451cf71-c97a-4969-8cef-e1acf8eec5df_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value, 150 million shares authorized; outstanding: 58 million shares at September&#160;30, 2022 and December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_85c1c227-29c1-43bf-a7c1-f864cad74c3f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_dcbb9c5c-1fee-47a7-b46f-c7dcda8cbe76_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_HealthPlanNumberOfContracts_2b2cf662-0538-4f5b-87d3-f8503f1da678_terseLabel_en-US" xlink:label="lab_moh_HealthPlanNumberOfContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of contracts</link:label>
    <link:label id="lab_moh_HealthPlanNumberOfContracts_label_en-US" xlink:label="lab_moh_HealthPlanNumberOfContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Plan, Number Of Contracts</link:label>
    <link:label id="lab_moh_HealthPlanNumberOfContracts_documentation_en-US" xlink:label="lab_moh_HealthPlanNumberOfContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Plan, Number Of Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlanNumberOfContracts" xlink:href="moh-20220930.xsd#moh_HealthPlanNumberOfContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_HealthPlanNumberOfContracts" xlink:to="lab_moh_HealthPlanNumberOfContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_cff22db1-003c-46f1-822c-2da6b436c4ac_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember_b254d20d-94d8-4d67-bd3f-f84de6a3d458_terseLabel_en-US" xlink:label="lab_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cigna Corporation's Texas Medicaid and Medicare-Medicaid Plan</link:label>
    <link:label id="lab_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember_label_en-US" xlink:label="lab_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cigna Corporation's Texas Medicaid and Medicare-Medicaid Plan [Member]</link:label>
    <link:label id="lab_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember_documentation_en-US" xlink:label="lab_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cigna Corporation's Texas Medicaid and Medicare-Medicaid Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember" xlink:href="moh-20220930.xsd#moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember" xlink:to="lab_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_1dceba0f-ce5a-470a-9ccf-8fa30227a044_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of shares issued:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_622408df-dbe7-40dd-93d1-bec15bb046ea_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_7e627d98-0e3c-4c36-8540-c98fbfe0277c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_f3ddf990-1d63-4744-9df3-ba6c61a8abd7_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_43111b0f-6ba6-431e-93dd-ea86468a9c6e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_a794d5be-6a65-4896-b46b-427f8be8b399_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold_991298a9-ca32-4c4a-831a-f37c0624e7e8_terseLabel_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum MLR</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold_label_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Marketplace, Medical Loss Ratio Threshold</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold_documentation_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Marketplace, Medical Loss Ratio Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" xlink:href="moh-20220930.xsd#moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" xlink:to="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_3135fcf4-daf9-4ced-b6b0-da0b73e0801c_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract_2a9cbfd8-2356-44a3-a2ab-f0390d375ec1_terseLabel_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid program:</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract_label_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Medicaid Program [Abstract]</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract_documentation_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Medicaid Program [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract" xlink:href="moh-20220930.xsd#moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract" xlink:to="lab_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_cc4eb2a3-64ec-4310-bac4-618ef7284608_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_876fd998-6996-4325-b1f1-5b3c4b90e171_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Purchase Accounting Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:to="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6f8e8be5-d69a-4755-98fc-9179431a40db_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_f1778d5c-c803-4a2c-a52f-bb1e66f85eba_terseLabel_en-US" xlink:label="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Premium Revenue By Health Plan Type [Table]</link:label>
    <link:label id="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_label_en-US" xlink:label="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Premium Revenue by Health Plan Type [Table]</link:label>
    <link:label id="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_documentation_en-US" xlink:label="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of premium revenue by health plan type.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable" xlink:href="moh-20220930.xsd#moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable" xlink:to="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_c44bde23-5dd1-47b0-92ea-2c28d631b766_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior years</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_9cdfe818-b27c-4e69-9e5d-06f2c38e61b6_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_343e6ac0-2ae5-44d2-bf91-b4b61351f695_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock_37350d3b-0f76-4b6d-a99c-dbdd09ccc18e_terseLabel_en-US" xlink:label="lab_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation and Interim Financial Information</link:label>
    <link:label id="lab_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock_label_en-US" xlink:label="lab_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation And Interim Financial Information, Policy [Policy Text Block]</link:label>
    <link:label id="lab_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation And Interim Financial Information, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock" xlink:href="moh-20220930.xsd#moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock" xlink:to="lab_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_f2b55128-8ed7-4eb1-a886-087fe0c4133a_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_9cf3101f-6163-4f27-8021-1e9ce9d4572c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium Revenue Recognition and Amounts Due Government Agencies and Contractual Provisions That May Adjust or Limit Revenue or Profit</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_7388ee53-1ee8-4601-a473-cd772c9ccf67_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_6ced3d50-ad55-4260-88de-b0853f908e8f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms_9d5c3d4e-490b-46de-b60e-0eec61f1dcc0_terseLabel_en-US" xlink:label="lab_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of states with programs</link:label>
    <link:label id="lab_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms_label_en-US" xlink:label="lab_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of States With Government-Sponsored Healthcare Programs</link:label>
    <link:label id="lab_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms_documentation_en-US" xlink:label="lab_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of States With Government-Sponsored Healthcare Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms" xlink:href="moh-20220930.xsd#moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms" xlink:to="lab_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_d3afd680-c249-4eaa-9b8e-1c2c5c58d408_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0107baac-2184-45fb-b728-c78dba534b2a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable_fdfa1723-eb65-48ab-8fad-ba5276dfc2c7_terseLabel_en-US" xlink:label="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical claims and benefits payable</link:label>
    <link:label id="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable_label_en-US" xlink:label="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Medical Claims and Benefits Payable</link:label>
    <link:label id="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable_documentation_en-US" xlink:label="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Medical Claims and Benefits Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable" xlink:href="moh-20220930.xsd#moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable" xlink:to="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_04a8cb98-e6ee-41bb-9f68-36b8dd85be94_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_4acd0743-254a-4787-9be7-422a5bd8d03d_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_63a21ac0-60a7-456e-bcf5-3d07ceb1d013_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount_daff8a43-eea3-4b08-94ca-18676e8193f7_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost, due in one year or less</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_b6dbf85c-5950-4c83-8c5e-6638b45707de_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized gain (loss)</link:label>
    <link:label id="lab_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_label_en-US" xlink:label="lab_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Fair Value Hedges Recognized in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" xlink:to="lab_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_e6a2bd09-99cf-4854-a669-a4f74520f8e5_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_dfab17df-ab75-41b6-b238-be63cdcabf48_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_InvestmentsAverageMaturityPeriod_5930f7a9-4eb7-4ae2-b0ea-bd98b6c139d5_terseLabel_en-US" xlink:label="lab_moh_InvestmentsAverageMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average maturity period (less than)</link:label>
    <link:label id="lab_moh_InvestmentsAverageMaturityPeriod_label_en-US" xlink:label="lab_moh_InvestmentsAverageMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Average Maturity Period</link:label>
    <link:label id="lab_moh_InvestmentsAverageMaturityPeriod_documentation_en-US" xlink:label="lab_moh_InvestmentsAverageMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Average Maturity Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_InvestmentsAverageMaturityPeriod" xlink:href="moh-20220930.xsd#moh_InvestmentsAverageMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_InvestmentsAverageMaturityPeriod" xlink:to="lab_moh_InvestmentsAverageMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_e24f3031-4121-405c-a0ab-1a0eff3a8e8b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_a18909b9-9d84-4c89-bedf-97490c3e7e69_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemAxis_ea7f168b-54f3-4e85-8bc0-f5df699d05cd_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Axis]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemAxis_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis" xlink:to="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_7048aee7-eff7-4474-a183-9805d3892e10_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_7a642322-30c6-431b-ad06-97134f20b224_totalLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total paid</link:label>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:to="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_62310de8-0eaa-4001-98cb-0bc6164f5e17_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_f2d8edb0-a3ee-4950-b7ff-5e434d1fa946_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_cb251d37-4322-4553-8ea4-128c9f658eed_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_ada7e1a2-4a17-4590-8181-6f767932b8ce_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized investment loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_HealthPlanContractTerm_153e85ae-44be-4a40-a3d4-b94432ed095f_terseLabel_en-US" xlink:label="lab_moh_HealthPlanContractTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract term</link:label>
    <link:label id="lab_moh_HealthPlanContractTerm_label_en-US" xlink:label="lab_moh_HealthPlanContractTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Plan, Contract Term</link:label>
    <link:label id="lab_moh_HealthPlanContractTerm_documentation_en-US" xlink:label="lab_moh_HealthPlanContractTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Plan, Contract Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlanContractTerm" xlink:href="moh-20220930.xsd#moh_HealthPlanContractTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_HealthPlanContractTerm" xlink:to="lab_moh_HealthPlanContractTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_1b2bb5d6-9429-4174-b7b4-adf59c23c641_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired membership with a preliminary fair value</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_aa54fc38-a845-48c4-94c6-efca780cd4cd_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_62468dce-f8dd-4ed7-bf6f-5251a5e09302_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MyChoiceWisconsinMember_07f280ec-cc8a-4eb1-9dda-8519076c1d78_terseLabel_en-US" xlink:label="lab_moh_MyChoiceWisconsinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MCW</link:label>
    <link:label id="lab_moh_MyChoiceWisconsinMember_label_en-US" xlink:label="lab_moh_MyChoiceWisconsinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">My Choice Wisconsin [Member]</link:label>
    <link:label id="lab_moh_MyChoiceWisconsinMember_documentation_en-US" xlink:label="lab_moh_MyChoiceWisconsinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">My Choice Wisconsin</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MyChoiceWisconsinMember" xlink:href="moh-20220930.xsd#moh_MyChoiceWisconsinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MyChoiceWisconsinMember" xlink:to="lab_moh_MyChoiceWisconsinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_01382b5b-f39e-48f7-ab36-52ce32b03fa5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_80ffb2db-3f2d-44b5-b801-b5b37951b4a0_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock authorized</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_e5fd8676-24e9-4513-b28f-c23175519922_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_14809d8b-a501-4f9f-97c0-2afda44cfa6b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable_87b91cee-a6de-4252-ace3-ffdb922b1642_terseLabel_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk adjustment, net payable</link:label>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable_label_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net Payable</link:label>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable_documentation_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" xlink:href="moh-20220930.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" xlink:to="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_0d1cce4c-07b3-4c2f-a392-71f7e17d5c4c_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b3180dd0-f15c-4535-baf7-e5c9cbe7b38e_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_625d29ed-c45b-4646-95d4-d9d1c15e8db7_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_6ab7109a-5cf1-4841-83d4-731f294bc25a_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MedicareMember_a447561e-745a-4867-af5e-4e8776b7d543_terseLabel_en-US" xlink:label="lab_moh_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_moh_MedicareMember_label_en-US" xlink:label="lab_moh_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_moh_MedicareMember_documentation_en-US" xlink:label="lab_moh_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicareMember" xlink:href="moh-20220930.xsd#moh_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MedicareMember" xlink:to="lab_moh_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_cc3eb39b-626f-4031-a33f-d43eee08590c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_GovernmentReceivablesMember_57ef847d-c661-45fd-9798-0847e505b9f1_terseLabel_en-US" xlink:label="lab_moh_GovernmentReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government receivables</link:label>
    <link:label id="lab_moh_GovernmentReceivablesMember_label_en-US" xlink:label="lab_moh_GovernmentReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Receivables [Member]</link:label>
    <link:label id="lab_moh_GovernmentReceivablesMember_documentation_en-US" xlink:label="lab_moh_GovernmentReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Receivables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_GovernmentReceivablesMember" xlink:href="moh-20220930.xsd#moh_GovernmentReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_GovernmentReceivablesMember" xlink:to="lab_moh_GovernmentReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_0d1771c6-dbee-46b5-aa3d-6b200dd21bc9_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MemberListsMember_41f55c2c-4584-48e9-8c43-d71d65b21f52_terseLabel_en-US" xlink:label="lab_moh_MemberListsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Member list</link:label>
    <link:label id="lab_moh_MemberListsMember_label_en-US" xlink:label="lab_moh_MemberListsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Member Lists [Member]</link:label>
    <link:label id="lab_moh_MemberListsMember_documentation_en-US" xlink:label="lab_moh_MemberListsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Member Lists</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MemberListsMember" xlink:href="moh-20220930.xsd#moh_MemberListsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MemberListsMember" xlink:to="lab_moh_MemberListsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_4f06427e-82b4-4092-9233-72e98d7c29ba_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_b40f5b2a-e7ad-4c9c-bb8a-622b55850f6c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: effect of income taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0068cce9-db94-436d-8da9-71e11226f0ff_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_93bccb7a-219d-441d-b503-bba9584bbe60_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_e26c100f-efde-46ef-b5cd-ea97054ffdf0_verboseLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total margin</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_40b8d919-d5dc-46c5-9bb3-7115fe107594_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount_49fdb41e-e569-4518-9e8b-501f5582bb32_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost, due after five years</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, after Year 5 through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_HealthPlansMember_77b4bb3f-fdd3-4c2a-a5b2-b0542a6940b8_terseLabel_en-US" xlink:label="lab_moh_HealthPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Plans</link:label>
    <link:label id="lab_moh_HealthPlansMember_label_en-US" xlink:label="lab_moh_HealthPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Plans [Member]</link:label>
    <link:label id="lab_moh_HealthPlansMember_documentation_en-US" xlink:label="lab_moh_HealthPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlansMember" xlink:href="moh-20220930.xsd#moh_HealthPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_HealthPlansMember" xlink:to="lab_moh_HealthPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_7127211d-dbb8-4ca1-85eb-6b840c29deb4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_2db33101-bfa1-4443-ac94-e4d34e4371a7_terseLabel_en-US" xlink:label="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Premium Revenue by Health Plan Type [Line Items]</link:label>
    <link:label id="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_label_en-US" xlink:label="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Premium Revenue by Health Plan Type [Line Items]</link:label>
    <link:label id="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_documentation_en-US" xlink:label="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of premium revenue by health plan type.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems" xlink:href="moh-20220930.xsd#moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems" xlink:to="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_5bf55d01-e3e9-4997-b48c-ca95a2ea7531_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_acbd9cac-cd1a-4666-8bce-3d317c1bfa2f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_49eacbd0-56f4-496c-815a-4b86dab252d2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_5a2173ff-1a35-4ad3-a7a8-725a93fe9797_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_e89dd3df-de69-459c-812f-a160464a84b7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0e0bdb7f-f96d-4ba1-9bad-6756c73d0240_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a2bc6cd9-ce4c-46cb-87c4-53cd485d71b8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_50e78382-f1b6-4db0-a867-adeb2bedc62c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock purchases (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_fbb636ec-05ac-4ca9-adca-d1bbcfa2cb03_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_33b0af8f-c175-447e-a8ed-14bf0054b1c4_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_c07bdea1-f52c-4b03-9917-9aea6e890dd6_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_0d709f73-171c-4c07-a3bf-6937080eadfd_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average cost (USD per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_0f7cc899-b157-4bb2-8cb2-8616ca07dd69_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_f462c582-0b06-4c32-9711-aad205d44af6_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_58288e92-cc65-4647-af41-0361240f067a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_89908e7d-ff1f-4ee3-822e-9cd16669dba6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_5d4e6aaf-c79c-452d-b9ff-866632eb5491_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_6f57dc55-be40-4409-b1c9-d5bedd5ed007_netLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_2a5fce6a-67a5-43d3-ba1e-9a17125983c8_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Add: other operating revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_48ec27f0-9507-4ee0-87c1-37a62b16e57d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In&#160;a&#160;Continuous&#160;Loss Position for&#160;12&#160;Months or More, Total Number of Positions</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_cf917031-19aa-4af0-b1ec-4a481b47f72a_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_5fedd051-8342-475b-a0b4-8725366d18d0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued liabilities and other</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_3d589e28-b678-464c-9088-707557824c9e_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_c83c1022-9444-46c6-ab8d-2b7bb4d0a41e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In&#160;a&#160;Continuous&#160;Loss Position for&#160;12&#160;Months or More, Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_47579757-8f7a-41b1-8396-9c85de10bb1d_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_b478aebe-dfa1-422a-9ec5-ff3523b9c381_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share - Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_A4375SeniorNotesMember_248bd508-5328-4845-a4f5-62f61feb3ddd_terseLabel_en-US" xlink:label="lab_moh_A4375SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Notes due 2028</link:label>
    <link:label id="lab_moh_A4375SeniorNotesMember_label_en-US" xlink:label="lab_moh_A4375SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Senior Notes [Member]</link:label>
    <link:label id="lab_moh_A4375SeniorNotesMember_documentation_en-US" xlink:label="lab_moh_A4375SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4375SeniorNotesMember" xlink:href="moh-20220930.xsd#moh_A4375SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_A4375SeniorNotesMember" xlink:to="lab_moh_A4375SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_8ab4be00-5b13-4921-8ff3-496aed04fe82_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables_71f8f7dd-f2b3-4262-973d-07b4e9d47f5f_terseLabel_en-US" xlink:label="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase to receivables, net of amounts due government agencies</link:label>
    <link:label id="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables_label_en-US" xlink:label="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Receivables</link:label>
    <link:label id="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables_documentation_en-US" xlink:label="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables" xlink:href="moh-20220930.xsd#moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables" xlink:to="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_51f73c9d-620e-45a5-ac52-5bfd63bd21e9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_e8838e51-3dd6-404e-b639-2919fafdc7fd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_14e60b40-d768-421c-818c-568b826e7453_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_ee2cca13-e5f5-4b4c-a1aa-c2ebfc343290_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_66ece95b-e2d0-4a56-9258-0adcdae9bc56_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount_990b7814-0917-42c4-aa37-621768902a17_terseLabel_en-US" xlink:label="lab_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims incurred but not paid (&#8220;IBNP&#8221;)</link:label>
    <link:label id="lab_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount_label_en-US" xlink:label="lab_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Paid (IBNP), Fee-for-service Claims, Amount</link:label>
    <link:label id="lab_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount_documentation_en-US" xlink:label="lab_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Paid (IBNP), Fee-for-service Claims, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" xlink:href="moh-20220930.xsd#moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" xlink:to="lab_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_56c340a4-05aa-4bbb-8f67-29495d2087a1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDuetoGovernmentAgenciesOther_29bf766d-e411-4958-9005-e7b121aebc88_terseLabel_en-US" xlink:label="lab_moh_AmountsDuetoGovernmentAgenciesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_moh_AmountsDuetoGovernmentAgenciesOther_label_en-US" xlink:label="lab_moh_AmountsDuetoGovernmentAgenciesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due to Government Agencies, Other</link:label>
    <link:label id="lab_moh_AmountsDuetoGovernmentAgenciesOther_documentation_en-US" xlink:label="lab_moh_AmountsDuetoGovernmentAgenciesOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due to Government Agencies, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDuetoGovernmentAgenciesOther" xlink:href="moh-20220930.xsd#moh_AmountsDuetoGovernmentAgenciesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDuetoGovernmentAgenciesOther" xlink:to="lab_moh_AmountsDuetoGovernmentAgenciesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_0d6e8dd8-f28d-447d-aad8-fa15e99829e0_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialMortgageBackedSecuritiesMember_160f5e38-e1c3-48b2-8af1-33d0ef6e0e90_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage-backed securities</link:label>
    <link:label id="lab_us-gaap_CommercialMortgageBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Mortgage-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:to="lab_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_51dcd57f-2c02-404d-9ed7-0893e1b318ab_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_94bb05c0-aff7-48f3-921f-0ae99b352e15_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_8c3c52c2-dabf-4368-810d-4665120c3a01_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_81661a59-be30-4c3b-9187-066ea805c843_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_1ab57fa0-51de-4719-9086-d6e8def1c349_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayableTextBlock_669a2bc0-a78d-4b6a-bdc6-a3b9f40c02e1_terseLabel_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Claims and Benefits Payable</link:label>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayableTextBlock_label_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Claims And Benefits Payable [Text Block]</link:label>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayableTextBlock_documentation_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical claims and benefits payable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalClaimsAndBenefitsPayableTextBlock" xlink:href="moh-20220930.xsd#moh_MedicalClaimsAndBenefitsPayableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MedicalClaimsAndBenefitsPayableTextBlock" xlink:to="lab_moh_MedicalClaimsAndBenefitsPayableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_37d790ae-135b-4ab6-a27b-caef24a0c3e7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_02909703-b481-4c51-a1fb-c7ea39276475_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_db5eb403-ac08-4d76-b302-b27572237bf8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_2f9bf27a-f77b-4363-a065-8c12024df754_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6ebcd9ed-b2bf-4b79-827c-558b933da843_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_434786cd-08f4-4c1a-82b1-667d114e675b_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_1799fb9e-741b-41df-9829-48339dbd2235_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchases</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_3775ea52-d398-42d2-8fa4-b5f4588a7501_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchases</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_fda69073-5329-4e30-8ed4-f5acfb07e19c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayable_c6e1e39d-0026-479a-ab8e-a0c6cd5a083a_terseLabel_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-risk provider payables</link:label>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayable_label_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Claims And Benefits Payable</link:label>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayable_documentation_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Claims and Benefits Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalClaimsAndBenefitsPayable" xlink:href="moh-20220930.xsd#moh_MedicalClaimsAndBenefitsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MedicalClaimsAndBenefitsPayable" xlink:to="lab_moh_MedicalClaimsAndBenefitsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_c4f2bfce-a245-4b46-a6a7-faa14f642eb8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_6c405021-e9de-43f8-8ca2-c4a85d143b11_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_ComponentsOfMedicalCareCostsAbstract_f81fc34e-54d4-4663-a827-9f9e041024ea_terseLabel_en-US" xlink:label="lab_moh_ComponentsOfMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of medical care costs related to:</link:label>
    <link:label id="lab_moh_ComponentsOfMedicalCareCostsAbstract_label_en-US" xlink:label="lab_moh_ComponentsOfMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components Of Medical Care Costs [Abstract]</link:label>
    <link:label id="lab_moh_ComponentsOfMedicalCareCostsAbstract_documentation_en-US" xlink:label="lab_moh_ComponentsOfMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of medical care costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ComponentsOfMedicalCareCostsAbstract" xlink:href="moh-20220930.xsd#moh_ComponentsOfMedicalCareCostsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_ComponentsOfMedicalCareCostsAbstract" xlink:to="lab_moh_ComponentsOfMedicalCareCostsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold_db94d969-a91d-4156-96b2-d61bf7d3850f_terseLabel_en-US" xlink:label="lab_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum MLR and profit sharing</link:label>
    <link:label id="lab_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold_label_en-US" xlink:label="lab_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Premiums Liability, Medical Care Costs Threshold</link:label>
    <link:label id="lab_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold_documentation_en-US" xlink:label="lab_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Premiums Liability, Medical Care Costs Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold" xlink:href="moh-20220930.xsd#moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold" xlink:to="lab_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_c6f72bcf-3900-4703-8592-81e2aaac9f8f_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_b82d53cd-7e31-4eab-b628-22ed91980646_verboseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total receivables</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_03bcb4c5-e80d-470b-b4e1-41d2e7688961_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_8047e8d1-444e-4796-9090-4f03a9be7abe_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_95085535-6864-40cb-9bca-bdb02e445c30_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_OtherReceivablesMember_bbeb47f4-e5d5-486f-9f37-b1cb3bbd0e61_terseLabel_en-US" xlink:label="lab_moh_OtherReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_moh_OtherReceivablesMember_label_en-US" xlink:label="lab_moh_OtherReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables [Member]</link:label>
    <link:label id="lab_moh_OtherReceivablesMember_documentation_en-US" xlink:label="lab_moh_OtherReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherReceivablesMember" xlink:href="moh-20220930.xsd#moh_OtherReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_OtherReceivablesMember" xlink:to="lab_moh_OtherReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_e3069e0b-ae09-4a10-9df9-aa18a0bb21bc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liabilities settled</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_6e054f01-00aa-4a85-b6d5-54b84086bcf6_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liabilities settled</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedInvestmentsNoncurrent_3542bdfb-1405-4652-9e07-0c46fb4797e5_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedInvestmentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Investments, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestmentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedInvestmentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedInvestmentsNoncurrent" xlink:to="lab_us-gaap_RestrictedInvestmentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_34d0bd4b-6f74-477a-b9f6-e811f5d39ddc_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_c4a8a36b-69e0-4678-8b15-bbb3ee2a52c4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_f0e62a7a-8e6d-44cd-8032-41c64364bba7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MedicaidMember_efc5dfc3-1391-4b3c-9b7b-876de4a73cc1_terseLabel_en-US" xlink:label="lab_moh_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid</link:label>
    <link:label id="lab_moh_MedicaidMember_label_en-US" xlink:label="lab_moh_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid [Member]</link:label>
    <link:label id="lab_moh_MedicaidMember_documentation_en-US" xlink:label="lab_moh_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicaidMember" xlink:href="moh-20220930.xsd#moh_MedicaidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MedicaidMember" xlink:to="lab_moh_MedicaidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_7d145847-9179-4906-8af1-cc4ab89c9155_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_237e3aa4-3569-4e2c-a702-00788fb1feb0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_0828d5dd-878f-4cd9-ba0a-834ccda6ed40_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In&#160;a&#160;Continuous&#160;Loss Position for&#160;Less&#160;than&#160;12&#160;Months, Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_cb1d7fe8-23ec-44f8-9ff9-99f4ce4eb956_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AgeWellMember_a93b6b48-b892-432e-9328-526008cd7814_terseLabel_en-US" xlink:label="lab_moh_AgeWellMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AgeWell</link:label>
    <link:label id="lab_moh_AgeWellMember_label_en-US" xlink:label="lab_moh_AgeWellMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AgeWell [Member]</link:label>
    <link:label id="lab_moh_AgeWellMember_documentation_en-US" xlink:label="lab_moh_AgeWellMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AgeWell</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AgeWellMember" xlink:href="moh-20220930.xsd#moh_AgeWellMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AgeWellMember" xlink:to="lab_moh_AgeWellMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67b3c5ee-842d-4639-87fe-8008c6d37789_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_4fdf3d0b-226e-45a2-882f-b4238d544ca4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_EarningsPerShareBasicAndDilutedEPSAbstract_5810df76-d272-4cfd-9bf7-1e2f58a61f96_terseLabel_en-US" xlink:label="lab_moh_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_moh_EarningsPerShareBasicAndDilutedEPSAbstract_label_en-US" xlink:label="lab_moh_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted EPS [Abstract]</link:label>
    <link:label id="lab_moh_EarningsPerShareBasicAndDilutedEPSAbstract_documentation_en-US" xlink:label="lab_moh_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted EPS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:href="moh-20220930.xsd#moh_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:to="lab_moh_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_745395df-f323-4895-93de-8e0626abc6e8_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other expenses, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_e7f728b1-891e-4f59-9f6c-85af83e54440_negatedLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expenses, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1d56e5e6-7a0d-46be-8fae-cff428e5a05f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA_18607d88-273e-4851-a7bd-2bb1853c54e7_terseLabel_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CALIFORNIA</link:label>
    <link:label id="lab_stpr_CA_label_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CALIFORNIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA" xlink:to="lab_stpr_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_167b8cda-1509-4a6d-89c4-7aae67e4f99e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_217de410-6181-4980-baef-d9256ae288a9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchases</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_baaaf5c2-b2ed-48f6-81fd-fc9d966fc909_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_ThreePointEightSevenFivePercentSeniorNotesMember_b069f789-3d3d-4bb4-8bc8-8ae3187122e4_terseLabel_en-US" xlink:label="lab_moh_ThreePointEightSevenFivePercentSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.875% Notes due 2030</link:label>
    <link:label id="lab_moh_ThreePointEightSevenFivePercentSeniorNotesMember_label_en-US" xlink:label="lab_moh_ThreePointEightSevenFivePercentSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Eight Seven Five Percent Senior Notes [Member]</link:label>
    <link:label id="lab_moh_ThreePointEightSevenFivePercentSeniorNotesMember_documentation_en-US" xlink:label="lab_moh_ThreePointEightSevenFivePercentSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Eight Seven Five Percent Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember" xlink:href="moh-20220930.xsd#moh_ThreePointEightSevenFivePercentSeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember" xlink:to="lab_moh_ThreePointEightSevenFivePercentSeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_d062ee07-b0e2-4492-9b7b-94aa27863ef4_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_31196ea7-5c17-4b9e-879f-f0bfb7686fd1_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_00754f76-e097-42c8-a608-27ba69b3864b_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1482afd6-92fb-4a08-98e9-1161181061f7_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCostAndExpenseOperating_f58d0030-7c2d-414c-b00b-8a8f9acfa545_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCostAndExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherCostAndExpenseOperating_label_en-US" xlink:label="lab_us-gaap_OtherCostAndExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Cost and Expense, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCostAndExpenseOperating" xlink:to="lab_us-gaap_OtherCostAndExpenseOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss_c8f54dd7-d01a-43c5-8c78-f23a3335bebb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities held to maturity</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Excluding Accrued Interest, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e1d5e9b7-213e-4f10-955e-06ca26af694d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_2269b9bf-a04f-4195-aacc-4d6d259d9b05_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_5de79930-1823-4f4e-833b-56ea23137790_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_babe2a07-1c02-4852-8c74-ab591ca7cf06_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_3ea6c700-e1b8-4cae-9759-6c57717fc6ac_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchases (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_4b3e3039-95a6-42ee-8cf3-a96b7c142c84_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchased of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_291e6372-f3c3-4d82-95c1-0931981f1697_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_b85873af-9129-48e6-a064-fa27514eff2e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_9a40666f-baeb-4d33-af27-da7e472c31b4_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_58ea5d0d-b2f7-4da2-9d15-cb6d7aee8578_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_376d8eb4-7a5d-4894-b2c7-edbb5eb4cb57_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_0c035e67-fc92-4458-8220-eb456b4dbe00_terseLabel_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketplace program:</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_label_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Marketplace Program [Abstract]</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_documentation_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Marketplace Program [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract" xlink:href="moh-20220930.xsd#moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract" xlink:to="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_b6fbd80c-1a56-4548-ae43-34b2fc726404_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_02f5be54-b2ee-4900-a75c-dd2abd016789_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_1a6cb8b5-3d93-4655-986a-ba483b4b57d5_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical care costs</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b94f3399-d01e-4fa7-8ccf-25e9678baebf_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator for diluted net income per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ef050c64-d72b-48ec-b119-3b62d7491bef_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_2ab280dc-f37e-4ae1-a989-729ab69c2cfa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_PassportHealthPlanIncMember_b0568809-7859-4c89-a6ed-37ca08496637_terseLabel_en-US" xlink:label="lab_moh_PassportHealthPlanIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Passport Health Plan, Inc.</link:label>
    <link:label id="lab_moh_PassportHealthPlanIncMember_label_en-US" xlink:label="lab_moh_PassportHealthPlanIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Passport Health Plan Inc [Member]</link:label>
    <link:label id="lab_moh_PassportHealthPlanIncMember_documentation_en-US" xlink:label="lab_moh_PassportHealthPlanIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Passport Health Plan Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PassportHealthPlanIncMember" xlink:href="moh-20220930.xsd#moh_PassportHealthPlanIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_PassportHealthPlanIncMember" xlink:to="lab_moh_PassportHealthPlanIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_99e408b0-1860-4c54-abce-49e6f4432c39_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued liabilities and other</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_529ec9c9-212a-4cba-acbb-da0bafd37cd0_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_e0525724-a087-49ad-b397-7735aa8a7fb6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_f75f24f1-e110-4b14-b689-a95a22f33132_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_a3625b27-9dbe-4ee7-8589-7a90df4dd13a_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_b86ba70d-ef23-4782-8782-06c31c9196bf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Measurements of Senior Notes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_e253665a-58a6-4dbf-9fbc-a134ea31a641_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_3ee89e2f-e0c5-4e76-b1cc-f807f3e53d26_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8305401a-6156-4e67-bc4e-c2ecee339b51_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3c8cede3-e17b-41a0-801b-0d8ecfbcb18c_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_904d4aa0-4051-4e6b-84f5-dee91a0120aa_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_48852b53-14a6-48aa-a754-b206c8303cf2_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_56a63269-a654-4c83-bf9c-d601c709183e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_InvestmentsMaturityPeriod_b22ad5f9-8f3f-4a89-8914-6822a7f50713_terseLabel_en-US" xlink:label="lab_moh_InvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity period (less than)</link:label>
    <link:label id="lab_moh_InvestmentsMaturityPeriod_label_en-US" xlink:label="lab_moh_InvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Maturity Period</link:label>
    <link:label id="lab_moh_InvestmentsMaturityPeriod_documentation_en-US" xlink:label="lab_moh_InvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Maturity Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_InvestmentsMaturityPeriod" xlink:href="moh-20220930.xsd#moh_InvestmentsMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_InvestmentsMaturityPeriod" xlink:to="lab_moh_InvestmentsMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_3b8dd21d-ac05-4141-b135-977fbe4c775a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_04cae134-7bd4-4382-9acd-0883f6fafb29_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_613bb797-6da5-43b4-bac7-e5bec6f4da21_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_c470a09a-9038-4f4a-a3bb-798ee7be0784_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_ddd7b9e7-7976-42e4-9593-548eb15363f4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_f9b33428-ff6c-498f-a2d3-9fa7f6ec8e18_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_IA_8de10fa1-e863-4635-91b8-565d3129e7bb_terseLabel_en-US" xlink:label="lab_stpr_IA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IOWA</link:label>
    <link:label id="lab_stpr_IA_label_en-US" xlink:label="lab_stpr_IA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IOWA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_IA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_IA" xlink:to="lab_stpr_IA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_0c126cf0-072f-41da-a759-b632ef9b0270_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Segment Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_PaymentsForMedicalCareCostsAbstract_ffd37d14-4a23-4dfa-89de-99ba87105932_terseLabel_en-US" xlink:label="lab_moh_PaymentsForMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for medical care costs related to:</link:label>
    <link:label id="lab_moh_PaymentsForMedicalCareCostsAbstract_label_en-US" xlink:label="lab_moh_PaymentsForMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Medical Care Costs [Abstract]</link:label>
    <link:label id="lab_moh_PaymentsForMedicalCareCostsAbstract_documentation_en-US" xlink:label="lab_moh_PaymentsForMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for medical care costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PaymentsForMedicalCareCostsAbstract" xlink:href="moh-20220930.xsd#moh_PaymentsForMedicalCareCostsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_PaymentsForMedicalCareCostsAbstract" xlink:to="lab_moh_PaymentsForMedicalCareCostsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0249361c-4adb-4470-aeb7-9eb0e7b104a7_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_d61edbbe-04c4-41a1-a6f9-1eeb4f139fc2_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_1facd4ce-04fd-4abc-af52-44fefe16400c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_bbc2ce91-b49e-4200-98b1-771d19e417de_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_bd7e1123-ff69-4292-9b98-5f00b4e3663b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_853de19a-8234-409b-904f-a61c24ef13e5_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_70ceada8-f488-4a32-a20b-833d5e26f805_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense [Line Items]</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestAndDividendIncomeOperating_385b00f0-d4b5-41a1-bf5d-6200668dcbd4_terseLabel_en-US" xlink:label="lab_us-gaap_InterestAndDividendIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenue</link:label>
    <link:label id="lab_us-gaap_InterestAndDividendIncomeOperating_label_en-US" xlink:label="lab_us-gaap_InterestAndDividendIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and Dividend Income, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDividendIncomeOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDividendIncomeOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndDividendIncomeOperating" xlink:to="lab_us-gaap_InterestAndDividendIncomeOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_CapitationClaimsPayable_5cf2b92f-e2b8-4fff-b29b-49008b4d3607_terseLabel_en-US" xlink:label="lab_moh_CapitationClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitation payable</link:label>
    <link:label id="lab_moh_CapitationClaimsPayable_label_en-US" xlink:label="lab_moh_CapitationClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitation Claims Payable</link:label>
    <link:label id="lab_moh_CapitationClaimsPayable_documentation_en-US" xlink:label="lab_moh_CapitationClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitation Claims Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CapitationClaimsPayable" xlink:href="moh-20220930.xsd#moh_CapitationClaimsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_CapitationClaimsPayable" xlink:to="lab_moh_CapitationClaimsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicaidOther_2beedc79-f9fc-44c4-ba95-1088781a5f20_terseLabel_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicaidOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicaidOther_label_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicaidOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Medicaid, Other</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicaidOther_documentation_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicaidOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Medicaid, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicaidOther" xlink:href="moh-20220930.xsd#moh_AmountsDueToGovernmentAgenciesMedicaidOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicaidOther" xlink:to="lab_moh_AmountsDueToGovernmentAgenciesMedicaidOther" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_SharesOutstandingExcludingRestrictedStockAwards_1e782f20-ae35-40db-a1df-6c8d83451795_terseLabel_en-US" xlink:label="lab_moh_SharesOutstandingExcludingRestrictedStockAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding at the beginning of the period ( in shares)</link:label>
    <link:label id="lab_moh_SharesOutstandingExcludingRestrictedStockAwards_label_en-US" xlink:label="lab_moh_SharesOutstandingExcludingRestrictedStockAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding, Excluding Restricted Stock Awards</link:label>
    <link:label id="lab_moh_SharesOutstandingExcludingRestrictedStockAwards_documentation_en-US" xlink:label="lab_moh_SharesOutstandingExcludingRestrictedStockAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding, Excluding Restricted Stock Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_SharesOutstandingExcludingRestrictedStockAwards" xlink:href="moh-20220930.xsd#moh_SharesOutstandingExcludingRestrictedStockAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_SharesOutstandingExcludingRestrictedStockAwards" xlink:to="lab_moh_SharesOutstandingExcludingRestrictedStockAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities_1f2edb05-10f6-452b-909a-1ee919b79738_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical claims and benefits payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Health Care Insurance Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NE_98d45b11-6e13-407f-a74b-a79747000d6f_terseLabel_en-US" xlink:label="lab_stpr_NE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEBRASKA</link:label>
    <link:label id="lab_stpr_NE_label_en-US" xlink:label="lab_stpr_NE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEBRASKA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NE" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NE" xlink:to="lab_stpr_NE" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_cc695330-d9f7-4118-b40a-f289856db03f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_c89bd6db-1f61-4ba1-86f1-28b493b9f420_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, and intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_34a0547e-02ae-4baf-8e7f-67fec9034053_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In&#160;a&#160;Continuous&#160;Loss Position for&#160;Less&#160;than&#160;12&#160;Months, Total Number of Positions</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_dac998c6-cfec-43df-82d3-db36886e0dbc_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_MS_e532ad17-2eb5-4e6f-b209-be0125433c73_terseLabel_en-US" xlink:label="lab_stpr_MS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MISSISSIPPI</link:label>
    <link:label id="lab_stpr_MS_label_en-US" xlink:label="lab_stpr_MS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MISSISSIPPI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MS" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MS"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MS" xlink:to="lab_stpr_MS" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_edda17b5-ac5d-405c-b8ae-23e1db54e826_terseLabel_en-US" xlink:label="lab_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of long-term debt</link:label>
    <link:label id="lab_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_label_en-US" xlink:label="lab_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Noncurrent, Net Of Unamortized Debt Discount</link:label>
    <link:label id="lab_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_documentation_en-US" xlink:label="lab_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Noncurrent, Net Of Unamortized Debt Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" xlink:href="moh-20220930.xsd#moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" xlink:to="lab_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing_2fde29fc-00fd-445d-8b2e-9708af1ecc41_terseLabel_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk adjustment and Part D risk sharing</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing_label_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due to Government Agencies, Risk Adjustment and Part D risk sharing</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing_documentation_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due to Government Agencies, Risk Adjustment and Part D risk sharing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" xlink:href="moh-20220930.xsd#moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" xlink:to="lab_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_4478dbcb-7813-420f-80d9-e2c6fd33d61a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_bda3a1fb-505c-42fc-9d38-41fb46d2e644_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_75130143-0283-49bf-999e-a56e593a5a6c_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_23b032e3-c412-4403-92c7-085508688afc_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3bd281c8-8d5c-42b8-a3a6-3f14c8c9045d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_705a7570-0d25-43cd-a948-6defbefa5a57_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_bd64cc82-7342-4d2e-a227-963357468235_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_3e38244e-101f-4fcf-aac3-a1c794956c8c_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_08ca5b95-5d9f-458f-96d0-002108fe9dd0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_8aba5aff-5f82-44d6-8404-cccec4723e03_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_39633f49-e2a1-4d2e-a4ab-7ce9f71becc3_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0c4c2723-2c90-4642-a206-4b5a7dc88b02_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_400416ca-2d3e-4f73-bd28-2c5c125ebbd7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold_2cbeb6df-3e4b-4802-8d52-2170a8e8120e_terseLabel_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum MLR and profit sharing</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold_label_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Medicare, Medical Loss Ratio And Profit Sharing, Threshold</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold_documentation_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Medicare, Medical Loss Ratio And Profit Sharing, Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" xlink:href="moh-20220930.xsd#moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" xlink:to="lab_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider_018034e5-05aa-4690-b574-aa8178db8762_terseLabel_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in non-risk and other provider payables</link:label>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider_label_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Claims And Benefits Payable, Adjustments, Change In Provider</link:label>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider_documentation_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Claims and Benefits Payable, Adjustments, Change in Provider</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" xlink:href="moh-20220930.xsd#moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" xlink:to="lab_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemDomain_cea60921-17c5-4d4e-b1da-50dcf5212f7a_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Domain]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemDomain_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain" xlink:to="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_0f7f3051-f015-4772-92fb-db8e60b71b80_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Assets Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_fd79849d-5439-4823-a7fb-f01dbb0d6c9b_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PremiumsEarnedNet_91922d38-aeda-4069-94c8-55ac77b981ab_terseLabel_en-US" xlink:label="lab_us-gaap_PremiumsEarnedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium revenue</link:label>
    <link:label id="lab_us-gaap_PremiumsEarnedNet_label_en-US" xlink:label="lab_us-gaap_PremiumsEarnedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Earned, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PremiumsEarnedNet" xlink:to="lab_us-gaap_PremiumsEarnedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_03add169-a630-4473-a620-22fa1d1a6d1f_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_68d7bd3a-3139-4185-9068-58024a6e2b78_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount_737959f9-b585-4cb0-bfc1-ea1b00b9450e_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost, due one year through five years</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, after Year One through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency_c82c0417-e3f7-4da7-8972-cebdd9a6ad21_terseLabel_en-US" xlink:label="lab_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts due government agencies</link:label>
    <link:label id="lab_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency_label_en-US" xlink:label="lab_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Medical Premium Liability Due To Agency</link:label>
    <link:label id="lab_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency_documentation_en-US" xlink:label="lab_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Medical Premium Liability Due to Agency</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" xlink:href="moh-20220930.xsd#moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" xlink:to="lab_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AffinityHealthPlanIncMember_2323783e-06c2-4882-93ea-7bde45114335_terseLabel_en-US" xlink:label="lab_moh_AffinityHealthPlanIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affinity Health Plan, Inc</link:label>
    <link:label id="lab_moh_AffinityHealthPlanIncMember_label_en-US" xlink:label="lab_moh_AffinityHealthPlanIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affinity Health Plan, Inc [Member]</link:label>
    <link:label id="lab_moh_AffinityHealthPlanIncMember_documentation_en-US" xlink:label="lab_moh_AffinityHealthPlanIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affinity Health Plan, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffinityHealthPlanIncMember" xlink:href="moh-20220930.xsd#moh_AffinityHealthPlanIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AffinityHealthPlanIncMember" xlink:to="lab_moh_AffinityHealthPlanIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_742ce10c-40d5-4698-9f79-c26812f94c32_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_643ef0ca-7ba1-4e2f-972d-3152591f7c3b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: other operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_bc36c0d9-b060-48c1-b8d0-1933c1cb5d90_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_f4dec636-e960-4f18-b4b1-62e167d2d3c8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_33cc6722-abc3-4a94-beb0-c12b8bd94bbb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In&#160;a&#160;Continuous&#160;Loss Position for&#160;Less&#160;than&#160;12&#160;Months, Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_8b7d8ec4-c104-4326-bb34-43fd96cf1ace_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_PharmacyClaimsPayable_131aea03-9771-482a-b306-7d5f93046b6d_terseLabel_en-US" xlink:label="lab_moh_PharmacyClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy payable</link:label>
    <link:label id="lab_moh_PharmacyClaimsPayable_label_en-US" xlink:label="lab_moh_PharmacyClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy Claims Payable</link:label>
    <link:label id="lab_moh_PharmacyClaimsPayable_documentation_en-US" xlink:label="lab_moh_PharmacyClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy Claims Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PharmacyClaimsPayable" xlink:href="moh-20220930.xsd#moh_PharmacyClaimsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_PharmacyClaimsPayable" xlink:to="lab_moh_PharmacyClaimsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_600990fe-6a4b-41c8-aebf-c37688276990_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock_8862f15a-43e2-4589-9dc3-c839c9c82df2_terseLabel_en-US" xlink:label="lab_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of The Change in Medical Claims and Benefits Payable</link:label>
    <link:label id="lab_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock_label_en-US" xlink:label="lab_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components Of Change In Medical Claims And Benefits Payable [Table Text Block]</link:label>
    <link:label id="lab_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock_documentation_en-US" xlink:label="lab_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components Of Change In Medical Claims And Benefits Payable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" xlink:href="moh-20220930.xsd#moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" xlink:to="lab_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_54f73d06-2e13-48d3-8db6-31cb42e50be9_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_fbeff5cf-f174-4e74-bb5a-2b6a5b958a5f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In&#160;a&#160;Continuous&#160;Loss Position for&#160;12&#160;Months or More, Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2d32a9d1-328d-4d67-823b-b081383e4b06_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_e2d7a6bf-7afe-4277-8bc4-e865a1ed6dd7_verboseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e88cd834-c575-45f8-9ce5-efa72b3fe8b4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_16a2acf4-bddc-41fd-8d76-445e5c35c339_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current year</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_HealthCareOrganizationPremiumTaxRevenue_02511a7e-4a10-454a-a3bd-06370b014d4e_terseLabel_en-US" xlink:label="lab_moh_HealthCareOrganizationPremiumTaxRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium tax revenue</link:label>
    <link:label id="lab_moh_HealthCareOrganizationPremiumTaxRevenue_label_en-US" xlink:label="lab_moh_HealthCareOrganizationPremiumTaxRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Premium Tax Revenue</link:label>
    <link:label id="lab_moh_HealthCareOrganizationPremiumTaxRevenue_documentation_en-US" xlink:label="lab_moh_HealthCareOrganizationPremiumTaxRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Premium Tax Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareOrganizationPremiumTaxRevenue" xlink:href="moh-20220930.xsd#moh_HealthCareOrganizationPremiumTaxRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_HealthCareOrganizationPremiumTaxRevenue" xlink:to="lab_moh_HealthCareOrganizationPremiumTaxRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_2cc99c09-d78d-488b-8fc5-b31ecbe3390e_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Contractual Maturities of Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_PremiumTaxExpenses_e3487d5a-c7cb-4b84-a183-1befac97b89b_terseLabel_en-US" xlink:label="lab_moh_PremiumTaxExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium tax expenses</link:label>
    <link:label id="lab_moh_PremiumTaxExpenses_label_en-US" xlink:label="lab_moh_PremiumTaxExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium Tax Expenses</link:label>
    <link:label id="lab_moh_PremiumTaxExpenses_documentation_en-US" xlink:label="lab_moh_PremiumTaxExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">An assessment levied by a state government on the net premium income collected.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PremiumTaxExpenses" xlink:href="moh-20220930.xsd#moh_PremiumTaxExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_PremiumTaxExpenses" xlink:to="lab_moh_PremiumTaxExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_0be6d7af-e115-4abe-8aea-af3d57ae3dc7_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5a1f40c6-c5da-4c84-b132-d7670308012c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator for basic net income per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_WeightedAverageNumberofSharesShareBasedCompensation_59238a57-ff4a-4931-a329-be9fb3f384e9_terseLabel_en-US" xlink:label="lab_moh_WeightedAverageNumberofSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation (in shares)</link:label>
    <link:label id="lab_moh_WeightedAverageNumberofSharesShareBasedCompensation_label_en-US" xlink:label="lab_moh_WeightedAverageNumberofSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares, Share Based Compensation</link:label>
    <link:label id="lab_moh_WeightedAverageNumberofSharesShareBasedCompensation_documentation_en-US" xlink:label="lab_moh_WeightedAverageNumberofSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares, Share Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_WeightedAverageNumberofSharesShareBasedCompensation" xlink:href="moh-20220930.xsd#moh_WeightedAverageNumberofSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_WeightedAverageNumberofSharesShareBasedCompensation" xlink:to="lab_moh_WeightedAverageNumberofSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_OtherSecuritiesMember_21761571-8daa-4e67-a396-03c87268f97a_terseLabel_en-US" xlink:label="lab_moh_OtherSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_moh_OtherSecuritiesMember_label_en-US" xlink:label="lab_moh_OtherSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Securities [Member]</link:label>
    <link:label id="lab_moh_OtherSecuritiesMember_documentation_en-US" xlink:label="lab_moh_OtherSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherSecuritiesMember" xlink:href="moh-20220930.xsd#moh_OtherSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_OtherSecuritiesMember" xlink:to="lab_moh_OtherSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_17c09af2-ca36-48dd-bea1-10425503eaaa_verboseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior period claims, favorable development</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_078a2149-7252-4b0b-a51e-92b9cbab5aa2_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior years</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryNotesSecuritiesMember_094d9db7-f84b-4fe1-8a2b-57467e4a2e57_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryNotesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury notes</link:label>
    <link:label id="lab_us-gaap_USTreasuryNotesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryNotesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Notes Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryNotesSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryNotesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_6cac2739-0401-44fd-b3d9-e15873570b2c_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract_25c1d9a2-561b-4a74-9a02-529d3ffb3944_terseLabel_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare program:</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract_label_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies Medicare Program [Abstract]</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract_documentation_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies Medicare Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract" xlink:href="moh-20220930.xsd#moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract" xlink:to="lab_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_ea4c36a7-6259-41d0-805e-f1a2b1d00452_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d9b42aa3-6f8f-474e-971b-26ea07dde7f8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_7c73bddc-faa7-46df-972c-306c42920974_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_12de7e0a-0351-4787-b281-a91226ccc5d8_terseLabel_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating</link:label>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_label_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reconciling Items [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaterialReconcilingItemsMember" xlink:to="lab_us-gaap_MaterialReconcilingItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_99e2289c-d625-44b8-97bf-c75eb6bda3cc_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_7d37ffd0-82aa-4b8c-ab4a-9367386675b1_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining half of contingent consideration paid</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_4493bdd8-1401-4857-adab-b2565a46a13c_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_9558eb81-22fa-4277-aa8f-9a64c28099cd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_c603e948-7c3d-4670-bead-1c370d59ce65_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_19edfd5b-e055-4417-89ab-80624c6fea65_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_f09cb7d7-c40c-4638-8028-1d993d6d170a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_e9f9a8c8-d7e6-4227-84b9-64a866848775_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_d32cf7cb-3723-4d5c-8695-c40e05d95aca_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_ca380613-393d-4334-8da6-5c4e7e44ed96_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_f3322165-7a2a-4bfc-9a5c-75d26f214df6_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current year</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_c86e172d-c727-49f4-809c-440a09c525fc_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_b127a300-d10b-49ea-8fc9-d1210ff376ce_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_fe21e632-7268-4168-b736-4f42230fec35_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7bcf4203-805f-4360-8d1a-d4cb8b408c1d_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_cee7de22-6350-4ad2-ac37-14dc786f1a3a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash paid in business combinations</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_b3c2577c-25c8-4370-bace-f5622f51d1a0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_56759348-bfef-474f-869c-94d4d5691473_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_af51b163-b1c8-478a-a5f0-3d93263813b8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross realized investment gains</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_f56d83a7-92cb-4f22-86aa-beaf748b1e9c_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_c405a4fe-4668-4b43-bd04-03168b9df3fb_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share - Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_3be80074-d110-4f35-982c-90841ae40cf7_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_7e56a8ad-8922-4dab-85f6-35bc2ac605c1_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_OtherMedicareProgram_c2ac07a1-8aeb-446f-b0a4-5ecca45f2af4_terseLabel_en-US" xlink:label="lab_moh_OtherMedicareProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_moh_OtherMedicareProgram_label_en-US" xlink:label="lab_moh_OtherMedicareProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Medicare Program</link:label>
    <link:label id="lab_moh_OtherMedicareProgram_documentation_en-US" xlink:label="lab_moh_OtherMedicareProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Medicare Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherMedicareProgram" xlink:href="moh-20220930.xsd#moh_OtherMedicareProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_OtherMedicareProgram" xlink:to="lab_moh_OtherMedicareProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_ec654918-2881-472b-98c6-1656f1764759_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable_a95b354d-c066-4374-a305-d827e4a56c26_terseLabel_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk adjustment payable</link:label>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable_label_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affordable Care Act, Premium Stabilization Program, Risk Adjustment, (Payable)</link:label>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable_documentation_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affordable Care Act, Premium Stabilization Program, Risk Adjustment, (Payable)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" xlink:href="moh-20220930.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" xlink:to="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_a9ad521f-5d79-4bbe-90e9-6ac26bbde25e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Receivables</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_OtherProgramMember_783d8752-be96-4dfa-b23c-6cfb49d2422d_terseLabel_en-US" xlink:label="lab_moh_OtherProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_moh_OtherProgramMember_label_en-US" xlink:label="lab_moh_OtherProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Program [Member]</link:label>
    <link:label id="lab_moh_OtherProgramMember_documentation_en-US" xlink:label="lab_moh_OtherProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherProgramMember" xlink:href="moh-20220930.xsd#moh_OtherProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_OtherProgramMember" xlink:to="lab_moh_OtherProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_a5d7bbed-463a-4a21-b86e-8a96f5c27e9f_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_a95be767-29de-4cf6-beb8-e60bb6396007_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expenses, net:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities_723c0c03-a299-4aa5-bd6f-990994e22bf3_terseLabel_en-US" xlink:label="lab_moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration paid to seller included in financing and operating activities</link:label>
    <link:label id="lab_moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities_label_en-US" xlink:label="lab_moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment For Contingent Consideration Liability, Financing And Operating Activities</link:label>
    <link:label id="lab_moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities_documentation_en-US" xlink:label="lab_moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment For Contingent Consideration Liability, Financing And Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities" xlink:href="moh-20220930.xsd#moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities" xlink:to="lab_moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_a3695301-53c1-4866-8f48-486fc31479ba_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_c35f9553-5697-4229-86e5-a1bf12c27220_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_62d4165b-ef36-4640-8a34-7b73a01ee338_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_COVID19Member_4ec8cbfd-1434-4465-aeec-ab5e6c238689_terseLabel_en-US" xlink:label="lab_moh_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:label id="lab_moh_COVID19Member_label_en-US" xlink:label="lab_moh_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 [Member]</link:label>
    <link:label id="lab_moh_COVID19Member_documentation_en-US" xlink:label="lab_moh_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_COVID19Member" xlink:href="moh-20220930.xsd#moh_COVID19Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_COVID19Member" xlink:to="lab_moh_COVID19Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_ba6a180a-c122-4f4e-af09-2f337f0eec83_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_0f4496dc-80f5-4d7f-842e-6e44684a8374_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total medical care costs</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_fc57adff-769e-4fc0-b3b3-821bd109bb91_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_ba8b0e9e-463b-42c6-8458-42d2ba5f9a14_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_f42d36b6-d24d-4d1e-afa7-9348aa5cc9b8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_e4efb1e0-1ce9-49a6-9312-47a13c9fd1bf_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms_7c4cfc74-4ccc-4360-9b2a-0ead37aaeb51_terseLabel_en-US" xlink:label="lab_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of members eligible for the health care programs, approximately</link:label>
    <link:label id="lab_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms_label_en-US" xlink:label="lab_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Number Of Members Eligible For The Health Care Programs</link:label>
    <link:label id="lab_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms_documentation_en-US" xlink:label="lab_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of members eligible for the health care programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" xlink:href="moh-20220930.xsd#moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" xlink:to="lab_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_3b01b2d5-5e37-4e70-a29e-ceb033a5482b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MarketplaceMember_f77f62f3-4615-4a66-bee6-1bd742bf7db1_terseLabel_en-US" xlink:label="lab_moh_MarketplaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketplace</link:label>
    <link:label id="lab_moh_MarketplaceMember_label_en-US" xlink:label="lab_moh_MarketplaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketplace [Member]</link:label>
    <link:label id="lab_moh_MarketplaceMember_documentation_en-US" xlink:label="lab_moh_MarketplaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketplace</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MarketplaceMember" xlink:href="moh-20220930.xsd#moh_MarketplaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MarketplaceMember" xlink:to="lab_moh_MarketplaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_094cacef-514c-4542-853c-74b282699232_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPremiumsReceivable_9ffc04cd-dcc0-45ec-9247-01497b559767_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPremiumsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in premiums</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPremiumsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPremiumsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Premiums Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPremiumsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPremiumsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPremiumsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInPremiumsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MunicipalSecuritiesMember_dbf3642d-cd24-4a32-b303-0429cedf2659_terseLabel_en-US" xlink:label="lab_moh_MunicipalSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal securities</link:label>
    <link:label id="lab_moh_MunicipalSecuritiesMember_label_en-US" xlink:label="lab_moh_MunicipalSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal Securities [Member]</link:label>
    <link:label id="lab_moh_MunicipalSecuritiesMember_documentation_en-US" xlink:label="lab_moh_MunicipalSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MunicipalSecuritiesMember" xlink:href="moh-20220930.xsd#moh_MunicipalSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MunicipalSecuritiesMember" xlink:to="lab_moh_MunicipalSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5a121bb4-7be9-45b7-a5ab-66f95414a07c_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase in cash, cash equivalents, and restricted cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_d996d012-3e74-4395-9d6b-731b3dba0953_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_PharmacyRebateReceivablesMember_d069fa3b-f13c-42d6-988e-43538888b40d_terseLabel_en-US" xlink:label="lab_moh_PharmacyRebateReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy rebate receivables</link:label>
    <link:label id="lab_moh_PharmacyRebateReceivablesMember_label_en-US" xlink:label="lab_moh_PharmacyRebateReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy Rebate Receivables [Member]</link:label>
    <link:label id="lab_moh_PharmacyRebateReceivablesMember_documentation_en-US" xlink:label="lab_moh_PharmacyRebateReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy Rebate Receivables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PharmacyRebateReceivablesMember" xlink:href="moh-20220930.xsd#moh_PharmacyRebateReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_PharmacyRebateReceivablesMember" xlink:to="lab_moh_PharmacyRebateReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReservesReportedToOtherAgenciesTextBlock_e5491616-19d6-4ff1-9c63-4e8f73349e48_terseLabel_en-US" xlink:label="lab_us-gaap_ReservesReportedToOtherAgenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amounts Due to Government Agencies</link:label>
    <link:label id="lab_us-gaap_ReservesReportedToOtherAgenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_ReservesReportedToOtherAgenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves Reported to Other Agencies [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReservesReportedToOtherAgenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReservesReportedToOtherAgenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReservesReportedToOtherAgenciesTextBlock" xlink:to="lab_us-gaap_ReservesReportedToOtherAgenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7ff2a5d8-dc0c-4b65-880e-33188122ba6c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_1405c27f-9422-4dd2-bb1b-a1fc0e9fe68f_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_3fb2a7ec-4925-4040-8927-918701faca9c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_0fbad6eb-1d66-4f56-aa74-a829e90f6230_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_fa2ee555-5116-42c7-9c2f-120c68c703c3_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_b8c3c133-3195-4533-9a62-2249adddefaf_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_3bc5fe10-772d-40bf-b12c-bc357a07430f_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_00b62ce3-4f91-4760-9629-7991ac09f35e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Noncurrent, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_9c1cdcff-aba3-4f35-9b7e-46dcb06fae18_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_1bf86b0d-6208-4e8e-93b0-9bfcec4ebd13_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4e892afb-4e06-4e96-b5b3-649949a36990_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesMember_4120922a-45bb-4668-b40e-7ec6bc1a76b1_terseLabel_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage-backed securities</link:label>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateralized Mortgage-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgageBackedSecuritiesMember" xlink:to="lab_us-gaap_MortgageBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_59c8d62b-ae9b-4918-abf5-6d26aa83a907_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_340d8ac5-fa6d-4648-a3fb-211a62a86dd9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_27cfb23c-73db-43ea-bdd8-37d4ba5ce767_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b1b4e6d5-36b3-42d9-8c87-eb7baef4a57c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, equipment and capitalized software</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment_8a2af5d4-73ef-43d7-b3b4-cd3b0d736550_terseLabel_en-US" xlink:label="lab_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk adjustment</link:label>
    <link:label id="lab_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment_label_en-US" xlink:label="lab_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due to Government Agencies, Risk Adjustment</link:label>
    <link:label id="lab_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment_documentation_en-US" xlink:label="lab_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due to Government Agencies, Risk Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment" xlink:href="moh-20220930.xsd#moh_AmountsDuetoGovernmentAgenciesRiskAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment" xlink:to="lab_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments_03f58902-ec66-42f1-9baa-86eaf1e46849_terseLabel_en-US" xlink:label="lab_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired balances, net of post-acquisition adjustments</link:label>
    <link:label id="lab_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments_label_en-US" xlink:label="lab_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions, Net Of Post-Closing Adjustments</link:label>
    <link:label id="lab_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments_documentation_en-US" xlink:label="lab_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions, Net Of Post-Closing Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" xlink:href="moh-20220930.xsd#moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" xlink:to="lab_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_d733fa99-b416-45bc-9044-ca5dc257d4f3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Denominators for The Computation of Basic and Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_CommonStockWithheldToSettleEmployeeTaxObligations_8f0fa2f4-cfe3-41b3-994f-3f15140351c9_negatedLabel_en-US" xlink:label="lab_moh_CommonStockWithheldToSettleEmployeeTaxObligations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock withheld to settle employee tax obligations</link:label>
    <link:label id="lab_moh_CommonStockWithheldToSettleEmployeeTaxObligations_label_en-US" xlink:label="lab_moh_CommonStockWithheldToSettleEmployeeTaxObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Withheld to Settle Employee Tax Obligations</link:label>
    <link:label id="lab_moh_CommonStockWithheldToSettleEmployeeTaxObligations_documentation_en-US" xlink:label="lab_moh_CommonStockWithheldToSettleEmployeeTaxObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Withheld to Settle Employee Tax Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CommonStockWithheldToSettleEmployeeTaxObligations" xlink:href="moh-20220930.xsd#moh_CommonStockWithheldToSettleEmployeeTaxObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_CommonStockWithheldToSettleEmployeeTaxObligations" xlink:to="lab_moh_CommonStockWithheldToSettleEmployeeTaxObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_08ec0f62-8d82-4304-8ab5-aa30f0112e24_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross realized investment losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>moh-20220930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:723f88a6-3111-46ae-86a6-19eac5cb9305,g:31c414f1-6fb4-4584-ba8e-291448fd334e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CoverPage" xlink:type="simple" xlink:href="moh-20220930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_b7aeeac6-467e-4303-a6d1-263372c4d53e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_41e33534-151b-41e7-bfd2-27e7e83615f4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b7aeeac6-467e-4303-a6d1-263372c4d53e" xlink:to="loc_dei_DocumentType_41e33534-151b-41e7-bfd2-27e7e83615f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_0352e8a4-8d99-4ba1-98ed-1b9ec7a9fe38" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b7aeeac6-467e-4303-a6d1-263372c4d53e" xlink:to="loc_dei_DocumentQuarterlyReport_0352e8a4-8d99-4ba1-98ed-1b9ec7a9fe38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_d12e79d7-6523-44b6-8fa0-e7e4c71de55e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b7aeeac6-467e-4303-a6d1-263372c4d53e" xlink:to="loc_dei_DocumentPeriodEndDate_d12e79d7-6523-44b6-8fa0-e7e4c71de55e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_757ef727-6887-41ac-ae5a-432e027c7136" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b7aeeac6-467e-4303-a6d1-263372c4d53e" xlink:to="loc_dei_DocumentTransitionReport_757ef727-6887-41ac-ae5a-432e027c7136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_7a0ece01-c42d-4357-b1df-e6147d5b23f6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b7aeeac6-467e-4303-a6d1-263372c4d53e" xlink:to="loc_dei_EntityFileNumber_7a0ece01-c42d-4357-b1df-e6147d5b23f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_93fb0a5a-48ac-47c3-b6af-3e7420ceb8b7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b7aeeac6-467e-4303-a6d1-263372c4d53e" xlink:to="loc_dei_EntityRegistrantName_93fb0a5a-48ac-47c3-b6af-3e7420ceb8b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_de25e0e4-1a37-4af3-99db-1b5ec17a225f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b7aeeac6-467e-4303-a6d1-263372c4d53e" xlink:to="loc_dei_EntityIncorporationStateCountryCode_de25e0e4-1a37-4af3-99db-1b5ec17a225f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_9282e76a-3c26-4a88-9f6f-a9d88d8b096f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b7aeeac6-467e-4303-a6d1-263372c4d53e" xlink:to="loc_dei_EntityTaxIdentificationNumber_9282e76a-3c26-4a88-9f6f-a9d88d8b096f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_34753e5c-5656-40b9-87a8-94069229425f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b7aeeac6-467e-4303-a6d1-263372c4d53e" xlink:to="loc_dei_EntityAddressAddressLine1_34753e5c-5656-40b9-87a8-94069229425f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_4fe49c51-6c23-4f99-a321-ab7d310a0ffc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b7aeeac6-467e-4303-a6d1-263372c4d53e" xlink:to="loc_dei_EntityAddressAddressLine2_4fe49c51-6c23-4f99-a321-ab7d310a0ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_1ebfafb0-5435-411e-80a7-a84ef8ed4712" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b7aeeac6-467e-4303-a6d1-263372c4d53e" xlink:to="loc_dei_EntityAddressCityOrTown_1ebfafb0-5435-411e-80a7-a84ef8ed4712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_1604dbc8-50b8-4364-bf34-fe7ecc5edb30" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b7aeeac6-467e-4303-a6d1-263372c4d53e" xlink:to="loc_dei_EntityAddressStateOrProvince_1604dbc8-50b8-4364-bf34-fe7ecc5edb30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_10dafd33-aff7-4393-8c92-bef074d864e9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b7aeeac6-467e-4303-a6d1-263372c4d53e" xlink:to="loc_dei_EntityAddressPostalZipCode_10dafd33-aff7-4393-8c92-bef074d864e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_e7545cdf-bbfb-4c8a-b6e9-368cc8e564b3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b7aeeac6-467e-4303-a6d1-263372c4d53e" xlink:to="loc_dei_CityAreaCode_e7545cdf-bbfb-4c8a-b6e9-368cc8e564b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_b7e5eb31-eb65-43f4-a6e0-98f7b69478e3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b7aeeac6-467e-4303-a6d1-263372c4d53e" xlink:to="loc_dei_LocalPhoneNumber_b7e5eb31-eb65-43f4-a6e0-98f7b69478e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_27e1778e-3ee5-410a-9ca3-4215fa78be33" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b7aeeac6-467e-4303-a6d1-263372c4d53e" xlink:to="loc_dei_Security12bTitle_27e1778e-3ee5-410a-9ca3-4215fa78be33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_5e6756c7-a2d5-4792-a1c0-bc121ef59503" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b7aeeac6-467e-4303-a6d1-263372c4d53e" xlink:to="loc_dei_TradingSymbol_5e6756c7-a2d5-4792-a1c0-bc121ef59503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_8e7ee1a9-591a-428c-a7a2-fc655f7b2f71" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b7aeeac6-467e-4303-a6d1-263372c4d53e" xlink:to="loc_dei_SecurityExchangeName_8e7ee1a9-591a-428c-a7a2-fc655f7b2f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_b06e16bf-84ef-4bc4-87c5-02d26a32ad8c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b7aeeac6-467e-4303-a6d1-263372c4d53e" xlink:to="loc_dei_EntityCurrentReportingStatus_b06e16bf-84ef-4bc4-87c5-02d26a32ad8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_fd188801-42e4-4a50-97cc-6cf06f82f462" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b7aeeac6-467e-4303-a6d1-263372c4d53e" xlink:to="loc_dei_EntityInteractiveDataCurrent_fd188801-42e4-4a50-97cc-6cf06f82f462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_ce7c495a-adc0-4032-85e3-d1eeae4a5f5e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b7aeeac6-467e-4303-a6d1-263372c4d53e" xlink:to="loc_dei_EntityFilerCategory_ce7c495a-adc0-4032-85e3-d1eeae4a5f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_e97aa5f7-06cf-480e-895d-0d3e46314a23" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b7aeeac6-467e-4303-a6d1-263372c4d53e" xlink:to="loc_dei_EntitySmallBusiness_e97aa5f7-06cf-480e-895d-0d3e46314a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_9210a71a-3951-4f05-8c42-1a28367cf420" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b7aeeac6-467e-4303-a6d1-263372c4d53e" xlink:to="loc_dei_EntityEmergingGrowthCompany_9210a71a-3951-4f05-8c42-1a28367cf420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_e71092fa-1e12-413a-ad38-ac67e7f849bb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b7aeeac6-467e-4303-a6d1-263372c4d53e" xlink:to="loc_dei_EntityShellCompany_e71092fa-1e12-413a-ad38-ac67e7f849bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_281f022e-26da-4ad2-857d-21d9a86866d0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b7aeeac6-467e-4303-a6d1-263372c4d53e" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_281f022e-26da-4ad2-857d-21d9a86866d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_417a5387-c067-486b-8365-64534e2c0e90" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b7aeeac6-467e-4303-a6d1-263372c4d53e" xlink:to="loc_dei_EntityCentralIndexKey_417a5387-c067-486b-8365-64534e2c0e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_725027e8-4021-4d28-a974-e53032d370da" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b7aeeac6-467e-4303-a6d1-263372c4d53e" xlink:to="loc_dei_CurrentFiscalYearEndDate_725027e8-4021-4d28-a974-e53032d370da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_fa3124d5-ce8a-44d0-9bca-5393c7cc79e1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b7aeeac6-467e-4303-a6d1-263372c4d53e" xlink:to="loc_dei_DocumentFiscalYearFocus_fa3124d5-ce8a-44d0-9bca-5393c7cc79e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_a30a1ec5-955e-49aa-b037-a3f4542603f7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b7aeeac6-467e-4303-a6d1-263372c4d53e" xlink:to="loc_dei_DocumentFiscalPeriodFocus_a30a1ec5-955e-49aa-b037-a3f4542603f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_22b0a396-0207-4c31-86c8-2786a93716a2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b7aeeac6-467e-4303-a6d1-263372c4d53e" xlink:to="loc_dei_AmendmentFlag_22b0a396-0207-4c31-86c8-2786a93716a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="moh-20220930.xsd#CONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_f1d02a11-cfdc-47ad-9b0f-4c19f61db255" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_e244bbd6-d839-4720-aabd-4979b165a1f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f1d02a11-cfdc-47ad-9b0f-4c19f61db255" xlink:to="loc_us-gaap_RevenuesAbstract_e244bbd6-d839-4720-aabd-4979b165a1f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_46165b36-0fa0-4a18-8e3a-949fff0cb8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_e244bbd6-d839-4720-aabd-4979b165a1f3" xlink:to="loc_us-gaap_PremiumsEarnedNet_46165b36-0fa0-4a18-8e3a-949fff0cb8c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareOrganizationPremiumTaxRevenue_b57934a5-cdba-40ff-a68b-575fcdcb4c0e" xlink:href="moh-20220930.xsd#moh_HealthCareOrganizationPremiumTaxRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_e244bbd6-d839-4720-aabd-4979b165a1f3" xlink:to="loc_moh_HealthCareOrganizationPremiumTaxRevenue_b57934a5-cdba-40ff-a68b-575fcdcb4c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_4fe67e1c-0f3c-41b6-b2a9-a9269adeed38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_e244bbd6-d839-4720-aabd-4979b165a1f3" xlink:to="loc_us-gaap_NetInvestmentIncome_4fe67e1c-0f3c-41b6-b2a9-a9269adeed38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDividendIncomeOperating_8cdf1126-c7c7-41c3-aa1c-6f9457070215" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDividendIncomeOperating"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_e244bbd6-d839-4720-aabd-4979b165a1f3" xlink:to="loc_us-gaap_InterestAndDividendIncomeOperating_8cdf1126-c7c7-41c3-aa1c-6f9457070215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f0022470-d3fb-4574-bb3e-cf6f334fcfe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_e244bbd6-d839-4720-aabd-4979b165a1f3" xlink:to="loc_us-gaap_Revenues_f0022470-d3fb-4574-bb3e-cf6f334fcfe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_4cfc9a66-daa4-4fb5-b1bc-71e386f39e19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f1d02a11-cfdc-47ad-9b0f-4c19f61db255" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_4cfc9a66-daa4-4fb5-b1bc-71e386f39e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_ac79549e-d055-4229-bab8-b797725b9efa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4cfc9a66-daa4-4fb5-b1bc-71e386f39e19" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_ac79549e-d055-4229-bab8-b797725b9efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_19d56d99-a68d-4135-ad90-abb51de9f9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4cfc9a66-daa4-4fb5-b1bc-71e386f39e19" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_19d56d99-a68d-4135-ad90-abb51de9f9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PremiumTaxExpenses_49203f3c-f032-4f0b-ac5d-f14b940c9d30" xlink:href="moh-20220930.xsd#moh_PremiumTaxExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4cfc9a66-daa4-4fb5-b1bc-71e386f39e19" xlink:to="loc_moh_PremiumTaxExpenses_49203f3c-f032-4f0b-ac5d-f14b940c9d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_e9ce0122-ff0d-4fa3-982b-08dc4765a899" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4cfc9a66-daa4-4fb5-b1bc-71e386f39e19" xlink:to="loc_us-gaap_DepreciationAndAmortization_e9ce0122-ff0d-4fa3-982b-08dc4765a899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_5bdcc2cb-0f34-4271-b68e-f5f0dcfe0caf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4cfc9a66-daa4-4fb5-b1bc-71e386f39e19" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_5bdcc2cb-0f34-4271-b68e-f5f0dcfe0caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_f558ff4a-5129-481e-a835-e8cd5428c3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4cfc9a66-daa4-4fb5-b1bc-71e386f39e19" xlink:to="loc_us-gaap_CostsAndExpenses_f558ff4a-5129-481e-a835-e8cd5428c3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a8e460b2-18b0-4603-9b57-161dab8a8ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4cfc9a66-daa4-4fb5-b1bc-71e386f39e19" xlink:to="loc_us-gaap_OperatingIncomeLoss_a8e460b2-18b0-4603-9b57-161dab8a8ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_99d8c488-6d1c-4d9f-bf8a-a866f0fecf38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f1d02a11-cfdc-47ad-9b0f-4c19f61db255" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_99d8c488-6d1c-4d9f-bf8a-a866f0fecf38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_5b8f3f10-0b4b-482e-b360-fb7146283097" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_99d8c488-6d1c-4d9f-bf8a-a866f0fecf38" xlink:to="loc_us-gaap_InterestExpense_5b8f3f10-0b4b-482e-b360-fb7146283097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_30236622-0e29-4a2e-a33f-53d30a38038d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_99d8c488-6d1c-4d9f-bf8a-a866f0fecf38" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_30236622-0e29-4a2e-a33f-53d30a38038d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6d6c7030-8e2c-40cc-8e93-8994bdb18a38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f1d02a11-cfdc-47ad-9b0f-4c19f61db255" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6d6c7030-8e2c-40cc-8e93-8994bdb18a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_eda7ad09-8915-4f85-bcd9-78bbccb8427d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f1d02a11-cfdc-47ad-9b0f-4c19f61db255" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_eda7ad09-8915-4f85-bcd9-78bbccb8427d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_045d43ff-1afb-44bb-802b-53f39f11b10c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f1d02a11-cfdc-47ad-9b0f-4c19f61db255" xlink:to="loc_us-gaap_NetIncomeLoss_045d43ff-1afb-44bb-802b-53f39f11b10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_EarningsPerShareBasicAndDilutedEPSAbstract_7e790c1d-2d8f-40c4-9486-d4cb920c0ce9" xlink:href="moh-20220930.xsd#moh_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f1d02a11-cfdc-47ad-9b0f-4c19f61db255" xlink:to="loc_moh_EarningsPerShareBasicAndDilutedEPSAbstract_7e790c1d-2d8f-40c4-9486-d4cb920c0ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f4012691-ca0a-45ef-a2a5-e18a2e53dbd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_EarningsPerShareBasicAndDilutedEPSAbstract_7e790c1d-2d8f-40c4-9486-d4cb920c0ce9" xlink:to="loc_us-gaap_EarningsPerShareBasic_f4012691-ca0a-45ef-a2a5-e18a2e53dbd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_6beff93e-0799-4a2c-a8d6-045b910dbdc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_EarningsPerShareBasicAndDilutedEPSAbstract_7e790c1d-2d8f-40c4-9486-d4cb920c0ce9" xlink:to="loc_us-gaap_EarningsPerShareDiluted_6beff93e-0799-4a2c-a8d6-045b910dbdc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="moh-20220930.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e830bf14-538b-4eed-9058-9424e95ab960" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f8efc7b7-ceec-4f86-98b8-5e3ba1dcc013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e830bf14-538b-4eed-9058-9424e95ab960" xlink:to="loc_us-gaap_NetIncomeLoss_f8efc7b7-ceec-4f86-98b8-5e3ba1dcc013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_cbf1f613-f627-45f4-ac44-e681c93eb25f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e830bf14-538b-4eed-9058-9424e95ab960" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_cbf1f613-f627-45f4-ac44-e681c93eb25f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_49c5905a-4faf-47fd-b254-f6569807cb9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_cbf1f613-f627-45f4-ac44-e681c93eb25f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_49c5905a-4faf-47fd-b254-f6569807cb9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_88094693-4bce-4ccf-a2ad-3842831a8742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_cbf1f613-f627-45f4-ac44-e681c93eb25f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_88094693-4bce-4ccf-a2ad-3842831a8742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_11a5d069-3e8f-47e9-92e2-50742e7075b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_cbf1f613-f627-45f4-ac44-e681c93eb25f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_11a5d069-3e8f-47e9-92e2-50742e7075b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0746ff81-9f34-4362-baf7-4321c462a45d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e830bf14-538b-4eed-9058-9424e95ab960" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_0746ff81-9f34-4362-baf7-4321c462a45d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="moh-20220930.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_fb95c875-1142-454f-a529-c1c58b13f9d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_93c307d9-6a37-496c-9b2e-dca56ff62554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fb95c875-1142-454f-a529-c1c58b13f9d6" xlink:to="loc_us-gaap_AssetsAbstract_93c307d9-6a37-496c-9b2e-dca56ff62554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_c738936f-5528-448e-b5ae-e14021622843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_93c307d9-6a37-496c-9b2e-dca56ff62554" xlink:to="loc_us-gaap_AssetsCurrentAbstract_c738936f-5528-448e-b5ae-e14021622843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6533eca7-92ac-45ab-8d3e-4fa8b922f1ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c738936f-5528-448e-b5ae-e14021622843" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6533eca7-92ac-45ab-8d3e-4fa8b922f1ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_35af19d0-7081-454e-9c64-3e0867100634" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c738936f-5528-448e-b5ae-e14021622843" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_35af19d0-7081-454e-9c64-3e0867100634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_3b078a1a-4adb-49aa-8c08-d22d6063dc85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c738936f-5528-448e-b5ae-e14021622843" xlink:to="loc_us-gaap_ReceivablesNetCurrent_3b078a1a-4adb-49aa-8c08-d22d6063dc85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e19bd6b0-78aa-4b6a-8a03-4035c7dab8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c738936f-5528-448e-b5ae-e14021622843" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e19bd6b0-78aa-4b6a-8a03-4035c7dab8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c1134c9d-2033-4c33-9334-5b14399460c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c738936f-5528-448e-b5ae-e14021622843" xlink:to="loc_us-gaap_AssetsCurrent_c1134c9d-2033-4c33-9334-5b14399460c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_25f6e8e7-809b-4ab7-80ef-4fa550e5d990" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_93c307d9-6a37-496c-9b2e-dca56ff62554" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_25f6e8e7-809b-4ab7-80ef-4fa550e5d990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_bd055c74-0f44-4186-980a-cbad764dc4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_93c307d9-6a37-496c-9b2e-dca56ff62554" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_bd055c74-0f44-4186-980a-cbad764dc4ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestmentsNoncurrent_f8f50c3a-656d-4c56-a9d5-bdbd789be8c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedInvestmentsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_93c307d9-6a37-496c-9b2e-dca56ff62554" xlink:to="loc_us-gaap_RestrictedInvestmentsNoncurrent_f8f50c3a-656d-4c56-a9d5-bdbd789be8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_3fc770f2-c570-45c2-80e2-63fd53eb7257" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_93c307d9-6a37-496c-9b2e-dca56ff62554" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_3fc770f2-c570-45c2-80e2-63fd53eb7257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5dd8bb90-4713-47aa-baf9-47971ee35ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_93c307d9-6a37-496c-9b2e-dca56ff62554" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5dd8bb90-4713-47aa-baf9-47971ee35ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5d58e487-87b9-4b96-b41d-b93b552bb56d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_93c307d9-6a37-496c-9b2e-dca56ff62554" xlink:to="loc_us-gaap_Assets_5d58e487-87b9-4b96-b41d-b93b552bb56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cc71932e-8738-46ee-9206-d79419847fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fb95c875-1142-454f-a529-c1c58b13f9d6" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cc71932e-8738-46ee-9206-d79419847fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_a8d141cb-a054-480e-b9a1-1a570b788b32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cc71932e-8738-46ee-9206-d79419847fe1" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_a8d141cb-a054-480e-b9a1-1a570b788b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_1811b844-8587-45f3-9025-cd8d8f18f4be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a8d141cb-a054-480e-b9a1-1a570b788b32" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_1811b844-8587-45f3-9025-cd8d8f18f4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalPremiumLiabilityDueToAgency_ca389761-3e87-4616-a583-08099d7fb133" xlink:href="moh-20220930.xsd#moh_MedicalPremiumLiabilityDueToAgency"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a8d141cb-a054-480e-b9a1-1a570b788b32" xlink:to="loc_moh_MedicalPremiumLiabilityDueToAgency_ca389761-3e87-4616-a583-08099d7fb133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1e8a79b3-6322-49e3-be46-46c8dc9b0ace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a8d141cb-a054-480e-b9a1-1a570b788b32" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1e8a79b3-6322-49e3-be46-46c8dc9b0ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6bd57105-27b4-4f7f-9a64-a93b51a232ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a8d141cb-a054-480e-b9a1-1a570b788b32" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6bd57105-27b4-4f7f-9a64-a93b51a232ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a94b6a27-a0e6-4a84-ab0d-f27614952953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a8d141cb-a054-480e-b9a1-1a570b788b32" xlink:to="loc_us-gaap_LiabilitiesCurrent_a94b6a27-a0e6-4a84-ab0d-f27614952953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_16da956e-e519-4e45-acc2-a2a0905952ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cc71932e-8738-46ee-9206-d79419847fe1" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_16da956e-e519-4e45-acc2-a2a0905952ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_aaef043d-17d1-4ad5-8ee1-8958a58070b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cc71932e-8738-46ee-9206-d79419847fe1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_aaef043d-17d1-4ad5-8ee1-8958a58070b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_cdc98010-6b10-4a55-adae-19fbcb64f8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cc71932e-8738-46ee-9206-d79419847fe1" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_cdc98010-6b10-4a55-adae-19fbcb64f8cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7931cdd3-59d7-42fb-a99d-e221baf2d861" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cc71932e-8738-46ee-9206-d79419847fe1" xlink:to="loc_us-gaap_Liabilities_7931cdd3-59d7-42fb-a99d-e221baf2d861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_dda7b1c9-c991-4253-85cf-97651f8224fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cc71932e-8738-46ee-9206-d79419847fe1" xlink:to="loc_us-gaap_StockholdersEquityAbstract_dda7b1c9-c991-4253-85cf-97651f8224fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_2642ef31-eb20-46b1-982c-78b630f938e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dda7b1c9-c991-4253-85cf-97651f8224fc" xlink:to="loc_us-gaap_CommonStockValueOutstanding_2642ef31-eb20-46b1-982c-78b630f938e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_ebf1d34a-14fd-4a22-a1aa-9f4923198a73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dda7b1c9-c991-4253-85cf-97651f8224fc" xlink:to="loc_us-gaap_PreferredStockValue_ebf1d34a-14fd-4a22-a1aa-9f4923198a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_6322fd9c-a125-4cb2-b5ca-59bab3214651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dda7b1c9-c991-4253-85cf-97651f8224fc" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_6322fd9c-a125-4cb2-b5ca-59bab3214651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3ed8f1ac-c73e-4636-b46d-46ba71e88204" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dda7b1c9-c991-4253-85cf-97651f8224fc" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3ed8f1ac-c73e-4636-b46d-46ba71e88204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_edaf8936-aa74-4b6e-a947-142b37510c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dda7b1c9-c991-4253-85cf-97651f8224fc" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_edaf8936-aa74-4b6e-a947-142b37510c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e0e651d7-9207-4301-bf51-0cb882a51d33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dda7b1c9-c991-4253-85cf-97651f8224fc" xlink:to="loc_us-gaap_StockholdersEquity_e0e651d7-9207-4301-bf51-0cb882a51d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b7748e26-3d7c-4445-b4c6-e392b594d146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cc71932e-8738-46ee-9206-d79419847fe1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_b7748e26-3d7c-4445-b4c6-e392b594d146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="moh-20220930.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_35e80fc1-76da-43a4-8071-8239706dc15a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1d85b31f-d719-4d18-99bb-f6616b6eeecf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_35e80fc1-76da-43a4-8071-8239706dc15a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1d85b31f-d719-4d18-99bb-f6616b6eeecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c0b798af-0161-4bce-9b5b-eb0c7aeb885e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_35e80fc1-76da-43a4-8071-8239706dc15a" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c0b798af-0161-4bce-9b5b-eb0c7aeb885e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_866a1e1e-15d2-4519-b6c8-46c0cfe5fb7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_35e80fc1-76da-43a4-8071-8239706dc15a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_866a1e1e-15d2-4519-b6c8-46c0cfe5fb7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_75eb27ba-4080-4c7d-b8eb-fa5982577133" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_35e80fc1-76da-43a4-8071-8239706dc15a" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_75eb27ba-4080-4c7d-b8eb-fa5982577133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_10b90e55-0c05-42b9-88e9-0cf365c39345" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_35e80fc1-76da-43a4-8071-8239706dc15a" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_10b90e55-0c05-42b9-88e9-0cf365c39345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_89ad4946-61a7-4d28-b6f2-52b1e3d834fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_35e80fc1-76da-43a4-8071-8239706dc15a" xlink:to="loc_us-gaap_PreferredStockSharesIssued_89ad4946-61a7-4d28-b6f2-52b1e3d834fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_dec2a8d6-413d-4a8b-acd6-6a8f8d83bdca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_35e80fc1-76da-43a4-8071-8239706dc15a" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_dec2a8d6-413d-4a8b-acd6-6a8f8d83bdca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="moh-20220930.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_338f33a8-f463-49d8-91f0-17dcf861fa3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_fed178d7-21a5-4c62-9b34-9bd901aef383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_338f33a8-f463-49d8-91f0-17dcf861fa3e" xlink:to="loc_us-gaap_StatementTable_fed178d7-21a5-4c62-9b34-9bd901aef383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_21ec01ec-3e4c-4c20-ab63-5165f81eadad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_fed178d7-21a5-4c62-9b34-9bd901aef383" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_21ec01ec-3e4c-4c20-ab63-5165f81eadad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7472d53b-b6ae-42c9-b0d0-292f75b55190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_21ec01ec-3e4c-4c20-ab63-5165f81eadad" xlink:to="loc_us-gaap_EquityComponentDomain_7472d53b-b6ae-42c9-b0d0-292f75b55190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_039ade5d-e46c-4d22-83da-44af61700217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7472d53b-b6ae-42c9-b0d0-292f75b55190" xlink:to="loc_us-gaap_CommonStockMember_039ade5d-e46c-4d22-83da-44af61700217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_760744e1-baa6-4816-835d-0cfff36dae2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7472d53b-b6ae-42c9-b0d0-292f75b55190" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_760744e1-baa6-4816-835d-0cfff36dae2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_19ec3bc8-4526-4c94-bbd5-91aff73c48b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7472d53b-b6ae-42c9-b0d0-292f75b55190" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_19ec3bc8-4526-4c94-bbd5-91aff73c48b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_693a09e4-4c2b-469b-8bd1-0c039bbd88fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7472d53b-b6ae-42c9-b0d0-292f75b55190" xlink:to="loc_us-gaap_RetainedEarningsMember_693a09e4-4c2b-469b-8bd1-0c039bbd88fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ee74f456-da0e-4870-b84f-1cc3526ce51a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_fed178d7-21a5-4c62-9b34-9bd901aef383" xlink:to="loc_us-gaap_StatementLineItems_ee74f456-da0e-4870-b84f-1cc3526ce51a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e5cc174-ff2d-4c10-96f7-82e5d46a7ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ee74f456-da0e-4870-b84f-1cc3526ce51a" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e5cc174-ff2d-4c10-96f7-82e5d46a7ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_ec309b2f-2358-4744-945b-af919c89fddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e5cc174-ff2d-4c10-96f7-82e5d46a7ea4" xlink:to="loc_us-gaap_SharesOutstanding_ec309b2f-2358-4744-945b-af919c89fddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_98a96814-0710-49a5-a83b-a6d1c77de6db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e5cc174-ff2d-4c10-96f7-82e5d46a7ea4" xlink:to="loc_us-gaap_StockholdersEquity_98a96814-0710-49a5-a83b-a6d1c77de6db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a7f459d3-f010-4496-adf6-9f0bb2ed51c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e5cc174-ff2d-4c10-96f7-82e5d46a7ea4" xlink:to="loc_us-gaap_NetIncomeLoss_a7f459d3-f010-4496-adf6-9f0bb2ed51c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_b108525b-70cc-4123-b147-b630cb85e76b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e5cc174-ff2d-4c10-96f7-82e5d46a7ea4" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_b108525b-70cc-4123-b147-b630cb85e76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_5c0edc1c-a923-45fb-a2f1-93b64f87b8f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e5cc174-ff2d-4c10-96f7-82e5d46a7ea4" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_5c0edc1c-a923-45fb-a2f1-93b64f87b8f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c5ac30b2-a14d-4729-9cfc-f9d9f909ff39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e5cc174-ff2d-4c10-96f7-82e5d46a7ea4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c5ac30b2-a14d-4729-9cfc-f9d9f909ff39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_c2368d3a-81be-4179-876f-a14a8faba5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e5cc174-ff2d-4c10-96f7-82e5d46a7ea4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_c2368d3a-81be-4179-876f-a14a8faba5b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6ad4dde4-4296-4a5d-a9d9-1df221d43a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e5cc174-ff2d-4c10-96f7-82e5d46a7ea4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6ad4dde4-4296-4a5d-a9d9-1df221d43a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_0f4b4d35-2581-4676-9c1d-660acfc8645d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e5cc174-ff2d-4c10-96f7-82e5d46a7ea4" xlink:to="loc_us-gaap_SharesOutstanding_0f4b4d35-2581-4676-9c1d-660acfc8645d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f51ca55d-fc98-4911-8695-075db20e7490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e5cc174-ff2d-4c10-96f7-82e5d46a7ea4" xlink:to="loc_us-gaap_StockholdersEquity_f51ca55d-fc98-4911-8695-075db20e7490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="moh-20220930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_65c74c3c-d7d3-4fec-a525-ebaca897c3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_49426d3b-f662-4432-9306-b379a75679e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_65c74c3c-d7d3-4fec-a525-ebaca897c3b9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_49426d3b-f662-4432-9306-b379a75679e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_361f3749-ee96-47d1-9047-8268c6b62d81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_49426d3b-f662-4432-9306-b379a75679e1" xlink:to="loc_us-gaap_NetIncomeLoss_361f3749-ee96-47d1-9047-8268c6b62d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cd712625-90f7-4182-a832-62773545dd3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_49426d3b-f662-4432-9306-b379a75679e1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cd712625-90f7-4182-a832-62773545dd3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b3ca892f-de28-4fb8-8fc5-d38d48793faf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cd712625-90f7-4182-a832-62773545dd3a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b3ca892f-de28-4fb8-8fc5-d38d48793faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_8843a2b1-8eaa-4339-a54c-6b892198785f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cd712625-90f7-4182-a832-62773545dd3a" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_8843a2b1-8eaa-4339-a54c-6b892198785f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_dd49bf1c-d345-4b10-8681-cda860e237a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cd712625-90f7-4182-a832-62773545dd3a" xlink:to="loc_us-gaap_ShareBasedCompensation_dd49bf1c-d345-4b10-8681-cda860e237a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_10006108-5d3a-4ee8-a7bc-a17955c0b04f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cd712625-90f7-4182-a832-62773545dd3a" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_10006108-5d3a-4ee8-a7bc-a17955c0b04f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9de1b648-4e39-40cf-88e2-49243a735936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cd712625-90f7-4182-a832-62773545dd3a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9de1b648-4e39-40cf-88e2-49243a735936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_b0e8cbe8-8a88-4577-b8bd-ab7277a380c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9de1b648-4e39-40cf-88e2-49243a735936" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_b0e8cbe8-8a88-4577-b8bd-ab7277a380c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e9c5a0e7-de6c-4a4f-97e4-da51e415647b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9de1b648-4e39-40cf-88e2-49243a735936" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e9c5a0e7-de6c-4a4f-97e4-da51e415647b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities_a06625b8-bc9f-49ed-9d4e-517122758e28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9de1b648-4e39-40cf-88e2-49243a735936" xlink:to="loc_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities_a06625b8-bc9f-49ed-9d4e-517122758e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency_89c23328-2e5e-4cc8-9ff5-df67ac2a39a9" xlink:href="moh-20220930.xsd#moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9de1b648-4e39-40cf-88e2-49243a735936" xlink:to="loc_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency_89c23328-2e5e-4cc8-9ff5-df67ac2a39a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e577516d-c993-4237-9f9e-57b762fc5f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9de1b648-4e39-40cf-88e2-49243a735936" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e577516d-c993-4237-9f9e-57b762fc5f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a3f86af9-c440-4383-8309-c4c727a5dcb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9de1b648-4e39-40cf-88e2-49243a735936" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a3f86af9-c440-4383-8309-c4c727a5dcb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_f448bc71-4655-4e04-9ae0-17337a4e81ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9de1b648-4e39-40cf-88e2-49243a735936" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_f448bc71-4655-4e04-9ae0-17337a4e81ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d3662107-5d86-4fde-b12a-a4b3bba4cb2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_49426d3b-f662-4432-9306-b379a75679e1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d3662107-5d86-4fde-b12a-a4b3bba4cb2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7c3f1626-28a8-46f6-b230-d74f8c8b72dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_65c74c3c-d7d3-4fec-a525-ebaca897c3b9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7c3f1626-28a8-46f6-b230-d74f8c8b72dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_b424a96f-d60a-4df2-8db2-c91defd99197" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7c3f1626-28a8-46f6-b230-d74f8c8b72dc" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_b424a96f-d60a-4df2-8db2-c91defd99197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2e16c00a-7c81-49e4-aab5-3568273a1b53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7c3f1626-28a8-46f6-b230-d74f8c8b72dc" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2e16c00a-7c81-49e4-aab5-3568273a1b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_a2a4f455-60da-4cab-b4f4-545a8ba910ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7c3f1626-28a8-46f6-b230-d74f8c8b72dc" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_a2a4f455-60da-4cab-b4f4-545a8ba910ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_731ee85a-21f8-40de-9e85-6d7358aa36dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7c3f1626-28a8-46f6-b230-d74f8c8b72dc" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_731ee85a-21f8-40de-9e85-6d7358aa36dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_32828e11-ef82-4ee3-b76c-34828f2c03bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7c3f1626-28a8-46f6-b230-d74f8c8b72dc" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_32828e11-ef82-4ee3-b76c-34828f2c03bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_84d3bbf5-33fe-44ca-869f-cba7447a5ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7c3f1626-28a8-46f6-b230-d74f8c8b72dc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_84d3bbf5-33fe-44ca-869f-cba7447a5ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_73c17a57-e85e-4ea4-915a-ae68a83db03e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_65c74c3c-d7d3-4fec-a525-ebaca897c3b9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_73c17a57-e85e-4ea4-915a-ae68a83db03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_9dd22aec-b531-4c06-b97c-4a2a61a0dcb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_73c17a57-e85e-4ea4-915a-ae68a83db03e" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_9dd22aec-b531-4c06-b97c-4a2a61a0dcb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CommonStockWithheldToSettleEmployeeTaxObligations_2da11169-6ddc-4b66-a6ea-968e684d9d54" xlink:href="moh-20220930.xsd#moh_CommonStockWithheldToSettleEmployeeTaxObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_73c17a57-e85e-4ea4-915a-ae68a83db03e" xlink:to="loc_moh_CommonStockWithheldToSettleEmployeeTaxObligations_2da11169-6ddc-4b66-a6ea-968e684d9d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_ecbc6c2c-2356-48c9-865b-c1a974ad16ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_73c17a57-e85e-4ea4-915a-ae68a83db03e" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_ecbc6c2c-2356-48c9-865b-c1a974ad16ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_0b3828a8-a816-4366-8667-5a40faff0b47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_73c17a57-e85e-4ea4-915a-ae68a83db03e" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_0b3828a8-a816-4366-8667-5a40faff0b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d48698d7-324a-48d8-9add-9d9e15682829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_73c17a57-e85e-4ea4-915a-ae68a83db03e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d48698d7-324a-48d8-9add-9d9e15682829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e2def4af-b32e-4577-934b-bcb7f488a132" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_65c74c3c-d7d3-4fec-a525-ebaca897c3b9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e2def4af-b32e-4577-934b-bcb7f488a132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2ae70561-9915-45e4-a26e-e079629afd50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_65c74c3c-d7d3-4fec-a525-ebaca897c3b9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2ae70561-9915-45e4-a26e-e079629afd50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_001149f2-d8b5-430b-a067-e4692db16940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_65c74c3c-d7d3-4fec-a525-ebaca897c3b9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_001149f2-d8b5-430b-a067-e4692db16940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="moh-20220930.xsd#OrganizationandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1dd0cacc-78c4-48a9-a5aa-2f38c6e4c568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_bd5397ac-a4d0-45f9-a0f4-3be144a5ed66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1dd0cacc-78c4-48a9-a5aa-2f38c6e4c568" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_bd5397ac-a4d0-45f9-a0f4-3be144a5ed66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="moh-20220930.xsd#SignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_32efc043-6bdc-4b2d-8952-d50eda8abdec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_b86e0ad4-0278-4f2a-ba34-6e06cd836f57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_32efc043-6bdc-4b2d-8952-d50eda8abdec" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_b86e0ad4-0278-4f2a-ba34-6e06cd836f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/NetIncomePerShare" xlink:type="simple" xlink:href="moh-20220930.xsd#NetIncomePerShare"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/NetIncomePerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5b46cda3-5b97-4662-b4a8-d3af9a8e3608" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_5c29c8a7-17d1-42fc-aabc-1fec7d10ab75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5b46cda3-5b97-4662-b4a8-d3af9a8e3608" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_5c29c8a7-17d1-42fc-aabc-1fec7d10ab75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/BusinessCombinations" xlink:type="simple" xlink:href="moh-20220930.xsd#BusinessCombinations"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/BusinessCombinations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_83f1459d-67bd-489e-974b-3ebdc48c92b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_af67ec27-d40f-4aa2-a8ba-4c66a13c34ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_83f1459d-67bd-489e-974b-3ebdc48c92b0" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_af67ec27-d40f-4aa2-a8ba-4c66a13c34ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="moh-20220930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_02467878-4524-4efe-936a-274df494e56c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_ede3146a-3ae7-4a53-b4ca-657a85297fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_02467878-4524-4efe-936a-274df494e56c" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_ede3146a-3ae7-4a53-b4ca-657a85297fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/Investments" xlink:type="simple" xlink:href="moh-20220930.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a95b025b-59bf-4338-8fce-dbb80ad5930d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_9b3505a8-6f89-4b3b-b4ca-a769b47f5eef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a95b025b-59bf-4338-8fce-dbb80ad5930d" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_9b3505a8-6f89-4b3b-b4ca-a769b47f5eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable" xlink:type="simple" xlink:href="moh-20220930.xsd#MedicalClaimsandBenefitsPayable"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_ae3d47f8-5bab-4b42-8ddc-5ced7e175d03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalClaimsAndBenefitsPayableTextBlock_623295de-db03-481e-8042-6a333542642b" xlink:href="moh-20220930.xsd#moh_MedicalClaimsAndBenefitsPayableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_ae3d47f8-5bab-4b42-8ddc-5ced7e175d03" xlink:to="loc_moh_MedicalClaimsAndBenefitsPayableTextBlock_623295de-db03-481e-8042-6a333542642b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/Debt" xlink:type="simple" xlink:href="moh-20220930.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_900fcae1-6bd0-49eb-b8d1-9893be0ebdda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock_2224db7e-2686-405b-879f-5928fb118057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_900fcae1-6bd0-49eb-b8d1-9893be0ebdda" xlink:to="loc_us-gaap_LongTermDebtTextBlock_2224db7e-2686-405b-879f-5928fb118057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/StockholdersEquity" xlink:type="simple" xlink:href="moh-20220930.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c095b229-c5b8-4edf-9054-bfc89b3fec3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6b749b5a-4d08-4a5d-af10-ca3502d5e38b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c095b229-c5b8-4edf-9054-bfc89b3fec3e" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6b749b5a-4d08-4a5d-af10-ca3502d5e38b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/Segments" xlink:type="simple" xlink:href="moh-20220930.xsd#Segments"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/Segments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_4309b03c-ca91-4f10-9c8e-e7ee8a19c015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_ed003ba9-7050-4376-aa96-b5b054d2a0cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4309b03c-ca91-4f10-9c8e-e7ee8a19c015" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_ed003ba9-7050-4376-aa96-b5b054d2a0cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="moh-20220930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e78b6b73-c7ca-4c08-8ffd-87132a198973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4ebe378d-005c-4f67-95b3-e59708abf694" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e78b6b73-c7ca-4c08-8ffd-87132a198973" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4ebe378d-005c-4f67-95b3-e59708abf694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="moh-20220930.xsd#SignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6be6b089-4a32-4383-b1ff-866bf8d281e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock_253af0b2-d71a-4f7f-90d7-95b54f5ca9d2" xlink:href="moh-20220930.xsd#moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6be6b089-4a32-4383-b1ff-866bf8d281e1" xlink:to="loc_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock_253af0b2-d71a-4f7f-90d7-95b54f5ca9d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_6e9b77cf-8f78-42c6-81d7-62b59b08890c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6be6b089-4a32-4383-b1ff-866bf8d281e1" xlink:to="loc_us-gaap_UseOfEstimates_6e9b77cf-8f78-42c6-81d7-62b59b08890c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ba48378b-5eea-46fa-8ace-933881e52438" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6be6b089-4a32-4383-b1ff-866bf8d281e1" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ba48378b-5eea-46fa-8ace-933881e52438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_429764ee-034a-474d-806d-3c7744c0f390" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6be6b089-4a32-4383-b1ff-866bf8d281e1" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_429764ee-034a-474d-806d-3c7744c0f390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_ca9ceec9-9d61-45d4-b185-4148acbb8ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6be6b089-4a32-4383-b1ff-866bf8d281e1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_ca9ceec9-9d61-45d4-b185-4148acbb8ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_2d06fc05-7bd3-4e04-bf4f-37bc88fddeae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6be6b089-4a32-4383-b1ff-866bf8d281e1" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_2d06fc05-7bd3-4e04-bf4f-37bc88fddeae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_4a8ce78a-04ab-49cd-85ff-d4386be73819" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6be6b089-4a32-4383-b1ff-866bf8d281e1" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_4a8ce78a-04ab-49cd-85ff-d4386be73819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c02f9527-9de5-4319-bee1-10cd78b3c0ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6be6b089-4a32-4383-b1ff-866bf8d281e1" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c02f9527-9de5-4319-bee1-10cd78b3c0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="moh-20220930.xsd#SignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_abfb4d51-81be-47d5-a787-44270f026b34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_bbf35a4e-27e0-4b21-a48e-404583219761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_abfb4d51-81be-47d5-a787-44270f026b34" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_bbf35a4e-27e0-4b21-a48e-404583219761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_d592ff38-0591-4d19-9039-7fdd55dd16ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_abfb4d51-81be-47d5-a787-44270f026b34" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_d592ff38-0591-4d19-9039-7fdd55dd16ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_f67bc741-1ff7-4e48-8798-6f045ec4111a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_abfb4d51-81be-47d5-a787-44270f026b34" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_f67bc741-1ff7-4e48-8798-6f045ec4111a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReservesReportedToOtherAgenciesTextBlock_3708a3fc-b043-4c0f-8c84-6080b4dc36ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReservesReportedToOtherAgenciesTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_abfb4d51-81be-47d5-a787-44270f026b34" xlink:to="loc_us-gaap_ReservesReportedToOtherAgenciesTextBlock_3708a3fc-b043-4c0f-8c84-6080b4dc36ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/NetIncomePerShareTables" xlink:type="simple" xlink:href="moh-20220930.xsd#NetIncomePerShareTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/NetIncomePerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_dc5c7720-ba4f-4dd5-99ed-d7216b2a4a58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_50596609-b455-47b7-8106-de06ebb0f5b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dc5c7720-ba4f-4dd5-99ed-d7216b2a4a58" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_50596609-b455-47b7-8106-de06ebb0f5b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="moh-20220930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_eb1bc40b-e231-4a76-939d-8ab2c2785cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_c6e710ff-1e28-44da-8c39-be490f51768c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_eb1bc40b-e231-4a76-939d-8ab2c2785cf9" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_c6e710ff-1e28-44da-8c39-be490f51768c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_691bfe42-a83c-41eb-b913-2ea898c260b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_eb1bc40b-e231-4a76-939d-8ab2c2785cf9" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_691bfe42-a83c-41eb-b913-2ea898c260b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsTables" xlink:type="simple" xlink:href="moh-20220930.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_38486bdc-0feb-492f-b4a7-6fed113c2976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_3c8aeee2-ac5f-47b5-8106-80deb4779fee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_38486bdc-0feb-492f-b4a7-6fed113c2976" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_3c8aeee2-ac5f-47b5-8106-80deb4779fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_29e9faf4-58f7-496b-b8e6-50caeb92b6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_38486bdc-0feb-492f-b4a7-6fed113c2976" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_29e9faf4-58f7-496b-b8e6-50caeb92b6a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_6866dad2-362a-4923-991d-8337b71b95a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_38486bdc-0feb-492f-b4a7-6fed113c2976" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_6866dad2-362a-4923-991d-8337b71b95a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables" xlink:type="simple" xlink:href="moh-20220930.xsd#MedicalClaimsandBenefitsPayableTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_b5f8b205-48ec-4d13-9f5f-7573dd857559" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_a31db51e-7f31-4896-9a12-ec80b55c6c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_b5f8b205-48ec-4d13-9f5f-7573dd857559" xlink:to="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_a31db51e-7f31-4896-9a12-ec80b55c6c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock_62405aae-dd7f-40e2-baf0-855e170b382e" xlink:href="moh-20220930.xsd#moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_b5f8b205-48ec-4d13-9f5f-7573dd857559" xlink:to="loc_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock_62405aae-dd7f-40e2-baf0-855e170b382e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtTables" xlink:type="simple" xlink:href="moh-20220930.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7d6c561e-59b6-481b-95ca-ce72236e07a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_85859ba9-3e5e-4e4b-9b6c-dfb43cc73f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7d6c561e-59b6-481b-95ca-ce72236e07a2" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_85859ba9-3e5e-4e4b-9b6c-dfb43cc73f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SegmentsTables" xlink:type="simple" xlink:href="moh-20220930.xsd#SegmentsTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SegmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_e8f5fa98-fe51-489c-96d8-eceb48772993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_b74d82a0-fd19-4203-9bbe-d0d002c9c7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e8f5fa98-fe51-489c-96d8-eceb48772993" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_b74d82a0-fd19-4203-9bbe-d0d002c9c7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#OrganizationandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c2c1113f-6fa9-445c-8794-f9a7a7bdc2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a8ced87c-d52c-48c0-9ab7-e84db808bdc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c2c1113f-6fa9-445c-8794-f9a7a7bdc2a8" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a8ced87c-d52c-48c0-9ab7-e84db808bdc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a54cc275-39c7-4a7c-9124-ebf188712730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a8ced87c-d52c-48c0-9ab7-e84db808bdc9" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a54cc275-39c7-4a7c-9124-ebf188712730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_dad4ad6c-23e0-4bbe-8e23-d866eb1ddaaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a54cc275-39c7-4a7c-9124-ebf188712730" xlink:to="loc_us-gaap_SegmentDomain_dad4ad6c-23e0-4bbe-8e23-d866eb1ddaaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlansMember_f70953af-7d20-4933-9e1f-c6e158e39319" xlink:href="moh-20220930.xsd#moh_HealthPlansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_dad4ad6c-23e0-4bbe-8e23-d866eb1ddaaf" xlink:to="loc_moh_HealthPlansMember_f70953af-7d20-4933-9e1f-c6e158e39319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_016447cc-1e68-4030-b542-04213e75bca6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a8ced87c-d52c-48c0-9ab7-e84db808bdc9" xlink:to="loc_srt_RangeAxis_016447cc-1e68-4030-b542-04213e75bca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_408832ba-473a-4269-a83a-024878112357" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_016447cc-1e68-4030-b542-04213e75bca6" xlink:to="loc_srt_RangeMember_408832ba-473a-4269-a83a-024878112357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_89b238f3-e463-4eef-a99f-d9803e8aec34" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_408832ba-473a-4269-a83a-024878112357" xlink:to="loc_srt_MinimumMember_89b238f3-e463-4eef-a99f-d9803e8aec34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_adbdadcf-8aa4-4962-bcaa-1471eb10ff4c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_408832ba-473a-4269-a83a-024878112357" xlink:to="loc_srt_MaximumMember_adbdadcf-8aa4-4962-bcaa-1471eb10ff4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_293a3b39-d615-47c0-9210-8d161ea0e206" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a8ced87c-d52c-48c0-9ab7-e84db808bdc9" xlink:to="loc_srt_StatementGeographicalAxis_293a3b39-d615-47c0-9210-8d161ea0e206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e0ee4704-325e-4d09-a482-dde8850689e6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_293a3b39-d615-47c0-9210-8d161ea0e206" xlink:to="loc_srt_SegmentGeographicalDomain_e0ee4704-325e-4d09-a482-dde8850689e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NE_b51b60dd-0dc9-48cb-9c70-14d21500f80e" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NE"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e0ee4704-325e-4d09-a482-dde8850689e6" xlink:to="loc_stpr_NE_b51b60dd-0dc9-48cb-9c70-14d21500f80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IA_c2c589fe-0862-40f5-bfa4-4471f6bec26d" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_IA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e0ee4704-325e-4d09-a482-dde8850689e6" xlink:to="loc_stpr_IA_c2c589fe-0862-40f5-bfa4-4471f6bec26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_375b5d43-cc7c-4f66-a682-21299248e2c0" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e0ee4704-325e-4d09-a482-dde8850689e6" xlink:to="loc_stpr_CA_375b5d43-cc7c-4f66-a682-21299248e2c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MS_fdd97d47-fbdb-41de-a8af-71fd06a79679" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MS"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e0ee4704-325e-4d09-a482-dde8850689e6" xlink:to="loc_stpr_MS_fdd97d47-fbdb-41de-a8af-71fd06a79679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_dd1455df-44b1-41f2-9c02-1a58ddf0f1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a8ced87c-d52c-48c0-9ab7-e84db808bdc9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_dd1455df-44b1-41f2-9c02-1a58ddf0f1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4c2c410a-5f4c-4141-8d06-c358b286e0d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dd1455df-44b1-41f2-9c02-1a58ddf0f1e1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4c2c410a-5f4c-4141-8d06-c358b286e0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MyChoiceWisconsinMember_60aa1477-320c-4f65-ac6a-13e38fbe0ad9" xlink:href="moh-20220930.xsd#moh_MyChoiceWisconsinMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4c2c410a-5f4c-4141-8d06-c358b286e0d9" xlink:to="loc_moh_MyChoiceWisconsinMember_60aa1477-320c-4f65-ac6a-13e38fbe0ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_2cd31e24-2f3e-40f7-b400-ce2ca3a352a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a8ced87c-d52c-48c0-9ab7-e84db808bdc9" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_2cd31e24-2f3e-40f7-b400-ce2ca3a352a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_b1bbb22a-cd68-4f87-ad32-5530c08cde14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2cd31e24-2f3e-40f7-b400-ce2ca3a352a6" xlink:to="loc_us-gaap_NumberOfReportableSegments_b1bbb22a-cd68-4f87-ad32-5530c08cde14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms_c7e439a8-a5a7-4028-8ffd-1a4af56794db" xlink:href="moh-20220930.xsd#moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2cd31e24-2f3e-40f7-b400-ce2ca3a352a6" xlink:to="loc_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms_c7e439a8-a5a7-4028-8ffd-1a4af56794db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms_3932b51a-e9fb-46d3-8161-081f3aebd92d" xlink:href="moh-20220930.xsd#moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2cd31e24-2f3e-40f7-b400-ce2ca3a352a6" xlink:to="loc_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms_3932b51a-e9fb-46d3-8161-081f3aebd92d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlanContractTerm_d0c25b5b-76aa-45f4-802c-ed603889891c" xlink:href="moh-20220930.xsd#moh_HealthPlanContractTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2cd31e24-2f3e-40f7-b400-ce2ca3a352a6" xlink:to="loc_moh_HealthPlanContractTerm_d0c25b5b-76aa-45f4-802c-ed603889891c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlanExtensionOptionPeriod_b92f813c-4213-4143-b6d3-69469ab3d61a" xlink:href="moh-20220930.xsd#moh_HealthPlanExtensionOptionPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2cd31e24-2f3e-40f7-b400-ce2ca3a352a6" xlink:to="loc_moh_HealthPlanExtensionOptionPeriod_b92f813c-4213-4143-b6d3-69469ab3d61a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlanNumberOfContracts_1a7bd2e8-8732-4e0f-be98-45d26a85c82f" xlink:href="moh-20220930.xsd#moh_HealthPlanNumberOfContracts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2cd31e24-2f3e-40f7-b400-ce2ca3a352a6" xlink:to="loc_moh_HealthPlanNumberOfContracts_1a7bd2e8-8732-4e0f-be98-45d26a85c82f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_e52f976c-66e6-44b2-9f36-4f60ecab4070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2cd31e24-2f3e-40f7-b400-ce2ca3a352a6" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_e52f976c-66e6-44b2-9f36-4f60ecab4070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_34bd1699-f469-4eba-9ad2-4d4a8d529dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4a7ab170-4988-4ab3-9c7e-014bf9304100" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_34bd1699-f469-4eba-9ad2-4d4a8d529dc2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4a7ab170-4988-4ab3-9c7e-014bf9304100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_ea88737c-1277-4f5e-a73a-b9ed17f32e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_34bd1699-f469-4eba-9ad2-4d4a8d529dc2" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_ea88737c-1277-4f5e-a73a-b9ed17f32e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ed91f92a-23d8-49ce-b61c-9e0b1a603d08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_34bd1699-f469-4eba-9ad2-4d4a8d529dc2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ed91f92a-23d8-49ce-b61c-9e0b1a603d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#SignificantAccountingPoliciesReceivablesDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1b8c3fa7-0afa-4ad4-895a-d567e3860dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_5b3cc6d3-63b5-4b0c-9d45-79ee83804122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1b8c3fa7-0afa-4ad4-895a-d567e3860dbb" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_5b3cc6d3-63b5-4b0c-9d45-79ee83804122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_b2101f57-ce66-4a6f-a49f-31e2c569e442" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_5b3cc6d3-63b5-4b0c-9d45-79ee83804122" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_b2101f57-ce66-4a6f-a49f-31e2c569e442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_a29feea0-ad8c-4c9b-8d2a-c4cf7ea6ca0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_b2101f57-ce66-4a6f-a49f-31e2c569e442" xlink:to="loc_us-gaap_ReceivableTypeDomain_a29feea0-ad8c-4c9b-8d2a-c4cf7ea6ca0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_GovernmentReceivablesMember_9d089689-9c67-423b-bfdf-52dba7a0dc90" xlink:href="moh-20220930.xsd#moh_GovernmentReceivablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_a29feea0-ad8c-4c9b-8d2a-c4cf7ea6ca0b" xlink:to="loc_moh_GovernmentReceivablesMember_9d089689-9c67-423b-bfdf-52dba7a0dc90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PharmacyRebateReceivablesMember_90a5d368-d1ce-49dc-8edd-d0a26efea121" xlink:href="moh-20220930.xsd#moh_PharmacyRebateReceivablesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_a29feea0-ad8c-4c9b-8d2a-c4cf7ea6ca0b" xlink:to="loc_moh_PharmacyRebateReceivablesMember_90a5d368-d1ce-49dc-8edd-d0a26efea121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherReceivablesMember_4c47bbf4-4aeb-4b14-8a43-bb90a840e669" xlink:href="moh-20220930.xsd#moh_OtherReceivablesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_a29feea0-ad8c-4c9b-8d2a-c4cf7ea6ca0b" xlink:to="loc_moh_OtherReceivablesMember_4c47bbf4-4aeb-4b14-8a43-bb90a840e669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_3503db19-56e8-4c9e-88b0-31864fddcfd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_5b3cc6d3-63b5-4b0c-9d45-79ee83804122" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_3503db19-56e8-4c9e-88b0-31864fddcfd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_37d50f5d-3bc5-46b0-ad91-b713eba1227a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_3503db19-56e8-4c9e-88b0-31864fddcfd8" xlink:to="loc_us-gaap_ReceivablesNetCurrent_37d50f5d-3bc5-46b0-ad91-b713eba1227a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_83ef8e35-2793-4023-ab82-6a9f1f2d69aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract_067edb6c-7455-4c83-bd42-eef86e1e0de0" xlink:href="moh-20220930.xsd#moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_83ef8e35-2793-4023-ab82-6a9f1f2d69aa" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract_067edb6c-7455-4c83-bd42-eef86e1e0de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold_14362846-faf4-42d4-bd7c-33f12dccc0b0" xlink:href="moh-20220930.xsd#moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract_067edb6c-7455-4c83-bd42-eef86e1e0de0" xlink:to="loc_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold_14362846-faf4-42d4-bd7c-33f12dccc0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicaidOther_86f71cff-e3b1-4cff-b4ce-dd5b69632a8c" xlink:href="moh-20220930.xsd#moh_AmountsDueToGovernmentAgenciesMedicaidOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract_067edb6c-7455-4c83-bd42-eef86e1e0de0" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMedicaidOther_86f71cff-e3b1-4cff-b4ce-dd5b69632a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract_46a5e50d-a557-4831-a206-5e2022b0892c" xlink:href="moh-20220930.xsd#moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_83ef8e35-2793-4023-ab82-6a9f1f2d69aa" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract_46a5e50d-a557-4831-a206-5e2022b0892c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold_7f2c0b58-ad60-4d54-854f-815d0d1decd6" xlink:href="moh-20220930.xsd#moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract_46a5e50d-a557-4831-a206-5e2022b0892c" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold_7f2c0b58-ad60-4d54-854f-815d0d1decd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing_9406974a-a3be-4d42-8590-a74a13ceefaf" xlink:href="moh-20220930.xsd#moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract_46a5e50d-a557-4831-a206-5e2022b0892c" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing_9406974a-a3be-4d42-8590-a74a13ceefaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherMedicareProgram_234cd2c3-4429-428e-9719-38021e957537" xlink:href="moh-20220930.xsd#moh_OtherMedicareProgram"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract_46a5e50d-a557-4831-a206-5e2022b0892c" xlink:to="loc_moh_OtherMedicareProgram_234cd2c3-4429-428e-9719-38021e957537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_4907db44-7968-47a7-8112-c7f839fe947f" xlink:href="moh-20220930.xsd#moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_83ef8e35-2793-4023-ab82-6a9f1f2d69aa" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_4907db44-7968-47a7-8112-c7f839fe947f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment_8f23a760-6ebd-4bb9-bd07-f6c0744b222a" xlink:href="moh-20220930.xsd#moh_AmountsDuetoGovernmentAgenciesRiskAdjustment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_4907db44-7968-47a7-8112-c7f839fe947f" xlink:to="loc_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment_8f23a760-6ebd-4bb9-bd07-f6c0744b222a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold_54caa549-9403-42e5-8824-a7dc22bdbe8b" xlink:href="moh-20220930.xsd#moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_4907db44-7968-47a7-8112-c7f839fe947f" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold_54caa549-9403-42e5-8824-a7dc22bdbe8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDuetoGovernmentAgenciesOther_718f7366-1990-4864-9b2d-d44f3481a786" xlink:href="moh-20220930.xsd#moh_AmountsDuetoGovernmentAgenciesOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_4907db44-7968-47a7-8112-c7f839fe947f" xlink:to="loc_moh_AmountsDuetoGovernmentAgenciesOther_718f7366-1990-4864-9b2d-d44f3481a786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalPremiumLiabilityDueToAgency_79241ed0-de0d-40fa-b84a-c20671d7d384" xlink:href="moh-20220930.xsd#moh_MedicalPremiumLiabilityDueToAgency"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_83ef8e35-2793-4023-ab82-6a9f1f2d69aa" xlink:to="loc_moh_MedicalPremiumLiabilityDueToAgency_79241ed0-de0d-40fa-b84a-c20671d7d384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#SignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d5a2ae08-1a26-4f7f-a533-fda0799f55be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_9de62926-a9f8-4777-82d6-d7c74f581bbd" xlink:href="moh-20220930.xsd#moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d5a2ae08-1a26-4f7f-a533-fda0799f55be" xlink:to="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_9de62926-a9f8-4777-82d6-d7c74f581bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis_8056b7e3-0c57-49f8-a929-2e08c62ca30b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_9de62926-a9f8-4777-82d6-d7c74f581bbd" xlink:to="loc_us-gaap_UnusualOrInfrequentItemAxis_8056b7e3-0c57-49f8-a929-2e08c62ca30b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_fdc93129-a077-498e-b0ad-c8be2245198b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_8056b7e3-0c57-49f8-a929-2e08c62ca30b" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_fdc93129-a077-498e-b0ad-c8be2245198b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_COVID19Member_3a6e6e90-8b58-4385-a9fd-6941ce8da9cf" xlink:href="moh-20220930.xsd#moh_COVID19Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain_fdc93129-a077-498e-b0ad-c8be2245198b" xlink:to="loc_moh_COVID19Member_3a6e6e90-8b58-4385-a9fd-6941ce8da9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7c27f3b8-d403-46b7-960d-212ddcd191e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_9de62926-a9f8-4777-82d6-d7c74f581bbd" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7c27f3b8-d403-46b7-960d-212ddcd191e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4212689a-1d0d-46bf-b21e-8268d0b73ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7c27f3b8-d403-46b7-960d-212ddcd191e4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4212689a-1d0d-46bf-b21e-8268d0b73ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_StructuredSecuritiesMember_8a779668-1fbf-4da8-974d-7b183c013c71" xlink:href="moh-20220930.xsd#moh_StructuredSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4212689a-1d0d-46bf-b21e-8268d0b73ce8" xlink:to="loc_moh_StructuredSecuritiesMember_8a779668-1fbf-4da8-974d-7b183c013c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_f45c8015-bc90-4790-85bf-0489ce72eab3" xlink:href="moh-20220930.xsd#moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_9de62926-a9f8-4777-82d6-d7c74f581bbd" xlink:to="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_f45c8015-bc90-4790-85bf-0489ce72eab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPremiumsReceivable_9be99810-5a45-4d0a-a3f4-2240312e79a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPremiumsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_f45c8015-bc90-4790-85bf-0489ce72eab3" xlink:to="loc_us-gaap_IncreaseDecreaseInPremiumsReceivable_9be99810-5a45-4d0a-a3f4-2240312e79a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable_c79104e3-14bc-4d67-b16f-ada6f027cc4f" xlink:href="moh-20220930.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_f45c8015-bc90-4790-85bf-0489ce72eab3" xlink:to="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable_c79104e3-14bc-4d67-b16f-ada6f027cc4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable_b8732573-ccd1-4102-860d-243116e3e9f5" xlink:href="moh-20220930.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_f45c8015-bc90-4790-85bf-0489ce72eab3" xlink:to="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable_b8732573-ccd1-4102-860d-243116e3e9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable_e7f0b046-3677-4a4e-998f-35878ffb597b" xlink:href="moh-20220930.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_f45c8015-bc90-4790-85bf-0489ce72eab3" xlink:to="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable_e7f0b046-3677-4a4e-998f-35878ffb597b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_InvestmentsMaturityPeriod_cf600b6a-7f46-4b1f-82f5-fb3f52c62be6" xlink:href="moh-20220930.xsd#moh_InvestmentsMaturityPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_f45c8015-bc90-4790-85bf-0489ce72eab3" xlink:to="loc_moh_InvestmentsMaturityPeriod_cf600b6a-7f46-4b1f-82f5-fb3f52c62be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_InvestmentsAverageMaturityPeriod_e5f60b78-4fc3-4130-8eb5-a05907e2886a" xlink:href="moh-20220930.xsd#moh_InvestmentsAverageMaturityPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_f45c8015-bc90-4790-85bf-0489ce72eab3" xlink:to="loc_moh_InvestmentsAverageMaturityPeriod_e5f60b78-4fc3-4130-8eb5-a05907e2886a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/NetIncomePerShareDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#NetIncomePerShareDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/NetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1cecdff4-e764-441c-8758-500d9dd0388a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_83212010-4187-41fe-a63a-2cbaf8c6ccb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1cecdff4-e764-441c-8758-500d9dd0388a" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_83212010-4187-41fe-a63a-2cbaf8c6ccb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9956d7d0-4e8e-4322-9caf-c530361b3a14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_83212010-4187-41fe-a63a-2cbaf8c6ccb9" xlink:to="loc_us-gaap_NetIncomeLoss_9956d7d0-4e8e-4322-9caf-c530361b3a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_ec799187-99a7-40c3-89cb-a1204e269794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1cecdff4-e764-441c-8758-500d9dd0388a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_ec799187-99a7-40c3-89cb-a1204e269794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_SharesOutstandingExcludingRestrictedStockAwards_312385d9-8188-4da3-babd-44b39abeccc4" xlink:href="moh-20220930.xsd#moh_SharesOutstandingExcludingRestrictedStockAwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_ec799187-99a7-40c3-89cb-a1204e269794" xlink:to="loc_moh_SharesOutstandingExcludingRestrictedStockAwards_312385d9-8188-4da3-babd-44b39abeccc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_41726325-8fe6-4c19-8d4d-37f4aae2224d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_ec799187-99a7-40c3-89cb-a1204e269794" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_41726325-8fe6-4c19-8d4d-37f4aae2224d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_WeightedAverageNumberofSharesShareBasedCompensation_d57c4249-71af-442c-b2b8-a69234becc40" xlink:href="moh-20220930.xsd#moh_WeightedAverageNumberofSharesShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_41726325-8fe6-4c19-8d4d-37f4aae2224d" xlink:to="loc_moh_WeightedAverageNumberofSharesShareBasedCompensation_d57c4249-71af-442c-b2b8-a69234becc40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_b6c66a28-d55a-4832-9293-120747a95756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_41726325-8fe6-4c19-8d4d-37f4aae2224d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_b6c66a28-d55a-4832-9293-120747a95756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_917fd1f6-c12e-4e6b-9a0a-95276ea44112" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_41726325-8fe6-4c19-8d4d-37f4aae2224d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_917fd1f6-c12e-4e6b-9a0a-95276ea44112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_d719369a-edea-4e4e-852f-c1b559e31796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_ec799187-99a7-40c3-89cb-a1204e269794" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_d719369a-edea-4e4e-852f-c1b559e31796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_89d2903a-7c09-4308-aa09-cf168e34d6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_d719369a-edea-4e4e-852f-c1b559e31796" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_89d2903a-7c09-4308-aa09-cf168e34d6ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2b4e1663-3f88-499c-a2e8-e96b64ad6da6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1cecdff4-e764-441c-8758-500d9dd0388a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2b4e1663-3f88-499c-a2e8-e96b64ad6da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_EarningsPerShareBasicAndDilutedEPSAbstract_656c7c71-e8a2-47be-925f-79232b2180a2" xlink:href="moh-20220930.xsd#moh_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1cecdff4-e764-441c-8758-500d9dd0388a" xlink:to="loc_moh_EarningsPerShareBasicAndDilutedEPSAbstract_656c7c71-e8a2-47be-925f-79232b2180a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b041ea36-d1c1-4ef5-9acc-9bef88d631df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_EarningsPerShareBasicAndDilutedEPSAbstract_656c7c71-e8a2-47be-925f-79232b2180a2" xlink:to="loc_us-gaap_EarningsPerShareBasic_b041ea36-d1c1-4ef5-9acc-9bef88d631df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1d3c016d-97f8-4023-8fe6-59bcfd395be4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_EarningsPerShareBasicAndDilutedEPSAbstract_656c7c71-e8a2-47be-925f-79232b2180a2" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1d3c016d-97f8-4023-8fe6-59bcfd395be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/BusinessCombinationsDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#BusinessCombinationsDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/BusinessCombinationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_808fa11d-e03c-482c-b8fc-d1db4101e358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_ce9b9b05-7119-4b89-be4c-b893c27719bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_808fa11d-e03c-482c-b8fc-d1db4101e358" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_ce9b9b05-7119-4b89-be4c-b893c27719bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_aeede69c-8657-451e-a1d2-673aaaa0c674" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_ce9b9b05-7119-4b89-be4c-b893c27719bc" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_aeede69c-8657-451e-a1d2-673aaaa0c674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5faa97ac-a13d-43a0-af58-d3fb97e42ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_aeede69c-8657-451e-a1d2-673aaaa0c674" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5faa97ac-a13d-43a0-af58-d3fb97e42ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AgeWellMember_09d18354-8124-42ad-933c-86cb548c6017" xlink:href="moh-20220930.xsd#moh_AgeWellMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5faa97ac-a13d-43a0-af58-d3fb97e42ab4" xlink:to="loc_moh_AgeWellMember_09d18354-8124-42ad-933c-86cb548c6017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember_c43cc9de-e035-44a3-9f1c-6774eb1f25e1" xlink:href="moh-20220930.xsd#moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5faa97ac-a13d-43a0-af58-d3fb97e42ab4" xlink:to="loc_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember_c43cc9de-e035-44a3-9f1c-6774eb1f25e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffinityHealthPlanIncMember_8a341408-617d-4580-8c87-421bb392d715" xlink:href="moh-20220930.xsd#moh_AffinityHealthPlanIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5faa97ac-a13d-43a0-af58-d3fb97e42ab4" xlink:to="loc_moh_AffinityHealthPlanIncMember_8a341408-617d-4580-8c87-421bb392d715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e2f31cd8-878e-4e90-be24-1048ed994541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_ce9b9b05-7119-4b89-be4c-b893c27719bc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e2f31cd8-878e-4e90-be24-1048ed994541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_69a38255-9f63-4de7-9ced-012461279e72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e2f31cd8-878e-4e90-be24-1048ed994541" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_69a38255-9f63-4de7-9ced-012461279e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MemberListsMember_21c6dca2-5292-44d7-9cdf-6c4ce46daa4d" xlink:href="moh-20220930.xsd#moh_MemberListsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_69a38255-9f63-4de7-9ced-012461279e72" xlink:to="loc_moh_MemberListsMember_21c6dca2-5292-44d7-9cdf-6c4ce46daa4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_837bf588-5869-4cea-9ef8-1860a1cafea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_ce9b9b05-7119-4b89-be4c-b893c27719bc" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_837bf588-5869-4cea-9ef8-1860a1cafea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_af9776bc-adea-480e-8965-ae3b3b950272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_837bf588-5869-4cea-9ef8-1860a1cafea0" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_af9776bc-adea-480e-8965-ae3b3b950272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_fc0442d0-1c78-485c-800b-e8ae08a11a88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_837bf588-5869-4cea-9ef8-1860a1cafea0" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_fc0442d0-1c78-485c-800b-e8ae08a11a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_eef0b802-44c6-4442-9e6a-fcdba6d35ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_837bf588-5869-4cea-9ef8-1860a1cafea0" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_eef0b802-44c6-4442-9e6a-fcdba6d35ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable_429e5f71-510b-4d3c-864f-a8785ac1739d" xlink:href="moh-20220930.xsd#moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_837bf588-5869-4cea-9ef8-1860a1cafea0" xlink:to="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable_429e5f71-510b-4d3c-864f-a8785ac1739d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables_7ea4c23a-1e73-4a94-b829-9959ad8d59e4" xlink:href="moh-20220930.xsd#moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_837bf588-5869-4cea-9ef8-1860a1cafea0" xlink:to="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables_7ea4c23a-1e73-4a94-b829-9959ad8d59e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_208b2c4c-9d01-415a-8e07-b885ed9aff81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ef2e6986-e895-4eb2-b90b-01ce404e4295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_208b2c4c-9d01-415a-8e07-b885ed9aff81" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ef2e6986-e895-4eb2-b90b-01ce404e4295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dbb08f00-cfcc-4fe2-a2dc-615bad3eec29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ef2e6986-e895-4eb2-b90b-01ce404e4295" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dbb08f00-cfcc-4fe2-a2dc-615bad3eec29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78668811-6c28-4468-b496-be78dec08611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dbb08f00-cfcc-4fe2-a2dc-615bad3eec29" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78668811-6c28-4468-b496-be78dec08611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_46bb060c-2047-4659-a7c3-a0ad2bfd3681" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78668811-6c28-4468-b496-be78dec08611" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_46bb060c-2047-4659-a7c3-a0ad2bfd3681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1bd1b0f7-860e-4a3c-a54c-f931b0ba2a08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78668811-6c28-4468-b496-be78dec08611" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1bd1b0f7-860e-4a3c-a54c-f931b0ba2a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ff9755de-bf8b-4a68-afc2-fa7854f0ed08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78668811-6c28-4468-b496-be78dec08611" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ff9755de-bf8b-4a68-afc2-fa7854f0ed08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_60f5ec5b-ec99-43b8-a13b-cd671904b0eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ef2e6986-e895-4eb2-b90b-01ce404e4295" xlink:to="loc_us-gaap_FinancialInstrumentAxis_60f5ec5b-ec99-43b8-a13b-cd671904b0eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a75507f1-20a0-4d4c-b2f1-1ad028835f73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_60f5ec5b-ec99-43b8-a13b-cd671904b0eb" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a75507f1-20a0-4d4c-b2f1-1ad028835f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9884eb38-6c70-4c2d-989a-96c7e833a191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a75507f1-20a0-4d4c-b2f1-1ad028835f73" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9884eb38-6c70-4c2d-989a-96c7e833a191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_c771bd6e-7d6b-47e4-b0c0-2b4f0811dc93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a75507f1-20a0-4d4c-b2f1-1ad028835f73" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_c771bd6e-7d6b-47e4-b0c0-2b4f0811dc93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_4a72fb13-f33b-462d-aafa-4adc6d581279" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a75507f1-20a0-4d4c-b2f1-1ad028835f73" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_4a72fb13-f33b-462d-aafa-4adc6d581279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MunicipalSecuritiesMember_a4e870f6-3665-4385-9b69-da748c5f127c" xlink:href="moh-20220930.xsd#moh_MunicipalSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a75507f1-20a0-4d4c-b2f1-1ad028835f73" xlink:to="loc_moh_MunicipalSecuritiesMember_a4e870f6-3665-4385-9b69-da748c5f127c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_ec1edae8-06df-4afd-9357-4dfb212f9bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a75507f1-20a0-4d4c-b2f1-1ad028835f73" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_ec1edae8-06df-4afd-9357-4dfb212f9bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherSecuritiesMember_fa02f0c8-1232-49d0-9103-d2d44cf1df70" xlink:href="moh-20220930.xsd#moh_OtherSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a75507f1-20a0-4d4c-b2f1-1ad028835f73" xlink:to="loc_moh_OtherSecuritiesMember_fa02f0c8-1232-49d0-9103-d2d44cf1df70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42897a98-3274-4048-a521-dd58260ccff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ef2e6986-e895-4eb2-b90b-01ce404e4295" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42897a98-3274-4048-a521-dd58260ccff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_6ebac758-75aa-4d73-b6c6-50d6ad760147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42897a98-3274-4048-a521-dd58260ccff8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_6ebac758-75aa-4d73-b6c6-50d6ad760147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_1558e525-47cf-4222-93c1-dedeb4239d31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42897a98-3274-4048-a521-dd58260ccff8" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_1558e525-47cf-4222-93c1-dedeb4239d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9e8e3fb3-3e87-4cbd-b754-e46207c355d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42897a98-3274-4048-a521-dd58260ccff8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9e8e3fb3-3e87-4cbd-b754-e46207c355d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_f9e074e2-a1c4-4840-9e74-a092f146cfc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42897a98-3274-4048-a521-dd58260ccff8" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_f9e074e2-a1c4-4840-9e74-a092f146cfc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_de6f172d-ed80-4a45-92be-0a7f4da3b95a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a57805c7-ed23-45f8-9695-a50a3c46d9b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_de6f172d-ed80-4a45-92be-0a7f4da3b95a" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a57805c7-ed23-45f8-9695-a50a3c46d9b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_eef31dc5-c5db-4dbd-abcb-b5b82c6470ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a57805c7-ed23-45f8-9695-a50a3c46d9b5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_eef31dc5-c5db-4dbd-abcb-b5b82c6470ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4eee63d7-966d-42ab-b0a9-14caa9c62681" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_eef31dc5-c5db-4dbd-abcb-b5b82c6470ed" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4eee63d7-966d-42ab-b0a9-14caa9c62681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PassportHealthPlanIncMember_4ed2a67f-ca23-471c-8223-adee953c2c6b" xlink:href="moh-20220930.xsd#moh_PassportHealthPlanIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4eee63d7-966d-42ab-b0a9-14caa9c62681" xlink:to="loc_moh_PassportHealthPlanIncMember_4ed2a67f-ca23-471c-8223-adee953c2c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1b660b5f-b648-42fb-ad86-cd89ce31c488" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a57805c7-ed23-45f8-9695-a50a3c46d9b5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1b660b5f-b648-42fb-ad86-cd89ce31c488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_25de6241-62dd-4721-9d5e-53d670377cde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1b660b5f-b648-42fb-ad86-cd89ce31c488" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_25de6241-62dd-4721-9d5e-53d670377cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ea1d999f-dbe9-4a3b-93f1-9b0ce9b6b0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_25de6241-62dd-4721-9d5e-53d670377cde" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ea1d999f-dbe9-4a3b-93f1-9b0ce9b6b0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_3318e2a1-fc39-45b8-a38c-bbd22942704f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a57805c7-ed23-45f8-9695-a50a3c46d9b5" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_3318e2a1-fc39-45b8-a38c-bbd22942704f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_26272709-75e7-4ff5-9817-cc20e01760de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_3318e2a1-fc39-45b8-a38c-bbd22942704f" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_26272709-75e7-4ff5-9817-cc20e01760de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MinimumMemberEnrollmentTargetsMember_dd542508-a3ba-4c07-a1b9-e9a2e9a48db6" xlink:href="moh-20220930.xsd#moh_MinimumMemberEnrollmentTargetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_26272709-75e7-4ff5-9817-cc20e01760de" xlink:to="loc_moh_MinimumMemberEnrollmentTargetsMember_dd542508-a3ba-4c07-a1b9-e9a2e9a48db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OperatingIncomeGuaranteeMember_d7e0209d-0624-4f40-93bb-ec547ed6aa5d" xlink:href="moh-20220930.xsd#moh_OperatingIncomeGuaranteeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_26272709-75e7-4ff5-9817-cc20e01760de" xlink:to="loc_moh_OperatingIncomeGuaranteeMember_d7e0209d-0624-4f40-93bb-ec547ed6aa5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b2240dd9-4e6e-4b7a-8f3f-5d23d9394471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a57805c7-ed23-45f8-9695-a50a3c46d9b5" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b2240dd9-4e6e-4b7a-8f3f-5d23d9394471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_9170ac6a-d575-4208-b43a-a3df96d6df0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b2240dd9-4e6e-4b7a-8f3f-5d23d9394471" xlink:to="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_9170ac6a-d575-4208-b43a-a3df96d6df0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6ffa84a1-3c8a-4e0f-9126-727d6e397796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b2240dd9-4e6e-4b7a-8f3f-5d23d9394471" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6ffa84a1-3c8a-4e0f-9126-727d6e397796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities_9a289766-0c8c-4c2b-a8e9-b742bc048860" xlink:href="moh-20220930.xsd#moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b2240dd9-4e6e-4b7a-8f3f-5d23d9394471" xlink:to="loc_moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities_9a289766-0c8c-4c2b-a8e9-b742bc048860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_6d4076bc-699d-4e49-84d5-25067721f1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b2240dd9-4e6e-4b7a-8f3f-5d23d9394471" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_6d4076bc-699d-4e49-84d5-25067721f1b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_5f632fdc-4432-47d8-b195-d924402cc9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b2240dd9-4e6e-4b7a-8f3f-5d23d9394471" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_5f632fdc-4432-47d8-b195-d924402cc9f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#FairValueMeasurementsLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f27db2ab-a999-482d-9336-55c61a64c25a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_906dd3cf-44ae-4e55-afbe-daade1902679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f27db2ab-a999-482d-9336-55c61a64c25a" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_906dd3cf-44ae-4e55-afbe-daade1902679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_eb176fd5-b332-4778-8bfe-e4d2d2a33f11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_906dd3cf-44ae-4e55-afbe-daade1902679" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_eb176fd5-b332-4778-8bfe-e4d2d2a33f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9dcc3aa5-41bc-43d0-a892-35c568a10c63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_eb176fd5-b332-4778-8bfe-e4d2d2a33f11" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9dcc3aa5-41bc-43d0-a892-35c568a10c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_475ff62d-b7b5-44cf-8892-d36bc7d0756f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9dcc3aa5-41bc-43d0-a892-35c568a10c63" xlink:to="loc_us-gaap_SeniorNotesMember_475ff62d-b7b5-44cf-8892-d36bc7d0756f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3f1cbe91-501e-4ad5-9432-2fd78fcb7ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_906dd3cf-44ae-4e55-afbe-daade1902679" xlink:to="loc_us-gaap_DebtInstrumentAxis_3f1cbe91-501e-4ad5-9432-2fd78fcb7ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9343f87b-d7a7-4425-8190-254c5a433ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_3f1cbe91-501e-4ad5-9432-2fd78fcb7ba6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9343f87b-d7a7-4425-8190-254c5a433ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4375SeniorNotesMember_ea21fe32-9510-408d-8047-447c318f560f" xlink:href="moh-20220930.xsd#moh_A4375SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9343f87b-d7a7-4425-8190-254c5a433ef7" xlink:to="loc_moh_A4375SeniorNotesMember_ea21fe32-9510-408d-8047-447c318f560f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_f416ff39-221f-49fe-833e-c77bbbbf4b2f" xlink:href="moh-20220930.xsd#moh_ThreePointEightSevenFivePercentSeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9343f87b-d7a7-4425-8190-254c5a433ef7" xlink:to="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_f416ff39-221f-49fe-833e-c77bbbbf4b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A3875SeniorNotesMember_71f83635-93ca-4cbc-824f-d5cceb178d86" xlink:href="moh-20220930.xsd#moh_A3875SeniorNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9343f87b-d7a7-4425-8190-254c5a433ef7" xlink:to="loc_moh_A3875SeniorNotesMember_71f83635-93ca-4cbc-824f-d5cceb178d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_67f88632-719c-48d1-84d4-bb26d5486170" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_906dd3cf-44ae-4e55-afbe-daade1902679" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_67f88632-719c-48d1-84d4-bb26d5486170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1bc55c6d-b095-4883-9c8a-f520ed2d6e64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_67f88632-719c-48d1-84d4-bb26d5486170" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1bc55c6d-b095-4883-9c8a-f520ed2d6e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_739e4c63-1366-4db9-b4f7-de2f29c02e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1bc55c6d-b095-4883-9c8a-f520ed2d6e64" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_739e4c63-1366-4db9-b4f7-de2f29c02e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_e22a7ab2-9552-4371-8e6c-88589e029f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1bc55c6d-b095-4883-9c8a-f520ed2d6e64" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_e22a7ab2-9552-4371-8e6c-88589e029f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_ac7a3dd3-3a5b-45ac-9052-3aa50a3c65fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1bc55c6d-b095-4883-9c8a-f520ed2d6e64" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_ac7a3dd3-3a5b-45ac-9052-3aa50a3c65fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5db5e3fc-edfa-4dc1-ab4b-d41bb29300f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_906dd3cf-44ae-4e55-afbe-daade1902679" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5db5e3fc-edfa-4dc1-ab4b-d41bb29300f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b454598a-c314-4b57-a530-d7afd424b3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5db5e3fc-edfa-4dc1-ab4b-d41bb29300f3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b454598a-c314-4b57-a530-d7afd424b3d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_42723e84-7948-4d86-81fe-9b35502d19fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5db5e3fc-edfa-4dc1-ab4b-d41bb29300f3" xlink:to="loc_us-gaap_DebtInstrumentFairValue_42723e84-7948-4d86-81fe-9b35502d19fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#InvestmentsSummaryofInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_35c971cd-4fd5-4215-bcee-87593af8ee08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5de4e187-5587-4769-bb99-500440e6f3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_35c971cd-4fd5-4215-bcee-87593af8ee08" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5de4e187-5587-4769-bb99-500440e6f3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_195e71a7-ef28-4e40-a26f-e6cda865d216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5de4e187-5587-4769-bb99-500440e6f3a7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_195e71a7-ef28-4e40-a26f-e6cda865d216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8b1b1b50-d362-4959-9c2d-b864f0e19fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_195e71a7-ef28-4e40-a26f-e6cda865d216" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8b1b1b50-d362-4959-9c2d-b864f0e19fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_7c3fbb69-e30d-442b-ad3f-18918eb27ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8b1b1b50-d362-4959-9c2d-b864f0e19fdf" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_7c3fbb69-e30d-442b-ad3f-18918eb27ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember_2a7c5717-4303-47de-804b-3790ccadd367" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8b1b1b50-d362-4959-9c2d-b864f0e19fdf" xlink:to="loc_us-gaap_MortgageBackedSecuritiesMember_2a7c5717-4303-47de-804b-3790ccadd367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_a41ad8af-2dbe-4e7b-8996-dac9b2e40c85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8b1b1b50-d362-4959-9c2d-b864f0e19fdf" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_a41ad8af-2dbe-4e7b-8996-dac9b2e40c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MunicipalSecuritiesMember_2cf40214-e7c0-4460-bb92-5db9b8c4faad" xlink:href="moh-20220930.xsd#moh_MunicipalSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8b1b1b50-d362-4959-9c2d-b864f0e19fdf" xlink:to="loc_moh_MunicipalSecuritiesMember_2cf40214-e7c0-4460-bb92-5db9b8c4faad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_d93e5c3a-20c2-4444-a7ac-c6cb5e9ec377" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8b1b1b50-d362-4959-9c2d-b864f0e19fdf" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_d93e5c3a-20c2-4444-a7ac-c6cb5e9ec377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherSecuritiesMember_3f210c76-5bc1-4aa3-a83a-27f60d8a05ed" xlink:href="moh-20220930.xsd#moh_OtherSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8b1b1b50-d362-4959-9c2d-b864f0e19fdf" xlink:to="loc_moh_OtherSecuritiesMember_3f210c76-5bc1-4aa3-a83a-27f60d8a05ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7dca7ab0-5718-43f1-b559-8d9c26012205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5de4e187-5587-4769-bb99-500440e6f3a7" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7dca7ab0-5718-43f1-b559-8d9c26012205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_73784cef-db27-426d-a6e1-d5203b8d61dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7dca7ab0-5718-43f1-b559-8d9c26012205" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_73784cef-db27-426d-a6e1-d5203b8d61dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4cc89dd0-c1f2-4259-943c-a0277e8c0aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7dca7ab0-5718-43f1-b559-8d9c26012205" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4cc89dd0-c1f2-4259-943c-a0277e8c0aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_50a366a0-5b66-4027-b9bb-110b71436f23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7dca7ab0-5718-43f1-b559-8d9c26012205" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_50a366a0-5b66-4027-b9bb-110b71436f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_e6e5b256-3442-4909-9e50-fa7e2bb8bb23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7dca7ab0-5718-43f1-b559-8d9c26012205" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_e6e5b256-3442-4909-9e50-fa7e2bb8bb23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_54a3bcb0-6494-4c15-a6c6-c8338313add0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_56b095dd-2364-4425-90e4-2e4c82f57ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_54a3bcb0-6494-4c15-a6c6-c8338313add0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_56b095dd-2364-4425-90e4-2e4c82f57ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_8da7cdfe-a74d-4d9a-8cff-35787de95d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_56b095dd-2364-4425-90e4-2e4c82f57ca3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_8da7cdfe-a74d-4d9a-8cff-35787de95d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_0c8463d4-ca1c-4137-a6d4-e8c3bfe714ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_56b095dd-2364-4425-90e4-2e4c82f57ca3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_0c8463d4-ca1c-4137-a6d4-e8c3bfe714ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_8761a75d-6dad-4862-91ad-ef26d8551093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_56b095dd-2364-4425-90e4-2e4c82f57ca3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_8761a75d-6dad-4862-91ad-ef26d8551093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_1ae438de-a146-494c-83ee-7c6f3c842cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_56b095dd-2364-4425-90e4-2e4c82f57ca3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_1ae438de-a146-494c-83ee-7c6f3c842cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_b4a40e06-052f-4e98-a022-f33066e899c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_56b095dd-2364-4425-90e4-2e4c82f57ca3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_b4a40e06-052f-4e98-a022-f33066e899c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_13aadd69-9aa8-462c-8459-75cdcb58b9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_54a3bcb0-6494-4c15-a6c6-c8338313add0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_13aadd69-9aa8-462c-8459-75cdcb58b9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8fa0505b-9e51-41e0-b575-2c520bb8c883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_13aadd69-9aa8-462c-8459-75cdcb58b9cf" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8fa0505b-9e51-41e0-b575-2c520bb8c883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_e3098176-0480-464e-b9cf-b01bb55853c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_13aadd69-9aa8-462c-8459-75cdcb58b9cf" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_e3098176-0480-464e-b9cf-b01bb55853c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_f1d55617-09e7-4330-8085-32b4c8463cda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_13aadd69-9aa8-462c-8459-75cdcb58b9cf" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_f1d55617-09e7-4330-8085-32b4c8463cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_b68f3326-e44b-41de-9926-43619bd3e850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_13aadd69-9aa8-462c-8459-75cdcb58b9cf" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_b68f3326-e44b-41de-9926-43619bd3e850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_17b46e74-6d88-4e29-8fc2-a02ab036a42d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_13aadd69-9aa8-462c-8459-75cdcb58b9cf" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_17b46e74-6d88-4e29-8fc2-a02ab036a42d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#InvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7f165f2d-a92d-4136-af24-44bbae54d2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_0526b0d6-6271-413c-94a0-58c17c23c784" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7f165f2d-a92d-4136-af24-44bbae54d2e9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_0526b0d6-6271-413c-94a0-58c17c23c784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_88f00d81-7200-4541-babf-a7f1f9c2f0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7f165f2d-a92d-4136-af24-44bbae54d2e9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_88f00d81-7200-4541-babf-a7f1f9c2f0e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss_dfe50a57-2971-4e9c-8cd8-0fb0a69b022b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7f165f2d-a92d-4136-af24-44bbae54d2e9" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss_dfe50a57-2971-4e9c-8cd8-0fb0a69b022b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount_35a4594a-6df9-4d32-895d-372364806d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7f165f2d-a92d-4136-af24-44bbae54d2e9" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount_35a4594a-6df9-4d32-895d-372364806d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount_d208a457-933b-4dcc-8c09-49e8b62ce1e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7f165f2d-a92d-4136-af24-44bbae54d2e9" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount_d208a457-933b-4dcc-8c09-49e8b62ce1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount_5ed5cb58-48a9-496c-be6f-6ce76216b04c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7f165f2d-a92d-4136-af24-44bbae54d2e9" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount_5ed5cb58-48a9-496c-be6f-6ce76216b04c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#InvestmentsAvailableforSaleInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a2f3e097-f263-4e2e-b1fa-205ff4e0ff52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_75b74c17-189c-49db-ac6c-13d9a5154fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a2f3e097-f263-4e2e-b1fa-205ff4e0ff52" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_75b74c17-189c-49db-ac6c-13d9a5154fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0cce8d3f-f718-4998-ba06-ee98e601ab73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_75b74c17-189c-49db-ac6c-13d9a5154fd1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0cce8d3f-f718-4998-ba06-ee98e601ab73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a50ffe9f-3045-4bde-9bce-5a502cbbc149" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0cce8d3f-f718-4998-ba06-ee98e601ab73" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a50ffe9f-3045-4bde-9bce-5a502cbbc149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_3bb7d1b6-d031-400b-b278-090ca74f0667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a50ffe9f-3045-4bde-9bce-5a502cbbc149" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_3bb7d1b6-d031-400b-b278-090ca74f0667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember_fc84c6b7-a366-48e2-8a96-bd2c9e022afa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a50ffe9f-3045-4bde-9bce-5a502cbbc149" xlink:to="loc_us-gaap_MortgageBackedSecuritiesMember_fc84c6b7-a366-48e2-8a96-bd2c9e022afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_271ac39e-447c-4cdf-a3f1-5990cc63722b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a50ffe9f-3045-4bde-9bce-5a502cbbc149" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_271ac39e-447c-4cdf-a3f1-5990cc63722b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MunicipalSecuritiesMember_ca8d95c3-f9a1-4087-92a2-6842c233e431" xlink:href="moh-20220930.xsd#moh_MunicipalSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a50ffe9f-3045-4bde-9bce-5a502cbbc149" xlink:to="loc_moh_MunicipalSecuritiesMember_ca8d95c3-f9a1-4087-92a2-6842c233e431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_5ab55505-9112-4247-b42b-4a1ca5b6cb61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a50ffe9f-3045-4bde-9bce-5a502cbbc149" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_5ab55505-9112-4247-b42b-4a1ca5b6cb61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherSecuritiesMember_7c0472fa-5c20-47fe-a7fd-cbdf8e9237ed" xlink:href="moh-20220930.xsd#moh_OtherSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a50ffe9f-3045-4bde-9bce-5a502cbbc149" xlink:to="loc_moh_OtherSecuritiesMember_7c0472fa-5c20-47fe-a7fd-cbdf8e9237ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_61a1b19e-8b97-4bb0-8ffa-f1480b1330ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_75b74c17-189c-49db-ac6c-13d9a5154fd1" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_61a1b19e-8b97-4bb0-8ffa-f1480b1330ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_e1385939-7a87-4dc8-90ab-c1e18bddb7de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_61a1b19e-8b97-4bb0-8ffa-f1480b1330ba" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_e1385939-7a87-4dc8-90ab-c1e18bddb7de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_cebe42b7-161b-4a67-a5dc-109c72574517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_61a1b19e-8b97-4bb0-8ffa-f1480b1330ba" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_cebe42b7-161b-4a67-a5dc-109c72574517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_2a84c9cc-cffa-4423-be3b-588c474380e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_61a1b19e-8b97-4bb0-8ffa-f1480b1330ba" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_2a84c9cc-cffa-4423-be3b-588c474380e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_f7634d85-25b7-4df2-a579-1ac28815fdd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_61a1b19e-8b97-4bb0-8ffa-f1480b1330ba" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_f7634d85-25b7-4df2-a579-1ac28815fdd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_7181147e-a99e-4e65-9f4a-439c71cbe5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_61a1b19e-8b97-4bb0-8ffa-f1480b1330ba" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_7181147e-a99e-4e65-9f4a-439c71cbe5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_9bf2fbce-e0fc-4ccf-b463-647383d25885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_61a1b19e-8b97-4bb0-8ffa-f1480b1330ba" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_9bf2fbce-e0fc-4ccf-b463-647383d25885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_a2503d3e-542f-4c53-8a37-58bb8852be66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount_5bee8d38-96ed-45d6-8846-32b78df246f2" xlink:href="moh-20220930.xsd#moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_a2503d3e-542f-4c53-8a37-58bb8852be66" xlink:to="loc_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount_5bee8d38-96ed-45d6-8846-32b78df246f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PharmacyClaimsPayable_7ff5b11f-ab96-4494-8779-2e32c7b09575" xlink:href="moh-20220930.xsd#moh_PharmacyClaimsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_a2503d3e-542f-4c53-8a37-58bb8852be66" xlink:to="loc_moh_PharmacyClaimsPayable_7ff5b11f-ab96-4494-8779-2e32c7b09575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CapitationClaimsPayable_df6d881c-c525-4296-8302-e9ff3ee6ba9b" xlink:href="moh-20220930.xsd#moh_CapitationClaimsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_a2503d3e-542f-4c53-8a37-58bb8852be66" xlink:to="loc_moh_CapitationClaimsPayable_df6d881c-c525-4296-8302-e9ff3ee6ba9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherClaimsPayable_bad57eb6-9efa-4531-b1f1-f35d07691cfc" xlink:href="moh-20220930.xsd#moh_OtherClaimsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_a2503d3e-542f-4c53-8a37-58bb8852be66" xlink:to="loc_moh_OtherClaimsPayable_bad57eb6-9efa-4531-b1f1-f35d07691cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_26933830-775b-4000-807e-2879d888d865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_a2503d3e-542f-4c53-8a37-58bb8852be66" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_26933830-775b-4000-807e-2879d888d865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableNarrativeDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#MedicalClaimsandBenefitsPayableNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_5ed70a51-424b-4e2b-b541-3ead6ac26ded" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalClaimsAndBenefitsPayable_df4dda39-8b38-4678-95e3-d89a6dfc216c" xlink:href="moh-20220930.xsd#moh_MedicalClaimsAndBenefitsPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_5ed70a51-424b-4e2b-b541-3ead6ac26ded" xlink:to="loc_moh_MedicalClaimsAndBenefitsPayable_df4dda39-8b38-4678-95e3-d89a6dfc216c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_f3c6b9d4-8796-408a-b244-6d3d6da5869f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_5ed70a51-424b-4e2b-b541-3ead6ac26ded" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_f3c6b9d4-8796-408a-b244-6d3d6da5869f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_81ddd663-5eef-4f3a-a98a-d620e6dcd476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_deff403c-9677-41f9-9f30-ff2316587350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_81ddd663-5eef-4f3a-a98a-d620e6dcd476" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_deff403c-9677-41f9-9f30-ff2316587350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_badff41d-2605-46fd-a55c-1e83d8969dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_deff403c-9677-41f9-9f30-ff2316587350" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_badff41d-2605-46fd-a55c-1e83d8969dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8c421fb6-62e9-4070-8406-7a9e9c4e9996" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_badff41d-2605-46fd-a55c-1e83d8969dc0" xlink:to="loc_us-gaap_SegmentDomain_8c421fb6-62e9-4070-8406-7a9e9c4e9996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicaidMember_8ac03e7b-babe-48c5-97d9-77ce9d62417a" xlink:href="moh-20220930.xsd#moh_MedicaidMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8c421fb6-62e9-4070-8406-7a9e9c4e9996" xlink:to="loc_moh_MedicaidMember_8ac03e7b-babe-48c5-97d9-77ce9d62417a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicareMember_7121eee6-479d-4707-a865-5d243ce8fd17" xlink:href="moh-20220930.xsd#moh_MedicareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8c421fb6-62e9-4070-8406-7a9e9c4e9996" xlink:to="loc_moh_MedicareMember_7121eee6-479d-4707-a865-5d243ce8fd17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MarketplaceMember_b6146dcf-2ee0-4fd4-ba3b-5a295fa3bdb0" xlink:href="moh-20220930.xsd#moh_MarketplaceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8c421fb6-62e9-4070-8406-7a9e9c4e9996" xlink:to="loc_moh_MarketplaceMember_b6146dcf-2ee0-4fd4-ba3b-5a295fa3bdb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_d4549ddf-cd5e-4a20-a893-8011f46e0f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_deff403c-9677-41f9-9f30-ff2316587350" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_d4549ddf-cd5e-4a20-a893-8011f46e0f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ee8b4a3f-a08b-4fec-9408-f259be457500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_d4549ddf-cd5e-4a20-a893-8011f46e0f9b" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ee8b4a3f-a08b-4fec-9408-f259be457500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_eac4e058-8f4d-44ab-93a9-1db612ef1f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ee8b4a3f-a08b-4fec-9408-f259be457500" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_eac4e058-8f4d-44ab-93a9-1db612ef1f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ComponentsOfMedicalCareCostsAbstract_4b3418af-7c95-4c06-b4cf-1f3060fb71cf" xlink:href="moh-20220930.xsd#moh_ComponentsOfMedicalCareCostsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ee8b4a3f-a08b-4fec-9408-f259be457500" xlink:to="loc_moh_ComponentsOfMedicalCareCostsAbstract_4b3418af-7c95-4c06-b4cf-1f3060fb71cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_8fbeeda8-2b73-4494-bcc0-499322cd8465" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ComponentsOfMedicalCareCostsAbstract_4b3418af-7c95-4c06-b4cf-1f3060fb71cf" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_8fbeeda8-2b73-4494-bcc0-499322cd8465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_ec5cac32-4823-4b94-8bf0-9b0e1b7ec05e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ComponentsOfMedicalCareCostsAbstract_4b3418af-7c95-4c06-b4cf-1f3060fb71cf" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_ec5cac32-4823-4b94-8bf0-9b0e1b7ec05e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_58893ba3-a530-4328-aeef-6df45b80e4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ComponentsOfMedicalCareCostsAbstract_4b3418af-7c95-4c06-b4cf-1f3060fb71cf" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_58893ba3-a530-4328-aeef-6df45b80e4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PaymentsForMedicalCareCostsAbstract_42d0bae6-c094-4f48-8007-fe14c7ffe93d" xlink:href="moh-20220930.xsd#moh_PaymentsForMedicalCareCostsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ee8b4a3f-a08b-4fec-9408-f259be457500" xlink:to="loc_moh_PaymentsForMedicalCareCostsAbstract_42d0bae6-c094-4f48-8007-fe14c7ffe93d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_4b367e0a-635e-4e7f-8847-669c2f8af742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_PaymentsForMedicalCareCostsAbstract_42d0bae6-c094-4f48-8007-fe14c7ffe93d" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_4b367e0a-635e-4e7f-8847-669c2f8af742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_0513ae87-7e75-45b4-802a-fc5e2219c6d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_PaymentsForMedicalCareCostsAbstract_42d0bae6-c094-4f48-8007-fe14c7ffe93d" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_0513ae87-7e75-45b4-802a-fc5e2219c6d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_2dfe3a1e-34ba-4fa5-afe0-21a24a66368f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_PaymentsForMedicalCareCostsAbstract_42d0bae6-c094-4f48-8007-fe14c7ffe93d" xlink:to="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_2dfe3a1e-34ba-4fa5-afe0-21a24a66368f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments_3e96fcef-d084-4247-a45d-dc5b88490344" xlink:href="moh-20220930.xsd#moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ee8b4a3f-a08b-4fec-9408-f259be457500" xlink:to="loc_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments_3e96fcef-d084-4247-a45d-dc5b88490344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider_dc28ef38-260c-4192-8fbe-20b2111e9034" xlink:href="moh-20220930.xsd#moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ee8b4a3f-a08b-4fec-9408-f259be457500" xlink:to="loc_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider_dc28ef38-260c-4192-8fbe-20b2111e9034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_80d269e1-70f7-4542-a488-c10eb909aae8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ee8b4a3f-a08b-4fec-9408-f259be457500" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_80d269e1-70f7-4542-a488-c10eb909aae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#DebtScheduleofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d4bbfe24-a4e3-48cf-a05f-3c5f83fdc160" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c3b1f978-1718-4cd5-941e-72d5cc07efc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d4bbfe24-a4e3-48cf-a05f-3c5f83fdc160" xlink:to="loc_us-gaap_DebtInstrumentTable_c3b1f978-1718-4cd5-941e-72d5cc07efc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a1413a45-a173-4ba4-b27a-fe76fe5c68f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c3b1f978-1718-4cd5-941e-72d5cc07efc9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a1413a45-a173-4ba4-b27a-fe76fe5c68f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_27137f4c-9b4f-45ec-b135-835b5824cede" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a1413a45-a173-4ba4-b27a-fe76fe5c68f1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_27137f4c-9b4f-45ec-b135-835b5824cede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_084bd4c2-4bda-42a6-b24c-15546d1397bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_27137f4c-9b4f-45ec-b135-835b5824cede" xlink:to="loc_us-gaap_SeniorNotesMember_084bd4c2-4bda-42a6-b24c-15546d1397bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3ad27dee-55f5-4e84-b574-989c2a253ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c3b1f978-1718-4cd5-941e-72d5cc07efc9" xlink:to="loc_us-gaap_DebtInstrumentAxis_3ad27dee-55f5-4e84-b574-989c2a253ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_cb32bb31-ba5c-4f7a-b37c-c9919d470ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_3ad27dee-55f5-4e84-b574-989c2a253ec6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_cb32bb31-ba5c-4f7a-b37c-c9919d470ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4375SeniorNotesMember_0d086cc2-fb10-4dab-a366-df45444ac82c" xlink:href="moh-20220930.xsd#moh_A4375SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cb32bb31-ba5c-4f7a-b37c-c9919d470ee1" xlink:to="loc_moh_A4375SeniorNotesMember_0d086cc2-fb10-4dab-a366-df45444ac82c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_b1ba39fc-fc50-4746-9c60-dc4a5b139372" xlink:href="moh-20220930.xsd#moh_ThreePointEightSevenFivePercentSeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cb32bb31-ba5c-4f7a-b37c-c9919d470ee1" xlink:to="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_b1ba39fc-fc50-4746-9c60-dc4a5b139372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A3875SeniorNotesMember_e0d69df7-f865-4157-8a04-b9c555cccfce" xlink:href="moh-20220930.xsd#moh_A3875SeniorNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cb32bb31-ba5c-4f7a-b37c-c9919d470ee1" xlink:to="loc_moh_A3875SeniorNotesMember_e0d69df7-f865-4157-8a04-b9c555cccfce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e4017093-cc35-4767-a9e0-f81801e6ba1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c3b1f978-1718-4cd5-941e-72d5cc07efc9" xlink:to="loc_us-gaap_DebtInstrumentLineItems_e4017093-cc35-4767-a9e0-f81801e6ba1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3aebac39-d0c6-409e-b10b-85c1dbea317c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e4017093-cc35-4767-a9e0-f81801e6ba1a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3aebac39-d0c6-409e-b10b-85c1dbea317c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_274a9a20-bbe2-4317-8da1-86cf8bdc0588" xlink:href="moh-20220930.xsd#moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e4017093-cc35-4767-a9e0-f81801e6ba1a" xlink:to="loc_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_274a9a20-bbe2-4317-8da1-86cf8bdc0588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_9247c742-d47d-4c95-88c1-99a6215e931a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e4017093-cc35-4767-a9e0-f81801e6ba1a" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_9247c742-d47d-4c95-88c1-99a6215e931a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_57feaa79-0066-4d5b-ae36-0506b663f152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e4017093-cc35-4767-a9e0-f81801e6ba1a" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_57feaa79-0066-4d5b-ae36-0506b663f152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4f7e8f3d-ef25-425a-8e26-54d58f0968e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b4f57bc5-ccad-48e5-b833-0e4c41ca31af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4f7e8f3d-ef25-425a-8e26-54d58f0968e1" xlink:to="loc_us-gaap_DebtInstrumentTable_b4f57bc5-ccad-48e5-b833-0e4c41ca31af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_10a38b2c-ced6-4737-b2f7-7cd404901c30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b4f57bc5-ccad-48e5-b833-0e4c41ca31af" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_10a38b2c-ced6-4737-b2f7-7cd404901c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8b19e371-71ae-4773-a246-e57aa3c11c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_10a38b2c-ced6-4737-b2f7-7cd404901c30" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8b19e371-71ae-4773-a246-e57aa3c11c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_35763898-3552-4ce8-8a9a-f91fa69512b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8b19e371-71ae-4773-a246-e57aa3c11c8d" xlink:to="loc_us-gaap_LineOfCreditMember_35763898-3552-4ce8-8a9a-f91fa69512b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_2db4d320-b558-4c69-9405-dd4099ec4d18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8b19e371-71ae-4773-a246-e57aa3c11c8d" xlink:to="loc_us-gaap_SeniorNotesMember_2db4d320-b558-4c69-9405-dd4099ec4d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_51c5c2ea-7baf-488f-a861-403ba9bb68b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b4f57bc5-ccad-48e5-b833-0e4c41ca31af" xlink:to="loc_us-gaap_CreditFacilityAxis_51c5c2ea-7baf-488f-a861-403ba9bb68b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_91220e66-4d18-43a0-9917-109ee2baa5b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_51c5c2ea-7baf-488f-a861-403ba9bb68b0" xlink:to="loc_us-gaap_CreditFacilityDomain_91220e66-4d18-43a0-9917-109ee2baa5b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_5d56cd01-fc61-4842-8c9f-a1abad9c6fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_91220e66-4d18-43a0-9917-109ee2baa5b3" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_5d56cd01-fc61-4842-8c9f-a1abad9c6fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3a550b21-2b86-487f-9ac0-5782df5d9c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b4f57bc5-ccad-48e5-b833-0e4c41ca31af" xlink:to="loc_us-gaap_DebtInstrumentAxis_3a550b21-2b86-487f-9ac0-5782df5d9c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9ab54b49-2bbf-411d-9fb5-c93cffdd58fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_3a550b21-2b86-487f-9ac0-5782df5d9c9b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9ab54b49-2bbf-411d-9fb5-c93cffdd58fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4375SeniorNotesMember_99bf2fb4-9bb2-4178-89a3-25209c9b091e" xlink:href="moh-20220930.xsd#moh_A4375SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9ab54b49-2bbf-411d-9fb5-c93cffdd58fa" xlink:to="loc_moh_A4375SeniorNotesMember_99bf2fb4-9bb2-4178-89a3-25209c9b091e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_b092dd57-f78e-4a3f-a754-4ae059e92718" xlink:href="moh-20220930.xsd#moh_ThreePointEightSevenFivePercentSeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9ab54b49-2bbf-411d-9fb5-c93cffdd58fa" xlink:to="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_b092dd57-f78e-4a3f-a754-4ae059e92718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A3875SeniorNotesMember_b77f080f-42ab-457b-9079-64d98ba1d0b7" xlink:href="moh-20220930.xsd#moh_A3875SeniorNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9ab54b49-2bbf-411d-9fb5-c93cffdd58fa" xlink:to="loc_moh_A3875SeniorNotesMember_b77f080f-42ab-457b-9079-64d98ba1d0b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7f4d3bef-db79-4d60-a9fd-29da4c62ef6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b4f57bc5-ccad-48e5-b833-0e4c41ca31af" xlink:to="loc_us-gaap_DebtInstrumentLineItems_7f4d3bef-db79-4d60-a9fd-29da4c62ef6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d1272bce-d8c5-4fbb-a28b-9ba3e295ea21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7f4d3bef-db79-4d60-a9fd-29da4c62ef6f" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d1272bce-d8c5-4fbb-a28b-9ba3e295ea21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_009ce139-9aa9-47e7-989f-12605ca976ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7f4d3bef-db79-4d60-a9fd-29da4c62ef6f" xlink:to="loc_us-gaap_DebtInstrumentTerm_009ce139-9aa9-47e7-989f-12605ca976ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_1e246951-d7ef-4e12-b61d-863585f25dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7f4d3bef-db79-4d60-a9fd-29da4c62ef6f" xlink:to="loc_us-gaap_LineOfCredit_1e246951-d7ef-4e12-b61d-863585f25dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f1f3fa32-da0e-4b4d-b492-bdebf7498ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7f4d3bef-db79-4d60-a9fd-29da4c62ef6f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f1f3fa32-da0e-4b4d-b492-bdebf7498ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_560127ab-3237-4b8d-a043-6eab93f0ff56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7f4d3bef-db79-4d60-a9fd-29da4c62ef6f" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_560127ab-3237-4b8d-a043-6eab93f0ff56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c40b4064-dfec-4e27-9d18-639d17eebe41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_7f227ecd-86af-4a5e-ad39-8b6a628d15cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c40b4064-dfec-4e27-9d18-639d17eebe41" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_7f227ecd-86af-4a5e-ad39-8b6a628d15cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f255974f-603c-4774-ad26-ea074b931ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7f227ecd-86af-4a5e-ad39-8b6a628d15cf" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f255974f-603c-4774-ad26-ea074b931ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_76c537cb-3a8b-4d5f-96e9-724fec970bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f255974f-603c-4774-ad26-ea074b931ebb" xlink:to="loc_us-gaap_EquityComponentDomain_76c537cb-3a8b-4d5f-96e9-724fec970bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5a020975-e8df-4bab-8aeb-413ddb3e327e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_76c537cb-3a8b-4d5f-96e9-724fec970bd1" xlink:to="loc_us-gaap_CommonStockMember_5a020975-e8df-4bab-8aeb-413ddb3e327e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_37ccf195-4c3c-41c4-b4b6-bee31341dbec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7f227ecd-86af-4a5e-ad39-8b6a628d15cf" xlink:to="loc_us-gaap_ClassOfStockLineItems_37ccf195-4c3c-41c4-b4b6-bee31341dbec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_2bf96eed-4e10-4ee9-a75e-3396cbf143fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_37ccf195-4c3c-41c4-b4b6-bee31341dbec" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_2bf96eed-4e10-4ee9-a75e-3396cbf143fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_2e9bc036-a635-4190-8cc1-f79da2b005a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_37ccf195-4c3c-41c4-b4b6-bee31341dbec" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_2e9bc036-a635-4190-8cc1-f79da2b005a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_444de233-8ae2-4271-9b4b-c9149db2702c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_37ccf195-4c3c-41c4-b4b6-bee31341dbec" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_444de233-8ae2-4271-9b4b-c9149db2702c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_8971845b-e4f6-4c74-8a40-db03672d6908" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_37ccf195-4c3c-41c4-b4b6-bee31341dbec" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_8971845b-e4f6-4c74-8a40-db03672d6908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SegmentsNarrativeDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#SegmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SegmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_e044d1a8-2c37-4510-a6c3-f33106a1b607" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_6862455b-d170-4bf0-91ef-e706e0771225" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e044d1a8-2c37-4510-a6c3-f33106a1b607" xlink:to="loc_us-gaap_NumberOfReportableSegments_6862455b-d170-4bf0-91ef-e706e0771225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#SegmentsScheduleofOperatingSegmentInformationDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_a2fda80c-aa54-4000-a134-e43c7d6d622e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e9685202-0890-425b-94fe-9d30ae1a0fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a2fda80c-aa54-4000-a134-e43c7d6d622e" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e9685202-0890-425b-94fe-9d30ae1a0fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c7952726-87e3-4e84-9b1f-c59cf91bd016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e9685202-0890-425b-94fe-9d30ae1a0fa5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c7952726-87e3-4e84-9b1f-c59cf91bd016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_72e65d59-0772-4633-8b01-02cd53148f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c7952726-87e3-4e84-9b1f-c59cf91bd016" xlink:to="loc_us-gaap_SegmentDomain_72e65d59-0772-4633-8b01-02cd53148f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicaidMember_287a5636-fa6c-4a5b-8c75-e551595c8216" xlink:href="moh-20220930.xsd#moh_MedicaidMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_72e65d59-0772-4633-8b01-02cd53148f5d" xlink:to="loc_moh_MedicaidMember_287a5636-fa6c-4a5b-8c75-e551595c8216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicareMember_7eef5adc-be10-4a9e-875b-f26904b9a8f8" xlink:href="moh-20220930.xsd#moh_MedicareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_72e65d59-0772-4633-8b01-02cd53148f5d" xlink:to="loc_moh_MedicareMember_7eef5adc-be10-4a9e-875b-f26904b9a8f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MarketplaceMember_89a1981d-b7e0-4a3c-991b-bee3541ac913" xlink:href="moh-20220930.xsd#moh_MarketplaceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_72e65d59-0772-4633-8b01-02cd53148f5d" xlink:to="loc_moh_MarketplaceMember_89a1981d-b7e0-4a3c-991b-bee3541ac913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherProgramMember_2574360b-38c7-4afe-91d5-dfe26c3f903b" xlink:href="moh-20220930.xsd#moh_OtherProgramMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_72e65d59-0772-4633-8b01-02cd53148f5d" xlink:to="loc_moh_OtherProgramMember_2574360b-38c7-4afe-91d5-dfe26c3f903b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_96cb06a3-7acb-48ae-8319-875e5845c634" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e9685202-0890-425b-94fe-9d30ae1a0fa5" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_96cb06a3-7acb-48ae-8319-875e5845c634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_7a01813d-f733-4f50-8017-664ca1077509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_96cb06a3-7acb-48ae-8319-875e5845c634" xlink:to="loc_us-gaap_Revenues_7a01813d-f733-4f50-8017-664ca1077509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" xlink:type="simple" xlink:href="moh-20220930.xsd#SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_61d0a920-12e4-420f-8c0e-fbe72b5b57ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1a69f4ea-373c-45c6-9557-79adeeca6d18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_61d0a920-12e4-420f-8c0e-fbe72b5b57ee" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1a69f4ea-373c-45c6-9557-79adeeca6d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_8b6417d4-161a-4f31-baa6-32fdd78008e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1a69f4ea-373c-45c6-9557-79adeeca6d18" xlink:to="loc_srt_ConsolidationItemsAxis_8b6417d4-161a-4f31-baa6-32fdd78008e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_f14cc286-0606-44bc-9b19-c0f2a78d29cd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_8b6417d4-161a-4f31-baa6-32fdd78008e5" xlink:to="loc_srt_ConsolidationItemsDomain_f14cc286-0606-44bc-9b19-c0f2a78d29cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_3f244c57-e5ec-4852-9f7f-50366d0d5df9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_f14cc286-0606-44bc-9b19-c0f2a78d29cd" xlink:to="loc_us-gaap_OperatingSegmentsMember_3f244c57-e5ec-4852-9f7f-50366d0d5df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_6767457d-ae32-4c66-9850-15a26a7a2116" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_f14cc286-0606-44bc-9b19-c0f2a78d29cd" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_6767457d-ae32-4c66-9850-15a26a7a2116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c40f80d4-00a9-4e61-9bfe-a2c98f14609d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1a69f4ea-373c-45c6-9557-79adeeca6d18" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c40f80d4-00a9-4e61-9bfe-a2c98f14609d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c0ed9049-3847-49f7-a977-7968c546e1f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c40f80d4-00a9-4e61-9bfe-a2c98f14609d" xlink:to="loc_us-gaap_SegmentDomain_c0ed9049-3847-49f7-a977-7968c546e1f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicaidMember_192d68d6-29ef-48b6-9743-86fe7c14237e" xlink:href="moh-20220930.xsd#moh_MedicaidMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c0ed9049-3847-49f7-a977-7968c546e1f9" xlink:to="loc_moh_MedicaidMember_192d68d6-29ef-48b6-9743-86fe7c14237e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicareMember_9f7d5e2a-aaaf-42ef-b86e-2f98088f7d43" xlink:href="moh-20220930.xsd#moh_MedicareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c0ed9049-3847-49f7-a977-7968c546e1f9" xlink:to="loc_moh_MedicareMember_9f7d5e2a-aaaf-42ef-b86e-2f98088f7d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MarketplaceMember_5f47dbd8-483f-454a-8e33-5d8b9776e9ba" xlink:href="moh-20220930.xsd#moh_MarketplaceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c0ed9049-3847-49f7-a977-7968c546e1f9" xlink:to="loc_moh_MarketplaceMember_5f47dbd8-483f-454a-8e33-5d8b9776e9ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherProgramMember_70ff5a1c-99da-42c8-8780-cc046f1bc60d" xlink:href="moh-20220930.xsd#moh_OtherProgramMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c0ed9049-3847-49f7-a977-7968c546e1f9" xlink:to="loc_moh_OtherProgramMember_70ff5a1c-99da-42c8-8780-cc046f1bc60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_7e0fa74a-d157-45e7-9129-59aec91b86e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1a69f4ea-373c-45c6-9557-79adeeca6d18" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_7e0fa74a-d157-45e7-9129-59aec91b86e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_bada00fa-0744-4607-bbec-77d57f0f1c29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7e0fa74a-d157-45e7-9129-59aec91b86e3" xlink:to="loc_us-gaap_GrossProfit_bada00fa-0744-4607-bbec-77d57f0f1c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_8010e3eb-1c6c-40a5-8947-316ab85cac9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7e0fa74a-d157-45e7-9129-59aec91b86e3" xlink:to="loc_us-gaap_Revenues_8010e3eb-1c6c-40a5-8947-316ab85cac9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_aec94557-033c-4964-bd1c-2d1d4b3dbf79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7e0fa74a-d157-45e7-9129-59aec91b86e3" xlink:to="loc_us-gaap_CostsAndExpenses_aec94557-033c-4964-bd1c-2d1d4b3dbf79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_19c6d56d-ad98-4219-92fd-240077a19149" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7e0fa74a-d157-45e7-9129-59aec91b86e3" xlink:to="loc_us-gaap_OperatingIncomeLoss_19c6d56d-ad98-4219-92fd-240077a19149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_7ad325e6-5cce-4054-8bef-83d8c349700e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7e0fa74a-d157-45e7-9129-59aec91b86e3" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_7ad325e6-5cce-4054-8bef-83d8c349700e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ff6a3465-0cf5-4fa3-af98-9e0da226b081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7e0fa74a-d157-45e7-9129-59aec91b86e3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ff6a3465-0cf5-4fa3-af98-9e0da226b081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>exhibit101_changexreques001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit101_changexreques001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8WWQMMR#QP,E#5G1].M[7Q-X'>Q74I+5H]5G$FH1A9<R%&W,  %W$D@8'!H
MWF^)WA];*2Z\O4C';N4O0+&0FR(.#YW'R_KQS76SW4-O927CN/(CC,K,.?E
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MF,F1VVCH3MZ]^@JWJ/B=K>[\/:_8WHN?#NJ.EI*FT8C:3_52@XR/F^5@?4<
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M[OR+K3[B^!$LFR-?+ES@<;T&. <8H ]+O_$.G:9JMKIUU,4N+F*6=>/E2.,
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M&.Q6>*T%Y<W-Z'9$5F*HBJI!+$JQSG  [UP'Q!UW5?$7PZVO#9V[0ZNNG:E
M2[!I4E &P\90\$@C."* /98IHIXEEAD22-NC(P(/XBAY8XB@DD5"[;5W'&X^
M@]36586=YIGA@6MO!I=M=Q1OY<=M"4ME;)(PHY YY]\UY;:ZEX@O_ ?@34+Q
MX+V\GUR)K<L[ MF.<?O&.>A]!T'2@#VJBN G\<:IH2>(8-=MK&6ZTR"WG@>T
M9HXYA,Q1%;>25PXP3D\'-7_#GBJ\O/$3Z)J5QI%U,UH;N&?2Y"R !@KHP))!
M!92#GD'H,4 =A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M >4;\YQ@ELYXS0!QUYX0OM-UG4)M,T+1]6AOXX1&^H,%:UD2,1Y(*,60A5.
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MO#6G7\.HRW-UX=T71XA"(U6SQ)+(^<D[PJ@)P.,$GKQBNIHH **** "BBB@
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M3NX^YZ=^U9WBC5[[Q%X%\;7%I<1V]G8+=62Q&+<9?+3$C,<Y&26"XQC )SG
MZB[\*F\AT))-1E!T>9)XF$:_O&5"@W?@QZ8ZUGWGP^CF_MV"SUB\L[#6Q(UW
M:(B,OFNNUG4L"5SW'?VH JQZYK-VDVE:'"_GZ=I]LVX)&P>62,LH;>ZX3 '3
MDY/(QRY-;\5W7B72]'E%EILMWI#W4Z-%YS03*Z*V"'PP^8XZ=><XQ5N?P&5U
M"VU#3/$&I:=>QVR6EQ-$L3?:8T^[O5DV[ADX8#BM!/"T</B"SU>&]F62ULWL
MTC<!PRLP9F8GDL64'.?YT <7<:_K>L^'?"=R][';W$NO_8;KR8ODE,;R@-@G
M@9B!QGJ?:NGCUS5U\6:]I1:TF2RTV&ZM<J8@7;S!AVR>,H.1C -,3P!#'H=K
MIJ:K=JUIJ1U*"X")O24LS$$$$$?.W;O5B[\%6]]?:O<7-_<NNJ:>-/F0!1B,
M!@"#C.[YV.>G/2@"AX?\3:A=>+;72;BXCNX+G23>F9("BB5716$;?QQG?P>>
MG4U-\+/^2>6'_7:Y_P#2B2IK#P7)9:MI^J/KM]<75G9M9 R1QA7C)4@$!1T*
M@\<GUQQ6GX8T!/#.B1:5%=27$43NZO*H#?.Y<YQQU8T <_>^)-:@U/QI;1R6
M>-(T^&[L]T#$99)6(?YOF^X!D8^E1Z7XAU[^U_"BW]Q:36VO63NT44!1H76)
M9,AMQW9R01@=L5K7/A!;F_U^[_M&9#K5JMI,HC7$:*K*"OOAVZY^E$7A!8[G
MPY-_:,Q.A1-% /+7]Z&01G?[[0.F.>?:@#D;'5[CPU9?$#6[Z9+R.RU)B83$
M%\R00PA.<G:,[1[=:Z2]UC6="U[0[2\N(+JWU=GMRZP[?L]P$+J5 /S(<$8/
M(X^:K,'@JU%OKUK>W,EY:ZW*TMU$Z!=K,H7Y2.0,*,=3D9S4MGX6:*33I+W4
MIKY],1ELFEC4%25V[WQ]]PN1G@<GC/- '(1^*/&$GP\O?%?V[2U%O!=?Z/\
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M%(222!N"[F SP"<#CJ0#0!SGAOQ!JFG>#8+B>Y-]>:AK4UE"6C4%6,\N6/S
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MXM;>]ELI94*I<P@%XSZC/%68D,<2(SL[*H!=L9;W.* '4444 %%%% !1110
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MVXS\K9SD^G2@#J:*\J_X6;XX_P"B5:E_X%G_ .-4?\+-\<?]$JU+_P "S_\
M&J /5:*\J_X6;XX_Z)5J7_@6?_C5'_"S?''_ $2K4O\ P+/_ ,:H ]5HKRK_
M (6;XX_Z)5J7_@6?_C5'_"S?''_1*M2_\"S_ /&J /5:*\J_X6;XX_Z)5J7_
M (%G_P"-4?\ "S?''_1*M2_\"S_\:H ]5HKRK_A9OCC_ *)5J7_@6?\ XU1_
MPLWQQ_T2K4O_  +/_P :H ]5HKRK_A9OCC_HE6I?^!9_^-4?\+-\<?\ 1*M2
M_P# L_\ QJ@#U6BO*O\ A9OCC_HE6I?^!9_^-4?\+-\<?]$JU+_P+/\ \:H
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M,KALKT^4-@9X]#[UE^#_  ]J_P 0M;UCQ[#KUYHWVJ=K:S,$:LS6ZX ^]T'
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MJC_A9OCC_HE6I?\ @6?_ (U0!ZK17E7_  LWQQ_T2K4O_ L__&J/^%F^./\
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M.U>,DCIVKH: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7&_$R\N;/P
MQ;M;7T]D9=1M89)X)-C*CR!6PW;@FNRKD_B'H]QKGA^TL[>T^U#^TK626(@$
M&)907R#P1C.10!S.N2#PS_9UWHGC+4=1OY;Z"!=.N;U+E;E7<*R[<9!"DG<.
MF*Z/5/&\UC<ZH]IHLUYIND$+J%VLZJ8SM#N$0C+[58$\CT&:IZOX3AT#7]*\
M2>&-$MED@;[-?6EK"D?FV[GEU P-Z'!]2,BL74O"T=MKNO"[\(WFM/J-S]HL
MYH;DQPD.BAHY3O&P!@3G:<@]^E $7B*\U76/BYIFF?8IY]-CT]KJ&"'4V@6;
MYP!,2N.G3:?ZUU*>.W>:.[_L>4:#)>_84U+SUR7\SRPWEXR(R_R[LY[XQ4)T
M*\B^+6F:C#9E=,M]#:T\U3E4?S 0G//2N=T;PA!I\T.DW?@^[O+N*_9O[0:Z
M*VQA\TNLOW_O!<?)M^\/3F@#J+;QT]UJ^K6R:/(MAI$\L5_?O.H2)43>&"XR
MQ/.0.G!SS4NE>,;J\OM/AU#0Y=.AU2)I+"5IUD,FU=^UU ^1BF6QST/.15#2
M_#5]/IGCS3[F(V_]KWUS]GD;HR/"B!^.V<_E5#PEH-O#J.F;O!=Y8WME"WVB
M]N;HF..79L_=#>V_=EN<  >_% %RP^)%Q>:=I&KOX=GAT;49X[<737*EHW=M
M@/EXR4W<;LCUQC&;MWXWNDN]0;3O#UUJ&FZ;/]GN[J&5=X<8WB.+&7V[AGD<
MYQG%8L'AW5E^$_AK2FL9!?6MW9O-#D914G5F)YQP!FK%J_B'PM<:[IUAX?GO
MYK_4I;VQN@RBW E()$IW!EVG=V.1C% &EJ/CJ2SFU*>VT6:ZTC2I!'?WHF52
MA"AGV1D9<(&!/([XSBNP5E=0RD%2,@CN*\HO/"B6VKZY%>^$;K6IM0O&N+6X
MBN3';LL@7<LIWC9M;=_"<C&,UZK%&L,*1(H5$4*H'8"@#@;#Q;I^G)XKNK;3
MKHS6NKK:-&]T6$\[LJ*5W'$:Y8>PY-=9HNI:A?BXCU+2)--N(' QYHECD!&0
M4< 9]",#!KA]-T/4;&'QN;[PZ=2M=0U@RK:.R@W$!QEDSP2!R 2.1U%;?@2Q
MN[&35 EIJ5EHK/']@M-1EWR1D ^9C+,50G;@$]CZT :'B'Q/)HNKZ3I=MIDE
M]=ZF)O)5) @!C"D[B>@PQ.>V.A.!6"WQ'U :;JEV/"LY;1I'35$^UH!%M&3Y
M9Q^\^7YNB\8K9UK3;RY\>^%K^&!GM;1+P3R#&$+H@7/U(-8K:%J9\.?$6W%F
M_G:E/<M9KD9F#6R(I'/=@1S0!M:MXHU"V*MI/A^XU* 6@O))VE$*!#G"J2#O
M? )V\8XR>:AE\;-=7.EVN@Z4^I7%]8+J6UYQ L5NV I8D'YB3@#V/-<QJ&@:
MA<WWV;4=!N]31]*MH-._>@6]K*%82F4;A@YVG.&) P/2CP];:UX<N="U2;P]
MJ,\8T"'2;F" 1F6&:%N&P6 *-DX(/89QF@"?PMXLN8-,NQ'8W-YJ6H:_>Q6M
ME+*$*!268.QR%5 ,'&>< 9S7:^'M=.MV]T)K1[.]L[@VUU;,X?RW ####[RE
M64@\=:\U3PEJDMM!J>L:#/<>3K=]<W&GV\P\PQ3]&0AANVL%XSR,UWO@S3K>
MQT^ZEM]!DT9;BX+B&:8R2R*% #OR=I.,;<G  ^@ */B;Q'K>F>.?#FDZ=8)/
M:WRSM)F94,FQ>1R"5VY#9[]*;>>/;F)=5OK+0)KS1]*E>*[O%N%1\Q_ZPQQD
M?.%YR<C.#C-+XNM[^'QCX5UJUTRZO[:Q-U'<+:A2Z>;&JJ<,1QD'//%8K6FN
MZ1H'B/PO;Z#=W<NH7%T;&[C*>1LN"3F1BP*E2QR,<XXSF@#TJWGBNK:*X@</
M%*@=&'\2D9!_*O(]?\4^(-1\,_$&*YM?LL&GL8H)H[A=T)"Q_*-H!.<EMV>,
MXKU32+'^R]%L=/W[_LMO'!N_O;5"Y_2O,=:T;6WL/B%H\6C7DKZK+]JL[A-G
ME2#9&NW.[(;*GC':@#K[7QC<C7[73M5T633H;Z"6>SG>X5]XC +!U ^0[2#C
M)J/2_&\U]<:7)<Z+-9Z9J[%-/O&G5C(=I=-Z 93<JDCD^AQ2^*-$NM6\5^'W
MCB8VD<%]%<3#&(_,B"K^9S7-^$?#,-E/HEG<^#;J/4-/ %SJ$MT?(5D4@21?
M.=Y8XP-HP"<XQB@#T'7YI+?PYJDT+LDL=I*Z.IP5(0D$5Q?PEU_4;[1&TS6[
MN2YU"&""]2>9LM+!/&'4Y[[6WK^ KM=>@ENO#VIV\"%Y9;25$4=68H0!^=>:
MZEX4\1P^%?"LVBP&+5UTE-&U!2P!CBDC +DY_P"6;C/'J: )?"'B75=:^*5_
M<RWD[:+=:=-/86H)*>7',D2R!?5BKGZ-74Z;XPO9]4L+75/#]QID6I)(]G)+
M,&<[%W%9(\ QMMR<9/0CK68WAF_T[QBC:-;F*TMO"[Z?:SDC:LPD!0'WP,U@
M:-HE[:ZSX6U.W\*:A#/9EXM2N+J4-+++)"R%\[R2@<Y+?[0P#@T =9IOC/5-
M4LH[^#PQ-]ANK=Y[*<72$. ,@2 #]V6'3KSP>:S?#7CK5[GP5HEW?:7]JU;5
M'\NTCCF11<?*S,[$#$:JJG/!/ ]:KZ)I-V/$MK-IGAW4= 1TF_M>%YE^QR,R
M$+Y:AB"=^"&55XSGKBLBQ\.:A-X-\+0ZEX;U"5O#\KQ7EGO5'G1D92\15QNV
MG:<9&1F@#K;SXAIIVC2W=[I,\=Y;:C%I]U9I('9&?:592!\X*LI'3.<<5U.D
MW5]>:='/J.G?V?<L3NM_.67:,\?,O!R,'VKSNZ\-27'A^ Z3X8GTW?KUI<-#
M+/OE>&-US(X+';@9^7). /I7J- 'F_B;4[=?',MAXC\07^B:7]EB;3WM[@VT
M4\A+>87E'\0PF%) P<XYK7AU6\\.Z1IUBMTWB2_O[B1-/?S%0R0@%\R2<@[5
M'+ <\<9-3:SJVJ66J75K?^&)M7T69$-N]C&DC X^=94=AWY!'&#7$IX)NHK2
MRU*Z\/3-81ZI=7 T6WF EM[>9%4;=K 9#IN* XPYQTH ZN\^(B6&C"[N=(N%
MO(]333+FR20,T<K#(*GHX(*D=,[NU:&E^*;JX\00Z)JVCMIM[-9->1C[0LJL
M%DV%<@ ;@-K?1O:N6G\-RS:-I;:7X:FTT?\ "1VMW)#)/YDIA0@&63).TX'W
M03P!]!O^/-/U,II6O:':&[U72;@LD"D RQ2*4D7GCNK?\!H RO$GC+3[FSN3
M<:;=36=EKL&G1RPW1B,DW\1^7G:I.".0:VM5\7WEOJM_8Z1H,VJ_V9&CWSI.
ML90LNX(@()=]O...HYR:YC6_!FI0?#7P[I%I;O=7\&I6]W>E2,ERQ>5R3U^9
MC6K,VL^%_$_B*YM-!N]4BU<Q3VCVQ3:DRQB,I+N8%1E5.[D8)]* -"\\9W+7
M,D.C:#<:B;>TCN[L/*(&B5P65 K#)DP"=O&.,GFHG\=2WDH_X1_19=6B2RAO
MIF6=8F$<H8H$4\NV%/' Z#.:Y_5/#LL?B2]U36?#%UK$FHVEN5_LZ<JL5PB;
M7C.77"GY2&.>].U_0PMI;VL/@V^AOK>P2/3+W1[L9MY,',3.64A5;'+ J02>
MO% 'IT;^9$C[67<H.UA@C/J/6N%\=7>JZMK.G^$M U"6PO9H9;VYNH6PT,2@
MJ@SZ-(0/HIKM+!;E-.M5O75[M84$S+T9\#<1^.:\_P!$\%WNMZIJ_B76[K5]
M+OKZY9(8+2[,)CM4^6,-M[G!;\: -C1?&\$GPX/B74U9);*%EOXE'S+/'\KH
M!ZEAP/<46GC._&OZ/H^K>'9M/N-5$C0M]I650J1ESD@?>& "/<8)YKD]3\#Z
MKIL7BK0].-Q<Z7J]H+V*YNYPWEWB,"RNQY^<*IW'TK2N=6U#5_B'X)DN=&N=
M,C0W9*W3(7=_LYSM"L?E'')QG(XH T-,^(YO]%O-<ET.XM](M8Y0UP9E9I)D
MDV"-$ZG/'S<#/'O5O_A.'T[[:GB+29-+EM[%K]%2=9Q+$I 8 @#YP2HV_P"T
M,$UAV7A+4[GX+W&@36OEZ@TLTJP2/MW$7+2JI(/&X <]LU4E\(V^NZ3K%OIG
MA*[TB>33VBCN=0N3N:4LK>6J[V^4E!E\CMC- '4P^,;N&::WUG0I-.N/L,M]
M;)]I643)'C>I( VN-RY'(YZG%9T?Q'NVBT:Z?PQ=+9ZRH6QD6X0N\K)N567C
M:IP<,3T&2!5+3M"MKA;Z2R\%WNFW"Z;/'Y]Y<EF\UUQY<:[V# \Y;@<#KGBV
MNA:F-#^'4'V1_-TV:W:\7(_<A;9T.>>S$#B@"['X^,-IK"ZEI$MMJ6FSPP&R
MBF67SWFQY(1\ ?,3CD<<TEWX\FTK3M9DU?1GM+[3+5+PVR7 D6:)B5#*X Z%
M2""...N:Q?$?A+4M4U3Q7.E@T\<EQIMU;Q&0(+H0\R(&R,$C(SQR15;4/#:W
M_A/Q,NB>$+W3YY[$6\#7<^9KABV64(78!1@<DC))X[T =3'XQU#^V+?3KGP[
M+;M?V\TVG,]TI,YC ;8X _=D@@]_TH^&_B#5O$OA*#4M6MEC>5G,<JNI\Q?,
M8?= &W;@#WQFIM9TV\N/&_A2]A@9[:S%WY\@QB/?$ N?J:I_#&WO],\(0Z+J
M6F75G<Z>SHSRA=DVZ1V!0@G(P1U ZT :>N^))].U>QT?3=,.HZE=QO-Y9G$*
M1Q)@%V8@]V   Y]JYGPOXBU%;/Q-=II-]>7C:^UO'8[^8B8X@0S<A44Y);IZ
M=:U=?AO]*\=:=XDMM,NM1M382V%Q':!3)&2Z.K!6(R,J0>>*Y;^R/$#Z?J$]
M]HU\+6Z\2&\N["VE'FRVAA4*,JPW8<+N /.T]10!J^)?'FKVG@W6;FUTO['K
M&FW45M<QM.LBP^9L*NIQAP0ZC&!C)]*VKGQ9JJWG]GV?AQKO48;9;F]A6\55
M@5BP10^/G=MK$# '')KAKOPQJS>&_&5A8>&YK-;Z2TO+*W#H040Q[D)W'$GR
M$D=.<9-:FJ:2EWXEG\07_A+5K^VU&SB6.&-PDUM+&7!611(!A@5(.3C'.* .
MA/CK[?-I=OX?TM]2N+^R_M K).(!##D*"Q(/S%B1M'<'FF?#>^FU'3-;N)Q.
MK'6[L".<Y:(;A\AY(&.G'%9EOIU]X5\1:9JMMX;N'LI=&6QEL]/D69K259#(
M!EBNY3O8;O45L_#^QU.RTW5FU:S-I<W6K7-T(MP;"NP(P1U_^M0!I^)]:DT;
M2P;2-9M2NI!;6,!_Y:3-TS_L@ LQ[!369\.)[^?PEC4[Z6^NX;VZ@>XEZOLF
M=1].!TJQKOA:ZU;7;/5K37;G3Y[6!X8UC@BE4;CEF =3@D #([#W-8?A/P3<
M2>&KS3O$MS>3QOJ,\\<0?[.5_>R'?NA*D[PV[!.!V H =\1[NYCU?PG8QZM=
MZ;;7M\\5S+;3^4Q4(3][ZU>TW0=/@U*WEB\9:Q=R(X86\NJ+(LGL5QR*S?%/
M@N.YO/!NGVNF&\TBQOI'N8[AS.%C*G[YD)+#<>^:ZBS\&^&-/NX[NR\.Z5;7
M,1S'+#9QHZGU! R* ,FU\=O<36ETVCRQZ'>7?V.VU$SJ2SEBBL8\9",PP#G/
M(R!FN;T'QEJ6BZ%K-[)HUS?:;8ZM>"[NS<@-&GGM]Q#RX52,\CT'2H_#?A"#
M2WTW2;KP?=W%[9W0+ZB]T5MO+5RR3+\YRV OR;>O7 YH-IXBA\&^(O#(\.WC
MW&JWMZ+6X5D\E8YI&^>0[LK@$MT.1C'.0 #I]2\=3P^*7\.Z3H<NIWWV-+R,
MK<+&C(Q()9F'R@8'KDL.*V-&\0KJVKZSIWV5H9-+FCB=BX8.7C#\>F,XK!TG
M0+ZP^*5Q?&!SIZZ'#:)<'&&=7Y'KG'-0VQU?PYXV\32)H-[?PZM+!/:36Y3R
MPRQ!&60LPV8(ZX/'Y4 7[+QK=:MX9TO5=*T"YNY]1EDC2 2!4B",P+22XPH^
M7CC)) %07/Q"%CX4US5KS298;S19A#=V7G!OF.S!5P,$$.#G ^E<I8>'M:L/
M"GA"SU;2+^[T^U:[_M*PLY &:1G)A9AN7<G).,]QFJUYX6UG_A$/'6D6GAN:
MU.I/!<V,,;HR;?W8*9W??&TDCIUP2,9 .[MO&EX;[3%O] FL;#4[CR+2ZDN%
M8L2C.A9 ,INVX )SR*V=/UQ=1U_5M,BMV":;Y223[N&D==Q4#_94J3_O5E^-
M=/:Y\ 7;*ZPW5A"M[!(QP(Y8<2*<]N5P?8FJ?AOPU!K7@J-]:AF6;5+AM4G2
M*XDA97D)*KN0@_*A5<?[- &SX@T;4=:N;&&'5I]/TY"[78M',<\QP-BAQ]U<
MY)QR>*X.WUG5VTPZ-::S=S6]YXB_LRSU1V#3?9@F^4J^/F(*.@?G]*V?%EC?
M:;I^E>'M&TO5[C0W,AOWLIM\YCSD1!Y'# ,6.3G( P.O"7\%YJ6AZ7<:3X8O
M=/DT"_BN(-/N!%&9H@K(ZQ[7*CY7.,D<B@"UIG]HZ'XQO/#D&I7-]#<:6;ZS
M;493*T4JOL92_P!XH=R'';G%.\$RZJFO>*K#5-4EU&2TNH LCJ%4;X$=@BCA
M5RQP/S)/-)IIU&_\4W_BRXT6^M8+;3/L=I9S!!<3G?YCG:&PN2J* 3SR>*J>
M%;[54\9Z[<77A?5[6WU>YADBFE$6V() J'?B0D<J>F>HH Y]-4U*W\ V_P 0
MIO$%\;TW*R3633?Z*8S/Y;0"/H"%/7[V1G->PUY'J7A7^W;F;3AX*DT^_N;[
M==Z@)0UHL0DRTL8W?ZQU&.$!RQR:]<.<''6@#DHO&-ZNJ6<=]X>N;+3KZ[:S
MMKJ64"0R#=M+18RJML.#D]L@9K.E^)-Q'IEWJZ^'9VTFPNY+:\N3<J&39(4+
M(F,N.A/3KCG!KE[30-50:'>3>&-0EUC3]12?5+^:57:?E@?*R_S+\P;L  !6
MU<>'=6?X2^(])6QD-_=75X\,.1EU>X9E(YQR"#0!T5]XNNEUS4--TS19;^/3
M8T:^G6=8S&77<%12/G;;SC(ZCFD^&<TMQ\-= FGD>65[12SNQ8DY/4FLU5UC
MP[XM\1-;Z)=7\6L&&>TF@*;$D6(1LLI9@5&5!S@\$]^*V/A]IUWI/@#1;"_@
M:"Z@M@DL;8RIR>.* (=7\875EJ&HV^G:)+J,6EQK)?RK.L9CRN_:BD?.VWYL
M<=1SDU'/XVFGUD:7H>COJ4SZ?#J$<AN!#&8I"P&6(.#\HP,'.[M@FN>USPU'
M!XKUR\N_"U[K:ZEY4MH]K/L57$8C:.3YUVC*@[L'ACZ8KH-$T2XT[QO-.MB+
M;3UT2TM(@C[D1D>3* GDX!7DB@#&O_B!JUW#X3N=%TH[-3O)(9X99D5MT:R!
MX<D''S+G</[OO6QJ'CJ:SEU&>'1);C2=*D$5_>K.JF-@ S[$QEP@89.1WQG%
M<Q'HFM:7HGA>Z.D75P^FZW=W%Q;0;3*(I'FVL 2 ?OJ>O>DN?"T<.JZU'>>#
MKW5Y=2O&N;69;GRX2D@&Y)2'^3:=V?E.1C&: .M7QC<7/C&[\/:?HLET;)H#
M<W7GJD<<4BAM_(Y(R<*.N#TJ*R\=27<UC<OHTL6B:A<_9;34#.I+L20A:/&5
M5B, Y/49 S3_  _H]U9>./%ES);-%97:626SYX<)$5;'?@\<UROA;PC#ICZ3
MI=UX.NI;^PN!YFHO=$6VU"2DR?.<L<*0FT<DYQB@"7QKXSO]0\"^([C3])N$
MTN+S;6/4DN0'+JVPN$'.S<"-V<]\8KU&+_5)_NBO(K_3O$5K\.];\%6WAZ\N
M+DRW'V>[5D\B2%Y6D!R6SNPQ7;CKCMS7KL8(B0'J * //;7QCINCZ?XRU2'3
M[K&FZIY5RKW+2>:Y95+(#G8/FSM'I6O#XNU+^V?[*O/#LEK=3VDEU8JUVC>?
ML*@HQ _=M\R_WA[UR,OA;6V\/^/[<:?*9=1UI;BT7(_>Q^9&=PYZ8!Z^E=IJ
MNFW<_P 0O#^H1P,UI;V=Y'-*,81G\K:#]=I_*@#GO#7Q U2?P3I%_J&EM=:G
MJDWDV444R+]I.6)8\ 1JJJ<GGI[UU.@^(Y=3U*^TK4-.;3]3LE21X?.$J/&^
M=KHX R,J0>!@BN T#2-=T[PSX4=]!O?MOAFZD6XMR4'VB.19$9H3NPQ 93@X
MSVKK_#UK?ZCXRU3Q+=:?<:?;R6D-E:PW.T2N$9W9V4$[1EL 9SQVH A^(VH3
MZ;!X;GMTGD<ZY GDP-AILI)A.H')QUX]:>/'OV'^UX=>TJ33KO3K9+OR8YEG
M$\3$JNQ@!SN&W! Y(J3Q]9:G=0:!-I=BU[+9:Q#=21*P4^6J/NY) SR /<BN
M:USP_JWC:ZU_4%TJXL8SI<5E:0WI5'N)$F\YL[2=JY"KDGN30!MW_C75K.PU
M2&ZT V>JP:<]_;1&[61)8U(#G<!PR9!*X.<C!-/\)^,+^_&@V&LV!@NM1TS[
M7'<B566<J$W?* -I(?=CM639>'K>]M=7&F^#[S2YY-*GMDN+^Y.]I)%QY:KO
M8;> 2V1T&,]JMY9>()?A]X<O-+T2]AU_0E6W6VGV*S@V_E.5PQ!7)!R<'Y.E
M '067Q(L;SP_XAU<VDD46CL^$9P3<( =CKZ!R"!1<^/+J&.]N8O#\TUCIBK_
M &E,+A08&V*[JBD?O-BL">1[9KG]2\$:C;:CH.DV%J9-(N+2TM=4D4@!1:R>
M8"WKORRT:CX6CMM=UX7?A&\UI]1NC<6<T-R8X2'10T<IWC8 P/.TY![]* .H
MU/QI/;WE]'I6C2:G;Z;"DU[,DZQ[ R[PJ CYVV8;''4<Y--G\;33ZRNEZ)H[
MZE-)I\6H1R&X$,9BD+ 98@X/RC'!SN[8)KFM4\*06'B+6)I_"=YK$5\D+61M
M+@JB,L2QF*0[UVCY =Q!X)],5TFBZ)<:=XXEG2Q%MIZ:':VD6Q]R(R/)E 3R
M< KR10!M>&=>C\2Z!;ZI'!);^:71X9""T;HQ1E)'7#*>:UJYGP%IUWI7A86M
M] T,_P!LNY-C8SM:>1E/'J"#^-=-0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5:^U"RTNT>[U"\M
M[2V3 ::XE6-%R<#+$@#GBK-</\6XDG\ S12J&C>\M%93T(,Z B@#MHY$EC62
M-U>-P&5E.0P/0@U7LM3T_4FG6QOK:Z-O(8IA!,K^6XZJV#P?8UYUIGB.Y\+^
M =9T>0F75]"F_LVT1OO3>80+5L>X91_P$UA>''N/ .@>,K>P9);Z#4+2TCDE
M&5,TD<2&0^OS.6H ]LK#3QAH$FCQ:NFHHUA+/]G28(V#)NV[<8SU!%8T-QK/
MAWQEHVE7NM3:M::M%.,W$,:/#+&H?*F-5^4C<,'.,#FN \/:[J/A_P""NE76
MF7'D32:X8';8K91IV### ]: /=**X623Q#KGC7Q%I%KKTFFV=A%;/"8;>)WW
MR(QQEU/RY7)'7I@CG.5%XLOM5\*^&+N[\0/I<U]:O).MA9?:+F=UPN40(X5,
MY+';W XH ]/J".]M)KN>TBNH7N8 IFA60%XPW*EEZC.#C/7%8G@76+K7O!UC
MJ%Z^^X<RQN_E^7O,<KQ[BO\ "3MR1V)KD8=4U33?BUXO_LW0+C5O,M['S/)N
M(HO+PCXSO89SD]/2@#TG[;:?;_L'VJ'[9Y7G?9_,'F>7G&_;UVYXSTS4]>2M
MXAOX/B;J6L:EH<VG26/A2:86\T\<AD5)MV<H2!GD>O%6_#/BR_FUK14?6KO5
M%U&-_ML4NFM!%:/Y9<-&_EK\N04^8MG(- 'I]4--UO3=8AN)K"[2:.WG:VE8
M @+(N-R\^F17GVA^*[YO%&APGQ%-JT>IRS17"+IYBM$(C=U,$OEKN *8Y9L@
MYKD4CN7^'&O_ &>^EM@?&#*XC53O!GB SN!Z'!X].<CB@#W1-2LWU273%G4W
ML4*SO%@Y",2 ?3DJ?RJU7FQTO5;GXGWMG!KUQ;.FAVOGWJ0Q&:0B67'!78,\
MDX7L,8J+2_$VO:[8>&=)&I?9;Z_DO1=W\,*%RELY3Y58%0S$KG@XYP* /3J*
MX75KG7-$T2"VU;Q/#;O)?F-+V"U\RZG@VDJJQ!"OFYZD*1@9ZUS[>,?$$GAF
M 6.HN]X/$T>DI=75F(WEB8 @R1E1@_.,X"D[>V: /6J*\TUK7+[2=<M/#=YX
MHO[?R;$W<VH0:<LTUP[R,$4JL;*JJ%.?E&>.>M=;X,U:[UOPI97U^A6Z;>DA
M,1CWE'9-^T\@,%#8]Z -N::*WADFFD2.*-2[N[ *J@9))/0"FVMU;WMK'=6D
M\5Q;RKNCEB<.CCU!'!%9GBW_ )$S7?\ L'W'_HMJ\^T#4-7A\'_#C3-*OA9_
MVC$\4\AB5\*L+/D!AU&,CMG&<CB@#UFBO,;CQ+KVAIXBT=M2^W7EO?65K8WE
MS"@9?M.T9<( K;<L1QSQFNPT33M>TW4)X[_6?[4T]XE:*2>-$GCER=P^10I0
MC!'<'B@#>IC31)(L;R(KN"54L 3CK@>U/KA- 23QEHOB:[>Y>"2^N[BQMYE4
M,888SL0 '@C(9B.^XT =NL\+^7ME0^8NY,,/F'J/4<BH-.U73M7MVN-,O[6]
M@5BADMIED4,.HRI(SR./>L>T\/ZK;ZQ8:C/X@DN/)LA;7D1M4473#<1("/\
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M'RD-C!S]:YU?&.H6]_I=U'XFFU1KK58[2>WATTBP$<DFS$<WEC)7(YWG)!H
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M<6-WJKZCLOX#%*\*QLD?F+A#M^\1SECR22: /7*I:MJ^GZ'I\E_JEW%:VL>
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M+'C/$4MZVD_%"UL$XMM:L9)&0=!/"5^?ZE&P?7:OI0!UU%%% !1110 4444
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M/ 6W%"N=N,^V: /*[J-_!^@ZK;?V!%H^N#1)Q#?:=/N@O%38'D(P&$B[@P+
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MY1QT]!0!YWX8TO6-2T_1==BT33H-0DU$7$^LOJ'^D3 RD2QLOEY(*[D";L#
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M\99O["?3DF_L"+S#?([+M^T2=-A!SFNQT7PUI/A]KEM,M3"]T5:=C(SF0J,
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MX>"9[R9W0 $!-Q8G9@D;/N^U:>B:'IWAW35T[2K?[/:J[.$WLW+').6)/4T
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M%55&2< GZ UI5ROCO^RAIMD^JW-]8I'=!X=1M.MI+M;#L<'"D$KR"/FP>N:
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M@1+<?9# UNXG\_./*\O&[?D],>_2N7T.^M-7\5^#;NR?SX8M%N8VD"D!7'D
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ)#(O1E/8]1]":HW/@73KOPUI&D//=1RZ3'&ME?0.$GB9%"[@<8Y Y&,'TH
MS_'/B"STR-GUCPE?ZCIUE)'<"\01&.-\C:PRX8$$@=*S-5NM8MOC5*^C:;;W
M\Q\/QATGNO("KY[\@[&R<XXQ6Q-X$NM55;?Q%XIU+5;!6#&S\N*WCEP<@2&-
M06&0.,BK.L>#9]0\3_V_8:_>Z7=FS6S;R(HG#('+_P :GN?TH T=$O/$%U),
M-:T>TL$4#RV@OC.7/<$;%Q^M<K\0;FZM/&O@:>SL7OKA+F[V6R2*A?\ <$'Y
MF( P,GGTKI='T/5M/O3/>^*+[4XMA7R)[>!%SQSE$!S^/>IM4\/P:IKNBZK)
M-(DNE22R1HN,.70H<_@: .&U&^U/QGXPTC0+K1?[%FTNYAU>22YN$DD>-"0!
M%LR#D\,<\4:=>:_:_$_QP-%T>TOU:6R\TSWI@V'[.,8^1LYY]*[?6_#<&L:C
MI>HB>6UOM-F\R&>+&2I&'C;/56'4>U9-SX(N_P#A(]4UG3/$U_ILFI&)IXH8
M(74F- BXWH3T'ZT 9'C[4O$'_"J=>EU&PATR?$<7^BW9G_<M(BN<[%Q\I88K
MN[+3["UTF'3[6WA6P2(1I$J@H4QC&.A!'YUF6/ARZ6UO;36];N=;M;N+RFAN
MH(D4*<@_ZM5SD'O7%Z]X<\1>&;?3[72-<\07/AHNT-U;6D<4MW;1D?+Y3E-Y
M4'CN0,8H Y^/]SX,BLXF)L+'QPEO9<Y"P+." #Z EA7H'Q8('PL\09./]&_]
MF6KD'A30M1\"0: EC/;:6\2F.)PT<T39W!CGD/NYR><]:I/X"N-1\BWU[Q/J
M6K:;!(LBV4L<4:R%3E?-9%!< @'!ZD<T 8=_<:O:?&"T;1]-M[ZX_P"$957B
MGNC %7[1USM;)S@8QWKL+"37]6@O;/7-(M=.@EA*+);7YG8[A@\;%QP>O-5M
M:\'3:EXGCU^QUZ\TN\6S^Q$P11.&CWE^CJ>^/RJ2T\,:AF>+5O$U]JUE/"\,
MMK/;PHK!A@\H@;IGO0!RSS:QX/\ #=OIGBC0K#5O#=DL41O[1_FCC0@(\D##
MDC"DE2<8S6G\9>?A+KI_V(O_ $<E2_\ "O[B:RCTF^\4:G=Z''M'V&1(@712
M"$>4+N9>!W!([UN^*O#L'BOPS>:'<S200W04-)%C<NU@W&>/X: -:+_4I_NB
MGTBKM4+Z#%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9FI:RFG7=
MM:BSN[J>X2214ME4D*A4,3N8=W7\ZTZQ;O\ Y'72O^P?>?\ HRVH 3_A()_^
MA>UC_OW%_P#'*/\ A()_^A>UC_OW%_\ '*VZYW5?'GA?1;Y[*_UFWBN4&9(E
MR[1_[VT';^.* )_^$@G_ .A>UC_OW%_\<H_X2"?_ *%[6/\ OW%_\<I\WBC1
MH=,L]2%]'-97D\=O!-!^\5W=MJC*^_'M6Q0!B?\ "03_ /0O:Q_W[B_^.4?\
M)!/_ -"]K'_?N+_XY6W10!B?\)!/_P!"]K'_ '[B_P#CE'_"03_]"]K'_?N+
M_P".5MT4 8G_  D$_P#T+VL?]^XO_CE'_"03_P#0O:Q_W[B_^.5MUA:UXS\.
M^'KU+/5M5@M+EXQ*L;YR4)(SP/4'\J '?\)!/_T+VL?]^XO_ (Y1_P )!/\
M]"]K'_?N+_XY3]%\5Z#XB>2/2-5M;N2(9>.-_G4>I4\X]ZV* ,3_ (2"?_H7
MM8_[]Q?_ !RC_A()_P#H7M8_[]Q?_'*VZ* ,3_A()_\ H7M8_P"_<7_QRC_A
M()_^A>UC_OW%_P#'*VZ* ,3_ (2"?_H7M8_[]Q?_ !RC_A()_P#H7M8_[]Q?
M_'*UYYX;:!YYY4BAC4L\DC!54#J23T%/!# $$$'D$4 8O_"03_\ 0O:Q_P!^
MXO\ XY1_PD$__0O:Q_W[B_\ CE;=% &)_P )!/\ ]"]K'_?N+_XY1_PD$_\
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M!)&P;*G&>P]"*V]/U"TU73X;^QG6>UG7='*G1AZB@#-_X2"?_H7M8_[]Q?\
MQRC_ (2"?_H7M8_[]Q?_ !RMNB@#$_X2"?\ Z%[6/^_<7_QRC_A()_\ H7M8
M_P"_<7_QRMNB@#$_X2"?_H7M8_[]Q?\ QRC_ (2"?_H7M8_[]Q?_ !RMNB@#
M$_X2"?\ Z%[6/^_<7_QRC_A()_\ H7M8_P"_<7_QRMNB@#$_X2"?_H7M8_[]
MQ?\ QRC_ (2"?_H7M8_[]Q?_ !RMNB@#$_X2"?\ Z%[6/^_<7_QRC_A()_\
MH7M8_P"_<7_QRMNB@#$_X2"?_H7M8_[]Q?\ QRC_ (2"?_H7M8_[]Q?_ !RM
MNB@#$_X2"?\ Z%[6/^_<7_QRC_A()_\ H7M8_P"_<7_QRMNB@#$_X2"?_H7M
M8_[]Q?\ QRC_ (2"?_H7M8_[]Q?_ !RMNB@#$_X2"?\ Z%[6/^_<7_QRC_A(
M)_\ H7M8_P"_<7_QRMNB@#$_X2"?_H7M8_[]Q?\ QRC_ (2"?_H7M8_[]Q?_
M !RMNB@#$_X2"?\ Z%[6/^_<7_QRC_A()_\ H7M8_P"_<7_QRMNB@#$_X2"?
M_H7M8_[]Q?\ QRC_ (2"?_H7M8_[]Q?_ !RMNB@#$_X2"?\ Z%[6/^_<7_QR
MC_A()_\ H7M8_P"_<7_QRMNB@#$_X2"?_H7M8_[]Q?\ QRC_ (2"?_H7M8_[
M]Q?_ !RMNB@#$_X2"?\ Z%[6/^_<7_QRC_A()_\ H7M8_P"_<7_QRMNB@#$_
MX2"?_H7M8_[]Q?\ QRC_ (2"?_H7M8_[]Q?_ !RMNB@#$_X2"?\ Z%[6/^_<
M7_QRC_A()_\ H7M8_P"_<7_QRMNB@#$_X2"?_H7M8_[]Q?\ QRC_ (2"?_H7
MM8_[]Q?_ !RMNB@#$_X2"?\ Z%[6/^_<7_QRC_A()_\ H7M8_P"_<7_QRMNB
M@#$_X2"?_H7M8_[]Q?\ QRC_ (2"?_H7M8_[]Q?_ !RMNB@#$_X2"?\ Z%[6
M/^_<7_QRC_A()_\ H7M8_P"_<7_QRMNB@#$_X2"?_H7M8_[]Q?\ QRC_ (2"
M?_H7M8_[]Q?_ !RMNB@#$_X2"?\ Z%[6/^_<7_QRC_A()_\ H7M8_P"_<7_Q
MRMNB@#$_X2"?_H7M8_[]Q?\ QRC_ (2"?_H7M8_[]Q?_ !RMNB@#$_X2"?\
MZ%[6/^_<7_QRC_A()_\ H7M8_P"_<7_QRMNB@#$_X2"?_H7M8_[]Q?\ QRC_
M (2"?_H7M8_[]Q?_ !RMNB@#$_X2"?\ Z%[6/^_<7_QRC_A()_\ H7M8_P"_
M<7_QRMNB@#$_X2"?_H7M8_[]Q?\ QRC_ (2"?_H7M8_[]Q?_ !RMNB@#$_X2
M"?\ Z%[6/^_<7_QRC_A()_\ H7M8_P"_<7_QRMNB@#$_X2"?_H7M8_[]Q?\
MQRC_ (2"?_H7M8_[]Q?_ !RMNB@#$_X2"?\ Z%[6/^_<7_QRC_A()_\ H7M8
M_P"_<7_QRMNB@#$_X2"?_H7M8_[]Q?\ QRC_ (2"?_H7M8_[]Q?_ !RMNB@#
M$_X2"?\ Z%[6/^_<7_QRC_A()_\ H7M8_P"_<7_QRMNB@#$_X2"?_H7M8_[]
MQ?\ QRC_ (2"?_H7M8_[]Q?_ !RMNB@#$_X2"?\ Z%[6/^_<7_QRC_A()_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** ,7P[UU?_L)2_R6MJL7P[UU?_L)2_R6
MMJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "L6[_Y';2O^P?>?^C+:MJL6[_Y';2O^P?>?^C+:@#:
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** ,7P[UU?_L)2_R6MJL7P[UU?_L)2_R6MJ@
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MR#/RJ=V[G:<$J <<&@#J:*X[_A8VG3:S?:18Z7JU]?6-QY$\=M K;/\ ;)+
M!>>^"<' X-=1J#WD=A.VGPQ2W87]RDSE4+=MQ )Q]* +-%<IX#U+5M1L-636
M;N.ZNK/59[421Q"-=J;<  =N3U)/J:ZN@ HKSSQ1-XOTK2M;\1OKL-C%8LSV
M>G);QR131+C:)&(W[WZ84C!(ZU;EO->\2^)K[3=.U5]$@TVU@>4QV\<LDD\J
MEMIW@@*J@<#!)/6@#N**X/3-0\4>+=#TIK6]ATPJ\\.J74,:O()(G,86-7!
M#$$DG.!@4S2=2\5ZGHNKZ=9WUM<7]EJQL%U22)5'D@*7DV#Y6==Q7 P"1]:
M._HKC?#]YK%EXVO_  [?:LVKV\=C'=K<20I')"S.R^6VP '(&X<9ZUV5 !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% &+X=ZZO_P!A*7^2UM5B^'>NK_\
M82E_DM;5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %8MW_P CMI7_ &#[S_T9;5M5BW?_ ".VE?\
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MA/WRN"%S[XQ^-=)10!Y[/J7_  F'B/PLNGV&H0KI]RUY>O<VDD(M\1,@C)<
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M&NM(C$]E8Q:O)>R@W-Y>ZC830M<OP"Q9U SR,*.@' XKLZ** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** ,7P[UU?_L)2_P EK:K%\.]=7_["4O\ ):VJ
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *Q;O_D=M*_[!]Y_Z,MJVJQ;O_D=M*_[!]Y_Z,MJ -JBB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH Q?#O75_^PE+_ "6MJL7P[UU?_L)2_P EK:H
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MSW&]<#?C/'J* (O[8U;_ *%F]_\  FW_ /CE']L:M_T+-[_X$V__ ,<K;HH
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M3^V-6_Z%F]_\";?_ ..4?VQJW_0LWO\ X$V__P <K;HH Q/[8U;_ *%F]_\
M FW_ /CE']L:M_T+-[_X$V__ ,<K;J.XGBM;:6XF;;%$A=VQG"@9)XH R/[8
MU;_H6;W_ ,";?_XY1_;&K?\ 0LWO_@3;_P#QRLJ+XH^#IDCD&K-'#)C;--9S
MQ1G/0[V0+C\:ZV*6.:))8G62-U#*ZG(8'H0>XH Q_P"V-6_Z%F]_\";?_P".
M4?VQJW_0LWO_ ($V_P#\<K;HH Q/[8U;_H6;W_P)M_\ XY1_;&K?]"S>_P#@
M3;__ !RMNJ6K:DNDZ<]XUI>780J/*LX3+(<D#A1R<9R?:@"C_;&K?]"S>_\
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M<K;HH Q/[8U;_H6;W_P)M_\ XY1_;&K?]"S>_P#@3;__ !RMNB@#$_MC5O\
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M&I4MYS[D.]2C<8.,9'!XK0F^'&EW'A*]T&:[O9&O;G[9<7Q=?.>?<&W]-O\
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MO_V$I?Y+6U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !6+=_\CMI7_8/O/_1EM6U6+=_\CMI7_8/O
M/_1EM0!M5Q?P\\>_\)O:7K36(L;JVD'[H2;P\39"N#@=U<>VVNTKPOPW=IX1
M\(^%/&A5OLBQW6GZD%')C::1HF_"08_X'0!Z#)X\_P"+GV_A""R$D31,9;OS
M,;)0GF% N.?E*$\_Q5MOXK\/QZP-(?6K%=0+!/LYG7?N/1<9^][=:\ZT;3+C
M3_%O@*XOUQJ6I?VGJ%Y[22QQMM_X"NU?^ U3,MF/@+J-I,\?]L&>9)(LCSC?
M&X.WCKOSM([XQVH ]1U3Q/HNDW2V-WJMG!?2)NBMY9@K-Z<9[G@>M8VB>*;W
M5=/\)7<UUI-LVK6[2W%M(6$LI"!L0#=V)RV<\8K$L+C3[?5/B$FNR0+.S1F5
M92 7@^S*%P#U&=XX[^]<_I/_ !^?!?\ Z]+O_P!$+0!TVD_$C^W_ !QJ.EV&
MHZ&FG6GRPM)(6FNSY98LF& VJ1SP> >E=-8^)+2W\*6VL:UK&DB-QAKNVDVV
M[G<0 A8DGITSU!KD_#2C_A*OB9P.)HL?]^#7/>"9(H-'^%TUZR)9!+Y0\A 0
M3G/EY)XSCS,4 >L-XFT)-%766U>R&FL<+=><OEDYQ@'/7/&.M9NL^/O#VCZ#
M;ZR=1MKBTN9DAA:*9<.2X5B#G^$$D^@!KG=1U+1GU*RM/#:::D]SK$[27UU$
MSPPW*0Y=T&Y0SD$#@@9SW!KEIKE'\(:T\M];W/E^,+=WGBC\J-@3 2X7)PI.
M3G)!ZYYH ]5M=;%[XEBM[74M*FL)M/%U'#&Y-R^7P)!SM,6.,XZ]ZE@\5^'[
MK5SI4&M6,E^&*_9UG4ON'48SR1W'45Q%\TDWQNNC8.&E;P@WD,AX+>>=N#]<
M5FF;3I/@[X2MM/>'^TOM5@MO&I'F+<B5?-XZAA^\W?CF@#T:]\8>&].F\F]U
MW3X)/-,)62X4$.,9!YXQD=?45M9&,Y&/6O+H;.W?PK\4I6A1I)+N]5F*Y)"V
MZE1^!)(]S76)?+8?#%;^: W*P:.)GBS_ *T"')7\>E &AIGB?0M:N9[?3-7L
MKR: 9D2"96*C.,\=L]^E10>,/#=U?V]C!KFGRW5PH:&)+A2S@C(QSW'-<!ID
M\R>,_",=QJ6DR@Z;<>5;:=;F-;=&C0JFXNVX';QP/NDXJM8VL$'P8\%O%$B,
M-2L)=P'.]K@9;/KR: .^\2>,])T.UU*!=3L/[8MK.2>*SEE&YF5"R@KD'G'3
MJ16SI%V^H:+87LJJLEQ;QRL%Z LH)Q[<UY;+<Z9%X%^),&I20"[;4+[?'(1O
M8E?W& >>FS;^E=S$MRWPQ1;/=]J.C 0[>N_R?EQ[YQ0!?L_%&@ZC=W%I9:Q9
M7%Q; M+'%,K,H'!.!V!Z^E3G7-*73(M3.HVOV&8J(KCS1L<L<* >A)/%>;^%
M;66Y7P1-)XAT3RK:$O9VMI9LDSKY!5T9O,8<9RWRCYE'>L_2&M$\:VFH/'(/
M!4NI3#2=S#R4OB /,QCB-F\T)S@,2>,B@#T32O'&AZQKVIZ1;7T!N+!@&_>K
M^\&T%BH]%)P3V(-7+#Q5H&J0W4UCK-C<16BE[AHIE81J 3N/H.#STXKS36';
M[+\5[>W=1<L\3;!]XQ_9TWG'4C;NJSJEI/-%>7L_B#1+F2+PY>I%;:;:-$7M
MV1<$GS&&T$+CIU.* /0K3Q5H%_JG]F6FLV,]]MW>1'.K.1C/ !YXYIUKXFT*
M^U:72K35[*>_BR'MXYE+C'7C/;OZ5Q$UK!::1\,/(B2/9=P*"HP0&M9"WYGD
M^M,T*9-'U#P]9P7>E:WHES=RKITJIMO+1V21R3U#  ,I.%(SS0!V&DZ]&=$N
MM2U75=(:"WGD1[FTD*PQJ#@!BQ.&'0^]6;/Q1H.H:=<ZA9ZO9S6EJ"9YDF!6
M( 9RW]WCGFO'M!,:>$=*DNBHT^/QH[71?[@7+A"W;;O*=>^*V_'$D,^N>,)+
M%T>-/"4BWC1$$>:78QAL?Q;=_OB@#T>S\3Z%J.J2Z99:O97%]$"7@BF5G&.O
M ]._I5O4-1LM)LI+S4+N&UMH_ORS.$4>G)KB+VU@M-?^&Z6\21K&TT:A1C"_
M9'X_05<\<-''XA\&RWI4:8FIMYQD^X)3"XA)_P"!]/?% &G=^-M @\,WFNV^
MJ6=S:VRL-R3K@R 9$>>S'@ >]4OAYXINO%NA?VC=W6E22.%;R+ L6M\C.R3)
M/S?EWKG]4:&?Q+X^EL61[8>'T2Z:,@J;@+-C./X@F/TKI_AN /AMX<P.NGP_
M^@B@!]MXJ,_C[4_#;VRI%964=W]I\SEMQP01CC'KFK=OXN\.7>H0:?;ZY82W
M<Z!XH4G4LX(W# SSD<_3FN.M_P#DM7BG_L!Q?SK,M+6"W^%'P],42(?[3TZ3
M('.YI!N/U.3^= &U:_$A-4^(MSH-EJ&BQZ=:",-)+*6ENG8$LL6& ^7&#D&N
MKB\6^'9TG>+6[!TMX5N)F6=2(XVZ,QS@ _UKD="4?\+6^(G XMK'''_3%JR-
M!-MI?P2\-+%8V,DM]-;Q;[M<Q)(\N1))@@L%(&!D= * /3])UO2]=M6N=*O[
M>\A5MC/!(&"MZ''0U?KS[P3/*_C_ ,61W&IVE_.(;+=+:P>2C$"4'"[FR1P"
M<]1CM7H- !1110 4444 %%%% !1110 4444 8OA;_D$W'_82OO\ TJEK(\?^
M.)/!$&FSIIWVU+F=EE DVF.-$+NPX.<*"<>U:_A;_D$W'_82OO\ TJEKG_'<
M$5UXI\%6\Z"2&6_G1T;HRFW<$'\* .EUO7[31?#%WKKL);>"W,Z;3_K./E /
M^T2 /K65X8\:0ZOX)C\1ZPL&DIOD2999QLC*2,GWCCJ1^M<3HPNM0U+2_AW=
M!W30+UY[MV_Y:VL6UK4'L=Q=./\ IF:IZ&8X_#?@J6]*C34\1W9G+_<#[YQ$
M6_X'C\<4 >M:?X@T?5;"6^L-3M+BUASYLL<H*QX&3N/\/'/-8:>.;'4?$^AZ
M=HM]8W]K>_:1<21/O:,QH&7&#QG)ZCGM7#>/G2XU+QI+IS![5=(LEU!H3D%Q
M<$L#CN(<Y]JZ74[G2;GXK>#/L$MM+*MI>9,!! B,:[,X[?>Q^- #M<^(8\.>
M!+W6KF^T:^OEF>*UBLY2(Y6# ;>2264'+ >G:K^C^);R^.A;];\-S_;7G686
MK/F;8H(6#+')7/S9SQCI7F$@'_#.7BCC_F)R?^E*5W7BX ?%'X; #'S7W_HE
M: .P;Q/H*:T-&;6+(:D3@6IF7S,]<8SUQVZT/XGT*/6ET9]7LEU)B +4S+YF
M2,@8]<=NM<+X8N_#L7@<V_B%H6O%UJ47$1R9C=FZ;80%^8MRA!';VK&U[4Y+
MG1[N[2YTFPM&\1HJV,=N3<O)'=(K2O(7^5L*6/R_=P,\YH ] A\=Z/?ZQK.C
M6>H6:WVG1D[II1L9@I+< YPA&&]*NVWB*SM/#%IJVLZMI:1RH-UU!)MMY&/_
M #S+')SV')KC!+"OB/XI1F2,2/;0,BY&6'V/J!WK+\+/%%;_  MEO61;,6-R
ML;2'""X*+LY/&[:'Q^- 'J$'B+1KK3$U*#5+.2R>01"=9E*;R0H7/KD@8ZY-
M)I7B31-=EGBTK5;.]D@_UJP3!RON<=O>O*O$:6][-XT\@)+IDVL:3&VSF-YM
M\8E''&<% ?>NWDC2+XQ6/EHJ;M F4[1C($\>!^&3^= '0ZOKVDZ! DVK:C;6
M4<C;4:>0+N/H,]:2?Q#HUK:074^JV<=O<1F6&5YU"2(!DLIS@@#FN;\37\H\
M9V%G;3:7I]Q%I\UR=2U"(R[(]RJR(N]!DX!))Z 5QWA1(+W_ (5TDOESK'>Z
MJ<;-H#*9"ORG[N."!VXH ]3M?$FB7ND2ZM;:K9RZ?#GS;E9EV1XZ[CVZCKZU
MD:?XSM=9\96VF:5=6=YITFG2W33PMN99$DC7;D' &'S@C/2N$\2".'5_%/FA
M5TY?$.DR7H/W/**1ERW;&=N:ZB*XT^X^.4;6<D,DP\/2"=HB#_RWCV@D=\?H
M1[4 =AJNM:9H=J+G5;^WLX6;8KS2!0S>@SU-)%K>ESM9+#J-K(;Y6>TVR@^>
M%&24_O8')Q7'>+AJ ^(OAYK6]L+/-C=+!+?P&6/S=T>0 '7#E,X.>@;BL.]M
M(+;P/':VNHV^I:U=:S)+HTEA&8DBNO,);8"6Q&I\PMR1M)'<4 =SXD\;Z)X9
MTV_NKJ]@>6R*+);)*OF;W&53'8D D>P)JS<^+_#EG86U]<:Y81VMUGR)FG7;
M+C@E3GD#N>U>8:FT"?!'Q);3*RZW!<J=8$IR[7)F0E\_W"N"IZ;<#L:W]4DO
M9?B=/+8:KI%K')HL8@DOH#,DB"63S0A$B@8.S=UXV^E ';WWB/1=-C62]U6S
MMT:'SU:290&CR!N'/(RRCCU%,?Q1H,>BIK+ZQ9#39#M2Z,R[&/3 /<\'CKQ7
M >%=+MK?Q?X4A%W!J4=MH5U);W,<95"#.FTH"20 K;1STJ&PLXI9+\6^JVVF
M:C;>*KR33_M$6^&1_+PR%<CJK,>"".HH [N_\0Q26FD7FE:MH_V6]O8X?-N)
M"RSJ<Y2(J>9#C@'/0\58U+Q5X?T>]2RU+6;&TN7 (BFG56P>A()X'N:\OU[4
M/[0TWPJSV=E;7$/C6&&X-B<PS2@MND0]<'/?G.16[IEQIEM#\1$UJ2!)S?3-
M<"<@,UN84\KKU7&0/?- '<:EXCT71]W]I:K:6A6,2$32A3M)P#@]<D$5;L;^
MTU.RBO;&YBN;64;HY8G#*P]B*\R\#VDA\5^&VU"+-W!X0AQY@^9"9 ._0XX]
M>372?#=5CT;5HD 6./6[]44=% G;@>U &S>^*_#^FZFNFWNM6-O>MC$$LZJP
MSTR,\9[9ZUROC'XBKHOBO3_#UA?Z-;SRJ[W=QJ,AV6P"@JI52#N;/&363!/I
MD'@7X@PZK) MV;Z_^TI*1O;=GR>#R<KLV_I4D$=PGQ#^'B7RG[4-#F$^_KO$
M:[L^^<T >@^(M5;0_#.IZNL0F:RM9+@1EMH?:I;&>V<53L?%FFOX;TK5M4N[
M73S?V:W82:8  %%9L$XSC</S%1?$'_DG/B3_ +!EQ_Z+:N/TJWBN+CX3":-7
M":7*ZAAD!A;Q8/X4 =/X@^(.BZ5X+NO$5EJ%E>H@9+<+.,2S 9"9]>^.N*C\
M.>-K.Y\.0ZCK>NZ$)9MS VDNV-0J*S*=S$EEW<_4<5Q_B1%3P[\6(T4*@GC<
M*!QN-O$2?J36KJ%I;W?B7X813Q))'Y-P^QAD$K;*02/8@'\* .RG\8>'+66S
MCN-<L(GO(UEMU>=09$;[K#/8]CWK:KR'QK?//:>.T@FTG3H+: 6LZ26QEN;U
MO(#+@[P%'SA5X;H3VKTNWU&WM/#$6I7,ZBVALQ-)+G(VA,DYH YKQ3\0E\.>
M(X-.6P^T6D212ZG=>9@6:22"-"1CGDDD<<"NOO\ 4;+2K&2]U"[AM;6,9>:9
MPJKZ<FO)M"T?Q9K_ (>UO4)-)T>6+Q46G<W=Y(DJ0%=L2X6,@;5P1SWID&LR
MW?A_PE9Z\R+/HGB!+#5"Y^7?''((G)/\).PY/&: /3[?Q1H-W;27-OK%C+!%
M!]HD=)U(2+)&\\\#*L,GT-,/BSP\+:[N3K5CY%FXCN)//7;&QZ*3ZGTKS7Q)
M-IT^O?$:33VB?/AD>>\9!#28ESR.IQM!^E:&K6<EC8?#Q-/DL;&%7'[V[@,D
M(F-N=A8!ERQ._!S]X^M 'H*^(=&?13K*ZI9G3 ,FZ\Y?+'./O9QG/&/7BFV_
MB31+K34U&#5;.2R>40K.LR[?,) "Y_O9(&.O->7:G97ELT-RFO:1<>=XGBDN
MI([1A:VT_P!G*C<OF<Y;RR?F^\1]*7Q!II:PU=[W5M.U*2\UG3$NH;*W,4<;
MB10=P+MEF4KGGL* /1%\<^%6LY[M?$.FFWMW"2R"X4A6.<#KWP<>N#Z5=N/$
M6C6ND1ZM/JEI'ITN/+N3*-CYZ;3WS[5S2V=M_P +M>7R(]Z^'DVG:./W[#/Y
M<?3BN(T=;V.U\%"RN[*SCCO=7CBDO83)"LOG-L& RX;:) .?6@#UW_A(=&_L
MZWU#^U;,65R2(;@S+L<@$D!LXX"L?P/I65??$#PW:^&K[78-5M+NVM 0P@F4
MEI,$K&/]IL<5P\VEQ!=$2?4;'5$N?&(FD^R0&.&.3R)-R!2S9^92QYZDT>.4
M5;KXCA% WZ%:.V!U(,HR?P% 'J>E:I9ZUIL.H:?<17%M,,K)$X9<C@C(]#D?
MA5RJ>DS0SZ3:202))&8EPR,"#P/2KE !1110 4444 %%%% &+X=ZZO\ ]A*7
M^2UM5B^'>NK_ /82E_DM;5 !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %8MW_R.VE?]@^\_P#1EM6U
M6+=_\CMI7_8/O/\ T9;4 ;54_P"RM._L[^SO[/M?L/\ S[>2OE]=WW<8Z\_6
MKE>7>,O$'B";7]2F\/7,BV?A>WCN+V%,8NY&8.T1]A$K'CG+4 >ER6EM+<PW
M,EO$\\&X12L@+1[N&VGJ,X&<=:JMH.CMJ@U1M*L3J Z71MT\T?\  \9K/U3Q
M=9V'A^PU6VAEOO[2>**Q@A(#3O(,J,DX QDDGH :S/\ A/Q!+K-M?:-=6MWI
M.FG4+B)I$8,HW8",.#D+U]\=0: .DNM$TF^OH;Z[TRSN+N'_ %4\L"LZ?1B,
MBGII.FQFT*:?:J;,$6I$*CR 1@A./ER..,5S47CN671X-1_L"\5;Z6.'2XC+
M'OO"ZELXS\B@*6RW;GVJ3_A.8X=/NVN]+N8=5MKJ.S.G!T=Y)9,&/8P.TJP.
M<G&,-GI0!TL=A9PRW$D=I DER09V6, RG&/F/\7''-02:)I,NEC2Y-,LFT\=
M+4P*8ASG[F,=>>E<Y=?$"/3-)U6YU72;BTN]+:#[1:"19"4F<*CHR\,.OOE2
M*;_PG5^NLG1G\*WR:G+!]IM8#<18EBSAF9P<(0<9'/48S0!T<OA_19],CTR7
M2+"2PB(,=JUNAB0^H7&!U/YTLF@Z/*ERDFE6+I<JB3JUNA$JK]T-Q\P';/2L
M"#Q[%=:)975MI=S)J5Y=R62:=O4.LT9;S S9VA5"$[O3'<XIL_Q @M-,$]UI
M5VEXFI)ID]BI5I$E< K@@X8$%2#WW=N: .EMM)TVSFCFM=/M()8H1;QO%"JL
MD0.0@('"YYQTJ.'0='M]3?4X=*L8[]\[KI+=!*V>N6 S7):KX\U&TTKQ#$^@
MS6>KZ;8?;8X7GC=6B.X"0,#CY2IRO7CC-=-X9U"^U3PW97NH6AM[F6%69"ZM
MORH.[Y>!GKCM0!?%A9B*XB%I ([DLTZ>6,2EAABPQ\V1P<]:E6&)(! D:+$J
M[!&% 4+C&,>F*\BU+QGKNH^"_$=U=V<]BMCK,<$<L,REE"W$2M%A#DG!;)Z'
M.*[:T\8S'5Y]-U/0[G3KA;)[ZW$DR2":-" P^4G:P)''/7K0!KV_AO0K2...
MWT73H4BE\^-8[5%"2?WQ@<-[]:LC3+ 6D-H+&V%M"RM%"(EV1E3E2JXP"#R,
M=*Y*R^(T=UX:;Q#+HE[!ISI%]D8NC274KD+Y:)G/WCC)P#R>E6X_&LMO<W=G
MK&BSZ=>0V,E_%&9DE6>-/O!67@,"1D'USS0!MW&@:-=WQOKG2;&:[*&,SR6Z
M,Y4C!&XC.,<8J_'&D,211(J1HH5448"@= !V%8,GBN"/3/#M\;:0KK<T,,2Y
M&8S)&T@)]<!<<5B:C\2UL=.U/5TT&]GT6PED@-\DB8DD1MIPF=VS=\N[U[8Y
MH ZJ#P_HMM<W-Q!I%A%/= K/(ELBM*#U#$#D'OFIWTRPET]=/DL;9[)0JBV:
M)3& O0;<8P,#'TKA(O$6JV?CGQ9#9:7>:L(DM)1"LZHD*^3DX+'&6/8#G!SB
MNVT35[;7]#LM6M-PM[N%9D#C# $9P?<=* '_ -D:;_:9U+^S[3[>4\LW7DKY
MI7TW8SCVJ*T\/Z+I\=Q'9:186R7((G6&V1!*#U# #D<GKZUYU87LNOW6I0W7
MC:\TCQ/'=31PZ<94CBB"N1$!$R_O5*A23SG-=??^)KZQO4TJTTB75]2AM$N;
MP6\BQ)&#D#!<\EBK87T')H WVL;1EMU:U@*VQ#0 QC$1 P"O]W )''8U7MM!
MT>SU&74+;2K&"]ESYEQ';HLCYZY8#)S7//\ $"&XNM+M=(TNYU&;4[ WUL%=
M8P%! (<L?EQGGW&.IK(U;XB:BUAI,NEZ/,MS+K2Z9>V\LD8:*0<F+).#N'(8
M<8],T =XNDZ:EE+9)I]HMI,2TL A4(Y/4LN,'/?-1VNA:18V$MA::5906<V1
M);Q6Z+&^>#N4#!S[U@:CXWELI[X0:%=W<&F1H^IRQ2H/LY*!RJ@G]XRJ03CU
M'4\47?CB0ZM>:;I&B7.J3VUM%=[HY4C1HY 2#N;OQP.^?8T =2UG:O)!(]M"
MSVY)A8H"8LC!VGMP2..U%W9VU_:R6MY;Q7%O(,/%,@=6'N#P:XZR^(\=\FC7
MJ:)>QZ/JTR6T%](Z#$KYPICSNQN!7=ZCTP3C:1XSU#28/%%P^D7^I6.GZS=F
MYN1,O[B(-G:BL<MM7G P #0!Z'::1IEA8-86>G6EO9N"&MXH56-L\'*@8.:L
MV]O#:6\=O;0QPPQJ%2.-0JJ!T  X KF-0\:&.[EATC2+G5EMK9+JZDAD1!'&
MX)4+N(WN5!.T=L<\U#>>/T&IV&GZ/I-SJMQ?Z>NH6PBD2-6C+8^8L0%XYR?8
M=30!U(L+,7<EV+2 7,J".2;RQO=1T4MU(]J:--L1:P6PLK;[/;LK0Q>4NR,K
M]TJ,8!';'2H=;BU.?1;J+1IX;?473;#-,,K&2>6Q@Y(&2/?%<6+B]\)>+XK)
M-<U#5[0Z7<7E_%>NKM!Y>W8X( V[CN&WIQ[4 =XEC:1W,]S':P+<7 432K&
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M&C<H\;J<JZL,%6![BJ^B>&K#09+F>W:YGNKK;Y]U=SM-+(%X4%F/09. ..:
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M'J[62(#.ELJ>6"4S][@$C/>O3FT>T;7X]:(?[9':M:*=WR^6S*QX]<J.:OT
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M.;P[X/L=.N4CCN1OEF2+[J/([.5&.P+8_"NBHH **** "BBB@ HHHH ****
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M^A=?_P #(ZVZ* ,3^U-;_P"A=?\ \#(Z/[4UO_H77_\  R.MNB@#$_M36_\
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M .A=?_P,CK;HH Y_PI)++!J;SP&"5M1E+1E@VT_+QD<&N@K%\.]=7_["4O\
M):VJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *Q;O_D=M*_[!]Y_Z,MJVJQ;O_D=M*_[!]Y_Z,MJ
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!B^'>NK_\ 82E_DM;58OAWKJ__ &$I?Y+6
MU0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !6+=_\ ([:5_P!@^\_]&6U;58MW_P CMI7_ &#[S_T9
M;4 ;5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!B^'>NK_\ 82E_DM;58OAWKJ__ &$I
M?Y+6U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,R_*P4#HNYD'<XZDGFK.C:MK]S\0]!T:;6II7CTXZEK2+M"!W'R1@8^4#<O
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M2/QD_,,D9YR!QG- 'JE%>*Z7XF\8R_!R\URVOY+G4+W4F6TEF1#)%;EP@VH
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M*W=Y=-#YYAL;9[ADBS@.VP' )Z>O:@!K^"/#\EYJUV; _:-60)>2"9P9%QC
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M3@$_A6>OCC1#H>H:M)+<00Z<P2\BGMW26!CC 9",\A@1VP: -^"".UMXK>%
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6+=_\CMI7_8/O/\
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M6:Y\DV\T:E QX.Y"I&<<\5-IN@ZQ%XYM=:U":&<+H2V4\T?R[Y_-WL0O9<4
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M_J&CW4\LMC.ZM%/'*7! 8@@, RL,C&17=>%K">RLKAKC1M,TEIIBR6MBH^5
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M;]DF>ORY^88Y4C'>L6[M-2\3_$&6PU:""Q^T^&KJW,$,WGF%9'1=[-@#).<
M=EZ\\;/A;0;^RO[$77A30=/^QPE)KZW"-).^W:#'A04!Y)W<\X]Z .ZHHHH
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M,/51&_\ WU6G<0:EX<'@W4H]=U&>2_OK>RN[>60&W9)(V)VQXPNTJ,8Y]2:
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M7)QGUK5U/PS!J=KHD$EQ(@TF\ANXRH'SM&I4 ^QS3O(\4?\ 02T?_P %\O\
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MP?!GVR?[*83%]HP-^"^[..E:7D>*/^@EH_\ X+Y?_CU+Y'BC_H):/_X+Y?\
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MD(,C+GJJJJKGN2<=*U_(\4?]!+1__!?+_P#'J/(\4?\ 02T?_P %\O\ \>H
MNZ58RZ=9M!-?3WKF5Y/-G(W ,Q(7Z ' ]A5VL3R/%'_02T?_ ,%\O_QZE\CQ
M1_T$M'_\%\O_ ,>H VJ*Q?(\4?\ 02T?_P %\O\ \>I/(\4?]!+1_P#P7R__
M !Z@#;HK%\CQ1_T$M'_\%\O_ ,>I/(\4?]!+1_\ P7R__'J -NBL7R/%'_02
MT?\ \%\O_P >H\CQ1_T$M'_\%\O_ ,>H VJ*Q/(\4?\ 02T?_P %\O\ \>I?
M(\4?]!+1_P#P7R__ !Z@#:HK$\CQ1_T$M'_\%\O_ ,>H\CQ1_P!!+1__  7R
M_P#QZ@#;HK$\CQ1_T$M'_P#!?+_\>H\CQ1_T$M'_ /!?+_\ 'J -NBL7R/%'
M_02T?_P7R_\ QZD\CQ1_T$M'_P#!?+_\>H VZ*Q?(\4?]!+1_P#P7R__ !ZD
M\CQ1_P!!+1__  7R_P#QZ@#;HK%\CQ1_T$M'_P#!?+_\>H\CQ1_T$M'_ /!?
M+_\ 'J -JBL7R/%'_02T?_P7R_\ QZCR/%'_ $$M'_\ !?+_ /'J -JBL3R/
M%'_02T?_ ,%\O_QZE\CQ1_T$M'_\%\O_ ,>H VJ*Q?(\4?\ 02T?_P %\O\
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MM'_\%\O_ ,>H 7P[UU?_ +"4O\EK:K,T33KC3K>X%W<13SW%P\[M%$8U!;'
M!9CV]:TZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ***S]0UJRTN>""Y-PTLZN\<<%K+.Q5=H8XC4X W+U]:
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MU;_P477_ ,;H_P"$GT__ )]]6_\ !1=?_&Z -FBL;_A)]/\ ^??5O_!1=?\
MQNHW\7:5%)%'(FIJ\K%8U;2;H%R 3@?N^3@$_@: -VBL;_A)]/\ ^??5O_!1
M=?\ QNC_ (2?3_\ GWU;_P %%U_\;H V:*QO^$GT_P#Y]]6_\%%U_P#&Z/\
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MK&_X2?3_ /GWU;_P477_ ,;H_P"$GT__ )]]6_\ !1=?_&Z -FBL;_A)]/\
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M_P"$GT__ )]]6_\ !1=?_&Z -FBL;_A)]/\ ^??5O_!1=?\ QNC_ (2?3_\
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M  477_QN@#9HK&_X2?3_ /GWU;_P477_ ,;H_P"$GT__ )]]6_\ !1=?_&Z
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MU;_P477_ ,;H_P"$GT__ )]]6_\ !1=?_&Z -FBL;_A)]/\ ^??5O_!1=?\
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MQ('VN3T&#@8P>ISTIVJ^+=3?5H8VURV\/Q3V4$]A]JM0\%W*X)97E/W0#M&
M0><\T >ET5B^*=<;PWX1U+63$LDMI;-((\_*SXX&?3.*YV2\\3>'M2T%=4UF
M.^AU>8V<RBT2/[-,T;.K1D=5RI&&S]: .I3Q%HTFN-HL>IVKZFHW-:K(#(HQ
MGD=N.:N37UI;W$-O/=013SDB*-Y K28Z[0>3^%>:?"ZQU&/Q)XOFFU4S)'K,
ML<Z&W1?/<*,.2.5Z]!Q4/Q4TNZU7Q?X=33R5U&VLKR[LR.OG1&)U'XE=OXT
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK_GJ(X=/ELS#MY)>1'W9_P" 8_&L2Y\"SS^"_$&@B^C$FJ7L]RLNPXC$DN\
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M'6?_ *,N:VJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *Q;O_ )';2O\ L'WG_HRVK:K%N_\ D=M*
M_P"P?>?^C+:@#:HHHH **** "BBB@ HHHH *\_\ '+:DGCWP4=)BM);W-]L6
M[D9(R/*7.2H)Z9[5Z!5&ZTBRO-4L-2GA+7=AYGV=]Q&S>NUN <'('>@#DWT+
M7KS4Y_$'B%]/C>TTZ>WM;6P9W W@%G9W )/R@  5S-_*H_9QTC+@%H; #GJ?
M.CX_0UZ^0""",@]0:Y)?AGX66V:U-G</:;@\=L]Y,T4)W;LQH6PAR.W;(Z$B
M@#E+W1++Q!\>[^QU)#-9#0XY7MRQ"2L)  & Z@9SCID#TJU#X:T74?BSJFFW
MEI%-8VNCV@AL7YBP"Z@[>AVC@9Z;J[Q- TV/Q'+X@2W(U.6V%J\V]N8P0V-N
M<=0.<9KF)_!K:I\1-6U.^AN(K22QMXK:[MKIH9 ZE]Z@HP8#!7(/!X]* .,L
M4WI%X6>20Z /%\]B(RYVF!8C(L!.>5W\8]L5L:EH"P>)?$'ACP^T&G6E[H\%
MP8 QC@6?SRN,+]SS%&T[>OO7;CP9H"^'ET); "Q63S5 D<.),[O,$F=V_/.[
M.:9!X)T*'3[ZS>VEN%O]INI;FXDEFE*_=S(S%AM[8(P>10!YSJ;IINCZAH]I
MX<;1+^YNK".\L(;L"VFADE*;HW483?@HQV@],@UU/ACPY=6^K:O;7&AV>D:+
M?621R:?:WGF*9,LK. JKLW*<''7;GK6[!X)T**QOK26WFNTOE5+F2\N9)I)%
M7[HWLQ8!2<C!&#R.:EL/".D:?;7T,<=Q,;^/RKF:YNI)I9$P0%WLQ8  G !&
M,T :.F:;::/IEOIUA%Y-I;H(XH]Q;:H[9))/XFJ&L_\ (;\._P#7[)_Z3S5?
MTS3;71],M].LHS':VZ!(T+EB /<DD_C5#6?^0WX=_P"OV3_TGFH UY?]2_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!BVO_ ".^J_\ 8.L__1ES6U6+:_\ ([ZK_P!@ZS_]&7-;5 !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %8MW_R.VE?]@^\_]&6U;58MW_R.VE?]@^\_]&6U &U1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !6+K/_ "&_#O\ U^R?^D\U;58N
ML_\ (;\._P#7[)_Z3S4 ;5%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &+:_\
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M_"+>'O\ H Z7_P" <?\ A1_PBWA[_H Z7_X!Q_X4 :7VB'_GM'_WT*/M$/\
MSVC_ .^A6;_PBWA[_H Z7_X!Q_X4?\(MX>_Z .E_^ <?^% &E]HA_P">T?\
MWT*/M$/_ #VC_P"^A6;_ ,(MX>_Z .E_^ <?^%'_  BWA[_H Z7_ . <?^%
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M_P"@#I?_ (!Q_P"%'_"+>'O^@#I?_@''_A0!I?:(?^>T?_?0H^T0_P#/:/\
M[Z%9O_"+>'O^@#I?_@''_A1_PBWA[_H Z7_X!Q_X4 :7VB'_ )[1_P#?0H^T
M0_\ /:/_ +Z%9O\ PBWA[_H Z7_X!Q_X4?\ "+>'O^@#I?\ X!Q_X4 :7VB'
M_GM'_P!]"C[1#_SVC_[Z%9O_  BWA[_H Z7_ . <?^%'_"+>'O\ H Z7_P"
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MO_"+>'O^@#I?_@''_A1_PBWA[_H Z7_X!Q_X4 :7VB'_ )[1_P#?0H^T0_\
M/:/_ +Z%9O\ PBWA[_H Z7_X!Q_X4?\ "+>'O^@#I?\ X!Q_X4 :7VB'_GM'
M_P!]"C[1#_SVC_[Z%9O_  BWA[_H Z7_ . <?^%'_"+>'O\ H Z7_P" <?\
MA0!I?:(?^>T?_?0H^T0_\]H_^^A6;_PBWA[_ * .E_\ @''_ (4?\(MX>_Z
M.E_^ <?^% &E]HA_Y[1_]]"C[1#_ ,]H_P#OH5F_\(MX>_Z .E_^ <?^%'_"
M+>'O^@#I?_@''_A0!I?:(?\ GM'_ -]"C[1#_P ]H_\ OH5F_P#"+>'O^@#I
M?_@''_A1_P (MX>_Z .E_P#@''_A0!I?:(?^>T?_ 'T*/M$/_/:/_OH5F_\
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M_P#B*/\ A+-'_P">MS_X!3?_ !% &W16)_PEFC_\];G_ , IO_B*/^$LT?\
MYZW/_@%-_P#$4 ;=%8G_  EFC_\ /6Y_\ IO_B*/^$LT?_GK<_\ @%-_\10!
MMT5B?\)9H_\ SUN?_ *;_P"(H_X2S1_^>MS_ . 4W_Q% &W16)_PEFC_ //6
MY_\  *;_ .(H_P"$LT?_ )ZW/_@%-_\ $4 ;=%8G_"6:/_SUN?\ P"F_^(H_
MX2S1_P#GK<_^ 4W_ ,10!MT5B?\ "6:/_P ];G_P"F_^(H_X2S1_^>MS_P"
M4W_Q% &W16)_PEFC_P#/6Y_\ IO_ (BC_A+-'_YZW/\ X!3?_$4 ;=%8G_"6
M:/\ \];G_P  IO\ XBC_ (2S1_\ GK<_^ 4W_P 10!MT5B?\)9H__/6Y_P#
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M (2S1_\ GK<_^ 4W_P 10!MT55T_4;75+07-G+YD19DR5*D%3@@@@$8(-6J
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K%'_([M_V#1_Z,-;58H_Y'
M=O\ L&C_ -&&@#7EECAB:65UCC0;F=C@*/4FJ<>MZ3-(L<6J63NQPJK<(23]
M,UD_$3_DF_B3_L&S_P#H!KSQM1\!?\(C96D_@V:6]NK:.WA_XD;1-/.R<!)2
M@&2><@^] 'M%%>6/KVI^%M'\+>&]5URVTJ^>P:6\O[E!,5V;56-<G!8EN2<\
M(?6I+;QUJVM6>AZ7IUW:+J6H:A<VCZBL.Z,Q0 L940GJR[, G )- 'I]%><7
M'B+Q+I&O>(-,O+VWNDL/#[ZA;3+;A"[@M@N,GIMQ@<'&>,UH:GXHU*U\"^&M
M6B:,76H3:>DY*9!$Q7?@=NIQZ4 =O17D^M_$F>TOM;N(==T^V_LFY:"+2)(=
MTEV(\;R7SE2QW!<>@SG-:L_BC5)_&%QI\>MZ?ICI-$++3[ZW*B^A949G$N?O
M$LX 4'!49!H ]#H) &2< 5YGX:76I?C%XMCEUD/!:)9AHC;##HR.RJ.?EQN/
M/.:T?B%NU+5O"_AF25X[#5KR3[9L8J98XHR_EDCLQP#]* .NMM9TN]N&M[74
MK.>=>L<4ZLP_ '-7:XCQ9X&\.GPG?266EV>G7=E;O/:7=I"L,D$B*64AE /4
M<^M0>%O%NJ7NJZ!#J93[-K6B)=V[!-I%R@!E7W!5@P^AH [ZBO*[CX@W[6:7
M3ZC::=9:IJTUM8WDT6Y8;6%3F3&?F9V4@9XY%5]5^)&I6?P_U_4+'4+2_N]*
MO888[Z.'$=Q$Y0Y*YP&&YE..,KF@#URFR2)%&TDC!40%F8G@ =37!:OJ/BSP
MSI,>OZGJ5K/;?;+<WEI%:!1;6[,5<*^27(+(<G'W3QSQH:GX@OW\87.EV#1?
M8]/TI[N]9DW9D?(B3VX5F/J,4 =/8W]IJ=E%>V-S%<VLHS'+$P96&<<$58KR
M2S^(%T?"/A$7.IV.CS:M#/-<7K6X*1K&V-J)TW,67KP #6EX=\=:AJ&K:1%-
M=6MU8S7=WILMU#'M6:5$66*1>>-R;@1TR* /2:*\QL/B)J']D^*=0OA%LM[9
M[[20J8WPF26*,'U):-3_ ,#%=REW=Z=X5%[J962\M[+SKG:-H+JF6P.PR#0!
M=AOK2XN[BTAN(Y+BVV^=&K M'N&5W#MD<U'%J^F3WC6<.HVDETN<PI.I<8_V
M0<UY>PNK+X.Z6R7+Q7_B6\MS>WB'#YNI 7;/;"$*/0 5V-U\./"MQI4=A!I-
MO9&':8;JT18YXF4Y#+)C.[CJ<Y[T =717%/?>(-=\3:SIND:I!IUOI BB,DE
MJ)FN)G3>=V2,* 5''))/-9&F^,/$'B:Z\.VUC-;:>VHZ?<RW3F'S?*DAE6-B
M@)YYR ">ASSCD ],HKR>7Q/XQA\):UK;ZE8[O#]Y-;21BTXOA%)AF8[OW>5(
M "]P3GG WYM0\2ZQXTUG1=,U*WT^TLK:VF69K43/ND#_ "X) P=N2>O''6@#
MK[G4K&SN[6UN;N&*XNV*V\;N TI R0H[X%6J\=FURX\1:U\,=1O(XX[LWM[%
M.L?W?,C!1B/8E<_C4_\ PLR5K@ZB-=T_RQJ/V8:)Y'[TP>=Y6_?G._'SXZ8X
M]Z /6Z*\FMM:U?P]>?$+6[G44NX["=52W>$*K.8HQ&<@_*HR 0.O)K8\*^,)
M+SQ3%H[^(;+7([FT>?SK:#RC!(A7*$ G*D-D9Y^4]: /0:*YJ^UVYTSQW9V%
MU)&NE7FG32QDKRLT3 MD^FQLX_V37(V'Q UR3P1K=[<QPC5U:!].C"8!2Z"^
M0".Y!9@?7;0!Z3;ZE8W5]=V-O=PRW5IL^T0HX+1;AE=P[9'(I\M[:P7=O:2W
M$:7%SN\F-FPTFT9; [X'->:W>N:Q<7'Q+TY+J""32+&W>&XCMQO8F!G?=ZYV
MD#^[FJ4$&M%OAI'%J43WDUI.8[B2#B&,VR'&T'YR!G!)&2030!Z]17+>$=4U
M2XO]>TC5KF.[N-*NDB6ZCB$7FH\2R+E0< C<1Q6%XW\6:AH5[J+P^(=,M/L5
MJ)[?3O(,TMR0"Q$I_P"68.,+CZY[4 >C45YSJWBO4V\1?8XM:L-$#VT,VGQ7
M]OF.^=P2RF7(Q@X7"\]^>E=7XNU.ZT;P9K&IVI1;JULY)H\C<H95)'U&: -N
MBO.9=5\8PZWX?LVU2Q8:_!*<?9.+%D19,K\V9."1SCG!Z<4Q/%NNV=C=6MU<
MP7%Y9>([;3&N1 $$L,C1G)7. V'(X]* /2::[K%&TCL%1069CT '>N.\1>+K
MG0/$6H1NJR6-GH$FI>7C#-(LFT#/H1Q3((_%R6'VC4[^RO;*[L)7N(T@\EK6
M39E0AR=Z\D'// /M0!V-K=07MI#=6LR36\R"2.1#E74C((/<5+7D_AK4?$6B
M>$_ UY)?VTFG7IM+%K 6^"B.F%<29R6X!(QCG';)[7QIK5YHVD6RZ;Y2W]_>
MP6-O)*NY(VD;&\CO@9.* -PWMJ+\6!N(_M9B,PAW?.4!P6QZ9(&:GKRJ_P!0
MU/PMX[O]0U6ZCU(V/A>>XBE6$0F3$RG8P!(SD=1V/3CF;1/&=[?:O::7'XGT
M[4IM1M)6W6UKC[#.JAA@9^=,;ASSE1SS0!Z?574=2L=)LVN]1NX;6W4A3+,X
M502< 9/J:\O\*ZIJ]A\*-$O9_$EC:+=R_-<W<.6A0ER51<_O7+ =>@SP<4FJ
M>.]2'PSU?4HI[2]N=/U5+)+EK;"3H6C(8QGH<28^HS0!ZC_:5C_:O]E_:X?M
M_D_:/LV\;_+SMWXZXSQFK5>>?\W#_P#<L?\ MS6_XQU2XTRRM&AUBQTF.6?9
M+=7*[W"[20L4?1F) Z]!DX- '245Y8OCO4I?#MO,^J06\":K-8W6M"R+(L:*
M61S'GY"Q*J2> <^HKOO#EQ=76B037=_97[L6V7=E_JYDW':V.0#C&0"1G.#0
M!JT5YB^O^,+K1_$^M6NH64,.B7UVD5JUKN^TQPL20S9!7Y1@8YR,GKQI6NN:
MYXNUB^@T348=*M+&WMWW/;"=YI9HQ( <D *%*CCDDGF@#O**\L;Q[J-]IN@W
M%SJ5KX>@O(9Q<7TEMYT7VF.3R_*RQ 0'#-ECR!C-7-9\3ZS::CI]C=Z]I6C>
M;IZ31WK6YEM;RX)8,@D8@*H 4XZD/P>* .]?4[&/4TTU[N%;YXC,MN7&\H#@
ML!Z9[T^SO;;4;.*\LYX[BVE7='+&VY6'J#7'2:[J"_$[3-%F6T\N;1&N9C&F
MX^:'P=KGG;7)^%]3\1^'OAAX?U\WULVEQ-##+I_V?DPO*(]_F9SORP;ICM[D
M ]:@U*QNKZZL8+N&2[M-OVB%7!:+<,KN';(Y%/O+RVT^TEN[N9(+>)=TDLAP
MJ#U)["O*X]</AOQG\5=8$:R/:PV+HC' 9O)(4'VR1FM;PUXL.I>(X]#N->T_
MQ!;WMG)([6]OY?DNI4,A&2"C!CC//RG.<T >B(ZR(KHP96&0P.01ZTM<9\-Y
M9(=)U317=G31=3GL8&8Y/DC#1@GV5POX5V= !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8OAG_
M (\KW_L)7?\ Z.>MJL7PS_QY7O\ V$KO_P!'/6U0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %8H_Y'=O\ L&C_ -&&MJL4?\CNW_8-'_HPT 2^)M)D
MUWPMJFDQ2K%)>6LD"NXR%+*1D_G5/4?"L&K^"D\/7DF"EM'&D\?#1RH!MD7T
M(8 UT-% ''S:!XBW:-JT5[8/KUE;/:W)E1A!=(Y4D\<J<HK=.Y%,U/PMKU]!
MHNI?VK:/XATNYDG21X"MNRR JT6 =P4*0 W)^7)ZUV=% 'E]MI6H7_Q.UNRU
MNZ@>:_\ #8C?[*A"0HTKIM7<<GN<GN3TJT?!7BB\T+1=&O\ 5-,6UTBXM9(V
MMXGWW"PL,;\G"_*.@SSCD 8/H?DQ>>9_*3SBNPR;1NV]<9]*?0!QY\/>(M/U
M#44T/4K&WT_4;HW3O-"SS6[MCS-@^ZV<9&[H2>M,\1>&O$&O&ZTV6^TV32+B
M9)%DF@/VFV *DJF/E)R#AC@C/?%=G10!R%MX9U?3OB)J>OV5U9/8:JD"W44R
MOYL?E*5&PC@Y![UH^*_#*^);"W6.[>RO[.=;FRO(U#&&5>Y!^\I!(([BMZB@
M#AK_ $#QIXAL7TG6-7TFUTV8;+F33H)!/-'W4;V(3<.">>M7/%O@^75M!L+3
M0[B/3;W37!LIBI(C788RO'.-C'\0*ZVB@#D[OP?):Z1H$.A3PP7FA$?9C.A,
M<B^68W5\<C<#G(Z$"J'B?P?KWBWP)J&C:CJEF+Z[G21#%$1# BLIV#^)ONDY
M/=NPKNZ* *>J:;!J^CW>F70W074+PR#V88/\ZYKPIX.O-$\/ZE;ZC?QWFJZ@
M-LUTJD JL0CC'// 7/U)KL:* . TOP+JNA:#X;33[ZS;5=%CFA)F1O)GCE.6
M4X^8<A2#SR.G-7M;\+ZYKOA);6YU:W77(KM;RWN8X2L4#!N% ZD!"RY/)S^%
M=C10!P.I_#G[4?#,-K=QPVFF0QVMY&RD_:88WBD5?;YHO_'C7;WUHE_87-G+
MGRYXFB;'HP(/\ZGHH \\\.:5#XF^&C>$-59X+[2P+"X\LX>&2(@Q2K[$!&![
MU;ET+QUJ-F-*U'Q!IT5D<)->V-NZ7<J=P,MM1B.I&<=J[588EE>58T$C@!G"
MC+ =,GO3Z .0N/#NNZ;KVHZEX<O+!5U-(A<1WZNWER1KL$BE3\V5QD'NN<\T
MS0O W]@ZGH4T%V)8--T^>U?>N'EDD=7+^@Y#''O7944 <3<^![J?P=XHT07D
M(EUB\N;F.0J=L8E8$ ^XQ6=%!KH^)OB=]#GL5E6SL4>.]5BC963# KR",'CO
MGM7H],6&)97E6-!(X =PHRV.F3WQF@#@[;X=S6;^#O+OTD_L.:>>Y=T(,[RY
M+%1V^8D\]JO:=X=\1:/-_9VGZE8Q:)]L:Y5FA+7"(\AD:$9^7!)8;CR >F1F
MNQHH X6Y\#W]U?\ BF![RV&DZ[B7(1O/@F"*H(_A(!4-^E;FBVWB=;TRZY?:
M>T"0^6L-E"P$CY'[QBW(X& HXY/)XK>HH Y3Q[X3N?%FDV\%C>I97D,C%9V4
MG$;QO'(O'JKG\0*K:GX$-YXPT75+>XCAT^R2)9[7:<RF'>8,'I\K.3^ KM**
M .,3P1,=9\;W<EY&(?$=O%!&%4EH=L+1DGU^]FFZ/X4UB"7PM+J=U8LVA1RP
M8ME?$J-$L:GYOXOE)/:NUHH Q-(T.73?$/B#4GF1TU2>*5$4'*!(EC(/XKFL
M#5?!NLWEUXDM[/4;.#3M>4&>1XF:XC/DB,JO.TJ0HY/(R<>M=U10!P>I>&/%
M6I:'+HT][HLUE=6J6\HFMV8VQ";6:+^]_>&[!#=\8%=%K^AOJW@V_P!"AGV/
M<63VJ2R\X)7:"?6MJB@#G+CPY--K?AF_$\831XYDD7!S)OB"#'T(S63J'@6\
MNK?7#!?01W5YJT.J6C.A*QO$(\*X[@F,]/6NYHH X9O!>IZSJU_?>(;VT9+[
M2)-,>"S1@L09L[E+<D]3DX[<<<SV&@^*V$-OJNLV9L[6TDMT6TB93=,R; \N
MXG&!SA>YZ]J[*B@#C_\ A#KC_A%?"ND?:HO,T:XM)I)-IQ((1@@?6M/Q;H,W
MB#2(H;2Y2VOK6YBO+661=R++&VX;@.H/(/UK=HH X-_!6JZUK%]?^(KVS*7N
MCRZ6T%DC!8@S!MP+<D]3DX[<<9.QHMAXHBN(EUG4K"2T@@,06TA8-<-P [EL
M[< 'Y5[D\\8KI** /-M*\#>)-(TS0H(;W29IM"FD^R>9'(%EBD5E)?T<;AC'
M'7UINI?#K6=2\.:]I,VJVDC:GJ$6H+.8F4JXV>8NWGY?W8V\DXZYKTNB@#F?
M^$8G_P"%F_\ "5?:(_(_LG^S_(P=V[S=^[/3&.*=XDT34K[5M'U;29K-;O3F
MF CO%8QNLBA2<KR&&!CZD5TE% '"Z=X9\6:*+TV>KZ;<&XOGNW2Y@8+/YB .
MK8R4VL,KC/!P<]:W?">A2>'](DMYY(&FGN9;J1;="D4;.V=J*>BC_$]ZW:*
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MBBB@ HHHH **** ,7PS_ ,>5[_V$KO\ ]'/6U6+X9_X\KW_L)7?_ *.>MJ@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q1_P CNW_8-'_HPUM5BC_D
M=V_[!H_]&&@#:HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#%\,_P#'E>_]A*[_ /1SUM5B^&?^/*]_["5W_P"CGK:H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "L4?\ ([M_V#1_Z,-;58H_
MY'=O^P:/_1AH VJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH Q?#/\ QY7O_82N_P#T<];58OAG_CRO?^PE=_\ HYZV
MJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K%'_ ".[?]@T?^C#6U6*
M/^1W;_L&C_T8: -JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** ,7PS_ ,>5[_V$KO\ ]'/6U6+X9_X\KW_L)7?_ *.>
MMJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q1_P CNW_8-'_HPUM5
MBC_D=V_[!H_]&&@#:HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@#%\,_P#'E>_]A*[_ /1SUM5B^&?^/*]_["5W_P"C
MGK:H **** "BBB@ HHHH **** "BBB@ HHHH **** "L4?\ ([M_V#1_Z,-;
M58H_Y'=O^P:/_1AH VJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH Q?#/\ QY7O_82N_P#T<];58OAG_CRO?^PE=_\
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M/*]_["5W_P"CGK:H **** "BBB@ HHHH **** "BBB@ HHHH **** "L4?\
M([M_V#1_Z,-;58H_Y'=O^P:/_1AH VJ*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH Q?#/\ QY7O_82N_P#T<];58OAG
M_CRO?^PE=_\ HYZVJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K%'_
M ".[?]@T?^C#6U6*/^1W;_L&C_T8: -JBBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** ,7PS_ ,>5[_V$KO\ ]'/6U6+X
M9_X\KW_L)7?_ *.>MJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q1
M_P CNW_8-'_HPUM5BC_D=V_[!H_]&&@#:HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@#%\,_P#'E>_]A*[_ /1SUM5B
M^&?^/*]_["5W_P"CGK:H **** "BBB@ HHHH **** "BBB@ HHHH **** "N
M?FN[:U\;$W%Q%"&TX &1PN?WA]:Z"J]Q8VEVP:YM8)F48!DC#8_.@"+^U],_
MZ"-I_P!_U_QH_M?3/^@C:?\ ?]?\:/[&TO\ Z!MG_P!^%_PH_L;2_P#H&V?_
M 'X7_"@ _M?3/^@C:?\ ?]?\:/[7TS_H(VG_ '_7_&C^QM+_ .@;9_\ ?A?\
M*/[&TO\ Z!MG_P!^%_PH /[7TS_H(VG_ '_7_&C^U],_Z"-I_P!_U_QH_L;2
M_P#H&V?_ 'X7_"C^QM+_ .@;9_\ ?A?\* #^U],_Z"-I_P!_U_QH_M?3/^@C
M:?\ ?]?\:/[&TO\ Z!MG_P!^%_PH_L;2_P#H&V?_ 'X7_"@ _M?3/^@C:?\
M?]?\:/[7TS_H(VG_ '_7_&C^QM+_ .@;9_\ ?A?\*/[&TO\ Z!MG_P!^%_PH
M /[7TS_H(VG_ '_7_&C^U],_Z"-I_P!_U_QH_L;2_P#H&V?_ 'X7_"C^QM+_
M .@;9_\ ?A?\* #^U],_Z"-I_P!_U_QH_M?3/^@C:?\ ?]?\:/[&TO\ Z!MG
M_P!^%_PH_L;2_P#H&V?_ 'X7_"@ _M?3/^@C:?\ ?]?\:/[7TS_H(VG_ '_7
M_&C^QM+_ .@;9_\ ?A?\*/[&TO\ Z!MG_P!^%_PH /[7TS_H(VG_ '_7_&C^
MU],_Z"-I_P!_U_QH_L;2_P#H&V?_ 'X7_"C^QM+_ .@;9_\ ?A?\* #^U],_
MZ"-I_P!_U_QH_M?3/^@C:?\ ?]?\:/[&TO\ Z!MG_P!^%_PH_L;2_P#H&V?_
M 'X7_"@ _M?3/^@C:?\ ?]?\:/[7TS_H(VG_ '_7_&C^QM+_ .@;9_\ ?A?\
M*/[&TO\ Z!MG_P!^%_PH /[7TS_H(VG_ '_7_&C^U],_Z"-I_P!_U_QH_L;2
M_P#H&V?_ 'X7_"C^QM+_ .@;9_\ ?A?\* #^U],_Z"-I_P!_U_QH_M?3/^@C
M:?\ ?]?\:/[&TO\ Z!MG_P!^%_PH_L;2_P#H&V?_ 'X7_"@ _M?3/^@C:?\
M?]?\:/[7TS_H(VG_ '_7_&C^QM+_ .@;9_\ ?A?\*/[&TO\ Z!MG_P!^%_PH
M /[7TS_H(VG_ '_7_&C^U],_Z"-I_P!_U_QH_L;2_P#H&V?_ 'X7_"C^QM+_
M .@;9_\ ?A?\* #^U],_Z"-I_P!_U_QH_M?3/^@C:?\ ?]?\:/[&TO\ Z!MG
M_P!^%_PH_L;2_P#H&V?_ 'X7_"@ _M?3/^@C:?\ ?]?\:/[7TS_H(VG_ '_7
M_&C^QM+_ .@;9_\ ?A?\*/[&TO\ Z!MG_P!^%_PH /[7TS_H(VG_ '_7_&C^
MU],_Z"-I_P!_U_QH_L;2_P#H&V?_ 'X7_"C^QM+_ .@;9_\ ?A?\* #^U],_
MZ"-I_P!_U_QH_M?3/^@C:?\ ?]?\:/[&TO\ Z!MG_P!^%_PH_L;2_P#H&V?_
M 'X7_"@ _M?3/^@C:?\ ?]?\:/[7TS_H(VG_ '_7_&C^QM+_ .@;9_\ ?A?\
M*/[&TO\ Z!MG_P!^%_PH /[7TS_H(VG_ '_7_&C^U],_Z"-I_P!_U_QH_L;2
M_P#H&V?_ 'X7_"C^QM+_ .@;9_\ ?A?\* #^U],_Z"-I_P!_U_QH_M?3/^@C
M:?\ ?]?\:/[&TO\ Z!MG_P!^%_PH_L;2_P#H&V?_ 'X7_"@ _M?3/^@C:?\
M?]?\:/[7TS_H(VG_ '_7_&C^QM+_ .@;9_\ ?A?\*/[&TO\ Z!MG_P!^%_PH
M /[7TS_H(VG_ '_7_&C^U],_Z"-I_P!_U_QH_L;2_P#H&V?_ 'X7_"C^QM+_
M .@;9_\ ?A?\* #^U],_Z"-I_P!_U_QH_M?3/^@C:?\ ?]?\:/[&TO\ Z!MG
M_P!^%_PH_L;2_P#H&V?_ 'X7_"@ _M?3/^@C:?\ ?]?\:/[7TS_H(VG_ '_7
M_&C^QM+_ .@;9_\ ?A?\*/[&TO\ Z!MG_P!^%_PH /[7TS_H(VG_ '_7_&C^
MU],_Z"-I_P!_U_QH_L;2_P#H&V?_ 'X7_"C^QM+_ .@;9_\ ?A?\* #^U],_
MZ"-I_P!_U_QH_M?3/^@C:?\ ?]?\:/[&TO\ Z!MG_P!^%_PH_L;2_P#H&V?_
M 'X7_"@ _M?3/^@C:?\ ?]?\:/[7TS_H(VG_ '_7_&C^QM+_ .@;9_\ ?A?\
M*/[&TO\ Z!MG_P!^%_PH /[7TS_H(VG_ '_7_&C^U],_Z"-I_P!_U_QH_L;2
M_P#H&V?_ 'X7_"C^QM+_ .@;9_\ ?A?\* #^U],_Z"-I_P!_U_QH_M?3/^@C
M:?\ ?]?\:/[&TO\ Z!MG_P!^%_PH_L;2_P#H&V?_ 'X7_"@ _M?3/^@C:?\
M?]?\:/[7TS_H(VG_ '_7_&C^QM+_ .@;9_\ ?A?\*/[&TO\ Z!MG_P!^%_PH
M /[7TS_H(VG_ '_7_&C^U],_Z"-I_P!_U_QH_L;2_P#H&V?_ 'X7_"C^QM+_
M .@;9_\ ?A?\* #^U],_Z"-I_P!_U_QH_M?3/^@C:?\ ?]?\:/[&TO\ Z!MG
M_P!^%_PH_L;2_P#H&V?_ 'X7_"@ _M?3/^@C:?\ ?]?\:/[7TS_H(VG_ '_7
M_&C^QM+_ .@;9_\ ?A?\*/[&TO\ Z!MG_P!^%_PH /[7TS_H(VG_ '_7_&C^
MU],_Z"-I_P!_U_QH_L;2_P#H&V?_ 'X7_"C^QM+_ .@;9_\ ?A?\* #^U],_
MZ"-I_P!_U_QH_M?3/^@C:?\ ?]?\:/[&TO\ Z!MG_P!^%_PH_L;2_P#H&V?_
M 'X7_"@ _M?3/^@C:?\ ?]?\:/[7TS_H(VG_ '_7_&C^QM+_ .@;9_\ ?A?\
M*/[&TO\ Z!MG_P!^%_PH /[7TS_H(VG_ '_7_&C^U],_Z"-I_P!_U_QH_L;2
M_P#H&V?_ 'X7_"C^QM+_ .@;9_\ ?A?\* #^U],_Z"-I_P!_U_QH_M?3/^@C
M:?\ ?]?\:/[&TO\ Z!MG_P!^%_PH_L;2_P#H&V?_ 'X7_"@ _M?3/^@C:?\
M?]?\:/[7TS_H(VG_ '_7_&C^QM+_ .@;9_\ ?A?\*/[&TO\ Z!MG_P!^%_PH
M /[7TS_H(VG_ '_7_&C^U],_Z"-I_P!_U_QH_L;2_P#H&V?_ 'X7_"C^QM+_
M .@;9_\ ?A?\* #^U],_Z"-I_P!_U_QH_M?3/^@C:?\ ?]?\:/[&TO\ Z!MG
M_P!^%_PH_L;2_P#H&V?_ 'X7_"@ _M?3/^@C:?\ ?]?\:/[7TS_H(VG_ '_7
M_&C^QM+_ .@;9_\ ?A?\*/[&TO\ Z!MG_P!^%_PH /[7TS_H(VG_ '_7_&C^
MU],_Z"-I_P!_U_QH_L;2_P#H&V?_ 'X7_"C^QM+_ .@;9_\ ?A?\* #^U],_
MZ"-I_P!_U_QH_M?3/^@C:?\ ?]?\:/[&TO\ Z!MG_P!^%_PH_L;2_P#H&V?_
M 'X7_"@ _M?3/^@C:?\ ?]?\:/[7TS_H(VG_ '_7_&C^QM+_ .@;9_\ ?A?\
M*/[&TO\ Z!MG_P!^%_PH /[7TS_H(VG_ '_7_&C^U],_Z"-I_P!_U_QH_L;2
M_P#H&V?_ 'X7_"C^QM+_ .@;9_\ ?A?\* #^U],_Z"-I_P!_U_QH_M?3/^@C
M:?\ ?]?\:/[&TO\ Z!MG_P!^%_PH_L;2_P#H&V?_ 'X7_"@ _M?3/^@C:?\
M?]?\:/[7TS_H(VG_ '_7_&C^QM+_ .@;9_\ ?A?\*/[&TO\ Z!MG_P!^%_PH
M /[7TS_H(VG_ '_7_&C^U],_Z"-I_P!_U_QH_L;2_P#H&V?_ 'X7_"C^QM+_
M .@;9_\ ?A?\* #^U],_Z"-I_P!_U_QH_M?3/^@C:?\ ?]?\:/[&TO\ Z!MG
M_P!^%_PH_L;2_P#H&V?_ 'X7_"@ _M?3/^@C:?\ ?]?\:/[7TS_H(VG_ '_7
M_&C^QM+_ .@;9_\ ?A?\*/[&TO\ Z!MG_P!^%_PH /[7TS_H(VG_ '_7_&C^
MU],_Z"-I_P!_U_QH_L;2_P#H&V?_ 'X7_"C^QM+_ .@;9_\ ?A?\* #^U],_
MZ"-I_P!_U_QH_M?3/^@C:?\ ?]?\:/[&TO\ Z!MG_P!^%_PH_L;2_P#H&V?_
M 'X7_"@ _M?3/^@C:?\ ?]?\:/[7TS_H(VG_ '_7_&C^QM+_ .@;9_\ ?A?\
M*/[&TO\ Z!MG_P!^%_PH /[7TS_H(VG_ '_7_&C^U],_Z"-I_P!_U_QH_L;2
M_P#H&V?_ 'X7_"C^QM+_ .@;9_\ ?A?\* *'A61)=.O)(W5T;4;LAE.01YS]
MZW*CA@AMHA%!$D48Z(BA0/P%24 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !6!?>#M,U&]ENY[C5EDE.6$.JW,2#C'"JX _ 5OT4 <O
M_P (#H__ #]:Y_X.[O\ ^.4?\(#H_P#S]:Y_X.[O_P".5U%% '+_ /" Z/\
M\_6N?^#N[_\ CE'_  @.C_\ /UKG_@[N_P#XY7444 <O_P (#H__ #]:Y_X.
M[O\ ^.4?\(#H_P#S]:Y_X.[O_P".5U%% '+_ /" Z/\ \_6N?^#N[_\ CE'_
M  @.C_\ /UKG_@[N_P#XY7444 <O_P (#H__ #]:Y_X.[O\ ^.4?\(#H_P#S
M]:Y_X.[O_P".5U%% '+_ /" Z/\ \_6N?^#N[_\ CE'_  @.C_\ /UKG_@[N
M_P#XY7444 <O_P (#H__ #]:Y_X.[O\ ^.4?\(#H_P#S]:Y_X.[O_P".5U%%
M '+_ /" Z/\ \_6N?^#N[_\ CE'_  @.C_\ /UKG_@[N_P#XY7444 <O_P (
M#H__ #]:Y_X.[O\ ^.4?\(#H_P#S]:Y_X.[O_P".5U%% '+_ /" Z/\ \_6N
M?^#N[_\ CE'_  @.C_\ /UKG_@[N_P#XY7444 <O_P (#H__ #]:Y_X.[O\
M^.4?\(#H_P#S]:Y_X.[O_P".5U%% '+_ /" Z/\ \_6N?^#N[_\ CE'_  @.
MC_\ /UKG_@[N_P#XY7444 <O_P (#H__ #]:Y_X.[O\ ^.4?\(#H_P#S]:Y_
MX.[O_P".5U%% '+_ /" Z/\ \_6N?^#N[_\ CE'_  @.C_\ /UKG_@[N_P#X
MY7444 <O_P (#H__ #]:Y_X.[O\ ^.4?\(#H_P#S]:Y_X.[O_P".5U%% '+_
M /" Z/\ \_6N?^#N[_\ CE'_  @.C_\ /UKG_@[N_P#XY7444 <O_P (#H__
M #]:Y_X.[O\ ^.4?\(#H_P#S]:Y_X.[O_P".5U%% '+_ /" Z/\ \_6N?^#N
M[_\ CE'_  @.C_\ /UKG_@[N_P#XY7444 <O_P (#H__ #]:Y_X.[O\ ^.4?
M\(#H_P#S]:Y_X.[O_P".5U%% '+_ /" Z/\ \_6N?^#N[_\ CE'_  @.C_\
M/UKG_@[N_P#XY7444 <O_P (#H__ #]:Y_X.[O\ ^.4?\(#H_P#S]:Y_X.[O
M_P".5U%% '+_ /" Z/\ \_6N?^#N[_\ CE'_  @.C_\ /UKG_@[N_P#XY744
M4 <O_P (#H__ #]:Y_X.[O\ ^.4?\(#H_P#S]:Y_X.[O_P".5U%% '+_ /"
MZ/\ \_6N?^#N[_\ CE'_  @.C_\ /UKG_@[N_P#XY7444 <O_P (#H__ #]:
MY_X.[O\ ^.4?\(#H_P#S]:Y_X.[O_P".5U%% '+_ /" Z/\ \_6N?^#N[_\
MCE'_  @.C_\ /UKG_@[N_P#XY7444 <O_P (#H__ #]:Y_X.[O\ ^.4?\(#H
M_P#S]:Y_X.[O_P".5U%% '+_ /" Z/\ \_6N?^#N[_\ CE'_  @.C_\ /UKG
M_@[N_P#XY7444 <O_P (#H__ #]:Y_X.[O\ ^.4?\(#H_P#S]:Y_X.[O_P".
M5U%% '+_ /" Z/\ \_6N?^#N[_\ CE'_  @.C_\ /UKG_@[N_P#XY7444 <O
M_P (#H__ #]:Y_X.[O\ ^.4?\(#H_P#S]:Y_X.[O_P".5U%% '+_ /" Z/\
M\_6N?^#N[_\ CE'_  @.C_\ /UKG_@[N_P#XY7444 <O_P (#H__ #]:Y_X.
M[O\ ^.4?\(#H_P#S]:Y_X.[O_P".5U%% '+_ /" Z/\ \_6N?^#N[_\ CE'_
M  @.C_\ /UKG_@[N_P#XY7444 <O_P (#H__ #]:Y_X.[O\ ^.4?\(#H_P#S
M]:Y_X.[O_P".5U%% '+_ /" Z/\ \_6N?^#N[_\ CE'_  @.C_\ /UKG_@[N
M_P#XY7444 <O_P (#H__ #]:Y_X.[O\ ^.4?\(#H_P#S]:Y_X.[O_P".5U%%
M '+_ /" Z/\ \_6N?^#N[_\ CE'_  @.C_\ /UKG_@[N_P#XY7444 <O_P (
M#H__ #]:Y_X.[O\ ^.4?\(#H_P#S]:Y_X.[O_P".5U%% '+_ /" Z/\ \_6N
M?^#N[_\ CE'_  @.C_\ /UKG_@[N_P#XY7444 <O_P (#H__ #]:Y_X.[O\
M^.4?\(#H_P#S]:Y_X.[O_P".5U%% '+_ /" Z/\ \_6N?^#N[_\ CE'_  @.
MC_\ /UKG_@[N_P#XY7444 <O_P (#H__ #]:Y_X.[O\ ^.4?\(#H_P#S]:Y_
MX.[O_P".5U%% '+_ /" Z/\ \_6N?^#N[_\ CE'_  @.C_\ /UKG_@[N_P#X
MY7444 <O_P (#H__ #]:Y_X.[O\ ^.4?\(#H_P#S]:Y_X.[O_P".5U%% '+_
M /" Z/\ \_6N?^#N[_\ CE'_  @.C_\ /UKG_@[N_P#XY7444 <O_P (#H__
M #]:Y_X.[O\ ^.4?\(#H_P#S]:Y_X.[O_P".5U%% '+_ /" Z/\ \_6N?^#N
M[_\ CE'_  @.C_\ /UKG_@[N_P#XY7444 <O_P (#H__ #]:Y_X.[O\ ^.4?
M\(#H_P#S]:Y_X.[O_P".5U%% '+_ /" Z/\ \_6N?^#N[_\ CE'_  @.C_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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C HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>exhibit101_changexreques002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit101_changexreques002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !117+>,X?&LJ67_"'7&FPL"_VG[<"<CY=NW /^UG\* .
MIHKRK['\;/\ H(^&?^^6_P#B*/L?QL_Z"/AG_OEO_B* /5:*\J^Q_&S_ *"/
MAG_OEO\ XBC['\;/^@CX9_[Y;_XB@#U6BO*OL?QL_P"@CX9_[Y;_ .(H^Q_&
MS_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?QL_Z"/AG_OEO_B*
M/5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB@#U6BO*OL?QL_P"@
MCX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?
MQL_Z"/AG_OEO_B* /5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB
M@#U6BO*OL?QL_P"@CX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\
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M_=H5\A,A'SW(*=?QJA)X2^+UUXFM?$<U]X?_ +0M[=K>(,6VHK')X"8R<]:
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MB#I?BKX<7UIX=^T7D6Z)[R<V[QQP()%P"6 RQ;:,#/&3VK=^Q_&S_H(^&?\
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MS_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?QL_Z"/AG_OEO_B*
M/5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB@#U6BO*OL?QL_P"@
MCX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?
MQL_Z"/AG_OEO_B* /5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB
M@#U6BO*OL?QL_P"@CX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)"JN(QT0,!G;QTZ5=HHH *JWFFV&HF$WUE;7)@<21>?$K^6PZ,N1P?<5:HH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBL._NM6EU]=.TZYLK=%M?/=[BU>8D
MEBN!MD3'3WH W**Q/LOBC_H,:/\ ^"J7_P"2*/LOBC_H,:/_ ."J7_Y(H VZ
M*Q/LOBC_ *#&C_\ @JE_^2*/LOBC_H,:/_X*I?\ Y(H VZ*Q/LOBC_H,:/\
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M_P"@QH__ (*I?_DB@#;HK$^R^*/^@QH__@JE_P#DBC[+XH_Z#&C_ /@JE_\
MDB@#;HK$^R^*/^@QH_\ X*I?_DBC[+XH_P"@QH__ (*I?_DB@#;HK$^R^*/^
M@QH__@JE_P#DBC[+XH_Z#&C_ /@JE_\ DB@#;HK$^R^*/^@QH_\ X*I?_DBC
M[+XH_P"@QH__ (*I?_DB@#;HK$^R^*/^@QH__@JE_P#DBC[+XH_Z#&C_ /@J
ME_\ DB@#;HK$^R^*/^@QH_\ X*I?_DBC[+XH_P"@QH__ (*I?_DB@#;HK$^R
M^*/^@QH__@JE_P#DBC[+XH_Z#&C_ /@JE_\ DB@#;HK$^R^*/^@QH_\ X*I?
M_DBC[+XH_P"@QH__ (*I?_DB@#;HK$^R^*/^@QH__@JE_P#DBC[+XH_Z#&C_
M /@JE_\ DB@#;HK$^R^*/^@QH_\ X*I?_DBC[+XH_P"@QH__ (*I?_DB@#;H
MK$^R^*/^@QH__@JE_P#DBC[+XH_Z#&C_ /@JE_\ DB@#;HK$^R^*/^@QH_\
MX*I?_DBC[+XH_P"@QH__ (*I?_DB@#;HK$^R^*/^@QH__@JE_P#DBC[+XH_Z
M#&C_ /@JE_\ DB@#;HK$^R^*/^@QH_\ X*I?_DBC[+XH_P"@QH__ (*I?_DB
M@#;HK$^R^*/^@QH__@JE_P#DBC[+XH_Z#&C_ /@JE_\ DB@#;HK$^R^*/^@Q
MH_\ X*I?_DBC[+XH_P"@QH__ (*I?_DB@#;HK$^R^*/^@QH__@JE_P#DBC[+
MXH_Z#&C_ /@JE_\ DB@#;HK$^R^*/^@QH_\ X*I?_DBC[+XH_P"@QH__ (*I
M?_DB@#;HK$^R^*/^@QH__@JE_P#DBC[+XH_Z#&C_ /@JE_\ DB@#;HK$^R^*
M/^@QH_\ X*I?_DBC[+XH_P"@QH__ (*I?_DB@#;HK$^R^*/^@QH__@JE_P#D
MBC[+XH_Z#&C_ /@JE_\ DB@#;HK$^R^*/^@QH_\ X*I?_DBC[+XH_P"@QH__
M (*I?_DB@#;HK$^R^*/^@QH__@JE_P#DBC[+XH_Z#&C_ /@JE_\ DB@#;HK$
M^R^*/^@QH_\ X*I?_DBC[+XH_P"@QH__ (*I?_DB@#;HK$^R^*/^@QH__@JE
M_P#DBC[+XH_Z#&C_ /@JE_\ DB@#;HK$^R^*/^@QH_\ X*I?_DBC[+XH_P"@
MQH__ (*I?_DB@#;HK$^R^*/^@QH__@JE_P#DBC[+XH_Z#&C_ /@JE_\ DB@#
M;HK$^R^*/^@QH_\ X*I?_DBC[+XH_P"@QH__ (*I?_DB@#;HK$^R^*/^@QH_
M_@JE_P#DBC[+XH_Z#&C_ /@JE_\ DB@#;HK$^R^*/^@QH_\ X*I?_DBC[+XH
M_P"@QH__ (*I?_DB@#;HK$^R^*/^@QH__@JE_P#DBC[+XH_Z#&C_ /@JE_\
MDB@#;HK$^R^*/^@QH_\ X*I?_DBC[+XH_P"@QH__ (*I?_DB@#;HK$^R^*/^
M@QH__@JE_P#DBC[+XH_Z#&C_ /@JE_\ DB@#;HK$^R^*/^@QH_\ X*I?_DBC
M[+XH_P"@QH__ (*I?_DB@#;HK$^R^*/^@QH__@JE_P#DBC[+XH_Z#&C_ /@J
ME_\ DB@#;HK$^R^*/^@QH_\ X*I?_DBC[+XH_P"@QH__ (*I?_DB@#;HK$^R
M^*/^@QH__@JE_P#DBC[+XH_Z#&C_ /@JE_\ DB@#;HK$^R^*/^@QH_\ X*I?
M_DBC[+XH_P"@QH__ (*I?_DB@#;HK$^R^*/^@QH__@JE_P#DBC[+XH_Z#&C_
M /@JE_\ DB@#;HK$^R^*/^@QH_\ X*I?_DBC[+XH_P"@QH__ (*I?_DB@#;H
MK$^R^*/^@QH__@JE_P#DBC[+XH_Z#&C_ /@JE_\ DB@#;HK$^R^*/^@QH_\
MX*I?_DBC[+XH_P"@QH__ (*I?_DB@#;HK$^R^*/^@QH__@JE_P#DBC[+XH_Z
M#&C_ /@JE_\ DB@#;HK*T"]N[[3Y6OF@:XBN9H&:",HK;)&4$*68C('J:U:
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M%CM;.#@*QX[ ^E>6Z#*RV6A:38VVG"Z.J:K):W%\C/%:K'*P.U%9<L0^!R,
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M'6XF!A821DER">26X^\M;_Q1CFFTSP_%;S_9YWU^R6.8(&\MBQPV#P<'G!H
MGE\8:WI-W9#Q#X9CLK&[N$M1=6NH"X$<CG";E**0">,C.*Z*YU_1[/4X=-N=
M5LH;^;'EVTDZK(^>F%)R<UP6IZ=J=OXV\/V?BO7IM1T::426A6WC@3[:AW(D
MNT9((R5YY9<8K)NK"_U&#QS!/J.A65N^I2+<37T+F>(;4\EPP<  +M*\=: /
M4[S7]'TZ_@L;W5;*VNY_]5!-.J._.!@$Y//%2VFK:=?-"MI?VT[30^?$(Y58
MO'G&\ 'E<D#/2N"TX:>-<^((UUH'E40B5I0.;?[,N",_P[M_X^]97PZDCAU?
MPB975!)X3=4+'&XB>,D#WQS0!ZA-K6EV]G<7DVI6D=K;.8YYFF4)&X."K'.
M0>,'FF?\)!HW]D?VO_:UE_9O_/W]H7RNN/O9QUXKR*":>]FLIK">Q-M+XPOV
M26\0O;LY1S$2%(SGG;SUQ6W_ &%)(]WYGB'1(M3;6X[FWBA@8VRW:P$-&Z%B
M<LGS'!SGGK0!UVJ>/?#>E6NFW,NJV<D&H3B&&6.X0KC^)R<XVKW/;(KHA-$T
M G$J&$KO$@8;=N,YSZ8[UY#J%U%=?V&EWIMA9W=KXPB@O#:-N@ED,)8NI('4
M%00><CFO0?&M];Z=X(U:YGM$N[<6Q5H&<JD@;Y<$CHO//MF@"Y8^)-#U.WN9
M['6+"YAM03/)#<(RQ  G+$'@8!Y/I34\4^'Y+B:W37--::&/SI4%TF43&=QY
MX&,'->9:F+JW\0:W:WMUI4DR^$+L&/3;=HDC *[5.7;<0"<=, ].:O/I&G[/
MA9']CAVYR1L'S'[*S\^N6 8^IH ]&L]<TG4--?4;/4[.>QCSON(YU:-<<G+
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M8OLWVG[?8^5Y6-^W;^\SCG&[&<_Q8[T_3K +X%^)%]9P*=2;4-45)@N9 !G
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M;;,C.-V&+@$_7!(S[FLW0D@B\1^';>=8UT^+7]92)& $:RACY8 Z \OCWZ4
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M_J\=[ISJKO/*-D+D#_48.57'K0!Z)9:78:<9#965O;&0(',,87<%4*N<=<*
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M<FC^'[[4HK62Y>VA:411[<G ]R!@=3ST!QD\4 6$TRPCBN8DL[=8[HDW"K&
M)25"DL._  Y["JE_X9T+5+>VM[_1["YAM0%@CFMU81  #"@C@8 X]JX,>-=4
MN$\!ZE<66H1-?"7S[2';_IC&V#*54.1M+'(W$8QDXQ72Q>/K'^SK^:ZT^_M;
MVRN8[233W1&F:60 QJFUBK;MPP<XZYQB@#JD1(HUCC1410%55&  .@ JD=#T
MDPWD)TVT\J^8O=)Y*XG8]2XQ\Q^M5=#\0IK,UY:RV-UI]_9E//M;G8657!*L
M"C,K*<'D'J"*YWQ/K$__  FUKH4_B)O#]A)8_:(YT$:M<S;RIC#R*5&T!3@#
M)W4 =I)9VLMS!<R6\3SV^[R9&0%H]PP=I[9'!Q5?^P])^QW5G_9EG]ENY&EN
M8?)79,[8W,PQAB<#)/I6)%J=_P"%M"D?7KPZN[W8AT][:-1/<A\;$91M3?G=
MR,# R<<U'<?$'3[#1M1O]3L;ZRDTV:&*[M9%0R1^:RA'RK%64[LY!['N,4 ;
M^J:)I>MVR6^J:=:WL*,'2.XB#A6'< U)::5I]A///9V-M;RW&T3/%$$,FT87
M) YP.!Z5BZ=XRBO=8L]+NM)U'3;B]AEFMOMB(HD6,C(X8D-A@V".E9GB[QCI
M<.C^)8)GU>&+1Q;BZNM.94D#2,I"QL3]X C=G'!H ["TL+.P\[[':PV_GRM-
M+Y2!?,D;JS8ZL>Y--N=/M+N>"YEMX7N;;<;>=XPSPEA@E2>F1U]:Q-2\7QZ=
M>)I]GI6HZM=K;+<S1V@0F*(Y +%V4%C@X49)P:BE\=6DJ67]DZ=?ZM+=VHO1
M#:JBM'#G&YM[* 2<@+U)!]* ,.P\":H=3T\WUIX=M8+2\6]GNM-@,<][(F[9
MO7: @RVXX+<CC%=_;65K9+*MK;0P":1II!&@7>[<LQQU)[FN<D\=6DL5@VDZ
M;J&K27EJ;P16JHK1Q [26WLHSGC:,G(-=%87D>HZ?;WL2R+'/&LBK*A1P",X
M*GD'VH J:;X<T31KB:XTS2;*SFG_ -9);P*C-WP2!TS18^'-$TR_FO['2+&V
MNYL^9/# JNV>3D@9Y-:=% %)='TQ+*WLUT^U6UMG62"$1+LB93E648P"#R".
M]2FQM#=O=FVA^TR1B%Y=@W,@)(4GJ1DGCW-6** ,JP\,:#I27*:?HUA:K= K
M.(;=5$@/9L#D<GCIS5LZ;8M#:0FSMS%9LK6R&,8A*C"E!_"0"0,=C5JB@"A;
M:)I=EJ5SJ-KIUK#>W/\ K[B.)5>3_>(&3276@Z1?:E!J5WIEG/?6XQ#<20JS
MIW&&(R.:T** *%AH>DZ4RMI^F6EJRH8U,$*H0A;<5&!TW$G'K3+KP[HM[826
M-UI5E-:22F=X7@4JTA.2Y&/O$DG/7FM*B@"G8:1INE*PT^PMK0,JJP@B5,A1
MA0<#L.E96N:#<W.N:3KNER0I?V+-%(LQ*I/;OC>A(!(((#+QU'O70T4 8]QX
M3\.W=TEU<:%ITLZ2&99'MD+!R<ELXZD\_6JTF@W-]XVAUJ_DA-II\#1Z? A)
M/F2#$DCY P< * ,\9/?%=#10!!>65KJ-G+:7MO%<VTHVR12H&5AZ$'K4%CHV
MF:88S8Z?:VQCB$"&&)5*Q@EM@P.F23CU)J]10!G7'A_1[O3I-/N-+LY;*20R
MO \"E"Y.2V,8R22<]<FK-C86>F6<=G86L-K;1C"0PH$5?H!5BB@"K_9EAY=X
MGV*WV7I)NE\L8GRNT[_[V0 .>U*=.LBUHQM(-UG_ ,>Q\L?N?EV_)_=^7CCM
M5FB@#%3PAX;C$P30=-432K-(!:I\[@Y#'CJ"3^9JZ=(TUK":P;3[4V<S,TMN
M8EV.6.YB5Q@Y/)]ZNT4 0QV=M#<SW,5O$D]QM\Z54 :3:,+N/? Z9JA=>&="
MO=,ATVZT>QEL8/\ 4V[VZE(_]T8P/PK5HH III6G1M9M'86R&R4K:E8E'D C
M!"<?+D<<=JN444 %%%% &+X9_P"/*]_["5W_ .CGK:K%\,_\>5[_ -A*[_\
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M=KEE3)66-7/F@(S=@"><9 KT^B@#QK4KC4H='LG(U:_TZ#Q+9-IW]I1E+J5
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?O+AG0MB%0,-MQ@\\5OZ7KB?\(S#JNM7^D0@[O-N+:Z#6P^8@8D;&>@S[Y%
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M@ HHHH **** "L4?\CNW_8-'_HPUM5BC_D=V_P"P:/\ T8: -JBBB@ HHHH
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M3I]O):20V<*/9PFWMV5 #%&<?*OH/E7CV%26UC:V;W#VUO'$UQ*9IBBX\QR
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M(%TW1K\VL#VS6\KP.DEUME1Y-D3*&PH'7OSCI0!Z'97+7EE%</;3VK2#)AG
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M4 >BWWC1+(PQ_P!A:S/=/;FZEMH88R\$8)&7RX7)(. I)..E8VI>))KOXA>
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M/H\L\5R-HW,81EMHSR/3./PJI=>.;.'4CIMKIFIW]]]DBO!!:Q(28GW8.68
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MNA9R7\<*F!)B0-I.[=P2 3MP#WHM/&EI>:FEK%INI_99+E[6/4/)'V=Y4)!
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M=W7 SS0!Z/17F-S\2+^ST'6)(I-*U6^TR[M(Q-9$^3<1SN ,#>=KCYAC<1D
M^U:&J>*-;TBYT[1]0U/P_8ZE=I+<RWDX9;>*)2H5%5G4NY+?WAPI.* .XGN[
M:U:);BXBB,SB.,2.%WL>BC/4^U35Y?<^.&U"R\+3R6.DWD\WB :;-)M\Z-&5
MF'FP-G@D $'G&>]:%WXE\574_BC^RUTF&#0YB%-S%(YN (5DV<.-IY/S<]1Q
MP20#T"BJ.BZB-8T+3M3$?EB\MH[@)G.W>H;'ZU>H **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N2D\ V<US
M^^U;59=-^U?:_P"S))U:#S-V\?P[RN[G;NQGM76T4 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4=8TJ'6]+FL+B6
M>))<'S+>0QR(000RL.A! K/T7PM%I.ISZG/J-]J>H2Q"#[3>,A*1 YV*$55
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!B^&?^/*]_P"PE=_^CGK:K%\,_P#'E>_]A*[_ /1S
MUM4 %%%% !1110 4444 %%%% !1110 4444 %%%% !6*/^1W;_L&C_T8:VJQ
M1_R.[?\ 8-'_ *,- &U1110 4444 %%%% !1110 4444 %%%% !1110 5BZQ
M_P A[P]_U]2_^B)*VJQ=8_Y#WA[_ *^I?_1$E &U1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!B^&?^/*]_["5W_Z.>MJL7PS_P >5[_V$KO_ -'/6U0 4444 %%%% !1110
M4444 %%%% !1110 4444 %8H_P"1W;_L&C_T8:VJQ1_R.[?]@T?^C#0!M444
M4 %%%% !1110 4444 %%%% !1110 4444 %8NL?\A[P]_P!?4O\ Z(DK:K%U
MC_D/>'O^OJ7_ -$24 ;5%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% &+X9_P"/*]_["5W_ .CG
MK:K%\,_\>5[_ -A*[_\ 1SUM4 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !6*/^1W;_ +!H_P#1AK:K%'_([M_V#1_Z,- &U1110 4444 %%%% !111
M0 4444 %%%% !1110 5BZQ_R'O#W_7U+_P"B)*VJQ=8_Y#WA[_KZE_\ 1$E
M&U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!B^&?^/*]_["5W_P"CGK:K%\,_\>5[_P!A*[_]
M'/6U0 4444 %%%% !1110 4444 %%%% !1110 4444 %8H_Y'=O^P:/_ $8:
MVJQ1_P CNW_8-'_HPT ;5%%% !1110 4444 %%%% !1110 4444 %%%% !6+
MK'_(>\/?]?4O_HB2MJL76/\ D/>'O^OJ7_T1)0!M4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M 8OAG_CRO?\ L)7?_HYZVJQ?#/\ QY7O_82N_P#T<];5 !1110 4444 %%%%
M !1110 4444 %%%% !1110 5BC_D=V_[!H_]&&MJL4?\CNW_ &#1_P"C#0!M
M4444 %%%% !1110 4444 %%%% !1110 4444 %8NL?\ (>\/?]?4O_HB2MJL
M76/^0]X>_P"OJ7_T1)0!M4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 8OAG_CRO?^PE=_^CGK
M:K%\,_\ 'E>_]A*[_P#1SUM4 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !6*/\ D=V_[!H_]&&MJL4?\CNW_8-'_HPT ;5%%% !1110 4444 %%%% !
M1110 4444 %%%% !6+K'_(>\/?\ 7U+_ .B)*VJQ=8_Y#WA[_KZE_P#1$E &
MU1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!B^&?\ CRO?^PE=_P#HYZVJQ?#/_'E>_P#82N__
M $<];5 !1110 4444 %%%% !1110 4444 %%%% !1110 5BC_D=V_P"P:/\
MT8:VJQ1_R.[?]@T?^C#0!M4444 %%%% !1110 4444 %%%% !1110 4444 %
M8NL?\A[P]_U]2_\ HB2MJL76/^0]X>_Z^I?_ $1)0!M4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 8OAG_CRO?^PE=_\ HYZVJQ?#/_'E>_\ 82N__1SUM4 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !6*/^1W;_L&C_P!&&MJL4?\ ([M_V#1_Z,-
M&U1110 4444 %%%% !1110 4444 %%%% !1110 5BZQ_R'O#W_7U+_Z(DK:K
M%UC_ )#WA[_KZE_]$24 ;5%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &+X9_X\KW_ +"5W_Z.
M>MJL7PS_ ,>5[_V$KO\ ]'/6U0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %8H_Y'=O^P:/_1AK:KF[^_@TSQ>)[I9Q$]@$5X[=Y!N$A./E!QQ0!TE%
M8G_"6:1_STN__ &?_P"(H_X2S2/^>EW_ . ,_P#\10!MT5B?\)9I'_/2[_\
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M>EW_ . ,_P#\11_PEFD?\]+O_P  9_\ XB@#;HK$_P"$LTC_ )Z7?_@#/_\
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M?\)9I'_/2[_\ 9__ (B@#;HK$_X2S2/^>EW_ . ,_P#\11_PEFD?\]+O_P
M9_\ XB@#;HK$_P"$LTC_ )Z7?_@#/_\ $4?\)9I'_/2[_P# &?\ ^(H VZ*Q
M/^$LTC_GI=_^ ,__ ,11_P )9I'_ #TN_P#P!G_^(H VZ*Q/^$LTC_GI=_\
M@#/_ /$4?\)9I'_/2[_\ 9__ (B@#;HK$_X2S2/^>EW_ . ,_P#\11_PEFD?
M\]+O_P  9_\ XB@#;HK$_P"$LTC_ )Z7?_@#/_\ $4?\)9I'_/2[_P# &?\
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MI'_/2[_\ 9__ (B@#;HK$_X2S2/^>EW_ . ,_P#\11_PEFD?\]+O_P  9_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNS[)(G?<AZ]SGY6[$'T.@#E_^$!T?_GZUS_P=W?_ ,<H_P"$!T?_ )^M<_\
M!W=__'*ZBB@#E_\ A ='_P"?K7/_  =W?_QRC_A ='_Y^M<_\'=W_P#'*ZBB
M@#E_^$!T?_GZUS_P=W?_ ,<H_P"$!T?_ )^M<_\ !W=__'*ZBB@#E_\ A ='
M_P"?K7/_  =W?_QRC_A ='_Y^M<_\'=W_P#'*ZBB@#E_^$!T?_GZUS_P=W?_
M ,<H_P"$!T?_ )^M<_\ !W=__'*ZBB@#E_\ A ='_P"?K7/_  =W?_QRC_A
M='_Y^M<_\'=W_P#'*ZBB@#E_^$!T?_GZUS_P=W?_ ,<H_P"$!T?_ )^M<_\
M!W=__'*ZBB@#E_\ A ='_P"?K7/_  =W?_QRC_A ='_Y^M<_\'=W_P#'*ZBB
M@#E_^$!T?_GZUS_P=W?_ ,<H_P"$!T?_ )^M<_\ !W=__'*ZBB@#E_\ A ='
M_P"?K7/_  =W?_QRC_A ='_Y^M<_\'=W_P#'*ZBB@#E_^$!T?_GZUS_P=W?_
M ,<H_P"$!T?_ )^M<_\ !W=__'*ZBB@#E_\ A ='_P"?K7/_  =W?_QRC_A
M='_Y^M<_\'=W_P#'*ZBB@#E_^$!T?_GZUS_P=W?_ ,<H_P"$!T?_ )^M<_\
M!W=__'*ZBB@#E_\ A ='_P"?K7/_  =W?_QRC_A ='_Y^M<_\'=W_P#'*ZBB
M@#E_^$!T?_GZUS_P=W?_ ,<H_P"$!T?_ )^M<_\ !W=__'*ZBN9\?3M;^$I'
M5[I ;RS1_LKNLI1KF)652A#9*DCCGF@!O_" Z/\ \_6N?^#N[_\ CE'_  @.
MC_\ /UKG_@[N_P#XY6+;7U]I U">Q:^M=-F:VAM%UE;BXD\XE_-,<9)E<;=F
M%R!D,> #4^G>+=:UD6T-E'91W"6]S/<-<02*)/*G:$*JE@T>XJ2=VXKP,&@#
M3_X0'1_^?K7/_!W=_P#QRC_A ='_ .?K7/\ P=W?_P <K M/B!JEXEC+%9AR
M;2RFN((;"XE,K3*&<)(N5C"JV1NSGVZUT_BN*Q-G!<:E>WL5K$Y M;.5XWNI
M&&$0;"&8YSA0>3R>E %?_A ='_Y^M<_\'=W_ /'*/^$!T?\ Y^M<_P#!W=__
M !RD6^U/PU\.X[K4 ;G4[>W52LLF[,C,%4.PZXW*"W?!-<SXYU?7XO#?B#29
MKRT2ZM[>UN/M-M!)'OAFE:,H!YA*L"AYR<@XP.M '3_\(#H__/UKG_@[N_\
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M/_S]:Y_X.[O_ ..4?\(#H_\ S]:Y_P"#N[_^.5U%% '+_P#" Z/_ ,_6N?\
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MUKG_ (.[O_XY7444 <O_ ,(#H_\ S]:Y_P"#N[_^.4?\(#H__/UKG_@[N_\
MXY745R-[ =?\<7.DWEU=16%C80W"V]O</!YSRO("S,A#$*(P ,XRQSVH F_X
M0'1_^?K7/_!W=_\ QRC_ (0'1_\ GZUS_P '=W_\<K-O+'4=-\0^']/TW56F
M;%[MEORT_EKB,A6PRL^.@W-GG))QS4E\?:BNFV-Z!9[A!'+=6T=K/,S$RM&W
MSK\L*_*2I?.3D=LD W?^$!T?_GZUS_P=W?\ \<H_X0'1_P#GZUS_ ,'=W_\
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MI<6BPB]DG5TEVC:BL!Y:!0>,D\@9PHKOZ* ,_2](BTI) ES>7+R8R]U.9&
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M%6WLX<X(Y )&"/0D58U/3K?5]-GL+L,UO,-KA3@D9SU_"K=% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
/ **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>exhibit101_changexreques003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit101_changexreques003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !117+>,X?&LJ67_"'7&FPL"_VG[<"<CY=NW /^UG\* .
MIHKRK['\;/\ H(^&?^^6_P#B*/L?QL_Z"/AG_OEO_B* /5:*\J^Q_&S_ *"/
MAG_OEO\ XBC['\;/^@CX9_[Y;_XB@#U6BO*OL?QL_P"@CX9_[Y;_ .(H^Q_&
MS_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?QL_Z"/AG_OEO_B*
M/5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB@#U6BO*OL?QL_P"@
MCX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?
MQL_Z"/AG_OEO_B* /5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB
M@#U6BO*OL?QL_P"@CX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\
MH(^&?^^6_P#B*/L?QL_Z"/AG_OEO_B* /5:*\J^Q_&S_ *"/AG_OEO\ XBC[
M'\;/^@CX9_[Y;_XB@#U6BO*OL?QL_P"@CX9_[Y;_ .(H^Q_&S_H(^&?^^6_^
M(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?QL_Z"/AG_OEO_B* /5:*\J^Q_&S_
M *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB@#U6BO*OL?QL_P"@CX9_[Y;_ .(H
M^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?QL_Z"/AG_OEO
M_B* /5:ANN;.?_KFW\J\P^Q_&S_H(^&?^^6_^(H^Q_&S_H(^&?\ OEO_ (B@
M"M\+/#T>N_ V70[^-HTNVN(SO7!0ELJV#Z'!_"LWX8V&M>(/%=G+XAMY$C\(
M6C6$(D!P]P69=XSUP@ _!36W]C^-G_01\,_]\M_\11]C^-G_ $$?#/\ WRW_
M ,10!+X=AE7]H3QA*T;B-K"W"N5.#\D70U8C^)Q\.:GJ&F^.K:33Y([AOLEY
M;VLCV]Q#_"01N.[UJE]C^-G_ $$?#/\ WRW_ ,11]C^-G_01\,_]\M_\10!%
MIVK6^O\ Q(N/'%C8W5OH.F:3)%->RP&,WC9W853RP '7U 'I6=X%^'MCXZM-
M0\7^+K.X:]U6[>2",3R1>5"#M ^4CTP,]E%:WV/XV?\ 01\,_P#?+?\ Q%'V
M/XV?]!'PS_WRW_Q% %/QO\'M$L/"EWJ7AFUN8-8L +JW?[3)(3L.X@!F/. <
M>X%>C^$=='B7PIIVK&,QR7$(,L9&-D@X<8/^T#^%<)]C^-G_ $$?#/\ WRW_
M ,11]C^-G_01\,_]\M_\10!:^(FAZS8^)]'\=^';-KZ[TY#!>62??G@.?N^I
M&YO4\@XXIX^-OA5H,"'5CJ&/^0>+%_.W?W?[N?QJE]C^-G_01\,_]\M_\11]
MC^-G_01\,_\ ?+?_ !% %Z&Y\5ZK\.?%NH>([9;3[79W+6.GA/WD$7E, '/<
MGC@C/YX&S\+D>/X8^'TD5E86H!5A@CDUS'V/XV?]!'PS_P!\M_\ $4?8_C9_
MT$?#/_?+?_$4 <?I]CJLO[/NO06=O<F0ZK(TT4:D.\(="^!UZ=?8&KWC'4?#
M/B#X<WNF>!-!6=HX4DGFBT\Q_98T96(+%06<XQ@9.-Q)XKHOL?QL_P"@CX9_
M[Y;_ .(H^Q_&S_H(^&?^^6_^(H I^(-1M]?U;X7:AIWF36WVU@S>4R[2 @.0
M1Q@@C\*UOCG%)-\/XUBC>1O[0@.%4D]357['\;/^@CX9_P"^6_\ B*/L?QL_
MZ"/AG_OEO_B* )?$UW_PAOQ<M?%5];W#:+?:6;">XAB:002!]P+!03@@ ?GZ
M5GIKK>(?CIX;O8+:>+3?L%REK)/&8VGPI+.%;!"\@#(&<&G2Z7\;C>)=#6-!
M_=H5\A,A'SW(*=?QJA)X2^+UUXFM?$<U]X?_ +0M[=K>(,6VHK')X"8R<]:
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MB#I?BKX<7UIX=^T7D6Z)[R<V[QQP()%P"6 RQ;:,#/&3VK=^Q_&S_H(^&?\
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MS_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?QL_Z"/AG_OEO_B*
M/5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB@#U6BO*OL?QL_P"@
MCX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?
MQL_Z"/AG_OEO_B* /5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB
M@#U6BO*OL?QL_P"@CX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)"JN(QT0,!G;QTZ5=HHH *JWFFV&HF$WUE;7)@<21>?$K^6PZ,N1P?<5:HH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBL._NM6EU]=.TZYLK=%M?/=[BU>8D
MEBN!MD3'3WH W**Q/LOBC_H,:/\ ^"J7_P"2*/LOBC_H,:/_ ."J7_Y(H VZ
M*Q/LOBC_ *#&C_\ @JE_^2*/LOBC_H,:/_X*I?\ Y(H VZ*Q/LOBC_H,:/\
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M_P"@QH__ (*I?_DB@#;HK$^R^*/^@QH__@JE_P#DBC[+XH_Z#&C_ /@JE_\
MDB@#;HK$^R^*/^@QH_\ X*I?_DBC[+XH_P"@QH__ (*I?_DB@#;HK$^R^*/^
M@QH__@JE_P#DBC[+XH_Z#&C_ /@JE_\ DB@#;HK$^R^*/^@QH_\ X*I?_DBC
M[+XH_P"@QH__ (*I?_DB@#;HK$^R^*/^@QH__@JE_P#DBC[+XH_Z#&C_ /@J
ME_\ DB@#;HK$^R^*/^@QH_\ X*I?_DBC[+XH_P"@QH__ (*I?_DB@#;HK$^R
M^*/^@QH__@JE_P#DBC[+XH_Z#&C_ /@JE_\ DB@#;HK$^R^*/^@QH_\ X*I?
M_DBC[+XH_P"@QH__ (*I?_DB@#;HK$^R^*/^@QH__@JE_P#DBC[+XH_Z#&C_
M /@JE_\ DB@#;HK$^R^*/^@QH_\ X*I?_DBC[+XH_P"@QH__ (*I?_DB@#;H
MK$^R^*/^@QH__@JE_P#DBC[+XH_Z#&C_ /@JE_\ DB@#;HK$^R^*/^@QH_\
MX*I?_DBC[+XH_P"@QH__ (*I?_DB@#;HK$^R^*/^@QH__@JE_P#DBC[+XH_Z
M#&C_ /@JE_\ DB@#;HK$^R^*/^@QH_\ X*I?_DBC[+XH_P"@QH__ (*I?_DB
M@#;HK$^R^*/^@QH__@JE_P#DBC[+XH_Z#&C_ /@JE_\ DB@#;HK$^R^*/^@Q
MH_\ X*I?_DBC[+XH_P"@QH__ (*I?_DB@#;HK$^R^*/^@QH__@JE_P#DBC[+
MXH_Z#&C_ /@JE_\ DB@#;HK$^R^*/^@QH_\ X*I?_DBC[+XH_P"@QH__ (*I
M?_DB@#;HK$^R^*/^@QH__@JE_P#DBC[+XH_Z#&C_ /@JE_\ DB@#;HK$^R^*
M/^@QH_\ X*I?_DBC[+XH_P"@QH__ (*I?_DB@#;HK$^R^*/^@QH__@JE_P#D
MBC[+XH_Z#&C_ /@JE_\ DB@#;HK$^R^*/^@QH_\ X*I?_DBC[+XH_P"@QH__
M (*I?_DB@#;HK$^R^*/^@QH__@JE_P#DBC[+XH_Z#&C_ /@JE_\ DB@#;HK$
M^R^*/^@QH_\ X*I?_DBC[+XH_P"@QH__ (*I?_DB@#;HK$^R^*/^@QH__@JE
M_P#DBC[+XH_Z#&C_ /@JE_\ DB@#;HK$^R^*/^@QH_\ X*I?_DBC[+XH_P"@
MQH__ (*I?_DB@#;HK$^R^*/^@QH__@JE_P#DBC[+XH_Z#&C_ /@JE_\ DB@#
M;HK$^R^*/^@QH_\ X*I?_DBC[+XH_P"@QH__ (*I?_DB@#;HK$^R^*/^@QH_
M_@JE_P#DBC[+XH_Z#&C_ /@JE_\ DB@#;HK$^R^*/^@QH_\ X*I?_DBC[+XH
M_P"@QH__ (*I?_DB@#;HK$^R^*/^@QH__@JE_P#DBC[+XH_Z#&C_ /@JE_\
MDB@#;HK$^R^*/^@QH_\ X*I?_DBC[+XH_P"@QH__ (*I?_DB@#;HK$^R^*/^
M@QH__@JE_P#DBC[+XH_Z#&C_ /@JE_\ DB@#;HK$^R^*/^@QH_\ X*I?_DBC
M[+XH_P"@QH__ (*I?_DB@#;HK$^R^*/^@QH__@JE_P#DBC[+XH_Z#&C_ /@J
ME_\ DB@#;HK$^R^*/^@QH_\ X*I?_DBC[+XH_P"@QH__ (*I?_DB@#;HK$^R
M^*/^@QH__@JE_P#DBC[+XH_Z#&C_ /@JE_\ DB@#;HK$^R^*/^@QH_\ X*I?
M_DBC[+XH_P"@QH__ (*I?_DB@#;HK$^R^*/^@QH__@JE_P#DBC[+XH_Z#&C_
M /@JE_\ DB@#;HK$^R^*/^@QH_\ X*I?_DBC[+XH_P"@QH__ (*I?_DB@#;H
MK$^R^*/^@QH__@JE_P#DBC[+XH_Z#&C_ /@JE_\ DB@#;HK$^R^*/^@QH_\
MX*I?_DBC[+XH_P"@QH__ (*I?_DB@#;HK$^R^*/^@QH__@JE_P#DBC[+XH_Z
M#&C_ /@JE_\ DB@#;HK*T"]N[[3Y6OF@:XBN9H&:",HK;)&4$*68C('J:U:
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K%'_([M_V#1_Z,-;58H_Y'
M=O\ L&C_ -&&@"?Q%J_]@>&]2U?R//\ L5L\_E;]N_:I.,X..G7!KGK3Q'XT
MO;*"[A\&V'E3QK(F=;P<,,C_ )8^]7_B)_R3?Q)_V#9__0#7-Z)H:/H&G/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX8;:>V1Q4UQ!#=6TMO<1K+#*A22-QE64C!!'<$5)10!PVO>%+IM2LY=-\/\
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MESGSIHHPK/DY.<>I -:M% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@W.,'!*9QNYX->OT4 <QX%DU)]$G_M"2^EB6ZD6REU"/9<26_&TR @'.=W4
MD $UT]%% !1110 4444 %8NL?\A[P]_U]2_^B)*VJQ=8_P"0]X>_Z^I?_1$E
M &U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_IDV/+N[>2!L]@RD9_6O(]"AOO%G@CQ)J<R.+^UL+:P@W#D3VB>:Q'UE;]*
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M80B2+"_(?G/'3I7"Z(+W0?A7XRUFQU?4$N;>_NHXU,@* B5/GQC[YZ$^YXH
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M/O\ *E238Q1]C [6'4'T/M5;^U;?^V_[)VS_ &G[/]HW>2WE[-VW[^-N[/\
M#G..:XOX5V+V]KKT[ZA>W!.LW<6V>0,ORR$;N@^8]S4MUJVK?\+CETBVNF^S
M?\(VUS';L?W?G^=M#'\.* .\JE<ZM9VNK6.F32$75ZLC0*%)#", MST'WA7$
M>![^=]6BM=1UG6H]7^REKW3-5A $D@*YD@8 +M!R,*2"".!BK'C&SGO_ (@^
M$+:&\FL]\5]OF@QY@79'D*2" 3TSC@$XYP: .\HKR*[\0ZMI$&H:%_:6IW(7
M7X[!+N./SKM;=H!,RK@?,W!4'!(!SVINIZ_K^G>#?$K6DNM11VLUDVG76JV[
M1S'S)562,D@;@".O7#XH ]?JC>:M9V.H:?8W$A6>_D>.W4*3N94+G)[< ]:X
M#79[W1=6TKP]+J_B.\BGAGOKJXLHO-N78%%5%V+\D8+$\#T&>:S))-:UBY\'
M6UW/J%G<IJUY!'=W,'E7#P"%RKE6& Y0XSCJ,T >P45Y3J5WXAT=O$^GV&K7
MMXVB"TU6V,[AI)(CN,L#MCY@0C$=^1721ZY-X@\<:3!I5VXTJWT[^T;HITF\
M[Y8$/X!W_ 4 =E17"^.M9N+;7-$T>.358K:Z2>>X;2H3)<,(]@51@$J,ODD>
M@'>LU-2\11>";G6#<7T$NAWLDB#4X_(:_M% .V0$#YMK$!L?>0>IH ])FFBM
MH))YY4BBC4L\CL%50.I)/04\'(R.E>-^([V^\4?"?Q-XGDU&YAM+I2+*RBD
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ML54[5PK$XQDD5JZ'XCUJQU;2)M?EO8[.YM;VV87</DLS0.9(YF0@89H0V?\
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MJQ?#/_'E>_\ 82N__1SUM4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZG(T8B1#&L,:*#G.Q>"Q[L?H,5MT4 8&LZ%J=]??:M-\0W.G;X1#+%Y2S1L
M20RJWW7^8C(Z\9!P*S1X#-A=V$^A:U<Z:;;3X]-DQ$DOFPH25/S#AP2><'KT
MKL:* .+A^'D-CHVF6FGZK<VU[I=S//:7I179?-9BZ,K<,I#8/?@'-6(?!"JE
M@]UJUU=W=OJG]IRSR*/WLGELFT*.$4!N /3WKK** ,JVT..V\3W^MB9FDO+>
M&!HB.%$9<@@^^\_E5/4/#,EUXNL?$5IJ<EI<06YM9HQ$KK/"7#E>?NG(ZBNA
MHH Y7_A![?\ X07_ (1;[9+Y/F^;Y^T;L^?YV,=.O%4]3^'O]I)K5I_;=W!I
M6K2-/-:1QID3,H&X/UVY56V^HZX)%=M10!S%EX4N;+Q3_;J:U*SSVT4%]";=
M-MR8PP5@>J?>)P*G\2^&9-=N]*OK74I-/OM,F>2"9(ED&'0HP*MP<@UT%% '
M/1>$X8M+\16/VJ0KK<TTTC[1F,R1+&0/7 7/XU3D\%W%O);SZ-KD^FW*6,5C
M.ZP)()TC!V-M;HXRV#[]#76T4 5[&U%C86]H)II_)C6/S9WWR/@8W,W<GN:X
M[3O NN:-:&STOQK=VUF)9)$A^P0/M+N7/+*2>6-=S10!S:>%IKF_TF[UG5I=
M2;30[QH\*1J\S$XE95XRJG:!CCD]:Y7Q)X/;3;;1-.T^[NELI/$D5S D2 FQ
M!24G8<$; _(!&!G'(KTZB@#D4\$-/%KDFJ:O->W^K61L&N?)6,0PX8!40<=7
M).3R:GLO!=O9R^%G6\E8^'K:2WB!4?O@T:QY;TX7/%=/10!YQXWT^V\9^*-%
MT.W@NFEL;HRZA<")TBCMBN6B+D88R?(, GH<]*]'Z444 <1;^!=6T^YU)M+\
M7W=C;W][+>20I9POM>0Y.&8$^@_"K'_"OM/A\/2Z=:7EU'>27<=\VI2D2S/<
M(P97?(PW*@8P!BNOHH XMO #7,VJRWVMW5R^K:>;*])B10WWMK(!]S:'(QSG
MJ<G),B>"[^*WTR6+Q%,FK:?$UO'>BU3#P-M_=O'T/**0<YR*["B@"EI%A)IF
MFQVLU]<7TJEF>XN&R[LQ)/3@#G  X P*P(/! M&UZ6TU>\MKC5KQ;T30@ P.
MN" !T93CD'@@D5UE% &'H7A^;2[V^U"^U)]0U"]$:23&)8E"1[MJJJ]/O,<D
MG.:W*** ,7PS_P >5[_V$KO_ -'/6U6+X9_X\KW_ +"5W_Z.>MJ@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *Q1_R.[?\ 8-'_ *,-;58H_P"1W;_L
M&C_T8: (/&^A2^)/"%[ID"123/Y<D<<WW)&C=7"-[-MQ^-<_H^F7&E+J.HZ+
M\/[32;M;3RK=&EA$L\I/()1BHC& 22<G' KO9YH[:WDGF<)%&I=W/15 R34=
MA?VNJ6,-]8SI/:S+NCE0Y5AZB@#SR'PSJ?A#2M:MT=K[3]1TV>YO9V8 QWNP
M[W .#MD]!G!7T-5]'M=>\0^&_!.FRZ.UO:6)L[V;4#/&8Y(XD#($4'?N8[<Y
M  YY->G7-O%>6LUM.F^&9&CD7)&Y2,$<>U)9VD%A8V]G:Q^7;V\:Q1)DG:JC
M &3ST% 'F&D^"%TR]CL)? ]A>2I?-(-:E:+88#(7#$9\SS IV@8QD YQ6I:V
MWBOPW)J^EZ3HT=TM[J,MW::A).@AA65MS"5-P<E26^Z#GCD5Z#10!YKJ7A;6
M+[5?'&G&P/V/7X8WMK_S4\M'2$+M=<[_ +RCH#Q2:?X0CO[>^M4\#6/AYI]-
MFMGN]T3.99%VXC\LGY,%B2V">..M>D2S1P1-+-(D<:#+.[ !1ZDFGT >9BR\
M5ZI;>$;&Y\/FT31[ZWDO)FNHF$@C1DW1@-DKSGG!Z  \UZ9110 4444 %%%%
M !6+K'_(>\/?]?4O_HB2MJL76/\ D/>'O^OJ7_T1)0!M4444 %%%% !1110
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MK[NN[N2?4\T :@(8 @@@\@CO2TU$6.-40!54  #L*=0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8OAG_CRO?\ L)7?
M_HYZVJQ?#/\ QY7O_82N_P#T<];5 !1110 4444 %%%% !1110 4444 %%%%
M !1110 5BC_D=V_[!H_]&&MJL4?\CNW_ &#1_P"C#0!-XE_Y%76/^O&;_P!
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M %]2_P#HB2MJL76/^0]X>_Z^I?\ T1)0!M4444 %%%% !1110 4444 %%%%
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M73PI<%E!Y&95QG\C7(:/865YX,^%?VJTMYP]Z8V\V,-E=DIVG(Z9 ./:@#W
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MU5@#W(SD#W-:MO<P7=O'<6TT<T$@W))&P96'J".#0!+137=8T9W8*BC)9C@
M4Z@ HJI?:G9Z<]HEW,(VNYQ;P#:3OD()"\#CA3UXXJW0 4444 %%5;K4K&QG
MMH+J\@@FNG\N".20*TK>B@]3]*M4 %%5K_4+/2[*2\O[J&UMHAEY9G"*OU)J
MOIGB#1]9L9+W3=3M+JVBR))8I0RI@9.X]N.>: -&BLO2/$FB:^TRZ1JMG?-#
M_K!;S!RON<=O>H[?Q7X>NM7;2;?6K"74%)4VR3J7R.HQGJ.XH V**Q[[Q7X>
MTO4DTZ_UJPMKU\;8)9U5N>F03QGMGK6Q0 44UG1"H9E!8X4$]3UP/R-5K'4[
M/4C="SF$IM)VMIL*1LD4 E>1SU'3B@"W1110 45AW'C+PS:ZI_9EQKVG17H;
M887N%#!O[IYX/M6Y0 454_M.S_M?^R?.'V[R/M/E;3_J]VW=G&.O'7-6Z "B
MBJD>IV<NJSZ8DP-[!$DTD6T_*CDA3G&.2K?E0!;HHK/TC6].UZUDN=,N1<0Q
MS/ [!67#J<,.0.E &A1156]U*QT[R/MMY!;>?*(8?-D"^8YZ*N>I/H* +5%%
M49M9T^#4QILERJW9@:Y,>"=L0."['&%&?7&><=* +U%<]!X[\(W4RPP>)M(>
M1CA5%Y'DGT'-=#U&10 455U+4K+1].GU#4;F.VM(%W22R' 4=/YX%9]GXLT6
M_?3DMKMV;4?,^R@V\B^9Y8RW51MP/7&>V: -JBBJ2:O8R:S+I"S$WT4(G>/R
MVP$)P#NQCKVSF@"[15#4-:T_3(+:>[N-L5S,D$3(C.&=ONCY0?3KTJ_0 444
M4 %%%% !1110 454TW4[/5[(7EA,)H"[QAPI'S(Q5A@@'AE(_"EAU*RN+^YL
M(;N&2[M@IG@5P7C##*[AU&1TH M444U71RP5E8J<-@YP?0T .HHHH **** "
MBFNZ1C+LJ@D#)..2< 4Z@ HIN]/,\O<N_&=N><>N*J:7J]CK5H;K3YC+")&C
M+&-D^93@C# &@"[112,P1"QS@#)P,G\A0 M%5-,U.RUC3XK_ $^=9[:7.UP"
M.AP00>00000>015DN@=4+*'8$A<\D#K_ #% #J**0D*"20 .23VH 6BJ<NJV
M,&H65C)<*+F]5VMT )\P( 6((XX!'7UJY0 4455GU*QM;VULI[N&*ZN]WV>%
MW >7:,MM'? Y.* +5%%9&L>*-&T"XM;?4KU89[HGR8E1I'?'4A5!.!Z]* ->
MBBB@ HHHH **** "BBB@ HHHH Q?#/\ QY7O_82N_P#T<];58OAG_CRO?^PE
M=_\ HYZVJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K%'_ ".[?]@T
M?^C#6U6*/^1W;_L&C_T8: -*^LK;4K&>RO(5FMIT,<L;=&4C!!J*;2-/N-'_
M +(FLXI-/\H0_9W7*[   /PP/RJMXGUV+PSX9U#69HS(MI"7$8.-[=%7/N2!
M^-<V-*^(3:8-1_X26U74BGF_V9]@3[,&QGRM_P#K/;=N_"@#>@\'>'K;3+K3
MH]*@-K=D&X1\N92.A9F))QCCGCM1#X.\/0:3=Z6FEPFSO"#<)(2YE(Z;F8DG
M&!CGCM7.W/BK4-.\?)9W5I>W!DT.&?\ LVR E*S&5P[ D@8  &XD#IW(K7'C
MO2GT&QU6W@OK@WTS6\%G%!F=I5+!D*D@ KM;)) &.M %RP\(:!I;.UGIL43O
M"T#OEF9T;&X,Q))SM7KZ"DN/!_A^ZT2UT:;3(6T^T8/;P@L/*89P5(.0>3W[
MU2/C[2(]"U#5;J*\M%TV9(+RWGB"S0LY4+D9((.]3D$C%2Z?XTL;W59-.GL]
M0TZ9;9KN,WT(C66%2 SJ<GID9#8(STH WVM8'M#:/$CVY3RS&XW*5QC!!ZC%
M96D>$=!T&Y:YTS38H)RGEB3+,53KM7<3M7V&!61;?$C2;AM.+6.J00ZG.D-C
M/-;;4N=QP&4YX'?G!(Y -6I/'6F1ZD]N;:_-JET+)]1$(^S).2%V%LY^\0N<
M;0>,T ;FG:;9Z19+9V%NL%NK,PC7H"S%F/XDD_C5&Y\*:'>:K-J<^G1/>SPF
MWEER09(RI4A@#@_*2,GG%;-% %%]'T^2.PC:U0II[J]J.?W3*I4$?121^-5)
M/"6@RVE]:R:9 T-]<&ZN%.?GF)!WYSD-P.1BMFB@#/TC1--T*U:VTRT2WB=S
M(^"278\99B22< <D]JT*** "L76/^0]X>_Z^I?\ T1)6U6+K'_(>\/?]?4O_
M *(DH VJ*** "BBB@ HHHH **** .)^+9(^&NI%4WD2VV$SC=_I$?%6-/U#6
M)M0@CN/ 36<3.-UP;NV;RA_>PIR?PK3\7>'V\4^&;K1UN_LC3-&PG\OS-I21
M7'RY&?NXZ]ZSX=$\9I-&TOC*UDC# L@T=5W#/(SYG% '(Z+HM]-\7_%\2>(]
M2A=+>U8RQI!N<,C8!S&1A>V /?-8OA6]O_#/P^UC5+?5[MI)=9DLDC>!)$C=
MYT0S[53<S@$G;D@GC;7JFG>&18>,]9\1?:RYU.*"/R/+QY?E@C.[/.<^@Q67
M9?#Z*U\)7^A-J,C-<WSW\5RD05H)#()$(!)SM91]: .9E\::GH]CK8L;W4M3
M@2UA>TN]4T]H&BG>81%3F- X^=7''8BMO7-&\1Z;X:UXOXHN;NS.ERR>9+'$
ML\<RC=\FU OEL 00>1V/>M.;PGJ&L:3J=CXBUPWBWL*Q(+6W\A(-IW!U4LQ+
M[L')./E Q38?">K7:WO]O>(Y+X7%C)8I';V_V>-5<8:1EW,&DZ<\ <X'- '*
MVVHZMH&B?#6TM]6N)8M2EA2<2I'_ *HPJ1&,*,*.QZ^I-:@\87VAZ-XRCU28
MW&H:+.S6I* &6.89MQ@  G<=GX5:A\ WKVOA>&_UR.=O#]RLL+1V?E^;&J!%
M0C><'C.[WZ5<U[P+!KGBW3M<:]:&.WV?:;41Y6Z\MR\63GC:Q)Z'/2@#E;G7
MM6AU)=#U7Q%JMG<Z?IUN\L^GZ8;EI[J0,6+[(G 1< !<+G)YXKOO#.IWFJ^$
M]/U&^MFAO9;<--"R%") ,'Y3R,D=#ZU3U3PWJ4FN2ZOH>L1Z=<W-NMO=++:^
M>D@0L48#<N'&YAGD$'D<5NV-L]G86]M)<2W+Q1JC3S'+R$#!9L=SUH XOX66
M%I<^!K;5YX8I]0U4R7%[<.H9I79VR"3V&,8Z#%<\-1N/"FH>+=$T)DMXFU6P
MAL<H&2UDN@/,*KTP/O!>F374IX-UC2+BZ7PSXC73K"YE:8V=Q9"X6%V.6,1W
M*5!/.TY&:D_X5_:?\(Q=Z8U_<O?75RM[+J;@&4W*L&63'0 %0 HXP,>] '.?
M$#2=?TSX?>)!-XCN;S3_ +(KHTR1B?=G:\;%4 ,9!![,",9Q6M(=7N?$MAX3
MB\07T,,&F&_N;Y4A^T3EI-B)G9M4#!Y"Y.![FK%YX(U+6])UBUUWQ$]S-J%J
M+5/(M_*A@4'=N$>X[F)ZDGH,#%32>%-9-S8:M#KUNFNVUN]I-<&QS#<0EMP4
MQ[\@@@$$-Z^N* ..U34-9U.#2],FOPVHZ;XN6Q2^,2Y9/)=ED*CY=P5^F,$C
MI5[6?$NM>"Y_$&G2:I-J7EZ?;WEE<74*M)"TLQ@(81J-X#$,!C/;FMF7X=M)
MI=I"NM2IJ$6K'6)[T0 F6?:PX3.%497CGA<=\U*W@.74AK$^O:K]KOM1MX[9
M9K:W\A;:.-BZ;%+-SO.[))Y H YP^*-3LK37X['5M7U""+1+B\BO-0TQK=K>
MYC' !:)%8-G(&#C:?6NU\&Q:HVAP:AJVJR7MQ?PQ3F,QHB097.U-H!(YZG.<
M9XJK)X8UK4=*U:RUGQ&MS]NL7LHQ!9B*.+<"#(5WDL_/J![<UT6F6?\ 9VE6
M=CYGF?9H$AWXQNVJ!G';I0!QGCC2+&+7_#.K" &^FURVB:9B20@23Y5S]T9Y
M('4]:[VN/\3^$]<U_4K6>#Q)#9VUG=1W=M =.$I215(R6\P;A\S'&.]:*V^O
M1:OHJ2:A]HMT@G%^R6ZQI*_R[#U)4YS@ \\YZ4 6M=T_2;RUAN=9$?V;3Y1>
M!I7VHC(#AFYP0,GKQWKS+7HI-1T?Q'XCBMWL],UJ73[&)678\\(G"O,R]0'#
ME1GG:,GK7?\ C'PU=>*=.M;2WU-+)(;E+B19+;STFV\A67<N5W8./857D\+:
MKJND:AI?B'7H[^UNH@B?9[$6[0L#D.#O;)! (]Q0!4UZV@M/B%X/-M$L)G2\
MLY/*&S,(AWA>.P9%QZ9K/OM+TRZO]$\(^'+1%CT6]AO+JX7E;14.X(7/)E?I
MC)."2:VK#PKJO]JIJFLZ\NH7EK;26]DT=F(4A+XW2%=QW.<#N!C/'-4O#W@W
MQ)X=MH+2W\5VSVRRF68-I(\R8ELN6?S<EFYYH @\76.E6VGZKX=TJP2ZUSQ)
MYCM$Q+E=PVF>1CG8B<$>X 49KN+"V-EI]M:F1I3#$L9D;JV !D_7%<?'X-\1
M6>N:MJ=AXJMXGU&?S6\[2A*Z(.$CW>8/E4<#@=SWK=@BUF/Q+:^=>&;3UTTI
M.!"J*UR'7#CDD97?\O0<=<T <QX\L[N[\;^"XH-6O+)9;F<#R!&=C+ YWC<I
MYP2O.1@],\UB1PZS%I?C[5]/UV>P_L[4[RXAAABC9972)&/F;E)(( &!CN>>
MW=>*/#5SK=UI%]8:DMA?:9.TT4DEOYR,&0HP*[E['KFHX_"&S0O$VFF^R=<E
MN)3+Y6/)\V,)C&?FQC/49H Y/4?%]SJ.L26S:QJ6D);Z?;3QC3M->Z\R>52^
M9"(WPBC:-O!.3SQ7?>&=1NM6\,:;?WUNUO=SVZ//$R%2CX^88/(YSUK%?P?J
M5E<I<Z%KB6,[V4-G=&6S\Y91$"$D4;AM< D=2.G'%=19VQM;""V>>6X:.-4:
M:4Y>0@8W,1W/6@#S/[/>^$O#]]HFO^%?[7\.EYI)M0L75W:-W9RTL1PVX \L
MI/3(Z5K+=7WBCQ%=Z;HNNSZ9IFG6%M+#+;(CM.\P9D+&16R@51QP3DY-2GP7
MX@CTZ;1K?Q>ZZ/(&C"RV0DN4B;.4$Q;!X) 8J2*L7'@NZLKY+OPSJZZ4YLHK
M&9);87"O''D1L!N7#J"1GD'N* ,233];OOB18VMSJHLKW_A'?],N;!%)8B?G
MR]ZD+DX/(/H/6J!\8ZI'I>GZ7?:K=QROJU[97&I6MGYL[16Y."L:(P#-E 3M
M( R:[;2?"0TK6[34?[1N+DV^EC3S]HR\DA\S>9&<GDD]L50_X026WB$UCJWD
M:E%JEQJ-O<-;[E7SBV^)DW?,N&QG(/ /% '.P^)];O(K30H-0OD:[UG[)#JM
MQ9>3,]J(?-)".@&\$%-VW'&<52UFXU?PSJGCFYBU66XO+31;5[:[EC3S -\N
M-P"A2021G:.,=^:[.]\'ZEJ&FVS7/B!GUFUOOMUO>?9AY<3;=OEB+=_J]I(Q
MNSDYS55OA[+?'Q!)J^M-=3:W8I:3&*W$2Q%-V&0;CQ\PX.>03GG@ T]8U2\M
MO&OA:PAG*VMZ+O[1'M!W[(P5YQD8)[5YIX;UZ?1?! @@N9[0ZAXFN;>2YM[<
MSR11C<[%$"MECMP/E.,Y[5Z%9^$=6;7](UC6/$"WL^F)+'''%9^2C!TVDGYR
M=W )/3C  YS5L?AT=.T$65OJ[+>PZH^J6MW]G&(I&R-I3=\R[693R,Y[4 6?
M VL7=_-JUG-<7][:6LD9M+V^LVMY)$=>58%$W%6!Y"C@BJ/Q'TBQ;^R=7: -
M?+JMA DK$G8GVA20HZ#)/)')P,]!75:)8:E91W#ZKJO]H7,\F_*0^5%$   J
M)DD#C)R2236-XM\*ZSXDFA6W\0Q6-G#-#<)"=/$K>;&VX'=O'&0.,4 =;7GG
MAC_3],\;:Y-\UQ=WMU;ACU6&!3'&OX88_5C7<:9!>VVGQ1:C>I>W:YWSI#Y0
M?DX^3)Q@8'7M7'Z#:'2]:\2^%K@F)-1FFU&PE(X=)1^\4>Z/GCT8&@!W@'1M
M,U/X5Z#!?:?:W,4M@@=98E;=Q[BN.TKQ+=:5H5KX?34KVWLUUR]L([ZWMVN9
MUM(.5" *^3DA=V#@ ^E=9IO@?Q/INA6VB0^-O*L((A"IM],1)@@XX<NV#[XK
M2E\#6UIH^D6F@W)TZXTB0RVD[Q^<"6!$@D&1N#[CGD'.".E 'F_CF^U'5_A1
MXA$^HZE);Z?>1)!-<6?V<WL+/$5\Q7C4Y1BPRH7.T$YKMM1O]7T/Q[X*T,:Q
M<W=K??;3=-<1Q;IMD89 =J #!/8#WS5W6_!5]XB\$ZAH6J:\TMS?3+*UT+8!
M(MK*P1(]W"_)W8G))S6AJWA<:KXO\/Z^;PQ'1Q< 0>7GS?-0+][/RXQGH<T
M<)-K'B<>!M2\5GQ#.)=.OIUAM%AB\J6)+@IMD^7<3C(!!& !WR3M7VL:M<?$
M/Q!H<>I36]G#H:W,(B1-T<N[E@2I[<<Y%:<G@42>!-1\,_VB0+R::7[1Y/W/
M,F,N-N[G&<=:M#PBA\::AXA>\8B]TY;!K<1XV@'.[=G],4 >?6.I:MX;^$_@
MF>RU:X9K[4+*%_,2,A(7!W1K\OW>.IRWO76!]:\4^(O$,-IKUSI5MI4J6MLE
MM%$V^7RU=GDWJQ(RP 48X%0I\.+M_"NCZ#=ZZDL6D7\%U;2+9[28XLXC;Y^2
M<_>_2M2^\*:HFLZE?Z#KB:<-3"?:XY;3SL.J[1)&=R[6V@#G(X!Q0!S.B>(M
M>\8ZAH-NFJ2:;#>:(]U=FVC0MYJ3",E"ZG;D^N>/?D-_X2#7QH CNM1U VUC
MK5U87^IV-JLEP(8]WEL4"$#)VAB%/3WKK=%\%6N@ZKIUU9W#""QTLZ:D++DL
M"ZN7+9ZY7D8[U#%X2U/3DN7TC7OLUQ-J5Q?'S+7S(F$O6-TW G'&&!'TH T_
M"EW]N\/07 UF/6$9G\N]1 A==QP& P-P'!X'(Z"N&NO%%[;>(;>>W\07U]YF
MM1V,EM%IY^PI$\OE[/-\O_6+D$G?R01CM7=^'-#.@Z=+#+=?:KFXN)+JXF$8
MC5I'.3M4$[1[9/UKF'^'FI?V=%IT7B,1V5E?"^T^/[%DQR";S0)3O_>*"2,#
M;UR<X% &;=7OB6^TKQIJD7B*XM!HEW="SAAAB*L(XU?;)N4DKS@ 8[DD\8T;
M34=8\6^))+6WU>XTJVL=-M+EEM8XV,LTX9AN+JWR +C QG/6MF+PALT/Q-II
MOMQUR:XE,@BQY/FQA,8S\V,9ZC-53X,U"RU&"^T37$LIC80V-WYMH)EF6/.Q
MU&X;7&3UR.>E #/A5YO_  @-OYY4S?:[S>4&!N^TR9Q[9K!LIY;7XE_$RX@?
M9+%I]JZ-C.&$!(//O7;^$O#J^%?#L.D+=O=+%)*XE=<,=\C/SR>1NQGOC/%4
M$\%A?$'BC5?MY)UVVCMS%Y7^HV1E,YS\V<YQ@4 <W9:AXBL['P5KEWKT]T=9
MFMX+JS:&-80LL+,"N%W!@0"3GDYX XK(TS4-2\->'O&6IIK-Y/.-?>QC\Z%)
M KL\2>=M1 S.%/W1P< !:[]_"(?1?#&G?;2/[#FMY1)Y7^N\J,IC&?ESG/?'
MO6?_ ,(!,R^(+1M8(T_5;LW\<:VX$MM<[D8.'W88!D!V[1]: .;N/%6JV&D^
M)%T_5=6O8+?26O+>^U'3C \$ZG!3YHD5@00P&#C!K1U*?Q1I^F>&RGB"1KW6
MM3B29V@C*01O"[,D:[>@P",Y)(YX)%;=UX4UC5]$UBPUGQ$L[7]K]E3R+/RH
MH1SE]F\EF.>?F XZ"L_QWITS1>#+&WNGAECU>)4N%0':RP2X8J>",@9'<<4
M96N:YKWA>+Q9I8UF>\DM=(34K&[GCC\V(EF1E.U0K#*Y&1WJ;5]6U;18-#M-
M0\07XDUF1[BYN;6R$KVZ)&"8H42-C@LRC<P8@9-:MSX"NM4LO$!U;64GU'5[
M1;/[1#:>7';Q+D@*A<D\L2<M^5;&L>&YKZ+2I["_%GJ6EDFWN&A\Q""FQU=,
MC*D>A!! YH \XUJ_U76O#UA#)JFII';^)K6UANI;,0/<Q,Z,DC*\8^9&R.%
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MZAT9&^ZPP><4 >0W.M+>Z)X"TP:;?07-EJEA'=BXM7B6!T4KM#, &).<;<\
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M:C^UVVR-_M$6V4XC;>,.?;UKR:VT!CK/@?1]:2TN((Y-4 MXIC/$(AM*1,Q
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MV<N0<9!8\GU[TD&AZ;I&F?#?4K&TBAU">ZMXYKI5_>S+);.6#MU8' X/3'%
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M_2J^H^#/#^K:DVH7NGB2=]OFXE=4FV_=\Q 0KX_V@:WJ* *=OI5C::G>ZE!
M$N[T1K<2;B=XC!"<9P, GIZUFQ>"_#\&L?VI'IX%R)3.!YKF-93U<1YV!CD_
M,!FMZB@#F9_A]X7N)Y)I-+!,L[7$R">0)-(6+DR(&VO\Q)PP(%4_$>AZAXJ\
M0Z997>FPQ:'IMVE\UT\JL]PZK\J*@Y4;F.XGJ!QUKLJ* "N8'P]\+CS,:80'
MD\U<7$H\IMV_,?S?N_F /R8S73T4 9+^&='DTS4-->R4V>HRR3746]OWCN<L
M<YR,^V*M2Z58SZC::A+ &NK-'C@DW'Y%? 88S@YVCKZ5<HH P=-\&>'](U%;
MZQL/*G3=Y6979(=WWO+0DJF?]D"K \,Z.-"CT062_P!G1NKK!O; 8/Y@.<Y^
M]SUK6HH YZ_\#>'-3U&>_O--$D]P )P)I%27 P"Z!@K$#H2,CCTI]_X+T#4H
M;2*XL6 M(!;PM%/)$PBP!L+(P++P."2*WJ* ,+4/!V@ZG#8Q7%@%6P3R[4V\
MKPM$F "H9"#MP!QTXJ[I&B:;H-K);:7:):P22&5HT)QN( )YZ=!P*T** ,AO
M#.D-X@;73:8U%X_*DD$CA9%P5 9 =K<$CD&JVF>"?#VCW\5[9:?LFA#"#=-(
MZ0!NOEHS%4S_ +(%=!10!0UG1-.\0::^GZI;"XM'96:,LRY*G(Y!!Z@5)'IE
MG#JEQJ<<(6\N(TBEEW'YD0DJ,9QQN;\ZMT4 8,_@W0+C2+?2WT\"UMY6F@"2
MNKQ.Q+%E<'<"2QZ'O2KX-\/I86%DNFH+>PNEO;==[96<$D2$YRQR3]XG/>MV
MB@# O_!?A_4]5DU*[T_S+F9568B9U24*,+O0,%;'8D'%)>>"?#]];:?!-8$+
MIT0@M6BGDC>./ &S<K!BN ."37044 8!\%>'3I/]F+IB1VGV@W2I$[H8Y3_&
MC @H?]TBM'2='L-#LOL>G6XAAWEV^8LSL>K,S$EB?4DFKU% &)<^$M$O-7GU
M6:R)O+B V\SK,ZB5"I7#*&"GY6(!(R.U6GT+37M]-MVM08M,=)+1=S?NF12B
MGKSA21SFM&B@#!B\%^'X=8_M6/3P+H3&<#S7,:RGJXCSL#')^8#-:FI:=::O
MIMQI]_")K2X0QRQDD;E/49'-6J* ,G4/#.D:IIUK87=IN@M-OV?9(Z/"5& 5
M=2&!QQD&JS>"O#S^'I]!?35;3KA_,GB,CEI7R&W,^=S'*CDGM6_10!GG1-.;
M74ULVP_M*.W-JL^YLB+=NVXSCKSG&:SH/ _ARVU--0BTX+,DQG1/.<Q)(>KK
M$6V*W)Y S70T4 9K:!I;^(4UYK-#JB0?9UN,G(CR3C&<=2><9IMCX<TC39-2
MDL[)(GU.0RWA#-^]8YR3D\=3TQUK4HH Q[/PMHNGV^EV]K8K'%I3,]DH=CY1
M8,&/)YR&;KGK53Q%X<AN]*UE['3+*ZO]12,3Q7C/Y=P(_N@X/RD#.".AP>U=
M'10!P/A/PM=6GBMM9ET9-'MXK%K6.!KO[3-,[NK,[OD\ (J@$D_3I75:UX=T
MOQ#% FIVQE,#^9#(DKQ/&V,$JZ$,./0UJ44 8,7@OP[!IM[I\>EQ"TO65KB,
MLQWLH #9)R&^4'(YR,]>:?:>$=$LM,O]/BLR8+]2EV99GD>92NW#.S%CP2!S
MQVK;HH R)?#&C3VFE6LEDK0:3)')8IO;]RT8PA'/.!ZYJQ'HNGQ'42EL!_:+
M;[OYC^].P)GKQ\H XQ5^B@#(B\,:-!=:7<QV2K-I4!MK)M[?N8RH7;UYX '.
M351_ GAMX=4@;3LP:HV^\B\^0)(V[<2%W84DC)VXS7144 8NJ>$]%UEK=[RT
M?S+>/RHI89Y(9%3NNY&!*\="<5-!X<TBV&F+!8QQ+I98V:ID"(LI5L 'G(8]
M<]<]:U** ,>]\+:+J)OVNK%9&OVB:X;>P+-&,(P(.5([%<&H$\%>'TTF;3#8
M&2VGF2>;S9I'>1U(*LSEBQQM'4]JWZ* *?\ 95E_;/\ :_D#[?\ 9_LOG;CG
MRMV[;C..O/3-7*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_9D:/>N+D1%2R[@D:D'>^W!QP.0,\TL_B^]N=3_L[0=#>^N([2.[N1=3_91
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M))R4^8'KDD=:ZKQAX\UKPT-4/V"VA33[:*6.:Y1MFH.V-Z1$,"NW/HW0YQW
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M.;1/%5UXIUOPY_PE<ZPV<$-U%>?9(#/F0, A^39M!0G[N>0,UDP^/[W4]/\
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M!XQ7">(-=U'7O@SX\DU&<3-:ZO+:0G8J[8DEBVKP!G&3R>: /:D=9(U=#E6
M(/J#5>PU*TU2!YK*=9HTE>%F4$8=&*L.?0@BN.^U:OK'BI-#L-7ETNTL-+@N
M97AAC=Y9)"P4'>K * G;!.>M3?"[SO\ A$[C[24,_P#:E[YA084MY[YP/3-
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M5**X3P)K5QJ=XR3>)I+^9;8-=Z=>V:V]Q:S9'W5"J=GWASNYQ@UW= !1110
M4444 8OAG_CRO?\ L)7?_HYZVJQ?#/\ QY7O_82N_P#T<];5 !1110 4444
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M-SX?DU37[>XCT.0&"."S,?FKY31Y<ES\W(Y& ,'@YXKR?#1I/!/B3P[_ &J
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MIZ-9:Y%;Z!J4TDLT)M2T\:R',D<<F\*%8ENJDC<>M=O++'#"\LC!8XU+,Q[
M=:AL+^VU/3K;4+23S+6YB6:)\%=R,,@X/(X/>@#F9?"&HVNO7E[HFK0V-IJ$
M$,%U"]J9'01*55HFW *=IQR&'&<'I5*S\ W^C6F@/H^L01:CI5H]D\MQ:EXK
MB%B&P4#@@@J",-7>44 <]X3\-3>&XM4%QJ)OIM0OGO7E,7EX9E0$8R>,J2/0
M$#MFJ.K^%M9U>::SGUR!]%FNDN##):9N(PK*_EI)N "Y7@E20#^-=?1G% '(
MQ>%M9L+VYBTS7H[72+F]-X\7V7=.C,V^1$?=M"LV3RI(W&M/2?#YTOQ%K^JF
MY$@U:6&01;,>5Y<03&<\YQGM6A<:G9VNH6=A-,%N;S?Y$>"=^P9;Z8'K5OOB
M@#C[?P)';^/Y?$GVTFV)>>.P\O CN'1(WEW9YRJ8QCJQ.:1O $%SJ?C"XO+L
MRV_B2*&)HECVM (XRF0V3D\Y' QCO78T4 <=#X1UB^22W\1^(/MUE]BDLA;V
ML!MQ*'&TR2_.P9\#C@ $D@5/I_A_Q)'%]GO_ !,'MXK5[: VEH(I"2 !+(S,
MP++CC  SS[5U5% '+Z5X=U9?$$&L:YJEI>3VEK):P?9;0P;@Y4LSDNV3\@P!
M@#)]:ZBBB@ HHHH **** ,7PS_QY7O\ V$KO_P!'/6U6+X9_X\KW_L)7?_HY
MZVJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K%'_([M_V#1_Z,-;58
MH_Y'=O\ L&C_ -&&@#5N;B&TMI;FXE6*"%#))(YP%4#))/H!7&_\+*MOL?\
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MX5T"_P!.\0Z3=VF@6.D69M9([MX=0$S7BE04=EV#<P8 [CD_,:B^"OA_3O\
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M85NM/M-(2X@M)3F-I'E96<KT) 50,],^]=;HVCV6@:1;Z7IT9CM+=2L:%BQ
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M^1W;_L&C_P!&&MJL4?\ ([M_V#1_Z,- &U1110 4444 %%%% !1110 4444
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MZ0LJ)-\DC3+(09-^]2"21G(QC)QVQMZIXCT30Y(H]5U>QL7E_P!6MS.L9;W
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MB $>U NS: ,8QSDUE>)_!LEIX9\4ZD+Z_P!4U6^TAK5]Z*3(5W%=J(HQ][&
M.WJ23V5YXBT73]1AT^]U:QM[V;'EV\LZJ[YZ84G/-+>^(=&TV^@L;[5;*VNY
M\>5!-.J.^3@8!.3SQ0!B:1X-\F]TJ_O=6OKU-.B(L;6<(%MRR;220H9R%RH+
M$D#U/-<WX-\#37_@O3;?4M1U*"P,[7%QI+HJJ[K,S $E=X4D*Q7.#^-=_=^(
M=%L-2ATZ\U:QM[V;'EV\LZK(^>!A2<\]J)/$.BPZNFDRZM8IJ3XVVC3J)3GD
M?+G- &-J/@G[5?ZC<6&MW^F1:H!]N@MA&5E(7;N4LI*,5 !(]!WYJ[8^$]/T
MW7;34[0R1"TTS^S(K<8V"(.K ^N?E ZUL75W;64/G7=Q%!%N5=\KA5RQ  R>
MY) 'N:RAXQ\,M;W-POB#3##:L%GD%TF(R>@)SQG!Q]* *9\)O:ZWK6K6.J7L
M7]J1?OK2/R\&41[%=6(W*0 .^,UL:)!=VN@Z=;W\IFO8K6-+B0MN+R!0&.>^
M3GFFS:_H]OI":M-JME'IS@%;IIU$39Z8;.#2IKNDR6$%^FIV;6=PVV&<3KLD
M;G@-G!/!X]C0!3T+PQ;:#J.LWL$\TCZK=?:I5DQA&QC"X'3ZU+9>'[>R\3:I
MKJ32M/J,4,<D;8VJ(PP&._.XYJ73O$&C:O;SW&FZK97<,!Q+)!.KK'W^8@\<
M4NE^(-&UN.9]+U6SO4A.)3;SJX3ZX/'0T 3:G8+JFF7%D\\\ F0KYMN^R1#V
M*GL17.GP)%>QWW]MZM>ZI/=VRVHF=8XC#&&WC8$4#=NPV3GE16O9>*- U*01
MV.M:?<N9/*"PW*.2^"=H /7"D_0'TJ2+Q!HT^KOI,6JV3ZBF=UJLZF48ZY7.
M: ,=O!LMWINJ6FJ^(-2U!K^T-F7DV((HR#RJ(H7=SRQ!/X5KW6A6E[X9DT&X
MW/:26OV5B<;BNW;GZ]_K4;^*?#\=Y#:/K>G+<S.8XXC<IN=PQ4J!GKN!&/48
MJ;3]?T?5;JXMM.U2SNY[<XFC@G5VC[<@'CF@#(M/ ]C:>"+WPP+JYDBO4F%Q
M=.09I&E)W.3C&>?3L*;/X)B^RZ,-/U2[T^^TFU%G!>1*C,\6U5*NK*58':#T
MX(XK8L?$&C:G>SV5AJME=74'^MAAG5W3G!R <CGBHH_%7AZ:]M[*+7-.>ZN
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MC$:?Y7]K_P!D*;LP[L>7\WE[L?+G[V/XL>V*[Y],L)#=E[&V8W@"W):)3YP
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MJ\>DV*ZDV=UVL"B4YX/S8SG%7+>SMK0S&VMXH3/(993&@7S'. 6;'4\#D^E
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M$T >A45Y[JWC;6K3XJV'@VUCT\QWUJ;E+F2-R4 $AVD!AG_5]>.O2K>A>/\
M[5XIU3PMK=K#8:OIZ&8.LN8)XL [U) *\$$@].>>#0!V]%<SX6\17=YX6;5?
M$;Z59NDKJ[VUVKP*H.%)?<0#^/Y=*LZEXFLET:_GTG4M+N;R&!WB1[Q A<<
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M\6O9@=)66."4,2'EV\E0#G:.3V(KZ+@C,<0#[#(1\[(NT,?7'/\ .I" >HH
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M:VXU.Z\206.LW6N/<Z+";>:58Q]J$4[/*D/EHH<!<] 3DD9KW8C(P>E(%
M  ' QVH \X\2:_I'C30-7TWPVG]I:@^D3LMS!&"(00/W+,>5=_[G7Y><8IUU
MXCT7Q7H)T?0HA>ZI)I%PL;11@FP)BV[7)YC+$A<=3CTKT4*JYV@#)R<"@*JD
MD  GDX'6@#R+0FTG5?[%6X\3:CJ\MC9RR-I4=I$#;CR#&\<FQ%93ABH!/)Q1
M8:GIS0RZ+%K4GB3PT^DS^=&L(:[T^,!0$+H 3D$C:PW97OBO70J@D@ $]2!U
MH"JI)"@9.3@=: .!\%:R]QXBFTVU\01>(],CLA*E]Y:^;;MO $4CI@,2,GD
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M,$8XR,XY/W><9Q5KQGHVIW-_H6O:/ EU>Z-</)]D>01^?'(A1U5CP&P<C/%
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M!&3VQ6MXAT[7?&&DBXO_  \BVUEJ,-S:Z7/(HGN(E5ED#D,4!.\E1G^'D\T
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MVH6;I 94\Z6.*569WPQ5<?-@;B<4 =18^*M1'B+3]'UO14TZ74+>::W=+L3
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MJZ<EQ=WE^UI81Q7 W7$C32*$;Y $50N-W.0N>O%;(\<2:9-J=MXETY+"XL;
MZB/LUQYZ30@X.TE5.X-@8([CFN8TWP[XA@\(V%@=&E6_\/ZP;^(/-&$OD,LI
M*QL&X.R3^(#G'OB]J_AO5?'-WK%Y<:?-I$4FC/IMI'=NAD>1W#EV",P5054=
M<GDT ;5GXNU5-1TF#7-!CT^WU9BEK+'>><4DV%PDJ[%VD@'H6&1BN5\(>(YM
M%TOQ+(L/VRYN/%US9VT<L_EIN;;C<Y!VJ #T!] .:W6BU[Q1J?AR.^T*?2X=
M*N1>7<T\L3+)*L;(J1;&)8$N3D@<#UK,TCP]JFF:#XD@U'PRFJ6]_P"(KBZ:
MR>2,M+;/C$B9.W=D @$@\'H<4 =]HM]J%[;2_P!J:9_9]U%*8RBS>:CC (='
MP,J<]P#D$5AZ[XMU319;VZ/A\OHM@Z+<7<ESLD<-MW-%'M.Y5W<Y89P<=*?X
M$TV\TRQOTEM;JRL)+K?865W.)9+>+8H()#-@%@Q"[C@&N*\4>$-4U;_A)H'\
M,#4-4N9VEL=4N)8S'' %4K&F6W*_!7  &3DF@#L;SQ;JS^(=6T71M CO9]-2
M*1Y)KSR48.I8 ?(QW<$ =."21W@B\>S:K!H2:%I*W5[JUHUX8KBY\E+>)<!B
MS!6).Y@HP.?:KGA^POU\6>(M5N;&2U@U"&S,*RLA;*QL'4[2<$$@>GH37*>'
M]"U_PK'X7U,Z+/>R6^ERZ=>VEO+'YL1:02*PW,%89&#SWH W_AS>7%ZWBJ6Y
MAD@E&NRJT+ON\LB*(%0>A&<X(Z]:M+XKU.ZUJ\@T_0ENM/L;Q;.YF6[ F5B%
M)81;>5&[NP) ) I/ FGZM9+X@GUBR%I-?ZM)=Q1B17Q&T<8'(/4;2#[@]L5B
M>(-'U#4/$33V?AB:UUE+J,V^N6MPB1- &4DR_,&8[=RE"K>QQ0!I7GCC40NK
MWVFZ MYI&D2R17,[7GERN8QF3RH]A#;>>K#)!Q7*^,;O4/$7Q!\,V4.GQ7ND
MW%I+=6T!U)X$N@44[WVIE2N>!\V?;-:[V'B'1]+\2>'K/0IKT:G<W,ME>I-&
ML*+/DGS=S!@4+'HIR ,5;3PKJ%CXV\&2P0F73])TN6SFN-RC#;%5>"<\X["@
M#/TSQ[K]JNO7VKZ5 ^GV>M+9.\=YDVRDQ(0!Y8W*-^[)()R1QBNG?QC&OQ 3
MPM]C8JUOO-WYG E(+"+;CKL4MG/X5@6?AS4+B+QQX>OM,E2VU>YN+JVOMZ&(
M^8B*HQNW!@1GICCKTK.C\/>*_P#A#SK<FG9\6#5$OQ;&5,D*@@V[\[?]7N/7
MO0!TUOXPU;5H-^B^'A<A[VYMXYI;KRX?+A;;YC,$)&YL@* >A.:JS?$646&A
MR6VAR3WFJW,]G]E^T!3#/%N!4MC!7<A&[C YQVK*N?"-QIUMX8LKG0I=>TRR
MTYX9K-)(]HNV*'S75V"L#^\YYQG.*AT#PMKEE<^%[>;2!;Q:3J]]+*T4B>4(
MI5D*-&,YV_.%Q@$8Z4 =-<>*];%S+96/AZ&ZO+&UCN-10WVQ8F<$B*,[#O;"
MD\A1TYYKHM/U6WU30K;5K3+6]S;K<1[N#M9=P!]#7!^(O"J#QAJ6JW'A(^(8
MM0@B\DQR1J8)44J5?>RX0C:=PSC!XKN=/L?L?AVWLH[6&V,=L$^SP'*1G;RJ
MD]0#TH XJ#XEZE+I.BZP_A=AINK2);P;+T--YS@[1L*@;2PQNW#U(%;%CXOU
M!IM<LM0T%H]3TN".X6VL[CSQ<HX;:$)5><J0<BL:U\,ZQ'X"\#Z<]F1=Z;?V
MDUW'O7]TB;MQSG!QD=,T_P 3>'M=N]5\5W.FP./MFF6D,#I,$,I21S)&#G*D
MH<9.!\W6@#0D\;:CIL6KIK.AQ6UY8Z8^IQQ07GFI-&N<J6V#:P( Z$<YI]CX
MRU&75]&@O]"%I8ZRK?8YQ=;Y PC,@$B;1MRH.,,>G-<A<>%+XSZO+HW@TZ7:
M:EH%S81Q*T*R>=]Y6EP^/F^Z,%CQDXSQV&H:+J,UYX)>*W)73IBUT=R_NA]F
M=,]>?F('&: '1^+=4BU2Q34?#YL]-O[MK.WG:YS,' 8J7BVC:K;#C#'&1GK6
M9J/Q(OK/1=5U^W\._:=#L99(5N!>!9)61MA;9L.$WC&<D]\5SECX5U: :%=/
MX1=M7TW4$GU+47EA::\Y8,8V+Y*_-N.XKC  ![1:^NL:-\*_$GA]=-62UAEN
M=FIK<1M$8GF+[=H;?YF6V[=N ><T =WJ?B_4(;[48=)T1;^'2HDDOG:Z\I@6
M7?LC&T[V"8/)4<@9J*3QO>WNL-IOA_14OW.GP:A'--=^3&T<F[ /R,0>!CKG
M)Z8YP=9\)+'XGU>_G\'?V^-26*2VD66-1#(L8C*2;F!"_*&R >IXKHM#T*ZT
MWQM=77V*.WT_^Q[2TA\IP45HVDRBCK@ CD@4 9UE\1[R\T_1]8/AXQ:-J%S'
M:-.]V/-CE=MF?+V\H'^7.X$]<8JYJ'CF[M7U*\@T83Z'I=Q]GO+PW.V0%<>8
MR1[3N5,\Y89P<=*R+;POK,?PQ\/Z2UD1?6NIP3S1>8OR(MUO)SG!^7G@U4N/
M!B6^LZO%/X)BUF6_OWN;>_>9%A5)"&82Y;<-I+=%.1B@#H[SQEJS:SKFFZ/X
M?CO6TCRVEEEO?*617B$@"_(?FY(QTXR2,@5FIXTUG5?%WA=-*L8CI>IZ:]XR
M2W.UF!\O)/R'!3)P ?FR>1BMK2]'O;7Q%XPN'M]EO?-!]E;</W@6W5#QGC##
M'.*YG1M"UW0KGP-=OH\]P++2GL+R.&6/= [;,$Y8 K\IS@GI0!ZC15+3;J]N
MA=_;=/-GY5R\4.91)YT8QMDX^[N_NGD8J[0 4444 %%%% &+X9_X\KW_ +"5
MW_Z.>MJL7PS_ ,>5[_V$KO\ ]'/6U0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %8H_Y'=O^P:/_1AK:K%'_([M_P!@T?\ HPT ;5%%% !1110 4444
M %%%% !1110 4444 %%%% !6+K'_ "'O#W_7U+_Z(DK:K%UC_D/>'O\ KZE_
M]$24 ;5%%% !1110 4444 %%%>5#XQ:<=%COYI+B!6U$VET?LI/V0;68*!_$
MQV@9/?<<8 ! /5:*\J\>>-_$O@GQ5#>)&M]X858FO%$0$D/F%U&&&./DR">_
M!ZBNSL=5;5=;L;G3]3$VD7=BURB*BX8AE ^;&0/F.1UR/PH Z*BL>V\5:'>7
M8MK?48WD82%, A9/+.'V-C#[3UVDXKGM$^*6@:M!J]Y),UM96%R85FDA?#(
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M,GF<O+):1.[L>6)0$DU7U[Q%;:"+1'M[F[N[R0Q6UI:J&DE8 DXR0  !DDD
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M-LD.URK1Y4YP<C!&,UIZ!XNCU>[@TZXL+RRU![!;TI<(@5D+;"5VLW?GZ,*
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M@ HHHH *Q1_R.[?]@T?^C#6U6*/^1W;_ +!H_P#1AH VJ*** "BBB@ HHHH
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M* ,K5-,U*]G1[+7KK3D5<&.&"%PQSURZ$TW2]+U.RNFEO/$%UJ$90J(I8(4
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M?E\LIRP(0X..<8KO?$]K<2>-_#=S'82W<$-IJ E54RI+)'M0D\#=@@9KLJ*
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M8#,<D#9GIFI+1-6TKX+^'X88K^TD1;9+X6T+?:88"X\TJN-P8#T&1R:]-HH
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MC*7'V:WB6?CRXP-CC;M(V!CC)KVJB@#QF_TC4Y-&^*:+IUVS7ETC6RB!LSC
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M856Z\X@';G.WCIU_.I9M!\3:5=Z]#H*Z;+9ZQ,UR)+J9T>TE= KG:$(<?*&
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MV;;?VG]G^W^6OVC[-GR]^.=N[G&>F:M4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!B^&?^/*]_P"PE=_^CGK:K%\,_P#'E>_]A*[_
M /1SUM4 %%%% !1110 4444 %%%% !1110 4444 %%%% !6*/^1W;_L&C_T8
M:VJQ1_R.[?\ 8-'_ *,- &U1110 4444 %%%% !1110 4444 %%%% !1110
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M7!E%Y/9LROY@ V*67# #). 03[XQ6SHVNZ9:Z1J?B#_A)!?^'E1)(9I'WFW
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MX(YR.E4=$\:6>F^#VU'3M E5)=<:P^RK=F1GD9]I<,P[G^'@>XH ],HKB_\
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M>')^H ;\:X>YNM5E\%:3K6K:O?V(U_Q##+)MO'B^S6;[@L88$;5V ,?KSTH
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M/*]_["5W_P"CGK:H **** "BBB@ HHHH **** "BBB@ HHHH **** "L4?\
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M)!SFNHHH YO7/MLNK?9+G1/[4T">UVW"X1MDFXX^1B-P(ZXR1@5YQ+\*+M]
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M_AC6'^%?B/1ULR=0N[J\D@A\Q?G5YV93G.!E2#R:](I&944LQ 4#))/ % '
M :QH7BOQ*;#34OHM2$,ZS+<QJMI((@A\Y68,%^0,"H.1FN4T'PPMUX9\(:U<
M^'3KUHND&UEM4*"2,E]Z2*'901]X'GN#S7?^(M#\):AK=D-8A/\ :&H*T$7E
M2RQ_:%4;BK^60& !Z-QS740016MO';P1I%#$H2.-!A54#  '8 4 >>W6A(GA
M[3K*[^'\-Q8L997L[&=/.LY2V5*LS*,E?O%6X/J.:UO#]UJ^AV7AK1=4MI)Y
M[L7"RSR7(=[<*"\:MU\P[<*6SC*]3D5V%-,:-(LA12Z@A6(Y /7!_ 4 <QXU
MTF^U;_A'OL4'F_9-;MKJ?Y@-D2;MS<D9QD<#FL?Q;X8CN/&$>MW/ADZ_:2V(
MM6AC9!)#(KLRL [*"I#D'GC XKM-/U>QU1[M+*?S6M)VMYQL9=DB]1R!GZCB
MKM 'G<6BZEX=O]"US3O#B;(K":SO-+L)DW0"21904+E5;# AN1UXS4MW;>*)
MK[0?%-SI"275E)=1RZ9;2KYBV\N OS,VUI%V*3@@')Q7?T4 >5ZMX9U[7+/7
M]4.F/;W6IWVGF"Q>5#(D%NZDLY#;03ES@$\ #K72>)+/4[/Q?H_B/3]-EU**
M"WGL[JW@=%E"N4977>5!P4P1GO7844 >/:[X4\4:QX0\7Q-I&R^U358+JWMQ
M/&<Q*(NK;L9 4@\]0<9&">]LM+O(OB+J^J/#BRGT^VABEW#YG1Y2PQG/ 9>W
M>NDHH \ITS1-:\.#PM?'3?M%W:OJ,,]@EQ$LSQS3&173<P5L *2,]&]JGT76
MM1TJ7Q]K4VF++=17T#&T2<# \F,;=^"-RJ1G&<D8&>*[S6O#^F>(((HM2MO-
M$+^9$Z2-&\;8QE74AAQZ&G:7H.EZ-IYL;"S2.W,AE96)<NY.2S,Q)9L@<DD\
M"@"#Q9_R)VN?]@^?_P!%M7#Z7!KGB'1/!.G2:-+;6VGO:7L]^TL9BD2*/*!
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MON+AL_AC'XU1L_!&LPW&@3W/B*&5]#8);(ECL1X?+,;!AYG+E2,-G Q]TY-
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MF)))].F*U+/P/JXD\/\ ]I>(8[F+0YE:WCBLO+\Q1&R?.=YRV".1@#!X.<@
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M?*M#&LX= @&-YVD =><^@J&Z\":@T&JZ78Z\MKH>J322W%N;3?,GF<RK')N
M4-D]5.,G% %2TU#6_%?BB\M+76I]+TX:99WB"WBC:17E#G 9U/''/&>!@CG/
M0> ]6O-<\%:=?Z@ZR7;ATE=5"AV21DW8' SMS^-3Z9X;BTOQ%?:I#,/*N;2W
MM4MPF/+6'?CYL\YW^G&*D\+:%_PC7AVVTG[1]H\EI&\W9LSOD9^F3TW8Z]J
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M+N?>T0EW8"%B?X<X)&:GC\)>7I'B>P^VY_MR>XFW^5_J?-B6/&,_-C;GMG-
M&+::GK/BWQ%]DM=7FTFVL]+M;N06T4;-+-.&89+JWR +T&"<]:Y_PE?ZO+I/
MA[P[:W_V&:_N]3GO+NWC5G58IVRL8<$#<SCD@X KK?\ A#-2L-0MK[1-;BM)
M_P"SX;"[\ZS\U9ECSMD4;QM89/4D<].*KV?P[FTK2])33M9*ZGI4]S+!=SV^
M]9$G8LZ2(&&>HY!'*Y]J ,/6O$_B/1+#7]+BU+[3?:9J%@EO>31(&DBN&7Y)
M  %R/F&0!Q@\&O2-'LKO3]/6"^U.74;C<6:XEC5"<]@%   [5RT_P^EOM.OA
M?:L)=3U"^M[RYNEM]J8A92D:)NX4!<9))Y)YKN* //\ 0)?$_B2QA\36FN")
M)KUPFF2PI]G^S)*R%2P4OYA52V[.,\8Q5234?$>K:'XB\36>NRV8TZ>Z6RL4
M@C:%T@)!\S<I8ERIZ,,9&*UK?P3J=D_V"S\126V@?;#=BUB@*SKE_,,0F#<1
MEB?X<X)&:;=^!=1:+5M-T_7DM-%U::2:Y@-IOFC\S_6K')N 4-SU4XR<4 7_
M /A/M"MX-,^WW36]SJ%K%<QQ""1^)!QRJD=<BNHJ*VMHK.TAM8$V0PHL:*.R
M@8 _(5+0 4444 %%%% !1110 4444 8OAG_CRO?^PE=_^CGK:K%\,_\ 'E>_
M]A*[_P#1SUM4 %%%% !1110 4444 %%%% !1110 4444 %%%% !6*/\ D=V_
M[!H_]&&MJL4?\CNW_8-'_HPT ;5%%% !1110 4444 %%%% !1110 4444 %%
M%% !6+K'_(>\/?\ 7U+_ .B)*VJQ=8_Y#WA[_KZE_P#1$E &U1110 4444 %
M%%% !3/.B\[RO,3S2,[-PSCZ4^O$FTZQD^"]UXLD@C_X23S)+O\ M';_ *0M
MP)R H?J ,!-O3'&* /:FEC0@-(JDD* 3CD]!61XF\11>'-#N=1\M;E[=H@T
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@CE\N>2-9D'19%5@' ST8&F:AX(\/:I?-=W5BQDD"K*D<\D<<P48421JP5\
M ?,#P,=*Z&B@"E;Z38VFJ7FI00!+N]6-;B3<3O$8(3C.!@,>GK5VBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q?#/_'E>_\ 82N__1SU
MM5B^&?\ CRO?^PE=_P#HYZVJ "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ K%'_([M_V#1_Z,-;58H_Y'=O^P:/_ $8: -JBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K%UC_D/>'O\ KZE_]$25M5BZQ_R'O#W_ %]2_P#HB2@#
M:HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH Q?#/\ QY7O_82N_P#T<];58OAG_CRO?^PE=_\
MHYZVJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K%'_ ".[?]@T?^C#
M6U6*/^1W;_L&C_T8: -JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ K%U
MC_D/>'O^OJ7_ -$25M5BZQ_R'O#W_7U+_P"B)* -JBBB@ HHHH **** "BBB
M@""\O;33K1[N^NH;6VCQOFGD"(N3@9)X') K,A\8^&+B>."#Q'I$LLC!$C2^
MB9F8G   ;DDUA?%PX^&FI'R_,_>VWR#'S?Z1'QS3M.N6FU*W1_AS<62F0?Z2
MXM,1?[7RN3Q[#- '07/B71K/6X-&GU&%=2G ,=MG+D'H2!T_&BQ\2Z-J>K7.
MEV.HPW%[:Y\^*,YV8(!!/3() QFO.]%TG59OC!XO2+Q%<PRI;6I:5;:$E@R'
M:N"F %]NO?-8WA/4=2\+_#_6=5CU9V,FL2VB1R6R,B2O.J&<[5W,0"3MZ'IB
M@#W*BO)V\>W^EV>M+:ZE-K2Q6D4EI=W=B;<QS/*(BC (@8 NC# SC(S6UK>F
M^*].\.:Z9O$OVRU_LN603O;QQSQ3*,D*%7:49<CGYAV- '87NL:?IUQ907=T
MD4M[)Y5LIS^\?&<#%7J\JL]6UG0-#^&]I%J;S1:G+#'-YD,8_<F%2(QA>@]>
MOJ:U4\97NCZ+XQ&KRB>_T.=S =@7S8I!NM^  ,DG;]10!Z!17E-UXHU>WOTT
M75/$TVF7EEIT$L\\&G"<W%S(&)! 1@J+@#  )SUXKO?#.KW&L^$]/U2YMS#<
MSVX>6+:5P^/F !Y R#C- $NI>)="T>=8-3UG3[*9QE8[BY2-B/7!/2M&*6.>
M%)89$DC<!E=&!##U!'6N"^&6D:?J/@NWUR^M+>[U+5S)<7EQ-&'9V+D;<GHJ
M@  =!BL2+4[CPA>>*]!T39%$-3L8=.5UW1VKW8&_ _NJ<L%Z<T >M$@ DD #
MJ32UY;\0+#Q/IWP_\2+=>(?MMC]D5DE:"-)R22LD3!5"["""",,.1TK7DFUV
M?Q%8>%+?7IH3%IQO[K4!;Q&:7,FQ$ *[% YR=N3@>YH [&\U&TL'M4NIUB:Z
MF$$(;/SR$$A1[X4_E5JO(-6U36=4M]*T^:ZB;5=-\6K8"\,( <>2[+*4'&[:
M_0<9'O6AJ_BK6_!LVOZ?>:E_:;PV$%Y97,\"JT9EF,)#K& & ;#<#.,B@#T^
MBO*5\9:C:VVO16>N7.K+#HD]]#>7&G>0UO/&/NXV*K*=P(!!(VGDUVO@\:Q-
MHD.HZQJ?VN:^ACG6%851+<,N=H(Y;J,D]QQCI0!M7%[:6DD$=S=0PO._EPK)
M(%,C?W5!ZGV%3UP'CG1[*/Q%X8U?RRU])K=M#YKL6V1A)#M4=%!(R<=3UZ"N
M_H AN[NVL+62ZO+B*WMXQEY9G"*H]23P*@T_6-,U:T:[T[4;6[ME)#2P3*Z@
MCKD@X%5]>TG2M3M8)-8"FTL9A=XD?$8* X+YX(&2<'CC/:O+]:B^VZ/XFU^Q
MMVLM'UJ73["$!/+-Q'YP228KV#+(5&>2!GN* /5=-UW2-9,HTO5+*^,1Q)]F
MG638??:3BFP^(=%N-4?2X-7L)-00D-:I<(901U^4'/%<QK-A:Z9\0?")L+>.
MU^U1W=E+Y"A-T0AWJ./1D&/3-9U_HFD'4M!\*>'+-//TF]AO;NZ49-K&IW$.
M_4R2=,=2"2>* .XN_$.BZ??QV%YJ]A;WDN-EO-<(CMGIA2<\UI5YWXQTG1;;
M3M5T:RT]+[Q!XD,A2-QO<,P"^:S'E(X^".PQ@<FN\L+=[33K:VDE,KPQ+&TC
M=7( !)^M $Y(&,D#/2JUGJ-IJ!N1:3K*;:9K>;;GY)% )4^_(_.N(\>6^H7'
MC;P7#::M-9)+=3X$<4;['6!SO^8')P2N#QSZUB0C7K;3?'NK:7K7V!-/U2[N
M$A6W203ND:,0Y8$[2  -N#U.3Q@ ]<HKRW5/&]Q>:N]JNNRZ(D&GV]P@@L#<
M^=-*I?#'8V$4;1@8)R>>*[KP]J-SKWA*PU"5&L[N[M59UV<Q2$<X#>AZ9H ?
M!XET:ZUR;1;?489=1A!,L"')3'4$C@'VZUJUXCX:O=3\+Z)\0-<34Y+I[36K
MJ(6\L,82>8E%61B%!'+#*@@>U=L+C7_#?B70+34=;;5;75GDMY1+;QQF&58R
MZLFP#Y3M(PV>W- &Z?%^@#1'UDZG#_9R2^0UQ@[0^[;MZ9Z\5MU\]2_\F]ZA
M_P!AL_\ I2*]1N;K6O$'C/5=(T_6)-)M-)@@+O#!'(\TLH9AG>" H '  ))Z
MT =I17F_ASQGJMSJFBG5IXA;74%[:3A(PJBZMI#EP>H#1ACC..*S[#QYKW_"
M&^(+J[D4ZHR07&E#RE!6.Z^6!<8^;:V>N<]Z /2[?5["[U2\TR"Y1[VR"&XA
M&<QAQE<_45=KS.3Q3KUMJ7Q#LWOQ)_8>E0S6C>2@VRFW9V8\<Y89P>*M6NI>
M([#5/"=S?:R+N#6R8KBS^SHB0L86D4QL!NX*X.2<Y[4 >A45Y+<>(O%LGP^D
M\:VVM(BW$P*6!M8RD,)F\M=K8W%\8)))')&!P:]#\476I6/AC4;G2(3-?QPE
MH45-YSZA?XB!D@=\8H UZK:AJ%II.GS7]].L%K NZ21NBCUXKSE?%UY!X>O9
M],\3Q:U+-<6UG;FYM5BFM)I9-A\Q%"_* <@$ Y!'(IWC>P\0Z=X!\3QZCJZ:
MK8-8AHI98EBG27=\RX10I3&"#U!XYH ]-!R,T5P,VI:[X:\3Z7'J6K_VA::A
M:74LL'V=(U@>% _[L@;L8)&&)/O6-X<\<7]Y?:!</K,U^VJ.%O-/&G-'':!T
M+*8Y-@)"D*IRS9SD4 >FZAJ-II5C)>WTZP6T94-(V<#)"CI[D"K5>,:[=Z_K
M_P *Y_$MQJV;6]GC8:;Y"".*'[2JIM<#?O&%)))!Y&.AKM[/7=1F'C;?.#_9
M<[):?(O[L"W1QVY^8D\YH Z.?6-/M=6M-+FND2^O%=K>$YS($&6(^@J[7DT=
M[<:GX]^%U_=OON;G1YYI7P!N=K=23@<#DFH]-^(%[>S6&J1ZQ-,UWJ"POHZZ
M<WEQV[2; 1+LR748<G=@\C% 'KM(2 ,D@#WKSO0]?U.[\5_8[_Q"+6_%W,KZ
M)=6BQHT +!&ADP&<[0K9W$=>!5CXJQW<FC:.MK?R6JOK%I&X1%;<3*I4_,#]
MT@$#H>^: .]HKA8Y?$&N>)-6TBU\0RV$6BQ6\+3QVL3O=3O'O+N&4@+@K\J@
M=3R*VO!>M7/B/P?9:C=A([MQ)%-Y8^7S(W:-B >Q*DX]Z -:_P!2L],M3<WM
MPD,(D2/>W3<S!5''J2!^-6J\+:#5%\!^)II-5DNY!XG6)$FB15,BW<8WDJ >
M<#(Z#L!787VO:UX0UO4(=0U5M7MET.XU-%E@2(I)$RC:-@'RG=WR1CK0!Z)5
M>\O[/3H!/?7<%M$6""2>0(NX]!D]S7GGA;Q9?7'B'2;1];GU=-0AD^U(^G&!
M;20)O!1MBY0X9<,2>AS4_P :/^1%A_["5M_Z'0!Z)5+5=7T_0[![[5+R*TM4
M(#2RM@9/0>Y]JY:_N=>U/X@7NA66LMIUC#IL%SOBMXWD#L\BX!<$8(49R#]W
MC&2:X7Q1>:OXB\"^$KZ\U1DG_M^.TE$<$>UY$FDC$V"#@X7.W[O/2@#VBQOK
M;4K**\LY1+;S+N1P"-P_&K%>?23^)Y_'X\-0>(6CM;?2X;R:Y-K$9)'\UU(
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M\8 /3Z*JZ9=F_P!)L[QE"M<0)*5';<H./UJU0 4444 8OAG_ (\KW_L)7?\
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MC9D@1@ID8#A03P">G- '*GPGK&G72W6@:O:VTTMC#9W8N;0RJQB!"2H ZX8
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ME?83R,CD9Z$\UUM% &/HMGK<$US<:UJEO=/*%6."UMS%%$!G)&YF8L<\DG'
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M*\C6*:3>2"H ' Z#[JY]<"JMCX)T+3?#VHZ':VK1V&H&0W">8Q+;U"M@YR.
M ,=,4 >?0:/8:GJ?PH>]MEG:;2'$A<G+;+:-ES]"Q/XU%<^'M/O/"?Q!UBX2
M1[ZSU'4);27S&!MV0!@4P>#GJ>IX'0"O1KOP5H]W9Z/;XNH/['01V4MO<O')
M&NP(5W Y(*@ ^M6?^$9TO^R]6TWR7^S:K)-)=KYARS2C#X/;(]* (-1C35/
M<XO%$HFT_?(#W.S/\Z\UTO0;!_#7PQM4B,45[+YMSY3E3(QM'W9(.>0,'':O
M8TM(4LEL]F8!'Y6QN<KC&#^%8.E^!]'TB/3X[?[8Z:=,TUHL]T\@A)0IM7)X
M7:3QTH \]U>-_#[^+]$T6.2&Q>\TN-;:*8QA!.VV4*Q^YO  SVS76^#='U'2
MO$5Z4T1-&TB:U3_1$O%F7SPQ^=0/NY4X/KM%=!=>%M(O9-6:YM?-_M5(X[L,
MYPPC!"8Y^4C.<CG.#2Z+X:L=#GGN(9+NXNIU5)+B\N7GD*+G:H9B<*,G@>M
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M@ K%'_([M_V#1_Z,-;58H_Y'=O\ L&C_ -&&@#:HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *Q=8_P"0]X>_Z^I?_1$E;58NL?\ (>\/?]?4O_HB2@#:
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$9+1DKR W ..V1WJ/3=*UVXLKC2O$,>AG29;5K<0:?%(A (VX^8D!=N1Q[4
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M>V*Z&\U'Q'K7B76=.T&_M+"/1TB!\ZV\TW,SIOVD[AM0 J..>3Z4W7/ )O?
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MHH **** "BBB@ HHHH *Q=8_Y#WA[_KZE_\ 1$E;58NL?\A[P]_U]2_^B)*
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M-;58H_Y'=O\ L&C_ -&&@#:HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*Q=8_P"0]X>_Z^I?_1$E;58NL?\ (>\/?]?4O_HB2@#:HHHH **** "BBB@
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M]O-*9&DNYYURY?:KR,RC)YX!'TZ"M:BB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#%\,_\ 'E>_]A*[
M_P#1SUM5B^&?^/*]_P"PE=_^CGK:H **** "BBB@ HHHH **** "BBB@ HHH
MH **** "L4?\CNW_ &#1_P"C#6U6*/\ D=V_[!H_]&&@#:HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *Q=8_Y#WA[_KZE_\ 1$E;58NL?\A[P]_U]2_^
MB)* -JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8@2F0OM9N Q7;T.!S7,:9K'B/0/"&N:W9-I_]G:?J]Z\EM-$S27"_:&WD.&
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MWEU9O]>[YVQH-ZX "Y9N<;AQ75^&=:7Q'X9T[6$3ROM<"R% <[&[@'O@YYH
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M6NO:OI#:8EAH\\T"VUQ [279A'[P[PX"9((7@].: .Y:]M5O5LFN81=.AD6
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MSO*27R_,,F[&<J3MV].^: /8J*\_\:^,-2\.75[*FJZ!9PVEN)X+.\?=<7Q
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M00XV'DA1M.<<]: /1:*X2\\4:S)XROM(LKW1K9[.2(1:??*RS7R,JLSH^X
M991A6Y4YKNZ "BBB@ HHHH **** ,7PS_P >5[_V$KO_ -'/6U6+X9_X\KW_
M +"5W_Z.>MJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q1_R.[?\
M8-'_ *,-;58H_P"1W;_L&C_T8: -JBBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!B^&?\
MCRO?^PE=_P#HYZVJQ?#/_'E>_P#82N__ $<];5 !1110 4444 %%%% !1110
M 4444 %%%% !1110 5BC_D=V_P"P:/\ T8:VJQ1_R.[?]@T?^C#0!M4444 %
M%%% !1110 4444 %%%% !1110 4444 %8NL?\A[P]_U]2_\ HB2MJL76/^0]
MX>_Z^I?_ $1)0!M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 8OAG_CRO?^PE=_\ HYZVJQ?#
M/_'E>_\ 82N__1SUM4 %%%% !1110 4444 %%%% !1110 4444 %%%% !6*/
M^1W;_L&C_P!&&MJL4?\ ([M_V#1_Z,- &U1110 4444 %%%% !1110 4444
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M(HY4:2(@2*K E"1D9';CF@"2BBB@ HHHH **** "BBB@ HHHH **1F"J68@
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M2,BE#C)'E?P].#MYJKJK:IXH^'-_K-Q;I8W4!;4='"J1+"(QNC9\G[S '('
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M,LT$3AT01;<*QVJ"=Q'7K73^--%NM=\/BULU@DECN8+CR+AB(IQ'(KF-B <
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M]@T?^C#6U6*/^1W;_L&C_P!&&@#:HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *Q=8_Y#WA[_ *^I?_1$E;58NL?\A[P]_P!?4O\ Z(DH VJ*** "BBB@
M HHHH **** ,W7=$M]?T]+.ZDE2-9XK@&(@'=&X<#D'C*C-07WAFPU'6FU.Z
M\R1GT^73GA)'EO%(RLV>,Y^7'7H36S10!S>C^$CI=Q%)+KFJW\=O ;>VAN9$
MV1(<?W5!<X &6R:=!X+TR#P3%X4,ER]C%&$24N!*I5MRN&  #!@"#CM7144
M<PO@R.?3M4M-5UC4M3.HVWV622=T79'@C"*BA0?F)S@DG\JB/@?_ $732NO:
MFNI:<K1V^H@1>9Y;  QLNS8R_*.HSD9S7644 <Y:^#[>RT>:Q@U+44FN+L7E
MS?+,%GFDW*3N(&,$*%P !MXKHZ** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH Q?#/_'E>_P#82N__ $<];58OAG_CRO?^PE=_^CGK:H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "L4?\CNW_8-'_HPUM5BC_D=V_P"P:/\
MT8: -JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ K%UC_ )#WA[_KZE_]
M$25M5BZQ_P A[P]_U]2_^B)* -JBBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!VU(S*BEF8*H&22< 5Q%QXPU>PUZUBU"TTR&RNM0%BEL+K==J&8JDK*/EP2
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M*MCY@B]ESG%7:HPZO:3ZU=:2CL;RVACFE7:<!7+!3GO]TT <4R^,CX[77O\
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M]:UM7\.>(?$TNOZA=:?#833:'+I5E;&Y$A=G.YG9@,*,A0/Q)Q7?WFGVFH"
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M@$]:JVW@ZZT[4+FS3PGH5_%-J#W,>JW:HS)%))O960KO9URRK@X^[R,8KO\
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MDP$4QG*?[I[BNPT_X=FSMM'T^;7;RZTC2I(YH;.2-!NE3E2S@9*AOF"_3G
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,7PS_QY7O\
MV$KO_P!'/6U6+X9_X\KW_L)7?_HYZVJ "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ K%'_([M_V#1_Z,-;58H_Y'=O\ L&C_ -&&@#:HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *Q=8_P"0]X>_Z^I?_1$E;58NL?\ (>\/?]?4
MO_HB2@#:HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+*A^0%<@CDD#@5OZ;XIU?5_%NIZ3:Z5;K9Z7="&ZNI9R"5:,,NQ0O+9)SD@
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MT3GT^8$<UC:5HGB+PQ>Z/J%MI U'.@VVFWEO'<QQM#+%R&RQPR_,0<'/&>:
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M@!Y3N.]@!VVCDG%06O@>*#X>VOA5K^0FU1/*O$C"LDB/O1PI)Z,!QGFNLHH
MY2;PMJFJZ-K%AKNO_:CJ%J;51;VHAC@&#\P0LQ+$GDD]@.*@_P"$/U=%TJ]C
MUZ!=;TZ%[877V']U- VWY'CWYX*J<AASFNRHH Y>P\*WNG:7=I;ZVZZK?7JW
MEW?_ &=3O.5!14)PJ[%"CDD=>M=1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% &+X9_X\KW_ +"5W_Z.>MJL7PS_ ,>5[_V$KO\ ]'/6U0 4444
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M*::]I=R7MA<V%C<R('D6U.[YRI*J7+,!SQ@9K9;X/^!F='.CRY3./]/N._\
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MK^A>%K&)]*NKV62^9!!-=J9;2U9V*%W).\HNT$ D\XSQ47_"HO!'_0(E_P#
M^X_^.4?\*B\$?] B7_P/N/\ XY0!V]%5M/L+;2]/M[&SC,=M;H(XT+%L*.@R
M22?Q-6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q?#/_'E>_P#82N__ $<]
M;58OAG_CRO?^PE=_^CGK:H **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC/H4.I2^7 DC!S(00I8'KP.<\+P,G- '>7E];6%G<7=S*L<%LADF?KL4#))
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M 3H,$YZUB:IXGU6/6DT75->DTFXL]/BFGFTRP:Y$]PY8=XVVH F<8!.[&>*
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M.OEHN?E4;^,ECQ[UTZLK#*D$>H-95_XFT;3-6M=*O-0BCO[K'DV^"SL"=H.
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MDR>19V,6F&:.\=(U9C*XC.-[$J K+MX->CWL#Z[X7N((W>U>_LF16(^:(NA
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M_B2/P+!X^DUERCNEP^E>1'Y MVD"[ VW?O"G.[=U[8K5TN?Q%K_B_P 26O\
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M4'!&10!EZ#;ZDWQ:\2RW&K3D06EH7MU2,QL&64A,[=VU2201@GOFLSPYXO\
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MVC8--2X7RMF?,\U5'7/&-OH<YH V:*** "BBB@ HHHH **** "BBB@ HHHH
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M']C:G_T,^H_]^+;_ .-5M44 8O\ 8VI_]#/J/_?BV_\ C5']C:G_ -#/J/\
MWXMO_C5;5% &+_8VI_\ 0SZC_P!^+;_XU1_8VI_]#/J/_?BV_P#C5;5% &+_
M &-J?_0SZC_WXMO_ (U1_8VI_P#0SZC_ -^+;_XU6U10!B_V-J?_ $,^H_\
M?BV_^-4?V-J?_0SZC_WXMO\ XU6U10!B_P!C:G_T,^H_]^+;_P"-4?V-J?\
MT,^H_P#?BV_^-5M44 8O]C:G_P!#/J/_ 'XMO_C5']C:G_T,^H_]^+;_ .-5
MM44 8O\ 8VI_]#/J/_?BV_\ C5']C:G_ -#/J/\ WXMO_C5;5% &+_8VI_\
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M']C:G_T,^H_]^+;_ .-5M44 8O\ 8VI_]#/J/_?BV_\ C5']C:G_ -#/J/\
MWXMO_C5;5% &+_8VI_\ 0SZC_P!^+;_XU1_8VI_]#/J/_?BV_P#C5;5% &+_
M &-J?_0SZC_WXMO_ (U1_8VI_P#0SZC_ -^+;_XU6U10!B_V-J?_ $,^H_\
M?BV_^-4?V-J?_0SZC_WXMO\ XU6U10!B_P!C:G_T,^H_]^+;_P"-4?V-J?\
MT,^H_P#?BV_^-5M44 8O]C:G_P!#/J/_ 'XMO_C5']C:G_T,^H_]^+;_ .-5
MM44 8O\ 8VI_]#/J/_?BV_\ C5']C:G_ -#/J/\ WXMO_C5;5% &+_8VI_\
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M']C:G_T,^H_]^+;_ .-5M44 8O\ 8VI_]#/J/_?BV_\ C5']C:G_ -#/J/\
MWXMO_C5;5% &+_8VI_\ 0SZC_P!^+;_XU1_8VI_]#/J/_?BV_P#C5;5% &+_
M &-J?_0SZC_WXMO_ (U1_8VI_P#0SZC_ -^+;_XU6U10!B_V-J?_ $,^H_\
M?BV_^-4?V-J?_0SZC_WXMO\ XU6U10!B_P!C:G_T,^H_]^+;_P"-4?V-J?\
MT,^H_P#?BV_^-5M44 8O]C:G_P!#/J/_ 'XMO_C5']C:G_T,^H_]^+;_ .-5
MM44 8O\ 8VI_]#/J/_?BV_\ C5']C:G_ -#/J/\ WXMO_C5;5% &+_8VI_\
M0SZC_P!^+;_XU1_8VI_]#/J/_?BV_P#C5;5% &+_ &-J?_0SZC_WXMO_ (U1
M_8VI_P#0SZC_ -^+;_XU6U10!B_V-J?_ $,^H_\ ?BV_^-4?V-J?_0SZC_WX
MMO\ XU6U10!B_P!C:G_T,^H_]^+;_P"-4?V-J?\ T,^H_P#?BV_^-5M44 4-
M(TP:39-;BYEN6>629Y90H9F=BQ^Z .I["K]%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/I79>)]<>W\"7>L:5.N9+='M[C&0H<@"3!] V[\* (O^$!T?_GZUS_P=W?\
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M(#H__/UKG_@[N_\ XY7444 <O_P@.C_\_6N?^#N[_P#CE'_" Z/_ ,_6N?\
M@[N__CE=110!R_\ P@.C_P#/UKG_ (.[O_XY1_P@.C_\_6N?^#N[_P#CE=11
M0!R__" Z/_S]:Y_X.[O_ ..4?\(#H_\ S]:Y_P"#N[_^.5U%% '+_P#" Z/_
M ,_6N?\ @[N__CE'_" Z/_S]:Y_X.[O_ ..5U%% '+_\(#H__/UKG_@[N_\
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MM<_\'=W_ /'*ZBB@#E_^$!T?_GZUS_P=W?\ \<H_X0'1_P#GZUS_ ,'=W_\
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M,,O2O/S=RR:5=-;_ /"1#7KG5;NVL;S[=*MJ)1<2B,$-)Y>T!0"NWG& "2*
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MUI<6BPB]DG5TEVC:BL!Y:!0>,D\@9PHKOZ* ,_2](BTI) ES>7+R8R]U.9&
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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1** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>exhibit101_changexreques004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit101_changexreques004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !117+>,X?&LJ67_"'7&FPL"_VG[<"<CY=NW /^UG\* .
MIHKRK['\;/\ H(^&?^^6_P#B*/L?QL_Z"/AG_OEO_B* /5:*\J^Q_&S_ *"/
MAG_OEO\ XBC['\;/^@CX9_[Y;_XB@#U6BO*OL?QL_P"@CX9_[Y;_ .(H^Q_&
MS_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?QL_Z"/AG_OEO_B*
M/5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB@#U6BO*OL?QL_P"@
MCX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?
MQL_Z"/AG_OEO_B* /5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB
M@#U6BO*OL?QL_P"@CX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\
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M_=H5\A,A'SW(*=?QJA)X2^+UUXFM?$<U]X?_ +0M[=K>(,6VHK')X"8R<]:
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MB#I?BKX<7UIX=^T7D6Z)[R<V[QQP()%P"6 RQ;:,#/&3VK=^Q_&S_H(^&?\
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MS_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?QL_Z"/AG_OEO_B*
M/5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB@#U6BO*OL?QL_P"@
MCX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?
MQL_Z"/AG_OEO_B* /5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB
M@#U6BO*OL?QL_P"@CX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%%  0""",@]151-*TZ+3#IL=A:I8%2GV585$6T]1LQC!R>,5;H
MH JS:;87-I':3V5M+;1[2D+Q*R+M^[A2,#';TJ'5-"TC6TC75=+LKY8SE!<P
M+)M/MN!Q6A10!3GTG3;FQCL9]/M9;2/;L@DA5HUQTPI&!CM4C6%F]^E^UI U
MXB&-+@Q@R*IZJ&Z@>U6** *\%A9VL,D-O:00Q2LSR)'&%5V;[Q('4GN>]5+K
MPYH=[806%UH^GS6<',-O);(T<?\ NJ1@?A6G10!2ATC3+>\6\@TZTBNEB$"S
M)"JN(QT0,!G;QTZ5=HHH *JWFFV&HF$WUE;7)@<21>?$K^6PZ,N1P?<5:HH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBL._NM6EU]=.TZYLK=%M?/=[BU>8D
MEBN!MD3'3WH W**Q/LOBC_H,:/\ ^"J7_P"2*/LOBC_H,:/_ ."J7_Y(H VZ
M*Q/LOBC_ *#&C_\ @JE_^2*/LOBC_H,:/_X*I?\ Y(H VZ*Q/LOBC_H,:/\
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M_P"@QH__ (*I?_DB@#;HK$^R^*/^@QH__@JE_P#DBC[+XH_Z#&C_ /@JE_\
MDB@#;HK$^R^*/^@QH_\ X*I?_DBC[+XH_P"@QH__ (*I?_DB@#;HK$^R^*/^
M@QH__@JE_P#DBC[+XH_Z#&C_ /@JE_\ DB@#;HK$^R^*/^@QH_\ X*I?_DBC
M[+XH_P"@QH__ (*I?_DB@#;HK$^R^*/^@QH__@JE_P#DBC[+XH_Z#&C_ /@J
ME_\ DB@#;HK$^R^*/^@QH_\ X*I?_DBC[+XH_P"@QH__ (*I?_DB@#;HK$^R
M^*/^@QH__@JE_P#DBC[+XH_Z#&C_ /@JE_\ DB@#;HK$^R^*/^@QH_\ X*I?
M_DBC[+XH_P"@QH__ (*I?_DB@#;HK$^R^*/^@QH__@JE_P#DBC[+XH_Z#&C_
M /@JE_\ DB@#;HK$^R^*/^@QH_\ X*I?_DBC[+XH_P"@QH__ (*I?_DB@#;H
MK$^R^*/^@QH__@JE_P#DBC[+XH_Z#&C_ /@JE_\ DB@#;HK$^R^*/^@QH_\
MX*I?_DBC[+XH_P"@QH__ (*I?_DB@#;HK$^R^*/^@QH__@JE_P#DBC[+XH_Z
M#&C_ /@JE_\ DB@#;HK$^R^*/^@QH_\ X*I?_DBC[+XH_P"@QH__ (*I?_DB
M@#;HK$^R^*/^@QH__@JE_P#DBC[+XH_Z#&C_ /@JE_\ DB@#;HK$^R^*/^@Q
MH_\ X*I?_DBC[+XH_P"@QH__ (*I?_DB@#;HK$^R^*/^@QH__@JE_P#DBC[+
MXH_Z#&C_ /@JE_\ DB@#;HK$^R^*/^@QH_\ X*I?_DBC[+XH_P"@QH__ (*I
M?_DB@#;HK$^R^*/^@QH__@JE_P#DBC[+XH_Z#&C_ /@JE_\ DB@#;HK$^R^*
M/^@QH_\ X*I?_DBC[+XH_P"@QH__ (*I?_DB@#;HK$^R^*/^@QH__@JE_P#D
MBC[+XH_Z#&C_ /@JE_\ DB@#;HK$^R^*/^@QH_\ X*I?_DBC[+XH_P"@QH__
M (*I?_DB@#;HK$^R^*/^@QH__@JE_P#DBC[+XH_Z#&C_ /@JE_\ DB@#;HK$
M^R^*/^@QH_\ X*I?_DBC[+XH_P"@QH__ (*I?_DB@#;HK$^R^*/^@QH__@JE
M_P#DBC[+XH_Z#&C_ /@JE_\ DB@#;HK$^R^*/^@QH_\ X*I?_DBC[+XH_P"@
MQH__ (*I?_DB@#;HK$^R^*/^@QH__@JE_P#DBC[+XH_Z#&C_ /@JE_\ DB@#
M;HK$^R^*/^@QH_\ X*I?_DBC[+XH_P"@QH__ (*I?_DB@#;HK$^R^*/^@QH_
M_@JE_P#DBC[+XH_Z#&C_ /@JE_\ DB@#;HK$^R^*/^@QH_\ X*I?_DBC[+XH
M_P"@QH__ (*I?_DB@#;HK$^R^*/^@QH__@JE_P#DBC[+XH_Z#&C_ /@JE_\
MDB@#;HK$^R^*/^@QH_\ X*I?_DBC[+XH_P"@QH__ (*I?_DB@#;HK$^R^*/^
M@QH__@JE_P#DBC[+XH_Z#&C_ /@JE_\ DB@#;HK$^R^*/^@QH_\ X*I?_DBC
M[+XH_P"@QH__ (*I?_DB@#;HK$^R^*/^@QH__@JE_P#DBC[+XH_Z#&C_ /@J
ME_\ DB@#;HK$^R^*/^@QH_\ X*I?_DBC[+XH_P"@QH__ (*I?_DB@#;HK$^R
M^*/^@QH__@JE_P#DBC[+XH_Z#&C_ /@JE_\ DB@#;HK$^R^*/^@QH_\ X*I?
M_DBC[+XH_P"@QH__ (*I?_DB@#;HK$^R^*/^@QH__@JE_P#DBC[+XH_Z#&C_
M /@JE_\ DB@#;HK$^R^*/^@QH_\ X*I?_DBC[+XH_P"@QH__ (*I?_DB@#;H
MK$^R^*/^@QH__@JE_P#DBC[+XH_Z#&C_ /@JE_\ DB@#;HK$^R^*/^@QH_\
MX*I?_DBC[+XH_P"@QH__ (*I?_DB@#;HK$^R^*/^@QH__@JE_P#DBC[+XH_Z
M#&C_ /@JE_\ DB@#;HK*T"]N[[3Y6OF@:XBN9H&:",HK;)&4$*68C('J:U:
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M]&:9(MCD8V@L 7" D#(!K@19W#2:C;PV&L%9?$.FWD)O8Y9)'@'E*79V!/\
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M?%-SX5TNSN+6PENY;B\AM_D4,%#.H(/S#YB"0OOC/%8HU8>(_B1X9OK"PO\
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MQQ+N<@12YP.I('.!R<<5ROBY+CQ1%XPU?2[&]>T_L2'3X2]K(C7$HE:1MB,
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M%WXTN[#3=12":WTR6U8PM#)<K#*SOL# $-@$ 'G[I[BI-0T.U\1:+XA.B?\
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M0 4444 %%%% !1110 5BC_D=V_[!H_\ 1AK:K%'_ ".[?]@T?^C#0!M4444
M%%%% !1110 4444 %%%% !1110 4444 %8NL?\A[P]_U]2_^B)*VJQ=8_P"0
M]X>_Z^I?_1$E &U1110 4444 %%%% !1110 450UG6+70M,>_O/,,:LJ*D2%
MWD=F"JJJ.I)(%9$?CG3#IU]=3V]_:S6,D<4UG-!B??(0(PJ@G=N) &#_ "H
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M1110 4444 %8NL?\A[P]_P!?4O\ Z(DK:K%UC_D/>'O^OJ7_ -$24 ;5%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ;Q-H=OK*:/-JUFFHN0%MFF <D\@8]3V'4T :M%,FFCMX))IG5(HU+N[' 4
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M>1YLNX8*@]2!N^;W]Z]ZHH **** .<\=>()/#?A*[O+8;[^7%M91CJ\\AVH
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M,@\=: .0MK>&7XS:G*\:LZ:';JI(S@-++G\\"N-L+2WM_@OX=>*%$8:W!(&
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M:-=VJ6MSI-C-;I(95BDMT9%<DDL 1C)))S[U(NCZ8EP;A=.M%G,@E,@@4,7
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M$R 11JN[PW=H0HQD"2+ _#)_.NPBTC3(+!;"+3K2.S0AEMUA41@@Y!"XQD$
M_6K!MK=KI;HP1FX5#&LI0;PI()4'K@D#CVH \2GGAF^%WPP$4J.4UK3U<*P.
MT_/P?0UV6F6EO)XI^(TDD*,[F&)BPSE/LJ_+].:ZZ'P[HEO&$AT?3XT$PN J
M6R "4='X'WAZ]:N+:6R23R);Q*]Q@S,$ ,F!@;CWXXY[4 >5^";J&UUKP=+=
MSI$LOA 1H\K!0S"2(D GN!S]*RH+B6[DLKRQO;2&U?Q??NES=Q&6 .T;^4Q
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M@ HHHH **** "BBB@ HHHH **** "L4?\CNW_8-'_HPUM5BC_D=V_P"P:/\
MT8: -JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ K%UC_ )#WA[_KZE_]
M$25M5BZQ_P A[P]_U]2_^B)* -JBBB@ HHHH **** "BBB@""]O;73K.6\O;
MB*WMHEW22RN%51[DU0M?$^A7NER:G;:M9R6,3A))UE&U&)  8]CDCKZBLSQY
M>BTT6TC^SV<KW6H6\$;WJEH87+Y$C $9P5X&1SBO,_$-QYFE?$>.[U*VU!_+
MTXR2VL/E*^)"&PNYLD8"D@]1CM0!Z_I_BC0=6N+FWT_5[*ZFM@6F2*8,4 X)
M..WOTJ.U\7^'+W4(;"UURPFNYD#Q0I.I9P1N&.>>.<>G-<EKTVGW/C?PQ_9$
MEO((]-OC)]F((6W,2A,X_AW;<?C7.V4VF2?!_P %6^GO ;_^T+'R40C>)Q*#
M(<=>F\GVH [?2?&OG>(_%-EJLEG:66DW-O!!,24W>8O\1)QG. ,8ZUU5U?VE
MBUNMU<Q0M<2B&$2,!YDASA1ZG@\>U>8Z1HL/B+Q)\4M'N.$NY;>/=_=;RCM;
MZ@X/X5)X0U&Y\:>(M)EOT82>&K-DO%;_ )_V+1'/T6-F_P"V@H ]0=TCC:21
ME5%!+,QP !W)K*TWQ5H&L1W+Z=K%G=+:KOF,4H;RU_O'VX//3BH?&E_'IG@K
M6+R6T2[CCM7W02?<D!&,-_L\\^V:\^FFGB\7S07>K:;>2#PO=H%L+?RHXQF,
MA,[VW8&2!P0.<<T >BVOBWP]?:G'IMKK5C->R('2&.92S#&[@=^.?I63XN\>
MZ9H.E:NMEJ6GRZU96[2I9R29)8#."H(/3G&<XKFQ:P6W@?X7F&)$(OK!LJ,'
M+P.6/XDG/K6)J%UID?P0\46U_)!_:7VZ\$\3D>8;C[0Q4XZYQM.?0>E 'MD3
M%XD<]64&LN3Q1H46M+HTFKV:ZDQ"BV,PWY(R!CU([=:TH/\ CWB_W!_*O&O$
M.J/<Z-?W2W6E6%J?$*H+".W)N))([I%:5Y-_RMA"WW>%P,\T =G'XPOW\2^-
M]-,-MY.@VL$ULVUMSEX3(=_/(R.V.*V?!FM7'B/P=I6L7:11W%W )'6($*#[
M9)/ZUPMN0?'7Q8(.0=/M,$?]>K5U'PL_Y)?X>_Z]%_F: -O5_$FBZ!Y7]KZI
M:V1FSY8GD"EL=2!Z#UHOO$FB:9&KWVJV=NK0^>IDF W1Y W#U&64<>HKE/$>
MHN?&5Y;0W&E:8;72DDGO;VV,TDT;NX\M%WJ-H*<]<E@,5SW@1(;K6O CR!9&
M@\-3%2>2C"2-?P(!(H ]#_X37PQFR']OZ=_IN#;?Z0O[S)V\<^H(^H(J?5_$
M^A:#+'%JVK6EG)*-R)-*%)'KCT]^E>67MG;P_"3X@M'"BDZO>-D+W68;?RQQ
M76Z5<65I\1_&1U66"*1X;1XC<,%!MA$0<9_A#[\^_6@#LEU*Q:>V@6[@:6ZC
M,L"JX)E08RR^H^8<CU%0R:YI4(E,FHVJ"*X%K(6E "2D A#Z-@CCWKROP9*M
ME=^ )+MQ!!)9:FMN93M&PRHT8Y_V,$>U0W#VFK0:J5*7%I/XYM4/=9%VP@_4
M'GZB@#T>7QYX971=1U6#6;.YM[!-TQBF4X)^Z/JQX'J:2W\>>&I-!L]8GUBR
MM[:Z "^9.O#X!9/<KGGTKD_&D:KXF\4A% +^#)2V!]XAY *DA\NXL?"M]HVO
M:;:ZQ;Z.$2&\7S(9XBL6\$@@J057D'//(Q0!Z1!/#=6\=Q;RI+#*H>.2-@RL
MIY!!'45EZGXK\/Z-))'J6LV5K)&5#I+, READ9'7D#-0^#+Z'4O"&G7<%E#9
M1NA MX/]6I#$'9P,J2"0?0BN<TVXTJW^+/C W\EO',;*SVF<@9BV-OQGM]W/
MX4 =;J/B71-)L8+V_P!5M+>UN,>3*\HVRY&?E]>.>*F@UG3+J>WAM[^VEEN8
M?M$"I("9(^!O7'4<CD>M>3>$KZ>/2?#-E!-ING21Z?>7<6HZC"9"EN;C"I&-
MZ@97822>@%)IG^A_#KP]XKMW$DN@ZE<M<;$VDVLEQ(DJ[?X<*5;!Z;: /6+O
M7=)L'N4N]2M8&M8EFG$DH7RD)P&;/0$C ]:P]=\:VL7@N[U[0+NSOQ!-%%D-
MO0%I40AL$$'#9_*N16X\S1)_$CV]G)<>)=<A2TEOE+16\*$K [*",X"%@,C)
M<5A^(+@2Z/\ $6.\U&VU!MVFF66UA\I7Q(%;"[FSC&TD$\C':@#V'2_$NAZW
M<SVVEZM9WD\',D<,H8J,XSQVSWZ5@^#/&ZZQ\/H/$VOS65@&>19'!*1KMD*#
M[Q)R<#OUJK>36%S\3O"1TF2WD\NPNS,;8@@6Y6,)G'\.[&/QKS_PJ+H?#SP$
M\%U:VL2ZQ=9FNXC)"DA\X1EE#+WR <C!(H ]RTW5+#6+);S3;N&ZMF) EA<,
MN1U''?VIFHZSIFCJC:E?VUH'#,IGD";@HRV,^@KG_!5F\%]X@N)-8L=1FN+M
M#.MC;F***41J",%VRQ&PGGK5'QK)8Q>/? KZ@T:P"YNL-+C:'\KY,Y_VL8]\
M4 =/:^)M#O=,&I6VJVDMD91#YRR@J)"0 I/9B2!CW%6KC4[&UN&@N+N&*98&
MN61W (B7AGQ_=&1DUY%XBE@-_P"-+RV=/[/CU31VEE0CRQ(KIYIR.,@%,_K6
MSXGO[2\\<:C';7$<QB\)WN\QL&"DNA )'?'./<>M ':#QAX;-O=3C7+ PVJQ
MM/)YZ[8Q(,ID_P"UVJQ:^(=&O;6UN;74[2:&[E\F!TE!$DF"=@_VL \=>*X>
MRTNP'PO\&QQZA!I%V%M;BTGDB#H]SY1;#CC.X%^XYZ'.*SI]6\ZZT=[^'3K>
M>S\5K%>75B<6\\C6K8DR>APRJ02<$8S0!ZB^J6$4MU%)>0)):1B:X5I /*0Y
MPS>@^4\GT-4K+Q7X?U&PNKZSUBRFM;0;KB5)01$,9RWH, \UYYKFM62Z_P".
M[F**TU");/3;9DF.8-S22+ER.JJ6!./0BL[Q#//]N\90W>K65_<#PLRL]I;^
M2@(9SLQO;<0&SUX#"@#U2W\6>'KJ^N+*WUFQEN;=&>6))E)15^\3]._I5?PM
MXQTCQ?!=2:9<QR&VF>)T60,VT.RJ^!T#!21[5@7]K!:^(?APD$21K&9XU"C&
M%^R-Q].!^53?"J:)O"US"LB&:/4KS>@8;E_?OC([4 ;'B7QIH_A2XTZ'4[J*
M)[Z<1+OD"[%P29#G^$8 ^I%6-1\6^'M(N(K?4-:L;::50Z)+,JDJ>C>P/J>*
MP/B!)'!K'@N69UCC76UW.YP!F*3J35'1[O2K:_\ B!_;4UNLCW9DE\YA\]H8
M$\OKU7&X#WS0!Z*K!E#*05(R".AK'U+Q;X>T>62+4=9LK66-@CI+,%921N&1
MUZ$&J7P[2ZB^'7AY+P,)Q8Q9#]0-OR@_ABL+2KC1[?XG^.3J$EM'(8+3)G(
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MVC:Q)!91ZI92:HT"R2VL4H+*=H+ #/;N.W>K,'BC0KK67TB#5[.344)#6RS
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MZK &QN$N6))4'G&*[:U\9:/::-87&L^(='\ZZ#%)H)-D4N&(RH9B<#H23C-
M&M>6<MM;WEQHEK81ZG<%27F0JLA'&7*C<<#.*I^%/#S>'].G%S.MSJ%[</=W
MLZ)M5Y7Z[1V4   >@JUJWB/1M"@AFU74[6TCF.(FED W]^/6LO4_'WA_2]8T
MG3YM1MB=20R1RB9=BIC*L3W#$8'J: .EDCCFB>*5%DC=2K(PR&!Z@CN*SH?#
MFAV\4,4.C:=''"6,2):H!&6&&*@#C(X..M4K/Q##'=ZDNHZMI)BAO5MH1"Y#
M1LWW8Y<G&\GTQ6O<ZA:6<UM#<W,44MR_EP([ &1L9PH[G )H 4V%F8;>$VD!
MBMBK0)Y8VQ%1A2HQ\N!P,=*JS>'M$N+R6\GT?3Y;J5"DD[VR,[J1@@L1DC'&
M*98^)M#U/49M/L=6L[B\ASOABE#,,'!X[X/!]*TI98X(GEE=8XT4L[N<!0.2
M2>PH >    , = *SG\/Z++<7-Q)I%@\UTNRXD:V0M,OHYQEAP.#46F>*-"UF
M&XETW5[.YCMANF:.4$1CKD^@X//3BGZ1XCT;7Q+_ &3J=K>^20)!!(&*YZ9Q
MV/8T 6(]+T^%IVBL+5&N$6.8K"H,BJ-JJW'( X /05-;6T%G;I;VL$<$$8PD
M<2!54>@ X%,OK^TTRREO+ZYBMK:(9>69PJJ/<FLG_A,_#SZ)=ZO!J]G-:6@Q
M*ZS#",>BGT). ,^M &E=:3IM]=V]W=Z?:7%S;G,$TL*N\1_V6(R/PHM=(TVR
ME$MIIUI!(-P#Q0JA&XY;D#N0"?4BN5^&WC"[\9Z3+J%W<Z47.UA:66XR6P)8
M 2DDY)"@C '>M7Q-XFDT6>PTZPL#J&KZ@S+;6PD$:[5&7=WP=JJ".Q)R * -
M=M,L'M9[5K&V-O.S/-$8EV2,3DEAC!)/4FHM1T32=7:)M2TNRO6B.8S<VZ2%
M/IN!Q7.+XIUW1M4L+7Q3I-G!;7\PMX+VPN6EC25ONI(&52-W0$9&:V[OQ3H-
MCJT>E7>L64-_(0%MWF <D]!CL3V]: +=_I&F:K;);:CIUI>0(0R17$"R*I'0
M@,"!0NDZ<B;%T^U5?-6; A4#S% "MT^\   >HP*R-+\;Z)JWB74M"MKR$W=B
M0"/,'[PXRVT?[/0^]6]-\5^']8O7LM-UFRNKE028HI@Q('4CU ]10!I-9VKW
M#7#VT+3-'Y32% 6*9SM)Z[<]NE9S>%?#KV263:!I;6B.9%@-G&45CU8+C /'
M6L/PU\0-,U&RMH]6U+3[75+BYGA2V$FTL%F>-."2<D*/J>E;U[XFT/3M3BTV
M\U:S@O9<;())0&.>!QVSV]: -....&)(HD5(T 5448"@= !V%<RO@ZTNO$^N
M:CJUI87]I?BV\F&>$2>6T2LI)## ^]QBM2\\2:)87HL[O5+2&Z,D<0A>4!R\
MF=@QUR<''TK39@JECT SQ0!2N]&TJ_%N+S3+.Y%L<P":!7\H^JY'R]!T]*Q/
M$GAR]U*PGTK1O[.TZRU(N-3G$)\YPV Q0 8+,N06;I[T>&/%ESX@US5["XTB
M73DLXX)8A.X\V1)=^"RC[A^3IDGGG!XKJ: *3:/IKZ1'I,MC;S:>D:Q"VFC#
MIM4 *"IX.,"HQH&C#;C2; ;8EA'^C)Q&&#!.GW0P! Z9&:I^(-6U:SN;&QT7
M2A>7=V7)FG=H[>W50"2[A2<G( 4#)Y]*PU\?7,.C7WVO2E&N6FHII@LX9\QS
M3OM*%7(&%(;)R,@ \4 =98Z-I>F3336&FV=I+.<S/! L;2'U8@<_C1_8VEC3
M6TT:;9_8&SFU\A?*.3D_)C'7GI7/6?BK4[6_O],U[2XTO[>Q-_"NFR-.MS$#
MAE4%0V\-@8QSN%06?BO7X-5T>'7]$M;.UUAC';F"Z:22"387"2J4 R0IY4G!
M% '6V5A9Z;:K:V%I!:VZ?=B@C"(OT XK&UWPY_;7B'0[V46\EG8_:!<03+N\
MT21[ ,8P>>N:P[_QKK^GVEQKD_AZ*'P_;W/DOYT[)=F/S-GFB,I@#/(4G)'/
M>N]H I0:-I=KIK:;;Z;9Q6# AK6.!5B(/7*@8Y^E,M=!T>RB\JTTFPMX]C1[
M(K9$&QL;EP!T.!D=\5/?ZA9Z5927M_=16UK$,O+,X55[=3[U3MO$NB7FE_VG
M;ZK:26/F"(SK*-H<D*%)[') P?44 6I]+T^YTX:=/8VLMB%""VDA5HPHZ#:1
MC J+^PM(_LK^R_[*L?[._P"?3[.GE=<_<QCK[5%I?B70];GGATO5;2\E@YE6
M&4,5'KQV]^E86H^/]-:\TJVT/4=/OI+C5(K.Y5)-Y1&#Y88/JH&>10!T<>B:
M3#;26T6EV2021"%XEMT"M&,X0C&"O)XZ<FHU\.:&D,<*:-IRQ1(\<:"U0*B-
M]Y0,< ]QWK3K(L/%.@ZIJ,NGV&L65S>19WPQ3!F&.#P.N.^.E &BUI;/)!(]
MO$SVY)A8H"8\C!VGMQQQVJ*UTK3K*ZN+JTL+6"XN3NGEBA5'E/JQ RW4]:HV
M_BSP]=ZL=*M]:L9;\,5\A)E+%AU ]2.X'(IMWXQ\-V%QY%WKEA!+YQ@*/.H(
M<8RI],9'7U% &C?Z;8ZK;?9M1LK:\@W!O*N(ED7(Z'# C-07?A_1;^6"6\TB
MPN9+<!87FMD<Q@= I(X_"F6?B31-0U6?2[/5;2>^@!,EO'*"ZX.#Q['@^E5H
MO&GAF:[AM(]>T]IYUWQH+A<L,9]?09H W:Y:/P;:7'B37=0U>SL+^VOWMW@B
MGA$AC,<>PDAA@'/I6KI7B31=;CN)-+U2TNTMSB8PRAO+]SZ#@\^U,T[Q3H.K
M1W+Z?J]G<K:KOG,4H;8O]X^W!YZ<4 :!L[4SPSFVA,T"E(I/+&Z-3C(4]@<#
MIZ5!=:)I-]>PWMWIEE<7</\ JIY;=7DC[_*Q&1^%5+7Q;X>OM333;76K&:]D
M3>D,<REF&-W'KQSCTIQ\4Z"-;&C'6+(:D3M^S><-^[KC'KCMUH OW-C:7IA-
MU:P3F&02Q&6,-Y;CHRYZ$>HI9K*UN9X)I[:&66W8M"[QAFC)X)4GH?I61:Z\
MD5UKCZAJNE?8["11^Z8A[92,GSB3@'TQCBK-CXFT/4]3GTVQU:SN+V $R012
MAF7!P>/8\'TH EGT+2+G44U&?2K&6^CQLN9+=&E7'3#$9'YTZ\T;2]1N8+F]
MTVSN;B YAEG@5VC[_*2,C\*I1>,?#<]W):Q:YI[W$<BQ-&LZD[RP4#KR=Q ^
MIQ6W0!FW/A[1;VTBM+O1]/GMHF+1PRVR,B$G)(4C )-:$<<<,211(J1H JHH
MP% Z #L*R['Q1H.IZE+IUCJ]G<7D6=\,4H9A@X/'?!ZXZ46/B?0M3U*73K'5
M[.XO8L[X(I@S#!P>.^#U]* +E_IMAJML;;4;*VO("<^5<1+(N?HP(IEOI&F6
MFGOI]MIUI#9."KVT4"K&P(P05 P015J::.WA>::1(XHU+.[L J@=22>@K'L?
M&'AS4H;J6RUJQG2UC,LY28'RT'5S_L^_2@#4:SM7-N6MH2;<Y@S&/W1QC*^G
M!(X[53_X1O0@+@?V+IW^DN))_P#14_>L#D,W'S$'G)KE/ GCV7QEK.IJ+K25
MM()94M[2(LURR(R@2L<XVG/8=QS6]XG\8Z3X2^P?VG<1QF]N%A0,X7 S\SG/
M\*Y&?J* -<Z=8FUGM396YMYV9IHO*79(6.6+#&"2>N>M<WK^@:U=:U'?::-"
MG1(@D*ZE:;GM'!/SQNHR<Y'RG'3@U%'\0--M=?UJVU;4;"TL;4VWV29WVF42
M1;R>3SC(Z#@'FMW4O$VAZ/:6]WJ&JVEO;W(S!(\HQ*,9ROJ,$'(H J:5X0TR
MR\)6'AZ^MK?4K:TC /VJ!75WZEMIR!DDGVS6Y!!#:P)!;Q)%#&H5(XU"JH]
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M!Z GBKL=_:2SW4$=S$TMI@7"!AF+*[AN';(YH <;*T,D\AM8=]PH29O+&95
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MJ&JV=LIA\\&24#,>0-P]1EE'XBM1'61%=""K#(([B@#&\,_\>5[_ -A*[_\
M1SUM5B^&?^/*]_["5W_Z.>MJ@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *Q1_R.[?]@T?^C#6U6*/^1W;_ +!H_P#1AH VJ*** "BBB@ HHHH ****
M "BBB@ HHHH **** "L76/\ D/>'O^OJ7_T1)6U6+K'_ "'O#W_7U+_Z(DH
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M$D#D\ 5KWVCZ9J=JEK?Z=:75O&04BG@5U7'3 (P*M111P1)%$BQQH JH@P%
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MN\"F-F)R25QC.>?K0!Y7);Q6%_H]U>:Q8W]C+XI:6ZDMH3%!#.;<JHP6;^,
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MD@CDR_EC:&7!QO"\]37H/@>T-O\ VW,=7L]1>XU R3&R@,444OEH&4 LV2<
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MMG;Y\^=9AMBP,_,>W'K6=J/C_P .V7A>]U^'4K:[M;8%<0RC+28R(_9CVS7
M^(K_ %">WO[*^;1FNK6]TR6[U6UA)AE@,K!//3=GY67)7=C#=J=XKLYSX?\
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MRRN([BVE&Z.6,Y5AZ@]ZXJZ\:^(+&T&N7GAV*WT'[2L#++.RWB(T@C$IC*8
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MY7O_ &$KO_T<];58OAG_ (\KW_L)7?\ Z.>MJ@ HHHH **** "BBB@ HHHH
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M.#Q3DMH([B2X2&-9Y0HDD" ,X&< GJ<9./K4M% $4%K;VMNMO;P10P+D".-
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q?#/
M_'E>_P#82N__ $<];58OAG_CRO?^PE=_^CGK:H **** "BBB@ HHHH ****
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M TF36;);_>(_(,PW;ST7_>]NM<IJ/Q&!^)$/AC3[_1X8(XU:YFNF9F>4R;#
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M]J]IXJ:"[N;,XMYI# W[P$^NX Y)Y!&:M>(+^UOO'WB7[)/',(?!\T<C1MN
M;S&.,CO@C\Z .]L_%GA[4=3&FV>LV4]Z5W"&.8%B,9X]>.:C_P"$S\,_;(+/
M^W;#[1.Q2./SURS!BN/KN!'U%<"L^F3^$_AI;Z7) UVM]9E(XB-ZA8SY^0.1
MQNW>_6LI+C2?^%(>(K97@^WO?72^4"/,:X-P?*P.I/W,?2@#UG5?%6@:%<QV
M^J:O9VDTB[ECFE"G;G&2.P]SQ4M]X@T?3!";[4[2W$T;RQ&64*'10"S ]P 0
M?QKCM"NK"Q\3^-QK\UO'.SPO(;A@ ]MY"@8SU7(<?7-<EHUB;B]^$%MJ4)<?
M9[YQ'*,_*(PT60?0!#^ H ]%MOB+X;O?$MMHEKJ5O++<6XFCD60;6)("H/\
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M HHHH *Q1_R.[?\ 8-'_ *,-;58H_P"1W;_L&C_T8: -JBBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN4E>,'L#UYQ5:6SM;ZZ%QJ_BS29K1=#NHVCTNQ:-A9NJAF)$CX5<*0,>N.]
M'?:1XET37WF32=4M;UH<&189 Q4'H?I[]*HR>-]%B\:+X7>[B6^,(DYD ^<D
M!8\?WB#N^E8OA:]N(/%$&D7MQI.K,-,9[35+*,)*(5=!LD ) !W*000#M/%1
MZC,8OC#=)',D=Q-X8V6^Y@I:3SVP!GJ<XH Z>'Q=X>N-7.E0ZS927X8IY"S
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M%TJPNY;NSTRRMKF;_6S0P*COW^9@,G\:;!H6D6W^HTJQB_?"?]W;HO[T9P_
M^]R>>O-:%% %._TC3=5$0U'3[2\$3;H_M$*R;#ZC<#@T2Z5ITUI+:2Z?:R6T
MS%Y87A4H[$Y)9<8))YR:N44 43HNE-I@TQM,LCIXZ6I@7RASG[F,=>>E))H6
MD2SVT\FE6+S6BA;>1K="T('0(<?*![5?HH K1:;8PFW,5E;QFV4K 5B4>4IZ
MA>/E!P,XJ.[T;2]0NH;F]TVSN;B#_52S0*[Q]_E)&1^%7:*  @$$$9!K.L_#
M^BZ==-=6.CZ?:W+9W306R(YSUR0,UHT4 4GT;2Y-274GTVS:_486Z:!3*![/
MC/ZU8AM;>W>5X8(HVF??*R( 7;&,MCJ< <FI:* ($LK2.\EO([:%+J4!9)EC
M =P.@+=2!1'96D,T\T5K"DMQ@S.L8#2X&!N/?CUJ>B@"E8:/IFE"4:=IUI9B
M4YD%O L>\^IV@9I++1=*TTS?8-,L[7SSF7R(%3S/][ Y_&KU% %+3]&TO2?,
M_LW3;.S\TYD^S0+'O/OM S3[C3-/O+J"ZN;&VGN+<YAFEB5GB/JI(R/PJU10
M!0CT328=2?4HM+LDOWSNNEMT$K9ZY?&?UJU<VMO>0F&Z@BGB)!*2H&4D'(.#
MZ$ U+10!$]M;R7,5P\$33Q B.5D!9 >H!ZC.!GZ4B6EM')/)';PJ]P<S,J &
M0XQ\Q[\<<U-10!1T_1M+TDR'3=-L[,RG,GV:!8]Y]]H&:7^Q],^R"T_LZS^S
M!_,$/D+L#YSNVXQG/.:NT4 1);01W$MPD,:S2A1)(J@,X&<9/4XR<?6JDVA:
M/<VT%M/I5C+!;MNAB>W1EC/JH(P#]*T** ((+.UM9)I+>VAA>=]\K1QA3(WJ
MQ'4^YI8+.VMI)I(+>&)YVWRM&@4R-ZL1U/N:FHH HV6B:3IMQ+<6&F65K-+_
M *R2"W1&?ZD#)JS;VMO9PB&U@B@B!)"1(%4$G).!ZDDU+10!4N-*TZ\NX;NY
ML+6>Y@_U4TL*L\?^ZQ&1^%.&GV0MH;86=OY$!5HHO*7;&5^Z5&, CMCI5FB@
M"E)HVERZDFI2:;9O?H,)=- IE7Z/C(_.KM%% &+X9_X\KW_L)7?_ *.>MJL7
MPS_QY7O_ &$KO_T<];5 !1110 4444 %%%% !1110 4444 %%%% !1110 5B
MC_D=V_[!H_\ 1AK:K%'_ ".[?]@T?^C#0!M4444 %%%% !1110 4444 %%%%
M !1110 4444 %8NL?\A[P]_U]2_^B)*VJQ=8_P"0]X>_Z^I?_1$E &U1110
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ML3^&*]1N;&TO'A>ZM8)W@<21-+&&,;#HRYZ'W%.NK2VO[9[:\MXKBW?&^*9
MZM@Y&0>#R!0!P=I:P3_&:*6:)9&A\,Q&,L,[29V&1[XR,^Y]:YN\N=)B^&?C
M^UU*2#[>VHWY>)R/,:0L3"0.IXV$'T'M7L"VELMU]J6WB%QY8B\T(-^P'(7/
M7&><5Q&O^#=;UB\U2)9]%^S:BIB-])9?Z9;PLNUXU9>&&,X).1GG- &78?\
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M1110 4444 %8NL?\A[P]_P!?4O\ Z(DK:K%UC_D/>'O^OJ7_ -$24 ;5%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MCTC_ ,#8_P#XJC_A,O"__0QZ1_X&Q_\ Q5<U10!TO_"9>%_^ACTC_P #8_\
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M^ACTC_P-C_\ BJ/^$R\+_P#0QZ1_X&Q__%5R$VIV%N',]];1"-@CEY57:QZ
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M_P#BJYJB@#I?^$R\+_\ 0QZ1_P"!L?\ \51_PF7A?_H8](_\#8__ (JN:HH
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MTC_P-C_^*KFJ* .E_P"$R\+_ /0QZ1_X&Q__ !5'_"9>%_\ H8](_P# V/\
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MTO\ PF7A?_H8](_\#8__ (JC_A,O"_\ T,>D?^!L?_Q5<U10!TO_  F7A?\
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M\KW_ +"5W_Z.>MJL7PS_ ,>5[_V$KO\ ]'/6U0 4444 %%%% !1110 4444
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M@!#]T_2L[P]_R+.E?]></_H K1/W3]*SO#W_ "+.E?\ 7G#_ .@"@#2HHHH
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MX\KW_L)7?_HYZVJQ?#/_ !Y7O_82N_\ T<];5 !1110 4444 %%%% !1110
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MB8U)-=B_W&^E8_A'_D2]"_[!UO\ ^BUH C_X0SPY_P! >U_[XH_X0SPY_P!
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MK?7/B'^SAF$"/8TA7D#\"2.: .WN?"OA6SM9KFYTNRB@A0R22.N%10,DD^@
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MZXP .@H LQ^&O"4U[/9QZ=8M<P*K2Q ?,@;.TD=LX./I4_\ PAGAS_H#VO\
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M]U&?*NA.V^0':<K\^",9QC'-=*_B*S7Q7%X<5)I+Y[4W;E%!2*,-M!8YX)/
M&#5+5_'&CZ)XET_0;LS_ &N]V[71 8XMS%4WG/&Y@0.#0!AWO@'4K_1-4>;4
M;4Z[J%_!?-*(F$"&$KY<8&=VT*F,]<G-;VDZ'?V_B>[UR_GMFENK&"V>.!6"
MJ\;.21GL=XQ]*Z*B@#$\):'+X<\.PZ9-,DSQRS2%T! .^5W'7T#8_"MNBB@
MHHHH **** *>K?\ (&OO^O>3_P!!--T3_D Z=_UZQ?\ H(IVK?\ (&OO^O>3
M_P!!--T3_D Z=_UZQ?\ H(H I^&?^/*]_P"PE=_^CGK:K%\,_P#'E>_]A*[_
M /1SUM4 %%%% !1110 4444 %%%% !1110 4444 %%%% !6*/^1W;_L&C_T8
M:VJQ1_R.[?\ 8-'_ *,- &U1110 4444 %%%% !1110 4444 %%%% !1110
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M&"./7K7H=<[IWAF;2_%FJ:O!J;?9-299)K)H0<2*@0,'SD# Z8KHJ "BBB@
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M7%OI#2Q$=F6'(_45!?\ P]\/:E<WTMQ#=>7?DM=6R7<B02N1C>8PVW=TYQU
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M=HK &53UW@L,[@&PW>MA?A[X?,BRSQW=U-Y4D$DMS>2R/-&X 9');YEX& >
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MX7>2K2$8+ '@$X&<=:T: "BBB@ HHHH **** *>K?\@:^_Z]Y/\ T$TW1/\
MD Z=_P!>L7_H(IVK?\@:^_Z]Y/\ T$TW1/\ D Z=_P!>L7_H(H I^&?^/*]_
M["5W_P"CGK:K%\,_\>5[_P!A*[_]'/6U0 4444 %%%% !1110 4444 %%%%
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M,C*P9"I&XG!QD>M=910!2TG2[71=*M].LU86\"[5WMN8]R2>Y)))/O5VBB@
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M>@@$8(R*** $5510JJ%4= !@4M%% !2;%W[]HW8QG'.*6B@ HHHH 0(H<N%
M8\$XY-!52P8J-PZ''(I:* "BBB@ HHHH 0HK$%E!*\@D=*6BB@ HHHH 3:/0
M=<].]+@9HHH 1D5UVNH93V(S2T44 %-9%8@LH.#D9'0TZB@ I" <9 ..E+10
M   =!1110 C*KJ5=0RGJ",BC (QCCTI:* $50JA5  '0 =*"BL064$CH2.E+
M10 THK)L905Z8(XIP&!@444 %(J*N=J@9.3@=32T4 %%%% #=B[]^T;L8W8Y
MQ3J** "BBB@!BQ1J[.L:AVZL!R:5D1U*NJL#P01G-.HH 0 *    .@%+110
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M34L,$-NA2&)(U+%B$4 $GDGCN: )**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH 1_N-]*Q_"/\ R)>A?]@ZW_\ 1:UL/]QOI6/X1_Y$O0O^
MP=;_ /HM: -FBBB@ HHHH \]N_!NH:GXQ\8S3((M/UC24LH+C>#\^TJ?E!SQ
MGO2)IWB37$\-Z9J6B_8(M)NH;JZNS<QNDS0J=HB526PS8/S!<#UKT,D 9)P*
M.M 'GVBVGBWPY9CPY8:3"\"7SO%JLLZF);=Y3(=T>0Y<!BN ,9P<XK!U'P=K
M,\.I(/"]M<ZI_:GVX:O++$9)XA.)$CC).Y&V )@[5 !YYKU^H;J\MK&W:XO+
MB&WA4@&29PBC)P.3QUH X.+2-=CUGQFG]D.;;7(!);W'GQX1Q;A/+9=V<[AC
M(R/>JFC^&M>\.Z;X/U&+3?M5YI=A+97MBDZ*Y5]I!1B=I(9!QGD&O3:* /,[
MCPMKNI"^U:>Q6"\U#6["Z-GYRL8;>W9!EF!VEL!F(!/8#-;NKZ3JY\:3ZQ86
M=O<1C0Y+6-;AP$DF,H8(PZX*@\XQ77T4 >>^'M(U/2-2U74]*\+MI%NUB0FE
M-=Q[+FZ!R&4(S)&,?+GC.>G%=];O+);1//$(IF0%XPV[8V.1GO@]ZDJ*VN;>
M\MUN+6>.>%_NR1.&5N<<$<4 2T444 %%%% !1110 45#->6UM+#%/<0Q23MM
MB1W"F0^B@]3]*FH **** "BBHI+B"&2*.6:.-YFVQJS %SC. .YP"?PH EHH
MHH **A>\MH[J*U>XA6YE!:.%G =P.I ZG%34 %%%0B\MC>&S%Q";H)YA@WC>
M$SC=MZXSQF@":BHIKB"V"&>:.(.XC0NP7<QZ*,]2?2I: "BBB@ HHJ&XO+:T
M,0N;B&$S2".(2.%WN>BKGJ3Z"@":BBB@ HJ*:X@M_+\^:.+S'$:;V"[F/11G
MJ3Z5+0 4444 %%%% !1110 45#->6UO-##-<0QRSDK$CN TA'4*#U_"IJ "B
MBD) &20/K0 M%%% !14-S>6UF(S=7$, D<1H97"[G/11GJ3Z5*S!5+,0 !DD
M]J %HJ.">&Y@2>"5)89%#))&P96!Z$$=14E !1110 4444 %%%% %/5O^0-?
M?]>\G_H)INB?\@'3O^O6+_T$4[5O^0-??]>\G_H)INB?\@'3O^O6+_T$4 4_
M#/\ QY7O_82N_P#T<];58OAG_CRO?^PE=_\ HYZVJ "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ K%'_ ".[?]@T?^C#6U6*/^1W;_L&C_T8: -JBBB@
M HHHH **** "BBB@ HHHH **** "BBB@ K%UC_D/>'O^OJ7_ -$25M5BZQ_R
M'O#W_7U+_P"B)* #Q;_R+5U_O1_^C%K:K%\6_P#(M77^]'_Z,6MJ@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** $?[C?2L?PC_R)>A?]@ZW_P#1:UL/]QOI6/X1_P"1+T+_ +!UO_Z+
M6@#E?'_Q<TKP%JMMILUC<7MU+&)G6)@HC0D@')ZDX/'ZUVNC:M:Z[HUGJMDS
M-;7<2RQEA@X(Z$>HZ5S'C3X6^'O'5_;7VI_:H;J!/+\RVD"ETR2%;(/<GI@\
MUU>FZ=:Z1IEMIUC$(K6VC6*)!SM4# ^M %JBBB@#@OB!,FLZIHO@L2!8]0E^
MU:A\V,6D1!*D]M[;5_.H_ VM+HOAO6M&U"8RR>%F="X.3):A2\+_ /?''_ :
MM6_@"VU3Q+K6M>*K+3]1DN95CL8G3S5M[=!A1\P&&8DDXR/>H;GX<VUKXBCN
M="MK*PTN\L9]/U6VB'E^8C#Y'0 8+@D]<<4 6='U#QM?P:??RQ:4UGJ5N9-D
M<;![ LFZ,L2_[T9P& "GGCBN*A\1:U8_ ZYUW4QINK%KMO*AN[9G7F[96WY<
M[N>5QC: !SBNW\/Z9XQLSI.G7USIL6F:;'Y<DULS/+?*J;4!5EQ'V)P2<C X
MKG+CX?\ B.Y^&%_X-9M,4K<B2SN?/?\ >(;@RMO&SY2 <#&[/M0!T][K&NZE
MXKO=#T&6PM5TZWBFN;B[@:;<\F[8BJKK@84DMD]1Q61!XYUS4U\.VUC:V,-_
MJ$]Y:78F#/'!)!D,RX()'RDX[Y R.M:]]H^NZ;XKO-<T"*PNEU&WBAN;>\G:
M':\>[8ZLJ-D88@K@=!S5/2/ ][IEWX:G>Z@FDL)KVYOW&5\R6X!)V#'0,<<D
M<"@#4\*:SJ=[?:WI6L&UDO-*N4B,]K&T:2H\:NIVDD@_-@\FL>SNM?D^+NL6
M_P!MMGL+>P@<6WE,"58R%0#OP'SU;!R,# Q70:-HESI_B;Q'J4SQ&'4YH)(0
MA)90D*H=W''(/3/%8^I^&-9E\8:I?63V@L-6TQ;*:1Y66:W90^&50I#??'<?
MX@%/0O&NH3^*=.TJ_P!3T"]>_27S+737W26+HN[:S;V#C ()PO(K%^''B.ZE
M\(>'_#N@+;S:@J/-?33 M'9PF9_O $$NW\*Y]SQUV-,\+>)H+SPO/+;Z+;PZ
M)F!K>WF?$J-&8VEW>6,,."$QSDY;TKZ)\.+_ ,.Z%HEQI;V$'B/3W<7#J6$-
M[$\A+1R,%W'C!!(."M #-5^)<UG<ZM>1ZIH45GI=XULVF3R?Z7<JA"R.IWC:
M<[MJ[3G;UYK3N=?\4W^M>)K/2&TJ"#1C&8Y+F%Y#-N@639@.,<D_-Z$<=32K
MX8UW3M0U"'3K71);*^OFO!=W8+2V^\AI%V;</SNVG<O7GI6M8^'[NUU?Q5=N
M\)CU9XVMPI.5"P+&=W''(/3/% %[0]5FU_PC8:K L=O<7MDDRAP76-V3/(R"
M0"?49]J\^\+^)_$5G\/[&ZFGM+Z_U;57LK'S(W C=IY=S2'<2R@*2 ,8  YZ
MUZ!X4TJ?0O"6D:5=-&T]G:1P2-&25+*H!P2 <?A7&V'@?Q!;>&(-)+Z<L^D:
MG_:&EW E=A.3+(Y65=HV K(5X+=<]N0#H-'UC6+?Q;+X<UR2SN96LOMMM=6D
M+0AE#['5D9FP02I!!Y!IVN:QJS^);3P[H;V<%U):O>SW-W$TJQQJP0!45ERQ
M8^O !ZTW1]&UB?Q9+XDUQ+.WF6R^Q6UK:3-*$0OO=F=E7))"\ < 4NNZ-JZ>
M)K/Q'H2V<UU':O93VUW*T:R1LP<%756PP8>G()Z4 <IXFFU6?Q!\/&UJUAMK
M]=6E2187W1OA<!UY) 88.#R,X-:L_B;Q/?6^OZMH_P#9B:=H\\T"VUQ"[279
MA'[P[PX"<@A?E/3FGWGA/Q%J=YX4OM1U"SGNM-OY;N[V@HH5ONQQ +R%&!EL
M$XR:9/X9\36,&O:1HYTUM.UB>:=;FXE=9;0S#]X-@4A^22OS#KS0!%/XWU/4
M=6AM](N](L?-L+>]M+?4U;??^:"VU&#*%Q@#(#')Z8J'7?B%=VFH:T+;4M L
MTT?"M8WTO[^]<1AW5#O7:/FVJ=K98&K>N>$]8N-%_P"$=M++1K_2!91VMM)?
M,R2V95-F\ (V\\!A@J0?SH/A37=)O=0&DQ:1>Q:@8Y#<ZCN\RWE$:QLVT*?,
M!V!L;EY)H ZF^OY[GPI+J.ERQQRR6GVB!YD+J,KN&0",\>]>7V4VOS>&OAO<
M27-M=WTUUNMWD5P%4VKC,A+$N1R21C/3CK7KMQ:^?IDMGN"^9"8MP7 &1C./
MZ5PVA^$?$%OI_A&TU :<G]@7)RT$[OYT0A>,$ H,-EAQZ=^U $5UXYU?0HM=
ML=6?3);^QGM(K:Z"M! WVCA6D!8[0F&)^;D#M6MX3\5R:IK=]HUQJFDZI)!!
M'<Q7FEG",K%E*,N]]K*0._(8=*JZUX(OM3U77KZ.:T5[I[">Q$N6 EMBQ(D&
M/NMG'&>":W/#UIJ\=Q<W&J66E6*.JI#;V!+D8SN9I"JYSQ@8XQU.: ,W5]8:
MW^*7AS2A964BW5K<N;F2+,T6T=$;/ /?UK!;QIXJ'A6?Q24TI;"SO)();7R7
M,D\:W!C+*^_"$#M@Y()[X'2ZIX:O;WXC:#XACD@%II]M<12HS'>2XP-HQC'K
MDBLV3P5J3_#&_P##0FM?MMQ<32H^]O+ >Y,HR=N<[3Z=?SH FGUSQ1JNI:U_
MPCD>FFVTB;[-Y-TC%[R8(KNH<,!&,, "0>>O%1-XE-K\2K^UN=-M(DMO#POY
M)Q&#<C#\QEP<%1Z>M/N-"\4Z5J>M_P#".2Z:+;6)A<>==.PDLYBBH[!0I$@P
MH(!(YZ\4]O!EY<>.[W5[NYBEL;K0?[+<YQ*SE\LQ4#: 1GH>O:@#FM5U#Q+J
MFC^$-5U3^SOL>HZQ83I;V\3K);!G#("Y8A^.#PN#ZBK5Y\3)8+B]OUU304L;
M._-H=+DD_P!,EC63RWD!W\'.6"[#E1UYJ>/PIXOGTOPYH]Y)I*6FAWEK+Y\<
MTA>ZCA( RI3"';SC)R0.0*O6WAC7-+O;FSL;71)-.N+][M;RY!::%)'WO'Y>
MW#')8 [AP1QQ0!%=>(_%=U<>*?[,.E00:',0AN(7D-P!"LFPX<;>I^;GJ.."
M34L=:UW6?B1H<UO=VT.GW7A];_[*\3MA'>+<N0X!?/1L8 R,'.:Z&U\-7L"^
M+PTD!_MB9I+?#'Y08$C^;CCE3TSQ678>$]=TC6?#5]:FPF%GHB:1>K)*Z[<%
M"9(_E.[[IP#M[=.P!)X-\4:SXCN(KB2[T:6W<.+JPA#)=:>PSM5\L=QR,'Y5
MYY'%6?'FL-I-UX51;*RNOMFMP6Q-U%O,0;/SQ\_*XQP:KV7AS7KKQ3I6JZO:
MZ-!-IWF>9?V3MYUZ&C*!64H-J\AB"S<J,>M7_&?AJ]\17/AN2SD@0:9J\-]-
MYK$;HTSD+@'+<]\#WH RKKQ%XKN[WQ1'I9TJ"'0Y<(UQ"\AG'DK)L.'&WJ?F
MYZCC@D]5IFHSZWX4L]3M1';W%[9)/$)%+I&SH&&0""0"?49]JS+3PY>02^+F
M:2 C6)B]OAC\H\A8_FXXY4],\5J>&M-FT?PMI.F7#(T]G9Q02-&25+*@4XR!
MQD>E 'DME>:_>?#KPA?W5Q;WMS/K\36P964AM\P_>,6.1GT P!CFNLN_&FL>
M&7\0VVN_8+R73[&*]MI;:-H%?S':,(X9FQAP.<]#4&C^"O$%IX>T/1;HZ<(M
M&U:.[CGCF<F:(-(QRI3Y6^=<#)'7D5J>(O!-QK^L:U.;B&*WOM)ALXFY9DFC
ME>0,5Q@KDKW[&@!GAGQ?/>^)5T6[UC0]6:>T:YCGTEN(F5E#1N-[_P!\$-QG
M!XJ;Q5XEO].\16.D6E_I6EBXMWF6ZU.-F29PP B7#J ><GDG!&!5[0++7$U!
MI]5L-%LH4A\M4L"TC229&7+%5VK@<+SUY/%)XFL=:O9!%::?H^J:;+%LEM-1
M8IM?)PX(1]PP<$8'3@\T 8>K>--1@U:+2&U/P_HEY#81W5T^HR;T>5R0(H_G
M3(&TDMS@%>*6R\::KXH&BVF@BRM+J\T]K^ZFN4:9(55Q'M0*R[B7W<Y'"^]1
M6G@K6?#YL9].BTO591ID-C<I?NT8#1%BDB-M<X^<@J<<!>:T+CP]K]CJ6EZY
MIO\ 9MSJ4-@UC>V\A:WAE4L'W(55MI# \$'()Z4 36WB'78M<\.Z5JUC:V]Q
M?1WANA&Q<$P[=C1G/"L&S@Y(SCM65K?CO5M.AUQ[:TM9GL-9MK"&-@P\Q)%C
M)R<_>RYP>@XX-6KGP_XK\_0-9-SI^H:QI[W/GPR,8(6CFQ\B,J$_)M4 D9.#
MFJ,O@77KNUU,W5SIYN;W6[74OD9PBI&(]R<KG(V$#UX)QG  +.K:KJVF>(/!
MECJ]OI%Y>7UW.DDZ6S#R %R/*+,2I[$]_:L33M?\7:;I7C/66N;*_33=7D$E
MO]GD#%$6+S/+/F$*HCR0N#SDY.:[#Q-X:O=9\4^%M3MI(%@TFYEEG61B&8,@
M4;< @G/J14&AZ-?:!J?B0:D=.;0M2O);X3M,0X,BHIC=2NW&%/.[TX] "W>>
M)9I?$GA[2](\B:+4(I+VYE8$[+95&UEP1RS,H!.>_%8/QJ_Y)\?^OZV_]&"H
MOA)H[16=]JLEP;FW+G3]+F8<FQA=MA'L2Q^H45O?$/PU>^+/"QTRPD@CG^TP
MR[IV(7",">@//X4 1:CK/B*Y\;W/AW2&T^WCBT^*\-U<PO*5+.ZE=H9<YVC'
M(Q@]<BLRR\:ZUK&F:!:6D5C;ZUJ<MU'-+(C/!"+=BLCA0P)R=N!GOR>*Z6#1
M;F+QY>ZXSQ?99].AM54$[PZ22,21C&,.._K7,VO@K6])L]'O+&2QEU73+N]D
M\F61EBFAN)&8KO"DJP&PYP1D&@!OB77=<TK2-%&MZ5I4]W)XA@LED:/?$\;9
MQ/&I8F-^W)."#V-7+[6_$.K:AXCATC^STT_2!Y#QSQ.TEU(8@[@,& C #  X
M;FH=:\*>)_$.E:7_ &C>V)O+?7H=2:)21'! F1Y2-MR[<YRP&23T %6+CP]X
MDL=8U\:,VG-8:VPE:6XE=9+23RQ&Q"A2'!"@@97F@#F= \7S6/AOPSH=KJ^B
MZ2R:'!=RW.JG*ONRJ1HN]/[K$G)P,<<UM6GCC6M>E\.0:/%I\3ZM9W,LTLP:
M5('A=48KM8;UR6 &1G(.>#EFG^"M:T&#2+BSMM(U"ZATF+3KN"ZD9$W1DE9$
M?8Q_B8$%1D8K<M?#FI)XBT#4[J6R)L;"X@N1 AC!DD:,_(N/N_*>ISTH Y#7
M_$GB:[\+2Q?:K*VO['Q%#IEQ-#$X68;XF1E&_*@[AN7)R,C(S7JMJMPMI"MW
M)')<! )7B0HC-CD@$D@9[9/UK@=4\#ZO<:3KD=M+9FZN=>CU:U61V"%4$7RN
M0N03Y;= >U=Y9M<O9PM>QQ17)4&5(G+HK=P&(!(]\"@">BBB@ HHHH IZM_R
M!K[_ *]Y/_033=$_Y .G?]>L7_H(IVK?\@:^_P"O>3_T$TW1/^0#IW_7K%_Z
M"* *?AG_ (\KW_L)7?\ Z.>MJL7PS_QY7O\ V$KO_P!'/6U0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %8H_Y'=O\ L&C_ -&&MJL4?\CNW_8-'_HP
MT ;5%%% !1110 4444 %%%% !1110 4444 %%%% !6+K'_(>\/?]?4O_ *(D
MK:K%UC_D/>'O^OJ7_P!$24 'BW_D6KK_ 'H__1BUM5B^+?\ D6KK_>C_ /1B
MUM4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 C_<;Z5C^$?^1+T+_L'6__ *+6MA_N-]*Q_"/_ ")>
MA?\ 8.M__1:T ;-%%% !1110!S&H>.]*T[6;K2C;:I<W=J$,PL]/EG";UW+D
MH".16CH7B72_$<4[Z=,Y>W?RYX9HFBEA;&0&1@"/RKB;:[U^U^)_C/\ L32;
M2_!6Q\W[1>F J?).,?(V<\^G2LA-2U.3P=XI\;*ZV^J:F]O8FTM&^>RV2>25
M+-C]Z/,8Y. .,<4 >QT5Y;:Z1XE5]5M-$TO5M&M;G2Y$0W^H)-B[##8R$2.R
MEE+@GCD ]:S-5NH=,\&>*8+2+7-#U2*PCE>QO+MI5'SX\Z*3<V<G@D,.@R*
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MUTZY\1^.)[/7Y;M$70K*6XLH;IXT\]FD#$F-AT((X.#P><"N:L+%-<G^'?\
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M9'(<G#?,1QCK6<^EMIF@^!M6@U74#>:CJ-@;YI+R1UNC(-YRI.!STP!QD<T
M>E:WKUAX>M8+K4I'C@FN$MQ($+!6<X4MCH,]^E:+ND4;22,%1069B<  =ZS?
M$FAV_B3PY?Z/=?ZJ[A,>['W&ZJP]P0#^%>;7/B;4-=^'%AX;WE/$>H71T.[[
MM&8^)Y#[>6,_\#% '<?\)YH \.6NNM<RK9WCF.U7R',L[9(PD8&YLX/;ISTI
M=*\<:3JFJ)I;1W]A?RJ7AM]0M'MVE4=2FX8;'H#FL-K&TT[XK>&]/\M4LK70
MYX].1N@E5T#8]_+_ $J]KOB"]T[Q#IL5]X5AEL9-0BM;746ND9D>3C>$VY7N
M.O\ .@#LJ*Y#XGSW-OX!O9+2YDMI_.M@DL9PRYGC']:PG\,VT?Q*CT1+W4_[
M,NM)>[NK<W\Q\^5)50,6W;A]_)P0#@4 >F45XK!?ZC)8Z/X?,6IZG9C5M2@>
M&"["3310.1&C2,ZDJ-V3\V2% J[=PZ[;Z/IFGW2ZII5O+XGAAM!+=AYUM7C.
M4+J[=&W@9)(&/2@#UVLV?6[:W\166BO'*;F[@EG1P!L"QE003G.?G&./6N#L
M?"UI<>-_$.@O=ZE_9$%K;7,5H+^;"RR;P6W;MW\&<$XR<XZ5BZ'%)XHNOA\-
M4O+E_-T>\^T,DS(\X5HP 74AN< G!YQSU- 'M%5[VPL]2M7M;^T@NK9\%H9X
MPZ-@Y&0>.HS7D%W?7^G->^%K4ZE>V*^(H[5(XKK$Y@:V\\P+*[ @;AC)8'!(
MS3];&OZ5X(\1+':ZEHUG]KL6TT75VLTD1:5%D4,KL=N0#@G^(CI0![%'&D,2
M11(J1H JHHP% Z #M52PU![Z6\1K"[M1;S&(-<( )@/XTP3E3ZG!]J9HVC6V
MAV'V2U>XD4N9&>XG:5W8]268D\^G2O)9]1U$^%/B.\>H7*30>(!'!)YA)B7S
MHAA?0<].E 'M5<]X;\7VGBF6Z.GV-^+.!VC6]FC58IF5MI"?,6//J!7.RZ%;
M:7\0-/TN"XU!K/5M-NOML<M]*QD=&CP^2V5;YCRN.M<3X4MAIWPNM)K">ZM;
MG5-9739KA+F3,<3W.TE03M5L#&X#//6@#WFBO-=0M%\*>*/[.TJ>[2RU#1;R
M26WDN9)1')%MVR*7)*DAB#@\\=ZPTL)[;X6>'M435-1_M35)],6>[:Z=F"EU
M "@G P#CISWS0![-17F<7ABT_P"%D7F@?:]2_L>32H[V2T-_,0TWFNF[=NW=
M!R,X)P3T%9VF7AU+P9X9TZ];6-5NI+B\5;.UN1$US'#*Z RREE(51L_BY..#
M0!ZK=WUK8^3]IF6+SY5ABW?QNW11[FHH]0>36)M/-A=HD42R"[91Y+D_PJ<Y
MW#OQ7C<]J-6TCPW!J(O!]F\6R:>D<EZ[/'#F0["ZM\Q7  ;)( X/6MZ\U6\T
M?X@>,6MIIFCT_P -K/;P/(SJ'520<$]>!SU- 'J=%>6-I_\ PC^C^$->L[^^
MEU*]O;.*]EENY)!=K/@/N1B5_BR, 8QQ69>6,D_@CQCK\FHZC_:.G:G?M8R+
M=R*+<1S$@!0=I'7J#QQT H ]FHJ.W<RVT4C=60,?Q%24 4]6_P"0-??]>\G_
M *":;HG_ " =._Z]8O\ T$4[5O\ D#7W_7O)_P"@FFZ)_P @'3O^O6+_ -!%
M %/PS_QY7O\ V$KO_P!'/6U6+X9_X\KW_L)7?_HYZVJ "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ K%'_([M_V#1_Z,-;58H_Y'=O\ L&C_ -&&@#:H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q=8_P"0]X>_Z^I?_1$E;58N
ML?\ (>\/?]?4O_HB2@ \6_\ (M77^]'_ .C%K:K%\6_\BU=?[T?_ *,6MJ@
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M:6EM=W&K6D=O=1F6"4R#;*H )*GOU'YU2;Q_X32T@NFU^Q$,[%48R=P<'/\
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MYGF#2NT;*RC.-H V@8 '>NGHH *Y@^ ]':PUJS+77E:Q>B]N?W@R) RM\O'
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M+H_M?5?^A:O/_ B#_P"+H VJ*Q?[7U7_ *%J\_\  B#_ .+H_M?5?^A:O/\
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MM?5?^A:O/_ B#_XNC^U]5_Z%J\_\"(/_ (N@#:HK%_M?5?\ H6KS_P "(/\
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M0 4444 %%%% !1110 5BC_D=V_[!H_\ 1AK:K%'_ ".[?]@T?^C#0!M4444
M%%%% !1110 4444 %%%% !1110 4444 %8NL?\A[P]_U]2_^B)*VJQ=8_P"0
M]X>_Z^I?_1$E &U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!B^&?^/*]_P"PE=_^CGK:K%\,
M_P#'E>_]A*[_ /1SUM4 %%%% !1110 4444 %%%% !1110 4444 %%%% !6*
M/^1W;_L&C_T8:VJQ1_R.[?\ 8-'_ *,- &U1110 4444 %%%% !1110 4444
M %%%% !1110 5BZQ_P A[P]_U]2_^B)*VJQ=8_Y#WA[_ *^I?_1$E &U1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!B^&?^/*]_["5W_Z.>MJL7PS_P >5[_V$KO_ -'/6U0
M4444 %%%% !1110 4444 %%%% !1110 4444 %8H_P"1W;_L&C_T8:VJQ1_R
M.[?]@T?^C#0!M4444 %%%% !1110 4444 %%%% !1110 4444 %8NL?\A[P]
M_P!?4O\ Z(DK:K%UC_D/>'O^OJ7_ -$24 ;5%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M $4+Q%_WU'_\37>T4 <%_P *^UK_ **%XB_[ZC_^)H_X5]K7_10O$7_?4?\
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M]!-<=X,_Y(EI_P#V"&_] -=VRJZ%'4,K#!!&014,-G:V]FMG#;0QVJKL6%$
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M_P"/.?\ ZYM_*JJZ#HZ:J=572K$:B>MV+=/-/;[^,U?(# @@$'@@T > :?\
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MF0.C8.>0>#R!0!X\UG?CPYX>UV22VM;G6O$']I7$EY$9(HM\<@MU<!E. /+
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MYIG( ,7V<;^O;/7\,]JW?#/@FQTJQA.I6.GW6HP7-Q-%=>2&>,/,\BA689!
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M,-;58H_Y'=O^P:/_ $8: -JBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0_94VF3&-V,=<<?2K!\-:$SR.=&T\M(R,Y-LGS%%*J3QSA20/0$BKUS=6]E
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MB@ K%'_([M_V#1_Z,-;58H_Y'=O^P:/_ $8: -JBBB@ HHHH **** "BBB@
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M9@"Q)))) [>E=/0!B^&?^/*]_P"PE=_^CGK:K%\,_P#'E>_]A*[_ /1SUM4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN>JGBN2\ LLOBJP34VN6TZ.VE_X10W(P'AWD,Q[F0)L"Y_Y9\^M.U'3['0/
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M+C1XI+BSM!+9Z86!1A+\LC ]"0<9[[!Z4 >JQZYI$SW21:I9.UH";E5N$)A
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MG(8#USSGUJ_-#'<0203(KQ2*4=&&0RD8(-/HH CM[>&TMHK:WC6*&%!'&BC
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MPE=_^CGK:K%\,_\ 'E>_]A*[_P#1SUM4 %%%% !1110 4444 %%%% !1110
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M["A"N>N.?2N-\*VOAV7P-!?^($A6^_MB1IYSD3B\^TL$&5^;=]T8_N^U>G@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH Q?#/_'E>_\ 82N__1SUM5B^&?\ CRO?^PE=_P#HYZVJ "BBB@ HHHH
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M5#@G&&P,D@=*O6M]:7R,]I=07"*VUFAD#@'T..] $]%4AJ5M<6UR]A<VMS)
MIRJS A6 X#$9VU%9:I_Q(X+_ %5[.T9E!D*7(>)3GM(< T :5%86E>(TU+6]
M=L=D:0:8T(6X$F1(LD0DW>@ SZUJ1:C93VINH;RWDM@<&9)5* _4'% %FBJJ
MZE8.\Z+>VS-;_P"N E4F+_>YX_&JV@Z_I_B32X]1TV820/G'(W#!(Y /'2@#
M3HJO)?V<-U':RW<"7$GW(6D =_H,Y--N-2L+,,;F]MH I"MYLJK@GD Y/4T
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MYJ5I9$1RW,"3LI:.%Y K28]!U-5/#&LMXA\,:;K#0"!KRW28Q!MP3(SC/&:
M-:BN*?QW>RVUSJ6G^%[V]T:WDD1KN.>,/((V*NT<1.6 *GT)QTKJFU2QCAMI
M9KN&!;D PB9Q&7R,@ '!SSTH MT57N+^SM-WVF[@AVKO;S) N%SC)SVSQFI(
M9X;A"\,J2("5+(P(R.HXH DHK*&J32ZW;6]L+*:PE@:0SBZ'F;@<85 /F7U.
M>*NK?V;WC6:W<!NE&YH!(-X'J5ZT 6**KB^M#>FS%U ;H#<8!(-X'KMZXJQ0
M 4444 %%%% !1110!B^&?^/*]_["5W_Z.>MJL7PS_P >5[_V$KO_ -'/6U0
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M:R7=NDKVDPG@+?\ +.0 C</?!/YT ><:CH]Q<_$+4-.LM&T"XM+72K=;>VU
MM''%&[R[S&JHPY( )XZ+5"SM;BR\;_"ZUN;RWO)(;&^3[1;RF2-U$6%*L0,C
M;CFO2=9\+Z+X@>)]4L([AX@51R2K!3U7*D$J?0\5-_8.E?;-/NQ80K/IT;16
M;*,>2C+M(4#@#'% 'E#%96\.ZW9Z7I=A:7OB)&@F,K27TI:5@Y9B.C#=E<G
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M4,CS*HV9!X) 9R*]+TSP9X=T?[1]@TJ"$W$1AD(R28S_   DG"^PP*=<>$-
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M $<];5 !1110 4444 %%%% !1110 4444 %%%% !1110 5BC_D=V_P"P:/\
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MNH1VEY,;>TU"2#%O<2#/RJV<\[3@D ''%/MO'6G7.IPVHLM12WN+A[6WOI(
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M-D8C']U@"/Q%>8V^BWK_  1\,QBWOHY;":VNKB&W4K<!%D)<H,9W $L!C/%
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M(B#JS%" /SKS_P /RG4/^%:M#;78_LZ*6VNO-MI(_)D6T"D'<!QDXST)X!H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>$2*HB7_ '=IR/J:Q/%TKZ;XU\2SZ;(UO-)X0N+BX>%MI$J,1$^1_$!N /7
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!B^&?\ CRO?^PE=_P#HYZVJQ?#/_'E>_P#82N__ $<];5 !1110 444
M4 %%%% !1110 4444 %%%% !1110 5BC_D=V_P"P:/\ T8:VJQ1_R.[?]@T?
M^C#0!M4444 %%%% !1110 4444 %%%% !1110 4444 %8NL?\A[P]_U]2_\
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M %%%% !1110 4444 %%%% &+X9_X\KW_ +"5W_Z.>MJL7PS_ ,>5[_V$KO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#%\,_\ 'E>_]A*[_P#1SUM5B^&?^/*]_P"PE=_^
MCGK:H **** "BBB@ HHHH **** "BBB@ HHHH **** "L4?\CNW_ &#1_P"C
M#6U6*/\ D=V_[!H_]&&@#:HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MQ=8_Y#WA[_KZE_\ 1$E;58NL?\A[P]_U]2_^B)* -JBBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **\?^/'B?Q/X<T[2O[#FFM+29W^TW4*\AAMV
MKN_ASEC[X]J[#X7ZKK6M> -.OM?5A>R!OG=-K2(&(5R/<?GU[T =A1110!S>
MK^-M+T7Q7I?AV\2X%SJ2YBE508EYV@,<Y!+8 X/)%7?$WB.Q\)Z#/J^H"5H(
M2J[(0"[LQ "J"1DY-<)XXT-O$7Q#_LZ)MERWAR:2VD!P4F2XC:-L]OF K/U+
M6_\ A86G6[;"MOI6CSZC?QXX6\*/$D9]U*RM^ H ]5TO4X-6T:RU2 .D%W E
MP@DP&"LH89YQG!J[FO)M%L[;7;KP-HVK1+<:8GAE;M;:49CEF B3++T;:I)
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M,HR#ZUAZWH,$'C'3_#VG>&;/4=*M]-DNDT^>Y\J+S6E"M(<JV]@,#GIO)[T
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MN-YY8;@&'6M6#PKJL4NJ6]CIEAX7M+S2);9A;W_F*9L@1RD!5P0"P+=3D=Z
M/4P0>A!^E+7!>";>TTK7[K37\.#0=3:T61XK6<26MS&K;?,7&/F!.#N ;!'6
MN]H **** ,7PS_QY7O\ V$KO_P!'/6U6+X9_X\KW_L)7?_HYZVJ "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ K%'_([M_V#1_Z,-;58H_Y'=O\ L&C_
M -&&@#:HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q=8_P"0]X>_Z^I?
M_1$E;58NL?\ (>\/?]?4O_HB2@#:HHHH **** "BBB@ HHHH **** "BBB@
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M>Z>'8O,@DVAMV,].V<4 :EWX/T:[T[3K)H)HDTU!'92P7$D4L"A0N%D4AN0
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MT5L;N5H1(.CF,MM+#U(I]U\/O#E[->27%I,ZW;M+)%]JE$:R-]Z14#85S_>
M!Z^IJG-XUDN?AEJ7B.RB6'4+*VE\ZVF&?(N(Q\T;#V(_$8/>DU#Q'K-]JUAX
M?T$6D=_+8K?7EY<H7CMXR=H"H"-S,<X!(  H V(_".D1ZVVKK%/]K>%8)B;F
M0I.JJ5'F*6VN0"1E@35;3O 7A[3)S+;VLQ(A>")9KJ218(W&&6)68A 1_=Q6
M?#K/B'P]XCTW2_$4]GJ%EJCM#;7]M 8&CF"E@DB%F&& ."#U'-0VFK>*/%]S
M?7.A7MAI6D6UP]M!-/:FXDNF0[6;&]0J;@0.IX- '2_\(WI1TW2]/^S'[+I;
MQ26B>8W[MHAA#G.3@>N<UG>/M&N-?\,BPMK87+->6KR1,0 8UF1GSDX^Z#Q5
M_P .7.N7%A*GB"RAM[V&9H_,MWS%<*,8D4$DJ#GH>>*V* ,"P\&Z-ITUW-'%
M<RS74!MGEN;J29Q#_P \U9V)5?85:;PWI,GAM/#TEFKZ6D*P+ S,<*N-OS9S
MD8!!SG(S6K10!AZ9X1T?2VNI$AFN9KJ+R9IKVX>X=X^?DW2$G;R>.E0Z3X(T
M'1;K[1:VTSNL1@B%S<R3+#$>J1AV(53@<"NBHH YW3? ^@Z7<":"VE?;$T,4
M=Q<R31P1M]Y8T=B$!'' Z<=*BMOA_P"';99$-K/<1- ULL5U=RS)%$V-R1AV
M(0' Z8/ KIZ* .>LO!6AV<=VC03W?VN#[-*U]<R7!,/_ #S!=CA?84VT\#:#
M:PW<36T]T+J#[-(;RZDG;R?^>:EV)5>^!CG![5T=% '.VW@C1+>VOH&CN[@7
MUN;6>2ZO)9I#"<_(K,Q*KR>A%;UO!':VT5O"NV*) B#.< # YJ2B@ HHHH Q
M?#/_ !Y7O_82N_\ T<];58OAG_CRO?\ L)7?_HYZVJ "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ K%'_([M_P!@T?\ HPUM5BC_ )'=O^P:/_1AH VJ
M*** "BBB@ HHHH **** "BBB@ HHHH **** "L76/^0]X>_Z^I?_ $1)6U6+
MK'_(>\/?]?4O_HB2@#:HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M .&^(GPSM/B&=-:YU&>S-DS_ .K4,'5MN1@]#\HP?T-=7?1"'0KF%"Q"6S*,
MG).%(J]10!X#X:C^&;^ M.CU/S#K"VP+I;_:#,)ATVJO&[.,=JZ:TU2^TB_\
M"ZQXQD-I*VFW5O<W$R[0DK&,H'QPK%5[]P:]8HH \'\3S?VA\-/'ES#%*$G\
M0QO&'C*LR?Z/AL'G!'-=EJL,LOQSM!'E2WAR5%?L&,IQS7HU% 'B']MZ>WPN
M\/\ AU5<ZO8WEE%=6GEG?;,DZAF?CY03P#WW"K.H1O\ ;_C/\C?-96^WCK_H
MS]*]FHH X/5H2->^'JQKM"O,H('W?]$<5Q$VKV4/P?T[PW)')_;%C=6T-U;&
M)MUNRW*Y=CC !['ON%>YUQ\W@F\NYH[>_P#$E[=Z/'=BZ%E+&I=BK[U1I?O,
M@;''7  S0!9^(T,D_P ./$,<,;22&QEPJC)/'I6#IFH66L^-_"5[83)<6XT:
MZ42J. P:$$>QZBO1:* /&-0MIEEU&^-U<V-I9^,9)KBZMXU9H$:V""3#*PP&
M8 D@X!)[5VO@6*PENM8U.QUF_P!8^TR11R7ES'&L<A1>/+*(H8 -@G'4>U=E
M10!YPGB'2?#WQ2\53:M<+:QR6=EMGD!VY"R?+GU.<@=\''2N2T:TGT9/#^HZ
MGJ][X=LKFPNUCN4BCQ&7NC*L;^8C!-R,".GW<5Z[9:$MGXEU;61.7;48X(S$
M5P$\H,,YSSG=^E:] 'DUK86D6K^ &M);V[MIM2O[H37L01V+1R-OVA0 "WS#
M@<$5>U*UGNOC=>Q0Y5Y?"3QH_8,9R!S7I=% 'CHU2SU/X=>'?"-GN'B"*:R@
MELMA$ELT,B&1W&/E4!&.[OGWHNM8LM(\*>/O#]]N&KW%UJ$L-KY9+SI*I*2+
MQRH!Y/;:<U[%10!Y+86\TWQ.T1(]R,W@P(KXX5B_%:'@OQ+I,'A[PUX9ELY)
M];MBEM/9>3E[1XP0TKYX51C.[ON&,UZ510!YY\9O^1(@_P"PE:_^ATY-9T_P
MG\0?$\^NW LXM12UFLYI%.V54CV,BD#E@P)V]?FZ5M>+?",GBU[*"XU1X-,@
MF2>6UCA4F9D;(^<\J/8"NGH \6T5QX<NO -UK$$EK"L.J3,9$/\ HJ2R*R%_
M[HPP!STSS79^!94U+7?%FMVF6TV^O8A:RX(67RX41W7U!8$9[XKMJ* /+/$6
MJ6^B^(=2GT/5[BVUF2YB\[0[B /'J#810T8QN&5P-ZG'R\CBH;G6WT36OB3%
M;JK:K((KFUMY(RWF(+=07"_Q 8.1[8KUFB@#QZWO+:X\81-;:]?:U%=:%>6T
M-U.B".2<F-C%%L11G R1SCIV-1:3K>G0^&?AQJ;W*BSTF3[-?RX.+:0VS( _
M''S$#/N*]FHQ0!Y(][HVKZKXTO;Q[Z/2I)M-:*^MD*M&5!VSJ<9"JPSNP1@9
MY%=5X#U:ZU)]5A?5%UFQMI(UMM46$1F?*Y93M^5BO'S#UKL:* .)\/1?\74\
M;2E,$PV"J^.WEOG%<9X7M+1K/0M U+Q+K!U.ROD+Z-'!%^ZDBD+;R?+W"/C.
M[=R&ZG->TT4 >++K^EVW@;QQHDI(U.]U'4H;6VV$O=/([(I08^;!P#CIMYK=
MT?4;3P1XJUH>([D6GVRTL7MYY 2LWE0^6Z*1U8,"=O7YJ[7P_H2Z#;7D*SF;
M[3?3WF2NW:97+;>O;.,UKT >/>%].N+76?AT+NU>%_+U>X6.1<&)9&#(".QV
ML.*T[^[TVS^(OBZSUB.5XM2T>!8[>-"7ND59?,6/'4X)X!S7IU(2!UQ0!Y]X
M)U9I/$+:7IVOOX@T9+(R"XFB'FVCAE"Q-( -VX%C@C<-G-/\6ZP;;QE;V-WK
M%SH]B=/\V&6TA1IKN8R$&)69&Z *=JC)+>U=_10!X]X,*RWGP^C(8S6<6J0S
MJX^:&0%,JWHV#^M)K*O;ZIKFHO%(;.P\665W=%4+;8E@C#/@=0"03]*]BHH
M\]T?6+'7?B]+>Z8_GV@T'RA=*IV2,)\D*?XL9'([Y'8T_P ;7.EV.OPW;^(+
MGP]JRVA$-V8@\%RFXGRF5@0Y!YP,-\W%=]D XX^E+0!YWX6N+O4/'MIJ&H68
MMKN;PM;-+&$*A&,SDJ >1].U<_9:G)ING:=;SZD^C:=<:QJAGU!(E+H1*VR-
M6=6";LMSC)VX'6O8\@$ D9/04M 'AUHR3PZ9:L]S-+'XX2=Q=IB8HZ,T;NN!
MC<!GH*[#Q$C'XU>#&"DJ+2]R<<#Y*] !!S@CBEH \@FA(^!.O*(SO:]NV(V\
MG_3&Y_("KW]K6>@WGCK3-320WM_</<6L/E,QNXG@15"<8."K ^G? KU&N8UG
MPOJFI7=XUGXGO+*TOHQ'/;>4LH48VDQ%O]62.O7GGK0 _P"'O_).?#?_ &#;
M?_T6*\SCUFS7X4Z=X<#.VKVFHP1W5J$.^WVWBDL_' Z8/?<*]FTZRMM,TVUT
M^T7;;VL2P1KG.%4  ?D*M4 >2V_B32-&_P"%@VNH2>7/<:C.(4*$FY)@11&G
M'S-GM_M#UH\-747@?7;-?$LIM/M'AVQ@AEE4D>9%N$D0('WLL#CJ:]#T70TT
M6?5YA<&7^T;YKT@KCRR41=O7G[G7WK7H \5T;5Y+'P_HD4][+H.G76IZDT]W
MY*^9"PE8I$"ZL$+9;MGY<#K5;[9#;^'/-GFNBMCXS@O+F2[3$J0,P999  ,
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M'0"J_ACQ'IW@*UN_#7B69M/>UNYY+2>6-O+NH9)&=65@""PW$%>O%>F=*.M
M&-X<UR3Q#9SWW]GSVEIYQ6U:<%7N(P!^\V$ J"<X!Y(&>];-%% !1110 444
M@(/0@XXH 6BC(SC//I10 4444 %%%% !1110!B^&?^/*]_["5W_Z.>MJL7PS
M_P >5[_V$KO_ -'/6U0 4444 %%%% !1110 4444 %%%% !1110 4444 %8H
M_P"1W;_L&C_T8:VJQ1_R.[?]@T?^C#0!M4444 %%%% !1110 4444 %%%% !
M1110 4444 %8NL?\A[P]_P!?4O\ Z(DK:K%UC_D/>'O^OJ7_ -$24 ;5%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!ROC+XA:#X%-DNLO.&O&81K
M#'O("XRQY' R/?T%=+^ZN[4%78Q2J"&1RI(/<$8(K-UWPMH?B86PUK3(+W[,
MY>'S1]TG&>G8X&1T.*U')BA)CB9]HXC3 )]AD@?K0!X99Z]?V_PUTS5=.UZ^
MNO%;W[11VDEZ\YNAY[+L:)F( V#.0 1C.>:]3U?QGI^C17D\T%U-:V+JEY/
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MF1@T?WRXW,HQQT.: ,_1_$2:%J'B^.&!KW4[O7WBLK)#AIG\F+O_  J.K,>
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M HHHH **** "L4?\CNW_ &#1_P"C#6U6*/\ D=V_[!H_]&&@#:HHHH ****
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M4EVC<YBD#@$=.2,5?U3Q!_9FOZ+I;6<D@U262)9PX"QE(V?D=3D+_P#7K:H
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M K%UC_D/>'O^OJ7_ -$25M5BZQ_R'O#W_7U+_P"B)* -JBBB@ HHHH ****
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M+KR>4W$!0H) )"JJKG SC.!FGZ?X?TO2VB:SM%C,,9BA&YF$2'&50$D(#@9
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M^X._O(B*J_,3SM. /<<'M)O!?AJ>6YEET2S=[F83REHP=T@(.[V.0"<=>^:
M.2UU-6U"^\86D1O);WRX1HTEI(P$#&/(!93B-M_S-NQE6'48%3RI<77BQ?"E
MU?A!'I$4T2S2RL9Y&=Q*X;>&)7:N,DD9XQ45_P""I+WQ!?W&H^$](U3[1-N@
MO1>-;LD04*J.H0G*@=03GVZ5TC^"-%U#1M/L-:L8=1^Q+B)YLL4]@Q.[;T')
M/ &<T 7/#-M<6WAFTM+S5CJLT2M$][M*&7:Q&>I.1C&<\D9[UY7)906WPEU_
MR3(C'7GC'[UFP%OU P"2,^^.>]>T0016UO'!!$D4,:A$C10%51P  .@K(E\(
M>'YENUDTFV*W<PGN %P)9,YW-CJ<\_7GK0!Q>L7=YX5\0^*4TF>ZD"^'/[12
M.>=Y@)P\B[P')QP!D#@XK8T/3G.K:/K=IXBC>RNK=D:W3S'%[E=RN2TC89<$
MDX[D&NG31-.34SJ0M@;TP^09F9F8Q_W3D\COCUYZU6T?PEX?\/W4]SI.DVMG
M-/Q(\28)&<X'H,]A@4 97B74=GC'PUHUS*T6GWXN2^'*":5%79&2.QW,<=R!
M]*Q]9MCH@T""SUB^N /$T<3EYV_=QN&;R"1]Y1E<!L]A7;:SH6E^(+'[%JUC
M#>6^X.$E7.UAT(/4'W%0R^&=$GT1-%?3+?\ LZ,@I;A<*I!R",<@YYSUH \Y
M\4W=S';?$Y8-0O(Q9Q6LD'EW3CR6,66VX/ )ZCH:U?$FBKIEWX;6VU/5E_M'
M6D6Z)OY3O!A?< ,X )0'C&.V.*ZIO!OAQH[F,Z/:[;I52<!,>8JCA6]1[>O/
M6K=SH&EWJ6:W-J)19,'MMSMF)AT8'/!'KUH X<6#7?B+5?"$>IR01V5C$;(7
M,TKR[7WEIE8.I8JV!DYQM &,G*6]E-=^--#TV]UR\OX)-!F,\L,\D*7+)+$H
M?"MQD'JIY]2#SV>M>%-!\12P2ZQI5M>20?ZMY4R5'IGN/8\58;0M-;48M0^R
MJMW%%Y$<JL5*1_W1@\#V% 'E21G4?"W@W[;/<3O!XG>T65YWW^6LDZ@%LY)P
MJC/7BN^\>:I=Z#\/M6U#3-WVBWMQY;CYB@) +\]=H);GTJ]_PB>@G3?[..EP
M-9^=]H$+ E1)G.\9Z')/(]36J8(6MS;F)#"5V&,J-NW&,8Z8QVH X?4(FTKQ
M7X5_L>YN'M-4\ZWNXS<.XFC$1=9<D\,"/O#D[L9Z5Q\=O?Q_"ZS\4VVKZI)K
M=I?LL.^\D=90;QH_*9"<-N!ZD$].< "O6+'0=,T<>986(5HXRD:ABVQ.NQ-Q
MPBD@<# X'I7/^!O"0TG0;>'5;%5OH+F:?_6[X]S2.RN%SC<%8#.,\4 8TBWG
MBJ;Q/'_;R:7>:;?LD<IW[[2- I1P!(J[6&2<CG)!R ,6=+TW^U?B!XB2\U+4
M6ALAI]S$B7<L:*Y5V/RYX4D?=Z<GBNJOO"/A[4]8BU>]T>TGU"+&V=X\MQTS
MZX[9SBK=OHVGVNIW.I06RI>7( GF#',@'0'GG';T[4 >;Z;?2G6?!M[9WMS-
M::C=W2/=SSD27J>7(P+1CY54$#;SD #A>E5X+..Q^'_Q#N+2>ZM[B"_U#RGB
MNI%9=F"#PW7/4]^]>@P^"?#-N8C%H=DABG^T1XB'R/SR/3J>.G-3R>%M#E-^
M7TRW)U YN\+CSO7=CKG SZ]Z .:@O'U/QOI^A7[R?81H*7<<?F,HGE+A6)(/
MS%0!@=MQ/H:YM[G5)--L[2;4K\)9^,1IL%PMPP>:VST<Y^<@Y7)S]VO3;CP]
MI5U%:1RV@/V/_CV=797A&,$*X.X#''!HG\.Z1<6UI;26,1AM)!+;HN5$;@Y#
MC'\623GKR?6@#A%M]1@U#QIHFD:@\?DR6$MHM[=2.N^3EX]Y)8"3;MX/!;BN
MA\$:DMXVK6TNGW>FZA;SI]JL9YO-2$L@V^4V<%"%SQCG/%:TWA?1;B:[EFL$
M>2\*&X9F;,A0@H3S_"0,>G:KMEIUKIXD^S1;6E;=([,7=SC +,Q)/  Y/04
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MT<,1&5'<-([XQUH 9X5\>I+HWAJ+4;+5%%_!# FISHODSW'EC(SNW9)#8)4
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M#!)7:Q(."#M8 XYQ7$ZU)+XQ\9W]K86=U;BY\*7EO;O=PM TCM)&/NN P7)
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M.>MJL7PS_P >5[_V$KO_ -'/6U0 4444 %%%% !1110 4444 %%%% !1110
M4444 %8M_IVIG6UU'3KBT0FW\ATN(F;^+=D;6'K6U10!B^7XG_Y^=(_\!Y/_
M (NCR_$__/SI'_@/)_\ %UM44 8OE^)_^?G2/_ >3_XNCR_$_P#S\Z1_X#R?
M_%UM44 8OE^)_P#GYTC_ ,!Y/_BZ/+\3_P#/SI'_ (#R?_%UM44 8OE^)_\
MGYTC_P !Y/\ XNCR_$__ #\Z1_X#R?\ Q=;5% &+Y?B?_GYTC_P'D_\ BZ/+
M\3_\_.D?^ \G_P 76U10!B^7XG_Y^=(_\!Y/_BZ/+\3_ //SI'_@/)_\76U1
M0!B^7XG_ .?G2/\ P'D_^+H\OQ/_ ,_.D?\ @/)_\76U10!B^7XG_P"?G2/_
M  'D_P#BZJ76F>([J]L;EKS2E:TD:10+>3#$HR<_/Z,:Z6B@#%\OQ/\ \_.D
M?^ \G_Q='E^)_P#GYTC_ ,!Y/_BZVJ* ,7R_$_\ S\Z1_P" \G_Q='E^)_\
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M .+K:HH Q?+\3_\ /SI'_@/)_P#%U#!8^(+4S&&31T,TAED(MY<LQ &3\_H
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MTC_P'D_^+H\OQ/\ \_.D?^ \G_Q=;5% &+Y?B?\ Y^=(_P# >3_XNCR_$_\
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M?G2/_ >3_P"+H\OQ/_S\Z1_X#R?_ !=;5% &+Y?B?_GYTC_P'D_^+H\OQ/\
M\_.D?^ \G_Q=;5% &+Y?B?\ Y^=(_P# >3_XNCR_$_\ S\Z1_P" \G_Q=;5%
M &+Y?B?_ )^=(_\  >3_ .+H\OQ/_P _.D?^ \G_ ,76U10!B^7XG_Y^=(_\
M!Y/_ (NJ.L:-K^MZ5/I]S=Z<D<H'SP1RHZ$$$,K!^"" :ZBB@#A]&\):_I&I
M3:G+K%OJ6H2Q"#[3>QLS)$#G8H4J ,\GC)-;WE^)_P#GYTC_ ,!Y/_BZVJ*
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M:TJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MYY[]:Y[QSJ^OQ>&_$&DS7EHEU;V]K<?:;:"2/?#-*T90#S"58%#SDY!Q@=:
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MM[AX/.>5Y 69D(8A1& !G&6.>U $W_" Z/\ \_6N?^#N[_\ CE'_  @.C_\
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M/MTJVHE%Q*(P0TGE[0% *[><8 )(H [O_A ='_Y^M<_\'=W_ /'*/^$!T?\
MY^M<_P#!W=__ !RL\^-+X:_/"MJTMC;W;6LB1V$Y8!4R9?._U8&[C;Z<YSQ5
M"Y\:^(;#2;34+B/3'2]T:?4XHTB<&(H(BL;'>=PQ+RPQG'04 ;__  @.C_\
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MO(;D7*W3W!,A8(8\$]-NTD8QW]>:Z&BB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
:%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>exhibit101_changexreques005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit101_changexreques005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !117+>,X?&LJ67_"'7&FPL"_VG[<"<CY=NW /^UG\* .
MIHKRK['\;/\ H(^&?^^6_P#B*/L?QL_Z"/AG_OEO_B* /5:*\J^Q_&S_ *"/
MAG_OEO\ XBC['\;/^@CX9_[Y;_XB@#U6BO*OL?QL_P"@CX9_[Y;_ .(H^Q_&
MS_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?QL_Z"/AG_OEO_B*
M/5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB@#U6BO*OL?QL_P"@
MCX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?
MQL_Z"/AG_OEO_B* /5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB
M@#U6BO*OL?QL_P"@CX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\
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M_=H5\A,A'SW(*=?QJA)X2^+UUXFM?$<U]X?_ +0M[=K>(,6VHK')X"8R<]:
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MB#I?BKX<7UIX=^T7D6Z)[R<V[QQP()%P"6 RQ;:,#/&3VK=^Q_&S_H(^&?\
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MS_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?QL_Z"/AG_OEO_B*
M/5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB@#U6BO*OL?QL_P"@
MCX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?
MQL_Z"/AG_OEO_B* /5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB
M@#U6BO*OL?QL_P"@CX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)"JN(QT0,!G;QTZ5=HHH *JWFFV&HF$WUE;7)@<21>?$K^6PZ,N1P?<5:HH
M@-G:M>K>M;0FZ1#&LY0;PA.2H;KC/:D6QM$N9[E;6!9[A0LTHC :0#@!CU(&
M3C/K5BB@"K!IMA:Z?_9]O96T5EM*_9HXE6/!R2-H&,')_.H=,T'1]$$@TK2K
M*Q$IR_V:!8]WUV@9K0HH RK;P]I&E3W%[I>C:=;WTBG,L4"QLYZX9E&<$]:R
M/#WA_5#XEO?$_B'[&NI30+9V\%HQ=+> $L1N8 LS,<DX'05UE% &9>^'=$U*
M^CO;[1["ZNXL;)YK9'=<=,,1FM.BB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBL._NM6EU]=.TZYLK=%M?/=[BU>8D
MEBN!MD3'3WH W**Q/LOBC_H,:/\ ^"J7_P"2*/LOBC_H,:/_ ."J7_Y(H VZ
M*Q/LOBC_ *#&C_\ @JE_^2*/LOBC_H,:/_X*I?\ Y(H VZ*Q/LOBC_H,:/\
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M_P"@QH__ (*I?_DB@#;HK$^R^*/^@QH__@JE_P#DBC[+XH_Z#&C_ /@JE_\
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MB610R:UHS*>A&ER$'_R8I?LOBC_H,:/_ ."J7_Y(H VZ*Q/LOBC_ *#&C_\
M@JE_^2*/LOBC_H,:/_X*I?\ Y(H VZ*Q/LOBC_H,:/\ ^"J7_P"2*/LOBC_H
M,:/_ ."J7_Y(H VZ*Q/LOBC_ *#&C_\ @JE_^2*/LOBC_H,:/_X*I?\ Y(H
MVZ*Q/LOBC_H,:/\ ^"J7_P"2*/LOBC_H,:/_ ."J7_Y(H VZ*Q/LOBC_ *#&
MC_\ @JE_^2*/LOBC_H,:/_X*I?\ Y(H VZ*Q/LOBC_H,:/\ ^"J7_P"2*/LO
MBC_H,:/_ ."J7_Y(H VZ*Q/LOBC_ *#&C_\ @JE_^2*/LOBC_H,:/_X*I?\
MY(H VZ*Q/LOBC_H,:/\ ^"J7_P"2*/LOBC_H,:/_ ."J7_Y(H VZ*Q/LOBC_
M *#&C_\ @JE_^2*/LOBC_H,:/_X*I?\ Y(H VZ*Q/LOBC_H,:/\ ^"J7_P"2
M*/LOBC_H,:/_ ."J7_Y(H VZ*Q/LOBC_ *#&C_\ @JE_^2*/LOBC_H,:/_X*
MI?\ Y(H VZ*Q/LOBC_H,:/\ ^"J7_P"2*/LOBC_H,:/_ ."J7_Y(H VZ*Q/L
MOBC_ *#&C_\ @JE_^2*/LOBC_H,:/_X*I?\ Y(H VZ*Q/LOBC_H,:/\ ^"J7
M_P"2*/LOBC_H,:/_ ."J7_Y(H VZ*Q/LOBC_ *#&C_\ @JE_^2*/LOBC_H,:
M/_X*I?\ Y(H VZ*Q/LOBC_H,:/\ ^"J7_P"2*/LOBC_H,:/_ ."J7_Y(H VZ
M*Q/LOBC_ *#&C_\ @JE_^2*/LOBC_H,:/_X*I?\ Y(H VZ*Q/LOBC_H,:/\
M^"J7_P"2*/LOBC_H,:/_ ."J7_Y(H VZ*Q/LOBC_ *#&C_\ @JE_^2*/LOBC
M_H,:/_X*I?\ Y(H VZ*Q/LOBC_H,:/\ ^"J7_P"2*/LOBC_H,:/_ ."J7_Y(
MH VZ*Q/LOBC_ *#&C_\ @JE_^2*/LOBC_H,:/_X*I?\ Y(H VZ*Q/LOBC_H,
M:/\ ^"J7_P"2*/LOBC_H,:/_ ."J7_Y(H VZ*Q/LOBC_ *#&C_\ @JE_^2*/
MLOBC_H,:/_X*I?\ Y(H VZ*Q/LOBC_H,:/\ ^"J7_P"2*/LOBC_H,:/_ ."J
M7_Y(H VZ*Q/LOBC_ *#&C_\ @JE_^2*/LOBC_H,:/_X*I?\ Y(H VZ*Q/LOB
MC_H,:/\ ^"J7_P"2*/LOBC_H,:/_ ."J7_Y(H VZ*Q/LOBC_ *#&C_\ @JE_
M^2*/LOBC_H,:/_X*I?\ Y(H VZ*Q/LOBC_H,:/\ ^"J7_P"2*/LOBC_H,:/_
M ."J7_Y(H VZ*Q/LOBC_ *#&C_\ @JE_^2*/LOBC_H,:/_X*I?\ Y(H VZ*Q
M/LOBC_H,:/\ ^"J7_P"2*/LOBC_H,:/_ ."J7_Y(H VZ*Q/LOBC_ *#&C_\
M@JE_^2*/LOBC_H,:/_X*I?\ Y(H VZ*Q/LOBC_H,:/\ ^"J7_P"2*/LOBC_H
M,:/_ ."J7_Y(H VZ*Q/LOBC_ *#&C_\ @JE_^2*/LOBC_H,:/_X*I?\ Y(H
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MMI)I=E:PM]G=WRJM'(RX&,;FX#_08S4L>G^+M#N-:M]%T^TFCU:Z-[#=37(
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MP455"LXR27SNST'3GCIO#-YK-[HX?7K%;._21XV5"-LB@_*X )V@C'!)(YH
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M]HE1%=@2&&U?F"C'.03STK*76HO$?B?X=:S#&8DO+6]E\MCDH3$F1GO@Y&:
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M?:O+IVI/:6VL'=>0>4'Q(5VM)&<C8Q&,Y##(SBMX7L:FVBGQ%=3H66 L"V0
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MGIKMS#I]W?B_2%84)BD,HE8;C]X;@< ],]ZT_P#A%)1J>NWPU(E]7MH[>0-
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M@ HHHH *Q1_R.[?]@T?^C#6U6*/^1W;_ +!H_P#1AH VJ*** "BBB@ HHHH
M**** "BBB@ HHHH **** "L76/\ D/>'O^OJ7_T1)6U6+K'_ "'O#W_7U+_Z
M(DH VJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S[XG>&O&/B'^
MR?\ A%-9_L\02L;A1.T6[.-K94?,!@\>_>N^A5TAC65]\@4!GQC<<<G%/ILD
M:RQ-&^=K @X)!Q]10!YQXDT?4?&.GZY/9V<3EB(M,N3<;&C:!B0ZC:>LH;G/
M*A:C\2Z^GB?X$76K ;9)K>,3)TV2K*JNOX,#7H5CIEGIE@MC90^1:J"%C1CA
M0>PYX_"LY/!OAZ/3;C3DTN%;*X?S)K<%MDC=<L,X)SC\AZ4 9=Y)-'\6M)B6
MXG$,VE7+/#YK&,LKQ -MS@'!/.*YRUL]:UG3]/3S;_\ M9-<D^WWD$\D<4EJ
M)7W!9%(&W:%4*#D,.@Y->A/H=@;Z+4%@!OX(C%#.[LQ13VZ]#QD=Z\]LOA])
M+'Y5]X8TVWU$Y,FL6M^Z9D)R94C55(;)R%X Z9Q0 W4[)[F\^(ZOJ.IA=.MX
MIK14OI5$+_9B^1AL_>YP>/:O0]!GDO\ PSIEQ<,7EN+.)Y&Z9+("3Q]:C;PU
MI#-?NUF&;4%"WA+M^_ &,/SSQQ]..E7[.T@L+.*TM8_+@A4)&@)(51T SV%
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M/9&!RH]@<5;TO1-+T1)DTRQ@M%GD,LHB0+O8]2: .-U.&XF^-UFMM=?9I/\
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M$BQQ(B$E%4!<L3Q]3UKR;PEX9E\6> ;S2KG4!!I4VK7)GBAA_>R*LY;;YA;
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M=(_M<64UFD(M&;S$DB1H583J%=1G>6SD=@#QQ777WA+P_J>KQ:K>Z3:SW\0
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M$X4]L[CG'6N,\+PM:?!/POXF@4F?0;Z6Z;:.6@,SI,O_ 'PQ/_ :]LM-.L[
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MC,#/Y]Y&\#;T((PY.=[=>5S7.:G;6\/[.^JR0P11R/J;J[(@!(%Z< D>@Z4
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M 4444 %%%% !1110!B^&?^/*]_["5W_Z.>MJL7PS_P >5[_V$KO_ -'/6U0
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M^M,U#PIH&JZ;;Z=?:3:S6EL<PQE,",^JD<C^M;%% &1<>%M!NH[&.;2;1TL
M1:KY8 B!X( ]#@9'0TQ?"/A]+6.U32K=(([C[4D: J%ESG?Q_$#T/;M6U10!
MAW7@WPY>S7<USHUI+)=[?/9TR9",8)]^!SUXJT?#^D'4$OQI\"W<<'V=)D7:
MRQ\X4$=,9./3)K2HH R5\,:(FCC2%TV :>K[TM\':C9SE?[ISSD8YYI9?#>D
M3Z;-I\UBDMK<,'G20EO.(QRY)RW0=2>@]*U:* ,]=#TY-2BU$6W^F11>3',7
M8LJ?W<D]/:M"BB@#BO#7A/RKS7IM8TX#[;JCWD0,VY'C(78'4'!8%2>00,\&
MNG71M/76&U86RB_:/RC/N.XI_=Z],\XZ9YJ]10!ER>'-'EOY+U["(SRLKRD9
M"RLOW6=<[6(P,$@D8%1ZMX4T'7KN"[U72;6[N(!B.25,D#K@^H]CQ6Q10!CZ
MUX5T'Q$8#J^E6UV;?_5&1.4]@1V]NE27'AS2+J42262!A +8^6Q0-",XC(4@
M%.3\IXYK4HH RY_#FD7%Q)-+9(6D54D 8A9%7[JNH.& [ @BM2BB@"AJ&BZ=
MJD]M->VPFDMG\R!BQ!C;^\N#P??K4=YX>TG4+O[5<V2/.8_):3)4R1_W'P?G
M7V;(K3HH SWT339-2M]1:T3[7;IY<,H)!C7NHYX'M6A110!DZUX9T3Q%Y']K
MZ9;WA@),32KRF>N#UP>XZ&I7T'2Y+RRNS91B>Q79:LN5\E<8(4#@ @ $#J!6
MC10!131M/CU2;4UME%[,@CEFR<NHZ*>>0/2J2>$/#\5G!:1:5;QV]O-]HBC0
M%0D@Z.,'[P['MVK;HH QK[PGH&I:O#JM[I-K/?Q !)W3+<=,^N.V<XI+WPAX
M>U&ZN[J\T>TFGNT"3N\>3( ,#/OCC/7%;5% &=%H.EP:A%?PV4<=U##Y$<B9
M!2/^X.VWOCIGFK=V]PEE.]I%'+<K&QBCD?8KMC@%L' )[X-344 <WH>B3KJ6
MM:MJ=O%'+JPA1[0.)518X]N"< ')+=NF*TM.T#2])96L;-(BB>7'R6\M,YVI
MDG:O X&!P*TJ* ,JU\-:-97/VBVT^*)Q(955<[%<]75/NJQR>0 >33E\/Z4M
MXUT+1?,:;[0PW-L,O]\IG;N_VL9%:=% !6?)HFG2:HVIM;#[<T7D&<.P;R_[
MN0>F><>O/6M"B@#&7PIH:65I9IIT:VUI+YUM$K,%A?KN49X/)Y'J?6MFBB@#
M%\,_\>5[_P!A*[_]'/6U6+X9_P"/*]_["5W_ .CGK:H **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^0]X>_Z^I?\ T1)6U6+K'_(>\/?]?4O_ *(DH VJ*** "BBB@ HHHH ****
M,+Q>VA_\([-!XB.W3+F2."1CN 5F8!6+#[N&P=W '%<PIU/PGXCT.PMO$L^L
MV.IS-!]COBDD\2B-G\U9% )4%0#NSUKO[BW@N[>2WN88YH)%*O'(H96'H0>"
M*S-)\*^']"G>?2M&L;*9QAI((%5B/3(&<>U '$>#$\-GP#X;GUE8?MYOQA_F
M\XWYE;.2OS;MV<YXQUXK*\NP;X(^(Y;U(O[4^TWIN&8#S1=^>_E\]=W^KQ[8
MKT^/PSH46LMK$>CV*:DQ)-TL"B0D]3NQG)]>M)+X6T"?5UU:71K!]14AA<M
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MTR+3)8/B*^M) TPOIA<&<#<+?R4\KK_#MSCWS6;X3LS>^+_!YU6$2W$/A(2
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M%+!GVY^8@<8/7%2WWCFW@\01:)8:9>ZE=S6D=Y']FV;#"[,-Y9F& -O_ (\
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MIRL@E,2K,<@90?-P,M]: .BO?'MU;:;J+2^&M2M+Z"Q>]MX;@Q$2QK@$[@Y
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M.X!BH;H6YZUR/C'3]2U:7Q997.G:[>WTB%=)6"29+-8?)'.5(0MNWY5LDG
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M=>:+XD.IZ>4\][BZG^QP/&I D0LWEL"1\JKV;MBO6: "BBB@ HHHH Q?#/\
MQY7O_82N_P#T<];58OAG_CRO?^PE=_\ HYZVJ "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K%'_ ".[?]@T?^C#6U6*/^1W;_L&C_T8: -JBBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ K%UC_D/>'O^OJ7_ -$25M5BZQ_R'O#W
M_7U+_P"B)* -JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *"0!D
MG%<'\1_B9#\/#I@DTJ:^-ZS\I)L"*NW/.#D_,,#CZUVC1V^HV(2>W62"9 6B
MF0$$$=&4T 6,C&<\4@(/0@UY-X-OKGP/%I>G:I(9?#6LHILKB3I9SL,F!_\
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M!"S3.N1\H!R5)/3DUH#QR]E;>)FUK3EMYM!1)94MI_.65'0LFTE5.>"#D<4
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MK[1L?,OR*"0",D\GTZ<Y !Z317/^"=:NO$'A"PU*]6-;J0.DOEC"ED=D) [
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M[:07^I3Z@IA9CL\P@[""!TQU_2I+C1-0/CR/Q!";8P1Z;)9")W8,69U?=PI
M&5 _'/M71T4 <7_PBFK0:UIFOVEQ:KJXWIJI9W\N[B;H@&.-I VG^'&#NR36
MSI%SK$NMZQ#?_9'L8G3[');JP(!W;D<G@L,*<CCYL>PVZ* .0U/P[KMOXOD\
M0>';RQ0WENEO>VU\CE&V$[)%*G.X!B,="*>_AK4K/Q/;>(;&ZAN;LV7V*^BN
M28UG&[>KJ5#;2&)XP1@XXQFNLHH X&?P!>0)9ZEIE[;IKMOJ<^ILTJGR)6F&
MV2,XY"[=J@\GY<XYIMUX%U75Y/$LE_J%K;/JXM7A-JC,UO-  4;+8R P'89]
MJ] HH PM M_$JGS/$5YI\CHGEHEA&ZJ_3+N6/7C@  #)ZY&(K[1+ZX\;Z;KD
M36_V>SM)K=HV=@[&0H<CC'&P?G7144 >?S^"-7F\':OHOG6*S7^J-?K+O<J@
M:<3;2-O)XQGWS[5JPZ!JNE>)-5U72WLWCU9(WN+>X=@(9T7;O0A3N!&,J0O3
MJ*ZNB@#@;7P#>>';G0[WP[=V[7&GV;V-S'>!E2YC=_,9@5!*MORW0]<5%)X&
MUN3P]JVG/>:>TM]K(U,,%=50"5)-O?).P#VSWKT.B@#F[C1=1F\=6&O*;46U
MO926K1&1MYWLC%A\N.-F,=_:L6;P'?WFD:_:R7L%M<WNK#5K*XAR_D2KLVA@
M0,X\L<_[1]*[ZB@#C=0T+Q7KGA:_L]0U2PMM0FC5(A9)((1A@S;R3N.\#:<8
MP">N:K_\(9JUS?:U+<W6G0P:KI"Z>T5M"W[D@2 ;<G!4>9UXZ8P.M=U10!Q4
MGA?6Y]-\*P3SZ>9=&NHYY"A=5<)&T849!Y.XG/X8[TB>$-3L;3Q!I%C<VITO
M699I@\I82VAF&) J@8<=2,E<9YS7;44 <I9>%[G2_%<.HV8MOL%MHZ:7#"\C
M!\(VY6)VXQV_7VK,T[P7J%KX4L/#^H6VD:I8PQS+/!.S*KLS[D=3L)4C+#\0
M017?44 97AK29-!\-Z?I4MT]T]K"(S,V<MCZ]AT'L!7*#P!J+>')=+;4+9)+
M75&U/3)TC8E)/-:4>8,\CYBN!VY]J] HH Y^TT2ZN/$T7B#5!;QW,%F;2&&W
M=G50S!G<L54DG:H QP >3GBMXE\/ZO<ZWI^O>'KVU@U*TC>WDBO%8PW$+D$J
MVWD$%00174T4 <[+H^J:C;6UGJ\UI<VLK,^H1H&19./EC53G]V.,Y.6QSP2#
MAOX-UR3X>ZGX3>]M9(I0T%C/([EH8"?E1_E^8J. >,\>G/?44 <7XF\)WOB:
MRFLKRWTR2-X%%M.SL);&;&#(A"Y;G:0,KTP>O%VW\/:E8^,9]8M[J":WN+"&
MVF6<-YA>(N001Q\V_D]L=#73T4 >?6O@C5[?PMH&D^?8M+I>JB_>3>X$BB1Y
M-H&W@_/C/M[\'B*PN=$B\9:W=W%C%;:M;06\1D4R")@#$ID! 4J3("<\ #G-
M>@TCHLB,CJ&5A@J1D$4 >=^&&O\ 3];L8F'AV]2:+[,);"]FFGBA4%@0)"V(
M\@ C(&2.IP*T?&LT.H7.@V5I/%/=6^OVC30QN&>, ,YW <CY03SVKJ[/3K'3
MU9;*SM[8.<L(8E3)]\"G+96JWC7BVT(NG7:TPC&]AZ%NN* .8B\-:II6JZ[)
MI,UHUGK+^>R7!8-;3E=K.H .\' .TE>1UJ&U\&7&@ZAH5SHKV\T6F:<^G-!=
M.T>]69&W[U#8;*=-N.>U=I10!R$?A.YMK&6'9I^H#4+R6[U."[4B*8N  %X;
M&W:H&0<A?4\:?A+0#X9T!-,\W>B2R/&@8LL*,Y98U)Y*J" ">N.W2MRB@#SF
M?P-XA.DS:1;ZEIR646HG4;9S$YDF?S_."3'I@'(R.3A>F"#N6GA:ZATWQ5;R
MW$)DUN:65"H.(]\*1X/XJ3]*ZJB@#A8/".NZ+>V%]HEYIYG72H--O([M'*-Y
M7W9%VG.>6&#U'<5M>#?#UQX9T%M/NKM;N4W4\YF"[=WF2%^1Z\\UT%% '"'P
MSXJTSQEK^M:)>:-Y.KM 6CO8I69/*CV<;2!SS^E/U[0/%_B'P\EA=WFB+)]K
M62>..*80SP*,^6PW;N6ZX(R!CUKN** ,30HO$<+.FM-H_P!G5 L*Z?%(A4CU
MW$C&/2L[5_#^M/XRB\1Z/=V2O'IYLS;W2L5DS)O.2O([8//3IS7644 >>VW@
M;6M.EL-5M;W3YM9CN[NZNA/&X@=K@*&V8^8;0B@>HSTS44O@+7A8/&FJ6,UU
M%KD>M6\LL3*KO@[T<#HN2<8SQ7H]% '$W'AOQ/:ZEJ5YHNHZ; ^KQQF\\Z)V
M\B=4"&2'!YR .&[@<]:U-(\.W&F^);W5);PW*SV-K:[G'[QFBWY=NW._/'O7
M144 8GA'0Y?#GAFVTN:9)I(GE8N@(!WRLXZ^S8K;HHH Q?#/_'E>_P#82N__
M $<];58OAG_CRO?^PE=_^CGK:H **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "L4?\CNW_8-'_HPUM5BC_D=V_P"P:/\ T8: -JBBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ K%UC_ )#WA[_KZE_]$25M5BZQ_P A[P]_U]2_^B)*
M -JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X?Q%;IKOQ#TG0;]
MI#I:Z?/>M LC(L\H=$4-@C(4,3CWKC]2$UNM[X>M[^ZBL+7Q58V]O()VWQ1R
MHK-&KDYP"QQSQFO4=;\-V6NO:S327-O=VA8V]U:RF.6/<,, 1U! &0<C@5S'
MB3P3;KH.EZ7IUK/<1/K=O=7SO*S2R#=^\D=R<YQW'3 QTH Y[Q.9/ ^JZ];>
M'GFMX)O#SW9B\YG$4PF6,2+N)VG:Y_[Y!J]8Z1JNE7-S-::#=Z3IK:7<)=^=
MJ*3^;(%!CDP')W\.">^[VKK[+P7I5J=0>X:ZU&6_@^S3R7\YE8P\_NP3T7D]
M.I.32:=X*TW3WE<W&H7;O;-:(UW=-*886QE$STS@<]>!S0!Q&DZ?86/PJTJ]
MN7U6YU#6H;.&3[/=$2W+'!2$,QPB8RI(Q\N><U@^(+0IX2\?:9-I[V%O91V=
MS;V7VLS"!WW!B"#T( .WIWKUJ;PCI<WAFRT'_2([6R$7V:2.4K+$T?W&5O48
MJBWP[T)X]0CE-[*-2MA;WIDN68SX)(=B>KC)P>PXQB@#!U6W32/B=\/=-L3)
M#9^5?YB$C$']T#SDG/)/6L)K5;CX4WOCF2XN%\1JTUVEWY[@Q,DS!8@N<;,*
M%VXQUKT>#P=IT5]HU]+/>W5WI"S+;37$Y=B)1AMQ_BXX'I563X?Z++=2.S7H
MLY;C[5)IPN6%J\N[=N,?^]SCIGM0!SL.AVOB?QAXQ75C<20PI:&&W$[HL3M;
M@E@%(^;@8/;GU-95M::GK/A;PQK.HZ;>>(+#^R%2:"WNS'/%+G_7!=R^8Q48
MZYR..M>HVVBV=KJ6I7\2N)]1\O[02V0=B;%P.W%8O_"O])CMK*&SNM2L3:6P
MM%DM+MHWDA!)"N1UP2<'J,GF@"]I^I6"^"(-3BO[F73TL!,+N7F4QA,[VXY;
M R>.M<#X:CDTWQ?X8:VTR^L(-2M[CS9KR_$TM\!&'5Y4!(#YP<]MQ'M7ID.C
MV$&B+HT=LHT];?[,(,G'E[=NWUZ5AV?@#2;*YT^Z6YU*6YT]P;:::[9VC0 K
MY0SQL(/([\9/% 'GFD6\NG_!J?Q+!/=RZS<[K,3_ &AMT<+7?EE4R=J\<[NH
M)SFNP\(Z3J>F>*)&BT&XTC1I;(K+#+?I.&G#KM< ,Q!*EP3WP*Z.T\*:1:>%
MF\-BW,FF,LB-%(Q)(=BS<]>K'![4FC>%[/1;N2[6ZO[RZ>,0B:]N6E9(P<[%
MST&>?4]R: .>U_3HM9^*.F:==R3&Q;1[B26W25D64B6, -@C(YS^%<Q;&4P6
MWA?[3<II3^*[BQ8"9MWV=(S(L._.[:3QUSCBO5'T>T?7H=:97^V16SVJG=\N
MQF5CQZY45FS^"]'N;&[M7CF N;XZB9$E*R17!Q\Z,.5(Q_/UH \^\5Z9:Z5_
MPF.@6@D&E'PY_:*VQE<K#.K2+E<G@$*"1T.*](\(V%MIOA/3(;2,I&;:.0@L
M6^9E!)R2>]06O@S2;>RU.WF-U>OJD7DWEQ=SF265-I4+N[  G &.M:&B:/%H
M6EQ:?!<W=Q%%PC74ID<#H!D]@!P* .$\'Z+:ZSX>TOQ;>ZC<VVM3W1N);O[2
M1N_>LOD%2=NS&$VX^G-9;:?'JOP^\1>+[JXN4UV&6]F@N5N'4VIA=Q'&H!P%
MP@R,<Y.:[B/P!HL>IK=J;SR4N?MB6)N6^S+/G/F"/IG/..F><4EW\/\ 1;RZ
MN9)'O5M;N;[1=6$=RRVT\F02S)[D D# /<&@#F],TN#Q=XSUL:UY\EN-.T^7
M[*)G1!)(DA+84CD8X^IK*TVRU36?!WA?4KRPNO$-A!:30W%I'>&*;>),),,L
M!(0J%<$@\Y%>IVVCVEIK%]JD*L+F]2*.8EN,1[MN!V^\:Q!X TF&TLH+*YU&
MQ:SC>&.:TNFCD:-FWE6/<;CD<<=J .3MK^*X\?\ P]_L^]O9K&73;O!NG/F/
MM3'[SU8$8.>XK"U#2[?4O@S?>*KJ6<ZQ=S-)-.9VY'VK8(MN<;0  %QP0#UK
MU2W\&:-::AH][;P21RZ1"\%J!(2 KC#;L_>)]3WK-NOAIH%VMU#(^H"RN)6G
M-DMVP@20G<75.@.<GT!.0!0!R>K6VJ^(?$'BHPZ-?7MU:3BUT^ZAU!8!9$0H
MRE5+#DLVXG'(P.V*T--TN37/B;?KKC3$VFFV%PUJD[+&+CY_F^4X."#['/?B
MNJU;P3I>KW]Q=RRWT!NT6.\BMKEHH[I5& ) .O'&1@XXK1M="L;+6KK5H$9;
MFYAB@D^;Y=D>=H [?>- 'E?ANWU_5;;2?$%KH=Y_:<U^)[G4WU%-DD)E(DC,
M9?[H3("XX*@]:CU/2[?6/AGXO\27LT_]JF:]43>>P\N-)&180N<;=JXQCOGK
MBO18? VDP:FEW')>B%+DW<=C]I;[,DQ).\1],Y)..@)SBJU_\.-"U%]069[]
M;74':6XLH[IE@>1AS)L_O9P?3(!QF@#?0D>'U(."+7_V2O(/#8GU/P!\-8)[
MRZ NM1G2=TF97D3;<94L#G! Q_*O:1;QBT%MSY>SR^O.,8K#T[P5H^EZ?HMC
M;),(-'F>:T#2$D,P<')[_?:@#)\'VD6D>-O%6CV7F)I\*6<\,#2,RQM(K[]N
M2<9V@UE^-=-D@UV^U?5=.U"_T?[,GE7>G792;3"H;>XCR,]FW#)XP017>6VC
MVEIK-_JL2N+J^2))B6R"(PP7 [?>-9>K>"M,UB^N+F6XU" 7:!+R&VNFCCN5
M P ZCK\O&1@D<4 <S;Z59>-/$'BB34[NY*6+0P6$L=PT?V9# LGFK@@;B6SD
MCL!TJ2TTNU\4^-=6L=9N)=1M-+L;-+4><560R*S/-A" 6) Y[8XK?U7P)H^J
MW<EPSWMH9X5@N8[.Y:%+F-1A5D Z@ D=C@XSBI+_ ,%Z9>7,-S;RWFFSQ6XM
M1)I]P82T(^ZAQP0.W<=C0!YUIGGZ[<>"],U"_NI;876JVKOY[*UU%"2$#,#D
M\* ?4 ^IIFJ/=:/J>K>%=,2[GTMM9L8UM$NBC!)8'DDA61C\JLT8XR.&([UU
MNL>"H'UKPA8V%I/!I6G)= RVTI1K<E%V-NSG<6!YYSSG.36Q'X%T9-(NK"3[
M5,UU<"ZENY;AC<&9<;9!)U!7:,8P!CZT 4?!&GZIIM_JT<VDS:7I,GE/9VLM
MVL_EOAA)MPQVJ<(<>I-=G65HGA^UT,7+PS75S<7+!I[F[F,DDF!A02>@ Z 8
M%:M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!B^&?\ CRO?^PE=_P#HYZVJQ?#/_'E>_P#82N__ $<];5 !1110 4444 %%
M%% !1110 4444 %%%% !1110 5BC_D=V_P"P:/\ T8:VJQ1_R.[?]@T?^C#0
M!M4444 %%%% !1110 4444 %%%% !1110 4444 %8NL?\A[P]_U]2_\ HB2M
MJL76/^0]X>_Z^I?_ $1)0!M4444 %%%% !1110 4444 %%%% !1110 4444
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MQ9K6$L3DDQC)J>B@"![*TD@,#VL+0DY,;1@J3ZXJ5$2-%2-55%& JC  IU%
M",JN,,H8=<$9HVKO+[1N(P3CG%+10!"]I;R7"7#V\33(,)(R LOT/44[[/!Y
MWG>3'YO]_:,_G4E% $ LK4*5%M#@]1Y8YJ3RHQ%Y01?+QC;CC'IBGT4 11VT
M$2LL<,:!N&"J!GZTV.RM88#!%;0I"3DQK& I/TZ5/10 V...)-D:*BCLHP*Y
M23POJL/C^?Q+8:C9I%<V\5M/;SVS.VQ&R=K!Q@G/<'Z5UM% #41(UVHJJ.N
M,4R&W@MPP@ACB#'<VQ0N3ZG%2T4 0I:6T1)CMXD);>2J 9;U^OO1]DMOWG^C
MQ?O3ND^0?.?4^IJ:B@"(V\#7 N##&9E&!(5&X#TSUI?(A\_S_*3SL;?,VC=C
MTS4E% $4-O!;AA!#'$&.Y@BA<GU.*:+2")6\B"&-R2X(C'WO4XJ>B@#D_#GA
M?4]-\4ZQK^JZA:7-QJ,4,12UMVB5!&" ?F=B<Y]:ZIHT9U=D4LOW21R/I3J*
M &>5'L9/+7:V2PQP<]<TV6V@GV>=#')L.4WH#M/J,]*EHH :8T,@D*+O P&Q
MSCZU&+2V$CR"WB#R8+ML&6QTR>]344 1/;023+,\,;2J"JNR L!Z9IPAB#(P
MC0%!A3M'RCT'I3Z* &>3%Y?E^6FSKMVC'7/3ZUR^N>&]=U"^O'L/$$-M:7D7
ME-'/9"9[<;=K&%PR[<CLP;GGVKJZ* *FEZ=!I&DV>FVH(M[2%((]QR=J@ 9]
M\"LWPKX;C\.:!8:?(T5S<6B,@N/*"DAF+<=2.OK6[10 SRHPSL(UR_WCC[WU
M]:;':V\2QK'!$BQYV!4 VYZX]*EHH A6TMD4JMO$JEMY 0 %O7Z^]+/;07*!
M9X8Y5!R!(H8 ^O-2T4 -,:%E8HI*_=)'3Z4!%#EPH#$8+8Y-.HH 9Y,014$:
M;%.0NT8!I719%*NH93V(R*=10 W8N\/M&\#&['.*9):V\L1BD@B>-CN*L@()
M]<>M2T4 1-;P,6+0QDMC)*CG'3\J>$4.7"@,>"<<FG44 1/:V\D:QO!$T:G<
M%9 0#ZXH-O UPLYAC,RC D*C<!Z9ZU+10 WRT 8;%P_+#'WOK3#;0-)'(88R
M\0Q&Q493Z'M4M% $:00Q',<2(>>54#J<G]:4PQ%'0QH4?.Y=HPV>N?6GT4 1
MI;PQP>0D4:PXQY:J N/3%(EM;QP>0D$:P_\ /-4 7\NE2T4 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8OAG_CRO
M?^PE=_\ HYZVJQ?#/_'E>_\ 82N__1SUM4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !6*/^1W;_L&C_P!&&MJL4?\ ([M_V#1_Z,- &U1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#%\,_\>5[
M_P!A*[_]'/6U6+X9_P"/*]_["5W_ .CGK:H **** "BBB@ HHHH **** "BB
MB@ HHHH **** "L4?\CNW_8-'_HPUM5BC_D=V_[!H_\ 1AH VJ*** "BBB@
MHHHH **** "BBB@ HHHH **** "L76/^0]X>_P"OJ7_T1)6U6+K'_(>\/?\
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M1FN4\4+8:)9?#WPHNJ6]SJ.G:WIZO$K!9"BAAO*9) .1^= 'KM%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!B^&?^/*]_P"PE=_^CGK:K%\,_P#'E>_]A*[_ /1SUM4 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !6*/^1W;_L&C_T8:VJQ1_R.[?\
M8-'_ *,- &U1110 4444 %%%% !1110 4444 %%%% !1110 5BZQ_P A[P]_
MU]2_^B)*VJQ=8_Y#WA[_ *^I?_1$E &U1110 4444 %%%% !1110 4$ ]111
M0 4444 (0",$ _6E  & ,"BB@ HHHH **** "BBB@ I-JDY*C/KBEHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#%\,_\>5[_ -A*[_\ 1SUM5B^&?^/*]_["5W_Z.>MJ
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q1_R.[?]@T?^C#6U6*/^
M1W;_ +!H_P#1AH VJ*** "BBB@ HHHH **** "BBB@ HHHH **** "L76/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<#IQ6?9>#/#^GZJ-2M=.$=RKLZ?O7*1LV=S)&3L0G)R5 ZF@#>HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH Q?#/_ !Y7O_82N_\ T<];58OA
MG_CRO?\ L)7?_HYZVJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K%'
M_([M_P!@T?\ HPUM5BC_ )'=O^P:/_1AH VJ*** "BBB@ HHHH **** "BBB
M@ HHHH **** "L76/^0]X>_Z^I?_ $1)6U6+K'_(>\/?]?4O_HB2@#:HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3Z@=* +%%5&U33T>)'O[56E8K&IF4%R#@@<\G/%/N[^SL$5[R[@MU8X4S2!
M3Z#- %BBHGN((A&9)HT$K!8]S ;R>@'J:R-7\7Z'HMDMU<W\+HUPEL!#(K-O
M9@N,9[;@3Z"@#<HID4L<\2RPR))&PRKH<@_0BGT %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &+X
M9_X\KW_L)7?_ *.>MJL7PS_QY7O_ &$KO_T<];5 !1110 4444 %%%% !111
M0 4444 %%%% !1110 5BC_D=V_[!H_\ 1AK:K%'_ ".[?]@T?^C#0!M4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!B^
M&?\ CRO?^PE=_P#HYZVJQ?#/_'E>_P#82N__ $<];5 !1110 4444 %%%% !
M1110 4444 %%%% !1110 5BC_D=V_P"P:/\ T8:VJQ1_R.[?]@T?^C#0!M44
M44 %%%% !1110 4444 %%%% !1110 4444 %8NL?\A[P]_U]2_\ HB2MJL76
M/^0]X>_Z^I?_ $1)0!M4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 8OAG_CRO?^PE=_\ HYZV
MJQ?#/_'E>_\ 82N__1SUM4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!B^&?^/*]_["5W_P"C
MGK:K%\,_\>5[_P!A*[_]'/6U0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %8H_Y'=O^P:/_ $8:VJQ1_P CNW_8-'_HPT ;5%%% !1110 4444 %%%%
M !1110 4444 %%%% !6+K'_(>\/?]?4O_HB2MJL76/\ D/>'O^OJ7_T1)0!M
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0=X"GY023P<'BJM[X[^SW=\;70[^]TW3I_L]Y?0%"(WXW!4SN?;N&<#UQG%
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M6!8A6&2P.#Z'FJ-]X,\37O@R[M);*'^T+CQ)_:1C2=2HB+AB0Q(Z<CG!XZ4
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M;)^X<JIW#KD9!]16+_9WB'3?&WB>\LM)ANK?5K>!K>>6=1&DD43+LD7.[#'
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M0$R2P YP.N:OS^*->T*_N=/UM--GF?3)[ZSGM(WC0M$!NC=68G^)3D'IG@4
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MQ0!Z5145J\TEI"]Q$(9V13)&&W!&QR,]\'C-2T %%%% !1110 4444 %%%%
M!1110!B^&?\ CRO?^PE=_P#HYZVJQ?#/_'E>_P#82N__ $<];5 !1110 444
M4 %%%% !1110 4444 %%%% !1110 5BC_D=V_P"P:/\ T8:VJQ1_R.[?]@T?
M^C#0!M4444 %%%% !1110 4444 %%%% !1110 4444 %8NL?\A[P]_U]2_\
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M09-VP9Y087T[\\>B44 <'%X.U-/A_P"&-#+6_P!KTRZLYISO.PK%(&;:<<G
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M@ HHHH *Q=8_Y#WA[_KZE_\ 1$E;58NL?\A[P]_U]2_^B)* -JBBB@ HHHH
M**** "BBB@ HHHH **** ./^(_CR+X?^'8]1:S:[GGF$,,._:"V"26.#@ #_
M #UIOPW\?1?$#0);\69L[BWF\F:+?O7. 05.!P0?TK;\1^&=)\6:2VF:S:BX
MMBP<#<59&'1E(Y!Y/YTGAKPOI'A+2AINC6HM[?>7;YBS.QZLQ/)/ _*@#8HH
MHH \X^(D]A;^-O!LNI:?)?VH%]NMX[0W+,?+3'R '.#STXJ:;7-)M?"OB/4/
M#^@3:5>6>G2S"2XT@VP8A20/F4!N1TKI=3T&2_\ %>@ZRLZHFF"Y#1E<F3S4
M"C![8Q5GQ'I3ZYX9U328Y5B>]M9+=9&&0I92,D?C0!QEMKWB'5)/!UC9WT-H
M=6T0WEU-]G5BCA8CN1>F<N1CH,YP<8JE/XXU73='FL;_ %.!+V/7GTHZFUMP
ML2Q^:9#&."^WY<=,D&NHTGPC-IU[X:N&NT<:/I!TYP$(\QB(AN'H/W9X]ZJ2
M^![L?;;JUU"&/4#K1U>SD>(LB$QB,QN,@D%=P)!'4>E $W@;Q'+K4VK64FH+
MJ:6,D?DWZP>3YR.N<,N -RD,,C (QQ6.G]K)\6/$<RZLWDVNE0R+"8%(*GS2
MJ9[8;)SU/0UVFB6VLPQW$FM7UO<3RR;DCMHMD4"@ ;5SEFS@DDGOP!63/X9O
MQXXN=9M[NV^PW]FEI>02QL9 $W8*,#@9W=P>E &:OBC5#X(\&:IYJ?:M4NK&
M*Z;RQAEEQOP.WX5F7>N>+)]&\6ZQ;:O!;1:%>72P0?9%?STB&[:Y/(&.!C!Z
MDGTN6G@7Q NG:#I5WK-BVGZ'>03V_DVS+).L3<"0EB =O' Z\]L5K#P?,/#7
MBK2OM<>_6Y[N5)-AQ%YR[0".^* .<UGQW/-K-S:1:_!H@M;*"9$>T\\W$LB;
M\,<'" ;1Q@G)YXKNM!U$>(O"UAJ%Q;*GVZU1Y8'7(!9?F4@]1U'-8;>%]<TV
M^>[T#4K&%[JTAMKI;N!G >)2JRIM8<X.-IX.!766D4L%G!#/<-<2I&JO,RA3
M(P'+$#@9ZX% 'G6K>'=$3XM>'+9-&T];>33[MGB%J@5B"F"1C!(K7O9K]_%D
M7A/P_<0:+:6UA]MFE@M48Y>0JJ(I&U1D,Q.#VK5O?#TEWXWTK7Q<*L=C:SP-
M$5Y8R;<$'VVU!K&@:F?$D/B#0KNTBO?LILYXKR-FCECW;U.5((923ZY!- '+
MOXO\1O96%C'<6JZFOB-]%N;@P_)(@C=A)LSP<;#@'J",@&IK>Y\8W.L^(M#7
MQ%$ITJ.*>.]-C&9)/,0LJ,OW0H*MD@9.1TK2M_ <T,.EM)J"2WD.M-K%[+Y6
MU9I&1U*JN3M #*!DGA:U[3P]);^(_$&J&X5DU6&"-8PO,?EJRDD]\[OTH Y?
M3/$^N>+3H-C8WL>ES7.C+J=Y<I LI)+! B*W !.XG.> !5O6-5UW3-.TFWU?
MQ!IVDW4C2K<3V\!FEN-I^0Q1%3@$'+=<' '6DLO ^K:%;:'<:-J-F-3T_3O[
M.G^U0LT-Q'D,#A2"I##(^I%3+X2\0VE[IVIVVN6UUJD5O-;74U] S(PDD$F8
MU5AMVE0 N<8QS0!RM[K&L^)=+\#W:ZL+>6;69;9WCMAAWC\Y%EVMR,A<[3QE
MO:O1/%E_J.D^$[N[TY3+>1*@W"$R%5+*'D"#[Q52S8[XKF!X UBVTC3[:UU:
MTDN=+U>34;26XA8B17+EEE"D?-F0\KCITKL]3MM3N=(,=A?1VFH#8RS>5OC+
M @E2I.=K8(.#D \'- '!S^-+G3_"LU];^*-/U6*XO8+2WO\ [/A[8N?WAEC7
M'*@$@8!/<>M&\^(&HV7AWQ.UEJZ:K)IUO!<VM^;01D[Y-CQLN I(QD$#HWM6
M_)X&U*_;4=2O;^R@UFXEM9H'L[=A#$]NS,C,&;+EM[!N1Q@#I5C6/"_B'Q)X
M6UG3-7U:S$U^D:0I;6Y$, 5@Q/)+,6[Y.!@8'7(!%-J'B/PYK'A\ZQJ<-Y9:
MG=O;7(2V6-;>1T!A52.2-RLN3UW"L[7/'.I6=SXBN;:>"+3K.YMM*MI)(MRB
MY<CS9&QR0@8?+W(KL?%6@_\ "1^'+G35F$$[;9()\9\J5&#(WX,!^%8\/@9H
M_ \>B_;P-26X%\;\1YS=B7S=Y7/(W<8STXH YF3QW?VVC^)TL]:35GL=-%[:
MWYM!$5?)5HV7 4XPI''1N>E:&JZQXCT?2M,NM4UU;6VU"4R7-[#IX==/4QY6
M/'.06XWL.W;/&OJ'AWQ%KWAS6].UC5;(/?VWV>".UMR(H>N7)8EF)R.,@  ?
M6M/4;#7$M; :+?VL4ELGES0W<)>*<;0,DJ0RD$9&#CDY'H 6?#EQ<76A6T]S
MJ%GJ#ONVW=GQ',FX[6QT!QC('&<XKS/2]7UOP_IOC75/[26]N%UPV,$,T"JI
MF;R(UD)'. "/E''%>C>%M"?P_HQM)98I9I)Y;F4PQ^7&K2.7*HN3A1G YKG)
M? -].OB6P?4K==-U:[.H0NL+>?;W.8RISG:5!C!QC)]10!:M[W7=!\8:3I&J
M:LNJVVK13[)#;+"\,L2AN-O!4J3P>1@<U9\3ZIJ?]OZ+X>TFY2SFU 33379B
M$ABBB"Y"J>-Q+J,G.!GBDL/#VLW7B.RUKQ#>V4LFGPR1VD-E"R+NDP'D8LQ.
M<#  X&3UJUXCT"\U#4=+U?2KJ&WU/36D$?VB,O%+'( '1@"".BD$=".E '(Z
MIXM\1Z/8Z[IOVFWN]4TR^L8X;IX0@GBN&4 .HX!'S D8[' J[>W_ (ET?6Y=
M%NM<2Y%]ID]U:W0LT1[>6(KN4*."I#<9R1CK69XO\-WEEX6U*^O[^.35M6U7
M3S+-;1[4A"S1HBH&))VC)R>I-=/;^%]5OM??5M?OK.5X[&2RMH[*%D51(07D
M;<Q.X[0,= /6@#B[#5]8\/?"SP1-'?)<-?ZA90'S8%_=PNIR@]3Q][KS6YJ.
MK>*+S4_&4=AJ\-C;Z'L>W'V59&D)MUD*,3T7.>>OS=1CD7X?:Q/X2T#0KS4[
M$_V+J-O<PRPPN/,BBS\K L?F.>HXKH$\+2K<^+)?M28UP+L&T_NL0"+GUY&:
M ,"QU_Q(MSX0U2]OX)+/Q P22P2W"K!OA:1"K_>)&W!SP<G %6/"NK:SXDLO
M%40U&.QFLM=N+6"X2V1MD2%< J>"<$\FM(>$9OL'A"V^UIG07C:1MA_?;8&B
MX].6S60WP_U6'PYXFTRRU>"*36]6EO6D,;86&0C=&<$') P2.Q- &=;>+M?L
M?".O>(KG4HKVP$\=MI,\UJ(P^7$;3$)U3<V0.I">]:_@_P 4RW_B:XT<ZVNM
MVYL_M278M/(:-PX5D(  (.Y2._7.:N/X9UK4O#=QHFIW6E6\ CB%DVG6KI]G
M>-@R$AW((!5>!CI6MHMKXB2ZFN-<U"RE4QK'%;64!1 022Y+$L2>F.@ []:
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M !6*/^1W;_L&C_T8:VJQ1_R.[?\ 8-'_ *,- &U1110 4444 %%%% !1110
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M-JUN;9L$3,2#YC'^]P>G'S&MVB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#%\,_\>5[_P!A*[_]'/6U6+X9
M_P"/*]_["5W_ .CGK:H **** "BBB@ HHHH **** "BBB@ HHHH **** "L4
M?\CNW_8-'_HPUM5BC_D=V_[!H_\ 1AH VJ*** "BBB@ HHHH **** "BBB@
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MT34-)T'Q=(FAV.AZ;+H,P:SM+P2AIE!VR;0J[25+ GO@4 >O[ER1N&1U&>E
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M ,7PS_QY7O\ V$KO_P!'/6U6+X9_X\KW_L)7?_HYZVJ "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ K%'_([M_V#1_Z,-;58H_Y'=O\ L&C_ -&&@#:H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q=8_P"0]X>_Z^I?_1$E;58N
ML?\ (>\/?]?4O_HB2@#:HHHH **** "BBB@ HHHH **** "BBB@ (!&#R*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN(X?LZ2*@!6/(.P>BY X]JIW?AK1+ZQGL;K2K2:UGG-S+$\0*M*3DN?]KWH
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M:2:YLH)I)(#;.TD88M$3DH<]5)[5GV_@[PW:1PQP:)8QK#O\O;",KO7:_/N
M ?8#TH X1--LK'PI\,KBUMHHIS?6>Z55 =O,MW+Y/4[CUK%U*WTJ3X&^(;N_
M2#^U#?W?G2L!YHN?M# #/7.W:,?W<]J]E.E:>UO9VYLX3#9,CVR;!B$J-JE1
MVP"0*X#7? >J:S>ZI"=-\.JFH2%6UA4*74<!(RFS9AGQE=VX9'4=J ,^]L-0
MU/Q)XUB/]A"W\B".5]35RT=N;<$%2. NXR'/]X'TKTG18I8/#6GQ3W274J6<
M:O<(<K*0@!<'T/7\:BU/PMH.LW$-QJ>D6=W-" L;S1!B!G..>HSS@\5K8&W;
M@8Z8H \,\*W\?@GPOX4\72@C3KO39+'4 O\ >0O)"WUR'3_@0K7T'3)]*\9^
M$)]04_VE?VFHZA?<<^;)Y;%?^ C"_P# :],.@:0=(CT@Z;:G3H\;+4Q QK@[
MAA>G!YJS)86DU]!?26T3W4"LD4Q4%D5L;@#VS@?E0!Y#93/)+X&U&&VTBPL[
M[5#-:V]NKM=!'27<7E+?-G<-PQU(&>*;=:99'X2^.;PVL37)U*_D\XJ"X*3M
MMP>HQC(_'UKTM/!?AB(3!-!T]?.E65\0+RX.0?;!)/'J:OMHNF-I]S8-86YL
M[EG>>$QC9(SG+$COD\F@#RKQK,U]I7CB[M[32+>&VB6VNKB[5Y+B>40JR[/F
M CQO4+UR<G%;FD1:;?\ C?Q2^N);S!=-LMAN@"!;F-BY&>B[]V3]*["X\+:#
M=ZF^I7&CV4MX\?E-,\(+,NW;@^ORDCZ<5SFN>$KG^T;.32M \-WUG:VXBMHK
M]#&]JX)(*L$;<G(^7C!'!YH X7PI%?7%IX%BL182)]BU%[<:FK,C2"<9( YW
M["<>VZM2WT5(]7\(6%Y/IU[ VN:A*(K/)@B/E.YC /3:X/':NXTGP3IL'@W3
M_#^KV]OJ2VPWLTL?!E)+,R]QRQQ[5LP:'I5LEBD&G6T26&XVBI& (<@@[?3(
M)!^IH \YCT33#??$_-A;D*H"J8QA,VBL=H[9/)QU('I5+2(=5U#6M%6!=)F;
M_A$[-HQJB.X*MN\TJ!W^YN]MM>KC3+$->,+2'=>_\?1V#]]\NWYO7Y>/I5._
M\*Z#JEG:VE]I%G<6]HH2WC>($1+@#"^@P ,>U 'GNAZ-;KXC\$6=W/9ZG';:
M7?-%+"=\) ECV;<]0JD 9]*S+^UM8[:\A\B(01>/8%5-@VHK>46 '8$DY%>P
MQZ7813VTT=G DEK$88&6,#RHSC*KZ#Y1Q["J]UX=T:]L[NSNM,M9;>\E\ZXC
M>,$2R<?,?4_*.?:@"Y'/:K/]BCEA$T<8;R%8;E3H#M[#C'X5/5&ST?3;"5);
M2Q@@D2W2V5D0 B)?NIG^Z,G J]0 4444 %%%% !1110 4444 %%%% !1110
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MT_3+34;C4H1:WF/LSIES-D9^4*"3QZ"DC\7>'Y=.N]0CU6V:SM-HGF#?*A8
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M$'\,5N5YKX6.J^%_B)?Z1K1LQ'XA5M0M39AA$+A,"50&YR5PY^E>E4 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M''6O2AG'/6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#%\,_\>5[_P!A*[_]'/6U6+X9_P"/*]_["5W_ .CGK:H **** "BB
MB@ HHHH **** "BBB@ HHHH **** "L4?\CNW_8-'_HPUM5BC_D=V_[!H_\
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M"VWD#H,GJ15J.198DD0Y1P&4^H->+VU_K?AWX;^-]:MM<N9+NWU6YCC,L,1
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M<@$D#DD@"AO'-_I%AKQM;^]UB&"RCFM+K4+!K<I.\GEE&_=H&7+(PP,XR,T
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M]3*:OI^FZ['::-J\TDUS"UIOFC,G^M$3[P &YZJ<9.*UK#PK%IWBK^V+><+
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M!A@!UP%[U;O_  M>3:YJ>KV&L-975W;6\,96 .(S$[-ELGYE;=@CCCO73T4
M<%J?P^O==T3Q!!J>L0?VAK4<$3SVUF4BB2%MRX0N2Q.6R2W<>E:-]X5U)-<@
MUC1-7AL[K[$MC<K<6IF25%)*L '4A@2W<CFNLHH X2R^'UWI-C9'3];']J65
MW<W$5U<6V]9$G.7CD0,,_P /((Y7..U:%SX2O]1M-(&I:V;BZL=534GE^SA5
M?:&'E(N[Y5^;@DL>.^:ZNB@#FM6\/:F^O-K.A:I!8W4ULMK<K<6IG2158LC
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M"Q!"@CHH)P,UUE%% !1110 4444 8OAG_CRO?^PE=_\ HYZVJQ?#/_'E>_\
M82N__1SUM4 %%%% !1110 4444 %%%% !1110 4444 %%%% !6*/^1W;_L&C
M_P!&&MJL4?\ ([M_V#1_Z,- &U1110 4444 %%%% !1110 4444 %%%% !11
M10 5BZQ_R'O#W_7U+_Z(DK:K%UC_ )#WA[_KZE_]$24 ;5%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% &+X9_X\KW_ +"5W_Z.>MJL7PS_ ,>5[_V$KO\ ]'/6U0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %8H_Y'=O^P:/_1AK:K%'_([M_P!@T?\
MHPT ;5%%% !1110 4444 %%%% !1110 4444 %%%% !6+K'_ "'O#W_7U+_Z
M(DK:K%UC_D/>'O\ KZE_]$24 ;5%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &+X9_X\KW_L)7
M?_HYZVJQ?#/_ !Y7O_82N_\ T<];5 !1110 4444 %%%% !1110 4444 %%%
M% !1110 5BC_ )'=O^P:/_1AK:K%'_([M_V#1_Z,- &U1110 4444 %%%% !
M1110 4444 %%%% !1110 5BZQ_R'O#W_ %]2_P#HB2MJL76/^0]X>_Z^I?\
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M6"1HRZ"0$ '<%/3H?6J;>/=8_L%_%BZ99'PTDQ&#,WVDPB389@,;?]K;Z=Z
M/0Z*X>3Q;KU[XXU?PWH^F6+_ -GBWE:ZNIF5-DB;B"%!);/3MP<TG@?5/$.I
M>(/$Z:HUHUI:Z@T"".1RT;"./"J",;,$D]]Q/% '<T444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% &+X9_X\KW_L)7?_HYZVJQ?#/_ !Y7O_82N_\ T<];5 !1
M110 4444 %%%% !1110 4444 %%%% !1110 5BC_ )'=O^P:/_1AK:K%'_([
MM_V#1_Z,- &U1110 4444 %%%% !1110 4444 %%%% !1110 5BZQ_R'O#W_
M %]2_P#HB2MJL76/^0]X>_Z^I?\ T1)0!M4444 %%%% !1110 4444 <UXWT
M"3Q#H<,4%O;7,UK=Q7:6UUCRI]AYC;(. REAG'7%5-$BA\/6>K:Q>^&])\.V
M<40;;;+'YK*H)8R,@"XZ;0,]_7%=A574-.L]5M?LU];I<0;U<QORI*G(R._(
M!P>* .=^&MA<Z?X"T\7D9BN;DR7<D9ZJ99&D /N P%=9110 5P-EX @UC6]:
MUOQ3:>9=W5ULM4CN7416R *@^1AR>6/N:[ZB@#S.X\):_P"&O^$CLO"%NHT_
M5(HI(-USAK:<G9,5+$G)3# GN*M:EH&L:KX .C6FA0:7+I\EM)8P/>+(LHB<
M-M+*/E)V]3U)KT*B@#A?L'B36O'/A[6[[2H=/LM.CND>$W*RR9D0#<2O&,@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#%\,_\>5[_ -A*[_\ 1SUM5B^&?^/*]_["
M5W_Z.>MJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q1_R.[?]@T?^
MC#6U6*/^1W;_ +!H_P#1AH VJ*** "BBB@ HHHH **** "BBB@ HHHH ****
M "L76/\ D/>'O^OJ7_T1)6U6+K'_ "'O#W_7U+_Z(DH VJ*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRS9X&1T- '3T5Q%_XLUBUDTO2GATJQUBZBFGGDN[@FWCCC8*&4C!;>64@9!
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M$;HCF1!]T* _&<Y*GD5V] !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!B^&?^/*]_P"PE=_^CGK:K%\,_P#'E>_]A*[_
M /1SUM4 %%%% !1110 4444 %%%% !1110 4444 %%%% !6*/^1W;_L&C_T8
M:VJQ1_R.[?\ 8-'_ *,- &U1110 4444 %%%% !1110 4444 %%%% !1110
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MT_=P6W AL!3@Y&<<UZ%110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 8OAG_CRO?^PE=_\ HYZVJQ?#/_'E>_\ 82N_
M_1SUM4 %%%% !1110 4444 %%%% !1110 4444 %%%% !6*/^1W;_L&C_P!&
M&MJL4?\ ([M_V#1_Z,- &U1110 4444 %%%% !1110 4444 %%%% !1110 5
MBZQ_R'O#W_7U+_Z(DK:K%UC_ )#WA[_KZE_]$24 ;5%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% &+X9_X\KW_ +"5W_Z.>MJL7PS_ ,>5[_V$KO\ ]'/6U0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %8H_Y'=O^P:/_1AK:K%'_([M_P!@T?\ HPT
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MI?Q4\,:+%J-Y)8OIURTJ33%S*R]&8]R/6L$WVKO\-9/B"-;U :D"UVMJ)O\
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M0VX6/&<R.$!Y[ M6;IWB]KOQA+X:N]'N["[6S-ZC2R1NKQ"0("-C'&2>A]*
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M?8VG=4C\J($D!$4!<Y.23G.!4R^"S+J'AS4+_5[F\N]#,WER-&B>:)%"X8*
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MCNW_ &#1_P"C#6U6*/\ D=V_[!H_]&&@#:HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;4(Y;5'5@/-"!3N8CIDT =C1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!B^&?^/*]_P"PE=_^CGK:K%\,_P#'E>_]A*[_
M /1SUM4 %%%% !1110 4444 %%%% !1110 4444 %%%% !6*/^1W;_L&C_T8
M:VJQ1_R.[?\ 8-'_ *,- &U1110 4444 %%%% !1110 4444 %%%% !1110
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MIIIT-L-+;3XX[:=Y'/[X.&.Y% XSQDT =G1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!B^&?^/*]_["5W_P"CGK:K%\,_
M\>5[_P!A*[_]'/6U0 4444 %%%% !1110 4444 %%%% !1110 4444 %8H_Y
M'=O^P:/_ $8:VJQ1_P CNW_8-'_HPT ;5%%% !1110 4444 %%%% !1110 4
M444 %%%% !6+K'_(>\/?]?4O_HB2MJL76/\ D/>'O^OJ7_T1)0!M4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% $4]Q!:Q&6XFCAC'5Y&"@?B:D5@
MRAE(*D9!'0UY)\<O!7B/Q=9Z4^A1FZCM6D\ZT$@0DMC#C<0#C!'J,\=376_#
M'0-5\-> =/TO69-UY'N)0/N\I2Q(3/? ]./2@#KZ*** .(UW5=;E^)&G>'=-
MU)+&VFTZ2[D<VRRL65PN.>@P:VX_&&@S:T='BOP]^)G@:%8G.QU4,=QQA1@C
MDG!Z DUSM_\ \EUTC_L!S_\ HT54\/V<ES#\2DM%Q>3ZA<0QL."3]G7:,_5C
M^= '6:7XQT'6;_[%87_FSLK-'F)T64*<,8V8!7 _V2:Y_P 2?$73HM/9=$U!
M7O!?06X9H'\M\SHDBHY&UR 6^Z3C&>U<]X86VU0>%H%\8&ZO;. O;Z;%:1J]
MLRP-&RR%1N0#<5^;&2!WK,.M:0?A%X=T03PG5K:]LXIK,$&6WD2X4.SKU49R
M,GKN'K0!ZG<^,] M-8_LJ:_VW0E6%L1.8TD;&U&D"[%8Y'!(/(I-6\:>']$O
MS9:AJ BG55:0+$[K"K=#(R@A ?5B*\Q\5ZV;K2_$22ZU#:20ZJ4.C6UO$&9(
MY4_?RD@O@JN_?D#H*W[+Q%H.A:CXT37[FW87ERMW#$Y5C?6SP(J+$#_K,[67
M SUH Z6T\<Z==^-KOPTBR>9!"CB;RWVLYWEESMP %4$,3@YP.E7-*\8Z#K=]
M]CT^_P#-F*L\>8G1954X+1LP <#U4FN&GFA_X3'Q9IT!6QO-2\/6\>G6LA$;
MLWER@*J^JY P.F*K^'%M]6_X1N*+QB;R]M+5WM].BM(U:V(@,;+(4&4 W8^;
M&2!WH Z'Q#\1=.2SC30]062Z.H6]MN:!_+D!F5) CL-KD G[I..O:I=.U76[
M;XJ2>'+[4DO+)](:_3_1EC9&\X(!D=0!G\ZX@ZWH[_"OPKHR3PMJEM?6,<UH
M"/-MY$G4.SKU7G(R<9+#UKL3_P E_'_8L'_TI% '?4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 8OAG_CRO?^PE=_^CGK
M:K%\,_\ 'E>_]A*[_P#1SUM4 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !6%?V^JP^(5U&PL[:YC:U\AEEN3$5(<MG[C9ZUNT4 8GV[Q'_T ['_ ,&1
M_P#C5'V[Q'_T ['_ ,&1_P#C5;=% &)]N\1_] .Q_P#!D?\ XU1]N\1_] .Q
M_P#!D?\ XU6W10!B?;O$?_0#L?\ P9'_ .-4?;O$?_0#L?\ P9'_ .-5MT4
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M'_P9'_XU1]N\1_\ 0#L?_!D?_C5;=% &)]N\1_\ 0#L?_!D?_C5'V[Q'_P!
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MB%22N@V W')QJ)Y/_?JMRB@#!2?78Y'D3P]IRN_WV74""WU/E<TGFZYO=_\
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MQ'_T ['_ ,&1_P#C5;=% &)]N\1_] .Q_P#!D?\ XU1]N\1_] .Q_P#!D?\
MXU6W10!B?;O$?_0#L?\ P9'_ .-4?;O$?_0#L?\ P9'_ .-5MT4 8GV[Q'_T
M ['_ ,&1_P#C5'V[Q'_T ['_ ,&1_P#C5;=% &)]N\1_] .Q_P#!D?\ XU1]
MN\1_] .Q_P#!D?\ XU6W10!B?;O$?_0#L?\ P9'_ .-4?;O$?_0#L?\ P9'_
M .-5MT4 8GV[Q'_T ['_ ,&1_P#C5'V[Q'_T ['_ ,&1_P#C5;=% &)]N\1_
M] .Q_P#!D?\ XU1]N\1_] .Q_P#!D?\ XU6W10!B?;O$?_0#L?\ P9'_ .-4
M?;O$?_0#L?\ P9'_ .-5MT4 8GV[Q'_T ['_ ,&1_P#C5'V[Q'_T ['_ ,&1
M_P#C5;=% &)]N\1_] .Q_P#!D?\ XU1]N\1_] .Q_P#!D?\ XU6W10!B?;O$
M?_0#L?\ P9'_ .-4?;O$?_0#L?\ P9'_ .-5MT4 8GV[Q'_T ['_ ,&1_P#C
M5'V[Q'_T ['_ ,&1_P#C5;=% &)]N\1_] .Q_P#!D?\ XU1]N\1_] .Q_P#!
MD?\ XU6W10!B?;O$?_0#L?\ P9'_ .-4?;O$?_0#L?\ P9'_ .-5MT4 8GV[
MQ'_T ['_ ,&1_P#C5'V[Q'_T ['_ ,&1_P#C5;=% &)]N\1_] .Q_P#!D?\
MXU1]N\1_] .Q_P#!D?\ XU6W10!B?;O$?_0#L?\ P9'_ .-4?;O$?_0#L?\
MP9'_ .-5MT4 8GV[Q'_T ['_ ,&1_P#C5'V[Q'_T ['_ ,&1_P#C5;=% &)]
MN\1_] .Q_P#!D?\ XU1]N\1_] .Q_P#!D?\ XU6W10!B?;O$?_0#L?\ P9'_
M .-4?;O$?_0#L?\ P9'_ .-5MT4 8GV[Q'_T ['_ ,&1_P#C5'V[Q'_T ['_
M ,&1_P#C5;=% &5X>L[NST^5;V.*.>6ZGG*12%U4/(S 9(&>#Z5JT44 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK$-*A X;$0VC/1G/I79>)]<>W\"7>L:5.N9+='M[C&0H<@"3!] V[\* (O\
MA ='_P"?K7/_  =W?_QRC_A ='_Y^M<_\'=W_P#'*CN/#$&DVKW=IJNJ+*D$
MHF%Q>R3+=9C;[RN2 P/S J!TQTXK'TGQ'K&EZ+8PWTVG%9-"6\MY&20>6R^6
MFV0@L9,^8OW0"2,8Y% &Y_P@.C_\_6N?^#N[_P#CE'_" Z/_ ,_6N?\ @[N_
M_CE9-GXMUN_O(-,@%H+E[^2T:YGL9H0%6W68-Y+L&!^;;@MSUSS26OB_7M0@
M=;6+3DN+*SFN;KS(W*S,DTL05,,-@)A8Y.[&0,&@#7_X0'1_^?K7/_!W=_\
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M1/A;=GV21.^Y#U[G/RMV(/H= '+_ /" Z/\ \_6N?^#N[_\ CE'_  @.C_\
M/UKG_@[N_P#XY7444 <O_P (#H__ #]:Y_X.[O\ ^.4?\(#H_P#S]:Y_X.[O
M_P".5U%% '+_ /" Z/\ \_6N?^#N[_\ CE'_  @.C_\ /UKG_@[N_P#XY744
M4 <O_P (#H__ #]:Y_X.[O\ ^.4?\(#H_P#S]:Y_X.[O_P".5U%% '+_ /"
MZ/\ \_6N?^#N[_\ CE'_  @.C_\ /UKG_@[N_P#XY7444 <O_P (#H__ #]:
MY_X.[O\ ^.4?\(#H_P#S]:Y_X.[O_P".5U%% '+_ /" Z/\ \_6N?^#N[_\
MCE'_  @.C_\ /UKG_@[N_P#XY7444 <O_P (#H__ #]:Y_X.[O\ ^.4?\(#H
M_P#S]:Y_X.[O_P".5U%% '+_ /" Z/\ \_6N?^#N[_\ CE'_  @.C_\ /UKG
M_@[N_P#XY7444 <O_P (#H__ #]:Y_X.[O\ ^.4?\(#H_P#S]:Y_X.[O_P".
M5U%% '+_ /" Z/\ \_6N?^#N[_\ CE'_  @.C_\ /UKG_@[N_P#XY7444 <O
M_P (#H__ #]:Y_X.[O\ ^.4?\(#H_P#S]:Y_X.[O_P".5U%% '+_ /" Z/\
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M2*WG=9;R5XE"KE"'9LDD 'D\GI0!H_\ " Z/_P _6N?^#N[_ /CE'_" Z/\
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M_'*E\+ZUJ&J2WL%]$3Y C9+D6$]HDF[=E0LO)*E>2#C#+TKS\W<LFE736_\
MPD0UZYU6[MK&\^W2K:B47$HC!#2>7M 4 KMYQ@ DB@#N_P#A ='_ .?K7/\
MP=W?_P <H_X0'1_^?K7/_!W=_P#QRL\^-+X:_/"MJTMC;W;6LB1V$Y8!4R9?
M._U8&[C;Z<YSQ5"Y\:^(;#2;34+B/3'2]T:?4XHTB<&(H(BL;'>=PQ+RPQG'
M04 ;_P#P@.C_ //UKG_@[N__ (Y1_P (#H__ #]:Y_X.[O\ ^.56\0^+KK2=
M5O;&**,[([(0OY$DQ5IY)E8E$^9P%BR%7!)[^E&7QCK4=G;330PV4(>9);V[
MTZX2&0HR[,C(:!64D[WW $$<T :__" Z/_S]:Y_X.[O_ ..4?\(#H_\ S]:Y
M_P"#N[_^.4[P?>:I>R:XVHW<,Z0ZE+! L<)0HJXXR6.1T]._7/')Z9K.I:78
M:LU_?7$UGJ=QJ2V<\DA)MKB.691$#V5D0%?0JP[B@#JO^$!T?_GZUS_P=W?_
M ,<H_P"$!T?_ )^M<_\ !W=__'*RK'Q9?P>%KZ<I%+)I\%D$:3<3(9(HV8N<
M\G+FG3>)_$+7F;==,6V;67TI$DB<N."1*6#@<8Y7'/\ >&> #3_X0'1_^?K7
M/_!W=_\ QRC_ (0'1_\ GZUS_P '=W_\<K MM5\0:KXLL8H)["*^@M]2MI96
MA=H6\N>!0PC#@Y/'\7&3UZ4D'Q$U*^6VEM;$DK;6\T]O'8SW#2O(3O5)$^6,
M*!D%@<Y[8S0!T'_" Z/_ ,_6N?\ @[N__CE'_" Z/_S]:Y_X.[O_ ..4FCZI
MK^L-JLD9TV**VOY;2!6B<EA'+AF8[NI3(  Z\YQQ6GXDAT]M%N+K4Y+J.ULT
M:X=K:ZE@;"J2>8V4GC/&<4 1:9X5T[2+T7=M/J;R!2N+C4KB=.?]EW(_2MNL
M3PGIUQIOAVWBNY)WN9,S2+/.\QB+G=Y89R6(4$+R>V>];= !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %4[_3+;4OLOVE6/V6X2YCVMC#KG&?SJY67XA@NKC0[I+2^DLG"%FFB4%]H
M!)"D\*3ZX..W/- %7_A#M%$6H1K;LHO[Q+V?:YR94=7&/0;ESCU+>M-G\':9
M<74TC2WJV\\WGS6:W+""1\@DE/<C) X/<')JC8PW&L_#[P_-=:U<649LK>YO
MKA)"DDJ^3E@9<@IEB"6'. 1QG-4M&MOMWA2[N]2U75XM+@N9I[*Y^V213-:
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M]:ZBB@""RM196D=N)IY@@/[R=][MSGDGK4]%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !61JWAVSU:ZAO&DNK6
M]A4QI<VDQBDV'DJ2.&7(!P0>>16O10!CV'AC2]-EM);>.02VQE82/*SL[2XW
ML['EF.T<FL^3P#HLD#0 WD<+PB*2..X95<!F92?4JSL1^&<X%=110!D+X;T]
M85BVR,%O?M^6?DS9SD^V3TKE])\#3C4H5U*UA33;:TN+181>R3JZ2[1M16 \
MM H/&2>0,X45W]% &?I>D1:4D@2YO+EY,9>ZG,C  8 &>@_GWS5=_#.F/H<^
MCM&_V6::2<_.0RR/*92RMU!#G(],"MBB@#'3PW9)JC7ZRW0+OYKP"<B%Y-NP
MN4Z$D=NF><9YK";X?V::E:1*9YM)73KJQDAGN&8QQR>7M2/T "MSUZ<\#':T
M4 <ZO@S3,7+237TUQ<B$/<RW#&4&%F:-E/8@L>G7OGG+KCPA8W5FMM+=ZD4*
M2),?M;9N%<Y97]0?;&!P,"N@HH SM-T2UTFZOIK5I@+V7SI(F?**^,$J.V>]
M5KCPKI-UX?N=#FA9[*XEDF==YW!WD,I8-U!#L2/3BMJB@#FI_ VCSY4M=I"T
M4,<D*7#*DGE "-F'<@ ?7 STJ^/#FG J=C_+?G4!\Y_UQSS].3Q6M10!STW@
MS3)+O[7%+>6UR&G836]P48&9E:3\RH^E.3P?I<#VQM3=6L<$,4'E6]PR+*D9
MR@?UP2>>IR0<BM^B@#,CT*T@L[FV@DN(5N+IKN1HIBK;V<.<$<@$C!'H2*L:
MGIUOJ^FSV%V&:WF&UPIP2,YZ_A5NB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K/UJROM0T
MU[:POH[*63Y6EDM_.&T@@C;N7GGKFM"B@#B'\$:M+X5T[0I/$$#Q6,D6TMIW
MR2Q1IA8Y$\SYAD!CS@X'&*UKS0-1U7PM?Z/JFK13278*>?#:>4%C.,KMWG.<
M,,Y[^U=#10!F:_HXUW19--,_D)(\99@N[*JZL5QD=0I7\:@US1+C4;JQU#3[
MY;+4;(N(I9(?-1D< .C+N4D':IX(Y45M44 <A'X+N+%+.YTS5_)U:$W!FNY[
M82+<>>X>3<@9<?,JE<'C&.:;J'@F[F\*PZ!8ZTMO!EGNI9K02O/(TGF%^&4+
ME]QQSU]J[&B@#+M[+6$$!N-7BE=()$D"6@19)"P*/C<2-H!&W/.<\5F:!X=U
MC2-8O[V[UR"\COY1-/$EAY1WB-(P0WF' P@XQ73T4 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>exhibit101_changexreques006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit101_changexreques006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !117+>,X?&LJ67_"'7&FPL"_VG[<"<CY=NW /^UG\* .
MIHKRK['\;/\ H(^&?^^6_P#B*/L?QL_Z"/AG_OEO_B* /5:*\J^Q_&S_ *"/
MAG_OEO\ XBC['\;/^@CX9_[Y;_XB@#U6BO*OL?QL_P"@CX9_[Y;_ .(H^Q_&
MS_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?QL_Z"/AG_OEO_B*
M/5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB@#U6BO*OL?QL_P"@
MCX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?
MQL_Z"/AG_OEO_B* /5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB
M@#U6BO*OL?QL_P"@CX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\
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M_=H5\A,A'SW(*=?QJA)X2^+UUXFM?$<U]X?_ +0M[=K>(,6VHK')X"8R<]:
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MB#I?BKX<7UIX=^T7D6Z)[R<V[QQP()%P"6 RQ;:,#/&3VK=^Q_&S_H(^&?\
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MS_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?QL_Z"/AG_OEO_B*
M/5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB@#U6BO*OL?QL_P"@
MCX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?
MQL_Z"/AG_OEO_B* /5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB
M@#U6BO*OL?QL_P"@CX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)"JN(QT0,!G;QTZ5=HHH *JWFFV&HF$WUE;7)@<21>?$K^6PZ,N1P?<5:HH
M@-G:M>K>M;0FZ1#&LY0;PA.2H;KC/:D6QM$N9[E;6!9[A0LTHC :0#@!CU(&
M3C/K5BB@"K!IMA:Z?_9]O96T5EM*_9HXE6/!R2-H&,')_.H=,T'1]$$@TK2K
M*Q$IR_V:!8]WUV@9K0HH RK;P]I&E3W%[I>C:=;WTBG,L4"QLYZX9E&<$]:R
M/#WA_5#XEO?$_B'[&NI30+9V\%HQ=+> $L1N8 LS,<DX'05UE% &9>^'=$U*
M^CO;[1["ZNXL;)YK9'=<=,,1FM.BB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBL._NM6EU]=.TZYLK=%M?/=[BU>8D
MEBN!MD3'3WH W**Q/LOBC_H,:/\ ^"J7_P"2*/LOBC_H,:/_ ."J7_Y(H VZ
M*Q/LOBC_ *#&C_\ @JE_^2*/LOBC_H,:/_X*I?\ Y(H VZ*Q/LOBC_H,:/\
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M:/\ ^"J7_P"2* -NBL3[+XH_Z#&C_P#@JE_^2*/LOBC_ *#&C_\ @JE_^2*
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M/LOBC_H,:/\ ^"J7_P"2* -NBL3[+XH_Z#&C_P#@JE_^2*/LOBC_ *#&C_\
M@JE_^2* -NBL3[+XH_Z#&C_^"J7_ .2*/LOBC_H,:/\ ^"J7_P"2* -NBL3[
M+XH_Z#&C_P#@JE_^2*/LOBC_ *#&C_\ @JE_^2* -NBL3[+XH_Z#&C_^"J7_
M .2*/LOBC_H,:/\ ^"J7_P"2* -NBL3[+XH_Z#&C_P#@JE_^2*/LOBC_ *#&
MC_\ @JE_^2* -NBL3[+XH_Z#&C_^"J7_ .2*/LOBC_H,:/\ ^"J7_P"2* -N
MBL3[+XH_Z#&C_P#@JE_^2*/LOBC_ *#&C_\ @JE_^2* -NBL3[+XH_Z#&C_^
M"J7_ .2*/LOBC_H,:/\ ^"J7_P"2* -NBL3[+XH_Z#&C_P#@JE_^2*/LOBC_
M *#&C_\ @JE_^2* -NBL3[+XH_Z#&C_^"J7_ .2*/LOBC_H,:/\ ^"J7_P"2
M* -NBL3[+XH_Z#&C_P#@JE_^2*/LOBC_ *#&C_\ @JE_^2* -NBL3[+XH_Z#
M&C_^"J7_ .2*/LOBC_H,:/\ ^"J7_P"2* -NBL3[+XH_Z#&C_P#@JE_^2*/L
MOBC_ *#&C_\ @JE_^2* -NBL3[+XH_Z#&C_^"J7_ .2*/LOBC_H,:/\ ^"J7
M_P"2* -NBL3[+XH_Z#&C_P#@JE_^2*/LOBC_ *#&C_\ @JE_^2* -NBL3[+X
MH_Z#&C_^"J7_ .2*/LOBC_H,:/\ ^"J7_P"2* -NBL3[+XH_Z#&C_P#@JE_^
M2*/LOBC_ *#&C_\ @JE_^2* -NBL3[+XH_Z#&C_^"J7_ .2*/LOBC_H,:/\
M^"J7_P"2* -NBL3[+XH_Z#&C_P#@JE_^2*/LOBC_ *#&C_\ @JE_^2* -NBL
M3[+XH_Z#&C_^"J7_ .2*/LOBC_H,:/\ ^"J7_P"2* -NBL3[+XH_Z#&C_P#@
MJE_^2*/LOBC_ *#&C_\ @JE_^2* -NBL3[+XH_Z#&C_^"J7_ .2*/LOBC_H,
M:/\ ^"J7_P"2* -NBL3[+XH_Z#&C_P#@JE_^2*/LOBC_ *#&C_\ @JE_^2*
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M/LOBC_H,:/\ ^"J7_P"2* -NBL3[+XH_Z#&C_P#@JE_^2*/LOBC_ *#&C_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,7P
MS_QY7O\ V$KO_P!'/6U6+X9_X\KW_L)7?_HYZVJ "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ K%'_([M_V#1_Z,-;58H_Y'=O\ L&C_ -&&@#:HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *Q=8_P"0]X>_Z^I?_1$E;58NL?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!B^&?^/*]
M_P"PE=_^CGK:K%\,_P#'E>_]A*[_ /1SUM4 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !6*/^1W;_L&C_T8:VJQ1_R.[?\ 8-'_ *,- &U1110 4444
M %%%% !1110 4444 %%%% !1110 5BZQ_P A[P]_U]2_^B)*VJQ=8_Y#WA[_
M *^I?_1$E &U1110 4444 %%%% !1110 4444 %%%% !1110 4444 >/?'FU
M\6W.FZ7_ ,(^E])8AW^UI8ABY;Y=A8+R5^][9Z]J['X7Q:_#X TZ/Q*9O[0
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M4\/V<EQ#\2A9I_IL^H3Q1LOWB?LZ[1GZL?SH Z[3/%^@:SJ!L=/U&.:XPS*
MC*) IPQ1B ' [E2:P/$GQ%TVWL'31=1AEODO8+?YHF*-F9$D"L0%8@$_=)Q^
M%<WX92'4T\*1KXPAN+JT@+VNG0V2+)"1 R,DA4Y0#.#NQD@=\5F'6-'/P?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** ,7PS_QY7O\ V$KO_P!'/6U6
M+X9_X\KW_L)7?_HYZVJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K%
M'_([M_V#1_Z,-;58H_Y'=O\ L&C_ -&&@#:HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *Q=8_P"0]X>_Z^I?_1$E;58NL?\ (>\/?]?4O_HB2@#:HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** /+/C+\.M8\=6^ES://%YMD
M9 UO,^T,'V_,#TR-O?U]N>H^''A>[\'>"++1KVY6>YC+NY0DHI9B=JY[#/YY
MKJZ* "BBB@#@;_\ Y+KI'_8#G_\ 1HJ/0M+N;JV^(ELD3137NH7$<+L-N[=
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MHVDCN*K>&[+3]4DT6U&J>);C4[.W<FVN4"PV$GDF,B3,:X^\5 !.?IS7K=%
M'BO]J1R_#?P[X;2QO/[6L+RRBO+?[,X^S^7,H9V;&,' Q@\[O8XZP_\ )?Q_
MV+!_]*17?5S&G>$9;7QE)XFO-8FO;IK(V21M"D:I&9 X^Z.2"._K0!T]%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &+X9
M_P"/*]_["5W_ .CGK:K%\,_\>5[_ -A*[_\ 1SUM4 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !6*/^1W;_ +!H_P#1AK:K%'_([M_V#1_Z,- &U111
M0 4444 %%%% !1110 4444 %%%% !1110 5BZQ_R'O#W_7U+_P"B)*VJQ=8_
MY#WA[_KZE_\ 1$E &U1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3@9!^;^]WS77W>FS#Q5H_A%=8U?[!]CN+^YE-ZXGN&#HJH900P4%R< CMVH
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M*LIP.".H&*VZ* ..NOASIM[X;NM'N;V]D:\NUO+J\9E\Z:4$$$_+M ^4#
M JUK/@XZQ<WO_$\U.VLK]0E[91,ACE&W:0"REDRHP=I&?KS73T4 4+72_LNJ
M7-XM[=/%-''&EH[@PP[ 1E!C@G///85?HHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG]"1T)JAIUMJE_\ %^379=&O;+3X]%:Q$MR8_GD$X?@*[<$<\XZ4 =[1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!B^&?
M^/*]_P"PE=_^CGK:K%\,_P#'E>_]A*[_ /1SUM4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !6*/^1W;_L&C_T8:VJQ1_R.[?\ 8-'_ *,- &U1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 8OAG_CRO?^PE=_\ HYZVJQ?#/_'E>_\ 82N__1SUM4 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !6*/^1W;_L&C_P!&&MJL4?\
M([M_V#1_Z,- &U1110 4444 %%%% !1110 4444 %%%% !1110 5BZQ_R'O#
MW_7U+_Z(DK:K%UC_ )#WA[_KZE_]$24 ;5%%% !1110 4444 %%%% !1110
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MJL76/^0]X>_Z^I?_ $1)0!M4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 8OAG_CRO?^PE=_\ HYZVJQ?#
M/_'E>_\ 82N__1SUM4 %%%% !1110 4444 %%%% !1110 4444 %%%% !6*/
M^1W;_L&C_P!&&MJL4?\ ([M_V#1_Z,- &U1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,GJ*SK__ )+KI'_8#G_]&BI=%T"]EM_'=G<0O;C5+^?R)'& R/ B!A[9S^5
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M4 %%%% !1110 4444 %%%% !1110 4444 8OAG_CRO?^PE=_^CGK:K%\,_\
M'E>_]A*[_P#1SUM4 %%%% !1110 4444 %%%% !1110 4444 %%%% !6*/\
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M19G$<\8==PE&#@]^:U;+QEJ5[K6M1#3;:+2M%N98[R[DG.XHL88;%"\MZY(
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M1110 4444 %8NL?\A[P]_P!?4O\ Z(DK:K%UC_D/>'O^OJ7_ -$24 ;5%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!Q'Q$^&FG_$*WL_M%W+9W5H
M6\J:-0P*MC(*G&>@[\5M^$?"UEX-\-VVBV#2/%#EFDD^\[$Y)/\ GI6Y10 4
M444 <#?_ /)==(_[ <__ *-%7='\,7:P^,K6^410ZQ?3/"RL&)B>%$SQTY!X
M-6/$MCX,FU2VN?$5Q8P7RQ%(6GO?(?9GH,,,C-=30!YOX7\)R6<^GVMSX(T:
MQ>UA,=SJL8B+S,$VAHMHW L>26Q@9'-4/^$?\7GP7IOA/^QX0FFW5ONOOM2;
M+B&*96!1?O!L $[L=#C.17J]17%U;V<7FW,\4$>X+OE<*,DX R>Y) 'UH \I
MUGP7K5Y%KT">'+*YO[B_:\AU>>6,N\0=72),_,K  )SA0,G-;B6OBO0K_7'T
M?18KI=9E6\ADEND06<[1JCB49RR@J#\F<\CWKOZ* //[GPYK4OBS6!/:K<6&
MN:1'93WL4BH('59%8F,G<0=_&,U!X9\)O;S65M<^"-&TY[>W:*YU.,1,\K;-
MFZ':-PW9));'&1S7H]% 'E(T'Q>_A#1_"S:/"J:7=VQ>]^UH4N(8I5(*+]X'
M: 3NQT(&<UL'_DOX_P"Q8/\ Z4BNYN+JWM(Q)<SQ0H65 TCA06)P!D]R2 !7
M-Z#8^#(_$-Q=Z)<6,VKF)HYC%>^=((]P+ J6.!NQVX- '4T444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\A[P]_U]2_\ HB2MJL76/^0]X>_Z^I?_ $1)0!M4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 4+_0M(U65)=1TJQO)$&U'N+=)"HZ
MX!8'%7Z** "BBB@ HHHH **** "J%GH6D:==/=6.E6-K<2 AY8+=$=@3D@D#
M)Y -7Z* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4 %%%% !1110 4444 %8H_Y'=O\ L&C_ -&&MJL4?\CNW_8-'_HPT ;5%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 8OAG_ (\KW_L)7?\ Z.>MJL7PS_QY7O\ V$KO_P!'/6U0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %8H_Y'=O\ L&C_ -&&MJL4?\CN
MW_8-'_HPT ;5%%% !1110 4444 %%%% !1110 4444 %%%% !6+K'_(>\/?]
M?4O_ *(DK:K%UC_D/>'O^OJ7_P!$24 ;5%%% !1110 4444 %%%% !1110 4
M444 %<98:]KNJ?$;7M&AET^'3-(-J6#V[M+*)8]Q ;> I!!_A/6NSK@?"O\
MR5WX@?[NG?\ HAJ .EM/%OAZ^EDCM=9LI6CMS=2;91A(@<%R>PSZU+I?B71=
M:@GGTW5+6YBM^9F20?NQC.6]!@$YZ<5Y3I]F(_V<Q);+'&TDWFW,ACW H+OY
MV8#!8!%Y&?NC%3^*K.^N-,\2WO\ PDFFZE?CP^\36^G69B_<EPP9F\QP>!(
M/1C0!V+^/=/OO$.@V&AW]C?0WMS+%<E&W,BK"[J1@]RG7!!YQ6W9^*M!U#5I
M-*M-7M)[Z/<&@24%LK]X#U([XZ5Q>M:EHD_C3P ^ER6]PT7VEXEMR&*P_9FP
M..F<# ]CZ&L.PU-KB?P#=/J&DPV]Q?>=#IMC;[/LBO#+PTF\Y.6P1@9;/I0!
MZ?\ \)5H']M_V-_:]G_:6[;]F\T;]V,[?][VZU0T'Q]H'B"355MK^!5TZ1Q(
MS2C#1J%)E]DRQ&3Z5RWA._\ #T'@6SLM>:&2_35W26W/S3_;#<L5.T?-NR0<
M^GM6+>2AO!WCRVCN(4E3Q.9IT<;]L E@W.R9!*8R3TR >: /5M,\2:+K-M/<
M:=JEK<PV_,SI(,1C&<MZ#'.37/7'CNVU'7-%T[PWJ.GW8OI)XI9.9/**PNZ-
M@,."R_B <'O7(>*[.\GTKQ/>MXCT[4[T:'Y4EOIUF8OW/F!@S-YC@_*) !Z$
MUNZI?Z+>_$3X?C3)K:9E%T4,#!MD)MFV@XZ XX'L?>@#8\'^(-8U/7?$>DZN
MUE))I,\,22VL+1!PZ;B2&=O;O77UP/@G_DH?Q _Z_+7_ -$UWU !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!B^&?^/*]_["5W_Z.>MJL7PS_P >5[_V$KO_ -'/6U0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %8H_P"1W;_L&C_T8:VJQ1_R.[?]@T?^
MC#0!M4444 %%%% !1110 4444 %%%% !1110 4444 %8NL?\A[P]_P!?4O\
MZ(DK:K%UC_D/>'O^OJ7_ -$24 ;5%%% !1110 4444 %%%% !1110 4444 %
M<=8^'-:TSXA:WKEO)I\FGZN;82I(SB6,11[>,#!))/4UV-% $,-G;6UJ+6"W
MABMP"!%&@5 #R>!QSD_G4-AI&FZ7%)%I^GVEI'(<NMO"L88^I  S5RB@#/M-
M!T>P8-9Z38VS!S(##;HA#$$%N!UP2,^](GA_18UE5-(L%66032!;9 '<'(8\
M<L#WZUHT4 4O['TS^T_[2_LZS^WXQ]J\A?-QC'W\9_6E72M.6]GO%T^U%U.F
MR:<0KOD7T9L9(X'!]*N44 4['2--TN&2'3]/M+2*0Y=+>%8U8^I  S5>/0M-
MT^%VTK2=-M[E=TD)6W6-1(5(R2HR,YP2.<$UJ44 <EX1\.:KI.M>(=5U66S:
M;5IHI1':EBJ;$VXRP!]*ZVBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q?#/_ !Y7O_82N_\
MT<];58OAG_CRO?\ L)7?_HYZVJ "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ K%'_([M_P!@T?\ HPUM5BC_ )'=O^P:/_1AH VJ*** "BBB@ HHHH *
M*** "BBB@ HHHH **** "L76/^0]X>_Z^I?_ $1)6U6+K'_(>\/?]?4O_HB2
M@#:HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?XP?\B_HG_8=M/\ T(U-KEKX6UGQ3=QRZM=Z'K]E$BM=077V9Y8B-RD9^61
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M<GW-;O@NXA7QGXWMFE03G4T<1%AN*^0G..N* .YHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,7P
MS_QY7O\ V$KO_P!'/6U6+X9_X\KW_L)7?_HYZVJ "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ K%'_([M_V#1_Z,-;58H_Y'=O\ L&C_ -&&@#:HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *Q=8_P"0]X>_Z^I?_1$E;58NL?\
M(>\/?]?4O_HB2@#:HHHH **** "BBB@ HHHH CG@ANH'@N(HYH7&UXY%#*P]
M"#UK"USPZ^MWNDV[O%%HUE*+F6W4?--(G^J7'0(#\Q'<@"NAHH **** (;FT
MMKQ%2ZMXIU1PZK*@8*PZ$9[CUJOJ&BZ5JVS^TM,L[WR_N?:8%DV_3<#BKU%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!B^&?\ CRO?^PE=_P#HYZVJQ?#/_'E>_P#82N__
M $<];5 !1110 4444 %%%% !1110 4444 %%%% !1110 5BC_D=V_P"P:/\
MT8:VJQ1_R.[?]@T?^C#0!M4444 %%%% !1110 4444 %%%% !1110 4444 %
M8NL?\A[P]_U]2_\ HB2MJL76/^0]X>_Z^I?_ $1)0!M4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 8OAG_CRO?^PE=_\ HYZVJQ?#/_'E>_\ 82N__1SUM4 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !6*/^1W;_L&C_P!&&MJL4?\ ([M_V#1_Z,-
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M3V[@#8R99?\ :!(8$<=>: &S>+-1_P")=96WA^1M:O$ED>RN+D1K D;!69I
M&R"2NW YSGBJ%]\24LM*TJZ_L>XEN;W4'TV2S60;X;A=P*YZ-EEP#D#!!XKG
MCX2OPFBZEKFB7NLP0175L]F;A7NH(GE#P$MO =E4;6^;N.N*O7/A>\>W\(-I
M_AT:;';:W]MN;5)@YACPP#N<\L1MR 3@GO0!U&D^);ZXUZ/1M7T==.O);-KN
M,)="96"R;&7(4<@%#_P+VK N_%]AJFH>')YM)F=+C69K2QF6[9!^[)7S2H #
M D'"G/3-:7Q TW6);>PU?P[;&XU>P>5(XPP7<DL91N20.&V-_P  K,U?P?=V
MLGP_L],MC-:Z-=+]ID! VJ$P7.3SDY/'K0!IW/C:^^UZ@^F^'9]0TS3KG[+=
M7$4P\TN,;_*BVDOMSSR,D'&<4NI^.+FTFU2>TT1[O2M(;9?W8N C*0H=_+C*
MG?M5@3DKW SBLZU_X27PO-K>F:=H$E])?:E+>6-X9$%LHE8,WF_,'&T[N #G
MC%9=_P"$5M];UP77@U]<EU&Z-Q:72SB.$!U4,DN7!4*P8Y"MD'UH ZEO&%]/
MJUY!I>A-?V-C-'#<SI=*L@+JKY2+'S *X.21GG&<5UM>9^)-%N[C5)!IOA>Z
MM=:B:)-/UBQN%2+RAM_UQW D ;@5*MD 8ZUZ90 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 8OAG_CRO?^PE=_\ HYZV
MJQ?#/_'E>_\ 82N__1SUM4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!6*/^1W;_L&C_P!&&MJL4?\ ([M_V#1_Z,- &U1110 4444 %%%% !1110 4
M444 %%%% !1110 5BZQ_R'O#W_7U+_Z(DK:K%UC_ )#WA[_KZE_]$24 ;5%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!2T_2;/2VO&M(BAO+EKJ?
M+$[I& !//3A1P*NT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M* "BBB@ HHHH **** "BBB@#D_''Q"T7P#:VTNJ_:)9+EB(H+= SL!C)Y(
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% &+X9_X\KW_L)7?_ *.>MJL7
MPS_QY7O_ &$KO_T<];5 !1110 4444 %%%% !1110 4444 %%%% !1110 5B
MC_D=V_[!H_\ 1AK:K%'_ ".[?]@T?^C#0!M4444 %%%% !1110 4444 %%%%
M !1110 4444 %8NL?\A[P]_U]2_^B)*VJQ=8_P"0]X>_Z^I?_1$E &U1110
M4444 %%%% !1110 4444 %%%% !1110 4444 <QXR\!:'XZM;>'6(I=UNQ:&
M:!]KIG&1G!&#@=1VK5T#0=.\,Z+;Z3I<'DVD (52<DDG))/<DFM*B@ HHHH
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M0Q[@"=Q09&['?DT =11110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^*Z8_P#)?Q_V+!_]*14:_#G4O[)LM$?Q)NTC3KJ*>TB%F!)B.0,J2/O^8 9
MP!V)SC%0:=JMAJ_QYDFTZ[BNHXO#K0R/$VX*XN02I]^10!Z31110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!B^&?^/*]_["
M5W_Z.>MJL7PS_P >5[_V$KO_ -'/6U0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %8H_P"1W;_L&C_T8:VJQ1_R.[?]@T?^C#0!M4444 %%%% !1110
M 4444 %%%% !1110 4444 %8NL?\A[P]_P!?4O\ Z(DK:K%UC_D/>'O^OJ7_
M -$24 ;5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% &+X9_P"/*]_["5W_ .CGK:K%\,_\>5[_
M -A*[_\ 1SUM4 %%%% !1110 4444 %%%% !1110 4444 %%%% !6*/^1W;_
M +!H_P#1AK:K%'_([M_V#1_Z,- &U1110 4444 %%%% !1110 4444 %%%%
M!1110 5BZQ_R'O#W_7U+_P"B)*VJQ=8_Y#WA[_KZE_\ 1$E &U1110 4444
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MB^&?^/*]_P"PE=_^CGK:K%\,_P#'E>_]A*[_ /1SUM4 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!B^&?^/*]_["5W_P"C
MGK:K%\,_\>5[_P!A*[_]'/6U0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %8H_Y'=O^P:/_ $8:VJQ1_P CNW_8-'_HPT ;5%%% !1110 4444 %%%%
M !1110 4444 %%%% !6+K'_(>\/?]?4O_HB2MJL76/\ D/>'O^OJ7_T1)0!M
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &-XB\5Z'X3M([K7-0C
MLXI6VQ[@69SWPJ@D_E5[3-3LM8TZ#4-.N8[FTG7='+&<AA_GC%<%\5_AE/\
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ML7_A%=*]+W_P83__ !='_"*Z5Z7O_@PG_P#BZ -JBL7_ (172O2]_P#!A/\
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M1_PBNE>E[_X,)_\ XN@#:HK%_P"$5TKTO?\ P83_ /Q='_"*Z5Z7O_@PG_\
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M VJ*Q?\ A%=*]+W_ ,&$_P#\71_PBNE>E[_X,)__ (N@#:HK%_X172O2]_\
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MA/\ _%T?\(KI7I>_^#"?_P"+H VJ*Q?^$5TKTO?_  83_P#Q='_"*Z5Z7O\
MX,)__BZ -JBL7_A%=*]+W_P83_\ Q='_  BNE>E[_P"#"?\ ^+H VJ*Q?^$5
MTKTO?_!A/_\ %T?\(KI7I>_^#"?_ .+H VJ*Q?\ A%=*]+W_ ,&$_P#\71_P
MBNE>E[_X,)__ (N@#:HK%_X172O2]_\ !A/_ /%T?\(KI7I>_P#@PG_^+H V
MJ*Q?^$5TKTO?_!A/_P#%T?\ "*Z5Z7O_ (,)_P#XN@#:HK%_X172O2]_\&$_
M_P 71_PBNE>E[_X,)_\ XN@#:HK%_P"$5TKTO?\ P83_ /Q='_"*Z5Z7O_@P
MG_\ BZ -JBL7_A%=*]+W_P &$_\ \71_PBNE>E[_ .#"?_XN@#:HK%_X172O
M2]_\&$__ ,71_P (KI7I>_\ @PG_ /BZ -JBL7_A%=*]+W_P83__ !='_"*Z
M5Z7O_@PG_P#BZ -JBL7_ (172O2]_P#!A/\ _%T?\(KI7I>_^#"?_P"+H VJ
M*Q?^$5TKTO?_  83_P#Q='_"*Z5Z7O\ X,)__BZ #PS_ ,>5[_V$KO\ ]'/6
MU56PT^UTNU%M:1E(MS/@NSDLQR22Q))))JU0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %8%]X.TS4;V6[GN-6624Y80ZK<Q(.,<*K@#\!6_7'?$A=0ET33
M[;2[Z:RN[C48HHY8G*X)#8!QU7(&1WH L_\ " Z/_P _6N?^#N[_ /CE'_"
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MQ7*K831/A;=GV21.^Y#U[G/RMV(/H= '+_\ " Z/_P _6N?^#N[_ /CE'_"
MZ/\ \_6N?^#N[_\ CE=110!R_P#P@.C_ //UKG_@[N__ (Y1_P (#H__ #]:
MY_X.[O\ ^.5U%% '+_\ " Z/_P _6N?^#N[_ /CE'_" Z/\ \_6N?^#N[_\
MCE=110!R_P#P@.C_ //UKG_@[N__ (Y1_P (#H__ #]:Y_X.[O\ ^.5U%% '
M+_\ " Z/_P _6N?^#N[_ /CE'_" Z/\ \_6N?^#N[_\ CE=110!R_P#P@.C_
M //UKG_@[N__ (Y1_P (#H__ #]:Y_X.[O\ ^.5U%% '+_\ " Z/_P _6N?^
M#N[_ /CE'_" Z/\ \_6N?^#N[_\ CE=110!R_P#P@.C_ //UKG_@[N__ (Y1
M_P (#H__ #]:Y_X.[O\ ^.5U%% '+_\ " Z/_P _6N?^#N[_ /CE'_" Z/\
M\_6N?^#N[_\ CE=110!R_P#P@.C_ //UKG_@[N__ (Y1_P (#H__ #]:Y_X.
M[O\ ^.5U%% '+_\ " Z/_P _6N?^#N[_ /CE'_" Z/\ \_6N?^#N[_\ CE=1
M10!R_P#P@.C_ //UKG_@[N__ (Y1_P (#H__ #]:Y_X.[O\ ^.5U%% '+_\
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M@FM:@#E_^$!T?_GZUS_P=W?_ ,<H_P"$!T?_ )^M<_\ !W=__'*ZBB@#E_\
MA ='_P"?K7/_  =W?_QRC_A ='_Y^M<_\'=W_P#'*ZBB@#E_^$!T?_GZUS_P
M=W?_ ,<H_P"$!T?_ )^M<_\ !W=__'*ZBB@#E_\ A ='_P"?K7/_  =W?_QR
MC_A ='_Y^M<_\'=W_P#'*ZBB@#E_^$!T?_GZUS_P=W?_ ,<H_P"$!T?_ )^M
M<_\ !W=__'*ZBB@#E_\ A ='_P"?K7/_  =W?_QRC_A ='_Y^M<_\'=W_P#'
M*ZBB@#E_^$!T?_GZUS_P=W?_ ,<H_P"$!T?_ )^M<_\ !W=__'*ZBB@#E_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
)HH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>exhibit101_changexreques007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit101_changexreques007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !117+>,X?&LJ67_"'7&FPL"_VG[<"<CY=NW /^UG\* .
MIHKRK['\;/\ H(^&?^^6_P#B*/L?QL_Z"/AG_OEO_B* /5:*\J^Q_&S_ *"/
MAG_OEO\ XBC['\;/^@CX9_[Y;_XB@#U6BO*OL?QL_P"@CX9_[Y;_ .(H^Q_&
MS_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?QL_Z"/AG_OEO_B*
M/5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB@#U6BO*OL?QL_P"@
MCX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?
MQL_Z"/AG_OEO_B* /5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB
M@#U6BO*OL?QL_P"@CX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\
MH(^&?^^6_P#B*/L?QL_Z"/AG_OEO_B* /5:*\J^Q_&S_ *"/AG_OEO\ XBC[
M'\;/^@CX9_[Y;_XB@#U6BO*OL?QL_P"@CX9_[Y;_ .(H^Q_&S_H(^&?^^6_^
M(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?QL_Z"/AG_OEO_B* /5:*\J^Q_&S_
M *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB@#U6BO*OL?QL_P"@CX9_[Y;_ .(H
M^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?QL_Z"/AG_OEO
M_B* /5:ANN;.?_KFW\J\P^Q_&S_H(^&?^^6_^(H^Q_&S_H(^&?\ OEO_ (B@
M"M\+/#T>N_ V70[^-HTNVN(SO7!0ELJV#Z'!_"LWX8V&M>(/%=G+XAMY$C\(
M6C6$(D!P]P69=XSUP@ _!36W]C^-G_01\,_]\M_\11]C^-G_ $$?#/\ WRW_
M ,10!+X=AE7]H3QA*T;B-K"W"N5.#\D70U8C^)Q\.:GJ&F^.K:33Y([AOLEY
M;VLCV]Q#_"01N.[UJE]C^-G_ $$?#/\ WRW_ ,11]C^-G_01\,_]\M_\10!%
MIVK6^O\ Q(N/'%C8W5OH.F:3)%->RP&,WC9W853RP '7U 'I6=X%^'MCXZM-
M0\7^+K.X:]U6[>2",3R1>5"#M ^4CTP,]E%:WV/XV?\ 01\,_P#?+?\ Q%'V
M/XV?]!'PS_WRW_Q% %/QO\'M$L/"EWJ7AFUN8-8L +JW?[3)(3L.X@!F/. <
M>X%>C^$=='B7PIIVK&,QR7$(,L9&-D@X<8/^T#^%<)]C^-G_ $$?#/\ WRW_
M ,11]C^-G_01\,_]\M_\10!:^(FAZS8^)]'\=^';-KZ[TY#!>62??G@.?N^I
M&YO4\@XXIX^-OA5H,"'5CJ&/^0>+%_.W?W?[N?QJE]C^-G_01\,_]\M_\11]
MC^-G_01\,_\ ?+?_ !% %Z&Y\5ZK\.?%NH>([9;3[79W+6.GA/WD$7E, '/<
MGC@C/YX&S\+D>/X8^'TD5E86H!5A@CDUS'V/XV?]!'PS_P!\M_\ $4?8_C9_
MT$?#/_?+?_$4 <?I]CJLO[/NO06=O<F0ZK(TT4:D.\(="^!UZ=?8&KWC'4?#
M/B#X<WNF>!-!6=HX4DGFBT\Q_98T96(+%06<XQ@9.-Q)XKHOL?QL_P"@CX9_
M[Y;_ .(H^Q_&S_H(^&?^^6_^(H I^(-1M]?U;X7:AIWF36WVU@S>4R[2 @.0
M1Q@@C\*UOCG%)-\/XUBC>1O[0@.%4D]357['\;/^@CX9_P"^6_\ B*/L?QL_
MZ"/AG_OEO_B* )?$UW_PAOQ<M?%5];W#:+?:6;">XAB:002!]P+!03@@ ?GZ
M5GIKK>(?CIX;O8+:>+3?L%REK)/&8VGPI+.%;!"\@#(&<&G2Z7\;C>)=#6-!
M_=H5\A,A'SW(*=?QJA)X2^+UUXFM?$<U]X?_ +0M[=K>(,6VHK')X"8R<]:
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MB#I?BKX<7UIX=^T7D6Z)[R<V[QQP()%P"6 RQ;:,#/&3VK=^Q_&S_H(^&?\
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MS_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?QL_Z"/AG_OEO_B*
M/5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB@#U6BO*OL?QL_P"@
MCX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?
MQL_Z"/AG_OEO_B* /5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB
M@#U6BO*OL?QL_P"@CX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)"JN(QT0,!G;QTZ5=HHH *JWFFV&HF$WUE;7)@<21>?$K^6PZ,N1P?<5:HH
M@-G:M>K>M;0FZ1#&LY0;PA.2H;KC/:D6QM$N9[E;6!9[A0LTHC :0#@!CU(&
M3C/K5BB@"K!IMA:Z?_9]O96T5EM*_9HXE6/!R2-H&,')_.H=,T'1]$$@TK2K
M*Q$IR_V:!8]WUV@9K0HH RK;P]I&E3W%[I>C:=;WTBG,L4"QLYZX9E&<$]:R
M/#WA_5#XEO?$_B'[&NI30+9V\%HQ=+> $L1N8 LS,<DX'05UE% &9>^'=$U*
M^CO;[1["ZNXL;)YK9'=<=,,1FM.BB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7$0"R1K[L#&WYT >BT5S_@G2KG1_"5A;W\CR7\BF>[=SDF:0[V'X$X^@KH*
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M 8D@DC=D ?+]*[FB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;);7\EW?7%GJ4UHJ6TN]E\Z/:V%*E@",,,\E<C->J7%M!=PF*XACFC/5)%#
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M;HQ*X;:0IQT49QVKM?)B"R*(DVR$EQM&&)X.?6@#QZQEFL=;,MSXFM=#CN=
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*Y3XCZUJ'A_P/>ZCI4J17J20I&[H' WRHAX/7AC75UQ7Q8MYKGX>7L5O#)+(
M9[8A(U+$XGC)X'M0!I>#?$3Z[X5CO;_9#?6Q>WU!.@CFC.'SZ#C=]"*Y+P7\
M0-2UC6O$5UJK+'HMO:"_LT$0#I;[GPS'J250-^-0>+M)UBS\4WVD:1#-]@\8
M+&D\T:Y6UD4A9W/8;H?S(J]%X=%QXW\6:3' ]O87&@6]C$X0[%4JZ8![X!%
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M6TL"D?ZQ"IPP!ZJ1GTK$U"&]\/:YX<\6QV%S=V2:4-.U".WC+RPH=KK($')
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !4%O9V]H]P\$>UKB4S2G))9\!<\^R@?0"IZ*
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7<0^5Y$?D;/)VCR]F-NW'&,=L4 /HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!45S:V][;26UU!%/!(-KQ2H&5AZ$'@U+10!F:5X=T30S(VDZ18V+2<.;:!8R
MWU('-4=;\.B7PZ^FZ)::5;J91*UK<6BM;3#=EE=0.-W]X#.:Z&B@#C?#O@Y[
M:[U&[UBSTE4N[:.R33K*+-M% A9B"&4;BS.2?E KJWLK62:WF>VA:6VR8'9
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MF>.?^?7P[_X$S_\ Q%=-10!S/F>.?^?7P[_X$S__ !%'F>.?^?7P[_X$S_\
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MF+<,7&,,3WSUJU10!G2^']&GO[>^ETFRDN[= D,[0*7C4= IQD"HAX7T "R
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MXY_Y]?#O_@3/_P#$4>9XY_Y]?#O_ ($S_P#Q%=-10!S/F>.?^?7P[_X$S_\
MQ%'F>.?^?7P[_P"!,_\ \17344 <SYGCG_GU\._^!,__ ,11YGCG_GU\._\
M@3/_ /$5TU% ',^9XY_Y]?#O_@3/_P#$4>9XY_Y]?#O_ ($S_P#Q%=-10!S/
MF>.?^?7P[_X$S_\ Q%'F>.?^?7P[_P"!,_\ \17344 <SYGCG_GU\._^!,__
M ,11YGCG_GU\._\ @3/_ /$5TU% ',^9XY_Y]?#O_@3/_P#$5K:2VL-#)_;$
M=BDN[Y!9R.Z[<=]P'-:%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M":@L'V(F%7#HI(^8L^[=WP!VKT'2M)8RV&LZDKC6AIR6MQME)0$X9QM!VYW
M\T ;5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 8/A7QAI'C&RN+G2I)"+>4Q2QRKM=3U!(]#V-7=)UJTUHWXM?
M,_T&[DLY=ZX_>)C./4<CFO)_"\4OAOP;H/C:R1FBA26WUB%!DRVOGOB3'=HR
M<_[I85;L[JRN-!UZ%EN[Q-1\62QV]O93"/[42JN%9STC*J22#T'O0!Z]17B-
M^;NS\*>,M,BB?2DMM2T[R+:*Z\[[,9'A+;6[ _>QT&370/X2TF/XG)HZ).-,
MN=(:ZN;7[1(4N)4E"JSY.6.'/U.">E 'IU%>)V\U[+I&A^'X[6XU*Q_MK48#
M:?:O+,T4#/Y<;.QY4=<$\[ *[+PUX:NKC2=1TS6=/GL=.%^EQ86PO?,:% %;
M;O4_=#AB!Z''2@#NJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ JAJ^CV>N6:6MZK-$DT<X"MM.]&#+^H%7Z* ,?
MQ+X8TKQ=I#:9K%N9K<N'&UBK*P[@CIP2/H356[\%:1>:@MW)]J0F%+>>&.X9
M([F-,[5E4'#@9/7J"0<CBNBHH P='\'Z5H=Q9SV@N"]G:-90&68OLA9@VWGT
M*@#T Q1)X0TB70M0T9XI?L=_/)<3KYAR7=][8/;YJWJ* .=U?P7I6LWTUW,]
M[ ]Q&(KI;6Z>);E!G"R!3\W!(SUP<9Q6C'HMG#K$>IQ"1)8[3[&D:R$1B/<&
M^YTSD=?3BM&B@ HHHH *H:MJ$^FVJS0:7>:BS.%,5IY>X#!^8[W48XQUSR.*
MOT4 <Q_PE>I?]"5XA_.T_P#C]'_"5ZE_T)7B'\[3_P"/UT]% ',?\)7J7_0E
M>(?SM/\ X_1_PE>I?]"5XA_.T_\ C]=/10!S'_"5ZE_T)7B'\[3_ ./T?\)7
MJ7_0E>(?SM/_ (_73T4 <Q_PE>I?]"5XA_.T_P#C]'_"5ZE_T)7B'\[3_P"/
MUT]% ',?\)7J7_0E>(?SM/\ X_1_PE>I?]"5XA_.T_\ C]=/10!S'_"5ZE_T
M)7B'\[3_ ./T?\)7J7_0E>(?SM/_ (_73T4 <Q_PE>I?]"5XA_.T_P#C]'_"
M5ZE_T)7B'\[3_P"/UT]% ',?\)7J7_0E>(?SM/\ X_1_PE>I?]"5XA_.T_\
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M2O$/YVG_ ,?KIZ* .8_X2O4O^A*\0_G:?_'Z/^$KU+_H2O$/YVG_ ,?KIZ*
M.8_X2O4O^A*\0_G:?_'Z/^$KU+_H2O$/YVG_ ,?KIZ* .8_X2O4O^A*\0_G:
M?_'Z/^$KU+_H2O$/YVG_ ,?KIZ* .8_X2O4O^A*\0_G:?_'Z/^$KU+_H2O$/
MYVG_ ,?KIZ* (K>5I[6*9X9(&D0,8I,;D)&=IP2,CIP2/>I:** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LW6/
M$&D>'X8YM7U&WLHI6V(T[[0QQG K2IK(KC#*&^HS0!S4/Q%\'7,\<$/B33I)
M9&"(BS EF)P *V+76K"\DOTBF8?8',=PTD;1JA R>6 !&.XR*Y/X:Q1D>+28
MUR/$M[CCIRM<GX@U75-6\)?$V"XU*X$6G7;10*FT8CV\QGCE3GGO[T >K76N
MZ;9:QIVDW%SMO=1$AM8]C'S B[FY P, ]R*T:\MU&T>R^)/PT@DN[B[98;\F
M:X*EVS"#SM '&<#CH*I6'B_5[YK?6;>YUZ>YEU'8=.32W:S^R^=L($@CQN"?
M-OW=01[4 >OT51L[*ZM]0O[B;4)+B&X=&AMV0 6X"X(!')R>>:O4 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5%<W
M,-G:S75S*L4$*&221C@*H&23[ 5+00""",@T <K_ ,++\$_]#/IG_?\ %:=O
MXGT>\ETV.UO!<#4A(;62%&>.01_>^<#:,8/4C/:N;U**/_A<^A+Y:8_LBZXV
MC^^E2^(=6O[+XF^#=)M;EH;&^2]^TPJ!A]D6Y>W&#SQ0!T^IZWIVCZ5=:G?7
M2QVEI_KY%!?9TX(7)SR.*MP3QW-O%/"VZ*5 Z-C&01D5X=<64\/PK^(DTNIW
MMUC4KJ#9.4*DK*@W\*#N(Z\X] *Z*_U^<ZEIVBF_UJRM+?1K>Y+:18M/(\KY
M4;B(WPH"=,#)/M0!ZG17*^&WUK7-$T#4[ZZN;&XA\S[9;/;>7]JQE 65@"G0
M. /6NJH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT4 <Q_PL+PQ_T$9/_ 2;_P"(H_X6%X8_Z",G_@)-_P#$5T]% ',?\+"\,?\
M01D_\!)O_B*/^%A>&/\ H(R?^ DW_P 173T4 <Q_PL+PQ_T$9/\ P$F_^(H_
MX6%X8_Z",G_@)-_\173T4 <Q_P +"\,?]!&3_P !)O\ XBC_ (6%X8_Z",G_
M ("3?_$5T]% ',?\+"\,?]!&3_P$F_\ B*/^%A>&/^@C)_X"3?\ Q%=/10!S
M'_"PO#'_ $$9/_ 2;_XBC_A87AC_ *",G_@)-_\ $5T]% ',?\+"\,?]!&3_
M ,!)O_B*/^%A>&/^@C)_X"3?_$5T]% ',?\ "PO#'_01D_\  2;_ .(H_P"%
MA>&/^@C)_P" DW_Q%=/10!S'_"PO#'_01D_\!)O_ (BC_A87AC_H(R?^ DW_
M ,173T4 <Q_PL+PP?^8C)_X"3?\ Q%'_  L+PQ_T$9/_  $F_P#B*Z>B@#F/
M^%A>&/\ H(R?^ DW_P 11_PL+PQ_T$9/_ 2;_P"(KIZ* .8_X6%X8_Z",G_@
M)-_\11_PL+PQ_P!!&3_P$F_^(KIZ* &QNLL:R(<JP# XQP:=110 4444 %%%
M% !1110 4444 %%%% &+<^'DN/&-CXA-RRO:6DML(=G#!RISG/&-OI46J>%T
MU/QAH/B W31OI"W 6$)D2^:FWDYXQUZ5OT4 <+<?#N6?2_$ND_VVRZ=K<\ER
M(C:@M!)(RLQW;OF'' P.M:-WX3O$N[2^T;6?[/O8;);&5WMA,DT:G*Y4L,,"
M6(.?XCP:ZFB@#'ATB_MUTA$UNY>.S#"Z\Y%=KW*X&YOX<'GCZ5L444 %%%%
M!5/4]4L]'LFN[Z4Q0*0I8(S\GIPH)JY10!S'_"PO#'_01D_\!)O_ (BC_A87
MAC_H(R?^ DW_ ,173T4 <Q_PL+PP?^8C)_X"3?\ Q%'_  L+PQ_T$9/_  $F
M_P#B*Z>B@#F/^%A>&/\ H(R?^ DW_P 11_PL+PQ_T$9/_ 2;_P"(KIZ* .8_
MX6%X8_Z",G_@)-_\11_PL+PQ_P!!&3_P$F_^(KIZ* .8_P"%A>&/^@C)_P"
MDW_Q%'_"PO#'_01D_P# 2;_XBNGHH YC_A87AC_H(R?^ DW_ ,11_P +"\,?
M]!&3_P !)O\ XBNGHH YC_A87AC_ *",G_@)-_\ $4?\+"\,?]!&3_P$F_\
MB*Z>B@#F/^%A>&/^@C)_X"3?_$4?\+"\,?\ 01D_\!)O_B*Z>B@#F/\ A87A
MC_H(R?\ @)-_\11_PL+PQ_T$9/\ P$F_^(KIZ* .8_X6%X8_Z",G_@)-_P#$
M4?\ "PO#'_01D_\  2;_ .(KIZ* .8_X6%X8_P"@C)_X"3?_ !%'_"PO#'_0
M1D_\!)O_ (BNGHH YC_A87AC_H(R?^ DW_Q%'_"PO#'_ $$9/_ 2;_XBNGHH
M YC_ (6%X8_Z",G_ ("3?_$4?\+"\,?]!&3_ ,!)O_B*Z>B@#F/^%A>&/^@C
M)_X"3?\ Q%'_  L+PQ_T$9/_  $F_P#B*Z>B@#F/^%A>&/\ H(R?^ DW_P 1
M1_PL+PQ_T$9/_ 2;_P"(KIZ* .8_X6%X8_Z",G_@)-_\11_PL+PQ_P!!&3_P
M$F_^(KIZ* .8_P"%A>&!_P Q&3_P$F_^(H_X6%X8_P"@C)_X"3?_ !%=/10!
M%;7$5W:Q7,+;HI4$B-@C*D9!P>14M%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?45S.@Z[J?B32="U>QCL8[.X$G]H*[LS*5RN(B.#\ZGD]JZ:@ HHHH ****
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M?^ $7_Q- &E_:5A_S^VW_?U?\:/[2L/^?VV_[^K_ (UF_P#"%^%?^A9T;_P
MB_\ B:/^$+\*_P#0LZ-_X 1?_$T :7]I6'_/[;?]_5_QH_M*P_Y_;;_OZO\
MC6;_ ,(7X5_Z%G1O_ "+_P")H_X0OPK_ -"SHW_@!%_\30!I?VE8?\_MM_W]
M7_&C^TK#_G]MO^_J_P"-9O\ PA?A7_H6=&_\ (O_ (FC_A"_"O\ T+.C?^ $
M7_Q- &E_:5A_S^VW_?U?\:/[2L/^?VV_[^K_ (UF_P#"%^%?^A9T;_P B_\
MB:/^$+\*_P#0LZ-_X 1?_$T :7]I6'_/[;?]_5_QH_M*P_Y_;;_OZO\ C6;_
M ,(7X5_Z%G1O_ "+_P")H_X0OPK_ -"SHW_@!%_\30!I?VE8?\_MM_W]7_&C
M^TK#_G]MO^_J_P"-9O\ PA?A7_H6=&_\ (O_ (FC_A"_"O\ T+.C?^ $7_Q-
M &E_:5A_S^VW_?U?\:/[2L/^?VV_[^K_ (UF_P#"%^%?^A9T;_P B_\ B:/^
M$+\*_P#0LZ-_X 1?_$T :7]I6'_/[;?]_5_QH_M*P_Y_;;_OZO\ C6;_ ,(7
MX5_Z%G1O_ "+_P")H_X0OPK_ -"SHW_@!%_\30!I?VE8?\_MM_W]7_&C^TK#
M_G]MO^_J_P"-9O\ PA?A7_H6=&_\ (O_ (FC_A"_"O\ T+.C?^ $7_Q- &E_
M:5A_S^VW_?U?\:/[2L/^?VV_[^K_ (UF_P#"%^%?^A9T;_P B_\ B:/^$+\*
M_P#0LZ-_X 1?_$T :7]I6'_/[;?]_5_QH_M*P_Y_;;_OZO\ C6;_ ,(7X5_Z
M%G1O_ "+_P")H_X0OPK_ -"SHW_@!%_\30!I?VE8?\_MM_W]7_&C^TK#_G]M
MO^_J_P"-9O\ PA?A7_H6=&_\ (O_ (FC_A"_"O\ T+.C?^ $7_Q- &E_:5A_
MS^VW_?U?\:/[2L/^?VV_[^K_ (UF_P#"%^%?^A9T;_P B_\ B:/^$+\*_P#0
MLZ-_X 1?_$T :7]I6'_/[;?]_5_QJ6&ZM[@D0SQ2$=0C@X_*LC_A"_"O_0LZ
M-_X 1?\ Q-7=.T+2-(=WTS2K&R:0 .UM;I&6 Z9V@9H OT444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %8%]X.TS4;V6[GN-6624Y80ZK<Q(.,<*K@
M#\!6_7'?$A=0ET33[;2[Z:RN[C48HHY8G*X)#8!QU7(&1WH L_\ " Z/_P _
M6N?^#N[_ /CE'_" Z/\ \_6N?^#N[_\ CE<IXE\4WFN:;HDFF7$]GY3VEYJ
MB<JRL]RD @8C_:,V1_TSK2U2.?3=<N[[6EUE+8W:26VJ6-X3#;Q?* DD.[ &
M<ACL8$')([ &S_P@.C_\_6N?^#N[_P#CE'_" Z/_ ,_6N?\ @[N__CE<EXQ\
M6%/$UY-::L\ \/)&PM$D(%[*Q#2H0.&Q$-HST9SZ5V7B?7'M_ EWK&E3KF2W
M1[>XQD*'( DP?0-N_"@"+_A ='_Y^M<_\'=W_P#'*/\ A ='_P"?K7/_  =W
M?_QRH[CPQ!I-J]W::KJBRI!*)A<7LDRW68V^\KD@,#\P*@=,=.*Q])\1ZQI>
MBV,-]-IQ630EO+>1DD'ELOEIMD(+&3/F+]T DC&.10!N?\(#H_\ S]:Y_P"#
MN[_^.4?\(#H__/UKG_@[N_\ XY639^+=;O[R#3(!:"Y>_DM&N9[&:$!5MUF#
M>2[!@?FVX+<]<\TEKXOU[4('6UBTY+BRLYKFZ\R-RLS)-+$%3##8"86.3NQD
M#!H U_\ A ='_P"?K7/_  =W?_QRC_A ='_Y^M<_\'=W_P#'*QK;QWJ=W>6Z
MPVF]%^QK<0Q6$\A<S)&[LLJY2,(L@.&R3M/(R#5KQI(#XF\/6TJ:K-:RQ7;2
M0:;/)$[E?*VD^6ZD@9/?O0!?_P"$!T?_ )^M<_\ !W=__'*/^$!T?_GZUS_P
M=W?_ ,<KF]-\1WNG:09[-KS[#J.J&VT[[>DM[- BQ,9"R(QD;YXI %+9&><
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M (Y1_P (#H__ #]:Y_X.[O\ ^.5U%% '+_\ " Z/_P _6N?^#N[_ /CE'_"
MZ/\ \_6N?^#N[_\ CE=110!R_P#P@.C_ //UKG_@[N__ (Y1_P (#H__ #]:
MY_X.[O\ ^.5U%% '+_\ " Z/_P _6N?^#N[_ /CE'_" Z/\ \_6N?^#N[_\
MCE=110!R_P#P@.C_ //UKG_@[N__ (Y1_P (#H__ #]:Y_X.[O\ ^.5U%% '
M+_\ " Z/_P _6N?^#N[_ /CE'_" Z/\ \_6N?^#N[_\ CE=110!R_P#P@.C_
M //UKG_@[N__ (Y1_P (#H__ #]:Y_X.[O\ ^.5U%% '+_\ " Z/_P _6N?^
M#N[_ /CE'_" Z/\ \_6N?^#N[_\ CE=110!R_P#P@.C_ //UKG_@[N__ (Y1
M_P (#H__ #]:Y_X.[O\ ^.5U%% '+_\ " Z/_P _6N?^#N[_ /CE'_" Z/\
M\_6N?^#N[_\ CE=110!R_P#P@.C_ //UKG_@[N__ (Y1_P (#H__ #]:Y_X.
M[O\ ^.5U%% '+_\ " Z/_P _6N?^#N[_ /CE'_" Z/\ \_6N?^#N[_\ CE=1
M10!R_P#P@.C_ //UKG_@[N__ (Y1_P (#H__ #]:Y_X.[O\ ^.5U%% '+_\
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MM!)'OAFE:,H!YA*L"AYR<@XP.M '3_\ " Z/_P _6N?^#N[_ /CE'_" Z/\
M\_6N?^#N[_\ CE7Y=+EB\+_V<MV;9XXMIELE,> .2%W%BN1QG)(SP<\US\1M
MKGX>>&K_ %G4=0\H6-NTD5O.ZRWDKQ*%7*$.S9)( /)Y/2@#1_X0'1_^?K7/
M_!W=_P#QRC_A ='_ .?K7/\ P=W?_P <K2\,V^H6OANPAU21WO5B'F&1][#T
M#-_$0, GN036M0!R_P#P@.C_ //UKG_@[N__ (Y1_P (#H__ #]:Y_X.[O\
M^.5U%% '+_\ " Z/_P _6N?^#N[_ /CE'_" Z/\ \_6N?^#N[_\ CE=110!R
M_P#P@.C_ //UKG_@[N__ (Y1_P (#H__ #]:Y_X.[O\ ^.5U%% '+_\ " Z/
M_P _6N?^#N[_ /CE'_" Z/\ \_6N?^#N[_\ CE=110!R_P#P@.C_ //UKG_@
M[N__ (Y1_P (#H__ #]:Y_X.[O\ ^.5U%% '+_\ " Z/_P _6N?^#N[_ /CE
M'_" Z/\ \_6N?^#N[_\ CE=110!R_P#P@.C_ //UKG_@[N__ (Y1_P (#H__
M #]:Y_X.[O\ ^.5U%% '+_\ " Z/_P _6N?^#N[_ /CE'_" Z/\ \_6N?^#N
M[_\ CE=110!R_P#P@.C_ //UKG_@[N__ (Y1_P (#H__ #]:Y_X.[O\ ^.5U
M%% '+_\ " Z/_P _6N?^#N[_ /CE'_" Z/\ \_6N?^#N[_\ CE=110!R_P#P
M@.C_ //UKG_@[N__ (Y1_P (#H__ #]:Y_X.[O\ ^.5U%% '+_\ " Z/_P _
M6N?^#N[_ /CE'_" Z/\ \_6N?^#N[_\ CE=110!R_P#P@.C_ //UKG_@[N__
M (Y1_P (#H__ #]:Y_X.[O\ ^.5U%<C>P'7_ !Q<Z3>75U%86-A#<+;V]P\'
MG/*\@+,R$,0HC  SC+'/:@";_A ='_Y^M<_\'=W_ /'*/^$!T?\ Y^M<_P#!
MW=__ !RLV\L=1TWQ#X?T_3=5:9L7NV6_+3^6N(R%;#*SXZ#<V><DG'-27Q]J
M*Z;8WH%GN$$<MU;1VL\S,3*T;?.ORPK\I*E\Y.1VR0#=_P"$!T?_ )^M<_\
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M7\*MT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
<B@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>exhibit101_changexreques008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit101_changexreques008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !117+>,X?&LJ67_"'7&FPL"_VG[<"<CY=NW /^UG\* .
MIHKRK['\;/\ H(^&?^^6_P#B*/L?QL_Z"/AG_OEO_B* /5:*\J^Q_&S_ *"/
MAG_OEO\ XBC['\;/^@CX9_[Y;_XB@#U6BO*OL?QL_P"@CX9_[Y;_ .(H^Q_&
MS_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?QL_Z"/AG_OEO_B*
M/5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB@#U6BO*OL?QL_P"@
MCX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?
MQL_Z"/AG_OEO_B* /5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB
M@#U6BO*OL?QL_P"@CX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\
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M_=H5\A,A'SW(*=?QJA)X2^+UUXFM?$<U]X?_ +0M[=K>(,6VHK')X"8R<]:
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MB#I?BKX<7UIX=^T7D6Z)[R<V[QQP()%P"6 RQ;:,#/&3VK=^Q_&S_H(^&?\
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MS_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?QL_Z"/AG_OEO_B*
M/5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB@#U6BO*OL?QL_P"@
MCX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?
MQL_Z"/AG_OEO_B* /5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB
M@#U6BO*OL?QL_P"@CX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)"JN(QT0,!G;QTZ5=HHH *JWFFV&HF$WUE;7)@<21>?$K^6PZ,N1P?<5:HH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6DA..#M;(+ >J@UB:UIFLWOA;Q;XHN[=K74;W26MK2R4Y>WME#-AB.LC;F)
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M+>Y7!/TKT2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=0O/MTKK*5=)_EPZ,.5(V+C%0'P+I$NCW^FW+WETNH,C74]Q<,\TFP@H-QZ
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\V,'"R<=-PYVGD4 7:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;3BLFA+>6\C)(/+9?+3;(06,F?,7[H!)&,<B@#<_X0'1_P#GZUS_ ,'=W_\
M'*/^$!T?_GZUS_P=W?\ \<K)L_%NMW]Y!ID M!<O?R6C7,]C-" JVZS!O)=@
MP/S;<%N>N>:2U\7Z]J$#K:Q:<EQ96<US=>9&Y69DFEB"IAAL!,+')W8R!@T
M:_\ P@.C_P#/UKG_ (.[O_XY1_P@.C_\_6N?^#N[_P#CE8UMX[U.[O+=8;3>
MB_8UN(8K">0N9DC=V65<I&$60'#9)VGD9!JUXTD!\3>'K:5-5FM98KMI(--G
MDB=ROE;2?+=20,GOWH O_P#" Z/_ ,_6N?\ @[N__CE'_" Z/_S]:Y_X.[O_
M ..5S>F^([W3M(,]FUY]AU'5#;:=]O26]F@18F,A9$8R-\\4@"ELC/. ,5<7
MQ?X@O+:Z:VMK6VFT_3FO;A;NVE0SGS)D0(I96C5A"6RP8@,O% &Q_P (#H__
M #]:Y_X.[O\ ^.4?\(#H_P#S]:Y_X.[O_P".52C\87[:-J=X8+;S+2YLH4&U
ML$3);LQ//4&9L?0=>]:#QKK%W=W)LM-:[C+7<4$"V,Z;6AW["TY_=L',>,#&
M"P&3@T :W_" Z/\ \_6N?^#N[_\ CE'_  @.C_\ /UKG_@[N_P#XY6)%XCUO
M4-7\/P0:K8;9=0EBN56PFB?"V[/LDB=]R'KW.?E;L0?0Z .7_P"$!T?_ )^M
M<_\ !W=__'*/^$!T?_GZUS_P=W?_ ,<KJ** .7_X0'1_^?K7/_!W=_\ QRC_
M (0'1_\ GZUS_P '=W_\<KJ** .7_P"$!T?_ )^M<_\ !W=__'*/^$!T?_GZ
MUS_P=W?_ ,<KJ** .7_X0'1_^?K7/_!W=_\ QRC_ (0'1_\ GZUS_P '=W_\
M<KJ** .7_P"$!T?_ )^M<_\ !W=__'*/^$!T?_GZUS_P=W?_ ,<KJ** .7_X
M0'1_^?K7/_!W=_\ QRC_ (0'1_\ GZUS_P '=W_\<KJ** .7_P"$!T?_ )^M
M<_\ !W=__'*/^$!T?_GZUS_P=W?_ ,<KJ** .7_X0'1_^?K7/_!W=_\ QRC_
M (0'1_\ GZUS_P '=W_\<KJ** .7_P"$!T?_ )^M<_\ !W=__'*/^$!T?_GZ
MUS_P=W?_ ,<KJ** .7_X0'1_^?K7/_!W=_\ QRC_ (0'1_\ GZUS_P '=W_\
M<KJ** .7_P"$!T?_ )^M<_\ !W=__'*/^$!T?_GZUS_P=W?_ ,<KJ** .7_X
M0'1_^?K7/_!W=_\ QRC_ (0'1_\ GZUS_P '=W_\<KJ** .7_P"$!T?_ )^M
M<_\ !W=__'*/^$!T?_GZUS_P=W?_ ,<KJ** .7_X0'1_^?K7/_!W=_\ QRC_
M (0'1_\ GZUS_P '=W_\<KJ** .7_P"$!T?_ )^M<_\ !W=__'*/^$!T?_GZ
MUS_P=W?_ ,<KJ*YGQ].UOX2D=7ND!O+-'^RNZRE&N8E95*$-DJ2..>: &_\
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M_P#!W=__ !RNHHH Y?\ X0'1_P#GZUS_ ,'=W_\ '*/^$!T?_GZUS_P=W?\
M\<KJ** .7_X0'1_^?K7/_!W=_P#QRC_A ='_ .?K7/\ P=W?_P <KJ** .7_
M .$!T?\ Y^M<_P#!W=__ !RC_A ='_Y^M<_\'=W_ /'*ZBB@#E_^$!T?_GZU
MS_P=W?\ \<H_X0'1_P#GZUS_ ,'=W_\ '*ZBB@#E_P#A ='_ .?K7/\ P=W?
M_P <H_X0'1_^?K7/_!W=_P#QRNHHH Y?_A ='_Y^M<_\'=W_ /'*/^$!T?\
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M5TUO_P )$->N=5N[:QO/MTJVHE%Q*(P0TGE[0% *[><8 )(H [O_ (0'1_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0)@'T"C ],GUKJ** (+*U%E:1VXFGF" _O)WWNW.>2>M3T44 %%%% !1110
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MFO )R(7DV["Y3H21VZ9YQGFL)OA_9IJ5I$IGFTE=.NK&2&>X9C'')Y>U(_0
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)%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>exhibit101_changexreques009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit101_changexreques009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !117+>,X?&LJ67_"'7&FPL"_VG[<"<CY=NW /^UG\* .
MIHKRK['\;/\ H(^&?^^6_P#B*/L?QL_Z"/AG_OEO_B* /5:*\J^Q_&S_ *"/
MAG_OEO\ XBC['\;/^@CX9_[Y;_XB@#U6BO*OL?QL_P"@CX9_[Y;_ .(H^Q_&
MS_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?QL_Z"/AG_OEO_B*
M/5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB@#U6BO*OL?QL_P"@
MCX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?
MQL_Z"/AG_OEO_B* /5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB
M@#U6BO*OL?QL_P"@CX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\
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M_=H5\A,A'SW(*=?QJA)X2^+UUXFM?$<U]X?_ +0M[=K>(,6VHK')X"8R<]:
M&Z2W@[P5=:QHWC30K4W:WTL]E<S:9YYNX'.Y K!#DCD8)X_.O4?!K0R^&;:X
MA\/QZ"EP6E^PK&J%03@%@H !( .,9'2N(^Q_&S_H(^&?^^6_^(H^Q_&S_H(^
M&?\ OEO_ (B@";XT0RS6?A7RHW?;KL!.U2<##<UW/B;P]9>*?#UYHU^N8;E-
MNX#E&ZJP]P<&N ^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB@"[\/=4U
M"_TC4_!7B,2)J^EHUJTS XN(",+(">O!'Y@]ZY'P]J'@SPOX:70_$_A6UD\3
MV&^'[,VDB62](8[&1]A#!ACDFNA^Q_&S_H(^&?\ OEO_ (BC['\;/^@CX9_[
MY;_XB@"#Q[I]U9:5X*\466@&UBT2Z6>ZTRT0$P1R;2X 4 <%<' ZG/K63\5O
MB#I?BKX<7UIX=^T7D6Z)[R<V[QQP()%P"6 RQ;:,#/&3VK=^Q_&S_H(^&?\
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MS_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?QL_Z"/AG_OEO_B*
M/5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB@#U6BO*OL?QL_P"@
MCX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?
MQL_Z"/AG_OEO_B* /5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB
M@#U6BO*OL?QL_P"@CX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)"JN(QT0,!G;QTZ5=HHH *JWFFV&HF$WUE;7)@<21>?$K^6PZ,N1P?<5:HH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-#'B +,-=&E@#:(!8>9[YW;_ ,,8]ZUZ "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S+G0;&[\
M066MSH[WEC&\=OE_ECW_ 'B%]2.,^E/US1;'Q%HUSI6I1&2TN%"NH.#P000>
MQ! -:%% &78>'['3K[4+R'S6N-0$0N'D<L6\M-BGZXZU4'@[2%\-67A\1R_8
M+)XY(5\P[@4?>N3WY%;]% '-ZEX'TC5-0N+J9KV-;LJ;RW@N6CANBH 'F(#@
M\  ],@8.:T[71;*SUJ_U:%&%W?)%',2W!$8(7 [?>-:-% '-3>!-#GT=M-,<
MZ1&]:_CECF998IV8MO1ARIR3^=.T[P1H^G:I)J?^E7=[-;-:S37D[3-+&Q!(
M;/\ N@8Z8SQS71T4 <[I'@O2]&O(;F&6^G-O&T5K'=73RI;(>JQJ3QP .YP,
M=*S)?A;X=FL9M.=M0.FR%F2P^V/Y$+$YRB9P.2<=0,\5VM% %>]L;;4=/N+"
M[B$MM<1-#+&?XE88(_(US4?P[T=?L;O<ZI-<64BO:W$UZ[20A01L4]E()!'?
MC.<#'6T4 8]MX9TVTTG4M,B206VHR3RW +DDM-G?@]NI^E4KKP-I-Q'I?E27
MMG/IEN+6WN;2Y:.40@ ;&8?>' Z]ZZ6B@#&T'POIGAHWATV.5#>2B68R2LY9
MPH7<2>23C))ZDDU8&B60\1MKP5_M[6@LRV[Y?+#E\8]<GK6C10!ESZ!83^(;
M;72CI?V\+6XD1L"2-N=KC^( \CT-9VG^!='TV^@N(3>/%;,[6MI+<L\%N6!!
M*(>!PS =< G&*Z6B@#F]+\$:5I-];7,,M_*MGN^QV\]T\D5MD%3Y:D\?*2!G
M. <"JJ_#?04@U&V5K];2^D,S6PNW$<4I</YD8_A8,H((_E7744 <U:>"-+L]
M6M=66?4)=1MPRFZFNF=Y4;'R.3U7Y00O !Y[FH;/X>:%96%_I\?VUM/O"6:S
M>Z<Q1,6W[HQGY"& ((Y%=710!SUKX+TF&TU""Z-UJ/\ :$0@N9+ZX:5WC&<(
M">@&XGC')SUJI;?#S1H;C3YY;C4KN73IEEM&NKQY/)V@@*H/&.>?7 YXKK**
M *.KZ/8Z[IDVG:C )K:7&Y<E2"#D$$<@@@$$5DZ;X)T[3]2@U"6[U/4+FV!%
MNVH7CSB#(P2H)P"1QGK[UTE% '+VG@'1++4H;N+[68K>=KFWLGN7:V@E.<ND
M>< Y)([#)P!5^W\+Z9;:'J&CQI(+2_:=IP7)),V=^#VZGZ5LT4 <Y=^"=+N4
ML1%-?64MG:BSCGL[EHI&A&,(Q'WAQGU!Z8I+WP/HUW;:9%"+FQ?3$,=G/9SM
M'+&A !7=W!P,YSFNDHH YFV\ Z!;6>KVOV>6:+5T5;WSIV=I2 1N+$YW').<
M]:9:> =)MKRPO);C4;RZT^3?;2WEVTIC&TKM&> ,'GUP,YP*ZFB@#GAX)T3[
M+K%LT$C1:O<FZN093GS<@AE(Y4@@$8Z$59T7PY::)+<3Q3WEU=7 59;F\G:6
M1E7.U<GH!D\#U-;%% &%K?A/3]<O8;^2:]L[^&,Q+=V-PT,GEDY*$CJN><'H
M>E7-$T.P\/::MCI\;)%O:1F=R[R.QRSLQY9B>YK1HH Y6/3+S1_B%<ZC;0--
MINM0HMV5QF">($(Y']UD^4XZ%1ZUM:)HUGX?TF'3+!76VA+E [;C\S%CS]6-
M:%% &3J/AW3]4US2M7N4<W>EF0VQ5R /, 5LCOP!3M2\/V&K:KI>HW2.;C3)
M'DMBKD ,PP<COQ6I10!R]YX!T2^U&>ZE^UK%<S+<7-DERZVT\@QAGC!P3P,]
MC@9S5I_!^D/<^()VCE\S7H5AOOWA^950H-O]WY6-;U% &1=>&M.O--TVPF20
MP:=-#-;@.00T7W,GOTK@?%/AR[NKSQ!:VOAC4I)=2!\F2WU "QE=D"B::,L-
MK*>2-ISM!Y->JT4 4;+38[?0K?2YPLT<=LMNX(X<!=I_.N<7X:Z&+6WMVGU.
M06C(UDTEZ[-:;2"!%S\O0#UP *[&B@#,L-!L=-74A;JX_M&X>YN-SDY=E"DC
MTX45E2^ =%?3=)LX3>6K:2I2RN;:X9)HE(PPW#J".H-=110!B:%X4TOP[=7U
MU8+/Y]]Y9N9)IFD:1DSAB6YR=QR:?J_AG3=;U72=2O4D:YTJ5I;4JY #'&<C
MO]T5L44 9]MHMG::W?ZO$KB[ODB2<EL@B,$+@=OO&J:>$=(3P_J&B>2[6-^\
MTDZ,Y)+2$LQ![<G(]*W** ,6'PKH\7A7_A&S:^9I?EF-HI&)+ G<26Z[LG.>
MN>:CTCPE8:1J!U 3WU[>B+R$GOKEIFCCSDJN>@) SW..36]10!S,/@+0K?PO
M#X?BBG2SMYC<0.LS"6&7<6#JXY!!)_/%1R_#W0KC1+S2[D7=PE[,D]U<37#/
M-,Z$;2SGG P !TQ7544 9Z:+9Q^()M;57^VS6RVKMN^78K%AQZY8\USGB'PI
M:P>'[U-/TB;4'N-3&I2Q1W?DS+(2-TD+\8<8R!D#J,\UV=% 'FN@Z9J.EZGK
MOB6WT+4E9[&*VM;:]G62ZNY59F+R-N8*,LJ\GA5Z  "NL\':#)X<\-6]C<2B
M:\9GGNY1T>:1B[D>V3@>P%;U% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX-BM/$>K7+^"X]=COUB:S=)(U6!UB6,QOO8$)\@.0#U/%>D6=HMKI4%G'#%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K OO!V
MF:C>RW<]QJRR2G+"'5;F)!QCA5< ?@*WZX[XD+J$NB:?;:7?365W<:C%%'+$
MY7!(; ..JY R.] %G_A ='_Y^M<_\'=W_P#'*/\ A ='_P"?K7/_  =W?_QR
MN4\2^*;S7--T233+B>S\I[2\U 1.596>Y2 0,1_M&;(_Z9UI:I'/INN7=]K2
MZREL;M)+;5+&\)AMXOE 22'=@#.0QV,"#DD=@#9_X0'1_P#GZUS_ ,'=W_\
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MAZ!F_B(& 3W()K6H Y?_ (0'1_\ GZUS_P '=W_\<H_X0'1_^?K7/_!W=_\
MQRNHHH Y?_A ='_Y^M<_\'=W_P#'*/\ A ='_P"?K7/_  =W?_QRNHHH Y?_
M (0'1_\ GZUS_P '=W_\<H_X0'1_^?K7/_!W=_\ QRNHHH Y?_A ='_Y^M<_
M\'=W_P#'*/\ A ='_P"?K7/_  =W?_QRNHHH Y?_ (0'1_\ GZUS_P '=W_\
M<H_X0'1_^?K7/_!W=_\ QRNHHH Y?_A ='_Y^M<_\'=W_P#'*/\ A ='_P"?
MK7/_  =W?_QRNHHH Y?_ (0'1_\ GZUS_P '=W_\<H_X0'1_^?K7/_!W=_\
MQRNHHH Y?_A ='_Y^M<_\'=W_P#'*/\ A ='_P"?K7/_  =W?_QRNHHH Y?_
M (0'1_\ GZUS_P '=W_\<H_X0'1_^?K7/_!W=_\ QRNHHH Y?_A ='_Y^M<_
M\'=W_P#'*/\ A ='_P"?K7/_  =W?_QRNHHH Y?_ (0'1_\ GZUS_P '=W_\
M<H_X0'1_^?K7/_!W=_\ QRNHHH Y?_A ='_Y^M<_\'=W_P#'*/\ A ='_P"?
MK7/_  =W?_QRNHHH Y?_ (0'1_\ GZUS_P '=W_\<H_X0'1_^?K7/_!W=_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;GG.>*S- \.ZQI&L7][=ZY!>1W\HFGB2P\H[Q&D8(;S#@80<8KIZ* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
*HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>exhibit101_changexreques010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit101_changexreques010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !117+>,X?&LJ67_"'7&FPL"_VG[<"<CY=NW /^UG\* .
MIHKRK['\;/\ H(^&?^^6_P#B*/L?QL_Z"/AG_OEO_B* /5:*\J^Q_&S_ *"/
MAG_OEO\ XBC['\;/^@CX9_[Y;_XB@#U6BO*OL?QL_P"@CX9_[Y;_ .(H^Q_&
MS_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?QL_Z"/AG_OEO_B*
M/5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB@#U6BO*OL?QL_P"@
MCX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?
MQL_Z"/AG_OEO_B* /5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB
M@#U6BO*OL?QL_P"@CX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\
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M_=H5\A,A'SW(*=?QJA)X2^+UUXFM?$<U]X?_ +0M[=K>(,6VHK')X"8R<]:
M&Z2W@[P5=:QHWC30K4W:WTL]E<S:9YYNX'.Y K!#DCD8)X_.O4?!K0R^&;:X
MA\/QZ"EP6E^PK&J%03@%@H !( .,9'2N(^Q_&S_H(^&?^^6_^(H^Q_&S_H(^
M&?\ OEO_ (B@";XT0RS6?A7RHW?;KL!.U2<##<UW/B;P]9>*?#UYHU^N8;E-
MNX#E&ZJP]P<&N ^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB@"[\/=4U
M"_TC4_!7B,2)J^EHUJTS XN(",+(">O!'Y@]ZY'P]J'@SPOX:70_$_A6UD\3
MV&^'[,VDB62](8[&1]A#!ACDFNA^Q_&S_H(^&?\ OEO_ (BC['\;/^@CX9_[
MY;_XB@"#Q[I]U9:5X*\466@&UBT2Z6>ZTRT0$P1R;2X 4 <%<' ZG/K63\5O
MB#I?BKX<7UIX=^T7D6Z)[R<V[QQP()%P"6 RQ;:,#/&3VK=^Q_&S_H(^&?\
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MS_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?QL_Z"/AG_OEO_B*
M/5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB@#U6BO*OL?QL_P"@
MCX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?
MQL_Z"/AG_OEO_B* /5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB
M@#U6BO*OL?QL_P"@CX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\
MH(^&?^^6_P#B*/L?QL_Z"/AG_OEO_B* /5:*\J^Q_&S_ *"/AG_OEO\ XBC[
M'\;/^@CX9_[Y;_XB@#U6BO*OL?QL_P"@CX9_[Y;_ .(H^Q_&S_H(^&?^^6_^
M(H ]5HKGO!\?BJ+2IAXNGL9K[SR8VL@0@CVK@'('.=WZ5T- !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,E8I"
M[#JJDBO./A1X_P!2\707%MKJ6\=^(EN[<PH566!B4) )/*NI!^HKT:X_X]I?
M]P_RKPWPZC:'\-_ WC6 $#3&DM[_ !_%:2S,K$^NUL,/QH ZOXD?$#4_#>M:
M=IFBQV[R?)+?/,A81QO(L: 8(^8DL?H*Z_6O%VCZ#=Q6=Y/,UW*AE6WMK:2>
M38#@L5120N>YKR76;>6^^']UXMNT*W6O:U:SQJW6.V60+"O_ 'S\W_ J[K2K
MB"P^+GBE=0FCADN;*SDM#*P7=$H</M)[!^OUH @^('C.6W^'MMKWA?4EVSWD
M,:7"(&RI8AAA@<'C!R,BNAN=2CC\?66FG77CDDLFE&E"V!64!B/,\W'&.FW/
M:O(?$1$OPNUN[@YL;KQ<\UHP^Z\1D W+[%@U=QJ?_)PFB?\ 8#E_]#:@#<N/
MB5X6MDE<W\TJP.Z3F&SFD\G8Q5B^U3M&0>3UQQFM+4?%NB:9IEGJ%Q>AH+W'
MV3R(VE>?(R-BH"S<<\"N0\ 0QCP3XI(1<RZIJ)?C[WS$<_@*P_#NIW0\/?#W
M2+6>QL)KC3YIAJ5U LKQ!  4BW$ ,P;GV% 'J.A^(=,\16LL^FW#2"&0Q2H\
M;1R1./X61@&!Y[BM2O-?AQ<B;QKXU#:JNI.9;0_:1&L?FXB*DA5XP",9'7%=
M=J3>*A>N-+AT9K3 VFZEE63..<A5(ZT ;E<-\1O%NI>%I/#JZ<("-0U)+6;S
M4+?(>N.1@UT.DMXD-R_]L1:4EOL^4V<DC-NR.NY0,8S^E<#\:O\ 7>"_^PY%
M_,4 =WJ_BW1-#OEL=0O#%=/"9XX5B=VD7<%^4*#N.2/E'/M52'QYH5WHVH:C
M:SSR+8,$N(3:RB:-C]T-'MW\^N,=?0UDW\:2?'+1V=0S1Z).R$C[I\U1D?@2
M/QJ#2P!\3O'^.,V-D3[GRI* ,_X<>.9-2\-W/B'Q)X@D($;2S0/8^3;VRB0J
MNR0)^\)P.-S')QUKM='\9:)K=Y)9VMQ-'=)'YWDW5M);NT?3>!(HRON*\HT;
M"? /P=<S?\>-MJ\,UZ3T$(NWR6]@2M=EXGNK"_\ B/X66&>.=+:UOYKTPMOV
M6[0A03MYP6QCZ<4 ;EI\0O#5[*\<%[*<123(S6LJK,B#+&(E<28 S\N?:M0>
M(-*/AS_A(!>)_97V?[5]HP<>7C.<8ST[8SVQFN$T"ZET34O#6EP:Q8>(-!O0
MT6GEHE%U:HL+,IR.&7:NTD@'D5@_9Y8YY?A1AO)?5A,AYQ_9AS.1GV8%/QQ0
M!Z)=_$+PU921K/?2@-%',[K:RLL*.,H9"%Q'D'/S8KIU8,H92"",@CO7FGB-
MQI%_XCUG0=>T]7AC5M5T;4(@8Y2D0QM/#*6CV@8RI/XUZ)I\XNM-M;@0F$2P
MHXB(Y3(!V_ATH L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)"JN(QT0,!G;QTZ5=HHH *JWFFV&HF$WUE;7)@<21>?$K^6PZ,N1P?<5:HH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7,^&=!U.QU75]:UJ>U?4-2\I6BLPWE11Q A0"W+'YB22!734 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% &?KFLV?A[1KG5;]V6VMUW-M&6.2  !W))  ]Z30M;L_$6C6^J6
M#,;><':'7:RD$@@CL00017">/=7-[XST/0(["^U"TL7&IZC%91>8WRY$*D9
MQNRQ![ 4>!=7-CXYUO0WT^_T^SU)CJ=A%?0^6VXX$Z@9(QNPP ]30!Z917@L
M.DHGP4TWQ,EU=KKD=S%Y-[Y[;H@;H1[5&<;=I/&.3R:ZR_LH?!_CVW.BK-&+
MG1;R6>-YGD$TD6QD9MQ.6R3SUYH ].HKR3P?INLF7PSJ]KHMU \RK)J6H2ZD
MD@O8Y(B2S)NSG>58<<8Q69;:%;7GP?UG7KF6ZDU.U-]+:7!N'#6QCED*A,'
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M5@3C:<\#&!@8JQH^D6GB8>,=9U668W]MJEU:6TXG93:1Q !-@!P/[Q]<\YH
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MTT?Q?]N&EO+OLI?*F25-I!Y (]02K#/L:76_&>D:!KVDZ->/*;W5) D"1IN
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0TR[\0M!X%MAI>IQ6SIIP>$*40LLB,-VWS2&WC^'MNR.0#IKCQ7JVGV&-0T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS^[8.8\8&,%@,G!H UO^$!T?_GZUS_P=W?\ \<H_X0'1_P#GZUS_ ,'=W_\
M'*Q(O$>MZAJ_A^"#5;#;+J$L5RJV$T3X6W9]DD3ON0]>YS\K=B#Z'0!R_P#P
M@.C_ //UKG_@[N__ (Y1_P (#H__ #]:Y_X.[O\ ^.5U%% '+_\ " Z/_P _
M6N?^#N[_ /CE'_" Z/\ \_6N?^#N[_\ CE=110!R_P#P@.C_ //UKG_@[N__
M (Y1_P (#H__ #]:Y_X.[O\ ^.5U%% '+_\ " Z/_P _6N?^#N[_ /CE'_"
MZ/\ \_6N?^#N[_\ CE=110!R_P#P@.C_ //UKG_@[N__ (Y1_P (#H__ #]:
MY_X.[O\ ^.5U%% '+_\ " Z/_P _6N?^#N[_ /CE'_" Z/\ \_6N?^#N[_\
MCE=110!R_P#P@.C_ //UKG_@[N__ (Y1_P (#H__ #]:Y_X.[O\ ^.5U%% '
M+_\ " Z/_P _6N?^#N[_ /CE'_" Z/\ \_6N?^#N[_\ CE=110!R_P#P@.C_
M //UKG_@[N__ (Y1_P (#H__ #]:Y_X.[O\ ^.5U%% '+_\ " Z/_P _6N?^
M#N[_ /CE'_" Z/\ \_6N?^#N[_\ CE=110!R_P#P@.C_ //UKG_@[N__ (Y1
M_P (#H__ #]:Y_X.[O\ ^.5U%% '+_\ " Z/_P _6N?^#N[_ /CE'_" Z/\
M\_6N?^#N[_\ CE=110!R_P#P@.C_ //UKG_@[N__ (Y1_P (#H__ #]:Y_X.
M[O\ ^.5U%% '+_\ " Z/_P _6N?^#N[_ /CE'_" Z/\ \_6N?^#N[_\ CE=1
M10!R_P#P@.C_ //UKG_@[N__ (Y1_P (#H__ #]:Y_X.[O\ ^.5U%>:Z\[7'
MB?Q# J^(9KR."$6(TZ>=8XW,9QG:PC&6P?GX]>* .B_X0'1_^?K7/_!W=_\
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M[TV"V,%W<75R\JW%V''S)N) *@.&VX7+ ?PD#LZ .7_X0'1_^?K7/_!W=_\
MQRC_ (0'1_\ GZUS_P '=W_\<KJ** .7_P"$!T?_ )^M<_\ !W=__'*/^$!T
M?_GZUS_P=W?_ ,<KJ** .7_X0'1_^?K7/_!W=_\ QRC_ (0'1_\ GZUS_P '
M=W_\<KJ** .7_P"$!T?_ )^M<_\ !W=__'*/^$!T?_GZUS_P=W?_ ,<KJ**
M.7_X0'1_^?K7/_!W=_\ QRC_ (0'1_\ GZUS_P '=W_\<KJ** .7_P"$!T?_
M )^M<_\ !W=__'*/^$!T?_GZUS_P=W?_ ,<KJ** .7_X0'1_^?K7/_!W=_\
MQRC_ (0'1_\ GZUS_P '=W_\<KJ** .7_P"$!T?_ )^M<_\ !W=__'*/^$!T
M?_GZUS_P=W?_ ,<KJ** .7_X0'1_^?K7/_!W=_\ QRC_ (0'1_\ GZUS_P '
M=W_\<KJ** .7_P"$!T?_ )^M<_\ !W=__'*/^$!T?_GZUS_P=W?_ ,<KJ**
M.7_X0'1_^?K7/_!W=_\ QRC_ (0'1_\ GZUS_P '=W_\<KJ** .7_P"$!T?_
M )^M<_\ !W=__'*/^$!T?_GZUS_P=W?_ ,<KJ** .7_X0'1_^?K7/_!W=_\
MQRC_ (0'1_\ GZUS_P '=W_\<KJ*Y&]@.O\ CBYTF\NKJ*PL;"&X6WM[AX/.
M>5Y 69D(8A1& !G&6.>U $W_  @.C_\ /UKG_@[N_P#XY1_P@.C_ //UKG_@
M[N__ (Y6;>6.HZ;XA\/Z?INJM,V+W;+?EI_+7$9"MAE9\=!N;/.23CFI+X^U
M%=-L;T"SW"".6ZMH[6>9F)E:-OG7Y85^4E2^<G([9(!N_P#" Z/_ ,_6N?\
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MB"6'. 1QG-4M&MOMWA2[N]2U75XM+@N9I[*Y^V213-: ##.P(9APY&[G;M-
M'6Z5I%IH]H]M:JVR2:2>1G;<SN[%F)/?D_E@5%9:!IUCH']AI!YFG;'B\F4[
MQL8G*<_P\X ].*Y73]+$/@8ZKKFK:W!&HEU @:C*)(8B 5C9@V6(51P?XBV.
MM5K&RU1G\.Z!J&IZG']MANM1N]MXXF4*8PD'FYWX7S1G!Y*>AQ0!TEMX*TR"
M2-I)K^Z6%&2WCNKMY5@#*5.P$]=I(R<D GGFI;GPCI5U;6\$B3!;>S^QQ,LA
M#(@9&!!_O!HD(/M7(:1<W^NZY'X:N]4OUMM/-]YD\%PT4UQY<R)%ND7#<*YS
M@\D#-%_?:S-\.)+M=9N89],O9K666, 27/E77E*6;L-HR<8R>^,@@'76/A'3
M;#4EU"-[J2Y$IG+33%]TAC\LL<]RN!Z<# &*Q->\&S%1'HMK&RR07$,K/?R0
M',LADP^U3O3<S''!&<#@FNX8,4(4@-C@D9P:Y7P:;Z/4/$MG?ZE/?O;:@B++
M-@8#6\+D*HX5=S-@#I[]: +5EX1L[3[&XN+I9((H$E6*9DCG:)0$9U'4C ^H
M !R!6K/IMM<:I::C(K&XM$D2(AN 'V[LCO\ =%7** ,2;PKILOV@H9X'FNA>
MAX92IBFV[2Z>A(SD=#DY')JAJ_@FSO--F2WFO%NC926I<W3_ .D*=S!93U8;
MF)_X$1T.*ZJB@#E8O ^GRV\1NWN1(R6[7$,5PPBDEA50KE>Y&Q1Z<#C(J\OA
M73UGN766]6*?S2;=;EUC1I,[V4 C!)).>Q)(QFMRB@#GE\&Z>)H+AKB^>\AN
M1<K=/<$R%@ACP3TV[21C'?UYKH:** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *JP:=;VVH7=[&K"
M:[V>:2>#L&!@=N*M44 8,_A#3;C47O6DNU<W*W8C2<A%F4 ;PO3)"X/L3ZFN
M>TKP/.-5A&H6L*:;:VUS;+"+R29727 V(C >6FT'(R3T&< 5W]% &?I6CQ:2
ML@2YO+AI-H+W4YD("C  ST R?<YYS5&/PI9QZY-JQN]0DGF79)')<EHV3+$(
M5Z;07; ]ZWJ* ,;1_#&GZ)/YULUS(ZPBWB^T3M)Y,0.?+3/1>![G R>!3+GP
MIIMUJ4EY(;@"6:.XFMUF(AFE3&QV7N1M7V.T9SBMRB@"CIVD6FES7\MLK!KZ
MY-S/N;.7*JO'H,*.*SO^$2M/[9GU7[?J?VF=#&X^UMMV98A0.P!=B/2M^B@#
M$T/PS;>'UCCM+S4'@BB\J.">X+QHO&,+V/%;=%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !61JWAVSU:ZAO&DN
MK6]A4QI<VDQBDV'DJ2.&7(!P0>>16O10!CV'AC2]-EM);>.02VQE82/*SL[2
MXWL['EF.T<FL^3P#HLD#0 WD<+PB*2..X95<!F92?4JSL1^&<X%=110!D+X;
MT]85BVR,%O?M^6?DS9SD^V3TKE])\#3C4H5U*UA33;:TN+181>R3JZ2[1M16
M \M H/&2>0,X45W]% &?I>D1:4D@2YO+EY,9>ZG,C  8 &>@_GWS5=_#.F/H
M<^CM&_V6::2<_.0RR/*92RMU!#G(],"MBB@#'3PW9)JC7ZRW0+OYKP"<B%Y-
MNPN4Z$D=NF><9YK";X?V::E:1*9YM)73KJQDAGN&8QQR>7M2/T "MSUZ<\#'
M:T4 <ZO@S3,7+237TUQ<B$/<RW#&4&%F:-E/8@L>G7OGG+KCPA8W5FMM+=ZD
M4*2),?M;9N%<Y97]0?;&!P,"N@HH SM-T2UTFZOIK5I@+V7SI(F?**^,$J.V
M>]5KCPKI-UX?N=#FA9[*XEDF==YW!WD,I8-U!#L2/3BMJB@#FI_ VCSY4M=I
M"T4,<D*7#*DGE "-F'<@ ?7 STJ^/#FG J=C_+?G4!\Y_P!<<\_3D\5K44 <
M]-X,TR2[^UQ2WEM<AIV$UO<%&!F96D_,J/I3D\'Z7 ]L;4W5K'!#%!Y5O<,B
MRI&<H']<$GGJ<D'(K?HH S(]"M(+.YMH)+B%;BZ:[D:*8JV]G#G!'(!(P1Z$
MBK&IZ=;ZOIL]A=AFMYAM<*<$C.>OX5;HH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S]:LK
M[4-->VL+Z.RED^5I9+?SAM(((V[EYYZYK0HH XA_!&K2^%=.T*3Q! \5C)%M
M+:=\DL4:86.1/,^89 8\X.!QBM:\T#4=5\+7^CZIJT4TEV"GGPVGE!8SC*[=
MYSG##.>_M70T4 9FOZ.-=T6333/Y"2/&68+NRJNK%<9'4*5_&H-<T2XU&ZL=
M0T^^6RU&R+B*62'S49' #HR[E)!VJ>".5%;5% '(1^"[BQ2SN=,U?R=6A-P9
MKN>V$BW'GN'DW(&7'S*I7!XQCFFZAX)NYO"L.@6.M+;P99[J6:T$KSR-)YA?
MAE"Y?<<<]?:NQHH R[>RUA! ;C5XI72"1) EH$620L"CXW$C: 1MSSG/%9F@
M>'=8TC6+^]N]<@O([^433Q)8>4=XC2,$-YAP,(.,5T]% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
$ '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>exhibit101_changexreques011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit101_changexreques011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !117+>,X?&LJ67_"'7&FPL"_VG[<"<CY=NW /^UG\* .
MIHKRK['\;/\ H(^&?^^6_P#B*/L?QL_Z"/AG_OEO_B* /5:*\J^Q_&S_ *"/
MAG_OEO\ XBC['\;/^@CX9_[Y;_XB@#U6BO*OL?QL_P"@CX9_[Y;_ .(H^Q_&
MS_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?QL_Z"/AG_OEO_B*
M/5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB@#U6BO*OL?QL_P"@
MCX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?
MQL_Z"/AG_OEO_B* /5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB
M@#U6BO*OL?QL_P"@CX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\
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M_=H5\A,A'SW(*=?QJA)X2^+UUXFM?$<U]X?_ +0M[=K>(,6VHK')X"8R<]:
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MB#I?BKX<7UIX=^T7D6Z)[R<V[QQP()%P"6 RQ;:,#/&3VK=^Q_&S_H(^&?\
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MS_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?QL_Z"/AG_OEO_B*
M/5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB@#U6BO*OL?QL_P"@
MCX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?
MQL_Z"/AG_OEO_B* /5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB
M@#U6BO*OL?QL_P"@CX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)"JN(QT0,!G;QTZ5=HHH *JWFFV&HF$WUE;7)@<21>?$K^6PZ,N1P?<5:HH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7E_Q'%B?B!X/&HZ
M-)J]MY-]NM([83LQVQX.P\''6O4*Y#Q3X?UR^\3:'KFAS:>LVFQW"-'>[]K>
M:%'&SGC:: *WAJ#PZ^KAM-\#7.BW:1L4O)M)2 +Q@@,.Y!Z=^:J6_B[7[G48
MO"?D0IXDBN#]KN/*/D+: @_:%&?X@54+GALYZ5NV/_"<B\0Z@/#IM>=XMS.'
M/!Q@GCKC\,UC1^ K^W6WUN*^@;Q:+LW-Q=L&$4R-A6MSW$80 +Z%0>YH H:1
M;Z_=^./'$>CZA::>JWD#-+-;&=G;R$PH&Y0H]3R3D8QBF?\ "<7^H:%X!U%[
M2S\[5M26WN0T6X(065FCR?E.5R#VS78Z%H-QI6O^(M1EEB>/5+F.:-4SE L2
MH0>/45S%K\.M0@T'P;8->6IDT+43>3L-V)%WNV%XZ_,.M %;0K?Q%=^+/&\>
MC:A::?&FI*QDGMC.9',*87&X;5&.3R3GMCD3QU>ZG8>!+UK.S6;4]1:UNU>/
M?Y;(65C&3]WE3CKP:UX/#OBK1M;\0:AI%SI,R:M<B98;LR+Y.$50V5!R>#E?
M8<CFJT7PYN+33_!UI!?12?V'>M=W,D@(,S,2S;0,X^9CU[4 5O"#:]/\4_&$
M=SK$4MM:26JR1?92-ZM$Q4)\_P F,\\'=[5UGBK5KFPLH;'3"IU?4I/L]F",
MA#C+2L/[J+EC^ [UFZ=X;UG2?B#K6LVTUA+I>L&!ITD+B:(QQE?EP-ISUY(K
M8UKPIHOB&X@N-3LS-- K)$ZS/&5#8R/E8=<#\J ,#X7Z?'I6D:U81/)(EOK-
MS&'D;+-C:,D]R>IKN*Y7P;X,MO";ZJ\0&Z\O))4*RNVV(G**=QZCG)[^IKJJ
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M59@?O-N)_BSB@#V*LGP_K\/B&WO)H(9(A:WLUFP?'+1MM)&.QKB].TY/%GQ
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MBTN"['8D\2>8CGW*^8/PKG5;4K_3M$N9K.YO5\4:I<7\UDMSY)>!8V,$6XD
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MT-=C10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2WEO(R2#RV7RTVR$%C)GS%^Z 21C'(H W/\ A ='_P"?K7/_  =W?_QRC_A
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M$!T?_GZUS_P=W?\ \<KJ** .7_X0'1_^?K7/_!W=_P#QRC_A ='_ .?K7/\
MP=W?_P <KJ** .7_ .$!T?\ Y^M<_P#!W=__ !RC_A ='_Y^M<_\'=W_ /'*
MZBB@#E_^$!T?_GZUS_P=W?\ \<H_X0'1_P#GZUS_ ,'=W_\ '*ZBB@#E_P#A
M ='_ .?K7/\ P=W?_P <H_X0'1_^?K7/_!W=_P#QRNHHH Y?_A ='_Y^M<_\
M'=W_ /'*/^$!T?\ Y^M<_P#!W=__ !RNHHH Y?\ X0'1_P#GZUS_ ,'=W_\
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M@TZWMM0N[V-6$UWL\TD\'8,# [<5:HH P9_"&FW&HO>M)=JYN5NQ&DY"+,H
MWA>F2%P?8GU-<]I7@><:K"-0M84TVUMKFV6$7DDRNDN!L1& \M-H.1DGH,X
MKOZ* ,_2M'BTE9 ES>7#2;07NIS(0%& !GH!D^YSSFJ47A6UAUV76%OM2-U*
MNQPUTQ0H"Q"[?0%V(';-;M% &)HWABUT2]N;NWO-0E>Y;?,+BY,BNV%7<0>^
M$49]!27/A33;K4I+R0W $LT=Q-;K,1#-*F-CLO<C:OL=HSG%;E% %'3M(M-+
MFOY;96#7UR;F?<V<N55>/084<5G?\(E:?VS/JOV_4_M,Z&-Q]K;;LRQ"@=@"
M[$>E;]% &)H?AFV\/K'':7FH/!%%Y4<$]P7C1>,87L>*VZ** "BBB@ HHHH
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MS7@$Y$+R;=A<IT)([=,\XSS6$WP_LTU*TB4SS:2NG75C)#/<,QCCD\O:D?H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
)BB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>exhibit101_changexreques012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit101_changexreques012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !117+>,X?&LJ67_"'7&FPL"_VG[<"<CY=NW /^UG\* .
MIHKRK['\;/\ H(^&?^^6_P#B*/L?QL_Z"/AG_OEO_B* /5:*\J^Q_&S_ *"/
MAG_OEO\ XBC['\;/^@CX9_[Y;_XB@#U6BO*OL?QL_P"@CX9_[Y;_ .(H^Q_&
MS_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?QL_Z"/AG_OEO_B*
M/5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB@#U6BO*OL?QL_P"@
MCX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?
MQL_Z"/AG_OEO_B* /5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB
M@#U6BO*OL?QL_P"@CX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\
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M_=H5\A,A'SW(*=?QJA)X2^+UUXFM?$<U]X?_ +0M[=K>(,6VHK')X"8R<]:
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MB#I?BKX<7UIX=^T7D6Z)[R<V[QQP()%P"6 RQ;:,#/&3VK=^Q_&S_H(^&?\
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MS_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?QL_Z"/AG_OEO_B*
M/5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB@#U6BO*OL?QL_P"@
MCX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\ H(^&?^^6_P#B*/L?
MQL_Z"/AG_OEO_B* /5:*\J^Q_&S_ *"/AG_OEO\ XBC['\;/^@CX9_[Y;_XB
M@#U6BO*OL?QL_P"@CX9_[Y;_ .(H^Q_&S_H(^&?^^6_^(H ]5HKRK['\;/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)"JN(QT0,!G;QTZ5=HHH *JWFFV&HF$WUE;7)@<21>?$K^6PZ,N1P?<5:HH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ***AGN[:VV_:+B*+=T\QPN?SH FH
MJO%?V<\@CANX)'/14D!)_ &K% !14$%[:W,]Q!!<Q2S6[!)HT<%HV(R P['!
M!YIMUJ%E8R6\=W=P0/<R"*!99 IE<]%7/4^PH LT5!!>VMU+/%;W,4LEN_ES
M*CAC&V <,!T."#@^M-N=0LK*:WBNKN""2Y?RX$DD"F5O[J@]3["@"S1144US
M!;*&GFCB4G ,C!03^- $M%107,%RI:":.4 X)C<-C\JEH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *\O^(XL3\0/!XU'1I-7MO)OMUI';"=F.V/!V'@XZUZA7(>*?#^N7WB
M;0]<T.;3UFTV.X1H[W?M;S0HXV<\;30!6\-0>'7U<-IO@:YT6[2-BEY-I*0!
M>,$!AW(/3OS52W\7:_<ZC%X3\B%/$D5P?M=QY1\A;0$'[0HS_$"JA<\-G/2M
MVQ_X3D7B'4!X=-KSO%N9PYX.,$\=<?AFL:/P%?VZV^MQ7T#>+1=FYN+M@PBF
M1L*UN>XC" !?0J#W- %#2+?7[OQQXXCT?4+33U6\@9I9K8SL[>0F% W*%'J>
M2<C&,4S_ (3B_P!0T+P#J+VEGYVK:DMO<AHMP0@LK-'D_*<KD'MFNQT+0;C2
MM?\ $6HRRQ/'JES'-&J9R@6)4(/'J*YBU^'6H0:#X-L&O+4R:%J)O)V&[$B[
MW;"\=?F'6@"MH5OXBN_%GC>/1M0M-/C34E8R3VQG,CF%,+C<-JC')Y)SVQR)
MXZO=3L/ EZUG9K-J>HM:W:O'O\MD+*QC)^[RIQUX-:\'AWQ5HVM^(-0TBYTF
M9-6N1,L-V9%\G"*H;*@Y/!ROL.1S5:+X<W%II_@ZT@OHI/[#O6N[F20$&9F)
M9MH&<?,QZ]J *WA!M>G^*?C".YUB*6VM)+59(OLI&]6B8J$^?Y,9YX.[VK1^
M(.G3ZAJGAK'A]];M(;F:2>UVH4.865-Y?Y0-S Y/IQS5G3O#>LZ3\0=:UFVF
ML)=+U@P-.DA<31&.,K\N!M.>O)%:WB"TUZ9K.YT&^MX9K=V,MM=J?)N5(QAB
MHW*1U!'X@T 9W@J[THG4M-L_#T>@7]G(GVRR2.-1\RY1PR<," >?8BNLKFO#
M6@ZA8ZGJNM:S<6TFI:D8E:.U#"*&.,$(JEN2?F8DG'7I72T %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 R:6."&2:5U2.-2SLQP% &236)X5\7Z5XQL)KO2VFV12!'
M2>/8XRH93CT(8$'O7._%?594T2U\.V4=S->:W-Y#1VJ;Y1;+\TS*._R\?\"K
M'L=9CT7XEZ?<0:)JFDZ5J]NFFS"]MQ$@GC!\@@@G)*@ICZ4 >L45Y$=#M=:M
M_B)=7[W$SV=[<?9!Y[J+=E@1MR@'@YQ^7URBV"V.D?#WQ(D]R^LZA>V:7EV\
M[LTR31,75@3C;TP,<8H ]>HKQF*VU[6SJ6KV.AW,VL)JTPMM2_M%$6)8IRHB
M\LL/DVJ5(QSN)[UN:9X>L?$OCGQK%J_G75M!=6ZPVYF=4C)@0E@%(YZ<]NV,
MF@#TJLF'7X9_%=WH AD$]M:QW32'&TJ[,H [Y^6O*M"GG\0Z5\.M%U6YGGL;
MO[>URK2L#<?9R1&KD') '..^*=K2'PIX@\<'19I8S#H5OY(\PL;?=(P(4D\
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M (R?NCG(&..IJ7PU:1:SH_Q"M]0U"6UCB\07;QW?F$&UV;65P<\!2,XZ8R*
M/4;N66"SFFA@:XE1"RPJP!<@?=!/&3[U5T/6;3Q!HUMJ=DS&"=<[7&&1@<,K
M#LP(((]17"_#G4[OQ;JMQK>M2[-0LH([>"R 9%2-T#&XVG'^M/3C@#'K6IX&
M_P!'\1>-+"/_ (]XM6$R#L&EB1W _P"!9/XT =M1110 4444 %%%% !1110
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MO'NIVE,Z<_>)[\X^@ &,5TM% '/:7X-TS2YWF,E[>NT!M5-]<M/Y<)QE%#=
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH+..&*!8H%B6*(Y1 %QA?8=!0!Y);>)=?U/PWX$U:^M!/=3ZI^Z$4XS<YAF
MW?* @!QZX S[5V"^/+BS@UR/6-($&H:48 +>VN/-6X\\[8@C%5P2WRG(XZU@
M>&] U^+1/!FFW>BS6TFA:@3<R/+$4=/+E&],,21EE'0'GI5SQ-X.U+6M1\6.
MEI')%=PZ<]JLL@"7#P.[O&><@'A<G^]0!T^C>(+^YUF;1M9TR*QOTMUNHQ!<
M^?'+$6VG#%5(93@$8[C!J76]4UFTO(+71]%2^=XVEDFN+GR(D ( 7<%;+G/
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MD>&+%F(4X*C&37HNFW5[=1W!O=/-DT=Q)'$IE$GFQ@X63CIN'.#R* +M%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'6UBTY+BRLYKFZ\R-RLS)-+$%3##8"86.3NQD#!H U_^$!T?_GZUS_P=W?\
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M_P#XY1_P@.C_ //UKG_@[N__ (Y7444 <O\ \(#H_P#S]:Y_X.[O_P".4?\
M" Z/_P _6N?^#N[_ /CE=110!R__  @.C_\ /UKG_@[N_P#XY1_P@.C_ //U
MKG_@[N__ (Y7444 <O\ \(#H_P#S]:Y_X.[O_P".4?\ " Z/_P _6N?^#N[_
M /CE=110!R__  @.C_\ /UKG_@[N_P#XY1_P@.C_ //UKG_@[N__ (Y7444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
**** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>moh-20220930_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 moh-20220930_g1.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1$&17AI9@  34T *@    @ ! $[  (
M   4   (2H=I  0    !   (7IR=  $    H   0UNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %-H96EL82!(
M861E<G-B97)G97(   60 P "    %   $*R0!  "    %   $,"2D0 "
M S<R  "2D@ "     S<R  #J'  '   (#   "*      '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ_\  $0@
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M7HK!0MJV?,2S[$<UXQ5OG_F?2MM=07D"S6DT<\3?=>-@P/XBI:^?/#WB2_\
M#E\)[&0F,G][ Q^20>X]??M7NVD:K;ZUI4%_9G,4RYP>JGH0?<&N*O0=)WZ'
MNX#,88Q-6M)=/\B[1117.>H%%%% !1110 4444 %%%% !1110 4444 %%%%
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M??".%F\17LX^ZEKL/'=G4C_T$USXE)TG<]+*Y2CC(6_K0]<HHHKQ#[\****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$\5U;QSVTJ30RJ'CD1@RNI&001U%? M>P_!;XM'PU<Q>'?$4W_$GF?%O._\
MRZ.3W/\ <)//H>>F:!V/IVBD4AE!4@@C(([TM BIJU\=,T6]OUB,YM;>281
MXW[5)VYP<9QCI7E/A3X_P^*O%6G:);^')87O9=AE:[#!!@DG&SGI[5ZCK_\
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MQ.!6O9?"G6II@+R:VMHL_,VXNWX ?XBO2_#WARQ\-Z?]FL$)9N99G^](??\
MH*TK8F"BU%W9S8#*JTZJG55HKOU-:BBBO(/M KY^\7V:6'B_4K>( ()RR@=
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M4444 >D?!_\ X^]5_P!R/^;5ZE7EOP?_ ./O5?\ <C_FU>I5XN*_C,^[R?\
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M^UM7CN'MA*L3?9T#,I;.#@D<<8_&L+P?\7?#GC?7#I6BQWPN!"TQ,\*JNU2
M>0QYY%9WQ_B\SX1WC9QY=Q WU^<#^M>5_LU?\E)U#_L$R?\ HZ&@9]/UYWXD
M^-?ACPIXCN]$U:#41=VA4.8X496W(K@@[_1AUQ7HE8-WX'\+ZAJ<VHZAX?TZ
M\NYB#)-<VZREB %&=P/8"@1PW_#1O@K_ )Y:K_X#+_\ %T?\-&^"O^>6J_\
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MOUZI7-/\.?!CR!_^$7TI&!!!BM$3!'<;0,5TM @HHHH **** "BBB@ HHHH
M*^??%O\ R..J_P#7T_\ .OH*OGWQ;_R..J_]?3_SKOP7QL^=S[^##U_0QZ**
M*]0^0"BBB@#TCX/_ /'WJO\ N1_S:N9\>_\ (]:G_OK_ .@+73?!_P#X^]5_
MW(_YM7,^/?\ D>M3_P!]?_0%KCA_O,O3_(]RM_R*J7^)_J<[11178>&%%%%
M!7I'P?\ ^/O5?]R/^;5YO7I'P?\ ^/O5?]R/^;5SXG^"ST\J_P!]A\_R9S/C
MW_D>M3_WU_\ 0%KG:Z+Q[_R/6I_[Z_\ H"USM:TOX<?0Y<7_ +Q4]7^84445
M9S!1110!Z1\'_P#C[U7_ '(_YM7J5>6_!_\ X^]5_P!R/^;5ZE7BXK^,S[O)
M_P#<H?/\V?"FK^9_PEU]Y'^M^W2;/][S#CK7M\;_ +0Z-EHUD&/NL;#'Z$5X
MGJ+!/&EVSD*HU!R23@ >8:^Z*YCUSY<\?GXQ'PC<GQP,:+O3S@/LG7<-O^K^
M;[V.GXU)^S5_R4G4/^P3)_Z.AKUCX]_\D@U+_KM!_P"C5KR;]FQU7XE7H8X+
M:5(%]SYL1_H: Z'U!7P;HTMU!KMA+IL8EO([F-H(R,[I P*C'N<5]Y5\,>$/
M^1WT/_L(V_\ Z,6@$>W/XU^. C8_\(I".#RMF21]!OKUOP3>:QJ'@S3[KQ-
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M:>)O^?./_O\ I_C7M]%..+J122L9U,EPU2;FV[MWW7^1XA_PK3Q-_P ^<?\
MW_3_ !H_X5IXF_Y\X_\ O^G^->WT57UVIY$?V%A>[^]?Y'B'_"M/$W_/G'_W
M_3_&C_A6OB;_ )\X_P#O^G^->WT4?7:GD']A87N_O7^1PGPZ\,:IX>N+]]4@
M6(3*@3;(&S@G/3ZUW=%%<M2;J2YF>KA\/##4E2ALCY3U#X%>/KR^N[S^S[7,
MT[N$^UIDY.<]<=_6OJM22H)&TD<@]J6BH.@XGXM^'=5\5?#VYTG0H$GNIIHC
MM>0)\JL&)R3CM7GWP?\ A;XI\%^/3J.MVD*VCV<D7F17"MAB5(&.O\->[T4
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MM(J *N23DD5Y!X6^%'Q5\)7[ZCX>:SL+N6$PNS312'86!(PP8=54Y'-?3-%
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M]P))"/T-=K\-/"FL^&M)OIO%5^NH:UJ5SY]Q.KE\*% 5,D#I@].!G XKM**
M/&?#?P^\47GQPG\9>++2*&U4RRVRB=9"IQY<2$ ]D.<],CUKV:BB@#SKXS^!
M+SQSX2MXM'B234K.X$D*LX7<A&'7)X'8_P# :Y'X/_#_ ,;^ _%S2:G90_V7
M?0>7=&.Y1C&PY1L9R2#D<=F->YT4 <A\5-"U+Q-\-]2T?18%GO+HQ!%:0(,+
M*CDY/'1:\Q^$WPI\6>#OB%;:GK%G MG]GD1Y([A6VEEX&.IY _.O?:* /*_C
M5\,;KQO9V>H:!$CZO:GRF5G">;"><9/&5/(^I]JQ/A!X)\>^ ?$#1ZE90OHU
M^O\ I*I=(QA<#Y7 SR>QQV/? KV^B@#A?C!X:U7Q;X!?2M"MUN+I[F-]K2*@
M"KDDY)KR#PM\*/BKX2OWU'P\UG87<L)A=FFBD.PL"1A@PZJIR.:^F:* /"?[
M(^.\FHP_;=2$EOYB&4V\MO'E<\@8 [5[M110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
' 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701216698016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 21, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-31719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MOLINA HEALTHCARE, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-4204626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">200 Oceangate<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Long Beach,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">90802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">435-3666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 Par Value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MOH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001179929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701218293264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF INCOME - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premium revenue</a></td>
<td class="nump">$ 7,636<span></span>
</td>
<td class="nump">$ 6,800<span></span>
</td>
<td class="nump">$ 22,966<span></span>
</td>
<td class="nump">$ 19,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_HealthCareOrganizationPremiumTaxRevenue', window );">Premium tax revenue</a></td>
<td class="nump">223<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="nump">646<span></span>
</td>
<td class="nump">576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Investment income</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDividendIncomeOperating', window );">Other revenue</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">7,927<span></span>
</td>
<td class="nump">7,040<span></span>
</td>
<td class="nump">23,751<span></span>
</td>
<td class="nump">20,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Medical care costs</a></td>
<td class="nump">6,748<span></span>
</td>
<td class="nump">6,049<span></span>
</td>
<td class="nump">20,183<span></span>
</td>
<td class="nump">17,342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">560<span></span>
</td>
<td class="nump">532<span></span>
</td>
<td class="nump">1,682<span></span>
</td>
<td class="nump">1,489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_PremiumTaxExpenses', window );">Premium tax expenses</a></td>
<td class="nump">223<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="nump">646<span></span>
</td>
<td class="nump">576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Other</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">7,592<span></span>
</td>
<td class="nump">6,819<span></span>
</td>
<td class="nump">22,683<span></span>
</td>
<td class="nump">19,533<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">335<span></span>
</td>
<td class="nump">221<span></span>
</td>
<td class="nump">1,068<span></span>
</td>
<td class="nump">829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other expenses, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expenses, net</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income tax expense</a></td>
<td class="nump">307<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="nump">985<span></span>
</td>
<td class="nump">739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">249<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 230<span></span>
</td>
<td class="nump">$ 143<span></span>
</td>
<td class="nump">$ 736<span></span>
</td>
<td class="nump">$ 556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_EarningsPerShareBasicAndDilutedEPSAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share - Basic (in dollars per share)</a></td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="nump">$ 2.49<span></span>
</td>
<td class="nump">$ 12.74<span></span>
</td>
<td class="nump">$ 9.63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share - Diluted (in dollars per share)</a></td>
<td class="nump">$ 3.95<span></span>
</td>
<td class="nump">$ 2.46<span></span>
</td>
<td class="nump">$ 12.58<span></span>
</td>
<td class="nump">$ 9.51<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_EarningsPerShareBasicAndDilutedEPSAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Basic and Diluted EPS</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_EarningsPerShareBasicAndDilutedEPSAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_HealthCareOrganizationPremiumTaxRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Health Care Organization, Premium Tax Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_HealthCareOrganizationPremiumTaxRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_PremiumTaxExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An assessment levied by a state government on the net premium income collected.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_PremiumTaxExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDividendIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.1-5)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDividendIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetInvestmentIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetInvestmentIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PremiumsEarnedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 235<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-17(Column E))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401096&amp;loc=d3e574992-122915<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PremiumsEarnedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701218296480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 230<span></span>
</td>
<td class="nump">$ 143<span></span>
</td>
<td class="nump">$ 736<span></span>
</td>
<td class="nump">$ 556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized investment loss</a></td>
<td class="num">(75)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="num">(237)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Less: effect of income taxes</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss, net of tax</a></td>
<td class="num">(57)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(180)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 173<span></span>
</td>
<td class="nump">$ 134<span></span>
</td>
<td class="nump">$ 556<span></span>
</td>
<td class="nump">$ 536<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701216702160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,242<span></span>
</td>
<td class="nump">$ 4,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments</a></td>
<td class="nump">3,639<span></span>
</td>
<td class="nump">3,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">2,220<span></span>
</td>
<td class="nump">2,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">391<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">10,492<span></span>
</td>
<td class="nump">10,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property, equipment, and capitalized software, net</a></td>
<td class="nump">412<span></span>
</td>
<td class="nump">396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Goodwill, and intangible assets, net</a></td>
<td class="nump">1,263<span></span>
</td>
<td class="nump">1,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsNoncurrent', window );">Restricted investments</a></td>
<td class="nump">242<span></span>
</td>
<td class="nump">212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income taxes</a></td>
<td class="nump">198<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">186<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">12,793<span></span>
</td>
<td class="nump">12,209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable</a></td>
<td class="nump">3,622<span></span>
</td>
<td class="nump">3,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_MedicalPremiumLiabilityDueToAgency', window );">Amounts due government agencies</a></td>
<td class="nump">2,139<span></span>
</td>
<td class="nump">2,472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable, accrued liabilities and other</a></td>
<td class="nump">818<span></span>
</td>
<td class="nump">842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">663<span></span>
</td>
<td class="nump">370<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">7,242<span></span>
</td>
<td class="nump">7,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">2,175<span></span>
</td>
<td class="nump">2,173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">9,752<span></span>
</td>
<td class="nump">9,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, $0.001 par value, 150 million shares authorized; outstanding: 58 million shares at September&#160;30, 2022 and December&#160;31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">289<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(185)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">2,937<span></span>
</td>
<td class="nump">2,399<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">3,041<span></span>
</td>
<td class="nump">2,630<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 12,793<span></span>
</td>
<td class="nump">$ 12,209<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_MedicalPremiumLiabilityDueToAgency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Medical Premium Liability Due to Agency</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_MedicalPremiumLiabilityDueToAgency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the noncurrent portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=127002003&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701217951552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">58,000,000<span></span>
</td>
<td class="nump">58,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701213383424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Retained Earnings</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 2,096<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 1,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Common stock purchases (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Common stock purchases</a></td>
<td class="num">(122)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(120)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss, net</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">2,164<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">1,968<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">2,096<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">1,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss, net</a></td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">2,518<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">205<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">2,296<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">2,164<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">1,968<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">2,370<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">2,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss, net</a></td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">2,518<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">205<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">2,296<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">2,630<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">236<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="nump">2,399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss, net</a></td>
<td class="num">(76)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(76)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="num">(18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">2,794<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="num">(81)<span></span>
</td>
<td class="nump">2,657<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">2,630<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">236<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="nump">2,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss, net</a></td>
<td class="num">(180)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">3,041<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">289<span></span>
</td>
<td class="num">(185)<span></span>
</td>
<td class="nump">2,937<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">2,794<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="num">(81)<span></span>
</td>
<td class="nump">2,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Common stock purchases (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(658)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Common stock purchases</a></td>
<td class="num">(200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(198)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss, net</a></td>
<td class="num">(47)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">2,830<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">251<span></span>
</td>
<td class="num">(128)<span></span>
</td>
<td class="nump">2,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss, net</a></td>
<td class="num">(57)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(57)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">$ 3,041<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 289<span></span>
</td>
<td class="num">$ (185)<span></span>
</td>
<td class="nump">$ 2,937<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701218218000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 736<span></span>
</td>
<td class="nump">$ 556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred income taxes</a></td>
<td class="num">(35)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other, net</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Receivables</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(247)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(110)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities', window );">Medical claims and benefits payable</a></td>
<td class="nump">251<span></span>
</td>
<td class="nump">522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency', window );">Amounts due government agencies</a></td>
<td class="num">(360)<span></span>
</td>
<td class="nump">810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued liabilities and other</a></td>
<td class="num">(40)<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">293<span></span>
</td>
<td class="num">(374)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">985<span></span>
</td>
<td class="nump">1,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of investments</a></td>
<td class="num">(1,764)<span></span>
</td>
<td class="num">(2,018)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sales and maturities of investments</a></td>
<td class="nump">1,082<span></span>
</td>
<td class="nump">965<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Net cash paid in business combinations</a></td>
<td class="num">(134)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, equipment and capitalized software</a></td>
<td class="num">(81)<span></span>
</td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other, net</a></td>
<td class="num">(41)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(938)<span></span>
</td>
<td class="num">(1,106)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Common stock purchases</a></td>
<td class="num">(200)<span></span>
</td>
<td class="num">(128)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_CommonStockWithheldToSettleEmployeeTaxObligations', window );">Common stock withheld to settle employee tax obligations</a></td>
<td class="num">(53)<span></span>
</td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Contingent consideration liabilities settled</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other, net</a></td>
<td class="nump">15<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(258)<span></span>
</td>
<td class="num">(204)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents, and restricted cash and cash equivalents</a></td>
<td class="num">(211)<span></span>
</td>
<td class="nump">212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period</a></td>
<td class="nump">4,506<span></span>
</td>
<td class="nump">4,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash and cash equivalents at end of period</a></td>
<td class="nump">$ 4,295<span></span>
</td>
<td class="nump">$ 4,435<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_CommonStockWithheldToSettleEmployeeTaxObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Withheld to Settle Employee Tax Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_CommonStockWithheldToSettleEmployeeTaxObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Medical Premium Liability Due to Agency</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in health care insurance liability balances during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701219079856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text">Organization and Basis of Presentation <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization and Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. provides managed healthcare services under the Medicaid and Medicare programs, and through the state insurance marketplaces (the &#8220;Marketplace&#8221;). We currently have four reportable segments consisting of: 1)&#160;Medicaid; 2)&#160;Medicare; 3)&#160;Marketplace; and 4)&#160;Other. Our reportable segments are consistent with how we currently manage the business and view the markets we serve. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, we served approximately 5.2&#160;million members eligible for government-sponsored healthcare programs, located across 19 states.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our state Medicaid contracts typically have terms of&#160;<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfNjE0_de89890f-e645-4a35-a3a8-f77327830d82">three</span>&#160;to&#160;five years, contain renewal options exercisable by the state Medicaid agency, and allow either the state or the health plan to terminate the contract with or without cause. Such contracts are subject to risk of loss in states that issue requests for proposal (&#8220;RFPs&#8221;) open to competitive bidding by other health plans. If one of our health plans is not a successful responsive bidder to a state RFP, its contract may not be renewed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to contract renewal, our state Medicaid contracts may be periodically amended to include or exclude certain health benefits (such as pharmacy services, behavioral health services, or long-term care services); populations such as the aged, blind or disabled (&#8220;ABD&#8221;); and regions or service areas.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New York Acquisition&#8212;Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2022, we closed on our acquisition of the Medicaid Managed Long Term Care business of AgeWell New York. See Note 4, &#8220;Business Combinations,&#8221; for further information. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nebraska Procurement&#8212;Medicaid.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In September 2022, we announced that our Nebraska health plan had been selected by the Nebraska Department of Health and Human Services (DHHS) to provide health care services to Nebraskans under the state&#8217;s Medicaid managed care program. The new five-year contract is expected to begin on January 1, 2024, and may be extended for an additional two-years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Iowa Procurement&#8212;Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we announced that our Iowa health plan had been notified by the Iowa Department of Health and Human Services (HHS) of its intent to award a Medicaid managed care contract pursuant to the Request for Proposal issued by HHS on February 17, 2022. The new four-year contract is expected to begin on July 1, 2023, and may be extended for an additional four years. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">California Procurement&#8212;Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we announced that our California health plan had been notified by the California Department of Health Care Services of its intent to award a Medi-Cal contract in each of Los Angeles, Riverside, San Bernardino, Sacramento, and San Diego Counties. The  five Medi-Cal contracts are expected to commence on January 1, 2024, which enables us to continue serving Medi-Cal members in our existing counties and expand footprint with the addition of the Los Angeles County contract. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mississippi Procurement&#8212;Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we announced that our Mississippi health plan had been notified by the Mississippi Division of Medicaid (DOM) of its intent to award a Medicaid Coordinated Care Contract for its Mississippi Coordinated Access Program and Mississippi Children&#8217;s Health Insurance Program pursuant to the Request for Qualifications issued by DOM on December 10, 2021. The <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfMTA5OTUxMTY0MjE5OA_6c2d1c0d-cdab-4160-9874-52b55f757a29">four</span>-year contract is expected to begin on July 1, 2023, and may be extended for an additional two years. The award enables us to continue serving Medicaid members across the state. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wisconsin Acquisition &#8212; Medicaid and Medicare. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 13, 2022, we announced a definitive agreement to acquire substantially all the assets of My Choice Wisconsin (&#8220;MCW&#8221;).  The purchase price for the transaction is approximately $150&#160;million, net of expected tax benefits and required regulatory capital, which we intend to fund with cash on hand. The transaction is subject to receipt of applicable federal and state regulatory approvals, and the satisfaction of other customary closing conditions. We currently expect the transaction to close in early 2023. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Texas Procurement&#8212;Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the Texas Health and Human Services Commission posted the ABD program (known in Texas as STAR+PLUS) RFP. We submitted our proposal in June 2022 to continue serving STAR+PLUS members, with awards estimated to be announced in the first quarter of 2023, and start of operations in February 2024. Further, in October 2022, the draft RFP was posted for the TANF and CHIP programs (known as </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the STAR &amp; CHIP programs, and both existing contracts for us), with awards expected in late Q4 2023 or early Q1 2024 and the start of operations in late Q4 2024 or early Q1 2025. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nevada Procurement&#8212;Medicaid.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our new contract in Clark and Washoe Counties commenced on January 1, 2022, and offers health coverage to TANF, CHIP and Medicaid Expansion beneficiaries. This new contract is four years  with a potential two-year extension.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Texas Acquisition&#8212;Medicaid and Medicare. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, we closed on our acquisition of Cigna Corporation&#8217;s Texas Medicaid and Medicare-Medicaid Plan (&#8220;MMP&#8221;) contracts, along with certain operating assets. See Note 4, &#8220;Business Combinations,&#8221; for further information. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation and Interim Financial Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Molina Healthcare, Inc., and its subsidiaries. In the opinion of management, these financial statements reflect all normal recurring adjustments, which are considered necessary for a fair presentation of the results as of the dates and for the interim periods presented. All significant intercompany balances and transactions have been eliminated. The consolidated results of operations for the nine months ended September 30, 2022 are not necessarily indicative of the results for the entire year ending December&#160;31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited consolidated interim financial statements have been prepared under the assumption that users of the interim financial data have either read or have access to our audited consolidated financial statements for the fiscal year ended December&#160;31, 2021. Accordingly, certain disclosures that would substantially duplicate the disclosures contained in our December&#160;31, 2021, audited consolidated financial statements have been omitted. These unaudited consolidated interim financial statements should be read in conjunction with our audited consolidated financial statements for the fiscal year ended December&#160;31, 2021. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div>The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701219111072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text">Significant Accounting Policies <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash and short-term, highly liquid investments that are both readily convertible into known amounts of cash and have a maturity of three months or less on the date of purchase. The following table provides a reconciliation of cash and cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in &#8220;Restricted investments&#8221; in the accompanying consolidated balance sheets.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,435&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables consist primarily of premium amounts due from government agencies, which are subject to potential retroactive adjustments. Because substantially all of our receivable amounts are readily determinable and substantially all of our creditors are governmental authorities, our allowance for credit losses is insignificant. Any amounts determined to be uncollectible are charged to expense when such determination is made.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:72.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government receivables</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy rebate receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,220&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,177&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Premium Revenue Recognition and Amounts Due Government Agencies</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium revenue is generated from our contracts with state and federal agencies, in connection with our participation in the Medicaid, Medicare, and Marketplace programs. Premium revenue is generally received based on per member per month (&#8220;PMPM&#8221;) rates established in advance of the periods covered. These premium revenues are recognized in the month that members are entitled to receive healthcare services, and premiums collected in advance are deferred. State Medicaid programs and the federal Medicare program periodically adjust premium rates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain components of premium revenue are subject to accounting estimates and are described in further detail below, and in our 2021 Annual Report on Form 10-K, Note 2, &#8220;Significant Accounting Policies,&#8221; under &#8220;Contractual Provisions That May Adjust or Limit Revenue or Profit,&#8221; and &#8220;Quality Incentives.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Provisions That May Adjust or Limit Revenue or Profit</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our contracts contain provisions that may adjust or limit revenue or profit, as described below. Consequently, we recognize premium revenue as it is earned under such provisions. Liabilities accrued for premiums to be returned under such provisions are reported in the aggregate as &#8220;Amounts due government agencies,&#8221; in the accompanying consolidated balance sheets. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth amounts due government agencies, categorized by program:</span></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid program:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR and profit sharing</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare program:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR and profit sharing </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk adjustment and Part D risk sharing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace program:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total amounts due government agencies</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,139&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,472&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicaid Program</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Minimum MLR and Retroactive Premium Adjustments. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State Medicaid programs periodically adjust premium rates on a retroactive basis. In these cases, we adjust our premium revenue in the period in which we determine that the adjustment is probable and reasonably estimable, based on our best estimate of the ultimate premium we expect to realize for the period being adjusted. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2020, various states enacted temporary risk corridors in response to the reduced demand for medical services stemming from COVID-1</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which have resulted in a reduction of our medical margin. In some cases, these risk corridors were retroactive to earlier periods in 2020, or as early as the beginning of the states&#8217; fiscal years in 2019. Since the second quarter of 2020, we have recognized risk corridors that we believe to be probable, and where the ultimate premium amount is reasonably estimable. For the three and nine months ended September 30, 2022, we recognized approximately $34&#160;million and $156&#160;million, respectively, related to such risk corridors, primarily in the Medicaid segment, compared to $17&#160;million and $183&#160;million, respectively, recognized in the three and nine months ended September&#160;30, 2021. The decrease is due to the elimination of several of the COVID-19 risk corridors. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that certain states could change the structure of existing risk corridors, implement new risk corridors in the future or discontinue existing risk corridors. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Marketplace Program</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Adjustment.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under this program, our health plans&#8217; composite risk scores are compared with the overall average risk score for the relevant state and market pool. Generally, our health plans will make a risk adjustment payment into the pool if their composite risk scores are below the average risk score (risk adjustment payable), and will receive a risk adjustment payment from the pool if their composite risk scores are above the average risk score (risk adjustment receivable). We estimate our ultimate premium based on insurance policy year-to-date experience, and recognize estimated premiums relating to the risk adjustment program as an adjustment to premium revenue in our consolidated statements of income. As of September&#160;30, 2022, Marketplace risk adjustment payables amounted to $179 million and related receivables amounted to $94 million, for a net payable of $85 million. As of December&#160;31, 2021, Marketplace risk adjustment payables amounted to $902 million and related receivables amounted to $7 million, for a net payable of $895 million. </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than 15 years, or less than 15 years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents, and U.S. Treasury securities. Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and governments of each state in which our health plan subsidiaries operate.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is determined using an estimated annual effective tax rate, which generally differs from the U.S.&#160;federal statutory rate primarily because of foreign and state taxes, and nondeductible expenses such as certain compensation and other general and administrative expenses.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate may be subject to fluctuations during the year as new information is obtained. Such information may affect the assumptions used to estimate the annual effective tax rate, including projected pretax earnings, the mix of pretax earnings in the various tax jurisdictions in which we operate, valuation allowances against deferred tax assets, the recognition or the reversal of the recognition of tax benefits related to uncertain tax positions, and changes in or the interpretation of tax laws in jurisdictions where we conduct business. We recognize deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of our assets and liabilities, along with net operating loss and tax credit carryovers.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (&#8220;SEC&#8221;) did not have, nor does management expect such pronouncements to have, a significant impact on our present or future consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701323919520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income Per Share</a></td>
<td class="text">Net Income Per Share <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the calculation of basic and diluted net income per share:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.981%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except net income per share)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares outstanding at the beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average number of shares issued:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator for basic net income per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator for diluted net income per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Basic </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Diluted </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.95&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.46&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.58&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.51&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Source data for calculations in thousands.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701221535936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combinations</a></td>
<td class="text">Business Combinations<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AgeWell.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As described in Note 1, &#8220;Organization and Basis of Presentation,&#8221; we announced this acquisition closed on October 1, 2022. Because the closing date fell on a weekend, the $134&#160;million purchase price was paid on September 30, 2022 and was recorded to prepaid expenses and other assets. Such amounts are reported in investing activities in the accompanying consolidated statements of cash flows. The initial accounting for this transaction is incomplete. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cigna. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, we closed on our acquisition of Cigna Corporation&#8217;s Texas Medicaid and Medicare-Medicaid Plan contracts, along with certain operating assets, for purchase consideration of approximately $60&#160;million. We acquired membership and a provider network with a preliminary fair value of approximately $36&#160;million. We allocated the remaining $24 million of purchase consideration to goodwill, primarily in the Medicaid segment, which relates to future economic benefits arising from expected synergies from the use of our existing infrastructure to support the added membership, and from the assembled workforce. The goodwill is deductible for income tax purposes. </span></div>Affinity. On October 25, 2021, we closed on our acquisition of substantially all of the assets of Affinity Health Plan, Inc., a Medicaid health plan in New York, for initial purchase consideration of approximately $176&#160;million. In the nine months ended September 30, 2022, we recorded various measurement period adjustments, including an increase of $8&#160;million to &#8220;Medical claims and benefits payable,&#8221; and an increase of $1&#160;million to &#8220;Receivables&#8221; net of &#8220;Amounts due government agencies.&#8221; In the aggregate, we recorded a net increase of $7&#160;million to goodwill for these measurement period adjustments and various purchase price adjustments.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701221541792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements We consider the carrying amounts of current assets and current liabilities to approximate their fair values because of the relatively short period of time between the origination of these instruments and their expected realization or payment. For our financial instruments measured at fair value on a recurring basis, we prioritize the inputs used in measuring fair value according to the three-tier fair value hierarchy. For a description of the methods and assumptions used to: a) estimate the fair value; and b) determine the classification according to the fair value <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hierarchy for each financial instrument, refer to our 2021 Annual Report on Form 10-K, Note 5, &#8220;Fair Value Measurements.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net changes in fair value of Level 3 financial instruments are reported in &#8220;Other&#8221; operating expenses in our consolidated statements of income. In the nine months ended September 30, 2022 and 2021, we recognized a loss of $4&#160;million and $3&#160;million, respectively, for the increase in the fair value of the contingent consideration liabilities described below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments measured at fair value on a recurring basis at September&#160;30, 2022, were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Directly or Indirectly Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(Level 3)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments measured at fair value on a recurring basis at December&#160;31, 2021, were as follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Directly or Indirectly Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Level 3 financial instruments at September&#160;30, 2022 are comprised solely of contingent consideration liabilities of $8 million, in connection with our 2020 acquisition of certain assets of Passport Health Plan, Inc., a Medicaid health plan in Kentucky. Such liabilities are recorded at fair value on a recurring basis. In the nine months ended September 30, 2022, the estimated fair value of contingent purchase consideration increased by approximately $4&#160;million, relating to an operating income guarantee. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the nine months ended September 30, 2022, we paid the seller $43&#160;million, of which $23&#160;million was for the remaining half of the consideration due for minimum member enrollment targets and $20&#160;million was for the first payment of the consideration due for the operating income guarantee. For the amounts paid in the nine months ended September 30, 2022, $20 million has been presented in &#8220;Financing activities&#8221; in the accompanying consolidated statements of cash flows, with the balance reflected in &#8220;Operating activities.&#8221; The remaining balance of </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the liabilities is reported in &#8220;Accounts payable, accrued liabilities and other&#8221; in the accompanying consolidated balance sheets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements &#8211; Disclosure Only</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and estimated fair values of our notes payable are classified as Level 2 financial instruments. Fair value for these securities is determined using a market approach based on quoted market prices for similar securities in active markets or quoted prices for identical securities in inactive markets.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.375% Notes due 2028</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.875% Notes due 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.875% Notes due 2032</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,868&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,173&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,264&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701221585280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text">Investments <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Available-for-Sale</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all of our investments classified as current assets to be available-for-sale. The following tables summarize our current investments as of the dates indicated:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,882&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,208&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of our current investments as of September&#160;30, 2022 are summarized below:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,882&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross realized gains and losses from sales of available-for-sale securities are calculated under the specific identification method and are included in investment income. Gross realized investment gains were insignificant for the three and nine months ended September&#160;30, 2022, respectively. Gross realized investment gains amounted to $6&#160;million and $7&#160;million for the three and nine months ended September&#160;30, 2021, respectively. Gross realized investment losses were insignificant for the three and nine months ended September&#160;30, 2022, and 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have determined that unrealized losses at September&#160;30, 2022, and December&#160;31, 2021, primarily resulted from fluctuating interest rates, rather than a deterioration of the creditworthiness of the issuers. Therefore, we determined that an allowance for credit losses was not necessary. So long as we maintain the intent and ability to hold these securities to maturity, we are unlikely to experience losses. In the event that we dispose of these securities before maturity, we expect that realized losses, if any, will be insignificant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table segregates those available-for-sale investments that have been in a continuous loss position for less than 12 months, and those that have been in a continuous loss position for 12 months or more as of September&#160;30, 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:24.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">In&#160;a&#160;Continuous&#160;Loss Position<br/>for&#160;Less&#160;than&#160;12&#160;Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">In&#160;a&#160;Continuous&#160;Loss Position<br/>for&#160;12&#160;Months or More</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Positions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Positions</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">909&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,815&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,457&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">708&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table segregates those available-for-sale investments that have been in a continuous loss position for less than 12 months, and those that have been in a continuous loss position for 12 months or more as of December&#160;31, 2021:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:24.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.651%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">In&#160;a&#160;Continuous&#160;Loss Position<br/>for&#160;Less&#160;than&#160;12&#160;Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">In&#160;a&#160;Continuous&#160;Loss Position<br/>for&#160;12&#160;Months or More</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Positions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Positions</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,706&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">677&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Investments Held-to-Maturity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the regulations governing our state health plan subsidiaries, we maintain statutory deposits and deposits required by government authorities primarily in cash, cash equivalents, U.S. Treasury securities, and corporate debt securities. We also maintain restricted investments as protection against the insolvency of certain capitated providers. The use of these funds is limited as required by regulations in the various states in which we operate, or as needed in the event of insolvency of capitated providers. Therefore, such investments are reported as &#8220;Restricted investments&#8221; in the accompanying consolidated balance sheets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have the ability to hold these restricted investments until maturity and, as a result, we would not expect the value of these investments to decline significantly due to a sudden change in market interest rates. Our held-to-maturity restricted investments are carried at amortized cost, which approximates fair value. Such investments amounted to $242 million at September&#160;30, 2022, of which $201 million will mature in one year or less, $37&#160;million will mature in one through five years, and $4 million will mature after five years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701221532208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Claims and Benefits Payable<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_MedicalClaimsAndBenefitsPayableTextBlock', window );">Medical Claims and Benefits Payable</a></td>
<td class="text">Medical Claims and Benefits Payable <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the details of our medical claims and benefits payable as of the dates indicated:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Claims incurred but not paid (&#8220;IBNP&#8221;)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitation payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,622&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Other&#8221; medical claims and benefits payable include amounts payable to certain providers for which we act as an intermediary on behalf of various government agencies without assuming financial risk. Such receipts and payments do not impact our consolidated statements of income. Non-risk provider payables amounted to $317 million and $226 million as of September&#160;30, 2022, and December&#160;31, 2021, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the components of the change in our medical claims and benefits payable for the periods indicated. The amounts presented for &#8220;Components of medical care costs related to: Prior years&#8221; represent the amount by which our original estimate of medical claims and benefits payable at the beginning of the year varied from the actual liabilities, based on information (principally the payment of claims) developed since those liabilities were first reported. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicaid </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicare </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketplace</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Components of medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(282)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,238&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,487&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,458&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,183&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,994&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,440&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,585&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,019&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired balances, net of post-acquisition adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in non-risk and other provider payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,923&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,622&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicaid </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicare</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketplace</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Components of medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,558&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(216)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,333&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,068&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,888&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired balances, net of post-acquisition adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in non-risk and other provider payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,443&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,191&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimates of medical claims and benefits payable recorded at December 31, 2021, and 2020 developed favorably by approximately $338 million and $216 million as of September&#160;30, 2022, and 2021, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The favorable prior year development recognized in the nine months ended September 30, 2022 was primarily due to lower than expected utilization of medical services by our members and improved operating performance. Consequently, the ultimate costs recognized in 2022, as claims payments were processed, were lower than our estimates in 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_MedicalClaimsAndBenefitsPayableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Medical claims and benefits payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_MedicalClaimsAndBenefitsPayableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701221570784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Debt</a></td>
<td class="text">Debt <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All our debt is held at the parent, which is reported in the Other segment. The following table summarizes our outstanding debt obligations, all of which are non-current as of the dates reported below:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-current long-term debt:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.375% Notes due 2028</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.875% Notes due 2030 </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.875% Notes due 2032</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred debt issuance costs </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,173&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to a credit agreement (the &#8220;Credit Agreement&#8221;) which includes a revolving credit facility (&#8220;Credit Facility&#8221;) of $1.0 billion, among other provisions. The Credit Agreement has a term of five years, and all amounts outstanding will be due and payable on June 8, 2025. Borrowings under the Credit Agreement bear interest based, at our election, on a base rate or other defined rate, plus in each case, the applicable margin. In addition to interest payable on the principal amount of indebtedness outstanding from time to time under the Credit Agreement, we are required to pay a quarterly commitment fee.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains customary non-financial and financial covenants. As of September&#160;30, 2022, we were in compliance with all financial and non-financial covenants under the Credit Agreement. As of September&#160;30, 2022, no amounts were outstanding under the Credit Facility.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Notes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our senior notes are described below. Each of these notes are senior unsecured obligations of Molina and rank equally in right of payment with all existing and future senior debt, and senior to all existing and future subordinated </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">debt of Molina. In addition, each of the indentures governing the senior notes contain customary non-financial covenants and change of control provisions. As of September&#160;30, 2022, we were in compliance with all non-financial covenants in the indentures governing the senior notes. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indentures governing the senior notes contain cross-default provisions that are triggered upon default by us or any of our subsidiaries on any indebtedness in excess of the amount specified in the applicable indenture. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">4.375% Notes due 2028.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $800 million aggregate principal amount of senior notes (the &#8220;4.375% Notes&#8221;) outstanding as of September&#160;30, 2022, which are due June 15, 2028, unless earlier redeemed. Interest, at a rate of 4.375% per annum, is payable semiannually in arrears on June 15 and December 15.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">3.875% Notes due 2030. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $650 million aggregate principal amount of senior notes (the &#8220;3.875% Notes due 2030&#8221;) outstanding as of September&#160;30, 2022, which are due November 15, 2030, unless earlier redeemed. Interest, at a rate of 3.875% per annum, is payable semiannually in arrears on May 15 and November 15.</span></div>3.875% Notes due 2032. We had $750 million aggregate principal amount of senior notes (the &#8220;3.875% Notes due 2032&#8221;) outstanding as of September&#160;30, 2022, which are due May 15, 2032, unless earlier redeemed. Interest, at a rate of 3.875% per annum, is payable semiannually in arrears on May 15 and November 15.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701219079264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity In September 2021, our board of directors authorized the purchase of up to $500&#160;million, in the aggregate, of our common stock. This new program, which superseded the stock purchase program approved by our board of directors in September 2020, is funded with cash on hand and extends through December 31, 2022. The exact timing and amount of any repurchase is determined by management based on market conditions and share price, in addition to other factors, and subject to the restrictions relating to volume, price, and timing under applicable law.  Under this program, pursuant to a Rule 10b5-1 trading plan, we purchased approximately 658,000 shares for $200&#160;million in the second quarter of 2022 (average cost of $304.13 per share).<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701221635168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segments</a></td>
<td class="text">Segments <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have four reportable segments consisting of: 1)&#160;Medicaid; 2)&#160;Medicare; 3)&#160;Marketplace; and 4)&#160;Other. Our reportable segments are consistent with how we currently manage the business and view the markets we serve. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which we offer managed healthcare services. The Other segment, which is insignificant to our consolidated results of operations, includes certain corporate amounts not associated with or allocated to the Medicaid, Medicare, or Marketplace segments. Additionally, the Other segment includes service revenues and service costs associated with the long-term services and supports consultative services we provide in Wisconsin.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key metrics used to assess the performance of our Medicaid, Medicare, and Marketplace segments are premium revenue, medical margin and medical care ratio (&#8220;MCR&#8221;). MCR represents the amount of medical care costs as a percentage of premium revenue. Therefore, the underlying medical margin, or the amount earned by the Medicaid, Medicare, and Marketplace segments after medical costs are deducted from premium revenue, represents the most important measure of earnings reviewed by management, and is used by our chief executive officer to review results, assess performance, and allocate resources. The key metric used to assess the performance of our Other segment is service margin. The service margin is equal to service revenue minus cost of service revenue. We do not report total assets by segment because this is not a metric used to assess segment performance or allocate resources.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total revenue by segment. Inter-segment revenue was insignificant for all periods presented.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:42.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.539%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,927&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,040&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,751&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,362&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles margin by segment to consolidated income before income taxes. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:42.238%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Margin:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">703&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total margin </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">755&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,791&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,358&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: other operating revenues </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: other operating expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(829)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(756)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,455)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,068&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expenses, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">985&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">739&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Other operating revenues include premium tax revenue, investment income, and other revenue.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Other operating expenses include general and administrative expenses, premium tax expenses, depreciation and amortization, and other operating expenses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701221505216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor and assess the estimated operating and financial impact of the COVID-19 pandemic on our business and, as it evolves, we continue to process, assemble, and assess member utilization information. We believe that our cash resources, borrowing capacity available under the Credit Agreement, and cash flow generated from operations will be sufficient to withstand the financial impact of the pandemic, and will enable us to continue to support our operations, regulatory requirements, debt repayment obligations, and capital expenditures for the foreseeable future.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The healthcare industry is subject to numerous laws and regulations of federal, state, and local governments. Compliance with these laws and regulations can be subject to government review and interpretation, as well as regulatory actions unknown and unasserted at this time. Penalties associated with violations of these laws and regulations include significant fines and penalties, exclusion from participating in publicly funded programs, the repayment of previously billed and collected revenues and reputational damage.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in legal actions in the ordinary course of business including, but not limited to, various employment claims, vendor disputes and provider claims. Some of these legal actions seek monetary damages, including claims for punitive damages, which may not be covered by insurance. We review legal matters and update our estimates of </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reasonably possible losses and related disclosures, as necessary. We have accrued liabilities for legal matters for which we deem the loss to be both probable and reasonably estimable. These liability estimates could change as a result of further developments of the matters. The outcome of legal actions is inherently uncertain. An adverse determination in one or more of these pending matters could have an adverse effect on our consolidated financial position, results of operations, or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kentucky RFP</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On September 4, 2020, Anthem Kentucky Managed Care Plan, Inc. brought an action in Franklin County Circuit Court against the Kentucky Finance and Administration Cabinet, the Kentucky Cabinet for Health and Family Services, and all of the five winning bidder health plans, including our Kentucky health plan. On September 9, 2022, the Court of Appeal ruled, among other things, that the Circuit Court should not have invalidated the 2020 procurement and thus should not have awarded a contract to Anthem. Anthem filed a petition for rehearing with the Kentucky Court of Appeals and will likely seek review by the Kentucky Supreme Court. Pending further Court order, our Kentucky health plan will continue to operate for the foreseeable future under its current Medicaid contract.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Puerto Rico.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On August 13, 2021, Molina Healthcare of Puerto Rico, Inc. (&#8220;MHPR&#8221;) filed a complaint against the Puerto Rico Health Insurance Administration (&#8220;ASES&#8221;), asserting, among other claims, breach of contract. On September 13, 2021, ASES filed a counterclaim and a third-party complaint against MHPR and the Company. This matter remains subject to significant additional proceedings, and no prediction can be made as to the outcome.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701217840608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock', window );">Consolidation and Interim Financial Information</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation and Interim Financial Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Molina Healthcare, Inc., and its subsidiaries. In the opinion of management, these financial statements reflect all normal recurring adjustments, which are considered necessary for a fair presentation of the results as of the dates and for the interim periods presented. All significant intercompany balances and transactions have been eliminated. The consolidated results of operations for the nine months ended September 30, 2022 are not necessarily indicative of the results for the entire year ending December&#160;31, 2022.</span></div>The unaudited consolidated interim financial statements have been prepared under the assumption that users of the interim financial data have either read or have access to our audited consolidated financial statements for the fiscal year ended December&#160;31, 2021. Accordingly, certain disclosures that would substantially duplicate the disclosures contained in our December&#160;31, 2021, audited consolidated financial statements have been omitted. These unaudited consolidated interim financial statements should be read in conjunction with our audited consolidated financial statements for the fiscal year ended December&#160;31, 2021.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">Use of EstimatesThe preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">Cash and Cash EquivalentsCash and cash equivalents consist of cash and short-term, highly liquid investments that are both readily convertible into known amounts of cash and have a maturity of three months or less on the date of purchase.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Receivables</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables consist primarily of premium amounts due from government agencies, which are subject to potential retroactive adjustments. Because substantially all of our receivable amounts are readily determinable and substantially all of our creditors are governmental authorities, our allowance for credit losses is insignificant. Any amounts determined to be uncollectible are charged to expense when such determination is made.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Premium Revenue Recognition and Amounts Due Government Agencies and Contractual Provisions That May Adjust or Limit Revenue or Profit</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Premium Revenue Recognition and Amounts Due Government Agencies</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium revenue is generated from our contracts with state and federal agencies, in connection with our participation in the Medicaid, Medicare, and Marketplace programs. Premium revenue is generally received based on per member per month (&#8220;PMPM&#8221;) rates established in advance of the periods covered. These premium revenues are recognized in the month that members are entitled to receive healthcare services, and premiums collected in advance are deferred. State Medicaid programs and the federal Medicare program periodically adjust premium rates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain components of premium revenue are subject to accounting estimates and are described in further detail below, and in our 2021 Annual Report on Form 10-K, Note 2, &#8220;Significant Accounting Policies,&#8221; under &#8220;Contractual Provisions That May Adjust or Limit Revenue or Profit,&#8221; and &#8220;Quality Incentives.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Provisions That May Adjust or Limit Revenue or Profit</span></div>Many of our contracts contain provisions that may adjust or limit revenue or profit, as described below. Consequently, we recognize premium revenue as it is earned under such provisions.<div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicaid Program</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Minimum MLR and Retroactive Premium Adjustments. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State Medicaid programs periodically adjust premium rates on a retroactive basis. In these cases, we adjust our premium revenue in the period in which we determine that the adjustment is probable and reasonably estimable, based on our best estimate of the ultimate premium we expect to realize for the period being adjusted. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2020, various states enacted temporary risk corridors in response to the reduced demand for medical services stemming from COVID-1</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which have resulted in a reduction of our medical margin. In some cases, these risk corridors were retroactive to earlier periods in 2020, or as early as the beginning of the states&#8217; fiscal years in 2019. Since the second quarter of 2020, we have recognized risk corridors that we believe to be probable, and where the ultimate premium amount is reasonably estimable. For the three and nine months ended September 30, 2022, we recognized approximately $34&#160;million and $156&#160;million, respectively, related to such risk corridors, primarily in the Medicaid segment, compared to $17&#160;million and $183&#160;million, respectively, recognized in the three and nine months ended September&#160;30, 2021. The decrease is due to the elimination of several of the COVID-19 risk corridors. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that certain states could change the structure of existing risk corridors, implement new risk corridors in the future or discontinue existing risk corridors. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Marketplace Program</span></div>Risk Adjustment. Under this program, our health plans&#8217; composite risk scores are compared with the overall average risk score for the relevant state and market pool. Generally, our health plans will make a risk adjustment payment into the pool if their composite risk scores are below the average risk score (risk adjustment payable), and will receive a risk adjustment payment from the pool if their composite risk scores are above the average risk score (risk adjustment receivable). We estimate our ultimate premium based on insurance policy year-to-date experience, and recognize estimated premiums relating to the risk adjustment program as an adjustment to premium revenue in our consolidated statements of income.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than 15 years, or less than 15 years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents, and U.S. Treasury securities. Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and governments of each state in which our health plan subsidiaries operate.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is determined using an estimated annual effective tax rate, which generally differs from the U.S.&#160;federal statutory rate primarily because of foreign and state taxes, and nondeductible expenses such as certain compensation and other general and administrative expenses.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate may be subject to fluctuations during the year as new information is obtained. Such information may affect the assumptions used to estimate the annual effective tax rate, including projected pretax earnings, the mix of pretax earnings in the various tax jurisdictions in which we operate, valuation allowances against deferred tax assets, the recognition or the reversal of the recognition of tax benefits related to uncertain tax positions, and changes in or the interpretation of tax laws in jurisdictions where we conduct business. We recognize deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of our assets and liabilities, along with net operating loss and tax credit carryovers.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (&#8220;SEC&#8221;) did not have, nor does management expect such pronouncements to have, a significant impact on our present or future consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consolidation And Interim Financial Information, Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701222321936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text">The following table provides a reconciliation of cash and cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in &#8220;Restricted investments&#8221; in the accompanying consolidated balance sheets.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,435&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Restricted Cash and Cash Equivalents</a></td>
<td class="text">The following table provides a reconciliation of cash and cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in &#8220;Restricted investments&#8221; in the accompanying consolidated balance sheets.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,435&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Receivables</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:72.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government receivables</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy rebate receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,220&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,177&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReservesReportedToOtherAgenciesTextBlock', window );">Schedule of Amounts Due to Government Agencies</a></td>
<td class="text">Liabilities accrued for premiums to be returned under such provisions are reported in the aggregate as &#8220;Amounts due government agencies,&#8221; in the accompanying consolidated balance sheets. <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth amounts due government agencies, categorized by program:</span></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid program:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR and profit sharing</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare program:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR and profit sharing </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk adjustment and Part D risk sharing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace program:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total amounts due government agencies</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,139&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,472&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReservesReportedToOtherAgenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of reserves reported to other federal agencies or authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReservesReportedToOtherAgenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701221560192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of Denominators for The Computation of Basic and Diluted Earnings Per Share</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the calculation of basic and diluted net income per share:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.981%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except net income per share)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares outstanding at the beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average number of shares issued:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator for basic net income per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator for diluted net income per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Basic </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Diluted </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.95&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.46&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.58&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.51&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Source data for calculations in thousands.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701221526944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value of Assets Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments measured at fair value on a recurring basis at September&#160;30, 2022, were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Directly or Indirectly Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(Level 3)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments measured at fair value on a recurring basis at December&#160;31, 2021, were as follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Directly or Indirectly Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value Measurements of Senior Notes</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.375% Notes due 2028</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.875% Notes due 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.875% Notes due 2032</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,868&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,173&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,264&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701219163744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Investments</a></td>
<td class="text">The following tables summarize our current investments as of the dates indicated:<div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,882&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,208&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Contractual Maturities of Investments</a></td>
<td class="text"><div style="margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of our current investments as of September&#160;30, 2022 are summarized below:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,882&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of Available-for-Sale Investments</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table segregates those available-for-sale investments that have been in a continuous loss position for less than 12 months, and those that have been in a continuous loss position for 12 months or more as of September&#160;30, 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:24.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">In&#160;a&#160;Continuous&#160;Loss Position<br/>for&#160;Less&#160;than&#160;12&#160;Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">In&#160;a&#160;Continuous&#160;Loss Position<br/>for&#160;12&#160;Months or More</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Positions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Positions</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">909&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,815&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,457&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">708&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table segregates those available-for-sale investments that have been in a continuous loss position for less than 12 months, and those that have been in a continuous loss position for 12 months or more as of December&#160;31, 2021:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:24.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.651%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">In&#160;a&#160;Continuous&#160;Loss Position<br/>for&#160;Less&#160;than&#160;12&#160;Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">In&#160;a&#160;Continuous&#160;Loss Position<br/>for&#160;12&#160;Months or More</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Positions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Positions</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,706&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">677&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701221452800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Claims and Benefits Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense', window );">Schedule of Liability for Unpaid Claims and Claims Adjustment Expense</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the details of our medical claims and benefits payable as of the dates indicated:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Claims incurred but not paid (&#8220;IBNP&#8221;)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitation payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,622&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock', window );">Schedule of Components of The Change in Medical Claims and Benefits Payable</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the components of the change in our medical claims and benefits payable for the periods indicated. The amounts presented for &#8220;Components of medical care costs related to: Prior years&#8221; represent the amount by which our original estimate of medical claims and benefits payable at the beginning of the year varied from the actual liabilities, based on information (principally the payment of claims) developed since those liabilities were first reported. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicaid </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicare </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketplace</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Components of medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(282)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,238&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,487&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,458&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,183&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,994&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,440&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,585&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,019&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired balances, net of post-acquisition adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in non-risk and other provider payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,923&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,622&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicaid </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicare</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketplace</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Components of medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,558&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(216)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,333&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,068&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,888&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired balances, net of post-acquisition adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in non-risk and other provider payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,443&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,191&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Components Of Change In Medical Claims And Benefits Payable [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701221627040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long Term Debt</a></td>
<td class="text">The following table summarizes our outstanding debt obligations, all of which are non-current as of the dates reported below:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-current long-term debt:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.375% Notes due 2028</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.875% Notes due 2030 </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.875% Notes due 2032</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred debt issuance costs </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,173&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701221585280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Operating Segment Information</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total revenue by segment. Inter-segment revenue was insignificant for all periods presented.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:42.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.539%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,927&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,040&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,751&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,362&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles margin by segment to consolidated income before income taxes. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:42.238%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Margin:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">703&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total margin </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">755&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,791&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,358&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: other operating revenues </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: other operating expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(829)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(756)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,455)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,068&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expenses, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">985&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">739&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Other operating revenues include premium tax revenue, investment income, and other revenue.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Other operating expenses include general and administrative expenses, premium tax expenses, depreciation and amortization, and other operating expenses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701214344000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Details)<br> member in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 13, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>state </div>
<div>member</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>contract</div>
</th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>segment </div>
<div>state </div>
<div>member</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_HealthPlanContractTerm', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_HealthPlanExtensionOptionPeriod', window );">Extension option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=moh_MyChoiceWisconsinMember', window );">MCW</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Purchase price | $</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_NE', window );">NEBRASKA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_HealthPlanContractTerm', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_HealthPlanExtensionOptionPeriod', window );">Extension option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_IA', window );">IOWA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_HealthPlanContractTerm', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_HealthPlanExtensionOptionPeriod', window );">Extension option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">CALIFORNIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_HealthPlanNumberOfContracts', window );">Number of contracts | contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MS', window );">MISSISSIPPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_HealthPlanContractTerm', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_HealthPlanExtensionOptionPeriod', window );">Extension option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_HealthPlansMember', window );">Health Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms', window );">Number of members eligible for the health care programs, approximately | member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms', window );">Number of states with programs | state</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_HealthPlansMember', window );">Health Plans | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_HealthPlanContractTerm', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_HealthPlansMember', window );">Health Plans | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_HealthPlanContractTerm', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of members eligible for the health care programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_HealthPlanContractTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Health Plan, Contract Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_HealthPlanContractTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_HealthPlanExtensionOptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Health Plan, Extension Option, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_HealthPlanExtensionOptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_HealthPlanNumberOfContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Health Plan, Number Of Contracts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_HealthPlanNumberOfContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of States With Government-Sponsored Healthcare Programs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=moh_MyChoiceWisconsinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=moh_MyChoiceWisconsinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_IA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_IA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_HealthPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_HealthPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701216675440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,242<span></span>
</td>
<td class="nump">$ 4,438<span></span>
</td>
<td class="nump">$ 4,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash and cash equivalents</a></td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows</a></td>
<td class="nump">$ 4,295<span></span>
</td>
<td class="nump">$ 4,506<span></span>
</td>
<td class="nump">$ 4,435<span></span>
</td>
<td class="nump">$ 4,223<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701218219840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Receivables (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Total receivables</a></td>
<td class="nump">$ 2,220<span></span>
</td>
<td class="nump">$ 2,177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_GovernmentReceivablesMember', window );">Government receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Total receivables</a></td>
<td class="nump">1,545<span></span>
</td>
<td class="nump">1,566<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_PharmacyRebateReceivablesMember', window );">Pharmacy rebate receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Total receivables</a></td>
<td class="nump">290<span></span>
</td>
<td class="nump">276<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_OtherReceivablesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Total receivables</a></td>
<td class="nump">$ 385<span></span>
</td>
<td class="nump">$ 335<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_GovernmentReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_GovernmentReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_PharmacyRebateReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_PharmacyRebateReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_OtherReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_OtherReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701218223792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Amounts Due To Government Agencies (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract', window );"><strong>Medicaid program:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold', window );">Minimum MLR and profit sharing</a></td>
<td class="nump">$ 1,091<span></span>
</td>
<td class="nump">$ 1,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_AmountsDueToGovernmentAgenciesMedicaidOther', window );">Other</a></td>
<td class="nump">617<span></span>
</td>
<td class="nump">263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract', window );"><strong>Medicare program:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold', window );">Minimum MLR and profit sharing</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing', window );">Risk adjustment and Part D risk sharing</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_OtherMedicareProgram', window );">Other</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract', window );"><strong>Marketplace program:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment', window );">Risk adjustment</a></td>
<td class="nump">179<span></span>
</td>
<td class="nump">902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold', window );">Minimum MLR</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_AmountsDuetoGovernmentAgenciesOther', window );">Other</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_MedicalPremiumLiabilityDueToAgency', window );">Total amounts due government agencies</a></td>
<td class="nump">$ 2,139<span></span>
</td>
<td class="nump">$ 2,472<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts Due To Government Agencies, Marketplace, Medical Loss Ratio Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts Due To Government Agencies, Marketplace Program [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDueToGovernmentAgenciesMedicaidOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts Due To Government Agencies, Medicaid, Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDueToGovernmentAgenciesMedicaidOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts Due To Government Agencies, Medicaid Program [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts Due To Government Agencies, Medicare, Medical Loss Ratio And Profit Sharing, Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts Due To Government Agencies Medicare Program</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts Due to Government Agencies, Risk Adjustment and Part D risk sharing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDuetoGovernmentAgenciesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts Due to Government Agencies, Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDuetoGovernmentAgenciesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts Due to Government Agencies, Risk Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDuetoGovernmentAgenciesRiskAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_MedicalPremiumLiabilityDueToAgency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Medical Premium Liability Due to Agency</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_MedicalPremiumLiabilityDueToAgency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Medical Premiums Liability, Medical Care Costs Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_OtherMedicareProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Medicare Program</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_OtherMedicareProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701214419712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems', window );"><strong>Schedule of Premium Revenue by Health Plan Type [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable', window );">Risk adjustment payable</a></td>
<td class="nump">$ 179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable', window );">Risk adjustment receivable</a></td>
<td class="nump">94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable', window );">Risk adjustment, net payable</a></td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_InvestmentsMaturityPeriod', window );">Maturity period (less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=moh_StructuredSecuritiesMember', window );">Structured Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems', window );"><strong>Schedule of Premium Revenue by Health Plan Type [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_InvestmentsAverageMaturityPeriod', window );">Average maturity period (less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemAxis=moh_COVID19Member', window );">COVID-19</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems', window );"><strong>Schedule of Premium Revenue by Health Plan Type [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPremiumsReceivable', window );">Reduction in premiums</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 156<span></span>
</td>
<td class="nump">$ 183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Affordable Care Act, Premium Stabilization Program, Risk Adjustment, (Payable)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_InvestmentsAverageMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments, Average Maturity Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_InvestmentsAverageMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_InvestmentsMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments, Maturity Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_InvestmentsMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of premium revenue by health plan type.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPremiumsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The change in the premium receivable balance on the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPremiumsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=moh_StructuredSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=moh_StructuredSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualOrInfrequentItemAxis=moh_COVID19Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualOrInfrequentItemAxis=moh_COVID19Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701212673952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 230<span></span>
</td>
<td class="nump">$ 248<span></span>
</td>
<td class="nump">$ 258<span></span>
</td>
<td class="nump">$ 143<span></span>
</td>
<td class="nump">$ 185<span></span>
</td>
<td class="nump">$ 228<span></span>
</td>
<td class="nump">$ 736<span></span>
</td>
<td class="nump">$ 556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_SharesOutstandingExcludingRestrictedStockAwards', window );">Shares outstanding at the beginning of the period ( in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.9<span></span>
</td>
<td class="nump">58.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Weighted-average number of shares issued:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_WeightedAverageNumberofSharesShareBasedCompensation', window );">Stock-based compensation (in shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation', window );">Stock purchases (in shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Denominator for basic net income per share (in shares)</a></td>
<td class="nump">57.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.8<span></span>
</td>
<td class="nump">57.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock-based compensation (in shares)</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Denominator for diluted net income per share (in shares)</a></td>
<td class="nump">58.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.5<span></span>
</td>
<td class="nump">58.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_EarningsPerShareBasicAndDilutedEPSAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share - Basic (in dollars per share)</a></td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.74<span></span>
</td>
<td class="nump">$ 9.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share - Diluted (in dollars per share)</a></td>
<td class="nump">$ 3.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.58<span></span>
</td>
<td class="nump">$ 9.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_EarningsPerShareBasicAndDilutedEPSAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Basic and Diluted EPS</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_EarningsPerShareBasicAndDilutedEPSAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_SharesOutstandingExcludingRestrictedStockAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares, Outstanding, Excluding Restricted Stock Awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_SharesOutstandingExcludingRestrictedStockAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_WeightedAverageNumberofSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Number of Shares, Share Based Compensation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_WeightedAverageNumberofSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126962052&amp;loc=d3e4991-113900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1500-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701216913648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Oct. 25, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=moh_AgeWellMember', window );">AgeWell</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total purchase price</a></td>
<td class="nump">$ 134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember', window );">Cigna Corporation's Texas Medicaid and Medicare-Medicaid Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember', window );">Cigna Corporation's Texas Medicaid and Medicare-Medicaid Plan | Member list</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Acquired membership with a preliminary fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=moh_AffinityHealthPlanIncMember', window );">Affinity Health Plan, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable', window );">Medical claims and benefits payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables', window );">Increase to receivables, net of amounts due government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Medical Claims and Benefits Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Receivables</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e961-128460<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=moh_AgeWellMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=moh_AgeWellMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=moh_MemberListsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=moh_MemberListsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=moh_AffinityHealthPlanIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=moh_AffinityHealthPlanIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701212915472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Instruments on a Recurring Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">$ 3,639<span></span>
</td>
<td class="nump">$ 3,202<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">3,639<span></span>
</td>
<td class="nump">3,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">2,283<span></span>
</td>
<td class="nump">1,833<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember', window );">Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">743<span></span>
</td>
<td class="nump">614<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">303<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember', window );">Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember', window );">U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=moh_OtherSecuritiesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">(Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">(Level 1) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">(Level 1) | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">(Level 1) | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">(Level 1) | Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">(Level 1) | U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">(Level 1) | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">(Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">3,639<span></span>
</td>
<td class="nump">3,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">(Level 2) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">2,283<span></span>
</td>
<td class="nump">1,833<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">(Level 2) | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">743<span></span>
</td>
<td class="nump">614<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">(Level 2) | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">303<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">(Level 2) | Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">(Level 2) | U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">(Level 2) | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3) | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3) | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3) | Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3) | U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3) | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=moh_OtherSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=moh_OtherSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701214131584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings', window );">Recognized gain (loss)</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Contingent consideration liabilities settled</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=moh_PassportHealthPlanIncMember', window );">Passport Health Plan, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities', window );">Contingent consideration paid to seller included in financing and operating activities</a></td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=moh_PassportHealthPlanIncMember', window );">Passport Health Plan, Inc. | Minimum Member Enrollment Targets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities', window );">Remaining half of contingent consideration paid</a></td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=moh_PassportHealthPlanIncMember', window );">Passport Health Plan, Inc. | Operating Income Guarantee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Contingent consideration liabilities settled</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=moh_PassportHealthPlanIncMember', window );">Passport Health Plan, Inc. | (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment For Contingent Consideration Liability, Financing And Operating Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of gain (loss) derived from fair value hedges recognized in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (ee)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=moh_PassportHealthPlanIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=moh_PassportHealthPlanIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=moh_MinimumMemberEnrollmentTargetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=moh_MinimumMemberEnrollmentTargetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=moh_OperatingIncomeGuaranteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=moh_OperatingIncomeGuaranteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701214305088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Long-Term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">$ 2,175<span></span>
</td>
<td class="nump">$ 2,173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">$ 1,868<span></span>
</td>
<td class="nump">2,264<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.375% Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="nump">4.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.375% Notes due 2028 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">$ 792<span></span>
</td>
<td class="nump">791<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.375% Notes due 2028 | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">$ 715<span></span>
</td>
<td class="nump">829<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% Notes due 2030 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">$ 642<span></span>
</td>
<td class="nump">642<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% Notes due 2030 | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">$ 541<span></span>
</td>
<td class="nump">675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% Notes due 2032</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% Notes due 2032 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">$ 741<span></span>
</td>
<td class="nump">740<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% Notes due 2032 | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">$ 612<span></span>
</td>
<td class="nump">$ 760<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_A4375SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_A4375SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_ThreePointEightSevenFivePercentSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_ThreePointEightSevenFivePercentSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_A3875SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_A3875SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701214273216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Summary of Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">$ 3,882<span></span>
</td>
<td class="nump">$ 3,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">243<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">3,639<span></span>
</td>
<td class="nump">3,202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">2,431<span></span>
</td>
<td class="nump">1,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">2,283<span></span>
</td>
<td class="nump">1,833<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember', window );">Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">804<span></span>
</td>
<td class="nump">616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">743<span></span>
</td>
<td class="nump">614<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">322<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">303<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember', window );">Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember', window );">U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=moh_OtherSecuritiesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=moh_OtherSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=moh_OtherSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701214270960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Contractual Maturities of Available-for-Sale Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due in one year or less</a></td>
<td class="nump">$ 378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years</a></td>
<td class="nump">2,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost', window );">Due after five years through ten years</a></td>
<td class="nump">390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost', window );">Due after ten years</a></td>
<td class="nump">784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">3,882<span></span>
</td>
<td class="nump">$ 3,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less</a></td>
<td class="nump">374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years</a></td>
<td class="nump">2,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Due after five years through ten years</a></td>
<td class="nump">364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue', window );">Due after ten years</a></td>
<td class="nump">715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total</a></td>
<td class="nump">$ 3,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701217898096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Gross realized investment gains</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Gross realized investment losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss', window );">Debt securities held to maturity</a></td>
<td class="nump">242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount', window );">Amortized cost, due in one year or less</a></td>
<td class="nump">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount', window );">Amortized cost, due one year through five years</a></td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount', window );">Amortized cost, due after five years</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL120267963-210447<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62586-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701212839488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Available-for-Sale Investments (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>security </div>
<div>position</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>position </div>
<div>security</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;Less&#160;than&#160;12&#160;Months, Estimated Fair Value</a></td>
<td class="nump">$ 2,815<span></span>
</td>
<td class="nump">$ 1,706<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;Less&#160;than&#160;12&#160;Months, Gross Unrealized Losses</a></td>
<td class="nump">$ 163<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;Less&#160;than&#160;12&#160;Months, Total Number of Positions | position</a></td>
<td class="nump">1,457<span></span>
</td>
<td class="nump">677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;12&#160;Months or More, Estimated Fair Value</a></td>
<td class="nump">$ 708<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;12&#160;Months or More, Gross Unrealized Losses</a></td>
<td class="nump">$ 80<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;12&#160;Months or More, Total Number of Positions</a></td>
<td class="nump">305<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;Less&#160;than&#160;12&#160;Months, Estimated Fair Value</a></td>
<td class="nump">$ 1,764<span></span>
</td>
<td class="nump">$ 1,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;Less&#160;than&#160;12&#160;Months, Gross Unrealized Losses</a></td>
<td class="nump">$ 103<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;Less&#160;than&#160;12&#160;Months, Total Number of Positions | position</a></td>
<td class="nump">909<span></span>
</td>
<td class="nump">395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;12&#160;Months or More, Estimated Fair Value</a></td>
<td class="nump">$ 433<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;12&#160;Months or More, Gross Unrealized Losses</a></td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;12&#160;Months or More, Total Number of Positions | position</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember', window );">Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;Less&#160;than&#160;12&#160;Months, Estimated Fair Value</a></td>
<td class="nump">$ 555<span></span>
</td>
<td class="nump">$ 408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;Less&#160;than&#160;12&#160;Months, Gross Unrealized Losses</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;Less&#160;than&#160;12&#160;Months, Total Number of Positions | position</a></td>
<td class="nump">282<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;12&#160;Months or More, Estimated Fair Value</a></td>
<td class="nump">$ 188<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;12&#160;Months or More, Gross Unrealized Losses</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;12&#160;Months or More, Total Number of Positions | position</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;Less&#160;than&#160;12&#160;Months, Estimated Fair Value</a></td>
<td class="nump">$ 242<span></span>
</td>
<td class="nump">$ 166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;Less&#160;than&#160;12&#160;Months, Gross Unrealized Losses</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;Less&#160;than&#160;12&#160;Months, Total Number of Positions | security</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;12&#160;Months or More, Estimated Fair Value</a></td>
<td class="nump">$ 56<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;12&#160;Months or More, Gross Unrealized Losses</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;12&#160;Months or More, Total Number of Positions | security</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember', window );">Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;Less&#160;than&#160;12&#160;Months, Estimated Fair Value</a></td>
<td class="nump">$ 106<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;Less&#160;than&#160;12&#160;Months, Gross Unrealized Losses</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;Less&#160;than&#160;12&#160;Months, Total Number of Positions | security</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;12&#160;Months or More, Estimated Fair Value</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;12&#160;Months or More, Gross Unrealized Losses</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;12&#160;Months or More, Total Number of Positions | security</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember', window );">U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;Less&#160;than&#160;12&#160;Months, Estimated Fair Value</a></td>
<td class="nump">$ 116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;Less&#160;than&#160;12&#160;Months, Gross Unrealized Losses</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;Less&#160;than&#160;12&#160;Months, Total Number of Positions | security</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;12&#160;Months or More, Estimated Fair Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;12&#160;Months or More, Gross Unrealized Losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;12&#160;Months or More, Total Number of Positions | security</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=moh_OtherSecuritiesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;Less&#160;than&#160;12&#160;Months, Estimated Fair Value</a></td>
<td class="nump">$ 32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;Less&#160;than&#160;12&#160;Months, Gross Unrealized Losses</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;Less&#160;than&#160;12&#160;Months, Total Number of Positions | security</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;12&#160;Months or More, Estimated Fair Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;12&#160;Months or More, Gross Unrealized Losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;12&#160;Months or More, Total Number of Positions | security</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=moh_OtherSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=moh_OtherSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701217829392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Medical Claims and Benefits Payable - Medical Claims and Benefits Payable (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount', window );">Claims incurred but not paid (&#8220;IBNP&#8221;)</a></td>
<td class="nump">$ 2,553<span></span>
</td>
<td class="nump">$ 2,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_PharmacyClaimsPayable', window );">Pharmacy payable</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_CapitationClaimsPayable', window );">Capitation payable</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_OtherClaimsPayable', window );">Other</a></td>
<td class="nump">738<span></span>
</td>
<td class="nump">576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Total</a></td>
<td class="nump">$ 3,622<span></span>
</td>
<td class="nump">$ 3,363<span></span>
</td>
<td class="nump">$ 3,191<span></span>
</td>
<td class="nump">$ 2,696<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_CapitationClaimsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitation Claims Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_CapitationClaimsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Paid (IBNP), Fee-for-service Claims, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_OtherClaimsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Claims Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_OtherClaimsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_PharmacyClaimsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pharmacy Claims Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_PharmacyClaimsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701216736032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Claims and Benefits Payable - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_MedicalClaimsAndBenefitsPayable', window );">Non-risk provider payables</a></td>
<td class="nump">$ 317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior period claims, favorable development</a></td>
<td class="num">$ (338)<span></span>
</td>
<td class="num">$ (216)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_MedicalClaimsAndBenefitsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Medical Claims and Benefits Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_MedicalClaimsAndBenefitsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701212710384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Claims and Benefits Payable - Components of Change in Medical Claims and Benefits Payable (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Insurance Claims</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable, beginning balance</a></td>
<td class="nump">$ 3,363<span></span>
</td>
<td class="nump">$ 2,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_ComponentsOfMedicalCareCostsAbstract', window );"><strong>Components of medical care costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current year</a></td>
<td class="nump">20,521<span></span>
</td>
<td class="nump">17,558<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior years</a></td>
<td class="num">(338)<span></span>
</td>
<td class="num">(216)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Total medical care costs</a></td>
<td class="nump">20,183<span></span>
</td>
<td class="nump">17,342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_PaymentsForMedicalCareCostsAbstract', window );"><strong>Payments for medical care costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Current year</a></td>
<td class="nump">17,538<span></span>
</td>
<td class="nump">14,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Prior years</a></td>
<td class="nump">2,481<span></span>
</td>
<td class="nump">2,008<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Total paid</a></td>
<td class="nump">20,019<span></span>
</td>
<td class="nump">16,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments', window );">Acquired balances, net of post-acquisition adjustments</a></td>
<td class="nump">8<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider', window );">Change in non-risk and other provider payables</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable, ending balance</a></td>
<td class="nump">3,622<span></span>
</td>
<td class="nump">3,191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicaidMember', window );">Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Insurance Claims</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable, beginning balance</a></td>
<td class="nump">2,580<span></span>
</td>
<td class="nump">2,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_ComponentsOfMedicalCareCostsAbstract', window );"><strong>Components of medical care costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current year</a></td>
<td class="nump">16,520<span></span>
</td>
<td class="nump">13,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior years</a></td>
<td class="num">(282)<span></span>
</td>
<td class="num">(158)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Total medical care costs</a></td>
<td class="nump">16,238<span></span>
</td>
<td class="nump">13,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_PaymentsForMedicalCareCostsAbstract', window );"><strong>Payments for medical care costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Current year</a></td>
<td class="nump">14,133<span></span>
</td>
<td class="nump">11,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Prior years</a></td>
<td class="nump">1,861<span></span>
</td>
<td class="nump">1,538<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Total paid</a></td>
<td class="nump">15,994<span></span>
</td>
<td class="nump">13,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments', window );">Acquired balances, net of post-acquisition adjustments</a></td>
<td class="nump">8<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider', window );">Change in non-risk and other provider payables</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable, ending balance</a></td>
<td class="nump">2,923<span></span>
</td>
<td class="nump">2,443<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicareMember', window );">Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Insurance Claims</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable, beginning balance</a></td>
<td class="nump">404<span></span>
</td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_ComponentsOfMedicalCareCostsAbstract', window );"><strong>Components of medical care costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current year</a></td>
<td class="nump">2,525<span></span>
</td>
<td class="nump">2,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior years</a></td>
<td class="num">(38)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Total medical care costs</a></td>
<td class="nump">2,487<span></span>
</td>
<td class="nump">2,159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_PaymentsForMedicalCareCostsAbstract', window );"><strong>Payments for medical care costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Current year</a></td>
<td class="nump">2,103<span></span>
</td>
<td class="nump">1,816<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Prior years</a></td>
<td class="nump">337<span></span>
</td>
<td class="nump">340<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Total paid</a></td>
<td class="nump">2,440<span></span>
</td>
<td class="nump">2,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments', window );">Acquired balances, net of post-acquisition adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider', window );">Change in non-risk and other provider payables</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable, ending balance</a></td>
<td class="nump">447<span></span>
</td>
<td class="nump">387<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_MarketplaceMember', window );">Marketplace</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Insurance Claims</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable, beginning balance</a></td>
<td class="nump">379<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_ComponentsOfMedicalCareCostsAbstract', window );"><strong>Components of medical care costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current year</a></td>
<td class="nump">1,476<span></span>
</td>
<td class="nump">1,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior years</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Total medical care costs</a></td>
<td class="nump">1,458<span></span>
</td>
<td class="nump">1,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_PaymentsForMedicalCareCostsAbstract', window );"><strong>Payments for medical care costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Current year</a></td>
<td class="nump">1,302<span></span>
</td>
<td class="nump">1,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Prior years</a></td>
<td class="nump">283<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Total paid</a></td>
<td class="nump">1,585<span></span>
</td>
<td class="nump">1,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments', window );">Acquired balances, net of post-acquisition adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider', window );">Change in non-risk and other provider payables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable, ending balance</a></td>
<td class="nump">$ 252<span></span>
</td>
<td class="nump">$ 361<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_ComponentsOfMedicalCareCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Components of medical care costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_ComponentsOfMedicalCareCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions, Net Of Post-Closing Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Medical Claims and Benefits Payable, Adjustments, Change in Provider</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_PaymentsForMedicalCareCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for medical care costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_PaymentsForMedicalCareCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLossesAndLossAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_MedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_MarketplaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_MarketplaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701217785024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule of Long-Term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentNet', window );">Deferred debt issuance costs</a></td>
<td class="num">$ (25)<span></span>
</td>
<td class="num">$ (27)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total</a></td>
<td class="nump">$ 2,175<span></span>
</td>
<td class="nump">2,173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.375% Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="nump">4.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount', window );">Non-current portion of long-term debt</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount', window );">Non-current portion of long-term debt</a></td>
<td class="nump">$ 650<span></span>
</td>
<td class="nump">650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% Notes due 2032</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount', window );">Non-current portion of long-term debt</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Noncurrent, Net Of Unamortized Debt Discount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNoncurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_A4375SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_A4375SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_ThreePointEightSevenFivePercentSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_ThreePointEightSevenFivePercentSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_A3875SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_A3875SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701218000864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding under letter of credit</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.375% Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="nump">4.375%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 800,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="nump">3.875%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 650,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% Notes due 2032</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="nump">3.875%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 750,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_A4375SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_A4375SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_ThreePointEightSevenFivePercentSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_ThreePointEightSevenFivePercentSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_A3875SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_A3875SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701213477648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br> $ / shares in Units, shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Common stock purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="nump">$ 128,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Common stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased of common stock (in shares)</a></td>
<td class="nump">658<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Common stock purchases</a></td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Average cost (USD per share)</a></td>
<td class="nump">$ 304.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701301279248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Reportable segments</a></td>
<td class="nump">4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701216866672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Schedule of Operating Segment Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 7,927<span></span>
</td>
<td class="nump">$ 7,040<span></span>
</td>
<td class="nump">$ 23,751<span></span>
</td>
<td class="nump">$ 20,362<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicaidMember', window );">Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">6,380<span></span>
</td>
<td class="nump">5,354<span></span>
</td>
<td class="nump">19,091<span></span>
</td>
<td class="nump">15,583<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicareMember', window );">Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">955<span></span>
</td>
<td class="nump">875<span></span>
</td>
<td class="nump">2,867<span></span>
</td>
<td class="nump">2,502<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_MarketplaceMember', window );">Marketplace</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">575<span></span>
</td>
<td class="nump">793<span></span>
</td>
<td class="nump">1,740<span></span>
</td>
<td class="nump">2,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_OtherProgramMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_MedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_MarketplaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_MarketplaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_OtherProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_OtherProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139701213417360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Reconciliation of Gross Margin to Consolidated Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Add: other operating revenues</a></td>
<td class="nump">$ 7,927<span></span>
</td>
<td class="nump">$ 7,040<span></span>
</td>
<td class="nump">$ 23,751<span></span>
</td>
<td class="nump">$ 20,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Less: other operating expenses</a></td>
<td class="num">(7,592)<span></span>
</td>
<td class="num">(6,819)<span></span>
</td>
<td class="num">(22,683)<span></span>
</td>
<td class="num">(19,533)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">335<span></span>
</td>
<td class="nump">221<span></span>
</td>
<td class="nump">1,068<span></span>
</td>
<td class="nump">829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other expenses, net</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income tax expense</a></td>
<td class="nump">307<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="nump">985<span></span>
</td>
<td class="nump">739<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicaidMember', window );">Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Add: other operating revenues</a></td>
<td class="nump">6,380<span></span>
</td>
<td class="nump">5,354<span></span>
</td>
<td class="nump">19,091<span></span>
</td>
<td class="nump">15,583<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicareMember', window );">Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Add: other operating revenues</a></td>
<td class="nump">955<span></span>
</td>
<td class="nump">875<span></span>
</td>
<td class="nump">2,867<span></span>
</td>
<td class="nump">2,502<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_MarketplaceMember', window );">Marketplace</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Add: other operating revenues</a></td>
<td class="nump">575<span></span>
</td>
<td class="nump">793<span></span>
</td>
<td class="nump">1,740<span></span>
</td>
<td class="nump">2,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_OtherProgramMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Add: other operating revenues</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Total margin</a></td>
<td class="nump">890<span></span>
</td>
<td class="nump">755<span></span>
</td>
<td class="nump">2,791<span></span>
</td>
<td class="nump">2,358<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating segments | Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Total margin</a></td>
<td class="nump">703<span></span>
</td>
<td class="nump">532<span></span>
</td>
<td class="nump">2,168<span></span>
</td>
<td class="nump">1,687<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating segments | Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Total margin</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">151<span></span>
</td>
<td class="nump">360<span></span>
</td>
<td class="nump">329<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating segments | Marketplace</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Total margin</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">255<span></span>
</td>
<td class="nump">331<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating segments | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Total margin</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Other operating</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Add: other operating revenues</a></td>
<td class="nump">274<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="nump">732<span></span>
</td>
<td class="nump">620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Less: other operating expenses</a></td>
<td class="num">$ (829)<span></span>
</td>
<td class="num">$ (756)<span></span>
</td>
<td class="num">$ (2,455)<span></span>
</td>
<td class="num">$ (2,149)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_MedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_MarketplaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_MarketplaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_OtherProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_OtherProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>moh-20220930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:moh="http://www.molinahealthcare.com/20220930"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="moh-20220930.xsd" xlink:type="simple"/>
    <context id="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1c7c2651aec54121a7e2d1337e16d200_I20221021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <instant>2022-10-21</instant>
        </period>
    </context>
    <context id="i406df5b5e82345ae890a914938d5a913_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3214220ebe41400a954cc43a8c3bc8a6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie7f3faa154394153bb16052f2634e5ad_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6b47298aedfe41eaaf18cdcaa7e274a7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia401e1c073f74cc0bc3f1d03b289141d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7930891295544d92bc8b7e75fd28dc75_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if63417ae06ef4f8b883c07503fb48ab9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if8bb2347c1c74af789d99f414d0ee364_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i42dd4296d82f4c08b4d55cc720bdb12d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib2231609c373451c812f4a754b56a154_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i94c67ce05a9d467fa8cb7a3f9e74c0c5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic1de449cbf8144a291a8fc6482edab09_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ida3920fde58740b88b1e9ac9cbfe5f21_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1e2a1318dc6046958feb391581e30a94_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3d767141fe3341cc9b7f0780cdd981aa_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ica80de08aa4c4c9d909fb642df773c14_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i75b496131ef6441490d3a25b5be4a503_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iee37a02facff450d8937998e321e35c8_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i16cbf61d2b0f4733ab8a1652cc5c9228_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iea66be3daee34721bcd1e066d3260b58_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id6415db3777c4bc0ba788481e7f6f6a4_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0ea7b01bc00445d1911e3e5649c2eae4_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iae60640358eb455d83e9b4666e0a100f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i77bb9190b3c84feb87f1e61f1cc38b98_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7e036f16290b4c31b64755ffadb70e68_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4f386ed67c194239ae7a35c709bffd56_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4ff0d3fa206d42d891fbf8e9323bc625_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4a43605ec78e4bd4a614f90f345653d2_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ieafa9072188340c68922f7235c0a9ea9_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5042921868d8416ab4c1cacfa352f6c8_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i59e4f5842c904666b3fb7db23c51d515_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id664e6d044d749808e62c38646f27526_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i12140879b9244c3988d010fac8673b76_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i512b545761cf451e8d1c4ca94328ff1a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i451df05f2b96426fa20d0b547ba7f6e3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic06c267aa75849648ac7102abce3ac17_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib77ad153c44c4a38a1c8a62dce893409_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i54fa9d4a70464bfba0620acea592dfcf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibf4e6756a1ee42d88901c783fdeb783f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2a1055b0f36c4bbd91048d943dbf64df_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1fc11daa88ad420c868e573c62e337b6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i50e1491b70c745b18a2d6a77e80a0767_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idbd7705702274d08b6c28ba730c1cb95_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if41dccce65fd47dcb255d39bf13108da_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibf628f2aee5246458d9a78b310344afd_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic7e7bb770a6f4c6b8a0473d3f6b6e0a0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8ff566bb63944df8beba8ba4c7fb611e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic162d9697e6b4d94a6bef51a77ade2ed_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i805d18c7f2ad420b968387db21f34edd_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id0213fdc467c492b85eaf3335f924d02_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ifda22f12ec864b9e9f5599a56418760e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1ba9041f2d9b466cb1a515f5d8e1062a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3da409025f3442429d56b3eea13ff924_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i979c2a87e5b84e029cc57393d0f5bb45_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4cc1928bdc20474e8a08b2106e966451_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9ff4a92d31b249949399aa9150b3fe6f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3eb5e283ce6f47e8a415eea081892818_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5995f351e20f4535ba42664bfb529a7e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia1e3a144f80c4ceabad966148dbe65c1_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1891d2cf47cc4c98846d01e9e63fa59b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia20771157a414430a9cd2b49d2eaff24_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i98de094b8bc642c2838aa6ef19a8ed9a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia30b2ea5e1494758ab3b2970581abe18_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9057c313471247b8a336f64bcb9d3f3a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6b53263877dc45a79b580bcde5a07dcf_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia5f8e83b346f4a789040e8611fbb11f6_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8ed85c9690854763a35bee8fec51d9ff_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id7583dd9238b48f98a56475a351d24c8_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7577c1358178462db84325596d1c3ae1_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i64ed765381cb451194df42962e56b1f0_D20220901-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic4564dde8b7249e29348178f0f8c6242_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="i2a0dfc53f05140aba2d6a2c5d9aaf8ed_I20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="i832dd038bfde4b259f4caf8354280d4d_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="i88592161984e4e54bea14bf302d598e3_D20220713-20220713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:MyChoiceWisconsinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-13</startDate>
            <endDate>2022-07-13</endDate>
        </period>
    </context>
    <context id="i80a687f2f90f401b9e47d7da8ba17754_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia4a4422c70fb4ddfa9b1095fc58b9f0e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:GovernmentReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id1cd70f1c470416e9209148ce673af71_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:GovernmentReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib597d981d44b40f195e0cdd71848ddf5_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:PharmacyRebateReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8343c8068f1a4df093d799fc8ff37927_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:PharmacyRebateReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0dbb6f52c8d941e5b0f25c3d3e677cda_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:OtherReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id139c6fc382249198e7f8ea8f0212f81_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:OtherReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4f40864acf524f78958e876e105a300f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">moh:COVID19Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4bd869502a4d4c3db24a30f94752e48f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">moh:COVID19Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i27e41e19da6946b9947bc20349bd2d6a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">moh:COVID19Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6507e164e60348edb5cc46669f1a17c3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">moh:COVID19Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9caa39ee3eca46f2935a54a04a4c6a37_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:StructuredSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="icbfe7220cac34928b948892e17e59eda_D20220930-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:AgeWellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-30</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i304daf24495747efa3683f468f95e408_D20220101-20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="idc61f272749348f58770423142c1f016_D20220101-20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">moh:MemberListsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="if7af8f685cdb4a2d91d3b3aae5939f99_D20211025-20211025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:AffinityHealthPlanIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-25</startDate>
            <endDate>2021-10-25</endDate>
        </period>
    </context>
    <context id="i54a931e10c744083ad5d1a9a95d0e7f7_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:AffinityHealthPlanIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i53d38d8c7935408fa0af30bea62c9c0f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i99e503b9ded046b2afc06e32c386be06_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i950dd07f9ee54e9ba07c4dcd9f68f6bf_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0350794e08ab4b36a1ac51538215ba52_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1115ede7452a40c1914f7984dbb1b080_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6df1fa1ed0d04f3e8713afe89886bc9a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0dcbde7850b84d7aacf9b339a9622cde_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i15df11d145d34fffaa859bf80bdfc980_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i56ac79c2434a4a848f5a258701b2729d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i71f0d1fdbe7447868ed74e5f69926324_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i164adb7da96e462788cd4e44a57cc798_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ibca4b67f345a40a898863f3cc798be1f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i89c330693cd24ca895c0f7f61021a016_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1fc1ad95c96a4d70b55ac85d939aa4b3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7d2c3542c7de425cb80651f619d775c6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ice50ff36424e47d78d882897177a7ed7_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic927869e96d94755b6560a3286b613c8_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5331694495d843a4bf88a8892738d1e9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3c2dbf685f2c45e58cd349ed403d70e8_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i50d78ee64ba8431dacba700dd2a8bdbf_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if95e6b6b2720412788aaa02f055f8e57_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie087b593b0544c8399e87f02d57c34f2_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i51b54536f2594623b231d19ba7ca1a3d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="idd1da81e23914a71942537034bdbd756_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="icc33e78bc16f451cbbfd17b41149f635_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7e214513a58b4f5a9acb2468d174594b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0d6c05f8ebb14ba2abafe737776caa0d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if45c5ec7debc4e2298c33d69169aae1b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:PassportHealthPlanIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib564c222a94b4914a72dc2e0ec855b08_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i12ad09b4f8ea44969f6dd60429d526fb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if3b352b10300485c87431f796047c44f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic0e7c52b9c5349f8bffbe5f1faf3f147_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i736beb8bf714488bb38d432dfc0890b4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8d240d4e03e64770aff2769aaa40f08a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3aa389c40f6a42229f5941193027a3ab_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i73fb739837584de6b651f049cc43ad72_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8ba2d36cfa1140b1984c163783c2d57a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6f77531e7d74403b8efb3fc5faf7b062_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i52539c799fb64d0eb14c78750d80da4d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic5856f1b277e43efad233155501d11a8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9d4d9de95590481dad9718e28b15a44b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if802abab93b446539c01d453d4296995_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iff4bfd6a6e384d5aa22561a59e8cbecf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iea7d8648b1c445ab828552784316706f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic30b2001e92f42a0889f7aa593c567f1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i55ac2e82cfc843eb861e766012517f6d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie507227240b34d9a9c9e73630984e2b4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0bdb0cb65c134e058441720032db3ad6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0781e4f6fe144460945ffc19971a5b88_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i10c0362a739347dfa9baf8391b5ebcf5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic41dd5a8ce43444caa047c867c1a7d68_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i025b5d81cf3b4ab089c2cfb73ed7fde2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8e9b92c4cf3944d6bcffae91f86005e4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5b0e199731ea42a99e977bd922403d3b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i786c434041fb4ace8a427a0d0e1e025f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idf0d9b897df24113b68bdf8a453bb9a6_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:PassportHealthPlanIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1924badac4254104ab5cdb4dd26159ab_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:PassportHealthPlanIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">moh:MinimumMemberEnrollmentTargetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i076cf1c584a94c74b356f13c7adb5c28_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:PassportHealthPlanIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">moh:OperatingIncomeGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2215166a13a24f4ea0beb4f9ec5386b9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib052c71d45c24815afd7307c29d879aa_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i448407d80cec44e08a45d31f149e357a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6f612d887153413e9b30f0319ba1b896_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5c267f45c1bb4b4bba5c6d0aa9d3c25a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4568007f62514af188a722dbbfff6949_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iafab2ab6349040358f61b4a6104ff30b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6633be4c8bbc48bcbc0664990b24b759_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iec39088e3cdd4e6bb7e04b07ff271fbe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5a9279d92caf4fc380a01f6bfb0014fc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i68670e57970547ba9f2bb65e407ef0c3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A3875SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9dfc15175d74475c91b12b778c7b87c2_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A3875SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id3afb2257e99458fa208ad148ca26252_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A3875SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6fd3944eda144945832b087213cd2c9d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A3875SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic0939ce4f5154b368577c64da2123599_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A3875SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic8580906fd604a64a726120c54b6cf42_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i150352dcdff64ad5be9688ff28c71149_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1f569fe006e84fdea4bf95c5b662a515_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5aa0518df13a4a3ea99cdd1f8dc0e2cc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9a952061d42f4cf594d018fa3c95b81c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7295c4737a694828803c5153905fdd31_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2b797bdb341b4b52895da42aa2124960_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i869f5f0099fe46b693a48fd139483e93_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia584820ec62b4608b407558882249b92_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4ec20456c73b4f1f8e73015480eac437_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0963d8c883c844e6b0f9b360576e525d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7b425cf2189f45f795be7031fbb9489a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i787d3e77233e4de9930c7143d7f3e1a7_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="idc0945cdffc8424d957d806d4e965885_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i01ba4967c8b8496c94ad918efed3e1d4_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if4629290b4494a1da97fe2a340b52e86_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9817ab0688744030bccbbc4527c6ad07_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icd9f5b7b16064fb4b96d01f818feee51_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie7d644d1ac344e6fa4918cd4a83af717_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2212dcd7830b49eca79d05facc1aaac8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3877802cf9094a9eabfc486981832840_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia1698bae97ab44ee92e15544064ddc75_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i77d77fe305a64bacbf04f03c5378f673_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic24da3c878854020a39db2e88f0312b7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic26c41034fae49aeaa64c74ef2218d5a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i50750950b870483d9018a954d9657216_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if5dabbb9212b4359ba854b1a8c18e537_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A3875SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i45addfb2824d4400bae53112a7856042_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if5d5359290144d4f933ac919de58b333_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iedddb1611ce1453d8bc04f5aa0c8509c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id30882aba8a04db99646163bc2413884_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i37c0ca418ca74d69b9c15307c7e58df1_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ifa97e16d76c6408f8338e08b5bea4b44_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1f6a30e4c3a945b1bae228351989449f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i87816e2186d3470b93fba05f0ffe1f2d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if2aaee23745f4ff297ec360508e852a7_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:OtherProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia7ee1c4d62614df782f74c5d44f474c9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:OtherProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8eff537979cc43da94a627c160916e60_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:OtherProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iabdb88db75e64d48bbc614f435a60acc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:OtherProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0164340d3f1942a3a1a5f79ab8a7363e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie2109ad9aef8463798890611406b526f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i226c2214fece4fadb73439a12ab95d6f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i362d995290d84c1597a463618a6f4a5f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i763ba496c6a742eca5a9885bbbc7830e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8cef013ef54740e8857e7e00eac7dd4d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i48a45433b5894e268eab6a5f260ad9d0_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1fe9ad49fa264be4b25af966a5e6c09c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia1896656ef924935b656c0a3948916bf_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i454009dcb5f24035b7bb46ce50254cae_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i670ed9482960439bb9d74ff2ffeb3f5e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i812649e7c9904b4abd14942568ab571c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic51dd760fd294631a25b501d900f5f1d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:OtherProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id4a763210a0a4713b5050f956ee2aac7_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:OtherProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4ff31abf6c8c49da85cb7c5b5b247423_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:OtherProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i328833ca29384ce2b4440be9a5f1bf23_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:OtherProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3648beb8cc65477dac1c4d580ec26c84_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i858448d6578c463ea667e35c5c992219_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i50521a7d515b41458530732201de3623_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4d6e9de0146e4e0ab67af6591b50afd1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4fa84dba36794309afacfe9bdfbc2bde_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8e17562a155a4b4899cfccb2754c67e4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i87b6e21917b64be8a7e28cf2b5ac0018_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i945971ba12124c429f508ca0dd49999b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>moh:segment</measure>
    </unit>
    <unit id="member">
        <measure>moh:member</measure>
    </unit>
    <unit id="state">
        <measure>moh:state</measure>
    </unit>
    <unit id="contract">
        <measure>moh:contract</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="position">
        <measure>moh:position</measure>
    </unit>
    <unit id="security">
        <measure>moh:security</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80L2ZyYWc6OTQxNjk1YzkzODY3NGFlNDg3Y2RhMzE4YzI2YTcwOGQvdGFibGU6YzBlMTE2NjU1OTcxNGY4ZTg3NzY2YTE1OTkxODA4MjEvdGFibGVyYW5nZTpjMGUxMTY2NTU5NzE0ZjhlODc3NjZhMTU5OTE4MDgyMV8zLTEtMS0xLTU4NTk4_8b7474c2-cb67-42d1-84be-8f62b934abe6">0001179929</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80L2ZyYWc6OTQxNjk1YzkzODY3NGFlNDg3Y2RhMzE4YzI2YTcwOGQvdGFibGU6YzBlMTE2NjU1OTcxNGY4ZTg3NzY2YTE1OTkxODA4MjEvdGFibGVyYW5nZTpjMGUxMTY2NTU5NzE0ZjhlODc3NjZhMTU5OTE4MDgyMV80LTEtMS0xLTU4NTk4_511225d7-96d2-4f0d-b3c7-ab25e3801128">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80L2ZyYWc6OTQxNjk1YzkzODY3NGFlNDg3Y2RhMzE4YzI2YTcwOGQvdGFibGU6YzBlMTE2NjU1OTcxNGY4ZTg3NzY2YTE1OTkxODA4MjEvdGFibGVyYW5nZTpjMGUxMTY2NTU5NzE0ZjhlODc3NjZhMTU5OTE4MDgyMV81LTEtMS0xLTU4NTk4_b8e2e3dc-3cc7-44b6-864e-96596db3b518">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80L2ZyYWc6OTQxNjk1YzkzODY3NGFlNDg3Y2RhMzE4YzI2YTcwOGQvdGFibGU6YzBlMTE2NjU1OTcxNGY4ZTg3NzY2YTE1OTkxODA4MjEvdGFibGVyYW5nZTpjMGUxMTY2NTU5NzE0ZjhlODc3NjZhMTU5OTE4MDgyMV82LTEtMS0xLTU4NTk4_848b2533-cdda-4a18-a1be-6bceda49dd0f">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80L2ZyYWc6OTQxNjk1YzkzODY3NGFlNDg3Y2RhMzE4YzI2YTcwOGQvdGFibGU6YzBlMTE2NjU1OTcxNGY4ZTg3NzY2YTE1OTkxODA4MjEvdGFibGVyYW5nZTpjMGUxMTY2NTU5NzE0ZjhlODc3NjZhMTU5OTE4MDgyMV83LTEtMS0xLTU4NTk4_564b7fa0-91a9-476e-a1bf-7b9a99b71a03">false</dei:AmendmentFlag>
    <moh:HealthPlanContractTerm
      contextRef="id7583dd9238b48f98a56475a351d24c8_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfNjE0_de89890f-e645-4a35-a3a8-f77327830d82">P3Y</moh:HealthPlanContractTerm>
    <moh:HealthPlanContractTerm
      contextRef="i832dd038bfde4b259f4caf8354280d4d_D20220801-20220831"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfMTA5OTUxMTY0MjE5OA_6c2d1c0d-cdab-4160-9874-52b55f757a29">P4Y</moh:HealthPlanContractTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80OS9mcmFnOmE1ZDYyYTdhZjZjYzQ0ODZhZTVkYTIzNmU4NzQzYmVjL3RhYmxlOjU4OTFhYTYzY2M2OTQ3NmViNDk3OGE1ZWIxNmY3NDYxL3RhYmxlcmFuZ2U6NTg5MWFhNjNjYzY5NDc2ZWI0OTc4YTVlYjE2Zjc0NjFfMS0xLTEtMS01ODU5OA_1256dafd-a892-46bc-9ded-e2ae982b42e3"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80OS9mcmFnOmE1ZDYyYTdhZjZjYzQ0ODZhZTVkYTIzNmU4NzQzYmVjL3RhYmxlOjU4OTFhYTYzY2M2OTQ3NmViNDk3OGE1ZWIxNmY3NDYxL3RhYmxlcmFuZ2U6NTg5MWFhNjNjYzY5NDc2ZWI0OTc4YTVlYjE2Zjc0NjFfMS0yLTEtMS01ODU5OA_a8e16550-8b7f-4201-9c84-56f8bb722b5f"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80OS9mcmFnOmE1ZDYyYTdhZjZjYzQ0ODZhZTVkYTIzNmU4NzQzYmVjL3RhYmxlOjU4OTFhYTYzY2M2OTQ3NmViNDk3OGE1ZWIxNmY3NDYxL3RhYmxlcmFuZ2U6NTg5MWFhNjNjYzY5NDc2ZWI0OTc4YTVlYjE2Zjc0NjFfMi0xLTEtMS01ODU5OA_2690c693-d19d-461d-80c7-6207ea5d5527"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80OS9mcmFnOmE1ZDYyYTdhZjZjYzQ0ODZhZTVkYTIzNmU4NzQzYmVjL3RhYmxlOjU4OTFhYTYzY2M2OTQ3NmViNDk3OGE1ZWIxNmY3NDYxL3RhYmxlcmFuZ2U6NTg5MWFhNjNjYzY5NDc2ZWI0OTc4YTVlYjE2Zjc0NjFfMi0yLTEtMS01ODU5OA_8c867659-a3c7-4f42-b3ac-da7cbb72166a"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80OS9mcmFnOmE1ZDYyYTdhZjZjYzQ0ODZhZTVkYTIzNmU4NzQzYmVjL3RhYmxlOjU4OTFhYTYzY2M2OTQ3NmViNDk3OGE1ZWIxNmY3NDYxL3RhYmxlcmFuZ2U6NTg5MWFhNjNjYzY5NDc2ZWI0OTc4YTVlYjE2Zjc0NjFfMi0zLTEtMS01ODU5OA_5d8617b1-da1b-48b9-86aa-bafb021d7d47"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80OS9mcmFnOmE1ZDYyYTdhZjZjYzQ0ODZhZTVkYTIzNmU4NzQzYmVjL3RhYmxlOjU4OTFhYTYzY2M2OTQ3NmViNDk3OGE1ZWIxNmY3NDYxL3RhYmxlcmFuZ2U6NTg5MWFhNjNjYzY5NDc2ZWI0OTc4YTVlYjE2Zjc0NjFfMi00LTEtMS01ODU5OA_a06e97c8-3a2c-4ddd-bc5f-b45a13f47b0e"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <dei:DocumentType
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGV4dHJlZ2lvbjo4ZThkZDk5OTIxZGI0M2VjOGQ5ODcwYzg4N2RhYzM2Ml8yMDk5_b728e06b-6001-49c3-b956-529513e48b42">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGFibGU6YzljYjNlNjMxYmJiNDM2OGFhMTNmNjhjMTNiZjI1MGUvdGFibGVyYW5nZTpjOWNiM2U2MzFiYmI0MzY4YWExM2Y2OGMxM2JmMjUwZV8wLTAtMS0xLTU4NTk4_3a82e81a-cf8a-4830-9d43-1cbf6692447a">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGV4dHJlZ2lvbjo4ZThkZDk5OTIxZGI0M2VjOGQ5ODcwYzg4N2RhYzM2Ml8xMzc_d53ecb27-d83b-4de2-87ce-ff52cd3256cc">2022-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGFibGU6NDFhNjBjMDM4ODZiNDFjY2E4M2ZlYTlmMzM3ZmRmZWEvdGFibGVyYW5nZTo0MWE2MGMwMzg4NmI0MWNjYTgzZmVhOWYzMzdmZGZlYV8wLTAtMS0xLTU4NTk4_a4d05cd5-caa9-48a5-8f2e-560f1ab0bb5f">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGV4dHJlZ2lvbjo4ZThkZDk5OTIxZGI0M2VjOGQ5ODcwYzg4N2RhYzM2Ml8yMDk0_96b34dbe-b7c5-4066-b2d5-3eebd0f9795e">001-31719</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGV4dHJlZ2lvbjo4ZThkZDk5OTIxZGI0M2VjOGQ5ODcwYzg4N2RhYzM2Ml8yMTAw_c39e7419-4ed6-4226-8718-ee972f35ed86">MOLINA HEALTHCARE, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGFibGU6YWI2MjFmZWY0NGY2NDY3YWFhNTg3NzA2NTQ1NTk4ZWQvdGFibGVyYW5nZTphYjYyMWZlZjQ0ZjY0NjdhYWE1ODc3MDY1NDU1OThlZF8wLTAtMS0xLTU4NTk4_d82dd5d7-b964-4fd4-82b6-bb1f6c140436">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGFibGU6YWI2MjFmZWY0NGY2NDY3YWFhNTg3NzA2NTQ1NTk4ZWQvdGFibGVyYW5nZTphYjYyMWZlZjQ0ZjY0NjdhYWE1ODc3MDY1NDU1OThlZF8wLTMtMS0xLTU4NTk4_5262ce51-af46-4037-9e3c-15e9585937ba">13-4204626</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGFibGU6YWI2MjFmZWY0NGY2NDY3YWFhNTg3NzA2NTQ1NTk4ZWQvdGFibGVyYW5nZTphYjYyMWZlZjQ0ZjY0NjdhYWE1ODc3MDY1NDU1OThlZF8zLTAtMS0xLTU4NTk4L3RleHRyZWdpb246ZmViNTBjZDI2Njc3NDlmOGI2YTE0NzdlYTdjNmRhZTdfNA_45cdbb92-5f60-47e7-a6cb-98c676f987d6">200 Oceangate</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGFibGU6YWI2MjFmZWY0NGY2NDY3YWFhNTg3NzA2NTQ1NTk4ZWQvdGFibGVyYW5nZTphYjYyMWZlZjQ0ZjY0NjdhYWE1ODc3MDY1NDU1OThlZF8zLTAtMS0xLTU4NTk4L3RleHRyZWdpb246ZmViNTBjZDI2Njc3NDlmOGI2YTE0NzdlYTdjNmRhZTdfOA_c2c1f857-af77-41ee-87b8-73c0e50e09c6">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGFibGU6YWI2MjFmZWY0NGY2NDY3YWFhNTg3NzA2NTQ1NTk4ZWQvdGFibGVyYW5nZTphYjYyMWZlZjQ0ZjY0NjdhYWE1ODc3MDY1NDU1OThlZF80LTAtMS0xLTU4NTk4_5c8fde8a-72a3-4e33-a857-4404d605b957">Long Beach,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGFibGU6YWI2MjFmZWY0NGY2NDY3YWFhNTg3NzA2NTQ1NTk4ZWQvdGFibGVyYW5nZTphYjYyMWZlZjQ0ZjY0NjdhYWE1ODc3MDY1NDU1OThlZF80LTEtMS0xLTU4NTk4_299157a1-01f4-4978-9525-1afd4059f4a6">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGFibGU6YWI2MjFmZWY0NGY2NDY3YWFhNTg3NzA2NTQ1NTk4ZWQvdGFibGVyYW5nZTphYjYyMWZlZjQ0ZjY0NjdhYWE1ODc3MDY1NDU1OThlZF80LTMtMS0xLTU4NTk4_54cd25e4-4254-4609-b9d5-c6b19acdaaed">90802</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGV4dHJlZ2lvbjo4ZThkZDk5OTIxZGI0M2VjOGQ5ODcwYzg4N2RhYzM2Ml8yMDk1_e06c7c81-0470-45b2-a32e-8a44e39ae05b">562</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGV4dHJlZ2lvbjo4ZThkZDk5OTIxZGI0M2VjOGQ5ODcwYzg4N2RhYzM2Ml8yMTAx_39137fa9-8172-4623-b7ef-07eea0a081f5">435-3666</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGFibGU6OGY4ZjIxMjJiNGUyNDdiZmE0MjVmYzQ2N2JlYjllMzAvdGFibGVyYW5nZTo4ZjhmMjEyMmI0ZTI0N2JmYTQyNWZjNDY3YmViOWUzMF8xLTAtMS0xLTU4NTk4_2d5e4bee-939b-4664-8238-a02453b6ad35">Common Stock, $0.001 Par Value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGFibGU6OGY4ZjIxMjJiNGUyNDdiZmE0MjVmYzQ2N2JlYjllMzAvdGFibGVyYW5nZTo4ZjhmMjEyMmI0ZTI0N2JmYTQyNWZjNDY3YmViOWUzMF8xLTEtMS0xLTU4NTk4_d4358e37-ecc3-4cda-9ff8-91a2c806563a">MOH</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGFibGU6OGY4ZjIxMjJiNGUyNDdiZmE0MjVmYzQ2N2JlYjllMzAvdGFibGVyYW5nZTo4ZjhmMjEyMmI0ZTI0N2JmYTQyNWZjNDY3YmViOWUzMF8xLTItMS0xLTU4NTk4_090bbd98-7bb8-4204-82bf-236b76c9fd4f">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGV4dHJlZ2lvbjo4ZThkZDk5OTIxZGI0M2VjOGQ5ODcwYzg4N2RhYzM2Ml8yMTAy_a2220a02-6c8f-445b-ac5b-41d96f8f1712">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGV4dHJlZ2lvbjo4ZThkZDk5OTIxZGI0M2VjOGQ5ODcwYzg4N2RhYzM2Ml8yMDk2_1fcdfe1d-ed2c-4f6c-a72c-b414ad3cc045">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGV4dHJlZ2lvbjo4ZThkZDk5OTIxZGI0M2VjOGQ5ODcwYzg4N2RhYzM2Ml8yMDk3_ff0b5706-f1f8-4ede-86b8-d5a35a7d614d">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGV4dHJlZ2lvbjo4ZThkZDk5OTIxZGI0M2VjOGQ5ODcwYzg4N2RhYzM2Ml8yMTAz_1e0ac975-74bc-492c-a40f-f00fe97b2313">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGV4dHJlZ2lvbjo4ZThkZDk5OTIxZGI0M2VjOGQ5ODcwYzg4N2RhYzM2Ml8yMDk4_f03d2a44-f1ca-4bc1-84ac-9a8115a68354">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGV4dHJlZ2lvbjo4ZThkZDk5OTIxZGI0M2VjOGQ5ODcwYzg4N2RhYzM2Ml8yMTA0_aa0319de-4e2d-4869-9673-17b0b21c0728">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i1c7c2651aec54121a7e2d1337e16d200_I20221021"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xL2ZyYWc6OGU4ZGQ5OTkyMWRiNDNlYzhkOTg3MGM4ODdkYWMzNjIvdGV4dHJlZ2lvbjo4ZThkZDk5OTIxZGI0M2VjOGQ5ODcwYzg4N2RhYzM2Ml8yMDky_d106cca2-ef8b-437a-a78b-e4ec0fc9bd25"
      unitRef="shares">58400000</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:PremiumsEarnedNet
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfNS0xLTEtMS01ODU5OA_e20a726f-c81f-4c62-88bc-b2b335adb874"
      unitRef="usd">7636000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfNS0zLTEtMS01ODU5OA_5e936e45-994d-40e3-bbc2-41f12f46abf3"
      unitRef="usd">6800000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfNS01LTEtMS01ODU5OA_84d6e95a-62d9-4d6a-a0fe-d807aa6009dd"
      unitRef="usd">22966000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfNS03LTEtMS01ODU5OA_e4ef984e-f6e1-4941-a5cb-ff1dc3612c0e"
      unitRef="usd">19689000000</us-gaap:PremiumsEarnedNet>
    <moh:HealthCareOrganizationPremiumTaxRevenue
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfNi0xLTEtMS01ODU5OA_f751de98-4dac-49fc-b152-dc58fd836880"
      unitRef="usd">223000000</moh:HealthCareOrganizationPremiumTaxRevenue>
    <moh:HealthCareOrganizationPremiumTaxRevenue
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfNi0zLTEtMS01ODU5OA_a30fe714-5c2a-44ee-9315-bc15b90b3994"
      unitRef="usd">204000000</moh:HealthCareOrganizationPremiumTaxRevenue>
    <moh:HealthCareOrganizationPremiumTaxRevenue
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfNi01LTEtMS01ODU5OA_0cd87d4f-a94c-4713-b862-06d8d2aa9d6e"
      unitRef="usd">646000000</moh:HealthCareOrganizationPremiumTaxRevenue>
    <moh:HealthCareOrganizationPremiumTaxRevenue
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfNi03LTEtMS01ODU5OA_d492208c-9c17-48c1-a07f-b6dd04ba5fac"
      unitRef="usd">576000000</moh:HealthCareOrganizationPremiumTaxRevenue>
    <us-gaap:NetInvestmentIncome
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfOC0xLTEtMS01ODU5OA_c49de8ec-55f7-4f0a-8381-023969e2881f"
      unitRef="usd">49000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfOC0zLTEtMS01ODU5OA_1581361a-0198-4707-9489-49ad7612b57c"
      unitRef="usd">20000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfOC01LTEtMS01ODU5OA_1792c473-d1f9-4542-80ed-c772a913e1c3"
      unitRef="usd">82000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfOC03LTEtMS01ODU5OA_a44582b1-8059-4df0-9036-a4216c086a09"
      unitRef="usd">39000000</us-gaap:NetInvestmentIncome>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfOS0xLTEtMS01ODU5OA_256ad9d2-e109-4e8f-bd74-0ed587e728c2"
      unitRef="usd">19000000</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfOS0zLTEtMS01ODU5OA_92213561-9c5b-4802-af20-ab42b52de013"
      unitRef="usd">16000000</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfOS01LTEtMS01ODU5OA_5dd77448-90a5-432d-9627-35de40d34df6"
      unitRef="usd">57000000</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfOS03LTEtMS01ODU5OA_9c8787fb-ddff-45c0-8c5a-e4d737a3f4a4"
      unitRef="usd">58000000</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:Revenues
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTAtMS0xLTEtNTg1OTg_1aa6cb1f-6804-470e-8910-f245e2e060f7"
      unitRef="usd">7927000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTAtMy0xLTEtNTg1OTg_f3057c5f-7888-4ebb-a23f-2072c505b799"
      unitRef="usd">7040000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTAtNS0xLTEtNTg1OTg_05a6638c-2395-46be-8776-84424ea4d53d"
      unitRef="usd">23751000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTAtNy0xLTEtNTg1OTg_ba436621-db24-4a37-bacb-89b95fcdd3d3"
      unitRef="usd">20362000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTItMS0xLTEtNTg1OTg_048ff930-33c4-4359-b35b-acde860eada3"
      unitRef="usd">6748000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTItMy0xLTEtNTg1OTg_50b8d3c6-95d0-4556-a737-ba440718339a"
      unitRef="usd">6049000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTItNS0xLTEtNTg1OTg_f6177c37-1b88-4eb1-b9e2-5b43b2428efa"
      unitRef="usd">20183000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTItNy0xLTEtNTg1OTg_ca3c5b8e-fc52-406d-91df-eb6945e1d158"
      unitRef="usd">17342000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTMtMS0xLTEtNTg1OTg_890401ea-622b-44f9-a58e-777a548721b6"
      unitRef="usd">560000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTMtMy0xLTEtNTg1OTg_5d7b9bc9-709e-4d5c-86bd-08e164ffe047"
      unitRef="usd">532000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTMtNS0xLTEtNTg1OTg_59c792b9-d2cb-4584-a217-8f3c0bc77e8d"
      unitRef="usd">1682000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTMtNy0xLTEtNTg1OTg_2e67e7e5-ced4-4fbb-88e4-f8d4d87d6f19"
      unitRef="usd">1489000000</us-gaap:GeneralAndAdministrativeExpense>
    <moh:PremiumTaxExpenses
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTQtMS0xLTEtNTg1OTg_390a5ffc-79d4-4ef4-89a4-812539f419bf"
      unitRef="usd">223000000</moh:PremiumTaxExpenses>
    <moh:PremiumTaxExpenses
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTQtMy0xLTEtNTg1OTg_0455b041-d3b0-405d-9e5b-aab2d041f780"
      unitRef="usd">204000000</moh:PremiumTaxExpenses>
    <moh:PremiumTaxExpenses
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTQtNS0xLTEtNTg1OTg_8a19e1db-0832-44db-8e4b-c2e2b7156944"
      unitRef="usd">646000000</moh:PremiumTaxExpenses>
    <moh:PremiumTaxExpenses
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTQtNy0xLTEtNTg1OTg_a2c0376c-2d3e-4f03-bd77-97c5a4db4e51"
      unitRef="usd">576000000</moh:PremiumTaxExpenses>
    <us-gaap:DepreciationAndAmortization
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTYtMS0xLTEtNTg1OTg_e5aca23b-330c-44c7-8412-434910420dd5"
      unitRef="usd">45000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTYtMy0xLTEtNTg1OTg_0f6f7185-e207-4265-a8a5-f03b0dcef448"
      unitRef="usd">32000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTYtNS0xLTEtNTg1OTg_b8902bab-71c6-47dc-a4a3-417890616a7b"
      unitRef="usd">129000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTYtNy0xLTEtNTg1OTg_6dceff49-0c31-42a6-995b-d0fe17e00e55"
      unitRef="usd">96000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTctMS0xLTEtNTg1OTg_c9bcd341-3e53-4d2b-b649-219eb844d71d"
      unitRef="usd">16000000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTctMy0xLTEtNTg1OTg_9e7bb17c-b3de-418e-9685-b0e065c07b27"
      unitRef="usd">2000000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTctNS0xLTEtNTg1OTg_5992b473-abf8-48f3-97c7-d7e28bebe516"
      unitRef="usd">43000000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTctNy0xLTEtNTg1OTg_e75b8027-9c79-4592-b519-b36e65c671d8"
      unitRef="usd">30000000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:CostsAndExpenses
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTgtMS0xLTEtNTg1OTg_3b5c804d-31bf-4683-8f82-fde4736806fe"
      unitRef="usd">7592000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTgtMy0xLTEtNTg1OTg_4cc5e17d-c5e9-4b33-bf4c-f78a8fe71c94"
      unitRef="usd">6819000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTgtNS0xLTEtNTg1OTg_e2779230-62bf-4e94-9bf4-4ff1aaa0c49a"
      unitRef="usd">22683000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTgtNy0xLTEtNTg1OTg_5b3b1f8d-3dea-4996-8053-a486bb164686"
      unitRef="usd">19533000000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTktMS0xLTEtNTg1OTg_847631bf-870c-445d-a462-abfa0c4d812b"
      unitRef="usd">335000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTktMy0xLTEtNTg1OTg_81bab26c-bc77-4096-9be9-ae71c221da51"
      unitRef="usd">221000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTktNS0xLTEtNTg1OTg_db0c603b-bbcb-4969-a837-27dc258dfb7c"
      unitRef="usd">1068000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMTktNy0xLTEtNTg1OTg_9d3539c2-1414-412a-9867-80abd385ba64"
      unitRef="usd">829000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjEtMS0xLTEtNTg1OTg_473acc17-56f2-495f-9ca4-33836116e466"
      unitRef="usd">28000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjEtMy0xLTEtNTg1OTg_c22c8bd6-e715-49a7-a27d-7710f154ea9e"
      unitRef="usd">30000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjEtNS0xLTEtNTg1OTg_50d5a082-85bc-403e-a930-e48e436425de"
      unitRef="usd">83000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjEtNy0xLTEtNTg1OTg_985aa927-62ca-4854-b98d-5e9f3eadebbe"
      unitRef="usd">90000000</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjMtMS0xLTEtNTg1OTg_071149d2-5abf-487f-97b7-095307feff8d"
      unitRef="usd">-28000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjMtMy0xLTEtNTg1OTg_fb5822f0-427f-411a-9233-9a0f2a12704d"
      unitRef="usd">-30000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjMtNS0xLTEtNTg1OTg_8eb6876a-b139-49d5-90ba-19aa8279ffb1"
      unitRef="usd">-83000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjMtNy0xLTEtNTg1OTg_4a3693f1-7dc3-4eec-8fc1-f9df025c6929"
      unitRef="usd">-90000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjQtMS0xLTEtNTg1OTg_ed00f7fd-c269-4796-a890-2f6cac4c12fb"
      unitRef="usd">307000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjQtMy0xLTEtNTg1OTg_bbc219cf-b4e9-4f12-8ac3-3777d0cbc96e"
      unitRef="usd">191000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjQtNS0xLTEtNTg1OTg_e57b17a5-3014-4122-a028-55c966bfede4"
      unitRef="usd">985000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjQtNy0xLTEtNTg1OTg_b51ea325-9b77-49b0-99a1-3c83cbbfddba"
      unitRef="usd">739000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjUtMS0xLTEtNTg1OTg_cc4d9904-7181-4e68-8789-50f7437ceedc"
      unitRef="usd">77000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjUtMy0xLTEtNTg1OTg_b258dde0-589c-43c7-9f74-95aeda4e1731"
      unitRef="usd">48000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjUtNS0xLTEtNTg1OTg_a2d92721-ffbb-45ec-a194-984176628e9f"
      unitRef="usd">249000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjUtNy0xLTEtNTg1OTg_a34ccd33-8a5b-4f29-86cc-1cc2daebb88f"
      unitRef="usd">183000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjYtMS0xLTEtNTg1OTg_9eb228b3-bfde-4add-b92c-851a683d4707"
      unitRef="usd">230000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjYtMy0xLTEtNTg1OTg_b163ba53-adeb-44ee-9b2c-c89001ddc797"
      unitRef="usd">143000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjYtNS0xLTEtNTg1OTg_7485841e-a987-4170-8a8e-eae9b548b9b0"
      unitRef="usd">736000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjYtNy0xLTEtNTg1OTg_f14f23bf-f3dc-40cf-ae6a-d28f60c3e290"
      unitRef="usd">556000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjgtMS0xLTEtNTg1OTg_4d6d63a8-6bca-42e7-8abe-59e663a839da"
      unitRef="usdPerShare">4.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjgtMy0xLTEtNTg1OTg_49b97091-b418-4004-a290-e500e2bd4360"
      unitRef="usdPerShare">2.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjgtNS0xLTEtNTg1OTg_11b42f69-c366-485b-a1bd-e89d11ac6c8d"
      unitRef="usdPerShare">12.74</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjgtNy0xLTEtNTg1OTg_9b455cd8-15dc-493b-ae24-d9f66ebff4a1"
      unitRef="usdPerShare">9.63</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjktMS0xLTEtNTg1OTg_d75fb7af-7a97-4e49-b242-b1205014d850"
      unitRef="usdPerShare">3.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjktMy0xLTEtNTg1OTg_3a795c22-d2b0-4341-ab42-8877cb9d050c"
      unitRef="usdPerShare">2.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjktNS0xLTEtNTg1OTg_98ae9026-ab51-4f6d-95fc-26f28858ce7d"
      unitRef="usdPerShare">12.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmE3NjM5NmE4ZjNhOTRmZmE4OWNiYjUxOGZiN2Y0MjRiL3RhYmxlcmFuZ2U6YTc2Mzk2YThmM2E5NGZmYTg5Y2JiNTE4ZmI3ZjQyNGJfMjktNy0xLTEtNTg1OTg_fc81afe0-846d-4b05-afbd-7e5d9d7fa19d"
      unitRef="usdPerShare">9.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmUyM2FiY2E3MjEzYjQxZTc5N2E4ZWQxM2I4OWYzOWJlL3RhYmxlcmFuZ2U6ZTIzYWJjYTcyMTNiNDFlNzk3YThlZDEzYjg5ZjM5YmVfNC0xLTEtMS01ODU5OA_f1a52862-ccd0-4b0a-84db-62dcba930792"
      unitRef="usd">230000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmUyM2FiY2E3MjEzYjQxZTc5N2E4ZWQxM2I4OWYzOWJlL3RhYmxlcmFuZ2U6ZTIzYWJjYTcyMTNiNDFlNzk3YThlZDEzYjg5ZjM5YmVfNC0zLTEtMS01ODU5OA_8ef3e239-9a5d-4b5e-ba2d-75d45b34ceba"
      unitRef="usd">143000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmUyM2FiY2E3MjEzYjQxZTc5N2E4ZWQxM2I4OWYzOWJlL3RhYmxlcmFuZ2U6ZTIzYWJjYTcyMTNiNDFlNzk3YThlZDEzYjg5ZjM5YmVfNC01LTEtMS01ODU5OA_950ee250-7d23-491d-83a4-3a42dd930af4"
      unitRef="usd">736000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmUyM2FiY2E3MjEzYjQxZTc5N2E4ZWQxM2I4OWYzOWJlL3RhYmxlcmFuZ2U6ZTIzYWJjYTcyMTNiNDFlNzk3YThlZDEzYjg5ZjM5YmVfNC03LTEtMS01ODU5OA_81811332-1a08-48a4-b66d-0a434da3b756"
      unitRef="usd">556000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmUyM2FiY2E3MjEzYjQxZTc5N2E4ZWQxM2I4OWYzOWJlL3RhYmxlcmFuZ2U6ZTIzYWJjYTcyMTNiNDFlNzk3YThlZDEzYjg5ZjM5YmVfNi0xLTEtMS01ODU5OA_1f5c65a8-9197-4540-a69b-cdf9a40fbd39"
      unitRef="usd">-75000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmUyM2FiY2E3MjEzYjQxZTc5N2E4ZWQxM2I4OWYzOWJlL3RhYmxlcmFuZ2U6ZTIzYWJjYTcyMTNiNDFlNzk3YThlZDEzYjg5ZjM5YmVfNi0zLTEtMS01ODU5OA_443dab9a-e4cc-4db1-9523-864868a7ef19"
      unitRef="usd">-13000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmUyM2FiY2E3MjEzYjQxZTc5N2E4ZWQxM2I4OWYzOWJlL3RhYmxlcmFuZ2U6ZTIzYWJjYTcyMTNiNDFlNzk3YThlZDEzYjg5ZjM5YmVfNi01LTEtMS01ODU5OA_025ea16f-b6aa-4c17-8134-dbdaeb8f248c"
      unitRef="usd">-237000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmUyM2FiY2E3MjEzYjQxZTc5N2E4ZWQxM2I4OWYzOWJlL3RhYmxlcmFuZ2U6ZTIzYWJjYTcyMTNiNDFlNzk3YThlZDEzYjg5ZjM5YmVfNi03LTEtMS01ODU5OA_535a3e27-f049-44bf-ad4c-95531a37e6a6"
      unitRef="usd">-27000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmUyM2FiY2E3MjEzYjQxZTc5N2E4ZWQxM2I4OWYzOWJlL3RhYmxlcmFuZ2U6ZTIzYWJjYTcyMTNiNDFlNzk3YThlZDEzYjg5ZjM5YmVfNy0xLTEtMS01ODU5OA_923126cc-64e8-42ac-9506-d31b20ac0012"
      unitRef="usd">-18000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmUyM2FiY2E3MjEzYjQxZTc5N2E4ZWQxM2I4OWYzOWJlL3RhYmxlcmFuZ2U6ZTIzYWJjYTcyMTNiNDFlNzk3YThlZDEzYjg5ZjM5YmVfNy0zLTEtMS01ODU5OA_8814e306-fde3-4349-afbc-8f2b460faf76"
      unitRef="usd">-4000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmUyM2FiY2E3MjEzYjQxZTc5N2E4ZWQxM2I4OWYzOWJlL3RhYmxlcmFuZ2U6ZTIzYWJjYTcyMTNiNDFlNzk3YThlZDEzYjg5ZjM5YmVfNy01LTEtMS01ODU5OA_b4234e96-ae01-40a8-bb15-5edba8eec0dd"
      unitRef="usd">-57000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmUyM2FiY2E3MjEzYjQxZTc5N2E4ZWQxM2I4OWYzOWJlL3RhYmxlcmFuZ2U6ZTIzYWJjYTcyMTNiNDFlNzk3YThlZDEzYjg5ZjM5YmVfNy03LTEtMS01ODU5OA_c1688503-4b6f-4d30-8721-e635082e4db7"
      unitRef="usd">-7000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmUyM2FiY2E3MjEzYjQxZTc5N2E4ZWQxM2I4OWYzOWJlL3RhYmxlcmFuZ2U6ZTIzYWJjYTcyMTNiNDFlNzk3YThlZDEzYjg5ZjM5YmVfOC0xLTEtMS01ODU5OA_336de38e-0a69-496f-b73b-145ed2bebc12"
      unitRef="usd">-57000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmUyM2FiY2E3MjEzYjQxZTc5N2E4ZWQxM2I4OWYzOWJlL3RhYmxlcmFuZ2U6ZTIzYWJjYTcyMTNiNDFlNzk3YThlZDEzYjg5ZjM5YmVfOC0zLTEtMS01ODU5OA_1d52bdf5-23c5-4f50-b69b-cf6f67aa1eb0"
      unitRef="usd">-9000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmUyM2FiY2E3MjEzYjQxZTc5N2E4ZWQxM2I4OWYzOWJlL3RhYmxlcmFuZ2U6ZTIzYWJjYTcyMTNiNDFlNzk3YThlZDEzYjg5ZjM5YmVfOC01LTEtMS01ODU5OA_e8e4f094-77db-4785-829f-f673f2c45792"
      unitRef="usd">-180000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmUyM2FiY2E3MjEzYjQxZTc5N2E4ZWQxM2I4OWYzOWJlL3RhYmxlcmFuZ2U6ZTIzYWJjYTcyMTNiNDFlNzk3YThlZDEzYjg5ZjM5YmVfOC03LTEtMS01ODU5OA_0ca4ceb5-4639-4775-99b3-e7b06ca5b325"
      unitRef="usd">-20000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmUyM2FiY2E3MjEzYjQxZTc5N2E4ZWQxM2I4OWYzOWJlL3RhYmxlcmFuZ2U6ZTIzYWJjYTcyMTNiNDFlNzk3YThlZDEzYjg5ZjM5YmVfOS0xLTEtMS01ODU5OA_6a508b9a-c50c-414f-a4ec-bd68146d6f11"
      unitRef="usd">173000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmUyM2FiY2E3MjEzYjQxZTc5N2E4ZWQxM2I4OWYzOWJlL3RhYmxlcmFuZ2U6ZTIzYWJjYTcyMTNiNDFlNzk3YThlZDEzYjg5ZjM5YmVfOS0zLTEtMS01ODU5OA_65d3bff6-a555-4140-b6b4-1127da09d07c"
      unitRef="usd">134000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmUyM2FiY2E3MjEzYjQxZTc5N2E4ZWQxM2I4OWYzOWJlL3RhYmxlcmFuZ2U6ZTIzYWJjYTcyMTNiNDFlNzk3YThlZDEzYjg5ZjM5YmVfOS01LTEtMS01ODU5OA_f81c0edb-f528-48ac-92a1-33079cf90f98"
      unitRef="usd">556000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xMy9mcmFnOjMxYzg0MGVjYjY4ODQ1MGRiMzQxYzdhMmNjODE5YzIxL3RhYmxlOmUyM2FiY2E3MjEzYjQxZTc5N2E4ZWQxM2I4OWYzOWJlL3RhYmxlcmFuZ2U6ZTIzYWJjYTcyMTNiNDFlNzk3YThlZDEzYjg5ZjM5YmVfOS03LTEtMS01ODU5OA_d68bb838-0b02-4ac8-908f-ec96875e73ba"
      unitRef="usd">536000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfNi0xLTEtMS01ODU5OA_f31741a9-bafd-44d0-9239-3f698fce4de0"
      unitRef="usd">4242000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfNi0zLTEtMS01ODU5OA_d06abd0b-f3cf-4c5b-8337-bb0e845c25b0"
      unitRef="usd">4438000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfNy0xLTEtMS01ODU5OA_505fae8b-a294-4c13-9e34-73121c1d64c2"
      unitRef="usd">3639000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfNy0zLTEtMS01ODU5OA_b178bdae-6028-42cd-b1e9-1b5d607ef7ae"
      unitRef="usd">3202000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfOC0xLTEtMS01ODU5OA_1e47af74-ab28-478f-a27b-a1f75c2a8e5c"
      unitRef="usd">2220000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfOC0zLTEtMS01ODU5OA_f2ac7629-2acb-4f2f-901b-0bba4e233def"
      unitRef="usd">2177000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfOS0xLTEtMS01ODU5OA_9f7da568-12c1-4c97-ab9e-a6d98171e652"
      unitRef="usd">391000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfOS0zLTEtMS01ODU5OA_dca1d00c-8395-4893-8439-c973be8aacb8"
      unitRef="usd">247000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMTAtMS0xLTEtNTg1OTg_dd6d553a-b3db-490f-b67b-d67ed319aa98"
      unitRef="usd">10492000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMTAtMy0xLTEtNTg1OTg_81f05f13-775a-45ef-b463-76c35ddd7fb9"
      unitRef="usd">10064000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMTEtMS0xLTEtNTg1OTg_1535baf2-a9c9-43e5-afbc-ce005ce32b43"
      unitRef="usd">412000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMTEtMy0xLTEtNTg1OTg_3c5c41a2-c6df-4f08-8f91-c205029d3058"
      unitRef="usd">396000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMTItMS0xLTEtNTg1OTg_a5a4176d-6d93-4799-9ce4-7124ab933789"
      unitRef="usd">1263000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMTItMy0xLTEtNTg1OTg_35c1f60b-edf2-432f-b8c8-c059ef25d332"
      unitRef="usd">1252000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:RestrictedInvestmentsNoncurrent
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMTMtMS0xLTEtNTg1OTg_f7b01656-772f-4205-8650-25ee699a7241"
      unitRef="usd">242000000</us-gaap:RestrictedInvestmentsNoncurrent>
    <us-gaap:RestrictedInvestmentsNoncurrent
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMTMtMy0xLTEtNTg1OTg_9fcbf483-ad0e-48a0-80ab-c92c43f4907d"
      unitRef="usd">212000000</us-gaap:RestrictedInvestmentsNoncurrent>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMTQtMS0xLTEtNTg1OTg_6da04f72-93f5-47b9-af0d-78b61b9b57df"
      unitRef="usd">198000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMTQtMy0xLTEtNTg1OTg_a2ac9fc4-ce6d-4f01-b6a4-4d4db32ce3f8"
      unitRef="usd">106000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMTUtMS0xLTEtNTg1OTg_7539526d-7fd1-4667-bbe7-f5eb867e07db"
      unitRef="usd">186000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMTUtMy0xLTEtNTg1OTg_0ed59c7a-aecb-480d-8c7c-8ab57a56a761"
      unitRef="usd">179000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMTYtMS0xLTEtNTg1OTg_2ca70f5d-263d-4546-8dcc-f716835f1e29"
      unitRef="usd">12793000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMTYtMy0xLTEtNTg1OTg_9258bfc8-a4ec-4a61-8d08-6e24fb5152ce"
      unitRef="usd">12209000000</us-gaap:Assets>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMjAtMS0xLTEtNTg1OTg_7235d2a7-c962-496e-a4a7-039e8e720429"
      unitRef="usd">3622000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMjAtMy0xLTEtNTg1OTg_02a7a1ae-730e-4475-94ec-56acbc83a5fc"
      unitRef="usd">3363000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <moh:MedicalPremiumLiabilityDueToAgency
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMjEtMS0xLTEtNTg1OTg_cba5e457-c3e7-451a-9c60-36590894aa52"
      unitRef="usd">2139000000</moh:MedicalPremiumLiabilityDueToAgency>
    <moh:MedicalPremiumLiabilityDueToAgency
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMjEtMy0xLTEtNTg1OTg_ed7d2687-d34d-45b8-af07-73d8ea474b55"
      unitRef="usd">2472000000</moh:MedicalPremiumLiabilityDueToAgency>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMjItMS0xLTEtNTg1OTg_577e8f15-eac0-4846-88ae-47bb5e7372bf"
      unitRef="usd">818000000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMjItMy0xLTEtNTg1OTg_f5434984-0a10-47f1-a5fb-2fc4526051e3"
      unitRef="usd">842000000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMjMtMS0xLTEtNTg1OTg_0b5fd69e-311a-4ae0-9ee0-da8a6d658c8f"
      unitRef="usd">663000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMjMtMy0xLTEtNTg1OTg_43087e72-346d-4c29-a5ed-fc1c006e3917"
      unitRef="usd">370000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMjQtMS0xLTEtNTg1OTg_7ede241f-4702-4c86-aa5a-7abf8aeda896"
      unitRef="usd">7242000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMjQtMy0xLTEtNTg1OTg_74e72d57-8880-44cf-b568-43809c2990fb"
      unitRef="usd">7047000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMjUtMS0xLTEtNTg1OTg_af78336a-3431-4e2f-8106-858d37e2a186"
      unitRef="usd">2175000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMjUtMy0xLTEtNTg1OTg_cdca0a25-5317-4089-9fce-4bb206079759"
      unitRef="usd">2173000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMjYtMS0xLTEtNTg1OTg_fec502c3-5ca4-4108-8732-5c55bc6cb331"
      unitRef="usd">217000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMjYtMy0xLTEtNTg1OTg_5ac903b2-dbcd-48fc-8cac-7a2436944df7"
      unitRef="usd">219000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMjctMS0xLTEtNTg1OTg_99de8293-1eb6-4942-9c9d-4f15e1fd9af8"
      unitRef="usd">118000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMjctMy0xLTEtNTg1OTg_5da2c7e3-e23e-497f-a7f4-7a4cf9ef8a5f"
      unitRef="usd">140000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMjgtMS0xLTEtNTg1OTg_1911f7f7-4584-4b4c-8255-935c6ba9ec6d"
      unitRef="usd">9752000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMjgtMy0xLTEtNTg1OTg_814c4454-8e02-417a-b204-bef9f2743842"
      unitRef="usd">9579000000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzAtMC0xLTEtNTg1OTgvdGV4dHJlZ2lvbjoyZTczZGUxM2FiYzg0MjQyYTMyNTM2ZWJkZDJiZjI0NF8xOQ_5a6f2860-095c-41e0-b7b3-9d7a00213452"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzAtMC0xLTEtNTg1OTgvdGV4dHJlZ2lvbjoyZTczZGUxM2FiYzg0MjQyYTMyNTM2ZWJkZDJiZjI0NF8xOQ_8011de86-ecf1-4e3e-a065-da217c3282eb"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzAtMC0xLTEtNTg1OTgvdGV4dHJlZ2lvbjoyZTczZGUxM2FiYzg0MjQyYTMyNTM2ZWJkZDJiZjI0NF8zMw_d598f5ac-f298-4329-850a-f32b12ac4c1f"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzAtMC0xLTEtNTg1OTgvdGV4dHJlZ2lvbjoyZTczZGUxM2FiYzg0MjQyYTMyNTM2ZWJkZDJiZjI0NF8zMw_e0a338a8-3b77-437b-b6d1-3ee3c73c4846"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzAtMC0xLTEtNTg1OTgvdGV4dHJlZ2lvbjoyZTczZGUxM2FiYzg0MjQyYTMyNTM2ZWJkZDJiZjI0NF82OA_22b8bd19-c24e-400e-a69c-a4a3eaa2952e"
      unitRef="shares">58000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzAtMC0xLTEtNTg1OTgvdGV4dHJlZ2lvbjoyZTczZGUxM2FiYzg0MjQyYTMyNTM2ZWJkZDJiZjI0NF82OA_44871194-764c-4148-9acb-1551332b6e19"
      unitRef="shares">58000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzAtMS0xLTEtNTg1OTg_bfef368c-6e8a-47dd-b38c-0090603877cc"
      unitRef="usd">0</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzAtMy0xLTEtNTg1OTg_5478787e-027f-4aab-a70f-bc5f443772e3"
      unitRef="usd">0</us-gaap:CommonStockValueOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzEtMC0xLTEtNTg1OTgvdGV4dHJlZ2lvbjpkMmJjZGVmMjMzZTk0MDM3ODJjYzQ4NGJhZDZhZTZkZl8yMg_35b7c1ca-120a-4885-864d-482e4ce9a23f"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzEtMC0xLTEtNTg1OTgvdGV4dHJlZ2lvbjpkMmJjZGVmMjMzZTk0MDM3ODJjYzQ4NGJhZDZhZTZkZl8yMg_69724726-b3e1-4ec9-96da-e6cf3de92f4d"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzEtMC0xLTEtNTg1OTgvdGV4dHJlZ2lvbjpkMmJjZGVmMjMzZTk0MDM3ODJjYzQ4NGJhZDZhZTZkZl8zNg_3c7478e6-affe-4472-bd0a-410dcc46c8bb"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzEtMC0xLTEtNTg1OTgvdGV4dHJlZ2lvbjpkMmJjZGVmMjMzZTk0MDM3ODJjYzQ4NGJhZDZhZTZkZl8zNg_e3c2f5b3-eaa9-4981-ac21-41f74c27e648"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzEtMC0xLTEtNTg1OTgvdGV4dHJlZ2lvbjpkMmJjZGVmMjMzZTk0MDM3ODJjYzQ4NGJhZDZhZTZkZl81OA_41642417-ecf5-4375-9e94-b9b15a94d98f"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzEtMC0xLTEtNTg1OTgvdGV4dHJlZ2lvbjpkMmJjZGVmMjMzZTk0MDM3ODJjYzQ4NGJhZDZhZTZkZl81OA_6fd09784-be35-40e7-9d21-e5337c2d84a4"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzEtMC0xLTEtNTg1OTgvdGV4dHJlZ2lvbjpkMmJjZGVmMjMzZTk0MDM3ODJjYzQ4NGJhZDZhZTZkZl81OA_cf0b6ecd-ff30-4b76-b105-83b2b80b12c2"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzEtMC0xLTEtNTg1OTgvdGV4dHJlZ2lvbjpkMmJjZGVmMjMzZTk0MDM3ODJjYzQ4NGJhZDZhZTZkZl81OA_e361b13c-e090-4c2c-afae-4ff535a0e44e"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzEtMS0xLTEtNTg1OTg_cda59f12-8a1c-47a1-9b73-5c5b0c245bfa"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzEtMy0xLTEtNTg1OTg_d2229e96-a87f-48cd-b569-b99452456752"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzItMS0xLTEtNTg1OTg_3dd37056-a9d5-4141-b0c5-03a8b91c457a"
      unitRef="usd">289000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzItMy0xLTEtNTg1OTg_cc2029d5-ce77-42d6-a5f7-aae43ab8845a"
      unitRef="usd">236000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzMtMS0xLTEtNTg1OTg_6237cf25-e951-4b8c-bf44-a4845f9fd8b8"
      unitRef="usd">-185000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzMtMy0xLTEtNTg1OTg_39c394fd-be1c-4e7a-8b0a-9195067a0b5d"
      unitRef="usd">-5000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzQtMS0xLTEtNTg1OTg_e8046ec1-4ed0-4617-a436-7550055d4d84"
      unitRef="usd">2937000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzQtMy0xLTEtNTg1OTg_209bb2c9-707a-4643-8465-f2d44c804bdb"
      unitRef="usd">2399000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzUtMS0xLTEtNTg1OTg_fa7c4c68-dd19-4588-b18e-0444c6aeaf60"
      unitRef="usd">3041000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzUtMy0xLTEtNTg1OTg_16ffaa4f-4843-4ea9-a08d-df3e5bf862d7"
      unitRef="usd">2630000000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzYtMS0xLTEtNTg1OTg_71dedbfc-196c-43ed-8a62-eb6c2af981e0"
      unitRef="usd">12793000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xNi9mcmFnOjk0MjVmMDAwM2MwMDRiMDhhNzE3OTc1M2QwODFiNWFmL3RhYmxlOmFkNzJkOWJjZGM2NjRjN2I4ZDAxOTBiOGUwNTA0YjE0L3RhYmxlcmFuZ2U6YWQ3MmQ5YmNkYzY2NGM3YjhkMDE5MGI4ZTA1MDRiMTRfMzYtMy0xLTEtNTg1OTg_047fdbfa-2d0b-4547-8fb7-d108b57645f0"
      unitRef="usd">12209000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i6b47298aedfe41eaaf18cdcaa7e274a7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfNS0xLTEtMS01ODU5OA_a96c4082-01f0-4604-817d-e088683fc09b"
      unitRef="shares">58000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i6b47298aedfe41eaaf18cdcaa7e274a7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfNS0zLTEtMS01ODU5OA_0e7a13ff-6046-4780-b934-73981d5a1a5e"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia401e1c073f74cc0bc3f1d03b289141d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfNS01LTEtMS01ODU5OA_c7a63389-1cbb-46f9-b021-6261cb69f7cc"
      unitRef="usd">236000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7930891295544d92bc8b7e75fd28dc75_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfNS03LTEtMS01ODU5OA_a7f4e280-8435-407e-b2e5-ade278400a17"
      unitRef="usd">-5000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if63417ae06ef4f8b883c07503fb48ab9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfNS05LTEtMS01ODU5OA_aab3c334-0625-4e8f-9356-bf2cdfc61580"
      unitRef="usd">2399000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfNS0xMS0xLTEtNTg1OTg_8afcf786-18dd-4d7c-8e2d-96d26d81ea00"
      unitRef="usd">2630000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="if8bb2347c1c74af789d99f414d0ee364_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfNi05LTEtMS01ODU5OA_4b7f3194-f114-4a03-a57b-998874940a1e"
      unitRef="usd">258000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i42dd4296d82f4c08b4d55cc720bdb12d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfNi0xMS0xLTEtNTg1OTg_111db46c-6448-40da-b151-99a3a72c6bf6"
      unitRef="usd">258000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ib2231609c373451c812f4a754b56a154_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMTYtNy0xLTEtNTg1OTg_1f1eb3a7-8086-4283-a71b-a40f87087f99"
      unitRef="usd">-76000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i42dd4296d82f4c08b4d55cc720bdb12d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMTYtMTEtMS0xLTU4NTk4_27defaa0-cfbb-4115-8d26-ecf7c8c14ff2"
      unitRef="usd">-76000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i94c67ce05a9d467fa8cb7a3f9e74c0c5_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMTctMS0xLTEtNTg1OTg_4447fc8a-92f7-4e26-8359-009907d9fc88"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic1de449cbf8144a291a8fc6482edab09_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMTctNS0xLTEtNTg1OTg_382d249d-9716-4123-9771-04bf35d0716b"
      unitRef="usd">-18000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i42dd4296d82f4c08b4d55cc720bdb12d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMTctMTEtMS0xLTU4NTk4_fc6c69ae-42cf-4ed0-a78c-1ed7ccf81c76"
      unitRef="usd">-18000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="ida3920fde58740b88b1e9ac9cbfe5f21_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMTgtMS0xLTEtNTg1OTg_3ad2c75e-1793-4248-b25b-c128115c186d"
      unitRef="shares">59000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ida3920fde58740b88b1e9ac9cbfe5f21_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMTgtMy0xLTEtNTg1OTg_86384b78-5e8a-4bdd-8416-e49f63b30114"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1e2a1318dc6046958feb391581e30a94_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMTgtNS0xLTEtNTg1OTg_4c54e9f1-644a-4d55-ba8c-65aa293c9f8e"
      unitRef="usd">218000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3d767141fe3341cc9b7f0780cdd981aa_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMTgtNy0xLTEtNTg1OTg_a3ab1669-167d-4e3c-afa9-87db23e8097a"
      unitRef="usd">-81000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ica80de08aa4c4c9d909fb642df773c14_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMTgtOS0xLTEtNTg1OTg_2396f91f-4a23-4c16-a3fa-76967126309c"
      unitRef="usd">2657000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i75b496131ef6441490d3a25b5be4a503_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMTgtMTEtMS0xLTU4NTk4_a5d4e549-b85a-4a02-8ce1-1194db3de759"
      unitRef="usd">2794000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="iee37a02facff450d8937998e321e35c8_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMTktOS0xLTEtNTg1OTg_dbb60eb7-f8d7-42c8-8bb0-d87ca2565151"
      unitRef="usd">248000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i16cbf61d2b0f4733ab8a1652cc5c9228_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMTktMTEtMS0xLTU4NTk4_85bf187a-fe43-4aca-a1ac-78f20c1cb2b5"
      unitRef="usd">248000000</us-gaap:NetIncomeLoss>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="iea66be3daee34721bcd1e066d3260b58_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMjAtMS0xLTEtNTg1OTg_5ded7bb3-4fed-4596-8bef-40af2d8234ba"
      unitRef="shares">1000000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="id6415db3777c4bc0ba788481e7f6f6a4_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMjAtNS0xLTEtNTg1OTg_89ee6d2c-5167-40e7-9973-1e251932c411"
      unitRef="usd">2000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="iee37a02facff450d8937998e321e35c8_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMjAtOS0xLTEtNTg1OTg_8bcd7b83-fd17-4d92-bf40-3326bc77e139"
      unitRef="usd">198000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i16cbf61d2b0f4733ab8a1652cc5c9228_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMjAtMTEtMS0xLTU4NTk4_f950a8eb-994c-4db6-93d0-5d0fff0b9e6d"
      unitRef="usd">200000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i0ea7b01bc00445d1911e3e5649c2eae4_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMjktNy0xLTEtNTg1OTg_8eaace61-509c-4f46-8fe9-6e1480b22e36"
      unitRef="usd">-47000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i16cbf61d2b0f4733ab8a1652cc5c9228_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMjktMTEtMS0xLTU4NTk4_5021b1da-a3fa-46b7-9fdc-be803629887a"
      unitRef="usd">-47000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id6415db3777c4bc0ba788481e7f6f6a4_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMzAtNS0xLTEtNTg1OTg_93c6ee54-8fb5-466b-97a3-5d62b2e079fd"
      unitRef="usd">35000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i16cbf61d2b0f4733ab8a1652cc5c9228_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMzAtMTEtMS0xLTU4NTk4_be145a4a-6dab-4946-80c1-546eb6a30f4e"
      unitRef="usd">35000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="iae60640358eb455d83e9b4666e0a100f_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMzEtMS0xLTEtNTg1OTg_d753ccf3-d431-4588-a253-8280a6f859e4"
      unitRef="shares">58000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iae60640358eb455d83e9b4666e0a100f_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMzEtMy0xLTEtNTg1OTg_7d454c87-99ea-441c-92fb-7067dceef4fb"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i77bb9190b3c84feb87f1e61f1cc38b98_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMzEtNS0xLTEtNTg1OTg_41580818-350f-408b-aa4d-55fdebc4f9c2"
      unitRef="usd">251000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7e036f16290b4c31b64755ffadb70e68_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMzEtNy0xLTEtNTg1OTg_27d6a41f-be66-43e7-a3f0-ad4f979d4fde"
      unitRef="usd">-128000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4f386ed67c194239ae7a35c709bffd56_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMzEtOS0xLTEtNTg1OTg_1dc40e3c-c638-443e-90e6-d07049fe8116"
      unitRef="usd">2707000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4ff0d3fa206d42d891fbf8e9323bc625_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMzEtMTEtMS0xLTU4NTk4_1141955a-7c38-4732-b439-b0449a2627f8"
      unitRef="usd">2830000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i4a43605ec78e4bd4a614f90f345653d2_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMzItOS0xLTEtNTg1OTg_7e1aed8c-708e-467c-a4d9-62a4326ef3b5"
      unitRef="usd">230000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfMzItMTEtMS0xLTU4NTk4_1d1ce41c-c2dd-4d86-8bd5-00c22b375560"
      unitRef="usd">230000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ieafa9072188340c68922f7235c0a9ea9_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfNDItNy0xLTEtNTg1OTg_551cde19-ba57-4ec7-bd89-ae3fe34d8887"
      unitRef="usd">-57000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfNDItMTEtMS0xLTU4NTk4_b1fa7e58-83dc-4955-a970-10e36d0c61b3"
      unitRef="usd">-57000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i5042921868d8416ab4c1cacfa352f6c8_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfNDMtMS0xLTEtNTg1OTg_8843f7e4-fc7b-435c-b0b8-688ee5006347"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i59e4f5842c904666b3fb7db23c51d515_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfNDMtNS0xLTEtNTg1OTg_e5603952-1575-42a0-93aa-7835db523a11"
      unitRef="usd">38000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfNDMtMTEtMS0xLTU4NTk4_2b4626c0-d040-4b2b-990c-f834a4d759c2"
      unitRef="usd">38000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="id664e6d044d749808e62c38646f27526_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfNDQtMS0xLTEtNTg1OTg_d7edd9db-1410-47be-9489-11ffbc1d76dc"
      unitRef="shares">58000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id664e6d044d749808e62c38646f27526_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfNDQtMy0xLTEtNTg1OTg_00369e2a-332c-4f58-842c-a4ee30bf36c7"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i12140879b9244c3988d010fac8673b76_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfNDQtNS0xLTEtNTg1OTg_4a9b2c18-9552-4c16-be27-aca6ac3fa594"
      unitRef="usd">289000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i512b545761cf451e8d1c4ca94328ff1a_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfNDQtNy0xLTEtNTg1OTg_d734cff0-1feb-485e-b2ce-f6af4f131581"
      unitRef="usd">-185000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i451df05f2b96426fa20d0b547ba7f6e3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfNDQtOS0xLTEtNTg1OTg_2e01ef85-3b7e-4ef4-bce3-75f75c81ed4e"
      unitRef="usd">2937000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOmQxMGEwNGI0MTQ5MjQ3Y2ZiNGJmYTA2MGNiZjI4MjU3L3RhYmxlcmFuZ2U6ZDEwYTA0YjQxNDkyNDdjZmI0YmZhMDYwY2JmMjgyNTdfNDQtMTEtMS0xLTU4NTk4_d81012bd-1008-4f10-a143-143fa44a19a0"
      unitRef="usd">3041000000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ic06c267aa75849648ac7102abce3ac17_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNS0xLTEtMS01ODU5OA_403e5b6f-89dd-4cb1-85e1-a1cad181523d"
      unitRef="shares">59000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic06c267aa75849648ac7102abce3ac17_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNS0zLTEtMS01ODU5OA_96586671-d867-4b19-b969-3a314fc60399"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib77ad153c44c4a38a1c8a62dce893409_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNS01LTEtMS01ODU5OA_811d95a0-fe47-4828-b93b-2c4d72e5a77f"
      unitRef="usd">199000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i54fa9d4a70464bfba0620acea592dfcf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNS03LTEtMS01ODU5OA_7f58b65d-0eb1-4cd0-aeb7-23815b1a72db"
      unitRef="usd">37000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibf4e6756a1ee42d88901c783fdeb783f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNS05LTEtMS01ODU5OA_eaa2d192-8e37-4509-b895-e462eb91b132"
      unitRef="usd">1860000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2a1055b0f36c4bbd91048d943dbf64df_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNS0xMS0xLTEtNTg1OTg_518544dc-ba72-44df-85c4-b523537d4950"
      unitRef="usd">2096000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i1fc11daa88ad420c868e573c62e337b6_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNi05LTEtMS01ODU5OA_9048e193-ca5a-4265-88e8-46706824db41"
      unitRef="usd">228000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i50e1491b70c745b18a2d6a77e80a0767_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNi0xMS0xLTEtNTg1OTg_5aae09ff-61a8-41ca-b889-fe26c45852f4"
      unitRef="usd">228000000</us-gaap:NetIncomeLoss>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="idbd7705702274d08b6c28ba730c1cb95_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNy0xLTEtMS01ODU5OA_2e3c3ad7-3996-4712-b264-03a9ce9719da"
      unitRef="shares">1000000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="if41dccce65fd47dcb255d39bf13108da_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNy01LTEtMS01ODU5OA_656683aa-6a0b-4f45-8f16-99e21a5580b7"
      unitRef="usd">2000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i1fc11daa88ad420c868e573c62e337b6_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNy05LTEtMS01ODU5OA_a9a84d89-c9a5-4b47-a027-049d3804aeec"
      unitRef="usd">120000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i50e1491b70c745b18a2d6a77e80a0767_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNy0xMS0xLTEtNTg1OTg_7714a3da-82eb-4dfe-867e-d2a104bb3c2b"
      unitRef="usd">122000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ibf628f2aee5246458d9a78b310344afd_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMTYtNy0xLTEtNTg1OTg_97a8d213-e4f1-49bb-9220-350ec832d798"
      unitRef="usd">-11000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i50e1491b70c745b18a2d6a77e80a0767_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMTYtMTEtMS0xLTU4NTk4_6a8a5696-8a55-4677-b5bc-06d58a520b98"
      unitRef="usd">-11000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if41dccce65fd47dcb255d39bf13108da_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMTctNS0xLTEtNTg1OTg_35055e9f-8467-47f0-864b-4ba17788c886"
      unitRef="usd">-27000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i50e1491b70c745b18a2d6a77e80a0767_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMTctMTEtMS0xLTU4NTk4_82440320-65d0-471d-91d0-f2f22dc060a6"
      unitRef="usd">-27000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="ic7e7bb770a6f4c6b8a0473d3f6b6e0a0_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMTgtMS0xLTEtNTg1OTg_57a831fd-d154-4efe-b8cd-891f06593204"
      unitRef="shares">58000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic7e7bb770a6f4c6b8a0473d3f6b6e0a0_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMTgtMy0xLTEtNTg1OTg_ef94fd71-ba2c-4ae6-b830-7e4792d5bcd0"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8ff566bb63944df8beba8ba4c7fb611e_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMTgtNS0xLTEtNTg1OTg_fcaeca2e-4acb-48ed-a3a5-39958e9121f2"
      unitRef="usd">170000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic162d9697e6b4d94a6bef51a77ade2ed_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMTgtNy0xLTEtNTg1OTg_f9bf7e14-1aba-49d3-a39f-36e3b2eb4cf3"
      unitRef="usd">26000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i805d18c7f2ad420b968387db21f34edd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMTgtOS0xLTEtNTg1OTg_13eb15d5-f6f3-4666-8a53-18d0d94842e3"
      unitRef="usd">1968000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id0213fdc467c492b85eaf3335f924d02_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMTgtMTEtMS0xLTU4NTk4_da069f49-1b84-40d1-8e3d-17858bca842c"
      unitRef="usd">2164000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ifda22f12ec864b9e9f5599a56418760e_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMTktOS0xLTEtNTg1OTg_5f243700-ed0f-4eb4-862f-bc64f0cb2bc6"
      unitRef="usd">185000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1ba9041f2d9b466cb1a515f5d8e1062a_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMTktMTEtMS0xLTU4NTk4_a97ebee4-de91-4551-9fa4-a1a3a76f4795"
      unitRef="usd">185000000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i3da409025f3442429d56b3eea13ff924_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMzAtNS0xLTEtNTg1OTg_90190689-9d24-472a-b0a0-9d40248df52c"
      unitRef="usd">21000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i1ba9041f2d9b466cb1a515f5d8e1062a_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMzAtMTEtMS0xLTU4NTk4_bd99f30e-14b0-45e0-acf6-f10999bbed66"
      unitRef="usd">21000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="i979c2a87e5b84e029cc57393d0f5bb45_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMzEtMS0xLTEtNTg1OTg_bef50d36-1606-4219-baa5-b8683a389eb0"
      unitRef="shares">58000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i979c2a87e5b84e029cc57393d0f5bb45_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMzEtMy0xLTEtNTg1OTg_ac6ccfbc-1aa1-47e2-90f0-319ea5fb0475"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4cc1928bdc20474e8a08b2106e966451_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMzEtNS0xLTEtNTg1OTg_4ba45ad0-8144-4392-b326-2714dc3a05e5"
      unitRef="usd">191000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9ff4a92d31b249949399aa9150b3fe6f_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMzEtNy0xLTEtNTg1OTg_a9ed1a43-e8c3-4f55-b34b-7adca5be8230"
      unitRef="usd">26000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3eb5e283ce6f47e8a415eea081892818_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMzEtOS0xLTEtNTg1OTg_f8ef94bf-194c-4ae4-a1a3-15eeb130f73a"
      unitRef="usd">2153000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5995f351e20f4535ba42664bfb529a7e_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMzEtMTEtMS0xLTU4NTk4_5add079a-d53e-40c5-9bca-ab93ccdd6218"
      unitRef="usd">2370000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ia1e3a144f80c4ceabad966148dbe65c1_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMzItOS0xLTEtNTg1OTg_bdffc812-ed2a-42b6-9c57-c7411e1e582c"
      unitRef="usd">143000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfMzItMTEtMS0xLTU4NTk4_ca264bb2-5a4a-4455-ac5e-7a77321cd9c4"
      unitRef="usd">143000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i1891d2cf47cc4c98846d01e9e63fa59b_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNDItNy0xLTEtNTg1OTg_b312404d-09ce-44cb-a0b3-b9feb6125291"
      unitRef="usd">-9000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNDItMTEtMS0xLTU4NTk4_c583bf7d-eb13-421d-8cec-7b06cb251d8f"
      unitRef="usd">-9000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia20771157a414430a9cd2b49d2eaff24_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNDMtNS0xLTEtNTg1OTg_33bb3058-a828-48b5-926f-1838d4989893"
      unitRef="usd">14000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNDMtMTEtMS0xLTU4NTk4_9a50b175-1218-4a6e-b22d-259423fe0a13"
      unitRef="usd">14000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="i98de094b8bc642c2838aa6ef19a8ed9a_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNDQtMS0xLTEtNTg1OTg_a51a0728-4411-489a-9df4-f60f4dba36d6"
      unitRef="shares">58000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i98de094b8bc642c2838aa6ef19a8ed9a_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNDQtMy0xLTEtNTg1OTg_dda52ac7-e16c-464d-9923-d99b9ffd2d7a"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia30b2ea5e1494758ab3b2970581abe18_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNDQtNS0xLTEtNTg1OTg_49e4db89-d552-4de3-89a6-4dfbbb53161b"
      unitRef="usd">205000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9057c313471247b8a336f64bcb9d3f3a_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNDQtNy0xLTEtNTg1OTg_814c678e-4b13-4ade-98c6-8a9f60e09d72"
      unitRef="usd">17000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6b53263877dc45a79b580bcde5a07dcf_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNDQtOS0xLTEtNTg1OTg_dce3649d-d8aa-44b7-9e83-ccb8acec10e0"
      unitRef="usd">2296000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia5f8e83b346f4a789040e8611fbb11f6_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8xOS9mcmFnOmZkNzA3MjcyMGU0MzQzNDlhNTc0NDk1YjMzMTAyOGM2L3RhYmxlOjhhNmM5OWI2NDhlYjQyMjBiOTk2NzUwOWZhNjEyYWIwL3RhYmxlcmFuZ2U6OGE2Yzk5YjY0OGViNDIyMGI5OTY3NTA5ZmE2MTJhYjBfNDQtMTEtMS0xLTU4NTk4_8e01f7cf-4e12-4e0a-a7f1-02133fa278df"
      unitRef="usd">2518000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfNS0xLTEtMS01ODU5OA_5f3fca68-182d-4e47-bf72-5a158b3c7acd"
      unitRef="usd">736000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfNS0zLTEtMS01ODU5OA_8167ec8d-4288-4619-8828-0752b63ae0c5"
      unitRef="usd">556000000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfNy0xLTEtMS01ODU5OA_68bd70fd-cd19-4927-b3fe-bba235e000a9"
      unitRef="usd">129000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfNy0zLTEtMS01ODU5OA_5551494c-f9c9-403c-b4e8-41b3f400bc83"
      unitRef="usd">96000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfOC0xLTEtMS01ODU5OA_01084530-c74b-4fd7-9130-3c081fac55a1"
      unitRef="usd">35000000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfOC0zLTEtMS01ODU5OA_90aed60e-0e4f-4bb4-bf0d-e82fa1f02cef"
      unitRef="usd">8000000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:ShareBasedCompensation
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfOS0xLTEtMS01ODU5OA_41d7d4be-065b-456d-9365-0e7aa6088e2a"
      unitRef="usd">80000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfOS0zLTEtMS01ODU5OA_43dd9ccf-42dd-41dd-a848-9f587e121519"
      unitRef="usd">49000000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMTEtMS0xLTEtNTg1OTg_f4fa59f2-4a83-4d15-bf44-9b9e77f36700"
      unitRef="usd">-3000000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMTEtMy0xLTEtNTg1OTg_404ef286-5f3a-4477-9aff-9b0ec2c4a1dd"
      unitRef="usd">9000000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMTMtMS0xLTEtNTg1OTg_d798e780-f052-4faf-b98b-6cb8a938ec58"
      unitRef="usd">15000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMTMtMy0xLTEtNTg1OTg_a9448ed3-cc42-4770-a426-593ef8c8c335"
      unitRef="usd">247000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMTQtMS0xLTEtNTg1OTg_fc723257-91c9-43e3-afef-ea0d18931bc7"
      unitRef="usd">110000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMTQtMy0xLTEtNTg1OTg_092e2e1f-a390-4e6d-9fbf-7db826b7f9bb"
      unitRef="usd">43000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMTUtMS0xLTEtNTg1OTg_bcb94629-19ed-4e06-916d-4842e2de15ed"
      unitRef="usd">251000000</us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities>
    <us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMTUtMy0xLTEtNTg1OTg_650c8d06-8a8d-45d2-8d5d-13ffb5dc83a0"
      unitRef="usd">522000000</us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities>
    <moh:IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMTYtMS0xLTEtNTg1OTg_ed65c270-628a-432b-9528-81940c776f0a"
      unitRef="usd">-360000000</moh:IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency>
    <moh:IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMTYtMy0xLTEtNTg1OTg_d4f32448-c9fe-4871-9820-6b2423fed81f"
      unitRef="usd">810000000</moh:IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMTctMS0xLTEtNTg1OTg_5491d1bb-4170-468a-802c-0ba7313d1b84"
      unitRef="usd">-40000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMTctMy0xLTEtNTg1OTg_ee0fc6da-0da2-443d-87fb-98f1dfc0a9d0"
      unitRef="usd">129000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMTgtMS0xLTEtNTg1OTg_e413b4cd-929d-4b8c-aca5-f835a19a68ff"
      unitRef="usd">293000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMTgtMy0xLTEtNTg1OTg_7b9c24ed-e785-42f5-a33e-34d9f2f04f45"
      unitRef="usd">-374000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMTktMS0xLTEtNTg1OTg_a0a85b2d-8512-4204-ace5-715c303fd119"
      unitRef="usd">59000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMTktMy0xLTEtNTg1OTg_b3360e27-2e42-427a-aa12-e23013c65472"
      unitRef="usd">23000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMjAtMS0xLTEtNTg1OTg_39cb71db-5c11-458a-ab65-87c00507334c"
      unitRef="usd">985000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMjAtMy0xLTEtNTg1OTg_8225a273-8565-44ba-afd6-7894bb4d0ac8"
      unitRef="usd">1522000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMjItMS0xLTEtNTg1OTg_af6abf22-81cb-447e-947e-f56d42e8f0e8"
      unitRef="usd">1764000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMjItMy0xLTEtNTg1OTg_880ca2dc-2ebb-4079-9845-c2ea80bfec25"
      unitRef="usd">2018000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMjMtMS0xLTEtNTg1OTg_c84fd284-333d-4312-b58c-3e11b4e329b3"
      unitRef="usd">1082000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMjMtMy0xLTEtNTg1OTg_3b225a13-d89e-436d-9b4f-8d438255aa60"
      unitRef="usd">965000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMjQtMS0xLTEtNjYwNTM_b6cb9ff8-75c2-4b54-bb77-30574610ea01"
      unitRef="usd">134000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMjQtMy0xLTEtNjYwNTM_dec9cf35-becf-4d70-b3c8-da5deab89b21"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMjQtMS0xLTEtNTg1OTg_369b02ad-3fe3-4e36-ab54-b5e3bbd2b977"
      unitRef="usd">81000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMjQtMy0xLTEtNTg1OTg_e4a1bd88-be3b-44e8-af8f-e91239c53244"
      unitRef="usd">56000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMjYtMS0xLTEtNTg1OTg_1f511b1d-0a31-403a-bfb4-8f535fbae6f4"
      unitRef="usd">41000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMjYtMy0xLTEtNTg1OTg_46f6b141-a5b7-4ee9-b728-9f12d757b5ff"
      unitRef="usd">-3000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMjctMS0xLTEtNTg1OTg_e66d25b0-25d6-4e1e-88ea-55831912876f"
      unitRef="usd">-938000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMjctMy0xLTEtNTg1OTg_dfb42f3c-15ce-4e1f-b029-c4132c1587e1"
      unitRef="usd">-1106000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMjktMS0xLTEtNTg1OTg_42801f37-360b-4f1f-99cc-54f7fb834c10"
      unitRef="usd">200000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMjktMy0xLTEtNTg1OTg_922a6ce9-64f8-4bc5-91d9-46606f40d09c"
      unitRef="usd">128000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <moh:CommonStockWithheldToSettleEmployeeTaxObligations
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMzAtMS0xLTEtNTg1OTg_5a046d87-1a2e-4df1-a7b0-c43f26f805ed"
      unitRef="usd">53000000</moh:CommonStockWithheldToSettleEmployeeTaxObligations>
    <moh:CommonStockWithheldToSettleEmployeeTaxObligations
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMzAtMy0xLTEtNTg1OTg_d4b3dfbe-37e4-4dc2-b8c5-2fb822e0b468"
      unitRef="usd">52000000</moh:CommonStockWithheldToSettleEmployeeTaxObligations>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMzEtMS0xLTEtNTg1OTg_19be52cc-3787-40f4-8939-e31a16b20bbc"
      unitRef="usd">20000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfMzEtMy0xLTEtNTg1OTg_44a1e1ea-75d7-435d-9fb4-5b31791bdeb7"
      unitRef="usd">20000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfNDAtMS0xLTEtNTg1OTg_b9d4c7d3-863a-4bd9-9cdd-f6991f344329"
      unitRef="usd">15000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfNDAtMy0xLTEtNTg1OTg_ee8807b9-47b2-4ea2-95f2-552943b9712f"
      unitRef="usd">-4000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfNDEtMS0xLTEtNTg1OTg_7ee7fc71-5156-4607-9a79-85db36060c90"
      unitRef="usd">-258000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfNDEtMy0xLTEtNTg1OTg_5b7972c9-b5bd-4866-8d8d-8696645070f3"
      unitRef="usd">-204000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfNDItMS0xLTEtNTg1OTg_934f5e6f-3da4-40f7-87b7-f49ce55981ec"
      unitRef="usd">-211000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfNDItMy0xLTEtNTg1OTg_0986602b-9d75-4694-a492-cc17519ceb52"
      unitRef="usd">212000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfNDMtMS0xLTEtNTg1OTg_2f0edff4-6e8c-4657-beb2-498a2e42370e"
      unitRef="usd">4506000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2a1055b0f36c4bbd91048d943dbf64df_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfNDMtMy0xLTEtNTg1OTg_54e61240-4d82-4309-aa44-1dc0401d5dcc"
      unitRef="usd">4223000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfNDQtMS0xLTEtNTg1OTg_143a70e1-9397-4ab9-811e-ef8961f55368"
      unitRef="usd">4295000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia5f8e83b346f4a789040e8611fbb11f6_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8yMi9mcmFnOjViNDliZWRjYjlmYTQ1MjQ5YzY2ODRjYjU4ZTFiZTU5L3RhYmxlOjcxNjQyNzhjNjJkNDQwNDhiNzE1NTA3YzM3NTM0ZjI1L3RhYmxlcmFuZ2U6NzE2NDI3OGM2MmQ0NDA0OGI3MTU1MDdjMzc1MzRmMjVfNDQtMy0xLTEtNTg1OTg_3042155d-5853-4457-a835-6a4523238fe9"
      unitRef="usd">4435000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfNTI1MA_8bd2f901-37d7-4500-96fd-b7ce391cfc93">Organization and Basis of Presentation &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Organization and Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Molina Healthcare, Inc. provides managed healthcare services under the Medicaid and Medicare programs, and through the state insurance marketplaces (the &#x201c;Marketplace&#x201d;). We currently have four reportable segments consisting of: 1)&#160;Medicaid; 2)&#160;Medicare; 3)&#160;Marketplace; and 4)&#160;Other. Our reportable segments are consistent with how we currently manage the business and view the markets we serve. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, we served approximately 5.2&#160;million members eligible for government-sponsored healthcare programs, located across 19 states.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our state Medicaid contracts typically have terms of&#160;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfNjE0_de89890f-e645-4a35-a3a8-f77327830d82"&gt;three&lt;/span&gt;&#160;to&#160;five years, contain renewal options exercisable by the state Medicaid agency, and allow either the state or the health plan to terminate the contract with or without cause. Such contracts are subject to risk of loss in states that issue requests for proposal (&#x201c;RFPs&#x201d;) open to competitive bidding by other health plans. If one of our health plans is not a successful responsive bidder to a state RFP, its contract may not be renewed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to contract renewal, our state Medicaid contracts may be periodically amended to include or exclude certain health benefits (such as pharmacy services, behavioral health services, or long-term care services); populations such as the aged, blind or disabled (&#x201c;ABD&#x201d;); and regions or service areas.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Developments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New York Acquisition&#x2014;Medicaid. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 1, 2022, we closed on our acquisition of the Medicaid Managed Long Term Care business of AgeWell New York. See Note 4, &#x201c;Business Combinations,&#x201d; for further information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Nebraska Procurement&#x2014;Medicaid.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In September 2022, we announced that our Nebraska health plan had been selected by the Nebraska Department of Health and Human Services (DHHS) to provide health care services to Nebraskans under the state&#x2019;s Medicaid managed care program. The new five-year contract is expected to begin on January 1, 2024, and may be extended for an additional two-years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Iowa Procurement&#x2014;Medicaid. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, we announced that our Iowa health plan had been notified by the Iowa Department of Health and Human Services (HHS) of its intent to award a Medicaid managed care contract pursuant to the Request for Proposal issued by HHS on February 17, 2022. The new four-year contract is expected to begin on July 1, 2023, and may be extended for an additional four years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;California Procurement&#x2014;Medicaid. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, we announced that our California health plan had been notified by the California Department of Health Care Services of its intent to award a Medi-Cal contract in each of Los Angeles, Riverside, San Bernardino, Sacramento, and San Diego Counties. The  five Medi-Cal contracts are expected to commence on January 1, 2024, which enables us to continue serving Medi-Cal members in our existing counties and expand footprint with the addition of the Los Angeles County contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Mississippi Procurement&#x2014;Medicaid. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, we announced that our Mississippi health plan had been notified by the Mississippi Division of Medicaid (DOM) of its intent to award a Medicaid Coordinated Care Contract for its Mississippi Coordinated Access Program and Mississippi Children&#x2019;s Health Insurance Program pursuant to the Request for Qualifications issued by DOM on December 10, 2021. The &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfMTA5OTUxMTY0MjE5OA_6c2d1c0d-cdab-4160-9874-52b55f757a29"&gt;four&lt;/span&gt;-year contract is expected to begin on July 1, 2023, and may be extended for an additional two years. The award enables us to continue serving Medicaid members across the state. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Wisconsin Acquisition &#x2014; Medicaid and Medicare. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 13, 2022, we announced a definitive agreement to acquire substantially all the assets of My Choice Wisconsin (&#x201c;MCW&#x201d;).  The purchase price for the transaction is approximately $150&#160;million, net of expected tax benefits and required regulatory capital, which we intend to fund with cash on hand. The transaction is subject to receipt of applicable federal and state regulatory approvals, and the satisfaction of other customary closing conditions. We currently expect the transaction to close in early 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Texas Procurement&#x2014;Medicaid. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, the Texas Health and Human Services Commission posted the ABD program (known in Texas as STAR+PLUS) RFP. We submitted our proposal in June 2022 to continue serving STAR+PLUS members, with awards estimated to be announced in the first quarter of 2023, and start of operations in February 2024. Further, in October 2022, the draft RFP was posted for the TANF and CHIP programs (known as &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the STAR &amp;amp; CHIP programs, and both existing contracts for us), with awards expected in late Q4 2023 or early Q1 2024 and the start of operations in late Q4 2024 or early Q1 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Nevada Procurement&#x2014;Medicaid.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Our new contract in Clark and Washoe Counties commenced on January 1, 2022, and offers health coverage to TANF, CHIP and Medicaid Expansion beneficiaries. This new contract is four years  with a potential two-year extension.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Texas Acquisition&#x2014;Medicaid and Medicare. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2022, we closed on our acquisition of Cigna Corporation&#x2019;s Texas Medicaid and Medicare-Medicaid Plan (&#x201c;MMP&#x201d;) contracts, along with certain operating assets. See Note 4, &#x201c;Business Combinations,&#x201d; for further information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidation and Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Molina Healthcare, Inc., and its subsidiaries. In the opinion of management, these financial statements reflect all normal recurring adjustments, which are considered necessary for a fair presentation of the results as of the dates and for the interim periods presented. All significant intercompany balances and transactions have been eliminated. The consolidated results of operations for the nine months ended September 30, 2022 are not necessarily indicative of the results for the entire year ending December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited consolidated interim financial statements have been prepared under the assumption that users of the interim financial data have either read or have access to our audited consolidated financial statements for the fiscal year ended December&#160;31, 2021. Accordingly, certain disclosures that would substantially duplicate the disclosures contained in our December&#160;31, 2021, audited consolidated financial statements have been omitted. These unaudited consolidated interim financial statements should be read in conjunction with our audited consolidated financial statements for the fiscal year ended December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfMjI4_6925dc79-7402-4807-b44c-808fb9018835"
      unitRef="segment">4</us-gaap:NumberOfReportableSegments>
    <moh:BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms
      contextRef="i8ed85c9690854763a35bee8fec51d9ff_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfNDY5_a264da09-3ad3-4a4b-871b-9f15f38033b6"
      unitRef="member">5200000</moh:BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms>
    <moh:NumberOfStatesWithGovernmentSponsoredHealthcarePrograms
      contextRef="i8ed85c9690854763a35bee8fec51d9ff_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfNTUw_5d155a2a-1e13-4490-9240-2bddd7711819"
      unitRef="state">19</moh:NumberOfStatesWithGovernmentSponsoredHealthcarePrograms>
    <moh:HealthPlanContractTerm
      contextRef="i7577c1358178462db84325596d1c3ae1_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfNjIw_0f5daf5a-7f8a-465b-96ab-8cfb8ae02c55">P5Y</moh:HealthPlanContractTerm>
    <moh:HealthPlanContractTerm
      contextRef="i64ed765381cb451194df42962e56b1f0_D20220901-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfMTA5OTUxMTYzNjc3NQ_d63a53a8-319f-4ace-a0c9-23f463ea794e">P5Y</moh:HealthPlanContractTerm>
    <moh:HealthPlanExtensionOptionPeriod
      contextRef="i64ed765381cb451194df42962e56b1f0_D20220901-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfMTA5OTUxMTY0MTE2NQ_2bc7e775-d872-4cf7-b2ef-f9983674bbb6">P2Y</moh:HealthPlanExtensionOptionPeriod>
    <moh:HealthPlanContractTerm
      contextRef="ic4564dde8b7249e29348178f0f8c6242_D20220801-20220831"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfMTA5OTUxMTYzNjIzNQ_4005a6de-5d16-4cb2-adae-bc02c38d062e">P4Y</moh:HealthPlanContractTerm>
    <moh:HealthPlanExtensionOptionPeriod
      contextRef="ic4564dde8b7249e29348178f0f8c6242_D20220801-20220831"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfMTA5OTUxMTYzNjIzNg_648e4286-3e04-40e9-92bf-f953d06c4d8c">P4Y</moh:HealthPlanExtensionOptionPeriod>
    <moh:HealthPlanNumberOfContracts
      contextRef="i2a0dfc53f05140aba2d6a2c5d9aaf8ed_I20220831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfMTA5OTUxMTY0MjExMA_e8ae8c6c-c010-4760-87e1-51fb47cc45b5"
      unitRef="contract">5</moh:HealthPlanNumberOfContracts>
    <moh:HealthPlanExtensionOptionPeriod
      contextRef="i832dd038bfde4b259f4caf8354280d4d_D20220801-20220831"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfMTA5OTUxMTY0MTY4OA_789a53a6-8f38-4991-bbd1-07c82183c7d9">P2Y</moh:HealthPlanExtensionOptionPeriod>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i88592161984e4e54bea14bf302d598e3_D20220713-20220713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfMTE3NDI_649e0023-5e81-4232-93e8-e738bf90b152"
      unitRef="usd">150000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <moh:HealthPlanContractTerm
      contextRef="i80a687f2f90f401b9e47d7da8ba17754_D20210901-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfNTI2OA_d4e70471-5698-4903-8f3f-963bec46dbe7">P4Y</moh:HealthPlanContractTerm>
    <moh:HealthPlanExtensionOptionPeriod
      contextRef="i80a687f2f90f401b9e47d7da8ba17754_D20210901-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfNTI4NA_f2f9e63d-8625-420b-bbe0-5efceee040bc">P2Y</moh:HealthPlanExtensionOptionPeriod>
    <moh:ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfNTI1NA_2be90a50-8b90-49de-bce0-9665d1537e51">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidation and Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Molina Healthcare, Inc., and its subsidiaries. In the opinion of management, these financial statements reflect all normal recurring adjustments, which are considered necessary for a fair presentation of the results as of the dates and for the interim periods presented. All significant intercompany balances and transactions have been eliminated. The consolidated results of operations for the nine months ended September 30, 2022 are not necessarily indicative of the results for the entire year ending December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;The unaudited consolidated interim financial statements have been prepared under the assumption that users of the interim financial data have either read or have access to our audited consolidated financial statements for the fiscal year ended December&#160;31, 2021. Accordingly, certain disclosures that would substantially duplicate the disclosures contained in our December&#160;31, 2021, audited consolidated financial statements have been omitted. These unaudited consolidated interim financial statements should be read in conjunction with our audited consolidated financial statements for the fiscal year ended December&#160;31, 2021.</moh:ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zMS9mcmFnOmJjMTM1YTVlMzNjNzQ4Yzc5OGUyYTk0MDI5OTA3NDEyL3RleHRyZWdpb246YmMxMzVhNWUzM2M3NDhjNzk4ZTJhOTQwMjk5MDc0MTJfNTI1NQ_feb55c4e-8f1c-42e0-9d2e-f380bf0ef31a">Use of EstimatesThe preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</us-gaap:UseOfEstimates>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfNzc2MQ_d4811468-b22e-4fb5-9108-b0e84d366839">Significant Accounting Policies &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of cash and short-term, highly liquid investments that are both readily convertible into known amounts of cash and have a maturity of three months or less on the date of purchase. The following table provides a reconciliation of cash and cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in &#x201c;Restricted investments&#x201d; in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Receivables&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables consist primarily of premium amounts due from government agencies, which are subject to potential retroactive adjustments. Because substantially all of our receivable amounts are readily determinable and substantially all of our creditors are governmental authorities, our allowance for credit losses is insignificant. Any amounts determined to be uncollectible are charged to expense when such determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmacy rebate receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Premium Revenue Recognition and Amounts Due Government Agencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Premium revenue is generated from our contracts with state and federal agencies, in connection with our participation in the Medicaid, Medicare, and Marketplace programs. Premium revenue is generally received based on per member per month (&#x201c;PMPM&#x201d;) rates established in advance of the periods covered. These premium revenues are recognized in the month that members are entitled to receive healthcare services, and premiums collected in advance are deferred. State Medicaid programs and the federal Medicare program periodically adjust premium rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain components of premium revenue are subject to accounting estimates and are described in further detail below, and in our 2021 Annual Report on Form 10-K, Note 2, &#x201c;Significant Accounting Policies,&#x201d; under &#x201c;Contractual Provisions That May Adjust or Limit Revenue or Profit,&#x201d; and &#x201c;Quality Incentives.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual Provisions That May Adjust or Limit Revenue or Profit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Many of our contracts contain provisions that may adjust or limit revenue or profit, as described below. Consequently, we recognize premium revenue as it is earned under such provisions. Liabilities accrued for premiums to be returned under such provisions are reported in the aggregate as &#x201c;Amounts due government agencies,&#x201d; in the accompanying consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth amounts due government agencies, categorized by program:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicaid program:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Minimum MLR and profit sharing&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicare program:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Minimum MLR and profit sharing &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk adjustment and Part D risk sharing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketplace program:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Minimum MLR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total amounts due government agencies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Medicaid Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Minimum MLR and Retroactive Premium Adjustments. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State Medicaid programs periodically adjust premium rates on a retroactive basis. In these cases, we adjust our premium revenue in the period in which we determine that the adjustment is probable and reasonably estimable, based on our best estimate of the ultimate premium we expect to realize for the period being adjusted. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in 2020, various states enacted temporary risk corridors in response to the reduced demand for medical services stemming from COVID-1&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which have resulted in a reduction of our medical margin. In some cases, these risk corridors were retroactive to earlier periods in 2020, or as early as the beginning of the states&#x2019; fiscal years in 2019. Since the second quarter of 2020, we have recognized risk corridors that we believe to be probable, and where the ultimate premium amount is reasonably estimable. For the three and nine months ended September 30, 2022, we recognized approximately $34&#160;million and $156&#160;million, respectively, related to such risk corridors, primarily in the Medicaid segment, compared to $17&#160;million and $183&#160;million, respectively, recognized in the three and nine months ended September&#160;30, 2021. The decrease is due to the elimination of several of the COVID-19 risk corridors. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is possible that certain states could change the structure of existing risk corridors, implement new risk corridors in the future or discontinue existing risk corridors. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Marketplace Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk Adjustment.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Under this program, our health plans&#x2019; composite risk scores are compared with the overall average risk score for the relevant state and market pool. Generally, our health plans will make a risk adjustment payment into the pool if their composite risk scores are below the average risk score (risk adjustment payable), and will receive a risk adjustment payment from the pool if their composite risk scores are above the average risk score (risk adjustment receivable). We estimate our ultimate premium based on insurance policy year-to-date experience, and recognize estimated premiums relating to the risk adjustment program as an adjustment to premium revenue in our consolidated statements of income. As of September&#160;30, 2022, Marketplace risk adjustment payables amounted to $179 million and related receivables amounted to $94 million, for a net payable of $85 million. As of December&#160;31, 2021, Marketplace risk adjustment payables amounted to $902 million and related receivables amounted to $7 million, for a net payable of $895 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than 15 years, or less than 15 years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents, and U.S. Treasury securities. Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and governments of each state in which our health plan subsidiaries operate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes is determined using an estimated annual effective tax rate, which generally differs from the U.S.&#160;federal statutory rate primarily because of foreign and state taxes, and nondeductible expenses such as certain compensation and other general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective tax rate may be subject to fluctuations during the year as new information is obtained. Such information may affect the assumptions used to estimate the annual effective tax rate, including projected pretax earnings, the mix of pretax earnings in the various tax jurisdictions in which we operate, valuation allowances against deferred tax assets, the recognition or the reversal of the recognition of tax benefits related to uncertain tax positions, and changes in or the interpretation of tax laws in jurisdictions where we conduct business. We recognize deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of our assets and liabilities, along with net operating loss and tax credit carryovers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (&#x201c;SEC&#x201d;) did not have, nor does management expect such pronouncements to have, a significant impact on our present or future consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfNzc0MQ_264c0bf0-b099-4111-b7d6-c34139d217d2">Cash and Cash EquivalentsCash and cash equivalents consist of cash and short-term, highly liquid investments that are both readily convertible into known amounts of cash and have a maturity of three months or less on the date of purchase.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfNzc0Mg_cccec8d4-095d-494b-93a4-7028eec4bc1c">The following table provides a reconciliation of cash and cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in &#x201c;Restricted investments&#x201d; in the accompanying consolidated balance sheets.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfNzc2Mg_b570197c-9cb3-4928-b701-ff50542d1e0d">The following table provides a reconciliation of cash and cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in &#x201c;Restricted investments&#x201d; in the accompanying consolidated balance sheets.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOjlhNTU2MGUxZDZiZjRlYTk5ZTIzMjA3ZTdiNjMyMWVjL3RhYmxlcmFuZ2U6OWE1NTYwZTFkNmJmNGVhOTllMjMyMDdlN2I2MzIxZWNfNC0xLTEtMS01ODU5OA_b1020bfe-1e6c-472c-8408-ddaa469a3829"
      unitRef="usd">4242000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia5f8e83b346f4a789040e8611fbb11f6_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOjlhNTU2MGUxZDZiZjRlYTk5ZTIzMjA3ZTdiNjMyMWVjL3RhYmxlcmFuZ2U6OWE1NTYwZTFkNmJmNGVhOTllMjMyMDdlN2I2MzIxZWNfNC0zLTEtMS01ODU5OA_68442557-0262-4487-9293-a1edd28eb3df"
      unitRef="usd">4357000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOjlhNTU2MGUxZDZiZjRlYTk5ZTIzMjA3ZTdiNjMyMWVjL3RhYmxlcmFuZ2U6OWE1NTYwZTFkNmJmNGVhOTllMjMyMDdlN2I2MzIxZWNfNS0xLTEtMS01ODU5OA_18658ee0-47a6-40e5-9483-455e4e8cd955"
      unitRef="usd">53000000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ia5f8e83b346f4a789040e8611fbb11f6_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOjlhNTU2MGUxZDZiZjRlYTk5ZTIzMjA3ZTdiNjMyMWVjL3RhYmxlcmFuZ2U6OWE1NTYwZTFkNmJmNGVhOTllMjMyMDdlN2I2MzIxZWNfNS0zLTEtMS01ODU5OA_b5af287c-a0be-4bc0-a181-9ae1fda646f3"
      unitRef="usd">78000000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOjlhNTU2MGUxZDZiZjRlYTk5ZTIzMjA3ZTdiNjMyMWVjL3RhYmxlcmFuZ2U6OWE1NTYwZTFkNmJmNGVhOTllMjMyMDdlN2I2MzIxZWNfNi0xLTEtMS01ODU5OA_1a95315e-0f14-4870-b3cf-a1ec41e41345"
      unitRef="usd">4295000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia5f8e83b346f4a789040e8611fbb11f6_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOjlhNTU2MGUxZDZiZjRlYTk5ZTIzMjA3ZTdiNjMyMWVjL3RhYmxlcmFuZ2U6OWE1NTYwZTFkNmJmNGVhOTllMjMyMDdlN2I2MzIxZWNfNi0zLTEtMS01ODU5OA_1a322e8f-9f87-40ba-9399-93a5dd380a18"
      unitRef="usd">4435000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfNzc2Mw_3f124e26-ec8b-4bcc-b266-76ee170c719f">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Receivables&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables consist primarily of premium amounts due from government agencies, which are subject to potential retroactive adjustments. Because substantially all of our receivable amounts are readily determinable and substantially all of our creditors are governmental authorities, our allowance for credit losses is insignificant. Any amounts determined to be uncollectible are charged to expense when such determination is made.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfNzc4NA_bbaf92c5-f3e5-4b7b-b086-c257ae60a1fb">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmacy rebate receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ia4a4422c70fb4ddfa9b1095fc58b9f0e_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOjZiOGUxN2Q3MmJiYjRjODRiMzM1ZTNkNzMzMGQzMmY4L3RhYmxlcmFuZ2U6NmI4ZTE3ZDcyYmJiNGM4NGIzMzVlM2Q3MzMwZDMyZjhfMy0xLTEtMS01ODU5OA_de78910f-6309-477a-9fc2-56f8b294d90c"
      unitRef="usd">1545000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="id1cd70f1c470416e9209148ce673af71_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOjZiOGUxN2Q3MmJiYjRjODRiMzM1ZTNkNzMzMGQzMmY4L3RhYmxlcmFuZ2U6NmI4ZTE3ZDcyYmJiNGM4NGIzMzVlM2Q3MzMwZDMyZjhfMy0zLTEtMS01ODU5OA_7bfeec8b-154e-4271-9d85-e6148c1ffca2"
      unitRef="usd">1566000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ib597d981d44b40f195e0cdd71848ddf5_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOjZiOGUxN2Q3MmJiYjRjODRiMzM1ZTNkNzMzMGQzMmY4L3RhYmxlcmFuZ2U6NmI4ZTE3ZDcyYmJiNGM4NGIzMzVlM2Q3MzMwZDMyZjhfNC0xLTEtMS01ODU5OA_e7580b01-7e44-4035-9251-e1467d419592"
      unitRef="usd">290000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i8343c8068f1a4df093d799fc8ff37927_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOjZiOGUxN2Q3MmJiYjRjODRiMzM1ZTNkNzMzMGQzMmY4L3RhYmxlcmFuZ2U6NmI4ZTE3ZDcyYmJiNGM4NGIzMzVlM2Q3MzMwZDMyZjhfNC0zLTEtMS01ODU5OA_3482f884-7a15-4c83-8f3c-df6be9de1f34"
      unitRef="usd">276000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i0dbb6f52c8d941e5b0f25c3d3e677cda_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOjZiOGUxN2Q3MmJiYjRjODRiMzM1ZTNkNzMzMGQzMmY4L3RhYmxlcmFuZ2U6NmI4ZTE3ZDcyYmJiNGM4NGIzMzVlM2Q3MzMwZDMyZjhfNi0xLTEtMS01ODU5OA_88383034-2479-4aa1-a17c-080618c2f4dc"
      unitRef="usd">385000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="id139c6fc382249198e7f8ea8f0212f81_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOjZiOGUxN2Q3MmJiYjRjODRiMzM1ZTNkNzMzMGQzMmY4L3RhYmxlcmFuZ2U6NmI4ZTE3ZDcyYmJiNGM4NGIzMzVlM2Q3MzMwZDMyZjhfNi0zLTEtMS01ODU5OA_5c002712-e50a-41fa-9e5a-0bbc80befbe7"
      unitRef="usd">335000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOjZiOGUxN2Q3MmJiYjRjODRiMzM1ZTNkNzMzMGQzMmY4L3RhYmxlcmFuZ2U6NmI4ZTE3ZDcyYmJiNGM4NGIzMzVlM2Q3MzMwZDMyZjhfOC0xLTEtMS01ODU5OA_5c06d05a-6b8b-4a8a-9954-ef22435e079d"
      unitRef="usd">2220000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOjZiOGUxN2Q3MmJiYjRjODRiMzM1ZTNkNzMzMGQzMmY4L3RhYmxlcmFuZ2U6NmI4ZTE3ZDcyYmJiNGM4NGIzMzVlM2Q3MzMwZDMyZjhfOC0zLTEtMS01ODU5OA_62a4967c-2bb8-4a31-99da-f365079a0fb1"
      unitRef="usd">2177000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfNzc1OA_ea21a237-9a77-4941-979e-9a42141c7e0c">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Premium Revenue Recognition and Amounts Due Government Agencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Premium revenue is generated from our contracts with state and federal agencies, in connection with our participation in the Medicaid, Medicare, and Marketplace programs. Premium revenue is generally received based on per member per month (&#x201c;PMPM&#x201d;) rates established in advance of the periods covered. These premium revenues are recognized in the month that members are entitled to receive healthcare services, and premiums collected in advance are deferred. State Medicaid programs and the federal Medicare program periodically adjust premium rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain components of premium revenue are subject to accounting estimates and are described in further detail below, and in our 2021 Annual Report on Form 10-K, Note 2, &#x201c;Significant Accounting Policies,&#x201d; under &#x201c;Contractual Provisions That May Adjust or Limit Revenue or Profit,&#x201d; and &#x201c;Quality Incentives.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual Provisions That May Adjust or Limit Revenue or Profit&lt;/span&gt;&lt;/div&gt;Many of our contracts contain provisions that may adjust or limit revenue or profit, as described below. Consequently, we recognize premium revenue as it is earned under such provisions.&lt;div style="margin-bottom:6pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Medicaid Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Minimum MLR and Retroactive Premium Adjustments. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State Medicaid programs periodically adjust premium rates on a retroactive basis. In these cases, we adjust our premium revenue in the period in which we determine that the adjustment is probable and reasonably estimable, based on our best estimate of the ultimate premium we expect to realize for the period being adjusted. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in 2020, various states enacted temporary risk corridors in response to the reduced demand for medical services stemming from COVID-1&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which have resulted in a reduction of our medical margin. In some cases, these risk corridors were retroactive to earlier periods in 2020, or as early as the beginning of the states&#x2019; fiscal years in 2019. Since the second quarter of 2020, we have recognized risk corridors that we believe to be probable, and where the ultimate premium amount is reasonably estimable. For the three and nine months ended September 30, 2022, we recognized approximately $34&#160;million and $156&#160;million, respectively, related to such risk corridors, primarily in the Medicaid segment, compared to $17&#160;million and $183&#160;million, respectively, recognized in the three and nine months ended September&#160;30, 2021. The decrease is due to the elimination of several of the COVID-19 risk corridors. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is possible that certain states could change the structure of existing risk corridors, implement new risk corridors in the future or discontinue existing risk corridors. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Marketplace Program&lt;/span&gt;&lt;/div&gt;Risk Adjustment. Under this program, our health plans&#x2019; composite risk scores are compared with the overall average risk score for the relevant state and market pool. Generally, our health plans will make a risk adjustment payment into the pool if their composite risk scores are below the average risk score (risk adjustment payable), and will receive a risk adjustment payment from the pool if their composite risk scores are above the average risk score (risk adjustment receivable). We estimate our ultimate premium based on insurance policy year-to-date experience, and recognize estimated premiums relating to the risk adjustment program as an adjustment to premium revenue in our consolidated statements of income.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ReservesReportedToOtherAgenciesTextBlock
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfNzc3Ng_3d5938f1-559b-412a-85a8-d3eb4e85e455">Liabilities accrued for premiums to be returned under such provisions are reported in the aggregate as &#x201c;Amounts due government agencies,&#x201d; in the accompanying consolidated balance sheets. &lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth amounts due government agencies, categorized by program:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicaid program:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Minimum MLR and profit sharing&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicare program:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Minimum MLR and profit sharing &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk adjustment and Part D risk sharing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketplace program:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Minimum MLR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total amounts due government agencies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReservesReportedToOtherAgenciesTextBlock>
    <moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOmU3MzQwNTc1OTUzNTQ3OGRiZWQ5M2E1YzlkNDIwMWNhL3RhYmxlcmFuZ2U6ZTczNDA1NzU5NTM1NDc4ZGJlZDkzYTVjOWQ0MjAxY2FfNC0xLTEtMS01ODU5OA_56b222a6-152a-4f5c-8497-45210a293d33"
      unitRef="usd">1091000000</moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold>
    <moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOmU3MzQwNTc1OTUzNTQ3OGRiZWQ5M2E1YzlkNDIwMWNhL3RhYmxlcmFuZ2U6ZTczNDA1NzU5NTM1NDc4ZGJlZDkzYTVjOWQ0MjAxY2FfNC0zLTEtMS01ODU5OA_754486af-9c5f-4296-9768-1c205929f142"
      unitRef="usd">1016000000</moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold>
    <moh:AmountsDueToGovernmentAgenciesMedicaidOther
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOmU3MzQwNTc1OTUzNTQ3OGRiZWQ5M2E1YzlkNDIwMWNhL3RhYmxlcmFuZ2U6ZTczNDA1NzU5NTM1NDc4ZGJlZDkzYTVjOWQ0MjAxY2FfNS0xLTEtMS01ODU5OA_12ed3215-bd34-4870-9738-c5a9c5233b0e"
      unitRef="usd">617000000</moh:AmountsDueToGovernmentAgenciesMedicaidOther>
    <moh:AmountsDueToGovernmentAgenciesMedicaidOther
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOmU3MzQwNTc1OTUzNTQ3OGRiZWQ5M2E1YzlkNDIwMWNhL3RhYmxlcmFuZ2U6ZTczNDA1NzU5NTM1NDc4ZGJlZDkzYTVjOWQ0MjAxY2FfNS0zLTEtMS01ODU5OA_c8d12000-7c21-479d-8a00-067652495d41"
      unitRef="usd">263000000</moh:AmountsDueToGovernmentAgenciesMedicaidOther>
    <moh:AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOmU3MzQwNTc1OTUzNTQ3OGRiZWQ5M2E1YzlkNDIwMWNhL3RhYmxlcmFuZ2U6ZTczNDA1NzU5NTM1NDc4ZGJlZDkzYTVjOWQ0MjAxY2FfNy0xLTEtMS02ODE4OA_2f03b235-b3e2-416f-8614-9d4f6aa87580"
      unitRef="usd">100000000</moh:AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold>
    <moh:AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOmU3MzQwNTc1OTUzNTQ3OGRiZWQ5M2E1YzlkNDIwMWNhL3RhYmxlcmFuZ2U6ZTczNDA1NzU5NTM1NDc4ZGJlZDkzYTVjOWQ0MjAxY2FfNy0zLTEtMS02ODE4OA_26595bbf-2e08-43fd-a81b-df15c3e9d58e"
      unitRef="usd">101000000</moh:AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold>
    <moh:AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOmU3MzQwNTc1OTUzNTQ3OGRiZWQ5M2E1YzlkNDIwMWNhL3RhYmxlcmFuZ2U6ZTczNDA1NzU5NTM1NDc4ZGJlZDkzYTVjOWQ0MjAxY2FfNy0xLTEtMS01ODU5OA_34105bd1-9a9e-4921-8c9a-e97a8f11933c"
      unitRef="usd">74000000</moh:AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing>
    <moh:AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOmU3MzQwNTc1OTUzNTQ3OGRiZWQ5M2E1YzlkNDIwMWNhL3RhYmxlcmFuZ2U6ZTczNDA1NzU5NTM1NDc4ZGJlZDkzYTVjOWQ0MjAxY2FfNy0zLTEtMS01ODU5OA_5589b0c9-8003-45b8-a6cb-98838a9727ba"
      unitRef="usd">89000000</moh:AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing>
    <moh:OtherMedicareProgram
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOmU3MzQwNTc1OTUzNTQ3OGRiZWQ5M2E1YzlkNDIwMWNhL3RhYmxlcmFuZ2U6ZTczNDA1NzU5NTM1NDc4ZGJlZDkzYTVjOWQ0MjAxY2FfOS0xLTEtMS01ODU5OA_4cb1aa2a-3416-460a-a412-cc653ec9eb10"
      unitRef="usd">23000000</moh:OtherMedicareProgram>
    <moh:OtherMedicareProgram
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOmU3MzQwNTc1OTUzNTQ3OGRiZWQ5M2E1YzlkNDIwMWNhL3RhYmxlcmFuZ2U6ZTczNDA1NzU5NTM1NDc4ZGJlZDkzYTVjOWQ0MjAxY2FfOS0zLTEtMS01ODU5OA_5a0c1469-68e4-4dcb-b06b-a36e56d61603"
      unitRef="usd">35000000</moh:OtherMedicareProgram>
    <moh:AmountsDuetoGovernmentAgenciesRiskAdjustment
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOmU3MzQwNTc1OTUzNTQ3OGRiZWQ5M2E1YzlkNDIwMWNhL3RhYmxlcmFuZ2U6ZTczNDA1NzU5NTM1NDc4ZGJlZDkzYTVjOWQ0MjAxY2FfMTEtMS0xLTEtNTg1OTg_7a495592-2a75-4802-a110-962f8a4e802e"
      unitRef="usd">179000000</moh:AmountsDuetoGovernmentAgenciesRiskAdjustment>
    <moh:AmountsDuetoGovernmentAgenciesRiskAdjustment
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOmU3MzQwNTc1OTUzNTQ3OGRiZWQ5M2E1YzlkNDIwMWNhL3RhYmxlcmFuZ2U6ZTczNDA1NzU5NTM1NDc4ZGJlZDkzYTVjOWQ0MjAxY2FfMTEtMy0xLTEtNTg1OTg_512b15d8-5061-4a92-869e-23b27d798263"
      unitRef="usd">902000000</moh:AmountsDuetoGovernmentAgenciesRiskAdjustment>
    <moh:AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOmU3MzQwNTc1OTUzNTQ3OGRiZWQ5M2E1YzlkNDIwMWNhL3RhYmxlcmFuZ2U6ZTczNDA1NzU5NTM1NDc4ZGJlZDkzYTVjOWQ0MjAxY2FfMTItMS0xLTEtNTg1OTg_ab665e50-a125-4434-b795-3121214f4b81"
      unitRef="usd">4000000</moh:AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold>
    <moh:AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOmU3MzQwNTc1OTUzNTQ3OGRiZWQ5M2E1YzlkNDIwMWNhL3RhYmxlcmFuZ2U6ZTczNDA1NzU5NTM1NDc4ZGJlZDkzYTVjOWQ0MjAxY2FfMTItMy0xLTEtNTg1OTg_55d9b41c-1c3c-4f93-8c5a-947486db51ce"
      unitRef="usd">18000000</moh:AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold>
    <moh:AmountsDuetoGovernmentAgenciesOther
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOmU3MzQwNTc1OTUzNTQ3OGRiZWQ5M2E1YzlkNDIwMWNhL3RhYmxlcmFuZ2U6ZTczNDA1NzU5NTM1NDc4ZGJlZDkzYTVjOWQ0MjAxY2FfMTMtMS0xLTEtNTg1OTg_87972f14-bc3c-41b0-a404-834d51bc2880"
      unitRef="usd">51000000</moh:AmountsDuetoGovernmentAgenciesOther>
    <moh:AmountsDuetoGovernmentAgenciesOther
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOmU3MzQwNTc1OTUzNTQ3OGRiZWQ5M2E1YzlkNDIwMWNhL3RhYmxlcmFuZ2U6ZTczNDA1NzU5NTM1NDc4ZGJlZDkzYTVjOWQ0MjAxY2FfMTMtMy0xLTEtNTg1OTg_6cb2832a-a073-49b2-ab6b-1b166463f3e8"
      unitRef="usd">48000000</moh:AmountsDuetoGovernmentAgenciesOther>
    <moh:MedicalPremiumLiabilityDueToAgency
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOmU3MzQwNTc1OTUzNTQ3OGRiZWQ5M2E1YzlkNDIwMWNhL3RhYmxlcmFuZ2U6ZTczNDA1NzU5NTM1NDc4ZGJlZDkzYTVjOWQ0MjAxY2FfMTUtMS0xLTEtNTg1OTg_9864d582-4ae8-499c-a344-910305ca9e59"
      unitRef="usd">2139000000</moh:MedicalPremiumLiabilityDueToAgency>
    <moh:MedicalPremiumLiabilityDueToAgency
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RhYmxlOmU3MzQwNTc1OTUzNTQ3OGRiZWQ5M2E1YzlkNDIwMWNhL3RhYmxlcmFuZ2U6ZTczNDA1NzU5NTM1NDc4ZGJlZDkzYTVjOWQ0MjAxY2FfMTUtMy0xLTEtNTg1OTg_0abb2dbe-a9aa-437a-aa9d-b4bbf7bf7171"
      unitRef="usd">2472000000</moh:MedicalPremiumLiabilityDueToAgency>
    <us-gaap:IncreaseDecreaseInPremiumsReceivable
      contextRef="i4f40864acf524f78958e876e105a300f_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfMzU0NA_88fe5816-427b-4d0a-9079-1f5244b59212"
      unitRef="usd">-34000000</us-gaap:IncreaseDecreaseInPremiumsReceivable>
    <us-gaap:IncreaseDecreaseInPremiumsReceivable
      contextRef="i4bd869502a4d4c3db24a30f94752e48f_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfMzU1MQ_55542289-0794-478d-81ae-def8941e7f9c"
      unitRef="usd">-156000000</us-gaap:IncreaseDecreaseInPremiumsReceivable>
    <us-gaap:IncreaseDecreaseInPremiumsReceivable
      contextRef="i27e41e19da6946b9947bc20349bd2d6a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfMzY0OA_497b6ac3-0832-4c13-86d7-ec39672cac3d"
      unitRef="usd">-17000000</us-gaap:IncreaseDecreaseInPremiumsReceivable>
    <us-gaap:IncreaseDecreaseInPremiumsReceivable
      contextRef="i6507e164e60348edb5cc46669f1a17c3_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfMzY1NQ_401d286b-4db2-42b6-9dde-eda526b4242e"
      unitRef="usd">-183000000</us-gaap:IncreaseDecreaseInPremiumsReceivable>
    <moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfNTA0MQ_cae11889-f62e-4ad2-9f59-f636c1d7a20e"
      unitRef="usd">179000000</moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable>
    <moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfNTA4MA_77831c30-7347-4347-8ff1-da7d24bc3cbd"
      unitRef="usd">94000000</moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable>
    <moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfNTEwNQ_75c6b22c-b76d-43f6-8388-936dba66b8cd"
      unitRef="usd">85000000</moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable>
    <moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfNTE2OA_1d1da0b7-be4c-453e-9d99-830470e72179"
      unitRef="usd">902000000</moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable>
    <moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfNTIwNw_4b9002f1-d1e8-49ed-a519-04dbab9aab4c"
      unitRef="usd">7000000</moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable>
    <moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfNTIzMg_2855360a-1aee-4fab-88f7-90c7d1d02cb1"
      unitRef="usd">895000000</moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfNzc3Mg_4e6b864c-9037-4590-99d1-2a4316918233">&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than 15 years, or less than 15 years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents, and U.S. Treasury securities. Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and governments of each state in which our health plan subsidiaries operate.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <moh:InvestmentsMaturityPeriod
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfNTg1OA_d04ac147-7ea4-4550-918d-6e620650868b">P15Y</moh:InvestmentsMaturityPeriod>
    <moh:InvestmentsAverageMaturityPeriod
      contextRef="i9caa39ee3eca46f2935a54a04a4c6a37_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfNTg3NQ_f7df4e6c-7e46-4706-bcbf-a582ba7e315c">P15Y</moh:InvestmentsAverageMaturityPeriod>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfNzc0Nw_877dfea6-69e1-490d-909a-d7fceb0b7ee8">&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes is determined using an estimated annual effective tax rate, which generally differs from the U.S.&#160;federal statutory rate primarily because of foreign and state taxes, and nondeductible expenses such as certain compensation and other general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective tax rate may be subject to fluctuations during the year as new information is obtained. Such information may affect the assumptions used to estimate the annual effective tax rate, including projected pretax earnings, the mix of pretax earnings in the various tax jurisdictions in which we operate, valuation allowances against deferred tax assets, the recognition or the reversal of the recognition of tax benefits related to uncertain tax positions, and changes in or the interpretation of tax laws in jurisdictions where we conduct business. We recognize deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of our assets and liabilities, along with net operating loss and tax credit carryovers.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNC9mcmFnOjkzZWJlYzU4OTMwMDQzMzVhYjg0MDA1MjI0ODEyZjQ2L3RleHRyZWdpb246OTNlYmVjNTg5MzAwNDMzNWFiODQwMDUyMjQ4MTJmNDZfNzc0NA_a0e6dab8-7f78-4039-92c2-992fb3891462">&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (&#x201c;SEC&#x201d;) did not have, nor does management expect such pronouncements to have, a significant impact on our present or future consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RleHRyZWdpb246N2U3ZTBlMzJkZGQ2NGUyMmJiYTM2ZjE4M2RlZGI2ZTNfMzEy_424c156d-211e-44f7-974e-05c4630e3dc2">Net Income Per Share &lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the calculation of basic and diluted net income per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions, except net income per share)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Shares outstanding at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average number of shares issued:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Denominator for basic net income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Denominator for diluted net income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income per share - Basic &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income per share - Diluted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&#160;&#160;&#160;&#160;Source data for calculations in thousands.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RleHRyZWdpb246N2U3ZTBlMzJkZGQ2NGUyMmJiYTM2ZjE4M2RlZGI2ZTNfMzEw_c539fabc-9005-4cf3-9cd4-0b6ad681c094">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the calculation of basic and diluted net income per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions, except net income per share)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Shares outstanding at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average number of shares issued:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Denominator for basic net income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Denominator for diluted net income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income per share - Basic &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income per share - Diluted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&#160;&#160;&#160;&#160;Source data for calculations in thousands.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfNS0xLTEtMS01ODU5OA_8592a340-c9b4-49d0-a240-e32504dbe30e"
      unitRef="usd">230000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfNS0zLTEtMS01ODU5OA_9ffa7bb4-1c61-4654-bf20-b2597283a477"
      unitRef="usd">143000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfNS01LTEtMS01ODU5OA_59ab63a3-a7e6-4322-9910-5527c25b7a84"
      unitRef="usd">736000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfNS03LTEtMS01ODU5OA_dd172ccb-b551-40fc-be28-9778c16b2b64"
      unitRef="usd">556000000</us-gaap:NetIncomeLoss>
    <moh:SharesOutstandingExcludingRestrictedStockAwards
      contextRef="i4ff0d3fa206d42d891fbf8e9323bc625_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfNy0xLTEtMS01ODU5OA_77d65921-2d26-4c03-b47c-e94eb572019f"
      unitRef="shares">57600000</moh:SharesOutstandingExcludingRestrictedStockAwards>
    <moh:SharesOutstandingExcludingRestrictedStockAwards
      contextRef="i5995f351e20f4535ba42664bfb529a7e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfNy0zLTEtMS01ODU5OA_7c0e661f-1fae-474d-b729-61e45edddd51"
      unitRef="shares">57800000</moh:SharesOutstandingExcludingRestrictedStockAwards>
    <moh:SharesOutstandingExcludingRestrictedStockAwards
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfNy01LTEtMS01ODU5OA_1e834812-b88b-41a7-a29d-319dfd0aa879"
      unitRef="shares">57900000</moh:SharesOutstandingExcludingRestrictedStockAwards>
    <moh:SharesOutstandingExcludingRestrictedStockAwards
      contextRef="i2a1055b0f36c4bbd91048d943dbf64df_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfNy03LTEtMS01ODU5OA_775d8400-c3b4-4fab-88e0-ac3c9a922232"
      unitRef="shares">58000000.0</moh:SharesOutstandingExcludingRestrictedStockAwards>
    <moh:WeightedAverageNumberofSharesShareBasedCompensation
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfOS0xLTEtMS01ODU5OA_8f3ceced-0d09-4fcf-9ba5-0e7f108df7de"
      unitRef="shares">0</moh:WeightedAverageNumberofSharesShareBasedCompensation>
    <moh:WeightedAverageNumberofSharesShareBasedCompensation
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfOS0zLTEtMS01ODU5OA_95465dad-f3e9-4663-aa3f-a1dc4e058b77"
      unitRef="shares">0</moh:WeightedAverageNumberofSharesShareBasedCompensation>
    <moh:WeightedAverageNumberofSharesShareBasedCompensation
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfOS01LTEtMS01ODU5OA_69a60b81-f14d-4e01-8baf-1fa55206437e"
      unitRef="shares">200000</moh:WeightedAverageNumberofSharesShareBasedCompensation>
    <moh:WeightedAverageNumberofSharesShareBasedCompensation
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfOS03LTEtMS01ODU5OA_734a4ce8-38dc-46e1-b875-a44fd670466b"
      unitRef="shares">300000</moh:WeightedAverageNumberofSharesShareBasedCompensation>
    <us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTAtMS0xLTEtNTg1OTg_c24ab5b9-3abd-4826-b2b6-60bc905f4d84"
      unitRef="shares">0</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
    <us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTAtMy0xLTEtNTg1OTg_58a79c8c-7464-4291-9e16-da0a0742c6a3"
      unitRef="shares">0</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
    <us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTAtNS0xLTEtNTg1OTg_c794a44a-8460-41d9-b12c-c3a5be146b22"
      unitRef="shares">300000</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
    <us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTAtNy0xLTEtNTg1OTg_6b705bf1-f813-4cdd-9dba-dae524752a6f"
      unitRef="shares">500000</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTEtMS0xLTEtNTg1OTg_2ea17dfb-a82b-4181-bf0d-5c1a7a93464f"
      unitRef="shares">57600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTEtMy0xLTEtNTg1OTg_7c2f6c3f-4994-4e43-be99-5ce1ec84119a"
      unitRef="shares">57800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTEtNS0xLTEtNTg1OTg_534a8403-3034-48e0-90e9-6fe4dbc7e334"
      unitRef="shares">57800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTEtNy0xLTEtNTg1OTg_0f25cab5-a598-42a2-b5ec-ec2328ee475c"
      unitRef="shares">57800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTMtMS0xLTEtNTg1OTg_f4eac754-66e6-4d18-9dcf-40f4deb6c353"
      unitRef="shares">700000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTMtMy0xLTEtNTg1OTg_590bae06-0f5c-43e8-9bbc-87826701e955"
      unitRef="shares">700000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTMtNS0xLTEtNTg1OTg_dc6c46ca-3ea2-4d33-974d-1bf9bd3fdf29"
      unitRef="shares">700000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTMtNy0xLTEtNTg1OTg_19015799-d3e5-473f-8ee6-3122053d7858"
      unitRef="shares">700000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTUtMS0xLTEtNTg1OTg_c9f52d9f-31f2-48f4-a43f-4ca437f722ee"
      unitRef="shares">58300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTUtMy0xLTEtNTg1OTg_02329321-c149-4739-bcfd-87601e677d35"
      unitRef="shares">58500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTUtNS0xLTEtNTg1OTg_5687c933-9fa4-4703-ac9d-047584c051eb"
      unitRef="shares">58500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTUtNy0xLTEtNTg1OTg_3f32158a-6695-4dd3-b95d-0a1706e354a8"
      unitRef="shares">58500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTctMS0xLTEtNTg1OTg_65a52cf1-2c34-4802-bafa-9721bcb44806"
      unitRef="usdPerShare">4.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTctMy0xLTEtNTg1OTg_4e876984-71a1-48af-b2c5-3868fda004af"
      unitRef="usdPerShare">2.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTctNS0xLTEtNTg1OTg_12193d8b-6af4-48bb-83a7-5e59f16ec86f"
      unitRef="usdPerShare">12.74</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTctNy0xLTEtNTg1OTg_3fba9436-4189-4d65-b0e0-5b3ad8db9014"
      unitRef="usdPerShare">9.63</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTgtMS0xLTEtNTg1OTg_b751b4f8-c794-4b5d-92b2-8dccea84d474"
      unitRef="usdPerShare">3.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTgtMy0xLTEtNTg1OTg_55864f86-8b8d-46bc-af14-78d1bbaee2b4"
      unitRef="usdPerShare">2.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTgtNS0xLTEtNTg1OTg_109a0746-dd1b-45a3-9a9f-05defd69a3a0"
      unitRef="usdPerShare">12.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF8zNy9mcmFnOjdlN2UwZTMyZGRkNjRlMjJiYmEzNmYxODNkZWRiNmUzL3RhYmxlOjJhMjY5YjJkMGM4MDRhMzVhZjA5ZTM3MDdhMTkxNmFmL3RhYmxlcmFuZ2U6MmEyNjliMmQwYzgwNGEzNWFmMDllMzcwN2ExOTE2YWZfMTgtNy0xLTEtNTg1OTg_c5385999-f8cc-4562-9844-e5ded1702bde"
      unitRef="usdPerShare">9.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80MC9mcmFnOjU0MjA4OTE0MTRmMjQyYTg5OGVjYmIxNGVlZWRmODUzL3RleHRyZWdpb246NTQyMDg5MTQxNGYyNDJhODk4ZWNiYjE0ZWVlZGY4NTNfMTI0NA_7b7b5fbd-846f-4611-af80-878966e91bd1">Business Combinations&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AgeWell.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; As described in Note 1, &#x201c;Organization and Basis of Presentation,&#x201d; we announced this acquisition closed on October 1, 2022. Because the closing date fell on a weekend, the $134&#160;million purchase price was paid on September 30, 2022 and was recorded to prepaid expenses and other assets. Such amounts are reported in investing activities in the accompanying consolidated statements of cash flows. The initial accounting for this transaction is incomplete. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cigna. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2022, we closed on our acquisition of Cigna Corporation&#x2019;s Texas Medicaid and Medicare-Medicaid Plan contracts, along with certain operating assets, for purchase consideration of approximately $60&#160;million. We acquired membership and a provider network with a preliminary fair value of approximately $36&#160;million. We allocated the remaining $24 million of purchase consideration to goodwill, primarily in the Medicaid segment, which relates to future economic benefits arising from expected synergies from the use of our existing infrastructure to support the added membership, and from the assembled workforce. The goodwill is deductible for income tax purposes. &lt;/span&gt;&lt;/div&gt;Affinity. On October 25, 2021, we closed on our acquisition of substantially all of the assets of Affinity Health Plan, Inc., a Medicaid health plan in New York, for initial purchase consideration of approximately $176&#160;million. In the nine months ended September 30, 2022, we recorded various measurement period adjustments, including an increase of $8&#160;million to &#x201c;Medical claims and benefits payable,&#x201d; and an increase of $1&#160;million to &#x201c;Receivables&#x201d; net of &#x201c;Amounts due government agencies.&#x201d; In the aggregate, we recorded a net increase of $7&#160;million to goodwill for these measurement period adjustments and various purchase price adjustments.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="icbfe7220cac34928b948892e17e59eda_D20220930-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80MC9mcmFnOjU0MjA4OTE0MTRmMjQyYTg5OGVjYmIxNGVlZWRmODUzL3RleHRyZWdpb246NTQyMDg5MTQxNGYyNDJhODk4ZWNiYjE0ZWVlZGY4NTNfMjIxOQ_2492b22e-250d-40c7-816a-b91909fd11f6"
      unitRef="usd">134000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i304daf24495747efa3683f468f95e408_D20220101-20220101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80MC9mcmFnOjU0MjA4OTE0MTRmMjQyYTg5OGVjYmIxNGVlZWRmODUzL3RleHRyZWdpb246NTQyMDg5MTQxNGYyNDJhODk4ZWNiYjE0ZWVlZGY4NTNfMjI1_00b74921-4be3-46cf-aaab-e63d4ae6d7f6"
      unitRef="usd">60000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="idc61f272749348f58770423142c1f016_D20220101-20220101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80MC9mcmFnOjU0MjA4OTE0MTRmMjQyYTg5OGVjYmIxNGVlZWRmODUzL3RleHRyZWdpb246NTQyMDg5MTQxNGYyNDJhODk4ZWNiYjE0ZWVlZGY4NTNfMjE5OTAyMzI1ODIwMw_554c5f91-5d87-45e2-a390-5276044dc09f"
      unitRef="usd">36000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="i304daf24495747efa3683f468f95e408_D20220101-20220101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80MC9mcmFnOjU0MjA4OTE0MTRmMjQyYTg5OGVjYmIxNGVlZWRmODUzL3RleHRyZWdpb246NTQyMDg5MTQxNGYyNDJhODk4ZWNiYjE0ZWVlZGY4NTNfMzUz_a5d9bf49-1929-48c1-9ff0-900b79289e10"
      unitRef="usd">24000000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="if7af8f685cdb4a2d91d3b3aae5939f99_D20211025-20211025"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80MC9mcmFnOjU0MjA4OTE0MTRmMjQyYTg5OGVjYmIxNGVlZWRmODUzL3RleHRyZWdpb246NTQyMDg5MTQxNGYyNDJhODk4ZWNiYjE0ZWVlZGY4NTNfODgy_e18295c7-9556-46c7-9fc9-9a9576bd890d"
      unitRef="usd">176000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <moh:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable
      contextRef="i54a931e10c744083ad5d1a9a95d0e7f7_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80MC9mcmFnOjU0MjA4OTE0MTRmMjQyYTg5OGVjYmIxNGVlZWRmODUzL3RleHRyZWdpb246NTQyMDg5MTQxNGYyNDJhODk4ZWNiYjE0ZWVlZGY4NTNfOTc0_b3cda912-5395-4d58-adc6-50ccde39922c"
      unitRef="usd">8000000</moh:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable>
    <moh:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables
      contextRef="i54a931e10c744083ad5d1a9a95d0e7f7_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80MC9mcmFnOjU0MjA4OTE0MTRmMjQyYTg5OGVjYmIxNGVlZWRmODUzL3RleHRyZWdpb246NTQyMDg5MTQxNGYyNDJhODk4ZWNiYjE0ZWVlZGY4NTNfMTAzOA_a1a49a14-4f73-4418-9668-1dde5a540003"
      unitRef="usd">1000000</moh:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="i54a931e10c744083ad5d1a9a95d0e7f7_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80MC9mcmFnOjU0MjA4OTE0MTRmMjQyYTg5OGVjYmIxNGVlZWRmODUzL3RleHRyZWdpb246NTQyMDg5MTQxNGYyNDJhODk4ZWNiYjE0ZWVlZGY4NTNfMTE0OA_fd1fc824-4aac-4391-abdd-cd241a522dd6"
      unitRef="usd">7000000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RleHRyZWdpb246MzZiM2FiNDY1OGFkNDdkZjhmNWY5ZTA4ODk2OWMwY2RfMjYzNA_15fd9d80-070b-4bfd-88ea-2f0f79d74dec">Fair Value Measurements We consider the carrying amounts of current assets and current liabilities to approximate their fair values because of the relatively short period of time between the origination of these instruments and their expected realization or payment. For our financial instruments measured at fair value on a recurring basis, we prioritize the inputs used in measuring fair value according to the three-tier fair value hierarchy. For a description of the methods and assumptions used to: a) estimate the fair value; and b) determine the classification according to the fair value &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;hierarchy for each financial instrument, refer to our 2021 Annual Report on Form 10-K, Note 5, &#x201c;Fair Value Measurements.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net changes in fair value of Level 3 financial instruments are reported in &#x201c;Other&#x201d; operating expenses in our consolidated statements of income. In the nine months ended September 30, 2022 and 2021, we recognized a loss of $4&#160;million and $3&#160;million, respectively, for the increase in the fair value of the contingent consideration liabilities described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments measured at fair value on a recurring basis at September&#160;30, 2022, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Directly or Indirectly Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments measured at fair value on a recurring basis at December&#160;31, 2021, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Directly or Indirectly Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Level 3 financial instruments at September&#160;30, 2022 are comprised solely of contingent consideration liabilities of $8 million, in connection with our 2020 acquisition of certain assets of Passport Health Plan, Inc., a Medicaid health plan in Kentucky. Such liabilities are recorded at fair value on a recurring basis. In the nine months ended September 30, 2022, the estimated fair value of contingent purchase consideration increased by approximately $4&#160;million, relating to an operating income guarantee. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the nine months ended September 30, 2022, we paid the seller $43&#160;million, of which $23&#160;million was for the remaining half of the consideration due for minimum member enrollment targets and $20&#160;million was for the first payment of the consideration due for the operating income guarantee. For the amounts paid in the nine months ended September 30, 2022, $20 million has been presented in &#x201c;Financing activities&#x201d; in the accompanying consolidated statements of cash flows, with the balance reflected in &#x201c;Operating activities.&#x201d; The remaining balance of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the liabilities is reported in &#x201c;Accounts payable, accrued liabilities and other&#x201d; in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements &#x2013; Disclosure Only&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and estimated fair values of our notes payable are classified as Level 2 financial instruments. Fair value for these securities is determined using a market approach based on quoted market prices for similar securities in active markets or quoted prices for identical securities in inactive markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.375% Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.875% Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.875% Notes due 2032&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RleHRyZWdpb246MzZiM2FiNDY1OGFkNDdkZjhmNWY5ZTA4ODk2OWMwY2RfODc3_d5bb701b-c789-4b17-8d00-fbcc5d40dbb5"
      unitRef="usd">-4000000</us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings>
    <us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RleHRyZWdpb246MzZiM2FiNDY1OGFkNDdkZjhmNWY5ZTA4ODk2OWMwY2RfODg0_83ee66ad-8f22-44c7-853c-b9dde12139c3"
      unitRef="usd">-3000000</us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RleHRyZWdpb246MzZiM2FiNDY1OGFkNDdkZjhmNWY5ZTA4ODk2OWMwY2RfMjYyNQ_65781979-39f7-4b78-8591-498053150534">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments measured at fair value on a recurring basis at September&#160;30, 2022, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Directly or Indirectly Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments measured at fair value on a recurring basis at December&#160;31, 2021, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Directly or Indirectly Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i53d38d8c7935408fa0af30bea62c9c0f_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfNC0xLTEtMS01ODU5OA_99d12320-3805-49ca-860b-823e029c463f"
      unitRef="usd">2283000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i99e503b9ded046b2afc06e32c386be06_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfNC0zLTEtMS01ODU5OA_8fd4d5ae-b32b-4e1b-847d-0c810c97f9d9"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i950dd07f9ee54e9ba07c4dcd9f68f6bf_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfNC01LTEtMS01ODU5OA_4380f31e-8f95-4b0e-8a94-4370fae7237c"
      unitRef="usd">2283000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i0350794e08ab4b36a1ac51538215ba52_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfNC03LTEtMS01ODU5OA_0c7b63cc-8321-447f-b1d8-6392aa0af7e7"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i1115ede7452a40c1914f7984dbb1b080_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfNS0xLTEtMS01ODU5OA_e7bd9472-5006-49f1-86a2-26cabef42d30"
      unitRef="usd">743000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i6df1fa1ed0d04f3e8713afe89886bc9a_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfNS0zLTEtMS01ODU5OA_52a0ab3d-b39e-4832-824f-54d98acb162c"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i0dcbde7850b84d7aacf9b339a9622cde_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfNS01LTEtMS01ODU5OA_e98ce094-cb73-43fc-853b-ab19c5535e53"
      unitRef="usd">743000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i15df11d145d34fffaa859bf80bdfc980_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfNS03LTEtMS01ODU5OA_25101d8c-3fbd-4c75-8632-f0c90af8aa91"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i56ac79c2434a4a848f5a258701b2729d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfNi0xLTEtMS01ODU5OA_31aba3fa-f674-454a-a20b-9ce97f37c0d7"
      unitRef="usd">303000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i71f0d1fdbe7447868ed74e5f69926324_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfNi0zLTEtMS01ODU5OA_b33bdd48-3a3a-4e03-86b3-90bc44354e0d"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i164adb7da96e462788cd4e44a57cc798_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfNi01LTEtMS01ODU5OA_84c3e371-b7b7-4b57-817c-b80abc94bda6"
      unitRef="usd">303000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ibca4b67f345a40a898863f3cc798be1f_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfNi03LTEtMS01ODU5OA_08ab62c6-49f5-4254-818a-d77b832982dd"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i89c330693cd24ca895c0f7f61021a016_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfNy0xLTEtMS01ODU5OA_30484057-aa54-42f6-a018-2fb662ed1496"
      unitRef="usd">148000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i1fc1ad95c96a4d70b55ac85d939aa4b3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfNy0zLTEtMS01ODU5OA_6ca527f2-9ce8-4dac-90b6-3f404ae017a2"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i7d2c3542c7de425cb80651f619d775c6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfNy01LTEtMS01ODU5OA_4494fbcb-ec66-4a1c-8b0b-e0a9d6f49fae"
      unitRef="usd">148000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ice50ff36424e47d78d882897177a7ed7_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfNy03LTEtMS01ODU5OA_a10a0fd6-2a1a-4473-b1fb-90d22bcf04b1"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ic927869e96d94755b6560a3286b613c8_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfOC0xLTEtMS01ODU5OA_00bb375d-b4e2-4be7-8226-76d248e656c2"
      unitRef="usd">116000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i5331694495d843a4bf88a8892738d1e9_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfOC0zLTEtMS01ODU5OA_c852c97f-1a22-4b5b-904d-fe5ef7440c64"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i3c2dbf685f2c45e58cd349ed403d70e8_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfOC01LTEtMS01ODU5OA_078c2079-8a4e-469c-9ffa-247d012ce15a"
      unitRef="usd">116000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i50d78ee64ba8431dacba700dd2a8bdbf_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfOC03LTEtMS01ODU5OA_eec75060-c0d4-4628-8e44-1fc37bdc2a89"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="if95e6b6b2720412788aaa02f055f8e57_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfMTItMS0xLTEtNTg1OTg_2b07fbb7-6bd5-4170-a523-9e40b4eff08c"
      unitRef="usd">46000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ie087b593b0544c8399e87f02d57c34f2_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfMTItMy0xLTEtNTg1OTg_46282029-28ca-40e6-8dc7-c2b8ec3991b3"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i51b54536f2594623b231d19ba7ca1a3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfMTItNS0xLTEtNTg1OTg_10a8a72e-b009-41f7-bb32-09f1a981ec68"
      unitRef="usd">46000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="idd1da81e23914a71942537034bdbd756_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfMTItNy0xLTEtNTg1OTg_2baff6b2-1ffe-4089-bc84-a4dffab4d2d1"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfMTMtMS0xLTEtNTg1OTg_7e7d12fe-958a-4a31-b866-27405070ab44"
      unitRef="usd">3639000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icc33e78bc16f451cbbfd17b41149f635_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfMTMtMy0xLTEtNTg1OTg_e29e27b4-271a-4c51-9136-ffdf7e3267c1"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7e214513a58b4f5a9acb2468d174594b_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfMTMtNS0xLTEtNTg1OTg_c8bd82e7-b8a0-428a-ac84-a75a814d2154"
      unitRef="usd">3639000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0d6c05f8ebb14ba2abafe737776caa0d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfMTMtNy0xLTEtNTg1OTg_80eab825-a679-4ff1-9008-842dc3461273"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfMTUtMS0xLTEtNTg1OTg_fe8937e9-7e1a-4867-9e73-e9f07d31abf1"
      unitRef="usd">8000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="icc33e78bc16f451cbbfd17b41149f635_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfMTUtMy0xLTEtNTg1OTg_b0164977-efdd-43f7-8f46-aede4f5d6395"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7e214513a58b4f5a9acb2468d174594b_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfMTUtNS0xLTEtNTg1OTg_489161f8-3520-41e7-a328-cf25d8eaca29"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if45c5ec7debc4e2298c33d69169aae1b_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfMTUtNy0xLTEtNTg1OTg_7125b16e-b800-494d-a890-e0a7d974e2ec"
      unitRef="usd">8000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfMTYtMS0xLTEtNTg1OTg_b2ee4c8e-639c-4b2b-afed-3355b388ef11"
      unitRef="usd">8000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="icc33e78bc16f451cbbfd17b41149f635_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfMTYtMy0xLTEtNTg1OTg_9b835db7-a439-4b0b-a974-4625577b5872"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i7e214513a58b4f5a9acb2468d174594b_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfMTYtNS0xLTEtNTg1OTg_a55467c9-25d1-4b3a-a7d9-09029e006b0c"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i0d6c05f8ebb14ba2abafe737776caa0d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjFhNTMwN2Q1OTY5NjQ5ZGRiMDMxYmM4NzBlMDQ5Mjc2L3RhYmxlcmFuZ2U6MWE1MzA3ZDU5Njk2NDlkZGIwMzFiYzg3MGUwNDkyNzZfMTYtNy0xLTEtNTg1OTg_02f8be23-cf15-4080-8e55-ad716c00c956"
      unitRef="usd">8000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ib564c222a94b4914a72dc2e0ec855b08_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfNC0xLTEtMS01ODU5OA_c2da30bf-cda1-43b6-b406-f087a668b643"
      unitRef="usd">1833000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i12ad09b4f8ea44969f6dd60429d526fb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfNC0zLTEtMS01ODU5OA_d073f755-a0cb-4958-9fe9-ae3c8d01f421"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="if3b352b10300485c87431f796047c44f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfNC01LTEtMS01ODU5OA_4d23e346-b17a-48b7-bb88-92c8b984a886"
      unitRef="usd">1833000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ic0e7c52b9c5349f8bffbe5f1faf3f147_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfNC03LTEtMS01ODU5OA_48de6917-b7b6-43ac-9de0-dba6bd22eca7"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i736beb8bf714488bb38d432dfc0890b4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfNS0xLTEtMS01ODU5OA_45a3a6d1-7ed4-497a-8f6c-c9116bf2a52c"
      unitRef="usd">614000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i8d240d4e03e64770aff2769aaa40f08a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfNS0zLTEtMS01ODU5OA_f3622b4c-2c54-4b43-88ea-489eee610a17"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i3aa389c40f6a42229f5941193027a3ab_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfNS01LTEtMS01ODU5OA_f5d122a4-961a-4dec-b79a-1129cfe5682b"
      unitRef="usd">614000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i73fb739837584de6b651f049cc43ad72_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfNS03LTEtMS01ODU5OA_50518a36-da92-4777-84cd-35ef08e1a53a"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i8ba2d36cfa1140b1984c163783c2d57a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfNi0xLTEtMS01ODU5OA_ad3cbcef-3077-494c-b622-191b26d6191b"
      unitRef="usd">247000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i6f77531e7d74403b8efb3fc5faf7b062_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfNi0zLTEtMS01ODU5OA_353c90f2-7005-4332-b72e-16c2c4d81c41"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i52539c799fb64d0eb14c78750d80da4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfNi01LTEtMS01ODU5OA_d9a68d11-d1af-4fbe-ac5f-b1a05abd3d78"
      unitRef="usd">247000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ic5856f1b277e43efad233155501d11a8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfNi03LTEtMS01ODU5OA_d373c251-c021-4174-9ba3-6db6ff93cdef"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i9d4d9de95590481dad9718e28b15a44b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfNy0xLTEtMS01ODU5OA_68a1f8cf-5ac1-47b7-a2fb-9ac4c7b21f56"
      unitRef="usd">123000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="if802abab93b446539c01d453d4296995_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfNy0zLTEtMS01ODU5OA_78a0a188-5fde-46dc-8da8-93bc72592d84"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="iff4bfd6a6e384d5aa22561a59e8cbecf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfNy01LTEtMS01ODU5OA_beb3e7ac-4a8c-41d9-981b-7c9fad262b72"
      unitRef="usd">123000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="iea7d8648b1c445ab828552784316706f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfNy03LTEtMS01ODU5OA_ba5e4221-f571-4140-a927-71df28b150f5"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ic30b2001e92f42a0889f7aa593c567f1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfOC0xLTEtMS01ODU5OA_59dae377-932a-4aac-8d9b-7df9cfe5f303"
      unitRef="usd">353000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i55ac2e82cfc843eb861e766012517f6d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfOC0zLTEtMS01ODU5OA_dbdc876d-145e-4169-949c-c64fbca65326"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ie507227240b34d9a9c9e73630984e2b4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfOC01LTEtMS01ODU5OA_68b18119-1e15-4645-8ea6-3b58dd2eb192"
      unitRef="usd">353000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i0bdb0cb65c134e058441720032db3ad6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfOC03LTEtMS01ODU5OA_0ac40235-4069-46ea-99a8-bcdb18dec6ac"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i0781e4f6fe144460945ffc19971a5b88_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfMTEtMS0xLTEtNTg1OTg_d4ca08ad-564c-45d5-9499-12972524f2bb"
      unitRef="usd">32000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i10c0362a739347dfa9baf8391b5ebcf5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfMTEtMy0xLTEtNTg1OTg_8f287eb6-fa13-4ae1-a9e1-e7055e52692f"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ic41dd5a8ce43444caa047c867c1a7d68_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfMTEtNS0xLTEtNTg1OTg_0e690063-9134-4afb-8b3b-a70010d62bb7"
      unitRef="usd">32000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i025b5d81cf3b4ab089c2cfb73ed7fde2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfMTEtNy0xLTEtNTg1OTg_d1fa3948-31ae-4acb-87e7-bc3a75ec07cd"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfMTItMS0xLTEtNTg1OTg_78239e5d-68d7-4c3f-9684-d5d1ecf02f97"
      unitRef="usd">3202000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8e9b92c4cf3944d6bcffae91f86005e4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfMTItMy0xLTEtNTg1OTg_dfb8b1f1-c243-46ae-8fd3-4d0d3992613a"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5b0e199731ea42a99e977bd922403d3b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfMTItNS0xLTEtNTg1OTg_0d321bca-b910-4ad7-b38d-b3020e789166"
      unitRef="usd">3202000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i786c434041fb4ace8a427a0d0e1e025f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfMTItNy0xLTEtNTg1OTg_50d1e6b9-cc32-4d8b-9b8d-4d1719f3445c"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfMTQtMS0xLTEtNTg1OTg_29d3f9ba-f2ab-4525-bb9e-ca8c0d735f6c"
      unitRef="usd">47000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i8e9b92c4cf3944d6bcffae91f86005e4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfMTQtMy0xLTEtNTg1OTg_5d0f8899-08d5-4dff-bd17-42459d42bdc1"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5b0e199731ea42a99e977bd922403d3b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfMTQtNS0xLTEtNTg1OTg_48929734-25b5-4ace-9e48-f1a34a14ed31"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i786c434041fb4ace8a427a0d0e1e025f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfMTQtNy0xLTEtNTg1OTg_c5995e19-8739-4acb-bbd3-ea9242948531"
      unitRef="usd">47000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfMTUtMS0xLTEtNTg1OTg_0a42cd7c-c5d1-40e9-aacc-0519718581a3"
      unitRef="usd">47000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i8e9b92c4cf3944d6bcffae91f86005e4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfMTUtMy0xLTEtNTg1OTg_02272c2c-8e18-4c9c-82ba-c82445ceed29"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i5b0e199731ea42a99e977bd922403d3b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfMTUtNS0xLTEtNTg1OTg_1239b804-9c2d-4fcb-8b00-f4d37b604a6f"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i786c434041fb4ace8a427a0d0e1e025f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOjQ3ZTU2MWFhZTE5NTRiOGViYWJhYjRjNDIxYTZlMzZiL3RhYmxlcmFuZ2U6NDdlNTYxYWFlMTk1NGI4ZWJhYmFiNGM0MjFhNmUzNmJfMTUtNy0xLTEtNTg1OTg_f3766ca0-adc7-414e-9ee1-a8de0eac5350"
      unitRef="usd">47000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if45c5ec7debc4e2298c33d69169aae1b_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RleHRyZWdpb246MzZiM2FiNDY1OGFkNDdkZjhmNWY5ZTA4ODk2OWMwY2RfMTMzMQ_7125b16e-b800-494d-a890-e0a7d974e2ec"
      unitRef="usd">8000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RleHRyZWdpb246MzZiM2FiNDY1OGFkNDdkZjhmNWY5ZTA4ODk2OWMwY2RfMTYyNg_d5bb701b-c789-4b17-8d00-fbcc5d40dbb5"
      unitRef="usd">-4000000</us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings>
    <moh:PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities
      contextRef="idf0d9b897df24113b68bdf8a453bb9a6_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RleHRyZWdpb246MzZiM2FiNDY1OGFkNDdkZjhmNWY5ZTA4ODk2OWMwY2RfMTcwNA_2c7ec7fa-c85e-4229-9234-08395f1fd3c2"
      unitRef="usd">43000000</moh:PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities
      contextRef="i1924badac4254104ab5cdb4dd26159ab_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RleHRyZWdpb246MzZiM2FiNDY1OGFkNDdkZjhmNWY5ZTA4ODk2OWMwY2RfMTcxNw_0d482c71-b0ba-408d-92f3-0bcb7e4aeae0"
      unitRef="usd">23000000</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i076cf1c584a94c74b356f13c7adb5c28_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RleHRyZWdpb246MzZiM2FiNDY1OGFkNDdkZjhmNWY5ZTA4ODk2OWMwY2RfMTgxNA_985eea67-b587-4c42-a6f5-ca782ad7af70"
      unitRef="usd">20000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RleHRyZWdpb246MzZiM2FiNDY1OGFkNDdkZjhmNWY5ZTA4ODk2OWMwY2RfMTkzNg_19be52cc-3787-40f4-8939-e31a16b20bbc"
      unitRef="usd">20000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RleHRyZWdpb246MzZiM2FiNDY1OGFkNDdkZjhmNWY5ZTA4ODk2OWMwY2RfMjYyMw_a4cacb6a-bb8e-4a2e-a533-1cc33ab4a55c">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.375% Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.875% Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.875% Notes due 2032&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2215166a13a24f4ea0beb4f9ec5386b9_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOmQzMjI5MmRkZDIwMTRmMWZiNTcwZjE2NzZmNzE2YjE4L3RhYmxlcmFuZ2U6ZDMyMjkyZGRkMjAxNGYxZmI1NzBmMTY3NmY3MTZiMThfNC0wLTEtMS01ODU5OC90ZXh0cmVnaW9uOjExZGYzNGI4ZDM4MTRjYTQ4NTk3MDNmYWJmZGM1YjMwXzQ_684c7b56-c616-4156-b6af-c055e1225af1"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ib052c71d45c24815afd7307c29d879aa_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOmQzMjI5MmRkZDIwMTRmMWZiNTcwZjE2NzZmNzE2YjE4L3RhYmxlcmFuZ2U6ZDMyMjkyZGRkMjAxNGYxZmI1NzBmMTY3NmY3MTZiMThfNC0xLTEtMS01ODU5OA_d664b348-283f-4e7e-830b-0b5a4d505a63"
      unitRef="usd">792000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i448407d80cec44e08a45d31f149e357a_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOmQzMjI5MmRkZDIwMTRmMWZiNTcwZjE2NzZmNzE2YjE4L3RhYmxlcmFuZ2U6ZDMyMjkyZGRkMjAxNGYxZmI1NzBmMTY3NmY3MTZiMThfNC0zLTEtMS01ODU5OA_8cc9b90f-f47b-4650-923e-4bf63c18f5f8"
      unitRef="usd">715000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i6f612d887153413e9b30f0319ba1b896_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOmQzMjI5MmRkZDIwMTRmMWZiNTcwZjE2NzZmNzE2YjE4L3RhYmxlcmFuZ2U6ZDMyMjkyZGRkMjAxNGYxZmI1NzBmMTY3NmY3MTZiMThfNC01LTEtMS01ODU5OA_9f10c229-d132-4955-9dd8-4eb8d6dcfd86"
      unitRef="usd">791000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i5c267f45c1bb4b4bba5c6d0aa9d3c25a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOmQzMjI5MmRkZDIwMTRmMWZiNTcwZjE2NzZmNzE2YjE4L3RhYmxlcmFuZ2U6ZDMyMjkyZGRkMjAxNGYxZmI1NzBmMTY3NmY3MTZiMThfNC03LTEtMS01ODU5OA_db2caa3e-e8a0-4142-b3f3-be9e1dce30a6"
      unitRef="usd">829000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4568007f62514af188a722dbbfff6949_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOmQzMjI5MmRkZDIwMTRmMWZiNTcwZjE2NzZmNzE2YjE4L3RhYmxlcmFuZ2U6ZDMyMjkyZGRkMjAxNGYxZmI1NzBmMTY3NmY3MTZiMThfNS0wLTEtMS01ODU5OC90ZXh0cmVnaW9uOjU5NDlmZjVmNDJiNDRkMTI5OTEwYjVkMWE1MTJkZTQ2XzQ_9cdb5704-1c74-42e5-96c0-beb98c5331f6"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFairValue
      contextRef="iafab2ab6349040358f61b4a6104ff30b_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOmQzMjI5MmRkZDIwMTRmMWZiNTcwZjE2NzZmNzE2YjE4L3RhYmxlcmFuZ2U6ZDMyMjkyZGRkMjAxNGYxZmI1NzBmMTY3NmY3MTZiMThfNS0xLTEtMS01ODU5OA_7732deb6-41a0-46a1-ac2d-0694461569f6"
      unitRef="usd">642000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i6633be4c8bbc48bcbc0664990b24b759_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOmQzMjI5MmRkZDIwMTRmMWZiNTcwZjE2NzZmNzE2YjE4L3RhYmxlcmFuZ2U6ZDMyMjkyZGRkMjAxNGYxZmI1NzBmMTY3NmY3MTZiMThfNS0zLTEtMS01ODU5OA_b111f87f-0ef7-4fae-8a72-8a5892e97e36"
      unitRef="usd">541000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="iec39088e3cdd4e6bb7e04b07ff271fbe_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOmQzMjI5MmRkZDIwMTRmMWZiNTcwZjE2NzZmNzE2YjE4L3RhYmxlcmFuZ2U6ZDMyMjkyZGRkMjAxNGYxZmI1NzBmMTY3NmY3MTZiMThfNS01LTEtMS01ODU5OA_140c07ef-03f9-4e25-9a80-0860966777ee"
      unitRef="usd">642000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i5a9279d92caf4fc380a01f6bfb0014fc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOmQzMjI5MmRkZDIwMTRmMWZiNTcwZjE2NzZmNzE2YjE4L3RhYmxlcmFuZ2U6ZDMyMjkyZGRkMjAxNGYxZmI1NzBmMTY3NmY3MTZiMThfNS03LTEtMS01ODU5OA_b0a4a584-3caf-4633-9b7f-1dd4ee03efc3"
      unitRef="usd">675000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i68670e57970547ba9f2bb65e407ef0c3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOmQzMjI5MmRkZDIwMTRmMWZiNTcwZjE2NzZmNzE2YjE4L3RhYmxlcmFuZ2U6ZDMyMjkyZGRkMjAxNGYxZmI1NzBmMTY3NmY3MTZiMThfNi0wLTEtMS01ODU5OC90ZXh0cmVnaW9uOjIwMjU2NDI1YTY2OTRlNDY5MWM5NmNjOGRmNTc4NzhjXzQ_8eaa68b5-c180-4f43-88af-764c0af6a117"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i9dfc15175d74475c91b12b778c7b87c2_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOmQzMjI5MmRkZDIwMTRmMWZiNTcwZjE2NzZmNzE2YjE4L3RhYmxlcmFuZ2U6ZDMyMjkyZGRkMjAxNGYxZmI1NzBmMTY3NmY3MTZiMThfNi0xLTEtMS01ODU5OA_6248f10a-1fbc-47d5-9d55-67a60f49db87"
      unitRef="usd">741000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="id3afb2257e99458fa208ad148ca26252_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOmQzMjI5MmRkZDIwMTRmMWZiNTcwZjE2NzZmNzE2YjE4L3RhYmxlcmFuZ2U6ZDMyMjkyZGRkMjAxNGYxZmI1NzBmMTY3NmY3MTZiMThfNi0zLTEtMS01ODU5OA_4ccd2a35-b6db-4b19-8b5f-dc3bbf459df3"
      unitRef="usd">612000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i6fd3944eda144945832b087213cd2c9d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOmQzMjI5MmRkZDIwMTRmMWZiNTcwZjE2NzZmNzE2YjE4L3RhYmxlcmFuZ2U6ZDMyMjkyZGRkMjAxNGYxZmI1NzBmMTY3NmY3MTZiMThfNi01LTEtMS01ODU5OA_4cace53b-99b9-45ca-aa78-b4db904efae5"
      unitRef="usd">740000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ic0939ce4f5154b368577c64da2123599_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOmQzMjI5MmRkZDIwMTRmMWZiNTcwZjE2NzZmNzE2YjE4L3RhYmxlcmFuZ2U6ZDMyMjkyZGRkMjAxNGYxZmI1NzBmMTY3NmY3MTZiMThfNi03LTEtMS01ODU5OA_bff44425-a1d8-4632-b0bd-4c10f1bf7d1a"
      unitRef="usd">760000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ic8580906fd604a64a726120c54b6cf42_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOmQzMjI5MmRkZDIwMTRmMWZiNTcwZjE2NzZmNzE2YjE4L3RhYmxlcmFuZ2U6ZDMyMjkyZGRkMjAxNGYxZmI1NzBmMTY3NmY3MTZiMThfNy0xLTEtMS01ODU5OA_e88237aa-7489-4a76-8ac7-7360fa4ad536"
      unitRef="usd">2175000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i150352dcdff64ad5be9688ff28c71149_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOmQzMjI5MmRkZDIwMTRmMWZiNTcwZjE2NzZmNzE2YjE4L3RhYmxlcmFuZ2U6ZDMyMjkyZGRkMjAxNGYxZmI1NzBmMTY3NmY3MTZiMThfNy0zLTEtMS01ODU5OA_1342af88-a1ca-4683-a6d9-395f86a1a2f6"
      unitRef="usd">1868000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i1f569fe006e84fdea4bf95c5b662a515_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOmQzMjI5MmRkZDIwMTRmMWZiNTcwZjE2NzZmNzE2YjE4L3RhYmxlcmFuZ2U6ZDMyMjkyZGRkMjAxNGYxZmI1NzBmMTY3NmY3MTZiMThfNy01LTEtMS01ODU5OA_dc27be43-4346-49d7-8414-3ccdb4417b4b"
      unitRef="usd">2173000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i5aa0518df13a4a3ea99cdd1f8dc0e2cc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80My9mcmFnOjM2YjNhYjQ2NThhZDQ3ZGY4ZjVmOWUwODg5NjljMGNkL3RhYmxlOmQzMjI5MmRkZDIwMTRmMWZiNTcwZjE2NzZmNzE2YjE4L3RhYmxlcmFuZ2U6ZDMyMjkyZGRkMjAxNGYxZmI1NzBmMTY3NmY3MTZiMThfNy03LTEtMS01ODU5OA_50862af9-a28b-44b6-9135-5525c38698c8"
      unitRef="usd">2264000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RleHRyZWdpb246MjFkNGU2Njc4YzdjNGIyYWIzNzc3YmY2NTQ4MjkyZGJfMTA2MA_d11116a4-5e3d-4b5a-ba79-6a7c0cf6b350">Investments &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Available-for-Sale&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all of our investments classified as current assets to be available-for-sale. The following tables summarize our current investments as of the dates indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual maturities of our current investments as of September&#160;30, 2022 are summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due after ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross realized gains and losses from sales of available-for-sale securities are calculated under the specific identification method and are included in investment income. Gross realized investment gains were insignificant for the three and nine months ended September&#160;30, 2022, respectively. Gross realized investment gains amounted to $6&#160;million and $7&#160;million for the three and nine months ended September&#160;30, 2021, respectively. Gross realized investment losses were insignificant for the three and nine months ended September&#160;30, 2022, and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have determined that unrealized losses at September&#160;30, 2022, and December&#160;31, 2021, primarily resulted from fluctuating interest rates, rather than a deterioration of the creditworthiness of the issuers. Therefore, we determined that an allowance for credit losses was not necessary. So long as we maintain the intent and ability to hold these securities to maturity, we are unlikely to experience losses. In the event that we dispose of these securities before maturity, we expect that realized losses, if any, will be insignificant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table segregates those available-for-sale investments that have been in a continuous loss position for less than 12 months, and those that have been in a continuous loss position for 12 months or more as of September&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;In&#160;a&#160;Continuous&#160;Loss Position&lt;br/&gt;for&#160;Less&#160;than&#160;12&#160;Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;In&#160;a&#160;Continuous&#160;Loss Position&lt;br/&gt;for&#160;12&#160;Months or More&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Number of Positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Number of Positions&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table segregates those available-for-sale investments that have been in a continuous loss position for less than 12 months, and those that have been in a continuous loss position for 12 months or more as of December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;In&#160;a&#160;Continuous&#160;Loss Position&lt;br/&gt;for&#160;Less&#160;than&#160;12&#160;Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;In&#160;a&#160;Continuous&#160;Loss Position&lt;br/&gt;for&#160;12&#160;Months or More&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Number of Positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Number of Positions&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Investments Held-to-Maturity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the regulations governing our state health plan subsidiaries, we maintain statutory deposits and deposits required by government authorities primarily in cash, cash equivalents, U.S. Treasury securities, and corporate debt securities. We also maintain restricted investments as protection against the insolvency of certain capitated providers. The use of these funds is limited as required by regulations in the various states in which we operate, or as needed in the event of insolvency of capitated providers. Therefore, such investments are reported as &#x201c;Restricted investments&#x201d; in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have the ability to hold these restricted investments until maturity and, as a result, we would not expect the value of these investments to decline significantly due to a sudden change in market interest rates. Our held-to-maturity restricted investments are carried at amortized cost, which approximates fair value. Such investments amounted to $242 million at September&#160;30, 2022, of which $201 million will mature in one year or less, $37&#160;million will mature in one through five years, and $4 million will mature after five years.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RleHRyZWdpb246MjFkNGU2Njc4YzdjNGIyYWIzNzc3YmY2NTQ4MjkyZGJfMTA1Ng_baf198ca-3680-445a-95d8-d5984fcd7f92">The following tables summarize our current investments as of the dates indicated:&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i53d38d8c7935408fa0af30bea62c9c0f_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfNS0xLTEtMS01ODU5OA_3467ac22-35a9-4766-96b9-477f78980b60"
      unitRef="usd">2431000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i53d38d8c7935408fa0af30bea62c9c0f_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfNS0zLTEtMS01ODU5OA_01993423-5018-476e-9a03-8fa7455c2e79"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i53d38d8c7935408fa0af30bea62c9c0f_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfNS01LTEtMS01ODU5OA_f8f8c9b2-d952-4965-b015-51d4a58120f5"
      unitRef="usd">148000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i53d38d8c7935408fa0af30bea62c9c0f_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfNS03LTEtMS01ODU5OA_a7b862bf-a071-497f-a29d-9cbf374ae33f"
      unitRef="usd">2283000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i9a952061d42f4cf594d018fa3c95b81c_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfNi0xLTEtMS01ODU5OA_8c1b6a53-9744-4ad1-818f-3dd19859e0c6"
      unitRef="usd">804000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9a952061d42f4cf594d018fa3c95b81c_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfNi0zLTEtMS01ODU5OA_06ee12fc-afa5-4d8c-a0c3-cef15eaecccc"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9a952061d42f4cf594d018fa3c95b81c_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfNi01LTEtMS01ODU5OA_f8aca986-875c-4a3d-aa8f-37018e3c60c2"
      unitRef="usd">61000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i9a952061d42f4cf594d018fa3c95b81c_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfNi03LTEtMS01ODU5OA_11fd0007-a737-4d16-94d0-23714eecdceb"
      unitRef="usd">743000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i56ac79c2434a4a848f5a258701b2729d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfNy0xLTEtMS01ODU5OA_e26c16e5-6a44-408f-a55d-747df9ad628c"
      unitRef="usd">322000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i56ac79c2434a4a848f5a258701b2729d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfNy0zLTEtMS01ODU5OA_8fce03d5-0f21-4b45-a2e9-eb5c2d8d72a1"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i56ac79c2434a4a848f5a258701b2729d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfNy01LTEtMS01ODU5OA_12ecb634-1063-403f-adf9-92a6277a9d4f"
      unitRef="usd">19000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i56ac79c2434a4a848f5a258701b2729d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfNy03LTEtMS01ODU5OA_e8d36a5a-3f11-4385-8709-a221fc9f6e16"
      unitRef="usd">303000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i89c330693cd24ca895c0f7f61021a016_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfOC0xLTEtMS01ODU5OA_138c964f-e02b-452d-a47e-2b191dab0542"
      unitRef="usd">159000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i89c330693cd24ca895c0f7f61021a016_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfOC0zLTEtMS01ODU5OA_a995067d-d9aa-456d-9c24-a56a257d4531"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i89c330693cd24ca895c0f7f61021a016_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfOC01LTEtMS01ODU5OA_12f42627-05ed-4b23-9c36-3770de62283e"
      unitRef="usd">11000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i89c330693cd24ca895c0f7f61021a016_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfOC03LTEtMS01ODU5OA_f5e25bb2-2514-4e27-a26f-2218cdb53363"
      unitRef="usd">148000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ic927869e96d94755b6560a3286b613c8_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfOS0xLTEtMS01ODU5OA_9488bbb7-21f1-4308-ad66-7e7e2b16f04b"
      unitRef="usd">117000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic927869e96d94755b6560a3286b613c8_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfOS0zLTEtMS01ODU5OA_a4287a24-184e-4768-9445-a6e164b79968"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic927869e96d94755b6560a3286b613c8_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfOS01LTEtMS01ODU5OA_55bf3401-4f85-4108-ada6-1825b2541e8b"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ic927869e96d94755b6560a3286b613c8_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfOS03LTEtMS01ODU5OA_e13036e7-38d3-4c0a-8415-3e15a686c89d"
      unitRef="usd">116000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="if95e6b6b2720412788aaa02f055f8e57_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfMTMtMS0xLTEtNTg1OTg_98eac3c2-516b-4e7b-81ad-88301c43fab3"
      unitRef="usd">49000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if95e6b6b2720412788aaa02f055f8e57_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfMTMtMy0xLTEtNTg1OTg_6c2ff8a7-26fb-48a8-a81e-5484b6c38753"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if95e6b6b2720412788aaa02f055f8e57_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfMTMtNS0xLTEtNTg1OTg_bd5957bb-6f66-4d6c-a13e-bf428c96dce7"
      unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="if95e6b6b2720412788aaa02f055f8e57_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfMTMtNy0xLTEtNTg1OTg_340d5156-112d-403b-9464-805a1d3ea7b3"
      unitRef="usd">46000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfMTQtMS0xLTEtNTg1OTg_a0f5fa47-0824-4c13-8781-2a53ec99a633"
      unitRef="usd">3882000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfMTQtMy0xLTEtNTg1OTg_d61ddea9-e855-4001-81e3-081ffec24fe9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfMTQtNS0xLTEtNTg1OTg_5453d289-4ac9-4d31-a510-cfceb3d17bb4"
      unitRef="usd">243000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmIzMzAyZjJiZTdmNzQxNDI5ZDY4NDM0ZGIzMThhMTY2L3RhYmxlcmFuZ2U6YjMzMDJmMmJlN2Y3NDE0MjlkNjg0MzRkYjMxOGExNjZfMTQtNy0xLTEtNTg1OTg_a9ec234f-e678-4a88-9220-49562c7d7ce3"
      unitRef="usd">3639000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ib564c222a94b4914a72dc2e0ec855b08_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfNS0xLTEtMS01ODU5OA_1ee51029-df74-4d5a-bfb8-1cf13593dc52"
      unitRef="usd">1836000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib564c222a94b4914a72dc2e0ec855b08_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfNS0zLTEtMS01ODU5OA_22a06d8f-e928-406d-ab26-a97502b7a487"
      unitRef="usd">9000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib564c222a94b4914a72dc2e0ec855b08_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfNS01LTEtMS01ODU5OA_308ab507-cb3f-4c51-9926-54744818691e"
      unitRef="usd">12000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ib564c222a94b4914a72dc2e0ec855b08_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfNS03LTEtMS01ODU5OA_9092271d-7a66-4cc2-a6a8-cf4f38e5c5ae"
      unitRef="usd">1833000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i7295c4737a694828803c5153905fdd31_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfNi0xLTEtMS01ODU5OA_3914a63c-fe83-4856-9e64-26e93df163da"
      unitRef="usd">616000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7295c4737a694828803c5153905fdd31_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfNi0zLTEtMS01ODU5OA_ffa45e44-b432-4fd0-93ce-31629d09a6b5"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7295c4737a694828803c5153905fdd31_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfNi01LTEtMS01ODU5OA_f289f17d-fe6c-4ffd-a020-204ea9aa7b34"
      unitRef="usd">4000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i7295c4737a694828803c5153905fdd31_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfNi03LTEtMS01ODU5OA_146df252-8cd2-4484-9576-74f5bed463e0"
      unitRef="usd">614000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i8ba2d36cfa1140b1984c163783c2d57a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfNy0xLTEtMS01ODU5OA_0bc46308-0a1d-4be3-a06a-e3b460e12d66"
      unitRef="usd">248000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8ba2d36cfa1140b1984c163783c2d57a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfNy0zLTEtMS01ODU5OA_88926c3c-d8c5-4488-a118-9bf87c453ee5"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8ba2d36cfa1140b1984c163783c2d57a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfNy01LTEtMS01ODU5OA_03476223-c35e-457a-be68-68ff73bb5cba"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i8ba2d36cfa1140b1984c163783c2d57a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfNy03LTEtMS01ODU5OA_6907f45e-b87d-49b8-9d98-6cd7ee5c1383"
      unitRef="usd">247000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i9d4d9de95590481dad9718e28b15a44b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfOC0xLTEtMS01ODU5OA_477b628c-9eb7-43c3-9ff6-288f90b153f4"
      unitRef="usd">123000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9d4d9de95590481dad9718e28b15a44b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfOC0zLTEtMS01ODU5OA_ff4bb3e4-2af2-4952-87ac-8ff4005a7e0b"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9d4d9de95590481dad9718e28b15a44b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfOC01LTEtMS01ODU5OA_9a7ea047-79b4-4c7b-944d-33bfa1543d27"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i9d4d9de95590481dad9718e28b15a44b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfOC03LTEtMS01ODU5OA_30ce1cdd-7162-42c6-9bda-913eba75d06b"
      unitRef="usd">123000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ic30b2001e92f42a0889f7aa593c567f1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfOS0xLTEtMS01ODU5OA_5dcb8e6f-7696-4431-ad68-da3be9113a82"
      unitRef="usd">353000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic30b2001e92f42a0889f7aa593c567f1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfOS0zLTEtMS01ODU5OA_3627c524-c166-4c95-ba4f-3ee5d1d26e41"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic30b2001e92f42a0889f7aa593c567f1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfOS01LTEtMS01ODU5OA_a1c87e4e-b38a-4234-a93a-2338042897f1"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ic30b2001e92f42a0889f7aa593c567f1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfOS03LTEtMS01ODU5OA_9319c517-141e-46c8-a258-370a4a7880c0"
      unitRef="usd">353000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i0781e4f6fe144460945ffc19971a5b88_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfMTItMS0xLTEtNTg1OTg_d855a187-ffc7-43f9-812e-424da5fcf9a0"
      unitRef="usd">32000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0781e4f6fe144460945ffc19971a5b88_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfMTItMy0xLTEtNTg1OTg_d5189ed8-4cef-4373-a771-f05c03b2b972"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0781e4f6fe144460945ffc19971a5b88_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfMTItNS0xLTEtNTg1OTg_cc81e175-6436-46ce-8f04-31685f51375f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i0781e4f6fe144460945ffc19971a5b88_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfMTItNy0xLTEtNTg1OTg_8e29ece3-95d2-494f-9a8d-bba4ca73773e"
      unitRef="usd">32000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfMTMtMS0xLTEtNTg1OTg_2a092012-c28b-406a-817c-c4a3b8d6e8d6"
      unitRef="usd">3208000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfMTMtMy0xLTEtNTg1OTg_8bd9b53c-48f2-4871-ae6c-18fb753776c2"
      unitRef="usd">12000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfMTMtNS0xLTEtNTg1OTg_ff7e5f52-0cfb-4ec8-8bae-cf3403579309"
      unitRef="usd">18000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOmMwNTc0YmIwOWE2ODQ1NWQ4MDFiYmE0MGExM2VlYTRiL3RhYmxlcmFuZ2U6YzA1NzRiYjA5YTY4NDU1ZDgwMWJiYTQwYTEzZWVhNGJfMTMtNy0xLTEtNTg1OTg_8c654e99-3113-460e-b964-9069538fce15"
      unitRef="usd">3202000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RleHRyZWdpb246MjFkNGU2Njc4YzdjNGIyYWIzNzc3YmY2NTQ4MjkyZGJfMTA3NQ_9f5486a4-3db8-463e-93d0-f6553c55a9e3">&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual maturities of our current investments as of September&#160;30, 2022 are summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due after ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOjJlNTUwMWFjZDY4MTQ5OWNiNzcwNzYxZWY3ZmE3M2QxL3RhYmxlcmFuZ2U6MmU1NTAxYWNkNjgxNDk5Y2I3NzA3NjFlZjdmYTczZDFfMy0xLTEtMS01ODU5OA_71db239c-f539-4bde-81aa-75398c1c52d7"
      unitRef="usd">378000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOjJlNTUwMWFjZDY4MTQ5OWNiNzcwNzYxZWY3ZmE3M2QxL3RhYmxlcmFuZ2U6MmU1NTAxYWNkNjgxNDk5Y2I3NzA3NjFlZjdmYTczZDFfMy0zLTEtMS01ODU5OA_d59def08-f5fa-43d5-ad95-4f4decfa5bc9"
      unitRef="usd">374000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOjJlNTUwMWFjZDY4MTQ5OWNiNzcwNzYxZWY3ZmE3M2QxL3RhYmxlcmFuZ2U6MmU1NTAxYWNkNjgxNDk5Y2I3NzA3NjFlZjdmYTczZDFfNC0xLTEtMS01ODU5OA_7f68e64f-c603-488a-902d-56b7e03e6503"
      unitRef="usd">2330000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOjJlNTUwMWFjZDY4MTQ5OWNiNzcwNzYxZWY3ZmE3M2QxL3RhYmxlcmFuZ2U6MmU1NTAxYWNkNjgxNDk5Y2I3NzA3NjFlZjdmYTczZDFfNC0zLTEtMS01ODU5OA_7e0d78e4-6852-4cef-8b40-1239c65f2293"
      unitRef="usd">2186000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOjJlNTUwMWFjZDY4MTQ5OWNiNzcwNzYxZWY3ZmE3M2QxL3RhYmxlcmFuZ2U6MmU1NTAxYWNkNjgxNDk5Y2I3NzA3NjFlZjdmYTczZDFfNS0xLTEtMS01ODU5OA_fce449e3-bffe-4f98-9492-56cfdc3ae654"
      unitRef="usd">390000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOjJlNTUwMWFjZDY4MTQ5OWNiNzcwNzYxZWY3ZmE3M2QxL3RhYmxlcmFuZ2U6MmU1NTAxYWNkNjgxNDk5Y2I3NzA3NjFlZjdmYTczZDFfNS0zLTEtMS01ODU5OA_843444c1-9a82-422d-bd0d-86447686b9a2"
      unitRef="usd">364000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOjJlNTUwMWFjZDY4MTQ5OWNiNzcwNzYxZWY3ZmE3M2QxL3RhYmxlcmFuZ2U6MmU1NTAxYWNkNjgxNDk5Y2I3NzA3NjFlZjdmYTczZDFfNi0xLTEtMS01ODU5OA_5912a710-75eb-4d7b-87e6-f5bc62a3ddd0"
      unitRef="usd">784000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOjJlNTUwMWFjZDY4MTQ5OWNiNzcwNzYxZWY3ZmE3M2QxL3RhYmxlcmFuZ2U6MmU1NTAxYWNkNjgxNDk5Y2I3NzA3NjFlZjdmYTczZDFfNi0zLTEtMS01ODU5OA_d6e090d5-5f22-49bc-a3fb-88083ae317ef"
      unitRef="usd">715000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOjJlNTUwMWFjZDY4MTQ5OWNiNzcwNzYxZWY3ZmE3M2QxL3RhYmxlcmFuZ2U6MmU1NTAxYWNkNjgxNDk5Y2I3NzA3NjFlZjdmYTczZDFfNy0xLTEtMS01ODU5OA_23874e7e-bda0-4376-8552-4cda07165d91"
      unitRef="usd">3882000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RhYmxlOjJlNTUwMWFjZDY4MTQ5OWNiNzcwNzYxZWY3ZmE3M2QxL3RhYmxlcmFuZ2U6MmU1NTAxYWNkNjgxNDk5Y2I3NzA3NjFlZjdmYTczZDFfNy0zLTEtMS01ODU5OA_9558c7db-7997-4423-b5bb-cfc05797a0de"
      unitRef="usd">3639000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RleHRyZWdpb246MjFkNGU2Njc4YzdjNGIyYWIzNzc3YmY2NTQ4MjkyZGJfNjA0NzMxMzk1NDI3NQ_9c257fb3-5fc2-4230-8eea-2382020cb675"
      unitRef="usd">6000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF80Ni9mcmFnOjIxZDRlNjY3OGM3YzRiMmFiMzc3N2JmNjU0ODI5MmRiL3RleHRyZWdpb246MjFkNGU2Njc4YzdjNGIyYWIzNzc3YmY2NTQ4MjkyZGJfNjA0NzMxMzk1NDI4Nw_7157a156-ccd2-4fb4-91c5-06ace39f9185"
      unitRef="usd">7000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RleHRyZWdpb246MmJlODU5YjczYzc4NDU0YzhhZTFmZDUxYWY1NmUwZjJfNDU5_19ee6908-7e1d-4b6c-a4ef-0232b5e74892">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table segregates those available-for-sale investments that have been in a continuous loss position for less than 12 months, and those that have been in a continuous loss position for 12 months or more as of September&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;In&#160;a&#160;Continuous&#160;Loss Position&lt;br/&gt;for&#160;Less&#160;than&#160;12&#160;Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;In&#160;a&#160;Continuous&#160;Loss Position&lt;br/&gt;for&#160;12&#160;Months or More&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Number of Positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Number of Positions&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table segregates those available-for-sale investments that have been in a continuous loss position for less than 12 months, and those that have been in a continuous loss position for 12 months or more as of December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;In&#160;a&#160;Continuous&#160;Loss Position&lt;br/&gt;for&#160;Less&#160;than&#160;12&#160;Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;In&#160;a&#160;Continuous&#160;Loss Position&lt;br/&gt;for&#160;12&#160;Months or More&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Number of Positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Number of Positions&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i53d38d8c7935408fa0af30bea62c9c0f_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNC0xLTEtMS01ODU5OA_58b05685-c706-45f9-8d65-25e24ecba19c"
      unitRef="usd">1764000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i53d38d8c7935408fa0af30bea62c9c0f_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNC0zLTEtMS01ODU5OA_79664a77-2640-458e-89e8-02097c4cc68d"
      unitRef="usd">103000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i53d38d8c7935408fa0af30bea62c9c0f_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNC01LTEtMS01ODU5OA_ed8dee00-36a0-49d2-8e74-14cfb3605d08"
      unitRef="position">909</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i53d38d8c7935408fa0af30bea62c9c0f_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNC03LTEtMS01ODU5OA_66e89fb6-d8cb-4e69-bcc7-d28655b5e992"
      unitRef="usd">433000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i53d38d8c7935408fa0af30bea62c9c0f_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNC05LTEtMS01ODU5OA_8e94cb37-d1db-4512-b5f6-2b2ea6e43d45"
      unitRef="usd">45000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i53d38d8c7935408fa0af30bea62c9c0f_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNC0xMS0xLTEtNTg1OTg_7b43aac6-5ba3-432d-b1e7-61bd95387b05"
      unitRef="position">167</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i9a952061d42f4cf594d018fa3c95b81c_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNS0xLTEtMS01ODU5OA_d2b5b303-6d65-45eb-9f3a-a65c387d69a4"
      unitRef="usd">555000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i9a952061d42f4cf594d018fa3c95b81c_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNS0zLTEtMS01ODU5OA_a80c0bba-5c6d-416f-9566-fdaf95c0d0f1"
      unitRef="usd">36000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i9a952061d42f4cf594d018fa3c95b81c_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNS01LTEtMS01ODU5OA_2156d05c-784f-4567-9516-65fb58efcdcd"
      unitRef="position">282</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i9a952061d42f4cf594d018fa3c95b81c_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNS03LTEtMS01ODU5OA_fa05c21d-e797-4302-9358-4ceb437a9e60"
      unitRef="usd">188000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i9a952061d42f4cf594d018fa3c95b81c_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNS05LTEtMS01ODU5OA_6bdbfca2-944e-4d88-ad84-3e17e1aebf94"
      unitRef="usd">25000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i9a952061d42f4cf594d018fa3c95b81c_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNS0xMS0xLTEtNTg1OTg_d7aaa790-1d81-41e4-afcc-77c0359f2c72"
      unitRef="position">75</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i56ac79c2434a4a848f5a258701b2729d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNi0xLTEtMS01ODU5OA_ab181ad9-da04-40a6-9e20-81fdf9aca2f5"
      unitRef="usd">242000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i56ac79c2434a4a848f5a258701b2729d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNi0zLTEtMS01ODU5OA_10794bf2-630f-4ce3-b6aa-b6bd63c447fc"
      unitRef="usd">13000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i56ac79c2434a4a848f5a258701b2729d_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNi01LTEtMS01ODU5OA_37a453c0-2882-4e45-9b1c-c4e245d8628e"
      unitRef="security">128</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i56ac79c2434a4a848f5a258701b2729d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNi03LTEtMS01ODU5OA_e390e2c0-579f-4c36-bc5b-71f55312e1f4"
      unitRef="usd">56000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i56ac79c2434a4a848f5a258701b2729d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNi05LTEtMS01ODU5OA_3a2d7c85-4f68-4f37-a0b1-380633ff34b4"
      unitRef="usd">6000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i56ac79c2434a4a848f5a258701b2729d_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNi0xMS0xLTEtNTg1OTg_91f898e1-8d01-43e2-b508-eba05a241845"
      unitRef="security">28</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i89c330693cd24ca895c0f7f61021a016_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNy0xLTEtMS02NjI2OQ_6e0237cf-f498-449e-b498-ec61c362282f"
      unitRef="usd">106000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i89c330693cd24ca895c0f7f61021a016_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNy0zLTEtMS02NjI2OQ_9d390cea-1a52-4bce-994d-6d141da3a303"
      unitRef="usd">7000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i89c330693cd24ca895c0f7f61021a016_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNy01LTEtMS02NjI2OQ_f541cebc-f18d-4802-96da-bcc3a230a80f"
      unitRef="security">110</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i89c330693cd24ca895c0f7f61021a016_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNy03LTEtMS02NjI2OQ_c87dd3cc-a743-4063-b7cb-655024ad2b2f"
      unitRef="usd">31000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i89c330693cd24ca895c0f7f61021a016_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNy05LTEtMS02NjI2OQ_b11157cb-8b52-4966-bdad-12d39d64aad7"
      unitRef="usd">4000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i89c330693cd24ca895c0f7f61021a016_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNy0xMS0xLTEtNjYyNjk_eca075d5-68fb-46e9-a6fe-a1577b3e3359"
      unitRef="security">35</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ic927869e96d94755b6560a3286b613c8_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNy0xLTEtMS01ODU5OA_f80c06a2-2ada-4bd8-92d5-69bf3a11e252"
      unitRef="usd">116000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ic927869e96d94755b6560a3286b613c8_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNy0zLTEtMS01ODU5OA_b9f2a295-5d54-477c-967f-2bf29d0a8728"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="ic927869e96d94755b6560a3286b613c8_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNy01LTEtMS01ODU5OA_2baefe82-6185-4aff-b329-c064b6986096"
      unitRef="security">8</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ic927869e96d94755b6560a3286b613c8_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNy03LTEtMS01ODU5OA_d8dbea7f-b36f-4116-a3f1-7d81a9129a8e"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ic927869e96d94755b6560a3286b613c8_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNy05LTEtMS01ODU5OA_bfb1b798-3720-4de2-a70d-369c4e3a4377"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="ic927869e96d94755b6560a3286b613c8_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfNy0xMS0xLTEtNTg1OTg_067cddcf-c445-4e25-9049-9110e9fea004"
      unitRef="security">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="if95e6b6b2720412788aaa02f055f8e57_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfOS0xLTEtMS01ODU5OA_1dd3e2fe-65d5-480d-94a2-3e6d81699daf"
      unitRef="usd">32000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="if95e6b6b2720412788aaa02f055f8e57_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfOS0zLTEtMS01ODU5OA_d1faa46c-89f9-4cc9-89bb-9c92b4334d60"
      unitRef="usd">3000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="if95e6b6b2720412788aaa02f055f8e57_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfOS01LTEtMS01ODU5OA_d59a7d8e-2386-45e4-a42f-539ba52726a6"
      unitRef="security">20</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="if95e6b6b2720412788aaa02f055f8e57_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfOS03LTEtMS01ODU5OA_6a4c4fa7-e724-4db4-820f-2e3325fe095e"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="if95e6b6b2720412788aaa02f055f8e57_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfOS05LTEtMS01ODU5OA_363b20fa-8a0c-4821-a40d-9209a186ee19"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="if95e6b6b2720412788aaa02f055f8e57_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfOS0xMS0xLTEtNTg1OTg_41d18db0-ed87-4653-8495-5d445bcd2082"
      unitRef="security">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfMTMtMS0xLTEtNTg1OTg_31e34b7b-6afa-4afa-88f1-e21981189327"
      unitRef="usd">2815000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfMTMtMy0xLTEtNTg1OTg_f1790cec-aa47-4407-8e9b-3fb09ac0b885"
      unitRef="usd">163000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfMTMtNS0xLTEtNTg1OTg_70f23f58-1976-4825-8182-f91aec9333f7"
      unitRef="position">1457</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfMTMtNy0xLTEtNTg1OTg_fb780820-ceba-4e78-8ab2-05e830e802fb"
      unitRef="usd">708000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfMTMtOS0xLTEtNTg1OTg_26c2eef8-907e-488f-894e-a04b26de06e4"
      unitRef="usd">80000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOjYzMDViNTNmMTE2NjQwZGU4MTU4Yjc0M2FhNGNjMDA4L3RhYmxlcmFuZ2U6NjMwNWI1M2YxMTY2NDBkZTgxNThiNzQzYWE0Y2MwMDhfMTMtMTEtMS0xLTU4NTk4_0c356aab-30d9-4846-92fa-f9037d5dfca6"
      unitRef="position">305</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ib564c222a94b4914a72dc2e0ec855b08_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfNC0xLTEtMS01ODU5OA_ddcdc773-4f22-4f45-8564-d2650bd5db00"
      unitRef="usd">1063000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ib564c222a94b4914a72dc2e0ec855b08_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfNC0zLTEtMS01ODU5OA_a235f1ff-26a1-40e6-add6-91003b89adb7"
      unitRef="usd">12000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="ib564c222a94b4914a72dc2e0ec855b08_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfNC01LTEtMS01ODU5OA_0919c70f-89d5-4b73-b70f-4e4d04ff9bd2"
      unitRef="position">395</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ib564c222a94b4914a72dc2e0ec855b08_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfNC03LTEtMS01ODU5OA_0221e593-2d00-4f40-adb7-6f886b7c31ad"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ib564c222a94b4914a72dc2e0ec855b08_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfNC05LTEtMS01ODU5OA_3913987f-d437-47c3-8a3a-b647a628fb0e"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="ib564c222a94b4914a72dc2e0ec855b08_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfNC0xMS0xLTEtNTg1OTg_1e5caea7-2a34-44e5-aed6-a92d44ecc62e"
      unitRef="position">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i7295c4737a694828803c5153905fdd31_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfNS0xLTEtMS01ODU5OA_ee577aa1-238b-43bd-802f-06aaabc2c6f9"
      unitRef="usd">408000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i7295c4737a694828803c5153905fdd31_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfNS0zLTEtMS01ODU5OA_537dedcb-8585-4183-82ae-de6ddae6ff42"
      unitRef="usd">4000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i7295c4737a694828803c5153905fdd31_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfNS01LTEtMS01ODU5OA_5633925d-d29c-4e0b-923d-afaa93501461"
      unitRef="position">146</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i7295c4737a694828803c5153905fdd31_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfNS03LTEtMS01ODU5OA_670e2570-7d69-4dfd-a017-d92ce197b904"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i7295c4737a694828803c5153905fdd31_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfNS05LTEtMS01ODU5OA_74bbf454-ab19-4dd6-b865-721f57f55639"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i7295c4737a694828803c5153905fdd31_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfNS0xMS0xLTEtNTg1OTg_4ae4b40d-b8b1-4a2a-8d22-be50dbcf7bcf"
      unitRef="position">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i8ba2d36cfa1140b1984c163783c2d57a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfNi0xLTEtMS01ODU5OA_c1841208-0259-4083-a1fc-486f528ad2e3"
      unitRef="usd">166000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i8ba2d36cfa1140b1984c163783c2d57a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfNi0zLTEtMS01ODU5OA_b69c280a-1a42-4798-98b5-137b5231cdca"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i8ba2d36cfa1140b1984c163783c2d57a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfNi01LTEtMS01ODU5OA_6ad94e9d-68ac-475b-806b-7c1a9aab33bf"
      unitRef="security">75</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i8ba2d36cfa1140b1984c163783c2d57a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfNi03LTEtMS01ODU5OA_9848f903-f950-4da8-a822-0813c67a17df"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i8ba2d36cfa1140b1984c163783c2d57a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfNi05LTEtMS01ODU5OA_ff96c851-6d7c-4eb8-a3b5-20ae0355541f"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i8ba2d36cfa1140b1984c163783c2d57a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfNi0xMS0xLTEtNTg1OTg_a2fa22d2-94b8-4ff9-a3fe-b01f72843cb8"
      unitRef="security">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i9d4d9de95590481dad9718e28b15a44b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfOC0xLTEtMS01ODU5OA_e41e6316-c362-4b07-a861-723cc11c6474"
      unitRef="usd">69000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i9d4d9de95590481dad9718e28b15a44b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfOC0zLTEtMS01ODU5OA_66c6b8fd-ebc5-4963-a617-544877b149ce"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i9d4d9de95590481dad9718e28b15a44b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfOC01LTEtMS01ODU5OA_62cad2d3-838c-42e2-ab8c-275ba100b233"
      unitRef="security">61</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i9d4d9de95590481dad9718e28b15a44b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfOC03LTEtMS01ODU5OA_96674722-05f1-46b1-9107-8bb47d8549a2"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i9d4d9de95590481dad9718e28b15a44b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfOC05LTEtMS01ODU5OA_3365246b-76d3-48bc-b0b3-bf3fed5229db"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i9d4d9de95590481dad9718e28b15a44b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfOC0xMS0xLTEtNTg1OTg_f5a419fd-919f-4b2f-a8ef-5a4626abee24"
      unitRef="security">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfMTItMS0xLTEtNTg1OTg_b501b49c-b23b-44c8-8ad6-455810831f74"
      unitRef="usd">1706000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfMTItMy0xLTEtNTg1OTg_a576c5ca-2d63-4f99-a60f-bb127fd02fe7"
      unitRef="usd">18000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfMTItNS0xLTEtNTg1OTg_f316202e-1bb3-449c-a8b0-16922884fbea"
      unitRef="position">677</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfMTItNy0xLTEtNTg1OTg_3c028701-b736-4856-bd2a-391f63ec507f"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfMTItOS0xLTEtNTg1OTg_5593fd23-f14a-4426-9d41-e475d4ac6398"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81NS9mcmFnOjJiZTg1OWI3M2M3ODQ1NGM4YWUxZmQ1MWFmNTZlMGYyL3RhYmxlOmRkYTY5Mzg2MjI3MjQyMDE4MGU5OGViOWY3NjFiOTUyL3RhYmxlcmFuZ2U6ZGRhNjkzODYyMjcyNDIwMTgwZTk4ZWI5Zjc2MWI5NTJfMTItMTEtMS0xLTU4NTk4_07d09a72-52f9-4fa8-8f28-89e89064efd4"
      unitRef="security">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81OC9mcmFnOmM4MDM0YzhlOWE5YjRkOWViM2ZkZjkzYTYyNzlkOTljL3RleHRyZWdpb246YzgwMzRjOGU5YTliNGQ5ZWIzZmRmOTNhNjI3OWQ5OWNfMTAxMA_c6f064e4-36e3-4131-aa28-ade50e701299"
      unitRef="usd">242000000</us-gaap:DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81OC9mcmFnOmM4MDM0YzhlOWE5YjRkOWViM2ZkZjkzYTYyNzlkOTljL3RleHRyZWdpb246YzgwMzRjOGU5YTliNGQ5ZWIzZmRmOTNhNjI3OWQ5OWNfMTAyOQ_ca1f7242-f5c1-4c19-aecd-72ef29e3ae7a"
      unitRef="usd">201000000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81OC9mcmFnOmM4MDM0YzhlOWE5YjRkOWViM2ZkZjkzYTYyNzlkOTljL3RleHRyZWdpb246YzgwMzRjOGU5YTliNGQ5ZWIzZmRmOTNhNjI3OWQ5OWNfMTA2OQ_8bd36224-05fb-4b5c-b85b-06b227e1325f"
      unitRef="usd">37000000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF81OC9mcmFnOmM4MDM0YzhlOWE5YjRkOWViM2ZkZjkzYTYyNzlkOTljL3RleHRyZWdpb246YzgwMzRjOGU5YTliNGQ5ZWIzZmRmOTNhNjI3OWQ5OWNfMTA5OTUxMTYyODkzNA_a935e30b-ca60-4be0-adbc-eec80bb688c9"
      unitRef="usd">4000000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount>
    <moh:MedicalClaimsAndBenefitsPayableTextBlock
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RleHRyZWdpb246MDgyZDY1NTQ0MzdlNDgyZjkyYjQ3MjI1NTRjNTNiZmZfMTQ3Mg_b5961976-6f68-48f9-8213-010d11d9927b">Medical Claims and Benefits Payable &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the details of our medical claims and benefits payable as of the dates indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Claims incurred but not paid (&#x201c;IBNP&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmacy payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capitation payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;Other&#x201d; medical claims and benefits payable include amounts payable to certain providers for which we act as an intermediary on behalf of various government agencies without assuming financial risk. Such receipts and payments do not impact our consolidated statements of income. Non-risk provider payables amounted to $317 million and $226 million as of September&#160;30, 2022, and December&#160;31, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the components of the change in our medical claims and benefits payable for the periods indicated. The amounts presented for &#x201c;Components of medical care costs related to: Prior years&#x201d; represent the amount by which our original estimate of medical claims and benefits payable at the beginning of the year varied from the actual liabilities, based on information (principally the payment of claims) developed since those liabilities were first reported. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medicaid &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medicare &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketplace&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable, beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Components of medical care costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(282)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total medical care costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments for medical care costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquired balances, net of post-acquisition adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in non-risk and other provider payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable, ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medicaid &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketplace&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable, beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Components of medical care costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(216)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total medical care costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments for medical care costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquired balances, net of post-acquisition adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in non-risk and other provider payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable, ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our estimates of medical claims and benefits payable recorded at December 31, 2021, and 2020 developed favorably by approximately $338 million and $216 million as of September&#160;30, 2022, and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The favorable prior year development recognized in the nine months ended September 30, 2022 was primarily due to lower than expected utilization of medical services by our members and improved operating performance. Consequently, the ultimate costs recognized in 2022, as claims payments were processed, were lower than our estimates in 2021.&lt;/span&gt;&lt;/div&gt;</moh:MedicalClaimsAndBenefitsPayableTextBlock>
    <us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RleHRyZWdpb246MDgyZDY1NTQ0MzdlNDgyZjkyYjQ3MjI1NTRjNTNiZmZfMTQ1Nw_8d03f732-52d9-46e4-a2f7-406cb2f8e04f">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the details of our medical claims and benefits payable as of the dates indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Claims incurred but not paid (&#x201c;IBNP&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmacy payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capitation payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOmNiMGUxYjFlODZhZTQ1NjA5N2FhZTFlMjcwYTllODFkL3RhYmxlcmFuZ2U6Y2IwZTFiMWU4NmFlNDU2MDk3YWFlMWUyNzBhOWU4MWRfMy0xLTEtMS01ODU5OA_374b7a14-527e-448c-880b-b9ec7fc3ed24"
      unitRef="usd">2553000000</moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount>
    <moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOmNiMGUxYjFlODZhZTQ1NjA5N2FhZTFlMjcwYTllODFkL3RhYmxlcmFuZ2U6Y2IwZTFiMWU4NmFlNDU2MDk3YWFlMWUyNzBhOWU4MWRfMy0zLTEtMS01ODU5OA_d41f4c08-a4a2-4b1d-aec9-31e67592856a"
      unitRef="usd">2486000000</moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount>
    <moh:PharmacyClaimsPayable
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOmNiMGUxYjFlODZhZTQ1NjA5N2FhZTFlMjcwYTllODFkL3RhYmxlcmFuZ2U6Y2IwZTFiMWU4NmFlNDU2MDk3YWFlMWUyNzBhOWU4MWRfNC0xLTEtMS01ODU5OA_10f6ea92-f091-47af-8a70-e6525cdb0bfe"
      unitRef="usd">241000000</moh:PharmacyClaimsPayable>
    <moh:PharmacyClaimsPayable
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOmNiMGUxYjFlODZhZTQ1NjA5N2FhZTFlMjcwYTllODFkL3RhYmxlcmFuZ2U6Y2IwZTFiMWU4NmFlNDU2MDk3YWFlMWUyNzBhOWU4MWRfNC0zLTEtMS01ODU5OA_c86882d7-7ad4-48a4-bb60-d67c60a859f2"
      unitRef="usd">219000000</moh:PharmacyClaimsPayable>
    <moh:CapitationClaimsPayable
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOmNiMGUxYjFlODZhZTQ1NjA5N2FhZTFlMjcwYTllODFkL3RhYmxlcmFuZ2U6Y2IwZTFiMWU4NmFlNDU2MDk3YWFlMWUyNzBhOWU4MWRfNS0xLTEtMS01ODU5OA_b508c3d0-59b3-4321-84ea-c7388deb2c6d"
      unitRef="usd">90000000</moh:CapitationClaimsPayable>
    <moh:CapitationClaimsPayable
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOmNiMGUxYjFlODZhZTQ1NjA5N2FhZTFlMjcwYTllODFkL3RhYmxlcmFuZ2U6Y2IwZTFiMWU4NmFlNDU2MDk3YWFlMWUyNzBhOWU4MWRfNS0zLTEtMS01ODU5OA_7abca0be-6a20-4c78-8a84-da75e056c198"
      unitRef="usd">82000000</moh:CapitationClaimsPayable>
    <moh:OtherClaimsPayable
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOmNiMGUxYjFlODZhZTQ1NjA5N2FhZTFlMjcwYTllODFkL3RhYmxlcmFuZ2U6Y2IwZTFiMWU4NmFlNDU2MDk3YWFlMWUyNzBhOWU4MWRfNi0xLTEtMS01ODU5OA_ff630f55-52ae-4c62-ac76-97d18d4eaabd"
      unitRef="usd">738000000</moh:OtherClaimsPayable>
    <moh:OtherClaimsPayable
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOmNiMGUxYjFlODZhZTQ1NjA5N2FhZTFlMjcwYTllODFkL3RhYmxlcmFuZ2U6Y2IwZTFiMWU4NmFlNDU2MDk3YWFlMWUyNzBhOWU4MWRfNi0zLTEtMS01ODU5OA_e2cbab1b-5f05-4da0-bc62-9f61e8f10089"
      unitRef="usd">576000000</moh:OtherClaimsPayable>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOmNiMGUxYjFlODZhZTQ1NjA5N2FhZTFlMjcwYTllODFkL3RhYmxlcmFuZ2U6Y2IwZTFiMWU4NmFlNDU2MDk3YWFlMWUyNzBhOWU4MWRfNy0xLTEtMS01ODU5OA_5d3b981e-2362-4949-bfa4-bff8de81326f"
      unitRef="usd">3622000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOmNiMGUxYjFlODZhZTQ1NjA5N2FhZTFlMjcwYTllODFkL3RhYmxlcmFuZ2U6Y2IwZTFiMWU4NmFlNDU2MDk3YWFlMWUyNzBhOWU4MWRfNy0zLTEtMS01ODU5OA_b382a397-d101-4117-98bf-eb7a17863ef9"
      unitRef="usd">3363000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <moh:MedicalClaimsAndBenefitsPayable
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RleHRyZWdpb246MDgyZDY1NTQ0MzdlNDgyZjkyYjQ3MjI1NTRjNTNiZmZfNDQ1_2b9947de-a52b-4cfe-b669-0b26fb6cb6a5"
      unitRef="usd">317000000</moh:MedicalClaimsAndBenefitsPayable>
    <moh:MedicalClaimsAndBenefitsPayable
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RleHRyZWdpb246MDgyZDY1NTQ0MzdlNDgyZjkyYjQ3MjI1NTRjNTNiZmZfNDUy_c0afc384-a804-49f9-9c06-fcb0c94c2a86"
      unitRef="usd">226000000</moh:MedicalClaimsAndBenefitsPayable>
    <moh:ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RleHRyZWdpb246MDgyZDY1NTQ0MzdlNDgyZjkyYjQ3MjI1NTRjNTNiZmZfMTQ0Nw_0f2ce2e8-e091-4ac5-a2c9-cd93f8a9f8b0">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the components of the change in our medical claims and benefits payable for the periods indicated. The amounts presented for &#x201c;Components of medical care costs related to: Prior years&#x201d; represent the amount by which our original estimate of medical claims and benefits payable at the beginning of the year varied from the actual liabilities, based on information (principally the payment of claims) developed since those liabilities were first reported. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medicaid &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medicare &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketplace&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable, beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Components of medical care costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(282)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total medical care costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments for medical care costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquired balances, net of post-acquisition adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in non-risk and other provider payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable, ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medicaid &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketplace&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable, beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Components of medical care costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(216)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total medical care costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments for medical care costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquired balances, net of post-acquisition adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in non-risk and other provider payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable, ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</moh:ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i2b797bdb341b4b52895da42aa2124960_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfNC0xLTEtMS01ODU5OA_142f8563-76f4-436e-a47c-4c695b1c1930"
      unitRef="usd">2580000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i869f5f0099fe46b693a48fd139483e93_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfNC0zLTEtMS01ODU5OA_5bcbf882-9b73-4e63-aace-d7f9fdf66b4e"
      unitRef="usd">404000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ia584820ec62b4608b407558882249b92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfNC01LTEtMS01ODU5OA_beee24b3-c4e1-4eff-8b90-be19437d9230"
      unitRef="usd">379000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfNC03LTEtMS01ODU5OA_98ddae3b-9071-4255-be19-d11675b349f4"
      unitRef="usd">3363000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i4ec20456c73b4f1f8e73015480eac437_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfNi0xLTEtMS01ODU5OA_5471da70-45ff-4833-8152-062fb76cbc61"
      unitRef="usd">16520000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i0963d8c883c844e6b0f9b360576e525d_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfNi0zLTEtMS01ODU5OA_613cf1a3-d557-48c2-9b17-d0706c67d935"
      unitRef="usd">2525000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i7b425cf2189f45f795be7031fbb9489a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfNi01LTEtMS01ODU5OA_16e508a1-cfab-419a-b575-3c5f97574642"
      unitRef="usd">1476000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfNi03LTEtMS01ODU5OA_6097a348-f0a6-4573-a84f-f369c789b18d"
      unitRef="usd">20521000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i4ec20456c73b4f1f8e73015480eac437_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfNy0xLTEtMS01ODU5OA_296fb3cb-3676-48ab-86dc-6455dc3d5121"
      unitRef="usd">-282000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i0963d8c883c844e6b0f9b360576e525d_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfNy0zLTEtMS01ODU5OA_acc418bd-80a0-4726-b130-f712255074bd"
      unitRef="usd">-38000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i7b425cf2189f45f795be7031fbb9489a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfNy01LTEtMS01ODU5OA_87abf53d-46f8-4752-8bb9-951d07190a54"
      unitRef="usd">-18000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfNy03LTEtMS01ODU5OA_1136879e-0222-4450-accf-2ee55c2b7980"
      unitRef="usd">-338000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i4ec20456c73b4f1f8e73015480eac437_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfOC0xLTEtMS01ODU5OA_dfba129e-aea8-442a-b10c-47eca61fb343"
      unitRef="usd">16238000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i0963d8c883c844e6b0f9b360576e525d_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfOC0zLTEtMS01ODU5OA_8b507429-7a32-4dc3-a4cb-2f54dc018dff"
      unitRef="usd">2487000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i7b425cf2189f45f795be7031fbb9489a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfOC01LTEtMS01ODU5OA_65229b1e-da8c-498e-b21c-d0c950db4ae6"
      unitRef="usd">1458000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfOC03LTEtMS01ODU5OA_49508de9-6ee2-4cb4-baea-05bfee21e52a"
      unitRef="usd">20183000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i4ec20456c73b4f1f8e73015480eac437_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTAtMS0xLTEtNTg1OTg_6090c282-d1c9-4c42-a232-01acfb316310"
      unitRef="usd">14133000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i0963d8c883c844e6b0f9b360576e525d_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTAtMy0xLTEtNTg1OTg_01a374cb-d3ef-45b6-9de5-876405b117ea"
      unitRef="usd">2103000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i7b425cf2189f45f795be7031fbb9489a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTAtNS0xLTEtNTg1OTg_d6c2a94c-c473-48e5-9024-8be7385ae4fa"
      unitRef="usd">1302000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTAtNy0xLTEtNTg1OTg_b11d2b85-44f5-44b8-baef-4f6724126c4c"
      unitRef="usd">17538000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i4ec20456c73b4f1f8e73015480eac437_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTEtMS0xLTEtNTg1OTg_b8929f15-bec5-4537-a72e-d5c5d624d742"
      unitRef="usd">1861000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i0963d8c883c844e6b0f9b360576e525d_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTEtMy0xLTEtNTg1OTg_ee9ad45c-86ba-437a-acec-9a5b6fc63090"
      unitRef="usd">337000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i7b425cf2189f45f795be7031fbb9489a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTEtNS0xLTEtNTg1OTg_3e311180-616e-470f-addc-b4663a06363c"
      unitRef="usd">283000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTEtNy0xLTEtNTg1OTg_44e65bc4-e39b-42f2-beec-4224a0751898"
      unitRef="usd">2481000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i4ec20456c73b4f1f8e73015480eac437_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTItMS0xLTEtNTg1OTg_f64db07f-1cdd-4faf-bc4c-68571d71387b"
      unitRef="usd">15994000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i0963d8c883c844e6b0f9b360576e525d_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTItMy0xLTEtNTg1OTg_bd113cc0-7637-4961-9339-31bb2a59467a"
      unitRef="usd">2440000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i7b425cf2189f45f795be7031fbb9489a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTItNS0xLTEtNTg1OTg_defd00d7-ee73-4440-b96f-ba7193c62e71"
      unitRef="usd">1585000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTItNy0xLTEtNTg1OTg_6273522c-e56b-4e70-84bb-914fe36ea7a3"
      unitRef="usd">20019000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments
      contextRef="i4ec20456c73b4f1f8e73015480eac437_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTMtMS0xLTEtNTg1OTg_4dcaf553-687f-415e-a35d-2cca0da7aa36"
      unitRef="usd">8000000</moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments>
    <moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments
      contextRef="i0963d8c883c844e6b0f9b360576e525d_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTMtMy0xLTEtNTg1OTg_51fe4998-1346-4add-954b-64359166c6ac"
      unitRef="usd">0</moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments>
    <moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments
      contextRef="i7b425cf2189f45f795be7031fbb9489a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTMtNS0xLTEtNTg1OTg_ba1e573b-ff61-4cb9-8956-b4056beb2eea"
      unitRef="usd">0</moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments>
    <moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTMtNy0xLTEtNTg1OTg_a4656cdc-d740-45d0-a7c2-6e0cee21319e"
      unitRef="usd">8000000</moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments>
    <moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
      contextRef="i4ec20456c73b4f1f8e73015480eac437_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTQtMS0xLTEtNTg1OTg_d4c87a69-36ac-440c-907f-35c0bb79d325"
      unitRef="usd">91000000</moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider>
    <moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
      contextRef="i0963d8c883c844e6b0f9b360576e525d_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTQtMy0xLTEtNTg1OTg_1a629d4e-b609-4bac-bf1c-6a594d74954d"
      unitRef="usd">-4000000</moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider>
    <moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
      contextRef="i7b425cf2189f45f795be7031fbb9489a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTQtNS0xLTEtNTg1OTg_958c23ec-eaa8-4e70-b425-db91b09d8c32"
      unitRef="usd">0</moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider>
    <moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTQtNy0xLTEtNTg1OTg_775138eb-f68d-48c7-be26-f346768f67f8"
      unitRef="usd">87000000</moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i787d3e77233e4de9930c7143d7f3e1a7_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTUtMS0xLTEtNTg1OTg_3aa1a115-a815-4d2a-848d-2a4e36e1be1c"
      unitRef="usd">2923000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="idc0945cdffc8424d957d806d4e965885_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTUtMy0xLTEtNTg1OTg_6d2d104d-482a-4a4b-aebb-043d53ef892c"
      unitRef="usd">447000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i01ba4967c8b8496c94ad918efed3e1d4_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTUtNS0xLTEtNTg1OTg_e5a06f20-6842-4624-8ccf-43c0d4b6300e"
      unitRef="usd">252000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjYwNDBiZDc4ODQzZTQwODY4ZDc5MDljZTZmODQ4YmYzL3RhYmxlcmFuZ2U6NjA0MGJkNzg4NDNlNDA4NjhkNzkwOWNlNmY4NDhiZjNfMTUtNy0xLTEtNTg1OTg_be6ee1fb-41cf-4e94-8db2-bd92002c16ce"
      unitRef="usd">3622000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="if4629290b4494a1da97fe2a340b52e86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfNC0xLTEtMS01ODU5OA_5538493d-7e7a-4ee7-928c-490b49b82124"
      unitRef="usd">2129000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i9817ab0688744030bccbbc4527c6ad07_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfNC0zLTEtMS01ODU5OA_79fd7fa4-12e1-4fbd-90ff-a81ca1dcd576"
      unitRef="usd">392000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="icd9f5b7b16064fb4b96d01f818feee51_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfNC01LTEtMS01ODU5OA_e43139a6-dfe3-4215-b80b-be983841b8f4"
      unitRef="usd">175000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i2a1055b0f36c4bbd91048d943dbf64df_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfNC03LTEtMS01ODU5OA_5257ca7e-9250-46bb-8315-e7ddff704e63"
      unitRef="usd">2696000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="ie7d644d1ac344e6fa4918cd4a83af717_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfNi0xLTEtMS01ODU5OA_776e4417-fac4-4a7f-9100-0f50cae1b0c1"
      unitRef="usd">13491000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i2212dcd7830b49eca79d05facc1aaac8_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfNi0zLTEtMS01ODU5OA_73d9829e-4ec6-4fc9-8205-dabee3864dd1"
      unitRef="usd">2195000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i3877802cf9094a9eabfc486981832840_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfNi01LTEtMS01ODU5OA_cfc3af8c-a77e-4ff6-b065-cb182820285f"
      unitRef="usd">1872000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfNi03LTEtMS01ODU5OA_eaa384de-37d8-471d-826e-66ff40346497"
      unitRef="usd">17558000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="ie7d644d1ac344e6fa4918cd4a83af717_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfNy0xLTEtMS01ODU5OA_3704311c-c8fc-4187-9565-53a2e6149714"
      unitRef="usd">-158000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i2212dcd7830b49eca79d05facc1aaac8_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfNy0zLTEtMS01ODU5OA_8c0ed572-6ff0-4c55-b2a9-3d53089b72a4"
      unitRef="usd">-36000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i3877802cf9094a9eabfc486981832840_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfNy01LTEtMS01ODU5OA_61a0f1f3-60bd-4b78-904d-7098bee6d0ca"
      unitRef="usd">-22000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfNy03LTEtMS01ODU5OA_7b818db2-ace5-4350-9ad7-88ee02fe496c"
      unitRef="usd">-216000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="ie7d644d1ac344e6fa4918cd4a83af717_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfOC0xLTEtMS01ODU5OA_bceea7dd-4d16-4c17-99e4-e7b012298d98"
      unitRef="usd">13333000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i2212dcd7830b49eca79d05facc1aaac8_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfOC0zLTEtMS01ODU5OA_7d52fc14-89c7-42b8-acff-a7678b4b0ddd"
      unitRef="usd">2159000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i3877802cf9094a9eabfc486981832840_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfOC01LTEtMS01ODU5OA_c411edf8-2ec3-45b5-b708-da596c336cab"
      unitRef="usd">1850000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfOC03LTEtMS01ODU5OA_4d1346a6-b8f4-4472-b337-426de04810a6"
      unitRef="usd">17342000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="ie7d644d1ac344e6fa4918cd4a83af717_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTAtMS0xLTEtNTg1OTg_ec080023-3c0a-4eb9-95a4-68a6d33f4798"
      unitRef="usd">11530000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i2212dcd7830b49eca79d05facc1aaac8_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTAtMy0xLTEtNTg1OTg_069495c9-c4c0-452a-bf20-41b824bc96fd"
      unitRef="usd">1816000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i3877802cf9094a9eabfc486981832840_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTAtNS0xLTEtNTg1OTg_1f7b3255-2b04-42e6-a215-d3f684fdca65"
      unitRef="usd">1534000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTAtNy0xLTEtNTg1OTg_62484998-096e-4ebf-b62c-a5a96a711486"
      unitRef="usd">14880000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="ie7d644d1ac344e6fa4918cd4a83af717_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTEtMS0xLTEtNTg1OTg_d00dfaaf-c8a2-4530-9a09-0cf210d72bab"
      unitRef="usd">1538000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i2212dcd7830b49eca79d05facc1aaac8_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTEtMy0xLTEtNTg1OTg_b0ea4082-5a9f-4812-9f1a-cc316971aee9"
      unitRef="usd">340000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i3877802cf9094a9eabfc486981832840_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTEtNS0xLTEtNTg1OTg_2170a761-6321-4f1c-9f6f-a79b0ce6d48c"
      unitRef="usd">130000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTEtNy0xLTEtNTg1OTg_bebee4f4-222c-4433-8431-b98af8d2710a"
      unitRef="usd">2008000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="ie7d644d1ac344e6fa4918cd4a83af717_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTItMS0xLTEtNTg1OTg_7b9e3560-de6a-45a5-bb0a-1c4006505be0"
      unitRef="usd">13068000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i2212dcd7830b49eca79d05facc1aaac8_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTItMy0xLTEtNTg1OTg_66f245b4-8898-4f44-90e7-b9e7801ce899"
      unitRef="usd">2156000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i3877802cf9094a9eabfc486981832840_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTItNS0xLTEtNTg1OTg_ba1260eb-4a01-4391-854b-2e201feb96c7"
      unitRef="usd">1664000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTItNy0xLTEtNTg1OTg_94b33189-8ba7-48dd-baa8-009c22799bc5"
      unitRef="usd">16888000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments
      contextRef="ie7d644d1ac344e6fa4918cd4a83af717_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTMtMS0xLTEtNTg1OTg_7ca24cbc-fec4-4bdc-9fde-885d83071f90"
      unitRef="usd">-19000000</moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments>
    <moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments
      contextRef="i2212dcd7830b49eca79d05facc1aaac8_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTMtMy0xLTEtNTg1OTg_81a2435b-2ac2-4abf-985a-91cb3985ae3e"
      unitRef="usd">-8000000</moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments>
    <moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments
      contextRef="i3877802cf9094a9eabfc486981832840_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTMtNS0xLTEtNTg1OTg_62074690-9257-46df-9b00-8a58bc2bdbfb"
      unitRef="usd">0</moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments>
    <moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTMtNy0xLTEtNTg1OTg_fa64e710-bb4e-4c01-b1d1-4eef5b7867cc"
      unitRef="usd">-27000000</moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments>
    <moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
      contextRef="ie7d644d1ac344e6fa4918cd4a83af717_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTQtMS0xLTEtNTg1OTg_14efdb8b-1fb3-46cd-893f-ed1e10f9a593"
      unitRef="usd">68000000</moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider>
    <moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
      contextRef="i2212dcd7830b49eca79d05facc1aaac8_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTQtMy0xLTEtNTg1OTg_126d12d0-6c9a-454c-ba7e-4551d62ff10e"
      unitRef="usd">0</moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider>
    <moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
      contextRef="i3877802cf9094a9eabfc486981832840_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTQtNS0xLTEtNTg1OTg_137732da-8796-4be2-b266-4b612f5d08d6"
      unitRef="usd">0</moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider>
    <moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTQtNy0xLTEtNTg1OTg_13646b27-6c51-4c1d-8306-66d26c6dfc2f"
      unitRef="usd">68000000</moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ia1698bae97ab44ee92e15544064ddc75_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTUtMS0xLTEtNTg1OTg_8f3e0f2a-650e-423f-bf56-c602f6228c3b"
      unitRef="usd">2443000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i77d77fe305a64bacbf04f03c5378f673_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTUtMy0xLTEtNTg1OTg_e35ca902-7cfd-4a82-af45-2c30f9a2874f"
      unitRef="usd">387000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ic24da3c878854020a39db2e88f0312b7_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTUtNS0xLTEtNTg1OTg_3122d3a9-4a6e-402b-bd61-dba49725dd61"
      unitRef="usd">361000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ia5f8e83b346f4a789040e8611fbb11f6_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RhYmxlOjE4ZWI4MDIxZmYzMjQ2OWQ4YjI5NjliMGQ4YTBlY2ZiL3RhYmxlcmFuZ2U6MThlYjgwMjFmZjMyNDY5ZDhiMjk2OWIwZDhhMGVjZmJfMTUtNy0xLTEtNTg1OTg_ae8eb354-c824-4806-b339-9e07351b43fd"
      unitRef="usd">3191000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RleHRyZWdpb246MDgyZDY1NTQ0MzdlNDgyZjkyYjQ3MjI1NTRjNTNiZmZfMTEwMA_1136879e-0222-4450-accf-2ee55c2b7980"
      unitRef="usd">-338000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82MS9mcmFnOjA4MmQ2NTU0NDM3ZTQ4MmY5MmI0NzIyNTU0YzUzYmZmL3RleHRyZWdpb246MDgyZDY1NTQ0MzdlNDgyZjkyYjQ3MjI1NTRjNTNiZmZfMTEwNw_7b818db2-ace5-4350-9ad7-88ee02fe496c"
      unitRef="usd">-216000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LongTermDebtTextBlock
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RleHRyZWdpb246NWFhMTA3MTI0OTc5NGFkNzhlZTQyNDM2M2M3YzE0ZDVfMjY1MA_803be1ff-2e36-4586-b607-24888aa0c5d7">Debt &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All our debt is held at the parent, which is reported in the Other segment. The following table summarizes our outstanding debt obligations, all of which are non-current as of the dates reported below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-current long-term debt:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.375% Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.875% Notes due 2030 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.875% Notes due 2032&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred debt issuance costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are party to a credit agreement (the &#x201c;Credit Agreement&#x201d;) which includes a revolving credit facility (&#x201c;Credit Facility&#x201d;) of $1.0 billion, among other provisions. The Credit Agreement has a term of five years, and all amounts outstanding will be due and payable on June 8, 2025. Borrowings under the Credit Agreement bear interest based, at our election, on a base rate or other defined rate, plus in each case, the applicable margin. In addition to interest payable on the principal amount of indebtedness outstanding from time to time under the Credit Agreement, we are required to pay a quarterly commitment fee.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Credit Agreement contains customary non-financial and financial covenants. As of September&#160;30, 2022, we were in compliance with all financial and non-financial covenants under the Credit Agreement. As of September&#160;30, 2022, no amounts were outstanding under the Credit Facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Senior Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our senior notes are described below. Each of these notes are senior unsecured obligations of Molina and rank equally in right of payment with all existing and future senior debt, and senior to all existing and future subordinated &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;debt of Molina. In addition, each of the indentures governing the senior notes contain customary non-financial covenants and change of control provisions. As of September&#160;30, 2022, we were in compliance with all non-financial covenants in the indentures governing the senior notes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The indentures governing the senior notes contain cross-default provisions that are triggered upon default by us or any of our subsidiaries on any indebtedness in excess of the amount specified in the applicable indenture. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;4.375% Notes due 2028.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had $800 million aggregate principal amount of senior notes (the &#x201c;4.375% Notes&#x201d;) outstanding as of September&#160;30, 2022, which are due June 15, 2028, unless earlier redeemed. Interest, at a rate of 4.375% per annum, is payable semiannually in arrears on June 15 and December 15.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;3.875% Notes due 2030. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had $650 million aggregate principal amount of senior notes (the &#x201c;3.875% Notes due 2030&#x201d;) outstanding as of September&#160;30, 2022, which are due November 15, 2030, unless earlier redeemed. Interest, at a rate of 3.875% per annum, is payable semiannually in arrears on May 15 and November 15.&lt;/span&gt;&lt;/div&gt;3.875% Notes due 2032. We had $750 million aggregate principal amount of senior notes (the &#x201c;3.875% Notes due 2032&#x201d;) outstanding as of September&#160;30, 2022, which are due May 15, 2032, unless earlier redeemed. Interest, at a rate of 3.875% per annum, is payable semiannually in arrears on May 15 and November 15.</us-gaap:LongTermDebtTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RleHRyZWdpb246NWFhMTA3MTI0OTc5NGFkNzhlZTQyNDM2M2M3YzE0ZDVfMjY0Nw_12b1382c-751e-44f0-af7e-b342374c0a84">The following table summarizes our outstanding debt obligations, all of which are non-current as of the dates reported below:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-current long-term debt:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.375% Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.875% Notes due 2030 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.875% Notes due 2032&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred debt issuance costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2215166a13a24f4ea0beb4f9ec5386b9_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RhYmxlOmM2ODUyYzdjNDFmNzRhMzliMzg2N2E5MjAyMWU0ODY1L3RhYmxlcmFuZ2U6YzY4NTJjN2M0MWY3NGEzOWIzODY3YTkyMDIxZTQ4NjVfOC0wLTEtMS01ODU5OC90ZXh0cmVnaW9uOjhmOWVkZjkwM2QzZTQ2Mzk4MzQ3MGY0NWI3NmEwYTAwXzQ_684c7b56-c616-4156-b6af-c055e1225af1"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount
      contextRef="i2215166a13a24f4ea0beb4f9ec5386b9_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RhYmxlOmM2ODUyYzdjNDFmNzRhMzliMzg2N2E5MjAyMWU0ODY1L3RhYmxlcmFuZ2U6YzY4NTJjN2M0MWY3NGEzOWIzODY3YTkyMDIxZTQ4NjVfOC0xLTEtMS01ODU5OA_6852a502-0f57-4ae6-b1e3-c12bcb65fe27"
      unitRef="usd">800000000</moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount>
    <moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount
      contextRef="ic26c41034fae49aeaa64c74ef2218d5a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RhYmxlOmM2ODUyYzdjNDFmNzRhMzliMzg2N2E5MjAyMWU0ODY1L3RhYmxlcmFuZ2U6YzY4NTJjN2M0MWY3NGEzOWIzODY3YTkyMDIxZTQ4NjVfOC0zLTEtMS01ODU5OA_4e79444b-ff29-4e5b-87f3-e09a8d3095e6"
      unitRef="usd">800000000</moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4568007f62514af188a722dbbfff6949_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RhYmxlOmM2ODUyYzdjNDFmNzRhMzliMzg2N2E5MjAyMWU0ODY1L3RhYmxlcmFuZ2U6YzY4NTJjN2M0MWY3NGEzOWIzODY3YTkyMDIxZTQ4NjVfOS0wLTEtMS01ODU5OC90ZXh0cmVnaW9uOmFlMDA3MmVmOWEyMzQzMDQ5Nzk1YjM5M2ZmODViNWY4XzQ_9cdb5704-1c74-42e5-96c0-beb98c5331f6"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount
      contextRef="i4568007f62514af188a722dbbfff6949_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RhYmxlOmM2ODUyYzdjNDFmNzRhMzliMzg2N2E5MjAyMWU0ODY1L3RhYmxlcmFuZ2U6YzY4NTJjN2M0MWY3NGEzOWIzODY3YTkyMDIxZTQ4NjVfOS0xLTEtMS01ODU5OA_93014218-7d8c-4ac9-8083-a7cb97e2fd3d"
      unitRef="usd">650000000</moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount>
    <moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount
      contextRef="i50750950b870483d9018a954d9657216_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RhYmxlOmM2ODUyYzdjNDFmNzRhMzliMzg2N2E5MjAyMWU0ODY1L3RhYmxlcmFuZ2U6YzY4NTJjN2M0MWY3NGEzOWIzODY3YTkyMDIxZTQ4NjVfOS0zLTEtMS01ODU5OA_8ce04534-a0c5-4907-a0dd-0d420a173568"
      unitRef="usd">650000000</moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i68670e57970547ba9f2bb65e407ef0c3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RhYmxlOmM2ODUyYzdjNDFmNzRhMzliMzg2N2E5MjAyMWU0ODY1L3RhYmxlcmFuZ2U6YzY4NTJjN2M0MWY3NGEzOWIzODY3YTkyMDIxZTQ4NjVfMTAtMC0xLTEtNTg1OTgvdGV4dHJlZ2lvbjpmMTgzN2I5YTkyNWM0ODI1YjU1MzU5ZmM5MjdlZDUwY180_8eaa68b5-c180-4f43-88af-764c0af6a117"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount
      contextRef="i68670e57970547ba9f2bb65e407ef0c3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RhYmxlOmM2ODUyYzdjNDFmNzRhMzliMzg2N2E5MjAyMWU0ODY1L3RhYmxlcmFuZ2U6YzY4NTJjN2M0MWY3NGEzOWIzODY3YTkyMDIxZTQ4NjVfMTAtMS0xLTEtNTg1OTg_95b1ee86-47cf-4cc1-8016-d67a5651d906"
      unitRef="usd">750000000</moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount>
    <moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount
      contextRef="if5dabbb9212b4359ba854b1a8c18e537_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RhYmxlOmM2ODUyYzdjNDFmNzRhMzliMzg2N2E5MjAyMWU0ODY1L3RhYmxlcmFuZ2U6YzY4NTJjN2M0MWY3NGEzOWIzODY3YTkyMDIxZTQ4NjVfMTAtMy0xLTEtNTg1OTg_7fce9dad-9be6-4ef1-9ace-869d177d521e"
      unitRef="usd">750000000</moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount>
    <us-gaap:DeferredFinanceCostsNoncurrentNet
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RhYmxlOmM2ODUyYzdjNDFmNzRhMzliMzg2N2E5MjAyMWU0ODY1L3RhYmxlcmFuZ2U6YzY4NTJjN2M0MWY3NGEzOWIzODY3YTkyMDIxZTQ4NjVfMTEtMS0xLTEtNTg1OTg_3959c940-421a-4511-9d2f-8963f8e4ba85"
      unitRef="usd">25000000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:DeferredFinanceCostsNoncurrentNet
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RhYmxlOmM2ODUyYzdjNDFmNzRhMzliMzg2N2E5MjAyMWU0ODY1L3RhYmxlcmFuZ2U6YzY4NTJjN2M0MWY3NGEzOWIzODY3YTkyMDIxZTQ4NjVfMTEtMy0xLTEtNTg1OTg_78ea4980-c7ee-4852-b121-69883b77bef2"
      unitRef="usd">27000000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3214220ebe41400a954cc43a8c3bc8a6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RhYmxlOmM2ODUyYzdjNDFmNzRhMzliMzg2N2E5MjAyMWU0ODY1L3RhYmxlcmFuZ2U6YzY4NTJjN2M0MWY3NGEzOWIzODY3YTkyMDIxZTQ4NjVfMTItMS0xLTEtNTg1OTg_a9d60da3-13f6-470a-88e0-40385a47b788"
      unitRef="usd">2175000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ie7f3faa154394153bb16052f2634e5ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RhYmxlOmM2ODUyYzdjNDFmNzRhMzliMzg2N2E5MjAyMWU0ODY1L3RhYmxlcmFuZ2U6YzY4NTJjN2M0MWY3NGEzOWIzODY3YTkyMDIxZTQ4NjVfMTItMy0xLTEtNTg1OTg_ef44a177-d40c-44a6-8759-3a212b658ed5"
      unitRef="usd">2173000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i45addfb2824d4400bae53112a7856042_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RleHRyZWdpb246NWFhMTA3MTI0OTc5NGFkNzhlZTQyNDM2M2M3YzE0ZDVfMzYw_170240bf-aea5-4049-9085-94434278e0cb"
      unitRef="usd">1000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm
      contextRef="if5d5359290144d4f933ac919de58b333_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RleHRyZWdpb246NWFhMTA3MTI0OTc5NGFkNzhlZTQyNDM2M2M3YzE0ZDVfNDIz_5f1013fe-af1a-463b-ab85-2a8086fa2dbe">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCredit
      contextRef="i45addfb2824d4400bae53112a7856042_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RleHRyZWdpb246NWFhMTA3MTI0OTc5NGFkNzhlZTQyNDM2M2M3YzE0ZDVfMTAyOQ_947a48d4-7c7e-41fb-8f96-447e6cbf789f"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2215166a13a24f4ea0beb4f9ec5386b9_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RleHRyZWdpb246NWFhMTA3MTI0OTc5NGFkNzhlZTQyNDM2M2M3YzE0ZDVfMTgyMA_684c7b56-c616-4156-b6af-c055e1225af1"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i2215166a13a24f4ea0beb4f9ec5386b9_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RleHRyZWdpb246NWFhMTA3MTI0OTc5NGFkNzhlZTQyNDM2M2M3YzE0ZDVfMTg0Ng_2d132671-b06c-47b3-bf27-c0ea14f2b33c"
      unitRef="usd">800000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2215166a13a24f4ea0beb4f9ec5386b9_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RleHRyZWdpb246NWFhMTA3MTI0OTc5NGFkNzhlZTQyNDM2M2M3YzE0ZDVfMTg5OA_684c7b56-c616-4156-b6af-c055e1225af1"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2215166a13a24f4ea0beb4f9ec5386b9_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RleHRyZWdpb246NWFhMTA3MTI0OTc5NGFkNzhlZTQyNDM2M2M3YzE0ZDVfMjAwOA_684c7b56-c616-4156-b6af-c055e1225af1"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4568007f62514af188a722dbbfff6949_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RleHRyZWdpb246NWFhMTA3MTI0OTc5NGFkNzhlZTQyNDM2M2M3YzE0ZDVfMjA4NQ_9cdb5704-1c74-42e5-96c0-beb98c5331f6"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i4568007f62514af188a722dbbfff6949_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RleHRyZWdpb246NWFhMTA3MTI0OTc5NGFkNzhlZTQyNDM2M2M3YzE0ZDVfMjExMQ_d494ff5c-6123-46ed-9e5b-850257dfb2a5"
      unitRef="usd">650000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4568007f62514af188a722dbbfff6949_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RleHRyZWdpb246NWFhMTA3MTI0OTc5NGFkNzhlZTQyNDM2M2M3YzE0ZDVfMjE2Mw_9cdb5704-1c74-42e5-96c0-beb98c5331f6"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4568007f62514af188a722dbbfff6949_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RleHRyZWdpb246NWFhMTA3MTI0OTc5NGFkNzhlZTQyNDM2M2M3YzE0ZDVfMjI4Ng_9cdb5704-1c74-42e5-96c0-beb98c5331f6"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i68670e57970547ba9f2bb65e407ef0c3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RleHRyZWdpb246NWFhMTA3MTI0OTc5NGFkNzhlZTQyNDM2M2M3YzE0ZDVfMjM2Mg_8eaa68b5-c180-4f43-88af-764c0af6a117"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i68670e57970547ba9f2bb65e407ef0c3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RleHRyZWdpb246NWFhMTA3MTI0OTc5NGFkNzhlZTQyNDM2M2M3YzE0ZDVfMjM4OA_0523e0fd-f61e-46dd-a1ca-e3418bca20e4"
      unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i68670e57970547ba9f2bb65e407ef0c3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RleHRyZWdpb246NWFhMTA3MTI0OTc5NGFkNzhlZTQyNDM2M2M3YzE0ZDVfMjQ0MA_8eaa68b5-c180-4f43-88af-764c0af6a117"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i68670e57970547ba9f2bb65e407ef0c3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82NC9mcmFnOjVhYTEwNzEyNDk3OTRhZDc4ZWU0MjQzNjNjN2MxNGQ1L3RleHRyZWdpb246NWFhMTA3MTI0OTc5NGFkNzhlZTQyNDM2M2M3YzE0ZDVfMjU1OA_8eaa68b5-c180-4f43-88af-764c0af6a117"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82Ny9mcmFnOmY2NTIwZWZlMTJhNzRkZWU4NGQ5YWQ5MWMwMDczNzJkL3RleHRyZWdpb246ZjY1MjBlZmUxMmE3NGRlZTg0ZDlhZDkxYzAwNzM3MmRfNzMw_d51737a9-d538-4f27-b0c6-54bf6e91a7cb">Stockholders' Equity In September 2021, our board of directors authorized the purchase of up to $500&#160;million, in the aggregate, of our common stock. This new program, which superseded the stock purchase program approved by our board of directors in September 2020, is funded with cash on hand and extends through December 31, 2022. The exact timing and amount of any repurchase is determined by management based on market conditions and share price, in addition to other factors, and subject to the restrictions relating to volume, price, and timing under applicable law.  Under this program, pursuant to a Rule 10b5-1 trading plan, we purchased approximately 658,000 shares for $200&#160;million in the second quarter of 2022 (average cost of $304.13 per share).</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i98de094b8bc642c2838aa6ef19a8ed9a_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82Ny9mcmFnOmY2NTIwZWZlMTJhNzRkZWU4NGQ5YWQ5MWMwMDczNzJkL3RleHRyZWdpb246ZjY1MjBlZmUxMmE3NGRlZTg0ZDlhZDkxYzAwNzM3MmRfODg_ca3c6266-f4c3-4e25-af66-bc8d72b9fad1"
      unitRef="usd">500000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="iea66be3daee34721bcd1e066d3260b58_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82Ny9mcmFnOmY2NTIwZWZlMTJhNzRkZWU4NGQ5YWQ5MWMwMDczNzJkL3RleHRyZWdpb246ZjY1MjBlZmUxMmE3NGRlZTg0ZDlhZDkxYzAwNzM3MmRfNjQy_200656c4-c416-495e-ad45-bf843fb87a1f"
      unitRef="shares">658000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="iea66be3daee34721bcd1e066d3260b58_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82Ny9mcmFnOmY2NTIwZWZlMTJhNzRkZWU4NGQ5YWQ5MWMwMDczNzJkL3RleHRyZWdpb246ZjY1MjBlZmUxMmE3NGRlZTg0ZDlhZDkxYzAwNzM3MmRfNjU2_1c043e63-66a2-432e-87d8-e75cbe6eb3ad"
      unitRef="usd">200000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="iea66be3daee34721bcd1e066d3260b58_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF82Ny9mcmFnOmY2NTIwZWZlMTJhNzRkZWU4NGQ5YWQ5MWMwMDczNzJkL3RleHRyZWdpb246ZjY1MjBlZmUxMmE3NGRlZTg0ZDlhZDkxYzAwNzM3MmRfNzA2_14d21e77-e2a8-4131-b28b-36edafbb3ed0"
      unitRef="usdPerShare">304.13</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RleHRyZWdpb246MzNjZTdlOWJkNTkwNDg2YmI0YTVjOTJmYjAxNTNhOGRfMjA2OA_e373b7d7-09a5-47e5-bfce-ac7eef012461">Segments &lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We currently have four reportable segments consisting of: 1)&#160;Medicaid; 2)&#160;Medicare; 3)&#160;Marketplace; and 4)&#160;Other. Our reportable segments are consistent with how we currently manage the business and view the markets we serve. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which we offer managed healthcare services. The Other segment, which is insignificant to our consolidated results of operations, includes certain corporate amounts not associated with or allocated to the Medicaid, Medicare, or Marketplace segments. Additionally, the Other segment includes service revenues and service costs associated with the long-term services and supports consultative services we provide in Wisconsin.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The key metrics used to assess the performance of our Medicaid, Medicare, and Marketplace segments are premium revenue, medical margin and medical care ratio (&#x201c;MCR&#x201d;). MCR represents the amount of medical care costs as a percentage of premium revenue. Therefore, the underlying medical margin, or the amount earned by the Medicaid, Medicare, and Marketplace segments after medical costs are deducted from premium revenue, represents the most important measure of earnings reviewed by management, and is used by our chief executive officer to review results, assess performance, and allocate resources. The key metric used to assess the performance of our Other segment is service margin. The service margin is equal to service revenue minus cost of service revenue. We do not report total assets by segment because this is not a metric used to assess segment performance or allocate resources.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents total revenue by segment. Inter-segment revenue was insignificant for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.301%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketplace&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles margin by segment to consolidated income before income taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.238%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Margin:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketplace&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total margin &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Add: other operating revenues &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: other operating expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(829)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(756)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,455)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other expenses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income before income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt"&gt;Other operating revenues include premium tax revenue, investment income, and other revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt"&gt;Other operating expenses include general and administrative expenses, premium tax expenses, depreciation and amortization, and other operating expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RleHRyZWdpb246MzNjZTdlOWJkNTkwNDg2YmI0YTVjOTJmYjAxNTNhOGRfMTY_6925dc79-7402-4807-b44c-808fb9018835"
      unitRef="segment">4</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RleHRyZWdpb246MzNjZTdlOWJkNTkwNDg2YmI0YTVjOTJmYjAxNTNhOGRfMjA1OA_479385cf-2e05-4dfc-8e81-8c884b08122a">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents total revenue by segment. Inter-segment revenue was insignificant for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.301%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketplace&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles margin by segment to consolidated income before income taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.238%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Margin:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketplace&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total margin &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Add: other operating revenues &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: other operating expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(829)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(756)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,455)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other expenses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income before income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt"&gt;Other operating revenues include premium tax revenue, investment income, and other revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt"&gt;Other operating expenses include general and administrative expenses, premium tax expenses, depreciation and amortization, and other operating expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues
      contextRef="iedddb1611ce1453d8bc04f5aa0c8509c_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjZmYTNlMTJmMTY5MjQyZjg4Y2Q1MGM4NTkyZTk2ODQyL3RhYmxlcmFuZ2U6NmZhM2UxMmYxNjkyNDJmODhjZDUwYzg1OTJlOTY4NDJfNS0xLTEtMS01ODU5OA_63d29387-cbec-4bd5-9f7d-296e5172486d"
      unitRef="usd">6380000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id30882aba8a04db99646163bc2413884_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjZmYTNlMTJmMTY5MjQyZjg4Y2Q1MGM4NTkyZTk2ODQyL3RhYmxlcmFuZ2U6NmZhM2UxMmYxNjkyNDJmODhjZDUwYzg1OTJlOTY4NDJfNS0zLTEtMS01ODU5OA_665439c3-918e-42c9-bb7a-e172be6f31f8"
      unitRef="usd">5354000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4ec20456c73b4f1f8e73015480eac437_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjZmYTNlMTJmMTY5MjQyZjg4Y2Q1MGM4NTkyZTk2ODQyL3RhYmxlcmFuZ2U6NmZhM2UxMmYxNjkyNDJmODhjZDUwYzg1OTJlOTY4NDJfNS01LTEtMS01ODU5OA_61e675cd-8211-4b84-a074-8c1196eed2ad"
      unitRef="usd">19091000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie7d644d1ac344e6fa4918cd4a83af717_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjZmYTNlMTJmMTY5MjQyZjg4Y2Q1MGM4NTkyZTk2ODQyL3RhYmxlcmFuZ2U6NmZhM2UxMmYxNjkyNDJmODhjZDUwYzg1OTJlOTY4NDJfNS03LTEtMS01ODU5OA_e81181a9-0be7-4d17-b366-d1f73bc93297"
      unitRef="usd">15583000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i37c0ca418ca74d69b9c15307c7e58df1_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjZmYTNlMTJmMTY5MjQyZjg4Y2Q1MGM4NTkyZTk2ODQyL3RhYmxlcmFuZ2U6NmZhM2UxMmYxNjkyNDJmODhjZDUwYzg1OTJlOTY4NDJfNi0xLTEtMS01ODU5OA_5e3d70b3-8118-48de-80f3-d7dc23651935"
      unitRef="usd">955000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifa97e16d76c6408f8338e08b5bea4b44_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjZmYTNlMTJmMTY5MjQyZjg4Y2Q1MGM4NTkyZTk2ODQyL3RhYmxlcmFuZ2U6NmZhM2UxMmYxNjkyNDJmODhjZDUwYzg1OTJlOTY4NDJfNi0zLTEtMS01ODU5OA_cb074b30-3ece-404f-aac0-dddba868bd72"
      unitRef="usd">875000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0963d8c883c844e6b0f9b360576e525d_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjZmYTNlMTJmMTY5MjQyZjg4Y2Q1MGM4NTkyZTk2ODQyL3RhYmxlcmFuZ2U6NmZhM2UxMmYxNjkyNDJmODhjZDUwYzg1OTJlOTY4NDJfNi01LTEtMS01ODU5OA_7527b840-bca3-46dc-b03a-5f266c08f1fd"
      unitRef="usd">2867000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2212dcd7830b49eca79d05facc1aaac8_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjZmYTNlMTJmMTY5MjQyZjg4Y2Q1MGM4NTkyZTk2ODQyL3RhYmxlcmFuZ2U6NmZhM2UxMmYxNjkyNDJmODhjZDUwYzg1OTJlOTY4NDJfNi03LTEtMS01ODU5OA_c22dd348-5f13-42c4-8a98-b0ac15968c81"
      unitRef="usd">2502000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1f6a30e4c3a945b1bae228351989449f_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjZmYTNlMTJmMTY5MjQyZjg4Y2Q1MGM4NTkyZTk2ODQyL3RhYmxlcmFuZ2U6NmZhM2UxMmYxNjkyNDJmODhjZDUwYzg1OTJlOTY4NDJfNy0xLTEtMS01ODU5OA_2ca4c708-17af-4ee6-9c6c-15d595894cd6"
      unitRef="usd">575000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i87816e2186d3470b93fba05f0ffe1f2d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjZmYTNlMTJmMTY5MjQyZjg4Y2Q1MGM4NTkyZTk2ODQyL3RhYmxlcmFuZ2U6NmZhM2UxMmYxNjkyNDJmODhjZDUwYzg1OTJlOTY4NDJfNy0zLTEtMS01ODU5OA_07f95bab-2d26-47dc-a330-c69c529f967f"
      unitRef="usd">793000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7b425cf2189f45f795be7031fbb9489a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjZmYTNlMTJmMTY5MjQyZjg4Y2Q1MGM4NTkyZTk2ODQyL3RhYmxlcmFuZ2U6NmZhM2UxMmYxNjkyNDJmODhjZDUwYzg1OTJlOTY4NDJfNy01LTEtMS01ODU5OA_9394be6a-48ee-433b-a40d-ff3ea271d9ea"
      unitRef="usd">1740000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3877802cf9094a9eabfc486981832840_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjZmYTNlMTJmMTY5MjQyZjg4Y2Q1MGM4NTkyZTk2ODQyL3RhYmxlcmFuZ2U6NmZhM2UxMmYxNjkyNDJmODhjZDUwYzg1OTJlOTY4NDJfNy03LTEtMS01ODU5OA_2cbfa2e5-de0b-4c54-9478-406accb381ca"
      unitRef="usd">2224000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if2aaee23745f4ff297ec360508e852a7_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjZmYTNlMTJmMTY5MjQyZjg4Y2Q1MGM4NTkyZTk2ODQyL3RhYmxlcmFuZ2U6NmZhM2UxMmYxNjkyNDJmODhjZDUwYzg1OTJlOTY4NDJfOC0xLTEtMS01ODU5OA_059176cc-f555-459f-81e2-f575832d9881"
      unitRef="usd">17000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia7ee1c4d62614df782f74c5d44f474c9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjZmYTNlMTJmMTY5MjQyZjg4Y2Q1MGM4NTkyZTk2ODQyL3RhYmxlcmFuZ2U6NmZhM2UxMmYxNjkyNDJmODhjZDUwYzg1OTJlOTY4NDJfOC0zLTEtMS01ODU5OA_9101c30e-3056-4e51-be8b-87b87f30eeb8"
      unitRef="usd">18000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8eff537979cc43da94a627c160916e60_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjZmYTNlMTJmMTY5MjQyZjg4Y2Q1MGM4NTkyZTk2ODQyL3RhYmxlcmFuZ2U6NmZhM2UxMmYxNjkyNDJmODhjZDUwYzg1OTJlOTY4NDJfOC01LTEtMS01ODU5OA_2ea2103e-ba32-4b27-ba7e-a2156d69fcf6"
      unitRef="usd">53000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iabdb88db75e64d48bbc614f435a60acc_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjZmYTNlMTJmMTY5MjQyZjg4Y2Q1MGM4NTkyZTk2ODQyL3RhYmxlcmFuZ2U6NmZhM2UxMmYxNjkyNDJmODhjZDUwYzg1OTJlOTY4NDJfOC03LTEtMS01ODU5OA_9a16ce14-c75f-40aa-9513-30e7670e1af0"
      unitRef="usd">53000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjZmYTNlMTJmMTY5MjQyZjg4Y2Q1MGM4NTkyZTk2ODQyL3RhYmxlcmFuZ2U6NmZhM2UxMmYxNjkyNDJmODhjZDUwYzg1OTJlOTY4NDJfOS0xLTEtMS01ODU5OA_b063036f-11c4-4195-a89a-9037efbed185"
      unitRef="usd">7927000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjZmYTNlMTJmMTY5MjQyZjg4Y2Q1MGM4NTkyZTk2ODQyL3RhYmxlcmFuZ2U6NmZhM2UxMmYxNjkyNDJmODhjZDUwYzg1OTJlOTY4NDJfOS0zLTEtMS01ODU5OA_a1f432d0-b53e-4b9d-aea0-943d04067b54"
      unitRef="usd">7040000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjZmYTNlMTJmMTY5MjQyZjg4Y2Q1MGM4NTkyZTk2ODQyL3RhYmxlcmFuZ2U6NmZhM2UxMmYxNjkyNDJmODhjZDUwYzg1OTJlOTY4NDJfOS01LTEtMS01ODU5OA_c3c79997-90b3-4df9-9429-ca5a08cf2c89"
      unitRef="usd">23751000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjZmYTNlMTJmMTY5MjQyZjg4Y2Q1MGM4NTkyZTk2ODQyL3RhYmxlcmFuZ2U6NmZhM2UxMmYxNjkyNDJmODhjZDUwYzg1OTJlOTY4NDJfOS03LTEtMS01ODU5OA_127608f4-883e-4250-a45e-640685dad388"
      unitRef="usd">20362000000</us-gaap:Revenues>
    <us-gaap:GrossProfit
      contextRef="i0164340d3f1942a3a1a5f79ab8a7363e_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfNS0xLTEtMS01ODU5OA_6d338754-c5c5-4bc9-aef4-8e859289055d"
      unitRef="usd">703000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ie2109ad9aef8463798890611406b526f_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfNS0zLTEtMS01ODU5OA_99bda6a7-2d03-4927-b3ac-251ea0d73f7e"
      unitRef="usd">532000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i226c2214fece4fadb73439a12ab95d6f_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfNS01LTEtMS01ODU5OA_8d5f9b81-3cd3-4d06-b9c3-7f3514009599"
      unitRef="usd">2168000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i362d995290d84c1597a463618a6f4a5f_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfNS03LTEtMS01ODU5OA_5401c027-b5a4-43eb-8d11-6f0330272b05"
      unitRef="usd">1687000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i763ba496c6a742eca5a9885bbbc7830e_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfNi0xLTEtMS01ODU5OA_1eb640f4-3adb-4b07-af3e-a2115bb5b47b"
      unitRef="usd">108000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i8cef013ef54740e8857e7e00eac7dd4d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfNi0zLTEtMS01ODU5OA_e655621e-fdfa-49fa-b8d7-9ea43e7451c2"
      unitRef="usd">151000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i48a45433b5894e268eab6a5f260ad9d0_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfNi01LTEtMS01ODU5OA_a2aafce5-2a3a-4b72-a33e-932a0954f85f"
      unitRef="usd">360000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i1fe9ad49fa264be4b25af966a5e6c09c_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfNi03LTEtMS01ODU5OA_ae96f5e6-3bff-490c-b348-042715555c4c"
      unitRef="usd">329000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ia1896656ef924935b656c0a3948916bf_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfNy0xLTEtMS01ODU5OA_c8542f65-661d-409a-ae16-64eff53580e2"
      unitRef="usd">77000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i454009dcb5f24035b7bb46ce50254cae_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfNy0zLTEtMS01ODU5OA_fca7737e-e886-4260-a45a-9731fcb0c5e4"
      unitRef="usd">68000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i670ed9482960439bb9d74ff2ffeb3f5e_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfNy01LTEtMS01ODU5OA_da9d6814-85de-4948-8274-514a55e97d5d"
      unitRef="usd">255000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i812649e7c9904b4abd14942568ab571c_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfNy03LTEtMS01ODU5OA_72296d67-d654-4ad4-bb38-1f4f7eeeff74"
      unitRef="usd">331000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ic51dd760fd294631a25b501d900f5f1d_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfOC0xLTEtMS01ODU5OA_57118f08-499c-40c6-a10a-240d688a9104"
      unitRef="usd">2000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="id4a763210a0a4713b5050f956ee2aac7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfOC0zLTEtMS01ODU5OA_1e757f15-eef2-4806-a723-ecd904cfb32d"
      unitRef="usd">4000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i4ff31abf6c8c49da85cb7c5b5b247423_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfOC01LTEtMS01ODU5OA_e779814c-9084-443a-8081-ca1928ae6941"
      unitRef="usd">8000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i328833ca29384ce2b4440be9a5f1bf23_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfOC03LTEtMS01ODU5OA_6da4eb7e-6fb6-464d-b2ca-6d134cb17b4c"
      unitRef="usd">11000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i3648beb8cc65477dac1c4d580ec26c84_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfOS0xLTEtMS01ODU5OA_bce981af-85f5-43bf-8109-51959d5ed848"
      unitRef="usd">890000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i858448d6578c463ea667e35c5c992219_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfOS0zLTEtMS01ODU5OA_38abb95c-824c-48bf-9656-6b7e4b494bdf"
      unitRef="usd">755000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i50521a7d515b41458530732201de3623_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfOS01LTEtMS01ODU5OA_568ad711-fbb2-40cf-8cc6-45b4af51dd2e"
      unitRef="usd">2791000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i4d6e9de0146e4e0ab67af6591b50afd1_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfOS03LTEtMS01ODU5OA_2359b575-2174-4bb6-a974-fbb42974bd07"
      unitRef="usd">2358000000</us-gaap:GrossProfit>
    <us-gaap:Revenues
      contextRef="i4fa84dba36794309afacfe9bdfbc2bde_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfMTAtMS0xLTEtNTg1OTg_5f3bcedc-113b-4ee1-b73e-1b34194c5573"
      unitRef="usd">274000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8e17562a155a4b4899cfccb2754c67e4_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfMTAtMy0xLTEtNTg1OTg_b6b490a6-d834-4e60-97a6-e88ce6dd8307"
      unitRef="usd">222000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i87b6e21917b64be8a7e28cf2b5ac0018_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfMTAtNS0xLTEtNTg1OTg_8775225f-7b41-4215-8eae-320e36c48f80"
      unitRef="usd">732000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i945971ba12124c429f508ca0dd49999b_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfMTAtNy0xLTEtNTg1OTg_cc60e45f-73c5-4bb3-a868-db07e7e06a8e"
      unitRef="usd">620000000</us-gaap:Revenues>
    <us-gaap:CostsAndExpenses
      contextRef="i4fa84dba36794309afacfe9bdfbc2bde_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfMTEtMS0xLTEtNTg1OTg_7c2b976e-bf48-4aef-aa18-7a5d651c24f9"
      unitRef="usd">829000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i8e17562a155a4b4899cfccb2754c67e4_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfMTEtMy0xLTEtNTg1OTg_8a326bfa-e054-4279-988d-9c14dd89ee18"
      unitRef="usd">756000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i87b6e21917b64be8a7e28cf2b5ac0018_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfMTEtNS0xLTEtNTg1OTg_6a54729e-3549-4de9-a756-a99e41d15262"
      unitRef="usd">2455000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i945971ba12124c429f508ca0dd49999b_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfMTEtNy0xLTEtNTg1OTg_1f0c2074-e52b-4c98-827f-717c8a1375b0"
      unitRef="usd">2149000000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfMTItMS0xLTEtNTg1OTg_91c6d8d2-0c16-46b5-a0e7-bf648ee92670"
      unitRef="usd">335000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfMTItMy0xLTEtNTg1OTg_33ade7e7-2beb-4685-aa56-2a27c3a3041f"
      unitRef="usd">221000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfMTItNS0xLTEtNTg1OTg_d04e35f5-c6b5-4dd0-8c02-8fa18492cbef"
      unitRef="usd">1068000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfMTItNy0xLTEtNTg1OTg_4cfef02c-b221-4398-ba01-371b19a966d2"
      unitRef="usd">829000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfMTMtMS0xLTEtNTg1OTg_388e805e-f083-4725-a8de-17b2bf689783"
      unitRef="usd">-28000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfMTMtMy0xLTEtNTg1OTg_29946e62-5ba6-419d-a9a1-5a3bed1f7396"
      unitRef="usd">-30000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfMTMtNS0xLTEtNTg1OTg_758378fa-c835-4778-8802-e4708fb2c09e"
      unitRef="usd">-83000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfMTMtNy0xLTEtNTg1OTg_86e60141-20c2-4eb3-b849-3d3a3f8711ec"
      unitRef="usd">-90000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i406df5b5e82345ae890a914938d5a913_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfMTQtMS0xLTEtNTg1OTg_987e2de9-9727-499d-b11a-598564d1f42c"
      unitRef="usd">307000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i73f4675203bd4e2591632f444f1ad336_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfMTQtMy0xLTEtNTg1OTg_4946bb73-6c05-4b6f-8311-931e01a0013b"
      unitRef="usd">191000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfMTQtNS0xLTEtNTg1OTg_1f461045-93d2-44ed-993c-238bf0679c28"
      unitRef="usd">985000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1eb1947f04684be1854aa9cd0494b8ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83MC9mcmFnOjMzY2U3ZTliZDU5MDQ4NmJiNGE1YzkyZmIwMTUzYThkL3RhYmxlOjY2NjIzNmFmNmFiNTRlOWJhYTRjYzcwNzY1NTFjNGQwL3RhYmxlcmFuZ2U6NjY2MjM2YWY2YWI1NGU5YmFhNGNjNzA3NjU1MWM0ZDBfMTQtNy0xLTEtNTg1OTg_39a2a65f-0b25-4911-8d62-a734fdd4ec37"
      unitRef="usd">739000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjODMzNjE4NjZmNzQ4MTc5N2YyMjE1YzhhZWRhZjI0L3NlYzpjYzgzMzYxODY2Zjc0ODE3OTdmMjIxNWM4YWVkYWYyNF83My9mcmFnOmUyNDYzYzEzMGU1ZTRlNWRiOTMwZTYyNTM3ZWQ0OWRhL3RleHRyZWdpb246ZTI0NjNjMTMwZTVlNGU1ZGI5MzBlNjI1MzdlZDQ5ZGFfMjYwMg_badbd20a-3be1-4314-ab35-e23586e80a78">Commitments and Contingencies &lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;COVID-19 Pandemic&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We continue to monitor and assess the estimated operating and financial impact of the COVID-19 pandemic on our business and, as it evolves, we continue to process, assemble, and assess member utilization information. We believe that our cash resources, borrowing capacity available under the Credit Agreement, and cash flow generated from operations will be sufficient to withstand the financial impact of the pandemic, and will enable us to continue to support our operations, regulatory requirements, debt repayment obligations, and capital expenditures for the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The healthcare industry is subject to numerous laws and regulations of federal, state, and local governments. Compliance with these laws and regulations can be subject to government review and interpretation, as well as regulatory actions unknown and unasserted at this time. Penalties associated with violations of these laws and regulations include significant fines and penalties, exclusion from participating in publicly funded programs, the repayment of previously billed and collected revenues and reputational damage.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are involved in legal actions in the ordinary course of business including, but not limited to, various employment claims, vendor disputes and provider claims. Some of these legal actions seek monetary damages, including claims for punitive damages, which may not be covered by insurance. We review legal matters and update our estimates of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reasonably possible losses and related disclosures, as necessary. We have accrued liabilities for legal matters for which we deem the loss to be both probable and reasonably estimable. These liability estimates could change as a result of further developments of the matters. The outcome of legal actions is inherently uncertain. An adverse determination in one or more of these pending matters could have an adverse effect on our consolidated financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Kentucky RFP&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. On September 4, 2020, Anthem Kentucky Managed Care Plan, Inc. brought an action in Franklin County Circuit Court against the Kentucky Finance and Administration Cabinet, the Kentucky Cabinet for Health and Family Services, and all of the five winning bidder health plans, including our Kentucky health plan. On September 9, 2022, the Court of Appeal ruled, among other things, that the Circuit Court should not have invalidated the 2020 procurement and thus should not have awarded a contract to Anthem. Anthem filed a petition for rehearing with the Kentucky Court of Appeals and will likely seek review by the Kentucky Supreme Court. Pending further Court order, our Kentucky health plan will continue to operate for the foreseeable future under its current Medicaid contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Puerto Rico.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; On August 13, 2021, Molina Healthcare of Puerto Rico, Inc. (&#x201c;MHPR&#x201d;) filed a complaint against the Puerto Rico Health Insurance Administration (&#x201c;ASES&#x201d;), asserting, among other claims, breach of contract. On September 13, 2021, ASES filed a counterclaim and a third-party complaint against MHPR and the Company. This matter remains subject to significant additional proceedings, and no prediction can be made as to the outcome.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>75
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MC0 8]BQ[(/7PB>;$6L*_T$)D7X;B8HWBM5"U:<7K;-S3+AO!%<#JP^Z:\@(
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M4"W=&.C?5YRKYQMSM%W]5\;T?U!+ P04    " !!5EM5\!)08N0"  "6"0
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M5_+-EC+02^OC]A2>F2-8:P6U_U :1]%4K:3]#\SVW]I[!KH%%AM6[5(&30E
M:0Q*XRB:JI_,'03FW$'_^@R]%8,^.Q#HMI[<7D!S"5 :1]%4.672(;!Z[K^7
MA'J&P!\%[8?3FE;&O84.\B;M]Z 1C<ZT1Q,YA9KZI[;3TLL'9B]O]:@X/5A(
M)ST+=/-.N4=H4 :E<11-550F P+;A_][J:B[=LI 3KNG/ '2#23Q/G[=0!*D
MDP8RE.XZ'#WC?CJ$5N.AM#F4QJ TCJ*IDT!F$4)S%J'CXY"(:GB@?1X2]+E^
M*(U!:;QC.%0)I.T/S;;_QSX5R0RU7F^$K8_:Q;@Y-":#TCB*IHHHDQ.A^7&
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M"\'B6CR5& :_NC0)5=BQN<'L+J3Z/J!^_HXYJZ;)M\I&#B[)&T_VFA@B9P"
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MJA*R1FT1KSW!OW$^=JQI^T@A<M)I&J%<8&"?4Y5*N;J1]HE?*Y#OC.;2"A'
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MO0!;*S1RC2=("_"1:YGR-HT^DK5/0(9JP01/\UZ;#BF;$[R4,SOB.V)75=6
MZ(.HR?$XAW(NBR8O?QVRWQ5DG0W9SS\MXWAR]@1R1VXY.F,?(52%<I;FO-H
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MRT8X _N/^_#@=.<_J!?:X?/<WZZE0,'0!KQ?:NV&!U*P_X?EZF]02P,$%
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M_]]J?Q5BIUABX?"%49]EZO.KP6( *:Y$I?P'LWZ-33QSUI<8Y<(WK.NST?D
MDLIY4S3"Y$$A=?TK'IH\] 06DP,"42,0!;]K0\'+6^'%\M*:-5@^3=KX3P@U
M2)-S4G-1/GI+NY+D_/(68W\Y]J2)G\=)(W532T4'I'Z%.Z-][N"E3C'=E1^3
M!YT;4>O&3714X4<L1S";#"&:1-$1?;,NK%G0-SL2%MQ*ERCC*HOPYW7LO"4(
M_+4OV%K7V7Y=W!87KA0)7@T(]P[M/0Z63QY-GTV>'_'TK//T[)CV@P7X=RFX
M5@I,90F$]" =Y*A2$!Y\CE *B]H/89W+).=-BZ6Q'E.0.AQX1U_4G)A1A_D1
M?**EE5'4HU)GX$6LL&E4^3>Z8(9:VGFA4SX03)I8R4QP<[DA"'9FU=@CXZ"-
M?II4EMT X7B/S:;"8\^9F%GA JC\'HN8'&(,W&+2/$R'</)&$^Z58BNG\+:G
M5!F=/?5HB^#-!9R-9N?S7^@(6T@K9"PMX#$L)I/F>S9:?'MB-H%G\_JS;S>"
M<]KASRVND.RF;;9=)72"D!CG'9Q$\U/Z.C^%3\8+1>:BX?1\WOS.X 4)2BI8
M9A$YW_ 90XZH2GX#WH" I#XBNB,GG*XGCQ91-'G^K7Q8GCX_;<NK$U6EY+6@
MS-X;=<\E:A2N1"*5)"LGN[I>->N=*BK0X^EH G&=;*IH00D&$W!26G,OF8A=
M#97O LH%6P_5($4K8EK8H+ ,#)T&<)"Z2GNW Z,UV2(,A&SSN5)L O*(KG^K
M-,(B$,)\!#?&V@!-!Q51C@U8^LZ)F"Q2,L@+=#Z0=3KDAF#TMG-@R,I%V 1+
M8 1CFQB)RZG+TK ZA%)5CGL%!24XH=/#8%.4I9))<))Z(Y-Z! 10D9(C/&2H
ME)W]7C"A(RV529:BS03G26I&$Z8:W6YB5M84X&GZL<;P>SAL:O(:31:_5I(A
M2C)DG*+\6A' T*H-X;0HI ]96B$>*&)"I$YSW#6#AX9TZ&)*"V%=LN=4H^U3
M8NZ1_M.E *Y#@^^V,5-Y\&U-^>!4D@^4O- V:^GS@(I=W;O6.OU'@C]F6IL.
M=,&%?H*_T]CVPXA4:4F@J'G@7<4D&19T6.!$4ZLE5L8M?XW@)8.D9CB'O8.-
M9*4=$FO1^1YE\OD[0\0N0NA6Z"] !:2D;#A9EJ\3?(8J&8K3I0P?I/,<0ZA&
MY:NM(493W7'- E/+(9$J-I9R(7Q+:IU#.Y@>UBW0\#<C5K.\@XS*8W48%SGN
M)JD!TD$<;2O+#B6YT!FR!9:S= ?JT\W_AM8AD\T _$^1U(WR@T%;X]S3YF;8
M"X4DB(L8%IZ*FR'CH2J)'=JC\0:(<TB?T!N.F6F+JN1D*FD,\Q3686N'-9BB
M'I+ 'W6%&G9Q)29R);<#O\=<73RC_4-SQ/,I%RD\YJG93%\:3=1T&5/F/BK;
M245_=O4M;(=-KQ7%X0)WEPGV+$R$Z3QLTF"HM.*HB?*5)"G*)C-"RMBM"3A0
MOVA(?M5&6B+G5U?%D&]%+4<[+"2OMMTG:-33].H&T70>D-K=3*8TD_;>)K:I
MXRO%3Z9NKX6?RN%;@F\3P#!H^_$\-D[]<![O:"(U:>QY,=IWA1[WWF<*M%EX
M:^,&HX35KS;=:O=B>%V_#VV/UV^5=V%(.U"X(M')Z'P^J*FU??"F#&]'L?%$
M5>%O3B^W:/D [:\,9;]Y8 /=Z_+R'U!+ P04    " !!5EM5M[OD4H(#  "'
M!P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6R55=MNXS80_96!&O0"
MN)8LVVF:V@:2W2VZ#PL$2;=]*/I BV.)#44J)&7'_?K.D+*2+I*@?;#%R\R9
M,U>N#M;=^P8QP&.KC5]G30C=99[[JL%6^*GMT-#-SKI6!-JZ.O>=0R&C4JOS
MLBC.\U8HDVU6\>S&;5:V#UH9O''@^[85[GB-VA[6V2P['=RJN@E\D&]6G:CQ
M#L/G[L;1+A]1I&K1>&4-.-RMLZO9Y?6"Y:/ ;PH/_MD:V).MM?>\^2C76<&$
M4&,5&$'09X_O4&L&(AH/ V8VFF3%Y^L3^L_1=_)E*SR^L_IW)4.SSBXRD+@3
MO0ZW]O +#OXL&:^RVL=_."39DBQ6O0^V'91IWRJ3ON)QB,,SA8OB%85R4"@C
M[V0HLGPO@MBLG#V 8VE"XT5T-6H3.64X*7?!T:TBO;"Y"[:Z;ZR6Z/PW\.&A
M5^&XR@,A\WU>#2C7":5\!>5'^&1-:#Q\,!+EO_5S8C32*D^TKLLW >^PF\*\
MF$!9E.4;>//1S7G$F[^"EQR#/ZZV/CBJA#]?\C%!+%Z&X.ZX])VH<)U1^7MT
M>\PV7W\U.R]^>H/@8B2X> O]/^?A_Z/ 1P,4SH#M%AW'<S8!VU,M6^$DV!U(
MY:A%K/,@^M!8I_Y&":%!Z'I7-53Q+-1W$"R<+8LBN=PJK:FK)J!,E!5U[; 6
M 2<LS?B5;5MJ.\^4IO!KHSP8:M+.V=J)=@*'1E4-#8..N*(<3$;I)\.#,(B.
M5GN2V1Y?XZZ^\))JARSN>BY(ZJG00"5\ \2H$48"__ QH)&>##O;UPV\QRJI
MSV>I\)@VDA@5# 1%W5='/=':W@0V+\R1)M-(EPQ*#.A(,G%MA:')1C,LQ-$A
MV3S-OGL:MI4U4O%@\A'3-\*QOZK"&%,ATRU'W5)D'.Q$='22Q/OM7\BL; P;
MU6,@U03G4(O 7.ER;W7?$N( S*J#(QP8QX'5JA);C:#%80KP.1X'SM:8*?+/
M]\)$:P)N>Q*>%=OE]S.@7I(,UFE!I7!X*AF94O:H:&ZB/L+Y\F)2%$5RD])B
M'9R57]32J90\<FS@H1>.8LEAYES MV*/CJ))D?,Q^&?S8C&=S8$**.%^-WVI
M$?-GP[%%5\<GP!,*Y3#-R?%T?&6NTG!]$D]/U"?A:D41UK@CU6+ZPS(#E\9^
MV@3;Q5&[M8$&=UPV]%*B8P&ZWUD;3ALV,+Z]FW\ 4$L#!!0    ( $%66U6Q
M-[3C8 8  .$/   9    >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;+57;8_;
MN!'^*P/?X9  BJT7R[+W#4C2'AJ@:8+DVGPHBH*6:)N()/I(:KW;7]]G2$FV
M-^O%]4,7"TLB.3////-"\N:@S7>[D]+10U.W]G:R<VY_-9O9<B<;8:=Z+UO,
M;+1IA,.GV<[LWDA1>:&FGJ5QO)@U0K63NQL_]MG<W>C.U:J5GPW9KFF$>7PG
M:WVXG2238>"+VNX<#\SN;O9B*[]*]_?]9X.OV:BE4HULK=(M&;FYG;Q-KM[-
M>;U?\ \E#_;DG=B3M=;?^>-#=3N)&9"L9>E8@\#C7KZ7=<V* ./W7N=D-,F"
MI^^#]E^][_!E+:Q\K^MOJG*[V\ER0I7<B*YV7_3A+[+W)V=]I:ZM_Z5#6)NN
M)E1VUNFF%P:"1K7A*1YZ'DX$EO$%@;072#WN8,BC_)-PXN[&Z ,97@UM_.)=
M]=( IUH.RE=G,*L@Y^Z^RBTH=O9FYJ"-QV9E+_DN2*87)%?T4;=N9^G/;26K
M<_D94(Q0T@'*N_1%A5_E?DI9'%$:I^D+^K+1M<SKRUYVC;[(O39.M5OZY]NU
M=0:)\*_GW W:YL]KX^*XLGM1RML)LM]*<R\G=[_\E"SBZQ>PSD>L\Y>TOQB&
M/R9)WR3RQ1B\UX^T$_>2-KHS*!SV7JQK27986FH4E?64Z,T5):_IHZQ4*51U
M3>GP8>0U9?@0YKMT^QJ>7Y-H*YJ_ID]N)\V4/EU0#]'!!/-_4&Y'._!Q.$78
MB!9%3]!$Z\["*6N]^GNN9!YMO&'+4I[M*?V&T0%H-**,O-@)S",0@.-0 0,K
MW.I[:5J>>;/I.&=)HSOM 50;?.R-WAK16.(Y0X>=*G=L7&\V^ QP*]I)4;L=
MV_6H5"EM .8Y&4Q'O;BRI,##ME4;8&4<FC@HS(ZN524<5 (B6HB%(4*O-8*[
ME8T@6-9=)1$M"8)5"R$#KB%"HM$=^]=J1\):72JOR!,-GT1=Z]*/P)R[0!K6
M/<?9E-Y6E6((T/(8>?$SUXZX>O^!_UZVG0SA&P9+;3D3GH!C;;5NMV^<-,U(
M8!#L]IQ)(3G!A^!N?5R"0"! ]ZJ2 $#?E/4)U@;NOTODDW1&E8B>#7[#-*<4
M6P2I?O=J2^E)1@#^IS3B8".1&M4U@[,1[+%<S6FZ!2(6'H9\=O@XTJM??EJF
M:7S]\?T7_Y9<OYX2/HZI&2"&B#*Z,R4#BR38B1++N6:PZ@D<3P.V,\U^L#Z?
MP_4C5_@Y4!_X$XM2F!:$K1\O)LIE6C:."V/ &Z "-"JK*SGD&Z.;'XE[XGD#
M.5*-[R+ TTAA.^-]9&AP@,N8FT) &>HPU!@C4WW$,>4+:Z<D)!]DV?G\0?$B
M?0PG1- R5%LT),A)<@2-0_7P2J@<"_R89'\PQYZ4S;%@0B2"UO,Q7B5_[T G
MM#^I+][].^MY9@M/9J?<_ROM6T+HR5#AH(@Q@FKP,R!9RU+  \#F]M1WD0NN
M#3)G[IF+'&TT)@Z<=6%+.$;:8QD\.8*9TH<66?1FL#.L.(BGG7,3S#(2I2L[
MJ)856S92GIU&"&<))YLU^.<#Q=^PO;PTSP<._DE.WEY]:,%X77,S?DV_G>*_
M&NN$?J9%E"UC//,HR^=X)JLH7B7\DD?Y,AL+B59Y3LLBIS1:+@K\YG%Z5E<Y
MYHI51DE4S&/,I^F\3Z&DH&1)><;_ <C/5$2KM/#/>,[FTRPJ<C:;QE&V2)^-
MAI%HFJ6JT4[[=#O)"L3\;%="F]<-0N6;RO#EQ$,(]?^=\(\>X!G319PQSUG*
M7D;)8LDD1XME<>0XB9?@/:%L$5.6KL[X+0J"2(HH9%G2,YO2G""1]+3VK"Q7
M,14Y1ZI )%,$=LF[XA5I+]1OTJ!UW/E>X0B5%G-*X4P!@(LTIK^B?GX4D0^X
M3ED6P4'KU3)=X;?(%_A-HWF>^V<RQ^BG4:3G/LN "#PE40P_(-G[,&B,J,4=
M+EV"8$+>P8</%T(XB("_+"Y\SG+FK)8YLYRMZ-_/_GDO/UVBH#\6C/V>[8P]
M7[7WTKKA^  8H=4&<L8.QI0\U3_R->C?RA9S=6C5%7JBXB.];_9')DY!'$<K
MWGGX..*O@RS?\,7@/W[@%-&/YJ?/G?%G)]>N1IJMOUQRA\;&&FY@X^AX?WT;
MKFW'Y>'R&]+=4BTW$(VG13XA$RZ4X</IO;_$K;7#E="_XBB*39X78'ZCM1L^
MV,!XJ[_[+U!+ P04    " !!5EM59:B_[J,'  "($0  &0   'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6RE6-MNXS80_17"!8H6<&W'R;9[20)XLPUVT08U
MDEX>BCY0$F6SH4B5%WO=K^^9H23+BVR MB^)+N3PS)DS%_ER[_QCV"H5Q<?&
MV' UV<;8OI[/0[E5C0PSURJ+-[7SC8RX]9MY:+V2%6]JS'RY6'P[;Z2VD^M+
M?K;VUY<N1:.M6GL14M-(?WBKC-M?3<XF_8-[O=E&>C"_OFSE1CVH^$N[]KB;
M#U8JW2@;M+/"J_IJLCI[_?:"UO."7[7:A]&U($\*YQ[IYD-U-5D0(&54&<F"
MQ+^=NE'&D"' ^*NS.1F.I(WCZ][Z+?L.7PH9U(TSO^DJ;J\F+R>B4K5,)MZ[
M_7O5^?."[)7.!/XK]GGMB^5$E"E$UW2;@:#1-O^7'SL>1AM>+CZS8=EM6#+N
M?!"C?">CO+[T;B\\K88UNF!7>3? :4M!>8@>;S7VQ>L;US0Z@N48A+25N'$V
M:KM1MM0J7,XCCJ"%\[(S]S:;6W[&W"MQ!P/;(+ZWE:I.]\\!;<"W[/&]73YK
M\$&U,W&^F(KE8KE\QM[YX.\YVSO_+_Z*=SJ4QH7DE?A]583H(9H_GF(A'W+Q
M]"&42*]#*TMU-4&F!.5W:G+]Y1=GWR[>/./"Q>#"Q7/6_WW(_H<Y<?/3KQ_>
M?7/V2JSQ3C6Z%+\I4?*2I$1THG%61^=YJPQ!A2#B5@D5HD;.J$J@?GA)%GE)
MK:V$96F$;L!0%*[F]<,Y;7\.4M8EI%P* !P8VQ0G"!V%VCFS4V$J]J=86N]*
M+)TRD*8P:CJ&U>"1\B)%;?3?DFN"MKFLX7I&CA7*:+6#K:V,?'HIPQ:U)^"Z
MI ,+YQ$M<J:4@*_C0<B=U$;B,)& W&=OO*J <[7Q2A&S&0<;JU$&!=@E4L!.
M[5W34^1L0/8; Q@HDG6M$0$;R;&]1DY%LD'6/\=A3UT^C2TIFY$%LC*F*J2V
M=3X[>3Q^"E\WR4@$](#+OY+VC!\O*E5$/&KE@1X(5QB]Z3=EYUH= 4E]1+^
M\\BA(,!N1NPH#11CJ1.]FXD?U0;+UQ0RD&4W0?R,E5LE3=R6$AFH;87Z!R Z
M &[Q)^HX(;>I4=[!(R/W6;$=9N8/5-0*89!F*L!8["1@7(G#-FZGO&6'9M!Y
MTQH-(A732SB#>MIH*6V.R0#B: D+=]1\:(^V47ED?.1]K-8]^@W]'_$JRVPU
MV4?K]I9W)DLB]:0(*"]NX3+R!RRM$4$3*1.QP"'HM(3Q[K0;.?T,>FU+DRK
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MO9@(G[_[\TUT+7]KHZGARYTOH6+(D!;@?>U<[&_H@.''E^M_ %!+ P04
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M4!%9>,,!GOA&QZ0*LF&B/L%D$.@K$^<>^^#?(HAFR^*,KZ*2#*3DCY6$>MJ
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MHI-YX$3]!C<.#P>8K"D^7NGKQ6>'#T3GY/ (I?&.P'2.AA\SV/L^SA$5+HU
M=B3?(P.$?96N8 MM**,6K2T-F3VIM4-0S:1BQMDLW,)2J2'PA&K =91,JA6
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;.U746_;-A#^*P>U*%K
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MU_5UL)Y85;HKV$)9O-"YQQ7>H+DF UQ?*F6;"3EH[^23?P!02P,$%     @
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M*B"[#">.3!V9038-8_CN[PPL+M@3 =DCR,;[1I*F-<"-:; @>U;ECQ?N^BF
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MNG#O]>87V>;C \QT8?TO;)J]HZ0'V=HZ7;;&&$&IJN8I/K=UV#-(@Z\8\-:
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MPPW:+]6MII7?LV2\1&FXDJ Q7WF7X\75Q/DW#E\Y[LW!'%PFB5+W;G&=K;S
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MS!K"C"SN6V..%#=K4^?&U$RF"*DRUL!9.!W0,!O 5EDF*%PX',^FW3^"8R_
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MNDX2OF**L"6:<4H2 A)]0F,L\YY]HNGCBJPQ!:9D#V&6HCN02I!$05H9G$Y
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M1A!C><)7P/2=!1<Q5GHHEK9<"<#S!!13VW.<CAUCPJQ@D,Q-1##@:T4)@XE
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M"Y1F@](<4)H+2O- :3X4K5UNVJG<M/]E2E]AV_/&17<(D;9]=BU!TLPA';!
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MJMP'+$^,S(N-KH4T1F;%X1JH7:I= WM_*:5Y/'$)ZMW8^;]02P,$%     @
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M@PL+W*H-M(6FLZ6,(#2ZI[X"#]L"AZWU/FP)?(A&3PA<^2]H-F!' L>#X;'
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M&F7"V(MNW,T&AJ4C @I3J2VPNJQ@")1J)Q7'W\+4*.?4PNK]N_MM!J]@)EC
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MN^SCU)'%O:)H:+&P!^>)T'@,MX\)7L5 F@1\/Q-"KQN&H+K<!;\!4$L#!!0
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MI"3V@. X04TH4R=F]6Z6P/'1"1P!Y3"AC)F#5 -?F[0LN9_6*8RJ%,(74O@
M$\%UKN 3SS#;Q_M&3J,IW&H:A0<)9UB>0Q2<0AB$84L^X]?#.RWPY# \P=3
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M17$RCN)$QS-FF T'"K!""V88*<5P,HKA1*?S5)."H)%AEY4H@I-+"'Z99B7
M/C75]D$@*XE]0Z"*YL2^N!ZI6(G3=;<K;_V^4+* G)$%YVH=6B?[0V@"5B@T
M[=L3!7YB!_^Y6M=138A60X 1-2AIJG!.[3BWJU6JKUBEAABN:R$KQ R=1A6
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M@?Q]*T3Y\J6Z07<2?/DO4$L#!!0    ( $%66U6UMYE;H0,  '@0   9
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M%C'2/A1YH*6Q340B79):[P+]^ XI67*S,I,:7C_8HL0Y/)PYXO%,=U)]U1L
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MS )\%32H!PCFKW^*A]$[#[M^PZ[OT!-?26Z%-JI$^1OREZ-[:Z#07[JX]E^
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M66583C)?FU\JQ2*58K$BL8'[O<[]WCL6 $]E@%2*12K%8D5B@P#Y78#\-Q>
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M;"]W;W)K<VAE971S+W-H965T-#DN>&ULM5MK;]LV%/TKA%<,+=#6(FF],L=
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M^K/]&TP?VO=VC/,7]&Q)@?,1/8MW[R=I^MWK4KLW8&J2B1MU*>>]K])4[=Y
MVAW(<MN^8G-=2EGF[<>-2-:B:@#J^YNRE$\'S07Z]\ 6_P)02P,$%     @
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MV"Y@M0/Y_7F@IOR<*()=Q;QA3S".) F&0"WZ:S2.D=6)X>/?'^PIB:(D\2.
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MHAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%
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M7<ERS\6V&L;>1=>YC7H>CL=F$F_4_YE&N=GP%,8R+0L0IIE'!7D%*/2.[W5
M!"M@$(SD 119LBU4-V4_99HU-V@LF3-=ZH;;#C7-:D://(MYLGB8CH>KR9@D
M*WN83>:KA"SNR'0^6CB0$0(9M08Y6LR6#F2,0,87A+P=/@SGHPE)[B>35>(
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M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( $%66U4X9I-T[P   "L"   1
M          "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( $%6
M6U697)PC$ 8  )PG   3              "  <T!  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ 059;58(.[N'L!0  P!\  !@
M ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( $%6
M6U4%)E><S04  "X=   8              " @3 .  !X;"]W;W)K<VAE971S
M+W-H965T,BYX;6Q02P$"% ,4    " !!5EM5@+CMHX0#   9#0  &
M        @($S%   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%
M  @ 059;54;;-MS_!0  UA@  !@              ("![1<  'AL+W=O<FMS
M:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( $%66U7P$E!BY (  )8)   8
M              " @2(>  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"
M% ,4    " !!5EM51";EXHP*   &:0  &               @($\(0  >&PO
M=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ 059;5>G'LCN.!@
M_!L  !@              ("!_BL  'AL+W=O<FMS:&5E=',O<VAE970W+GAM
M;%!+ 0(4 Q0    ( $%66U6(X93E? H  (@<   8              " @<(R
M  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " !!5EM5/D;G
M4CD.   &)P  &               @(%T/0  >&PO=V]R:W-H965T<R]S:&5E
M=#DN>&UL4$L! A0#%     @ 059;56/GVZ6G P  D@@  !D
M ("!XTL  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " !!
M5EM5*20G3%@$  !B"0  &0              @('!3P  >&PO=V]R:W-H965T
M<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( $%66U5> >UMB <  *\5   9
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M970Q-BYX;6Q02P$"% ,4    " !!5EM5L3>TXV &  #A#P  &0
M    @(%==0  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (
M $%66U5EJ+_NHP<  (@1   9              " @?1[  !X;"]W;W)K<VAE
M971S+W-H965T,3@N>&UL4$L! A0#%     @ 059;5>#G57SH#   >"0  !D
M             ("!SH,  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"
M% ,4    " !!5EM5T6N5'98$  "?#P  &0              @('MD   >&PO
M=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( $%66U4Y](/8PP,
M ,4(   9              " @;J5  !X;"]W;W)K<VAE971S+W-H965T,C$N
M>&UL4$L! A0#%     @ 059;5?D90/8.!   Y@L  !D              ("!
MM)D  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " !!5EM5
M4"?8P2@%  !9$   &0              @('YG0  >&PO=V]R:W-H965T<R]S
M:&5E=#(S+GAM;%!+ 0(4 Q0    ( $%66U5[J.#?=P4  (\.   9
M      " @5BC  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%
M  @ 059;5;26P%[( @   @8  !D              ("!!JD  'AL+W=O<FMS
M:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " !!5EM5J/?JZ!\$  """0
M&0              @($%K   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+
M 0(4 Q0    ( $%66U4CWG?/H08  $]    9              " @5NP  !X
M;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ 059;5<Y(12'J
M @  Q D  !D              ("!,[<  'AL+W=O<FMS:&5E=',O<VAE970R
M."YX;6Q02P$"% ,4    " !!5EM58T"5N1(#   N#0  &0
M@(%4N@  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( $%6
M6U6,>\#A3P,    ,   9              " @9V]  !X;"]W;W)K<VAE971S
M+W-H965T,S N>&UL4$L! A0#%     @ 059;52[)8DTX!   ?1@  !D
M         ("!(\$  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
M    " !!5EM50!#ECB0&  #*,0  &0              @(&2Q0  >&PO=V]R
M:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( $%66U6MUH4CI@0  )D=
M   9              " @>W+  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL
M4$L! A0#%     @ 059;5<Z'C,J_"   G5D  !D              ("!RM
M 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " !!5EM5P^M8
MZ[,$  #Z'   &0              @(' V0  >&PO=V]R:W-H965T<R]S:&5E
M=#,U+GAM;%!+ 0(4 Q0    ( $%66U6K<<P,!04  (TC   9
M  " @:K>  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @
M059;57=:E*IS!0  *B(  !D              ("!YN,  'AL+W=O<FMS:&5E
M=',O<VAE970S-RYX;6Q02P$"% ,4    " !!5EM5A5"$UC@#  !C#0  &0
M            @(&0Z0  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4
M Q0    ( $%66U6. U;V:0,  .@-   9              " @?_L  !X;"]W
M;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ 059;50X6[I/[!@
MXCL  !D              ("!G_   'AL+W=O<FMS:&5E=',O<VAE970T,"YX
M;6Q02P$"% ,4    " !!5EM5K9(G<20#  #>"P  &0              @('1
M]P  >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( $%66U4&
MMZ/?S0(  -D'   9              " @2S[  !X;"]W;W)K<VAE971S+W-H
M965T-#(N>&UL4$L! A0#%     @ 059;5>[$!P,X!P  %2X  !D
M     ("!,/X  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4
M" !!5EM5M;>96Z$#  !X$   &0              @(&?!0$ >&PO=V]R:W-H
M965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( $%66U5H-XVAFP,  "T/   9
M              " @7<) 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L!
M A0#%     @ 059;54F4JH6$ P  WA   !D              ("!20T! 'AL
M+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " !!5EM51@XB"18"
M  "3!   &0              @($$$0$ >&PO=V]R:W-H965T<R]S:&5E=#0W
M+GAM;%!+ 0(4 Q0    ( $%66U5R]0^?! 0  /X7   9              "
M@5$3 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ 059;
M54Z)'OGF!@  $S8  !D              ("!C!<! 'AL+W=O<FMS:&5E=',O
M<VAE970T.2YX;6Q02P$"% ,4    " !!5EM5]/3B(2<#  !.$@  #0
M        @ &I'@$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( $%66U67BKL<
MP    !,"   +              "  ?LA 0!?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( $%66U5$R1\+-@0  +X@   /              "  >0B 0!X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    " !!5EM5CF$X^KT!  !Z'0  &@
M    @ %')P$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" !!5EM5G"O3#[T!  !W'0  $P              @ $\*0$ 6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     .0 Y (8/   J*P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>231</ContextCount>
  <ElementCount>237</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>48</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED STATEMENTS OF INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2110103 - Disclosure - Net Income Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/NetIncomePerShare</Role>
      <ShortName>Net Income Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2113104 - Disclosure - Business Combinations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/BusinessCombinations</Role>
      <ShortName>Business Combinations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2115105 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2120106 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2126107 - Disclosure - Medical Claims and Benefits Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable</Role>
      <ShortName>Medical Claims and Benefits Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2131108 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2135109 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2137110 - Disclosure - Segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/Segments</Role>
      <ShortName>Segments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2142111 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Net Income Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/NetIncomePerShareTables</Role>
      <ShortName>Net Income Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/NetIncomePerShare</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2316303 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/FairValueMeasurements</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2321304 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/Investments</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2327305 - Disclosure - Medical Claims and Benefits Payable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables</Role>
      <ShortName>Medical Claims and Benefits Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2332306 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/Debt</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2338307 - Disclosure - Segments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SegmentsTables</Role>
      <ShortName>Segments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/Segments</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Organization and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails</Role>
      <ShortName>Organization and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Significant Accounting Policies - Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails</Role>
      <ShortName>Significant Accounting Policies - Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Significant Accounting Policies - Amounts Due To Government Agencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails</Role>
      <ShortName>Significant Accounting Policies - Amounts Due To Government Agencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Net Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/NetIncomePerShareDetails</Role>
      <ShortName>Net Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/NetIncomePerShareTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - Business Combinations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/BusinessCombinationsDetails</Role>
      <ShortName>Business Combinations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/BusinessCombinations</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2417408 - Disclosure - Fair Value Measurements - Financial Instruments on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Financial Instruments on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2419410 - Disclosure - Fair Value Measurements - Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails</Role>
      <ShortName>Fair Value Measurements - Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - Investments - Summary of Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails</Role>
      <ShortName>Investments - Summary of Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - Investments - Contractual Maturities of Available-for-Sale Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails</Role>
      <ShortName>Investments - Contractual Maturities of Available-for-Sale Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2424413 - Disclosure - Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails</Role>
      <ShortName>Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2425414 - Disclosure - Investments - Available-for-Sale Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails</Role>
      <ShortName>Investments - Available-for-Sale Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - Medical Claims and Benefits Payable - Medical Claims and Benefits Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails</Role>
      <ShortName>Medical Claims and Benefits Payable - Medical Claims and Benefits Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2429416 - Disclosure - Medical Claims and Benefits Payable - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableNarrativeDetails</Role>
      <ShortName>Medical Claims and Benefits Payable - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2430417 - Disclosure - Medical Claims and Benefits Payable - Components of Change in Medical Claims and Benefits Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails</Role>
      <ShortName>Medical Claims and Benefits Payable - Components of Change in Medical Claims and Benefits Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2433418 - Disclosure - Debt - Schedule of Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails</Role>
      <ShortName>Debt - Schedule of Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2434419 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2436420 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/StockholdersEquity</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2439421 - Disclosure - Segments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SegmentsNarrativeDetails</Role>
      <ShortName>Segments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2440422 - Disclosure - Segments - Schedule of Operating Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails</Role>
      <ShortName>Segments - Schedule of Operating Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="moh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2441423 - Disclosure - Segments - Reconciliation of Gross Margin to Consolidated Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails</Role>
      <ShortName>Segments - Reconciliation of Gross Margin to Consolidated Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 8 fact(s) appearing in ix:hidden were eligible for transformation: moh:HealthPlanContractTerm, us-gaap:DebtSecuritiesAvailableForSaleRealizedGain, us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss -  moh-20220930.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="moh-20220930.htm">moh-20220930.htm</File>
    <File>exhibit101_changexreques.htm</File>
    <File>moh-20220930.xsd</File>
    <File>moh-20220930_cal.xml</File>
    <File>moh-20220930_def.xml</File>
    <File>moh-20220930_lab.xml</File>
    <File>moh-20220930_pre.xml</File>
    <File>moh3q22_ex311.htm</File>
    <File>moh3q22_ex312.htm</File>
    <File>moh3q22_ex321.htm</File>
    <File>moh3q22_ex322.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>moh-20220930_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="783">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>81
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "moh-20220930.htm": {
   "axisCustom": 0,
   "axisStandard": 16,
   "contextCount": 231,
   "dts": {
    "calculationLink": {
     "local": [
      "moh-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "moh-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "moh-20220930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "moh-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "moh-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "moh-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 385,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 6,
    "http://www.molinahealthcare.com/20220930": 2,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 13
   },
   "keyCustom": 39,
   "keyStandard": 198,
   "memberCustom": 23,
   "memberStandard": 25,
   "nsprefix": "moh",
   "nsuri": "http://www.molinahealthcare.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.molinahealthcare.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110103 - Disclosure - Net Income Per Share",
     "role": "http://www.molinahealthcare.com/role/NetIncomePerShare",
     "shortName": "Net Income Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113104 - Disclosure - Business Combinations",
     "role": "http://www.molinahealthcare.com/role/BusinessCombinations",
     "shortName": "Business Combinations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115105 - Disclosure - Fair Value Measurements",
     "role": "http://www.molinahealthcare.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120106 - Disclosure - Investments",
     "role": "http://www.molinahealthcare.com/role/Investments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moh:MedicalClaimsAndBenefitsPayableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126107 - Disclosure - Medical Claims and Benefits Payable",
     "role": "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable",
     "shortName": "Medical Claims and Benefits Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moh:MedicalClaimsAndBenefitsPayableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131108 - Disclosure - Debt",
     "role": "http://www.molinahealthcare.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135109 - Disclosure - Stockholders' Equity",
     "role": "http://www.molinahealthcare.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137110 - Disclosure - Segments",
     "role": "http://www.molinahealthcare.com/role/Segments",
     "shortName": "Segments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142111 - Disclosure - Commitments and Contingencies",
     "role": "http://www.molinahealthcare.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moh:ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Significant Accounting Policies (Policies)",
     "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moh:ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "i406df5b5e82345ae890a914938d5a913_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PremiumsEarnedNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED STATEMENTS OF INCOME",
     "role": "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
     "shortName": "CONSOLIDATED STATEMENTS OF INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "i406df5b5e82345ae890a914938d5a913_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PremiumsEarnedNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Significant Accounting Policies (Tables)",
     "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables",
     "shortName": "Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Net Income Per Share (Tables)",
     "role": "http://www.molinahealthcare.com/role/NetIncomePerShareTables",
     "shortName": "Net Income Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316303 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.molinahealthcare.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321304 - Disclosure - Investments (Tables)",
     "role": "http://www.molinahealthcare.com/role/InvestmentsTables",
     "shortName": "Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327305 - Disclosure - Medical Claims and Benefits Payable (Tables)",
     "role": "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables",
     "shortName": "Medical Claims and Benefits Payable (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332306 - Disclosure - Debt (Tables)",
     "role": "http://www.molinahealthcare.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2338307 - Disclosure - Segments (Tables)",
     "role": "http://www.molinahealthcare.com/role/SegmentsTables",
     "shortName": "Segments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Organization and Basis of Presentation (Details)",
     "role": "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails",
     "shortName": "Organization and Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "i80a687f2f90f401b9e47d7da8ba17754_D20210901-20210930",
      "decimals": null,
      "lang": "en-US",
      "name": "moh:HealthPlanContractTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "i3214220ebe41400a954cc43a8c3bc8a6_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details)",
     "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "ia5f8e83b346f4a789040e8611fbb11f6_I20210930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "i3214220ebe41400a954cc43a8c3bc8a6_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Significant Accounting Policies - Receivables (Details)",
     "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails",
     "shortName": "Significant Accounting Policies - Receivables (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "ia4a4422c70fb4ddfa9b1095fc58b9f0e_I20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "i406df5b5e82345ae890a914938d5a913_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "role": "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "i406df5b5e82345ae890a914938d5a913_D20220701-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "i3214220ebe41400a954cc43a8c3bc8a6_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Significant Accounting Policies - Amounts Due To Government Agencies (Details)",
     "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails",
     "shortName": "Significant Accounting Policies - Amounts Due To Government Agencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "i3214220ebe41400a954cc43a8c3bc8a6_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "i3214220ebe41400a954cc43a8c3bc8a6_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Significant Accounting Policies - Narrative (Details)",
     "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "ie7f3faa154394153bb16052f2634e5ad_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "i406df5b5e82345ae890a914938d5a913_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Net Income Per Share (Details)",
     "role": "http://www.molinahealthcare.com/role/NetIncomePerShareDetails",
     "shortName": "Net Income Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "i4ff0d3fa206d42d891fbf8e9323bc625_I20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "moh:SharesOutstandingExcludingRestrictedStockAwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icbfe7220cac34928b948892e17e59eda_D20220930-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - Business Combinations (Details)",
     "role": "http://www.molinahealthcare.com/role/BusinessCombinationsDetails",
     "shortName": "Business Combinations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icbfe7220cac34928b948892e17e59eda_D20220930-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "i3214220ebe41400a954cc43a8c3bc8a6_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417408 - Disclosure - Fair Value Measurements - Financial Instruments on a Recurring Basis (Details)",
     "role": "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Financial Instruments on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "i3214220ebe41400a954cc43a8c3bc8a6_I20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "role": "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "ic8580906fd604a64a726120c54b6cf42_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419410 - Disclosure - Fair Value Measurements - Long-Term Debt (Details)",
     "role": "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails",
     "shortName": "Fair Value Measurements - Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "ic8580906fd604a64a726120c54b6cf42_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "i3214220ebe41400a954cc43a8c3bc8a6_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - Investments - Summary of Investments (Details)",
     "role": "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails",
     "shortName": "Investments - Summary of Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "i3214220ebe41400a954cc43a8c3bc8a6_I20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "i3214220ebe41400a954cc43a8c3bc8a6_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - Investments - Contractual Maturities of Available-for-Sale Investments (Details)",
     "role": "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails",
     "shortName": "Investments - Contractual Maturities of Available-for-Sale Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "i3214220ebe41400a954cc43a8c3bc8a6_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "i73f4675203bd4e2591632f444f1ad336_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424413 - Disclosure - Investments - Narrative (Details)",
     "role": "http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails",
     "shortName": "Investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "i73f4675203bd4e2591632f444f1ad336_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "i3214220ebe41400a954cc43a8c3bc8a6_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "i3214220ebe41400a954cc43a8c3bc8a6_I20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "i3214220ebe41400a954cc43a8c3bc8a6_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425414 - Disclosure - Investments - Available-for-Sale Investments (Details)",
     "role": "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails",
     "shortName": "Investments - Available-for-Sale Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "i3214220ebe41400a954cc43a8c3bc8a6_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "i3214220ebe41400a954cc43a8c3bc8a6_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - Medical Claims and Benefits Payable - Medical Claims and Benefits Payable (Details)",
     "role": "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails",
     "shortName": "Medical Claims and Benefits Payable - Medical Claims and Benefits Payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "i3214220ebe41400a954cc43a8c3bc8a6_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "i3214220ebe41400a954cc43a8c3bc8a6_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:MedicalClaimsAndBenefitsPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429416 - Disclosure - Medical Claims and Benefits Payable - Narrative (Details)",
     "role": "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableNarrativeDetails",
     "shortName": "Medical Claims and Benefits Payable - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "i3214220ebe41400a954cc43a8c3bc8a6_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:MedicalClaimsAndBenefitsPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "ie7f3faa154394153bb16052f2634e5ad_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430417 - Disclosure - Medical Claims and Benefits Payable - Components of Change in Medical Claims and Benefits Payable (Details)",
     "role": "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails",
     "shortName": "Medical Claims and Benefits Payable - Components of Change in Medical Claims and Benefits Payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "moh:ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "i3214220ebe41400a954cc43a8c3bc8a6_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsNoncurrentNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433418 - Disclosure - Debt - Schedule of Long-Term Debt (Details)",
     "role": "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
     "shortName": "Debt - Schedule of Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "i3214220ebe41400a954cc43a8c3bc8a6_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsNoncurrentNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "if5d5359290144d4f933ac919de58b333_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434419 - Disclosure - Debt - Narrative (Details)",
     "role": "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
     "shortName": "Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "if5d5359290144d4f933ac919de58b333_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436420 - Disclosure - Stockholders' Equity (Details)",
     "role": "http://www.molinahealthcare.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "i98de094b8bc642c2838aa6ef19a8ed9a_I20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439421 - Disclosure - Segments - Narrative (Details)",
     "role": "http://www.molinahealthcare.com/role/SegmentsNarrativeDetails",
     "shortName": "Segments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "i406df5b5e82345ae890a914938d5a913_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440422 - Disclosure - Segments - Schedule of Operating Segment Information (Details)",
     "role": "http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails",
     "shortName": "Segments - Schedule of Operating Segment Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "i406df5b5e82345ae890a914938d5a913_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441423 - Disclosure - Segments - Reconciliation of Gross Margin to Consolidated Income (Details)",
     "role": "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails",
     "shortName": "Segments - Reconciliation of Gross Margin to Consolidated Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "i3648beb8cc65477dac1c4d580ec26c84_D20220701-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GrossProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "i3214220ebe41400a954cc43a8c3bc8a6_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "i3214220ebe41400a954cc43a8c3bc8a6_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "ic06c267aa75849648ac7102abce3ac17_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "i1fc11daa88ad420c868e573c62e337b6_D20210101-20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Basis of Presentation",
     "role": "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation",
     "shortName": "Organization and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Significant Accounting Policies",
     "role": "http://www.molinahealthcare.com/role/SignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220930.htm",
      "contextRef": "icb010fc3ca094c3b956aefa2584be42b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 48,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "moh_A3875SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.875% Senior Notes",
        "label": "3.875% Senior Notes [Member]",
        "terseLabel": "3.875% Notes due 2032"
       }
      }
     },
     "localname": "A3875SeniorNotesMember",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_A4375SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.375% Senior Notes",
        "label": "4.375% Senior Notes [Member]",
        "terseLabel": "4.375% Notes due 2028"
       }
      }
     },
     "localname": "A4375SeniorNotesMember",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_AffinityHealthPlanIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affinity Health Plan, Inc",
        "label": "Affinity Health Plan, Inc [Member]",
        "terseLabel": "Affinity Health Plan, Inc"
       }
      }
     },
     "localname": "AffinityHealthPlanIncMember",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net Payable",
        "label": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net Payable",
        "terseLabel": "Risk adjustment, net payable"
       }
      }
     },
     "localname": "AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, (Payable)",
        "label": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, (Payable)",
        "terseLabel": "Risk adjustment payable"
       }
      }
     },
     "localname": "AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable",
        "label": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable",
        "terseLabel": "Risk adjustment receivable"
       }
      }
     },
     "localname": "AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AgeWellMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AgeWell",
        "label": "AgeWell [Member]",
        "terseLabel": "AgeWell"
       }
      }
     },
     "localname": "AgeWellMember",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 3.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Due To Government Agencies, Marketplace, Medical Loss Ratio Threshold",
        "label": "Amounts Due To Government Agencies, Marketplace, Medical Loss Ratio Threshold",
        "terseLabel": "Minimum MLR"
       }
      }
     },
     "localname": "AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Due To Government Agencies, Marketplace Program [Abstract]",
        "label": "Amounts Due To Government Agencies, Marketplace Program [Abstract]",
        "terseLabel": "Marketplace program:"
       }
      }
     },
     "localname": "AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_AmountsDueToGovernmentAgenciesMedicaidOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 5.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Due To Government Agencies, Medicaid, Other",
        "label": "Amounts Due To Government Agencies, Medicaid, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AmountsDueToGovernmentAgenciesMedicaidOther",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Due To Government Agencies, Medicaid Program [Abstract]",
        "label": "Amounts Due To Government Agencies, Medicaid Program [Abstract]",
        "terseLabel": "Medicaid program:"
       }
      }
     },
     "localname": "AmountsDueToGovernmentAgenciesMedicaidProgramAbstract",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 4.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Due To Government Agencies, Medicare, Medical Loss Ratio And Profit Sharing, Threshold",
        "label": "Amounts Due To Government Agencies, Medicare, Medical Loss Ratio And Profit Sharing, Threshold",
        "terseLabel": "Minimum MLR and profit sharing"
       }
      }
     },
     "localname": "AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Due To Government Agencies Medicare Program",
        "label": "Amounts Due To Government Agencies Medicare Program [Abstract]",
        "terseLabel": "Medicare program:"
       }
      }
     },
     "localname": "AmountsDueToGovernmentAgenciesMedicareProgramAbstract",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 1.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Due to Government Agencies, Risk Adjustment and Part D risk sharing",
        "label": "Amounts Due to Government Agencies, Risk Adjustment and Part D risk sharing",
        "terseLabel": "Risk adjustment and Part D risk sharing"
       }
      }
     },
     "localname": "AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AmountsDuetoGovernmentAgenciesOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 6.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Due to Government Agencies, Other",
        "label": "Amounts Due to Government Agencies, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AmountsDuetoGovernmentAgenciesOther",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AmountsDuetoGovernmentAgenciesRiskAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 7.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Due to Government Agencies, Risk Adjustment",
        "label": "Amounts Due to Government Agencies, Risk Adjustment",
        "terseLabel": "Risk adjustment"
       }
      }
     },
     "localname": "AmountsDuetoGovernmentAgenciesRiskAdjustment",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of members eligible for the health care programs.",
        "label": "Business Combination, Number Of Members Eligible For The Health Care Programs",
        "terseLabel": "Number of members eligible for the health care programs, approximately"
       }
      }
     },
     "localname": "BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Medical Claims and Benefits Payable",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Medical Claims and Benefits Payable",
        "terseLabel": "Medical claims and benefits payable"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Receivables",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Receivables",
        "terseLabel": "Increase to receivables, net of amounts due government agencies"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_COVID19Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19",
        "label": "COVID-19 [Member]",
        "terseLabel": "COVID-19"
       }
      }
     },
     "localname": "COVID19Member",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_CapitationClaimsPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitation Claims Payable",
        "label": "Capitation Claims Payable",
        "terseLabel": "Capitation payable"
       }
      }
     },
     "localname": "CapitationClaimsPayable",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cigna Corporation's Texas Medicaid and Medicare-Medicaid Plan",
        "label": "Cigna Corporation's Texas Medicaid and Medicare-Medicaid Plan [Member]",
        "terseLabel": "Cigna Corporation's Texas Medicaid and Medicare-Medicaid Plan"
       }
      }
     },
     "localname": "CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_CommonStockWithheldToSettleEmployeeTaxObligations": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Withheld to Settle Employee Tax Obligations",
        "label": "Common Stock Withheld to Settle Employee Tax Obligations",
        "negatedLabel": "Common stock withheld to settle employee tax obligations"
       }
      }
     },
     "localname": "CommonStockWithheldToSettleEmployeeTaxObligations",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components Of Change In Medical Claims And Benefits Payable [Table Text Block]",
        "label": "Components Of Change In Medical Claims And Benefits Payable [Table Text Block]",
        "terseLabel": "Schedule of Components of The Change in Medical Claims and Benefits Payable"
       }
      }
     },
     "localname": "ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "moh_ComponentsOfMedicalCareCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of medical care costs.",
        "label": "Components Of Medical Care Costs [Abstract]",
        "terseLabel": "Components of medical care costs related to:"
       }
      }
     },
     "localname": "ComponentsOfMedicalCareCostsAbstract",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidation And Interim Financial Information, Policy [Policy Text Block]",
        "label": "Consolidation And Interim Financial Information, Policy [Policy Text Block]",
        "terseLabel": "Consolidation and Interim Financial Information"
       }
      }
     },
     "localname": "ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "moh_EarningsPerShareBasicAndDilutedEPSAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Per Share, Basic and Diluted EPS",
        "label": "Earnings Per Share, Basic and Diluted EPS [Abstract]",
        "terseLabel": "Net income per share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedEPSAbstract",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_GovernmentReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Receivables [Member]",
        "label": "Government Receivables [Member]",
        "terseLabel": "Government receivables"
       }
      }
     },
     "localname": "GovernmentReceivablesMember",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_HealthCareOrganizationPremiumTaxRevenue": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care Organization, Premium Tax Revenue",
        "label": "Health Care Organization, Premium Tax Revenue",
        "terseLabel": "Premium tax revenue"
       }
      }
     },
     "localname": "HealthCareOrganizationPremiumTaxRevenue",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_HealthPlanContractTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Plan, Contract Term",
        "label": "Health Plan, Contract Term",
        "terseLabel": "Contract term"
       }
      }
     },
     "localname": "HealthPlanContractTerm",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "moh_HealthPlanExtensionOptionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Plan, Extension Option, Period",
        "label": "Health Plan, Extension Option, Period",
        "terseLabel": "Extension option"
       }
      }
     },
     "localname": "HealthPlanExtensionOptionPeriod",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "moh_HealthPlanNumberOfContracts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Plan, Number Of Contracts",
        "label": "Health Plan, Number Of Contracts",
        "terseLabel": "Number of contracts"
       }
      }
     },
     "localname": "HealthPlanNumberOfContracts",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "moh_HealthPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health plans.",
        "label": "Health Plans [Member]",
        "terseLabel": "Health Plans"
       }
      }
     },
     "localname": "HealthPlansMember",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Medical Premium Liability Due to Agency",
        "label": "Increase (Decrease) In Medical Premium Liability Due To Agency",
        "terseLabel": "Amounts due government agencies"
       }
      }
     },
     "localname": "IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_InvestmentsAverageMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments, Average Maturity Period",
        "label": "Investments, Average Maturity Period",
        "terseLabel": "Average maturity period (less than)"
       }
      }
     },
     "localname": "InvestmentsAverageMaturityPeriod",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "moh_InvestmentsMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments, Maturity Period",
        "label": "Investments, Maturity Period",
        "terseLabel": "Maturity period (less than)"
       }
      }
     },
     "localname": "InvestmentsMaturityPeriod",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions, Net Of Post-Closing Adjustments",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions, Net Of Post-Closing Adjustments",
        "terseLabel": "Acquired balances, net of post-acquisition adjustments"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Paid (IBNP), Fee-for-service Claims, Amount",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Paid (IBNP), Fee-for-service Claims, Amount",
        "terseLabel": "Claims incurred but not paid (\u201cIBNP\u201d)"
       }
      }
     },
     "localname": "LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt, Noncurrent, Net Of Unamortized Debt Discount",
        "label": "Long-Term Debt, Noncurrent, Net Of Unamortized Debt Discount",
        "terseLabel": "Non-current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_MarketplaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketplace",
        "label": "Marketplace [Member]",
        "terseLabel": "Marketplace"
       }
      }
     },
     "localname": "MarketplaceMember",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails",
      "http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_MedicaidMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicaid",
        "label": "Medicaid [Member]",
        "terseLabel": "Medicaid"
       }
      }
     },
     "localname": "MedicaidMember",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails",
      "http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_MedicalClaimsAndBenefitsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Claims and Benefits Payable",
        "label": "Medical Claims And Benefits Payable",
        "terseLabel": "Non-risk provider payables"
       }
      }
     },
     "localname": "MedicalClaimsAndBenefitsPayable",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Claims and Benefits Payable, Adjustments, Change in Provider",
        "label": "Medical Claims And Benefits Payable, Adjustments, Change In Provider",
        "terseLabel": "Change in non-risk and other provider payables"
       }
      }
     },
     "localname": "MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_MedicalClaimsAndBenefitsPayableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical claims and benefits payable.",
        "label": "Medical Claims And Benefits Payable [Text Block]",
        "terseLabel": "Medical Claims and Benefits Payable"
       }
      }
     },
     "localname": "MedicalClaimsAndBenefitsPayableTextBlock",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "moh_MedicalPremiumLiabilityDueToAgency": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Premium Liability Due to Agency",
        "label": "Medical Premium Liability Due To Agency",
        "terseLabel": "Amounts due government agencies",
        "totalLabel": "Total amounts due government agencies"
       }
      }
     },
     "localname": "MedicalPremiumLiabilityDueToAgency",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 8.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Premiums Liability, Medical Care Costs Threshold",
        "label": "Medical Premiums Liability, Medical Care Costs Threshold",
        "terseLabel": "Minimum MLR and profit sharing"
       }
      }
     },
     "localname": "MedicalPremiumsLiabilityMedicalCareCostsThreshold",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_MedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare",
        "label": "Medicare [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareMember",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails",
      "http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_MemberListsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member Lists",
        "label": "Member Lists [Member]",
        "terseLabel": "Member list"
       }
      }
     },
     "localname": "MemberListsMember",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_MinimumMemberEnrollmentTargetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum Member Enrollment Targets",
        "label": "Minimum Member Enrollment Targets [Member]",
        "terseLabel": "Minimum Member Enrollment Targets"
       }
      }
     },
     "localname": "MinimumMemberEnrollmentTargetsMember",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_MunicipalSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Municipal securities.",
        "label": "Municipal Securities [Member]",
        "terseLabel": "Municipal securities"
       }
      }
     },
     "localname": "MunicipalSecuritiesMember",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_MyChoiceWisconsinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "My Choice Wisconsin",
        "label": "My Choice Wisconsin [Member]",
        "terseLabel": "MCW"
       }
      }
     },
     "localname": "MyChoiceWisconsinMember",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of States With Government-Sponsored Healthcare Programs",
        "label": "Number Of States With Government-Sponsored Healthcare Programs",
        "terseLabel": "Number of states with programs"
       }
      }
     },
     "localname": "NumberOfStatesWithGovernmentSponsoredHealthcarePrograms",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "moh_OperatingIncomeGuaranteeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Income Guarantee",
        "label": "Operating Income Guarantee [Member]",
        "terseLabel": "Operating Income Guarantee"
       }
      }
     },
     "localname": "OperatingIncomeGuaranteeMember",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_OtherClaimsPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Claims Payable",
        "label": "Other Claims Payable",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherClaimsPayable",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_OtherMedicareProgram": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 2.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Medicare Program",
        "label": "Other Medicare Program",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherMedicareProgram",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_OtherProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Program",
        "label": "Other Program [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherProgramMember",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails",
      "http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_OtherReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Receivables [Member]",
        "label": "Other Receivables [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherReceivablesMember",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_OtherSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Securities",
        "label": "Other Securities [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherSecuritiesMember",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_PassportHealthPlanIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Passport Health Plan Inc",
        "label": "Passport Health Plan Inc [Member]",
        "terseLabel": "Passport Health Plan, Inc."
       }
      }
     },
     "localname": "PassportHealthPlanIncMember",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment For Contingent Consideration Liability, Financing And Operating Activities",
        "label": "Payment For Contingent Consideration Liability, Financing And Operating Activities",
        "terseLabel": "Contingent consideration paid to seller included in financing and operating activities"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_PaymentsForMedicalCareCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for medical care costs.",
        "label": "Payments For Medical Care Costs [Abstract]",
        "terseLabel": "Payments for medical care costs related to:"
       }
      }
     },
     "localname": "PaymentsForMedicalCareCostsAbstract",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_PharmacyClaimsPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmacy Claims Payable",
        "label": "Pharmacy Claims Payable",
        "terseLabel": "Pharmacy payable"
       }
      }
     },
     "localname": "PharmacyClaimsPayable",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_PharmacyRebateReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmacy Rebate Receivables [Member]",
        "label": "Pharmacy Rebate Receivables [Member]",
        "terseLabel": "Pharmacy rebate receivables"
       }
      }
     },
     "localname": "PharmacyRebateReceivablesMember",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_PremiumTaxExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An assessment levied by a state government on the net premium income collected.",
        "label": "Premium Tax Expenses",
        "terseLabel": "Premium tax expenses"
       }
      }
     },
     "localname": "PremiumTaxExpenses",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of premium revenue by health plan type.",
        "label": "Schedule of Premium Revenue by Health Plan Type [Line Items]",
        "terseLabel": "Schedule of Premium Revenue by Health Plan Type [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfPremiumRevenueByHealthPlanTypeLineItems",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of premium revenue by health plan type.",
        "label": "Schedule of Premium Revenue by Health Plan Type [Table]",
        "terseLabel": "Schedule Of Premium Revenue By Health Plan Type [Table]"
       }
      }
     },
     "localname": "ScheduleOfPremiumRevenueByHealthPlanTypeTable",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_SharesOutstandingExcludingRestrictedStockAwards": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares, Outstanding, Excluding Restricted Stock Awards",
        "label": "Shares, Outstanding, Excluding Restricted Stock Awards",
        "terseLabel": "Shares outstanding at the beginning of the period ( in shares)"
       }
      }
     },
     "localname": "SharesOutstandingExcludingRestrictedStockAwards",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "moh_StructuredSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structured Securities [Member]",
        "label": "Structured Securities [Member]",
        "terseLabel": "Structured Securities"
       }
      }
     },
     "localname": "StructuredSecuritiesMember",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_ThreePointEightSevenFivePercentSeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Eight Seven Five Percent Senior Notes",
        "label": "Three Point Eight Seven Five Percent Senior Notes [Member]",
        "terseLabel": "3.875% Notes due 2030"
       }
      }
     },
     "localname": "ThreePointEightSevenFivePercentSeniorNotesMember",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_WeightedAverageNumberofSharesShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Number of Shares, Share Based Compensation",
        "label": "Weighted Average Number of Shares, Share Based Compensation",
        "terseLabel": "Stock-based compensation (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberofSharesShareBasedCompensation",
     "nsuri": "http://www.molinahealthcare.com/20220930",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r87",
      "r135",
      "r148",
      "r149",
      "r150",
      "r151",
      "r153",
      "r155",
      "r159",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r253",
      "r255",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r87",
      "r135",
      "r148",
      "r149",
      "r150",
      "r151",
      "r153",
      "r155",
      "r159",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r253",
      "r255",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r240",
      "r261",
      "r286",
      "r334",
      "r336",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r445",
      "r498",
      "r500",
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r240",
      "r261",
      "r286",
      "r334",
      "r336",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r445",
      "r498",
      "r500",
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r231",
      "r237",
      "r238",
      "r239",
      "r240",
      "r261",
      "r286",
      "r324",
      "r334",
      "r336",
      "r339",
      "r340",
      "r341",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r445",
      "r498",
      "r500",
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r231",
      "r237",
      "r238",
      "r239",
      "r240",
      "r261",
      "r286",
      "r324",
      "r334",
      "r336",
      "r339",
      "r340",
      "r341",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r445",
      "r498",
      "r500",
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r162",
      "r163",
      "r320",
      "r322",
      "r499",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r162",
      "r163",
      "r320",
      "r322",
      "r499",
      "r511",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "CALIFORNIA"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_IA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IOWA",
        "terseLabel": "IOWA"
       }
      }
     },
     "localname": "IA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_MS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MISSISSIPPI",
        "terseLabel": "MISSISSIPPI"
       }
      }
     },
     "localname": "MS",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEBRASKA",
        "terseLabel": "NEBRASKA"
       }
      }
     },
     "localname": "NE",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]",
        "terseLabel": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable, accrued liabilities and other"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r18",
      "r35",
      "r37",
      "r38",
      "r480",
      "r505",
      "r506"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r34",
      "r38",
      "r46",
      "r47",
      "r48",
      "r89",
      "r90",
      "r91",
      "r376",
      "r411",
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r342",
      "r343",
      "r344",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r185",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-Backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r9",
      "r85",
      "r143",
      "r150",
      "r157",
      "r195",
      "r243",
      "r244",
      "r245",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r254",
      "r256",
      "r257",
      "r373",
      "r377",
      "r395",
      "r412",
      "r414",
      "r453",
      "r478"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r22",
      "r85",
      "r195",
      "r243",
      "r244",
      "r245",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r254",
      "r256",
      "r257",
      "r373",
      "r377",
      "r395",
      "r412",
      "r414"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r386"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r174"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r175"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "terseLabel": "Gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": {
     "auth_ref": [
      "r179"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "Due after five years through ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "auth_ref": [
      "r176",
      "r179",
      "r471"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "Due after five years through ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r178"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r176",
      "r178",
      "r470"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost": {
     "auth_ref": [
      "r180"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10",
        "terseLabel": "Due after ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue": {
     "auth_ref": [
      "r176",
      "r180",
      "r472"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10",
        "terseLabel": "Due after ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "auth_ref": [
      "r176",
      "r181",
      "r473"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r177"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r176",
      "r177",
      "r469"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r333",
      "r335",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r333",
      "r335",
      "r359",
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition, Contingent Consideration [Line Items]",
        "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r364",
      "r365",
      "r367"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Total purchase price",
        "verboseLabel": "Purchase price"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsDetails",
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r363",
      "r366",
      "r368"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration liabilities"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r362",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r393",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Amount"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r7",
      "r77"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r71",
      "r77",
      "r79"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash and cash equivalents at end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period",
        "totalLabel": "Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r71",
      "r396"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents, and restricted cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialMortgageBackedSecuritiesMember": {
     "auth_ref": [
      "r181",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities collateralized by commercial real estate mortgage loans.",
        "label": "Commercial Mortgage-Backed Securities [Member]",
        "verboseLabel": "Mortgage-backed securities"
       }
      }
     },
     "localname": "CommercialMortgageBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r234",
      "r235",
      "r236",
      "r241",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r89",
      "r90",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.molinahealthcare.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r15",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Common stock, $0.001 par value, 150 million shares authorized; outstanding: 58 million shares at September\u00a030, 2022 and December\u00a031, 2021"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r41",
      "r43",
      "r44",
      "r53",
      "r460",
      "r487"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r124",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r310",
      "r311",
      "r321"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r325",
      "r332",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r57",
      "r447"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Medical care costs"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "negatedTerseLabel": "Less: other operating expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r84",
      "r87",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r276",
      "r277",
      "r278",
      "r279",
      "r407",
      "r454",
      "r455",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r258",
      "r276",
      "r277",
      "r405",
      "r407",
      "r408"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r267",
      "r276",
      "r277",
      "r392"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Fair value of debt"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r27",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Percentage of contractual interest rate on notes",
        "verboseLabel": "Debt instrument, interest rate, stated percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r28",
      "r84",
      "r87",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r276",
      "r277",
      "r278",
      "r279",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r28",
      "r84",
      "r87",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r301",
      "r304",
      "r305",
      "r306",
      "r404",
      "r405",
      "r407",
      "r408",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss": {
     "auth_ref": [
      "r205"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r188",
      "r208",
      "r211"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "In\u00a0a\u00a0Continuous\u00a0Loss Position for\u00a012\u00a0Months or More, Estimated Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r188",
      "r208"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "terseLabel": "In\u00a0a\u00a0Continuous\u00a0Loss Position for\u00a012\u00a0Months or More, Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions",
        "terseLabel": "In\u00a0a\u00a0Continuous\u00a0Loss Position for\u00a012\u00a0Months or More, Total Number of Positions"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r188",
      "r208",
      "r211"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "In\u00a0a\u00a0Continuous\u00a0Loss Position for\u00a0Less\u00a0than\u00a012\u00a0Months, Estimated Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r188",
      "r208"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "terseLabel": "In\u00a0a\u00a0Continuous\u00a0Loss Position for\u00a0Less\u00a0than\u00a012\u00a0Months, Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions",
        "terseLabel": "In\u00a0a\u00a0Continuous\u00a0Loss Position for\u00a0Less\u00a0than\u00a012\u00a0Months, Total Number of Positions"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": {
     "auth_ref": [
      "r205"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest",
        "terseLabel": "Debt securities, available-for-sale",
        "verboseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "auth_ref": [
      "r189"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Realized Gain",
        "terseLabel": "Gross realized investment gains"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "auth_ref": [
      "r189"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Realized Loss",
        "terseLabel": "Gross realized investment losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r187",
      "r207",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Available-for-Sale Investments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss": {
     "auth_ref": [
      "r197",
      "r202",
      "r203"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount excluding accrued interest, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Excluding Accrued Interest, before Allowance for Credit Loss",
        "terseLabel": "Debt securities held to maturity"
       }
      }
     },
     "localname": "DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNoncurrentNet": {
     "auth_ref": [
      "r406"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Noncurrent, Net",
        "negatedTerseLabel": "Deferred debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNoncurrentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r347",
      "r348"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r75",
      "r228"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r75",
      "r138"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "DilutiveSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r54",
      "r94",
      "r95",
      "r96",
      "r97",
      "r98",
      "r102",
      "r105",
      "r110",
      "r111",
      "r112",
      "r116",
      "r117",
      "r384",
      "r385",
      "r461",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net income per share - Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r54",
      "r94",
      "r95",
      "r96",
      "r97",
      "r98",
      "r105",
      "r110",
      "r111",
      "r112",
      "r116",
      "r117",
      "r384",
      "r385",
      "r461",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Net income per share - Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Income Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomePerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r46",
      "r47",
      "r48",
      "r89",
      "r90",
      "r91",
      "r93",
      "r99",
      "r101",
      "r119",
      "r196",
      "r300",
      "r307",
      "r342",
      "r343",
      "r344",
      "r354",
      "r355",
      "r383",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r411",
      "r501",
      "r502",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.molinahealthcare.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r267",
      "r276",
      "r277",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r386",
      "r387",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Assets Measured on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r386",
      "r393",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r267",
      "r276",
      "r277",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r387",
      "r418",
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r267",
      "r276",
      "r277",
      "r386",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r267",
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r267",
      "r325",
      "r326",
      "r331",
      "r332",
      "r387",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "(Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r267",
      "r276",
      "r277",
      "r325",
      "r326",
      "r331",
      "r332",
      "r387",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "(Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r267",
      "r276",
      "r277",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r387",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "(Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r267",
      "r276",
      "r277",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r418",
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r409"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r185",
      "r186",
      "r192",
      "r193",
      "r194",
      "r198",
      "r199",
      "r200",
      "r201",
      "r204",
      "r207",
      "r209",
      "r210",
      "r211",
      "r275",
      "r298",
      "r381",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r222",
      "r224",
      "r226",
      "r227",
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r222",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-Lived Intangible Assets Acquired",
        "terseLabel": "Acquired membership with a preliminary fair value"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings": {
     "auth_ref": [
      "r380"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total amount of gain (loss) derived from fair value hedges recognized in earnings in the period.",
        "label": "Gain (Loss) on Fair Value Hedges Recognized in Earnings",
        "negatedLabel": "Recognized gain (loss)"
       }
      }
     },
     "localname": "GainLossOnFairValueHedgesRecognizedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillPurchaseAccountingAdjustments": {
     "auth_ref": [
      "r218",
      "r358"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Purchase Accounting Adjustments",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillPurchaseAccountingAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r56",
      "r85",
      "r143",
      "r149",
      "r153",
      "r156",
      "r159",
      "r195",
      "r243",
      "r244",
      "r245",
      "r248",
      "r249",
      "r250",
      "r252",
      "r254",
      "r256",
      "r257",
      "r395"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "verboseLabel": "Total margin"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount": {
     "auth_ref": [
      "r184",
      "r468"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, after Year 5 through 10",
        "terseLabel": "Amortized cost, due after five years"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount": {
     "auth_ref": [
      "r183",
      "r467"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, after Year One through Five",
        "terseLabel": "Amortized cost, due one year through five years"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount": {
     "auth_ref": [
      "r182",
      "r466"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Amortized cost, due in one year or less"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r51",
      "r143",
      "r149",
      "r153",
      "r156",
      "r159",
      "r450",
      "r458",
      "r464",
      "r489"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income tax expense"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r86",
      "r100",
      "r101",
      "r141",
      "r349",
      "r356",
      "r357",
      "r490"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r45",
      "r345",
      "r346",
      "r350",
      "r351",
      "r352",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable, accrued liabilities and other"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r74",
      "r446"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in health care insurance liability balances during the period.",
        "label": "Increase (Decrease) in Health Care Insurance Liabilities",
        "terseLabel": "Medical claims and benefits payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInHealthCareInsuranceLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPremiumsReceivable": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The change in the premium receivable balance on the balance sheet.",
        "label": "Increase (Decrease) in Premiums Receivable",
        "negatedTerseLabel": "Reduction in premiums"
       }
      }
     },
     "localname": "IncreaseDecreaseInPremiumsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Receivables",
        "negatedLabel": "Receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r112",
      "r337"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Stock-based compensation (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "terseLabel": "Goodwill, and intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestAndDividendIncomeOperating": {
     "auth_ref": [
      "r462"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein.",
        "label": "Interest and Dividend Income, Operating",
        "terseLabel": "Other revenue"
       }
      }
     },
     "localname": "InterestAndDividendIncomeOperating",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r49",
      "r137",
      "r403",
      "r406",
      "r463"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Schedule of Contractual Maturities of Investments"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r191",
      "r451",
      "r474",
      "r510",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/Investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r25",
      "r85",
      "r151",
      "r195",
      "r243",
      "r244",
      "r245",
      "r248",
      "r249",
      "r250",
      "r252",
      "r254",
      "r256",
      "r257",
      "r374",
      "r377",
      "r378",
      "r395",
      "r412",
      "r413"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r21",
      "r85",
      "r195",
      "r395",
      "r414",
      "r456",
      "r482"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r26",
      "r85",
      "r195",
      "r243",
      "r244",
      "r245",
      "r248",
      "r249",
      "r250",
      "r252",
      "r254",
      "r256",
      "r257",
      "r374",
      "r377",
      "r378",
      "r395",
      "r412",
      "r413",
      "r414"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r386"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r492",
      "r495"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.",
        "label": "Liability for Claims and Claims Adjustment Expense",
        "periodEndLabel": "Medical claims and benefits payable, ending balance",
        "periodStartLabel": "Medical claims and benefits payable, beginning balance",
        "totalLabel": "Total",
        "verboseLabel": "Medical claims and benefits payable"
       }
      }
     },
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Liability for Claims and Claims Adjustment Expense [Line Items]",
        "terseLabel": "Liability for Claims and Claims Adjustment Expense [Line Items]"
       }
      }
     },
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the liability for claims and claims adjustment expense.",
        "label": "Liability for Claims and Claims Adjustment Expense [Table]",
        "terseLabel": "Liability for Claims and Claims Adjustment Expense [Table]"
       }
      }
     },
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1": {
     "auth_ref": [
      "r494"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year",
        "terseLabel": "Current year"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": {
     "auth_ref": [
      "r494"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years",
        "terseLabel": "Prior years"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1": {
     "auth_ref": [
      "r493"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims",
        "totalLabel": "Total medical care costs"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]",
        "terseLabel": "Insurance Claims"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r12",
      "r455",
      "r477"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-Term Line of Credit",
        "terseLabel": "Amount outstanding under letter of credit"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r23"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-Term Debt [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r28",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MaterialReconcilingItemsMember": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.",
        "label": "Segment Reconciling Items [Member]",
        "terseLabel": "Other operating"
       }
      }
     },
     "localname": "MaterialReconcilingItemsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MortgageBackedSecuritiesMember": {
     "auth_ref": [
      "r173",
      "r325",
      "r326",
      "r332",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities collateralized by mortgage loans.",
        "label": "Collateralized Mortgage-Backed Securities [Member]",
        "terseLabel": "Mortgage-backed securities"
       }
      }
     },
     "localname": "MortgageBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r71",
      "r73",
      "r76"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r39",
      "r42",
      "r48",
      "r52",
      "r76",
      "r85",
      "r92",
      "r94",
      "r95",
      "r96",
      "r97",
      "r100",
      "r101",
      "r109",
      "r143",
      "r149",
      "r153",
      "r156",
      "r159",
      "r195",
      "r243",
      "r244",
      "r245",
      "r248",
      "r249",
      "r250",
      "r252",
      "r254",
      "r256",
      "r257",
      "r385",
      "r395",
      "r459",
      "r485"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetInvestmentIncome": {
     "auth_ref": [
      "r486"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments.",
        "label": "Net Investment Income",
        "terseLabel": "Investment income"
       }
      }
     },
     "localname": "NetInvestmentIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "negatedLabel": "Other expenses, net",
        "negatedTotalLabel": "Total other expenses, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other expenses, net:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.molinahealthcare.com/role/SegmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r143",
      "r149",
      "r153",
      "r156",
      "r159"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r148",
      "r149",
      "r150",
      "r151",
      "r153",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r3",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r8"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r40",
      "r43",
      "r371",
      "r372",
      "r375"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive loss, net",
        "totalLabel": "Other comprehensive loss, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r32",
      "r35",
      "r190"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax",
        "terseLabel": "Unrealized investment loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r33",
      "r36"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "terseLabel": "Less: effect of income taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCostAndExpenseOperating": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.",
        "label": "Other Cost and Expense, Operating",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCostAndExpenseOperating",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]",
        "terseLabel": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedTerseLabel": "Contingent consideration liabilities settled",
        "terseLabel": "Contingent consideration liabilities settled"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities": {
     "auth_ref": [
      "r70"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Operating Activities",
        "terseLabel": "Remaining half of contingent consideration paid"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLossesAndLossAdjustmentExpense": {
     "auth_ref": [
      "r72",
      "r494"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid",
        "totalLabel": "Total paid"
       }
      }
     },
     "localname": "PaymentsForLossesAndLossAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r62",
      "r65"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Common stock purchases",
        "terseLabel": "Common stock purchases"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.molinahealthcare.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedTerseLabel": "Net cash paid in business combinations"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r172"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, equipment and capitalized software"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r14",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r14",
      "r414"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PremiumsEarnedNet": {
     "auth_ref": [
      "r457",
      "r484",
      "r491",
      "r507"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 4.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned.",
        "label": "Premiums Earned, Net",
        "terseLabel": "Premium revenue"
       }
      }
     },
     "localname": "PremiumsEarnedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r66",
      "r69"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from sales and maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r229",
      "r410"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "terseLabel": "Property, equipment, and capitalized software, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r414",
      "r483",
      "r509"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Receivables",
        "verboseLabel": "Total receivables"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r167",
      "r169",
      "r170",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Receivables"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReservesReportedToOtherAgenciesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of reserves reported to other federal agencies or authorities.",
        "label": "Reserves Reported to Other Agencies [Table Text Block]",
        "terseLabel": "Schedule of Amounts Due to Government Agencies"
       }
      }
     },
     "localname": "ReservesReportedToOtherAgenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r7",
      "r77",
      "r79",
      "r452",
      "r479"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "verboseLabel": "Restricted cash and cash equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedInvestmentsNoncurrent": {
     "auth_ref": [
      "r512",
      "r513"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the noncurrent portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.",
        "label": "Restricted Investments, Noncurrent",
        "terseLabel": "Restricted investments"
       }
      }
     },
     "localname": "RestrictedInvestmentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r17",
      "r307",
      "r414",
      "r481",
      "r504",
      "r506"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r89",
      "r90",
      "r91",
      "r93",
      "r99",
      "r101",
      "r196",
      "r342",
      "r343",
      "r344",
      "r354",
      "r355",
      "r383",
      "r501",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r81",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Premium Revenue Recognition and Amounts Due Government Agencies and Contractual Provisions That May Adjust or Limit Revenue or Profit"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r50",
      "r85",
      "r134",
      "r135",
      "r148",
      "r154",
      "r155",
      "r161",
      "r162",
      "r165",
      "r195",
      "r243",
      "r244",
      "r245",
      "r248",
      "r249",
      "r250",
      "r252",
      "r254",
      "r256",
      "r257",
      "r395",
      "r464"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "netLabel": "Revenues",
        "totalLabel": "Total revenue",
        "verboseLabel": "Add: other operating revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails",
      "http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of Receivables"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Investments"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r28",
      "r87",
      "r276",
      "r278",
      "r301",
      "r304",
      "r305",
      "r306",
      "r404",
      "r405",
      "r408",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Long Term Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Summary of Denominators for The Computation of Basic and Diluted Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Measurements of Senior Notes"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.",
        "label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]",
        "terseLabel": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense"
       }
      }
     },
     "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r79",
      "r452",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Restricted Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r143",
      "r146",
      "r152",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails",
      "http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r143",
      "r146",
      "r152",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Operating Segment Information"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SegmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r82",
      "r120",
      "r121",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r293",
      "r298",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r130",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r148",
      "r149",
      "r150",
      "r151",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r159",
      "r165",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r232",
      "r233",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails",
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails",
      "http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r130",
      "r132",
      "r133",
      "r143",
      "r147",
      "r153",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r164",
      "r165",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/Segments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails",
      "http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r80",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r1",
      "r130",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r148",
      "r149",
      "r150",
      "r151",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r159",
      "r165",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r230",
      "r232",
      "r233",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails",
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails",
      "http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r30",
      "r46",
      "r47",
      "r48",
      "r89",
      "r90",
      "r91",
      "r93",
      "r99",
      "r101",
      "r119",
      "r196",
      "r300",
      "r307",
      "r342",
      "r343",
      "r344",
      "r354",
      "r355",
      "r383",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r411",
      "r501",
      "r502",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.molinahealthcare.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r119",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r14",
      "r15",
      "r300",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r14",
      "r15",
      "r307",
      "r338"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Common stock authorized"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r14",
      "r15",
      "r300",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Common stock purchases (in shares)",
        "terseLabel": "Repurchased of common stock (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.molinahealthcare.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r14",
      "r15",
      "r300",
      "r307"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedTerseLabel": "Common stock purchases"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r15",
      "r19",
      "r20",
      "r85",
      "r168",
      "r195",
      "r395",
      "r414"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r83",
      "r285",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r307",
      "r309",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r493"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.",
        "label": "Current Year Claims and Claims Adjustment Expense",
        "terseLabel": "Current year"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r493"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.",
        "label": "Prior Year Claims and Claims Adjustment Expense",
        "terseLabel": "Prior years",
        "verboseLabel": "Prior period claims, favorable development"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r185",
      "r186",
      "r192",
      "r193",
      "r194",
      "r275",
      "r298",
      "r381",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
        "label": "Treasury Stock Acquired, Average Cost Per Share",
        "terseLabel": "Average cost (USD per share)"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_USTreasuryNotesSecuritiesMember": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one to ten years, are interest bearing, and are backed by the full faith and credit of the United States government.",
        "label": "US Treasury Notes Securities [Member]",
        "terseLabel": "U.S. Treasury notes"
       }
      }
     },
     "localname": "USTreasuryNotesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnusualOrInfrequentItemAxis": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by an event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Axis]",
        "terseLabel": "Unusual or Infrequent Item, or Both [Axis]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualOrInfrequentItemDomain": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Domain]",
        "terseLabel": "Unusual or Infrequent Item, or Both [Domain]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r122",
      "r123",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r104",
      "r112"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Denominator for diluted net income per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).",
        "label": "Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation",
        "negatedTerseLabel": "Stock purchases (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r102",
      "r112"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Denominator for basic net income per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]",
        "terseLabel": "Weighted-average number of shares issued:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2646-109256"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL6283291-111563"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(3)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL120267963-210447"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "c",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(c))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.1-5)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(d)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120401096&loc=d3e574992-122915"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(cc)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "605",
   "Subparagraph": "(c)(3)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=127002003&loc=SL6242269-115581"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r526": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r527": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r528": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r529": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r530": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r531": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r532": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r533": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r534": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r535": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r536": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r537": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r538": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r539": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=114868883&loc=SL114871943-224233"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(ee)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>82
<FILENAME>0001179929-22-000172-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001179929-22-000172-xbrl.zip
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M&0XC0B F4D?(9TY6]).L4PV)3/>X"VG;1@<V)=U# 0!+Y02I)G43F;2=\_;
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M%Z'U&=_AVU-'"4P[[/5_4<RO79]_7(_=7J?5O>FVMS5AEV[Q['+K?Z9EG%%
M Q;1P5(@:.4$> _<:O2_7ELY]AT+(B27?,<EW._F.R[U0%2))VNI &Z "NX<
ME42PQ"2'*&P8]0"EC"^8]Z0%907_1>]YJ0>D \5,G@*84 JBM8EJ'[S-/$*!
M5;/K@7.)C_MY]'/\->##3H[:+=\:UF/'X2-""X^.IUY.0I6=(2I]OF;C/\=Y
M<E.O<]3KXM?!VDD+J<'D-/R]T^ON#'O^T_A>?SZ[\1$7O7;1DGE!8X'02#U!
M9ZA0,8GS/-& +I%IY"-TAL+YP-"LA=#*48MMO[&ML-E]88]:0]LN"4P*[2,"
MPHP0 ,$P-)U.12528#IX)98')N^/.\?M/*UY:W@0^_F\?CS(=_L<-[N^UXDE
M@2RA>:?*1@RQ$R3MM.:H9H+PY$!;9Y8&LNTXM*UN#!NVWVUU]P=EP4<[A\&7
M\AC=@DU*FV!,0I(22(Q<PM5D *^ NAO)OENJ@G^#ZCV"$V A #,R: SE/-$.
M@A#>*T9<<)2%.:!:BGYS# V1),9SQ4%0KRGVGU4"G)"9NBZ?-LS%T\P?: ->
M*A^)L": 5 D#,:<L3R8B_R->+!_0#TK*YP^HIR$"&.^2I@"6&6IU\A(TB\$Z
M8I8/T)E1^?F#&RPWC*00A59 D$,Z&HWU&>TH$J/GV9/R8SJKR/D*-/?@CS0R
M2SG%\$L2D$;H%!TW5&@:.;$&E@::>43.TX.)!R45!9HBQWC,>^-4(DH3'X+1
MU-KE@6G.D?/T(/-6DQ")MA8\> S+B$E.(K//L[0]71[-FFGD/#U\E'!@)-J^
MF"1@P&Q(X)8))UP$*PB?'3[SZH$8N;*$)>M3 D&"-AS;J"-G:/S%Q7H,F' N
M^?"C&Z47U:MD"VY/MN24!C8ETBI) W,D@>+<.FVI%,Q[X0UC\T"U%/T6K90N
M\F!1+4 QZGR@D4@9.)/$B274AIF&E+,'-$B@(CBNE/+@/'%6:0U(;%6225I8
M/D#G%E+.'EP2K7($E900 !&HH>BSHI!@/(LV+B.XBY#IFSW0-DHB@7"AHP,A
M@N;1.)!21F(I(>F<II4?WQGF#N1TIH0HY9RAACCN-:3HM$HT2IHP/N7:&;TT
MT,PI=S MF"+A,E')$"GPG+J\Z%JD9(-3),HE@FG^N8,I00:):QF#5)X:8-S8
MJ"Q&9(H8EU(0<FD@FW7N8&KX)!)XL@A! (:!,TTNZ6@XX\Y+)F:'S]QZP *7
M1$2O= 07P$H*R9#$04C! YO#U._2B^I<)J9?B8&3-02#7ZTY$"^U82PIAJ:'
M6!.M63Y4%X)5SQYH08 9A%GJH(%*B\2 >NL3>AF6Y$7J;XF GFFR8PZ F@A)
M:&#>D!P=.9Z<"HYQ+V@05"P?H'-+=LP>W" E1!D(0%!@--%1,@RQ),C$E& S
M7'U09B5]D&41E%$@6AEG&&!P9;0.>76FS4OAN5/+ \V<8N IP20H<P*$DM0G
M$#3J0#UX:X SG1*URP/3_&/@*4&&,(5$1&+.2& R!UN!((C*695DY$L#V:QC
MX"GAXXGT3"IK%=(.A$A;KRAAUOG(K:?CY5!D"58&S,HID:DM"G!*V4 %]^B2
MP')M:5ZCR(*/VF!<9Y8&FGDXI>G!)"#EZ<M6(6,'EYPEDA'KHQ6&A>33\L T
M9Z<T1<U*2,157DP08T[\:4.H5YJG$%W^LS20S=0I30\?9BD1PI'$I0?G@J$$
M=$":%UR2$&:(S[QZ@"9/:;!6:QN $8Q#=!2*>\DBY\K)JW4-JOF'/P?J'E47
MIC2#7I!(P5"GB%<@'-66!6F5BII8HJ2: ZJEZ+?@@E)$*"2^"@+1#CFKQ@""
M$T^],V+YM&%V><ZY )J !N]]E"(%4,$[)D3@QB7**='!+A^@\\ESS@5<]-%,
M)V9C% PIL4#/;95VB"P'L"DL(;AS'WZ:"]!>1>4P2B56)O#2:4M \<"3='E>
MU[@4VS+@.[M2*M-:%*!3$E(Z)[D!),S:16?18X)7R4E*X]) ,Y]2*E-;740E
M"T8:%:4##'"L=#$):G/F)[(8E@>FN9=2F9IF$1&H1CUBH\C,&:FYSF.T-'&(
M87D@FW$IE6GA$_!F/ 4/4GDPS&D1;>*<BV08Q@YL=OC,JP=2L(PERJ+7$IR)
M)@EA3-ZEAVHER:0F(DSX5S7_\.YDZ[8SZ.GT%H0Y:PC0A/XB3YSWCEI!11)!
M1X20V3F@6HI^X\$",80)-,_ @)D@I.,QYIK2V20LGS;,+=2</;A&&<^L5E$X
M#9$PX[U0W/! DG .SDO1+0&F,XQ IC6UV'MJF';!,XP*(6)PJ%W&(AHI0="E
M@69.$<B48#(I@34L<.H8& .&(U6PA@KB>(HR+0],\X] I@09CTY$IKE'>$"A
M8@$5Z,^(IAH5CNJE@6S6$<B4\$&RC61#T,A( L&%L\#D:&J 8,:J.#M\YM4#
MED9N*4#2Q(./UMF 1I^"#BY*X>D<JMF77E2ODJTYU-K7A@;FT>;X7 I':Y"!
MT&BBY,D*XY8/U87(Z\\>:,N(4I0*A9X%(!<0\X$Y,(%%F])%R+1,0,\K9)H]
MN$:'2/+F&,Y+8!YYA+96QD2-U3$8>^Z=RH_I#$.F*<W%M9PX5#&1)XF $MHZ
M[IA11&AJ\]XF2P/-G$*F*<%DB%">4PZ*,E!.6\YE0G[GG0D\\>71H 4(F:8$
MF72",\FU4L&#L,HXH8GS(0I+\*>T-)#-.F2:EN4324?-'0>9*WUK0X!$+2E-
MSN$_<G;XS+ 'OF[J-N[^:QN*=7H'$V@FM[CUAF+HR[7P1AJB!2C)+<:A,>H4
M\TI2DU*)UMW\?3Q D1X,=L:W.)?XW#G_1-L>'KQIV^X"+[>Y@+DS:LN-*'>^
M:?V/0?XJ-+E[;A:9?.3. A.0</ 0#./:@4Y&YP%#)5!N,.B#B[7DL]R/\JZ2
M,^@/GV_;[GX<2TC^6F]U6YWCSD^DHS0R>741\^RWWU1"*4\Y4E*%\3\+3@-G
M0A@9J.<VTA*(R8. ^4O":4]N(9RE%!,),2@IN*;>@:#40$AY*Q06A70TD7,Q
M,0LL)AFA"Q%Y%7O[?7MTT/*V?0[@\*C_O+'QD+"9F<.&Y%A""%$[Q<!$9CAD
M14\D:2\93.H!Z0EL>O%F.=T&MLVUAX1-WQXV/9V)N,R2D+S@B0@*Q+K1LA+F
M13#6(K$.YV2OI&B]F"I:EVF=_N4I5Q=$+/^>=R&_D8M-#MZ=OW,6 D$NED($
MQX1)X!%++H!I$B LB2;6=Y9+$[46AE%)C88(48"+EH)+G+ @<DWV20$?RHO)
MAT6#;4*/)JQHS?_GN#48Y>N^$J/ZZ8N#7LO'#ZT!OC^>.(N"/93?$LQO3[T/
MF,1*K1++%?& 4&<BJ*!"GDA/E1*3<1"SV)M+WY9%3''\""P 8UZ1Y)!-)&L<
M=HY #Z6=220N?NYAS?O>,48"C=XP#E[WD/ZO=</+5M=V?:N[OQU];'VVKAW_
M/OWZN7EZ%+\JR*O>Y]COYL=^/6.!DQ274P'4!\2.>E $J(P&L:*@?92*VZ3H
MXN\66D;\IK>;J!-&Y0V% H #Q-&(F+<84E2#1G44CT'_WAS8?L=Z/.[0BI5/
M!S4'[C61.E&+L3."%;"7D]<I<658";8I+RN&T]-#$IR323"?:U?0F M:,.%Y
MX&A(E0\E*%=V?PQ' X?E4[] N?$R>:X9 X-T/BH,I*U.*!\LZ4?A F<*W?2T
M#I"K:PG6H^9!WDI;Z*B5C)0(R_-6$^6IH?JN>SPXMNVM_F8W]>-_CO'J30RG
MOT+T8NO]YCHULPB^9IV*!!>T-((P='^ 1M,Q0/A2GAC#(NA4HH&&Q8%Q]@,!
M3$5T?=0$*PU(9Q _YQGA8%S(6<H2S25<$!CG,FM0"J(BS?6+$3H=@Q/>YP+5
M!NDI59Y?K>E1P7@+&.]0L6-:DS^]M=S$R*.WN>RTX<(*L 0L>&FY*I%1/:<R
MMKV)5*%_G*_^"N$._N*'Q_T8=J(_[K>&K8>@+_.WKGGK;84X>>O1HC+M#&AM
M6*0J"A//ZRB-8%QX/'^8;E[;CQ]B>P95X;_%9380<@+!)@9@A (5D^52\P08
M^!L1D<E>54G\4$H(7[3VN_9%KW_4Z]M\9-",)Q:5,K2\;06,3<8?^W'R4YYU
ML5 Z^^VI]REFYR5-3#$%>70]":T4 0PD@7F:")45X%.8J(7>H36,KUN?8]CL
M8B2YW\((=FTPB,/!WZ=U>]CKOVC;P3<S?<:W>MT:#!?+44Q)Z)*R22>IA0\.
M+ N&!NZXM>@FN$EFO"40I82)8O*AE$*WEE)&_O3KQ*W-KG]P)D?1O8K;,;E+
MI]ZGE"A8PS&PRI5$T4MP&T2@UE@C HDJE8G)+1R@<Z%R@@>N@_8*.3D"FBRQ
MB1,7K63>>%*""=O?9>1?5V2-G4%<CV[XD,3\05+"QD1!N#,A!@+2,9L\D9&/
MMO!QD91@CY@' NCVS[>M_GO;/HY_GUY\_ ??R/;]P>GK^#FV+S?GXJ3-[M'Q
M<# Z@Y9%6@0)@:B$P;: :)PERD/PP: 33M*509VG@!:;(I];9MM"N"#*0"3:
M.G!<6FJ]H()K1H6S@I5 6I; MO"22 NE5,00%0AF@7AJ*"1E- 3GJ".:+(6T
M=#JQG\^H]_K#?;L?_[;^T\.F\QX$*QD2398B9T#6D'C4BG*;HC8:68,W)9@#
M, NO70G.=9<0O$,=UX(XU&QEK4_&<8X1GF3,AQ),HBP;@5@2P:$"30X-%$3@
MD%*R5@OCDB8N)&\J[U#1BN]E(*3UN9XF<+!@=<Y-6R:T(M0QQ4Q8 L$998!+
MJM>*)A)H"@Z)'ZB\(510$$62V(N2,R@!/*5B$F66%2K!!J<"DH4(DBFM?8 (
M8(7RJ./Z<<C*[,A#F67%>0M.JL1!8#1I1Y$)3WPD)R[2,F2J'@*>BB+<("O:
M>,Z)--SGFB H*\*3I)*DA%&;QZ[+*RNC0>#C+EY]9-NE4^*\7Z0-)E?\L1@M
M$B>$]5H$@P$CJG<)MMDN!SDHMY2HP'Q>0>Y5B,"$=YI(05%]35!*^#*H;REH
M0;FEQ$=!4N(2&(P6/.N@-=-&4:6LPJ"C!%(R76 J*G"3E!@,*Z2)1H:\)D,X
M*22QG&GI).6^#"'&SVCCNYUF?U2OXW2TB*ITBBPXI]+DF:5! T<:D+2V>7ZP
MXCK0:$H 42E(P;+("_<L;["N16(>1!3:!PXF!B <*64L@TJ7@AXLB[P(@N0@
M1@G.HGVAP7IG%2$A,*M=*,4<EX>"J*(,-\A+7M& [""/)A"@.2MIK24L$9'+
M_XJR$\O1>NG2*7$D6CEAN","P&MN3-0JY7I5RG-(99YZ='=0%HJ8+(J$".H$
M""X3$P8DXXZAK:<&;;VWU/(RCPLNN(3\C(HLBH2$@,Y?T\BXH6 5-< $5X0#
MLH"@1!GR2B65D+*X?N\YCTH[3V4"0;US*5#E@%(P2?(2E*1Z3!9?1481)6Z%
M=I"$-<CL&4B-D 'Z /<XT"J+]25!>I(9M',40S%FG4U1<:64],BOR^"?'Y$E
M1//G1<PC,,Y#9,QH-(U!&BJ-M9&60+=^N%[OC1T,CGK]X5W6ZU5R<H.<."'!
M,\8LVEL8T2H6/(LD>BV$(WKQ*Y MY)J=Z=49H\P&8M _ZF@!C$0>$X(DHQWF
MF4SNT0*T1)1J>M*2N..".4HX(:"%UPHX3<J@P"@/D$H@+:7*K9?;MG@2E4=Q
M,5YP#)"T2\E%D5<2)9XHE*#ZZS+8EH>E"M.3%L6EBPZ%1%$ K9WC.@!G(7FB
M#7&P%-(RU]4YT\-*!P8D0"0\2E"*Y V55:;^%D@BVI8 JU*-R2^-X'!KN38>
MI41:P+C )&& 4HP3F;+<EH%NEHQ +(G@*)Z<XD9S)32$/  K:")@O =N@V(E
M$)QJ/>!<7%7>1XQ+GRRE0%S>T\A3R97.\X2$*H.K6KQU.].#1R:E!*=1A5P!
MC#L=D^/)"XP1E".R#'I=*B919ED13'#C\P8B3D(@T5'P2BM!@B;!0G@<LK+,
MZP&GF'L06LB4UWRK"#PF&QCG5 A!:*#4+D/B^9&O!YR>K)@ P81HA# $- TV
M&$5U9-I180'*$)0LTAJ>*::;-<GCP,YP!R"S\4?M!<%#WH39&%$"8$I!#DHN
M)0E<"M+*R#$T%-8R)B2UPD3M7?35H$0E)7F&L%5!2T";[@&$=9II(9C*4_ZE
M(K(,4E*M!WQXVLB)8XA>-"P!LT1KDY1%6\*]D"J58,>T!5VO,\4H4%C/HF8^
M>53>Z+2D44E)*!-4)?E(HL!E7P\X1<,OB&),,2".(\^WQINHN.0D[V[.2C&N
M6 IZL"SR0EQPQ#LI/.40B=  5*%/X"PX;H,L@;Q4ZP%G*2]*TPA)ID@!HU1B
M0*3DJ3$*8Q"GRYQIFO5ZP"E.:R2><,FLXH:#"LD:9Y/FACH1G4]ER!R4="U/
M6:8R>J A"*M]!(YZF]<8@/):*D\Q4I2/2VT7BHHLBH00)IP(FOK$'5A'M/$8
M=#C%8U IQ#(,39940LKB^G4TSC /*"$&($CT+,E&0Y.6A(CX2$*+LEA\X4C,
MM(S3:(%98Z)1R@7#6"X-P\LPS/.(K*_2TJ-G)D 36E\?-6*F+ F(843+7(9\
M[2.RA"&18)PV2+494,J=U"XDQ$QPYXR]MAWH8UH8^ L8S7\C/VH8.!NL!R:
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M+;!T6CKUV0*5EDY/2Z\F+!PR'>:L*Q3UL@ 5?&'!\@*HPB.22JO<RBIEBS2
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MRSM\W8:B-=K$M=K6<FY#_1,DQKOIONX-JI5/=[-#GZZ7V ,E1PD%K4;3Y45
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M"Z5FS/4^Y;ON],Z&.-B<:OXT,3V!CT_0O3L;= NX'O?QQ TSV7WMW?1_OCV
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MSO4[[XMY'W5NG'>#8O;!/?#6:'X-ML^'QV?]S,&Q^JPMG8>?]S_\':4U2;I
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M26!#A=-,:ZN%=+G1 NU/QPOMLKS(YO<:K<C0QTIST1:*P5"3@MD:/>9],/W
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M7M(DVE5_W@[KEW=.7[_VLY=Z1&[3(_Z7:+>[[+T>=T?=5?827_0!; U?Z,$
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MM<<+=_S%P#L@0?CI=]O <\MA X4''2,#V:!2CCV754J4<K" 6G":*5HPSI^
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M2!(C;1]3="&[)+KPUNGBZ^$0O7YGTV7O]9C4FU'EWOA!5#!6Z[QD\RK.2SW
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M?^>"X9^5O[, "K^PJ2NP:B^J?W\AB_D*NUD9+"8!9+)=5K;;!V;S^_"DO[K
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M>.ZZ7HB$.0:56% ^,R!M@CD)A6E(WF$,PM3\$TO2(QJF>X9IGF(@4>PT#R2
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M%(\T060->&0T83Z6K(V3H<GB=<2M5258Y9VRVM&\FV"T*!S\/!U%LK+)XE7
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M97="9^=\6DE)$2*RX 4G&YATLYH$GGYPR;-U7AC3U+)&9C\&F5EG(BC@($H
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MNY\>3P:_Y;_S:* &93C&<:1'#H;CZ6Q"0SZ>30<X&_R9W\SR8<B3!2DH?F]
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M$@(FC" U" X8=$P!4I)&:(]78=&SY'GU-=/6R=77R;O=MW_Q!([6BF"!!V3
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MO1?#G;V#LOL+?_O;HGJP>+K]3#_]Q?,7_^> Q\-_C_&Y/W[ZZN$[:NN'^1F
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MOMU_]>_7.\\?BIV]7U^_V/M=5E^DCREHRX&):(&!S*0-F,@)L,&[J!49A;5
MY:;[JB]2\8M]D9]B%]>#U(4">/4$%A8,$H-1X#EPI1UIQP'0" ZE*'[E_ A-
M8"T%/%T_GK5*IARJ&[X*+(."84TDQHGMP AM?%W_!F[LQ_M"PNKOE"#L!P>F
M,4J%#-&%$,&%&"(W!KSG04*P^A)1UX!Y2\#L^L""$*(X6QC/Q3(HM1 \Z2+T
M0SLOL[=9$3 UW-A,;<#L&3!S5)X[EU5,";()P68.@932(JTH(3<3[TZ!V?4?
M">"1VTS 5,4SR)(T1G2<<6>X-\9:FW.3F.L(3(U>6I\\F?@%2E2.(R?S()3
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MVQ'5(6FO;0C,%&,8)!,9"I59*"#KQMT4L]W8ZE.R@(;B/J&X^?SN!K8=$:R
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M%\L"<==]4:3S1=A$LMA$ G%)#+GD3'+(Z+&F@(&-+6@@;B!NJ9N^&VJ[QKT
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M,3 X*H-?JJP>SZ;_]1-N731K'3 LY&0TI:#V$F).H$H,SH+40A7N"D(*"Q6
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MR'!@_YS<#1B0(G*8)$4U9][I.F+ -=L&\RKW,-CX<]AHSGR>9SYV]LGC)9X
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M_8SSDJWH&GUQ[1=>7R&TEUWJ;%F)3N=CPJ^/!F]V.I>$NHNQ&B(P9S2)B#+
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MA.7P36P0]@G6."CJRKU+P>Z=6=I$;]>,XVOE@;C \0U3WXZIJXUV<;0<:XI
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M[IU'*>:&/R[D#9L0P4 2 :Q?14#U!01<+!AQZ[)8]=" EKB)\[H 8OD%<QN
MJ"5 5%0D30 @F #;R'H*]I)+R&AAD2'>L?PILKBROH3BV T^U X?GL)3\DBH
M<-ZJ2MT?,:"3.!HV:'%+M*@Z5B3%BDN#<^-?,*AD +1P&"-MA7:>NN"26P'+
M28,T>;ND'>$&.&H''$];F[=1+&H)%17%(EG)HR(8.<<CXA[6UY% $(\Q":>T
M5#Y7Y%5UURR6%$Q2/Y?+NWT[V(NM[J %LX]&W?&WEAV$UG"R'T>MP]'P>S?D
M#_;8NEZ\5]'>YP)K3Q%*DL&L7=;X.46P7^,@INYD_+Z<^W.H5*[9UN#];'D:
ME+H52GU8\(\0'E-PVB&2' .%Q@>D#4LH!A()3L8*PU;6EQ8V\DPW@UX@ R\M
M!.2^#-Q8*LMA[(KZ0:@,L,(826]R3!CWR-G<RE0($B1-B>"X-$NEX>Z:<?=2
MW14-=S\Y=R_4LF!*,1HLTLI(!&8E18[*_$D2FD3 .LB&NU\J=R\M7*-1OA^7
MBZLRFDDN'54@HP7)#2] ^698(BD#E5Z&Y&FJF?+]8@,PVO,ZLP4?%)X -^.$
MN0]@M14'^27F,1H/XZ>Y%*/J,4?__4!O_+S1V!+0JYR-1EG'>8R&1B($YUCR
M$+P27[=NGQ#8]'E_/%S^M. 4T8E%G*A%4F"PF"A+R"4AD9>8)DFI]LSE,'K.
M[]V'Z#GM\33X]BKQ3:F@5(H,"RLY3(4#O3-AY@53.DG%'@;?&@B['8155,O(
MA+<&4Z1\"HA;39%-7"#J6?;J4JTXJ)9,+VX_-0#6 -C+ C!/>;#,:Z7!4,84
M6V:"HU%K0#%"G6H K 8 5O5PP<K0P*P![,JE&S%UR 5)4'"6&T5%@"^Y?3UI
M *P!L!<.8%8D'35SC,O$K=(&<QRU)"0Y!W]D8V'6'MTJZIF-.CHF./*:<L0U
MEKD9E4$F8L4$<9SE\O-LE9CG@6\SM^!\%#-"9P5X78Y]M^GM<S9TN&,K#*>N
M%UMSMKS%C9IG+N.9Q5K_,LD>T?6".#-6=0=36U#GOWX)W>_K_RK^E!3J1K^L
MGU+K_.#\^7T[VNL.4$E-;V3QE"5 ,,'783#-&+P]';7B> *0-HGCG&S7O]X+
MW!I%GR<MM.RDM1E][+LX:C&RVLH@O%I< Y\P(/'WV!L>PHG)?A^.X-KCECMN
MV</#T?!'\4CXX;]OH\<Z3'#RS%MLN&?."&ECLE3D32!.7;'M0^?;/O0&D:1S
MP?#7]/"P%S/ZV][6H 1^& R(B?<C>(/1Y/B='4]M;W*\-1A/1]GY_6D =',T
MZD[B:'Q:CNQ5"Y5>_/?'XR^?PZ&C7+8W]XZ_;.Z2SLX'W#X)O4[^?O#M>/?@
M X-GPN\?#SH[G>Z7_I=<>.RHO?&5$":U,A'!VE'$N<#(>I\0C5$(#W:*T1AD
MPB45@%O $+TB-11H[S84M?S8Y(:BZD)1G:.ORFFBP=0%.HH"<29R5>F@D(:E
MQ31%;F0.0;ZDQ<T9116P^%<\G!0X5^H>#!=@1T_!#F!O%,>'$2X&S#M>NSG<
MOYW]D@708Z/_SGX\A>;8.CPM23]'[DQF!=KO#>"N(4<*3^"2 =RHU8>[[X_S
MAB <.)V>UGQF6D<P<7!'>#L8;2M,8VLR;/6&1W#.9!]>,/[(LP773B>@D9\4
MS'%> ,$K?>]Z$$H@,8;3W 8SW[^42-U^CDZ&:S,CP96#O19\*/@ V&BM]6X(
MC/&?*8R^=[Q:#'G:*V7<:0/-\^\T6\GQ7.@=SMMOPF#SM QA&.,85LOOY]YA
M>$%ZEG<BE;5?U ]N3PU7J1 %2WNO&9-$2YD4UT09E2@EPFL;@TV4?Y5\96F$
MJ&G^=^F$J-=:,]#N3/MP"[\$N5^Q_(:#O9TXZF]&-]F!&__:&_IO3PR*G7=S
M4/Q[?S<#ULEO8$=]@_/AGIL>;+-/&&PR>#[\2]L_.G]\(%50['S^?;^]L\':
M.UMX.X_MC]^_=4[V>P"L<*\VA7_9[LEO^,OFWZE]L$M S&K,0-*E+%>91%QH
M,+TD5HARK;6UV(N@2C$)-!O#1A8M/MJ4B,/4"<PY]TX#';BDI2))J"16@ ^\
M/80)GXRF<64]3W-K#JJS-:T0<(4O9L1\[7,NCBMZ;#".4@/C<>V,LR8Q++4@
MWAH90%VXA.:? FHW>KT"+D*>F.ZXM1][A?Z<P>G0YFXX "_[7;^?#X[BX7 T
M.0/<[2(C8QSW,BP].*O\Y?=CF/;B=LJK"-H)+&F!AZ^8;S H$X0ZPC3U2 D2
M03U-H)XF%9%CG#+%/;::5^DS.ZX2]SHYT"^5EB8P2TC2G*@8 W=5OBDD\K '
M,B8+M<+$;(VG_2Q%3[*!!A0TG$[&$UO&X134-'2][E[!0V.08IG.THR4<L?H
MG-KC9QUO2UTF4U0H)-8IG3F0]D=O?LZO/^.C2WGYVG<'D[Q\P0N6./!ASQZ.
MXYOYA[>A.S[LV>,WW4'!5\5%;R_*KUR@M^*?*?PWY>&W1]TPV7]CS)K"*GL>
M9_%;LP>71\E:X92LN)/*8PJO:<.O/(S7R)7'?G9;0M<$DW>Z[<^/"<8>9K#J
M1K>])D;N#HZ<2_SU'B@ZCA[2C:TKR*XN=6-?T'T+12T#ZPWZLK^L:9@[@F8&
M$CF="G)A*F[O)WV:YNBW=#C6;)#W#5*]<K3F7H&N=:'5?VP-YO;]^)^7D>=5
M$S>71" DX\\7\['.; ;<#/AV WX.^>J7LVWGG"K; WL> 9CT"QWXS0W$[=US
M;)[R'H^=;G!.RY_= N7SW\BB"48MP@,&TZQG+&;S"B*E)<Q2GGBTV$7'DXE>
M,"V=*2($%G:$MCJ_5ZW?BS;O5A98<3SY"/;27Q/X$]['419C=N\LP@G1YVD0
MET$ _3;=WOQTO'L2#CJ;O\/8/NZW3WK=]LD>[=#?1/M@X[@-U\,X2#4(8/=D
MEW=V_LSWQ.W/NZSSQV\GVY^W3N!<MKOS[;@(+-CY ._\=]I^AX_^IVS\2.!Y
M8ON=P5_^WS[V_;\']K.9;A_L][?AG;X<?#MJTP\G<!UMGWSC[9,/K/T'&."?
MMUBG_]O1[L[&T?\[^? 5;$JO7!&33B3B1&0O5NX?B86(A%)A$UE9YVM,B07G
M_O]I=8;9_LU>:2 +7?'8WJ%1S4N**'I!<4-W0X5*K;)SGF.00#,!5!0.^@1G
M#6$V3F+(1S>[8P_S.:G-KMLSP84?%W!A UA;4"LP13CE&F,V FN3R) GU'DG
M18I4K:QK_ )[S#68\^PQQU/I.<&,)QNYL=%:"9**Q[PKIX.P9:PBH8PTF/-T
MF'-2P1P>E>&<.Y02-8A'X9!6B:&(C=6!82.BK!OF/+:A]UQM RXD+)Q*D@K"
M02W4VBI*@W.P$-+PQC9X<G[\ZQK;H/][K[VYP=K]O\%&^.T8;(*3]N8'T3GY
M1G8/VJ)-O_2W-__N=C[O\FP;&!^<4)@C L"+.(T"&>DQ N7/:%#]&$G S&Q-
M7VL;,-RZW#AXY04X[L92C9![7*:J*M:P'(2#%H)4T!X4:V^0QIHAJ[PS*M(4
M6%A9E^+>0JXIF%,S?A58"=!AL-, BYH%@XFV1O!@I%"4R$8IK0._5I52[2/F
M@G&4@[(0-UC!IQ 0#IQB2Q0#%*X;O];&85UGC51JJ7 4RB@LN,I!:]0Y*2+'
M*B;L6:.1/C$SMG<V)NUW%U+6OH<__N;AWW_VOM#>=W=PV&_O[)UTZ);(U\([
MPC.W0!O]1-HGG\27/FBE!Z'W9?/3T2[1^*O.?@#M!/+P+3<F90ATIH24S(%C
M25I"U U54GH/C?2F;J3G)^'NQE*-A'MLIJIDN1OA2(Q:(JY\0MQ[ BHID2A(
M9844!#05,-74_45<_7R]KYQADPC6.6<HH8XS89S-'5J)U8"043#5J*3U8-A*
MXK9*/II@ S(N M?&1)"Q/J(<WTN4"H*26#>&79*CM'BV*IR=]=MRV8PICG+_
MS%F&P7B:<Z%F^4ZOH7?#;5K2,$HX* /114[@;MD2]IXSF^O:>6WE=<K"F?I=
M3OKOW4&>[7=YLB_@4 ,WMX*;WQ;T V:$\8:#RDQ)KN). &X"34@;R9*./$N-
ME76ZJ#3?O(E,XZRJ&WM&E5BRE@C.#">".0>20]!$)>-1V'"=:M"PYX.Q9U4;
M +N6&[!HO8H1<2TH<H02)(W6S"GE8J+W[/%4/]]4R66FCEK SG!B>TNKC/,J
MZV8MO'0-P?0)5)W+3:WG47WB>:#KUH+R8TV0.%B&"$O90X)MKEP!NA!F6EBN
MG-(ZEV$FES@-EUPDJ\H5-8^3:R#M!4/:LM3#!M(> =*J99D3YY8HA0+''L%G
MB;02!C&;_8!2Z!A$"6D/7EE^69!6WY36^Q71J]LH;UIV[T85;LCRZW\4]WG3
M!06\ZW^>S594!'D'AFEWTMK8&\6B3-CS*!GU.195)0[M:'*<*SK9EB_?P\[?
MH_6/7& B=]ZB^&WU)8N?R=M_SFN=#'QO&N(8;C.*WX>][[FHQ>R&R?JB5&OK
M'Q?O]?OL]]-;#=.M2KYQD! A.:HI#QQ>TMDH&$@+J[20F-,;[[W_#TS.=BI'
M-1]4V_[H]J?]7X>C45'"XYT]A".3XYL)%?,\A<K="ZN<[!Y])0I3CEU"-EH!
MJBTWR& MD.&<<:I W_5N99VL+6XHM%R9P[W:LGT0Y><;%X]S:O=:*Y=3J9)@
M:]]F>BMR1X%T?E9,)XD@F##48,*!6))AS'I#3(A".\;8#8KI7 S0R-K&!5(
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M#Y;TP_BQKLC;6[K<N35?T^5#Z;*DK0R8;?5&8];D;2S,L_K#YG P<)M#Q^R
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M7_2!#L[%Z4N0E<+J-)W"QAWQNR,4#QKLR1F%82RB'BDLCC.P[9XYZ/7&_<[
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M&4:"8\? C&,#N#0@3@(F8<)=C5WC(V,PZ@!=0$1XTQD8$T8XIN>SPYC)PS
M1\(T,D9I#$N(">% "H"H20Q^$_HW*#-NBVN91:$#CS9H(5-0#!OZLJ;P$8B/
M-/%\*55 ;(EB,_BY97S!3 '? V4!5L02FMUA\03TAQA^=G!"T%.C\!8W W3!
M'"^9&^R&>3YJH6!6@PXK=A-Q%]9Y<!UQCN0BUD&#C?WP5HI)/)TQ&,7JB, 6
M-FX]WX=E&'$Z'GM 5J#0P,9NO602)S@&CK[J#-71B=EH)!Z(E<4XBGY4<3J;
M@7BE3>;3-V"OUZG/ *!S^/'/U(MH_22>1PE\-&-STK+"$9A?ZB6QN1EBOI#)
ML'G@R#&6\HD5@X$?<TYK&:?XW3;*6*6H]A._AEV>(Z9Q5)#BRFQD+=5> 10F
MG/G)Q&&4"^.FH)G-#2\&5!C]P1W"LP!9=PC8XK-;P>(E/A!N IJ-N8OZ70,6
M#>@K( \R%T[D.@3+/"!D:8%@F,Y\#Y"4$^HB#L1\^: .G #A>[:(?"34W#U^
M2^]XZ/0!#3%1^B#0"@<,A_]K."O<$S&0XM<@O!5Z9!H@ XB0VH"JDPEL&7@3
M;QGG0!U^@J(+'@A1]>2N6.^-%VJ;7K-ZI?=BFIT'!,M@T6/D5_3D3$W0 +*
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M@"[A @N.<5\P$%"J,B' 4D$I!,P^TJ0!:<' YM71B'6+L\S'XF#KH@(O;!W
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MB>Q(0+:E(#SV2)4&PDV(VNA (P[;C? ,E!VC'7QQAW%N=?O>5PYG3RJ@U,]
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M:0HUN"BJRYDR.. !8I-+/@&*BJ"!\0:_4%['P\Q:?K<L%;H&[NZ *T!GN/,
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MT=B .O0 XB<>X,8UEG^?3;RP85P"_YA@=(BX@L"(.GK\%!Y%\OLG6<LYR0K
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M#>R<6]ZU[3AU)N6]/^2D):]RN>!51'82XXFJ?$]1 IU &">*OM1N2ZO9%_K
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M$BJP&3D<.C"4#UKJ/VK\_< 5X04&"'FRWT)1<F7<$^@L<+R9%-,KO2R?6Y>
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M(H?ZU](DI9]E/T/@6ZEH<PM&[5A9M&1W@H6;M_XL[:!"B+3V](^#C,$WY!W
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M*H<IT WVQ2KN3K^OZ^0TOR^_'F!A5\Y:N+ 4NDRXH!AF@9:,RS(H;YXL.Z@
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M/?Q^FUNBP@V'EJK.)ZPA/6TT_V8XKHVCLW4-&B0[T&;TU8!23O)3VH#5M/Q
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M0QE^ER,J)*EEHP<K@E@63 K7<;B#*+#DTBPJK1_VLUX\RQ4 U''HLS=GK[!
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M8WA-W/4,/8V>-C#Y<;I=3"I:I/5[K%EX_F*D13)G@X0+;5*ZF"E7424=(>8
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M;K2RIB]:?E[^"'X"__K'_P=02P,$%     @ 059;5? G#V^X.0  H7 " !0
M  !M;V@M,C R,C Y,S!?9&5F+GAM;.U]69=;-Y+F>_T*C>=UHHQ]J=-5?219
MKM(9;2/)7=U//%@"2K8S21476>I?/P$R-S')3"ZX)$7)/D[G>N^'B ] 1" 0
M\6___OGB_-$G'(W[P\%??^)_9C\]PD$:YO[@PU]_^NW]K^!^^O>__>E/__:_
M /[SR=L7CWX9IND%#B:/GHXP3# _^J,_.7OTSXSCWQ^5T?#BT3^'H]_[GP+
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M:0Z@FH86=45_!746/AC_LS\Y^_OP$XX&55[OR#@8#T>8_W&]VUQ#EEZ*J'D
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M)0.IYE0YESAX'XS@&KWL8/U\ -2WS91N9-]%2N-2.O>T+1B"]<!8+4J1=82
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MLY:4U#Z1:_;N@_6O::?Q)3E<FXNUB^#KC=F^>LA/OES^<&[.HS=.D[* .<]
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MP)'7#RDQ90J/R;"\AKZ.+P5R6X7M**--4R OOUT_Q##&O_WI_P-02P,$%
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MP0$EJB(3XO30*7>'IR8(;4I?"-N\'$P,>[H(=.;FU+'OB0C+2@9\4^;-E&L
M9L99;L*BX]BQFN/<96;"?E^^X&CFPNB;$"O65G]/WOV!UWU=N0M)G+(U2<^T
M^'1@]#;-&,OY?LSP5QL^+-L,5O@EUE.5"'3GITP1 :^4WMR5M\Y\B +GUT9<
M6D8T@@*)N^4T1<6V?'(Z]6CS^.61[_J/-1?"AH4]O+PS[=\$&49I0)KG4>PN
M$^?1T>>CMAS''-T^?J&B%>91_K%IDX\B AV5141@]#7ZB R5$D9[Y0*N,Z?X
M-.#R"N$L!!F(0-K=)AE:O+7.[E@+P8!K-NI_OZNWQ_E^IHOUI+#]N)%J]NI@
M_R<(W1X3!^Z1-#T48CSR=I+P%"0K[N?"1(..8X9PXX+G@SP^.%95^0H-5 ?Q
MU92Q)L-5J!"5,/9Y:)W][ G$*HKBP3+D^Q5&6#696/=A).Y^I5LCY &2%=YA
MW"R'/M&8) ^+$R "?8P:%5N[-//^Z)@^E\H'/)<DL]E3YY0"#PP\&9*%9_2Z
MV@65;5:<@44G@07;YFRQ..MGD]W YQKFDB:*%P;L+3>\A&*U#D;5^,FH"[FX
M=M0]]48J$H2U^^K48 F>E],V/<8_+\O:>R4SXU/3O<Z&0Z '[ ,X2?OL]>8T
M10M?<\4H._E S&'VO<JD?3)&C-[]UNL+RH"4=Y)F[]6\6!%2;F,#_M[(EM!G
MRI]2#K]%<:>P"B>)@INTSALNI!R:O1H="$P+.(K*3*M,DNB[5FO-Z<^^S-W>
MY%:UXM0OE9]QVD<P<]-_OX,3\B88^O"*29!PW^&-08EBL0\5['X'NEFC.K/6
MYPQL6],B3%Z49!J*VX>S+3*US-ZI3V_*<G4)K\N8F)# ?ZNJ#0/@,:CKF(-H
M"9A2P4G&%]H'RW>16WJA1""G1/S^O;PAZ_%OX5W%-]]EF3I_.#%P%<FKB]PD
M;PC#AF:80]%&E3' (Y\N:DV>Y?9U6\W12-P!0;?$\&2/Y(,SM1]M>6QT>YTZ
M0VC0D/[,3;;;-D78.1VV6V0VWS#MYBE&F$&+GM;%4KC$:7AX/&JIXXC,1LXF
M%1/4@;QSL_4^) F._6!E9?QZQGZT<^W2_?ET2U33"GB!_M(&S*Y(BX;NT?TN
M:JTJC_9U\XI^Z)_D5D]\S_YH$TTE>M[&)1#^XK8.N].E7Z;>0-+O10^I7=KW
M5?PA874NA0BH]8KC7X0"'R;J:F</(:[#NNY)WKB*X 3HBQ>%PRY@>.I0Z@U>
MWGJ-%?LH7'_H/M-CE86B9GUN;?6#CG=P;;>%IO=L,D8@/R%_5 $1<.'9*L.K
ME)<;[UB[TM#LF>H*[TU:,>$%0.8G&1L*Q9=\X?8*K>.-2W/?;[?/,BOU&Y;X
M9F<H,T5I7"0"CZ7;1P++&B9Y$+MN/5"64K 2GB)\1C/4;:.T]QJ.JN$S[NP"
M!'<-3\E>,?1J[Y3XF<'%[4[$-'J>2N.=,U6P#FSG6 _:^"W(:4Y<Z?!LZ_#R
MX'#'(?,)F21B/WV@?K!%90GUI$XU]+TK-?/=)@>[S#/JST-2PM6_P;HQM5=J
M<:E8#VO/N_P/SPR&-FRB'S=L3;>I?U*!^^OE,%W,IG7W$*JLNIIHGIF?SV@:
M\84:BPHY>2%-M<4R+K,8%W0+/F.'WK?81CP-0-OC<N<OU?O3.A"!AK%*PC?K
MT8W1H$6\)KI"F-Z[0(9_X],%B+8S^/*/5Z]B2B0=JZN\DK2?Z//NFH*$"*:8
M@[@Z7=_Y&?:9=;/'3VJ>/]>&#^?,F6%N48:Z8VVP&V%LT"?FG0PC3R00NF>9
M5H>Q4>2Z!3 0ILMMAF6AKAH1VI#"4B.0R/"27 9WVI( LC4W>QSV5?%=C5.,
M!T:I4U[&J4^LE(2PBJ=7J7X=C-5 ^R\P&ZXUNC%SFI_D>$3'F.J_0(E "B$[
M=?;6M_-UV&^@<I^V+_U#LT74 I&VIF%]_?EXT0"[%+X-B8;V)/Q3U/-"4; W
M5)@$9![G?^&^^<E[V=JR^'KB(ZWM*C!&P*T3[D($#JEP@81:0WQRC>?X\E(!
MSIC7?>#[OO-H]I32CKU5[R:$" C,,)+R*FEL\BVI@IZ]@P8DZ=JDY]$\LL/L
M"_N?V5L,I:3M(]@(<94^3$5O;A$!Y]'>O5WJ31TB(%MY4D\$-KD/"8^2#DY\
M2,B0""RFXQ"$+X/PU0LUL4L:(M?.XLSF+]S34SPMS;\ 'GED^*P<R; 6O)S^
MSO:'%]?"P,)=#],PS%4A#U"#3,IFKVLG*O#D1=!0G2[R<(%Z)[@(BYKCV)=/
MP2&;F>$M]9/^TZ_=B !_>VTAN#$$,:<Q31Z'I-"0"DW-P2"?_H1XZ2$,:WP)
M[_>?(@H.##VR9!"YQ;-T1Y!99&OOIMXLIO+I!\C@,XK2&OBA1XXW#W@KL1T]
M6G@A1*J$&:E3'Y-)*[EHI/NPB'T;V7AE&@LW4/7]S-7C/7AP0^Z(4+%'2E#X
M2 _X>AP1$+25".N%;]\A)7Z4/OI9#E/Q:MY+B=(O]-UR[W2YTP+MPW-\]'-T
M(PD##:+CGF]Q-N,$%Z9)J7!(DVQIY)YJHGH4R>TQ=1R%4-_F#*I2*%-*B65Y
MAR(1*#Y;1;T6Q1EJ^,:=5:D5E8!LNS?D">?<3#EDX2; +8Y "\)1]J,-9VQ:
MW>B>EE=P!'3E_XQI_YI/(*NR'V5C.(QKS!;TI,4M7!\!L?#5S=ZDAKY:(N%T
M6 H"9C89LR[ABOWH<(_NHS(%_QZ&+]0?<[F%"&"2\/)EB4[3_F_!I=W95;>W
MP<>S$<A;SE0!P071Y:$N^:&6-\KKH$\$@W+O./ U"B?=>>AWK"[U35)^4D]2
M<O!G,X4=2UBX]QV1'*U?F?8?[9;U2?'&XA@G;*[O!N/@9M+@7M%JCH&U^4Z6
MTSQUC#P]NFPM6(CES!*O7JM5<.3W,O2<)RFL^Z1F" 2%8(V*?(OU&I//2D7/
MO;<_*U_=:)XRZPU,^V0^8^@".:TE>!6W1TU5+Z'F/&S1;@+[[&C,%9GA73AE
M6W#(MX677"<"1Y231&"F[0V8 U5Y:L*ZFJ\Q*2IHFGUXS]4:(7YLS(4G NF'
M_&5V6$_#EX_6N&'[XP21,3WJ;4A/K8'TW<&]5W#(C=K$.=5--=00O^Z"K;)I
MB:I1[0#*:,LP*^<E$T,!JI2OO<+>F+2*;XQ3&D$6C,/ILL?(0[">V5\J4GU(
M4[: X6GGV]^C:"]J6'6HB"=6[2N3$MI9[!8>88$\)JTU1]+N<5S"G9<S628)
M-X2$^5Z=</7TZ["O@<^1D@; _@-,3006MDR)@ ]D>7AY[Z]\[U,"O;I:\<D^
M&-*9V8N +P8/D12W/2%SR_H0UX[>5G>%;Z$(X14](^7H:/#E= X"UGB88*?#
M9IKYA>0FZM<P,!% U)N==!"!5V9%9FGXO_)QL00YC2UADK#HWAVG7GCY)F$=
MQ>32%39OH!J_UVEJ>T)9/!QV9OP]F!8& >5]TG?XT'55BRE-N?=X>-:V7#%_
M?R86X<&HDY!Y:Z$OLY,$I"E#A6>/X9^@8.W/ I&,69[\M#TRW+'+ZKZ+AD_Y
M6>"4T.6#:W0SCI(K%C($$<N?.S.\10?&9F&GH=T$YEZPQ925?IEA+1&X6M<Y
M*\@/)I![A;W<0[F>Y*KQ*J"H+]2[\'O*1Z9/*$,Y\3,'G<TAI[Y7;.^!U%?V
M$["%&6ZV-&/74V/B7LT7%+,<E^,3%_9LK^T:1O(S\I_&P1\.MG\F D;D:RN"
ME#X:5_ <E46NAZ2#M6'4"G:E)<YSD^] \?-K:YNZ@H E*THC0ZM,AF"G@88O
M.;H=$-Z2AF_8.',!NP?,'>AX4>00-[RQN/<3[-[ \TS)IF^L83(RX'>QPR?Y
M[GAD+(L^$5#?77V]3IA$$;JM#)LG9S:(P%-^_JH>\K6+Q6 =)SKXKZJU1@1B
M PS@&%3+Q9QN^@OIH!,$*34[HN**MXKCH!]*'"NKK+$WHO@,_04IPOXH9\K>
M<])G;%<K[2HMNK25P>N":OEA8EHY>@=,X[%+EGI8RH_'V%Z&Z.RO[R'[QC;K
MMJ(P *L6S-$"^3C=(5@YG'=\2<*+(F<9TIO*OR&^-D$6Q79;$R%P\MIS9&9N
M^DV.YW=K5]KMHW?YI^'JZ"P8VJ;T6!-7 V&&?E<7Z](Z_R&QA,51^90<RW*8
MN>E1$4H#4QDM#;L[[Z;.<]/H0?4ST8<.5]$M*V,,&70:.3CZMPU(3%J;/M5(
M789E/%A[4G>9&=Q6S30!)V@U\!&!#X-$0(AT^MI=#Q74+Q]\G^Y8_UJ4X7*_
M"0!)A:;_6QT37 D^GC$D L_<*T^\#1?%9V/_S(I0F9-@,,LLN((#WS6S?T $
MRMU6CHY ^WE$X*4EX3L1V$^ $0$MO6-"U4Q<LH0M+4SS6R:/>UUPVBU(5H#I
M%_S#Y\T83YM[<JE1<.4_*IG\R0OXXOEYZ:-?A>J(J]\A(5F'(?YB5[, XMKA
MRKX=279Z#'H]'OQM?368JC<M3!9_P9-F^G-U3I/EE2P"M/U"?^</PMQ&B)]Z
MV1+-)F\LMM3,.-7QDL#1Z/>#@&>VX]]<@N@,/54X%Y^VF0[%,^O 4K%.<U'M
MX17(\KOBW;G3U<=J!4C1FL,;H;KV4R&1FH+#!#:\A2&[L[&SAL!+8XM'TX^-
MRN#M\U%J)&P$+ :NKR-43[+8P+%2>A0?D*)<?(R+*(E'0>X%B2%!W*+V]SI6
MQQP%<RG\%-:094A\*BUD@T^:\/@YV9YZ$+(=P0YO4L?\M!01F@PL+JW09#JG
M]N#R;GLW$0"A;J"2"4K0#$-V_(VTMH[RST<NQVPT=5LI$&704&7W5ODM<CP'
MUO,)C/V]*S<J9C'32OX<_6VV\QC:[I15Z.W#T5+()FA621NAL"[.P.Q.2V'"
M;;:Q-XLKGY1YI^.O/M^$=!;WT:Y[P?.16BMS>#P,P-'ID$E(Y2FOI7OV+AN0
MY6ZW?9 PLZCGOEP[%K2U_R#)JTTMJYJ_JC78;.-X'KEA",X2"U*<6&<Y-!>.
M$%O,Q8<Y$H$(N@IL\9Q-^FR6],TAO$I*G(NCL]253Y[-+,\%,4Q'9LEWI[_9
MA5).%[]8J4QR3&@W=52FWF%C.%Z.[<!\0%/'PD0+W.Z,T0>1UXHHCYUPP:DH
MPMA16F?_7 !_-5L-7"5!]Y09H0%Y.-IG.LLO=RM;?IB<"/0V@WLSMK[ 'AY.
M'>,N[ITP7!/)J[^\^.OM&],-'$3.<]B.P'ME-AC\ AZ]9(7Z<UY_BR-%/C@8
M=9Q$!!0_./TIQ[<S';P,AB?]- OL*H(_)12HZK"9V<W]VL*4P;I?B #N>!@^
MA3BL"*K_"^L[#W_4:RA&!$*C>[>=Y!9F#ODK( >C1$#38L4M[\]URK>B1'JN
MO6^IE0C4F>S][:!S\==!YZ\U:<UT"?U7?GX>'=];2\K^4[D[^'&L;DN)[K'9
MO&>,5*2'<:B0:Z@I8R/\//M^U'.PX\?*RD9^DVLO^*BHQ'N%<+2S02]?ITU@
M5P*E=A0&S]R_>5/W9L/P#].OP8N!S#K^[I+U7]V$Y,[JLSRY+,HI0&#'2B?"
M)*4C84Z%SI^2.RE>1O1B6Z9RCV9W?IX*K;="Q!&XH)YM1ZDE^[6><H8/LRW*
MC1Y^KRU[L@>L$([DR2(PPB3#8!*@5*K'A9]MUQ:M]).ZVHF Q.CV>?2LZ8_R
MF#ANL:NYMZ^RF]PC^W%=$_$*XE(8@"N[BCS>E\B"U)Z%'"M 6\NWW )/M=B&
M<9C9%BJS[\/C&WB=-52JRE_96D8KQJPS/[&.7!;(Q&Z((]-GF<(=;K$:UL2L
MO+-N@!LY\_7J5F9)E=ROBEDZK[D6&M.!TL"58CZ#P3^*?._W3Z[?B;UR&CV=
MJG+X,%36A\D>:6R]G&7/__+-Q)AF#]:BZ5F^GD^KJ28%TD;L&[D&RW!YJ'%S
M<-E=UY&4,9NF\8G9(O[X@JI=P=@#3X#0-V([CC6'KEYG;[DG,G0_OJ9#W5I7
MX#C<=U5\O +-N$H0*CN6JGT[.:.ML9IQ\1K85-WD.';'W7C?!Q.U4/;C@#LQ
M4W_N].US3%^^>.*#([*T<+6S"H^[8-==*KD:&2T)AVUPNAU(#*1<0LZ\^RV.
MW9%)8&+B>7'9/2+PUC6H]UB7<_>G)'C\2?/7#JQ"QXW=XW,K8.N9@<^[R/'>
MIC.R$AGQ1T]>:RT)/;\:C='D(<'^''D-SSXUU?=0U!W+4XP]EMWIRN[U;/"@
M%QCJ:E1Q& =>N@P7^J8\^9.U&X<8Y;<.L%AB+:LZQTR1VA'9J/,1?_K<,8M3
MWICEV"1B]M'%:HV"H>-LUQ,R+Q2IIKIR\-3)<'IHUISW)0)67O"L4#*K@C_\
MIOIWO\7^RV\B+%CK4';J3>G77YQX+S<?Q&/;V,). "&ZM04<:);MAB+2]VSO
M=[?*WE4=50*;</,O.-I+RCG)1 !KPC#_ >*R2Q]G2R=S:?T\X6+8(PVXRIYG
M=+8XLJV!H7)4RMV^W.VID&FLH@2;>"IO=D'LLL,)LH[JYUUW:4%JW)W-CQ"U
MC$TU\;D0,#4T3!*L[Y(Q(OS 4#WRXI3/54V^;\"OTGA6)3KZW/2S4BO%J=W.
MFW##@3KNAGYL=+,A$V[Y:&+=]GITB/-7[YBW8Q=O!C6^YVH H'2F3>;3VJ%&
MFYTG^CE2P?P9\]9B_4,_[T31:.04DH+P1"D5DWBH?++90MM^/$L$KNU:7G<H
M*WLRP7OHU5;Z82$E_*+<X1W#6/SY-[A>76LYJ[LVPP_N?FZ]T&1.3F58($^#
MF1E/O,I-J.<\+G%G!1?:(Y;=5B<6ZX0Q@\T-=,/"#9A=)6;U%AN3F)UT(UE&
MKZ!>_OIO_N6 Z2E/G8]8Q@3?-VLCZ]XN/E%"5T]HU&/4(L>&CT1 \S,QV61H
M#'7,1-N*WXBOX\;/TI:BU5!.)XHP=9H/J'V2,Y-SA4\BWY"P>')# M;L<3F"
MR[G@QJC[US[/TX*B$]B//PM*VW3[,MHQZ"8T U35@C#4Y_[S;/7V#6'8QEJ7
MGM#LP>PMU?2PL]!<&'C66M=LB@+;OC0)PAM5TK?#6%,V3L%Z,69:GJ=A=SZ&
MA#O&ME3L?IU:+)@6)E"9[:'>XJUG$X3;]D<^3QQ,\$],7!9K9GO#/LE)6=H+
M$O#1P+[[SHSSG)L!S5A/.S,;\*8[%Q(>OMDO%)IU2AK=92,;_O5+\E+#>6@@
MX30B.KCAQ=.&@/!N@ _6<OB<J8@3[S;_[OBH;KB!#'?F>K7'A;*:9UT;2QH#
M7?G"E\B\P^4B-/O;"-^R):89<^<L"Y8@ YNR(;RT;&&J-]4GZK>K)%EG1Z/4
ME.?IW9UTKD]:%CM-O?*X+D4C4$2M3''Z5& YS;^_<A1OK",=OP4_%!$!Z]YM
M]JV*G8.XIQHRPSZ^A.<G814SCW#C.^,'F+/K1YQ#MW6"H]M_E1[^) R<H+%G
M>R!(<+?J_5\K9'>(0)*I-!8RM.*<%[NA=I&$X0"4WI\?0RG]E?\ ,\3<_;%D
MN_7QD'!C&19"6NY( >&("*S26VWZV:B3)EPW)E4Z^"[EAX"*-_A+1[Q5Z(/8
M;-0.G4C>^^5?K^35!4GAC0]=0__4Q4_47ZNK_"MK989]>1 $.7ZN 7^E]M9V
M0OC+LPYL'?>'72%FR<%"TBX??9<[%1&;*N1$78B*JH#6$0$.VRLWU;I_<&B\
M?!9[_*X:8=6,]8R3)P*4JY+%:S]4+27BN+:9Y<BG+PEYF_.SX-!S,]SKS?K]
M=NACW><#:1GLIJ963L+>>WSOTMO1AT+<Z2<!D:3S3TF0\,8,2\J\>S<((7TC
M%8'>$@2/A&L@L^T\/86^OF^2ES -SF3 9FR_.<FO8^NBC;QCI#NMV)ETJ!Y<
MWD^;DWRAP\SH=6+5N09.3)V,%0ZM^VA>(4W4,T=7EXOAK0X%R]3]<-T!.*8_
MFXX(9%N@""!IDB8VD7,(EKNXLN:TFN\O4LZ7C)!JX\U<VR6? @'6:<.PU&NV
MT=FG7FIZTJTV@I#);0H$[<_R]5+M.H/Y'P=*[,O+8TH3.=/I:E^4-FYV"F-S
M=&J6U *Q'%=Q(6Y.BA5\0VW8<<'887;D$I?D$T=.+A#*V]H:EHZM;9'%Y<^?
MWY[P3&O6N>W*I27VGH>Q?5#JVDI#OR;X-@YN58Z5CGY?D25?^KDN1B^BD:'A
MG7?2,Q^FJA)N#!$8+VLA9?B^/:934QH.9?#RR4?PI5>8QA"J%0*US9PFIXTT
MU@,Y6T)_;&F6.+?YN)@U- LDF];#2,OKC6C[6 ?&!C9G*XTRIN:UPZ0H)&7D
MFM[5FH0',00MW@ELQ]7U/@Y,R P*9%8:70$=C:82OMEN&_DS'5.0T$Y^;H[3
MX-Y*F!!N= Y!!TW<NC*<,Z0SG7MK^=+MU,IS50);NW:C[*NID8&S</HU[LR)
MQ-RY$Y7MG_<94JPFW[^)(;L:"!JCH_":P?0W_-D+NGAYST?HE;1B(A!.@N"M
MHXEXWT$)><33,HL?=Q1'%.='+C!/:I?F"/%FBI#7(^?,(F%R[_"B_1[^TDPN
M@6:L5P@..W?;!B!;G#XM3CF@$I JB@Z7UMM*X/D\LMNQDCBR6!5O)6*F:I5[
MB>+ ^'NU+2O>%8-^C-</S',M=:5:&WVPPT#7$7BNZLN4ZL5-ZX;T-^:K&<'F
M+HJE$Q97S5_+,(AYW&\'50J1*IH1;A? ?2F:!6[<8MTZ?I/#5*2F,$]OR(8+
M&+483';X7,-@?_<Y5>/]:H'3JDXEED.>>8/RM<7'X=_8WTO+/>:Z_^YU9LBL
MF20F5B%N3CIZV#?2O19I]-5PYT.<[4JS139\9<#V!.@3C!@,TX#JWAE^OSLI
MHG"UJBY;%1JI&7XF@$XV$"/K-E@\;QM]F[;A L[=?/;4S>FJ_6?@'[;NMQ1U
M_/T]'=W.?UO$3GXYG99\UTHLAZ]3C<S&KH30UW!J8-GY8=CXNYI,CL\Q$D%$
M(*BC=XA<O#-,$7^Y!JL;^T'>371</D'1F#G!/$+MG5?/]RIET&3VWAJ:JN&,
MRP1U=(G"]/T!U:S[^PHO&=YQ6N1RW<K9?7@O930S5%-4]UAOM;\#/<'//^R^
MX)&H* .)$#P<S8->;K=@2GRX7(4Y&;R^[Y,'?1V?WV)YJ4.C2BT^4=SIUN#[
M/4M1B3U5<X_--YS0MYI=<) 5$7BD1OD6Q\AWC>_LHK/GA[J]N\HR4GWD3D7
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MW9FJ"*.*($$2[)Z9#>>K.R/R=3-=T]M;<4.!I\TI67*3LBO=G_X"?$BT)5$
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M-B\.8\@2+B$E")&$A4+0R*T D:,$<^-#]P"]IEB@XQF,^U+9$>.H"S R,8Z
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MPAFDF"B(TS@S5=X3J.T.I!0/B4ACM^/.P:!-<Z+I!S:[E]Q@*$9^'QD,:L'
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MA!R=LR;V6]")UF:B+>HXCXO3_M4#H#W[VW-&GVS_ZP&"[O[8QW##]L]_DZ:
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M09BF3@Y4VXGGMK]KY;ZHZ[U<@$KP3@\U\Y3M] "_&DU I8JC=]5Z:>QX;0S
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MR RZRY8R(IJR%'QY7V65O:YE!;L>51XSJ'IA\95+=7B2:;.J>A7=RZ_JOWI
M_=@J6;!\<R^OUG]9/\AB577BO99Z'R[+C[3X36[NEOJ;41]/+$V[R:_F(.-*
MKT%YLUZ*19:A,-.\"CF-0FU$8@I)A"A44<J#),0RE=:'W^>+,S=B_IBO\MO[
M6_#QPU>':JOGK\KI@^UIL1[;JJR5 ::QYM4:[/0!K4*F6>-6I8OF%'4)C%:@
M4@ML]9ITH1Q*Z$ZZ8!,=>D^S<&Z%>KWAW%?4]_Q)IBL [ V0)\6"_8UZ7IL:
M<XP0H2A67&$H:-5T1@K($A;H'P.61C(@ 7+J\MX9>Y8[7+#<"3BLAXS]X<M
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M<^1JK7>'M^M5U33T1N\%]7/XBI8YW[JL*(VQXA&!E&#3NX!C4^<K@5)QFI*
M"^P6GCE0CKF1UR?]BB_,8_$G-U8:N@QV1#4!N"-SE]:@KL<NVQ(Q6S7 9@UJ
M14!7DPM0Z3**__%,/#UQW5 I)J6_,Z%ZSHCG#C>8)%_3\J8JRBZD>/7X2VD8
MN2G#N+J^Y)O\H3*.%TF($R*XA(H( ;$4*60J43 .8T1C:7;$H4OPF_W4<XM^
M,X\LUZ*#^[*NV*1:F0'="NW,DK;K8$V,(Z [ 1<:J4$KMLGX^>&7&N4?P59X
M<'D:YB'4YXB8/[:SG7AJ@G,$Y "GN8[@[E[[^/CZ9IUS^;>\Y.;<>/6QLJX6
M0:I"$D@..2?4%-= ,!."0A*C+$@3CD1J52NG9XZY[=$^OOZ;O>/H&&ZG_6H>
MT!B92#X^@EI$L)41_%I+:7FRW8>0O6_- U(3.=<.(.;'JW8"@AZWVK$[)_.K
MG1"]ZU@[=>G U)]M.YPOZV7.S1%%:QX%*"(ABQE442:UE:I22%F4Z-T8EU'(
M@DA1JZI!IZ>:&\EU^EBUH@Z.6^D!V&Z;Y0>VD=EP(&+N24<GP?"5B'1\HFF3
MDTXJO)>P=/J.H=VKM('X5=[I[\P-+=L&Z9?WFYMU88X]Z[K*:$$"I5@H&(Q4
M*,S18PP9"1#45!*E68P8IH%;'RNK>>=&(HU;I332 [J5UK6SE1WF=E0R I(C
M\THE,=B)#!J9+\!.:E"+[;,3EA-,WGIBV<TZ<7<L)RCV^V2YW3Z,F#[D*_E9
MU2T$FOVSC)4P33-@B&4&<8PBR$*B( \CE,;:/,O"T(6#]J>8&]T8"4U9DUI&
M-Y8Y * =H9P'R\C<\121T\:9,T\<U]X3)1R88-*G_[B"SQ_TGBO/*$GPBO+?
MI-A%3S7?381)D G"((WUM@*KS-2IX@$,J1(48ZYHXE1=KV>NN3WEE:B05;*"
M<BOL@#H&1["UM$G\(#:V45*!58O9B1P=@0DL\/!9(.'(3--73>A7^6 IA1.W
MN#MG+Y72EYJ3K-<F8)]OOA3R-K^__;:IDN#_V;8$-CN/KWGYVR[V]Y/<M*W!
M2<HRQ*6$-!$2XC .H?Y.15 IP?16@:$$6^T7? DT-]XQ<@+:Z>.]DAMPY]KN
MW<M2G78>3[T 8]/85AU@]#$G4Z87>Z42>*+3SCJJUJO;=]V<>YWJKS[.>MF[
MLJ=>MXG\WI.MGY/3W"?8/1YV+]-,YH[W"4K7=^]UW#.\=TUXQ]M_W.>;QYVC
M7R#.)>8P2%D$,0\5I%$6PA2I5*)4Q!QS9X?=P:GF]EKK2OJO?R0A2O\,9"6Q
M8PA:#[H.KKFS,9O"&]<(^6^@%A-<;C9%SNXW;3C9%_T-KQK:^O?^GP;)IR_N
M\$33N]]Z%3[H<>N_8V )LT*:,E)-8:'+E:CRH.IXVM?WA5GS!8L0"80(H$(Q
MASB.8FVJJA3*F&><2<TNQ"D9U6+.N3%*(S*0M<QUO:VU$1OP6N)!I0=MT+<C
M&L^8CLPX+9R-N!6:E<!-X/T%:&3V6*S,'B!?9<HL9IRV0)D]!'NER1QN'49$
MNQ#6=UKPNJ+'?;ZZ_GS75/,HZXS*^KHK^EV6;[]K!M1S5,DO5:&/3QH(DYZT
M7NJ9KM^O-#7(TE0VBT6820$YCAG$"4Y@%@L,1::W2"B61+#4)0!U1%F=B&^"
MB-4FP+Q)L,[KGS;T>\N$;GPWYB+;\>1,EFYD?GV:%F"8 .Q4!3M=VW5MKJ_4
MU4;I$_5 JY\_+IY@$3QQ^)B23LK]$T#^_)TQQ90#C69Y;8SPIF=K0EF*@HS"
MF"L$,<$($I-.GT9(A1EF/(RIDYW<'7UN&]E&.->FMX>1L[2!A^(QMMEK#86[
M17M(95]&[).QI[5;#ZFU9ZH>O&A =+X4.:>%;$XP*<9IG" )4QQ3_90F*:0J
MEJ8+1IHF+!4QCJR#\I\,/;='M)7.(=S\*52GCU*& S#R,]D*-B3F_BD(#J'V
M@\&8*L+^U!?"+:S^H+I]T?1/;Y@NB/Z@H$]BYP]?X:?*XY7\OGFE9?EMP7DD
M690QF(2)@M@T@*11I*# D90R('$6.#G2C\XT-R;J9!AOBQ>>5]YQ!ZK=WL$+
M5"-SUJ$"CT9.4 DZ8HG'/3!&JO&XF^=%BSSNJ7NJRN/^#>Z[D+^L'V2Q,B3_
M57*9/YCCD#:H*DZE(C@5D">)-AQB)6"69@0&^I<R#F*6*:O*-"?FF1LK[$0%
MQ4Y6^Q=U'Z2GMRZ>@!J9$SH8=<0<L*OI \M^B^,)M(GV.T/!<]H&64#2LR?J
MNWNR#9*%"MW=DLWE Z-ZG[7 W84!FNJ>39MND[&D-#]]7LFKFV)]?WWS+G^0
M?Y>T*"]OU\7&) Z\7I=5W$*:(IY P4R?@83%D-)(P(1I@(0($>-.36N]2C<W
M,GYS+P$U@H/U2H)'+2_8U/(#I16H?N,:1^QU->WV>2^V1B._!ZRJVVZ%!T;Z
M"]#VM==_658DIO]B3DB_Z<W-4F[_#-[HOUPTJV]0 !H8T" ###0>(Z''6!]?
ML=->99LVVGH,6/?BLT>99(A#S[QJ/N3EIMW 8*3BF(<FIL2T)R<R@X3C"(H4
MB21FH?ZS=7CVWNAS8^I:*K#,>T[2+#"S<>Z=@<3H_KT*A$JX03Z^YW"XN/G.
M@&4R3]\.'E_>OB-:]SK\GM\SH<_OB+A/W7['+AI<AI9JR3Y(JDF@[;%H#AZ;
M""RL@@2'J80D9)JF@BR$61A%, UE1D3*PXPY'1">F&]NQ-6("Y9&7LU?M<#.
MZ6FG4+;;*'K$;F2J:V&K1+T 6V'K^ K?X6V6N/@K*=L[V]359&U4/U!(UNJV
M>;2&,9U#& Z4WA51*%,J(.89AXP1"I,P9'%,XD E3N<0(\@X-^[Z(,OR3T J
M)?G&)(WO MA<Z6N,!;6CO!=>II%I<L0F,!?S[@ S_]XO_]=W?9FPW\OP3B^M
M1*;@Y>5*F'],BL>#_M*O-F55[>EQ=VX:! GA7%O*@F5Z,QHE A)!,Y@BB5 8
M)BI05LU?G&:=&ZU7I5ZKEN?F0T=N-TZW0]R.I;WC.#+O'H7PHB[U]@A^;?X=
MY2S;"2Y/]&@WYZ2$YP3#<PISNWD8*76.BIX_%UG$.&<IA2'*3$$X)""+@TCO
M26D6$\R83)P*PAV?:F[T\]7UV-L"33N6\8/1R-2R$W)<#CD-AB?BZ)EH4K8X
MK?!SBK"X8Q@O_*706Z(OQ5KEFX4,$XZ"0$&I3)651"I-!%Q 2;,TB+%20@6+
M!UFPM2T5=$9W^5YWYQCOZWUETJ[ +2VN>RH=GP3-[GD?",3(#W@E%:C%\O<X
M']#5T_/;'7G2!_: 2L^?T$.7N#V20N:+MZM-OGG\*J]SDQ6^VGS2J[?  2,B
M0]I4B 77SR6/8<98I$T%%"N)@C3.L,T+^M@$<WLMUS*"G9# 2&GWB!X%L?\Y
M]0'-R ^K(RK6C^TIU0\\NZ7D/UVO'W[6M]:/K?ZP>UJ/#CC)(WM*G?:Y/7G=
ML/?I7^527*W;T([>(WIS,-^<T5_)575$7[7+*(I'TQFCJKVZP)D2#",)99Q4
ME5()S"1A, [,F3L)-0\X54KU+-_<J&,7@L.K$!RQ#:L:&D7E>T'M]@LON$PC
MT]B>B]BH"C=KV(F6>A9'52^@B:'ZO3J)4^NBK1IK''IG!%K%VR [%/C; (VT
M>)XV4;ZEFW0C-A*TSS=S8TUS3NOP-E(F31G6K*^@$J(J!T8AC5D(F3;10IID
M9K?HWC5\IL%6G8[/#ID)^Z#UL^[94(S,F5T4!D1;[<,QI#?X?*.M&GCNC) _
M^>X$;A]NM7_/"_3_[@FW.G[14#OU4@B]CN5K_?%S<;7^?;5(49B&" DH&".:
MG"B"))8,)HS@@(>9D,S15-V;8VX4U=AEC9P7P$BJ<01&5E>;=1]06[/U+)BF
ML5S=$!I@OQ[%X P3=G_,B:W8HTKM&[+'+W7?=WSC-U+<+^5GU=1"_2H?Y.I>
MOGK<T<B5'O9#OI)5@9=%*%@4(=-(2.FG'F,<0<HS#"46$98X2A%-;?<ESK//
MC11:!4RL4EM+N-'!=#3MO-"!T0/\:C0!E2H.+W;W13J]#QH5^I&)9JZHVV^W
M1D5_HNU8=Q7NFE4H=JMPL]NM 3.YIQW;8.1Z=G3N8TZVXQNL;G='.'P0MQ=*
M66P6'_-5?GM_VZ;<,Q7'0K\L9&0:0&59"ADF''*:Q324-(TCJY3[O9'G]B)H
MA+-CEWV<^OGZ+.U'YN)&+H_9WD>U[7.,Z9LZ3C']TVZ3MS_>)$_O437:)_/X
M!>-F=?\MW]SDJ\^K*EOP:?(OY4QDG.KG4R *<9(DD# N820BE'*D=WRA4[#B
M^2+-[3DW^=OY:I>\K<V;I=Z+CY.QW;-2=L<+T^(_]8F"_]SL-BM[^D3LTRLP
M<?9UCT"S3+D^#>#0/&N+D8?V M%?.K-1_ZSJY*:<+K^LR]QLV[=]*W F#2L'
M,$X4UCNHA$."3$5%1A)!61B'PNE@V&;2N9'N5F9C:FRE!JW8@YN"6RV '=/Z
MAG5L"_I\1 >T#;&'R%L#$8LI)VXE8@_"?E,1AWN'^OK?WDH3*'G]EV+]^^;&
M)-S0U>-"&VLHC92"B$8QQ%1$D*:4P#2,:18IF:69E=/OQ#QS(Y[&H]W*"FIA
M02.MJ]?_,+2VGO^S 9O&^^^*U0#_?R\29YP!'!YWXG. 7N7VSP+Z+Q^8V+:^
MO5VOJA9&7VCQN:AX1_P77=[+ME3C0I),B$@H*&05KY:9;8GI6(:2 ">8$LRL
M",%ASKF10RTR*(W,%^!.6PX/1ESP@[8/Q7JYI$4)[F0!2B/\CXZ9;A9+8+<Q
M\0SLR"328/JMQO1+;6#7(H-*9HO"MNZY;?80^<ILLYAQVKPV>PCVLMH<;AW.
M1WF5(5Z:]+FJ,<6UU-L?;:GE)5^NR_M"[MHHRH )EBJHLD1H,XDBF#$J8)+&
M"4\C$838*<W-:?8Y<E0C?)T\VA4?[.0?;$*YK8T]98V"^ 3DY0OL023F#)I'
M.K.?>W)B<X;E$,6Y#S+0*;0]JVL:<WR5=\;E9)KIJ'5Q6QWJOGIL_GA5]7:F
M(>,)%QFLVL?BA#-(4HYA''&!22Q29!<J>H8,<R.^[N%T(R?8:@$Z:ER8L^KV
MBE\K75R]2 -6S-*I-.XZC.UC&F4)W-U.PT'TY84:(,&T3JGA$.WYJ,X8:AAA
M_DWFUS=ZQWGY( MZ+3_=FZ-4/;W9>):=S>FW>_;?DF^NUEHB_16_H:7\7+PV
MB2;:5*L"=N) IB0B(52()1 +%D!:]2T2DH5,"IZ$?+&2UV9_>V7/IMX$M'JV
ML_K9WA-S3%^R%AZT(I>5_5O9O*6CT>MO)>WH==J%F89T6YU HQ2HM:HXN-+K
M G1M;-#H9CJ&[[0S1G=7/W]D[!UR3Q3M3ZY)B=L[G,_IW/\$ TN^TKRH7 J[
M_7:YJ\6B&$NB1'(8Q)2;;(1,<S:G4"#&N*(A9X%5KSFKV>:VTS7"-KZQCY(:
M66_=*VOUXVM'I]Y0&YDB.X!U)!VI!Y05*+ZJO/;.-6V-5QNU]RJ\6MWD?K!Y
M55!3&/#;XRU;+Q=1Q *JB((<I3'$.)5ZER<%1)BI((@Q0]PZ=>G)R',CAD8X
M4$MG?UCY%*[3QY.#01CY.;?4W^D \J"N@XX<GXXTV2'C006ZQXJ'+Q@:3? N
M7S:;A@4/4B8D15#%IH.$?B7#+$,IS*BDB219($3B%D*P&WQNCUYS%FX$;#;@
MKK$"'>!L P2&P3%-5( -$@,B ?95/N/XOS/8Q&?^^VKL'_0?N&;85OJJJ':)
MC]6^_9+_XSXOMOM[$]2X/5\.1!ID*HT@2I'950<II!%3,,FB-""!I$()EUVU
M[<1S>YA;2]I4F@$__/+MS>!3?6OH[3;<8P Z^CNY%KGQ/K1"7VS=%4;N,<[X
M7;'RM"6WGG;2W;DK&,\WZL[W#ZUE6VZ*G&^D.%PY=Q&HE'.299"A.-5;"A9"
MPLU_$I1P&J1Z1Y&Y%;(\-:7+HS1-=<N=Q("W):*K#W)HE>V3L-NQDT\H1V:E
M#H;NE<H'E,&U \9;,=P3TTU<$M=.^?W"N);W#:.:7TKY6;TM-_DMW<ARH7 2
M\IB$,&!!HK<^40BS%"%(J0B#6&!,E96M<GCXN6UP?BFK,]JM?&YT\0PZ.W(8
M#LC(5/ <BVFJZQ^&PQ,!/!M\TL?]L&+/'^XC5PU[E%_=E_G*E$=9W[)\51T^
M[/R).Y^V?KH)D5D(.4]BB!.LK1N%$0RB!(4X4$&2.C6)LYMV;H]^*S7HB.WX
M_%OB;<<+_E$<F2\. ?@DU&\4OG"#R1./6$XZ*;^X ?&<=QSO]MM9SI0T_20W
MG]45_?[%A,BL5Y<;O<=A]QL3%7.U_D)-7[MM[*RV<P(B4P&50@IB*2-(PE#"
MC N4)$DF&'7:DWB2:VZ,5JD%>%<OH!>T_).?]G&NJV9'>R^P%B/S8KT,3U0"
MM4[;_F]:,;/5TJJ935:E'.AJ9V)2:OU&"9CVC/G(+>%<I9I%&[B!4-JV?ALZ
M_%!O5%4SJ5QH^T\FE"K(T\RT0@\%9)E2D&@6CD+)8IRAQ<8T';'U.=4#.S'I
M=O@1?;55WY2FHI>K"ZG!*E%Q*G@<0R9Q #$.C*^.FPX73 H12Q$$Z6(E-R,@
MM0V$W(SN@:NE&@A12&/%]1<*:H-#&R*1B""C2+_7*4I1&&<DXL35B>G^A9K&
M67DIQ)_ NGHUK.]D0:M(\.(\_&R]D>Z8C.YU/*'W ,_B4R6]>1";82?V%#Y5
M9M\C^.SOPVC=U'KI- I]5A.FSO6Y7]^7NSZCYK73EEU X4=]Q4WYN?BP7EW+
MH@V0;/]>+C"1/$Q5 +,X2,VV/3"Y.0A&*4U"AA*I"=)EVSZRO'/;SK]?_>L?
M41+\F=;_[/2K?_Y0-;9JJY:H=5'_&H7UO[6R)ISYX[J0%Z!^I>U"HK=JNW'/
MV-\9.TJ;T3=A9*:TJORU4[C;>?K)%^0"H!#LOA.UXA=.WP=G3IYHE3Q1_=C2
M3OH&F0CZYR^FJ:8=]KY[OWJ0=;OU\OW*B'JY$A]I\9NL;"9SHM9MA&(.VF2Q
MH?FJB0N\+$NY*0\Y>+G*4!I$"**,4HBI?N4Q)+6!1#%!#*<J#9T<ZF,).K\W
MW%9/M[?0:"MI]_J9P_J,_-[IJ&B*?E:O(1,;L%,3U'IV7D[@ARIZH-85M#'(
MM;8_CG\R,/:J>'K/C";FI"^8L<%^_F89?;ZAKQ1N L+D&UG_^WYUR;GIAU5^
MH8]&,BV)_DUQK]]T.67YLA)O$2LI1! C2"(<0IS&#-* 86T>A7&4) (1X52H
M99@8<WL=M#*#NUKH"T!KF<%R)W3%0I4?Q?65,6BE;%\(8^,_.MW7@H,?6A5^
M-+2_79%&C0K\1A'0T<0GB9^#I#>*'B3$Q 1\#E#[]'K6: .+6U4-+M]1;H9[
M?+.^U7R]B$1,,AD2R)*4F. 4#K. $)@&:1RG),0\DTXUK Y,,C?B:SI]MD*"
M7VLQ7>M1'8+3CK_.!6ED=G+&Q[V$5 \ OBI%'9IBVH)0/4KNU7WJNW8.[N8%
M)Q%'&F2888Q-Y:<$4D8$#%G*&!8!Q<B)*/R*-S>*\>M,;@,6!=AEE+^D'_E%
MW,8S(LA1O<1S=0C/VO_[?[.[=QKO[IEO$]L6%G6WD[;9B>EULM#V=IKI_T.B
M4@HQ8L8.SQ*8<1(+B0+&D'")8ADNRBSC7L9IZ'-@'>Q(>QITYT#0;@U[+-Z\
MH[7L.8[UQ*UZ#@@RRQ8]QP$;VIJG9\1AA/J6%BL]9MEFL+ZB9<X7#*>$2B:A
MJ%K>AB&%F>0Q5"J*PXAE/")670Q[9YG;9MF$Y^9UQ.XVWQU 4,GJI<;]8:SM
M^/!L!$>FNE:^72K[18V</YKJA< 3 QV>8U)RZ57S.6_T7^S>'?L21VG\3:[R
M=?%IO9%ETZTSQ(2)." PCD(",<$QI%C%, E5@I1DD1!6,5W'IY@;&>"?M)3_
M$U02 G$O@?ZJ$/M6RD=P['_6_: S\H/> %.+V.!SLA6J+3[V_:3/QVFBIM$'
M\/+3%[H?@9[FST=NG*S#<[_@W3;.)ZX<PR'YI-WAV^]\>5\=)->'(.]7FGID
MN;E4^E^S6__=%/S4=]9^4V/W+@AEF,D@@#%#$<19J,U,O6TRC0RI% %6DH0N
M9N:XXL[-%'W:S=2G<_'LA?7A;)QRN>9@VSYO3KM5>7N<W"I] :A1&VSU-NYH
MT!P!&=6G\D?Z6J))_)-G"SLC?Z4OX-W\E]YF==]K'TC&_E*L'_)2?Z#+3O>
M]RLM.ETV9_-59P&3[KN4&WDI_ON^#I#Z*KG,'XQFY2)%BJA4"*A"IM\\86*J
MN40"!BG#,A,X5;%55_-1I9S;CG\;#+-9@V(GY@58U6F[]+8.BC'&P/7Z01:K
MJGT';?KBV.]]QUOWT^;%+%9SY#?3H0H5%Z"CYM-6+(VF8*<JV.FJ7V%;;2]
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MB$?8K4: Q:1S8X5&9K 5NELZ!/QJY :5X*X)K38+8$<>OF$=F4H\(.J>:N,
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MR2^", NR-(@@PP1!S&,$*5+ZJ4\EC;(P37 :NQ0 .5,>)XZ8H%I(I0[@77W
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M$=V(K0=5.P+S@]7(1%4+67<LV +V[11@SO1S&@M/--,ST:1T<EKAY[1A<<?
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M%-;_UGI>@+?E)K^MG,?O:%[4#9#<Z,[S%\..'U]NN>=P%K#3#^P4!$^^!1?
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M(04XX2DH>%X A1*:)$G*)&/^))^7"S@U8U0%_I5;!:,'K:&Y/7YL=+R$F#/
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M$$NED!-)WHE^IF;]&SNPH3_:&WGG>_>C<%I?K%\*TO WYP8?+>+VEORG1LJ
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MJU]7W^5Z637\32[Y7):_T?6?<O.TT!_#W=HX3(_;+SKF<9+*+#>TKH8L*RU
M@5 ,M)%(,X8%D[%5\-8E0DS-C'0D-8?71E2'$IG>0]%O7,8">.@SYEJ%2.L0
MW:^BG191J\95U,6_T<2KF*;W2-A3*XXQ(B-1+ XX,DZ<BY="VL.]Z-WT:!R,
MERK?Y6*\N"W?>UI1<;_1Q1V=BYOE>_HTW]!%R]&;*2:*F -(TPS@%!> 2IR
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M6Y&K&J&/!]6'H[5<5 EPFY5EM+,M[OT6<  T![9T6R"UN%%;QMD('%42VX1
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MN/&&VVX-F.8@#AV$THQ?1<3<"0-J@QBVHK?4/P'C\T;'.U28WWB"CQLM./J
M' 0=CB^!>^QBS6GWGJYEMP!"0PEZ3W]\J<N@S6*40DAS"3"%L=Y58 IHP@2(
MLR2/60Q-B7#;"$7+/J>V.K04MQOZPZTZG O._=9](/0&-LL-#Z41.7I=T:6%
M5(L=?1D*4OL OP&@'2F,+PS$3E%ZCF#UQ.+9MC1:Q)VC:MVX.M=7+XZ>J]A
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M.6$QA/ )+BA-.2=N)2O.=SFUJ=_-B_VT6GZ+[N7ZL4K1\,U#/@FVG3D("^'
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M#99YSBR%E,"ZI,@!#K6I40@@BG3)H$KD!#<V"TT(/[I-S3%$O)HNT]E\>;'
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M.0J:*?Y@^8VL^&O/]R\X_[P(7[_4N]JUZ1->!AFEAVQX?6-73SK!&;C,#<?
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MJ1[Y^/Y <80"YVVEV8&E><(LOR7)O:%@G$+OE"5'H4 46=O2%@M1,0:)7*Y
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MYCK"P*[GWB='+D56 I"D8I CR[A+]';0XET8OF,Q<=MW&UX%8[^1W$S>>;_
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M\2J<MY)G!S9JB^%_Q-2_O7ZC[J2-Y'$XT,Z0N4\8P&-QP)UA@:=0,+#&=NH
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MT9AT!$R^M@&I3>RXC)"RL=PS%1FV'B7>U4#@SL*#!EKJ &Q-!XP&VF;,%DY
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M\EM !AU!Z9# ,^*RIGIKS;S1I?5=]3[T=>+W#87$P535Q=R8HRM_=(X:94F
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M,^_-12UR_%_,;U>;R^=F5+\I].>;\_/5OVI"LC:FH64L+FL#QS,KK5,)ZZP
M07P7)D,PR"%KP61TV?#<ND)UVA7-&XV9$(J#\B)'Q46SH:@C7.4'ZW_ G92N
M+J[.:^G%?ZQI=7]?DH%S7ME3&YG^A&6U)C7TUYE*R?F<&21>Z,03]<13,D%@
MPEITB870NH:A">'SJO?C8?[X4N[@ #ATT74;WRZZEFL:$XCML1:XTU*!O,8(
MG+-HN9*FB-9UC4T(GS>RU#^T#Y=R!]!^^0Q[[M@Z0X,Z"FU *E4=$T8;&,E/
M*<&BB-'%V!S+AU$Z;SBK%UNDB1P;UCY.7Y=6&S_6PI>K</ZW<'G-EM6M&,J.
M,:VKU@Y_[50U;8T8<?R*-UVGIB7:#49Y!2IQ3>9O,I"<E$YR&<A^.-F*M^?5
M07WQK:#N.1&WK#'UUDG.(*11NWOLGJ$"@2HY4;1-86I+8A#!)U,E-P1SKYD/
MTXFT [-AW\7^U^+R\V+Y?HG_C6%];^5G+@>;<D$(5F50V0=PJ120VCJ;D9CA
M6H<]QE,]+Y*/"+$#P=U(WB>$\&T$AQ;\\?-Z=?7I<^T:4]=^7P9G+#EE9%:0
M D^@N+2D6.A'\G5E+$B. <X%]KT6,&]XHW_<MT?!J6V!NN3KU7_$Y1.+=];P
M8'4&DP/M?V<$>$[?81$F.ZTYV=-S;H'7%C!O&.1$MD!3%)S:%GAZQ3R@DB[3
MN<>5(1=;)7 2$6PR19)"$*FT;OPPGNIYPR8G O;Q\NX X1,GL:(*BB$SP+0H
MH-"[&N074*1DQJ#S/HG&Z.\@N3E9A=)\.Z,CG'28['Q.#M_N_WZ3 9<AY&P\
M^! <*"-(/2A=!^NFG*)VT:?6MWP.)G9>J[^SN,TX47:@Z0_RX6\OL+L2F&8Z
MU@0!)^<%&<0Z3%0D+5B,+CDWE_W^-,6G$:L9":L6<9K#9'Q"B'[..[]=.$I6
MYYG3\:,<(YXKA,IFB(S'J+73,K6NA&Y&_&G$9N;!>5O)GQKDG_#&;Q=>>-;:
M< O,8[V.)1DXYC1($=4V3I7RU)56!Q-_&K&8&2'?3/*G!OG'JXW&D1,A#*!2
MD<XT\LR]IQ^5--S'+-'IUGGD<12?1NQE1G"/D_$)(?H/\J'/\?KGK_\>+O&,
MVZ@,6@4FN]K/0'AP)8GJ+(?(I E*S!5-?$SM:<1*YD'R2-DVBX%,7XKU+JSK
MU-T_L4F%U:.G354X]3+9QZ^'LH4;742&X.F+XM) ***&\6(,J%46V'K6:B\=
MP'Z_4T1^QK0PD64#1MCJH\H$7M5Z6Y>X38+,===Z@L#^U)U,I=,0- T+!1\L
MK X.YOU6M@U8.U<8RXZ#)4) :<4AAE@@$&>+3Z)>SYP%AGLG*7H(W$X/P\'"
MZ@Z&_XGG^>/JQE)X+KFRNX'P3'8E%]0L: O"UVV(G@R:E!VP$EDP/A+26O=K
M:KV&>5W^62!]9,%W /S[*]XK>/T.+V\F.^PZ])])'<A85X',Z.)!92G >9U!
MVIKV=,QDC8W!WH+N>=W^(P'\Z (^&5 _%ZE^O/PLF",&6/!2QMJ=NNYI1HSP
MZ"+YJLBQ=2O@QDN8-R[0%=2G$?MIH?Z)8/7CY6O,NL9>0+E0%VT21#0%3$)K
M!"<O0[6NH&Z\A'G[TO2'^N9B/Z&V^5/?0YSQPF'_-PN#*!*9MU"$D37.BA!Y
MJ<VT="D*62FZ=4UB+Y&T7:<?JZ-5B=O:^C71ILH10J*=Q67V07.M2CYN[.*T
M>ND/P<\AO?2'B*>#D_ZYUMLL)72UP7#97F?WWD$,S "B=V@8#]$VG^-UJKWT
M!XE\SU[Z0_C? 8R:-LX+FG8A^@*2*0TJUH1P3 B:/A IQL15ZV3)]]]+?Q"@
MINRE/T2Z'2#[Y;;L,D:;>320F>2@&(L0A77 /$O!JL),\T;F/THO_4$X&=1+
M?XC0.D#@*TW92W(JF6@A;$<O.Q1 WI:!F$6JHVY%:#XX[H?II3\&@PW%U@$(
M7VK-+BP/27H$I2S9/RD76E3AH'T="V"D;9^@^C%ZZ8^!7RN!==M+/P67O4X2
MB@]5BSL+7@0!IM[2%%*BD@_\X!^VE_XA.&K'_ ZTUVLMV76(6FNFP7->6UHJ
M"[&.V%&!IZ"C2=&TCJG\.+WTQVBQEH+KLI>^34Q940+H)!@HNVVQ4S*DF(M#
M+Z3]OU[Z(S38>*9WH+V&-:(T//#(Z7!WT5MB563@"JVU<.58Y%*RV-H?^,YZ
MZ8^)YTTGJPZ ^#+S:K/*Q?)J=?6@O>Z'U6:Q34[A9O/Q<UAR\3?ZEY\W9\BE
MTUYZL*'.+,C)@6<A0N+(7<R9O/36M3YM5W!*O?('06U0WF-2N7]WJ+_3BGI;
MY)<P(EDLI&P,KW:+L1!T)F7#?+)"6Z7Y<4=CCUS0*?72[V=/C$'%=[=%WEU5
M*^U]N?E\<R:"4\FG!*F*1RDA(:*,H)U+RBKICEVO/WI)I]27OY]M,@X9)[]1
M;MCP?OW;:OFI!I&MD2H[#8),5CI)BR U83WPD(1S7)><6U>3MEW!*77XGV\;
MC)+[=X?ZAV>EY8YS9<F']S6DC4:#+XJ4@:2SDJ>(.INN-\$A%M1DH;]3W1-C
M4/'=;9''YZ2/190:,4-6:LJG-LE11H)15CJ9!9V7K2<L3KRD>:.;I[I-QB&C
M]R+MOV%>I'#^]CPL+C9AF7_")9;%Y>9#^%IY]LK'AQ=OMWEOTZ+N"5C1J-A[
M&Y/_;1'BXGQWNV"Q2>>KS=4:[Q3I:B:S1-"J-A1-6H(+TI)5'R/!440TK8_T
MUZD:D_RY>?#7LEK_??DE+/(WSN^^>9/_YVI7P?SS7U]PN<%?E[3E:7O%J\MW
MJ\L/]!N__O3NPR]8*_,WVW0*7O_F]5V+B+6^SX$WF$'1Z0;.*5/[0EE'!J(R
M1;R"XJ,0.F_,M#'V[J::^A+QS,G.#Y_#^B*DKSOZKY7*F2U%1\X+A.@-.>M>
M@;/DM@B4(MG:WMCJ/3#ZY,/GC3M.B*OQK)P9"V_#E\5.$O>7D$MME<03)"TT
M*$'K<)()0%^*1#0Q^+@'&IYY_+P!M@GQT(*=/91"W*<^AJPM1@,>:QQ/2UZO
MY7 H4F=FC>>II#W \/C)\T:8)L3!2"9VX/-^.S%KVXO=0??L67DFC*_MP!E8
MJV,MVJY]+\F]%\YZPKW+SK1V8(?0-V_09B*832ZHWAOAO>(E-6B.-_0-Q_01
MC])$;P_H:LR6A=K37-0&H2@BQ-H%2F+()B1A\L,:N<Z]P7M\?_.([W24JYR#
M]."BK"TL+9G\&B5DYX/))0EN]CD,7WE-]Y[8$+G?*UMNR-X.CLD_KKZ0'JDJ
MME9&DF]XL142Z>(/Z]477%]^?1LV5[2[O_ZZ)/[5/E)_IXVY_M=Z48GXL%ZL
MUK5!PZN:N\ADHL_5DZ@^!7,!HE"UHZG,)@?MC&\]W>18:^O>.SP$ZUT#I/^!
MXZ^<?F]7%U]6RUJ#O"IO/X?E)UPLYPH@CZ#EF 9#*Y8=S[1P/.=LC 2-2%9Q
MD0&")UAG(QB:G+*RIQ-H/L1<WU4\9RQ%L=K?U5@+BA</OI )7XJ0W&AG9?,V
M^X.)[-Y<&8*E,1[6<)'U8,20J+9'U$]7F\42-YL_\-.NXU!M3A!#IM7P#,(P
M3199R1"T3L#12;+*C,^I-?Y>)&A>K$T,AH?60S/)] "S'>W7MX9<4H*76!M8
MHR=[Q3)PBAFPP:-/"KWWK;7[/0)FOA_03K /(7,PE^>^3;PU1A;Y^AZ8"XE)
MM+'VDT90+FGP-GNP-J$GM:VX#:\8;H^?.K/0#Q?-(P_Z(#YU(>$UWMSTXX(C
M(CDKUF?ZPBP$9S3H+)1,Z$I^>+OB!0G?/'7F*PX-)7P0G^:6<%C_ R^_G(=T
M0WPT7)%]54 @,C*\R$&-H=: !^%UH>]R9/L(^>&#9Z[1;R/G4=SJX$0?8@S]
M]JW@+BNM?,X%4M:DL8)@A&<OP3'.BS+(RL/<\E$=FM_ZN Q[7$-S>DEV!M>[
M54#/+_4=WL[X1G11!5D@,!=I;V*=N,(<%*%]1*6M9E/ZX8,)/AT_Z4! O0#A
M::7;&91?#0UCH$.(:0>N*#(@5(C@9?# ,YTW @LOKG6.KGEZ_BA G1@V8S+W
M0V1X,#Z_X'JQRN2;KB_'5Y9]BS>_+S=Q9A+(V]7F\K;AKXI2<1<*V.3)T4UD
M-$5%Y@^G<\NP$BU/90_K<)]W]7.:'P=ED\B@ \TW,J'VME;U+B_W2JFY$A%S
M<""BE;LZSI@2JPU:I1 I.]6\K.EXJYM'ZTZ#RK8YUZD@<OJ;9_]L-":=0I("
ME!/$EUA+H&-AX"-#'BTFUGQ4U/==KG *&V<:>'2P;8:?WC?71W8?\S/MR(V)
M04+0Y)$K*1R$FHDTN2@='4.%K5OVCR9ZGA#;48!^7($VJZ0]\+Y/^+I-+=%:
MGV>FR"P&-) 8[455%#D:C%DHR%6RM;V?W*?5X1ZOFC=P.X\=WEH")ZD2;ZY#
MT+^\-;!XW<;&(@M@9 WYH"WUXIP%8^KX6-K?5K6>&=2*]OE,Z.: &JT?&TCW
MQ%']S?JATX%I+@,Z"Q8MG4TZDGW#1("2- K!?3*Y]2CU1J3/9]WVC.E#9=L!
MI.^PM?:>P+K>^LT3EX-R01DX@E0Q$'.#AE"0@>!!J&",-*YUB?G>Q,UGBTX-
MRVGD,[/).7ROW=1!O4G_O%I<MS\ATVO;#.7R[?EJ4R=7?ONES9E$;THB@SLS
MIW;-Q8/2&7(BZ]LISZ12>QBLDQ,Z[Q77><S=OJ0_=TG,RQ>>[JQJ5Y7_Z_+#
M>O7G@G!QEI-P6*2K98 )%/<":KR14!P%YQSK,L=?-7N!@GDOSLX#WB/)JP/+
M8%#^T;$LC$<.EA5+5H\2M..<@\091L]\",UGHS?/(4_6<.Q$<LA#9#@RA_SS
M,D]_26S;?>VZU]NJU!YJ'W%]4?_V\,M>KS^SZ:6M@4MH=/EJ^_S'EV2RBK&@
M4(0*E+64N$)2%Y!)%R=+3MRTKG!ZFI(6#1MOYY3LJN.2C+QXZX!O9VRFK&F7
MD3%M1=8I,8LEM1Y<^@09\P_,'2GWISH@CF%U#^<@[;K+ZUU7I]ULKV $KLC-
M5^1B\9K8C4'5.93DY:,U!74B7ZMU5_.GZ)@?+Z.$^_"T&LOI#M%R70,N+)>V
M*#JZHRITMM(A'KG4X*2.V@F5L/F\E*<IF;F:;K2$7X', >SN #1_X'*Q6F_'
MI%U7^I/?&K-*HL[+"N3!!E.OZR?@6BN3N?0VMJ[)?$1$7U Y1+*/[KZ-87,'
M.+FO<+>;1X8L;$8$K8L&A8XVC[8*O/-)!*$EIBDZJ-^G8OZY8"V/H9%<[@XG
M[\+%S>Y)48H8:V^YH!/YDJ1EH[0)DO?<9V493C*,Y2E:>C)=ALOX1<@<R/"9
M(Y%OE+3Z"169F3.)5&2)G('*(>[&7M="%J542$[LT]#JZ:?W!()#I;9JRL*9
M0?"11(@?5HOEY<^+3Y\O_\ _<?G+XD_\@.M$/'J\MLACD+ZDFM^L\SB5 9\,
M@YQ4T'0R>VGWZ5T]]+T]G3@-@#,IV^?6*](]M2F09>-SL5#J967%M047&.E<
MG[2F,SJ5]%HP[OFGSUM%UEZOC&=A=U;);]]N]:%BW))0(24RY)6M _,\,EH5
M=XS7[L>\]=3;9TCI"3:M[=C#^-T=;'Y=TI-Q<_E[N,1MEY1\K2/#)R03#F-(
MTD-FJ3:Y\TC.(8O@=.(Y8I#<IDF1]!)U/=DZ!X+A18 UD\S,Y]7=+,N[U:ZN
MF[1X+3?X^S)<K-:7=5#/3:Q\.]U!6!5\O8T<(PI0M!AP.7 @JZ^XF!/3SNUQ
ME@U_<T]FT#A,'8'S7>BRW6M_62SK[9AMF=B]E9YYH6RR2@"9 YD4OM?@7.+@
M?3"":_1R@L/P%:)Z.A9;::Z6<A@.++\#UA(_53WYL6GVX?$..M.V8 C6 V/D
M=JJLR0%%:8!I9J(QLG#=O(C^24KF+7>; DD-.-Y[)_WMTL:WRW_R,<VK)8[2
M^/Z91#DY=.B*S(!E.\9%!W H#&B2ORO,&S=)=/4X!1)1%6UCTK1) BE$AQJB
MDQ(8JJ1X(@LNM"[_/I4"B2%RWZ= 8@BK.S!JGDSJ<A:DBR)!PEQ;TTD+410+
M-F7%E&<\R>;MD$ZB0&*0</<ID!C"Z0[1<M,DK\Y8E9:#Y0%I%59"$,H :AN"
M3)RG]DV(3J5 8I"$]RN0&,+N'D!#MMK[\I9>O+B\#GY*;8UTWH'4FCR_A X<
MN8)0/"_!>,U%M*T!\XB*OL!RB&P?%0R/8G0'4'D<)A<YJBQKC$#K&D,UOA90
M:\BT>[S'I#)O79O>6;YJ J",8W,'.-EA_)>0MO7Q6SVK>=))8  ;0Z&CV97:
M29>#8K).8(S&/6Q&.QHHCZGH*:0WWF(9R>7N<'*]<SP7=3!$]>QK6D8&!MYS
M"YQY1!%#T+%UOY:GZ)CW^!DKVQ>A<@"C.P#+[_CGZOS/Q?+3_<5<:TB=M4F9
M<2BI\L0I 2YY8A$/,62?3&E^2>I%@GJ"SR'R7DW%_ Z0]&2!FM;UJB"(Z(A!
MSA;P(3'0UHE<-*VA>6/L TL]CYHB'W,\C>1R=SBY4VOB0]0J*D_KB*2*.<_@
M2R0N>9E*R34R-6U51=>EG@-DO&^IYQ"&SUV2]72=HO>QB!(5T$E-GAZWY.GY
M($%HP2I+F.=[E62=4JGG(*F]7NHYA(4G5^K)O""&6"C6U>[K]4JRU8J^0Z8]
M>F$?^M'?<ZGGH<"9E.USZY6GZQ2CM84Y5NH%FPB*3FOPS'HP*GL7 \_L8:CN
M]$L]#]8KXUG8G57RV[=,NRTJRU@;LT0B7F7#(/B20?@<5#("BYDVB?C;H%+/
M(U4BM+9C#^-W!["Y&WW^YKZ%OQ875Q<_K=;KU;^J<Q>^T">77\\R%U;$A)#K
M4#-58H0@'.V+&"0*KS&(YE>P!]#7D[US("!>R TTE4X'R'NP(7%]<<;(8$,N
M/;D&@5AET=:K8 5XG;J8@K<FM+ZR_9B*GHR?-B@:R>D.L')W'YQQ%*HFP2#;
M.CD8N8!HZ+!W1FJGB]"YM)]6=OO^GJR?]EIF$'<[0,: @OC"BRQ!"LB!D54?
M50:R%FEY&6.QRCM,K4LR&U]5.'J99CNMTTPRW6&.SF5\<[$MC=>&T1E,WH(4
MTM(Z7(; E 2#(7I96"EZVLX M[3,VRAP>CP=R/5FZ)FH\/>/RU7ZQ^?5.8EG
M\_,_KVJ6YN#JW^>?U;0$>$^2&]4![][PK0XT*185,PIR;=*G4) =4]-81M(?
M%C&B:NV1W*=@=.W,=:NY]V7+QY^^OCT/F\W./;5%"(NIGKTUM1LT0LADL[EH
M@A$N<_UP%MOX*IKGR9G7NQHA]T=U-(U8WL%)]&UH_8X]MU-:MCD7,M:TMZJ
MJ3-HE;6*%B,,8&!6D6KD&%L;RB\2-/.L]U9B?PBG9C+H % /UG =6;4F:6D3
MG;"A]D/-NH WZ,&*VAO56Q;S-%KV 2$S ZB=H%>MN=X!=(C\B]5RN[=NZC\"
M(VO$:D"72^TR%\$%I*5PF7.4*&G/M2[9>DA$#Z?6*,$^+-D:Q>4>8%*U[K4.
MOG4,B!VI\.W4L+I[>%+D 48#$5%RJ>J%]=9M!)XD9-[@WU1'U'B>=P"<+?6_
MXY>K=?H<-OAAO?JT#A=OKBX_K];UDOK.&^1G(A;:39AK[(K1%]I8P1*WI/0F
MQ<*5;%Z%LR=I,Q?_C0?!(\NGO43Z UK^]ZOU8OGIPVX2]V?B]>9,H(^)20/!
MU.O+W#-P*7$HUN<@(F,ZM&Y=_3I5\^JNR>$U5@X=(.O.9*';=;TO=\[T,Z54
M1B%E/<,%*&%Y;;L:(7FN?(["LH>]_T8CZW6JYDUYM$=68SET@*R/:PR;J_77
M+?';F3U$PYL_<1T^;5MMT*[9;IDSYRUW2D= 50SQCMP4%Q2#'&D;69&-9ZT+
MXO>E;=X42'N432*3[@/8^&F[M1ITKWCV46W#UWL1W"AZ??TR4CJUL]+RT^W$
M&4;ZAM>I]:GF,#392<$D"45*SDS@T;#65VN?HV6L*GIW5=W2]V7WX.J[W+#X
MS#@CE":@9V[)$-S.%^=8 "TSR*SE0NC&JWR>FIF#22V0\%#C-&+]J>B8VS$]
M[[]@W;S+3]<?_;HLJ_7%]H7C]<^@UTRBFPY?Z-1Z*XB2@V,)0JCUT8P16NE<
MI)-,)IM--D*T#O%-I;?N!%\>O.$.DW_Z>OWA+BB#WCA-% )SY'HH0?O+JX+@
MLV0!>6 EM%9H!Y#9J:8;@IT7<GB3"*L#D_Y;NN%F%.>--MBF&Y+U6EAAP-DZ
M(:JVSO>1%TC:I^)YS(RW+C5YD:!N<GO3P.&YG-]HV?0 M!WM-\D)@49G[8&,
M G)\376!(^- _F[6DBM7=/LQ.'<(Z"3'-UZPC[IW',KE+L;E+O)-SQ%G@S;2
M0"&SM.8A(KA4LT]:<^UU<N*AXGEA!.[-4[LXH0X1S:,QM0?QJ0L)K_&:<HM8
M=,@)XC9<'SP2WHG\(HQG*OK@RCZ7#N\_=>;$6D,)'\2GN24<UO_ RR_G(=T0
M[WS@WO$,T6(E7J;:]2%N UM:\9 \E_L(^>&#YPT5-Y+S*&[-+.KWEY]Q?9V*
MNU%%VBII6 1)&HBHKT8.S[K6S@F39/%,QCUD_?C)\T9LVPA[)+_ZL=^>,GEO
M ]DUT\I,D&!#BJ!<(&4EN:\:"[53.IF'D^N;.^I/T=5-O<5QW(;6DNH ?;_7
MV_17N#FS@7''989B:>^IHADXQBT8HU+@M"LU:YT3OWEW%^9C0ZD^[K(TG,4C
M.N1?'B^$^SNFU;+>:]T^>57^8[W:;.C\_;187J[>KI8;>D*NMX5^7=+O-D@F
M'?C"2<*Z+18_=8#7\,R"%PRX0$7JCA5R8QA"B6A%U%&3%?P=!WAY,+XH#"!M
MS?_2-@6OM07K0T9,P4S0R/2["? .P4Z+ .\08<UX<F[6EV>WNYN6L3TAM@$F
M%XWB-BO@A@=2\-NY=<& %"5GZQASN%<^@5YQ!VKTTRW,GG_[Z85P!PE\U93[
MW>'GV@TJ7*4DG %FF &E8AW;379&8D4$Z[+P::_P[6 $S1F];273%R%R (,[
M,,\?)HQONAO)(I1*M%>PSG-7Y-* +[: 9M*8S++.I;6U_@PI/4'F$!FOVC.\
M ]S\C>S.]2*<?[-120]7#EVOQEACE;:YCEBJ'>H-:5Y'[@C709A@@^#-TX\O
M4S1/(&$R%#5D?P=@>B6KIEAQC%0T8[47#9I::EL0@DC>$1,-\\TSCJ-3V5W%
MI ZQ@]K+I@>@W0L)DZ^1/5,>I%,6%*E;"-Y6MAB7M#+(FY]QIY/*'B+8%U/9
M0[@\=QKL?HJ6>Y&-RP:$KZV.R%0$;Y4$9PK:Q)60#^^GGE@J>Y!HGD]E#^%3
M%Q+^EJ*E%6>-(D (]=*D(/*C,PBB>,><HT_57EG.;E/9XR1\$)_FEO"CY*PN
MRN:8'2%3$O%:U5F 4H+.+A(O#/H8]A%RSZGL@^4\BEO]I;)M[>84>$V_9W+G
M17+@R(N'E)@RA<=D6-Y#UGVGL@\5]DA^]6._O9Q*L\A*L(3;S'6](5%[5W+A
M0?N R?.JN%I/ FJ6RIY.71S;;6@MJ0[0M\V_T?XIB\NS&')@1#TPJQ20.6SK
MO/L$E@Y*6UCA2;3V'>Z\O@LCLJ%L5VT8?3!&_L1U7+4N>'",,Y08@:=:X<F"
M!N=)84MN0G0ZA=0\;C&HX&%J$W0Z?!S$XB[ 4>_U;MXL\\]_?<'EAE90%ZNJ
M4F6RZEAO%,1,Y['(/*LH<RRVM1YY2$,7=NQT8!G%\A%5,I]J9<;']HF:7;''
M;Z0AR?%.)FN3(61/!KO@'KRH[5(58]8&7GL13)6DN26C"]-X.OR,9?SAALOJ
M,IPWP<Z[U7)U?Q77F^',ABR%1@,Z)20%JA6XVG_7R>R25-XRUKI\YUEBYFU)
M/#F.V@AAK$)J@J?;G? +\?'M:DEKNJ)E76^5U7+S$Q+W</?O/H:_<//S7Y?K
M0#)<+,/ZZY:9Q(]$OTG$;;-7U_V_STHQ02JC@:52IU0$":'0)O/(<A#"1.9:
M]Y*<<#E[8=J<+*9[ 4(S'?ML.>OU!_5+#!O\M__W_P%02P,$%     @ 059;
M57Q;GVQG"   :"4  !$   !M;V@S<3(R7V5X,S$Q+FAT;>U:;7/:.A;^OK]"
ME\RVR8QY,9#0D#0SE- ;=MJDF]#IW?VR(]LR:&(L7TF&L+]^SSFR TF@H>_)
MSNU,"49'1X_.RW..;!__=GK1'_WKPX!-[#1A'SZ^>3?LLTJU7O_4ZM?KIZ-3
M=C9Z_XZU:PV?C31/C;12I3RIUP?G%5:96)MUZ_7Y?%Z;MVI*C^NCRSJJ:M<3
MI8RH13:JG!SC+_ I>'3RM^/?JE5VJL)\*E++0BVX%1'+C4S'[%,DS#6K5@NI
MOLH66HXGEC4;S2;[I/2UG'$W;J5-Q$FIY[CNKH_KM,AQH*+%R7$D9TQ&KRNR
M[8O#A@C:?K/5:8<'^T$K:OEBOR,.@R;??W7P'Q] UD'<S3%VD8C7E:E,JQ.!
MZW?;S5IG/[-'<QG92==O-/Y>(=&3XUBE%M;3,-]]=6H>*+/BQE9Y(L=IE[94
M<5/+X5 E2G=W&O3O"$>J,9_*9-%]V=.2)R\] \:O&J%E[(:-_*\ ) "*+N<.
M: =F)S(5)7"_B5 '?YP-WPQ'K.77?'87Z.I^N1[#EJW*NOXKT+L".00;"_U3
M,?<'EZ/AVV&_-QI>G$-D7EY][)V/V.AB(_Y?B_?RX[O!%?-;O.JW=_G>BYUV
MY\C?C]S5$\7\\?QT<,E&9P-V->A_O!R.AK"%P1_]L][Y[X,GBKG7'[&+M\P_
M;+4]UKMBO?<#V,7I-E%]F/VHM&NOA3KTV#^ !+,)>U]C_\X#+:RY7G@L%-K*
M>,'LA-L7._NOCK8!?U!FI$PCL'JWV29*^JD;\FMLR"9\)I@6,RGF0-QV@A>9
MTI:IE+U5>LK\1O6?+%::QC)8245, .B(78G,BFD@](L=_Z!QU&IXQ.P>4S%[
MKV ]SLX$3^PDY%IX;)B&-;#/X;.Q3[/&WG #&P533!?L.E7S1$1CV,J*F2(E
M#$L5U#[0QV7*>+I@>6IU+@ E5$,JC& 1SJ9PA:A8S$/X23,UE999Y>0>"*0B
M%,9PO6"@5>E(:)2=\FM!Z]\J-_!;!*! *J'R"HNA0"@UE%,02T$/0$(%\XD,
M)\SD^+&</Q=:%$IP)U-I$JB[6,+GTDY@IR83(2%=B8%0S6!:Q(+%BCF>E7];
MG_5O#/&;ANB-I:4\\"Z(P[!>&9<II ?X#EHI^!XF.28'>&-I%@\\*G6R8!G8
M$N,!XR1)E@XO3&SNK0PQ%5&+YJ%$GH  .%>!!V@U0W!";B8L3M3<E)[78BR-
MA?[.,HX_.M@ TEMQH"G!W ?[K'S8KK'1G1V_-(5_"EK&*%9Q+.'2F6O(@(W(
MX&! &22"R$V DX-$F@G*H]@4<AGS&:\C:<)$F1SF899KE3A5F5:AB.!GPW;!
MT)$ SSEK7N:@E[J'_5VQ1\+4/=!5X:4K$>8:O NS!S?AA*=CP7HAI:\KAZ"2
M3XEJ]YP')9;GU,4%HF"8@BOAXOR'B-? ,26>^ Z>^"OQE!5A-=9 *Y:3KRZ"
M[</:SXX?Z.;8J3#0_8"EB!<?=[:'W!WRW&P_!;DS$."28B7'QBK7H #2<28-
M)3E(B93T8#.QI(=5AM$BX>3C@HZ7#O *]L%!"50!6 R4X8B.9"8/C(PDUQ(W
M(%W1(,Y+45-ND,@I<PRQ/E$"M#L R%)0>"SC$%QAGG!D,M@6@5@6!(P(5U]@
MMBGK(WP+!$H"VX "$7TUO?R*Z CN1\?6*?@@2+9/WJUC!>)K)B,, 6[@&(]<
MQ@V$#U9\C NNH])'$#62!S*1=H$)O6Y9C%AR)SG*!=L=T96.@2CSIMA0ENL,
M(L5050M#:%4( /4.8Y%"L4H@8& $^\6(1*!!<C$!$2LS(*=G%17A'AO,>))3
M8J')1!Q#]98SV*Q94X5?[+QJ^ITCLPU1N,NUA9EB .9!CAM7_0.5V\T MF$R
M?BLML+.)'^WP6%"V3!35PMD!X) '4?]S\6($N>TL],#0V,,7%?!VX($SOR"A
MD<Q5".45S;G"G&NT3I6Q\#L>Q4&7"4'1GSD0+ZC>W3 EAKB 5+LG70"'[E#0
M\0-/)FE^BVO/H9IP<UMF,$DICD1$[$4D7C#+ LX6UP+^T!'DGKSWS2;ZIN#Y
M%7WG_E?TG734CLJ0\Y:9A'F]ZO=E4J'GOJ#D/&@);CW!H2VPJH!2B-%OH'4*
MQU KQ&=X*U!02G \D@"1].Q"@ !/&.0A^(O]21G5XL]<P@XH@O,TI)/*WG-K
M"GMP/,,"+,&%V-QB-QU* 28O2/JV.9L+?HVTZPH@$2^5;CKAET>U+W)DT4:Y
M<\J:!.013#3B-O\V.KTH^# %W 9UV7/<;X#X33X%HX-1:#,%[ZT]TSX[8H>F
MK0<$'FL(< ]L*2@OP1MT<Z-PF^?X3Z8SE<P$DF#*Q\7-&EVDLIAFB5H(&)U/
ME$M??B<HP(G?I4+42M-^!RMUMC*2NV7WF$<#9:V:=OT-CP\LM9S%E(!N454!
M=<(S([KEER-@O"SABZY,"09-.KJ[ #Z,F2%O0@$K%J'UW'#QG.;PL-9I=/!1
MC=7P/RH7+I[BU.@I3MU&#\?:K=I!T]\XW*AM'ON<VL-:>[_SW;42V.96:NMD
M"%T*% YNN1OC%ANXQ&0\?5UI54J9C$=X)N@VF$]2Y1H_0+1 ]]B<9G;#[@58
M(N('\>!"X6<1"3T2/,7^GNH6NX"B%T#N-CON'O=MXCQNDU^PO_96V[M' 4]R
M)UMZBA[/&?I<]XSFSAX?"<N"QNBQ:0;P\08**W'_Y=.GMY.GZK#''X#2/K\Q
M7/]__/C73E;ZKT)%%>7Q0?>=GKKZXYY\KX_1_D2*F UN1)CC/29VX<ZU'ON@
MX:2#F.@0<5H<#N^].W,;Q75J_=9TF_=>R\F4>R^IZVYUS\2#%W66N4_M8V,Y
MA0=  +G=/&73ZPX;W_HI/MT[2/0VU,G_ %!+ P04    " !!5EM5/8/B0D$(
M  "S)   $0   &UO:#-Q,C)?97@S,3(N:'1M[5IM4QLY$OY^OT)KZK)0Y?<7
M7@RABACG<%T">V J>Y^NY!F-K6(\FI4T=GR__AZUQB]@'!QVE\#5IBK&8[5:
MK>ZGGV[-S,E/YU>=_K]_Z;*1'<?LE]L/GWH=5BA5*E\:G4KEO'_.+OJ?/[%F
MN5IC?<T3(ZU4"8\KE>YE@15&UJ;M2F4ZG9:GC;+2PTK_NN)4-2NQ4D:40QL6
M3D_<+_@4/#S]V\E/I1([5T$V%HEE@1;<BI!E1B9#]B44YHZ52KE41Z4S+8<C
MR^K5>IU]4?I.3K@?M]+&XG2NYZ3BKT\JM,C)0(6STY-03I@,WQ=D(V@=5 ^$
M.*P>UIO[1ZVC>A#L\U:=!U%+[-=J_ZG!R K$_1QC9[%X7QC+I#02;OUVLUX^
M:*7V>"I#.VK7JM6_%TCT]"12B<5Z&O/]5Z]F39D57VV)QW*8M&E+!3]U/ARH
M6.GV3I7^';N14L3',IZU?S[3DL<_%PV<7S)"R\@/&_E? 4M@%%U.O:$'F!W+
M1,P-K]6=J=U?+WH?>GW6J)7K[+ZAJ_OE>H@M6Y6V:X?0NV)R !\+_:(V=[K7
M_=['7N>LW[NZ!#*O;V[/+ONL?[71_A]K[_7MI^X-JS5XJ=;<Y7OO=IH'Q[56
MZ*]>J<VWE^?=:]:_Z+*;;N?VNM?O80O=7SL79Y?_Z+Y2F\\Z?7;UD=6.&LTB
M.[MA9Y^[V,7Y-J@^2O^LM&L^:FJOR#YS?<<^E=D_A1P762"TE=&,V1&W[W9:
MA\?;6+T_3T69A'!WN]XD+GK1G=3*K,=&?"*8%A,IIF!L.W(7J=*6J81]5'K,
M:M72OUBD-(VE6$F%3,#HD-V(U(KQ0.AW.[7]ZG&C6B1*+S(5L<\*ZW%V(7AL
M1P'7HLAZ25"&?X[>C'_J9?:!&VP4KAC/V%VBIK$(A]C*BIM")0Q+%(H>]'&9
M,)[,6)98G0E8B3)(%1$>X6R,*V<5BWB GS138VF955YN32 1@3"&ZQF#5J5#
MH9WLF-\)6G^AW."W$$9!*J:ZBL6<0" UZBC$$NB!24[!="2#$3.9^UC.GPHM
M<B5N)V-I8A1<5[NGTHZP4Y.*@"Q=P4"@)I@6LL%LQ1UO*KZ-;\8W GZ3P$5C
MZ:DBH@MQ#.N5<9D@/1 []%#X'L292PY$8^F6(B(J=3QC*7SI\.!P$L?+@.<N
M-@]6!J9"ZLV*3B*+(8#@*D2 5C-D3L#-B$6QFIIYY+482F/1V%G&W8_>;!A9
M7 F@F1OST-@W%<-FF?7O[?C=SF&]=G!L\BCEY.RPK*)(XM([K<? 2>1VN%$.
M8D$4)Q#J02S-R,D[L3$RVF6UNPZE"6)E,LQSN:Y5[%6E6@4BQ,^&[<+=H4#\
MO$^O,^BEYJ&U*_9(F)H'NLIC=2."3"/&F-W]&HQX,A3L+* D]M40*OF8"'?/
MQU&ZZIQX=#@KF$O$%=#X*#J+'S''S.V)[MD3/=.>>5U811RTNJ+R[%+8/"J_
M-(K0S+%S8=#\P%/$CD\'N^@8/."9V7Z*8]"!0$CRE3PGJTQ# 9)R(@VE.J1$
M0GI<2[$DB56>T2+F%..<E)<!*.8<Y 8E" .V&!3CD$YD)AL8&4JNI=N ]*6#
MF"]QFC+CZ)PRQQ#W$S'@R >#+(&BR%(.< 59S!V?85MDQ+(L.$3X*H/99EXE
M\6T@G"0X!PI$^&R2^1'H&#Q$Q]8IN :2[9-W:ZP 7Q,9.@AP@U.\XS)N !]7
M]QTNN [G,0)J)!_(6-J92^C'EG6(I7!2H#S8[HFN] U$F5_S#:693H$40[4M
M"-"PD '400Q%@I(5 S 8<5UC2")HDSPF@%B9@IS>%"J"/=:=\#BCQ'(N$U&$
M&BXGV*QYI!8O*M,61.$O'RW/A ',0XX;WP,,5&8W&[ -D_&%M'#]3?1DG\<&
M\\:)4"V\'V .1=#I?RM1#)';WD-KCG:=?%X!%P-KP?R.A'9DK@*45^?.%>9\
M1.M8&8O?W4D<NDP 1;]E(%ZHWMTP)0(ND&H/I'/#T2,*.H2X\TF2+>S:\U:-
MN%F4&9>DA",1$GL1B>?,,L,)XT[@#QU$'L@7?[>+?A=X?D3WV7IV]TG'[G .
MO.(RGUQVKT9_F5HN?M]1>-8:@X5M',V!5;DIN1C]!JUC'$FM$-]@KX%"07'C
MH82)I&<7, %;&,=&^.NZE#FVQ6^9Q X(QUD2T*EE[ZVUAF<XJKDR+!%"U^*Z
MGCJ0 B[/J7K1HDT%OW/DZ\L@T2\5<#KMSX]MWQ7(O)GRIY5'TI"'F&C$(@LW
M!CTO^YB"L*$Z%WT%,*!_DXWA=#B%-I.SWZ/GVS='[VC=SD#CD0; B_"EH+Q$
M-.A&1QZVHF=!F4Q4/!&."A,^S&_<Z#R5Q3B-U4Q@=#I2/GWY/5 @B'](G2A_
MURU:2_U>+C"@NT0EN#3FJ1'M^9=C$$T:\UE;)N0BFG2<1VJ@K%7CMGL0,G%T
MA>J1+T+K^>'\&<G14?FPU7"/2:S&_W"^</X$I4Q/4"HV7!]K-LJ'S<.-P]5R
M;>/8M]0>E:O5^A^NU1G;VCR\JK9"CM!S@1Q\#7]3VKKN*38I3]X7&H6Y3,I#
MUY"WJZQ&4O,U_@31W+JGYM33KV[6ZK.A6$1K>/!0>*G\I<=QYZZYIG+!KE!K
M!DB9^H&_S;Q(DZ=]\@/VU]QJ>_[&^>O>R9:1HD=CAC[O/1^YM[DG\)CS%SVK
M3&&WNVW!Y@;_%<S7MY/7&K"GGSK2/I^+T_^? /ZUDY=#6V<D1<0^+CJ^*W\B
MI)Z[[WK[3 N]#L,*=6LK[>#&UU-66L4';[BDRK_BT_:WC2=B[9V79493-UA=
M3N$#I'5F-T_9].; QA=H\D__.@^]6'3Z/U!+ P04    " !!5EM50,2?F*H$
M  !.$0  $0   &UO:#-Q,C)?97@S,C$N:'1MU5AM4^)($/Y^OZ(7ZURM(J^
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M4$L! A0#%     @ 059;546!NH$F$   6CL  !P              ( !
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M,#(R,#DS,%]D968N>&UL4$L! A0#%     @ 059;56+()!I/-P  -U<  !,
M             ( !+VT" &UO:"TR,#(R,#DS,%]G,2YJ<&=02P$"% ,4
M" !!5EM5)5Y;",2U  #F<0< %               @ &OI ( ;6]H+3(P,C(P
M.3,P7VQA8BYX;6Q02P$"% ,4    " !!5EM5_>V7X(MN  # X00 %
M        @ &E6@, ;6]H+3(P,C(P.3,P7W!R92YX;6Q02P$"% ,4    " !!
M5EM5?%N?;&<(  !H)0  $0              @ %BR0, ;6]H,W$R,E]E>#,Q
M,2YH=&U02P$"% ,4    " !!5EM5/8/B0D$(  "S)   $0
M@ 'XT0, ;6]H,W$R,E]E>#,Q,BYH=&U02P$"% ,4    " !!5EM50,2?F*H$
M  !.$0  $0              @ %HV@, ;6]H,W$R,E]E>#,R,2YH=&U02P$"
M% ,4    " !!5EM5ONN%CK<$  ">%   $0              @ %!WP, ;6]H
D,W$R,E]E>#,R,BYH=&U02P4&      P #  + P  )^0#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
